<SEC-DOCUMENT>0000927066-23-000011.txt : 20230222
<SEC-HEADER>0000927066-23-000011.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222171941
ACCESSION NUMBER:		0000927066-23-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		143
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAVITA INC.
		CENTRAL INDEX KEY:			0000927066
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				510354549
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14106
		FILM NUMBER:		23654637

	BUSINESS ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202
		BUSINESS PHONE:		310-536-2668

	MAIL ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA HEALTHCARE PARTNERS INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA INC
		DATE OF NAME CHANGE:	20001005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TOTAL RENAL CARE HOLDINGS INC
		DATE OF NAME CHANGE:	19950524
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dva-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0,d:b228226ec511491b87b183c6d217a21a--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dva="http://www.davita.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dva-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN18yLTEtMS0xLTQzMjM2MQ_5871b288-8d76-42df-8f3b-8f6534b178ef">false</ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN18zLTEtMS0xLTQzMjM2MQ_d59628a9-3f8d-41c9-9607-d5836597cc37">2022</ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN180LTEtMS0xLTQzMjM2MQ_d5a3724b-3c5d-443a-93c1-e4203e98bb4e">FY</ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN181LTEtMS0xLTQzMjM2MQ_e8b376c5-19f0-432a-a785-27a181c71564">0000927066</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzItMi0xLTEtNDMyMzYx_f799249e-a21f-4a81-a569-e7340ee836f3">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzMtMi0xLTEtNDMyMzYx_046b9973-72f6-4bfa-9009-e0b02f727254">5,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzQtMi0xLTEtNDMyMzYx_fe719cb0-6457-411a-8aa2-bcd14ec67500">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzUtMi0xLTEtNDMyMzYx_3186ec71-fe63-42ba-8c7e-a21cb6efcdf6">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzYtMi0xLTEtNDMyMzYx_5cb08682-4ae2-4c92-b707-25aa570c68f8">450,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzctMS0xLTEtNDMyMzYx_ff09a588-8ebb-4747-9470-337972f55a8d">90,411</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzctMi0xLTEtNDMyMzYx_ed7ad72c-bcb4-40c8-8d7a-24b2823d7375">97,289</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7af410a4e989429d8103daa89df89d50_D20210101-20211231" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzU_7c63ce61-685d-4d4e-9acc-71c3c700b705">No</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7af410a4e989429d8103daa89df89d50_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzYx_59c71f2d-14ce-4c4c-a7ff-264f5575f32e">10</ix:nonFraction><ix:nonNumeric contextRef="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzIzNjM5NDk5OTk3Mzk2_1a34c3fc-7ad6-46c4-86e3-9be7493fc7cc">six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDcvZnJhZzoyMDI3Y2EzMTNlNzg0NmVlOWJhNDAwZjBiMjZlZTIyZC90ZXh0cmVnaW9uOjIwMjdjYTMxM2U3ODQ2ZWU5YmE0MDBmMGIyNmVlMjJkXzY2_a44d3eef-96b6-490e-8c11-267ce0e116a0">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDcvZnJhZzoyMDI3Y2EzMTNlNzg0NmVlOWJhNDAwZjBiMjZlZTIyZC90ZXh0cmVnaW9uOjIwMjdjYTMxM2U3ODQ2ZWU5YmE0MDBmMGIyNmVlMjJkXzE5Ng_f060c318-be59-4eb6-9ed5-b1d33fab2f4f">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTMvZnJhZzoyZGMwMmVmNDY5MmU0YmE0ODI2MGZlOGJhYzVlNGU5OS90ZXh0cmVnaW9uOjJkYzAyZWY0NjkyZTRiYTQ4MjYwZmU4YmFjNWU0ZTk5XzE0Ng_c65b3fd6-8d44-427f-9761-97dbe3089d2b">no</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="4" name="dva:PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTkvZnJhZzphMWUyMDc3M2FmYjI0ODEwOTBjNTgwNzcwOTUwZGEyZC90ZXh0cmVnaW9uOmExZTIwNzczYWZiMjQ4MTA5MGM1ODA3NzA5NTBkYTJkXzgz_017e5bd4-65ba-49d3-8334-727b34548184">1.00</ix:nonFraction><ix:nonNumeric contextRef="i4bf82d2c8c7245f0a5bfe4df7220299e_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzY1_9bd5be62-eaa6-445b-abc6-e1e708ba188d">2036-12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8971b1ec05a244ceae22db238af44623_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzEwOQ_4972656b-fa8c-4927-8e9d-8971564a8f46">2029-12-31</ix:nonNumeric><ix:nonNumeric contextRef="i31f2351c37ba47eda635e1d9ce143c6a_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzE3OQ_ab3ae432-32fc-4aaa-aa77-808b356fa18e">2042-12-31</ix:nonNumeric><ix:nonNumeric contextRef="i34cd3fc8f85743c48fd5c0975951ea19_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzI1MQ_5fb7cbc5-47a4-42bb-a3ec-727a0198de1a">2023-12-31</ix:nonNumeric><ix:nonNumeric contextRef="i3287ae4a62414418844751404b975d19_D20220101-20221231" name="us-gaap:TaxCreditCarryforwardExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzM2Mg_8973a952-452c-4182-ba47-fba38e19f5be">2024-12-31</ix:nonNumeric><ix:nonNumeric contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be">http://fasb.org/us-gaap/2022#InterestAndDebtExpense</ix:nonNumeric><ix:nonNumeric contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf">http://fasb.org/us-gaap/2022#InterestAndDebtExpense</ix:nonNumeric><ix:nonNumeric contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7">http://fasb.org/us-gaap/2022#IncomeTaxExpenseBenefit</ix:nonNumeric><ix:nonNumeric contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_155f47b5-2149-4835-8f82-29569b70bc53">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_6bdf6749-42f6-44d7-86f8-0f1107e1b206">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzky_e2879539-8c2e-4337-98c6-8334143f0e09">1</ix:nonNumeric><ix:nonNumeric contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzk4_088db54a-3f7b-462a-8088-20c441d5eff9">2</ix:nonNumeric><ix:nonNumeric contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzE2Mw_322d8253-1623-4a22-9c2c-2ca6557fe34c">3</ix:nonNumeric><ix:nonNumeric contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzE2OQ_f50c8916-8bb4-4daf-980c-dd8178969ea6">4</ix:nonNumeric><ix:nonNumeric contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzE3NA_68ec31fb-0f5b-4e00-b2cd-b215d57406d3">0</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzMtMS0xLTEtNDMyMzYx_295638c8-5b01-4082-a642-756314a2ab0c">50.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzMtMi0xLTEtNDMyMzYx_93c229e6-aa26-4f40-a809-64ea57ab9355">60.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzQtMS0xLTEtNDMyMzYx_df3cf2ea-38e2-42eb-b41f-b704540ba9e4">60.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzQtMi0xLTEtNDMyMzYx_5684dfb1-aa62-4699-a442-b2294b2c0dbd">70.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzUtMS0xLTEtNDMyMzYx_aa55d987-fc98-46c4-b1fd-50302c534f13">70.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzUtMi0xLTEtNDMyMzYx_9c9701ec-5a17-4f56-bc73-9da824843a59">80.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzYtMS0xLTEtNDMyMzYx_49eb147f-0d57-407f-903a-aee0913cfc05">100.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzYtMi0xLTEtNDMyMzYx_425469b6-905b-4a01-97ef-10db06286d91">110.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzctMS0xLTEtNTM2NDYw_023d16ab-09b4-4ed8-a64c-9b16c8f6bbc4">110.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzctMi0xLTEtNTM2NDYz_990c11ef-ac1a-40d9-8934-0c12cc6db8d2">120.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i68b03430475b4c3fb8aa98e5d19c134d_D20220701-20220701" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzMxMA_9cd745d1-8849-4fe9-8ff7-d89e2938c0ab">100</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzQ5NQ_8688e474-1fdf-43bc-a94c-f64a5e165628">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzY1MA_4a6d92f5-147b-4228-bc3b-bcf75b7e0103">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzg2Ng_2c613cbd-4882-4b38-a1f1-9645ed28402f">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzkwMg_dd8c5970-080d-427b-b9d6-a57626480877">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzkzOA_a664d4df-bc87-4912-bdcc-d23f74253642">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzc2OTY1ODEzOTU4MzY_010b2c66-88d5-41d5-9c03-dc12e0cc6f88">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzc2OTY1ODEzOTU4Mzk_3b79439d-cf07-4254-bc80-3c56da347026">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i308dd243211b43dd8fa4201f3e66d956_I20201210" decimals="-3" name="dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1XzYx_953e28ab-0899-4e1b-b6b1-424cf75e62a9">329,302</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1XzIzNjM5NDk5OTk3ODY4_b1d75f13-b25f-41e5-82cb-9d150041aec6">8,095</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1Xzc2OTY1ODEzOTUxMTI_6b0980b2-57e8-4f8a-9be6-8e3cd294da63">13,877</ix:nonFraction><ix:nonNumeric contextRef="ifcfafbc8e4034cf19ed10d81cff9dd22_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzgxL2ZyYWc6YzJmNjgxNzQ0ZjczNDdmMjkwNjU4MmI4YWU5MjE4OWQvdGV4dHJlZ2lvbjpjMmY2ODE3NDRmNzM0N2YyOTA2NTgyYjhhZTkyMTg5ZF83Njk2NTgxMzk0NjUx_675d7e84-d0d8-46fc-9379-c45313900b20">0</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0Nzcz_0a0a7dff-dd24-434a-bba5-f6dc68361432">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NTYz_02a86387-9ef1-4c88-b26e-88707311fe7b">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NTgz_1f2f1dc4-5649-4cee-a511-477651f7d513">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjA1_1fb62dcb-5b9d-4de3-95ca-5f6c63b26dbc">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjA4_4200a34e-2238-47a2-8961-d2f318339d4c">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjEx_43b2fc60-30a2-45fe-88ab-19e351a81ba6">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzE1_9e56c00b-e5a6-46ae-af7c-e7b499f9e3eb">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzIy_5b916365-3cb6-4f80-accb-bcda90426e76">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzI3_13f68a1f-e31e-4727-bd5e-00a262402f6a">&#8212;</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dva-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74d2bf2b4fe417491b67a410b426f67_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia364a716386a4cb1a9c39177212dcb31_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic7cd26001e2547978cfb83fa3fade336_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe6cb82c75840eabfae089d02e1e485_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc55a2cfbea54cdea8e6196c16ac8898_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if800aa66d9654ca986d7798400011ed4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4c968889cbc45d597559733ee1e7c06_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50bdbd4176c403094afc0a6a0816442_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc1b76d4d30a4a71b13b8f4c91fb24db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a01430579214274b518179095689fae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24f4ad97c874df3a74ffade9b367052_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a7799ea30042b3b5483fabf59a20c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5116d4e90c42a2a3c059b946951971_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ebc619161a4e329c3ae8f647a68ea0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50da97fe1b274f648672b559db7812e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09cbd163c566489c8ab76a850aeba968_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c4cc40ee544f8d8fc58a0361ea6027_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d2f751df2e4644ba91a72008a0765e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i757a0e9ab6594add994f294dd3cdbf66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5427ec717e8648059aadaee70b6593f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72de044ff982442ba895166a41f82244_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27174288e0445f8870a700e378d7299_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4eaf9f852e421fbf29ec7d95adf14a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab32047366140518741cdd1c29b2986_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387afcd55d3346499dfe079c68d6aafd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d81a8050455482f899360e81a78be21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6896e2941a48e2963273fd62c1f8a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99bfee231c604920b47c088b54ff3344_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if842ebd0fa3647a485eee028263590d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50253e4de73648958a1dc9b043930734_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbaa5362c6b426aa3e151ee9c01964c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice9acef4149d442db28cf471388f4e4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ec121281ae42de864df9afaf5bbce5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i356a876fece547c98e1997006099bed6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55b58bdbade49e9b33062b2a125387c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf95daa74ecc406b87ec09f0ad0760f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260caeb3a4e44b659a7def8d723d8f28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f29989a080c4de4b210d915a9c0f8ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea9631c41ae445d9079a93421c94e37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>dva:clinic</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>dva:state</xbrli:measure></xbrli:unit><xbrli:context id="icf6d468c617d466c8c07ffbf3361572d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>dva:patient</xbrli:measure></xbrli:unit><xbrli:context id="ib6392b172fe84693a759b4ef47376ca3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie34b55b3589b41aa8b4dc4e6ab94e9e7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>dva:country</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="entity"><xbrli:measure>dva:entity</xbrli:measure></xbrli:unit><xbrli:context id="id71233621bbd4804ad59b2cce80ee34a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2c1e7f78214f40be85e6cb8292eb45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61831cf914934370a0e350538f48dd0e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a634cd0d2347eeba744537d4975ff3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e37ec44c0d4b32bdf6a4f6631a509d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c1650937a14aa6b693db780617d335_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a5fb336b324120926fdf3e7acd509f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd379d095ba4b25a0520096ae331749_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46a5e0f67ed4bad96cbd9179fa563a0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7b6a5928a24b238a1f7131f1574774_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a984146d6674799aba080454fdc2cda_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia742be54e94c45f2b3dd8ff5d6c056e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b009a1142c248539196c3fba5d59fb2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice87a48ce280447786bdab788445cea5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd3f694f7e44856ae0923f71f737ae4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482fd86c04c1456c8e86866bab4d7940_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e08b129ee741c09e555e16d959b1c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da226c056b94d07adbacb4d2befd882_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic954305add924c439027278f45b35571_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23acb46414744f3295a01b88b12f0852_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed0d2be726f4c74911502d210cc0c64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafefc99a68e9484292f1297292ffcc0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4439bdfa6abe4378a88454a4104bf810_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c2f5e21bcf4d3c8ee4481538d06f47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1724a3d8642c4b77958c204145d9b59e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6a7965dcd6428eb9c75d5330f6c0fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6712e682bfcc4d9f8819cac2f889a384_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15e5f5845074315a06e0d1ae4277176_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b6e5a2190441af8606765112836eee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca689ecc20e4fe0876e7b122b0bc25a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94685d28e10e4104afa0fc7accb57c02_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71b76b330e14df99ec3824e8fc1d7c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife78a29c23534d2a8188fe47f55108a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bfd61b594e04154b072d87e97ad8774_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bb8de9b00141a78c540283fa20d761_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3ef454cab24926be400fa579222ae9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77373f4271f44dbfa26dd7f49f949448_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55cc0568452c48b58599e76cbde4fd51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1cf19f60904659aa80c183b19b6dfb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4e3d014e894c2994a8742fc9556a3c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ab9fa77fa447caa055395318311262_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892eb918a47245d0a1e1b8efd2c4dc9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ddfba6879ce435ea2183e425ab9fb97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedf8dbec52a412e999eb8b8b3560486_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88924eaa86cb4ed39e38a15a834b05ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af410a4e989429d8103daa89df89d50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472c110640b34063a31c98fa592e7be7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b372339e32a430185d84a645290c6a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61e6177dbf07446383109217efb2dbd7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0dedc540e3748a180d94fe4b0c46a64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a7a6c01df54ffe95479935e6df2ee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a47a9e4ba544f1a9cd835d606410ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2adb818e8c884ebf9a40f34a6969b8d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96447c36e9e04484a7110d4eb4997b4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33e8b9fed27435c92a9faac2bd00b84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59ac085dc65418aa4e73ffc69429588_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40279a50dc004485905b9258f9cbe2dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780f1053c3cd4049860e874c14a7dd7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3212e1642e634c7ead8a2a1478b91244_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea71308947784543a7b3e618b843de25_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb851214d4345d1be8b32b72599be61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d843ebfcaa422a8ad48b287a882104_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d812bfa6d44d2987c3fd8e4134ce1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144a4dea34854fafa070bc26e0c1c022_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42361f6c10f406ea541fb7608221768_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c06c7b0e13047ef8e5353fe708bc498_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8a01cb9b6b4aa392aba562922d863e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763a119f616d4f0a8615b9b7ca2e724e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4342659ff7e0470e9df98f9b56908101_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae02ab521c84469d86508390fd7a2b8e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238f0b81bcfc460493a2272e9df9e660_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328084074c6a4e6a80b7d005923141b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ecc37a255b4ec79a6f4852457f2d7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5af4c78b3b84e59a62c25b4a0b8ba0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2d73ec57c84c15a3ad9c06782360e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aeafde1efc8421883fbe844a5ce2e26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957d7a2748724eb48b7c1a29ca66b93f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6927c570b591490ab67989e54cd02d0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868f0061ea624c47a87a5ed4482b8464_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07190fe863941af86705544dac7d29b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6a5d60792446838c6c118846730304_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id383f000ec994776adc163ceb21acbe7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4245725066c542b0a93347f794776227_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc19a6487a1842f39d795710dd4036dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8f487f85e74665806c5ec5125515e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59795d3026d44baeac66a9a81a351db4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b96f4bb392e462a82c7894ad36ec7d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92052f136ae48a8bd74fbaa0981d8de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc23e84f52624cb8b52bf0d015a4c3cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f8d1d725f847c09697e3d7b2b29851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9910e7304043403ca7bd1e6601890eba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8eba1380104ea6b216ee60a45a6e69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6523b9338e417b9035c6d604cf594a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:KidneyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf00b273a4bf4c79a1f721b650d77572_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:KidneyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911a2957827b44d79670188c18f6906f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dva:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0836866414f4437aac5b49b4350f9953_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e50d4b1d0e45d6998ef4a07f8412ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eace4b400364cb59a814210aca461e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b49cc670fc4f9b8a4a550217fc1379_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71d18b327ea4b429a6ba95d6c567050_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1f2af5eec44aa990c6433dc345a841_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9728c466394b4bc781a51da4125c31a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d510a76f30a4b18aeb57c119e82770e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0ee4ace34040a89985a562a8e65295_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf82d2c8c7245f0a5bfe4df7220299e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8971b1ec05a244ceae22db238af44623_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f2351c37ba47eda635e1d9ce143c6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34cd3fc8f85743c48fd5c0975951ea19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3287ae4a62414418844751404b975d19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606724ebb1074323bb48035cf6c598e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc4a5e5db954ccca57e0719d248d746_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddb2df1c2114de4a00fc604f1818904_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f13844d63440249e54982f46346b77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280e7c36267346f08232e69492322e25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e791ab248d24b63ae1da6cdf0df3eac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c2ea2f7c8b2414aaeb0fb9101c24607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e6ab0c8af4453689dd47207d80b526_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6d0ad8a3f149508ef910626c9379bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice20b77c90c04919a53292886212c09a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9c869de9534500954d1a4145291638_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c1764e202c483caac7e78fb4caf1b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d6664946ac4659978bc717989aed3f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d42086277b545f8973c9e4cd170ecc1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69de63a548f40878bfa7836ee961e78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94226c5496c4dc189b0f57a7e9d5b37_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711f403972ec4e66b0f07af1bd51bd85_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14241465c6d496e9fcbffe2bb81a4a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6332787d61e14213968fc6c3ed4533b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509b9358d5b848688db2af3f7c28f677_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAAndTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b283e992d44d15924be874a7cb3008_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAAndTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53250a642d1d4d75b53407d691d20e86_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia154eee2b5544902b0df5b93083def6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a6df8d1ce4240b99834c54100161749_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1024fd068b4449894448967a76d43e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bee71915f974aae9db45279fca80f9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4359a0f4c2824bf89e0c1d35492c622d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4946c95eb8498498d19a6faf87f113_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26fc0451360e403f820f0bba263549a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d695e6974549e6abbf008246487b2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5680e5007324449948b894d87e40d7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a6f14a780d4294baf4b2885e32978d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ab07f87a174fb2b7c3fee62cf056b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eff9aaeed62457e946eb316f31451f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9860868c23e043df847009e53cc53fdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61afa366cd62422b84371143b00ef79c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a6007fcdfb46cd8c45962e916984df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa80e3707e984cba98b264df4ba470fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94215c12b694944b79ef5ea39279483_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">dva:IncrementalCashPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569c0d52c6c6426faf8f5a35ede23d64_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">dva:CashPaidForPortionPreviouslyRefundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8274525480784946977c6314bbd7cc5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia707dbef043d49869bd8d75dec1d7c30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d73225bc934812a0e7e7641b1ce671_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a660eca1df4c6aac1cebc8b4113bc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7063491894094779acab6b28c5595e90_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75140de7fc2e44a4aae6591587030c31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2232a592ba45f98e9d502b586f1a60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5730e25527b841269e9c3b2c7b43ecbe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9218664971064274b79221f47df0c986_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bbcbd8a1eca4275a3ad805b14ce01b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d31f8da40914157a9a538177f086aea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9b576fd9a14515a102d4388e16984e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8065cc2fe8ad46cbbb4359c02e4ac3e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1e88888ab0427c992c8ee57d880fb7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473afde79b764c408f9a11119b563a06_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129545bae5ea4b86ba4108e9bde79749_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654c073e58bd41ae9d35684155b57deb_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i965432f8e1b1446f8d9cafc77f04fd6c_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6f172bac13b435484bfaf9fd3326e51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c9f860645046bd9f1febf1ee03749e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f354c25ca54754ab7b68f40dbd8a25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b03430475b4c3fb8aa98e5d19c134d_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee7f88346f374e438ede97086d426ca0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302d6e3229584f9787a6db6278186655_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf6a41128b04e829699ee3d9fad57ea_D20230101-20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308dd243211b43dd8fa4201f3e66d956_I20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42ecc99f0d34577b08bc4c77cf7a127_I20211217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70bc0dc3fda4a9fa940a388d85df82f_I20230221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99212cfd5b704e42ae8a23d830c5ab06_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4fb47b5503432094dda9552d7403d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b572b098200416eae5a1f8ac48e51d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023504d2da28478aa67984abd4233153_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3e2cfd5fd0429fb8ec56a202d18e12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db34850cf9c4bd1bf445296b1937a89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc719a947474ef084095e5dfbf5b1c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a8cf8431a94b6e8121190341001e59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b284e90b0e45778d854e5fc253a04f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d50e013b4f49c4ba46a1b25f6ce76f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a9b7a989584fa9b3645a2917356a30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26689de70cd749e4bc3293f6430b6501_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c27b8943f04af2b168da521c4dad46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26972a338b914625b313ef3169a93850_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d904111572c45258967451eb747b670_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49bba0c859f547afb380af3db15e5fbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i947410d04b404a509e32155ef061b479_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61bd7246d2204fc68658398f4ea88ed1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e816800cdb849e580bc97b00a96ade9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic2"><xbrli:measure>dva:Clinic</xbrli:measure></xbrli:unit><xbrli:context id="i9679bed327fc47d683813151fab6f1c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82caecf20efa484fb484a9604065ba79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70356fef993349ccbcc20e9d53a0537d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e5796ea824458fa6ca00e78cc84d11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e45f52112ed4e3c8f797f4c3e373333_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c876b3393e45aaadb4d03fd8cb132a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68ddedfe24d4a9f821e723337f057fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d9e6f88ef54849931ad26b2c3ccf31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1896d04bb1d34718b1f5a2d8398d5ca2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabeffcbc0b614275bf1f744a78a560d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0d0c8670b74d7aaae012b57540676b_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:RMSLifelineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19082384d6a4829ab61b3ab014ad7e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f53c09daa64d04b0b10d609326db79_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida34ede3bf60405f897e4559cf454b17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id450bd55eefa4117ababbc01a3cfbd33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6457f2f67848de859ac828fdbb8f3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcfafbc8e4034cf19ed10d81cff9dd22_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c251fa7a54142a9973f90b0af23a71a_D20190619-20190619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-19</xbrli:startDate><xbrli:endDate>2019-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2f49e543f14e95b6a4a28258a7479f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e67f2857a248e185adf3684768570e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55269373013d4ffc8c433eda840a84cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dva:CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc02c497e38f44dc90b9f84485fef045_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733bd4e24d7945f59bb981466bfb570e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e33e8346e24560ba9aa3c4a675008e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415b7bb770484bd0a68b62ea80a8dd97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05471993207b46e89aa70bd43a844aa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046167613ae64ec19f2ed82f74f07980_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f207592fe4649a4ad1c7bf0d4621f61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f1beaedb6546c7b32d23163c1577ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8717705e768d484989644fafcac6b11f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6032b5bb440b4d2795466e62c1aa5b59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d883f152f344fb4961979059e6695af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826c5858f92b46e7947460dfd1f33a3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0935c6e63e743ba9aba751b24c6f1de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5df7fafeef499c84ae47517afbb88c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2dfed1ea6e4e64a2d2a32df8448e91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde9a8c8bca04d5b852b3c6a3f47238c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib664746092484ebf93084b60e56443b0_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ac6f3c4f74f8ea1b571333627e886_D20190619-20190619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-19</xbrli:startDate><xbrli:endDate>2019-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7536f3521c54e9294023219e56f7c64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9e8067c67e4837babe07d810db9729_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac2a354bfd74090958bcef5319b2038_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ea4a40bae848aca9676ecbe296c2bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472575aaaeaa4644bf500b85f08f09c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i850cdf3eed294766a58ed299ab32d0dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13805c203e1b4b8b917db178e9c4d6dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d986fd59a394b0faac51a4aa5076ed3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fb71602ed14a41843e5942b0069a19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib228226ec511491b87b183c6d217a21a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.138%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI0_97db0f44-d022-481a-88ea-60bb8c8eba8d">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NjJkZjJkY2ZkODU1NDllYTg2OGFkNTEyOTc0YzQyNzAvdGFibGVyYW5nZTo2MmRmMmRjZmQ4NTU0OWVhODY4YWQ1MTI5NzRjNDI3MF8wLTAtMS0xLTQzMjM2MQ_5cb0c0cd-13f0-49b0-96d7-c2dcc4154902">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8xMjQ_91b4b6f4-21c4-4267-9bc3-7e002be91acc"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8xMjQ_98181737-6595-4704-b731-6d86826f25c3">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:22.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDczM2FmODkxZGY4NGM4NmE3YzZhY2JlMDhjMzU1ODAvdGFibGVyYW5nZTowNzMzYWY4OTFkZjg0Yzg2YTdjNmFjYmUwOGMzNTU4MF8wLTAtMS0xLTQzMjM2MQ_17a33611-7d7f-45b6-9933-c83293e38b66">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDM0_aaee72a3-5e1d-471b-828d-922a7a4d42ae">1-14106</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><img src="dva-20221231_g1.gif" alt="dva-20221231_g1.gif" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI5_63e62e4e-9b52-40b7-ab33-cf69d044c587">DAVITA INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:244.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:16.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:244.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NTk0YWFiODI4MmY1NGQ0ZDhlM2UzNTg4MGIzOGNlOTkvdGFibGVyYW5nZTo1OTRhYWI4MjgyZjU0ZDRkOGUzZTM1ODgwYjM4Y2U5OV8wLTAtMS0xLTQzMjM2MQ_8bf5d98b-508f-4be9-974d-245d09515632">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NTk0YWFiODI4MmY1NGQ0ZDhlM2UzNTg4MGIzOGNlOTkvdGFibGVyYW5nZTo1OTRhYWI4MjgyZjU0ZDRkOGUzZTM1ODgwYjM4Y2U5OV8wLTItMS0xLTQzMjM2MQ_59daa0a4-fd57-4137-9411-b2f3094304d9">51-0354549</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.50pt"><tr><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:30.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8wLTAtMS0xLTQzMjM2MQ_9da88a2e-d3fb-4fe5-a911-752b8c67c0ae">2000 16th Street</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTAtMS0xLTQzMjM2MQ_27e5eb06-fb85-46f0-b9fb-114e975325e5">Denver,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTEtMS0xLTQzMjM2MQ_6c6f2bdf-7a8b-4bb2-8fe1-8208a54f210f">CO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTItMS0xLTQzMjM2MQ_a6388923-3302-443a-b528-554996ab48e2">80202</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Telephone number (<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI1_8356f216-2ab3-486d-9625-75022663248a">720</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMw_5964701b-2e85-4289-993b-0086d5ace0ac">631-2100</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:30.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTAtMS0xLTQzMjM2MQ_548434ac-0363-4f9a-a14e-0a917c17a3b2">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTItMS0xLTQzMjM2MQ_cde08074-6797-48f6-b562-9ec1d79f1328">DVA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTQtMS0xLTQzMjM2MQ_15809f37-8092-4cf0-9931-b6e44ecacf13">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIy_2ceb4d22-51f7-4538-9cd4-2a699d8eeb42">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMx_75addd92-960a-4677-8743-2733f7d30c75">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI2_5a414cb2-6cba-472f-be8b-babe6d3d4847">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMy_a1275fd5-1797-4c1c-abec-dd951888296a">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:127.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18wLTAtMS0xLTQzMjM2MQ_b331db37-3d79-472b-8049-896fa89dfae4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18xLTUtMS0xLTQzMjM2MQ_939f0df8-925c-4b57-8c54-8879886b3efb">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18yLTUtMS0xLTQzMjM2MQ_8ab2ded2-e3b6-470f-9315-f9d4631b0f16">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its final report.     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIx_a66b1fe6-9817-46f6-91cb-a8c5eae2f8fa">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIz_20a35594-91c3-4d13-b392-3c56a0be8357">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the aggregate market value of the registrant's common stock outstanding held by non-affiliates based upon the closing price on the New York Stock Exchange was approximately $<ix:nonFraction unitRef="usd" contextRef="ic74d2bf2b4fe417491b67a410b426f67_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8yNjk4_3da2dba6-a340-4cf4-a066-1236a34fa537">7.4</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of January&#160;31, 2023, the number of shares of the registrant&#8217;s common stock outstanding was approximately <ix:nonFraction unitRef="shares" contextRef="ia364a716386a4cb1a9c39177212dcb31_I20230131" decimals="-5" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8yNzk2_9bf4fced-0062-40d6-bd5d-af41040aa9e4">90.4</ix:nonFraction> million shares.</span></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents incorporated by reference</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s proxy statement for its 2023 annual meeting of stockholders are incorporated by reference in Part III of this Form 10-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.230%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_13">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_58">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_58">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_136">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_136">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_139">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_139">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_142">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_142">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_145">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_145">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_151">Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_151">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_154">Reserved</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_154">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_157">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_157">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_205">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_205">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_208">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_208">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_211">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_211">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_214">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_214">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_217">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_217">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_220">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_220">78</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_226">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_226">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_229">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_229">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_232">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_232">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_235">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_235">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_238">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_238">80</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_244">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_244">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_247">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_247">81</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_382">Exhibit Index</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_382">1 of 4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_385">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_385">S-1</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ib228226ec511491b87b183c6d217a21a_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.</span></div><div id="ib228226ec511491b87b183c6d217a21a_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of DaVita Inc.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. We are one of the largest providers of kidney care services in the U.S. and have been a leader in clinical quality and innovation for more than 20 years. We care for our patients at every stage and setting along their kidney health journey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including earlier diagnosis and prevention, supporting the transplant process, helping with end of life and ensuring they are supported at home, in our dialysis centers and in the hospital and/or skilled nursing facilities. We are committed to bold, patient-centric care models, implementing the latest technologies and advancing integrated care offerings. We have established a value-based culture with a philosophy of caring that is focused on both our patients and teammates. This culture and philosophy fuel our continuous drive toward achieving our mission "to be the provider, partner and employer of choice."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five stages of chronic kidney disease (CKD). These stages are generally based on how well the kidneys work to filter waste and extra fluid out of the blood&#8211;with higher stages of CKD corresponding to progressing levels of kidney disease. Stage 1 CKD is the closest to healthy kidney function. Stage 5 classification indicates that a patient has severe kidney damage.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patient diagnosed with Stage 5 CKD has kidneys that have lost nearly all functionality or have failed. If the patient's kidneys fail, they are then diagnosed with end stage renal disease (ESRD), also known as end stage kidney disease (ESKD). Because loss of kidney function is normally irreversible, ESKD patients require continued dialysis treatments or a kidney transplant to sustain life. Dialysis is the removal of toxins, fluids and salt from the blood of patients by artificial means. Patients suffering from ESKD generally require regular life-sustaining dialysis therapy for the rest of their lives or until they receive a kidney transplant. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treatment goal for CKD patients prior to Stage 5 is to manage and slow the progression of the disease to preserve kidney functionality. Because kidney failure is typically caused by Type I and Type II diabetes, hypertension, polycystic kidney disease, long-term autoimmune attack on the kidneys and prolonged urinary tract obstruction, slowing the progression generally involves working with nephrologists or dieticians to help control blood pressure, monitor blood glucose and maintain healthy diet and exercise routines, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our businesses</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the two largest dialysis providers in the United States. Our U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, ESKD, in the United States, and is our largest line of business. Our robust platform to deliver kidney care services also includes established nephrology and payor relationships. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2022, our international operations provided dialysis and administrative services to a total of 350 outpatient dialysis centers located in 11 countries outside of the U.S., serving approximately 45,600 patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our U.S. integrated kidney care (IKC) business provided integrated care and disease management services to 42,000 patients in risk-based integrated care arrangements and to an additional 15,000 patients in other integrated care arrangements across the United States as of December&#160;31, 2022. A majority of the patients served by our integrated care business are also our dialysis patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain a few other ancillary services and investments outside of our U.S. dialysis, U.S. IKC, or international operations, which we refer to as our U.S. other ancillary services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to our U.S. integrated kidney care business, U.S. other ancillary services and international operations as, collectively, our "ancillary services." We also have a separate corporate administrative support function that supports our U.S. dialysis business and these ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of our businesses are described in greater detail in the sections that follow.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our care model</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care. We believe that the flexibility we offer coupled with a focus on comprehensive kidney care supports our commitments to help improve equitable clinical outcomes and quality of life for our patients. According to the most recently published data, for eight consecutive years, we have continued as an industry leader in the Centers for Medicare &amp; Medicaid Services&#8217; (CMS) Quality Incentive Program (QIP), which promotes high quality services in outpatient dialysis facilities treating patients with ESKD. In addition, according to the most recently published data, for seven consecutive years, we have also continued as an industry leader under CMS&#8217; Five-Star Quality Rating system, which rates eligible dialysis centers based on the quality of outcomes to help patients, their families, and caregivers make more informed decisions about where patients receive care. We are also among the early leaders in the ESRD Treatment Choices (ETC) Model, which was launched by the CMS Center for Medicare and Medicaid Innovation (CMMI) in January 2021 with the stated intent to "encourage greater use of home dialysis and kidney transplants for Medicare beneficiaries with ESKD, while reducing Medicare expenditures and preserving or enhancing the quality of care furnished to beneficiaries with ESKD."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value-based arrangements are proliferating in the kidney health space. These arrangements are allowing for a much larger degree of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between nephrologists, providers, and transplant programs, resulting in a more complete understanding of each patient&#8217;s clinical needs, which we believe leads to better care coordination and earlier intervention. Our IKC business is an active participant in CMMI&#8217;s Comprehensive Kidney Care Contracting (CKCC) model that seeks to manage the care of late stage CKD and ESKD patients to delay the progression of kidney disease, promote home dialysis, and incentivize transplants. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality clinical outcomes are driven by our experienced and knowledgeable caregivers. We employ registered nurses, licensed practical or vocational nurses, patient care technicians, social workers, registered dietitians, biomedical technicians and other administrative and support teammates who strive to achieve superior clinical outcomes at our dialysis facilities. In addition to our teammates at our dialysis facilities, as of December&#160;31, 2022, our domestic Chief Medical Officer leads a team of 23 nephrologists in our physician leadership team as part of our domestic Office of the Chief Medical Officer (OCMO). Our international Chief Medical Officer leads a team of nine nephrologists in our physician leadership team as part of our international OCMO as of December&#160;31, 2022. Our OCMO teammates represent a variety of academic, clinical practice, and clinical research backgrounds. We also have a Physician Council that serves as an advisory body to senior management, which was composed of 10 physicians with extensive experience in clinical practice and five Group Medical Directors as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, we completed the sale of our prior DaVita Medical Group (DMG) business, a patient and physician-focused integrated healthcare delivery and management company, to Collaborative Care Holdings, LLC, a subsidiary of UnitedHealth Group Inc. As a result, the DMG business has been classified as discontinued operations and its results of operations are reported as discontinued operations for all periods presented in the consolidated financial statements included in this report. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information about DMG, see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note 22 to the consolidated financial statements included in this report.</span></div><div id="ib228226ec511491b87b183c6d217a21a_19"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 and its impact on our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a caregiving organization, we are impacted by continued and compounding effects of the coronavirus (COVID-19) pandemic. We continue to closely monitor the impact on our business of the pandemic and the resulting economic and political environment, including the various impacts on our patients, teammates, physician partners, suppliers, vendors and business partners. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our top priorities continue to be the health, safety and well-being of our patients, teammates and physician partners and helping to ensure that our patients have the ability to maintain continuity of care throughout the pandemic, whether in the hospital, outpatient or home setting. To that end, we have dedicated and continue to dedicate substantial resources in response to COVID-19, including the implementation of additional protocols and initiatives to help safely maintain continuity of care for our patients and help protect our caregivers and provide access to vaccinations. These protocols and initiatives include, among other things, policies to implement dedicated care shifts for patients with confirmed or suspected COVID-19 and other enhanced clinical practices. These efforts are part of our wider Prepare, Prevent, Respond and Recover protocol that includes operational initiatives such as the redistribution of teammates, machines and supplies across the country as needed, increased investment in and utilization of telehealth capabilities, and administration of COVID-19 vaccines. These initiatives have increased our expenses and operational complexity, and also may involve increased execution and compliance risks.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the ultimate impact of this pandemic on the Company will depend on future developments that are highly uncertain and difficult to predict. For additional discussion of the COVID-19 pandemic and our response, including its impact </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on us and related risks and uncertainties, please see the discussion below under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Capital Management,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the risk factor in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"and the discussion under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19, General Economic and Marketplace Conditions, and Legal and Regulatory Developments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div id="ib228226ec511491b87b183c6d217a21a_22"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis business is a leading provider of kidney dialysis services for patients suffering from ESKD. As of December&#160;31, 2022, we provided dialysis and administrative services in the U.S. through a network of 2,724 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 199,400 patients. We also have contracts to provide hospital inpatient dialysis services in approximately 820 hospitals and related laboratory services throughout the U.S. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the United States Renal Data System (USRDS), there were over 562,000 ESKD dialysis patients in the U.S. in 2020. Based on the most recent 2022 annual data report from the USRDS, the underlying ESKD dialysis patient population grew at an approximate compound rate of 3.0% from 2010 to 2020 and 2.1% from 2015 to 2020 as compared to a decline in growth of (1.2)% from 2019 to 2020, which suggests that the rate of growth of the ESKD patient population is declining relative to long term trends. As the USRDS only presents data through December 31, 2020, it does not yet reflect the continued and compounding impact of COVID-19 on this patient base. A number of factors may impact ESKD growth rates, including, among others, mortality rates for dialysis patients or CKD patients, the aging of the U.S. population, transplant rates, incidence rates for diseases that cause kidney failure such as diabetes and hypertension and growth rates of minority populations with higher than average incidence rates of ESKD. Certain of these factors, in particular mortality rates for dialysis or CKD patients, have been impacted by the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment options for ESKD</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for ESKD are dialysis and kidney transplantation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis options</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hemodialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodialysis, the most common form of ESKD treatment, is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, in a skilled nursing facility or at the patient&#8217;s home. The hemodialysis machine uses an artificial kidney, called a dialyzer, to remove toxins, fluids and salt from the patient&#8217;s blood. The dialysis process occurs across a semi-permeable membrane that divides the dialyzer into two distinct chambers. While blood is circulated through one chamber, a pre-mixed fluid is circulated through the other chamber. The toxins, salt and excess fluids from the blood cross the membrane into the fluid, allowing cleansed blood to return back into the patient&#8217;s body. Each hemodialysis treatment that occurs in the outpatient dialysis centers typically lasts approximately three and one-half hours and is usually performed three times per week.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services are required for patients with acute kidney failure primarily resulting from trauma, patients in early stages of ESKD and ESKD patients who require hospitalization for other reasons. Hospital inpatient hemodialysis is generally performed at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some ESKD patients may perform hemodialysis with the help of a care partner in their home or residence through the use of a hemodialysis machine designed specifically for home therapy that is portable, smaller and easier to use. Patients receive training, support and monitoring from registered nurses, usually in our outpatient dialysis centers, in connection with their home hemodialysis treatment. Home hemodialysis is typically performed with greater frequency than dialysis treatments performed in outpatient dialysis centers and on varying schedules.</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Peritoneal dialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peritoneal dialysis uses the patient&#8217;s peritoneal or abdominal cavity to eliminate fluid and toxins and is typically performed at home. The most common methods of peritoneal dialysis are continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). Because it does not involve going to an outpatient dialysis center three times a week for treatment, peritoneal dialysis is generally an alternative to hemodialysis for patients who are healthier, more independent and desire more flexibility in their lifestyle. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAPD introduces dialysis solution into the patient&#8217;s peritoneal cavity through a surgically placed catheter. Toxins in the blood continuously cross the peritoneal membrane into the dialysis solution. After several hours, the patient drains the used dialysis solution and replaces it with fresh solution. This procedure is usually repeated four times per day.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCPD is performed in a manner similar to CAPD, but uses a mechanical device to cycle dialysis solution through the patient&#8217;s peritoneal cavity while the patient is sleeping or at rest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kidney transplantation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although kidney transplantation, when successful, is considered the most desirable form of therapeutic intervention, the shortage of suitable donors, side effects of immunosuppressive pharmaceuticals given to transplant recipients and dangers associated with transplant surgery for some patient populations have generally limited the use of this treatment option. An executive order signed in July 2019 (the 2019 Executive Order) directed HHS to develop policies addressing, among other things, the goal of making more kidneys available for transplant. As directed by the 2019 Executive Order, the CMS, through its Center for Medicare and Medicaid Innovation (CMMI), subsequently released the framework for certain proposed voluntary payment models that would adjust payment incentives to encourage kidney transplants. For more information regarding the 2019 Executive Order and these payment models, please see the discussion below under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care and Medicare and Medicaid program reforms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div id="ib228226ec511491b87b183c6d217a21a_25"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. dialysis services we provide</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outpatient hemodialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of our enrollment in Medicare for the provision of dialysis services, we contract with a nephrologist or a group of associated nephrologists to provide medical director services at each of our dialysis centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, typically a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total patient turnover at centers we consolidate, which is based upon all causes, averaged approximately 27% in both 2022 and 2021. The overall number of patients to whom we provided services in the U.S. in 2022 decreased by approximately 1.8% from 2021, primarily due to an increase in mortality rates, which have been impacted by the COVID-19 pandemic. This was partially offset by new dialysis patients who started treating at our centers acquired during the year.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have contracts to provide hospital inpatient hemodialysis services, excluding physician services, to patients in approximately 820 hospitals throughout the U.S. We render these services based on a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home-based dialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home-based dialysis services includes home hemodialysis and peritoneal dialysis. Many of our outpatient dialysis centers offer certain support services for dialysis patients who prefer and are able to perform either home hemodialysis or peritoneal dialysis in their homes. Home-based hemodialysis support services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance. Registered nurses train patients and their families or other caregivers to perform either home hemodialysis or peritoneal dialysis. The 2019 Executive Order and related HHS guidance described above also included a stated goal of increasing the relative number of new ESKD patients that receive dialysis at home.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the most recent 2022 annual data report from the USRDS, in 2020 approximately 14% of ESKD dialysis patients in the U.S. perform home-based dialysis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatments and revenues by modality:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph summarizes our U.S. dialysis treatments by modality and U.S. dialysis patient services revenues by modality for the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><img src="dva-20221231_g2.jpg" alt="dva-20221231_g2.jpg" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:625px"/></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESKD laboratory services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a separately licensed and highly automated clinical laboratory which specializes in ESKD patient testing. This specialized laboratory provides routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESKD patients. Our laboratory provides these tests predominantly for our ESKD patients throughout the U.S. These tests are performed for a variety of reasons, including to monitor a patient&#8217;s ESKD condition, including the adequacy of dialysis, as well as other medical conditions of the patient. Our laboratory utilizes information systems which provide information to certain members of the dialysis centers&#8217; staff and medical directors regarding critical outcome indicators.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate or provide management and administrative services pursuant to management and administrative services agreements to 56 outpatient dialysis centers located in the U.S. in which we either own a noncontrolling interest or which are wholly-owned by third parties. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the outpatient dialysis centers.</span></div><div id="ib228226ec511491b87b183c6d217a21a_28"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of revenue&#8212;concentrations and risks</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis revenues represent approximately 91% of our consolidated revenues for the year ended December&#160;31, 2022. Our U.S. dialysis revenues are derived primarily from our core business of providing dialysis services and related laboratory services and, to a lesser extent, the administration of pharmaceuticals and management fees generated from providing management and administrative services to certain outpatient dialysis centers, as discussed above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sources of our U.S. dialysis revenues are principally from government-based programs, including Medicare and Medicare Advantage plans, Medicaid and managed Medicaid plans, other government-based programs including our agreement with the Veterans Administration, and commercial insurance plans. The following table summarizes our U.S. dialysis revenues by payor source for U.S. dialysis patient services revenues the year ended December&#160;31, 2022:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.309%"><tr><td style="width:1.0%"></td><td style="width:75.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and managed Medicaid plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-based programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total government-based programs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial (including hospital dialysis services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare revenue</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare fee for service</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1972, the federal government has provided healthcare coverage for qualified ESRD patients under the Medicare ESRD program regardless of age or financial circumstances. ESRD is the first and only disease state eligible for Medicare coverage both for dialysis and dialysis-related services and for all benefits available under the Medicare program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government dialysis related payment rates in the U.S. are principally determined by federal Medicare and state Medicaid policy. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the dialysis treatment, including certain pharmaceuticals, such as erythropoiesis-stimulating agents (ESAs), calcimimetics, vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered to the patient or additional services performed. Most lab services are also included in the bundled payment.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Medicare reimbursement limits the allowable charge per treatment, it provides industry participants with a relatively predictable and recurring revenue stream for dialysis services provided to patients without commercial insurance. For the year ended December&#160;31, 2022, approximately 90% of our total dialysis patients were covered under some form of government-based program, with approximately 75% of our dialysis patients covered under Medicare and Medicare Advantage plans.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this ESRD Prospective Payment System (PPS), the bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility&#8217;s performance in specified quality measures set annually by CMS through its QIP. CMS established QIP through the Medicare Improvements for Patients and Providers Act of 2008 to promote high quality services in outpatient dialysis facilities treating patients with ESRD. QIP associates a portion of Medicare reimbursement directly with a facility&#8217;s performance on quality of care measures. Reductions in Medicare reimbursement result when a facility&#8217;s overall score on applicable measures does not meet established standards. For scoring and payment adjustment purposes in the performance year 2022 ESRD QIP, CMS determined that circumstances caused by COVID-19 have significantly affected the validity and reliability of the measures and resulting performance scores. The policies finalized in this rule are intended to ensure that these programs do not penalize facilities based on circumstances caused by COVID-19 that the measures were not designed to accommodate. In this final rule, the CMS finalized its proposal to suppress the use of certain measures impacted by COVID-19. Under these finalized policies, no facility will receive a payment reduction for 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty about future payment rates remains a material risk to our business, as well as the potential implementation of or changes in coverage determinations or other rules or regulations by CMS or Medicare Administrative Contractors that may impact reimbursement. An important provision in the Medicare ESRD statute is an annual adjustment, or market basket update, to the ESRD PPS base rate. Absent action by Congress, the ESRD PPS base rate is automatically updated annually by a formulaic inflation adjustment, but it does not always cover the actual inflationary increase. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, pursuant to the 2019 Executive Order, CMS, through CMMI, published the final ESRD Treatment Choices mandatory payment model (ETC). The ETC launched on January 1, 2021, administered through CMMI in approximately 20% of our dialysis clinics across the country.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, CMS issued a final rule to update the ESRD PPS payment rate and policies. Among other things, the rule updates payment rates under the ESRD PPS for renal dialysis services furnished to beneficiaries on or after January 1, 2023, finalizes updates to the Acute Kidney Injury (AKI) dialysis payment rate for dialysis services furnished by ESRD facilities for calendar year 2023 and updates requirements for the ESRD Quality Incentive Program. CMS estimates the final rule will affect ESRD facilities' average reimbursement by a productivity-adjusted market basket increase of 3.0% in 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Budget Control Act of 2011 (BCA) and subsequent activity in Congress, a $1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect in 2013 reducing Medicare payments by 2%, which was subsequently extended through fiscal year 2027. Federal COVID-19 relief legislation suspended the 2% Medicare sequestration from May 1, 2020 through December 31, 2021. The Protecting Medicare and American Farmers from Sequester Cuts Act, signed into law on December 10, 2021, extended the suspension of the 2% Medicare sequestration from December 31, 2021 through March 31, 2022, with 1% Medicare sequestration beginning April 1, 2022 through June 30, 2022 and 2% Medicare sequestration beginning July 1, 2022 and thereafter. While in effect, the suspension of sequestration significantly increased our revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESRD patients receiving dialysis services become eligible for primary Medicare coverage at various times, depending on their age or disability status, as well as whether they are covered by a commercial insurance plan. Generally, for a patient not covered by a commercial insurance plan, Medicare can become the primary payor for ESRD patients receiving dialysis services </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either immediately or after a three-month waiting period. For a patient covered by a commercial insurance plan, Medicare generally becomes the primary payor after 33 months, which includes the three-month waiting period, or earlier if the patient&#8217;s commercial insurance plan coverage terminates or if the patient chooses Medicare over the commercial plan. When Medicare becomes the primary payor, the payment rates we receive for that patient shift from the commercial insurance plan rates to Medicare payment rates, which are on average significantly lower than commercial insurance rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare pays 80% of the amount set by the Medicare system for each covered dialysis treatment. The patient is responsible for the remaining 20%. In many cases, a secondary payor, such as Medicare supplemental insurance, a state Medicaid program or a commercial health plan, covers all or part of these balances. Some patients who do not qualify for Medicaid, but otherwise cannot afford secondary insurance in the form of a Medicare Supplement Plan, can apply for premium payment assistance from charitable organizations to obtain secondary coverage. If a patient does not have secondary insurance coverage, we are generally unsuccessful in our efforts to collect from the patient the remaining 20% portion of the ESRD composite rate that Medicare does not pay. However, we are able to recover some portion of this unpaid patient balance from Medicare through an established cost reporting process by identifying these Medicare bad debts on each center&#8217;s Medicare cost report.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage (MA, managed Medicare or Medicare Part C) plans are offered by private health insurers who contract with CMS to provide their members with Medicare Part A, Part B and/or Part D benefits. These MA plans include health maintenance organizations, preferred provider organizations, private fee-for-service (FFS) organizations, special needs plans (SNPs) or Medicare medical savings account plans. The 21st Century Cures Act (the Cures Act) included a provision that, effective January 1, 2021, has allowed Medicare-eligible beneficiaries with ESRD to choose coverage under an MA plan. Prior to the Cures Act, MA plans were only available to ESRD patients if the patient was remaining on an MA plan that they had enrolled in prior to being diagnosed with ESRD, or in certain other limited situations such as a SNP. As a result, this provision under the Cures Act has broadened access for Medicare ESRD patients to certain enhanced benefits offered by MA plans. MA plans usually provide reimbursement to us at a negotiated rate that is generally higher than Medicare FFS rates. In February 2023, CMS released the CY 2024 MA Advance Notice (the Notice). Among other changes, the Notice contains information about potential future MA rate increases and updates certain policies associated with risk adjustments. We are continuing to assess the impact of the Notice and related MA regulations on our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under the Medicare program. Some Medicaid programs also pay for additional services, including some oral medications that are not covered by Medicare. We are enrolled in the Medicaid programs in the states in which we conduct our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, if a patient has commercial insurance, then that commercial insurance plan is generally responsible for payment of dialysis services for up to the first 33 months before that patient becomes eligible to elect to have Medicare as their primary payor for dialysis services. Although commercial payment rates vary, average commercial payment rates established under commercial contracts are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profits and all of our non-hospital dialysis profits come from commercial payors. Payment methods from commercial payors can include a single lump-sum per treatment, referred to as bundled rates, or in other cases separate payments for dialysis treatments and pharmaceuticals, if used as part of the treatment, referred to as FFS rates. Commercial payment rates are the result of negotiations between us and commercial payors or third party administrators. Our commercial contracts sometimes contain annual price escalator provisions. We are comprehensively contracted, and the vast majority of patients insured through commercial health plans are covered by one of our commercial contracts, though we also receive payments from a limited set of commercial patients that are covered by a health plan that considers us out-of-network. While our out-of-network payment rates are on average higher than in-network commercial contract payment rates, we have made efforts to be contracted with the majority of commercial payors offering health plans. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 26% of our U.S. dialysis patient services revenues and approximately 10% of our U.S. dialysis patients are associated with non-hospital commercial payors for the year ended December&#160;31, 2022. Non-hospital commercial patients as a percentage of our total U.S. dialysis patients for 2022 were relatively flat compared to 2021. Less than 1% of our U.S. dialysis revenues are due directly from patients. No single commercial payor accounted for more than 10% of total U.S. dialysis </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues for the year ended December&#160;31, 2022. See Note 2 to the consolidated financial statements included in this report for disclosure on our concentration related to our commercial payors on a total consolidated revenue basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the number of our patients under commercial plans and the rates under these commercial plans are subject to change based on a number of factors. For additional detail on these factors and other risks associated with on our commercial revenue, see the risk factors in Item 1A. Risk Factors under the headings "</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...;" "If the number or percentage of patients with higher-paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">" </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Macroeconomic conditions and global events..." </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from other pharmaceuticals</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the oral and intravenous forms of calcimimetics, a drug class taken by many patients with ESRD to treat mineral bone disorder, were separately reimbursed through the transitional drug add-on payment adjustment (TDAPA) model based on a pass-through rate of the average sales price plus 0%, before sequestration. Effective January 1, 2021, both oral and intravenous forms of calcimimetics were added to the ESRD PPS bundled payment and as a result our operating income from calcimimetics since then has been more stable as compared to the year ended December 31, 2020.</span></div><div id="ib228226ec511491b87b183c6d217a21a_31"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician relationships</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint venture partners</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and operate certain of our dialysis centers through entities that are structured as joint ventures. We generally hold controlling interests in these joint ventures, with nephrologists, hospitals, management services organizations, and/or other healthcare providers holding minority equity interests. These joint ventures are typically formed as limited liability companies. For the year ended December&#160;31, 2022, revenues from joint ventures in which we have a controlling interest represented approximately 28% of our U.S. dialysis revenues. We expect to continue to enter into new U.S. dialysis-related joint ventures in the ordinary course of business.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Community physicians</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ESKD patient generally seeks treatment or support for their home treatment at an outpatient dialysis center near their home where their treating nephrologist has practice privileges. Our relationships with local nephrologists and our ability to provide quality dialysis services and to meet the needs of their patients are key factors in the success of our dialysis operations. Over 4,900 nephrologists currently refer patients to our outpatient dialysis centers.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical directors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participation in the Medicare ESRD program requires that dialysis services at an outpatient dialysis center be under the general supervision of a medical director.&#160;Per these requirements, this individual is usually a board certified nephrologist. We engage physicians or groups of physicians to serve as medical directors for each of our outpatient dialysis centers. At some outpatient dialysis centers, we also separately contract with one or more other physicians or groups to serve as assistant or associate medical directors over other modalities such as home dialysis. We have over 900 individual physicians and physician groups under contract to provide medical director services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical directors for our dialysis centers enter into written contracts with us that specify their duties and fix their compensation generally for periods of ten years. The compensation of our medical directors is the result of arm&#8217;s length negotiations, consistent with fair market value, and generally depends upon an analysis of various factors such as the physician&#8217;s duties, responsibilities, professional qualifications and experience, as well as the time and effort required to provide such services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical director contracts and joint venture operating agreements generally include covenants not to compete or own interests in dialysis centers operated by other providers within a defined geographic area for various time periods, as applicable. These non-compete agreements do not restrict or limit the physicians from practicing medicine or prohibit the physicians from referring patients to any outpatient dialysis center, including dialysis centers operated by other providers. In January 2023, the Federal Trade Commission proposed a new rule that would generally prohibit employers from using noncompete clauses in contracts with workers that extend beyond the termination of the employment or independent contractor relationship. The proposed rule remains open for comment and a final rule has not been issued. We are monitoring these developments for any potential impact on us, including on our agreements with teammates, our arrangements with medical directors, joint venture operating agreements, or the terms of any of our existing agreements with physicians should the new rules ultimately be finalized and implemented in this area. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Location of our U.S. dialysis centers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated 2,724 outpatient dialysis centers in the U.S. as of December&#160;31, 2022 and 2,668 of these centers are consolidated in our financial statements. Of the remaining 56 nonconsolidated U.S. outpatient dialysis centers, we own noncontrolling interests in 54 centers and provide management and administrative services to two centers that are wholly-owned by third parties. The locations of the 2,668 U.S. outpatient dialysis centers consolidated in our financial statements at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:9pt"><img src="dva-20221231_g3.jpg" alt="dva-20221231_g3.jpg" style="height:461px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div id="ib228226ec511491b87b183c6d217a21a_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services, including our international operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ancillary services relate primarily to our core business of providing kidney care services. As of December&#160;31, 2022, these consisted primarily of our U.S. integrated kidney care (IKC) business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and continue to make investments in building our integrated care capabilities, including the operation of certain strategic business initiatives that are intended to integrate and coordinate care among healthcare participants across the renal care continuum from CKD to ESKD to kidney transplant. Through improved technology and data sharing, as well as an increasing focus on value-based contracting and care, these initiatives seek to bring together physicians, nurses, dieticians, pharmacists, hospitals, dialysis clinics, transplant centers, payors and other specialists with a view towards improving clinical outcomes for our patients and reducing the overall cost of comprehensive kidney care. Certain of our ancillary services are described below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Integrated Kidney Care</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Integrated Kidney Care.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;VillageHealth DM, LLC, also doing business as DaVita Integrated Kidney Care (DaVita IKC), provides advanced integrated care management services to health plans and government programs for members/beneficiaries diagnosed with ESKD and CKD. Through a combination of health monitoring, clinical coordination, innovative interventions, predictive analytics, medical claims analysis and information technology, we endeavor to assist our health plan and government program customers and patients in obtaining superior renal healthcare and improved clinical outcomes, as well as helping to reduce overall medical costs. Integrated kidney </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care management revenues from commercial and Medicare Advantage insurers can be based upon either an established contract fee recognized as earned for services provided over the contract period, or related to the operation of risk-based and value-based programs, including shared savings, pay-for-performance, and capitation contracts. DaVita IKC also contracts with payors to support Medicare Advantage ESKD special needs plans to provide ESKD patients full service healthcare. DaVita IKC supported our ESKD seamless care organizations (ESCO) joint venture programs until their completion in 2021, and DaVita IKC has commenced participation in both the involuntary and certain voluntary payment models administered by CMMI. As further described below under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", the Company has invested resources, and expects to continue to invest substantial resources in these models as part of the Company's overall plan to grow its integrated kidney care business and value-based care initiatives. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company's consolidated financial statements for more information on how the Company accounts for its integrated care arrangements.</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing, and has entered into, various forms of technology-based, administrative, financial and other collaboration and incentive arrangements with physician partners and other providers in support of our innovation, developing and expanding integrated kidney care programs and arrangements.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Physician services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Nephrology Practice Solutions (NPS) is an independent business that partners with physicians committed to providing outstanding clinical and integrated care to patients. NPS provides nephrologist recruitment and staffing services in select markets that are billed on a per-search basis. NPS also offers physician practice management services to nephrologists under administrative and management services agreements. These administrative and management services include physician practice management, billing and collections, credentialing, coding and other support services that enable physician practices to increase efficiency and manage their administrative needs. Fees generated from these services are recognized as earned typically based upon flat fees or cash collections generated by the physician practice.</span></div><div style="margin-top:9pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Other Ancillary services</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita Clinical Research (DCR) is a provider-based specialty clinical research organization with a full spectrum of services for clinical drug research and device development. DCR uses its extensive, applied database and real-world healthcare experience to assist in the design, recruitment and completion of retrospective and prospective pragmatic and clinical trials. Revenues are based upon an established fee per study, as determined by contract with drug companies and other sponsors and are recognized as earned according to the contract terms.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transplant software business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita's transplant software business, MedSleuth, works with transplant centers across the U.S. to provide greater connectivity among transplant candidates, transplant centers, physicians and care teams to help improve the experience and outcomes for kidney and liver transplant patients. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Venture Group. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Venture Group (DVG) focuses on innovative products, solutions and businesses that improve care for patients with kidney disease and related conditions. DVG identifies companies and products for acquisitions, strategic partnerships, and venture investment opportunities. DVG&#8217;s focus includes innovation in digital health, pharmaceuticals, medical devices, and care delivery models. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our ancillary services, see Part II, Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International dialysis operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated 350 outpatient dialysis centers located in 11 countries outside of the U.S. serving approximately 45,600 patients as of December&#160;31, 2022. Of these 350 dialysis centers, 299 are consolidated in our financial statements and we own a noncontrolling interest in the remaining centers. Our international dialysis operations have continued to grow steadily and expand as a result of acquiring and developing outpatient dialysis centers in various strategic markets. Our international operations are included in our ancillary services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the international outpatient dialysis centers we operate were located as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:67.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes centers that are operated or managed by our Asia Pacific joint venture (APAC JV).</span></div><div id="ib228226ec511491b87b183c6d217a21a_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of labor, benefits and long-term incentive compensation costs and professional fees for departments which provide support to all of our different operating lines of business. These expenses are included in our consolidated general and administrative expenses.</span></div><div id="ib228226ec511491b87b183c6d217a21a_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government regulation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state and local governmental laws, regulations and other requirements. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. Additional discussion on certain of these laws, regulations and other requirements is set forth below in this section.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows. The consequences could include, among others:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of required certifications, suspension or exclusion from or termination of our participation in federal or state government programs (including, without limitation, Medicare, Medicaid and CMMI demonstration programs);</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions in payment rates or coverage for dialysis and ancillary services and pharmaceuticals;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal or civil liability, fines, damages or monetary penalties;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of corporate integrity agreements, corrective action plans or consent agreements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by governmental agencies and/or state law claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including, among others, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Privacy Act of 1974; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations or audits by government agencies and/or initiated by qui tam relators related to interoperability and related data sharing and access requirements and regulations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated changes to our practices or procedures that significantly increase operating expenses that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices, which could lead to potential fines, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of various relationships and/or contracts related to our business, such as joint venture arrangements, medical director agreements, hospital services and skilled nursing home agreements, real estate leases, value based arrangements, clinical incentive programs, payor contracts and consulting or participating provider agreements with physicians, among others; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Harm to our reputation which could negatively impact our business relationships and stock price, our ability to attract and retain patients, physicians and teammates, our ability to obtain financing and our access to new business opportunities, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our industry will continue to be subject to extensive and complex regulation, the scope and effect of which are difficult to predict. We are currently subject to various legal proceedings, such as lawsuits, investigations, audits and inquiries by various government and regulatory agencies, as further described in Note 16 to the consolidated financial statements, and our operations and activities could be reviewed or challenged by regulatory authorities at any time in the future. In addition, each of the laws, regulations and other requirements, including interpretations thereof, that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets. For additional detail on risks related to each of the foregoing, see the discussion in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensure and Certification</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dialysis centers are certified by CMS, as required for the receipt of Medicare payments. Certain of our payor contracts also condition payment on Medicare certification. In some states, our outpatient dialysis centers also are required to secure additional state licenses and permits. Governmental authorities, primarily state departments of health, periodically inspect our centers to determine if we satisfy applicable federal and state standards and requirements, including the conditions for coverage in the Medicare ESRD program.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced some delays in obtaining Medicare certifications from CMS, though changes by CMS in the prioritizing of dialysis providers as well as legislation allowing private entities to perform initial dialysis facility surveys for certification has helped to decrease or limit certain delays.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in September 2019, CMS finalized updates to the Provider Enrollment Rule creating onerous disclosure obligations for all providers enrolling in Medicare, Medicaid and the Children&#8217;s Health Insurance Plan (CHIP). The final rule provides CMS with stronger revocation authority, increases the bar for re-enrollment, and permits CMS to impose a Medicare reapplication bar where a prospective provider's Medicare enrollment application is denied because the provider submitted incomplete, false, or misleading information for providers who are terminated from the Medicare program. CMS may also deny enrollment to providers who have affiliations with other providers that CMS has determined pose undue risk of fraud, waste or abuse. If we fail to comply with these and other applicable requirements on our licensure and certification programs, particularly in light of increased penalties that include a 10-year bar to Medicare re-enrollment, under certain circumstances it could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to certification by CMS, our dialysis centers are also certified by each state Medicaid program, are licensed in those states that require licensing for dialysis clinics, and are required to obtain licenses, permits and certificates, including for such areas as biomedical waste. Failure to obtain the correct certifications, permits and certificates as well as a failure to adhere to the requirements thereunder, may result in penalties, fines, and the loss of the right to operate, any of which could have a material adverse impact on our business, results of operations, financial condition, cash flow and reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Anti-Kickback Statute</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or kind, to induce or reward either the referral of an individual for, or the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal criminal penalties for the violation of the federal Anti-Kickback Statute include imprisonment, fines and exclusion of the provider from future participation in the federal healthcare programs, including Medicare and Medicaid. Violations of the federal Anti-Kickback Statute are punishable by imprisonment for up to ten years and statutory fines of up to $100,000 or both. Larger criminal fines can be imposed under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of violating the federal Anti-Kickback Statute are subject to mandatory exclusion from participation in Medicare, Medicaid and other federal healthcare programs for a minimum of five years. Civil penalties for violation of this law include statutory amounts of up to $100,000 (adjusted for inflation) in monetary penalties per violation, assessments of up to three times the total payments between the parties to the arrangement, and permissive exclusion from participation in the federal healthcare programs or suspension from future participation in Medicare and Medicaid. The ACA amended the federal Anti-Kickback Statute to clarify that the defendant may not need to have actual knowledge of the federal Anti-Kickback Statute or have the specific intent to violate it and to provide that any claims for items or services resulting from a violation of the federal Anti-Kickback Statute are considered false or fraudulent for purposes of the False Claims Act (FCA) and can result in treble damages and other penalties under the FCA. In addition, HHS' Office of Inspector General (OIG) and CMS in 2020 released a final rule implementing modifications to the Federal Anti-Kickback Statute and Civil Monetary Penalties Statute intended to promote value-based and coordinated care arrangements as well as reduce other regulatory burdens. Most changes implemented by the final rule went into effect on January 19, 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute includes statutory exceptions and regulatory safe harbors that protect certain arrangements. Business transactions and arrangements that are structured fully within an applicable safe harbor do not violate the federal Anti-Kickback Statute. When an arrangement is not structured fully within a safe harbor, the arrangement must be evaluated on a case-by-case basis in light of the parties&#8217; intent and the arrangement&#8217;s potential for abuse, and may be subject to greater scrutiny by enforcement agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business operations, DaVita and its ancillary businesses and subsidiaries enter into numerous arrangements with physicians and other potential referral sources, that potentially implicate the Anti-Kickback Statute. Examples of such arrangements include, among other things, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interests, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment and coverage agreements, and incentive performance arrangements. In addition, some referring physicians may own DaVita Inc. common stock. Furthermore, our dialysis centers and subsidiaries sometimes enter into certain rebate, pricing, or other contracts to acquire certain discounted items and services that may be reimbursed by a federal healthcare program.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements and other arrangements can still be appropriate under the federal Anti-Kickback Statute even if they fail to meet all parameters of a relevant safe harbor provision; and we endeavor to structure our arrangements within applicable safe harbors, although some arrangements are not structured fully within a safe harbor. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or previous business transactions or arrangements, including but not limited to those described above, were found to violate the federal Anti-Kickback Statute, we, among other things, could face criminal, civil or administrative sanctions, including possible exclusion from participation in Medicare, Medicaid and other state and federal healthcare programs. Any findings that we have violated these laws could have a material adverse impact on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stark Law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law is a strict liability civil law that prohibits a physician who has a financial relationship, or who has an immediate family member who has a financial relationship, with entities providing Designated Health Services (DHS), from referring Medicare and Medicaid patients to such entities for the furnishing of DHS, unless an exception applies. The types of financial arrangements between a physician and a DHS entity that trigger the self-referral prohibitions of the Stark Law are broad and include direct and indirect ownership and investment interests and compensation arrangements. The Stark Law also prohibits the DHS entity receiving a prohibited referral from presenting, or causing to be presented, a claim or billing for the services arising out of the prohibited referral. If the Stark Law is implicated, the financial relationship must fully satisfy a Stark Law exception. If an exception to the Stark Law is not satisfied, then the parties to the arrangement could be subject to sanctions. Sanctions for violation of the Stark Law include denial of payment for claims for services provided in violation of the prohibition, refunds of amounts collected in violation of the prohibition, a civil penalty of up to $15,000 (adjusted for inflation) for each service arising out of the prohibited referral, a statutory civil penalty of up to $100,000 (adjusted for inflation) against parties that enter into a scheme to circumvent the Stark Law prohibition, civil assessment of up to three times the amount </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claimed, and potential exclusion from the federal healthcare programs, including Medicare and Medicaid. Furthermore, Stark Law violations and failure to return overpayments timely can form the basis for FCA liability as discussed below. In addition, CMS released a final rule implementing modifications to the Stark Law intended to promote value-based and coordinated care arrangements as well as reduce other regulatory burdens. Most changes implemented by the final rule went into effect on January 19, 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of DHS under the Stark Law excludes services paid under a composite rate, even if some of the components bundled in the composite rate are DHS. Although the ESRD bundled payment system is no longer titled a composite rate, we believe that the former composite rate payment system and the current bundled system are both composite systems excluded from the Stark Law. Since most services furnished to Medicare beneficiaries provided in our dialysis centers are reimbursed through a bundled rate, we believe that the services performed in our facilities generally are not DHS. Certain separately billable drugs (drugs furnished to an ESRD patient that are not for the treatment of ESRD that CMS allows our centers to bill for using the so-called AY modifier) may be considered DHS. However, we have implemented certain billing controls designed to limit DHS being billed out of our dialysis clinics. Likewise, the definition of inpatient hospital services, for purposes of the Stark Law, also excludes inpatient dialysis performed in hospitals that are not certified to provide ESRD services. Consequently, we believe that our arrangements with such hospitals for the provision of dialysis services to hospital inpatients should not trigger the Stark Law referral prohibition.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although prescription drugs are DHS, there is an exception in the Stark Law for calcimimetics, EPO and other specifically enumerated dialysis drugs when furnished in or by an ESRD facility such that the arrangement for the furnishing of the drugs does not violate the Stark Law. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business operations, DaVita and its ancillary businesses and subsidiaries have many different types of financial arrangements with referring physicians that potentially implicate the Stark Law, including, but not limited to, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interest, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment agreements and incentive performance arrangements. In addition, some referring physicians may own our common stock in reliance on the Stark Law exception for investment interests in large publicly traded companies. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our interpretation of the applicability of the Stark Law to our operations is incorrect, the controls we have implemented fail, an arrangement is entered into outside of our processes, or we were to fail to satisfy an applicable exception to the Stark Law, we could be found to be in violation of the Stark Law and required to change our practices, face civil penalties, pay substantial fines, return certain payments received from Medicare and beneficiaries or otherwise experience a material adverse effect.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, it might be necessary to restructure existing compensation agreements with our medical directors and to repurchase or to request the sale of ownership interests in subsidiaries and partnerships held by referring physicians or, alternatively, to refuse to accept referrals for DHS from these physicians, or take other actions to modify our operations. Any finding by CMS or other regulatory or enforcement authorities that we have violated the Stark Law or related penalties and restructuring or other required actions could have a material adverse effect on our business, results of operations, financial condition, cash flows, stock price and reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal FCA is a means of policing false claims, false bills or false requests for payment in the healthcare delivery system. In part, the FCA authorizes the imposition of up to three times the government&#8217;s damages and civil penalties, plus up to approximately $25,000 per claim, on any person who, among other acts:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly presents or causes to be presented to the federal government, a false or fraudulent claim for payment or approval;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses, or causes to be made or used, a false record or statement material to an obligation to pay the government, or knowingly conceals or knowingly and improperly, avoids or decreases an obligation to pay or transmit money or property to the federal government; or</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conspires to commit the above acts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FCA imposes severe penalties for the knowing and improper retention of overpayments collected from government payors. Under these provisions, within 60 days of identifying and quantifying an overpayment, a provider is required to follow certain notification and repayment processes. An overpayment impermissibly retained could subject us to liability under the FCA, exclusion from government healthcare programs, and penalties under the federal Civil Monetary Penalty statute. As a result of these provisions, our procedures for identifying and processing overpayments may be subject to greater scrutiny.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including coding errors, billing for services not rendered, the submission of false cost reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code and billing for care that is not considered medically necessary. The ACA provides that claims tainted by a violation of the federal Anti-Kickback Statute are false for purposes of the FCA. Some courts have held that filing claims or failing to refund amounts collected in violation of the Stark Law can form the basis for liability under the FCA. In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government. In December 2022, proposed modifications relating to the application of FCA under the Medicare program were released. As proposed, the modifications would amend the knowledge requirement and remove references to quantification, among other things. We will monitor the comment process and finalization of the proposed rules, and will assess any changes relating to the FCA that are implemented to the extent they could impact our business. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraud and abuse under state law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State fraud and abuse laws related to anti-kickback, physician self-referral, beneficiary inducement and false claims often mirror those requirements of the applicable federal laws, or, in some instances contain additional or different requirements. If we were found to violate these state laws and regulations, we, among other things, could face criminal, civil or administrative sanctions, including loss of licensure or possible exclusion for Medicaid and other state and federal healthcare programs. Any findings that we have violated these laws and regulations could have a material adverse impact on our business, operations, financial condition, cash flows, reputation and stock price. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these fraud waste and abuse laws, some states in which we operate dialysis centers have laws prohibiting physicians from holding financial interests in various types of medical facilities to which they refer patients. Some of these laws could potentially be interpreted broadly as prohibiting physicians who hold shares of our publicly traded stock or are physician owners from referring patients to our dialysis centers if the centers use our laboratory subsidiary to perform laboratory services for their patients or do not otherwise satisfy an exception to the law. States also have laws similar to or stricter than the federal Anti-Kickback Statute that may affect our ability to receive referrals from physicians with whom we have financial relationships, such as our medical directors. Some state anti-kickback laws also include civil and criminal penalties. Some of these laws include exemptions that may be applicable to our medical directors and other physician relationships or for financial interests limited to shares of publicly traded stock. Some, however, may include no explicit exemption for certain types of agreements and/or relationships entered into with physicians. If these laws are interpreted to apply to referring physicians with whom we contract for items or services, including medical directors, or to referring physicians with whom we hold joint ownership interests or to referring physicians who hold interests in DaVita Inc. limited solely to our publicly traded stock, and for which no applicable exception exists, we may be required to terminate or restructure our relationships with or refuse referrals from these referring physicians and could be subject to criminal, civil and administrative sanctions, refund requirements and exclusions from participation in government healthcare programs, including Medicare and Medicaid, which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Practice of Medicine and Fee-Splitting</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are states in which we operate that have laws that prohibit business entities not owned by health care providers, such as our Company and our subsidiaries, from practicing medicine, employing physicians and other licensed health care providers providing certain clinical services or exercising control over medical or clinical decisions by physicians and potentially other types of licensed health care providers (known collectively as the corporate practice of medicine). These states may also prohibit entities from engaging in certain financial arrangements, such as fee-splitting, with physicians and potentially other types of licensed health care providers. Violations of the corporate practice of medicine, fee-splitting and related laws vary by state and may result in physicians and potentially other types of licensed health care providers being subject to disciplinary action, as well as to forfeiture of revenues from payors for services rendered. Violations may also bring both civil and, in more extreme cases, criminal liability for engaging in medical practice without a license and violating the corporate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practice of medicine, fee-splitting and related laws. Some of the relevant laws, regulations, and agency interpretations in states with corporate practice of medicine restrictions have been subject to limited judicial and regulatory interpretation. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Statute</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Civil Monetary Penalties Statute, 42 U.S.C. &#167; 1320a-7a, authorizes the imposition of civil money penalties, assessments, and exclusion against an individual or entity based on a variety of prohibited conduct, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that the individual or entity knows or should know are for an item or service that was not provided as claimed or is false or fraudulent; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arranging contracts with an entity or individual excluded from participation in the federal healthcare programs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Violating the federal Anti-Kickback Statute;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made any false statement, omission, or misrepresentation of a material fact in any application, bid, or contract to participate or enroll as a provider of services or a supplier under a federal healthcare program; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failing to report and return an overpayment owed to the federal government.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial civil monetary penalties may be imposed under the federal Civil Monetary Penalty Statute and vary, depending on the underlying violation. In addition, an assessment of not more than three times the total amount claimed for each item or service may also apply, and a violator may be subject to exclusion from participation in federal and state healthcare programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of the Foreign Corrupt Practices Act (FCPA) in the United States and similar laws in other countries, which generally prohibit companies and those acting on their behalf from making improper payments to foreign government officials and others for the purpose of obtaining or retaining business. A violation of the FCPA or other similar laws by us and/or our agents or representatives could result in, among other things, the imposition of fines and penalties, changes to our business practices, the termination of or other adverse impacts under our contracts or debarment from bidding on contracts, and/or harm to our reputation, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and stock price.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and Security</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH Act) (collectively referred to as HIPAA), require us to provide certain protections to patients and their health information. The HIPAA privacy and security regulations extensively regulate the use and disclosure of PHI and require covered entities, which include healthcare providers, to implement and maintain administrative, physical and technical safeguards to protect the security of such information. Additional security requirements apply to electronic PHI. These regulations also provide patients with substantive rights with respect to their health information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA privacy and security regulations also require us to enter into written agreements with certain contractors, known as business associates, to whom we disclose PHI. Covered entities may be subject to penalties for, among other activities, failing to enter into a business associate agreement where required by law or as a result of a business associate violating HIPAA if the business associate is found to be an agent of the covered entity and acting within the scope of the agency. Business associates are also directly subject to liability under the HIPAA privacy and security regulations. In instances where we act as a business associate to a covered entity, there is the potential for additional liability beyond our status as a covered entity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered entities must report breaches of unsecured PHI to affected individuals without unreasonable delay but not to exceed 60 days of discovery of the breach by a covered entity or its agents. Notification must also be made to the HHS and, for breaches of unsecured PHI involving more than 500 residents of a state or jurisdiction, to the media. All non-permitted uses or disclosures of unsecured PHI are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify affected individuals, and U.S. state attorneys general, or other regulators or law enforcement, in the event of a data breach involving individually identifiable information without regard to whether there is a low probability of the information being compromised.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for impermissible use or disclosure of PHI were increased by the HITECH Act by imposing tiered penalties of more than $50,000 per violation and up to $1.5&#160;million per year for identical violations. In addition, HIPAA provides for criminal penalties of up to $250,000 and ten years in prison, with the severest penalties for obtaining and disclosing PHI with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. Further, state attorneys general may bring civil actions seeking either injunction or damages in response to violations of the HIPAA privacy and security regulations that threaten the privacy of state residents.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection of PHI, healthcare companies must meet privacy and security requirements applicable to other categories of personal information. Companies may process consumer information in conjunction with website and corporate operations. They may also handle employee information, including Social Security Numbers, payroll information, and other categories of sensitive information, to further their employment practices. In processing this additional information, companies must comply with the applicable privacy and security requirements of comprehensive privacy and data protection laws, consumer protection laws, labor and employment laws, and its publicly-available notices.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data protection laws and regulations are evolving globally, and may continue to add additional compliance costs and legal risks to our international operations. In the European Union, the General Data Protection Regulation (EU GDPR) imposes a comprehensive data protection regime with the potential for regulatory fines as well as data breach litigation by impacted data subjects. Under the EU GDPR, regulatory penalties may be passed by data protection authorities for up to the greater of 4% of worldwide turnover or &#8364;20 million. The United Kingdom has implemented similar legislation (UK GDPR) that may carry similar compliance and operational costs as the EU GDPR, and non-compliance with which carries potential fines of up to the greater of &#163;17.5 million or 4% of global turnover. The costs of compliance with, and other burdens imposed by, the EU GDPR, UK GDPR and other new laws, regulations and policies implementing the EU GDPR and UK GDPR may impact our European and United Kingdom operations and may limit the ways in which we can provide services or use personal data collected while providing services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws are also evolving nationally, providing for enhanced state privacy rights that are broader than the current federal privacy rights, and may add additional compliance costs and legal risks to our U.S. operations. For example, the California Consumer Protection Act (CCPA), which became effective January 1, 2020, requires certain companies doing business in California to enhance privacy disclosures regarding the collection, use and sharing of a consumer's personal data. The CCPA also permits the imposition of civil penalties, grants enforcement authority to the state Attorney General and provides a private right of action for consumers where certain personal information is breached due to unreasonable information security practices. Additionally, the California Privacy Rights Act (CPRA), which took effect on January 1, 2023, significantly expands the data protection obligations imposed by the CCPA on companies doing business in California, including additional consumer rights processes, limitations on data uses, and opt outs for certain uses of sensitive data. California also has a new data protection agency, the California Privacy Protection Agency, which is in the process of promulgating regulations under the CPRA amendments to the CCPA and will have concurrent enforcement powers with the California Department of Justice. Under CPRA amendments, certain businesses with higher risk privacy and security practices are required to submit annual audits to the agency on a regular basis. In addition to California, other states have passed similar privacy laws that will come into effect in 2023. These state data protection laws will likely result in broader increased regulatory scrutiny in applicable states of businesses' privacy and security practices, could lead to a further rise in data protection litigation, and will require additional compliance investment and potential business process changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the breach reporting requirements under HIPAA, companies are subject to state breach notification laws. Each state enforces a law requiring companies to provide notice of a breach of certain categories of sensitive personal information, e.g. Social Security Number, financial account information, or username and password. A company impacted by a breach must notify affected individuals, attorney&#8217;s general or other agencies within a certain time frame. If a company does not provide timely notice with the required content, it may be subject to civil penalties brought by attorney&#8217;s generals or affected individuals. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies must also safeguard personal information in accordance with federal and state data security laws and requirements. These requirements are akin to the HIPAA requirements to safeguard PHI, described above. The Federal Trade </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission, for example, requires companies to implement reasonable data security measures relative to its operations and the volume and complexity of the information it processes. Also, various state data security laws require companies to safeguard data with technical security controls and underlying policies and processes. Due to the constant changes in the data security space, companies must continuously review and update data security practices to seek to mitigate any potential operational or legal liabilities stemming from data security risks. For additional details on the risks of compliance with applicable privacy and security laws, regulations and standards, see the discussion in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care and Medicare and Medicaid program reforms</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis business as well as for emerging comprehensive and integrated kidney care programs. The following discussion describes certain of these changes in further detail.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2019 Executive Order directed CMS to create payment models through CMMI to evaluate the effects of creating payment incentives for the greater use of home-based dialysis and kidney transplants for those already on dialysis, improve quality of care for kidney patients and reduce expenditures. The first of these, the ESRD Treatment Choices (ETC) mandatory payment model launched in approximately 30% of dialysis clinics across the country on January 1, 2021, and CMS subsequently issued several clarifying rules through November 2022. CMS also announced the implementation of two voluntary kidney care payment models, Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC), with the stated goal of helping healthcare providers reduce the cost and improve the quality of care for patients with late-stage chronic kidney disease and ESRD. CMS has stated these payment models are aimed to prevent or delay the need for dialysis and encourage kidney transplantation. Certain of these payment models, such as the First Performance Period for the Kidney Care Choices Model CKCC Options (the CKCC Model) commenced on January 1, 2022. As described above, the Company has invested substantial resources, and expects to continue to invest substantial resources in these models as part of the Company's overall plan to grow its integrated kidney care business and value-based care initiatives.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on the risks related to integrated kidney care and Medicare and Medicaid program reforms, see the discussion in Item 1A. Risk Factors under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "If we are unable to compete successfully..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform, ACA and related regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The ACA regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. For example, the expanded access to healthcare developed under the ACA has been both positively and negatively impacted over time by subsequent legal, regulatory and judicial action. In 2021 and 2022, the American Rescue Plan and Inflation Reduction Act of 2022 included several provisions designed to expand health coverage, including the expansion and extension of premium tax credits that assist consumers who purchase health insurance on marketplaces developed under the ACA and temporarily offering incentives to expand Medicaid coverage for states that have not yet done so. Our revenue and operating income levels are highly sensitive to the percentage of our patients with higher-paying commercial health insurance and any legislative, regulatory or other changes that decrease the accessibility and availability, including the duration, of commercial insurance is likely to have a material adverse impact on our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the political environment may increase the likelihood of legislative or regulatory changes that would impact us, such as changes to the healthcare regulatory landscape. Examples of such potential changes also could include, among other things, legislative developments or changes to the eligibility age for Medicare beneficiaries. Some of these or other changes could in turn impact the percentage of our patients with higher-paying commercial health insurance, impact the scope or terms of coverage under commercial health plans and/or increase our expenses, among other things. The timing of legislative or executive action related to these potential initiatives, if any, remains uncertain, particularly in light of the current economic environment, and as such, considerable uncertainty exists surrounding the continued development of the ACA and related regulations, programs and models, as well as similar healthcare reform measures and/or other potential changes at the federal and/or state level to laws, regulations and other requirements that govern our business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Century Cures Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Cures Act broadened patient access to certain enhanced benefits offered by MA plans. This change in benefit eligibility has increased the percentage of our patients on MA plans as compared to Medicare Part B plans, though it is unclear how many eligible ESRD patients will continue to seek to enroll in MA plans for their ESRD benefits over time. In addition, the Cures Act also includes provisions related to data interoperability, information blocking and patient access. For details on the risks associated with these provisions of the Cures Act, see the risk factors in Item 1A. Risk Factors under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "If the number or percentage of patients with higher-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Plan Price Transparency Rules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In addition, recent price transparency regulations require most group health plans, and health insurance issuers in the group and individual markets, to make certain pricing and patient responsibility information publicly available. On July 1, 2022, most group health plans and issuers of group or individual health insurance were required to begin publishing machine-readable files that include negotiated rates for all covered items and services with all providers and out-of-network allowed amounts. For plan years that begin on or after January 1, 2023, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with out-of-pocket cost and underlying provider negotiated rate information in a consumer-friendly format for an initial list of 500 designated services (which do not include dialysis). A plan or issuer may choose to include more than these 500 services, and for plan years that begin on or after January 1, 2024, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with this information for all covered items and services. Additionally, CMS released regulations associated with "surprise billing" which necessitate, among other requirements, that certain providers provide patients with information regarding patient financial accountability and costs of services in advance of care being provided. While the ultimate impact of these requirements remains uncertain, any changes by group health plans, health insurance issuers in the group and individual markets, or consumer choices resulting from these requirements could have a material adverse impact on our business, results of operations, and financial condition, and could materially harm our reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned pricing transparency rules, the government has also implemented certain additional pricing transparency requirements that apply to certain types of providers, including DaVita. Under the No Surprises Act, which went into effect January 1, 2022, certain providers, including DaVita, will be required to develop and disclose a &#8220;Good Faith Estimate&#8221; (GFE) that details the expected charges for furnishing an item or service to an uninsured or self-pay patient. The GFE must include certain specific information such as, among other things, co-provider service cost estimates, and is subject to certain format, availability and dispute resolution requirements. Similar to the aforementioned pricing transparency rules, the impact of the GFE requirements on DaVita remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as uncertainty around operational timeframes, potential penalties and patient reaction, among other things. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Response</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The COVID-19 pandemic has had a continuing and compounding impact on our community and our business. Through the pandemic, we have continued our focus on the health, safety and well-being of our patients, teammates and physician partners. Most importantly, we have continued to focus on helping to ensure that our patients have the ability to maintain continuity of care throughout this pandemic, whether in the hospital, outpatient or home setting. To that end, we have dedicated and continue to dedicate substantial resources in response to COVID-19, including the implementation of additional protocols and initiatives to help safely maintain continuity of care for our patients and help protect our caregivers. We carefully monitor the efficacy of our response protocols and their impact on our operations and strategic priorities as the pandemic continues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments have also responded to the pandemic through legislation, rule making, interpretive guidance and modifications to agency policies and procedures, designed to provide emergency economic relief measures. These governmental responses include, among other things, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations from OSHA and CMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that impact our operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19-related regulations have shaped our pandemic response, and have impacted our costs and operations. Certain of these increased costs relate to, among other things, personal protective equipment (PPE), fit-testing, paid time off, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surveillance testing of our teammates for COVID-19, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as other heightened obligations with which we must comply.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compliance with COVID-19-related safety rules and regulations is enforced with sanctions and/or fines, and non-compliance also has the potential for negative publicity or reputational impact. These rules have added complexity and uncertainty to the already complex and highly regulated environment that we operate in, and the novel nature of our COVID-19 response, including, among other things, with respect to waivers of certain regulatory requirements, temporary clinical and operational changes and administration of COVID-19 vaccines, some of which are currently available under emergency use authorizations, as well as our efforts to comply with these evolving rules and regulations, may increase our exposure to legal, regulatory and clinical risks. In addition, in the event any of our temporary clinical and operational changes in response to COVID-19 become permanent, it could have an adverse impact on our business to the extent such changes result in increased costs or otherwise negatively impact our operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic evolves, federal and state regulatory authorities continue to issue additional guidance with respect to COVID-19, and at this time we cannot predict the ultimate impact these government actions may have on our business, results of operations, financial condition and cash flows. We will continue to assess the impact of statutes, regulations and supervisory guidance related to the COVID-19 pandemic. For additional information on the risks to our business associated with COVID-19 and labor market conditions, see the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive and if our labor costs continue to rise...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other regulations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis and related lab services operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws. These laws do not classify as hazardous most of the waste produced from dialysis services. OSHA regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including dialysis centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers are required to provide or employ hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a few states in which we do business have certificate of need programs regulating the establishment or expansion of healthcare facilities, including dialysis centers.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State initiatives</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several state-based policy proposals to limit payments to dialysis providers or impose other burdensome operational requirements, which, if passed, could have a material adverse impact on our business, results of operation, financial condition and cash flows. For instance, in 2022, voters in California considered a statewide ballot initiative proposed by the Service Employees International Union - United Healthcare Workers West (SEIU) that sought to impose certain regulatory requirements on dialysis clinics, including requirements related to physician staffing levels, clinical reporting, clinical treatment options and limitations on the ability to make decisions on closing or reducing services for dialysis clinics. While voters rejected this most recent ballot initiative in 2022, we incurred substantial costs to oppose it. We may continue to face ballot initiatives or other proposed regulations or legislation in California or other states in future years, which may require us to incur further substantial costs and which, if passed, could have a material adverse impact on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving proposed or issued laws, requirements, rules and guidance that impact our business, including without limitation as may be described above, and any failure on our part to adequately adjust to any resulting marketplace developments could have a material adverse effect on our business, results of operations, financial condition and cash flows. For additional discussion on the risks associated with the evolving payment and regulatory landscape for kidney care, see the discussion in Item 1A. Risk Factors, including the discussion under the heading,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="ib228226ec511491b87b183c6d217a21a_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate compliance program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has designed and implemented a corporate compliance program as part of our commitment to comply fully with applicable criminal, civil and administrative laws and regulations and to maintain the high standards of conduct we expect from all of our teammates. We continuously review this program and work to enhance it as appropriate. The primary purposes of the program include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing and identifying health care regulatory risks for existing and new businesses;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Training and educating our teammates and affiliated professionals to promote awareness of legal and regulatory requirements, a culture of compliance, and the necessity of complying with all applicable laws, regulations and requirements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and implementing compliance policies and procedures and creating controls to support compliance with applicable laws, regulations and requirements and our policies and procedures;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Auditing and monitoring the activities of our operating units and business support functions to identify and mitigate risks and potential instances of noncompliance in a timely manner; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensuring that we promptly take steps to resolve any instances of noncompliance and address areas of weakness or potential noncompliance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a code of conduct that each of our teammates, members of our Board of Directors, affiliated professionals and certain third parties must follow, and we have an anonymous compliance hotline for teammates and patients to report potential instances of noncompliance that is managed by a third party. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Executive Officer (CEO) and the Chair of the Compliance and Quality Committee of our Board of Directors (Board).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future penalties, sanctions or other consequences could be more severe in certain circumstances if the OIG or a similar regulatory authority determines that we knowingly or repeatedly failed to comply with applicable laws, regulations or requirements, including substantial penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations, financial condition and cash flows, reputation and stock price.</span></div><div id="ib228226ec511491b87b183c6d217a21a_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dialysis industry remains highly competitive, with many new entrants aggressively entering the kidney healthcare business space. In our U.S. dialysis business, we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for limited acquisition targets, for individual patients who may choose to dialyze with us and to engage physicians qualified to provide required medical director services. In addition to these large and medium sized dialysis providers with substantial financial resources and other established participants in the dialysis space, we also compete with new dialysis providers, individual nephrologists, former medical directors or physicians that have opened their own dialysis units or facilities. Moreover, as we continue our international dialysis expansion into various international markets, we face competition from large and medium-sized providers, among others, for acquisition targets as well as physician relationships. We also experience competitive pressures from other dialysis and healthcare providers in recruiting and retaining qualified skilled clinical personnel as well as in connection with negotiating contracts with commercial healthcare payors and inpatient dialysis service agreements with hospitals. Acquisitions, developing new outpatient dialysis centers, patient retention and referrals, and referral source relationships, in which such sources understand us to be the clinical and operational leaders in the market are significant components of our growth strategy and our business could be adversely affected if we are not able to continue to make dialysis acquisitions on reasonable and acceptable terms, continue to develop new outpatient dialysis centers, maintain our referral sources' trust in our capabilities or if we experience significant patient attrition or lack of new patient growth relative to our competitors. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest competitor, Fresenius Medical Group (FMC), manufactures a full line of dialysis supplies and equipment in addition to owning and operating outpatient dialysis centers worldwide. This may, among other things, give FMC cost advantages over us because of its ability to manufacture its own products. Additionally, FMC has been one of our largest suppliers of dialysis products and equipment over the last several years. In 2021, we entered into and subsequently extended a new agreement with FMC to purchase a certain amount of dialysis equipment, parts and supplies from FMC which extends through December&#160;31, 2024. The amount of purchases from FMC over the remaining term of this agreement will depend upon a number of factors, including the operating requirements of our centers, the number of centers we acquire, and growth of our existing centers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to traditional dialysis providers, there have been a number of announcements, initiatives and capital raises by non-traditional dialysis providers and others along the full continuum of kidney care from CKD to dialysis to transplant. These business entities, certain of which command considerable resources and capital, may increasingly compete with us in the integrated kidney care market as we seek to grow in that space, or they may focus their efforts on the development of more conventional dialysis competition or the commencement of other new business activities or the development of innovative technologies that could be transformative to the industry. For additional discussion on these developments and associated risks, see the risk factor in Item 1A. Risk Factors under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div id="ib228226ec511491b87b183c6d217a21a_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are primarily self-insured with respect to professional and general liability, workers' compensation and automobile risks, and a portion of our employment liability practice risks, through wholly-owned captive insurance companies.&#160;We are also predominantly self-insured with respect to employee medical and other health benefits. We also maintain insurance, excess coverage, or reinsurance for property and general liability, professional liability, directors&#8217; and officers&#8217; liability, workers' compensation, cybersecurity and other coverage in amounts and on terms deemed appropriate by management, based on our actual claims experience and expectations for future claims. Future claims could, however, exceed our applicable insurance coverage. Physicians practicing at our dialysis centers are required to maintain their own malpractice insurance, and our medical directors are required to maintain coverage for their individual private medical practices. Our liability policies cover our medical directors for the performance of their duties as medical directors at our outpatient dialysis centers.</span></div><div id="ib228226ec511491b87b183c6d217a21a_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human capital management</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are guided by our Mission&#8212;to be the provider, partner and employer of choice&#8212;and a set of Core Values&#8212;Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment and Fun&#8212;which are reinforced at all levels of the organization. Our teammates share a common passion for equitably improving patients' lives and are the cornerstone for the health of DaVita.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to be a community first and a company second, and affectionately call ourselves a Village. To be a healthy Village, we need to attract, retain and develop highly qualified and diverse teammates. To do so, we have implemented strategies that support our mission to be the employer of choice, such as: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Designing programs and processes to cultivate a diverse talent pipeline that can allow us to hire ahead of needs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Providing development and professional growth opportunities; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering a robust and competitive total rewards program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These efforts are underpinned by a foundational focus on diversity and belonging that starts at the top with our Board and executive leadership and permeates through our Village as further described below. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this intentional investment of time and resources fosters a special community of teammates that, in turn, leads to better care of our patients and the communities we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we employed approximately 70,000 teammates, including our international teammates.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight &amp; Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board provides oversight on human capital matters, receiving regular updates from our Chief People Officer about People Services&#8217; activities, strategies and initiatives, and through the Board&#8217;s annual work with our CEO on management development and succession planning. Among other things, our Board and/or its committees also receive reports related to pay equity, risks and trends related to labor and human capital management issues and general issues pertaining to our teammates. The Board, in conjunction with its committees, also oversees the Company's activities, policies and programs related to corporate environmental and social responsibility, including considering the impact of such activities, policies and programs on the Company, teammates, patients and communities, among others.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reports and recommendations to the Board and its committees are part of our broader People Services leadership and oversight framework, which includes guidance from various stakeholders across the business and benefits from the broad participation of senior leadership.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity &amp; Belonging</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in our teammates is underscored by our commitment to Diversity &amp; Belonging (D&amp;B). We published our first D&amp;B Report in March 2021, which disclosed our diversity metrics and roadmap for delivering our vision of cultivating "a diverse Village where everyone belongs." Our 3,074 dialysis centers operate in communities large and small, in nearly every state in the U.S. as well as 11 other countries. Our Village's diversity is inherent in the teammates who work in our centers, the patients we care for, the physicians with whom we partner, and the communities where we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help achieve this vision, we empower all leaders and teammates to cultivate D&amp;B in their centers and on their teams. One way we do this is by sharing tools and resources like our Belonging Teammate and Belonging Leader Guides, which encourage teammates to connect with each other to learn about individual experiences with belonging and better understand the impact of unconscious bias. In addition, in 2022, we launched certain employee resource groups to create a community for teammates from underrepresented groups. Based on our most recent internal surveys, 81% of teammates indicated that they feel a sense of belonging within the DaVita community. We also launched our third annual Week of Belonging in 2022, engaging teammates globally with activities and education designed to further create a sense of belonging.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a collaborative, leader-led approach to building our D&amp;B program. Everyone from our front-line patient care technicians (PCTs) and nurses to our divisional vice presidents, our CEO and our Board has a role in implementing our strategy. It truly does take a Village to bring our vision to life. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, our D&amp;B efforts have focused primarily on supporting strong representation of women and people of color in our Company and ensuring that we are creating a welcoming, open environment where all teammates, patients, physicians and care partners belong. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our Village in the U.S. was comprised of 78% women and 56% people of color. We are proud of the fact that in the U.S. as of December&#160;31, 2022, 74% of our managers and 61% of our directors are women and that leaders with profit and loss responsibility are 53% women and 30% people of color. We also are proud that our Board is comprised of 30% women and 20% people of color. With respect to Board leadership positions, we are one of the few companies in the S&amp;P 500 to have a woman serving as the Chair of the Board. We are also among the 11% of a selected group of companies in the Fortune 500 and S&amp;P 500 to have a person of color serve as our CEO. We publish our demographic data in our EEO-1 Report, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is included in our Sustainability Accounting Standards Board (SASB) Report. As of December&#160;31, 2022, we are meeting or exceeding 79% of EEO-1 benchmarks.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Pipeline and Career Development</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand that a key component of developing strong representation of women and people of color in leadership is to have recruiting practices focused on diversity. Our practices include: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diverse Sourcing: Our recruiters are trained on how to source for diverse candidates to ensure we have a robust pipeline at all levels of the organization.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diversity In Hiring: We are committed to increasing diverse representation via our hiring practices. One way we do this is with diverse interview panels as well as diverse candidate slates to help ensure a fair and equitable process. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diverse Partnerships: We have external partnerships with organizations like Forte Foundation and Management Leadership for Tomorrow to help create equal opportunities for diverse candidates.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Redwoods Leadership: We partner closely with diverse student body organizations at colleges and universities to source applicants for our Redwoods leadership development programs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helping teammates reach the next stage in their career and increasing their earning potential is foundational to our Employer of Choice strategy. We have a robust set of career development offerings to support teammates in reaching their professional ambitions. We have invested in an end-to-end career development pipeline that includes programs and initiatives that provide financial, education and social support to our clinical and operations personnel to help achieve their higher education and leadership goals. We are proud of our Clinical Ladders program that ties performance to career progression. This program is designed to provide our teammates with clear expectations on what's needed to progress to the next level on the ladder and provide them access to tools to do so. Since rolling out Clinical Ladders, we have celebrated more than 9,000 promotions among our nurse and patient care technician teammates. Predominately all of our teammates are clinical field/operations personnel, and we have programs in place to help guide their potential journey at DaVita. Beginning with programs like Bridge to Your Dreams that cover certification fees for PCTs to coaching and tuition programs that help guide PCTs to becoming registered nurses (RNs) to programs that help develop high potential nurses, clinical coordinators and clinic nurse managers into operational managers and ultimately to programs that prepare and coach operational managers for potential regional operations director roles, our goal is to make resources available to teammates at each step of a possible career path. We are proud of the work we have done in this area, with approximately 56% of our Facility Administrators and managers having been promoted internally, and over 1,450 teammates enrolled in the Bridge to Your Dreams program, as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards Program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy and practices are designed to be competitive in the local market and reward strong team and individual performance. We believe merit-driven pay encourages teammates to do their best work, including in caring for our patients, and we strive to link pay to performance so we can continue to incentivize the provision of extraordinary care to our patients and grow our Village.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To attract, retain and grow our teammates, we have a holistic approach to total rewards that includes financial, physical and emotional support. Highlights include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare benefits including a menu of plan designs and health savings accounts.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health programs in support of the most prevalent health conditions affecting our teammates, including hypertension, diabetes prevention/maintenance, musculoskeletal issues and weight loss/management. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial wellness including 401(k) match, employee stock purchase plan (ESPP), a deferred compensation plan, financial planning support and access to free banking services.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Family support programs to our teammates and their families that include family care programs for back-up child and elder care, family planning support for fertility, adoption and surrogacy, parental support for children&#8217;s educational and special needs and parental leave programs. We also offer a number of scholarships for teammates' children and grandchildren.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Teammate Assistance Program that offers counseling sessions annually to all teammates and their household members, along with work/life resources and tools that include telephonic or face to face legal consultation and expert financial planning/consultation; each household member has access to ten free sessions per life event.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Free access to Headspace, an application for digital meditation and mindfulness, and referrals/consultations on everyday issues such as dependent care, auto repair, pet care and home improvement.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vitality Points, a voluntary wellness incentive program that encourages teammates and their spouses/domestic partners to engage with their provider to manage their overall health. In addition, it allows participating teammates and spouses/domestic partners to earn credits toward their medical premium for getting a biometric screening with a primary care provider.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Short &amp; Long term disability for full time teammates and Life/AD&amp;D coverage at both the basic and supplemental levels.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DailyPay, a service that provides teammates with financial flexibility by allowing them to access earned but unpaid wages before payday.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our DaVita Village Network, which provides financial support to eligible teammates experiencing a specific tragedy or hardship and helps cover additional costs that local fundraising and insurance do not fully cover.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Equity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are committed to equal pay for equal work; meaning, teammates in the same position, performing at the same level, and in similar geographies, are paid fairly relative to one another, regardless of their gender, race or ethnicity. We believe that equitable pay is a critical component of establishing a fair work environment where all teammates are valued and feel like they belong. Fair pay is essential to our ability to attract and motivate the highly qualified, and diverse, teammates who are at the center of our current and future success.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continued Response to COVID-19 Public Health Crisis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to test our ability to respond to external developments and care for not only our patients, but also our teammates in real time. We have maintained many of our initial COVID-19 practices and have adapted our guidance based on ongoing changes to regulatory requirements. As the pandemic continues into 2023, we are integrating certain COVID-19 response protocols into our standard workflows and monitoring for any change in the Public Health Emergency status. Following the surge in January 2022, we changed our capacity management process during potential surges which was a beneficial operational shift for our facilities. We also continued to include COVID-19 testing, treatments, vaccines and boosters in our teammate communications program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most importantly, the health, well-being and safety of our teammates, physician partners and their families remains a top priority throughout this ongoing pandemic. We implemented guidance early in the pandemic to help mitigate risks imposed by COVID-19 and maintain many practices, including, among other things, securing necessary supplies of PPE, restricting visitor access to our centers and implementing masking policies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also converted numerous leadership development programs to virtual delivery, to help ensure that our teammates across our global Village could continue to grow personally and professionally and have access to career development resources despite the ongoing pandemic. Additionally, we have been able to begin gathering in person with COVID-19 meeting guidance in place and opened up our Central Business Offices for teammates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to engage with teammates and respond to these developments has helped us to better care for them. By caring for our teammates, we have been generally able to maintain continuity of care for our patients and support the broader healthcare community throughout this unprecedented public health crisis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about certain risks associated with our human capital management and our response to the COVID-19 pandemic, see the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive and if our labor costs continue to rise...;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also encourage you to visit our website at davitacommunitycare.com for more detailed information regarding certain aspects of our human capital and ESG related programs and initiatives described herein, including our D&amp;B Report and Community Care Report, as well as our efforts to care for our patients, our community and our world. Nothing on our website, sections thereof or documents linked thereto, shall be deemed incorporated by reference into this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. Please read the cautionary notice regarding forward-looking statements in Item 7 of Part II of this Annual Report on Form 10-K under the heading "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations." These forward-looking statements involve risks and uncertainties, including those discussed below, which could have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation. The risks and uncertainties discussed below are not the only ones facing our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial could also have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks and uncertainties that could adversely affect our business, cash flows, financial condition and/or results of operations, and these adverse impacts may be material. This summary is qualified in its entirety by reference to the more detailed descriptions of the risks and uncertainties included in this Item 1A. below and you should read this summary together with those more detailed descriptions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These principal risk and uncertainties relate to, among other things: </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to the Operation of our Business</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_67">macroeconomic conditions and global events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_70">the complex set of governmental laws, regulations and other requirements that impact us, including potential changes thereto</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_73">the various lawsuits, demands, claims, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_73">qui tam</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_73"> suits, governmental investigations and audits and other legal matters that we may be subject to from time to time</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_76">the number or percentage of patients with higher-paying commercial insurance, the average rates that commercial payors pay us, any restrictions in plan designs or other contractual terms, including, without limitation, the scope and duration of coverage and in-network benefits</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_79">our ability to successfully implement our strategy with respect to integrated kidney care, value-based care and home-based dialysis</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_82">changes in the structure of and payment rates under government-based programs</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_85">increases in labor costs, including, without limitation, due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; currently pending or future governmental laws, rules, regulations or initiatives; our ability to attract and retain key leadership talent or employees; or union</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_85"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_85">organizing activities or other legislative or other changes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_88">our ability to comply with complex privacy and information security laws that impact us and/or our ability to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_91">our ability to establish and maintain supply relationships that meet our needs at cost-effective prices or at prices that allow for adequate reimbursement as applicable, our ability to access new technology or superior products in a cost-effective manner and our increasing reliance on third party service providers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_94">changes in clinical practices, payment rates or regulations impacting pharmaceuticals </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_94">and/or devices</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_97">our ability to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_100">our U.S. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_100">integrated kidney care, ancillary services and our international operations and our ability to expand within markets or to new markets, or invest in new products or services</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_2792">political, economic, legal, operational and other risks as we expand our operations and offer our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_103">our ability to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, and our ability to adhere to federal and state data sharing and access requirements and regulations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_106">our acquisitions, mergers, joint ventures, noncontrolling interest investments or dispositions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_109">our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_112">our ability to appropriately estimate the amount of dialysis revenues and related refund liabilities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risks</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_118">our current or future level of indebtedness, including, without limitation, our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_121">changes in tax laws, regulations and interpretations or challenges to our tax positions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_124">the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_127">liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_130">our ability to successfully maintain an effective internal control over financial reporting</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_133">provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law that may deter changes of control or make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="ib228226ec511491b87b183c6d217a21a_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Operation of our Business</span></div><div id="ib228226ec511491b87b183c6d217a21a_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic conditions and global events have impacted and will continue to impact our business and cost structure in a variety of ways, and there can be no assurance that we will be able to successfully execute cost savings initiatives in a manner that will offset the impact of these challenging conditions, which could result in a material adverse impact on us.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to be impacted by general conditions in the global economy and marketplace, many of which are interrelated. These conditions relate to, among other things, the COVID-19 pandemic, inflation, rising interest rates, challenging labor market conditions and supply chain challenges. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflict between Russia and Ukraine, which has continued to drive sociopolitical and economic uncertainty and volatility in Europe and across the globe. The ultimate impact of these and other conditions on our business over time depends on future developments that are highly uncertain and difficult to predict. With respect to COVID-19, these future developments include, among other things, the ultimate severity and duration of the pandemic; the evolution of new strains or variants of the virus that may present varying levels of infectivity or virulence; COVID-19's impact on the chronic kidney disease (CKD) patient population and our patient population, including on the mortality of these patients; the availability, acceptance, impact and efficacy of COVID-19 vaccines, treatments and therapies; the pandemic&#8217;s continuing impact on our revenue and non-acquired growth due to lower treatment volumes; the potential negative impact on our commercial mix or the number of patients covered by commercial insurance plans; continued increased COVID-related costs; supply chain challenges and disruptions, including with respect to our clinical supplies; the responses of our competitors to the pandemic and related changes in the marketplace; the timing, scope and effectiveness of federal, state and local government responses; and any potential changes to the extensive set of federal, state and local laws, regulations and requirements that govern our business. COVID-19 has also intensified certain conditions and developments in the U.S. and global economies, labor market conditions, inflation and monetary policies that continue to impact our business as further described below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience a negative impact on revenue and non-acquired growth from COVID-19 due to lower treatment volumes, including from the negative impact of COVID-19 on the mortality rates of our patients, which has in turn impacted our patient census, as well as the direct and indirect impact of COVID-19 on our missed treatment rate and new admissions. We expect that the impact of COVID-19 is likely to continue to negatively impact our revenue and non-acquired growth for a period of time even as the pandemic subsides due to the compounding impact of mortalities, among other things. Because ESKD patients may be older and generally have comorbidities, several of which are risk factors for COVID-19, we believe the mortality rate of infected patients has been higher in the dialysis population than in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the general population. Over the longer term, we believe that changes in mortality in both the ESKD and CKD populations due to COVID-19 will continue to depend primarily on the infection rate, case fatality rate, the age and health status of affected patients, and access to and continued efficacy of vaccinations or other treatments or therapies, particularly as it relates to variants of the virus, as well as willingness to be vaccinated. New admission rates, future revenues and non-acquired growth could also continue to be negatively impacted over time to the extent that the CKD population experiences elevated mortality levels due to the pandemic. There remains significant uncertainty as to the ultimate impact of COVID-19 on our treatment volumes, in part due to, among other things, the indeterminate severity and duration of the pandemic and the complexity of factors that may drive new admissions and missed treatment rates over time. Depending on the ultimate severity and duration of the pandemic, the magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows. For further information on our growth strategy and the rate of growth of the ESKD population, see the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 and other global conditions have also increased, and will continue to increase, our expenses, including, among others, staffing and labor costs. Our business is labor intensive and our financial and operating results have been and continue to be sensitive to variations in labor-related costs and productivity. We have historically faced and expect to continue to face difficulties in hiring and retaining caregivers due in part to a nationwide shortage of clinical personnel.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These challenges have been heightened by the increased demand for and demand upon such personnel by the ongoing pandemic and our COVID-19 response, as well as ongoing volatility and uncertainty in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">labor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> market, particularly in healthcare. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as part of our continuing efforts in this challenging and highly competitive labor market, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we incurred </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">higher than usual wage increases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and higher incentive pay. For additional details on the substantial resources dedicated, and costs incurred in response to COVID-19, see the discussion under Part I, Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 and its impact on our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">". In addition, potential staffing shortages or disruptions, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, and may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The staffing and labor cost inflation described above, in addition to higher equipment and clinical supply costs, among other things, have put pressure on our existing cost structure, and we expect that some of these increased costs will continue as labor market conditions remain challenging, global supply chains continue to experience volatility and disruptions and as inflationary pressures continue. Prolonged volatility, uncertainty, labor supply shortages and other challenging labor market conditions could have an adverse impact on our growth and ability to execute on our other strategic initiatives and a material adverse impact on our labor costs, among other things. Prolonged strain on global supply chains may result in equipment and clinical supply shortages, disruptions, delays or associated price increases that could impact our ability to provide dialysis services or the cost of providing those services, among other things. Moreover, to the extent that monetary policies or other factors impacting structural costs over the long term have contributed to or may in the future contribute to inflationary pressures, this may in turn continue to increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. In our value-based care and other programs where we assume financial accountability for total patient cost, an increase in COVID-19 rates among patients could have an impact on total cost of care. This increase may in turn impact the profitability of those programs relative to their respective funding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to implement cost savings opportunities to help mitigate these cost and volume pressures. These include, among other things, anticipated cost savings related to general and administrative cost efficiencies, such as ongoing initiatives that increase our use of third party service providers to perform certain activities, including financial reporting and information technology functions, initiatives relating to clinic optimization, initiatives for capacity utilization improvement, and procurement opportunities, such as our transition to a new erythropoiesis stimulating agent (ESA) contract. We have incurred, and expect to continue to incur charges in connection with the continued implementation of these initiatives, and there can be no assurance that we will be able to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions. Any failure on our part to adjust our business and operations in this manner, to adjust to other marketplace developments or dynamics or to appropriately implement these initiatives in accordance with applicable legal, regulatory or compliance requirements could adversely impact our ability to provide dialysis services or the cost of providing those services, among other things, and ultimately could have a material adverse effect on our business, reputation, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deterioration in economic conditions, whether in connection with the COVID-19 pandemic or driven by other macroeconomic conditions or global events, including the aforementioned inflationary and labor market pressures, volatility and uncertainty, as well as rising interest rates, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Among other things, the potential decline in federal and state tax revenues that may result from a deterioration in economic conditions may create additional pressures to contain or reduce reimbursements for our services from Medicare, Medicaid and other government sponsored programs. Increases in job losses in the U.S. as a result of adverse economic conditions, including economic deterioration, could ultimately result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower-paying government insurance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs or being uninsured. In the event a material reduction occurs in the share of our patients covered by commercial insurance plans, it would have a material adverse impact on our business, results of operations, financial condition and cash flows. The extent of these effects will depend upon, among other things, the extent and duration of any increased unemployment levels for our patient population, any economic deterioration or potential recession; the timing and scope of federal, state and local governmental responses to the ongoing pandemic; and patients&#8217; ability to retain existing insurance and their individual choices with respect to their coverage, all of which are highly uncertain and difficult to predict. In a declining economy, employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a slowdown in collections and a reduction in the amounts we expect to collect. For additional information on risks regarding the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If general economic conditions deteriorate further or remain uncertain for an extended period of time, we may incur future charges to recognize impairment in the carrying amount of our goodwill and other intangible assets. We may experience an increased need for additional liquidity funded by accessing existing credit facilities, raising new debt in the capital markets, or other sources, and we may seek to refinance existing debt, which may be more difficult or costly in an uncertain or declining economic environment. For additional information regarding the risks related to our indebtedness, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Furthermore, any extended billing or collection cycles, or deterioration in collectability of accounts receivable, will adversely impact our results of operations and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our revenues and financial results be materially, unfavorably impacted due to, among other things, a worsening of the economic and labor market conditions in the United States that negatively impacts reimbursement rates or the availability of insurance coverage for our patients, we may incur future charges to recognize impairment in the carrying amount of our goodwill and other intangible assets, which could have a material adverse effect on our business, results of operations and financial condition. As of December&#160;31, 2022, we had approximately $7 billion of goodwill recorded on our consolidated balance sheet. We account for impairments of goodwill in accordance with the provisions of applicable accounting guidance, and record impairment charges when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances concerning our businesses and to estimate their fair value when applicable. These assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these economic conditions or developments, as well as other consequences of these conditions or developments, none of which we can reasonably predict, could have a material adverse effect on our patients, teammates, physician partners, suppliers, business, results of operations, financial condition and/or cash flows or materially harm our reputation. In addition, these conditions or developments each may heighten many of the other risks and uncertainties discussed herein.</span></div><div id="ib228226ec511491b87b183c6d217a21a_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state and local governmental laws, regulations and other requirements that apply to us. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative, and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. Laws, regulations and other requirements that apply to or impact our business include, but are not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid reimbursement statutes, and other federal reimbursement statutes, rules and regulations (including, but not limited to, manual provisions, local coverage determinations, national coverage determinations, payment schedules and agency guidance); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid provider requirements, including, but not limited to, requirements associated with providing and updating certain information about the Medicare or Medicaid entity, as applicable, and its direct and indirect affiliates; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 1115A of the Social Security Act, which, among other things, authorizes the Center for Medicare and Medicaid Innovation (CMMI) to test certain innovation models;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fraud waste and abuse laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the 21st Century Cures Act (the Cures Act);</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal Acquisition Regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act (FCPA) and similar laws and regulations; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations related to the corporate practice of medicine;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the collection, use and disclosure of patient health information (e.g., Health Insurance Portability and Accountability Act of 1996 (HIPAA)); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the No Surprises Act;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the storage, handling, shipment, disposal and/or dispensing of pharmaceuticals and blood products and other biological materials; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">individualized state laws and regulations associated with the operation of our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors, or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows, including, among others:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of required certifications or suspension or exclusion from or termination of our participation in government programs (including, without limitation, Medicare, Medicaid and CMMI demonstration programs); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions in payment rates or coverage for dialysis and ancillary services and pharmaceuticals; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal or civil liability, fines, damages or monetary penalties; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of corporate integrity agreements, corrective action plans or consent agreements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by governmental agencies and/or state law claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including, among others, HIPAA and the Privacy Act of 1974; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by government agencies related to interoperability and related data sharing and access requirements and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated changes to our practices or procedures that significantly increase operating expenses that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines, among other things;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of various relationships and/or contracts related to our business, such as joint venture arrangements, medical director agreements, hospital services and skilled nursing home agreements, real estate leases, value-based care arrangements, clinical incentive programs, payor contracts and consulting or participating provider agreements with physicians, among others; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Harm to our reputation, which could negatively impact our business relationships and stock price, our ability to attract and retain patients, physicians and teammates, our ability to obtain financing and our access to new business opportunities, among other things.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future penalties, sanctions or other consequences could be more severe in certain circumstances if the OIG or a similar regulatory authority determines that we knowingly or repeatedly failed to comply with laws, regulations or requirements that apply to our business. Additionally, the healthcare sector, including the dialysis industry, is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding the U.S. healthcare system, among other things. Negative publicity, regardless of merit, regarding the dialysis industry generally, the U.S. healthcare system or DaVita in particular may adversely affect us. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 to the consolidated financial statements included in this report for further details regarding certain pending legal proceedings and regulatory matters to which we are or may be subject from time to time, any of which may include allegations of violations of applicable laws, regulations and requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complex and highly regulated environment that we operate in, the novel nature of our COVID-19 response and rulemaking responses to COVID-19 by certain state and federal agencies, including without limitation OSHA and CMS, may increase our exposure to legal, regulatory compliance and clinical risks. Compliance with COVID-19-related safety rules and regulations is enforced with sanctions and/or fines, and non-compliance also has the potential for negative publicity or reputational impact. In addition, our novel response to the pandemic included implementing certain restrictive operational protocols for an extended period of time. Maintaining these restrictive operational protocols may also have adversely impacted our strategic initiatives, such as our strategy to continue to build our abilities to offer home dialysis options and expanding our integrated care capabilities. Moreover, the expected expiration of the federal government's national emergency and public health emergency declarations in May 2023 may impact the coverage for certain services for Medicare and Medicaid patients and will end waivers for the provision of certain services, and returning our services to a pre-pandemic regulatory state similarly may increase our exposure to legal, regulatory, compliance and clinical risks. If we experience a failure of the fitness of our clinical laboratory, dialysis centers and related operations and/or other facilities as a result of operational changes implemented in connection with the COVID-19 pandemic or for any other reason, or if another event or occurrence adversely impacts the safety of our caregivers or patients (or is alleged to have done so), we could face adverse consequences, including without limitation, material negative impact on our brand, increased litigation, compliance or regulatory investigations, teammate unrest, work stoppages or other workforce disruptions. Any governmental investigations or legal actions brought by patients, teammates, caregivers or others relating to the safety of our caregivers or patients, or alleged exposure to COVID-19 at our facilities or by our caregivers, may involve significant demands and require substantial legal defense costs, which may not be adequately covered by our professional and general liability insurance, and may materially harm our reputation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the laws, regulations and other requirements that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis and ancillary businesses as well as for emerging comprehensive and integrated kidney care markets. For example, as further described below, we have made substantial investments in and dedicated resources to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our integrated care business, value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and home-based dialysis business to address recent regulatory developments that include innovative payment models, and there are risks to those investments, or additional investments may be required, in the event the regulatory environment changes and we do not adequately adapt to such changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, access to healthcare has been both positively and negatively impacted over time by legal, regulatory and judicial action and changes to the political environment may increase the likelihood of regulatory or legislative changes that would impact us. If access to healthcare is significantly altered or if other reforms limiting access to healthcare are enacted in the future, such changes could impact our business in a number of ways, some of which may be material. Considerable uncertainty exists surrounding the continued development of the healthcare regulatory environment including pilot programs and models, as well as similar healthcare reform measures and/or other changes to laws, regulations and other requirements at the federal and/or state level that govern our business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the continuously evolving healthcare regulatory landscape may also have the potential to generate opportunities with relative ease of entry for certain smaller and/or non-traditional providers and we may be competing with them for patients in an asymmetrical environment with respect to data and/or regulatory requirements given our status as an ESRD service provider. For example, CMS may consider opening for comment its established Medicare ESRD conditions for coverage. In the event that this process results in reductions or other changes in minimum health and safety standards for the provision of dialysis services, it may change the marketplace in which we operate. If we are unable to successfully adapt to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these marketplace developments in a timely and compliant manner, we may experience a material adverse reduction in our overall number of patients, among other things. For additional detail on our evolving competitive environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Broader changes to the regulatory landscape may also impact our business. For example, in January 2023, the Federal Trade Commission proposed a new rule that would generally prohibit employers from using noncompete clauses in contracts with workers that extend beyond the termination of the employment or independent contractor relationship. While the rule remains open for comment and the final rule has not been issued, we are monitoring these developments for any potential impact on our agreements with teammates, our arrangements with medical directors, joint venture operating agreements, or the terms of any of our existing agreements with physicians should the proposed rule be finalized and implemented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we cannot predict the short- or long-term effects of legislative or regulatory changes, future market changes could result in, among other things, more restrictive commercial plans with lower reimbursement rates or higher deductibles and co-payments that patients may not be able to pay. Because our revenue and operating income levels are highly sensitive to the percentage and number of our patients with higher-paying commercial health insurance, any legislative, regulatory or other changes that decrease the accessibility and availability, including the duration, of commercial insurance is likely to have a material adverse impact on our business. For additional information on the impact of economic conditions or legislative or regulatory changes on the coverage and rates for our services and the percentage or number of our patients with commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been several state initiatives to limit payments to dialysis providers or impose other burdensome operational requirements, which, if passed, could have a material adverse impact on our business, results of operation, financial condition and cash flow. For instance, in 2022, voters in California considered a statewide ballot initiative proposed by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Service Employees International Union - United Healthcare Workers West (SEIU-UHW) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that sought to impose certain regulatory requirements on dialysis clinics, including requirements related to physician staffing levels, clinical reporting, clinical treatment options and limitations on the ability to make decisions on closing or reducing services for dialysis clinics. While voters rejected this most recent ballot initiative in 2022, we incurred substantial costs to oppose it. We may face ballot initiatives or other proposed regulations or legislation in California or other states in future years, which may require us to incur further substantial costs and which, if passed, could have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, there have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> been rule making and legislative efforts at both the federal and state level regarding the use of charitable premium assistance for ESRD patients that may establish new conditions for coverage standards for dialysis facilities. For example, on October 13, 2019, a California bill (AB 290) was signed into law that limits the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance. The American Kidney Fund (AKF), an organization that provides charitable premium assistance, announced that it would be withdrawing from California as a result of AB 290. The implementation of AB 290 has been stayed pending resolution of legal challenges, but in the event AB 290 becomes effective and the AKF withdraws from California, it may cause other organizations that provide charitable premium assistance to withdraw from California, and we would expect an adverse impact on the ability of patients to afford Medicare premiums and Medicare supplemental and commercial coverage. We expect that such an adverse impact will in turn adversely impact our business, results of operations, financial condition and cash flows. In the past, bills similar to AB 290 have been introduced in other states, but none has become law. If these or similar bills are introduced and implemented in other jurisdictions, and organizations that provide charitable premium assistance in those jurisdictions are similarly impacted, it could in the aggregate have a material adverse impact on our business, results of operations, financial condition and cash flows. For additional information on risks associated with charitable premium assistance for ESRD patients and the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, legislation, regulations, regulatory guidance, ballot initiatives and any similar initiatives could result in a reduction in the percentage of our patients with commercial insurance; limit the scope or nature of coverage through the exchanges or other health insurance programs or otherwise reduce reimbursement rates for our services from commercial and/or government payors; restrict or prohibit the ability of patients with access to alternative coverage from selecting a marketplace plan on or off exchange; limit the amount of revenue that a dialysis provider can retain for caring for patients with commercial insurance; impose burdensome operational requirements; affect payments made to providers for services provided to patients who receive charitable premium assistance and/or otherwise restrict or prohibit the use of charitable premium assistance; or reduce the standards for network adequacy or require disclosure of certain pricing and patient responsibility information. In turn, these potential impacts could cause us to incur substantial costs to oppose any such proposed requirements or measures, impact our dialysis center development plans, and if passed and/or implemented, could materially reduce our revenues and increase our operating and other costs, adversely impact dialysis centers across the U.S. making certain centers economically </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unviable, lead to the closure of certain centers, restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and reduce the number of patients that select commercial insurance plans or MA plans for their dialysis care, among other things. The healthcare legislative and regulatory environment is dynamic and evolving, and any such proposed or issued laws, requirements, rules and guidance could impact our business, including as may be described above, and any failure on our part to adequately adjust to any resulting marketplace developments or regulatory compliance requirements, may, among other things, erode our patient base or reimbursement rates and could otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the information above describes statutory and regulatory provisions, it is qualified in its entirety by reference to the particular statutory and regulatory provisions that are referenced. For additional information related to the laws, rules and other regulations described above, please see Part I, Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="ib228226ec511491b87b183c6d217a21a_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are, and may in the future be, a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> suits, governmental investigations and audits and other legal matters, any of which could result in, among other things, substantial financial penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or awards against us, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future participation in Medicare, Medicaid and other healthcare programs and possible criminal penalties, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may in the future be, subject to investigations and audits by governmental agencies and/or private civil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators and other lawsuits, demands, claims, legal proceedings and/or other actions, including, without limitation, investigations or other actions resulting from our obligation to self-report certain suspected violations of law. Any allegations against us, our personnel or our representatives in such matters may among other things harm our reputation, stock price, and our various business relationships and/or contracts related to our business, and these impacts may be material.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings, as well as defending ourselves in such matters, will continue to require management's attention and cause us to incur significant legal expense. Negative developments, findings or terms and conditions that we might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters could result in, among other things, harm to our reputation, substantial financial penalties or awards against us, substantial payments made by us, required changes to our business practices, impacts on our various relationships and/or contracts related to our business, exclusion from future participation in Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on us. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with governmental investigations. Other than as may be described in Note 16 to the consolidated financial statements included in this report, we cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which we are or may be subject from time to time, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. See Note 16 to the consolidated financial statements included in this report for further details regarding these and other legal proceedings and regulatory matters.</span></div><div id="ib228226ec511491b87b183c6d217a21a_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us decline, if commercial plans subject patients to restriction in plan designs, or if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. dialysis net patient services revenues for the year ended December&#160;31, 2022 was generated from patients who have commercial payors as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. As such our revenue and net income levels are sensitive to the number of our patients with higher-paying commercial insurance coverage and the percentage of our patients under higher-paying commercial plans relative to government-based programs. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When traditional or original Medicare (Medicare) becomes the primary payor for a patient, the payment rate we receive for that patient decreases from the employer group health plan or commercial plan rate to the lower Medicare payment rate. If the number of our patients who have Medicare or another government-based program as their primary payor increases, it could negatively impact the percentage of our patients covered under commercial insurance plans. There are a number of factors that could drive a decline in the number or percentage of our patients covered under commercial insurance plans, including, among </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">others, a continued decline in the rate of growth of the ESRD patient population, improved mortality, changes in the patient's or a family member's employment status, reduced availability of commercial health plans or reduced coverage by such plans through the ACA exchanges or otherwise due to changes to the laws, marketplace, healthcare regulatory system or otherwise. Commercial payors could also cease paying in the primary position after providing 30 months of coverage resulting in potentially material reductions in payment as the patient moves to Medicare primary. Declining macroeconomic conditions could also negatively impact the percentage of our patients covered under commercial insurance plans. To the extent there are job losses in the U.S., we could experience a decrease in the number of patients covered under commercial plans and/or an increase in uninsured and underinsured patients independent of whether general economic conditions improve. If we experience higher numbers of uninsured or underinsured patients, it also would result in an increase in uncollectible accounts. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements and negotiations with payors also impact the number or percentage of patients with higher-paying commercial insurance. We continuously are in the process of negotiating existing and potential new agreements with commercial payors who aggressively negotiate terms with us, and we can make no assurances about the ultimate results of these negotiations or the timing of any potential rate changes resulting from these negotiations. Sometimes many significant agreements are being renegotiated at the same time. We believe payor consolidations have significantly increased the negotiating leverage of commercial payors, and ongoing consolidations may continue to increase this leverage in the future. In addition, our agreements and rates with commercial payors may be impacted by new business activities of these commercial payors as well as steps that these commercial payors have taken and may continue to take to control the cost of and/or the eligibility for access to the services that we provide, including, without limitation, relative to products on and off the healthcare exchanges. These efforts could impact the number of our patients who are eligible to enroll in commercial insurance plans, and remain on the plans, including plans offered through healthcare exchanges. We continue to experience downward pressure on some of our rates with commercial payors as a result of these and other general conditions in the market, including, among other things, as employers seek to shift to less expensive options for medical services or as commercial payors dedicate increased focus on dialysis services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations with commercial payors may relate to commercial fee-for-service contracts, value-based care (VBC) contracts in which we share risk with commercial payors or other structures that allow the parties to share in cost savings upon the achievement of certain outcomes, as well as contracts to provide dialysis services to Medicare Advantage (MA) patients. If we fail to maintain contracts with payors and other healthcare providers with competitive or favorable terms, either with respect to commercial plans, commercial VBC contracts, MA plans or otherwise, including, without limitation, with respect to reimbursement rates, scope and duration of coverage and in-network benefits, contract term or termination rights, or if we fail to accurately estimate the price for and manage our medical costs in an effective manner, whether due to inflationary pressures or otherwise, such that the profitability of our commercial or other value-based products is negatively impacted, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. The ultimate result of our negotiations with payors cannot be predicted as they occur in a highly competitive environment and are influenced by marketplace dynamics such as those previously discussed. Among other things, these negotiations may result in termination or non-renewals of existing agreements, decreases in contracted rates, and reduction in the number of our patients that are covered by commercial plans, and we may not be able to enter into new agreements on competitive terms or at all. In the event that our ongoing negotiations with commercial payors result in overall rate reductions in excess of overall rate increases, the cumulative effect could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, to the extent that these negotiations result in a reduction in the number of our patients covered by plans with commercial payors, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. A material portion of both our commercial revenue and MA revenue is concentrated with a limited number of commercial payors, and any changes impacting our highest paying commercial payors or our relationships with these payors will have a disproportionate impact on us.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain payors have been attempting to design and implement plans that restrict access to ESRD coverage both in the commercial and individual market. Among other things, these restrictive plan designs seek to limit the duration and/or the breadth of ESRD benefits, limit the number of in-network providers, set arbitrary provider reimbursement rates, or otherwise restrict access to care, all of which may result in a decrease in the number of patients covered by commercial insurance or the reimbursement rate for ESRD services, among other things. Payors have also disputed the scope and duration of ESRD benefit coverage under their plans, and, among other things, have required patients to seek Medicare coverage for ESRD treatments. On June 21, 2022, the U.S. Supreme Court issued a decision in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a case evaluating the scope of the Medicare Secondary Payor Act (MSPA), deciding that a group health plan that provides limited benefits for outpatient dialysis, but does so uniformly for all plan participants, does not violate the terms of the MSPA because the plan treats all patients uniformly, regardless of whether a participant has ESRD and regardless of whether the participant is eligible for Medicare. For additional information, see Note 16 to the consolidated financial statements included in this report. We cannot reasonably estimate the ultimate impact of the U.S. Supreme Court&#8217;s decision at this time, as there is significant uncertainty as to, among other things, whether and to what extent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors, including, among others employer group health plans, may seek to design and implement plans to restrict access to ESRD in light of the decision; whether and how regulators and legislators will respond to the decision, including whether they will issue regulatory guidance or adopt new legislation; how courts will interpret other anti-discriminatory provisions that may apply; whether there could be other potential negative impacts of the decision and any resultant plan behavior on our commercial or government mix or the number of our patients covered by commercial insurance; and the timing of each of these items. If more commercial or employer group health plans seek to implement or utilize plan designs that discourage or prevent ESRD patients from retaining their commercial coverage, it may lead to a decrease in the number of patients with commercial plans, the duration of benefits for patients under commercial plans and/or a decrease in the payment rates we receive, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some commercial payors are pursuing or have incorporated policies into their provider manuals limiting or refusing to accept charitable premium assistance from non-profit organizations, such as the American Kidney Fund, which may impact the number of patients who are able to afford commercial plans. Paying for coverage is a significant financial burden for many patients, and ESRD disproportionately affects the low-income population. Charitable premium assistance supports continuity of coverage and access to care for patients, many of whom are unable to continue working full-time as a result of their severe health condition. Many patients with commercial and government insurance also rely on financial assistance from charitable organizations, such as the American Kidney Fund. Certain payors have challenged our patients' and other providers' patients' ability to utilize assistance from charitable organizations for the payment of premiums, including, without limitation, through litigation and other legal proceedings. The use of charitable premium assistance for ESRD patients has also faced challenges and inquiries from legislators, regulators and other governmental authorities, and this may continue. In addition, CMS or another regulatory agency or legislative authority may issue a new rule or guidance that challenges or restricts charitable premium assistance. If any of these challenges to kidney patients' use of premium assistance is successful or restrictions are imposed on the use of financial assistance from such charitable organizations or if organizations providing such assistance are no longer available such that kidney patients are unable to obtain, or continue to receive or receive for a limited duration, such financial assistance, it may restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, if our assumptions about how kidney patients will respond to any change in financial assistance from charitable organizations are incorrect, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations and relationships with payors may also be impacted by legislative or regulatory developments and associated legal rulings. For example, the final rules for the Cures Act, which are described in detail in Part I, Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation&#8212;21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Century Cures Act,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broadened ESRD patient access to certain enhanced benefits offered by MA plans. While these rules increased our MA plan enrollment for ESRD benefits in their first year, the potential ultimate impact of this change in benefit eligibility remains subject to change as market participants continue to adjust to this new regulatory environment. As an example, the removal of objective time and distance standards relating to network adequacy for outpatient dialysis centers for MA plans that was included in the final rules may adversely impact the number of ESRD patients that select MA plans and also may result in the Company not being an in-network provider for significant MA plans in the event MA plans attempt to use this revision to the rules to limit or restrict their networks. If kidney patients choose not to enroll in MA plans or choose to leave MA plans, whether due to network adequacy standards or otherwise, or if we fail to provide education to kidney patients in the manner specified by CMS, we could be subject to certain clinical, operational, financial and legal risks, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, recent price transparency regulations require most group health plans and health insurance issuers in the group and individual markets to make certain pricing and patient responsibility information publicly available. For further detail on these regulations see the discussion in Part I, Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation&#8212;Health Plan Price Transparency Rules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" On July 1, 2022, enforcement began of the requirement that plans publish machine readable files that include negotiated rates for all covered items and services with all providers and out-of-network allowed amounts. To comply with these requirements, plans have begun to publish these files and make them available to the public. The information that has been made available to date is highly diverse and complex. While the ultimate impact of these requirements remains uncertain, any changes by group health plans, health insurance issuers in the group and individual markets, or consumer choices resulting from these requirements could have a material adverse impact on our business, results of operations, and financial condition, and our reputation could be materially harmed. We could also experience a further decrease in the payments we receive for services if changes to the marketplace or the healthcare regulatory system result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans, or plans with lower reimbursement rates, among other things. For additional details regarding potential legislative or regulatory changes, the specific risks we face in connection with any decrease in payments we receive for services due to, for example, fewer patients being covered under commercial plans or an increase of patients covered under more restrictive commercial plans, or plans with lower reimbursement rates, please see Part I, Item 1. Business of this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned pricing transparency rules, the government has also implemented certain additional pricing transparency requirements that apply to certain types of providers, including DaVita. Under the No Surprises Act, which went into effect January 1, 2022, certain providers, including DaVita, will be required to develop and disclose a &#8220;Good Faith Estimate&#8221; (GFE) that details the expected charges for furnishing an item or service to an uninsured or self-pay patient. The GFE must include certain specific information such as, among other things, co-provider service cost estimates, and is subject to certain format, availability and dispute resolution requirements. Similar to the aforementioned pricing transparency rules, the impact of the GFE requirements on DaVita remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as uncertainty around operational timeframes, potential penalties and patient reaction, among other things. Patient dissatisfaction with the GFE process, whether with respect to the level of charges, how such charges are communicated or otherwise, may impact patient choices and over time could have a material adverse impact on our business, results of operations and financial condition, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted, the foregoing dynamics of our arrangements and negotiations with commercial payors each may have an impact on, among other things, our ability to enter into and maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits as well as the number or percentage of our patients with higher-paying commercial insurance. If, as a result of these or other dynamics, we experience a decline in the average rates that commercial payors pay us or a reduction in the number of patients with ESRD coverage under higher-paying commercial plans either in total or relative to the number of patients under government-based programs that pay at lower rates or an increase in the number of patients that are uninsured or underinsured, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div id="ib228226ec511491b87b183c6d217a21a_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrated kidney care business manages patients and coordinates their care through value-based care arrangements with commercial payors and through government programs. We have continued to grow this portion of our business both with commercial payors, including as MA has expanded, and with government programs as CMS and CMMI implement new payment models focused on comprehensive and integrated kidney care. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s part of our growth strategy, we have invested and expect to continue to invest substantial resources in the further development of our integrated care business and value-based care initiatives. There can be no assurances that we will be able to successfully implement our strategies with respect to integrated kidney care and value-based care in a complex, evolving and highly competitive and regulated environment, including, among other things, maintaining our existing business; recovering our investments; entering into agreements with payors, physicians, third party vendors and others on competitive terms, as appropriate, that prove actuarially sound; structuring these agreements and arrangements to comply with evolving rules and regulations, including, among other things, rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations related to fraud and abuse and the use of protected health information. Implementing our expanded integrated kidney care strategies and value-based care initiatives at scale also increases certain execution and compliance risks associated with developing our operational, IT, billing and telehealth systems, including our ability to accurately capture relevant patient care data, among other things. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on risks associated with information systems and new technology generally, see the risk factor under the heading </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New entrants are aggressively pursuing opportunities to participate in the new CMMI payment models or otherwise establish value-based care programs, and with increasing investment and funding, these new entrants may adopt strategies that increase our costs to participate in these payment models and/or adversely impact our ability to enter into competitive arrangements with payors, physicians and hospitals. For additional detail on our evolving competitive environment, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other of our integrated kidney care and value-based care initiatives are unsuccessful, it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future legislative or regulatory action related to, among other things, integrated kidney care, including among others, CMMI, and/or full capitation demonstration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ESRD may impact our ability to provide a competitive and successful integrated care program at scale. There can be no assurances that any other legislation or regulation that aligns with our strategy and investments will be passed into law or enacted, and the ongoing COVID-19 pandemic may delay the progress of such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives. Additionally, the ultimate terms and conditions of any potential legislative or regulatory action impacting integrated kidney care, full capitation demonstrations or the existing CMMI program remain unclear. For example, our costs of care could exceed our associated reimbursement rates under such legislation. Irrespective of whether such laws are passed or regulations enacted, there can be no assurances that we will be able to successfully execute on the required strategic initiatives that would allow us to provide a competitive and successful integrated care program on a broad scale, and in the desired time frame. Any failure on our part to adequately implement strategic initiatives to adjust to any marketplace developments resulting from executive, legislative, regulatory or administrative changes could have a material adverse impact on our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home-based dialysis services, which include home hemodialysis and peritoneal dialysis (PD), represented approximately 18% of our U.S. dialysis patient services revenues for the year ended December&#160;31, 2022, and have increasingly become an important part of our overall strategy. In addition, home-based dialysis recently has been the subject of increased political and industry focus. For example, in connection with the 2019 Executive Order, HHS set out specific goals related to home dialysis and CMMI&#8217;s ESRD Treatment Choices (ETC) mandatory payment model and voluntary payment models included new incentives to encourage dialysis at home. More recently, CMS finalized changes to the ETC model and other regulations to encourage dialysis facilities and healthcare providers to seek to decrease disparities in health equity across racial and socioeconomic status in rates of home dialysis and kidney transplants among ESRD patients. We are a leader in home-based dialysis and have made investments in processes and infrastructure to continue to grow this modality. There are, however, risks associated with this growth, including, among other things, financial, legal and operational risks related to our ability to design and develop infrastructure and to plan for capacity in a modality that is part of an evolving marketplace. We may also be subject to associated risks related to our ability to successfully manage related operational initiatives, find, train and retain appropriate staff, contract with payors for appropriate reimbursement, and maintain processes to adhere to the complex regulatory and legal requirements, including without limitation those associated with billing Medicare. For additional detail on risks associated with operating in a highly regulated environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the above risks, certain risks inherent to home-based dialysis will increase as we expand our home-based dialysis offerings, including risks related to managing transitions between in-center and home-based dialysis, billing and telehealth systems, among others. For additional detail on risks associated with information systems and new technology generally, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increased focus on home-based dialysis is also indicative of the generally evolving market for kidney care. This developing market may create additional opportunities for competition with relative ease of entry, and if we are unable to successfully adapt to these or other marketplace developments, which, among other things, may include regulatory changes with respect to conditions of coverage, in a timely and compliant manner, we may experience a material adverse impact on our growth in home-based dialysis or a reduction in our overall number of patients, among other things. Our response to the COVID-19 pandemic has also required us to impose certain operational restrictions that may adversely impact certain home-based dialysis initiatives, and the extent of this impact may depend on the severity or duration of the pandemic, among other things. For additional detail on the competitive landscape in kidney care, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for additional detail on the impact of COVID-19 on our home-based dialysis business, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in the structure of and payment rates under the Medicare ESRD program or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our dialysis revenues are generated from patients who have Medicare as their primary payor. For patients with Medicare coverage, all ESRD payments for dialysis treatments are currently made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the treatment of dialysis, subject to certain adjustments as described below. Most lab services are also included in the bundled payment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESRD Prospective Payment System (PPS), bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility's performance in specified quality measures set annually by CMS through the ESRD Quality Incentive Program, which was established by the Medicare Improvements for Patients and Providers Act of 2008. The bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors. In addition, the ESRD PPS is subject to rebasing, which can have a positive financial effect, or a negative one if the government fails to rebase in a manner that adequately addresses the costs borne by dialysis facilities. Similarly, as new drugs, services or labs are added to the ESRD bundle, CMS' failure to adequately calculate or fund the costs associated with the drugs, services or labs could have a material adverse effect on our business, results of operations, financial condition and cash flows. In certain instances, new injectable, intravenous or oral products may be reimbursed separately from the bundled payment for a defined period of time through a transitional drug add-on payment adjustment (TDAPA). For a discussion of certain risks associated with this transitional pricing process, see the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current bundled payment system presents certain operating, clinical and financial risks, which include, without limitation:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that our rates are reduced by CMS. CMS publishes a final rule for the ESRD PPS each year and uncertainty about future payment rates remains a material risk to our business.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS, on its own or through its contracted Medicare Administrative Contractors (MACs) or otherwise, implements Local Coverage Determinations (LCDs) or implements payment provisions, policy or regulatory mandates, including changes to the existing or future PPS, that limit our ability to either be paid for covered dialysis services or bill for treatments or other drugs and services or other rules that may impact reimbursement. Such payment rules and regulations and coverage determinations or related decisions could have an adverse impact on our operations and revenue. There is also risk that commercial insurers could seek to incorporate the requirements or limitations associated with such LCDs or CMS guidance into their contracted terms with dialysis providers, which could have an adverse impact on our revenue. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance, or seek to implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS implements data and related reporting requirements that result in decreased reimbursement and/or increased technology and operational costs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect operating costs to continue to increase due to inflationary factors, such as increases in labor and supply costs, including, without limitation, increases in maintenance costs and capital expenditures to improve, renovate and maintain our facilities, equipment and information technology to meet changing regulatory requirements and business needs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of continued federal budget sequestration cuts or other disruptions in federal government operations and funding. As a result of the Budget Control Act of 2011, the Bipartisan Budget Act (BBA) and the CARES Act, an annual 2% reduction to Medicare payments took effect on April 1, 2013, and has been extended through 2030. These across-the-board spending cuts have affected and will continue to adversely affect our business, results of operations, financial condition and cash flows. Any extended disruption in federal government operations and funding, including an extended government shutdown, U.S. government debt default and/or failure of the U.S. government to enact annual appropriations could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, disruptions in federal government operations may delay or negatively impact regulatory approvals and guidance that are important to our operations, and create uncertainty about the pace of upcoming regulatory developments.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that failure to adequately develop and maintain our clinical or other operational systems or failure of our clinical or operational systems to operate effectively could have a material adverse effect on our business, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if our clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, we might be over-reimbursed by the government, which could, among other things, subject us to liability exclusion from participation in federal healthcare programs and penalties under the federal Civil Monetary Penalty statute, and could adversely impact our reputation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to similar risks for services billed separately from the ESRD bundled payment, including, without limitation, the risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance; or seek to implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks under the current Medicare ESRD program, changing legislation and other regulatory and executive developments have led and may continue to lead to the emergence of new models of care and other initiatives in both the government and private sector that, among other things, may impact the structure of, and payment rates under, the Medicare ESRD program. Moreover, the number of our patients with primary Medicare coverage may be subject to change, particularly with the effectiveness of the Cures Act, which allows Medicare-eligible individuals with ESRD to enroll in MA managed care plans. For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations or failing to adequately implement strategic initiatives to adjust to marketplace developments, see the risk factors above under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Changes in federal and state healthcare legislation or regulations..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary coverage for a significant number of our patients also comes from state Medicaid programs partially funded by the federal government as well as other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA). As state governments and other governmental organizations face increasing financial hardship and budgetary pressure, including as a result of the COVID-19 pandemic or changes in the political environment, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions, such as the VA's adoption of Medicare's bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a national contracting initiative. Since we are a non-VA provider, these reimbursements are tied to a percentage of Medicare reimbursement, and we have exposure to any dialysis reimbursement changes made by CMS. Approximately 3% of our U.S. dialysis patient services revenues for the year ended December&#160;31, 2022 were generated by the VA. In addition, in 2019, we entered into a Nationwide Dialysis Services contract with the VA that includes five separate one-year renewal periods throughout the term of the contract. The term structure is similar to our prior five-year agreement with the VA, and is consistent with VA practice for similar provider agreements. With this contract award, the VA has agreed to keep our percentage of Medicare reimbursement consistent with that under our prior agreement with the VA during the term of the contract. As with that prior agreement, this agreement provides the VA with the right to terminate the agreements without cause on short notice, among other things. Should the VA renegotiate, not renew or cancel these agreements for any reason, we may cease accepting patients under this program and may be forced to close centers or experience lower reimbursement rates, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing infrastructure, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our business, results of operations, financial condition and cash flows. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs, could reduce the rates paid by these programs for dialysis and related services, delay the receipt of payment for services provided and further limit eligibility for coverage which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div id="ib228226ec511491b87b183c6d217a21a_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is labor intensive and if our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain employees; or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity, we may experience disruptions in our business operations and increases in operating expenses, among other things, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increasing labor costs generally, and in particular, we continue to face increased labor costs and difficulties in hiring nurses due to a nationwide shortage of skilled clinical personnel that has been exacerbated by the ongoing COVID-19 pandemic and recent developments in the labor market. As referenced above, the current labor market is challenging and continues to experience volatility, uncertainty and labor supply shortages, particularly in healthcare. Our business is labor intensive, and our financial and operating results have been and continue to be sensitive to variations in labor-related costs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">productivity and the number of pending or potential claims against us related to labor and employment practices. We have incurred and expect to continue to incur increased labor costs and experience staffing challenges, including without limitation those related to COVID-19, the ultimate extent of which will depend on the severity and duration of the pandemic and ancillary impacts on the economy and labor market, among other things. For additional discussion of the risks facing us related to the current labor environment and COVID-19, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent that general inflationary pressures continue or further increase, this may in turn increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for nurses with hospitals and other healthcare providers. The ongoing nursing shortage may limit our ability to expand our operations. Furthermore, changes in certification requirements can impact our ability to maintain sufficient staff levels, including to the extent our teammates are not able to meet new requirements, among other things. In addition, if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth may be negatively impacted, which could adversely affect our business, results of operations, financial condition and cash flows. For example, in 2022, we did experience elevated rates of teammate turnover, which led to increased training costs and costs related to contract labor, among other things. We also face competition in attracting and retaining talent for key leadership positions. If we are unable to attract and retain qualified individuals, we may experience disruptions in our business operations, including, without limitation, our ability to achieve strategic goals, which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political or other efforts at the national or local level could result in actions or proposals that increase the likelihood of success of union organizing activities at our facilities and ongoing union organizing activities at our facilities could continue or increase for other reasons. We could experience an upward trend in wages and benefits and labor and employment claims, including, without limitation, the filing of class action suits, or adverse outcomes of such claims, or face work stoppages. In addition, we are and may continue to be subject to targeted corporate campaigns by union organizers in response to which we have been and expect to continue to be required to expend substantial resources, both time and financial. Any of these events or circumstances could have a material adverse effect on our employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous federal and state laws and regulations in both the U.S. and the foreign jurisdictions in which we operate governing the collection, dissemination, access, use, security and privacy of PHI, including, without limitation, HIPAA and its implementing privacy, security, and related regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH) and collectively referred to as HIPAA. We are also required to report known breaches of PHI and other certain personal information consistent with applicable breach reporting requirements set forth in applicable laws and regulations. From time to time, we may be subject to both federal and state inquiries or audits related to HIPAA, HITECH and other state privacy laws associated with complaints, desk audits, and data breaches. Requirements under HIPAA also continue to evolve. If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including PHI, or financial information or payroll data on our behalf, properly maintain the integrity of our data, protect our proprietary rights, or defend against cybersecurity attacks, it could materially harm our reputation and/or have a material adverse effect on our business, results of operations, financial condition and cash flows. These risks may be intensified to the extent that the laws change or to the extent that we increase our use of third-party service providers that utilize sensitive personal information, including PHI, on our behalf.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data protection laws are evolving globally, and may continue to add additional compliance costs and legal risks to our international operations. For more details on certain international data protection laws and regulations affecting our business, see Part I, Item 1. Business of this Form 10-K under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Government Regulation."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The costs of compliance with, and other burdens imposed by these international data protection laws and regulations including, among others, the General Data Protection Regulation (GDPR) in the EU and UK, and other new laws, regulations and policies implementing these regulations may impact our international operations and may limit the ways in which we can provide services or use personal data collected while providing services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws are also evolving nationally, providing for enhanced state privacy rights that are broader than the current federal privacy rights, and may add additional compliance costs and legal risks to our U.S. operations. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs of compliance with, and the burdens imposed by, these and other new federal and state laws, regulations or policies may impact our operations and/or limit the ways in which we can provide services or use personal data collected while providing services. If we fail to comply with the requirements of these and other new laws, regulations or policies, we could be subject to penalties that, in some cases, would have a material adverse impact on our business, results of operations, financial condition and cash flows. For more details on the privacy and other regulations affecting our business, see Part I, Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Scrutiny over cybersecurity standards in the health sector is also increasing, and ongoing developments in this area may cause us to invest additional resources in technology, personnel and programmatic cybersecurity controls as the cybersecurity risks we face continue to evolve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through remote work arrangements).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. Cybersecurity requires ongoing investment and diligence against evolving threats. Emerging and advanced security threats, including, without limitation, coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations. As with any security program, there always exists the risk that employees will violate our policies despite our compliance efforts or that certain attacks may be beyond the ability of our security and other systems to detect. There can be no assurance that investments, diligence and/or our internal controls will be sufficient to prevent or timely discover an attack.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including, among others, PHI, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, results of operations, financial condition, and cash flows and materially harm our reputation. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures, or to make required notifications. The occurrence of any of these events could, among other things, result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems and liability under privacy and security laws, all of which could have a material adverse effect on our business, results of operations, financial condition and cash flows, or materially harm our reputation and trigger regulatory actions and private party litigation. If we are unable to protect the physical and electronic security and privacy of our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients, physicians, vendors and other business partners would be harmed, and our business, results of operations, financial condition and cash flows could be materially and adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, and could further result in a material adverse effect on our business, results of operations, financial condition and cash flows or harm our reputation. As malicious cyber activity escalates, including activity that originates outside of the U.S., and as we continue with certain remote work arrangements and a broadened technology footprint, the risks we face relating to transmission of data and our use of service providers outside of our network, as well as the storing or processing of data within our network, have intensified. There have been increased international, federal and state and other privacy, data protection and security enforcement efforts and we expect this trend to continue. While we plan to maintain cyber liability insurance, there can be no assurance that we will successfully be able to obtain such insurance on terms and conditions that are favorable to us or at all. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, any cyber liability insurance may not cover us for all types of losses or harms and may not be sufficient to protect us against the amount of all losses.</span></div><div id="ib228226ec511491b87b183c6d217a21a_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. We are also subject to the risk associated with our increased reliance on third party service providers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant suppliers, with a substantial portion of our total vendor spend concentrated with a limited number of third party suppliers. These third party suppliers include, without limitation, suppliers of pharmaceuticals or clinical products that may be the primary source of products critical to the services we provide, or to which we have committed obligations to make purchases, sometimes at particular prices. We and other dialysis providers have experienced supply chain shortages with respect to certain of our equipment and clinical supplies, such as dialysate, which is the fluid solution used in hemodialysis to filter toxins and fluid from the blood, and in certain cases, we have had to make significant operational changes in response. Separately, the ongoing COVID-19 pandemic also has resulted in global supply chain challenges and has materially impacted global supply chain reliability, as further described in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our suppliers do not meet our needs for the products they supply, including, without limitation, in the event of COVID-19 related global supply chain challenges, a product recall, other shortage or dispute, and we are not able to find adequate alternative sources at competitive prices; if we experience material price increases from these suppliers or otherwise in connection with our actions to secure needed products that we are unable to mitigate; if some of the drugs that we purchase from our suppliers are not reimbursed or not adequately reimbursed by commercial or government payors; or if we are unable to secure products, including pharmaceuticals at competitive rates and within the desired time frame; it could negatively impact our ability to effectively provide the services we offer, have a material adverse impact on our business, results of operations, financial condition and cash flows, and could materially harm our reputation. In addition, the technology related to the products critical to the services we provide is subject to new developments which may result in superior products. If we are not able to access superior products on a cost-effective basis, either due to competitive conditions in the marketplace or otherwise, or if suppliers are not able to fulfill our requirements for such products, we could face patient attrition and other negative consequences which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely increasingly on third party service providers to perform certain functions, including, among others, finance and accounting and information technology functions. This reliance subjects us to risks arising from the loss of control over these services, changes in pricing that may affect our operating results, and potentially, termination of provisions of these services by our providers. There can be no assurance that our third party service providers will provide, or continue to provide, the level of services we require. Any failure by our third party service providers to adequately perform their obligations could negatively impact our ability to effectively execute certain important corporate functions and have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div id="ib228226ec511491b87b183c6d217a21a_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare bundles certain pharmaceuticals into the ESRD PPS payment rate at industry average doses and prices. Variations above the industry average may be subject to partial reimbursement through the PPS outlier reimbursement policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to industry averages, which can be caused by, among other things, changes in physician prescribing practices, including in response to the introduction of new drugs, treatments or technologies, changes in best and/or accepted clinical practice, changes in private or governmental payment criteria regarding pharmaceuticals and/or devices, or the introduction of administration policies may negatively impact our ability to obtain sufficient reimbursement levels for the care we provide, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Physician practice patterns, including their independent determinations as to appropriate pharmaceuticals and dosing, are subject to change, including, for example, as a result of changes in labeling of pharmaceuticals or the introduction of new pharmaceuticals. Additionally, commercial payors have increasingly examined their administration policies for pharmaceuticals and, in some cases, have modified those policies. If such policy and practice trends or other changes to private and governmental payment criteria make it more difficult to preserve our margins per treatment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. Further, increased utilization of certain pharmaceuticals whose costs are included in a bundled reimbursement rate, or decreases in reimbursement for pharmaceuticals </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whose costs are not included in a bundled reimbursement rate, could also have a material adverse effect on our business, results of operation, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations and processes impacting reimbursement for pharmaceuticals and/or devices and any changes thereto could similarly affect our operating results. Among other things, as new kidney care drugs, treatments or technologies are introduced over time, we expect that the use of transitional payment adjustments to incorporate certain of these new drugs, treatments or technologies as defined by the CMS policy into the bundled Medicare Part B ESRD payment may lead to fluctuations in associated levels of operating income and risk that the reimbursement levels of such drugs, treatments or technologies may not adequately cover our cost to obtain the drug or other associated costs. Drivers of these risks include, among other things, the risk that CMS may not provide adequate funding in the Medicare Part B ESRD payment in the post-transitional period or such items are not covered by transitional add on pricing, in which case there may be less clarity on the reimbursement, either of which may in turn materially adversely impact our business, results of operations, financial condition and cash flows. For example, in the event that a hypoxia-inducible factor (HIF) product is approved by the FDA we expect that HIF products will be subject to a TDAPA period prior to being incorporated into the payment bundle. We are developing operational and clinical processes designed to provide the drug as may be required under the applicable regulations and as may be prescribed by physicians and also are working to contract with manufacturers of drug(s) to establish terms and access to the product, as well as payors, as applicable, for reimbursement and/or administration of the drug. While the timing and details of a potential approval, including the contents of the applicable FDA label, remain uncertain, if HIF products are approved, we could experience significant fluctuations in our associated levels of operating income and could be subject to material financial, operational and/or legal risk if we are not adequately reimbursed for the cost of the drug, if we are unable to implement effective and appropriate operational measures to distribute the drug, if we fail to implement appropriate storage and diversion controls or if we cannot obtain competitive pricing for the HIF, the aggregate impact of these risks could have a material adverse effect on our business, results of operation, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar operating and clinical rigor and appropriate processes will be needed for other potential new drugs, treatments or technologies that are approved and come onto the market, as well as for drugs, treatments or technologies that we contract to receive from different suppliers. In 2022, for example, a new medication that assists with uremic pruritus in dialysis patients was available to patients, and we began our transition to our new ESA contract. In both cases, we developed systems and processes for all facets of operationalizing the availability and reimbursement of each medication. We anticipate other drugs and/or biologics to continue to come onto the market in subsequent years. Any failure to successfully contract with manufacturers for competitive pricing, failure to successfully contract with the government or other payors for appropriate reimbursement, or failure to prepare, develop and implement processes that provide for appropriate availability and use in our clinics in compliance with applicable laws, including those related to controlled substances, could have a material adverse impact on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties related to pharmaceuticals, which would require management's attention and could result in significant legal expense. Any negative findings could result in, among other things, substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation. For additional details, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="ib228226ec511491b87b183c6d217a21a_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive and continuously evolving environment across the spectrum of kidney care, and operating in this market requires us to successfully execute on strategic initiatives which, among other things, build or retain our patient population through acquisition or referrals, or that develop and maintain our relationships with physicians and hospitals in both the dialysis and pre-dialysis space. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for relationships with certain referral sources, including nephrologists and hospitals, in existing and expanding geographies or areas is intense, and we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for physicians qualified to serve as medical directors, for limited acquisition targets and for individual patients. In addition to these large and medium-sized competitors with substantial financial resources and other established participants in the dialysis space, we also compete with individual nephrologists who have opened their own dialysis units or facilities. Our largest competitor, Fresenius Medical Group, manufactures a full line of dialysis supplies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and equipment in addition to owning and operating dialysis centers, which may, among other things, give it cost advantages over us because of its ability to manufacture its own products. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously compete for maintaining or developing relationships with physicians that can serve as medical directors at our centers. Physicians, including medical directors, choose where they refer their patients, and neither of our current or former medical directors have an obligation to refer their patients to our centers. Certain physicians prefer to have their patients treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, referral sources for many of our centers include the physician or physician group providing medical director services to the center. Moreover, because Medicare regulations require medical directors for each of our Medicare certified dialysis centers, our ability to operate our centers depends in part on our ability to secure medical director agreements with a sufficient number of nephrologists. Our medical director contracts are for fixed periods, generally ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us and, under certain circumstances, our former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. If we are unable to contract with nephrologists to provide medical director services, then we may be unable to satisfy the federal Medicare requirements associated with medical directors and to operate our centers. The aging of the nephrologist population and opportunities presented by our competitors may negatively impact a medical director's decision to enter into or extend his or her agreement with us. In addition, if the terms of any existing agreement are found to violate applicable laws, there can be no assurances that we would be successful in restructuring the relationship, which would lead to the early termination of the agreement. If we are unable to obtain qualified medical directors to provide supervision of the operations and care provided at our dialysis centers, it could affect not only our ability to operate the center and for other physicians to feel confident in referring patients to our dialysis centers. If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to law, rule or regulation, new competition, a perceived decrease in the quality of service levels at our centers or other reasons, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we continue to expand our offerings across the kidney care continuum, our ability to enter into and maintain integrated kidney care relationships with payors, physicians and other providers may have an impact on dialysis patient retention and the continued referrals of patients from referral sources such as hospitals and nephrologists. This environment is highly competitive and has been evolving. For example, there have been a number of announcements, initiatives and capital raises by non-traditional dialysis providers and others, which relate to entry into the dialysis and pre-dialysis space, the development of innovative technologies, or the commencement of new business activities that could be transformative to the industry. Some of these new entrants have considerable financial resources. Although these and other potential competitors may face operational or financial challenges, the evolving nature of the dialysis and pre-dialysis marketplaces have presented some opportunities for relative ease of entry for these and other potential competitors. As a result, we may compete with these smaller or non-traditional providers or others in an asymmetrical environment with respect to data and regulatory requirements that we face as an ESRD service provider, thereby negatively impacting our ability to effectively compete. These and other factors have continued to drive change in the dialysis and pre-dialysis space, and if we are unable to successfully adapt to these dynamics, it could have a material adverse impact on our business, results of operations, financial condition and cash flows. As an example, new entrants are aggressively pursuing opportunities to participate in the new CMMI payment models or otherwise establish value-based care programs, and increasing investment in and availability of funding to new entrants in the dialysis and pre-dialysis marketplace that are not subject to the same regulatory restrictions as the Company, could adversely impact our ability to enter into competitive arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the aforementioned competitive pressures and related risks may be impacted by a continued decline in the rate of growth of the ESRD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, whether due to the development of innovative technologies or otherwise. The recent 2022 annual data report from the United States Renal Data System (USRDS) suggests that the rate of growth of the ESRD patient population is declining relative to long-term trends. A number of factors may impact ESRD growth rates, including, without limitation, the aging of the U.S. population, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, transplant rates, mortality rates for dialysis patients or CKD patients and growth rates of minority populations with higher than average incidence rates of ESRD. Certain of these factors, in particular the mortality rates for dialysis patients, have been impacted by the COVID-19 pandemic. The magnitude of these cumulative COVID-19 related impacts on our patient census and treatment volumes has been material and depending on the ultimate severity and duration of the pandemic, could continue to be material. While we have continued efforts to seek growth opportunities, such as by expanding our business into various international markets, we face ongoing competition from large and medium-sized providers, among others, for acquisition targets in those markets. Providers may reduce pricing in an attempt to capture more volume in the face of declining ESRD patient growth. Any failure on our part to appropriately adjust our business and operations in light of these complicated marketplace dynamics could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively compete in the markets in which we operate, including by implementing our growth strategy, effectively adjusting our business and operations in light of evolving marketplace dynamics, building or retaining our patient population, maintaining and developing relationships with nephrologists and hospitals, particularly medical director relationships, or making acquisitions at the desired pace or at all; if we are not able to continue to maintain the expected or desired level of non-acquired growth; or if we experience significant patient attrition either as a result of new business activities in the dialysis or pre-dialysis space by our existing competitors, other market participants, new entrants, new technology or other forms of competition, or as a result of reductions in demand for dialysis treatments, including, without limitation, due to increased mortality rates for dialysis patients resulting from COVID-19 or otherwise, reduced prevalence of ESRD, the development of innovative technologies or an increase in the number of kidney transplants, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div id="ib228226ec511491b87b183c6d217a21a_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. integrated kidney care and U.S. other ancillary services are subject to many of the same risks, regulations and laws, as described in the risk factors related to our dialysis business set forth in Part I, Item 1A. of this Form 10-K, and are also subject to additional risks, regulations and laws specific to the nature of the particular strategic initiative. We have added, and expect to continue to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare products or services not directly related to dialysis. Many of these initiatives require or would require investments of both management and financial resources and can generate significant losses for a substantial period of time and may not become profitable in the expected timeframe or at all. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions or business performance, including, without limitation, as a result of the COVID-19 pandemic, or in the political, legislative or regulatory environment, may impact the performance or economic viability of any of these strategic initiatives. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our U.S. integrated kidney care, U.S. ancillary services or international operations are unsuccessful, it may have a negative impact on our business, results of operations, financial condition and cash flows, and if we determine to exit that line of business we may incur significant termination costs. For discussion of risks and potential impacts specific to our integrated kidney care business and related growth strategy, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur material write-offs or impairments of our investments, including, without limitation, goodwill or other assets, in one or more of our U.S. integrated kidney care, U.S. ancillary services or international operations. In that regard, we have taken, and may in the future take, impairment and restructuring charges in addition to those described above related to our U.S. integrated kidney care, U.S. ancillary services and international operations, including, without limitation, in our prior pharmacy businesses.</span></div><div id="ib228226ec511491b87b183c6d217a21a_2792"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S., subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our operations by offering our services and entering new lines of business in certain markets outside of the U.S., and we have increased our utilization of third-party suppliers and service providers operating outside of the U.S., which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include those relating to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the local economic environment including, among other things, labor cost increases and other general inflationary pressures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political instability, armed conflicts or terrorism;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public health crises, such as pandemics or epidemics, including the COVID-19 pandemic;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">social changes;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property legal protections and remedies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional U.S. and foreign taxes;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export controls;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of reliable legal systems which may affect our ability to enforce contractual rights;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local laws or regulations, or interpretation or enforcement thereof;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially longer ramp-up times for starting up new operations and for payment and collection cycles;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial and operational, and information technology systems integration;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with U.S. laws, such as the FCPA, or local laws that prohibit us, our partners, or our partners' or our agents or intermediaries from making improper payments to foreign officials or any third party for the purpose of obtaining or retaining business; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data and privacy restrictions, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues relating to the failure to comply with applicable non-U.S. laws, requirements or restrictions may also impact our domestic business and/or raise scrutiny on our domestic practices.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some factors that will be critical to the success of our international business and operations will be different than those affecting our domestic business and operations. For example, conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations, including to fulfill financial reporting and records retention requirements among other things, and to overcome the numerous new challenges inherent in managing international operations, including, without limitation, challenges based on differing languages and cultures, challenges related to establishing clinical operations in differing regulatory and compliance environments, and challenges related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations in an environment with which we are not familiar.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expansion of our international operations through acquisitions or through organic growth could increase these risks. Additionally, while we may invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, including to start up or acquire new operations, we may not be able to operate them profitably on the anticipated timeline, or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, or failure to adhere to federal and state data sharing and access requirements and regulations could materially adversely affect our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends significantly on effective information systems. Our information systems require an ongoing commitment of significant resources to maintain, upgrade and enhance existing systems and develop or contract for new systems in order to keep pace with continuing changes in information processing technology, emerging cybersecurity risks and threats, evolving industry, legal and regulatory standards and requirements, new models of care, and other changes in our business, among other things. For example, the provisions related to data interoperability, information blocking, and patient access in the Cures Act and No Surprises Act include, among other things, changes to the Office of the National Coordinator for Health Information Technology&#8217;s (ONC's) Health IT Certification Program and requirements that CMS-regulated payors make relevant claims/care data and provider directory information available through standardized patient access and provider directory application programming interfaces (APIs) that connect to provider electronic health records. We have made and expect to continue to make significant investments in updating and integrating our clinical IT systems and continuing to build our data interoperability capabilities. Any failure to adequately comply with these and other provisions related to data interoperability, information blocking, and patient access may, among other things, result in fines and sanctions, adversely impact our Medicare business, our ability to scale our integrated care business and our ability to compete with certain smaller and/or non-traditional providers taking advantage of an asymmetrical environment with respect to data and/or regulatory requirements given our status as an ESRD service provider; or otherwise have a material adverse effect on our business, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition, results of operations and cash flows. Rulemaking in these areas is ongoing, and there can be no assurances that the implementation of planned enhancements to our systems, such as our implementation of these data interoperability provisions or our other ongoing efforts to upgrade and better integrate our clinical systems, will be successful once the regulatory environment settles or that we will ultimately realize anticipated benefits from investments in new or existing information systems. In addition, we may from time to time obtain significant portions of our systems-related support, technology or other services from independent third parties, which may make our operations vulnerable if such third parties fail to perform adequately.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully implement, operate and maintain effective and efficient information systems with adequate technological capabilities, deficiencies or defects in the systems and related technology, or our failure to efficiently and effectively implement ongoing system upgrades or consolidate our information systems to eliminate redundant or obsolete applications, could result in increased legal and compliance risks and competitive disadvantages, among other things, which could have a material adverse effect on our business, financial condition, results of operations and reputation. For additional information on the risks we face in a highly competitive market, see the risk factor under the heading, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the information we rely upon to run our business was found to be inaccurate or unreliable or if we or third parties on which we rely fail to adequately maintain information systems and data integrity effectively, whether due to software deficiencies, human coding or implementation error or otherwise, we could experience difficulty meeting clinical outcome goals, face regulatory problems, including sanctions and penalties, incur increases in operating expenses or suffer other adverse consequences, any of which could be material. Moreover, failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or information systems and data hosted by third parties upon which we rely, could subject us to severe consequences as described in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Privacy and information security laws are complex..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our billing systems, among others, are critical to our billing operations. This includes our systems for our dialysis clinics as well as our systems for our ancillary businesses including hospital services. If there are defects in our billing systems, or billing systems or services of third parties upon which we rely, we may experience difficulties in our ability to successfully bill and collect for services rendered, including, without limitation, a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement laws and related requirements, any or all of which could materially adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the clinical environment, a failure of our clinical systems, or the systems of our third-party service providers, to operate effectively could have a material adverse effect on our business, the clinical care provided to patients, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if relevant clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, this could impact our payments from government payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect the highly competitive environment in which we operate to become increasingly more competitive as the market evolves and new technologies are introduced. This dynamic environment requires continuous investment in new technologies and clinical applications. Machine learning and artificial intelligence are increasingly driving innovations in technology, and parts of our operations may employ robotics. If these technologies or applications fail to operate as anticipated or do not perform as specified, including due to potential design defects and defects in the development of algorithms or other technologies, human error or otherwise, our clinical operations, business and reputation may be harmed. If we are unable to successfully maintain, enhance or operate our information systems, including through the implementation of such technologies or applications in our clinical operations and laboratory, we may be, among other things, unable to efficiently adapt to evolving laws and requirements, unable to remain competitive with others who successfully implement and advance this technology, subject to increased risk under existing laws, regulations and requirements that apply to our business, and our patients' safety may be adversely impacted, any of which could have a material adverse impact on our business, results of operations and financial condition and could materially harm our reputation. For additional detail, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="ib228226ec511491b87b183c6d217a21a_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growth through acquisitions of dialysis centers and other businesses, as well as through entry into joint ventures. We may engage in acquisitions, mergers, joint ventures or dispositions or expand into new business lines or models, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business. For example, in 2022 we entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo). The transaction is expected to close in 2023, subject to customary closing conditions and regulatory approvals, and is expected to require us to make significant cash investments to help fund the business and fund additional consideration to Medtronic in certain circumstances. See the discussion under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II, Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to identify suitable acquisition or joint venture targets or merger partners or buyers for dispositions or that, if identified, we will be able to agree to acceptable terms or on the desired timetable. There can also be no assurance that we will be successful in completing any acquisitions, joint ventures, mergers or dispositions that we announce, executing new business lines or models or integrating any acquired business into our overall operations. There is no guarantee that we will be able to operate acquired businesses successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation. In addition, acquisition, merger or joint venture activity conducted as part of our overall growth strategy is subject to antitrust and competition laws, and antitrust regulators can investigate future (or pending) and consummated transactions. These laws could impact our ability to pursue these transactions, and under certain circumstances, could result in mandated divestitures, among other things. If a proposed transaction or series of transactions is subject to challenge under antitrust or competition laws, we may incur substantial legal costs, management&#8217;s attention and resources may be diverted, and if we are found to have violated these or other related laws, regulations or requirements, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation and stock price. For additional detail, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, we cannot be certain that key talented individuals at the business being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate resources to successfully operate any acquired business. In addition, certain of our acquired dialysis centers and facilities have been in service for many years, which may result in a higher level of maintenance costs. Further, our facilities, equipment and information technology may need to be improved or renovated to maintain or increase operational efficiency, compete for patients and medical directors, or meet changing regulatory requirements. Increases in maintenance costs and/or capital expenditures could have, under certain circumstances, a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated, and may have other issues, including, without limitation, those related to internal control over financial reporting or issues that could affect our ability to comply with healthcare laws and regulations and other laws applicable to our expanded business, which could harm our reputation. As a result, we cannot make any assurances that the acquisitions we consummate will be successful. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits, the amounts held in escrow for our benefit (if any), or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the equity purchase agreement for the DMG sale (the DMG sale agreement), we agreed to certain indemnification obligations, including with respect to claims for breaches of our representations and warranties regarding compliance with law, litigation, absence of undisclosed liabilities, employee benefit matters, labor matters, or taxes, among others, and other claims for which we provided the buyer with a special indemnity. As a result, we may become obligated to make payments to the buyer relating to our previous ownership and operation of the DMG business. Any such post-closing liabilities and required payments under the DMG sale agreement, or otherwise, or in connection with any other past or future disposition of material assets or businesses could individually or in the aggregate have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, joint ventures or noncontrolling interest investments, including, without limitation, our Asia Pacific joint venture, inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or noncontrolling interest investment. In addition, we may be dependent on joint venture partners, controlling shareholders or management who may have business interests, strategies or goals that are inconsistent with ours. Business decisions or other actions or omissions of the joint venture partner, controlling shareholders or management may require us to make capital contributions or necessitate other payments, result in litigation or regulatory action against us, result in reputational harm to us or adversely affect the value of our investment or partnership, among other things. In addition, we have potential obligations to purchase the interests held by third parties in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many of our joint ventures as a result of put provisions that are exercisable at the third party's discretion within specified time periods, pursuant to the applicable agreement. If these put provisions were exercised, we would be required to purchase the third party owner's equity interest, generally at the appraised market value. There can be no assurances that these joint ventures and/or noncontrolling interest investments, including, without limitation, our Asia Pacific joint venture, ultimately will be successful.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately 28% of our U.S. dialysis revenues for the year ended December&#160;31, 2022. In addition, we also owned noncontrolling equity investments in several other dialysis related joint ventures. We expect to continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have certain physician owners providing medical director services to centers we own and operate. Because our relationships with physicians are governed by the federal and state anti-kickback statutes, we have sought to structure our joint venture arrangements to satisfy as many federal safe harbor requirements as we believe are commercially reasonable. Our joint venture arrangements do not satisfy all of the elements of any safe harbor under the federal Anti-Kickback Statute, however, and therefore are susceptible to government scrutiny. Additionally, our joint ventures and minority investments inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or minority investment. If our joint ventures are found to violate applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. For additional information on these risks, see the risk factors under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions..."</span></div><div id="ib228226ec511491b87b183c6d217a21a_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters expose us to numerous risks, including without limitation risks to our reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a longstanding ESG program and have engaged with key stakeholders to develop ESG focus areas and to set ESG-related goals, many of which are aspirational. We have set and disclosed these focus areas, goals and related objectives as part of our continued commitment to ESG matters, but our goals and objectives reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, certain of which are outside of our control, and could have, under certain circumstances, a material adverse impact on us, including on our reputation and stock price. Examples of such risks include, among others: the availability and cost of low- or non-carbon-based energy sources and technologies for us and our vendors, evolving regulatory requirements affecting ESG standards, frameworks and disclosures, including evolving standards for measuring and reporting on related metrics, the availability of suppliers that can meet our sustainability and other standards, our ability to recruit, develop and retain diverse talent in our labor markets, and our ability to grow our home based dialysis business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquirer could be negatively impacted. Similarly, our failure or perceived failure to adequately pursue or fulfill our goals and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to other risks, which under certain circumstances could be material. If we are not able to adequately recognize and respond to the rapid and ongoing developments and governmental and social expectations relating to ESG matters, this failure could result in missed corporate opportunities, additional regulatory, social or other scrutiny of us, the imposition of unexpected costs, or damage to our reputation with governments, patients, teammates, third parties and the communities in which we operate, which in turn could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock to decline.</span></div><div id="ib228226ec511491b87b183c6d217a21a_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There are significant risks associated with estimating the amount of dialysis revenues and related refund liabilities that we recognize, and if our estimates of revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition or have a material adverse effect on our business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant risks associated with estimating the amount of U.S. dialysis net patient services revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues, such as ensuring appropriate documentation. Determining applicable primary and secondary coverage for approximately 199,400 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of U.S. dialysis patient services revenues estimating risk to be within 1% of revenues for the segment. If our estimates of U.S. dialysis patient services revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition and have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div id="ib228226ec511491b87b183c6d217a21a_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div id="ib228226ec511491b87b183c6d217a21a_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a substantial amount of indebtedness outstanding and we may incur substantial additional indebtedness in the future, including indebtedness incurred to finance repurchases of our common stock pursuant to our share repurchase authorization discussed under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II, Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." As described in Note 13 to the consolidated financial statements included in this report, we are party to a senior secured credit agreement (the Credit Agreement), which consists of an up to $1 billion secured revolving line of credit, a secured term loan A facility and a secured term loan B-1 facility. Our long-term indebtedness also includes $4.250 billion aggregate principal amount of senior notes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior secured credit facilities bear, and other indebtedness we may incur in the future may bear, interest at a variable rate. As a result, at any given time interest rates on the senior secured credit facilities and any other variable rate debt could be higher or lower than current levels. If interest rates increase, our debt service obligations on our variable rate indebtedness will increase even though the amount borrowed remains the same, and therefore net income and associated cash flows, including cash available for servicing our indebtedness, will correspondingly decrease.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness levels and the required payments on such indebtedness may also be impacted by developments related to LIBOR replacement. The variable interest rates payable under our senior secured credit facilities have historically been linked to LIBOR as the benchmark for establishing such rates. We expect that the LIBOR benchmark will cease to exist after June 30, 2023. Our senior secured credit facilities include mechanics to facilitate the adoption by us and our lenders of an alternative benchmark rate for use in place of LIBOR and through this mechanism or other amendments or agreements with our lenders we expect to reference a replacement index that measures the cost of borrowing cash overnight, backed by U.S. Treasury securities (Secured Overnight Financing Rate or SOFR) or a variation thereof; however, no assurance can be made that we and our lenders, or any lenders in a subsequent refinancing of our credit facilities, will agree on such an alternative rate and, even if agreed upon, such alternative rate may not perform in a manner similar to LIBOR and may result in interest rates that are higher or lower than those that would have resulted had LIBOR remained in effect, which could impact our cost of capital.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our indebtedness, to fund planned capital expenditures and expansion efforts, including, without limitation, any strategic acquisitions or investments we may make in the future, to repurchase our stock at the levels intended or announced and to meet our other liquidity needs such as for working capital or capital expenditures, will depend on our ability to generate cash. This depends not only on the success of our business but is also subject to economic, financial, competitive, regulatory and other factors that are beyond our control. We cannot provide assurances that our business will generate sufficient cash flows from operations in the future or that future borrowings will be available to us in amounts sufficient to enable us to service our indebtedness or to fund our working capital and other liquidity needs, including those described above. If we are unable to generate sufficient funds to service our outstanding indebtedness or to meet our working capital or other liquidity needs, including those described above, we would be required to refinance, restructure, or otherwise amend some or all of such indebtedness, sell assets, change or reduce our intended or announced uses or strategy for capital deployment, including, without limitation, for stock repurchases, reduce capital expenditures, planned expansions or other strategic initiatives, or raise additional cash through the sale of our equity or equity-related securities. We cannot make any assurances that any such refinancing, restructurings, amendments, sales of assets, or issuances of equity or equity-related securities can be accomplished or, if accomplished, will be on favorable terms or would raise sufficient funds to meet these obligations or our other liquidity needs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial. Although the Credit Agreement includes covenants that could limit our indebtedness, we currently have, and expect to continue to have, the ability to incur substantial additional debt. The risks described in this risk factor could intensify as new debt is added to current debt levels or if we incur any new debt obligations that subject us to restrictive covenants that limit our financial and operational flexibility. Any breach or failure to comply with any of these covenants could result in a default under our indebtedness. Other risks related to our ability to generate sufficient cash to service our indebtedness and for other intended purposes, include, for example:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expose us to interest rate volatility that could adversely affect our business, results of operations, financial condition and cash flows, and our ability to service our indebtedness;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our competitors that have less debt; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds, or to refinance existing debt on favorable terms when otherwise available or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to pay any of our indebtedness when due or any other default under our credit facilities or our other indebtedness could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could trigger cross default or cross acceleration provisions in our other debt instruments, thereby permitting the holders of that other indebtedness to demand immediate repayment or cease to make future extensions of credit, and, in the case of secured indebtedness, to take possession of and sell the collateral securing such indebtedness to satisfy our obligations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The borrowings under our senior secured credit facilities and senior indentures are guaranteed by certain of our domestic subsidiaries, and borrowings under our senior secured credit facilities are secured by substantially all of our and certain of our domestic subsidiaries' assets. Such guarantees and the fact that we have pledged such assets may make it more difficult and expensive for us to make, or under certain circumstances could effectively prevent us from making, additional secured and unsecured borrowings.</span></div><div id="ib228226ec511491b87b183c6d217a21a_121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to tax laws and regulations of the U.S. federal, state and local governments as well as various foreign jurisdictions. We compute our income tax provision based on enacted tax rates in the jurisdictions in which we operate. As the tax rates vary among jurisdictions, a change in earnings attributable to the various jurisdictions in which we operate could result in a change in our overall tax provision.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. There can be no assurance that changes in tax laws or regulations, both within the domestic and foreign jurisdictions in which we operate, will not materially and adversely affect our effective tax rate, tax payments, results of operations, financial condition and cash flows. Similarly, changes in tax laws and regulations that impact our patients, business partners and counterparties or the economy may also impact our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, tax laws and regulations are complex and subject to varying interpretations, and any significant failure to comply with applicable tax laws and regulations in all relevant jurisdictions could give rise to material penalties and liabilities. We are regularly subject to audits by various tax authorities. For example, our current audits include an audit by the Internal Revenue Service for the years 2016&#8211;2017, and it is possible that the final determination of this and any other tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. Any changes in enacted tax laws, rules or regulatory or judicial interpretations; any adverse development or outcome in connection with tax audits in any jurisdiction; or any change in the pronouncements relating to accounting for income taxes could materially and adversely impact our effective tax rate, tax payments, results of operations, financial condition and cash flows.</span></div><div id="ib228226ec511491b87b183c6d217a21a_124"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our operations, including our clinical laboratory, dialysis centers and other facilities, may be adversely impacted by the effects of natural or other disasters, political instability, public health crises such as global pandemics or epidemics, including the COVID-19 pandemic, or adverse weather events such as hurricanes, earthquakes, fires or flooding. Each of these effects and risks may be further intensified by the increasing impact of climate change on a global scale. In addition, these risks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are particularly heightened for our patients in part because individuals with chronic illness may be more susceptible to the adverse effects of epidemics or other public health crises and also because any natural or other disaster, political instability or adverse weather event that disrupts or limits the operation of any of our centers or other facilities or services may delay or otherwise impact the critical services we provide to dialysis patients. Further, any such event or other occurrence that results in a failure of the fitness of our clinical laboratory, dialysis centers and related operations and/or other facilities or otherwise adversely impacts the safety of our teammates or patients at any of those locations could lead us to face adverse consequences, including, without limitation, the potential loss of data, including PHI or PII, compliance or regulatory investigations, any of which could materially impact our business, results of operations and financial condition, and could materially harm our reputation. For example, our clinical laboratory is located in Florida, a state that has in the past experienced and may in the future experience hurricanes. Natural or other disasters or adverse weather events could significantly damage or destroy our facilities, disrupt operations, increase our costs to maintain operations and require substantial expenditures and recovery time to fully resume operations. In addition, as the effects of climate change progressively surface, such as through potential increases in the frequency and intensity of natural or other disasters or adverse weather events or through laws or regulations adopted in response, we may face increased costs associated with operating our clinics, including, without limitation, with respect to supplies of water or energy costs.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our presence in markets outside the U.S. may increase our exposure to these and similar risks related to natural disasters, public health crises, political instability, climate change or other catastrophic events outside our control. For additional information regarding the risks related to our international business, see the discussion in the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S....</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these factors, as well as other consequences of these events, none of which we can currently predict, could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_127"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and how we manage our business may subject us, as well as our officers and directors to whom we owe certain defense and indemnity obligations, to litigation and liability. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including, without limitation, claims related to adverse patient events, cybersecurity incidents, contractual disputes, antitrust and competition laws and regulations, professional and general liability and directors' and officers' duties. In addition, we have received notices of claims from commercial payors and other third parties, as well as subpoenas and civil investigative demands from the federal government, related to our business practices, including, without limitation, our historical billing practices and the historical billing practices of acquired businesses. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation. We maintain insurance coverage for those risks we deem are appropriate to insure against and make determinations about whether to self-insure as to other risks or layers of coverage. However, a successful claim, including, without limitation, a professional liability, malpractice or negligence claim or a claim related to antitrust and competition laws or a cybersecurity incident, which is in excess of any applicable insurance coverage, that is outside the scope or limits of any applicable insurance coverage, or that is subject to our self-insurance retentions, could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our business, results of operations, financial condition and cash flows could be materially and adversely affected by any of the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the collapse or insolvency of our insurance carriers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further increases in premiums and deductibles;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining insurance with exclusions for things such as communicable diseases; or</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to obtain one or more types of insurance on acceptable terms, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The integration of acquisitions and addition of new business lines into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and has increased, and is expected to continue to increase, our compliance costs. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price. In addition, we could be required to restate our financial results in the event of a significant failure of our internal control over financial reporting or in the event of inappropriate application of accounting principles.</span></div><div id="ib228226ec511491b87b183c6d217a21a_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our organizational documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent, advance notice requirements for director nominations and stockholder proposals and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control. These and any other change of control provisions may affect the price an acquirer would be willing to pay for our Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, prohibits us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions described above may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.</span></div><div id="ib228226ec511491b87b183c6d217a21a_136"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib228226ec511491b87b183c6d217a21a_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Denver, Colorado, consisting of one owned 240,000 square foot building and one leased 345,900 square foot location. Our headquarters are occupied by teammates engaged in management, finance, marketing, strategy, legal, compliance and other administrative functions. We lease six business offices located in California, Pennsylvania, Tennessee, and Washington in the U.S. In addition, our international headquarters is located in the United Kingdom and consists of one leased business office. Our laboratory is based in Florida where we operate our lab services out of one leased building. We also lease other administrative offices in the U.S. and worldwide. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our U.S. outpatient dialysis centers are located on premises that we lease. We regularly own an insignificant population of properties for development, including operating outpatient dialysis centers and properties we hold for sale.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our leases for our U.S. dialysis business cover periods from five years to 15 years and typically contain renewal options of five years to ten years at the fair rental value at the time of renewal. Our leases are generally subject to fixed escalation clauses, or contain consumer price index increases. Our outpatient dialysis centers range in size from approximately 1,000 to 33,000 square feet, with an average size of approximately 7,800 square feet. Our international leases generally range from one to ten years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our outpatient dialysis centers are operating at or near capacity. However, we believe that we have adequate capacity within most of our existing dialysis centers to accommodate additional patient volume through increased hours and/or days of operation, or, if additional space is available within an existing facility, by adding dialysis stations. We can usually </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relocate existing centers to larger facilities or open new centers if existing centers reach capacity. With respect to relocating centers or building new centers, we believe that we can generally lease space at economically reasonable rates in the areas planned for each of these centers, although there can be no assurances in this regard. Expansion of existing centers or relocation of our dialysis centers is subject to review for compliance with conditions relating to participation in the Medicare ESRD program, among other things. In states that require a certificate of need or center license, additional approvals would generally be necessary for expansion or relocation.</span></div><div id="ib228226ec511491b87b183c6d217a21a_142"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Part I, Item&#160;3&#160;is incorporated herein by reference to the information set forth under the caption "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 16 to the consolidated financial statements included in this report.</span></div><div id="ib228226ec511491b87b183c6d217a21a_145"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib228226ec511491b87b183c6d217a21a_151"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the New York Stock Exchange under the symbol DVA. The closing price of our common stock on January&#160;31, 2023 was $82.39 per share. According to Computershare, our registrar and transfer agent, as of January&#160;31, 2023, there were 6,987 holders of record of our common stock. This figure does not include the indeterminate number of beneficial holders whose shares are held of record by brokerage firms and clearing agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering was in 1994, and we have not declared or paid cash dividends to holders of our common stock since going public. We have no current plans to pay cash dividends and there are certain limitations on our ability to pay dividends under the terms of our senior secured credit facilities. See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and capital resources"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of our common stock during 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:30.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number<br/>of shares<br/>purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average price<br/>paid per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number of shares purchased as part of publicly announced plans or programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate dollar value<br/>of shares that may yet be purchased under the plans or programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1 - June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on December 10, 2020, the Board terminated all remaining prior share repurchase authorizations available to the Company and approved a new share repurchase authorization of $2.0 billion. Effective on December 17, 2021, the Board increased the Company's existing authorization by $2.0 billion. We are authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;22, 2023, we have a total of $1.596 billion available under the current repurchase authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, we remain subject to share repurchase limitations, including under the terms of our senior secured credit facilities.</span></div><div id="ib228226ec511491b87b183c6d217a21a_154"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="ib228226ec511491b87b183c6d217a21a_160"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements could include, among other things, DaVita's response to and the expected future impacts of the coronavirus (COVID-19), including statements about our balance sheet and liquidity, our expenses and expense offsets, revenues, billings and collections, availability or cost of supplies, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, the availability, acceptance, impact, administration and efficacy of COVID-19 vaccines, treatments and therapies, the continuing impact on the U.S. and global economies, labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, expenses, strategic initiatives, government and commercial payment rates, expectations related to value-based care, integrated kidney care and Medicare Advantage (MA) plan enrollment and our ongoing stock repurchase program. All statements in this report, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact of the COVID-19 pandemic, current macroeconomic and marketplace conditions, and global events, many of which are interrelated and which relate to, among other things, the impact of the COVID-19 pandemic on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition and results of operations; the government's response to the ongoing pandemic; the pandemic's continuing impact on the U.S. and global economies, labor market conditions, interest rates, inflation and evolving monetary policies; the availability, acceptance, impact and efficacy of COVID-19 vaccines, treatments and therapies; further spread or resurgence of the virus, including as a result of the emergence of new strains of the virus; the continuing impact of the pandemic on our revenues and non-acquired growth due to lower treatment volumes; COVID-19's impact on the chronic kidney disease (CKD) population and our patient population including on the mortality of these patients; any potential</span><span style="background-color:#dbdbdb;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">negative impact on our commercial mix or the number of our patients covered by commercial insurance plans; continued increased COVID-19-related costs; our ability to successfully implement cost savings initiatives; supply chain challenges and disruptions; and elevated teammate turnover and training costs and higher salary and wage expense, including, among other things, increased contract wages, driven in part by persisting labor market conditions and a high demand for our clinical personnel, any of which may also have the effect of heightening many of the other risks and uncertainties discussed below, and in many cases, the impact of the pandemic and the aforementioned global economic conditions on our business may persist even after the pandemic subsides; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof or related litigation result in a reduction in coverage or reimbursement rates for our services, a reduction in the number of patients enrolled in or that select higher-paying commercial plans, including for example MA plans or other material impacts to our business or operations; or our making incorrect assumptions about how our patients will respond to any such developments;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks arising from potential changes in laws, regulations or requirements applicable to us, such as potential and proposed federal and/or state legislation, regulation, ballot, executive action or other initiatives, including without limitation those related to healthcare and/or labor matters;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under such plans, including, without limitation, as a result of restrictions or prohibitions on the use and/or availability of charitable premium assistance, which may result in the loss of revenues or patients, as a result of our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations; or as a result of payors&#8217; implementing restrictive plan designs, including, without limitation, actions taken in response to the U.S. Supreme Court&#8217;s decision in Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. ("Marietta"); how and whether regulators and legislators will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">respond to the Marietta decision including, without limitation, whether they will issue regulatory guidance or adopt new legislation; how courts will interpret other anti-discriminatory provisions that may apply to restrictive plan designs; whether there could be other potential negative impacts of the Marietta decision; and the timing of each of these items;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, retain and motivate teammates and our ability to manage operating cost increases or productivity decreases whether due to union organizing activities, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, or other reasons; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and global economic and marketplace conditions, interest rates, inflation, unemployment, labor market conditions, and evolving monetary policies, and our ability to respond to these challenging conditions, including among other things our ability to successfully identify cost savings opportunities and to implement cost savings initiatives such as ongoing initiatives that increase our use of third-party service providers to perform certain activities, initiatives that relate to clinic optimization and capacity utilization improvement, and procurement opportunities, among other things; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully implement our strategies with respect to integrated kidney care and value-based care initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment, including, among other things, maintaining our existing business; meeting growth expectations; recovering our investments; entering into agreements with payors, third party vendors and others on terms that are competitive and, as appropriate, prove actuarially sound; structuring operations, agreements and arrangements to comply with evolving rules and regulations; finding, training and retaining appropriate staff; and further developing our integrated care and other capabilities to provide competitive programs at scale; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the Medicare Advantage benchmark structure;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">legal and compliance risks, such as our continued compliance with complex, and at times, evolving government regulations and requirements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the Affordable Care Act, the exchanges and many other core aspects of the current healthcare marketplace, as well as the composition of the U.S. Supreme Court and the current presidential administration and congressional majority;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to hypoxia inducible factors, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives introduced by the government or private sector that, among other things, may erode our patient base and impact reimbursement rates;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete acquisitions, mergers, dispositions, joint ventures or other strategic transactions that we might announce or be considering, on terms favorable to us or at all, or to successfully integrate any acquired businesses, or to successfully operate any acquired businesses, joint ventures or other strategic transactions, or to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">continued increased competition from dialysis providers and others, and other potential marketplace changes, including without limitation increased investment in and availability of funding to new entrants in the dialysis and pre-dialysis marketplace;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the variability of our cash flows, including without limitation any extended billing or collections cycles; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs; and the risk that we may not be able to refinance our indebtedness as it becomes due, on terms favorable to us or at all;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as our use of a considerable amount of available funds to repurchase stock;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks arising from the use of accounting estimates, judgments and interpretations in our financial statements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our goodwill, investments or other assets; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements; the availability of suppliers that can meet our sustainability standards; and our ability to recruit, develop and retain diverse talent in our labor markets; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the other risk factors, trends and uncertainties set forth in Part I, Item 1A. of this Annual Report on Form 10-K, and the other risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following should be read in conjunction with our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business. We also operate our U.S. integrated kidney care (IKC) business, our U.S. other ancillary services, and our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support. Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, we completed the sale of our prior DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC, a subsidiary of UnitedHealth Group Inc. The effects of the DMG sale have been reported in discontinued operations for all periods presented and DMG is not included below in this Management's Discussion and Analysis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to experience challenges related to the coronavirus pandemic (COVID-19) and certain interrelated macroeconomic developments and conditions which negatively impacted our year-over-year revenue and treatment volumes in 2022. We also incurred higher compensation expense and advocacy spend in 2022, as well as increases in severance costs and center closures costs as we continue to focus on cost savings initiatives. In addition, 2022 was negatively impacted by our increased investment in our integrated care support functions needed to support the IKC patient growth. These negative trends were partially offset by increased U.S. dialysis average patient services revenue per treatment and continued growth in international businesses. In addition our 2022 financial performance benefited from lower pharmaceutical unit costs and intensity, health benefits expenses and medical supply expense as compared to the prior year. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational and financial highlights for 2022 include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total U.S. dialysis revenue benefited from an increase in average patient services revenue per treatment growth of $6.00 per treatment offset by a decrease in the number of treatments primarily due to increased mortality due to COVID-19's impact on our patient population;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total revenue growth of 8.3% in our IKC business and 3.6% in our international operations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating income of $1,339 million and adjusted operating income of $1,450 million;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating cash flows of $1,565 million and free cash flows of $817 million; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repurchase of 8,094,661 shares of our common stock for aggregate consideration of $788 million, and a 7.1% reduction in our share count year-over-year.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional highlights include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">net decrease of 91 U.S. dialysis centers to improve center capacity and utilization, as well as a net increase of 11 international dialysis centers from acquisitions; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued patient growth in IKC to </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients in risk-based integrated care arrangements and an additional 15,000 patients in other integrated care arrangements; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued impact of COVID-19 and other macroeconomic conditions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we expect that COVID-19 and certain macroeconomic conditions will continue to impact our business and financial performance though the cumulative magnitude of these impacts remains difficult to predict and subject to significant uncertainty due to a number of factors, as described in further detail below </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19, General Economic and Marketplace Conditions, and Legal and Regulatory Developments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On treatment volume, we continue to face pressure primarily driven by the impact of COVID-19 on the mortality rates of dialysis patients, as well as the direct and indirect impact of COVID-19 on our missed treatment rate and new admissions. We anticipate that this pressure also will be magnified by continued slowing industry growth and continued competitive activity in 2023. On reimbursement rate, we expect growth in aggregate, primarily due to the increase in Medicare payment rates under the ESRD Prospective Payment System as well as a continuing increase in anticipated Medicare Advantage enrollment due to the 21st Century Cures Act, partially offset by a full year of the resumption of Medicare sequestration. On cost, we continue to expect increasing pressure on wage rates and other costs due to the challenging labor market and inflationary conditions and increased severance costs as we focus on efficiencies in our administrative support functions partially offset by continued anticipated savings on pharmaceutical costs and a decrease in depreciation and amortization. We expect to incur significantly less advocacy costs in 2023 than we experienced in 2022. We also expect to continue making investments to expand our ability to offer home-based dialysis service options and further advance our integrated care and value-based care initiatives in 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, considerable uncertainty exists surrounding the continued development of the various governmental laws, regulations and other requirements that impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion below includes analysis of our financial condition and results of operations for the years ended December&#160;31, 2022 compared to December&#160;31, 2021. Our Annual Report on Form 10-K for the year ended December&#160;31, 2021, includes a discussion and analysis of our financial condition and results of operations for the year ended December&#160;31, 2020, in its Part II, Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">".</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the "Notes" in the discussion below refer to the notes to the Company's consolidated financial statements included in this Annual Report on Form 10-K at Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="ib228226ec511491b87b183c6d217a21a_166"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19, General Economic and Marketplace Conditions, and Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above and described in further detail below, the continued impacts on our business in connection with the COVID-19 pandemic and general economic and market conditions could have a material adverse impact on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition, results of operations, cash flows and/or liquidity. Many of these external factors and conditions are interrelated, including, among other things, supply chain challenges, inflation, rising interest rates, labor market conditions and wage pressure. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflict between Russia and Ukraine, which has continued to drive sociopolitical and economic uncertainty and volatility in Europe and across the globe.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operational and Financial Impacts</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 we continued to experience a negative impact on revenue and non-acquired growth from COVID-19 due to lower treatment volumes. As noted above, these lower treatment volumes were driven primarily by the negative impact of COVID-19 on the mortality rates of our patients, which has in turn impacted our patient census, as well as the direct and indirect impact of COVID-19 on our missed treatment rate and new admissions. We expect that the impact of COVID-19 is likely to continue to negatively impact our revenue and non-acquired growth for a period of time even as the pandemic subsides due to the compounding impact of mortalities, among other things. During 2022, lower treatment volumes were also driven in part by declining new admissions and elevated missed treatment rates. New admission rates, future revenues and non-acquired growth could also continue to be negatively impacted over time to the extent that the CKD population experiences elevated mortality levels due to the pandemic. There remains significant uncertainty as to the ultimate impact of COVID-19 on our treatment volumes, in part due to, among other things, the indeterminate severity and duration of the pandemic and the complexity of factors that may drive new admissions and missed treatment rates over time. Depending on the ultimate severity and duration of the pandemic, the magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 and other global conditions have also increased, and will continue to increase, our expenses, including, among others, staffing and labor costs. In 2022, we incurred higher than usual wage increases, and higher incentive pay. During 2022 we also incurred increased costs due to an increased utilization of contract labor, inefficient productivity and increased investment in training expenses. Each of those cost drivers were in turn primarily the result of the combination of our ongoing COVID-19-related clinical protocols and general labor, supply chain and inflationary pressures. As noted above, we expect certain of these increased costs to continue, and the cumulative impact of these costs could be material. In addition, potential staffing shortages or disruptions, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, and may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things. In 2022, we also saw a continued increase, relative to pre-pandemic conditions, in the effort and cost needed to procure certain of our equipment and clinical supplies, including pharmaceuticals and personal protective equipment (PPE), and some of which have been substantial.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The staffing and labor cost inflation described above, in addition to higher equipment and clinical supply costs, have put pressure on our existing cost structure, and as noted above, we expect that certain of those increased costs will persist as global supply chains continue to experience volatility and disruptions and as inflationary pressures and challenging labor market conditions continue. Prolonged volatility, uncertainty, labor supply shortages and other challenging labor market conditions could have an adverse impact on our growth and ability to execute on our other strategic initiatives and a material adverse impact on our labor costs. Prolonged strain on global supply chains may result in equipment and clinical supply shortages, disruptions, delays or associated price increases that could impact our ability to provide dialysis services or the cost of providing those services, among other things. Moreover, to the extent that inflationary pressure persists, this may in turn continue to increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. In our value-based care and other programs where we assume financial accountability for total patient cost, an increase in COVID-19 rates among patients could have an impact on total cost of care. This increase may in turn impact the profitability of those programs relative to their respective funding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, we continue to implement cost savings opportunities to help mitigate these cost and volume pressures. These include, among other things, anticipated cost savings related to certain general and administrative cost efficiencies, such as ongoing initiatives that increase our use of third party service providers to perform certain activities, including, among others, finance and accounting functions as well as related information technology functions; initiatives relating to clinic optimization and initiatives for capacity utilization improvement; and procurement opportunities. We have incurred, and expect to continue to incur, charges in connection with the continued implementation of these initiatives, and there can be no assurance that we will be able to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions. Any failure on our part to adjust our business and operations in this manner, to adjust to other marketplace developments or dynamics or to appropriately implement these initiatives in accordance with applicable legal, regulatory or compliance requirements could adversely impact our ability to provide dialysis services or the cost of providing those services, among other things, and ultimately could have a material adverse effect on our business, reputation, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal, State and Local Government Response</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The government response to COVID-19 has been wide-ranging and will continue to develop over time. As a result, we may not be able to accurately predict the nature, timing or extent of the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets, or any potential changes to the extensive set of federal, state and local laws, regulations and requirements that govern our business. For example, federal COVID-19 relief legislation suspended the 2% Medicare sequestration from May 1, 2020 through March 31, 2022. The Medicare sequestration was reinstated in stages until the full 2% level was resumed as of July 1, 2022. While in effect, the suspension of sequestration significantly increased our revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the ultimate impact of the COVID-19 pandemic and the aforementioned general economic and marketplace conditions on the Company over time will depend on future developments that are highly uncertain and difficult to predict. With respect to COVID-19, these future developments include, among other things, the ultimate severity and duration of the pandemic; the evolution of new strains or variants of the virus that may present varying levels of infectivity or virulence; COVID-19's impact on the CKD patient population and our patient population, including on the mortality of these patients; the availability, acceptance, impact and efficacy of COVID-19 vaccines, treatments and therapies; the pandemic&#8217;s continuing impact on our revenue and non-acquired growth due to lower treatment volumes; the potential negative impact on our commercial mix or the number of patients covered by commercial insurance plans; continued increased COVID-related costs; supply chain challenges and disruptions, including with respect to our clinical supplies; the responses of our competitors to the pandemic and related changes in the marketplace; the timing, scope and effectiveness of federal, state and local government responses; and any potential changes to the extensive set of federal, state and local laws, regulations and requirements that govern our business. In certain cases, the impact of the pandemic on us may persist even after the pandemic subsides. COVID-19 has also intensified certain of the aforementioned general economic and marketplace conditions and developments in the U.S. and global economies, including labor market conditions, inflation and monetary policies, among others. We expect that these conditions will continue to impact our business in 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the COVID-19 pandemic and our response, the various general economic and marketplace conditions that may impact our business, and the risks and uncertainties related to each of these, please see the discussion in Part I Item 1. Business under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 and its impact on our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Capital Management,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as well as the risk factors in Part I Item 1A. Risk Factors, including, among others, the risks under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">...".</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the U.S. Supreme Court issued a decision in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a case evaluating the scope of the Medicare Secondary Payor Act (MSPA), deciding that a group health plan that provides limited benefits for outpatient dialysis, but does so uniformly for all plan participants, does not violate the terms of the MSPA because the plan treats all patients uniformly, regardless of whether a participant has ESRD and regardless of whether the participant is eligible for Medicare. For additional information, see Note 16 to the consolidated financial statements included in this report and the risk factor in Part I Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..." There is significant uncertainty as to the ultimate impact of the decision, but if a significant number of commercial plans, including employer group health plans, implement or utilize plan designs that discourage or prevent ESRD patients from retaining their commercial coverage, it may lead to a decrease in the number of patients with commercial plans, the duration of benefits for patients under commercial plans and/or decrease in the payment rates we receive, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated results of operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues, operating income (loss) and adjusted operating income (loss) by line of business. See the discussion of our results for each line of business following this table. When multiple drivers are identified in the following discussion of results, they are listed in order of magnitude: </span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:46.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted operating income (loss):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income (loss) by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div id="ib228226ec511491b87b183c6d217a21a_172"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our U.S. dialysis business is a leading provider of kidney dialysis services, operating 2,724 outpatient dialysis centers serving a total of approximately 199,400 patients, and contracted to provide hospital inpatient dialysis services in approximately 820 hospitals. We estimate that we have approximately a 36% share of the U.S. dialysis market based upon the number of patients we serve. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 91% of our 2022 consolidated revenues were derived directly from our U.S. dialysis business. The principal drivers of our U.S. dialysis revenues include&#160;&#160;&#160;&#160;:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our number of treatments, which is primarily a function of the number of chronic patients requiring approximately three in-center treatments per week as well as, to a lesser extent, the number of treatments for home-based dialysis and hospital inpatient dialysis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our average dialysis patient service revenue per treatment, including the mix of patients with commercial plans and government programs as primary payor.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our U.S. dialysis business, our home-based dialysis and hospital inpatient dialysis services are operationally integrated with our outpatient dialysis centers and related laboratory services. Our outpatient, home-based and hospital inpatient dialysis services comprise approximately 76%, 18% and 6% of our U.S. dialysis revenues, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., government dialysis-related payment rates are principally determined by federal Medicare and state Medicaid policy. For 2022, approximately 67% of our total U.S. dialysis patient services revenues were generated from government-based programs for services to approximately 90% of our total U.S. patients. These government-based programs are principally Medicare and Medicare Advantage, Medicaid and managed Medicaid plans, and other government plans, representing approximately 57%, 7% and 3% of our U.S. dialysis patient services revenues, respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, CMS issued a final rule to update the ESRD PPS payment rate and policies, as described further above. CMS estimates the final rule will affect ESRD facilities' average reimbursement by a productivity-adjusted market basket increase of 3.0% in 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis payment rates from commercial payors vary and a major portion of our commercial rates are set at contracted amounts with payors and are subject to intense negotiation pressure. On average, dialysis-related payment rates from contracted commercial payors are significantly higher than Medicare, Medicaid and other government program payment rates, and therefore the percentage of commercial patients in relation to total patients represents a significant driver of our total average dialysis patient service revenue per treatment. Commercial payors (including hospital dialysis services) represent approximately 33% of U.S. dialysis patient services revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion of government reimbursement, the Medicare ESRD bundled payment system, Medicare Advantage and commercial reimbursement, see the discussion in Part I. Item 1. Business under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis business &#8211; Sources of revenue-concentrations and risks."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with the Medicare ESRD bundled payment system, see the risk factor in Part I. Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with commercial payors, see the risk factor in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 1% of our total U.S. dialysis patient services revenues for each of the years 2022 and 2021 were associated with the administration of separately-billable physician-prescribed pharmaceuticals, the majority of which relate to the administration of calcimimetics. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will continue to experience increases in our operating costs in 2023 that may outpace any net Medicare, commercial or other rate increases that we may receive, which could significantly impact our operating results.&#160;In particular, we expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, including increases in maintenance costs, regardless of whether there is a compensating inflation-based increase in Medicare, commercial or other payor payment rates. We also continue to expect to incur additional COVID-19-related costs while the pandemic continues. In addition, we expect to continue to incur capital expenditures and associated depreciation and amortization to improve, renovate and maintain our facilities, equipment and information technology to meet evolving regulatory requirements and otherwise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers, home-based dialysis programs and hospital inpatient dialysis programs, and consist principally of labor, benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal drivers of our U.S. dialysis patient care costs include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical hours per treatment, labor rates and benefit costs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendor pricing and utilization levels of pharmaceuticals;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business infrastructure costs, which include the operating costs of our dialysis centers; and </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical supply costs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost categories that can present significant variability include insurance costs and professional fees. In addition, proposed ballot initiatives or referendums, legislation, regulations or policy changes could cause us to incur substantial costs to prepare for, or implement changes required. Any such changes could result in, among other things, increases in our labor costs or limitations on the amount of revenue that we can retain. For additional information on risks associated with potential and proposed ballot initiatives, referendums, legislation, regulations or policy changes, see the risk factor in Item 1A. Risk Factors under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our average clinical hours per treatment increased in 2022 compared to 2021. We are always striving for improved productivity levels, however, changes in factors such as federal and state policies or regulatory billing requirements can lead to increased labor costs. In 2022, the demand for skilled clinical personnel continued, exacerbated by the nationwide shortage caused by the continuing COVID-19 pandemic on these resources. In 2022 and 2021, we experienced increases in our clinical labor rates of approximately 7.4% and 3.9%, respectively. We expect to continue to see higher clinical labor rates and continued use of contract labor in 2023 due to the labor market conditions and the continued competition for skilled clinical personnel. In 2022, our overall clinical teammate turnover increased from 2021. We also continue to experience increases in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure and operating costs of our dialysis centers and general increases in rent and repairs and maintenance. In 2022, we continued to implement certain cost control initiatives to help manage our overall operating costs, including labor productivity, and we expect to continue these initiatives in 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis general and administrative expenses represented 9.8% and 8.7% of our U.S. dialysis revenues in 2022 and 2021, respectively. Increases in general and administrative expenses over the last several years were primarily related to strengthening our dialysis business and related compliance and operational processes, responding to certain legal and compliance matters, professional fees associated with enhancing our information technology (IT) systems, such as our new clinical system, and more recently advocacy costs in 2022 related to countering union policy efforts and severance costs related to planned administrative efficiencies. We expect that these levels of general and administrative expenses will be impacted by lower advocacy costs in 2023 compared to 2022, continued investment in developing our capabilities and executing on our strategic priorities, as well as additional severance costs as we implement the planned administrative efficiencies, among other things.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis results of operations</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment volume:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"></td><td style="width:47.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis treatments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,954,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,622,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average treatments per day</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Normalized non-acquired treatment growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given period versus the prior period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis treatment volume is directly correlated with our operating revenues and expenses. The decrease in our U.S. dialysis treatments in 2022 was primarily driven by the impact of increased mortality over recent periods on our patient population, and higher missed treatment rates, slightly offset by acquisition related growth. We believe the increased mortality rate is largely attributable to the impact of COVID-19 on our patient population.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"></td><td style="width:47.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average patient service revenue per treatment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;padding-right:31.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis average patient service revenue per treatment increased primarily driven by increases in both commercial mix and rates, an increase in the Medicare base rate in 2022, and the continued shift to Medicare Advantage plans, partially offset by the reinstatement of 1% Medicare sequestration beginning April 1, 2022 through June 30, 2022 and 2% Medicare sequestration beginning July 1, 2022 and thereafter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses and charges:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"></td><td style="width:47.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs per treatment</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.31&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.47&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.84&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">General and administrative expenses for the year ended December 31, 2022 included advocacy costs of approximately $51 million incurred to counter union policy efforts, including a California statewide ballot initiative (CA Proposition 29).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charges impacting operating income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Closure costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December 31, 2022, we incurred higher than normal charges for center capacity closures. These closures were the result of a strategic review of our outpatient clinic capacity requirements and utilization, which have been impacted both by declines in our patient census in some markets due to the COVID-19 pandemic, as well as by our initiatives toward, and advances in, increasing the proportion of our home dialysis patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 charges for U.S. dialysis center closures were approximately $86 million, which increased our patient care costs by $21 million, our general and administrative expenses by $19 million and our depreciation and amortization expense by $46 million. By comparison, 2021 charges for U.S. dialysis center closures were approximately $18 million, which increased our patient care costs by $2 million, our general and administrative expenses by $3 million and our depreciation and amortization expense by $12 million. These capacity closures costs included net losses on assets retired, lease costs, asset impairments and accelerated depreciation and amortization.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to optimize our U.S. dialysis center footprint through center mergers and/or closures and expect our center closure rates to remain at elevated levels over the next several quarters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our U.S. dialysis business of $17 million. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient care costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers and consist principally of compensation expenses including labor and benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs per treatment increased primarily due to increases in compensation expenses including increased wage rates and contract wages. Other drivers of this increase include increases in other direct operating expenses associated with our dialysis centers, including increases in utilities expense partially due to lower expense in 2021 related to our virtual power purchase arrangements, as well as center closure costs, as described above, insurance expenses and costs related to travel. In addition, our fixed other direct operating expenses negatively impacted patient care costs per treatment due to our decrease in treatments in 2022. These increases were partially offset by decreases in pharmaceutical unit costs, health benefit expenses and medical supply costs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis general and administrative expenses increased primarily due to increases in advocacy costs to counter union policy efforts, compensation expenses including increased wage rates and severance costs, as described above, travel costs, center closure, as described above, and higher IT-related costs. This increase in U.S. dialysis general and administrative expenses was partially offset by gains recognized on the sale of our self-developed properties, and decreases in professional fees and contributions to our charitable foundation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense is directly impacted by the number of dialysis centers and the information technology that we develop and acquire as well as changes in useful lives. U.S. dialysis depreciation and amortization expense increased in 2022 primarily due to accelerated depreciation for expected center closures, as described above, increased depreciation and amortization for hardware associated with our new clinical system and other corporate technology projects and the development of new centers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investment income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis equity investment income decreased primarily due to a decline in profitability at certain nonconsolidated dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating income and adjusted operating income</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:46.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis operating income was negatively impacted by center closure and severance costs, as described above. Operating income and adjusted operating income decreased compared to 2021 primarily due to decreased dialysis treatments and increases in compensation expenses, advocacy costs, other direct operating expenses associated with our dialysis centers, costs related to travel, depreciation expense related to IT projects and insurance expenses, each described above. Operating income and adjusted operating income were positively impacted by an increase in our average patient service revenue per treatment, as described above, as well as decreases in pharmaceutical unit costs, gains on sale of our self-developed properties and decreases in health benefit expenses and medical supply costs.</span></div><div id="ib228226ec511491b87b183c6d217a21a_175"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other - Ancillary services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other operations include ancillary services that are primarily aligned with our core business of providing dialysis services to our network of patients. As of December&#160;31, 2022, these consisted primarily of our U.S. integrated kidney care (IKC) business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ancillary services, including our international operations, generated revenues of approximately $1.101 billion in 2022, representing approximately 9% of our consolidated revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, DaVita IKC provided integrated care and disease management services to approximately </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients in risk-based integrated care arrangements and to an additional 15,000 patients in other integrated care arrangements. We also expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include, among other things, healthcare services not related to dialysis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the risks related to IKC and our ancillary services, see the discussion in the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The U.S. ancillary services and strategic initiatives and international operations that we operate or invest in now or in the future...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives..." </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our international dialysis business owned or operated 350 outpatient dialysis centers located in 11 countries outside of the U.S. For 2022, total revenues generated from our international operations were approximately 6% of our consolidated revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services results of operations</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:45.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating (loss) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjusted operating loss:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reported operating income and adjusted operating income for the years ended December&#160;31, 2022 and December&#160;31, 2021, includes foreign currency (losses) gains embedded in equity method income recognized from our APAC joint venture of approximately $(0.3) million and $3.3 million, respectively.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating (loss) income by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC revenues were impacted by an increase in shared savings, including savings from new programs, partially offset by a decrease in revenues from our special needs plans. Our other U.S. ancillary services revenues increased due to revenues from our newly acquired transplant software business, partially offset by decreased revenues in our clinical research programs. Our international revenues increased primarily due to acquisition-related growth, partially offset by the impact of increased mortality over recent periods on our patient population.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charges impacting operating income - Severance and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, similar to U.S. dialysis, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions and other overhead costs. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our IKC business and these expenses and other charges in our international operations of $0.5 million and $7.5 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating loss and adjusted operating loss:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC operating loss and adjusted operating loss increased primarily due to continued investments in our integrated care support functions, partially offset by an increase in shared savings and improved performance in our special needs plans. Our other U.S. ancillary services operating loss was impacted by a benefit received from run-off of a legacy business recognized in 2021 and decreased revenues in our clinical research programs in 2022. Our international operating income was impacted by severance and other costs in one of our international businesses, as described above. International operating income and adjusted operating income were impacted by acquisition-related growth, partially offset by the impact of increased mortality over recent periods on our patient population and losses on foreign exchange compared to gains in the prior year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">labor, benefits and long-term incentive compensation expense, as well as professional fees, for departments which provide support to all of our various operating lines of business. Corporate administrative support expenses are included in general and administrative expenses on our consolidated income statement. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support expenses increased $18 million primarily driven by increased legal fees and compensation expenses. These increases were partially offset by decreased long-term incentive compensation expense.</span></div><div id="ib228226ec511491b87b183c6d217a21a_181"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate-level charges</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate from continuing operations attributable to DaVita Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our effective income tax rate from continuing operations attributable to DaVita Inc., see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense increased primarily due to an increase in our overall weighted average effective interest rate and weighted average credit facility balance outstanding, which included draws on our revolving line of credit during 2022. Our overall weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 3.96% in 2022 compared to 3.28% in 2021. See Note 13 to the consolidated financial statements for further information on the components of our debt and changes in them since 2021. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income consists primarily of interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, and foreign currency transaction gains and losses. Other income decreased primarily due to increased losses on investments in 2022, partially offset by an increase in interest income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate and effective income tax rate from continuing operations attributable to DaVita Inc. increased in 2022 primarily due to increases in nondeductible advocacy expenses, foreign tax provision expense and a reduction in benefits from stock-based compensation. These increases were partially offset by benefits recognized in 2022 for uncertain tax positions outside the statute of limitations and a reduction in tax expense recognized in 2021 for deferred re-measurement. Additionally, our effective income tax rate was impacted by the portion of earnings attributable to our non-controlling interests.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in income attributable to noncontrolling interests in 2022 compared to 2021 was due to a decrease in earnings at certain U.S. dialysis partnerships.</span></div><div id="ib228226ec511491b87b183c6d217a21a_184"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Accounts receivable</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated accounts receivable balances at December&#160;31, 2022 and December&#160;31, 2021 were $2.132 billion and $1.958 billion, respectively, representing approximately 68 days and 62 days of revenue (DSO), respectively. The increase in consolidated DSO resulted primarily from an increase of five days of DSO in our U.S. dialysis business, primarily due to delays in collections related to certain payors, temporary billing holds and changes in payor mix related to the continued shift to Medicare Advantage plans for which average collection times are longer than that of Medicare.&#160;Our DSO calculation is based on the most recent quarter&#8217;s average revenues per day. There were no significant changes during 2022 from 2021 in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying amount of accounts receivable outstanding over one year old or in the amounts pending approval from third-party payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, our patient services accounts receivable balances that are more than six months old represented approximately 18% and 16%, respectively, of our total accounts receivable balances outstanding. Substantially all revenue realized for patient services is received from government and commercial payors, as discussed above. Less than 1% of our revenues in both periods were classified as patient pay.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts pending approval from third-party payors associated with Medicare bad debt claims as of December&#160;31, 2022 and 2021, other than the standard monthly billing, consisted of approximately $111 million and $133 million, respectively, and are classified as other receivables. A significant portion of our Medicare bad debt claims are typically paid to us before the Medicare fiscal intermediary audits the claims but are subject to subsequent adjustment based upon the actual results of those audits. Such audits typically occur one to four years after the claims are filed.</span></div><div id="ib228226ec511491b87b183c6d217a21a_187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our major sources and uses of cash, cash equivalents and restricted cash:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:53.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash items in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other working capital changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine maintenance/IT/other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developments and relocations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt (payments) issuances, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing and debt redemption costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock award exercises and other share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,782,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our free cash flow, see the "Reconciliations of Non-GAAP measures" section below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated cash flows</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated cash flows from operating activities for 2022 and 2021 were $1,565 million and $1,931 million, respectively. The decrease in cash flow from continuing operations was primarily driven by decreased earnings from operations and increases in tax and interest payments, partially offset by timing of working capital items.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used for investing activities in 2022 decreased $155 million compared to 2021 primarily due to decreases in acquisition expenditures combined with an increase in proceeds from the sale of self-developed properties, which was principally driven by the sale of one of our self-developed properties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities increased $38 million in 2022 compared to 2021. Significant sources of cash during 2022 included a net draw of $165 million on our revolving line of credit. Significant uses of cash during 2022 consisted primarily of regularly scheduled mandatory principal payments under our senior secured credit facilities totaling approximately $98 million on Term Loan A and $27 million on Term Loan B-1 and additional required principal payments under other debt arrangements. In addition, during the year ended December&#160;31, 2022 we used cash to repurchase 8,094,661 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By comparison, 2021 included the issuance of $1,000 million in aggregate principal amount of senior notes as an add-on offering to our 4.625% senior notes due 2030 which were issued at an offering price of 101.750% of the principal amount in February 2021. Significant uses of cash during 2021 consisted primarily of the repayment in full of $75 million of borrowings under our revolving line of credit, net payments of regularly scheduled mandatory principal amounts due under our senior secured credit facilities totaling approximately $88 million on Term Loan A and $27 million on Term Loan B-1 and additional required principal payments under other debt arrangements. In addition, we incurred bond issuance costs of approximately $9 million. During the year ended December&#160;31, 2021 we used cash to repurchase 13,877,193 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis center capacity and growth</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are typically able to increase our capacity by extending hours at our existing dialysis centers, expanding our existing dialysis centers, relocating our dialysis centers, developing new dialysis centers and by acquiring dialysis centers. The development of a typical new outpatient dialysis center generally requires approximately $2.0 million for leasehold improvements and other capital expenditures. Based on our experience, a new outpatient dialysis center typically opens within a year after the property lease is signed, normally achieves operating profitability in the second year after Medicare certification, and normally reaches maturity within three to five years. Acquiring an existing outpatient dialysis center requires a substantially greater initial investment, but profitability and cash flows are generally accelerated and more predictable. To a limited extent, we enter into agreements to provide management and administrative services to outpatient dialysis centers in which we own a noncontrolling interest or which are wholly-owned by third parties in return for management fees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the growth in our dialysis operations by number of dialysis centers owned or operated:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired centers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed centers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-owned managed or administered centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sold and closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers which we manage or provide administrative services to but in which we own a noncontrolling equity interest or which are wholly-owned by third parties, including our Asia Pacific joint venture centers.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were sold and/or closed for which the majority of patients were not retained.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were closed for which the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchases during the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.152%"><tr><td style="width:1.0%"></td><td style="width:40.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2022, we did not repurchase any shares through February&#160;22, 2023. We retired all shares of common stock held in treasury effective December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See further discussion of our share repurchase activity and authorizations in Note 19 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available liquidity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our cash balance was $244 million and we held approximately $78 million in short-term investments. At that time we also had $165 million outstanding and $835 million available on our $1.0 billion revolving line of credit under our senior secured credit facilities. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2022. As of December&#160;31, 2022 we separately had approximately $109 million in letters of credit outstanding under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 to the consolidated financial statements for components of our long-term debt and their interest rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and certain economic and marketplace conditions, including inflationary and labor pressures, have driven increased pressure on our cash flows. As of the date of this report, we have not experienced a material deterioration in our liquidity position as a result of COVID-19 or those global economic and market conditions. The ultimate impact of the pandemic and those economic and market conditions will depend on future developments that are highly uncertain and difficult to predict.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings, which are subject to general, economic, financial, competitive, regulatory and other factors that are beyond our control, as described in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="ib228226ec511491b87b183c6d217a21a_190"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliations of non-GAAP measures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide reconciliations of adjusted operating income (loss) to operating income (loss) as presented on a U.S. generally accepted accounting principles (GAAP) basis for our U.S. dialysis reportable segment as well as for our U.S. IKC business, our U.S. other ancillary services, our international business, and for our total ancillary services which combines them and is disclosed as our other segments category, in addition to our corporate administrative support. These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to, but not alternatives for, our GAAP results.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, management uses adjusted operating income (loss) to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe this non-GAAP measure is also useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe this presentation enhances a user's understanding of our normal operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our effective income tax rate on income from continuing operations attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities. We believe this adjusted effective income tax rate is useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our free cash flow from continuing operations represents net cash provided by operating activities from continuing operations less distributions to noncontrolling interests and all capital expenditures (including development capital expenditures, routine maintenance and information technology), plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities from continuing operations and other measures under GAAP.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Center closure charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Center closure charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:74.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Noncontrolling owners&#8217; income primarily attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense for continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense from continuing operations attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate on income from continuing operations attributable to DaVita Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:65.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net cash provided by continuing operating <br/>&#160;activities to free cash flow from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenditures for routine maintenance and information technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenditures for development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div id="ib228226ec511491b87b183c6d217a21a_193"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the debt obligations and operating lease liabilities reflected on our balance sheet, we have commitments associated with letters of credit as well as certain working capital funding obligations associated with our equity investments in nonconsolidated dialysis ventures that we manage and some we manage that are wholly-owned by third parties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have potential obligations to purchase the noncontrolling interests held by third parties in many of our majority-owned dialysis partnerships and other nonconsolidated entities. These obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods as outlined in each specific put provision. For additional information see Note 17 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of these cash contractual obligations and commitments as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:50.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024-2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026-2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt and leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments on credit facilities and senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, including imputed interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership interests subject to put provisions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Off-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-owned and minority owned put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 13 to the consolidated financial statements for components of our long-term debt and related interest rates. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 14 to the consolidated financial statements for components of our leases and related interest rates. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents amounts for which we are contractually committed, should the outside partner exercise its put option.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 we had outstanding letters of credit in the aggregate amount of approximately $109 million under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 we have outstanding purchase agreements with various suppliers to purchase set amounts of dialysis equipment, parts, pharmaceuticals, and supplies. If we fail to meet the minimum purchase commitments under these contracts during any year, we are required to pay the difference to the supplier. For additional information see Note 17 to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that we manage and in which we own a noncontrolling equity interest or which are wholly-owned by third parties. For additional information see Note 17 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect our 2023 capital expenditures to be in alignment with 2022 capital expenditures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have approximately $54 million of existing long-term income tax liabilities for unrecognized tax benefits, including interest and penalties, which are excluded from the table above as reasonably reliable estimates of their timing cannot be made.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, on May 25, 2022, we entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo). The transaction is expected to close in 2023, subject to customary closing conditions and regulatory approvals. At close, we will make a cash payment to Medtronic of approximately $75 million, subject to certain customary adjustments prior to the closing, and will contribute certain other non-cash assets to NewCo valued at approximately $25 million. Additionally, at close, each of DaVita and Medtronic will contribute approximately $200 million in cash to launch NewCo. We also agreed to pay Medtronic additional consideration of up to $300 million if certain regulatory and commercial milestones are achieved between 2024 and 2028.</span></div><div><span><br/></span></div><div id="ib228226ec511491b87b183c6d217a21a_196"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Note 16 to the consolidated financial statements included in this report is incorporated by reference in response to this item.</span></div><div id="ib228226ec511491b87b183c6d217a21a_199"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies, estimates and judgments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles. These accounting principles require us to make estimates, judgments and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions (redeemable equity interests). All significant estimates, judgments and assumptions are developed based on the best information available to us at the time made and are regularly reviewed and updated when necessary. Actual results will generally differ from these estimates, and such differences may be material. Changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Certain accounting estimates, including those concerning revenue recognition and accounts receivable, fair value estimates for goodwill and noncontrolling interests, accounting for income taxes, and loss contingencies are considered to be critical to evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates. For additional information, see Part II Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 1 &#8211; "Organization and summary of significant accounting policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis revenue recognition and accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are significant estimating risks associated with the amount of U.S. dialysis revenue that we recognize in a given reporting period. Payment rates are often subject to significant uncertainties related to wide variations in the coverage terms of the commercial healthcare plans under which we receive payments. In addition, ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues complicate the billing and collection process. The measurement and recognition of revenue requires the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are recognized based on (a)&#160;the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b)&#160;for the portion not paid by the primary government payor, the estimated amounts that will ultimately be collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient. Our dialysis-related reimbursements from Medicare are subject to certain variations under Medicare&#8217;s single bundled payment rate system whereby our reimbursements can be adjusted for certain patient characteristics and other variable factors. Our revenue recognition depends upon our ability to effectively capture, document and bill for Medicare&#8217;s base payment rate and these other factors. In addition, as a result of the potential range of variations that can occur in our dialysis-related reimbursements from Medicare under the single bundled payment rate system, our revenue recognition is subject to a greater degree of estimating risk.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial healthcare plans, including contracted managed-care payors, are billed at our usual and customary rates; however, revenue is recognized based on estimated net realizable revenue for the services provided. Net realizable revenue is estimated based on contractual terms for the patients covered under commercial healthcare plans with which we have formal agreements, non-contracted commercial healthcare plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in our billing and collection processes that can result in denied claims for payments, the estimated timing of collections, changes in our expectations of the amounts that we expect to collect and regulatory compliance matters. Determining applicable primary and secondary coverage for our approximately 199,400 U.S. dialysis patients at any given point in time, together with the changes in patient coverages that occur each month, requires complex, resource-intensive processes. Collections, refunds and payor retractions typically continue to occur for up to three years or longer after services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect the range of our U.S. dialysis revenue estimating risk to be within 1% of revenue, which can represent as much as approximately 5% of our U.S. dialysis business&#8217;s adjusted operating income. Changes in estimates are reflected in the then-current financial statements based on on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Changes in revenue estimates for prior periods are separately disclosed and reported if material to the current reporting period and longer term trend analyses, and have not been significant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for laboratory services, which are integrally related to our dialysis services, are recognized in the period services are provided at the estimated net realizable amounts to be received.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain fair value estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value measurements and estimates affect, or potentially affect, a variety of elements in the Company's financial statements. Two of the elements most significantly impacted by fair value estimates are the Company's goodwill impairment assessments and remeasurements of its noncontrolling interests subject to put provisions balance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is assessed for impairment when changes in circumstances warrant and at least annually. An impairment charge is recorded when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. Changes in circumstance that may trigger a goodwill impairment assessment for one of our business units can include, among others, changes in the legal environment, addressable market, business strategy, development or business plans, reimbursement structure or rates, operating performance, future prospects, relationships with partners, interest rates and/or market value indications for the subject business. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances for businesses subject to goodwill impairment assessment. However, these assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters. See Note 10 to the consolidated financial statements for a sensitivity summary on the Company's reporting units considered at risk of goodwill impairment as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to remeasure its noncontrolling interests subject to put provisions to estimated fair value each reporting period. These estimates also require substantive judgment on meaningful uncertainties concerning this significant balance. See Notes 17 and 24 to the consolidated financial statements for a summary of the Company's approach to these valuations, the variables and uncertainties involved, and the sensitivity of these valuations to changes in a primary aggregate valuation metric.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management&#8217;s best assessment of estimated current and future taxes to be paid. We are subject to income taxes in the United States and numerous state and foreign jurisdictions, and changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. The actual impact of any such laws or regulations could be materially different from our current estimates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments and estimates are required in determining our consolidated income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, results of recent operations, and assumptions about the amount of future federal, state, and foreign pre-tax operating income adjusted for items that do not have tax consequences. The assumptions about future taxable income require significant judgments and are consistent with the plans and estimates we use to manage the underlying businesses. To the extent that recovery is not likely, a valuation allowance is established. The allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about the realizability of the related deferred tax assets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss contingencies.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 16 to the consolidated financial statements, we operate in a highly regulated industry and are party to various lawsuits, claims, qui tam suits, governmental investigations and audits (including, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without limitation, investigations or other actions resulting from our obligation to self-report suspected violations of law), contract disputes and other legal proceedings.&#160;Assessments of such matters can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We record accruals for loss contingencies on such matters to the extent that we determine an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. See Note 16 to the consolidated financial statements included in this report for further discussion.</span></div><div id="ib228226ec511491b87b183c6d217a21a_202"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant new accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to the consolidated financial statements included in this report for information regarding certain recent financial accounting standards that have been issued by the Financial Accounting Standards Board (FASB).</span></div><div id="ib228226ec511491b87b183c6d217a21a_205"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide information about our financial instruments that are sensitive to changes in interest rates. The first table below presents scheduled principal repayments and current weighted average interest rates on our debt obligations as of December&#160;31, 2022. The variable rates presented reflect the weighted average LIBOR rates in effect for all debt tranches plus the interest rate margins in effect as of December&#160;31, 2022. At December&#160;31, 2022, the Term Loan A interest rate margin in effect was 1.75% and the Term Loan B-1 interest rate margin in effect was also 1.75%. The interest rates in effect on our Term Loan A and revolving line of credit are subject to adjustment depending upon changes in our leverage ratio.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.974%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average<br/>interest<br/>rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair&#160;value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed rate</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the fair value of our long-term debt excluding financing leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scheduled principal payments for all debt that bears a variable rate by its terms, including all of Term Loan B-1 and Term Loan A, have been included on the variable rate line of the schedule of expected maturities above. Additionally, the principal amounts of Term Loan B-1 and Term Loan A have been included in the calculation of the average variable interest rate presented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, principal amounts of $2,661&#160;million for Term Loan B-1 and $839&#160;million of Term Loan A (the capped debt) are hedged by our 2019 interest rate cap agreements through June 30, 2024. As of December 31, 2022, applicable LIBOR rates were above the 2.00% threshold of our cap agreements making the interest rates on this capped debt &#8220;economically fixed", unless or until applicable LIBOR rates were to fall back below 2.00% during the remaining term of the caps. As a result, as of December&#160;31, 2022, total fixed and economically fixed debt was $8,098 million, with an average interest rate of 4.28%, while total variable rate debt not subject to caps was $871 million with an average rate of 6.71%.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.076%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contract maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Receive variable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 interest rate cap agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR above 2.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of our debt and interest rate cap agreements, see Note 13 to our consolidated financial statements at Part II Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our current credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One means of assessing exposure to debt-related interest rate changes is a duration-based analysis that measures the potential loss in net income resulting from a hypothetical increase in interest rates of 100 basis points across all variable rate maturities (referred to as a parallel shift in the yield curve). Under this model, with all else held constant, it is estimated that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such an increase would have reduced net income by approximately $21.4 million, $33.8 million, and $34.8 million, net of tax and the effect of our interest rate caps, for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our business is predominantly conducted in the U.S., we have developing operations in 11 other countries as well. For financial reporting purposes, the U.S. dollar is our reporting currency. However, the functional currencies of our operating businesses in other countries are typically those of the countries in which they operate. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which our international operations are conducted affect our results of operations and financial position as reported in our consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have consolidated the balance sheets of our non-U.S. dollar denominated operations into U.S. dollars at the exchange rates prevailing at the balance sheet dates and have translated their revenues and expense at average exchange rates during each period.&#160;Additionally, our individual subsidiaries are exposed to transactional risks mainly resulting from intercompany transactions between and among subsidiaries with different functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing or obligation currencies and the currency in which their local operations are conducted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our exposure to foreign exchange risk through the judgment of our international and corporate management teams.&#160;Through 2022, our international operations have remained fairly small relative to the size of our consolidated financial statements, constituting approximately 10% of our consolidated assets and approximately 6% of our consolidated revenues for the year ended December&#160;31, 2022, with no single country constituting more than 4% of consolidated assets.&#160;In addition, our unrealized foreign currency translation losses were approximately 2.2%, 4.7%, and 0.4% of our consolidated operating income for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the relatively small size of our international operations, management does not consider our exposure to foreign exchange risk to be significant to the consolidated enterprise.&#160;As such, through December&#160;31, 2022, we have not engaged in transactions to hedge the exposure of our international transactions or net investments to foreign currency risk.&#160;</span></div><div id="ib228226ec511491b87b183c6d217a21a_208"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Index to Financial Statements and Index to Financial Statement Schedules included at Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules."</span></div><div id="ib228226ec511491b87b183c6d217a21a_211"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib228226ec511491b87b183c6d217a21a_214"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934 (Exchange Act) as amended is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO) as appropriate to allow for timely decisions regarding required disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures in accordance with the Exchange Act requirements as of December&#160;31, 2022. Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were effective as required by the Exchange Act as of such date for our Exchange Act reports, including this report. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fourth fiscal quarter of 2022 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.</span></div><div id="ib228226ec511491b87b183c6d217a21a_217"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ib228226ec511491b87b183c6d217a21a_226"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to disclose any amendments or waivers to the Code of Ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2002, we adopted a Corporate Governance Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and to all of our financial accounting and legal professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act reports. The Code of Ethics is posted on our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also maintain a Corporate Code of Conduct that applies to all of our employees, officers and directors, which is posted on our website.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Corporate Governance Guidelines all Board Committees including the Audit Committee, Nominating and Governance Committee and the Compensation Committee, which are comprised solely of independent directors as defined within the listing standards of the New York Stock Exchange, have written charters that outline the committee&#8217;s purpose, goals, membership requirements and responsibilities. These charters are regularly reviewed and updated as necessary by our Board of Directors. All Board Committee charters as well as the Corporate Governance Guidelines are posted on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information required to be disclosed by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 1 Election of Directors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2023 annual stockholder meeting.</span></div><div id="ib228226ec511491b87b183c6d217a21a_229"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Ratio Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" included in our definitive proxy statement relating to our 2023 annual stockholder meeting. The information required by Item&#160;407(e)(5) of Regulation S-K will appear in and is incorporated by reference from the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Report"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2023 annual stockholder meeting; however, this information shall not be deemed to be filed.</span></div><div id="ib228226ec511491b87b183c6d217a21a_232"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about our common stock that may be issued upon the exercise of stock-settled stock appreciation rights, restricted stock units, performance stock units and other rights under all of our existing equity compensation plans as of December&#160;31, 2022, which consist of our DaVita Inc. 2020 Incentive Award Plan, DaVita Healthcare Partners Inc. 2011 Incentive Award Plan and our DaVita Inc. Employee Stock Purchase Plan. The material terms of these plans are described in Note 18 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan category (shares in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares&#160;to&#160;be issued upon&#160;exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares remaining<br/>available&#160;for future issuance under&#160;equity<br/>compensation plans&#160;(excluding securities reflected&#160;in<br/>column&#160;(a))</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total of shares reflected in columns (a) and (c)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(d)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not requiring shareholder approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes 536 shares of common stock reserved for issuance in connection with performance share units at the maximum number of shares issuable thereunder.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;This weighted average excludes full value awards such as restricted stock units and performance share units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information required to be disclosed by Item&#160;12 will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2023 annual stockholder meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2023 annual stockholder meeting.</span></div><div id="ib228226ec511491b87b183c6d217a21a_238"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 2 Ratification of the Appointment of our Independent Registered Public Accounting Firm"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2023 annual stockholder meeting. Our independent registered public accounting firm is <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTE_a27fcee2-1d1f-4559-8c9a-78bb9ff1f723">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTI_0c69eeec-450f-40c1-ba4f-36fcf3263e02">Seattle, WA, USA</ix:nonNumeric> PCAOB ID: <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTQ_d8da0b8e-afbb-4c58-95cc-e6c18583e884">185</ix:nonNumeric>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib228226ec511491b87b183c6d217a21a_244"></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Documents filed as part of this Report:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)&#160;Index to Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_250">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_250">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_253">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_253">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_256">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_256">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_259">Consolidated Statements of Income for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_259">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_262">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_262">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_265">Consolidated Balance Sheets as of December&#160;31, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_265"> and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_265">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_271">Consolidated Statements of Cash Flow for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_271">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_274">Consolidated Statements of Equity for the years ended December&#160;31, 2022, 2021, and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_274">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_277">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_277">11</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2)&#160;Index to Financial Statement Schedules:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:87.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_388">Schedule II&#8212;Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib228226ec511491b87b183c6d217a21a_388">S-</a>3</span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3)&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in the Exhibit Index that precedes the signature pages of this Annual Report on Form 10-K.</span></div><div id="ib228226ec511491b87b183c6d217a21a_247"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 10-K Summary.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_250"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and which includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the last fiscal year, the Company conducted an evaluation, under the oversight of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s internal control over financial reporting. This evaluation was completed based on the criteria established in the report titled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our evaluation under the COSO framework, we have concluded that the Company&#8217;s internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent registered public accounting firm, KPMG LLP, has issued an attestation report on the Company&#8217;s internal control over financial reporting, which report is included in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of DaVita Inc. and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes and financial statement Schedule II - Valuation and Qualifying Accounts (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 22, 2023 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis patient service revenue recognition</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 2 to the consolidated financial statements, the Company recognized $10,575 million in U.S. dialysis patient service revenue for the year ended December 31, 2022. There are uncertainties associated with estimating U.S. dialysis patient service revenue, which generally take several years to resolve. As these estimates are refined over time, both positive and negative adjustments are recognized in the current period.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the recognition of the transaction price the Company expects to collect as a result of satisfying its performance obligations related to U.S. dialysis patient service revenue as a critical audit matter because it involves estimation that requires complex auditor judgment. The key assumptions and inputs used to estimate the transaction price relate to ongoing insurance coverage changes, differing interpretations of contract coverage, determination of applicable primary and secondary coverage, coordination of benefits, and varying patient characteristics impacting Medicare reimbursements. Changes to the key assumptions and inputs used in the application of the methodology may have a significant effect on the Company&#8217;s determination of the estimate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s U.S. dialysis patient service revenue recognition process, including controls related to the application of the methodology used to estimate the transaction price, and the key assumptions and inputs. We evaluated the Company&#8217;s key assumptions and inputs to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligation by comparing key assumptions to historical collection experience, trends of refunds and payor payment adjustments, delays in the Company&#8217;s billing and collection process and regulatory compliance matters. Additionally, we compared U.S. dialysis patient service revenue related to the transaction price estimates recognized in prior periods to actual cash collections related to performance obligations satisfied in prior periods to analyze the Company&#8217;s ability to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligations. We developed an estimate of U.S. dialysis patient service revenue recorded by the Company for the year ended December 31, 2022.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of legal proceedings and regulatory matters</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 16 to the consolidated financial statements, the Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violation of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent an unfavorable outcome is probable, and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of legal proceedings and regulatory matters as a critical audit matter. Due to the nature of the legal proceedings and regulatory matters, a high degree of subjectivity was required in evaluating the completeness of the Company&#8217;s population of legal proceedings and regulatory matters. Additionally, complex auditor judgment was required in evaluating the Company&#8217;s probability of outcome assessment, and related disclosures.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s legal proceedings and regulatory matters process. This includes controls over the Company&#8217;s determination of the completeness of the population of legal proceedings and regulatory matters, as well as controls over the Company&#8217;s probability of outcome assessment, and related disclosures. We tested existing legal proceedings and regulatory matters by reading certain written correspondence received from outside parties as well as reading certain written responses provided to outside parties. We read letters received directly from the Company&#8217;s external and internal legal counsel that described certain legal proceedings and regulatory matters. We involved forensic professionals with specialized skills and knowledge who inspected the Company&#8217;s compliance case log. Additionally, we assessed the completeness of the population of legal proceedings and regulatory matters and related disclosures by 1) inquiring of certain key executives and directors and 2) evaluating information received through procedures described above and through publicly available information about the Company, its competitors, and the industry.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-bottom:10pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2000. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited DaVita Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes and financial statement Schedule II - Valuation and Qualifying Accounts (collectively, the consolidated financial statements), and our report dated February 22, 2023 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_259"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis patient service revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtMS0xLTEtNDMyMzYx_9cb0786b-994c-4d3c-9a0b-da13bed74efa">11,176,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtMy0xLTEtNDMyMzYx_b3d0d846-7748-41a5-8a7a-1dcb6b289efc">11,213,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtNS0xLTEtNDMyMzYx_5082ff92-bd92-489b-b38d-13065cd7be06">11,026,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtMS0xLTEtNDMyMzYx_02ddce57-6177-4ed3-861f-04ec2fc3802f">433,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtMy0xLTEtNDMyMzYx_5e45395c-5ac5-4f60-b599-2ac78c9bdd23">405,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtNS0xLTEtNDMyMzYx_a9e7fdba-e5ee-453a-9cf6-f15c51162caf">524,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtMS0xLTEtNDMyMzYx_ff070a2d-74db-4dc4-93b8-e98280623d37">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtMy0xLTEtNDMyMzYx_67756e4c-2f1c-4c16-b87c-6bf7010b0519">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtNS0xLTEtNDMyMzYx_baebbb6f-cfaf-439b-82a5-7fb23365c47b">11,550,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtMS0xLTEtNDMyMzYx_d4e94472-0c64-4843-b7fc-506205a83fc0">8,209,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtMy0xLTEtNDMyMzYx_49ddb38f-56fb-4dd0-991d-1506e2a655b2">7,972,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtNS0xLTEtNDMyMzYx_f8f33a04-c840-4c62-b315-7e9596e2262a">7,988,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktMS0xLTEtNDMyMzYx_b4aee041-6107-4886-bc8e-bb53f0f383c6">1,355,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktMy0xLTEtNDMyMzYx_81d97a63-6bd1-4968-a924-5a3ab828a49f">1,195,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktNS0xLTEtNDMyMzYx_2f3e6a78-851a-4a83-9b12-a7836399383f">1,247,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTEtMS0xLTQzMjM2MQ_93fa2232-3044-4eeb-b11e-dc219aa22611">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTMtMS0xLTQzMjM2MQ_1cc29c7c-5296-4175-b4da-6098cae95b38">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTUtMS0xLTQzMjM2MQ_c95e7761-64c0-4d1e-ae17-155d415c3977">630,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTEtMS0xLTQzMjM2MQ_74b4058b-bf46-46c9-9c2b-022216e73e06">26,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTMtMS0xLTQzMjM2MQ_f277beab-949c-41cc-8b74-832de6656989">26,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTUtMS0xLTQzMjM2MQ_199f9623-f042-47aa-bf1d-aad9f687b20a">26,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on changes in ownership interest, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTEtMS0xLTQzMjM2MQ_69fb6bc7-1c4e-43de-a917-f7dc2cbfd72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTMtMS0xLTQzMjM2MQ_7328150a-7859-40aa-a77d-e504cb650d1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTUtMS0xLTQzMjM2MQ_ae080fc4-de73-454c-91df-9473f372c488">16,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTEtMS0xLTQzMjM2MQ_9ee93f44-9e70-4759-aba8-282066361fbe">10,270,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTMtMS0xLTQzMjM2MQ_76acd3b8-d510-4e32-97c8-37d7c1bce6e8">9,821,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTUtMS0xLTQzMjM2MQ_b2508325-71b6-4902-b091-14d42b872945">9,855,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTEtMS0xLTQzMjM2MQ_17fc152e-5dd0-49cd-b83b-c3d3ec81fa4f">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTMtMS0xLTQzMjM2MQ_e2a2423c-52f5-4ffa-9ee2-91fae0eb58ee">1,797,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTUtMS0xLTQzMjM2MQ_98fee497-f164-4aa5-93c6-377f8ee112b8">1,694,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTEtMS0xLTQzMjM2MQ_174b2be3-c97d-4959-af15-d59ea5dbe31c">357,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTMtMS0xLTQzMjM2MQ_3dac5cb4-056d-40ac-aed7-0ef2b971156c">285,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTUtMS0xLTQzMjM2MQ_fe3a0805-825e-4f60-a022-d8e7a9f76937">304,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, refinancing and redemption charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTEtMS0xLTQzMjM2MQ_d32061e7-8d2a-4a2c-be84-8cc4c2d48993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTMtMS0xLTQzMjM2MQ_43e84d1b-92a8-483b-8fb9-5020fce55a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTUtMS0xLTQzMjM2MQ_6d42a569-ae9f-4751-af0c-51414ed29561">89,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTEtMS0xLTQzMjM2MQ_a7fbaa39-18c8-4143-9606-4cebd59435c0">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTMtMS0xLTQzMjM2MQ_c11ce9a5-2ec4-4534-9266-5f23065eb8e9">6,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTUtMS0xLTQzMjM2MQ_405739fb-903e-4059-97e2-65f676fdc113">16,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTEtMS0xLTQzMjM2MQ_7ad1dc3e-0809-4e7b-92be-76f2631338c8">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTMtMS0xLTQzMjM2MQ_c01c2b67-9375-4ed1-9328-cc89e1096815">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTUtMS0xLTQzMjM2MQ_4e9f0316-a1ed-42e6-a03f-32a44aef5fe7">1,318,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTEtMS0xLTQzMjM2MQ_44b5306c-e059-4b67-8bb8-f2d28cf9cad1">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTMtMS0xLTQzMjM2MQ_fe890b45-9c22-4ee2-b28a-aeb21f2c3aa8">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTUtMS0xLTQzMjM2MQ_a4094cc8-9735-48cf-ba4c-350699e80958">313,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTEtMS0xLTQzMjM2MQ_add0940e-5599-4c54-94ef-8d303fee596d">768,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTMtMS0xLTQzMjM2MQ_afa08052-c177-4590-8c32-10213d26f4b4">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTUtMS0xLTQzMjM2MQ_07268fe5-afe1-4b5d-8a40-9ed0d6019476">1,004,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTEtMS0xLTQzMjM2MQ_35f6151a-73f2-4538-b9e9-2f3f06c1a510">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTMtMS0xLTQzMjM2MQ_704a96f1-98bf-4c93-96ca-f5e7eb13d55b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTUtMS0xLTQzMjM2MQ_287a5881-4d21-4dcd-b475-8a1d02035873">9,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTEtMS0xLTQzMjM2MQ_c12f9ae3-d2bd-4642-99fc-4de0a048f665">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTMtMS0xLTQzMjM2MQ_8c6df8b2-5ded-4b92-8024-3b5442bdef76">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTUtMS0xLTQzMjM2MQ_153aead1-fdb0-440f-bc6f-12aea58e5c7d">994,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTEtMS0xLTQzMjM2MQ_24cc7370-9942-4c0e-ad45-2b957d6e1b13">221,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTMtMS0xLTQzMjM2MQ_f44a2e4f-9bdd-4e29-8f69-80142a538b8b">233,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTUtMS0xLTQzMjM2MQ_1dd89227-b9a1-4b8b-bc12-ff2b761d2beb">221,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTEtMS0xLTQzMjM2MQ_752b50c9-55f4-4b24-beec-049345043404">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTMtMS0xLTQzMjM2MQ_bfbe13e8-3ff4-4db4-9eca-04af4d5b7d1d">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTUtMS0xLTQzMjM2MQ_a553d71f-a8cb-496e-ac66-b116c509720d">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTEtMS0xLTQzMjM2MQ_d1f13661-33c2-465a-8692-ca1019e2ef31">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTMtMS0xLTQzMjM2MQ_796b3127-146e-4b0e-bbf3-993fac549e6a">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTUtMS0xLTQzMjM2MQ_62f80181-513f-4a37-97af-a3f0c6bb6daa">6.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTEtMS0xLTQzMjM2MQ_d2680893-b9f5-42ac-bbce-b60ec3597b91">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTMtMS0xLTQzMjM2MQ_16751f0b-a879-490e-a11f-4466aa259f9c">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTUtMS0xLTQzMjM2MQ_fb867ab0-25c4-46a2-b964-9d437f30a03d">6.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income from continuing operations</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTEtMS0xLTQzMjM2MQ_c7755c73-8307-40a7-a3ab-949604b916cb">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTMtMS0xLTQzMjM2MQ_4990c8de-403f-4f96-85fd-e31e72f1596c">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTUtMS0xLTQzMjM2MQ_dca85895-9057-4050-ac1c-510e6fdac2f4">6.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTEtMS0xLTQzMjM2MQ_ca706add-12da-44c1-932b-5ec20a946bb8">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTMtMS0xLTQzMjM2MQ_0e53b85b-e209-408c-a9ba-fb11522b309f">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTUtMS0xLTQzMjM2MQ_fd63b458-df8e-4535-b982-b27139974939">6.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares for earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTEtMS0xLTQzMjM2MQ_ad91433d-d547-4686-a3fa-891b3cfb16cb">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTMtMS0xLTQzMjM2MQ_b7b37094-f9a1-4594-9f73-84e83cc7fa73">105,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTUtMS0xLTQzMjM2MQ_adb0cb75-e2c7-4ae4-ac4c-9e797ecd630c">119,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTEtMS0xLTQzMjM2MQ_5cc58850-53d2-435f-b523-4db4c8c8ea10">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTMtMS0xLTQzMjM2MQ_bf00a8ab-8714-4deb-8b82-8509a26c367c">109,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTUtMS0xLTQzMjM2MQ_09f98362-2f79-4480-8548-fcdd48c7c5a0">122,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTEtMS0xLTQzMjM2MQ_9696f61d-9968-49ec-bc9e-9f71296429a7">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTMtMS0xLTQzMjM2MQ_0456ca5a-e4e7-456e-ac29-134de1a41aaf">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTUtMS0xLTQzMjM2MQ_d7c7ab0d-e4d7-48ce-a525-ea1cd85e7fef">783,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTEtMS0xLTQzMjM2MQ_a032ef1e-6788-4c7e-9fa9-f8cd41fcf3e1">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTMtMS0xLTQzMjM2MQ_1b5c43e5-c443-4912-9f5d-ca7e41588117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTUtMS0xLTQzMjM2MQ_a85b1e69-0895-45a0-8bc7-876e84f9da3e">9,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTEtMS0xLTQzMjM2MQ_de2d7441-2220-4ce4-9804-c367a5a66a6d">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTMtMS0xLTQzMjM2MQ_1e27cf07-11f1-42bd-878f-6f6798f2ef4e">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTUtMS0xLTQzMjM2MQ_d0011813-0b73-44a0-a5ec-5998d5ec36b9">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItMS0xLTEtNDMyMzYx_c12f9ae3-d2bd-4642-99fc-4de0a048f665">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItMy0xLTEtNDMyMzYx_8c6df8b2-5ded-4b92-8024-3b5442bdef76">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItNS0xLTEtNDMyMzYx_153aead1-fdb0-440f-bc6f-12aea58e5c7d">994,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on interest rate cap agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtMS0xLTEtNDMyMzYx_5195d89c-bbb4-4bf5-a1e6-effb11595704">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtMy0xLTEtNDMyMzYx_b467a3a1-d8ae-4f95-89a7-6a1611afd674">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtNS0xLTEtNDMyMzYx_73647267-c426-4306-8caa-e1935e544695">16,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of net realized (gains) losses into net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtMS0xLTEtNDMyMzYx_741042f7-6218-4559-8579-9e814e7eef07">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtMy0xLTEtNDMyMzYx_ce9c69ec-e5b8-426d-9a84-432117fa07ad">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtNS0xLTEtNDMyMzYx_ca5bc5ac-252e-4abf-a53a-537785e7f24b">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctMS0xLTEtNDMyMzYx_83663247-4a80-451f-94e2-e50a73c7d557">29,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctMy0xLTEtNDMyMzYx_9bafc3c3-1d46-4d85-b978-a9886bd465f8">84,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctNS0xLTEtNDMyMzYx_0de0903a-a00e-4b58-8fab-494a9ef1dada">7,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtMS0xLTEtNDMyMzYx_2595c2d4-6e6b-4063-a487-dd792b485665">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtMy0xLTEtNDMyMzYx_e470bf58-7143-4f87-8588-58abe6a9750e">73,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtNS0xLTEtNDMyMzYx_fb11f981-6457-469d-9966-047bb43ab1b9">18,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktMS0xLTEtNDMyMzYx_d117c68b-9cf4-453b-be9b-b929457eb89a">851,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktMy0xLTEtNDMyMzYx_c4ca38ef-dd22-4625-ac5d-94b1208c6f5d">1,138,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktNS0xLTEtNDMyMzYx_8cd1666f-affa-4ba4-857f-ae543ddffca1">976,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTEtMS0xLTQzMjM2MQ_523d03f0-817c-49c2-880f-3e13bd563143">221,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTMtMS0xLTQzMjM2MQ_2d290f99-0ad9-4ae8-ba2d-f0d40c0997e9">233,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTUtMS0xLTQzMjM2MQ_f9424910-b575-4fb1-af53-565b91398152">221,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTEtMS0xLTQzMjM2MQ_cd6a770c-10d7-4234-b9a0-d4a17acc6c94">630,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTMtMS0xLTQzMjM2MQ_a52bc3a7-d056-41ab-820a-1c3adf6f64b5">905,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTUtMS0xLTQzMjM2MQ_1d343ae3-6203-4c93-a96f-ff4942473215">754,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_265"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzItMS0xLTEtNDMyMzYx_9c76a9cf-d750-4d8d-a042-ed7bf52e1a7f">244,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzItMy0xLTEtNDMyMzYx_50f3bc6a-9871-4585-bdcb-915da85d3da9">461,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMtMS0xLTEtNDMyMzYx_b4389ba4-638d-4f54-b8df-139a3d65396a">94,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMtMy0xLTEtNDMyMzYx_07059240-1b3f-43d2-b172-dfb65ad6cf95">93,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQtMS0xLTEtNDMyMzYx_b1eaaf70-a509-420c-ba85-31fa5b3661dd">77,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQtMy0xLTEtNDMyMzYx_096ccf26-e076-4c78-888f-daf161db0401">22,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzUtMS0xLTEtNDMyMzYx_b222280e-3fb3-48b8-8db9-bf949e2f18cd">2,132,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzUtMy0xLTEtNDMyMzYx_25ba53f8-7186-45e3-913b-66f0670064ba">1,957,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzYtMS0xLTEtNDMyMzYx_85e25cbf-5e88-42d5-abc6-c6977583f74d">109,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzYtMy0xLTEtNDMyMzYx_2fede081-7c4f-4429-a63c-6d625c95b4f2">107,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzctMS0xLTEtNDMyMzYx_7dfa6e77-bbec-4560-a709-6eeafb3f2674">413,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzctMy0xLTEtNDMyMzYx_f06ffd1f-ea52-4d0f-980e-aef9b9150448">427,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzgtMS0xLTEtNDMyMzYx_8dbd44c1-41c7-4d06-b070-9269d9b67c33">78,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzgtMy0xLTEtNDMyMzYx_7b56dfd2-4176-49f5-a801-fb86ae57e1dc">72,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzktMS0xLTEtNDMyMzYx_060fbf82-ab2b-4afa-8490-2ffd07fceee0">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzktMy0xLTEtNDMyMzYx_cb8aec41-74ac-4624-95ba-39990e638ff3">25,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEwLTEtMS0xLTQzMjM2MQ_14f8a0fc-5bb6-49d2-99e7-0c69250d9302">3,155,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEwLTMtMS0xLTQzMjM2MQ_d5ce1499-58db-4b07-9b88-d069a902982c">3,167,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzExLTEtMS0xLTQzMjM2MQ_ab526b2a-c3c8-4f13-a24f-f4465e04a74c">3,256,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzExLTMtMS0xLTQzMjM2MQ_ffe78f49-b393-4f3e-aa0d-93826f8aaf1c">3,479,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEyLTEtMS0xLTQzMjM2MQ_038f98bc-f057-41ab-9b8b-f61b25dd0b50">2,666,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEyLTMtMS0xLTQzMjM2MQ_91a59374-edfa-4e57-b663-107eeb120ebf">2,824,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEzLTEtMS0xLTQzMjM2MQ_932da64e-b89c-4adf-a800-56a6d89ed1c6">182,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEzLTMtMS0xLTQzMjM2MQ_6d06bb14-afe5-41ca-8860-de46d4832bf3">177,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE0LTEtMS0xLTQzMjM2MQ_9265bb60-2524-4264-9361-7a9a126b4b8b">231,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE0LTMtMS0xLTQzMjM2MQ_4dcb61f4-ef83-4924-bac3-c315ca16cd91">238,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE1LTEtMS0xLTQzMjM2MQ_0afb6658-e63c-4652-8454-8935b1b0d96a">44,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE1LTMtMS0xLTQzMjM2MQ_4b490bfe-a946-4363-80f6-6a0fadecbd97">49,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE2LTEtMS0xLTQzMjM2MQ_6d3e5259-0fa9-419d-a692-d92d7e0ad5db">315,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE2LTMtMS0xLTQzMjM2MQ_ded38189-ca81-4d72-ba21-daec5b15c459">136,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE3LTEtMS0xLTQzMjM2MQ_1b6b0e9f-0cca-4bfc-97a9-59718d6b7064">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE3LTMtMS0xLTQzMjM2MQ_3ed30060-06a3-49c3-8697-54f7fe8b9944">7,046,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE4LTEtMS0xLTQzMjM2MQ_3e900d76-bcfb-4632-b7cd-3f067e660033">16,928,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE4LTMtMS0xLTQzMjM2MQ_d53a8fb8-2e9d-49e3-b077-349052c312fd">17,121,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIwLTEtMS0xLTQzMjM2MQ_b982bc38-0b82-4fc5-864d-5d27e8129331">479,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIwLTMtMS0xLTQzMjM2MQ_341c7bd5-dfe7-460e-aa86-0a2cb825df86">402,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIxLTEtMS0xLTQzMjM2MQ_78507d4a-fa44-420a-9385-6374841b1156">802,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIxLTMtMS0xLTQzMjM2MQ_5281e3ae-99f6-4f95-a67c-0fa0664c4f4a">709,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIyLTEtMS0xLTQzMjM2MQ_c12ad698-f497-4935-b96c-75e3f33242c1">692,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIyLTMtMS0xLTQzMjM2MQ_0b949a6e-68de-4dc7-8348-c9c129f3d18f">659,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIzLTEtMS0xLTQzMjM2MQ_507320cd-5118-4f5f-b776-3b5edb15df2a">395,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIzLTMtMS0xLTQzMjM2MQ_680ffc29-9186-4b0c-9299-1ef1264a3a8d">394,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI0LTEtMS0xLTQzMjM2MQ_dbd374f1-8616-4714-b126-f44d400dbc1d">231,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI0LTMtMS0xLTQzMjM2MQ_8ede8d7a-94d2-4c56-b4da-0866192b0277">179,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI1LTEtMS0xLTQzMjM2MQ_bbda84d8-7df4-4dc3-9496-58786fb5eed2">18,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI1LTMtMS0xLTQzMjM2MQ_4502fdf2-8a79-44f1-b1b7-ea803741244b">53,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI2LTEtMS0xLTQzMjM2MQ_8f7fe471-562c-4973-89a1-49e6e9085db2">2,619,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI2LTMtMS0xLTQzMjM2MQ_9e8f3e60-1187-409c-b844-596b2269e29e">2,398,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI3LTEtMS0xLTQzMjM2MQ_c3c087f5-e481-4b42-92e7-bdac05f92180">2,503,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI3LTMtMS0xLTQzMjM2MQ_2829a67e-57aa-45c9-b90c-39cee1260248">2,672,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI4LTEtMS0xLTQzMjM2MQ_cc5d5ac0-26a3-49f6-b16a-a1f8024fe1db">8,692,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI4LTMtMS0xLTQzMjM2MQ_c3950dd1-d4db-469a-b03b-82ed44cdca3f">8,729,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI5LTEtMS0xLTQzMjM2MQ_d0455619-571f-49b8-9bab-e6b36cedd20e">105,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI5LTMtMS0xLTQzMjM2MQ_047b04b3-c10c-42b0-962d-5e750b708353">119,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMwLTEtMS0xLTQzMjM2MQ_c2e6af9c-5629-46d6-9520-d5d9bc08844f">782,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMwLTMtMS0xLTQzMjM2MQ_4e5afe3b-97d5-4c04-9ef4-2666928538c5">830,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMxLTEtMS0xLTQzMjM2MQ_d625b16b-5b2f-420d-8fad-cc542d4f4b26">14,703,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMxLTMtMS0xLTQzMjM2MQ_ebccba52-0dca-4b6e-9bcc-804db5be8046">14,750,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMzLTEtMS0xLTQzMjM2MQ_2bc64110-cd4b-43ec-a61b-e0254a196f6f">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMzLTMtMS0xLTQzMjM2MQ_6ada33c4-b1f0-4840-baa4-96e044479af1">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzIx_fd38237b-8d30-4476-865c-c3f36bcc8a46">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzM1_76c0ee90-16d5-4e30-880a-a7118cf33044">5,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzU3_24c54c65-5397-4c8b-9e42-f2eeed881ca5">none</ix:nonFraction> issued)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTEtMS0xLTQzMjM2MQ_19a50780-edce-40f7-a930-94afea5f6bc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTMtMS0xLTQzMjM2MQ_16b12f8f-4464-4728-b5ea-e606c8a443d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzE4_80e139ed-80e6-48ed-9a9f-d7c21fa79e91">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzMy_1f08ab34-94af-46db-b41b-bb177fd60522">450,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzU0_71ad23c4-2509-45b6-b87e-ef09d7f44961">90,411</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzYx_d8e788e2-9ad5-4a79-9ea4-1b4df749519d">97,289</ix:nonFraction> shares</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;issued and outstanding at December&#160;31, 2022, and 2021, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTEtMS0xLTQzMjM2MQ_8c7a40b1-db31-48bc-99f0-889dbbf41da7">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTMtMS0xLTQzMjM2MQ_225fcb3c-ecf6-48ca-83d5-297805d03139">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM3LTEtMS0xLTQzMjM2MQ_9dbe0980-407a-4e57-b190-f3d9b9faaa7e">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM3LTMtMS0xLTQzMjM2MQ_c3abca84-7066-4c2b-8bf9-8f89e81d1a01">540,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM4LTEtMS0xLTQzMjM2MQ_4fd07d4f-a459-4dae-a568-f8862ba08a55">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM4LTMtMS0xLTQzMjM2MQ_b610894a-fd98-4a8c-8b39-2cde29f15093">354,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM5LTEtMS0xLTQzMjM2MQ_710a0e96-5f44-48b6-8907-a061d112b0ff">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM5LTMtMS0xLTQzMjM2MQ_288549ed-42e9-493b-a2e6-a43c0c22472c">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DaVita Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQwLTEtMS0xLTQzMjM2MQ_285f381e-b24c-41b5-a388-04ced18eb783">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQwLTMtMS0xLTQzMjM2MQ_bb6d708b-84bf-4559-894e-af7f6cd1b98d">755,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests not subject to put provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQxLTEtMS0xLTQzMjM2MQ_4d1ee75c-613f-4b3a-aa10-5a63cf293ccb">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQxLTMtMS0xLTQzMjM2MQ_349cc20c-aca5-4edb-8dc6-ed34fbc6acdc">180,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQyLTEtMS0xLTQzMjM2MQ_816cccc3-5c41-482d-a60f-90fe8fe44020">875,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQyLTMtMS0xLTQzMjM2MQ_d5aceabc-b8b1-427e-8904-70fa867a38e9">936,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQzLTEtMS0xLTQzMjM2MQ_362c0206-fa23-4255-85f1-1972bf0fa531">16,928,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQzLTMtMS0xLTQzMjM2MQ_879ee6cf-16ca-4d31-9812-0b7804573106">17,121,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtMS0xLTEtNDMyMzYx_2d385e3a-e2e3-44a0-b39d-7b669753f2d5">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtMy0xLTEtNDMyMzYx_01555390-4d7f-4c4c-951f-a52df3fa8d36">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtNS0xLTEtNDMyMzYx_ee5489d2-b796-4089-b113-9a4fbe512a2d">994,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtMS0xLTEtNDMyMzYx_500a7593-4ed4-490d-90a5-ee3cb380e61f">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtMy0xLTEtNDMyMzYx_8b16fdcb-f28f-4e47-ab78-20ce5edccd1e">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtNS0xLTEtNDMyMzYx_86e02764-1097-46a7-9713-f018da173ab4">630,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt prepayment, refinancing and redemption charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctMS0xLTEtNDMyMzYx_f5606c5e-f236-4b0a-899f-057933c06494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctMy0xLTEtNDMyMzYx_b46b1027-dcf1-445e-afc6-05e7b76dea61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctNS0xLTEtNDMyMzYx_995dd062-72aa-4f6a-9809-efe9d111dab9">86,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtMS0xLTEtNDMyMzYx_00783c63-0d04-4efe-bd5b-39b7d94239e1">95,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtMy0xLTEtNDMyMzYx_578573c7-a7f8-4363-861d-e410a8642be6">102,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtNS0xLTEtNDMyMzYx_a044d800-5fc6-4c1d-a330-187567349288">91,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktMS0xLTEtNDMyMzYx_681e6f7f-ffee-4036-9bd6-bdde9522def4">75,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktMy0xLTEtNDMyMzYx_83a21b69-ab01-42af-b1b7-b574b0363ed5">60,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktNS0xLTEtNDMyMzYx_4fca3f80-ba2e-488c-b05c-a72072660029">240,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTEtMS0xLTQzMjM2MQ_23baacc7-c54f-4c61-b3ff-27a9186af5ba">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTMtMS0xLTQzMjM2MQ_9f18bcf7-86e0-4cf4-97b2-173dabce9786">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTUtMS0xLTQzMjM2MQ_05da0e7b-f5d1-483f-a5f1-5a9f01e536ae">13,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sales of business interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:LossGainOnDispositionOfBusinessInterestsBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTEtMS0xLTQzMjM2MQ_cdf0ec5d-3607-484e-bb36-23621dade58e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:LossGainOnDispositionOfBusinessInterestsBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTMtMS0xLTQzMjM2MQ_5fb6a06f-18bd-4db5-8fc6-d1b91b64b38f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:LossGainOnDispositionOfBusinessInterestsBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTUtMS0xLTQzMjM2MQ_4ec12103-74b8-4c4b-a4a0-e3397b38b992">24,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTEtMS0xLTQzMjM2MQ_a2594bc3-a98a-44bb-a72a-c35f04179f7c">21,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTMtMS0xLTQzMjM2MQ_0851b8ff-0d8f-4926-90d9-2d3b7bd1f886">11,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTUtMS0xLTQzMjM2MQ_53a60537-70bc-455d-ab8b-3aab4493942a">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTEtMS0xLTQzMjM2MQ_4381b47f-5139-4707-b7b1-ac396590ec65">148,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTMtMS0xLTQzMjM2MQ_f9439f0e-b68b-4ab6-aba6-a63bc5a0aed5">138,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTUtMS0xLTQzMjM2MQ_edb18e82-4748-469e-8b8f-621106357287">21,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTEtMS0xLTQzMjM2MQ_c440dd36-5521-433b-b398-0e461d70bc67">757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTMtMS0xLTQzMjM2MQ_ae29ed31-6e46-4266-b311-a3e8055992c7">5,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTUtMS0xLTQzMjM2MQ_d30f1b3e-b9c2-41c1-bf03-dfdc756761a3">12,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables and prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTEtMS0xLTQzMjM2MQ_85444a9d-3a87-4464-b0c9-12d6f0c6b87e">27,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTMtMS0xLTQzMjM2MQ_ad323b46-a9d2-4812-b32d-548e164aace6">128,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTUtMS0xLTQzMjM2MQ_56ec39fc-9a4d-4768-b1fb-9d63b7cc901d">79,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTEtMS0xLTQzMjM2MQ_23a2e56d-5000-45cd-a4eb-06de1ccf123f">50,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTMtMS0xLTQzMjM2MQ_d9af165c-029e-4257-ac47-1cca0eaae483">26,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTUtMS0xLTQzMjM2MQ_b776f273-359e-40b3-b29f-10ed7a11bbe5">6,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTEtMS0xLTQzMjM2MQ_2d5e3bce-eb92-448f-8b30-809cc091c873">87,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTMtMS0xLTQzMjM2MQ_a6479853-cea1-4a24-9469-8954fafb0c99">30,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTUtMS0xLTQzMjM2MQ_ff6cba83-03eb-43a6-aad8-eaf4d987655c">37,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTEtMS0xLTQzMjM2MQ_d25d0758-4ee9-44f1-bf44-63d91dc0b0c1">34,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTMtMS0xLTQzMjM2MQ_ac2f0a47-e511-468e-8cc9-fa3958030667">16,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTUtMS0xLTQzMjM2MQ_21987118-33fa-4247-b299-5367ec508b2d">20,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTEtMS0xLTQzMjM2MQ_d4a3ce86-0245-4ff3-a72f-c38538b976cf">89,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTMtMS0xLTQzMjM2MQ_d6750582-4e28-4043-b12b-7aee75009b4f">93,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTUtMS0xLTQzMjM2MQ_0572fe0f-fbfd-4b67-89a5-6de8dbc3ff73">105,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTEtMS0xLTQzMjM2MQ_4ceeffb9-8610-499a-a6fc-2ed8d8737952">24,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTMtMS0xLTQzMjM2MQ_dec448ae-032c-4e90-8083-e6b13f693683">36,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTUtMS0xLTQzMjM2MQ_60b1d25b-de8e-4663-b288-b78f5f0cbcbc">87,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTEtMS0xLTQzMjM2MQ_6d2d66b8-5816-4c40-ac09-aa7d8ca3595e">15,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTMtMS0xLTQzMjM2MQ_ee362926-e34e-4efb-a382-9bd0628816af">6,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTUtMS0xLTQzMjM2MQ_528be780-0386-46f9-8b09-2490f76262b5">19,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTEtMS0xLTQzMjM2MQ_3b81e09a-a270-4fb2-b1a2-9db91dee7c86">1,564,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTMtMS0xLTQzMjM2MQ_b201e98d-4e79-442d-8c8a-16614693519e">1,930,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTUtMS0xLTQzMjM2MQ_dba3e0b2-aae6-4acb-976d-85c9217ba078">1,979,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTEtMS0xLTQzMjM2MQ_5de7d78a-2dd3-42c5-b18a-6008abd4d68d">603,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTMtMS0xLTQzMjM2MQ_b3827df7-609a-413d-80fa-2fc6580b68df">641,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTUtMS0xLTQzMjM2MQ_8d53a5e4-f171-4afd-bb29-308fbdbb95c6">674,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTEtMS0xLTQzMjM2MQ_513fdfcf-9cb6-4ce5-ab33-cd1d919ce81e">57,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTMtMS0xLTQzMjM2MQ_81c6ef0f-bd6e-48e3-9148-0d38139ed6c3">187,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTUtMS0xLTQzMjM2MQ_0f43f01d-640a-484c-9b17-81ebdf72a44a">182,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from asset and business sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTEtMS0xLTQzMjM2MQ_b27b09be-17b5-4c35-8940-f8ffc6f27b62">117,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTMtMS0xLTQzMjM2MQ_6bdbc487-0c4d-459d-9aaf-ecc414573707">61,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTUtMS0xLTQzMjM2MQ_abc583fa-f971-4048-8de1-c4b0f000aa46">50,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTEtMS0xLTQzMjM2MQ_7b440059-19bb-4e03-86d8-310ecf63a84f">129,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTMtMS0xLTQzMjM2MQ_e5129126-0d7d-4457-be38-ce8dfddcfc79">30,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTUtMS0xLTQzMjM2MQ_260b2609-6650-4329-8810-e0b9baf41209">150,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of other debt and equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTEtMS0xLTQzMjM2MQ_e0f2588c-b2f0-4af8-9e1a-28b61d32c065">3,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTMtMS0xLTQzMjM2MQ_24fd99d3-12e1-42c3-872d-63fcb6a6ee1b">2,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTUtMS0xLTQzMjM2MQ_bf4ed3f9-8bcf-4903-9fa4-2a4229b57eb6">3,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTEtMS0xLTQzMjM2MQ_88d91121-3936-410a-86af-278d729ead25">71,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTMtMS0xLTQzMjM2MQ_df3b0938-1c53-478e-96f7-b23fe54a7e00">15,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTUtMS0xLTQzMjM2MQ_b99b0b3e-f897-4268-b149-4c16452952f4">151,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of other debt and equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTEtMS0xLTQzMjM2MQ_b6f301fa-1dea-44e6-baf2-d88936e8b5d3">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTMtMS0xLTQzMjM2MQ_ee1ff909-58ae-43cd-91f9-2f0217e8bb95">12,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTUtMS0xLTQzMjM2MQ_8eeba1d4-c687-4670-81d9-d5611d5bf3ee">3,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTEtMS0xLTQzMjM2MQ_c73beb6d-9c54-45e1-89e0-687b5ab7dac8">31,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTMtMS0xLTQzMjM2MQ_bcb602aa-7165-4e52-a4ee-adfcced78d35">13,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTUtMS0xLTQzMjM2MQ_e2637053-cd16-41fb-9642-11ba3032a7a9">22,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTEtMS0xLTQzMjM2MQ_f4adff87-7571-45e1-97bf-830310817db5">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTMtMS0xLTQzMjM2MQ_ae0937d3-8fc1-4267-bf58-3118620cfad0">2,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTUtMS0xLTQzMjM2MQ_91c781da-bb56-4300-9a04-92356e139de4">3,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTEtMS0xLTQzMjM2MQ_79d4caac-e9b0-4554-8583-cba041890de9">782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTMtMS0xLTQzMjM2MQ_c9a3657d-7940-444b-b381-62ad8b6c5070">745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTUtMS0xLTQzMjM2MQ_01f64c18-b8fd-402c-91eb-5239bdd9547a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTEtMS0xLTQzMjM2MQ_2134bc14-b63d-4bb3-b9ab-190b8be7ad8e">630,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTMtMS0xLTQzMjM2MQ_c0a6abfe-4635-4302-bf5d-c4af6a087078">784,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTUtMS0xLTQzMjM2MQ_4bae1451-8e32-43a8-a46b-298dbe276efb">825,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTEtMS0xLTQzMjM2MQ_0b7f01f5-6a4a-4f81-a749-ccbbedb83396">2,393,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTMtMS0xLTQzMjM2MQ_640e41ca-fd41-43d4-b484-5927b551f378">1,615,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTUtMS0xLTQzMjM2MQ_f465e912-d4a1-41d5-a519-95d208555e67">4,046,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTEtMS0xLTQzMjM2MQ_a744f377-7b6e-4496-b648-e767f259dd81">2,404,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTMtMS0xLTQzMjM2MQ_9eb2bb7a-d454-4928-bbe2-bd38f575e137">861,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTUtMS0xLTQzMjM2MQ_19c99c2d-8985-4c44-a7a1-e29297a08a2f">4,110,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing and debt redemption costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTEtMS0xLTQzMjM2MQ_a4098aea-06ec-4fe7-bafc-5bb21b57859b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTMtMS0xLTQzMjM2MQ_6b75734e-f263-43a2-8d4d-51b72fa5d9ac">9,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTUtMS0xLTQzMjM2MQ_24561ad6-6a9c-4ff4-9724-319b8eee4440">105,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTEtMS0xLTQzMjM2MQ_d4005b18-7866-48ee-bd30-7b6a1e6796cd">802,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTMtMS0xLTQzMjM2MQ_e4474552-f139-42f6-a769-0f55573f702b">1,538,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTUtMS0xLTQzMjM2MQ_09d94c01-65fe-4a3a-8662-902293f91a12">1,458,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTEtMS0xLTQzMjM2MQ_8d6387cc-cb9e-498d-b072-34c5bc2ad605">267,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTMtMS0xLTQzMjM2MQ_6634536f-20a2-4aca-bf3d-0ab88fffa26f">244,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTUtMS0xLTQzMjM2MQ_dbf53f67-445f-4fc3-832a-25e72211e6b7">253,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net payments related to stock purchases and awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTEtMS0xLTQzMjM2MQ_bacac77e-3ac5-4395-95d6-aa08246c6bc7">37,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTMtMS0xLTQzMjM2MQ_4a6f9f2f-7f32-48f1-aae3-5dc9b169e066">60,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTUtMS0xLTQzMjM2MQ_b223b624-1bc3-4b2d-88ac-7f44402f6ad1">975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTEtMS0xLTQzMjM2MQ_4f8097e4-a5b1-4906-89a9-d8b6474ff335">14,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTMtMS0xLTQzMjM2MQ_4cd40ac6-1a3e-4bdc-acec-721e370a7ecc">31,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTUtMS0xLTQzMjM2MQ_06274d2e-4978-45ae-9990-b06735f0d22b">42,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of additional noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTEtMS0xLTQzMjM2MQ_202472b2-c3f9-4138-9081-c4a41a90ca46">3,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTMtMS0xLTQzMjM2MQ_53b3a4ca-9560-4a6f-88a3-04942cbb0db9">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTUtMS0xLTQzMjM2MQ_aee320e5-1259-4e80-8731-2d4c8360563e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTEtMS0xLTQzMjM2MQ_ffa1c551-57c8-4c95-ac45-9d7b79b21bd8">20,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTMtMS0xLTQzMjM2MQ_65cefd2e-db75-4453-8c17-7af00ba11629">20,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTUtMS0xLTQzMjM2MQ_048f5cef-3ea1-4e1e-90aa-638b4ccc88fa">7,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTEtMS0xLTQzMjM2MQ_8ac7c084-8312-4f57-9fd4-2efd64eca74b">1,121,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTMtMS0xLTQzMjM2MQ_8954dbde-6735-4ae3-a541-fdad003faa8e">1,082,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTUtMS0xLTQzMjM2MQ_41ad7a63-124c-4637-953a-cde3e6067db7">1,846,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTEtMS0xLTQzMjM2MQ_fcafc441-976f-4fc6-bf5b-cdb3df048440">29,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTMtMS0xLTQzMjM2MQ_2877af0f-8dfe-455a-90c4-0754ea79e03a">10,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTUtMS0xLTQzMjM2MQ_260aede1-1955-4e21-8c00-07b066c3a5e7">13,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTEtMS0xLTQzMjM2MQ_9edd6eb5-257b-471a-a360-e519e464005e">215,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTMtMS0xLTQzMjM2MQ_462325e6-7025-4b76-b566-2cf9c0c10e96">53,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTUtMS0xLTQzMjM2MQ_24feb0c4-dbc8-4aaf-8de3-3a092f88d38f">706,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTEtMS0xLTQzMjM2MQ_f1f47420-6bc1-4b37-b526-5f325be3ea1a">554,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTMtMS0xLTQzMjM2MQ_6dd51862-7d2c-48c7-8686-6f6385544d17">501,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc55a2cfbea54cdea8e6196c16ac8898_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTUtMS0xLTQzMjM2MQ_ea0e90d6-b3dd-49d7-8f4a-b6ebc086d0cd">1,208,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTEtMS0xLTQzMjM2MQ_0fff2d2a-09da-4b1f-a45f-55a5a49a4cd6">338,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTMtMS0xLTQzMjM2MQ_21cd4b96-04eb-4abf-939f-d9b738beb6dc">554,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTUtMS0xLTQzMjM2MQ_86f0b661-b7dd-45db-bdae-e91c5ec49bc1">501,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_274"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.049%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if800aa66d9654ca986d7798400011ed4_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMS0xLTEtNDMyMzYx_d1683414-9253-485d-ac42-dfa958a1e8d0">1,180,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4c968889cbc45d597559733ee1e7c06_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMy0xLTEtNDMyMzYx_9f727a5b-8c2c-4db5-9392-bb5d79b1a678">125,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c968889cbc45d597559733ee1e7c06_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtNS0xLTEtNDMyMzYx_8f048ba1-2e29-42e2-88cd-1c6664657a10">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50bdbd4176c403094afc0a6a0816442_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtNy0xLTEtNDMyMzYx_ea9c7a30-9f13-4f58-8bab-25b4781cac71">749,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1b76d4d30a4a71b13b8f4c91fb24db_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtOS0xLTEtNDMyMzYx_9f3770e6-53c0-42bb-8dfb-9d63cd1dc091">1,431,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a01430579214274b518179095689fae_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTEtMS0xLTQzMjM2MQ_4c1fdd55-71ee-48f4-8ab5-b25961a43018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a01430579214274b518179095689fae_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTMtMS0xLTQzMjM2MQ_6ea3bc77-67e5-4bb0-b23b-f1d8c8b7d845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie24f4ad97c874df3a74ffade9b367052_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTUtMS0xLTQzMjM2MQ_8d9ac5a1-630c-4e22-a31b-ab1e9adf65a8">47,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a7799ea30042b3b5483fabf59a20c9_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTctMS0xLTQzMjM2MQ_d7fc9c69-adea-4fef-97a7-931fb24745d7">2,133,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5116d4e90c42a2a3c059b946951971_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTktMS0xLTQzMjM2MQ_6cbf7696-685b-4b84-91d4-830302585360">185,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMS0xLTEtNDMyMzYx_458207a9-06a1-4b20-a07a-399ede2f8e72">141,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctOS0xLTEtNDMyMzYx_1119926a-0796-4395-afce-3972062248d2">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMTctMS0xLTQzMjM2MQ_a8ee37c4-77e2-452a-9d34-eee1509f18c7">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMTktMS0xLTQzMjM2MQ_4024315a-661d-45f9-87f2-bc1122f81be7">79,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43ebc619161a4e329c3ae8f647a68ea0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzgtMTUtMS0xLTQzMjM2MQ_b034bb03-c5d5-416d-af0b-c30aa0368894">18,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzgtMTctMS0xLTQzMjM2MQ_e36ffcec-83d8-470e-aa56-5a9aadf28e97">18,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktMy0xLTEtNDMyMzYx_d17eeb45-5d79-4a77-b564-f06cd69b80b0">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktNS0xLTEtNDMyMzYx_7bcbe91e-05fe-4f85-ae2d-69bb8e790a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktNy0xLTEtNDMyMzYx_6b7565f6-7906-41a1-a75c-5fcf435aee54">17,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktMTctMS0xLTQzMjM2MQ_865abc20-dc66-43c4-a8df-c97fdf08c637">17,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTMtMS0xLTQzMjM2MQ_9306b077-9ada-4947-bf42-4fad4689d865">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTUtMS0xLTQzMjM2MQ_83a8eb99-8fc3-4799-a0ac-389fdc1ba15a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTctMS0xLTQzMjM2MQ_c9d29dbb-0dee-4021-afb3-1003698ba33b">17,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTE3LTEtMS00MzIzNjE_27ddc493-e3ff-4f74-92b8-5defd3d3c87a">17,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzExLTctMS0xLTQzMjM2MQ_4ca1d972-f38d-4eeb-ae75-9364827f8915">90,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzExLTE3LTEtMS00MzIzNjE_b8d994a7-b0d5-41e7-8cdd-d78737e2e22c">90,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEzLTEtMS0xLTQzMjM2MQ_8e59b40d-2f2c-480d-baa3-358417d6d14f">163,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEzLTE5LTEtMS00MzIzNjE_821b0301-5137-4ad2-96a2-a9d713fa6ba7">89,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE0LTEtMS0xLTQzMjM2MQ_34ba7a71-5a71-4cb9-b3fd-94020302a54b">30,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE0LTE5LTEtMS00MzIzNjE_d9d520e1-cf65-49b7-9b6a-86dce6ebb5b5">12,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE1LTEtMS0xLTQzMjM2MQ_3d1f77ea-831b-42cd-9154-de59e151a548">3,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE1LTE5LTEtMS00MzIzNjE_c89bf644-f936-4e3d-9583-14840d9dc07f">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTEtMS0xLTQzMjM2MQ_1027bec9-67b6-4ed4-87f8-50cc3a9496dd">7,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTctMS0xLTQzMjM2MQ_b89d76d5-430e-4f58-92ad-1356228d4407">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTE3LTEtMS00MzIzNjE_7288c21d-ceb3-47f5-be69-83d172d017ea">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTE5LTEtMS00MzIzNjE_a3b7739e-f4a7-41f9-a3e6-591bb1d48b67">4,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTEtMS0xLTQzMjM2MQ_fd65ad26-5728-4803-a03f-0edcd48c19a6">151,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTctMS0xLTQzMjM2MQ_cd7dc3b8-5711-45ca-ba81-6e03034c4b78">151,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTE3LTEtMS00MzIzNjE_21ad0778-d81e-4c4a-a98a-0120d4857265">151,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTExLTEtMS00MzIzNjE_020b4261-5882-42b4-95ad-8b48d0a3e18c">16,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTEzLTEtMS00MzIzNjE_9363757d-cd32-402b-9ed2-b80d78c85491">1,446,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTE3LTEtMS00MzIzNjE_293e6f63-5acd-4ada-b829-92265af597af">1,446,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTMtMS0xLTQzMjM2MQ_d36662f9-a809-474d-a47e-9d63322e3ff1">16,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTUtMS0xLTQzMjM2MQ_5eabe2a0-d8ed-4bc8-9fc2-fa98bb4b0740">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTctMS0xLTQzMjM2MQ_0f648f7d-6fd6-4b8e-8cdc-99cd8fc1b915">93,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTktMS0xLTQzMjM2MQ_ffbdd447-4c22-4c86-9307-770276e8cd08">1,352,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTExLTEtMS00MzIzNjE_84a6e54b-0332-4f34-befb-f248933bbe75">16,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTEzLTEtMS00MzIzNjE_3c952277-67b5-4834-9b53-23fdbdbed840">1,446,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTE3LTEtMS00MzIzNjE_89509270-bc9b-4b34-a563-7a23316b8ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cbd163c566489c8ab76a850aeba968_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTEtMS0xLTQzMjM2MQ_5f4b4f3d-b0d5-47a0-896c-da624aa732ae">1,330,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTMtMS0xLTQzMjM2MQ_43defead-cc5f-4dbe-9ba3-d6c9966c0820">109,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTUtMS0xLTQzMjM2MQ_b11778d9-8569-4793-8235-fe7a4aed94e0">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c4cc40ee544f8d8fc58a0361ea6027_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTctMS0xLTQzMjM2MQ_819d2112-76ab-4de0-b1b3-3a2af4f0278a">597,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d2f751df2e4644ba91a72008a0765e_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTktMS0xLTQzMjM2MQ_93644bcf-f98b-4b33-86af-8c78cf2352b4">852,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTExLTEtMS00MzIzNjE_03abb0e8-6fdb-4fca-87bd-13f06ca76944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTEzLTEtMS00MzIzNjE_870edba5-5127-4129-9585-0f6681244405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i757a0e9ab6594add994f294dd3cdbf66_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE1LTEtMS00MzIzNjE_06e61641-a1c4-4cd0-9ea2-460f6c708185">66,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5427ec717e8648059aadaee70b6593f7_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE3LTEtMS00MzIzNjE_ac449e3e-aa96-4279-8ed9-0fc00c71e096">1,383,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72de044ff982442ba895166a41f82244_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE5LTEtMS00MzIzNjE_bab16fae-1544-415d-a787-e1726b4231d0">183,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTEtMS0xLTQzMjM2MQ_5bfc1c4e-dbf9-4f03-9ba5-a86c37bf2d3a">160,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTktMS0xLTQzMjM2MQ_fa31cd19-82c7-42c6-a1c8-129073ce57d5">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTE3LTEtMS00MzIzNjE_c55b29e4-5ec3-4f15-a163-f1eff5da206b">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTE5LTEtMS00MzIzNjE_91652fbf-20b4-44cb-9c16-b04895305e5d">72,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e4eaf9f852e421fbf29ec7d95adf14a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI0LTE1LTEtMS00MzIzNjE_eef6b3fa-d72b-4f2b-bf5d-28883215ec5d">73,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI0LTE3LTEtMS00MzIzNjE_1f2a40eb-ed41-447f-88f6-cef4369c922d">73,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTMtMS0xLTQzMjM2MQ_b8a61982-1813-4740-a31f-23f6fb8dc35c">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTUtMS0xLTQzMjM2MQ_3cdefe46-891f-4fff-85a1-215d8bc86dd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTctMS0xLTQzMjM2MQ_22b0c37b-0968-42ca-b964-d5b291b72c39">19,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTE3LTEtMS00MzIzNjE_02b07713-3b3c-4cf5-b091-0585e23f5a9b">19,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTMtMS0xLTQzMjM2MQ_0a44752a-b67e-447e-b289-20f100d3987f">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTUtMS0xLTQzMjM2MQ_a303afb4-a638-4746-840e-3a411df8d965">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTctMS0xLTQzMjM2MQ_74e7c909-a0f7-4e64-b120-218eecce4491">80,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTE3LTEtMS00MzIzNjE_58aa8186-d2f5-4200-a3f2-88896827abe1">80,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI3LTctMS0xLTQzMjM2MQ_62f6d6ab-f101-40bb-8b4a-2cbe2a5636c2">100,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI3LTE3LTEtMS00MzIzNjE_95c14375-ea06-49e8-a0d9-d4d048d0bf29">100,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI5LTEtMS0xLTQzMjM2MQ_1a971f76-2999-410c-8cfb-440f899e5c0b">159,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI5LTE5LTEtMS00MzIzNjE_d7be3235-d099-4a55-910a-c0352f00b4de">84,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMwLTEtMS0xLTQzMjM2MQ_de24c25e-bb72-47aa-8244-80dfa318db2a">22,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMwLTE5LTEtMS00MzIzNjE_99810708-6b67-4bb2-a069-2c228ed9c4c8">9,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTEtMS0xLTQzMjM2MQ_520dcd10-2b1f-41a6-bdb4-350d025c22da">5,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTctMS0xLTQzMjM2MQ_8cf2d588-80da-4b3f-a84e-ffe1b458389e">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTE3LTEtMS00MzIzNjE_1fd5d123-4b30-465e-a80e-23e4b4a996b6">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTE5LTEtMS00MzIzNjE_b32e2345-548e-4690-b759-ac7d1020de24">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTEtMS0xLTQzMjM2MQ_8501dd63-a764-4f27-87cf-e30ed838e812">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTctMS0xLTQzMjM2MQ_763470c2-9185-4727-a10c-cc55cdfd0480">13,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTE3LTEtMS00MzIzNjE_cc64d57f-f725-43eb-9c24-1c1d0af4cc6a">13,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTE5LTEtMS00MzIzNjE_987378cf-18c7-4f92-b171-3a37e2e0bf65">1,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTEtMS0xLTQzMjM2MQ_dc33e4c7-a327-4ea4-b390-35816db3de21">75,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTctMS0xLTQzMjM2MQ_4c25c5a6-be86-467d-acb2-12bb0adc7953">75,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTE3LTEtMS00MzIzNjE_16708998-18cc-45b8-905b-cac001681311">75,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTExLTEtMS00MzIzNjE_c2382bde-6080-492c-85f2-758aa7e6e11d">13,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTEzLTEtMS00MzIzNjE_e949ba43-59dd-4a38-bc16-acac82bae3b2">1,546,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTE3LTEtMS00MzIzNjE_a24e6c51-6d39-4986-a81b-88bf56d82b79">1,546,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTMtMS0xLTQzMjM2MQ_d90a7a82-4b7d-4c30-8f98-ba440150cb77">13,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTUtMS0xLTQzMjM2MQ_3c1b264f-78db-42bc-85b9-225bd3aa14c6">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTctMS0xLTQzMjM2MQ_f3056b26-f893-4f04-b451-d4b9b156a0e6">69,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTktMS0xLTQzMjM2MQ_420bc374-aa1e-44b0-a637-1934346eae36">1,476,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTExLTEtMS00MzIzNjE_663a240a-1faa-431e-86c1-116c4316b36c">13,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTEzLTEtMS00MzIzNjE_55d64478-102f-4d08-a23f-a0a2ecf2069b">1,546,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTE3LTEtMS00MzIzNjE_4fc7dd48-b06f-4e00-a9a6-192aa5fb4539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes from partnership<br/>&#160;buyouts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTctMS0xLTQ5MDIxMQ_11cf0dd9-8fa1-4196-a457-e6991102cab4">62,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE3LTEtMS00OTAyMTE_f7d7a6a7-ff6b-48b2-9f54-67cfc0d9c1b0">62,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab32047366140518741cdd1c29b2986_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTEtMS0xLTQzMjM2MQ_5da68b8c-e42e-41fe-8c22-f932a0af6d20">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTMtMS0xLTQzMjM2MQ_135bf988-a728-4a72-8725-0c45d09bb6ee">97,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTUtMS0xLTQzMjM2MQ_eb7260ec-a575-4c67-b6d4-be5a280555a4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTctMS0xLTQzMjM2MQ_849c48b2-1939-436d-b3fc-dc6c003ba354">540,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d81a8050455482f899360e81a78be21_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTktMS0xLTQzMjM2MQ_40778cf5-8fe0-42ad-a399-32359509c964">354,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTExLTEtMS00MzIzNjE_d6d5466a-d801-49d0-b0ee-34504c52dec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTEzLTEtMS00MzIzNjE_1713cfea-12c1-45f4-86b9-068cff5e68b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d6896e2941a48e2963273fd62c1f8a1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE1LTEtMS00MzIzNjE_f19551fc-aba2-4fbb-a58f-8528a343ea12">139,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bfee231c604920b47c088b54ff3344_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE3LTEtMS00MzIzNjE_61fc4954-ead5-4a39-9732-4a15d657f4cd">755,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if842ebd0fa3647a485eee028263590d1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE5LTEtMS00MzIzNjE_68e1d013-93a7-4db8-a9cc-c01b9ff1acb6">180,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY - continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.049%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab32047366140518741cdd1c29b2986_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMS0xLTEtNDMyMzYx_5da68b8c-e42e-41fe-8c22-f932a0af6d20">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMy0xLTEtNDMyMzYx_135bf988-a728-4a72-8725-0c45d09bb6ee">97,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtNS0xLTEtNDMyMzYx_eb7260ec-a575-4c67-b6d4-be5a280555a4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtNy0xLTEtNDMyMzYx_849c48b2-1939-436d-b3fc-dc6c003ba354">540,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d81a8050455482f899360e81a78be21_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtOS0xLTEtNDMyMzYx_40778cf5-8fe0-42ad-a399-32359509c964">354,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTEtMS0xLTQzMjM2MQ_d6d5466a-d801-49d0-b0ee-34504c52dec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTMtMS0xLTQzMjM2MQ_1713cfea-12c1-45f4-86b9-068cff5e68b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d6896e2941a48e2963273fd62c1f8a1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTUtMS0xLTQzMjM2MQ_f19551fc-aba2-4fbb-a58f-8528a343ea12">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bfee231c604920b47c088b54ff3344_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTctMS0xLTQzMjM2MQ_61fc4954-ead5-4a39-9732-4a15d657f4cd">755,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if842ebd0fa3647a485eee028263590d1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTktMS0xLTQzMjM2MQ_68e1d013-93a7-4db8-a9cc-c01b9ff1acb6">180,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMS0xLTEtNDMyMzYx_7a48cfe9-5749-4964-954c-1f96e6595d93">151,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50253e4de73648958a1dc9b043930734_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtOS0xLTEtNDMyMzYx_1106946d-038b-4e2c-ad21-5d7385bf86d1">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMTctMS0xLTQzMjM2MQ_26390f88-eb9d-4a37-b96d-df5530a2b033">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMTktMS0xLTQzMjM2MQ_7397abc9-dd57-4a26-a68e-56d71db22dd5">69,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbaa5362c6b426aa3e151ee9c01964c_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzctMTUtMS0xLTQzMjM2MQ_01ab01cd-b318-4ea1-92c3-cefd151349f2">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzctMTctMS0xLTQzMjM2MQ_63452859-2f03-497b-8c70-04b3f29c32aa">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtMy0xLTEtNDMyMzYx_a711da4d-c644-4923-adc9-dbad222a9b12">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtNS0xLTEtNDMyMzYx_5512098b-aa7f-4cd2-8afe-2667e8ef3a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtNy0xLTEtNDMyMzYx_ad2ce2f2-0cce-4cc5-bb25-6e6edd3200a3">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtMTctMS0xLTQzMjM2MQ_a429813b-6485-42fd-9154-bb8a19f1a3af">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktMy0xLTEtNDMyMzYx_4c89b458-55ae-4473-ab24-5117b1a2129f">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktNS0xLTEtNDMyMzYx_4225034a-7ff4-4c59-8897-6f9dc33f0b28">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktNy0xLTEtNDMyMzYx_91207093-02cf-44b9-81d8-e218a55ba97c">55,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktMTctMS0xLTQzMjM2MQ_0e776824-5810-449b-b151-c757299f474f">55,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEwLTctMS0xLTQzMjM2MQ_17784afe-f779-41ea-b1ac-f0610b4d29e5">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEwLTE3LTEtMS00MzIzNjE_4475cc64-c253-491a-a127-94de8f1d6ee8">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEyLTEtMS0xLTQzMjM2MQ_fb360eb4-31fb-4d0e-8651-e12765c874e6">176,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEyLTE5LTEtMS00MzIzNjE_76135a58-21f3-46d9-b59b-4512ade609fe">90,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEzLTEtMS0xLTQzMjM2MQ_6095b9a2-d838-4936-b528-49a6b548cc54">10,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEzLTE5LTEtMS00MzIzNjE_8b7820d2-bbbb-461b-9bc1-a78fbda9e1bd">3,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTEtMS0xLTQzMjM2MQ_458fa826-93a4-44b1-a19f-373251e7e786">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTctMS0xLTQzMjM2MQ_db444fb0-10cb-4bf1-b82a-fe65359ae547">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTE3LTEtMS00MzIzNjE_4912f70b-ef10-4a8d-8d9b-122ec6dd368a">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTE5LTEtMS00MzIzNjE_88a45c96-03cb-42c9-b783-74601f80c155">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTEtMS0xLTQzMjM2MQ_215f455f-a411-42b8-8dee-13a656d5a12e">11,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTctMS0xLTQzMjM2MQ_10f63136-665b-44f8-be18-07bc68d3884d">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTE3LTEtMS00MzIzNjE_96e148e0-e62b-47e1-85a2-21c8e1d5c4fd">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTE5LTEtMS00MzIzNjE_df87beba-2b6a-41be-8392-67e4aaaa5756">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTEtMS0xLTQzMjM2MQ_ffe8a130-3c37-4c82-875b-65a2f9880f30">62,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTctMS0xLTQzMjM2MQ_8770201e-58a7-4ef7-8c90-6b7972118dba">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTE3LTEtMS00MzIzNjE_b5323705-5996-408c-96d9-1c0fac707897">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231" decimals="-3" name="us-gaap:TemporaryEquityOtherChanges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTEtMS0xLTU1MjM3Mg_665f503b-2d0d-4610-936c-2940ffe99716">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE3LTEtMS01NTIzNzI_9dcfb76a-bc45-4ff8-9bb0-51addca4de13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE5LTEtMS01NTIzNzI_03a21cf0-7b36-4cd8-835a-417ed97590e7">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTExLTEtMS00MzIzNjE_dd97214f-aad6-4f47-befb-97d429f6f5a8">8,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTEzLTEtMS00MzIzNjE_70b4ba11-b74b-45be-ae49-7e59b03983bb">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE3LTEtMS00MzIzNjE_c87bfbdb-feb3-4139-92bd-57c9a126aa73">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTMtMS0xLTQzMjM2MQ_1a9a157d-64b2-47bc-b365-f94935ab58c6">8,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTUtMS0xLTQzMjM2MQ_90565ab8-a15b-440d-9b01-a8d241400dd9">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTctMS0xLTQzMjM2MQ_b9500a25-a331-4be5-9b85-575a0d779258">47,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50253e4de73648958a1dc9b043930734_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTktMS0xLTQzMjM2MQ_538e4964-4edc-4e40-848f-1024896ec35c">740,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTExLTEtMS00MzIzNjE_9f724765-7de4-45f3-b0c2-d07d9262cf69">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTEzLTEtMS00MzIzNjE_c543fd62-2699-4005-b1bb-37becd5258ae">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTE3LTEtMS00MzIzNjE_e8eaa277-5cae-426c-8e1a-ff79a3a087eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9acef4149d442db28cf471388f4e4d_I20221231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTEtMS0xLTQzMjM2MQ_40f3273b-8355-4477-b3d7-d3afdd8fc65c">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52ec121281ae42de864df9afaf5bbce5_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTMtMS0xLTQzMjM2MQ_3e424148-0796-4199-ba92-29ef6fc7e2a2">90,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ec121281ae42de864df9afaf5bbce5_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTUtMS0xLTQzMjM2MQ_3cbf3df6-19b5-4032-bc45-0af42d62f263">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356a876fece547c98e1997006099bed6_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTctMS0xLTQzMjM2MQ_f5f98eac-e2a7-486f-9354-ef9da568ce69">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b58bdbade49e9b33062b2a125387c_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTktMS0xLTQzMjM2MQ_000af394-71f1-43a7-a5a8-dd97ffa90141">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf95daa74ecc406b87ec09f0ad0760f1_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTExLTEtMS00MzIzNjE_29d20359-e093-4f63-9a75-0250b1700e83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95daa74ecc406b87ec09f0ad0760f1_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTEzLTEtMS00MzIzNjE_c052f2f9-1995-4b90-ae7a-4460b64c6d7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i260caeb3a4e44b659a7def8d723d8f28_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE1LTEtMS00MzIzNjE_ca3af46f-9ade-41fc-a158-93ad5206066d">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f29989a080c4de4b210d915a9c0f8ff_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE3LTEtMS00MzIzNjE_247c41c9-9ba5-430d-8d95-8e470fd05836">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea9631c41ae445d9079a93421c94e37_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE5LTEtMS00MzIzNjE_aea1b8a6-9817-42d3-ad3d-56846c8d4ea1">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_277"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div id="ib228226ec511491b87b183c6d217a21a_280"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTAw_c3cf5cdd-2a99-40ea-81e8-9834488090b7" continuedAt="i06810b0e583849e0abd5f561cd6c3b39" escape="true">Organization and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i06810b0e583849e0abd5f561cd6c3b39" continuedAt="iecdd8473cf114a72ab877f2b03cb38ec"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are comprised of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or end stage kidney disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ESRD or ESKD). As of December&#160;31, 2022, the Company operated or provided administrative services through a network of <ix:nonFraction unitRef="clinic" contextRef="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231" decimals="INF" name="dva:NumberOfSites" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzc2Ng_b8f22124-c6bb-4841-b4ed-511c531850dd">2,724</ix:nonFraction> U.S. outpatient dialysis centers in <ix:nonFraction unitRef="state" contextRef="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzgwNQ_c6d07944-51b2-4c1d-b5d6-680e33f919bd">46</ix:nonFraction> states and the District of Columbia, serving a total of approximately <ix:nonFraction unitRef="patient" contextRef="icf6d468c617d466c8c07ffbf3361572d_D20220101-20221231" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzg3OA_eb57689e-5afc-4911-998a-3e16544af64d">199,400</ix:nonFraction> patients. In addition, as of December&#160;31, 2022, the Company operated or provided administrative services to a total of <ix:nonFraction unitRef="clinic" contextRef="ib6392b172fe84693a759b4ef47376ca3_I20221231" decimals="INF" name="dva:NumberOfSites" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzk4NQ_1af36fbc-790a-46db-b206-28dab7afd040">350</ix:nonFraction> outpatient dialysis centers serving approximately <ix:nonFraction unitRef="patient" contextRef="ie34b55b3589b41aa8b4dc4e6ab94e9e7_D20220101-20221231" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzEwMzg_00e07b2d-7d68-46c0-9657-f4fd296fa85d">45,600</ix:nonFraction> patients located in <ix:nonFraction unitRef="country" contextRef="ib6392b172fe84693a759b4ef47376ca3_I20221231" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzEwNjE_5c363a93-3ce3-4ea5-afa3-84a6321425b4">11</ix:nonFraction> countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, the Company completed the sale of its prior DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC (Optum), a subsidiary of UnitedHealth Group Inc. The effects of the DMG sale on the Company's consolidated financial statements have been reported in discontinued operations for all periods presented. For information on how the DMG sale has affected these results, see Note 22.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDkz_f86aaeab-ecb0-4552-8ca9-e2200f350362" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD). Prior year classifications have been conformed to the current year presentation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTMw_11549ed8-e9e3-4dc9-91ab-8113cd56a866" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTM1_405fafb4-b576-42d0-9e03-d549bafecf6d" continuedAt="iae0a5a4268144d9c99f85c49ffc3b188" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="iecdd8473cf114a72ab877f2b03cb38ec" continuedAt="i95b353eefc9d4f3f8fee9a5a34909091"><ix:continuation id="iae0a5a4268144d9c99f85c49ffc3b188"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., <ix:nonFraction unitRef="number" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzUxNzU_6d006d81-3752-4035-bcd2-53758222fef7">80</ix:nonFraction>% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment frequency than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of our commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated in the period services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, for most of its VBC arrangements, the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, for most of its VBC arrangements the Company does not include third party medical costs in its reported revenues and expenses, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i95b353eefc9d4f3f8fee9a5a34909091" continuedAt="ica6f729ba8d2480d87ad324fc9b8906b"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:OtherNonoperatingIncomeExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTUz_e1a373e5-4c43-4d5e-8844-a4f25969bdb5" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income includes interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, impairments on investments, and foreign currency transaction gains and losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYy_d59cbcba-0f89-4158-a3e1-b3125923874d" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDk0_ff3fa891-2cda-41f9-a819-7b387644ece7" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow. See Note 4 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYw_128d98a3-ce73-4234-bb59-53445bdc0b69" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other income. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 5 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYz_960af1b8-1a8c-4edc-8a2c-e9a0fa9f846b" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTIz_74bb7e83-3305-4c45-81c2-c8df93feba47" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTMx_09cb1565-cc53-4ee3-8882-a4e5a4363319" continuedAt="i29ad0998cab34c4aaad2e21ad311d5f9" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of the right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date.The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ica6f729ba8d2480d87ad324fc9b8906b" continuedAt="i01b53281764246df93b56be815d54110"><ix:continuation id="i29ad0998cab34c4aaad2e21ad311d5f9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets, and interest accretion on operating lease liabilities, are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased.</span></div></ix:continuation><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg2_579479b3-e7b5-45c7-a6e7-59452d497d48" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDk2_18437822-13c1-4498-954e-52f4a4d4116e" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg3_6abad38e-abb2-46e3-9012-131fc1fec302" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 9 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDgy_fe1396e2-f2b4-404b-9333-309c15c9ec1d" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 10 for further details.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:13.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i01b53281764246df93b56be815d54110" continuedAt="i6df9ebf8424a42e998e9bf0a92e6b60b"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:InsuranceAndSelfInsurancePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDgz_8c49dd01-bb39-4aea-83c9-60fed56b4c7f" continuedAt="i69a4fc69b4e6462dad778d91b1094172" escape="true">Self-insurance</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69a4fc69b4e6462dad778d91b1094172">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</ix:continuation> </span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTQz_ea46e292-0f0f-4021-8883-201dafda6d5d" continuedAt="iec555654a4df44baba650e83cb8119c0" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg0_4954e743-0c33-4cd0-a286-f11e794a7eed" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDkw_da428e8b-3e26-454d-ab0d-673c2c6b7cb2" continuedAt="i5dbc21f14c3549c39e54666a3970c405" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in LIBOR interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 13 for further details.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTQ0_1af61039-cd90-4312-9491-dbe0c0e38fc1" continuedAt="idf14a07801ee4f219e1edf473125c303" escape="true">Noncontrolling interests</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf14a07801ee4f219e1edf473125c303" continuedAt="iea6ea37368b84e08a8ef2284c5ced7c4">Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes.</ix:continuation> As of December&#160;31, 2022, third parties held noncontrolling equity interests in <ix:nonFraction unitRef="entity" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzU0OTc1NTg0ODkxMw_ee739966-bc07-44fd-88d8-08551c6f4731">689</ix:nonFraction> consolidated legal entities.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTI3_799aac4e-e260-4b90-9f7c-66c0d3500f80" continuedAt="ibb944987b8294cfaa020199fc0e70693" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6df9ebf8424a42e998e9bf0a92e6b60b"><ix:continuation id="ibb944987b8294cfaa020199fc0e70693"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement. See Note 24 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 24 for further details.</span></div></ix:continuation><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTA4_92a588ef-f7b3-4d22-afbd-9243ad0e2671" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which extends the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors will cease or become non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The Company is currently assessing the other effects this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU creates an exception to the general recognition and measurement principle in ASC 805 and will result in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Early adoption is permitted for all entities. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_283"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMyMzU_7377d7b1-4e48-4563-9d98-aec511944588" continuedAt="i3579e4fe31964930a7d355745ea25f06" escape="true">Revenue recognition and accounts receivable</ix:nonNumeric></span></div><ix:continuation id="i3579e4fe31964930a7d355745ea25f06" continuedAt="i2a28d42e4c334de4973ac4eeb207374f"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMyMzc_902f85b5-2c9e-4d3e-9fa8-b8d9fd0b76cc" continuedAt="ibf97ad82927f40c79a4bac431bfad0e2" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id71233621bbd4804ad59b2cce80ee34a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzMtMS0xLTEtNDMyMzYx_06f0456e-5958-4f06-aac8-937cf07a0094">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzMtNS0xLTEtNDMyMzYx_af6da4a2-97bb-4864-aff1-ed0288b9c519">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2c1e7f78214f40be85e6cb8292eb45_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzQtMS0xLTEtNDMyMzYx_424ab235-7547-417c-8876-861fbce0440b">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzQtNS0xLTEtNDMyMzYx_a0ff548d-d2d7-4fcd-9055-a838e2c82682">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61831cf914934370a0e350538f48dd0e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtMS0xLTEtNDMyMzYx_6903711a-5c90-4cd6-a34b-5de9b6ed2e63">336,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a634cd0d2347eeba744537d4975ff3_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtMy0xLTEtNDMyMzYx_5ae7f623-840c-49ad-abef-39f3e817e646">464,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e37ec44c0d4b32bdf6a4f6631a509d_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtNS0xLTEtNDMyMzYx_72db835d-4ac9-4d7e-ae2c-f58135096ee4">801,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c1650937a14aa6b693db780617d335_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtMS0xLTEtNDMyMzYx_58b0ea6d-852b-4268-9a8d-b2d871b5a760">3,437,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtMy0xLTEtNDMyMzYx_dc02079e-dee7-41fb-8009-11d009cbced2">223,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtNS0xLTEtNDMyMzYx_723474b8-4076-499d-8fc9-9c5f9638e1b8">3,660,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a5fb336b324120926fdf3e7acd509f_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzgtMy0xLTEtNDMyMzYx_1116c05a-50e3-4738-aae4-5cb1524bf466">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzgtNS0xLTEtNDMyMzYx_99bff99d-7be6-49e7-a259-1d9c2fc8ac35">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd379d095ba4b25a0520096ae331749_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzktMy0xLTEtNDMyMzYx_c61f9785-7869-4860-a08a-d489216752eb">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzktNS0xLTEtNDMyMzYx_b45508ba-8255-4c1a-ad1e-ac3ceca1b502">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEwLTMtMS0xLTQzMjM2MQ_a878d0f4-6e42-454c-9d25-e68255d1e7a0">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEwLTUtMS0xLTQzMjM2MQ_5eda80d4-94b2-4748-b971-ad525542944c">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46a5e0f67ed4bad96cbd9179fa563a0_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTEtMS0xLTQzMjM2MQ_1c733099-6474-43fb-b59f-ea1b9c8d83f0">24,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7b6a5928a24b238a1f7131f1574774_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTMtMS0xLTQzMjM2MQ_4718df3b-fce7-4b58-8724-f8c1d20c1e4f">44,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a984146d6674799aba080454fdc2cda_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTUtMS0xLTQzMjM2MQ_0d0d779d-6f15-40e5-b4c3-53f66846f2aa">68,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia742be54e94c45f2b3dd8ff5d6c056e9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTEtMS0xLTQzMjM2MQ_27a4dbb6-b1c0-4265-b9c4-296fd9a21436">87,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b009a1142c248539196c3fba5d59fb2_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTMtMS0xLTQzMjM2MQ_65fc31db-4af5-4376-be00-e017f2c4dac2">4,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTUtMS0xLTQzMjM2MQ_74113f7f-562a-4fa5-b852-63b002a41809">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTEtMS0xLTQzMjM2MQ_91508860-76d6-43d3-9986-cc6417ec08e8">10,512,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTMtMS0xLTQzMjM2MQ_23e637c9-cec3-4b68-8fb0-1ae1371c9ccb">1,097,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTUtMS0xLTQzMjM2MQ_8cb9688c-7fd5-4c59-b186-2070dc8a80fb">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd3f694f7e44856ae0923f71f737ae4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzMtMS0xLTEtNDMyMzYx_43076949-4c49-4b28-9e7f-9f2be9a055e2">6,133,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzMtNS0xLTEtNDMyMzYx_c6638507-6957-41ba-bb16-b538f5ad342f">6,133,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482fd86c04c1456c8e86866bab4d7940_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzQtMS0xLTEtNDMyMzYx_8017a110-f359-4c98-bf8a-5b7ecc334f20">782,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzQtNS0xLTEtNDMyMzYx_3a9fab04-4a65-4994-921c-7d743badfcf3">782,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e08b129ee741c09e555e16d959b1c5_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtMS0xLTEtNDMyMzYx_cf35888d-fc79-4bbd-b950-0a7ddc9cc35a">328,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da226c056b94d07adbacb4d2befd882_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtMy0xLTEtNDMyMzYx_441817ae-5a4f-45a7-92d7-47f5c8d9b89d">463,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic954305add924c439027278f45b35571_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtNS0xLTEtNDMyMzYx_1f88cf72-fe87-47a9-8aa2-6ba194ab2497">791,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23acb46414744f3295a01b88b12f0852_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtMS0xLTEtNDMyMzYx_1128b82b-ad29-4ea2-84f1-76c099873b2a">3,397,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtMy0xLTEtNDMyMzYx_b2c1da61-43ec-4bca-b75c-34003d54bce0">199,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtNS0xLTEtNDMyMzYx_e225b908-cd68-47dc-815c-14f0f6104453">3,596,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed0d2be726f4c74911502d210cc0c64_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzgtMy0xLTEtNDMyMzYx_982a2d38-3d99-4077-9a83-363546fd43fc">326,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzgtNS0xLTEtNDMyMzYx_3053781d-4494-45c5-b920-2ee923d8e391">326,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafefc99a68e9484292f1297292ffcc0f_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzktMy0xLTEtNDMyMzYx_a190023b-67f6-4515-b762-e4d7fdc2b908">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzktNS0xLTEtNDMyMzYx_be935c36-136a-4d04-b51c-86c1829916fe">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEwLTMtMS0xLTQzMjM2MQ_b037eb88-537f-4d82-83cc-42393ca9dd68">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEwLTUtMS0xLTQzMjM2MQ_5cd1d045-e87d-402b-b682-bf86c18b658d">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4439bdfa6abe4378a88454a4104bf810_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTEtMS0xLTQzMjM2MQ_2734b2fe-be20-486f-9f3d-d006d352fa6e">25,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c2f5e21bcf4d3c8ee4481538d06f47_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTMtMS0xLTQzMjM2MQ_586fe95c-64ea-49d0-820a-137847ce28c5">40,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1724a3d8642c4b77958c204145d9b59e_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTUtMS0xLTQzMjM2MQ_398e0071-44e0-4410-98aa-6627919e515f">66,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b6a7965dcd6428eb9c75d5330f6c0fc_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTEtMS0xLTQzMjM2MQ_b28844f5-f084-4489-9927-0f3ea7f7f33a">90,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6712e682bfcc4d9f8819cac2f889a384_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTMtMS0xLTQzMjM2MQ_3b763f6b-8090-45d7-8cf5-c134e8ab3a98">4,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTUtMS0xLTQzMjM2MQ_c4701c72-ac2a-481a-8fa6-d12b91c03763">95,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTEtMS0xLTQzMjM2MQ_b7615f94-f702-4948-8289-a61050a3a61f">10,576,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTMtMS0xLTQzMjM2MQ_a95e9bd0-c43e-4b91-a52f-edc8ba6651f9">1,042,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTUtMS0xLTQzMjM2MQ_975b0fc3-e59e-431f-849a-5ae7ce3c8560">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i2a28d42e4c334de4973ac4eeb207374f"><ix:continuation id="ibf97ad82927f40c79a4bac431bfad0e2"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15e5f5845074315a06e0d1ae4277176_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzMtMS0xLTEtNDMyMzYx_36925de5-f910-4d0e-8b5a-b5fba4c7ad90">6,169,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b6e5a2190441af8606765112836eee_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzMtNS0xLTEtNDMyMzYx_eb7f7b61-1e1e-41e0-bdbf-6df45afe7b9f">6,169,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca689ecc20e4fe0876e7b122b0bc25a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzQtMS0xLTEtNDMyMzYx_b0cb7589-c7d9-4f93-b945-9a1085cbd47f">744,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzQtNS0xLTEtNDMyMzYx_724450a7-78b7-4029-9e62-250a828828a4">744,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94685d28e10e4104afa0fc7accb57c02_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtMS0xLTEtNDMyMzYx_3660e877-d387-4944-98c4-d25d714db656">334,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71b76b330e14df99ec3824e8fc1d7c8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtMy0xLTEtNDMyMzYx_cc2b4d2b-7efb-4d47-b8c4-104791d1b7da">380,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife78a29c23534d2a8188fe47f55108a0_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtNS0xLTEtNDMyMzYx_33d11ee7-e158-40a6-bc6b-264e923b5d68">715,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfd61b594e04154b072d87e97ad8774_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtMS0xLTEtNDMyMzYx_d5a3368d-212f-40c3-be84-2d99af322fde">3,370,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtMy0xLTEtNDMyMzYx_69c061db-4731-43f6-8164-6067c9bcb52b">170,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtNS0xLTEtNDMyMzYx_69eb077a-378c-4a03-9606-d6d5a608b6dc">3,540,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bb8de9b00141a78c540283fa20d761_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzgtMy0xLTEtNDMyMzYx_898c9f71-76c4-43a7-8627-d42ef399ee66">419,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b6e5a2190441af8606765112836eee_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzgtNS0xLTEtNDMyMzYx_0a99f5d9-da73-4b34-8b8e-7ff4e4a40127">419,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3ef454cab24926be400fa579222ae9_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzktMy0xLTEtNDMyMzYx_338ec4b0-5839-442d-bc8d-dd8889310c7c">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzktNS0xLTEtNDMyMzYx_ad7afc73-bafa-4f19-bf87-afeddeb986f8">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEwLTMtMS0xLTQzMjM2MQ_eecf4740-7c29-4e17-bf72-c44f6c2e4824">33,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEwLTUtMS0xLTQzMjM2MQ_56dec09c-acd9-4291-a1f0-147de4d31980">33,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77373f4271f44dbfa26dd7f49f949448_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTEtMS0xLTQzMjM2MQ_5a5656a0-0775-4c49-ac71-7ca900d76150">40,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cc0568452c48b58599e76cbde4fd51_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTMtMS0xLTQzMjM2MQ_1ab148bf-08f9-4061-9552-0085cfcfdfec">47,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1cf19f60904659aa80c183b19b6dfb_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTUtMS0xLTQzMjM2MQ_9b0fb7cb-1beb-42de-828a-5cb1cf8fa1da">88,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida4e3d014e894c2994a8742fc9556a3c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTEtMS0xLTQzMjM2MQ_e38861ca-2581-4838-821d-29dc6356a02c">145,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7ab9fa77fa447caa055395318311262_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTMtMS0xLTQzMjM2MQ_f279847e-9ba8-4c1b-97d6-ba8413679e46">16,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTUtMS0xLTQzMjM2MQ_e9cb307e-ecf1-4607-a6e1-f12f2c4a232e">162,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTEtMS0xLTQzMjM2MQ_8617215b-baef-443f-a24e-5cb6431dcaed">10,514,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTMtMS0xLTQzMjM2MQ_91154d5c-0573-4c04-a31f-00f598a50fda">1,035,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTUtMS0xLTQzMjM2MQ_0b10f184-f56b-4a8b-b437-2ed5246a87a7">11,550,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December&#160;31, 2020 has also been recast to conform to this presentation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. integrated care and disease management business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1, there are significant risks associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues including determining applicable primary and secondary coverage, changes in patient coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI1NDM_750151c9-dd1a-4555-883e-a170d7397fb2">No</ix:nonFraction> single commercial payor accounted for more than <ix:nonFraction unitRef="number" contextRef="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI1OTQ_f325c691-2138-4358-8277-b652a6ee78c4">10</ix:nonFraction>% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $<ix:nonFraction unitRef="usd" contextRef="i892eb918a47245d0a1e1b8efd2c4dc9a_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI4Nzk_850a045f-17ef-413a-8120-9d2e86c92fdf">1,113,499</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ddfba6879ce435ea2183e425ab9fb97_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI4ODY_aeb3bfc5-ce1a-4520-a586-dac6d622b4db">1,174,123</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively. Approximately <ix:nonFraction unitRef="number" contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI5MzQ_23d05d0e-d088-49e5-878f-76df756066a9">18</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i88924eaa86cb4ed39e38a15a834b05ca_I20211231" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI5NDE_35329a61-c045-4997-8964-7e7afb3feb6d">16</ix:nonFraction>% of the Company&#8217;s patient services accounts receivable balances as of December&#160;31, 2022 and 2021, respectively, were more than <ix:nonNumeric contextRef="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMwNTM_1a34c3fc-7ad6-46c4-86e3-9be7493fc7cc">six months</ix:nonNumeric> old. There were <ix:nonFraction unitRef="usd" contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMwNzI_4fc8682b-0114-462c-8ce5-51d70ccfebed">no</ix:nonFraction> significant balances over <ix:nonNumeric contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231" name="us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMxMDE_6e95d036-cee9-416c-b846-bc50690ed7c2">one year</ix:nonNumeric> old at December&#160;31, 2022. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_289"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg4Mg_f8b47af1-dd86-4584-b86d-394917dd1ede" continuedAt="i73d7256527164533a86652ba0425c56c" escape="true">Earnings&#160;per share</ix:nonNumeric></span></div><ix:continuation id="i73d7256527164533a86652ba0425c56c" continuedAt="i90e5fb861b4149829546f6217bf206dc"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg4MQ_8bfc35ba-70af-44f9-aaf4-930baee7e45a" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i90e5fb861b4149829546f6217bf206dc"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg3OA_e7c10f37-5d8a-4d98-964b-9e826e959781" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtMS0xLTEtNDMyMzYx_9696f61d-9968-49ec-bc9e-9f71296429a7">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtMy0xLTEtNDMyMzYx_0456ca5a-e4e7-456e-ac29-134de1a41aaf">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtNS0xLTEtNDMyMzYx_d7c7ab0d-e4d7-48ce-a525-ea1cd85e7fef">783,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtMS0xLTEtNDMyMzYx_a032ef1e-6788-4c7e-9fa9-f8cd41fcf3e1">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtMy0xLTEtNDMyMzYx_1b5c43e5-c443-4912-9f5d-ca7e41588117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtNS0xLTEtNDMyMzYx_a85b1e69-0895-45a0-8bc7-876e84f9da3e">9,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtMS0xLTEtNDMyMzYx_de2d7441-2220-4ce4-9804-c367a5a66a6d">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtMy0xLTEtNDMyMzYx_1e27cf07-11f1-42bd-878f-6f6798f2ef4e">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtNS0xLTEtNDMyMzYx_d0011813-0b73-44a0-a5ec-5998d5ec36b9">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtMS0xLTEtNDMyMzYx_e03724af-269f-4170-8b8a-fd269f642ba4">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtMy0xLTEtNDMyMzYx_f4ecf64a-8d06-4ba0-933d-700ab0bd2148">105,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtNS0xLTEtNDMyMzYx_b1e84782-44fb-4c4d-8d36-87ab049cb903">119,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktMS0xLTEtNDMyMzYx_703430ad-af64-421f-b2a1-9842ce6805ea">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktMy0xLTEtNDMyMzYx_3b6ddfff-c230-41ab-9dc2-de3ed1f5f7b2">4,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktNS0xLTEtNDMyMzYx_2d456b1f-4c7c-4529-a53e-7fa7eb4e728e">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTEtMS0xLTQzMjM2MQ_ffa6a7fd-6ec0-4009-9a75-123c6d015393">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTMtMS0xLTQzMjM2MQ_3670fb45-3ab2-4ce9-bb45-54b2ff0e077a">109,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTUtMS0xLTQzMjM2MQ_3c399e4f-931f-42bc-9e54-a04554d03c36">122,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTEtMS0xLTQzMjM2MQ_d1f13661-33c2-465a-8692-ca1019e2ef31">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTMtMS0xLTQzMjM2MQ_796b3127-146e-4b0e-bbf3-993fac549e6a">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTUtMS0xLTQzMjM2MQ_62f80181-513f-4a37-97af-a3f0c6bb6daa">6.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTEtMS0xLTQzMjM2MQ_b2f7306d-4d26-4465-a639-85909743e64f">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTMtMS0xLTQzMjM2MQ_f09849bb-6650-4af8-b171-b85535f0ab1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTUtMS0xLTQzMjM2MQ_6fa712e0-0f41-4291-bd9b-2c05bfff8db9">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTEtMS0xLTQzMjM2MQ_d2680893-b9f5-42ac-bbce-b60ec3597b91">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTMtMS0xLTQzMjM2MQ_16751f0b-a879-490e-a11f-4466aa259f9c">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTUtMS0xLTQzMjM2MQ_fb867ab0-25c4-46a2-b964-9d437f30a03d">6.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTEtMS0xLTQzMjM2MQ_c7755c73-8307-40a7-a3ab-949604b916cb">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTMtMS0xLTQzMjM2MQ_4990c8de-403f-4f96-85fd-e31e72f1596c">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTUtMS0xLTQzMjM2MQ_dca85895-9057-4050-ac1c-510e6fdac2f4">6.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTEtMS0xLTQzMjM2MQ_60fc1b76-ccb5-445b-977c-c167b02d167c">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTMtMS0xLTQzMjM2MQ_1afc3929-9e7e-4fd1-8ce2-6608d40176a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTUtMS0xLTQzMjM2MQ_e187cf62-c9a7-42e2-bb45-d3986badd4ec">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTEtMS0xLTQzMjM2MQ_ca706add-12da-44c1-932b-5ec20a946bb8">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTMtMS0xLTQzMjM2MQ_0e53b85b-e209-408c-a9ba-fb11522b309f">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTUtMS0xLTQzMjM2MQ_fd63b458-df8e-4535-b982-b27139974939">6.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTEtMS0xLTQzMjM2MQ_07a8e764-9441-4bea-9d52-40490d763f1b">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTMtMS0xLTQzMjM2MQ_da04e765-1ef0-4e84-82f4-6263b94f342c">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTUtMS0xLTQzMjM2MQ_1f66e2a6-8801-464b-ad2b-d76c74694ecf">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div></ix:nonNumeric></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_292"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0Xzc5Ng_2d9693a3-e406-41cf-874c-cbd33f448f13" continuedAt="i4576e500b1a849f4b304e823b177b60a" escape="true">Restricted cash and equivalents</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4576e500b1a849f4b304e823b177b60a">The Company had restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0Xzk3_b4389ba4-638d-4f54-b8df-139a3d65396a">94,903</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0XzEwNA_07059240-1b3f-43d2-b172-dfb65ad6cf95">93,060</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively. Substantially all of the restricted cash and equivalents balance at December&#160;31, 2022 is held in trust to satisfy insurer and state regulatory requirements related to the wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company and the remaining restricted cash and cash equivalents held at December&#160;31, 2022 represents cash pledged to third parties in connection with the Company's ancillary operations.</ix:continuation></span></div><div id="ib228226ec511491b87b183c6d217a21a_295"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTk_462d78d7-282e-4cb6-817c-0fd3c3d54b31" continuedAt="i54a51de297554fd3a2cf8f4b52f1696e" escape="true">Short-term and long-term investments</ix:nonNumeric></span></div><ix:continuation id="i54a51de297554fd3a2cf8f4b52f1696e" continuedAt="idecd6e8bd0994d71b9edb51ef0a30740"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTY_6547cbde-8cb7-4992-a430-f5d26e3338c9" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472c110640b34063a31c98fa592e7be7_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMS0xLTEtNDMyMzYx_12aa6e73-9035-45e1-aee5-691320189b2e">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472c110640b34063a31c98fa592e7be7_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMy0xLTEtNDMyMzYx_4d0c62e8-0aec-441d-aff3-7a5e56caa065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472c110640b34063a31c98fa592e7be7_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItNS0xLTEtNDMyMzYx_c049cff8-f614-4b7c-a36b-ba39596b096b">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b372339e32a430185d84a645290c6a6_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItNy0xLTEtNDMyMzYx_2a4b2d2e-2352-4ff9-b3bf-9867692105ea">23,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b372339e32a430185d84a645290c6a6_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItOS0xLTEtNDMyMzYx_734793a9-31db-4947-af73-c2c778e209db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b372339e32a430185d84a645290c6a6_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMTEtMS0xLTQzMjM2MQ_6485241b-7480-49a9-8b1f-991313ff2443">23,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMS0xLTEtNDMyMzYx_e36c4ada-5291-4292-a5ff-ee43db728383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMy0xLTEtNDMyMzYx_f5d2ac01-2922-426c-aa7a-0acb5665cfed">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtNS0xLTEtNDMyMzYx_b082d43c-fd10-45c2-be91-3f4eef1c8b3b">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtNy0xLTEtNDMyMzYx_8b5491bd-0d4a-4fbc-a064-1a071eb00280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtOS0xLTEtNDMyMzYx_34b2a17e-8b90-477c-a820-06e27fa80be4">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMTEtMS0xLTQzMjM2MQ_e395d481-069b-48a8-9083-7ae375854d69">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMS0xLTEtNDMyMzYx_4a68dc16-513b-4e02-890f-6d0a84e7ba4c">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMy0xLTEtNDMyMzYx_41452aff-5ff3-4001-86db-7df8a6d0375c">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtNS0xLTEtNDMyMzYx_65eeef6c-6665-4147-a4da-024159252f71">122,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtNy0xLTEtNDMyMzYx_fbfbf3a3-0d38-4aff-89d4-dad4668dd892">23,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtOS0xLTEtNDMyMzYx_dc812737-ba08-418f-93be-d452bfe04173">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMTEtMS0xLTQzMjM2MQ_47145979-d618-4f54-8584-790aa5c14271">71,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMS0xLTEtNDMyMzYx_260ede19-2c9c-4f66-8ea2-2b66154daa8d">67,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0dedc540e3748a180d94fe4b0c46a64_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMy0xLTEtNDMyMzYx_c27c534a-ac95-4db9-8c18-64c5152d0561">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtNS0xLTEtNDMyMzYx_65106a0b-ee12-4b79-a78d-2d0c71f9eee7">77,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtNy0xLTEtNDMyMzYx_e8d31f71-cfa3-4773-820e-ad505a7adcc8">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a7a6c01df54ffe95479935e6df2ee7_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtOS0xLTEtNDMyMzYx_328387ae-b6ea-43fd-9c0a-aa008d7f533e">14,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMTEtMS0xLTQzMjM2MQ_1af47e08-549b-4399-ad9e-e1b9baf8a2e4">22,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMS0xLTEtNDMyMzYx_2e821977-7986-4b60-a457-c4e2dc1dc64c">15,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a47a9e4ba544f1a9cd835d606410ff_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMy0xLTEtNDMyMzYx_28d77d51-2b72-4fb0-b8d9-6a1aaa6c73b2">29,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtNS0xLTEtNDMyMzYx_b8ac94ef-3f8c-4088-85c2-e285dbaf4bb3">44,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtNy0xLTEtNDMyMzYx_ee4d7113-27c5-4cd5-99aa-3029dda22888">14,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2adb818e8c884ebf9a40f34a6969b8d7_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtOS0xLTEtNDMyMzYx_06afb960-d8e2-42d6-a6b3-e4bbd187e118">34,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMTEtMS0xLTQzMjM2MQ_068f3130-89f3-4315-96de-7d5a2c13f0cc">49,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMS0xLTEtNDMyMzYx_8d83822b-5342-4304-9cca-7d2aed48826a">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMy0xLTEtNDMyMzYx_51914e7e-e80c-47cc-88fb-2465e5c7507f">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctNS0xLTEtNDMyMzYx_5307e7d9-6393-48f0-8ee5-f737e08fb8fa">122,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctNy0xLTEtNDMyMzYx_50980e67-a813-496c-9bcb-5584e4992f32">23,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctOS0xLTEtNDMyMzYx_b55a4fc0-1630-4bc1-8dbf-23624536c0f0">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMTEtMS0xLTQzMjM2MQ_2acace04-2e58-4f87-9d99-c30f443c0b91">71,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTI_292d1024-91ee-4c6a-af53-4304348dbd49" continuedAt="i4ea370cffc264ca7abfe6ac305a76b9f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time </span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="idecd6e8bd0994d71b9edb51ef0a30740"><ix:continuation id="i4ea370cffc264ca7abfe6ac305a76b9f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company holds certain equity investments that have readily determinable fair values from public</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets. The Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div></ix:continuation></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_298"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90ZXh0cmVnaW9uOjY5M2JlNTUyMWZlNzRiYTdhMTRiZTI1MjU1MTJkYmEzXzgy_3506245b-2826-402a-9cfb-aa628a37227b" continuedAt="if14d2f3fb5c6439eba347d4ecb635408" escape="true">Other receivables</ix:nonNumeric></span></div><ix:continuation id="if14d2f3fb5c6439eba347d4ecb635408"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfOtherReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90ZXh0cmVnaW9uOjY5M2JlNTUyMWZlNzRiYTdhMTRiZTI1MjU1MTJkYmEzXzg2_26114b62-e793-40cf-a704-a9fc38c1ecb7" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables were comprised of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:56.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96447c36e9e04484a7110d4eb4997b4c_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzItMS0xLTEtNDMyMzYx_01cdb887-2c04-4769-ab49-121a85f04351">303,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33e8b9fed27435c92a9faac2bd00b84_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzItMy0xLTEtNDMyMzYx_93086feb-860c-4bce-a0c1-c93ba307dbf0">294,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59ac085dc65418aa4e73ffc69429588_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzMtMS0xLTEtNDMyMzYx_eb7c2a75-9d07-4c21-9497-449fbe1ff503">110,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40279a50dc004485905b9258f9cbe2dc_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzMtMy0xLTEtNDMyMzYx_6405eb02-54e1-452a-ad40-6646b5267342">132,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzQtMS0xLTEtNDMyMzYx_502abcbc-db7f-4abf-b27c-e6a03781eca1">413,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzQtMy0xLTEtNDMyMzYx_7c68943d-ba78-4b72-8a6f-555b649b8e45">427,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_301"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzgwMQ_c81f6d45-d3e2-4612-900c-18ebf6cf8344" continuedAt="ia8263254b0ee481490d28db8df8f2c3f" escape="true">Property and equipment</ix:nonNumeric></span></div><ix:continuation id="ia8263254b0ee481490d28db8df8f2c3f"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzgwNg_82352e9a-7260-4e94-ba26-5f273c38604f" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzItMS0xLTEtNDMyMzYx_59bd8397-d5e5-48ad-aa76-150672ff7f9e">32,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzItMy0xLTEtNDMyMzYx_c0322f64-2569-4aef-b7cd-18c87063c605">34,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzMtMS0xLTEtNDMyMzYx_b769ef75-e816-40f3-8105-c8cd3b8db57b">427,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzMtMy0xLTEtNDMyMzYx_3045899f-7347-40d0-84b6-ac6974201e98">496,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzQtMS0xLTEtNDMyMzYx_6e6d08d5-061a-4d15-81f3-5e278aa37825">3,925,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzQtMy0xLTEtNDMyMzYx_0ed07435-c9d6-4872-ae80-61233477b511">3,828,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzUtMS0xLTEtNDMyMzYx_31ae0eeb-2e9a-450c-a494-9bd2400b2127">3,759,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzUtMy0xLTEtNDMyMzYx_1b18580e-c73b-42ea-af1a-96fd02c67a1b">3,292,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzYtMS0xLTEtNDMyMzYx_5c8b7665-c6ad-4265-8ba4-8b54bacf6b86">376,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzYtMy0xLTEtNDMyMzYx_44a9331a-8550-4307-ad3c-45beaddd0479">592,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzctMS0xLTEtNDMyMzYx_f2cc344e-2d32-44d0-9efb-0dcc245ed161">8,521,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzctMy0xLTEtNDMyMzYx_e6f0df83-a64b-49cc-a747-539256fff124">8,243,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzgtMS0xLTEtNDMyMzYx_307e137f-fc08-4072-9f67-c0f2df8009a8">5,265,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzgtMy0xLTEtNDMyMzYx_78c473db-1fd4-4958-a923-ebebd7861c1f">4,763,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzktMS0xLTEtNDMyMzYx_691d2bf5-f691-4458-8411-7de12d6bbf0b">3,256,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzktMy0xLTEtNDMyMzYx_f4e1afc0-f66e-4314-971e-5beea0c69c6d">3,479,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, <ix:nonNumeric contextRef="i780f1053c3cd4049860e874c14a7dd7e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI0Mg_86758eea-fab2-42a7-bfad-dcb86a448e6f">25</ix:nonNumeric> years to <ix:nonNumeric contextRef="i3212e1642e634c7ead8a2a1478b91244_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI0OA_be56d87e-1479-4d02-a642-cb0451a8302f">40</ix:nonNumeric> years; leasehold improvements, the shorter of <ix:nonNumeric contextRef="iea71308947784543a7b3e618b843de25_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI5MQ_cc028e94-cddc-43d1-9ab1-32cf2767ae10">ten years</ix:nonNumeric> or the expected lease term; and equipment and information systems, including internally developed software, principally <ix:nonNumeric contextRef="i9cb851214d4345d1be8b32b72599be61_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQxNA_3f6d5642-2fb4-426e-ad5d-3f1ab60042d9">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="i19d843ebfcaa422a8ad48b287a882104_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQyMA_7a41f78f-d362-45bb-a702-a4041e3d5833">15</ix:nonNumeric> years. Depreciation expense on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ3NQ_2f1f858e-2532-433e-aa30-aca25d0252a0">721,133</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ3OQ_1f9abfd5-9436-4ccb-bdad-79160beb8822">667,755</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ4Nw_650c80d2-8688-4ae6-b121-d229682c6080">616,626</ix:nonFraction> for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc1Mg_28ca746d-a7b7-4947-92ce-38ca901cd48e">12,677</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc1Ng_1a7c64f9-04b2-4588-8ece-42685b8637e8">15,275</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc2Mw_1211a8a0-81ed-4a7f-a344-30d1635482e0">17,944</ix:nonFraction> for 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_304"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczMg_0b6398d6-25e6-420f-a651-cae08773f48a" continuedAt="i539a5f50fd534b21af9bdaf2e919b363" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="i539a5f50fd534b21af9bdaf2e919b363" continuedAt="i1a670ff3f2084f99b07621e80914f3d2"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczNw_42b811d8-9fa3-4576-ab20-c2a6b086aa02" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"></td><td style="width:59.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzItMS0xLTEtNDMyMzYx_682045bd-7675-4c66-90df-634afe2a86ac">127,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzItMy0xLTEtNDMyMzYx_56283df1-068d-4d3d-ab5c-f77a71ea75b9">104,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzMtMS0xLTEtNDMyMzYx_a0fb5138-0c06-4840-8457-4ca412e98d27">51,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzMtMy0xLTEtNDMyMzYx_e2a36594-5fa3-4d7e-9109-5927f1881110">70,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzQtMS0xLTEtNDMyMzYx_74bd99ed-8221-4574-94fc-e0a73aece3bf">53,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzQtMy0xLTEtNDMyMzYx_45e1ee0b-e9b7-4666-8ada-808acd5ac655">63,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzUtMS0xLTEtNDMyMzYx_6befa8ab-8262-4470-a8da-9fa551e3b399">232,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzUtMy0xLTEtNDMyMzYx_a0c17dd2-9757-443b-bbef-058cac73902e">238,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMS0xLTEtNTU3NjMy_4422ab42-10d8-4d98-828f-db2b7bb38f4d">39,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d812bfa6d44d2987c3fd8e4134ce1a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMy0xLTEtNTU3NjMy_00bcaba6-99c3-428a-ad13-d1d221b38416">52,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzgtMS0xLTEtNTU3NjQw_d5ad1feb-25c1-42a1-8f92-7a7a6dbe157d">10,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id42361f6c10f406ea541fb7608221768_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzgtMy0xLTEtNTU3NjQw_9c836eb2-e7ba-49c0-97b0-f068cb80d58f">7,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMS0xLTEtNDMyMzYx_932da64e-b89c-4adf-a800-56a6d89ed1c6">182,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMy0xLTEtNDMyMzYx_6d06bb14-afe5-41ca-8860-de46d4832bf3">177,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i1a670ff3f2084f99b07621e80914f3d2" continuedAt="i0e4d258796cb4ba69667209a31932692"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over <ix:nonNumeric contextRef="i3c06c7b0e13047ef8e5353fe708bc498_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzE1NQ_ae1cce33-16fb-41f3-a59b-e9e3a32f31e0">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="ibd8a01cb9b6b4aa392aba562922d863e_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzE2MQ_e7dbed38-db78-457f-bb14-974002f77199">10</ix:nonNumeric> years and customer relationships are principally amortized over <ix:nonNumeric contextRef="i763a119f616d4f0a8615b9b7ca2e724e_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzIyMg_df0239b0-0f97-4671-be32-278611586a8f">10</ix:nonNumeric> years to <ix:nonNumeric contextRef="i4342659ff7e0470e9df98f9b56908101_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzIyOA_dd47777a-7453-4834-a3ea-c32fb80dde83">20</ix:nonNumeric> years. The weighted average renewal or extension period of customer relationships was <ix:nonNumeric contextRef="iae02ab521c84469d86508390fd7a2b8e_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzMxMQ_b88da16e-c1c6-450e-ac54-0c6e250fa081">two years</ix:nonNumeric> and <ix:nonNumeric contextRef="i238f0b81bcfc460493a2272e9df9e660_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzMxOA_a642d6b3-8f2c-42d2-8d00-68f0a9294b1d">three years</ix:nonNumeric> as of December&#160;31, 2022 and 2021, respectively. Amortization expense from amortizable intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzQxMg_29e52c6e-8293-4ef0-b0c0-83dd1868fece">11,469</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzEwOTk1MTE2Mjg1MTk_52e458fa-80fb-45f4-a82e-8ab4a014d9ac">12,860</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzQyNA_39556704-0e68-4709-b0af-ba558b2d9d4a">13,809</ix:nonFraction> for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized <ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzUxOA_79ae94c7-fa25-43c4-b52f-1b498d6922ce">no</ix:nonFraction> impairment charges on any intangible assets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczMA_e00340d3-41c2-440e-a666-07faf1a01242" continuedAt="ieddc60a3b40049258e9dba628a188ac2" escape="true">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2022 were as follows:&#160;</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="i0e4d258796cb4ba69667209a31932692"><ix:continuation id="ieddc60a3b40049258e9dba628a188ac2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzEtMS0xLTEtNDMyMzYx_c6be858a-a9da-4e74-ac6a-65f70f1f55d7">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzEtMy0xLTEtNDMyMzYx_8a341e2f-68ec-451a-b0b6-6bbbea68b269">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzItMS0xLTEtNDMyMzYx_f74d6720-b151-4110-9c76-7b6bf71a7119">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzItMy0xLTEtNDMyMzYx_e31f4b1f-a4f9-4cd7-8ff3-b34bbf2d74c6">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzMtMS0xLTEtNDMyMzYx_37b9db4b-8c36-4de6-94d4-4199e5d0247c">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzMtMy0xLTEtNDMyMzYx_c0e3a820-8f8d-41cc-8506-67471aa38946">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzQtMS0xLTEtNDMyMzYx_64977303-d95b-4251-b047-1659a24c0d47">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzQtMy0xLTEtNDMyMzYx_96d86d66-39b5-4c8d-8452-dcdf7b6733ac">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzUtMS0xLTEtNDMyMzYx_d9f994de-e50f-4462-82a8-5e999cd169e2">730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzUtMy0xLTEtNDMyMzYx_d3729a9c-5f94-4cc6-aaf7-70cca512fbe8">3,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzYtMS0xLTEtNDMyMzYx_b85fe2ce-f905-4f37-8f32-41e9709ddd86">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzYtMy0xLTEtNDMyMzYx_fd330eb4-9743-4389-92c0-f13d731f9f4b">25,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzctMS0xLTEtNDMyMzYx_82bfa569-4e58-4525-8e56-0b72e54719d7">11,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzctMy0xLTEtNDMyMzYx_983ef207-e004-48f5-94bd-dd2bc8bb1b7d">43,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:27pt"><span><br/></span></div><div id="ib228226ec511491b87b183c6d217a21a_310"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE2NTk_745b6cc2-de77-4382-a0ef-794c1307a58b" continuedAt="i634dae01500440c0b38db5c69f683c9c" escape="true">Equity method and other investments</ix:nonNumeric></span></div><ix:continuation id="i634dae01500440c0b38db5c69f683c9c"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE2NjA_39aca4b0-5027-4274-a0df-e44bfa3f758a" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses, comprised as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328084074c6a4e6a80b7d005923141b5_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzItMS0xLTEtNDMyMzYx_3fde99ef-2b4f-4ca7-bb1a-3c690c015143">99,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ecc37a255b4ec79a6f4852457f2d7f_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzItMy0xLTEtNDMyMzYx_3fc68acf-5e50-40b1-bf6b-bb23b6812e7c">109,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5af4c78b3b84e59a62c25b4a0b8ba0e_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzMtMS0xLTEtNDMyMzYx_23e51f4c-82c0-4583-8621-b4aa0d95d12c">116,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d73ec57c84c15a3ad9c06782360e6_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzMtMy0xLTEtNDMyMzYx_1202149a-db9b-4531-a299-41cf8af980dc">115,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeafde1efc8421883fbe844a5ce2e26_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzQtMS0xLTEtNDMyMzYx_9b98c414-6b3c-4a2b-b471-4f9794e7e15f">15,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957d7a2748724eb48b7c1a29ca66b93f_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzQtMy0xLTEtNDMyMzYx_9aba951e-863a-4eaf-b71b-f16188037dc1">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzUtMS0xLTEtNDMyMzYx_adef49be-e2f2-4ca0-abcf-814c2ee70fce">231,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzUtMy0xLTEtNDMyMzYx_8b81d869-bb61-4c77-96f7-838402395e68">238,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the Company recognized equity investment income of $<ix:nonFraction unitRef="usd" contextRef="i6927c570b591490ab67989e54cd02d0a_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzI5MQ_a4e1e74a-9f73-4952-badf-229076b92a6f">26,520</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i868f0061ea624c47a87a5ed4482b8464_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzI5NQ_f7ebe98a-7dfc-4736-bebf-a765b918ab98">26,937</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if07190fe863941af86705544dac7d29b_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzMwMg_17cd16ea-1d3a-4e5e-9df9-d2ab407a44bf">26,916</ix:nonFraction>, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="ibd6a5d60792446838c6c118846730304_D20220101-20221231" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzgyNDYzMzcyMTE0MDQ_96149b4b-2c72-4190-869e-0d795c0f4a88">4,703</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id383f000ec994776adc163ceb21acbe7_D20210101-20211231" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzgyNDYzMzcyMTE0MTI_fcffe829-997d-48ae-ab2f-816b75b5a07c">1,292</ix:nonFraction> in other (loss) income during 2022 and 2021, respectively. There were <ix:nonFraction unitRef="usd" contextRef="i4245725066c542b0a93347f794776227_D20200101-20201231" decimals="-3" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzc2OTY1ODEzOTc4NDg_26ff73ef-a6c7-4500-9b89-2e2ec9865318">no</ix:nonFraction> equity investment losses from other equity method investments in 2020.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's largest equity method investment is its ownership interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV). The Company holds a <ix:nonFraction unitRef="number" contextRef="ibc19a6487a1842f39d795710dd4036dd_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzU0Mw_8584828b-f082-44ce-af7e-92c1f58d16fc">75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in the APAC JV and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i328084074c6a4e6a80b7d005923141b5_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzY0Nw_4a0f1a93-04c2-42ee-99da-25a1d83df498">25</ix:nonFraction>% voting and economic interest in the joint venture, however the Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include <ix:nonFraction unitRef="number" contextRef="i0e8f487f85e74665806c5ec5125515e3_I20221231" decimals="INF" name="dva:NumberOfPartnerships" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzk2Mg_58536e35-9bcd-435f-bedf-b3c7e7258445">23</ix:nonFraction> legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from <ix:nonFraction unitRef="number" contextRef="i59795d3026d44baeac66a9a81a351db4_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE0OTk_281d536c-2954-4303-b7c4-9a5bf7e7355c">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7b96f4bb392e462a82c7894ad36ec7d5_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE1MDU_15c3de5c-ed3f-4987-904c-ef79de11fc91">65</ix:nonFraction>%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $<ix:nonFraction unitRef="usd" contextRef="ibd6a5d60792446838c6c118846730304_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzcxNDY4MjU1ODI5ODA_1b5dba40-075f-40b5-b2e8-e7a36c71aada">20,154</ix:nonFraction> in other (loss) income, net. There were <ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzc2OTY1ODEzOTc4NTg_604902db-4675-4a21-bcbd-ad4266d6b53a">no</ix:nonFraction> significant investment impairments or other valuation adjustments for the years ended December 31, 2021 and 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_316"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:GoodwillDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MjI_3624fcb5-c3a4-4c40-aae4-ad85e9034580" continuedAt="ia0c4d3fc4f1e4b36b52c7042bb983e61" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="ia0c4d3fc4f1e4b36b52c7042bb983e61" continuedAt="ia94ab909c31f4ef19c9809376d545b23"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MTc_aa6dfaae-1096-4fa0-9ded-900a92a4ea52" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:40.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92052f136ae48a8bd74fbaa0981d8de_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtMS0xLTEtNDMyMzYx_4ff8f54e-5e73-4af5-b014-001e0a2c7c1f">6,309,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc23e84f52624cb8b52bf0d015a4c3cc_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtMy0xLTEtNDMyMzYx_8c7f0376-fb52-4a8c-906d-25ff2f612d9a">609,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtNS0xLTEtNDMyMzYx_8cadd8a9-d277-4061-b811-b56ac7593172">6,919,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItMS0xLTEtNDMyMzYx_30b28e48-6a7e-49de-8580-6f9fad9efc25">91,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItMy0xLTEtNDMyMzYx_4b887d77-db11-4d04-a72f-7fa61e45a0d6">81,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItNS0xLTEtNDMyMzYx_664aac41-e91c-4eb0-a6f3-c4798bc5f07d">173,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtMS0xLTEtNDMyMzYx_023525f1-f1c8-43bc-b311-7ce992bc1c3e">1,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtMy0xLTEtNDMyMzYx_1212029a-1733-4568-95ad-eefe7054246a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtNS0xLTEtNDMyMzYx_62f4c01b-1e2f-43b0-971e-e304ddf8982a">1,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtMS0xLTEtNDMyMzYx_60121e39-e791-4f12-93e6-af4c0fcc0f83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtMy0xLTEtNDMyMzYx_670c79e5-ca70-41e6-9b10-b8e399f80b94">44,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtNS0xLTEtNDMyMzYx_b59cb054-8fe7-47e3-a513-7366bf705fbe">44,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtMS0xLTEtNDMyMzYx_2a2f649e-a434-49c6-824f-1c24bf096f54">6,400,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtMy0xLTEtNDMyMzYx_f8576f6c-dccf-4b0a-bc51-1b85e2c1d6bf">646,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtNS0xLTEtNDMyMzYx_358355d2-a9cc-4ff5-a78a-22496530dca5">7,046,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctMS0xLTEtNDMyMzYx_af587c41-7ccd-473a-baa0-8e3bd082163e">16,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctMy0xLTEtNDMyMzYx_0fbf8452-0a5c-4ea2-8fa6-4e1963b8dcaa">32,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctNS0xLTEtNDMyMzYx_552313d1-1ee4-440f-8c81-99c292290ddc">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtMS0xLTEtNDMyMzYx_ca9681b7-cadd-46ec-804e-8caabd4b7bdc">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtMy0xLTEtNDMyMzYx_7ed599c3-a9bb-4c6a-90fb-d309da8d0884">3,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtNS0xLTEtNDMyMzYx_ec81cdcd-1ea9-4424-9137-a773e6871b3d">3,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktMS0xLTEtNDMyMzYx_37ee1d92-9cf5-417d-af08-bbdda7d38d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktMy0xLTEtNDMyMzYx_520b829b-a266-40d1-9553-cc256999b36e">15,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktNS0xLTEtNDMyMzYx_c4a30b02-da16-4201-9798-584f8687c330">15,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTEtMS0xLTQzMjM2MQ_66b83c75-8a16-432a-89e0-4af83b1edc70">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTMtMS0xLTQzMjM2MQ_1bfa485e-c236-40a8-87ec-f9c7aadeb904">659,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTUtMS0xLTQzMjM2MQ_c8ac16b5-b27d-45db-93c2-a7285423478f">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTEtMS0xLTQzMjM2MQ_d2cd22dd-1eab-4435-8829-5c13bc706faa">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTMtMS0xLTQzMjM2MQ_1d99609d-2b8b-46f6-a4ff-787e0fa79937">778,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTUtMS0xLTQzMjM2MQ_bc86aac6-3ba8-4c17-a09e-3598948e5370">7,195,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTEtMS0xLTQzMjM2MQ_0ea064b4-15a7-4325-ae68-0d0691ac044c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTMtMS0xLTQzMjM2MQ_390fc9c1-165a-471b-944b-a62c84ae3d11">118,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTUtMS0xLTQzMjM2MQ_adeeb60e-d8da-4ab7-9e8d-7b1061707404">118,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTEtMS0xLTQzMjM2MQ_13d9acf9-a37a-4df0-996b-24ec39f0c6ab">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTMtMS0xLTQzMjM2MQ_1b8d61b3-7746-4ac6-bfa6-f579026862f6">659,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTUtMS0xLTQzMjM2MQ_082c13da-a5d3-4e8d-8a53-53e538c1b963">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations continue to be impacted by the effects of the coronavirus (COVID-19) pandemic. While the Company does not currently expect a material adverse impact to its business as a result of the ongoing COVID-19 pandemic, there can be no assurance that the magnitude of the cumulative impacts of the COVID-19 pandemic, including certain conditions and developments in the U.S. and global economies, labor market conditions, inflation and monetary policies that may have been intensified by the pandemic, will not have a material adverse impact on one or more of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s operating segments described in Note 25 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the physician practices in its physician services reporting units, to the dialysis centers and other health operations within each international reporting unit, and to the vascular access service centers in its former vascular access services reporting unit. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia94ab909c31f4ef19c9809376d545b23" continuedAt="i8dfe416c1551413ab281fb9af7831fb8"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its most recent assessments, the Company determined that changes in its forecast concerning expected patient census, the timing or amount of expected reimbursement rate increases, expected treatment growth rates, or other significant adverse changes in expected future cash flows or other valuation assumptions could result in goodwill impairment charges in the future for the following reporting unit, which remains at risk of goodwill impairment as of December&#160;31, 2022:</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfReportingUnitsGoodwillBalancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MTk_0e7490a0-1a74-491e-81e2-5e9b7a5c30f6" escape="true"><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.660%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reporting unit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill<br/>balance</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Carrying amount<br/>coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sensitivities</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Operating<br/>income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Discount<br/>rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany kidney care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItMi0xLTEtNDMyMzYx_e596057f-5a15-4aba-8ad4-ccdd61c84e4c">281,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231" decimals="3" name="dva:ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItNC0xLTEtNDMyMzYx_08b5aad7-e97d-44f2-ae6b-bb48c5860283">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231" decimals="3" name="dva:PotentialImpactOnFairValueForReductionInOperatingIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItNi0xLTEtNDMyMzYx_12b4cc6d-5915-4cf4-a5ce-a343b4d4cd98">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idf00b273a4bf4c79a1f721b650d77572_D20220101-20221231" decimals="3" name="dva:PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItOC0xLTEtNDMyMzYx_96e39deb-0c3d-4518-81ad-1fa23794eb0f">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of a sustained, long-term reduction of <ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="dva:PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzUxNDQ_6612afbd-ac82-4127-bdc2-689e5b98219f">3</ix:nonFraction>% in operating income as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8dfe416c1551413ab281fb9af7831fb8">Except as described above, <ix:nonFraction unitRef="segment" contextRef="i911a2957827b44d79670188c18f6906f_D20220101-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzUzNTY_c12ff078-92b3-4011-9f5f-6490d2dbb3a2">no</ix:nonFraction>ne of the Company&#8217;s other reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2022.&#160;Since the dates of the Company&#8217;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#8217;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#8217;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2022.</ix:continuation> </span></div><div id="ib228226ec511491b87b183c6d217a21a_322"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90ZXh0cmVnaW9uOjRkZGFjOTU5NTdhMjRhMDI5MmU4MzU4OGMyYzJlNWRiXzc5_c8f7fc20-2d75-4f28-a17c-b35da96b69f5" continuedAt="i1ba19cc101c649dfb821354635c03440" escape="true">Other liabilities</ix:nonNumeric></span></div><ix:continuation id="i1ba19cc101c649dfb821354635c03440"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:OtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90ZXh0cmVnaW9uOjRkZGFjOTU5NTdhMjRhMDI5MmU4MzU4OGMyYzJlNWRiXzgz_ab13e75c-c19c-440d-b8e7-9c099372a840" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"></td><td style="width:51.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzItMS0xLTEtNDMyMzYx_c4c7d574-3479-491a-b643-7e1aa03ab2d1">475,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzItMy0xLTEtNDMyMzYx_489d7d52-73e8-40b4-8a4b-480cd8a42ee6">410,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzMtMS0xLTEtNDMyMzYx_d9c9e177-5f76-47bc-9954-1a68d97ff612">68,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzMtMy0xLTEtNDMyMzYx_3b5aba30-b320-48cc-9983-5f24c9936f08">55,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzQtMS0xLTEtNDMyMzYx_bcc8d191-aaf8-44cc-897b-71c35096b097">34,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzQtMy0xLTEtNDMyMzYx_8a60b603-9de2-4506-9f97-33220381386e">32,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzUtMS0xLTEtNDMyMzYx_8f646334-c7be-4b8a-89b9-67ce3846f1fb">42,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzUtMy0xLTEtNDMyMzYx_62888f7a-5af8-40b1-b53d-7fcf4fcb2af4">41,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzYtMS0xLTEtNDMyMzYx_3745aa6f-a7c8-49a9-b5b3-dcce3ae0b40e">181,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzYtMy0xLTEtNDMyMzYx_f6c6b4b6-6a01-4c87-952c-a51091cc43f9">169,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzctMS0xLTEtNDMyMzYx_e22b64b0-024f-43f6-a2bc-e135cbbb05e4">802,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzctMy0xLTEtNDMyMzYx_fa1dfad0-3791-47ae-8598-01ab761d3346">709,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_325"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNTk_e63329f0-b362-479e-84c7-27054a81db88" continuedAt="ie721127595d64b5a8088bd6ec1ddca49" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="ie721127595d64b5a8088bd6ec1ddca49" continuedAt="ifa850c3d7a10449688a3fc13df0d164e"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec555654a4df44baba650e83cb8119c0">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</ix:continuation></span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNzU_93073eb5-69d3-4359-bd4d-a2135d2043a6" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItMS0xLTEtNDMyMzYx_155592b1-a639-4fcc-864d-48749011a902">926,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItMy0xLTEtNDMyMzYx_5b384fca-3e92-470b-9fcb-a6777690559a">1,463,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItNS0xLTEtNDMyMzYx_1e8b86e1-e1ee-4b01-b13b-12ebfb1d37d3">1,287,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtMS0xLTEtNDMyMzYx_251b5292-99d3-443f-8012-938bcb0c0f1f">39,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtMy0xLTEtNDMyMzYx_ebb49646-c47d-442b-b935-10c9e7b3e183">55,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtNS0xLTEtNDMyMzYx_ac65273a-5c4e-4284-8de7-3fe43aea3dd0">30,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtMS0xLTEtNDMyMzYx_05ad6fb3-cd60-4c09-9e6a-63ec67063ad1">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtMy0xLTEtNDMyMzYx_64aee403-c99a-4631-9e5d-0e4f4247f75b">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtNS0xLTEtNDMyMzYx_947bb205-921e-4667-8742-ffb55677ed2c">1,318,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ifa850c3d7a10449688a3fc13df0d164e" continuedAt="i7b939dde63de41ef9cae2330f479ba06"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjc_774556a6-5b48-49ce-b6e6-ceacd818195e" continuedAt="i63ef02c69f5d4c53989a9d3d7bddd8b8" escape="true">Income tax expense for continuing operations consisted of the following:</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="i63ef02c69f5d4c53989a9d3d7bddd8b8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtMS0xLTEtNDMyMzYx_b0160ae7-ea56-4f05-9c07-4443af6257f8">201,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtMy0xLTEtNDMyMzYx_6b01744f-0029-4343-802e-2d97500832ad">216,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtNS0xLTEtNDMyMzYx_1f555fe9-bda1-44d9-8ae6-55be50f4266d">47,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtMS0xLTEtNDMyMzYx_3593e980-e667-44d1-a06b-31499b43d287">55,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtMy0xLTEtNDMyMzYx_0b4c3bb1-f37b-445c-96c8-5dc6f063b14b">15,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtNS0xLTEtNDMyMzYx_6cac47cf-fbc1-44d7-9149-1d08dbbfa6b3">21,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtMS0xLTEtNDMyMzYx_44fb33c3-772c-4f69-97e6-344ac42335a0">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtMy0xLTEtNDMyMzYx_fff777cb-ea06-45b1-8505-c725b5037284">14,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtNS0xLTEtNDMyMzYx_bb1f22ee-7d5c-4dd0-a277-2c59562a0680">17,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtMS0xLTEtNDMyMzYx_babb9137-ed57-4ba8-8ad0-9db8d9980fe3">273,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtMy0xLTEtNDMyMzYx_bc4778f9-9853-45e4-8485-775e61e3204e">246,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtNS0xLTEtNDMyMzYx_2199edc4-8adc-4c97-90bf-aacfe65c31eb">86,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtMS0xLTEtNDMyMzYx_7739d6e0-b358-4986-bb5f-0eb9ff128470">66,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtMy0xLTEtNDMyMzYx_33479d16-d478-4344-915c-e89ac6f2b6cb">59,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtNS0xLTEtNDMyMzYx_43a4be48-bdd4-4bb8-ac3e-1dc448a80f58">198,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktMS0xLTEtNDMyMzYx_f4ae91d7-98ef-4cba-87cc-136f2c68bd98">12,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktMy0xLTEtNDMyMzYx_746ff74f-fc53-4d13-a304-ff1a880408f7">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktNS0xLTEtNDMyMzYx_edc51601-df73-466a-978b-0ceba9ce2634">27,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTEtMS0xLTQzMjM2MQ_d40fe9bc-e9ee-4fcb-8cb5-6e455892c5a0">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTMtMS0xLTQzMjM2MQ_20a2dbee-9af6-4685-8825-5ecde2d6d641">4,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTUtMS0xLTQzMjM2MQ_3a4fa9ca-f5ad-4d17-ac3e-bc00002d1971">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTEtMS0xLTQzMjM2MQ_c45d66fc-4367-4a7f-8396-6f9aea4735f2">75,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTMtMS0xLTQzMjM2MQ_42cfcc6c-9b8c-47ea-a75a-9e92824a84d8">60,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTUtMS0xLTQzMjM2MQ_64c195cb-a929-42ce-8895-bffd4efd8eed">227,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTEtMS0xLTQzMjM2MQ_084a6cb5-a59f-42d4-a21c-8ba345c95008">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTMtMS0xLTQzMjM2MQ_ae83cd76-2954-4de3-9270-473cb92c28e2">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTUtMS0xLTQzMjM2MQ_1de07f91-dd61-406b-8076-faf7148df52d">313,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzODU_2d13296b-b6db-4625-b2cb-add271798df1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are allocated between continuing and discontinued operations as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItMS0xLTEtNDMyMzYx_49fc3e25-efb7-4169-9292-fbc0949323a9">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItMy0xLTEtNDMyMzYx_d2dea2f6-5f5f-4e9b-b56e-a5db9c30eb81">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItNS0xLTEtNDMyMzYx_dac3d8b4-4436-4515-b76b-a7120231b2e6">313,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtMS0xLTEtNDMyMzYx_22879211-464e-4bc1-ab01-99ce79d3e6b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtMy0xLTEtNDMyMzYx_5abda9f2-f8cb-4ad4-976f-723b89486ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtNS0xLTEtNDMyMzYx_6348bfa7-9ea1-486d-b30e-3b0006608272">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtMS0xLTEtNDMyMzYx_22ac2b28-c431-41be-8bac-1024e53d3a3e">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtMy0xLTEtNDMyMzYx_d2327c2f-8625-4813-928c-8b852afe40d6">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtNS0xLTEtNDMyMzYx_ccc6ff11-e845-4155-a4ae-c7c3964c0750">315,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjg_c560fc22-ead7-4cd1-be32-96a570576597" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"></td><td style="width:49.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItMS0xLTEtNDMyMzYx_d63aef5a-302b-4c5d-8876-1d4880725b8b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItMy0xLTEtNDMyMzYx_8887bb5a-1f34-4b20-a23e-f6c3dcaa447c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItNS0xLTEtNDMyMzYx_0e21944d-afbf-4d32-b943-3d8b78ef96df">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtMS0xLTEtNDMyMzYx_6c393e57-c92d-4fe0-b026-400523dc6fb3">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtMy0xLTEtNDMyMzYx_c179d591-b4bd-4464-bee0-87c23bd69fe6">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtNS0xLTEtNDMyMzYx_80ecf323-306d-4f5f-879d-8666923e9aaa">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtMS0xLTEtNDMyMzYx_0ed387aa-1b91-4bd2-b556-3a425dd7a234">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtMy0xLTEtNDMyMzYx_ad8d9f1c-79a9-4356-a443-7f1ca36a54bd">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtNS0xLTEtNDMyMzYx_672e0305-f917-4dbb-a28b-f6202bca255b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtMS0xLTEtNDMyMzYx_90b9e65d-433a-4260-b6be-5b5f63268083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtMy0xLTEtNDMyMzYx_a335007f-3353-4c43-b0c5-324ebf010697">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtNS0xLTEtNDMyMzYx_9adee00c-29a6-4bed-9a2c-1bdb6f7ebc7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtMS0xLTEtNDMyMzYx_0845fb6e-6b65-4365-9bc5-0589a14a0dad">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtMy0xLTEtNDMyMzYx_a2aa6d67-6ae9-4cc3-b62f-c006a9e96e36">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtNS0xLTEtNDMyMzYx_6bcc4663-5f10-4b53-84ea-2d5e25b8ec48">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctMS0xLTEtNDMyMzYx_54dc60eb-3e10-450d-9e5c-a390315d4aeb">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctMy0xLTEtNDMyMzYx_4e416886-6c00-4b05-8798-ca8729d4b073">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctNS0xLTEtNDMyMzYx_6b4f8043-bbc6-4cf7-991b-9290ab5d8507">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtMS0xLTEtNDMyMzYx_853193b7-b80a-4590-972a-5ccee397b9f9">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtMy0xLTEtNDMyMzYx_2a12200f-edd1-4d72-aac5-0a54e493c2ab">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtNS0xLTEtNDMyMzYx_0a00a88d-339d-499e-923c-efbf06b09a3c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktMS0xLTEtNDMyMzYx_df8528ab-4a91-441b-8242-3d1579d7c40a">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktMy0xLTEtNDMyMzYx_f5b7efea-774c-403b-bacb-8a64028964bb">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktNS0xLTEtNDMyMzYx_2e8eadbe-a22f-4433-ae54-c35442671659">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTEtMS0xLTU0NTA4OQ_bd6bb00f-8504-4b18-8cc1-7186db840db0">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTMtMS0xLTU0NTA4OQ_a3b7337e-8005-4dd0-a0aa-635740b81952">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTUtMS0xLTU0NTA4OQ_4e4b5443-358d-4fc7-960b-876d45eccafe">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTEtMS0xLTQzMjM2MQ_8fc7c382-7347-440b-987e-c3b3435405b9">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTMtMS0xLTQzMjM2MQ_6bdb4e32-eca6-4257-aff1-0b4f19a346c3">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTUtMS0xLTQzMjM2MQ_c10b0f06-d6ed-42a1-a331-b9ff8dbd4a7a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTEtMS0xLTQzMjM2MQ_8d8d0885-4518-4a5c-b1c6-74703c7ce968">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTMtMS0xLTQzMjM2MQ_b571f853-8472-4098-8c22-343d77211708">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTUtMS0xLTQzMjM2MQ_6ac67e21-cc12-4f09-b077-ef72ef963184">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTEtMS0xLTQzMjM2MQ_e8ebc1af-e6cf-454f-9795-578f70e14d5c">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTMtMS0xLTQzMjM2MQ_fac2358e-8aa7-47ef-9093-d1ed4a592201">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTUtMS0xLTQzMjM2MQ_63ae6457-f43a-4c86-bc6b-360afe596674">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i7b939dde63de41ef9cae2330f479ba06" continuedAt="ia102e121fcc24d79aa2b6c51e7e1646c"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjI_f56b0d03-b234-407f-93de-c737a24a4f5d" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:60.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzItMS0xLTEtNDMyMzYx_009b09e3-a855-4b8e-8a73-02569da276ca">18,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzItMy0xLTEtNDMyMzYx_22a5420c-5760-4868-a283-69a312f13970">8,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzMtMS0xLTEtNDMyMzYx_93a29f14-4391-4732-9f8b-5b032a52eb36">71,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzMtMy0xLTEtNDMyMzYx_783c253a-587e-456d-863a-4b7c0af4ad14">67,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzQtMS0xLTEtNDMyMzYx_a589d005-afba-41f3-9d5e-503fe26346e5">563,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzQtMy0xLTEtNDMyMzYx_855d8721-3d66-4588-86f1-6fbb3719cacb">581,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzUtMS0xLTEtNDMyMzYx_ed90f804-0b4c-404f-9226-d94bebe2cd3c">173,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzUtMy0xLTEtNDMyMzYx_209ae013-7b21-4dd2-86de-ef6b1f8197ea">162,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzYtMS0xLTEtNDMyMzYx_39f0ea62-7023-40db-9432-c366e4212235">58,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzYtMy0xLTEtNDMyMzYx_056ccb77-a0c7-44ef-a4d3-a8ec49b4a99a">52,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzctMS0xLTEtNDMyMzYx_f80e009f-514f-47f9-a411-a916feb38e77">885,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzctMy0xLTEtNDMyMzYx_341242f6-20e8-4ec4-a7c0-96dfe811f6d1">873,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzgtMS0xLTEtNDMyMzYx_4821b3cb-dc69-4b8a-9701-aadb181fe377">106,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzgtMy0xLTEtNDMyMzYx_02ef4f7e-5923-4725-8572-c99891411ceb">100,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzktMS0xLTEtNDMyMzYx_0c946340-9807-4ba0-a4ba-66241de016f8">779,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzktMy0xLTEtNDMyMzYx_fae74ed6-2085-4edd-8509-29c870bf3d77">772,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEwLTEtMS0xLTQzMjM2MQ_ffbbe5f9-9b97-4eb8-a82e-3efe0c5c21f4">690,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEwLTMtMS0xLTQzMjM2MQ_dd3ac7aa-ccf6-41fc-9dbc-dd042fe865fa">644,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzExLTEtMS0xLTQzMjM2MQ_70dbdb83-65fe-4730-97b9-4dc5a10cc6a2">181,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzExLTMtMS0xLTQzMjM2MQ_e3abbb0c-a9b3-4756-94b6-587ddeabf3e7">283,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEyLTEtMS0xLTQzMjM2MQ_7283bd8a-8968-46f6-97b1-3b64f181a743">515,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEyLTMtMS0xLTQzMjM2MQ_f703f1c1-dddb-4cfc-979a-5fde790fd8a5">530,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEzLTEtMS0xLTQzMjM2MQ_8c096c15-97af-4cbf-9741-2f464680a442">80,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEzLTMtMS0xLTQzMjM2MQ_7b3bf97c-41ac-481a-9cce-bad85efd7ead">84,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE0LTEtMS0xLTQzMjM2MQ_84dbb073-b3d5-4379-ba4e-6343b7072d88">65,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE0LTMtMS0xLTQzMjM2MQ_23b3d6ed-57d9-4636-a195-598ca5d14de1">37,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE1LTEtMS0xLTQzMjM2MQ_1db3abe5-f4e2-4af4-9877-dda53e8113ba">1,534,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE1LTMtMS0xLTQzMjM2MQ_cebc95d3-e144-496d-8f39-57ec4c1b2219">1,580,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE2LTEtMS0xLTQzMjM2MQ_d9253c03-29e0-40eb-8009-fabceb975723">755,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE2LTMtMS0xLTQzMjM2MQ_2182020d-9261-4cfa-8948-2f964b4fec0c">808,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0836866414f4437aac5b49b4350f9953_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE4LTEtMS0xLTQzMjM2MQ_8d7a9ba5-a83b-4fc4-a776-4f9d0514906e">782,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54e50d4b1d0e45d6998ef4a07f8412ca_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE4LTMtMS0xLTQzMjM2MQ_b40df824-d8ad-4138-b639-a1b376e00282">830,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eace4b400364cb59a814210aca461e9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE5LTEtMS0xLTQzMjM2MQ_e7369d01-705b-433d-ac2a-b5391237200e">27,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b49cc670fc4f9b8a4a550217fc1379_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE5LTMtMS0xLTQzMjM2MQ_9e447236-606c-490c-92f2-7b1f9aba6c88">22,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzIwLTEtMS0xLTQzMjM2MQ_8b804482-6746-48b3-ac55-441c2b2b6fab">755,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzIwLTMtMS0xLTQzMjM2MQ_ef327f40-240f-4ff3-afc2-2f1103144be8">808,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ic71d18b327ea4b429a6ba95d6c567050_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzExNDQ_c44bdf2e-fd89-4921-bcde-cf4b37f2f7cc">71,049</ix:nonFraction> that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i7a1f2af5eec44aa990c6433dc345a841_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEyNzg_13672519-f23b-456b-9839-62b0563bfa98">618,883</ix:nonFraction>, some of which have an indefinite life, although a substantial amount expire by 2042 and international net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i9728c466394b4bc781a51da4125c31a3_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE0MTg_b96f7c2c-b6e4-4e24-b480-bd1e22253864">357,266</ix:nonFraction>, some of which will begin to expire in 2023 though the majority have an indefinite life. The Company has a state capital loss carryover of $<ix:nonFraction unitRef="usd" contextRef="i5d510a76f30a4b18aeb57c119e82770e_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE1NTg_bb014181-6474-4a25-9be2-0fee32537576">306,949</ix:nonFraction>, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $<ix:nonFraction unitRef="usd" contextRef="i6f0ee4ace34040a89985a562a8e65295_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE4MzI_630d6940-9d73-43a5-9e93-e98b88802c95">6,159</ix:nonFraction> in the valuation allowance is primarily due to newly created net operating loss carryforwards in state and foreign jurisdictions that the Company does not anticipate being able to utilize.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:IncreaseInDeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNDk_09826bcb-19ae-49f4-9542-2d6d348039a6">46,692</ix:nonFraction> to net deferred tax assets, a charge of $<ix:nonFraction unitRef="usd" contextRef="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNTM_e5f5436f-616d-48a4-a252-7bb99b39d099">16,044</ix:nonFraction> to income tax expense, and an increase of $<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNjE_d379d3ca-dd0b-4738-959e-4208fca1a59e">62,736</ix:nonFraction> to additional paid-in capital. The Company&#8217;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $<ix:nonFraction unitRef="usd" contextRef="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNTc_e5f5436f-616d-48a4-a252-7bb99b39d099">16,044</ix:nonFraction> recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in a majority of the foreign jurisdictions in which it operates as of December&#160;31, 2022. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia102e121fcc24d79aa2b6c51e7e1646c"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNzM_706c45b0-93f3-480d-bdd2-45ad19a9b2d8" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzItMS0xLTEtNDMyMzYx_bdb16a80-1664-45dd-bc3a-cc3cf644e676">73,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzItMy0xLTEtNDMyMzYx_7ac08252-1e77-4b6c-8582-48ca577dee99">70,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzMtMS0xLTEtNDMyMzYx_ff5e6ec2-5b13-46f2-903c-49166682efa5">3,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzMtMy0xLTEtNDMyMzYx_0501b436-6837-436e-ac5c-9ae18a2e0dd5">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzQtMS0xLTEtNDMyMzYx_5d58a30b-d001-4167-8419-950d25103f04">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzQtMy0xLTEtNDMyMzYx_a674b2c7-bba5-4a32-9a0b-b5a99b46e59a">22,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzUtMS0xLTEtNDMyMzYx_33ee2051-9822-4f95-8dca-0afbb17c4db0">6,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzUtMy0xLTEtNDMyMzYx_95648ecc-df51-48a9-b2a0-d30a1ee637ce">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzYtMS0xLTEtNDMyMzYx_5c01e33a-aff7-4182-85b6-9e1a5619586a">31,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzYtMy0xLTEtNDMyMzYx_0bf1c63f-89c7-4372-a325-83631004c9e5">22,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzctMS0xLTEtNDMyMzYx_3820bed4-f1bf-4d2d-880f-b2d17ff89f84">63,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzctMy0xLTEtNDMyMzYx_bdb16a80-1664-45dd-bc3a-cc3cf644e676">73,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzMzOTY_729043d3-6b3c-44b3-9222-6ccf79974708">63,985</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM0MDk_be403102-5ec2-4261-ad34-75ea7055ba34">45,825</ix:nonFraction> would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company recognized an expense of $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzU2NTg_97fd5e64-4d36-429e-bc59-d3817efbb22b">10,459</ix:nonFraction> and a benefit of $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzU2OTI_f8f42b83-92ce-41dc-aed9-a158419e2f18">2,589</ix:nonFraction> related to interest and penalties net of federal tax benefit within tax expense in 2022 and 2021, respectively. At December&#160;31, 2022 and 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM3OTE_6ccf75f9-4da8-4174-af4f-acc4ff442570">8,208</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM3OTg_b919245f-fbc8-4993-aed8-01e8be57cd3d">15,275</ix:nonFraction>, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. The Company's federal tax returns are under examination by the Internal Revenue Service (IRS) for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014 and 2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. The refund claim is currently subject to IRS review. The Company is also open to U.S. federal examination for 2019 onward, and is no longer subject to U.S. state examinations by tax authorities for years before 2014.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_331"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0Njc_ef60d279-9a29-49e5-bee3-475687852147" continuedAt="i48a3c431342e4207b3629858368087f0" escape="true"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0NzE_7ab4b7dc-81c0-43a0-9293-68a048ee895d" continuedAt="ia6387bd983e94f9da07463c86f4b262e" escape="true">Long-term debt</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i48a3c431342e4207b3629858368087f0" continuedAt="i3b694f52de344a93be94b77d28d05e1d"><ix:continuation id="ia6387bd983e94f9da07463c86f4b262e" continuedAt="id43f945ffba447fcabab98836e3eaff5"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt was comprised of the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:34.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtMS0xLTEtNDMyMzYx_087042b7-13e8-400d-93c8-6525ac7914b1">1,498,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc4a5e5db954ccca57e0719d248d746_I20211231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtMy0xLTEtNDMyMzYx_9c342ddc-0a09-47a5-9174-cb94a3a95f4f">1,596,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtNS0xLTEtNDMyMzYx_61bc3b68-d539-4526-8d3a-272eb509168f">8/12/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtNy0xLTEtNDMyMzYx_dba44cf8-bcb2-4041-a633-ccfc0f4934ef">LIBOR + 1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtOS0xLTEtNDMyMzYx_08a32bad-d2f7-4edd-bc33-5194a31d80e9">1,468,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtMS0xLTEtNDMyMzYx_6b77f9e0-321f-4250-966b-b3f6b1d2de01">2,660,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddb2df1c2114de4a00fc604f1818904_I20211231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtMy0xLTEtNDMyMzYx_dfb37313-ffd0-4d28-83fd-e9b17ccf502a">2,688,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtNS0xLTEtNDMyMzYx_c0911c4c-4a5d-4894-9ad0-00b6928eb2c2">8/12/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtNy0xLTEtNDMyMzYx_03d5c125-c2a3-4c08-8548-02f97b602aca">LIBOR + 1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtOS0xLTEtNDMyMzYx_22f34dcd-1f23-41d5-8180-c5bfa87de76d">2,587,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280e7c36267346f08232e69492322e25_I20221231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtMS0xLTEtNDMyMzYx_e08007f3-71c1-4e47-92c4-d68196a92848">165,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e791ab248d24b63ae1da6cdf0df3eac_I20211231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtMy0xLTEtNDMyMzYx_aa910120-50c2-4602-9664-930d575f4c2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtNS0xLTEtNDMyMzYx_e6c8696d-a85c-4f0d-a372-aaba1032b9d1">8/12/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtNy0xLTEtNDMyMzYx_3fd7e68c-1df6-41cb-99fe-aff0418a2cef">LIBOR + 1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280e7c36267346f08232e69492322e25_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtOS0xLTEtNDMyMzYx_cc79f7fc-ac4c-4146-9223-ae263d4b6c8a">165,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctMS0xLTEtNDMyMzYx_6ce0044b-5c38-4d37-87af-7b52572df3ae">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2ea2f7c8b2414aaeb0fb9101c24607_I20211231" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctMy0xLTEtNDMyMzYx_8e221df5-c2f8-4939-923f-ee001788ee8d">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctNS0xLTEtNDMyMzYx_fb796baa-ec43-414b-b0a2-1bb921b57800">6/1/2030</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctNy0xLTEtNDMyMzYx_12e91537-1d85-491e-b199-a44921c5eb89">4.625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctOS0xLTEtNDMyMzYx_56af03c6-6d84-41f2-bac4-dac03fa1db2e">2,224,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e6ab0c8af4453689dd47207d80b526_I20221231" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtMS0xLTEtNDMyMzYx_17f3c612-7ca1-402a-8277-8f7fa095602c">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6d0ad8a3f149508ef910626c9379bd_I20211231" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtMy0xLTEtNDMyMzYx_fdcd9f33-c9f2-47ea-ae3d-f727bccee171">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice20b77c90c04919a53292886212c09a_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtNS0xLTEtNDMyMzYx_97ccf89d-b67b-4a13-9572-bd8ff6c18e68">2/15/2031</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice20b77c90c04919a53292886212c09a_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtNy0xLTEtNDMyMzYx_ca26660f-3c90-4743-b45e-372abe8fbd81">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e6ab0c8af4453689dd47207d80b526_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtOS0xLTEtNDMyMzYx_782ad7e3-2a27-43a7-90dc-fa200bca8af8">1,115,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition obligations and other notes<br/> payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9c869de9534500954d1a4145291638_I20221231" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktMS0xLTEtNDMyMzYx_d95083c0-ced6-4ceb-a1af-c33d0500112d">120,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c1764e202c483caac7e78fb4caf1b1_I20211231" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktMy0xLTEtNDMyMzYx_2a86fcf9-b8d1-401c-9293-3f4820d578fe">130,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61d6664946ac4659978bc717989aed3f_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDateDescription" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktNS0xLTEtNDMyMzYx_637d66bd-b992-4da6-b79c-5561293b880e">2023-2036</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e9c869de9534500954d1a4145291638_I20221231" decimals="INF" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktNy0xLTEtNDMyMzYx_3c4300ae-e591-4f70-b754-585d21358851">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9c869de9534500954d1a4145291638_I20221231" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayableFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktOS0xLTEtNDMyMzYx_4e4267a4-b10e-48a5-9972-383aecc86dd9">120,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTEtMS0xLTQzMjM2MQ_f26f119a-5858-4d1c-8fae-c1554572ecd1">273,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic69de63a548f40878bfa7836ee961e78_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTMtMS0xLTQzMjM2MQ_09b18b24-c914-4a3c-be84-ddaf9d482a14">299,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib94226c5496c4dc189b0f57a7e9d5b37_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDateDescription" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTUtMS0xLTQzMjM2MQ_82557a96-cce6-4d30-bfb8-0014b9cb76ce">2023-2038</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTctMS0xLTQzMjM2MQ_5e5217b2-04c7-479a-95d9-3219ae83fee5">4.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzExLTEtMS0xLTQzMjM2MQ_59c43f43-f286-49dd-84d4-0ba820254183">8,968,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzExLTMtMS0xLTQzMjM2MQ_f57d2c29-b1d9-4513-9e0c-963df867df4c">8,964,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:DiscountAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEyLTEtMS0xLTQzMjM2MQ_0c47b1a6-b341-4588-a768-37cef5310f35">44,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:DiscountAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEyLTMtMS0xLTQzMjM2MQ_158edb25-74cd-4f8e-ac5e-9573600e44d5">56,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEzLTEtMS0xLTQzMjM2MQ_3ccaa37c-a8d1-45d1-97db-842bf4f3b1c1">8,924,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEzLTMtMS0xLTQzMjM2MQ_bee78896-7766-4a1f-b9d4-ac4992c3f536">8,908,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE0LTEtMS0xLTQzMjM2MQ_35fd7958-1e9d-4fee-97c4-e4c9021943c8">231,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE0LTMtMS0xLTQzMjM2MQ_e2b38100-f454-4432-9588-eba7228ba3ca">179,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE1LTEtMS0xLTQzMjM2MQ_ea2716b7-bb9b-44b7-98b7-6fd2d6e3504b">8,692,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE1LTMtMS0xLTQzMjM2MQ_53f35147-6925-4300-bcdd-899b56388a9f">8,729,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values using level 2 interest rate inputs. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i3b694f52de344a93be94b77d28d05e1d" continuedAt="i537a412fe07f461c822eb2e08362f9e3"><ix:continuation id="id43f945ffba447fcabab98836e3eaff5"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and LIBOR interest rate components in effect as of December&#160;31, 2022.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="i711f403972ec4e66b0f07af1bd51bd85_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwNzE_2b4baeb0-074a-4a57-a914-a3ebabf58dd5">3,497</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i711f403972ec4e66b0f07af1bd51bd85_I20221231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzExMDY_35021ae7-41b8-46ea-b49c-1cb280c40796">18,816</ix:nonFraction> and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="id14241465c6d496e9fcbffe2bb81a4a5_I20221231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEyMTI_4cc26cf6-e088-490d-bb4f-beb6bdbf8a7b">36,203</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="id14241465c6d496e9fcbffe2bb81a4a5_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEyNTA_ec286937-3746-4519-9603-04f313efce3c">14,018</ix:nonFraction>. As of December&#160;31, 2021, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="i6332787d61e14213968fc6c3ed4533b9_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEzNjQ_f81baead-c1de-4af1-a52a-09a086f23b72">4,473</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i6332787d61e14213968fc6c3ed4533b9_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEzOTk_58665adf-2887-4922-952b-7808890b1ee9">27,207</ix:nonFraction>, and the carrying amount of the Company's senior notes was reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE1MDE_a2817060-af6d-4d2d-8042-0a7c5b245fd0">40,914</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2MzQ1Njk_69088458-ac0a-4506-a691-5dd7b667ee90">15,909</ix:nonFraction>.</span></div></ix:continuation><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0Nzk_fa95549e-59e9-4567-a227-083d4fb1dd66" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2022 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzAtMS0xLTEtNDMyMzYx_cf274d69-324d-4d0e-9094-3bd7b53fb770">231,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzEtMS0xLTEtNDMyMzYx_4fe94a8a-cf8b-44b4-9a8f-4fdfa243a7dc">1,587,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzItMS0xLTEtNDMyMzYx_131829bb-b5c0-4e84-b140-992e4152547d">67,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzMtMS0xLTEtNDMyMzYx_a004d617-1a4a-416b-bb01-d6cbf8f42b7d">2,627,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzQtMS0xLTEtNDMyMzYx_0cf797ad-cac8-47b0-ac00-0c61e026e489">35,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzUtMS0xLTEtNDMyMzYx_dca6177c-87fe-4480-95a7-976b1f39ff41">4,419,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company made regularly scheduled mandatory principal payments under its senior secured credit facilities totaling $<ix:nonFraction unitRef="usd" contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE3MTQ_e76d588a-4542-4421-9518-2bc9ac58ce1c">98,437</ix:nonFraction> on Term Loan A and $<ix:nonFraction unitRef="usd" contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE3MzY_12fcbb03-c85b-46cf-9c46-4482a8a70bc6">27,432</ix:nonFraction> on Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company's domestic subsidiaries' assets and are senior to all unsecured indebtedness. Borrowings under this facility's Term Loan A, Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. Borrowings under this credit facility are based on the London Interbank Offered Rate (LIBOR), unless another base rate is elected. This facility also provides a mechanism for transition to an alternative variable base rate upon cessation of LIBOR.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings under Term Loan A and Term Loan B-1 consist of tranches that can range in maturity from <ix:nonNumeric contextRef="i509b9358d5b848688db2af3f7c28f677_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDMzMTg_3121706c-c0bf-4389-9212-1d4278ee8522">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="if0b283e992d44d15924be874a7cb3008_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDMzMzU_f3536611-0ad2-4cbc-8e74-a507f30eb907">12</ix:nonNumeric> months. As of December 31, 2022, all outstanding term loan tranches are one month in duration. For Term Loan A and Term Loan B-1, each tranche bears interest at a LIBOR rate determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as the tranche matures and a new tranche is established.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the overall weighted average interest rate for Term Loan A and Term Loan B-1 was determined based upon the LIBOR interest rates in effect for all of their individual tranches plus the respective interest rate margins presented in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i280e7c36267346f08232e69492322e25_I20221231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ0MDQ_e08007f3-71c1-4e47-92c4-d68196a92848">165,000</ix:nonFraction> outstanding on the $<ix:nonFraction unitRef="usd" contextRef="i280e7c36267346f08232e69492322e25_I20221231" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ0Mjc_ceffc8aa-a453-4e43-82d8-573593906b2a">1,000,000</ix:nonFraction> revolving line of credit under its senior secured credit facilities. Each of these borrowings were priced on one-month LIBOR variable base rates as well. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were <ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ2NDc_bca2f8a3-478b-4271-9ffc-56f99eeed5f2">none</ix:nonFraction> as of December&#160;31, 2022. The Company also had letters of credit of approximately $<ix:nonFraction unitRef="usd" contextRef="i53250a642d1d4d75b53407d691d20e86_I20221231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ2OTc_71904e0a-bd4f-4c09-991c-620f837271df">108,826</ix:nonFraction> outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A. The remaining $<ix:nonFraction unitRef="usd" contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231" decimals="-3" name="dva:SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDEzNzI_c5034f0b-991b-4196-a782-f006471f2ed4">659,269</ix:nonFraction> outstanding principal balance of Term Loan A and the $<ix:nonFraction unitRef="usd" contextRef="i280e7c36267346f08232e69492322e25_I20221231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDM4ODg_e08007f3-71c1-4e47-92c4-d68196a92848">165,000</ix:nonFraction> balance outstanding on the revolving line of credit are subject to LIBOR-based interest rate volatility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i537a412fe07f461c822eb2e08362f9e3"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5dbc21f14c3549c39e54666a3970c405">The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. These cap agreements have variable legs priced at LIBOR to match the variable rates incurred on the senior secured credit facility borrowings that they hedge. Like the senior secured credit facilities, these interest rate cap agreements include a mechanism for transition to an alternative variable base rate upon cessation of LIBOR. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date.</ix:continuation> These cap agreements do not contain credit-risk contingent features.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0ODE_641cd5bc-8fd1-4c69-816c-ae76197adb88" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2022 and December&#160;31, 2021, which are classified in other long-term assets on its consolidated balance sheet:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">LIBOR maximum rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be">Debt expense</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Recorded OCI gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia154eee2b5544902b0df5b93083def6f_I20221231" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMS0xLTEtNDMyMzYx_560ada60-cae3-4f8f-a781-62e22afc4c4c">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a6df8d1ce4240b99834c54100161749_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMy0xLTEtNDMyMzYx_922c8301-623d-4452-8614-2fdd8b18c289">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f1024fd068b4449894448967a76d43e_D20220101-20221231" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtNS0xLTEtNDMyMzYx_e1726c6f-43e4-40e9-b58d-78ee8de2334c">6/30/2020</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f1024fd068b4449894448967a76d43e_D20220101-20221231" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtNy0xLTEtNDMyMzYx_833b9c0f-7b3d-459f-9256-5b0264d1be32">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtOS0xLTEtNDMyMzYx_216ba01c-2cba-4845-87d7-bcdc06f5156d">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTEtMS0xLTQzMjM2MQ_2f42a3e3-a556-47c4-b12d-7ac81773c99f">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bee71915f974aae9db45279fca80f9d_I20221231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTMtMS0xLTQzMjM2MQ_f707b9d5-f690-4acc-aedc-a0aa4265bba9">139,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4359a0f4c2824bf89e0c1d35492c622d_I20211231" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTUtMS0xLTQzMjM2MQ_cd407a6e-d05b-4481-a718-d5f951cab127">12,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0ODI_bb495593-2f6a-4fb3-aa88-56c7870e6060" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2022, 2021 and 2020:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.102%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location of losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMi0xLTEtNDMyMzYx_7e5aaa8c-3b51-497a-a6db-a5bd6135efa5">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtNC0xLTEtNDMyMzYx_3779a0a6-f371-49aa-81fd-90501615aa9f">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtNi0xLTEtNDMyMzYx_9633976f-29f4-481b-a6cb-0609319956a2">21,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTAtMS0xLTQzMjM2MQ_4b5ae866-e589-4fb3-aae5-2baedbb4b749">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTItMS0xLTQzMjM2MQ_4b721913-6792-4dad-82bd-998c535226df">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTQtMS0xLTQzMjM2MQ_033e91cd-a124-4a74-9084-792990105caa">7,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMi0xLTEtNDMyMzYx_f10a30b5-3342-45a5-86f2-1b865a0aff66">36,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtNC0xLTEtNDMyMzYx_da828a60-85e5-447d-864e-db9b7b2efc81">2,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtNi0xLTEtNDMyMzYx_6520726d-112d-4eae-976b-7558aacfed92">5,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTAtMS0xLTQzMjM2MQ_338e0c7e-0407-4e7e-ab2e-84761f149f71">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTItMS0xLTQzMjM2MQ_93633496-cc84-4b82-b85a-ee2fee8089c3">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTQtMS0xLTQzMjM2MQ_0d69f2fd-9967-4a0f-9b29-d0fe0b0702cc">1,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMi0xLTEtNDMyMzYx_2d2aaf33-b99d-4ca5-b00f-625434d13f41">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtNC0xLTEtNDMyMzYx_e2bfef1a-ca05-4039-82fa-ffb445621544">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtNi0xLTEtNDMyMzYx_ff72ce53-2337-40f7-aab4-25ca7d0faa0e">16,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTAtMS0xLTQzMjM2MQ_5f7ad3f0-d906-4de5-b6c5-4a84c858040d">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTItMS0xLTQzMjM2MQ_37f14e62-890f-4ff5-ad53-e5f4450ecf89">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTQtMS0xLTQzMjM2MQ_0da88264-3e7f-4b2e-871b-cc8c69e4bed8">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of 2022 was <ix:nonFraction unitRef="number" contextRef="i0b4946c95eb8498498d19a6faf87f113_I20221231" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQzMzE_de9632c6-547b-44a6-beda-345f5243fd7f">4.59</ix:nonFraction>%, based upon the current margins in effect for its senior secured credit facilities as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was <ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ1Nzc_f3ef8767-a07c-4f0f-8b24-969761238e98">3.96</ix:nonFraction>% for the year ended December&#160;31, 2022 and <ix:nonFraction unitRef="number" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ2MDY_4b982d23-4eb6-4ace-91cc-f1130afe632c">4.52</ix:nonFraction>% as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s interest rates were fixed on approximately <ix:nonFraction unitRef="number" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="4" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ2ODY_d184bdcc-2c37-4b9e-a2ca-c4ca71580d4d">51.3</ix:nonFraction>% of its total debt.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxNzg_66cc3ef9-d22f-4665-b49c-fe4c6de51e45">339,247</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxODI_d8487b32-9007-46d5-a072-7c43cac6b6c4">267,049</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxODk_011176e8-17e9-4577-9eb0-5fca64d95b7b">282,932</ix:nonFraction> and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs and the amortization of interest rate cap agreements of $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNTY_61916064-653a-4511-a097-8e094b353962">17,772</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNjA_303e4d43-8316-4078-9622-bd85564a6245">18,205</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNjc_a709af1f-bab9-4130-88ab-626885eb143e">21,179</ix:nonFraction> for 2022, 2021 and 2020, respectively. These interest expense amounts are net of capitalized interest.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_334"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:LeasesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjE_2e3aefa7-e241-43bc-9307-42dba88fc989" continuedAt="ib0d5e3afb45041e398f59c8c6b20127d" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ib0d5e3afb45041e398f59c8c6b20127d" continuedAt="i26e64259b6a2415a9eccb0625bc06d04"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from <ix:nonNumeric contextRef="i26fc0451360e403f820f0bba263549a0_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwMw_41707540-d62f-4595-b1fe-c84db16e1cb5">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwOQ_24a54570-7550-4045-8045-9b8564cdfbe1">15</ix:nonNumeric> years and which contain renewal options of <ix:nonNumeric contextRef="i26fc0451360e403f820f0bba263549a0_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzI0OQ_e83715ea-0eb7-4183-a8c5-080dc3f61169">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzI1NQ_bb268b4f-f111-4473-92d0-828f4b962f5c">ten years</ix:nonNumeric> at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and December&#160;31, 2021, assets recorded under <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_155f47b5-2149-4835-8f82-29569b70bc53"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_6bdf6749-42f6-44d7-86f8-0f1107e1b206">finance leases</span></span> were $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzU1OQ_b03f717e-a2b7-4c6c-b5d4-a9760177f05e">319,546</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzU2Ng_fa2216ec-a80f-4c6e-934e-7045daa239a4">322,060</ix:nonFraction>, respectively, and accumulated amortization associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzY0OA_1928aba3-8336-468f-acd7-a6d6fd320462">101,361</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzY1NQ_5d9d4033-585b-4f35-a43f-e5fba9149fd5">75,252</ix:nonFraction>, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long term basis. Both the sale and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i26e64259b6a2415a9eccb0625bc06d04" continuedAt="i10442e01b9b842679f67c9e27641055d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leaseback terms are generally market terms. The lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from <ix:nonNumeric contextRef="i26fc0451360e403f820f0bba263549a0_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyMTE_41707540-d62f-4595-b1fe-c84db16e1cb5">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyMTc_24a54570-7550-4045-8045-9b8564cdfbe1">15</ix:nonNumeric> years and which contain renewal options of <ix:nonNumeric contextRef="i26fc0451360e403f820f0bba263549a0_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyNTc_e83715ea-0eb7-4183-a8c5-080dc3f61169">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyNjM_bb268b4f-f111-4473-92d0-828f4b962f5c">ten years</ix:nonNumeric> at the fair rental value at the time of renewal.</span></div><div style="margin-top:3pt;text-indent:27pt"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjg_8415bb60-37e2-46b1-9629-a4a2d400f177" continuedAt="i2a1d9d3977654e49bff3af4119331422" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtMi0xLTEtNDMyMzYx_79f0053b-cedd-4a4d-8d5a-e06f2f4e9d83">552,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtNC0xLTEtNDMyMzYx_cfe0d300-4841-458b-8a9e-da3636b01dc0">547,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtNi0xLTEtNDMyMzYx_ca10351c-a954-4769-9b6e-bbf29edff9c3">541,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtMi0xLTEtNDMyMzYx_74072d4a-7b33-44ec-b351-da33018c805e">127,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtNC0xLTEtNDMyMzYx_15f6e419-366e-4709-a97f-f43ad0eabb55">125,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtNi0xLTEtNDMyMzYx_1c72abb1-3036-4ba9-b815-40f77274bf18">122,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtMi0xLTEtNDMyMzYx_f9563b3e-3aac-4e94-a3e3-7b3c41158ee2">27,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtNC0xLTEtNDMyMzYx_e07d8284-0011-4039-8552-6156ffca401c">26,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtNi0xLTEtNDMyMzYx_4212a2df-2743-42bb-8e5d-f8e2ba794e83">24,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctMi0xLTEtNDMyMzYx_4d0c4cea-d53c-4fb4-81a0-3d20a4c8706e">12,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctNC0xLTEtNDMyMzYx_32acfabc-4b89-473d-80e7-8eba577b913b">13,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctNi0xLTEtNDMyMzYx_f64eb740-4267-4e32-a46d-3bd833b527f4">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtMi0xLTEtNDMyMzYx_87c73007-c2d9-49c6-be97-3ecf20f61a1c">719,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtNC0xLTEtNDMyMzYx_09a7e0f1-c7b9-4fb7-9875-51ff18e0bd4a">714,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtNi0xLTEtNDMyMzYx_6c7de1f0-7fe0-4d93-8ca6-3ba414009d7d">702,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i2a1d9d3977654e49bff3af4119331422">(1) Includes short-term lease expense and sublease income, which are immaterial.</ix:continuation> </span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:LeaseOtherInformationTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjk_995cfd0e-7c24-4e68-a43a-afa3e92aee70" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtMi0xLTEtNDMyMzYx_65151ab6-b3c9-4385-a090-371e36b48660">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtNC0xLTEtNDMyMzYx_e8bcb424-25fe-44f7-b825-bf2c9070995b">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtNi0xLTEtNDMyMzYx_9ce13d8c-0dff-4bd7-9e55-9e3ec80a73ea">8.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtMi0xLTEtNDMyMzYx_a0c3fbc1-1f4f-4a07-9bba-6ded1e78d10c">9.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtNC0xLTEtNDMyMzYx_9724dc06-987a-48b3-bd3c-babfe759e465">10.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtNi0xLTEtNDMyMzYx_7dc5897f-c2a6-46c1-83db-e4b361b1e5ee">10.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtMi0xLTEtNDMyMzYx_c9007351-6703-44af-8dde-53fc1d45a970">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtNC0xLTEtNDMyMzYx_a2e7d9aa-d13f-4b90-b3ec-5ac23edd9ecb">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtNi0xLTEtNDMyMzYx_90853a61-318f-4de2-bbd1-fae57a4d10ab">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctMi0xLTEtNDMyMzYx_28c0134e-7754-4adc-a98d-f1e84ff37cb4">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic69de63a548f40878bfa7836ee961e78_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctNC0xLTEtNDMyMzYx_95af0cc9-e41b-4a66-bb22-d37fb73b6e79">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5680e5007324449948b894d87e40d7b_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctNi0xLTEtNDMyMzYx_b590f873-aa40-47e8-a2c4-dcd1b6c88bb4">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItMi0xLTEtNDMyMzYx_f304a952-7ccb-41f7-8197-87aa2236d8d5">28,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItNC0xLTEtNDMyMzYx_b73cec6d-7fa6-43dc-9c17-b289f429e341">17,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItNi0xLTEtNDMyMzYx_7ac2dc4b-7896-497c-b914-ac6d187b44d1">34,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtMi0xLTEtNDMyMzYx_5f17f884-6592-4f51-b972-91d20adfa0e5">696,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtNC0xLTEtNDMyMzYx_af590bed-68e5-4d34-ac7d-fe157cf90e81">684,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtNi0xLTEtNDMyMzYx_0b96fd94-b12e-4da5-bda3-dd27c0612ffe">661,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtMi0xLTEtNDMyMzYx_da87101c-ba51-44e4-8599-fcf577ed9ea4">20,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtNC0xLTEtNDMyMzYx_c18f1779-f2d3-4f5b-90a0-28da0030f0f2">21,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtNi0xLTEtNDMyMzYx_6a950e68-a7e4-46cb-b1ea-387f59881ff1">20,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtMi0xLTEtNDMyMzYx_100e885e-7843-455d-8444-26d90bc816b8">24,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtNC0xLTEtNDMyMzYx_5ddd640a-d6ea-441f-addc-2b095124ba3a">22,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtNi0xLTEtNDMyMzYx_2e1413fd-6ee1-498c-9b10-27e05e071d4b">24,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctMi0xLTEtNDMyMzYx_549baf9d-538b-4598-8d57-8bf92ef262b4">278,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctNC0xLTEtNDMyMzYx_31b9d627-05b6-4dc3-b427-4b77542aec80">361,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctNi0xLTEtNDMyMzYx_98f24d66-c54a-4c0e-90c3-31b7688dd82a">401,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfMinimumLeasePaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNTk_240abcae-9b86-4aba-b17b-6b7112349572" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2022 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:52.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzEtMi0xLTEtNDMyMzYx_68aaf226-760d-493b-95e5-3e2f9b7fd026">492,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzEtNC0xLTEtNDMyMzYx_1bb1dbab-5d8c-4abc-8e6a-3c8aa7adaf0f">37,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzItMi0xLTEtNDMyMzYx_4f69a345-669a-4872-8e44-ef2993a3a524">500,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzItNC0xLTEtNDMyMzYx_c7ab1d8a-fa7a-44f3-97f9-892540f9d332">37,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzMtMi0xLTEtNDMyMzYx_d0ae8f29-6730-4d0c-b47b-eb83abd64421">452,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzMtNC0xLTEtNDMyMzYx_9cb814d4-8b7e-4154-82a8-4cd9cecf740b">38,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzQtMi0xLTEtNDMyMzYx_0617fd7d-2916-4835-8432-ee765f27f495">400,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzQtNC0xLTEtNDMyMzYx_72d9c47a-117f-46df-92f0-2e2627c67261">36,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzUtMi0xLTEtNDMyMzYx_db559aac-672c-4e1f-8d16-f9ccfaf0a42a">333,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzUtNC0xLTEtNDMyMzYx_61cb453e-5697-46e8-a0d1-256ee5ae7cba">35,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzYtMi0xLTEtNDMyMzYx_7f99c8c2-4830-4ef7-891a-82dae78c482e">1,175,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzYtNC0xLTEtNDMyMzYx_bb0442f4-852d-4570-ad5e-1d042e5c296b">145,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzctMi0xLTEtNDMyMzYx_9849bcf1-b7d1-45a7-b632-e722a27e6017">3,354,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzctNC0xLTEtNDMyMzYx_ae9f6d25-67ca-41ac-a63b-65c9ce222cc4">331,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzgtMi0xLTEtNDMyMzYx_dfa769d2-9d46-4284-8d37-64d22e83814c">456,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzgtNC0xLTEtNDMyMzYx_8e1f1ba1-9921-4c42-b06e-515eb4a2dd04">58,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMi0xLTEtNDMyMzYx_562b7567-953a-42ba-9962-3becef20068d">2,898,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktNC0xLTEtNDMyMzYx_3c233235-5445-402a-9348-3fb4b4eb7fed">273,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i09a6f14a780d4294baf4b2885e32978d_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NTM_6c6eca8f-e701-4550-abe9-35ea0dbbf44b">679,815</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i81ab07f87a174fb2b7c3fee62cf056b7_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NTc_9dd4e985-d800-487f-835a-50c1e993a2d5">673,904</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1eff9aaeed62457e946eb316f31451f1_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NjQ_3bb3fefe-7a11-4222-adf0-2cb50cc2cfe8">663,819</ix:nonFraction>, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10442e01b9b842679f67c9e27641055d">or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 13 for further details on long-term debt.</ix:continuation></span></div><div id="ib228226ec511491b87b183c6d217a21a_337"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzIyNTg_9ae9c813-f3ef-4728-8e61-81794f6a3e47" continuedAt="i017994576dbc43a49a3742bc640fdef7" escape="true">Employee benefit plans</ix:nonNumeric></span></div><ix:continuation id="i017994576dbc43a49a3742bc640fdef7"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches <ix:nonFraction unitRef="number" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzQ0NA_0909f6ed-f66b-4e68-8177-542b1bb8668a">50</ix:nonFraction>% of the employee's contribution up to <ix:nonFraction unitRef="number" contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzQ4NA_4fae016f-d737-49f7-80f4-4c131f590251">6</ix:nonFraction>% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2022, 2021 and 2020, the Company accrued matching contributions totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzczMg_23a7e76f-6fec-4fd7-8b8f-7a898c29ca38">70,084</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzczNg_4a647436-5113-4a05-ba8f-e49eed760ef3">68,658</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2Xzc0Mw_d7b8b9cf-2fd3-4898-8a45-cbc2cde23796">70,180</ix:nonFraction>, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan, as well as other legacy deferral plans. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to <ix:nonFraction unitRef="number" contextRef="i9860868c23e043df847009e53cc53fdc_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzExNTY_ac76dfe5-7663-4ceb-a8ca-e2c36b0c7f29">50</ix:nonFraction>% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyODY_0591438f-2b45-4069-9264-12fdedd656e6">3,573</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i61afa366cd62422b84371143b00ef79c_D20210101-20211231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyOTA_1f24aec3-32f7-4138-b2fb-4d75d970081d">2,962</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyOTc_d39b6588-0d6e-4765-a00a-80386b3e1f90">3,637</ix:nonFraction>, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2022, 2021 and 2020 the Company distributed $<ix:nonFraction unitRef="usd" contextRef="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE1OTg_e83dd24a-2ccf-4009-af4e-47c28f679503">3,731</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i61afa366cd62422b84371143b00ef79c_D20210101-20211231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE2MDI_936bec5b-fb2b-4f1b-8a7d-f81f31c70c4e">11,887</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE2MDk_e44413b0-ce65-42e3-ad6d-63d7ef2613c8">3,139</ix:nonFraction>, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2022 and 2021, the total fair value of assets held in these plans' trusts was $<ix:nonFraction unitRef="usd" contextRef="i86a6007fcdfb46cd8c45962e916984df_I20221231" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE5OTM_fc4a6e16-866a-4d0b-af82-810e047d92ca">32,944</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa80e3707e984cba98b264df4ba470fe_I20211231" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzIwMDA_a1fd6343-2dd5-461f-b5a5-2d0bed847c16">38,019</ix:nonFraction>, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other income. See Note 5 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_343"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:LossContingencyDisclosures" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzE4MTk1_b108fa69-c736-4f65-ac39-5dfb529d5cc5" continuedAt="i85a8be6ea014490bb2ab3a96e139dfb4" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i85a8be6ea014490bb2ab3a96e139dfb4" continuedAt="i9bae1fb8f82f4f5db62195e893663f3d"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#8217;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#8217;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i9bae1fb8f82f4f5db62195e893663f3d" continuedAt="i1d223e2a7ab746eea2a1ae9948ac16dd"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 U.S. Attorney Texas Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney&#8217;s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company&#8217;s relationships with pharmaceutical manufacturers. The government's investigation covers the period from January&#160;1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government's investigation and that included total monetary consideration of $<ix:nonFraction unitRef="usd" contextRef="if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM3NzQ_61d9d12c-c890-4cfe-a148-398c79c0282f">63,700</ix:nonFraction>, as previously disclosed, of which $<ix:nonFraction unitRef="usd" contextRef="ib94215c12b694944b79ef5ea39279483_D20171201-20171231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM4MTI_9c0c08da-1ab8-4a68-a018-8834bae25fd1">41,500</ix:nonFraction> was an incremental cash payment and $<ix:nonFraction unitRef="usd" contextRef="i569c0d52c6c6426faf8f5a35ede23d64_D20171201-20171231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM4NTE_abeef089-0c0d-487e-9fa2-88f5d4118460">22,200</ix:nonFraction> was for amounts previously refunded, and all of which was previously accrued. The government&#8217;s investigation is ongoing with respect to issues related to DaVita Rx's historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. On September 15, 2021, the U.S. Attorney&#8217;s Office notified the U.S. District Court, Northern District of Texas, of its decision and the decision of 31 states not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated September 17, 2021. The complaint was not served on the Company. In December 2021, the private party relator filed a notice of voluntary dismissal of all claims and the court entered an order dismissing the claims without prejudice. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. In January 2023, the private party relator served the Company with the amended complaint. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020, and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Department of Justice Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, the Company received a CID from the Department of Justice pursuant to an FCA investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. In February 2023, the Department of Justice notified the Company that it had closed its investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Company received a CID from the Office of the Attorney General for the District of Columbia in connection with an antitrust investigation concerning the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i1d223e2a7ab746eea2a1ae9948ac16dd" continuedAt="i0d28fddf5dfd4233b38d4d2457915927"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Kidney Fund (AKF). The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. No. 20-1641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On November 5, 2021, the United States Supreme Court granted certiorari of an appeal by an employer group health plan, the plan sponsor, and the plan&#8217;s advisor of the U.S. Court of Appeals for the Sixth Circuit (Sixth Circuit) decision in the Company's favor. The questions presented involved whether the health plan violates the Medicare Secondary Payor Act (MSPA) by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On December 23, 2021, the Solicitor General on behalf of the United States filed an amicus brief supporting the petitioners' request to overturn the Sixth Circuit decision. On January 19, 2022, the Company filed its brief in support of the Sixth Circuit decision. On June 21, 2022, the United States Supreme Court reversed the Sixth Circuit decision and held that the employee health plan for Marietta Memorial Hospital did not violate the MSPA. The case has been remanded back to the lower court for resolution of the outstanding claims. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 16, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0d28fddf5dfd4233b38d4d2457915927">the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.</ix:continuation></span></div><div id="ib228226ec511491b87b183c6d217a21a_346"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:CommitmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQ1ODA_5fd05404-3d7e-4f55-aa88-983c9d4354f0" continuedAt="i667625d7a1554d87a2f90cbf29de36ea" escape="true">Noncontrolling interests subject to put provisions and other commitments</ix:nonNumeric></span></div><ix:continuation id="i667625d7a1554d87a2f90cbf29de36ea"><ix:continuation id="iea6ea37368b84e08a8ef2284c5ced7c4"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from <ix:nonNumeric contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzI1OTI_bb4fad8c-3eb2-4524-b923-c198ecfd72b4">ten years</ix:nonNumeric> to <ix:nonNumeric contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzI1OTg_865a570a-8288-4f7f-a85a-75845398a67c">50</ix:nonNumeric> years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2022, the remaining minimum purchase commitments under these arrangements were approximately $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTA_0b052b54-358e-444c-9f0d-4fa4631073e6">712,802</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTQ_88075b70-30f9-4236-8adc-b55aca46dfc1">469,760</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTg_b30a9a7f-8d5e-4186-8e00-7ed773fb0e38">362,431</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NjY_34bd58fd-e214-4c5f-ab9c-2a0f6278118e">379,832</ix:nonFraction> for the years 2023, 2024, 2025 and 2026, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $<ix:nonFraction unitRef="usd" contextRef="i8274525480784946977c6314bbd7cc5b_I20221231" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQzNjg_e6572ae3-681b-4793-a144-84bd0566d458">9,038</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 13 to these consolidated financial statements, and the arrangements as described above, the Company has <ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="dva:OffBalanceSheetFinancingArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQ1Mjc_4c9d0a3e-4cfe-4b85-b867-53a2ffec7c6a">no</ix:nonFraction> off balance sheet financing arrangements as of December&#160;31, 2022.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_349"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5Nzg_1b84a222-d8a8-4046-a606-38919071183d" continuedAt="i873a97ef5aa34030a29a53667569938b" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="i873a97ef5aa34030a29a53667569938b" continuedAt="id70514ee885f4d2fa07663f10dc6a111"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="id70514ee885f4d2fa07663f10dc6a111" continuedAt="i93fc72740f354657b0fda3e7e042f6f7"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of <ix:nonNumeric contextRef="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzE5NjA_e0a866de-d1d5-4c1c-85cd-dd8ed6f0d841">10</ix:nonNumeric> years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are also stated on a full value share basis rather than on an option-equivalent basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by <ix:nonFraction unitRef="shares" contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231" decimals="INF" name="dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI0MTc_461a362a-baaf-4d94-972e-22192eaca955">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231" decimals="INF" name="dva:StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI0NDY_5dc47461-0422-4cf2-a0aa-d737c515e742">four</ix:nonFraction> shares underlying stock appreciation rights and stock options, and are reduced by <ix:nonFraction unitRef="shares" contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231" decimals="INF" name="dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI1MzE_e80a27b3-411f-472a-9578-a12590e7f336">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI1NjA_527fcb7e-4645-4506-858a-3cf341b6c4af">one</ix:nonFraction> share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ia707dbef043d49869bd8d75dec1d7c30_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI2NzM_91add530-bb04-4eba-96d9-28e4eed1d674">6,815</ix:nonFraction> shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over <ix:nonNumeric contextRef="i80d73225bc934812a0e7e7641b1ce671_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI4MDc_cd06a372-1001-4a79-a9f4-f12986f8d074">36</ix:nonNumeric> months to <ix:nonNumeric contextRef="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI4MTM_f5c0bd67-233b-4823-bb15-8a36a71435ae">48</ix:nonNumeric> months from the date of grant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Healthcare Partners Inc. 2011 Incentive Award Plan (the 2011 Plan) was the Company&#8217;s prior omnibus equity compensation plan and authorized the Company to award stock options, stock appreciation rights, restricted stock units, restricted stock, and other stock-based or performance-based awards. The 2011 Plan mandated a maximum award term of <ix:nonNumeric contextRef="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzMxMjk_10a77849-7ab2-46ba-91e2-87bdfe085124">five years</ix:nonNumeric> and stipulated that stock appreciation rights and stock options be granted with prices not less than fair market value on the date of grant. The 2011 Plan also required that full value share awards such as restricted stock units reduce shares available under the 2011 Plan at a ratio of <ix:nonFraction unitRef="number" contextRef="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231" decimals="INF" name="dva:SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM0MTk_ce9e09a6-c7ab-4357-bde6-87e2efc41ebd">3.5</ix:nonFraction>:1. The Company&#8217;s stock appreciation rights and stock units awarded under the 2011 Plan generally vest over <ix:nonNumeric contextRef="i26a660eca1df4c6aac1cebc8b4113bc0_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM1Mjk_e1342705-9f0f-414f-a5d9-cf0739075389">36</ix:nonNumeric> months to <ix:nonNumeric contextRef="i7063491894094779acab6b28c5595e90_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM1MzU_02971008-0ffc-4a0c-be07-8ab9e70b154d">48</ix:nonNumeric> months from the date of grant. The 2011 Plan was terminated with respect to any new awards upon stockholder approval of the 2020 Plan.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NzI_1529f44b-d67f-4823-972a-4004f716497f" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combined summary of the status of the Company&#8217;s stock-settled awards under both the 2020 Plan and 2011 Plan, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75140de7fc2e44a4aae6591587030c31_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtMS0xLTEtNDMyMzYx_b85f3c02-6907-434b-a68f-935f86a6fa58">5,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75140de7fc2e44a4aae6591587030c31_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtMy0xLTEtNDMyMzYx_e4f76ea1-bd20-4055-b038-431dafd9f17b">64.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f2232a592ba45f98e9d502b586f1a60_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtNy0xLTEtNDMyMzYx_82ecdaaa-8be4-40e1-8ac4-2207a51cddf7">3,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtMS0xLTEtNDMyMzYx_7bb8ad50-8eca-460c-9b31-03fb6bc023fd">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtMy0xLTEtNDMyMzYx_32574841-b1d8-4672-9cad-7767fdac57bf">110.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtNy0xLTEtNDMyMzYx_ad26ba32-f461-41d4-9eb9-ccce01f1e8cc">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" decimals="-3" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzUtNy0xLTEtNDMyMzYx_4daaf5f3-a497-4008-9efe-ed601cc200d4">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtMS0xLTEtNDMyMzYx_ace988a9-ad71-4064-8956-e54244c9568a">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtMy0xLTEtNDMyMzYx_9241b15f-eaa9-4dc9-b6ce-e54de4365a2f">63.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtNy0xLTEtNDMyMzYx_ab962d21-2d46-4a37-8c04-2e496e48c938">1,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctMS0xLTEtNDMyMzYx_de09ef91-a1b1-4522-8be7-264ed625f6c8">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctMy0xLTEtNDMyMzYx_d650a853-0b2d-49e4-9930-7a118dea7cd5">55.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctNy0xLTEtNDMyMzYx_18c642e1-4ee1-455c-969b-55af3e64f18e">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtMS0xLTEtNDMyMzYx_9454e602-bdb6-4a8a-ab52-f5b13966dd2c">5,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtMy0xLTEtNDMyMzYx_bf94e425-b0d5-4830-89ce-270ca0ac7ec4">66.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtNS0xLTEtNDMyMzYx_8a193ad2-cf75-4236-83d0-079a589a2805">1.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9218664971064274b79221f47df0c986_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtNy0xLTEtNDMyMzYx_7f78ff96-7401-4673-9407-c58390e732a0">3,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtOS0xLTEtNDMyMzYx_96ea0d73-7c92-46d8-972b-ba94e26e8556">1.93</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktMS0xLTEtNDMyMzYx_2877c3be-657d-496e-aafa-8b489abe66a2">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktMy0xLTEtNDMyMzYx_a1030c44-6e9a-480c-8c69-8035a5d6216b">64.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktNS0xLTEtNDMyMzYx_543a0bad-3f51-427d-9fb0-7f70ff61f3c1">1.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9218664971064274b79221f47df0c986_I20221231" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktNy0xLTEtNDMyMzYx_a2c13371-dfa5-44f0-950f-5a48eb020598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzExLTEtMS0xLTQzMjM2MQ_bb1d8998-96db-4397-9327-9ad9f571947e">35.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzExLTctMS0xLTQzMjM2MQ_f994e8f7-b05e-4eb2-a272-559a0bd89b4d">107.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bbcbd8a1eca4275a3ad805b14ce01b3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEyLTEtMS0xLTQzMjM2MQ_1b6828c4-80bb-4788-b90b-0ec661011266">32.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d31f8da40914157a9a538177f086aea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEyLTctMS0xLTQzMjM2MQ_69474836-d156-441a-a85d-815976d96862">109.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b9b576fd9a14515a102d4388e16984e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEzLTEtMS0xLTQzMjM2MQ_94aeeb5b-95cb-4cdc-a2e4-0f6bfefe3c1d">26.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8065cc2fe8ad46cbbb4359c02e4ac3e6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEzLTctMS0xLTQzMjM2MQ_732fef8a-3976-4d94-be16-3070cfad312e">77.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NjA_711bb92d-105c-4ef2-a71a-545ce92bd254" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:28.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.438%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItMi0xLTEtNDMyMzYx_5304b77d-dd7a-4e69-80ea-35061a3ba5e4">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItNC0xLTEtNDMyMzYx_776f3c79-ca01-4cb9-b32f-6369f1533a81">52.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItNi0xLTEtNDMyMzYx_3de68470-9090-416c-9d21-793f44763fe6">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItOC0xLTEtNDMyMzYx_89218c42-1c4d-4927-a545-ed7082a62ec6">52.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473afde79b764c408f9a11119b563a06_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtMi0xLTEtNDMyMzYx_d404c18e-3d7e-40fb-a7c6-48b04ba5de44">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i473afde79b764c408f9a11119b563a06_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtNC0xLTEtNDMyMzYx_2b3a51a8-b484-49ae-9ff4-acbc57241e51">67.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473afde79b764c408f9a11119b563a06_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtNi0xLTEtNDMyMzYx_973f8ce1-ef34-4500-80ec-173fba04a46b">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i473afde79b764c408f9a11119b563a06_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtOC0xLTEtNDMyMzYx_bcf07528-5a04-46c0-93d1-800c038e6895">67.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtMi0xLTEtNDMyMzYx_819b40a3-c0aa-4731-876f-f782eda9a293">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtNC0xLTEtNDMyMzYx_549756b9-a48a-434f-9582-558cce9c4f45">75.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtNi0xLTEtNDMyMzYx_80e47618-fde3-4412-9f0e-00acdcd7c45f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtOC0xLTEtNDMyMzYx_4e2b7e9a-5acf-494c-b07f-839910882c2e">70.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtMi0xLTEtNDMyMzYx_06e75e4c-791a-41d9-b82f-907219dee410">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtNC0xLTEtNDMyMzYx_701662d0-4247-4bf0-9de0-51d5e1ab954a">108.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtNi0xLTEtNDMyMzYx_0736e403-6df0-43f0-9080-083578d2cb20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtOC0xLTEtNDMyMzYx_ef8ef19f-107d-47aa-81d6-ddd979fd3493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtMi0xLTEtNDk4NTQ4_dc515b43-b3c3-475c-8941-afa6914cc87e">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNC0xLTEtNDk4NTQ4_884a22d5-ebe7-46a7-80a4-d4d1b1d77aff">110.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNi0xLTEtNDk4NTQ4_a2f08882-d07f-46fd-a6a2-e082645e8191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtOC0xLTEtNDk4NTU4_1c70de3c-503d-45e8-916f-0405585c496a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtMi0xLTEtNDMyMzYx_f66901e1-bc94-421b-91d7-07960d58fd03">5,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNC0xLTEtNDMyMzYx_fed62002-256e-4472-908d-5c53b4cbe794">66.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNi0xLTEtNDMyMzYx_f80b9b17-ba76-406a-be53-8494a7542f89">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtOC0xLTEtNDMyMzYx_d1aa2a1b-6944-4d40-8d71-0363fbc7e9c3">64.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i93fc72740f354657b0fda3e7e042f6f7" continuedAt="i0635edb823cc4d3a8049110d8b137174"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the aggregate intrinsic value of stock-based awards exercised was $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MDQ_4373086e-23b5-431c-9764-7bb18ae804f6">149,442</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MDg_b0cdb14b-1e54-4b8f-ba4a-021ccbfb5e84">208,585</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MTU_4bcf07bb-7139-4d05-9ec6-670700c647fd">49,258</ix:nonFraction>, respectively. At December&#160;31, 2022, the aggregate intrinsic value of stock-based awards outstanding was $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzQwMDg_91daaae9-9d7d-4cfa-9b60-ad0ae3d11e11">289,942</ix:nonFraction> and the aggregate intrinsic value of stock awards exercisable was $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzQwNzc_1e28f7cc-fa79-4c29-9a62-bc27d070e84e">25,508</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NjI_0397c07e-bcbb-4eaf-bc69-f256225b9fed" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:40.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItMS0xLTEtNDMyMzYx_6d1dd51e-a8b3-4524-90e6-3a8b76288b3d">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItMy0xLTEtNDMyMzYx_cfa36180-f588-4c7e-b314-471ec1db051a">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItNS0xLTEtNDMyMzYx_b6781c8d-ab8c-4d39-a17b-93c384813d66">4.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtMS0xLTEtNDMyMzYx_cd9c9706-4eb8-4641-90f9-6d9f42631ff9">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtMy0xLTEtNDMyMzYx_9d180dc0-f3c5-4e63-8157-70e626c6b5b7">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtNS0xLTEtNDMyMzYx_4ff6526e-9149-4454-bd23-7b38464c5fe6">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtMS0xLTEtNDMyMzYx_88063a08-fadf-4aa9-a9c3-932ca78aef4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtMy0xLTEtNDMyMzYx_42905482-61ef-4ed5-8ce4-ea1e6462c3a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtNS0xLTEtNDMyMzYx_c1e04357-cbc8-49e1-800a-f40fecb758d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtMS0xLTEtNDMyMzYx_6c2322ae-bad9-41f5-8a4d-3ed3a4a42513">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtMy0xLTEtNDMyMzYx_6b3f7abd-8f86-4ee5-a808-23ea0988645e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtNS0xLTEtNDMyMzYx_8243aaff-a5a4-404e-97b7-2bf4ba4d2356">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $<ix:nonFraction unitRef="usd" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc1NTY_6ee9707b-909c-4ff9-b705-9b8d588d36dc">25</ix:nonFraction> of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of <ix:nonFraction unitRef="number" contextRef="i654c073e58bd41ae9d35684155b57deb_D20220101-20220101" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc4NzM_7e95c406-053c-4dd9-b99f-b4a13c9b76fd">100</ix:nonFraction>% of its fair market value on the first day of the purchase right period or <ix:nonFraction unitRef="number" contextRef="i965432f8e1b1446f8d9cafc77f04fd6c_D20221231-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc5NTA_fd96a496-021f-4d11-a325-70aace75647b">85</ix:nonFraction>% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2022, 2021 and 2020 purchase periods were $<ix:nonFraction unitRef="usd" contextRef="ie6f172bac13b435484bfaf9fd3326e51_I20221231" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMjA_b78b3ae9-9af1-4f55-9bf5-c3e4623903df">18,061</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i47c9f860645046bd9f1febf1ee03749e_I20211231" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMjQ_f5fc5b6b-f8c7-44f8-a363-afd1ef163e0b">19,626</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i79f354c25ca54754ab7b68f40dbd8a25_I20201231" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMzE_9f71f338-50e5-4a1d-8593-eef7a4c675cb">17,148</ix:nonFraction>, respectively. Shares purchased pursuant to the plan&#8217;s 2022, 2021 and 2020 purchase periods were <ix:nonFraction unitRef="shares" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMjU_ab678efd-5fde-41cc-bfe0-b305039de7ab">285</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMjk_956f555c-e396-42cf-9317-95a80c6888f9">203</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMzY_e035adeb-39c9-4d42-a664-f268f1160e1a">222</ix:nonFraction>, respectively. At December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ie6f172bac13b435484bfaf9fd3326e51_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzNzI_34fd58ad-74a8-47a6-92cf-f93a7a7916b4">5,702</ix:nonFraction> shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2022, 2021 and 2020, respectively: expected volatility of <ix:nonFraction unitRef="number" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3MzI_bfd26127-1125-46db-a9a0-0525c9ff3052">31.7</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3MzY_7b98648a-ef4b-46d0-a551-4b1e2a1fa0e1">39.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3NDM_22e628f8-cdd2-40c1-93e4-9bd0011fb070">40.4</ix:nonFraction>%; risk-free interest rates of <ix:nonFraction unitRef="number" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3NzU_0884daa0-6e03-44ad-81c8-c15a8893da08">1.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3Nzk_9880203f-b9f3-4763-921d-567a94e90388">0.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3ODY_7dc17683-d644-46cd-9f4c-782390e2a3ca">1.0</ix:nonFraction>%; and <ix:nonFraction unitRef="usd" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3OTQ_ac7d2bb6-f46c-4f84-810f-cd1d4b64aab1">no</ix:nonFraction> dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $<ix:nonFraction unitRef="usdPerShare" contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MTI_755c82dd-20f6-43ba-b924-46b448be301f">26.50</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MTY_9686ea45-a16c-4a82-8934-ae10684af0a7">34.94</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MjM_be1516d9-40d1-4232-aff0-1957abea6871">22.06</ix:nonFraction> for 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i0635edb823cc4d3a8049110d8b137174"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNjM_09f81b71-3733-40ad-afe7-80a565f72b8b">95,427</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNjc_55ab2b7e-cdae-49c8-843c-b986adb7af2d">102,209</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNzQ_61fddbe9-e241-4a70-9090-2f1f9bff8796">91,458</ix:nonFraction> in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNjc_935c958b-ee29-43ac-96bd-38c7ea53fa4f">14,723</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNzE_7fb54eb7-5af5-4d83-af24-08caa2ead0cf">13,853</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNzg_14308b2a-ff64-48f9-87dc-0f1c70895fcc">11,775</ix:nonFraction>, respectively. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk0MTY_b849c9b1-25a5-4f01-a150-1423164b1500">149,081</ix:nonFraction> of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation and employee stock purchase plans. The Company expects to recognize this expense over a weighted average remaining period of <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk2NTM_b0831b01-fd6f-4f00-b089-819fadf8a11f">1.3</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MTM_86e66e39-7657-4466-b876-f47f86ddf6be">24,805</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MTc_1b497923-5625-456a-8c34-ca53fd5ed321">46,990</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MjQ_3faa4ae8-120c-477c-8d36-5c9013629a00">8,957</ix:nonFraction>, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were <ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5MTQ_4b08d433-7ea7-434c-8404-f80e9da17685">no</ix:nonFraction> cash proceeds from stock option exercises.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_355"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxNzk_eca59d31-593a-429e-9f7c-3982e2c6330c" continuedAt="ib472cfbbde8d48979ce029a64bc549df" escape="true">Shareholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="ib472cfbbde8d48979ce029a64bc549df" continuedAt="i8031df24fcaf4bcc8279ef9c8eea95e6"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxODE_c8a9a760-0da0-47e0-b33a-baa280c7713c" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:38.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItMS0xLTEtNDMyMzYx_f900b864-8f17-4f6f-9cd7-1d1849e66349">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItMy0xLTEtNDMyMzYx_730daf29-5d43-4c81-8ad6-dd5a5b69f459">13,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItNS0xLTEtNDMyMzYx_5cc67655-3f34-4784-a0b1-16c4c7d92830">8,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtMS0xLTEtNDMyMzYx_260a4fc3-de42-4dff-a584-b9e1ada8448c">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtMy0xLTEtNDMyMzYx_13d6c710-fe75-40cb-ba16-06fcc728fafa">1,546,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtNS0xLTEtNDMyMzYx_78c35132-6ab5-4dda-9030-13da3efb38f9">741,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtMS0xLTEtNDMyMzYx_f8581737-610e-43c2-8198-356ab6f59594">97.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtMy0xLTEtNDMyMzYx_d0867c44-c94c-479c-89ba-e77b3d436128">111.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtNS0xLTEtNDMyMzYx_f8e693d1-9533-4e81-8325-29ef7fe8b81b">87.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tender offer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctMS0xLTEtNDMyMzYx_72580129-a2dc-431e-bbf9-e016c6deddb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctMy0xLTEtNDMyMzYx_17667432-a647-431d-9304-0ccd0c26ee41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctNS0xLTEtNDMyMzYx_094bc759-a9f0-487e-96fd-253b939d1efb">7,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtMS0xLTEtNDMyMzYx_49bfca22-f47e-4869-913a-a25c94a02798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtMy0xLTEtNDMyMzYx_7ca2f130-49d5-47e3-b1a7-47b20de1605c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtNS0xLTEtNDMyMzYx_22090614-3596-410b-be97-4c69b7716e85">704,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktMS0xLTEtNDMyMzYx_3bbd36fb-98be-44e2-b85f-1c983af482d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktMy0xLTEtNDMyMzYx_8594d02a-a67d-48bf-a44d-88cdf4e5393f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktNS0xLTEtNDMyMzYx_d37c6dd3-59bf-4af6-bdf6-723ddff50991">88.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTEtMS0xLTQzMjM2MQ_95dda5ae-6864-4468-b227-7d04e6fadb8c">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTMtMS0xLTQzMjM2MQ_dbbbe27f-7e23-453e-9ce6-bf8c184a9ed4">13,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTUtMS0xLTQzMjM2MQ_af2be58b-0bb4-47f2-8f44-e0df4b968b85">16,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTEtMS0xLTQzMjM2MQ_bb101ee5-4d37-4ee8-a117-3f9eb774a9bf">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTMtMS0xLTQzMjM2MQ_a1789482-3bd4-4ed5-a641-7c2e35403b7d">1,546,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTUtMS0xLTQzMjM2MQ_feff5357-ac7c-4d89-9b54-12604fac4b8d">1,446,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTEtMS0xLTQzMjM2MQ_22b1e361-b992-47f5-919d-5ca99de1ee5d">97.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTMtMS0xLTQzMjM2MQ_a0eb0f61-e95d-44a0-a9a6-d8e0b2aac9dd">111.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTUtMS0xLTQzMjM2MQ_d8e9876c-0c65-4488-9169-666d5d13e605">87.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The aggregate amounts paid for shares repurchased pursuant to the Company's 2020 tender offer for its shares during the year ended 2020, include the clearing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231" decimals="2" name="dva:TreasuryStockAcquiredAverageCostPerShareClearingPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzM2Mw_55a35c14-f48a-4c9f-ace5-ced0aa01645b">88.00</ix:nonFraction> per share, plus related fees and expenses of $<ix:nonFraction unitRef="usd" contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231" decimals="-3" name="dva:ShareRepurchaseFeesAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzQzMw_30ca4536-968b-445f-a352-bf94e65b6f66">2,529</ix:nonFraction>.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2022 through February&#160;22, 2023, the Company did <ix:nonFraction unitRef="shares" contextRef="ifdf6a41128b04e829699ee3d9fad57ea_D20230101-20230221" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzc2OTY1ODEzOTc4NTc_ac6ed0fd-baef-46c4-aedd-234e2c7609ec">not</ix:nonFraction> repurchase any shares.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on December 10, 2020, the Board terminated all remaining prior share repurchase authorizations available to the Company and approved a new share repurchase authorization of $<ix:nonFraction unitRef="usd" contextRef="i308dd243211b43dd8fa4201f3e66d956_I20201210" decimals="-3" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzc2NA_765f6451-24b4-4c21-bfab-087e30b9c5cc">2,000,000</ix:nonFraction>. Effective on December 17, 2021, the Board increased the Company's existing authorization by $<ix:nonFraction unitRef="usd" contextRef="ia42ecc99f0d34577b08bc4c77cf7a127_I20211217" decimals="-3" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzg2MA_df317954-76fb-4ae1-acaa-225044b617cb">2,000,000</ix:nonFraction>. The Company is authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;22, 2023, the Company has a total of $<ix:nonFraction unitRef="usd" contextRef="ie70bc0dc3fda4a9fa940a388d85df82f_I20230221" decimals="-3" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzEyNTg_c45dfe83-bcff-415e-8899-370a89696389">1,596,085</ix:nonFraction> available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company retired all shares held in its treasury effective as of December&#160;31, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i8031df24fcaf4bcc8279ef9c8eea95e6"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to <ix:nonFraction unitRef="shares" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzIxODE_623ee99c-e1be-4c28-86a9-f79934dab34a">5,000</ix:nonFraction> shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of <ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzI1ODM_b47ca5aa-6fa4-4626-bfbd-67edf569f074">three years</ix:nonNumeric> following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxODI_e5a3e4b9-cc5d-4cb6-90ee-32df4bbc584b" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:52.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItMS0xLTEtNDMyMzYx_de2d7441-2220-4ce4-9804-c367a5a66a6d">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItMy0xLTEtNDMyMzYx_1e27cf07-11f1-42bd-878f-6f6798f2ef4e">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItNS0xLTEtNDMyMzYx_d0011813-0b73-44a0-a5ec-5998d5ec36b9">773,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtMS0xLTEtNDMyMzYx_b165d718-ae7a-4724-91ef-ddcb41f3ae8b">6,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtMy0xLTEtNDMyMzYx_44406b95-8b5f-45f4-860e-b75f2dea4b99">13,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtNS0xLTEtNDMyMzYx_fed7b504-52f1-4893-9b1f-4ea7e794785b">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtMS0xLTEtNDMyMzYx_3d673bed-f156-469b-9d80-82198b074e2c">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtMy0xLTEtNDMyMzYx_a9cb9a6f-0cdb-40ba-a830-47d1288c75a1">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtNS0xLTEtNDMyMzYx_5968c276-1a1a-49f2-98b4-e45c1dc314b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtMS0xLTEtNDMyMzYx_4b17e67c-29db-4363-900d-c771fdd15a3b">5,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtMy0xLTEtNDMyMzYx_c15cf372-217a-45e0-abe2-f7deb6f87e40">14,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtNS0xLTEtNDMyMzYx_82ac4089-499b-4c3f-8d74-75894a3020b3">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctMS0xLTEtNDMyMzYx_18e3a188-0324-4b87-91a0-3d08a270b3af">554,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctMy0xLTEtNDMyMzYx_758402f7-f918-43f7-8bc3-c9c0641b5bae">964,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctNS0xLTEtNDMyMzYx_b9afc14f-342b-49b3-aa73-1a55ceaea42a">778,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxMzM_c6ee5cd0-4fdf-4c0e-9cce-0ba279342434">20,775</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxMzc_aa456ffa-3cd5-49e7-bbcc-7eb69c09d2ff">20,104</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxNDU_eddd8eb1-a763-4bf2-8274-8184b9797d08">7,831</ix:nonFraction> in 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_361"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI4OQ_09ea3546-d738-469a-a863-844ae1844193" continuedAt="i64bd3b4c352345529a700593ffd8fe3f" escape="true">Accumulated other comprehensive loss</ix:nonNumeric></span></div><ix:continuation id="i64bd3b4c352345529a700593ffd8fe3f"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI5MQ_2af86319-7f0f-472e-a6c1-98c54cf3f632" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99212cfd5b704e42ae8a23d830c5ab06_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtMS0xLTEtNDMyMzYx_7f54fd7a-ef13-4b1c-85a7-414a8042f1eb">1,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc4fb47b5503432094dda9552d7403d8_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtMy0xLTEtNDMyMzYx_175edc17-4230-4db7-ab2c-892ab27fe5d2">46,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b572b098200416eae5a1f8ac48e51d4_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtNS0xLTEtNDMyMzYx_02cfe3e6-d3ba-41f9-9f87-b6cc15988f56">47,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItMS0xLTEtNDMyMzYx_36c843bc-aca6-4de6-b188-98fa9604c066">21,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItMy0xLTEtNDMyMzYx_75abfaf2-e7ed-4310-b3a1-fb7d737af2d4">7,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItNS0xLTEtNDMyMzYx_93b3e5c9-154a-4360-a4ab-ee5bf6064398">28,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtMS0xLTEtNDMyMzYx_cf03eabb-d8c5-4984-ac5e-86605769f314">5,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtMy0xLTEtNDMyMzYx_0a23e1c1-89fa-47c0-b63f-5bc72f2a8a52">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtNS0xLTEtNDMyMzYx_04cb4db2-81f6-493e-9828-082061947eaa">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtMS0xLTEtNDMyMzYx_5685a8f3-8b96-4ace-b0ce-18172671c774">16,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtMy0xLTEtNDMyMzYx_f4d5a327-92d6-4b51-96fe-76f2b8dcdbb0">7,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtNS0xLTEtNDMyMzYx_cda5c507-cd0c-427f-bee7-1c6833437654">23,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtMS0xLTEtNDMyMzYx_0e666e5c-a3b7-4234-8c1b-ffd8ac03b97d">7,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtMy0xLTEtNDMyMzYx_ec73e8ef-0879-43ff-9955-706222d7e561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtNS0xLTEtNDMyMzYx_70435649-4fbe-4ca1-a503-3be8c4e1333e">7,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtMS0xLTEtNDMyMzYx_e1c87bb1-2535-48e9-9eec-8650fb576af0">1,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtMy0xLTEtNDMyMzYx_77d058e7-aa31-4b94-ab06-7cb5f43aaa9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtNS0xLTEtNDMyMzYx_1ed8388e-ffd3-4c7f-8cf4-17c699c9ac07">1,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctMS0xLTEtNDMyMzYx_066ae9a7-b8ed-405b-b513-dcd99ec42a20">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctMy0xLTEtNDMyMzYx_27b0c8d6-c814-42cf-b6b4-6e4e88eb57c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctNS0xLTEtNDMyMzYx_32109c6b-1bf2-4cb9-a045-1353b2b9922f">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a3e2cfd5fd0429fb8ec56a202d18e12_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtMS0xLTEtNDMyMzYx_64f22739-1b05-4334-8f7e-736a6995d69a">12,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8db34850cf9c4bd1bf445296b1937a89_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtMy0xLTEtNDMyMzYx_31d9021f-12e2-41b8-9e81-edf92b9c506f">53,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabc719a947474ef084095e5dfbf5b1c5_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtNS0xLTEtNDMyMzYx_ba4c2c41-6820-41d6-9cbd-ede53e57c48d">66,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktMS0xLTEtNDMyMzYx_3ab15561-215b-4ce7-b01d-c31b46c5a708">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktMy0xLTEtNDMyMzYx_d0155f5b-ddcd-40b7-a95a-a83acc66f1e9">83,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktNS0xLTEtNDMyMzYx_897cf786-0d1d-4d61-a516-309f984fbcdc">73,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTEtMS0xLTQzMjM2MQ_6f2fc800-89b1-489a-b94d-80f52c279a84">2,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTMtMS0xLTQzMjM2MQ_9873ffe1-0bff-412f-a77f-3ec6406596b9">1,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTUtMS0xLTQzMjM2MQ_b5076430-5d74-4936-b71a-7fe6b5eb57c5">3,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTEtMS0xLTQzMjM2MQ_c208a887-208a-4e39-8414-80e4c1eee74a">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTMtMS0xLTQzMjM2MQ_01163ba9-bf22-4dab-991c-f177a0ff5b3e">84,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTUtMS0xLTQzMjM2MQ_06f10b46-6090-415e-977e-f9a6752a039b">77,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTEtMS0xLTQzMjM2MQ_580af43c-5ac1-445d-ab0b-f2c4084f01a7">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTMtMS0xLTQzMjM2MQ_0ecc7d83-830b-4642-ae41-9f231b08c267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTUtMS0xLTQzMjM2MQ_e74a3192-eab8-4553-84ef-c6d9a65bfc71">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTEtMS0xLTQzMjM2MQ_23b397a1-911e-4269-b4a6-258773d9d827">1,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTMtMS0xLTQzMjM2MQ_be57997c-ac90-49c2-ae00-886b9d5db3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTUtMS0xLTQzMjM2MQ_dc33c44b-0ee0-4e3a-87fd-9bccaca76864">1,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTEtMS0xLTQzMjM2MQ_84718422-1c22-4043-a581-2f70da7eee76">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTMtMS0xLTQzMjM2MQ_d0fe3d70-3eb9-456a-86a5-f624ae7633b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTUtMS0xLTQzMjM2MQ_a1682b16-2ae7-4243-a537-363004eeed9e">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a8cf8431a94b6e8121190341001e59_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTEtMS0xLTQzMjM2MQ_efe4b43f-fd01-49da-95fe-88e807723db6">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43b284e90b0e45778d854e5fc253a04f_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTMtMS0xLTQzMjM2MQ_22521b74-940d-48c1-bfb2-a357af78c498">138,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8d50e013b4f49c4ba46a1b25f6ce76f_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTUtMS0xLTQzMjM2MQ_043a7844-d43d-4e81-bcb6-4edcd8fd6e3e">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTEtMS0xLTQzMjM2MQ_1f823ff5-6504-4d8f-ae61-836649aba8fe">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTMtMS0xLTQzMjM2MQ_4b5888c3-da96-433d-8e81-210b50d36534">30,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTUtMS0xLTQzMjM2MQ_e56ac574-f2b7-489c-9c77-6908187dbd45">114,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTEtMS0xLTQzMjM2MQ_7e76166d-c242-4710-9561-aa2a3339bc5d">36,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTMtMS0xLTQzMjM2MQ_acce7ac1-e7df-4894-bbd9-99effaed5947">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTUtMS0xLTQzMjM2MQ_0ddd7dcf-d891-4aaf-a32c-821c073e441f">35,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTEtMS0xLTQzMjM2MQ_21d489dc-af23-4167-af03-fc36322307c4">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTMtMS0xLTQzMjM2MQ_222a2042-0123-447c-8139-c79d7605ee40">29,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTUtMS0xLTQzMjM2MQ_a11a1895-5eb3-4c43-ab2a-e69f9684abc6">78,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTEtMS0xLTQzMjM2MQ_c94bbdf3-d93e-42ec-961f-0c488e854cc5">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTMtMS0xLTQzMjM2MQ_6dbdcf81-fd90-4503-abd4-bf99b9ee0533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTUtMS0xLTQzMjM2MQ_f0a7cddf-1ff9-4b44-b53c-db33cda16d1f">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTEtMS0xLTQzMjM2MQ_dc63e0b0-6e0d-4d84-9248-360b978433d6">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTMtMS0xLTQzMjM2MQ_0fe00f57-25b2-4196-9636-d556c030e855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTUtMS0xLTQzMjM2MQ_437d6229-f37b-4964-b059-f4cd406afa59">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTEtMS0xLTQzMjM2MQ_2225ee1a-bd27-412a-b9b1-6b3ea78b7cda">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTMtMS0xLTQzMjM2MQ_980ac5fa-3929-42a9-a2e0-42eb9aaa2ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTUtMS0xLTQzMjM2MQ_948a38d2-e78f-44c0-97b2-e4f6c06990c9">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a9b7a989584fa9b3645a2917356a30_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTEtMS0xLTQzMjM2MQ_1f99c7ba-843a-443b-b8e7-3faa59b8104a">98,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26689de70cd749e4bc3293f6430b6501_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTMtMS0xLTQzMjM2MQ_ac78fee3-08f7-4c70-8d25-8babdf912373">167,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c27b8943f04af2b168da521c4dad46_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTUtMS0xLTQzMjM2MQ_62158d4c-4be6-4168-a180-481b7dc3698b">69,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI5NA_3e7596bb-2f18-4091-8731-e75726d57a1f" escape="true">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</ix:nonNumeric> See Note 13 for further details.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_364"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzA_b7f8baa5-8458-4a64-b324-e13094f21b4c" continuedAt="i28b1049180694558b7ca9ed41da7b7c9" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="i28b1049180694558b7ca9ed41da7b7c9" continuedAt="id5c7a7263c7a4a40be108ba110c5d834"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Routine acquisitions</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzg_fccf831f-8f46-4558-a159-326431a04343" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the Company acquired dialysis businesses and other businesses, including a transplant software company, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"></td><td style="width:53.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItMS0xLTEtNDMyMzYx_ce3b0247-733a-4433-b123-250f1188ce66">57,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItMy0xLTEtNDMyMzYx_cb15a8ab-327a-4504-994a-1f656b36c654">187,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItNS0xLTEtNDMyMzYx_d5bce40b-4563-482f-992e-f4978bd11537">182,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtMS0xLTEtNDMyMzYx_3c7b70f2-c1ae-4e99-96f5-b952d761d943">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtMy0xLTEtNDMyMzYx_5b96e5d1-1449-4d64-8d9c-e0a10472ef17">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtNS0xLTEtNDMyMzYx_e739cd7d-bf12-46d9-8079-dc5a7158dd98">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtMS0xLTEtNDMyMzYx_3d16ccb2-ef32-4d53-95fd-3d4aba7ccb92">15,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtMy0xLTEtNDMyMzYx_47f025a0-461f-4c23-99ca-7a045e1b56f6">10,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtNS0xLTEtNDMyMzYx_7d187fa9-d34e-4b67-b216-dc0e5876d0da">20,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtMS0xLTEtNDMyMzYx_2f801f58-76cb-46e0-b1dc-fc2503e81761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtMy0xLTEtNDMyMzYx_31287fc3-caa6-4875-b4b6-1cde82b91ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtNS0xLTEtNDMyMzYx_9a3fa27d-9a4b-480d-98bd-bc3a7772bb78">1,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtMS0xLTEtNDMyMzYx_b6905540-a8fc-4e9d-8c9d-af8428accbd3">76,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtMy0xLTEtNDMyMzYx_fce342b4-fb81-4cd9-bd45-063f5c510674">212,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtNS0xLTEtNDMyMzYx_b607d6d5-658e-4819-9761-3efdfa7373aa">218,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i0e816800cdb849e580bc97b00a96ade9_D20220101-20221231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctMS0xLTEtNDMyMzYx_716097c8-5b9e-4b3d-a70d-867877c5a079">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i9679bed327fc47d683813151fab6f1c7_D20210101-20211231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctMy0xLTEtNDMyMzYx_c8686ce1-6e16-42cd-bf8d-dd0ad9906aa1">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i82caecf20efa484fb484a9604065ba79_D20200101-20201231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctNS0xLTEtNDMyMzYx_ade365a4-a51f-41e7-b7a6-3074f27aa978">8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i70356fef993349ccbcc20e9d53a0537d_D20220101-20221231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtMS0xLTEtNDMyMzYx_0a251739-96e7-4521-af76-8b0da757d22c">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i80e5796ea824458fa6ca00e78cc84d11_D20210101-20211231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtMy0xLTEtNDMyMzYx_0680966a-e67e-488b-b524-6ed6a4ad2788">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="i1e45f52112ed4e3c8f797f4c3e373333_D20200101-20201231" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtNS0xLTEtNDMyMzYx_7624d9fc-6a95-40c6-b43c-95aefaabfd82">66</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="id5c7a7263c7a4a40be108ba110c5d834" continuedAt="i64b9d686c61b4e01bcded507fd567bed"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2022 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzI_7bb02827-17c0-4647-932c-eec874b15165" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:52.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItMS0xLTEtNDMyMzYx_5af167b7-7fe0-4f6e-b07f-5d4200915ead">6,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItMy0xLTEtNDMyMzYx_82a698a5-a975-485f-b849-ac90a77f439a">9,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItNS0xLTEtNDMyMzYx_2df9d7a2-5aa0-44ca-a40c-0246c587b100">23,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtMS0xLTEtNDMyMzYx_4e18610d-d651-4761-9731-86283d51f7f7">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtMy0xLTEtNDMyMzYx_a5bedcb8-2b01-4f41-9af3-4df1d25aa84c">9,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtNS0xLTEtNDMyMzYx_98fa0512-14cb-4f4d-aa95-10af54e4d9d3">37,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtMS0xLTEtNDMyMzYx_b4c59ac0-707a-44e0-a400-4d2824d04e36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtMy0xLTEtNDMyMzYx_390dc4aa-7346-46ad-a80b-672848937ecc">17,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtNS0xLTEtNDMyMzYx_1f8cf6ed-1c40-4d32-86e9-b644d4a862c3">34,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtMS0xLTEtNDMyMzYx_77e2134f-e333-4f05-afb6-c2b90690e6ef">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtMy0xLTEtNDMyMzYx_a3a1e96b-6eb0-4e94-bf4d-2b932c53e966">9,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtNS0xLTEtNDMyMzYx_41bce88a-5710-47a7-b787-298f01a6ea2e">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtMS0xLTEtNDMyMzYx_8244ba19-fee3-4314-b549-339ab7ce8a02">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtMy0xLTEtNDMyMzYx_6ec31968-b93f-401c-9f27-6600cd920974">11,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtNS0xLTEtNDMyMzYx_1a0321e7-20e5-402f-b85e-95cc596470bb">22,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctMS0xLTEtNDMyMzYx_90a2916b-20e0-4b81-b6bb-c14976a11e8b">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctMy0xLTEtNDMyMzYx_cf50a936-866e-4735-a3fa-0b0488d95c70">173,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctNS0xLTEtNDMyMzYx_e5067bc0-ea9e-44a6-9d02-9796d3484c03">130,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtMS0xLTEtNDMyMzYx_afe31183-f73f-4f69-bf41-adf807a9c088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtMy0xLTEtNDMyMzYx_8e9dceae-e830-46c7-8f7d-97004d960e09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtNS0xLTEtNDMyMzYx_62612a31-8b63-4cf7-8d96-e6b8bf4cf451">3,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktMS0xLTEtNDMyMzYx_6a784050-9cdb-43a0-ab4c-be9cb82fbafd">6,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktMy0xLTEtNDMyMzYx_24195b94-418c-45cc-b1c5-a05544796649">14,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktNS0xLTEtNDMyMzYx_f4c4c8f1-2f1c-4f7a-987a-6731bc8e03c8">34,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTEtMS0xLTQzMjM2MQ_221938e4-14c0-45b3-8b5f-28c12c9e0e32">867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTMtMS0xLTQzMjM2MQ_c658f53f-237e-4587-8870-47a5ccd3482c">3,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTUtMS0xLTQzMjM2MQ_22a21901-761d-445b-a6e4-a48272ee867a">1,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTEtMS0xLTQzMjM2MQ_71c81e20-1ec1-4daf-976b-6da1973e4390">76,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTMtMS0xLTQzMjM2MQ_15a4048d-0f10-4e2d-b57b-8e64977fd8e1">212,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTUtMS0xLTQzMjM2MQ_3d13f4d1-5b50-41f4-945d-0ee75c67c72b">218,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwNDE_2e647c44-8dcb-48a6-801c-e01dad504e29" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2022, 2021 and 2020, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:56.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98c876b3393e45aaadb4d03fd8cb132a_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzMtMy0xLTEtNDMyMzYx_12c17565-c5b6-44da-91ea-5ee1fc93a125">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic68ddedfe24d4a9f821e723337f057fa_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzMtNS0xLTEtNDMyMzYx_d2456973-5a1d-4ffa-827e-dd773b919680">18</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1d9e6f88ef54849931ad26b2c3ccf31_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtMS0xLTEtNDMyMzYx_36e7e85f-b554-4eb2-a87f-bd346233068e">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1896d04bb1d34718b1f5a2d8398d5ca2_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtMy0xLTEtNDMyMzYx_7c1e4a06-3f51-40fd-b3ad-95266801a9cc">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iabeffcbc0b614275bf1f744a78a560d6_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtNS0xLTEtNDMyMzYx_df2d0b98-c4d1-4aa3-89a9-3dfcfddd7857">5</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtMS0xLTEtNDMyMzYx_20936701-7ffc-4c2a-9f25-a95dd1f6b190">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtMy0xLTEtNDMyMzYx_ab6ba0b8-b1a8-4606-aa8c-f16e0d587f26">169,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtNS0xLTEtNDMyMzYx_420f24d6-1271-49a6-ba83-401245fae8af">94,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMjg_4153a927-95e2-41e5-8005-c4319e910839" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2022 and 2021 had been consummated as of the beginning of 2021, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:62.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzMtMS0xLTEtNDMyMzYx_173ff227-3d31-41e9-a327-70ac3a451193">11,624,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzMtMy0xLTEtNDMyMzYx_dde19100-6286-4b73-bc5b-0cc512355af7">11,706,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzQtMS0xLTEtNDMyMzYx_8108fb26-dc5b-416d-853f-3b536149dfda">545,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzQtMy0xLTEtNDMyMzYx_ed9b9181-acce-4ae8-b0b3-95c2078e9d81">984,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzUtMS0xLTEtNDMyMzYx_c1b551bb-bdd2-4cea-b37d-84d1e8a6b49f">5.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzUtMy0xLTEtNDMyMzYx_caf9c2e9-13ff-41b9-9713-1dc901c8c3bc">9.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzYtMS0xLTEtNDMyMzYx_d9dd8a4c-bbd2-453e-ba8d-a01631de3796">5.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzYtMy0xLTEtNDMyMzYx_13798c3b-47f9-4f72-80f2-8966d884b241">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of RMS Lifeline</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company divested its prior vascular access business, RMS Lifeline, Inc., effective May 1, 2020 and recognized a loss on sale of approximately $<ix:nonFraction unitRef="usd" contextRef="idc0d0c8670b74d7aaae012b57540676b_D20200501-20200501" decimals="-3" name="us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzIwOTc_63dbef9a-17a6-4f9d-8e6d-c5b3bda20847">16,252</ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i64b9d686c61b4e01bcded507fd567bed" continuedAt="i0d5bdfcf658040cfb18f82c3f5574494"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3Mzk_0698cfe7-81f2-44ec-9c59-d7ec7aec1978">58,947</ix:nonFraction> if certain performance targets or quality margins are met over the next <ix:nonNumeric contextRef="ia19082384d6a4829ab61b3ab014ad7e9_D20220101-20221231" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzIzOTc_88db0e4e-b3d3-4e63-b463-d33c0b5b430b">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="if4f53c09daa64d04b0b10d609326db79_D20220101-20221231" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzI0MDM_972d62e0-a245-416c-857a-9a9bce414c71">five years</ix:nonNumeric>. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 24 for further details. As of December&#160;31, 2022, the Company estimated the fair value of these contingent earn-out obligations to be $<ix:nonFraction unitRef="usd" contextRef="ida34ede3bf60405f897e4559cf454b17_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3NDQ_5c74c606-52d9-45c2-9582-c5a57b61e800">25,422</ix:nonFraction>, of which a total of $<ix:nonFraction unitRef="usd" contextRef="id450bd55eefa4117ababbc01a3cfbd33_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3MzM_87e70ddc-76da-4b6f-96c3-3a9a8a2b5404">11,308</ix:nonFraction> is included in other current liabilities, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i5f6457f2f67848de859ac828fdbb8f3e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3Mjg_63b10018-580f-4bc1-ac2f-71c9309dd6c8">14,114</ix:nonFraction> is included in other long-term liabilities in the Company&#8217;s consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwNDU_10845a42-0d71-4bcb-a4df-499a610523e0" continuedAt="i6c9fbb7949fd478bb6b9624b2330163d" escape="true">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2022 and 2021:&#160;</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="i0d5bdfcf658040cfb18f82c3f5574494"><ix:continuation id="i6c9fbb7949fd478bb6b9624b2330163d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzItMS0xLTEtNDMyMzYx_e69b0b74-9d8c-41e6-93c7-c2531a8bab35">33,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzItMy0xLTEtNDMyMzYx_b27fb64e-8066-4e94-809d-76ab0bdb69f2">30,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzMtMS0xLTEtNDMyMzYx_69538b15-b763-4681-9dac-1684d8b820f8">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzMtMy0xLTEtNDMyMzYx_c1b54980-a22b-46bb-859a-44cbfda921a1">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzQtMS0xLTEtNDMyMzYx_2b23dfa7-c9c4-4de8-a301-1e02ad08e690">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" sign="-" name="dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzQtMy0xLTEtNDMyMzYx_5652d48f-f853-44bd-b8f6-fa3350350cbf">1,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzUtMS0xLTEtNDMyMzYx_5a561bb0-ef27-4e8e-9f16-bc1ffae598f1">5,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzUtMy0xLTEtNDMyMzYx_21a847eb-dd2e-410a-898e-d89b91a9bb60">1,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzYtMS0xLTEtNDMyMzYx_ae9c09a9-180b-48d4-8116-52985caf24e5">7,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzYtMy0xLTEtNDMyMzYx_47bde8ba-6c5f-40d9-b3d6-4b1388eef9b8">8,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzctMS0xLTEtNDMyMzYx_d7a1fedf-98b4-4450-ac06-6a8f0f1216f3">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947410d04b404a509e32155ef061b479_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzctMy0xLTEtNDMyMzYx_1067a283-3124-45e4-8523-ea5221a6c161">33,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib228226ec511491b87b183c6d217a21a_367"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzI0NDQ_69e65536-a782-4df1-973c-ade09ea71094" continuedAt="i9e31c5d53ef14d34a7d76deb7f816b2e" escape="true">Discontinued operations previously held for sale</ix:nonNumeric></span></div><ix:continuation id="i9e31c5d53ef14d34a7d76deb7f816b2e"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i1c251fa7a54142a9973f90b0af23a71a_D20190619-20190619" name="dva:BusinessSaleEffectiveDateOfSale" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzg4_1aa71c19-b712-4f87-9f20-902607cd97ac">June&#160;19, 2019</ix:nonNumeric>, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December&#160;31, 2022, Optum made an additional purchase price payment of $<ix:nonFraction unitRef="usd" contextRef="ifc2f49e543f14e95b6a4a28258a7479f_D20220101-20221231" decimals="-3" name="dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzQzOTgwNDY1MTQxODM_bb994b96-386f-49f2-9155-67a4af5457a3">13,452</ix:nonFraction> to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. Upon resolution of certain prior post-closing adjustments with Optum in 2020, the Company recognized an additional loss on sale of $<ix:nonFraction unitRef="usd" contextRef="ib5e67f2857a248e185adf3684768570e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzQzOTgwNDY1MTU2Mzg_ae96d771-950f-401e-bc46-ef2432fe95b1">17,976</ix:nonFraction>, which was partially offset by $<ix:nonFraction unitRef="usd" contextRef="i55269373013d4ffc8c433eda840a84cd_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzE0MjY_ba1d9aa1-889a-4f34-92e8-fcf3ca83051a">9,980</ix:nonFraction> in additional tax benefits recognized under the Coronavirus Aid, Relief and Economic Security Act related to the Company's period of DMG ownership, and a related income tax benefit to the Company of $<ix:nonFraction unitRef="usd" contextRef="ib5e67f2857a248e185adf3684768570e_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzIzNjM5NTAwMDAyNjE3_e93d21e6-ee5e-41f3-b5f4-3e95e9ff15db">1,657</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzcxNDY4MjU1ODU3MDI_0a0a7dff-dd24-434a-bba5-f6dc68361432">no</ix:nonFraction> DMG operating, financing or investing cash flows for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_370"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzMyNDU_b31d128e-4d88-43f6-b037-c303aa5cfc55" continuedAt="i19ff8a06783e4ffcac8f23153fc8dafc" escape="true">Variable interest entities</ix:nonNumeric></span></div><ix:continuation id="i19ff8a06783e4ffcac8f23153fc8dafc" continuedAt="i2f3ff92d1b6d488d9548750f91ede9f4"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzMyNDc_98cd08fb-e49b-4624-b83b-fca80f2d2601" continuedAt="iec2c2e92ac634ee988a61ce799d47a03" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i2f3ff92d1b6d488d9548750f91ede9f4"><ix:continuation id="iec2c2e92ac634ee988a61ce799d47a03"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company wholly owns but does not wholly control these entities. However, the Company believes it has the most power over these entities' most significant activities, and the Company is fully exposed to their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, <ix:nonFraction unitRef="clinic2" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="0" name="dva:NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzc2OTY1ODE0MDM5MTA_1ed2033c-9de3-402a-8c69-376b1309d4b6">one</ix:nonFraction> of the Company's business units relies on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $<ix:nonFraction unitRef="usd" contextRef="ibc02c497e38f44dc90b9f84485fef045_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzI1NzU_84859472-f3df-4b02-bc63-252fe80be297">316,639</ix:nonFraction> and total liabilities and noncontrolling interests to third parties of $<ix:nonFraction unitRef="usd" contextRef="ibc02c497e38f44dc90b9f84485fef045_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzI2NDk_3023105a-97eb-4a98-86e5-2cc58f04b1b4">191,357</ix:nonFraction> at December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 5 and 15 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_373"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzQyNDg_d69aadb2-37b6-439f-ada9-664635569a6b" continuedAt="ic4d4d60e05dd4a018dddd732b8ca32a4" escape="true">Fair values of financial instruments</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4d4d60e05dd4a018dddd732b8ca32a4" continuedAt="i664cd115293740a58f6506ccfc4715d8">The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i664cd115293740a58f6506ccfc4715d8" continuedAt="i00727c3dd5104d68aea56ebe5c19398c"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzQyNTQ_3a20a377-58ef-47f6-b2c5-e3e98cab7017" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItMS0xLTEtNDMyMzYx_83d3f416-8caf-4aea-8dc4-293a93ca4bfd">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItMy0xLTEtNDMyMzYx_e7fc20f0-4aeb-4424-a356-c07e4c60e897">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItNS0xLTEtNDMyMzYx_8506e270-79a9-483b-b6bb-32261429bab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItNy0xLTEtNDMyMzYx_f53d5e21-f691-4e9d-b29e-9788ba9f9854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046167613ae64ec19f2ed82f74f07980_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtMS0xLTEtNDMyMzYx_a47e65f1-25cc-499c-8b94-d6f74528615a">139,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f207592fe4649a4ad1c7bf0d4621f61_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtMy0xLTEtNDMyMzYx_e5e9e161-6fbe-488e-9cd3-9d34cb189600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1beaedb6546c7b32d23163c1577ab_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtNS0xLTEtNDMyMzYx_fef8ab4f-6b71-460e-b742-410e8657c14e">139,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717705e768d484989644fafcac6b11f_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtNy0xLTEtNDMyMzYx_619256eb-d25b-4351-b8e2-9521cc0c4770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtMS0xLTEtNDMyMzYx_d8747771-ed2c-4416-8e9c-b035d14df9e8">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtMy0xLTEtNDMyMzYx_bd4c60d7-1056-4764-a7fd-9f530e9e1859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtNS0xLTEtNDMyMzYx_d5c3e534-9487-4d65-b90d-8930f295ae38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtNy0xLTEtNDMyMzYx_239a214c-4f69-442f-ad8e-acb37c28d20d">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctMS0xLTEtNDMyMzYx_083a38e8-c293-45ca-9fc4-23b8c00ba278">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctMy0xLTEtNDMyMzYx_7c2275a9-f72b-41b5-8947-ca4a1c08fad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctNS0xLTEtNDMyMzYx_3b63b841-748b-40d1-8a25-c3d3c3efb1d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctNy0xLTEtNDMyMzYx_ac5e4d86-f045-43cd-8366-5a45c4de367e">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTEtMS0xLTQzMjM2MQ_17ff0d63-3eaa-44e1-9741-e458c1686374">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d883f152f344fb4961979059e6695af_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTMtMS0xLTQzMjM2MQ_97bbb32e-43f1-4def-951d-4e444b9dcab5">48,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTUtMS0xLTQzMjM2MQ_aab11dae-c873-4468-ac44-7b6b1210be97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTctMS0xLTQzMjM2MQ_d9c55095-1988-4557-9b7d-dc5638a9c09a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0935c6e63e743ba9aba751b24c6f1de_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTEtMS0xLTQzMjM2MQ_66f7e702-7e20-49c8-a22a-7d0d439219ef">12,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5df7fafeef499c84ae47517afbb88c_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTMtMS0xLTQzMjM2MQ_948c6fb8-2f90-4c55-b6b2-3363fd878663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2dfed1ea6e4e64a2d2a32df8448e91_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTUtMS0xLTQzMjM2MQ_5db12087-2b3f-47b4-aee3-6329fa575764">12,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde9a8c8bca04d5b852b3c6a3f47238c_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTctMS0xLTQzMjM2MQ_562f86fb-9a96-4699-a393-6194bc57a8a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTEtMS0xLTQzMjM2MQ_3eb084b3-4d71-4f9a-9c66-b4123a03f1cd">33,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d883f152f344fb4961979059e6695af_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTMtMS0xLTQzMjM2MQ_b899eabe-1922-41d5-9436-cfc6ec26e847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTUtMS0xLTQzMjM2MQ_a166d2ba-c97b-4383-aefb-d32d16269258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTctMS0xLTQzMjM2MQ_2a427f56-0c7a-4d63-9f0d-655f1fe8ac39">33,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTEtMS0xLTQzMjM2MQ_b8c16009-64c9-49d2-9c1d-f4bb67f505a5">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d883f152f344fb4961979059e6695af_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTMtMS0xLTQzMjM2MQ_ba275f75-eca0-4d65-83a6-a12b964fe5e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTUtMS0xLTQzMjM2MQ_aebe1fbe-4e83-4852-b41d-6e29ae7a03c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTctMS0xLTQzMjM2MQ_401123c4-3f05-44f5-9596-7dd76452bf46">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For reconciliations of changes in contingent earn-out obligations and noncontrolling interests subject to put provisions during the year ended at December&#160;31, 2022 and 2021, see Note 21 and the consolidated statements of equity, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 5 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 13 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 21 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2022, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $<ix:nonFraction unitRef="usd" contextRef="ib664746092484ebf93084b60e56443b0_D20221231-20221231" decimals="-3" name="dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzM0MjE_cfedd12e-a0a9-4171-a54a-a1fd2f3801be">168,000</ix:nonFraction>. See Note 17 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 13 for further discussion of the Company's debt. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00727c3dd5104d68aea56ebe5c19398c">Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2022 and 2021 at their approximate fair values due to the short-term nature of their settlements.</ix:continuation></span></div><div id="ib228226ec511491b87b183c6d217a21a_376"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTU_4fd8cc54-ba5c-48d4-acee-5bc6a0807893" continuedAt="iee90b8b6654f4c74810a22ced2bb9e80" escape="true">Segment reporting</ix:nonNumeric></span></div><ix:continuation id="iee90b8b6654f4c74810a22ced2bb9e80" continuedAt="idcc357c192384586be3c4552af7cae4b"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i9d3ac6f3c4f74f8ea1b571333627e886_D20190619-20190619" name="dva:BusinessSaleEffectiveDateOfSale" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzQ0OA_8281586d-855c-496f-99b3-b6eb01f9abf2">June 19, 2019</ix:nonNumeric>, the Company completed the sale of its prior DMG business to Optum. As a result of this transaction, DMG's results of operations have been reported as discontinued operations for all periods presented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, and its equity method investment in the APAC joint venture. The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial performance of the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to all of the Company&#8217;s various operating lines of business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="idcc357c192384586be3c4552af7cae4b" continuedAt="i6ca718b898b849538f0a1e3a7818700c"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTE_2f531efb-e044-4486-8827-6caa42588366" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtMS0xLTEtNDMyMzYx_5c493ddc-3588-41ec-8201-dd709c61540e">10,488,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtMy0xLTEtNDMyMzYx_e9b25565-564f-4ee1-a7bf-ffde300be5f3">10,551,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7536f3521c54e9294023219e56f7c64_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtNS0xLTEtNDMyMzYx_88ad61a0-1e19-4883-9fda-eb6406e1a152">10,475,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtMS0xLTEtNDMyMzYx_1a31a45a-e74b-4fba-9262-3c4094ed596f">87,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtMy0xLTEtNDMyMzYx_d0447951-b0d0-474c-a74d-e10fec6d83a6">90,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtNS0xLTEtNDMyMzYx_ca462fad-c73d-4a84-b67a-49245077ac8d">144,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctMS0xLTEtNDMyMzYx_c35a0471-da8f-46e5-bda9-5c5e9394741b">10,575,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctMy0xLTEtNDMyMzYx_7bff6fe7-2936-4a91-91b9-1ca45d762513">10,641,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctNS0xLTEtNDMyMzYx_e1c4143c-9348-465e-937d-e31c2bb6ffa3">10,619,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktMS0xLTEtNDMyMzYx_39036bd8-c8e9-48c8-8db2-fa032d641f09">24,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktMy0xLTEtNDMyMzYx_cfd9e2ac-81fd-4398-bb3a-de39ae449cad">25,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7536f3521c54e9294023219e56f7c64_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktNS0xLTEtNDMyMzYx_f60fae0b-a172-40ae-8aaa-736b137ff435">39,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTEtMS0xLTQzMjM2MQ_ef188418-3fe8-4834-9427-b19b2bad5d57">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTMtMS0xLTQzMjM2MQ_da02ccde-1b4d-4cd8-b831-729cf63c60ca">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTUtMS0xLTQzMjM2MQ_b5b7e02a-73ee-4fc2-b0ce-24c9a8d11788">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTEtMS0xLTQzMjM2MQ_854ad6bf-b895-4dea-be49-a4379e09a9c9">10,599,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTMtMS0xLTQzMjM2MQ_f4b2c4d9-5295-430a-a126-8324be082c64">10,666,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTUtMS0xLTQzMjM2MQ_92d4ccdf-09fc-4983-b222-85147b39d539">10,659,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTEtMS0xLTQzMjM2MQ_f7851abb-cf02-46d0-b78e-cbd3bdcd939f">688,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTMtMS0xLTQzMjM2MQ_f72000f6-0803-4f5c-b07e-07be06292b0b">662,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTUtMS0xLTQzMjM2MQ_a68e13de-ccc9-4b45-a755-f8bc93a9a29f">550,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTEtMS0xLTQzMjM2MQ_a74b0c49-022e-4d89-9923-434f6d2982ed">408,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTMtMS0xLTQzMjM2MQ_b25c5c60-1dbd-442b-b53d-de4359deee96">380,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTUtMS0xLTQzMjM2MQ_04344502-cb89-4056-8368-90be88659dbe">484,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8067c67e4837babe07d810db9729_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTEtMS0xLTQzMjM2MQ_30d45efb-f5e0-4284-852f-ba8d89306af0">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac2a354bfd74090958bcef5319b2038_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTMtMS0xLTQzMjM2MQ_d912baea-b873-4346-94f8-eb5d7f7f4392">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea4a40bae848aca9676ecbe296c2bb_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTUtMS0xLTQzMjM2MQ_af432ced-91f6-402a-ad46-8cbe73085019">16,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTEtMS0xLTQzMjM2MQ_625b498e-a77d-4284-93f8-7bfe9d5b03d0">1,101,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTMtMS0xLTQzMjM2MQ_5e549e21-dd0d-4fab-bcda-5b63a90eea83">1,046,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTUtMS0xLTQzMjM2MQ_acea0e9a-a2d1-4741-8097-dfcae8f71922">1,052,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTEtMS0xLTQzMjM2MQ_0664af98-ad9e-4726-839b-1ddffb3685b3">11,701,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTMtMS0xLTQzMjM2MQ_6b288d0b-7c7f-40e4-948f-b8007ba5665e">11,713,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTUtMS0xLTQzMjM2MQ_f0500c55-bd43-4a3a-bb8e-ad2b5ec8cd09">11,712,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTEtMS0xLTQzMjM2MQ_dbfc0df7-e2e8-49ab-8a94-3710926431ad">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTMtMS0xLTQzMjM2MQ_415869a3-11e6-4ad2-be52-0966e072ed94">95,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTUtMS0xLTQzMjM2MQ_a8c7fd70-3112-44bd-9152-ae702bd8d597">162,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTEtMS0xLTQzMjM2MQ_add396db-c08e-4059-9168-17630fabc03b">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTMtMS0xLTQzMjM2MQ_b5efb199-bcd6-476f-9d4a-ae1cfcbaff3e">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTUtMS0xLTQzMjM2MQ_a67e81a5-49b5-4915-ba15-3167a2ca5ca1">11,550,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTEtMS0xLTQzMjM2MQ_34b3e0f1-a79e-4c0c-b3b0-5041c79de087">1,565,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTMtMS0xLTQzMjM2MQ_aedea622-2896-49eb-a119-c4c552c9e869">1,974,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTUtMS0xLTQzMjM2MQ_1731c4ec-0d30-4d6b-ad38-5f80325298f9">1,917,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTEtMS0xLTQzMjM2MQ_e155f6ea-80ca-45ae-ada6-3a00c60f18ea">96,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTMtMS0xLTQzMjM2MQ_3701bc95-3e03-42a0-9dbd-e7d674415b59">66,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTUtMS0xLTQzMjM2MQ_aa7e5771-b916-4678-8f12-d9c6e2c403d0">76,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTEtMS0xLTQzMjM2MQ_b19eb193-6817-48e9-bddf-e66c98b8a2f9">1,468,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTMtMS0xLTQzMjM2MQ_ecbf1503-b8d5-4879-9dca-e5fa0d55daf7">1,908,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTUtMS0xLTQzMjM2MQ_4537563e-a543-4cc8-8c9f-f8ee006d82f9">1,841,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTEtMS0xLTQzMjM2MQ_6ed37481-5265-4b1e-9a3c-fff2eb8c1758">129,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTMtMS0xLTQzMjM2MQ_10227f03-fa30-4bda-8cc9-c7c7900b7742">111,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTUtMS0xLTQzMjM2MQ_0b31253c-c2e3-42fa-a5dd-b85fe578507f">146,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTEtMS0xLTQzMjM2MQ_b92b4f98-1a05-4b48-acbd-c08e105e8745">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTMtMS0xLTQzMjM2MQ_59538317-96b7-487d-8103-ebfbbdb9e664">1,797,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTUtMS0xLTQzMjM2MQ_864d2b80-d8b2-437d-8c6b-9544cb05986f">1,694,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTEtMS0xLTQzMjM2MQ_174b2be3-c97d-4959-af15-d59ea5dbe31c">357,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTMtMS0xLTQzMjM2MQ_3dac5cb4-056d-40ac-aed7-0ef2b971156c">285,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTUtMS0xLTQzMjM2MQ_fe3a0805-825e-4f60-a022-d8e7a9f76937">304,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, refinancing and redemption charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTEtMS0xLTQzMjM2MQ_d32061e7-8d2a-4a2c-be84-8cc4c2d48993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTMtMS0xLTQzMjM2MQ_43e84d1b-92a8-483b-8fb9-5020fce55a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="dva:DebtPrepaymentRefinancingRedemptionCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTUtMS0xLTQzMjM2MQ_6d42a569-ae9f-4751-af0c-51414ed29561">89,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTEtMS0xLTQzMjM2MQ_a7fbaa39-18c8-4143-9606-4cebd59435c0">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTMtMS0xLTQzMjM2MQ_c11ce9a5-2ec4-4534-9266-5f23065eb8e9">6,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTUtMS0xLTQzMjM2MQ_405739fb-903e-4059-97e2-65f676fdc113">16,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTEtMS0xLTQzMjM2MQ_29d801c7-876c-4759-acec-b6dabe8a2660">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTMtMS0xLTQzMjM2MQ_f1c8450c-4399-448e-a8c8-0c2232bc9e3d">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTUtMS0xLTQzMjM2MQ_773dd8a4-2945-4f56-9930-05fc28e62c75">1,318,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity investment income of $<ix:nonFraction unitRef="usd" contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MjE_6d029ae2-e3b0-4fbb-ac27-7ed854318e5a">1,898</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MjU_529d0e11-fe75-48e8-a2bb-372dacef0575">3,177</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MzM_32f2bf39-28da-4737-a24f-39f623da745d">5,866</ix:nonFraction> in 2022, 2021 and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMDg_ffeedbe6-aeda-42c6-9cd0-0fe16b44e88f" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItMS0xLTEtNDMyMzYx_2919b2fd-ed0b-4faf-9e14-0b0090a50694">690,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItMy0xLTEtNDMyMzYx_cf44e902-7abc-495f-8a06-dc6eed065baa">642,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItNS0xLTEtNDMyMzYx_f7383b32-cbd0-4a31-81eb-9e1cc4a15490">594,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtMS0xLTEtNDMyMzYx_a59d38fd-0f99-4d9e-9e97-8c61d78e94c5">41,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtMy0xLTEtNDMyMzYx_74906ac3-b6cd-49c0-8fdc-23fdd92c8f92">37,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtNS0xLTEtNDMyMzYx_660d61ff-f485-4179-ae2c-edeb5a5c457b">35,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtMS0xLTEtNDMyMzYx_389fc2bf-cc75-412d-9130-f7cf9858be8d">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtMy0xLTEtNDMyMzYx_4a9b388a-9719-4b6c-b610-054fa044f805">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtNS0xLTEtNDMyMzYx_3457e8e0-0eb0-412c-a467-1f3246cd6bf3">630,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6ca718b898b849538f0a1e3a7818700c"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTI_ac66d93c-8552-4dbd-8695-fa3388a6c3e4" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItMS0xLTEtNDMyMzYx_7e0c4148-d0c5-44ad-9dc3-9c399c06f247">533,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItMy0xLTEtNDMyMzYx_027e243a-d275-4842-a5cb-2780954d0284">589,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItNS0xLTEtNDMyMzYx_203873cd-3546-444c-bc09-80622943ed39">646,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtMS0xLTEtNDMyMzYx_1a7c93d2-70a8-4e32-a753-22b8a1c10106">69,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtMy0xLTEtNDMyMzYx_ed71baae-d449-4213-8eeb-d7908ef4a47e">51,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtNS0xLTEtNDMyMzYx_8268ae98-16a1-4e7b-9190-b3a4bd0b2f05">27,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtMS0xLTEtNDMyMzYx_3b653394-ff17-4360-b739-a77ff0ccab81">603,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtMy0xLTEtNDMyMzYx_ed4dbf21-ec15-4d11-aa64-0d2181001ea1">641,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtNS0xLTEtNDMyMzYx_fd3013a6-1ab5-400b-b616-7815635f8eaa">674,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTM_b9c191b3-50c4-4989-b5b6-e088592afc6f" escape="true"><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary of assets by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:58.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzMtMS0xLTEtNDMyMzYx_5f3a0c28-41f2-4bbd-94b4-179e619fb17e">15,084,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzMtMy0xLTEtNDMyMzYx_0e47c6b4-0e56-44c4-a36a-f0c23f6c44bc">15,375,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzQtMS0xLTEtNDMyMzYx_7d34f0b4-e955-4b0a-9912-21978e2ce7e8">1,843,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzQtMy0xLTEtNDMyMzYx_cbf10b25-3fb0-4c9c-9b46-666a0e7023ac">1,746,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzUtMS0xLTEtNDMyMzYx_601c7587-3e3f-44c2-b7b5-0013419c991b">16,928,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzUtMy0xLTEtNDMyMzYx_9523dc4c-66b9-407a-974e-10a640bae9ac">17,121,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $<ix:nonFraction unitRef="usd" contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI4Mzg_3ab320ac-e699-4180-a90e-0ec338410488">113,781</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI4NDU_0d145c08-212f-4fea-9f20-d2d295fcfabe">112,500</ix:nonFraction> in 2022 and 2021, respectively. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $<ix:nonFraction unitRef="usd" contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5MjU_12d39cfb-8b92-40af-a757-04ddb770cb12">117,327</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5MzI_18e34de2-3f78-452f-8fdd-06de2d448e9f">126,381</ix:nonFraction> in 2022 and 2021, respectively and includes approximately $<ix:nonFraction unitRef="usd" contextRef="i472575aaaeaa4644bf500b85f08f09c2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5ODk_77b2df1e-e6d7-4498-a989-e2a8d7831810">207,162</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i850cdf3eed294766a58ed299ab32d0dc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5OTY_cbec6d74-b6c1-4adc-8b75-93fa76aed667">190,029</ix:nonFraction> in 2022 and 2021, respectively, of net property and equipment related to the Company&#8217;s international operations.</span></div></ix:nonNumeric></ix:continuation><div id="ib228226ec511491b87b183c6d217a21a_379"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">26.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90ZXh0cmVnaW9uOjdmOTNjMmUxYjUzMzRjNDY4MmFkYjA4Yjg4NzNhOTk1XzEwNg_2417337a-5e4a-4590-9b28-ed3292e9315b" continuedAt="i9f4015eb84c845028431ecd4ec47c382" escape="true">Supplemental cash flow information</ix:nonNumeric></span></div><ix:continuation id="i9f4015eb84c845028431ecd4ec47c382"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90ZXh0cmVnaW9uOjdmOTNjMmUxYjUzMzRjNDY4MmFkYjA4Yjg4NzNhOTk1XzExMQ_1a3b9419-c45d-4f55-89cf-dbf4219df541" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtMS0xLTEtNDMyMzYx_b38e93fb-3fc7-42de-9ce0-ce3f3031abd7">344,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtMy0xLTEtNDMyMzYx_f8cc3f23-a013-46e5-a294-b01a00063a99">209,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtNS0xLTEtNDMyMzYx_b98de2b8-4060-49f5-a88e-3eff1a73b1c4">154,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtMS0xLTEtNDMyMzYx_1e90923a-f898-49ee-bd14-19273e0d4f0f">350,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtMy0xLTEtNDMyMzYx_07d3b211-e5b3-4a8e-9379-1adb3ab415dd">279,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtNS0xLTEtNDMyMzYx_c7536df6-aee9-445e-9a00-eae266f0c08a">326,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtMS0xLTEtNDMyMzYx_49bf87fd-fa71-48c9-9f71-1bcd57874323">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtMy0xLTEtNDMyMzYx_5ce7537c-0359-4665-b2b3-1bdf91044b05">31,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtNS0xLTEtNDMyMzYx_763b7658-4f4a-42f7-8eeb-11cedc689082">22,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_382"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312517362136/d496893dex101.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated.(2)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312518280459/d621366dex101.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 dated as of September 20, 2018, to that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., a Delaware corporation, Collaborative Care Holdings, LLC, a Delaware limited liability company and a wholly owned subsidiary of Optum, Inc., and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated, a Delaware corporation.(14)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312518350364/d658923dex101.htm">2.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to Equity Purchase Agreement by and between DaVita Inc., a Delaware corporation, and Collaborative Care Holdings, LLC, a Delaware limited liability company, dated as of December 11, 2018, amending that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and, solely with respect to Section&#160;9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated (as previously amended).(9)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000156459016027049/dva-ex31_1170.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of DaVita Inc., as filed with the Secretary of State of Delaware on November 1, 2016.(1)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706622000160/ex31-amendedandrestatedbyl.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws for DaVita Inc. adopted on October 14, 2022.(23)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 4.625% Senior Notes due 2030, dated as of June 9, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 4.625% Senior Notes due 2030 and related Guarantee (included in Exhibit 4.1).(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 3.750% Senior Notes due 2031, dated August 11, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(11)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 3.750% Senior Notes due 2031 and related Guarantee (included in Exhibit 4.3).(11)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex45.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000137/ex1012019creditagreement.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, Credit Agricole Corporate and Investment Bank, JPMorgan Chase Bank, N.A. and MUFG Bank Ltd., as co-syndication agents, Bank of America, N.A., Barclays Bank PLC, Credit Suisse Loan Funding LLC, Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and Suntrust Bank, as co-documentation agents, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(16)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex103.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment, dated as of February 13, 2020, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519123788/d726706dex101.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated as of April 29, 2019, by and between Javier J. Rodriguez and DaVita Inc.(10)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#sE0D95A9952875B7195329C9BDDFC0BDC">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Appreciation Rights Agreement, effective November 4, 2019, by and between Javier J. Rodriguez and DaVita Inc.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1013_1293.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective February 21, 2017, by and between DaVita Inc. and Joel Ackerman.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000162828017004680/dva-33117ex102.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 27, 2016, by and between DaVita HealthCare Partners Inc. and Kathleen A. Waters.(4)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 1 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex1021.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 29, 2015, by and between DaVita HealthCare Partners Inc. and Michael Staffieri.(20)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312506257237/dex101.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(8)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312505041002/dex1028.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(5)*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1016_1294.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Deferred Compensation Plan.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000104746916013062/a2228594zdef14a.htm#du73201_stockholder_proposals_for_2017_annual_meeting">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan.(18)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706621000166/dva-93021ex101x2021davitai.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Severance Plan for Directors and Above.(3)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1014-nonxemployeedirecto.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Non-Employee Director Compensation Policy.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312514163315/d701196ddef14a.htm#toc701196_76">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(7)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#s443F0CA95E025906867096037A067CF7">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to the Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000064/dva-123119xdef14a.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. 2020 Incentive Award Plan.(21)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706618000167/exhibit102.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Rule of 65 Policy, adopted on August 19, 2018.(15)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706618000165/dva-63018xex101.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Board members (DaVita Inc. 2011 Incentive Award Plan).(24)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312513085450/d465470dex1061.htm">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(12)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312513085450/d465470dex1062.htm">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Long-Term Incentive Program Award Agreement (For 162(m) designated teammates) (DaVita Inc. 2011 Incentive Award Plan).(12)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312513085450/d465470dex1063.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Long-Term Incentive Program Award Agreement (DaVita Inc. 2011 Incentive Award Plan).(12)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d22.htm">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d23.htm">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d24.htm">10.24</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d25.htm">10.25</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d26.htm">10.26</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d27.htm">10.27</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d31.htm">10.28</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d32.htm">10.29</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d33.htm">10.30</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1031-formperformancecash.htm">10.31</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Award Agreement (DaVita Inc. 2020 Incentive Award Plan).</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.973%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of our subsidiaries.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of KPMG LLP, independent registered public accounting firm.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib228226ec511491b87b183c6d217a21a_385">24.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Powers of Attorney with respect to DaVita Inc. (Included on Page S-1).</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex31110xk.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;22, 2023, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex31210xk.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;22, 2023, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex32110xk.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;22, 2023, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123122ex32210xk.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;22, 2023, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in this filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or executive compensation plan or arrangement.</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on November 2, 2016 as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 6, 2017 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on October 28, 2021 as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on May 2, 2017 as an exhibit to the Company&#8217;s Quarterly Report on 10-Q for the quarter ended March 31, 2017.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on March 3, 2005 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2004.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on February 24, 2017 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on April 28, 2014 as an appendix to the Company's Definitive Proxy Statement on Schedule 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 20, 2006 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 17, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 29, 2019 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 11, 2020 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on March 1, 2013 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 3 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on June 9, 2020 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on September 24, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 23, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 14, 2019 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on July 22, 2019 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 10, 2016 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on December 6, 2019 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 21, 2020 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 27, 2020 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 17, 2020 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on October 18, 2022 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 1, 2018 as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 4 of 4</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_385"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this Annual Report on Form 10-K to be signed on our behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on February&#160;22, 2023.</span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.807%"><tr><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVITA INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez<br/>Chief Executive Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Javier J. Rodriguez, Joel Ackerman, and Kathleen Waters, and each of them his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CKERMAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joel Ackerman</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INSTEL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John D. Winstel</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RWAY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela M. Arway</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HARLES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERG</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles G. Berg</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESOER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara J. Desoer</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IAZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OLLAR</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REGORY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OORE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Moore</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EHRA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Nehra</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHECHTER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam H. Schechter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HYLLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R. Y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phyllis R. Yale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-2</span></div></div></div><div id="ib228226ec511491b87b183c6d217a21a_388"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90ZXh0cmVnaW9uOjc2YWU0ZmFlMzYzYTQwNzJhYzc4NGFlZGZmMmZiN2NiXzY2_026229fe-d1bf-4cd0-8ba3-adea41770fb8" escape="true"><ix:nonNumeric contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231" name="dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90ZXh0cmVnaW9uOjc2YWU0ZmFlMzYzYTQwNzJhYzc4NGFlZGZmMmZiN2NiXzY2_67c70093-0407-471e-92cf-974aa5cd5bd7" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:45.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.772%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts<br/>charged to income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts written off</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end of year</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13805c203e1b4b8b917db178e9c4d6dd_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtMi0xLTEtNDMyMzYx_def0fd78-18bc-4ce8-bfb4-87ec37550239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtNC0xLTEtNDMyMzYx_5d849147-8516-440d-b428-3cbef6eee6f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtNi0xLTEtNDMyMzYx_02705f77-c85d-4e31-b09b-99f621702a8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtOC0xLTEtNDMyMzYx_829be3fe-7a90-42de-9c14-efc16cf96b20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d986fd59a394b0faac51a4aa5076ed3_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtMTAtMS0xLTQzMjM2MQ_4cbea93d-662e-4350-af33-25983e7d8330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtMi0xLTEtNDMyMzYx_54a16155-ee12-4a4d-81e8-0a6c187a9a3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtNC0xLTEtNDMyMzYx_67057a60-5cd6-429e-b71b-37a75bdc28cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtNi0xLTEtNDMyMzYx_7d72f238-fc73-4793-a0c7-d00ec6ccb7f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtOC0xLTEtNDMyMzYx_c545885f-eb24-47eb-b71c-067dda10d928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13805c203e1b4b8b917db178e9c4d6dd_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtMTAtMS0xLTQzMjM2MQ_bfe94e4f-61cf-48e8-8166-564177c150a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fb71602ed14a41843e5942b0069a19_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtMi0xLTEtNDMyMzYx_d237cd83-31c7-4097-8634-63f0aebb71e9">8,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtNC0xLTEtNDMyMzYx_f4f22095-9fac-4c5b-bf31-96d55f944f80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtNi0xLTEtNDMyMzYx_6a03042b-59de-483d-9e5a-9a43282b5927">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtOC0xLTEtNDMyMzYx_1ae99666-2e51-442b-8367-0aa85a5101ca">21,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtMTAtMS0xLTQzMjM2MQ_5489e9fe-df7c-46ad-b84a-57dfeb8d7c17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>ex1014-nonxemployeedirecto.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie59d0963cae2460e8506cdf6e19a9e75_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 10.14</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:162%">DAVITA INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:162%">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:162%">(Effective as of January 1, 2023)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE I</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">PURPOSE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The primary purposes of the DaVita Inc. (the &#8220;Company&#8221;) Non-Employee Director Compensation Policy (this &#8220;Policy&#8221;) are as follows&#58;</font></div><div style="margin-bottom:9.08pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:140%;padding-left:12.53pt">to pay differentially higher compensation for higher levels of work, responsibility and performance&#59;</font></div><div style="margin-bottom:9.08pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:140%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:140%;padding-left:13.8pt">to provide a compensation structure that will attract highly competent candidates&#59; and</font></div><div style="margin-bottom:9.08pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:140%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:140%;padding-left:13.8pt">to provide a significant portion of compensation in the form of equity-based awards to further align non-employee director compensation with stockholder interests.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">All references to &#8220;Director&#8221; in this Policy shall mean a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) who is not employed by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">BASE ANNUAL RETAINER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Each Director shall receive a base annual retainer (the &#8220;Base Annual Retainer&#8221;) of up to Three Hundred Thousand Dollars&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$300,000) per fiscal year as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; One Hundred Thousand Dollars ($100,000) to be paid in quarterly installments made within five business days of the last calendar day of each fiscal quarter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Direct Stock Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Two Hundred Thousand Dollars ($200,000) to be paid in the form of direct stock issuances (&#8220;DSIs&#8221;). The DSIs shall be subject to the following terms and conditions (the &#8220;DSI Grant Terms&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The DSIs shall be granted in four equal installments on March 15, May 15, August 15, and November 15 (each, a &#8220;Grant Date&#8221;), subject to the Director&#8217;s continued service through the applicable Grant Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">, that a Grant Date will be accelerated in the event of a Director&#8217;s separation from the Board prior to a specified Grant Date in accordance with the applicable proration provisions in this Policy.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The number of DSIs to be granted on each Grant Date shall be the nearest whole number of shares as determined by dividing Fifty Thousand Dollars ($50,000) by the closing market price of the Company&#8217;s common stock as listed on the New York Stock Exchange (&#8220;NYSE&#8221;) on the Grant Date, and if the Grant Date does not fall on a NYSE trading day, then on the last trading day prior to the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Proration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The quarterly payments of the Base Annual Retainer shall be prorated, as applicable, based on the days of service on the Board during the applicable calendar quarter.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">ANNUAL RETAINER PREMIUM - LEAD INDEPENDENT DIRECTOR</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">A Director serving as the Lead Independent Director of the Board, as applicable, shall be paid a premium (the &#8220;Lead Director Premium&#8221;) of up to One Hundred Twenty-Five Thousand Dollars ($125,000) per fiscal year as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Thirty-Seven Thousand and Five Hundred Dollars ($37,500) to be paid in quarterly installments made within five business days of the last calendar day of each fiscal quarter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Direct Share Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Eighty-Seven Thousand and Five Hundred Dollars ($87,500) to be paid in the form of DSIs to be granted in accordance with, and subject to, the DSI Grant Terms provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> above. For the avoidance of doubt&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The DSI component of the Lead Director Premium shall be granted in four equal quarterly installments on a Grant Date, subject to the Lead Independent Director&#8217;s continued service in that role through the applicable Grant Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The number of DSIs to be granted as part of the Lead Director Premium on each Grant Date shall be the nearest whole number of shares as determined by dividing Twenty-One Thousand Eight Hundred and Seventy-Five Dollars ($21,875) by the closing market price of the Company&#8217;s common stock as listed on the New York Stock Exchange on the Grant Date, and if the Grant Date does not fall on a New York Stock Exchange trading day, then on the last trading day prior to the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Proration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; The quarterly payments of the Lead Director Premium shall be prorated, as applicable, based on the days of service as Lead Independent Director during the applicable calendar quarter.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE IV</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">ANNUAL RETAINER PREMIUM - INDEPENDENT CHAIR</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">A Director serving as the independent Chair of the Board (the &#8220;Independent Chair&#8221;) shall be paid a premium (the &#8220;Independent Chair Premium&#8221;) of up to One Hundred and Seventy-Five Thousand Dollars ($175,000) cash per fiscal year to be paid in quarterly installments made within five business days of the last calendar day of each fiscal quarter, with such quarterly payments prorated based on the days of service as the Independent Chair during the applicable calendar quarter.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE V</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">ANNUAL RETAINER PREMIUM - COMMITTEE CHAIRS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">A Director serving as a Chair of a standing committee (&#8220;Committee&#8221;) of the Board shall be paid a cash premium (the &#8220;Chair Premium&#8221;) per fiscal year as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Chairs of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Audit, Compensation, Nominating and Governance, and Compliance and Quality Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Fifty Thousand Dollars ($50,000) cash to be paid each in quarterly installments made within five business days of the last calendar day of each fiscal quarter, with such quarterly payment prorated based on the days of service as the Chair of the applicable Committee during the applicable calendar quarter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE VI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">MEETING FEES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">A Director shall be paid the following fees for his or her in person or telephonic attendance of Board and Committee meetings as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Two Thousand and Five Hundred Dollars ($2,500) cash for attendance of&#58; (1) special Board meetings held in person, irrespective of length&#59; and (2) special Board meetings held telephonically that last approximately one hour or more. No additional compensation shall be provided for attendance of regular Board meetings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Committees&#47;Sub-Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; Two Thousand and Five Hundred Dollars ($2,500) cash for attendance of the following Committee meetings, provided that the Director is a member of such Committee at the time of such meeting&#58; (1) regular or special Committee meetings held in person&#59; and (2) regular or special Committee meetings held telephonically that last approximately one hour or more. Notwithstanding the foregoing, each member of the Audit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Committee shall be paid Two Thousand and Five Hundred Dollars ($2,500) cash for his or her in person or telephonic attendance of each Audit Committee meeting related to quarterly earnings releases, regardless of the duration of such meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Committee Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Attendance by Non-Members.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;Notwithstanding anything herein to the contrary, a Director shall be paid Two Thousand and Five Hundred Dollars ($2,500) cash for attendance of a regular or special meeting of a Committee of which such Director is not a member, provided that such Director&#8217;s attendance was made at the request of the Chair of such Committee and provided further that such payment is made in accordance with the other requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">6.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">New Committee Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#58; A Director attending a Committee meeting held earlier on the same day of a Board meeting during which action was taken by the Board to appoint him or her to such Committee, will be eligible to receive Committee meeting fees as described under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">ARTICLE VII</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">EXPENSE REIMBURSEMENT AND COMPENSATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">FOR ADDITIONAL TIME EXPENDED</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Each Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board or its Committees or in connection with other Board-related business or activities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Compensation for Additional Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. Each Director shall be compensated in cash on a &#8220;per diem,&#8221; hourly or other basis at a rate that is reasonable and fair to the Company as determined in the discretion of the Lead Independent Director or Independent Chair, as applicable (or, should the matter be referred to them, the Board or the Compensation Committee),&#160;for significant time spent outside of Board or Committee meetings for meetings or activities outside the scope of normal Board duties, including, without limitation, director training, meeting with Company management or external auditors, interviewing director candidates or other activities deemed necessary by the Lead Independent Director or Independent Chair, as applicable (or should the matter be referred to them, the Compensation Committee or the entire Board). Any dollar amounts set for a particular unit of time shall be paid on a pro rata basis for time expended that is less than the full unit of time for which a rate was set. The Lead Independent Director or Independent Chair, as applicable, shall oversee requests for compensation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>ex1031-formperformancecash.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i06eb414e3bf741d29908b9e4f6439b33_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.31</font></div><div><font><br></font></div></div><div style="margin-top:3.95pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:658px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DaVita Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Award Agreement under the DaVita Inc. 2020 Incentive Award Plan</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:17.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Award Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(this &#8220;Agreement&#8221;) is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the &#8220;Company&#8221;), and the Grantee indicated below pursuant to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DaVita Inc. 2020 Incentive Award Plan </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Plan&#8221;).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div id="i06eb414e3bf741d29908b9e4f6439b33_4"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.762%"><div style="margin-top:4.6pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Primary Terms</font></div><div style="margin-top:0.1pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.475%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.763%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.355%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grantee&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#171;Grantee&#187;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#171;Grant Date&#187;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Conditions&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As indicated on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Conditions&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As indicated on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Period&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#171;Performance Period&#187;</font></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Target Amount&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#171;Target Amount&#187;</font></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan Name&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 Incentive Award Plan</font></td></tr></table></div></div><div style="display:inline-block;max-width:7.288%;min-width:6.288%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.357%"></div></div><div><font><br></font></div><div style="padding-left:10.1pt;padding-right:20.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement includes this cover page and the following Exhibits, which are expressly incorporated by reference in their entirety herein&#58;</font></div><div><font><br></font></div><div style="padding-left:46pt;padding-right:230.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8211; General Terms and Conditions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#8211; Performance and Vesting Conditions</font></div><div style="margin-top:0.05pt;padding-left:46pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:20.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee hereby expressly acknowledges and agrees that he&#47;she&#47;they is an employee at will and may be terminated by the Company or its applicable Affiliate at any time, with or without cause. By accepting this Award, Grantee hereby acknowledges he&#47;she&#47;they has a copy of the Plan, and accepts and agrees to the terms and provisions of this Agreement and the Plan. Capitalized terms that are used but not defined in this Agreement shall have the meanings set forth in the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:28.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:134%">IN WITNESS WHEREOF, the Company and the Grantee have accepted this Agreement effective as of the Grant Date.  </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.778%"><tr><td style="width:1.0%"></td><td style="width:46.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DaVita Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i06eb414e3bf741d29908b9e4f6439b33_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DaVita Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:209%">Performance Award Agreement </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:209%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:209%"> &#8211; General Terms and Conditions</font></div><div style="margin-top:2.2pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For valuable consideration, the receipt of which is acknowledged, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:15.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Grant and Payment of Performance Award. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company hereby grants to Grantee this performance award (the &#8220;Award&#8221;), subject to adjustment, forfeiture and the other terms and conditions set forth below and in the Plan. This Award represents Grantee&#8217;s right to receive a cash bonus in the amount indicated on the front page, subject to Grantee&#8217;s fulfillment of the conditions set forth in this Agreement including, without limitation, the achievement of the performance criteria as approved by the Committee and reflected in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;Performance Goals&#8221;) during the performance period reflected on the front page (the &#8220;Performance Period&#8221;).   To the extent that the Committee (or its delegate) determines that some or all of the Performance Goals have been achieved, then as soon as practicable following such determination (but in any event no later than March 15th following the year in which the applicable Performance Goal is achieved), the Company shall pay to Grantee the cash bonus determined pursuant to the Committee&#8217;s (or its delegate&#8217;s) determination of the level of achievement of the Performance Goals, subject to Grantee&#8217;s continued employment through the applicable payment date and Section 3 below. For the avoidance of doubt, the payment date of the Award shall be the date on which the Award is earned.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Termination of Employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as may be set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, the Award will terminate upon the date Grantee&#8217;s employment with the Company or any Affiliate is terminated for any reason. Upon the date that Grantee ceases being an Employee for any reason other than as may be expressly contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, Grantee will forfeit his&#47;her&#47;their right to any unpaid portion of the Award.</font></div><div style="padding-left:10pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Grantee is ultimately liable and responsible for all taxes under all applicable federal, state, local or other laws or regulations (the &#8220;Required Tax Payments&#8221;) owed in connection with the Award, regardless of any action the Company or any of its Affiliates takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any of its Affiliates makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or settlement  of the Award. The Company and its Affiliates do not commit and are under no obligation to structure the Award to reduce or eliminate Grantee&#8217;s tax liability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As a condition precedent to the payment to the Grantee of the bonus upon any settlement of the Award, the Grantee shall satisfy the Required Tax Payments by the Company withholding from the payments otherwise owed to Grantee under this Award, an amount equal to the Required Tax Payments. </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:16.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Assignment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee&#8217;s interest in this Award may not be assigned or alienated, whether voluntarily or involuntarily.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:15.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Clawback Provision. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any other provision in this Agreement to the contrary, Grantee and this Award shall be subject to the Company&#8217;s Compensation Clawback Policy or other clawback policy adopted by the Company, each as may be amended from time to time (the &#8220;Clawback Policy&#8221;). The provisions of this Section 5 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies (as defined herein below), or any laws or regulations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Amendments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may amend the provisions of this Agreement at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, an amendment that would adversely affect the Grantee&#8217;s rights under this Agreement in a material manner shall be subject to the written consent of the Grantee.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Change of Control of the Company. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a Change of Control prior to the end of the Performance Period, the payment of the Award shall be determined as specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:32.55pt;text-align:justify;text-indent:-22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.35pt">&#91;Non-Competition&#47;&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Solicitation&#47;Non-Disclosure</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10.1pt;padding-right:15.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Grantee acknowledges and recognizes the highly competitive nature of the business of the Company and the unique access to the Company&#8217;s confidential business, personnel, and customer and patient information that Grantee receives solely as a result of Grantee&#8217;s employment with the Company, and accordingly agrees that while Grantee is an Employee, and for the 12 month period following termination of such relationship for any reason (whether voluntary or involuntary) (the &#8220;Restricted Period&#8221;), Grantee shall not, as an employee, independent contractor, consultant, or in any other capacity, prepare to provide or provide any of the same or similar services that Grantee performed during his&#47;her&#47;their employment with or service to the Company for any other individual, partnership, limited liability company, corporation, independent practice association, management services organization, or any other entity (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) anywhere in the United States that competes in any way with the area of business of the Company, or any of its subsidiaries or affiliates, in which Grantee worked and&#47;or performed services. For purposes of the above, preparing to provide any of the same or similar services includes, but is not limited to, planning with any Person on how best to compete with the Company or any of its subsidiaries or affiliates, or discussing the Company&#8217;s, or any of its subsidiaries&#8217; or affiliates&#8217; business plans or strategies with any Person.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee further agrees that during the Restricted Period, Grantee shall not own, manage, control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any Person (other than the Company and its subsidiaries and affiliates) engaged in any activity that Grantee was responsible for during Grantee&#8217;s employment with or engagement by the Company where such activity is competitive with the activities carried on by the Company or any of its subsidiaries or affiliates.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee acknowledges that during the Restricted Period, Grantee may be exposed to confidential information and&#47;or trade secrets relating to business areas of the Company or any of its subsidiaries or affiliates that are different from and in addition to the areas in which Grantee primarily works for the Company (the &#8220;Additional Protected Areas of Business&#8221;). As a result, Grantee agrees he&#47;she&#47;they shall not own, manage, control, operate, invest in, acquire an interest in, or otherwise act for, act on behalf, or provide the same or similar services to, any Person that engages in the Additional Protected Areas of Business.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, nothing in this Section 8(a) prohibits Grantee from passively owning not in excess of 2% in the aggregate of any company&#8217;s stock or other ownership interests that are publicly traded on any national or regional stock exchange.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Grantee acknowledges and agrees that the geographical limitations and duration of this covenant not to compete are reasonable and appropriate, it being understood that the business of the Company can be, and is, practiced throughout the United States, and that the restrictions set forth herein will not impose any undue hardship on Grantee.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:15.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the extent that the provisions of this Section 8(a) conflict with any other agreement signed by Grantee relating to non-competition, the provisions that are most protective of the Company&#8217;s, and any of its subsidiaries&#8217; or affiliates&#8217;, interests shall govern.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Section 8(a) (Non-competition) and the rights and obligations of Company hereunder may be assigned by Company and shall inure to the benefit of and shall be enforceable by any such assignee, as well as any of Company&#8217;s successors in interest. This Section 8(a) (Non-competition) and the rights and obligations of Grantee hereunder may not be assigned by Grantee, but are binding upon Grantee's heirs, administrators, executors, and personal representatives.&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.23pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Grantee agrees that during the term of his&#47;her&#47;their employment and&#47;or service to the Company or any of its subsidiaries or affiliates and for the one-year period following the termination of his&#47;her&#47;their employment and&#47;or service for any reason (whether voluntary or involuntary), Grantee shall not (i) solicit any of the Company&#8217;s, or any of its subsidiaries&#8217; or affiliates&#8217;, employees with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised while with the Company to work for any Person&#59; (ii) hire any of the Company&#8217;s, or any of its </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To be included based on teammate jurisdiction.</font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">subsidiaries&#8217; or affiliates&#8217;, employees with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised while with the Company to work (as an employee or an independent contractor) for any Person&#59; (iii) take any action that may reasonably result in any of the Company&#8217;s, or any of its subsidiaries&#8217; or affiliates&#8217;, employees with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised while with the Company going to work (as an employee or an independent contractor) for any Person&#59; (iv) induce any patient or customer of the Company, or any of its subsidiaries or affiliates, either individually or collectively, to patronize any competing business&#59; (v) request or advise any patient, customer, or supplier of the Company, or any of its subsidiaries or affiliates, to withdraw, curtail, or cancel such person&#8217;s business with the Company, or any of its subsidiaries or affiliates&#59; (vi) enter into any contract the purpose or result of which would benefit Grantee if any patient or customer of the Company, or any of its subsidiaries or affiliates, were to withdraw, curtail, or cancel such person&#8217;s business with the Company, or any of its subsidiaries or affiliates&#59; (vii) solicit, induce, or encourage any physician (or former physician) affiliated with the Company, or any of its subsidiaries or affiliates, or induce or encourage any other person under contract with the Company, or any of its subsidiaries or affiliates, to curtail or terminate such person&#8217;s affiliation or contractual relationship with the Company, or any of its subsidiaries or affiliates&#59; or (viii) disclose to any Person the names or addresses of any patient or customer of the Company, or any of its subsidiaries or affiliates.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:15.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.85pt;text-decoration:underline">Non-Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition, Grantee agrees not to disclose or use for his&#47;her&#47;their own benefit or purposes or for the benefit or purposes of any Person other than the Company and any of its subsidiaries or affiliates, any trade secrets, information, data, or other confidential information relating to customers, development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company or any of its subsidiaries or affiliates (&#8220;Information&#8221;)&#59; provided, however, the foregoing shall not apply to (i) Information which is not unique to the Company or any of its subsidiaries or affiliates&#59; (ii) Information which is generally known to the industry or the public other than as a result of Grantee&#8217;s breach of this covenant&#59; or (iii) disclosure that is required by any applicable law, rule or regulation. If Grantee receives such a request to produce Information in his&#47;her&#47;their possession, Grantee shall provide the Company reasonable advance notice, in writing, prior to producing said Information, so as to give the Company reasonable time to object to Grantee producing said Information. Grantee also agrees that Grantee will not become employed by or enter into service with any Person other than the Company and any of its subsidiaries or affiliates in which Grantee will be obligated to disclose or use any Information, or where such disclosure would be inevitable because of the nature of the position. Grantee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made (a) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (b) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Disclosures to attorneys, made under seal, or pursuant to court order are also protected in certain circumstances under 18 U.S.C. &#167; 1833.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.23pt;text-decoration:underline">Non-Contravention.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Nothing in this Agreement (including with respect to Confidential Information, Trade Secrets, and other obligations) is intended to be or will be construed to prevent, impede, or interfere with Grantee&#8217;s right to respond accurately and fully to any question, inquiry, or request for information regarding Grantee&#8217;s employment with the Company when required by legal process by a Federal, State or other legal authority, or from initiating communications directly with, or responding to any inquiry from, or providing truthful testimony and information to, any Federal, State, or other regulatory authority in the course of an investigation or proceeding authorized by law and carried out by such agency. Grantee is not required to contact the Company regarding the subject matter of any such communications before Grantee engages in such communications. In addition, nothing in this Agreement is intended to restrict Grantee&#8217;s legally protected right to discuss wages, hours or other working conditions with co- workers or in any way limit Grantee&#8217;s rights under the National Labor Relations Act or any whistleblower law.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.85pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Grantee agrees that any breach of Section &#91;8(a),&#93; 8(b), or 8(c) will result in immediate and irreparable harm to the Company and its affiliates for which damages alone are an inadequate remedy and cannot readily be calculated. Accordingly, the Grantee agrees that the Company and its affiliates shall be entitled to temporary, preliminary and permanent injunctive relief to prevent any </font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:10pt;padding-right:15.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such actual or threatened breach, without posting a bond or other security or limiting other available remedies.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.07pt;text-decoration:underline">Termination of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement and the Award shall terminate effective on the date on which Grantee enters into any activity in breach of Section &#91;8(a),&#93; 8(b), or 8(c), or if at any time during Grantee&#8217;s employment with the Company or any of its subsidiaries or affiliates or within one (1) year after the termination of such employment for any reason (whether voluntary or involuntary), Grantee (i) is convicted of a felony&#59; (ii) has been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or indirectly in personal enrichment at the expense of the Company or any of its subsidiaries or affiliates&#59; or (iii) is excluded from participating in any federal health care program. In any of the aforementioned cases, in addition to injunctive relief as forth above, the Company may seek an order requiring Grantee to repay the Company any value, gain or other consideration received or realized by Grantee as a result of this Award. In the event of any conflict between the language of this Section 8(f), on the one hand, and the language of Section 5 of this Award or of the Clawback Policy, on the other hand, the language of Section 5 of this Award and of the Clawback Policy shall be controlling. The provisions of this Section 8(f) are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies (as defined herein below), or any laws or regulations.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.75pt">Section 409A of the Code. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement and the Award are intended to meet the requirements of or be exempt from Section 409A of the Code, as applicable, and shall be interpreted and construed consistent with that intent and each payment hereunder shall be considered a separate payment for purposes of Section 409A of the Code. Notwithstanding any other provisions of this Agreement, to the extent that the right to any payment to Grantee hereunder provides for non-qualified deferred compensation within the meaning of Section 409A(d)(1) of the Code that is subject to Section 409A of the Code, the payment shall be made in accordance with the following&#58;</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:15.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of Grantee&#8217;s &#8220;separation from service&#8221; within the meaning of Section 409A(a)(2)(A)(i) of the Code (the &#8220;Separation Date&#8221;), then no such payment shall be made during the period beginning on the Separation Date and ending on the date that is six months following the Separation Date or, if earlier, on the date of Grantee&#8217;s death, if the earlier making of such payment would result in tax penalties being imposed on Grantee under Section 409A of the Code. The amount of any payment that would otherwise be made during this period shall instead be made on the first business day following the date that is six months following the Separation Date or, if earlier, the date of Grantee&#8217;s death.  If the Grantee is subject to an employment or other agreement that specifies  a time and form of payment that differs from the time and form of payment set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then this Award shall be paid in accordance with such employment or other agreement to the extent required to comply with Section 409A of the Code in a manner permissible under the Plan.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.25pt">Compliance with Policies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is understood and agreed upon that at all times Grantee will act in full compliance with the Company&#8217;s policies and procedures as may be in effect from time to time, including without limitation, the Company&#8217;s Code of Conduct, Joint Venture Arrangements Policy, Medical Director Agreements Compliance Handbook, Acceptance of Gifts Policy and&#47;or credentialing process (collectively, the &#8220;Policies&#8221;). If Grantee&#8217;s conduct, whether related to the Award granted under this Agreement or otherwise, materially violates the requirements of the Policies, as determined by the Committee (with respect to a Grantee that is an &#8220;officer&#8221; under Section 16 of the Exchange Act) or the Company&#8217;s Chief Executive Officer, Chief Compliance Officer or Chief Legal Officer (with respect to a Grantee that is not an &#8220;officer&#8221; under Section 16 of the Exchange Act), then the Grantee will forfeit any unvested portion of the Award granted under this Agreement and be subject to immediate disciplinary action, up to and including termination. The provisions of this Section 10 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies or any laws or regulations. If at any time Grantee has questions or concerns about the provisions in this Section 10, or suspects any improper conduct related to the Policies, Grantee should immediately contact his&#47;her&#47;their supervisor or Team Quest. Grantee also may anonymously and confidentially call the Company&#8217;s Compliance Hotline.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.25pt">Compliance with Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any provision of this Agreement is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by </font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:10pt;padding-right:15.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">applicable law, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. Furthermore, if any provision of this Agreement is determined to be illegal under any applicable law, such provision shall be null and void to the extent necessary to comply with applicable law, but the other provisions of this Agreement shall remain in full force and effect.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:28pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:4.3pt">Interpretation of Award.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.7pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">This Award is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:16.3pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.18pt">Any provision in this Award inconsistent with the Plan shall be superseded and governed by the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:15.95pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.8pt">For all purposes under this Award, employment by the Company shall include employment by the Company or any Affiliate thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:16pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:31.18pt">This Award shall be subject to the terms of any written employment agreement between the Grantee and the Company or any Affiliate thereof to the extent permissible under the Plan.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:15.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.25pt">Electronic Delivery and Execution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to this Award or future awards made under the Plan by electronic means or request Grantee&#8217;s consent to participate in the Plan by electronic means. Grantee hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i06eb414e3bf741d29908b9e4f6439b33_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DaVita Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Cash Award Agreement </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> &#8211; Performance and Vesting Conditions</font></div><div style="margin-top:0.35pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The amount payable under this Agreement will be determined by the Committee (or its delegate) based on the level of performance achieved on the Performance Goal, as specified below. Except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, the payment of the Award shall be contingent on Grantee&#8217;s continued employment by the Company through the payment date of the Award (which, for the avoidance of doubt, shall be the date on which the Award is earned)&#59; provided, however, the Committee retains discretion to pay some or all of the Award notwithstanding the Grantee&#8217;s termination of employment in the event of the Grantee&#8217;s death or termination of employment due to Disability. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Award, &#8220;Disability&#8221; means that the Grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, determined in accordance with Section 409A of the Code.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a Change of Control of the Company, the Award shall survive and shall be expressly assumed by the acquiror or surviving entity in the Change of Control. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Performance Conditions Intentionally Omitted&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:69.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>dva-123122ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i61f56906155248f3a42b61acacf22177_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 21.1 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">SUBSIDIARIES OF THE COMPANY </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">as of December&#160;31, 2022&#160;</font></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aberdeen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adair Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ahern Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alenes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alomie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alterra Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Medical Insurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amity Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcadia Gardens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Artesia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashdow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atchison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austin Dialysis Centers, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bainbridge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bannon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barnell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bastrop Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beck Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bedell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bellevue Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Hills Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Birch Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bladon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blanco Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bliss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bluegrass Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bohama Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bothwell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bottle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bowan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braddock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branbur Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bretton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bridges Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brimfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brook Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brooksprings Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownsville Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruno Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buckhorn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buford Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burrill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Butano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cagles Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calante Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Campton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capron Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Virgin Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cascades Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caverns Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cedar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centennial LV, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Carolina Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Georgia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Iowa Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Kentucky Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chaffee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Channel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chantry Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheraw Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chipeta Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chouteau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Churchill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cinco Rios Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clark Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claymount Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clayton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinica Central do Bonfim S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinton Township Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clover Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clyfee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cobbles Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbus-RNA-DaVita, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commerce Township Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conconully Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conecuh Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continental Dialysis Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coral Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Couer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Court Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cowell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cowesett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crossings Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cuivre Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Culbert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curecanti Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curlew Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dallas-Fort Worth Nephrology, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Damon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daroga Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside II, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita &#38; Dignity Health Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Trading Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita &#193;guas Claras Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita APAC Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Brasil Participa&#231;&#245;es e Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Care (Saudi Arabia)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Ceil&#226;ndia Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Dakota Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Deutschland AG</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita EL Paso East, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita HealthCare Brasil Servi&#231;os M&#233;dicos Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita International Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Kidney Care Contracting, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Natal Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Nefromed Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Nephron Care Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Rien Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Asa Sul Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Bueno Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Cambu&#237; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Campinas Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Campo Grande Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia de Araraquara Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Franca Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Goi&#226;nia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Guarulhos Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Itabora&#237; Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Lagoa Nova Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Marco Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Pacini Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Santos Dumont Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Serra Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Sumar&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Taubat&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Valinhos Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Vila Aricanduva Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os Nefrologia Madalena Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sud-Niedersachsen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Transrim Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Tratamento Renal Participa&#231;&#245;es Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UK Holding Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UTR Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Value-Based Enterprise, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita VillageHealth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DC Healthcare International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deowee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Des Moines, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Northern Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Specialists of Dallas, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dierks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dighton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DNP Management Company, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dolores Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dome Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doves Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DPS CKD, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dresher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durango Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare - Southwest Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Maryland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Massachusetts, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of New London, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Norwich, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Tuscaloosa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Holdings Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Laboratory Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Renal Healthcare, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dworsher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East End Dialysis Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Ft. Lauderdale, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eavers Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebrea Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edisto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eldrist Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elk Grove Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire State DC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etowah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ettleton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eufaula Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EURODIAL - Centro de Nefrologia e Dialise de Leiria S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fairfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Falcon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanthorp Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Way Assurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ferne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fields Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flamingo Park Kidney Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forester Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freehold Artificial Kidney Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freeportbay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fremont Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frierton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fullerton Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganchis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gansett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garner Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garrett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gate Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gaviota Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDC International, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gebhard Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genesis KC Development, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geyser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilwards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GiveLife Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glassland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glosser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Golden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goldendale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goliad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gouache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gramleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grand Home Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Las Vegas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Los Angeles Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Country Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Desert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greylock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Griffin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Groten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gulch Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harmony Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haskell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hazelton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hegan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hewett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heyburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hightower Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hilgards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honeyman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Houston Kidney Center&#47;Total Renal Care Integrated Service Network Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humboldt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hummer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hunter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Artificial Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Park Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyattsville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyde Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDC -International Dialysis Centers, Lda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDC Mafra - International Dialysis Centers, LDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Camden, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Colorado, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Inland Empire California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care of Iowa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Kentucky And Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Lake Erie, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Long Island, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Maryland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Michigan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Missouri, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of New Jersey And Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Northern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Pennsylvania And Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Midwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Northeast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Pacific Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The South, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iroquois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Corpus Christi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD I Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD II Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Kendallville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Lees Summit, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Renal, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Schaumburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Spring Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Summit Renal Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacinto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jenness Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jericho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kadden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamiah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kavett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kearn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenai Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kershaw Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kidney HOME Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimball Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingston Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kinnick Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kinter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kittery Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knickerbocker Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knotts Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakeshore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lassen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasburg Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leawood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lees Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legare Development LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liberty RC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Dialysis Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincolnton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Little Rock Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Llano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lockhart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lofield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Logoley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long Beach Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lord Baltimore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loup Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lourdes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lyndale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madigan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magnolia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Makonee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mammoth Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maple Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marseille Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marysville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mashero Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mason-Dixon Dialysis Facilities, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matheson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mautino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mazonia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSleuth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Memorial Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mendocino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mermet Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milltown Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minneopa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moraine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morro Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mountain West Dialysis Services, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mulgee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Alzey GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Aurich GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad Aibling GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad D&#252;ben GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dillenburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dinkelsb&#252;hl GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dormagen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Duisburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Elsterland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Emden GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Geilenkirchen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Gera GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Iserlohn GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita M&#246;nchengladbach GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Neuss GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Aachen Alsdorf GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Berlin-Britz GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Hamm-Ahlen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Prenzlau-Pasewalk GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Rhein-Ahr GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Rhein-Ruhr GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Schwalm-Eder GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myrtle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nansen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natomas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nauvue Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Navarro Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Navin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA - Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-National, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-SoCal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoporte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Care Alliance, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Medical Associates of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Practice Solutions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Bay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicona Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norbert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Northeast Ohio Home Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Odiorne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ogano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio River Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Okanogan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olive Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orange Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordust Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orion Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osage Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owyhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palmetto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palomar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panther Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkside Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient Pathways, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patuk Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peaks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pearl Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pendster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percha Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pershing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfeiffer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philadelphia-Camden Integrated Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis Of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Acquisitions, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis of Lancaster, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Ventures, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pible Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pinewoods Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pittsburgh Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plaine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plattaz Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Benfica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Cascais, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Sacavem, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pobello Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poinsett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pokagon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ponca Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portola Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prineville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pruneau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pyramid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramsey Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rancho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randolph Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rayburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Red Willow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redcliff Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refuge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Flower Mound, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Fort Dodge, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Frisco, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Hamilton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Lewisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Morristown, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Newton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of North Denton, L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Port Arthur, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Sewell, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Storm Lake, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of the Hills, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Tyler, L.P.L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of West Beaumont, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Westwood, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Clinic of Houston, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Life Link, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - California, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Illinois, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Mid-Atlantic, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Northeast, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Southeast, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Ventures Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RenalServ LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhodes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rickwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riddle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ringwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rio Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">River Valley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA - DaVita Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rocky Mountain Dialysis Services, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rollins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roose Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rophets Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roushe Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rusk Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rutland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RV Academy, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saddleback Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sahara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAKDC-DaVita Dialysis Partners, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Marcos Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sands Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santa Fe Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santiam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sapelo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saunders Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seabay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secour Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensiba Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shadow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelby Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelling Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shetek Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shining Star Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shoals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siena Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simeon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sinewa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sloss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soledad Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Somerville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Central Florida Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Florida Integrated Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern Hills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southlake Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southwest Atlanta Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southwest Rocky Mountain Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sprague Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Springpond Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stevenson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stewart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stines Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Storrie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugarloaf Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun City Dialysis Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun City West Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunapee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunset Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talimena Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taylor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenack Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terbole Participa&#231;&#245;es Societ&#225;rias Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terre Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Woodlands Dialysis Center, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tolland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tortugas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Of North Carolina, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Texas Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Laboratories, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Research, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toulouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Townsend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transmountain Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Petersburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC EL Paso Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC-Georgetown Regional Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">District Of Columbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tross Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tugman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumalo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunnel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tustin Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twain Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ubonsie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukiah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unicoi Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upper Valley Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USC-DaVita Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valley Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of District of Columbia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Louisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of New Jersey and Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Northern Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of The South, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Western Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vancleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verde Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Victory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilander Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VillageHealth DM, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Villanueva Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vively Health, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vogel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waddell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wahconah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wakonda Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walker Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wallips Dialysis LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walteria Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washburne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Watkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wauseon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayside Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weldon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Elk Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Sacramento Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weston Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whitney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilder Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Willowbrook Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Winster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woodcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woodford Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wyandotte Central Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yargol Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yucaipa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zellier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zephyrhills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zillmar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>dva-123122ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia2048490e2e94c27bb027e5567f2322b_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:63pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the registration statements (Nos. 333-240022, 333-239191, 333-213119, 333-190434, 333-169467, 333-158220, 333-144097, 333-86550, and 333-30736) on Form S-8 and the registration statement (No. 333-182572) on Form S-4 of our reports dated February 22, 2023, with respect to the consolidated financial statements and financial statement Schedule II - Valuation and Qualifying Accounts of DaVita Inc. and the effectiveness of internal control over financial reporting.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:63pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>dva-123122ex31110xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2e8beebf191b42a7a272510440e3dc51_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Javier J. Rodriguez, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.00pt"><tr><td style="width:1.0pt"></td><td style="width:277.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;22, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>dva-123122ex31210xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7866372b6f714e50a068b23e74c36f41_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joel Ackerman, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;22, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>dva-123122ex32110xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibec02393c09e4679a73ac3e360790dc7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Javier J. Rodriguez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>dva-123122ex32210xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if4ef0b64b0ad45d8b79da6a0352e12a9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joel Ackerman, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;22, 2023</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>dva-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dva="http://www.davita.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.davita.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.davita.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.davita.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME_1" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.davita.com/role/RevenueRecognition">
        <link:definition>0000010 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.davita.com/role/EarningsPerShare">
        <link:definition>0000011 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashRestrictedCash" roleURI="http://www.davita.com/role/RestrictedCashRestrictedCash">
        <link:definition>0000012 - Disclosure - Restricted Cash Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shorttermandlongterminvestments" roleURI="http://www.davita.com/role/Shorttermandlongterminvestments">
        <link:definition>0000013 - Disclosure - Short-term and long-term investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesOtherReceivables" roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables">
        <link:definition>0000014 - Disclosure - Other Receivables Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.davita.com/role/PropertyandEquipment">
        <link:definition>0000015 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibles" roleURI="http://www.davita.com/role/Intangibles">
        <link:definition>0000016 - Disclosure - Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestments" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments">
        <link:definition>0000017 - Disclosure - Equity Method and Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.davita.com/role/Goodwill">
        <link:definition>0000018 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilities" roleURI="http://www.davita.com/role/OtherLiabilities">
        <link:definition>0000019 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.davita.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.davita.com/role/LongTermDebt">
        <link:definition>0000021 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.davita.com/role/Leases">
        <link:definition>0000022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.davita.com/role/EmployeeBenefitPlans">
        <link:definition>0000023 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.davita.com/role/Contingencies">
        <link:definition>0000024 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments">
        <link:definition>0000025 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.davita.com/role/Stockbasedcompensation">
        <link:definition>0000026 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.davita.com/role/Stockholdersequity">
        <link:definition>0000027 - Disclosure - Stockholder's equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncome" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome">
        <link:definition>0000028 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.davita.com/role/AcquisitionsandDivestitures">
        <link:definition>0000029 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperations" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations">
        <link:definition>0000030 - Disclosure - Held for Sale and Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.davita.com/role/VariableInterestEntities">
        <link:definition>0000031 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstruments" roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments">
        <link:definition>0000032 - Disclosure - Fair Values of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.davita.com/role/SegmentReporting">
        <link:definition>0000033 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.davita.com/role/SupplementalCashFlowInformation">
        <link:definition>0000034 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>0000035 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000036 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables">
        <link:definition>0000037 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.davita.com/role/EarningsPerShareTables">
        <link:definition>0000038 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvesmtentsTables" roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables">
        <link:definition>0000039 - Disclosure - Short-term and long-term invesmtents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesTables" roleURI="http://www.davita.com/role/OtherReceivablesTables">
        <link:definition>0000040 - Disclosure - Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.davita.com/role/PropertyandEquipmentTables">
        <link:definition>0000041 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesTables" roleURI="http://www.davita.com/role/IntangiblesTables">
        <link:definition>0000042 - Disclosure - Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables">
        <link:definition>0000043 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.davita.com/role/GoodwillTables">
        <link:definition>0000044 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesTables" roleURI="http://www.davita.com/role/OtherLiabilitiesTables">
        <link:definition>0000045 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.davita.com/role/IncomeTaxesTables">
        <link:definition>0000046 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.davita.com/role/LongTermDebtTables">
        <link:definition>0000047 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.davita.com/role/LeasesTables">
        <link:definition>0000048 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandShareholdersEquityTables" roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables">
        <link:definition>0000049 - Disclosure - Stock-based compensation and Shareholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.davita.com/role/StockholdersequityTables">
        <link:definition>0000050 - Disclosure - Stockholder's equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeTables" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables">
        <link:definition>0000051 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresTables" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables">
        <link:definition>0000052 - Disclosure - Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsTables" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables">
        <link:definition>0000053 - Disclosure - Fair Values of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.davita.com/role/SegmentReportingTables">
        <link:definition>0000054 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables">
        <link:definition>0000055 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SECScheduleArticle1209ValuationandQualifyingAccountsTables" roleURI="http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables">
        <link:definition>0000056 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails">
        <link:definition>0000058 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails">
        <link:definition>0000059 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000060 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashandEquivalentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails">
        <link:definition>0000061 - Disclosure - Restricted Cash and Equivalents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvestmentsDetails" roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails">
        <link:definition>0000062 - Disclosure - Short-term and long-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesDetails" roleURI="http://www.davita.com/role/OtherReceivablesDetails">
        <link:definition>0000063 - Disclosure - Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentDetails">
        <link:definition>0000064 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>0000065 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails">
        <link:definition>0000066 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails">
        <link:definition>0000068 - Disclosure - Intangibles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails">
        <link:definition>0000069 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails">
        <link:definition>0000070 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails">
        <link:definition>0000071 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails">
        <link:definition>0000072 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAdditionalInformationDetails" roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails">
        <link:definition>0000073 - Disclosure - Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesDetails" roleURI="http://www.davita.com/role/OtherLiabilitiesDetails">
        <link:definition>0000074 - Disclosure - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails">
        <link:definition>0000075 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseDetails" roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails">
        <link:definition>0000076 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails" roleURI="http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails">
        <link:definition>0000077 - Disclosure - Income Taxes Income Taxes - Allocation of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails">
        <link:definition>0000078 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails">
        <link:definition>0000079 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails">
        <link:definition>0000080 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>0000082 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduledMaturitiesofLongtermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails">
        <link:definition>0000083 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDerivativeInstrumentsDetails" roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails">
        <link:definition>0000084 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails">
        <link:definition>0000085 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalinformationDetail" roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail">
        <link:definition>0000086 - Disclosure - Long-Term Debt - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseComponentsDetails" roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails">
        <link:definition>0000087 - Disclosure - Leases Lease Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesOtherInformationDetails" roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails">
        <link:definition>0000088 - Disclosure - Leases Leases Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails">
        <link:definition>0000089 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails">
        <link:definition>0000090 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>0000091 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAdditionalInformationDetails" roleURI="http://www.davita.com/role/ContingenciesAdditionalInformationDetails">
        <link:definition>0000092 - Disclosure - Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails">
        <link:definition>0000093 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails">
        <link:definition>0000094 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails">
        <link:definition>0000095 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails">
        <link:definition>0000096 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails">
        <link:definition>0000097 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockRepurchasesTenderOfferDetails" roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails">
        <link:definition>0000098 - Disclosure - Stock Repurchases Tender Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails">
        <link:definition>0000099 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityDetails" roleURI="http://www.davita.com/role/ShareholdersequityDetails">
        <link:definition>0000100 - Disclosure - Shareholder's equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>0000101 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsComponentsofRoutineAcquisitionsDetails" roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails">
        <link:definition>0000102 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsacquiredandliabilitiesassumedDetails" roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails">
        <link:definition>0000103 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails">
        <link:definition>0000104 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails">
        <link:definition>0000105 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails">
        <link:definition>0000106 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresAdditionalInformationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails">
        <link:definition>0000107 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>0000108 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesAdditionalInformationDetails" roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails">
        <link:definition>0000109 - Disclosure - Variable Interest Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000110 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails">
        <link:definition>0000111 - Disclosure - Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails">
        <link:definition>0000112 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails">
        <link:definition>0000113 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails">
        <link:definition>0000114 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofAssetsbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails">
        <link:definition>0000115 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>0000116 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>0000117 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>0000118 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dva_CashPaidForPortionPreviouslyRefundedMember" abstract="true" name="CashPaidForPortionPreviouslyRefundedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" abstract="true" name="ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PaymentsToAcquireOtherDebtAndEquityInvestments" abstract="false" name="PaymentsToAcquireOtherDebtAndEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" abstract="true" name="CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" abstract="false" name="TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_NumberOfPartnerships" abstract="false" name="NumberOfPartnerships" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" abstract="false" name="StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" abstract="false" name="ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_LeaseOtherInformationTableTextBlockTableTextBlock" abstract="false" name="LeaseOtherInformationTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_DebtPrepaymentRefinancingRedemptionCharges" abstract="false" name="DebtPrepaymentRefinancingRedemptionCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" abstract="false" name="PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_LeasesDisclosureLineItems" abstract="true" name="LeasesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PotentialImpactOnFairValueForReductionInOperatingIncome" abstract="false" name="PotentialImpactOnFairValueForReductionInOperatingIncome" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_RMSLifelineMember" abstract="true" name="RMSLifelineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" abstract="false" name="ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" abstract="true" name="TemporaryEquityRedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" abstract="true" name="SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" abstract="false" name="NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_FinanceLeaseAccumulatedDepreciation" abstract="false" name="FinanceLeaseAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MutualFundsAndCommonStockMember" abstract="true" name="MutualFundsAndCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_BusinessSaleEffectiveDateOfSale" abstract="false" name="BusinessSaleEffectiveDateOfSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_OperatingLeaseMember" abstract="true" name="OperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" abstract="true" name="SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayable" abstract="false" name="AcquisitionObligationsAndOtherNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureLineItems" abstract="true" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_RangeFourMember" abstract="true" name="RangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureTable" abstract="true" name="CommitmentsAndContingenciesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_SupplierRebatesAndOtherNonTradeReceivablesMember" abstract="true" name="SupplierRebatesAndOtherNonTradeReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OtherSourcesofRevenueMember" abstract="true" name="OtherSourcesofRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" abstract="false" name="GainOnDispositionOfBusinessAdditionalPurchasePricePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_RangeFiveMember" abstract="true" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" abstract="false" name="NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" abstract="false" name="NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" abstract="false" name="ScheduleOfReportingUnitsGoodwillBalancesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_TermLoanB1Member" abstract="true" name="TermLoanB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NumberOfConcentrationRiskCustomers" abstract="false" name="NumberOfConcentrationRiskCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" abstract="false" name="RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayableFairValue" abstract="false" name="AcquisitionObligationsAndOtherNotesPayableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MedicaidandManagedMedicaidMember" abstract="true" name="MedicaidandManagedMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_MedicareandMedicareAdvantageMember" abstract="true" name="MedicareandMedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OffBalanceSheetFinancingArrangements" abstract="false" name="OffBalanceSheetFinancingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TenderOfferMember" abstract="true" name="TenderOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_IndefiniteLifeNetOperatingLossesMember" abstract="true" name="IndefiniteLifeNetOperatingLossesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SegmentRevenuebyMajorPayorAbstract" abstract="true" name="SegmentRevenuebyMajorPayorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" abstract="false" name="PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" abstract="false" name="StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" abstract="false" name="PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" abstract="true" name="PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OpenMarketPurchasesMember" abstract="true" name="OpenMarketPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" abstract="false" name="NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" abstract="false" name="TreasuryStockAcquiredAverageCostPerShareClearingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" abstract="false" name="RevenueRecognitionAndAccountsReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_StockIncentivePlanTwentyTwentyMember" abstract="true" name="StockIncentivePlanTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_InsuranceAndSelfInsurancePolicyTextBlock" abstract="false" name="InsuranceAndSelfInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_DebtRefinancingCharges" abstract="false" name="DebtRefinancingCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ShareRepurchaseFeesAndExpenses" abstract="false" name="ShareRepurchaseFeesAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncomeTaxRelatedToCashFlowHedgesMember" abstract="true" name="IncomeTaxRelatedToCashFlowHedgesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OtherGovernmentPayorsMember" abstract="true" name="OtherGovernmentPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_IncomeLossFromOtherEquityMethodInvestments" abstract="false" name="IncomeLossFromOtherEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" abstract="false" name="PercentageOfAccountsReceivableSixMonthsOrMorePastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_NumberOfSites" abstract="false" name="NumberOfSites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" abstract="false" name="PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" abstract="true" name="A2019InterestRateCapAgreementsEffectiveJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DeconsolidatedNoncontrollingEntityMember" abstract="true" name="DeconsolidatedNoncontrollingEntityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TermLoanAAndTermLoanB1Member" abstract="true" name="TermLoanAAndTermLoanB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" abstract="true" name="EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" abstract="false" name="SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_OtherCompaniesMember" abstract="true" name="OtherCompaniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LeasesDisclosureTable" abstract="true" name="LeasesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_CommitmentsToProvideOperatingCapitalMember" abstract="true" name="CommitmentsToProvideOperatingCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_PaymentsRelatedToStockPurchasesAndAwards" abstract="false" name="PaymentsRelatedToStockPurchasesAndAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" abstract="false" name="LossGainOnDispositionOfBusinessInterestsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_InternationalOperationsMember" abstract="true" name="InternationalOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ScheduleOfOtherReceivablesTableTextBlock" abstract="false" name="ScheduleOfOtherReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_IncrementalCashPortionMember" abstract="true" name="IncrementalCashPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LeasesDisclosureTextBlock" abstract="false" name="LeasesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" abstract="false" name="EffectiveIncomeTaxReconciliationInvestmentImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" abstract="false" name="SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ParentCompanyAndRestrictedSubsidiariesMember" abstract="true" name="ParentCompanyAndRestrictedSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DebtFinancingAndDebtRedemptionCosts" abstract="false" name="DebtFinancingAndDebtRedemptionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" abstract="false" name="StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_LesseeLeaseDescriptionLineItemsAbstract" abstract="true" name="LesseeLeaseDescriptionLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseTable" abstract="true" name="ExpectedAmortizationExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_ScheduleOfMinimumLeasePaymentsTextBlock" abstract="false" name="ScheduleOfMinimumLeasePaymentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" abstract="true" name="CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_StockSettledStockAppreciationRightsMember" abstract="true" name="StockSettledStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" abstract="false" name="EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PatientCareCosts" abstract="false" name="PatientCareCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SegmentReportingInformationCorporateExpenses" abstract="false" name="SegmentReportingInformationCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesOperatingLeaseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ExternalSourcesMember" abstract="true" name="ExternalSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" abstract="false" name="PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_AdjustmentIncomeLossFromEquityMethodInvestments" abstract="false" name="AdjustmentIncomeLossFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" abstract="false" name="IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AllTrustsMember" abstract="true" name="AllTrustsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" abstract="false" name="StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_IncreaseInDeferredTaxAssetsNet" abstract="false" name="IncreaseInDeferredTaxAssetsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OtherNonoperatingIncomeExpensePolicyTextBlock" abstract="false" name="OtherNonoperatingIncomeExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" abstract="false" name="EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" abstract="false" name="MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" abstract="false" name="NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" abstract="false" name="ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_CommercialPayorsMember" abstract="true" name="CommercialPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" abstract="false" name="NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_USAttorneyPrescriptionDrugInvestigationMember" abstract="true" name="USAttorneyPrescriptionDrugInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DiscountAndDeferredFinanceCosts" abstract="false" name="DiscountAndDeferredFinanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" abstract="false" name="ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_AuditorAbstract" abstract="true" name="AuditorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitions" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AccountsReceivablePeriodOutstanding" abstract="false" name="AccountsReceivablePeriodOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_ForeignDialysisCentersMember" abstract="true" name="ForeignDialysisCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DaVitaMedicalGroupMember" abstract="true" name="DaVitaMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" abstract="true" name="EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesMember" abstract="true" name="DeferredTaxLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LeasesOtherInformationAbstract" abstract="true" name="LeasesOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasePurchaseOfInterests" abstract="false" name="TemporaryEquityDecreasePurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OtherReportingUnitsMember" abstract="true" name="OtherReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DeferredTaxAssetsReceivables" abstract="false" name="DeferredTaxAssetsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseLineItems" abstract="true" name="ExpectedAmortizationExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_FinanceLeaseMember" abstract="true" name="FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_USDialysisAndRelatedLabServicesMember" abstract="true" name="USDialysisAndRelatedLabServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DissolutionTermOfJointVentures" abstract="false" name="DissolutionTermOfJointVentures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockIncentivePlanTwentyElevenMember" abstract="true" name="StockIncentivePlanTwentyElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CharterdocumentsandDelawarelawAbstract" abstract="true" name="CharterdocumentsandDelawarelawAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_TaxYear2029Member" abstract="true" name="TaxYear2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_StockUnitMember" abstract="true" name="StockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_KidneyCareMember" abstract="true" name="KidneyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_CashPaidDuringPeriodForAbstract" abstract="true" name="CashPaidDuringPeriodForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PayorRefundsAndRetractions" abstract="false" name="PayorRefundsAndRetractions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>dva-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_adff1ee0-655b-46b1-8ea9-7ce96230fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5919660a-be70-48f8-bb86-ed9e17b16159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adff1ee0-655b-46b1-8ea9-7ce96230fd17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5919660a-be70-48f8-bb86-ed9e17b16159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_38f27296-6929-465e-956b-167c0fce3c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adff1ee0-655b-46b1-8ea9-7ce96230fd17" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_38f27296-6929-465e-956b-167c0fce3c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76caf67c-08c4-490b-a65b-d2ccae9d5c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_35732bc0-767f-4783-92a2-da0d6fdb931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_76caf67c-08c4-490b-a65b-d2ccae9d5c8b" xlink:to="loc_us-gaap_Revenues_35732bc0-767f-4783-92a2-da0d6fdb931b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3c1b38b4-0145-4196-9703-f2462bc98a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_76caf67c-08c4-490b-a65b-d2ccae9d5c8b" xlink:to="loc_us-gaap_CostsAndExpenses_3c1b38b4-0145-4196-9703-f2462bc98a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d259c532-b3d3-43f0-87eb-234a5260088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e50c1d77-db1b-4418-81a3-7dc2ceb74212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d259c532-b3d3-43f0-87eb-234a5260088f" xlink:to="loc_us-gaap_ProfitLoss_e50c1d77-db1b-4418-81a3-7dc2ceb74212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_92f1a67c-505d-4669-a12d-42e234da5454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d259c532-b3d3-43f0-87eb-234a5260088f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_92f1a67c-505d-4669-a12d-42e234da5454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_7a038000-478f-442e-9672-4ced82c0d15f" xlink:href="dva-20221231.xsd#dva_PatientCareCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:to="loc_dva_PatientCareCosts_7a038000-478f-442e-9672-4ced82c0d15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_75c3b188-44b3-400b-8b20-9a1ba5c7224b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_75c3b188-44b3-400b-8b20-9a1ba5c7224b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_dcdb2d43-a5f6-4b74-9f63-605f4c713f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:to="loc_us-gaap_DepreciationAndAmortization_dcdb2d43-a5f6-4b74-9f63-605f4c713f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6433ba3-c4b4-4e28-9ccc-59fe90707754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e6433ba3-c4b4-4e28-9ccc-59fe90707754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_1c9c52a1-88da-414e-9b88-8fc9e1012122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6401fc85-8dbb-49e8-b2cd-7fd1530235b3" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_1c9c52a1-88da-414e-9b88-8fc9e1012122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06454855-a404-499e-9322-31e8da50bd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_068553ba-0e74-4dc2-905b-d95867f06b65" xlink:href="dva-20221231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_06454855-a404-499e-9322-31e8da50bd87" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_068553ba-0e74-4dc2-905b-d95867f06b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_1d733388-b857-4839-b213-51575a2785b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_06454855-a404-499e-9322-31e8da50bd87" xlink:to="loc_us-gaap_OtherIncome_1d733388-b857-4839-b213-51575a2785b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c0ba4199-783c-47d5-b0be-66b5a9c35726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cfc16ac-47c3-4c8c-8def-440dc6715173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c0ba4199-783c-47d5-b0be-66b5a9c35726" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cfc16ac-47c3-4c8c-8def-440dc6715173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e401277a-2717-46d9-9ee9-00145112947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c0ba4199-783c-47d5-b0be-66b5a9c35726" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e401277a-2717-46d9-9ee9-00145112947f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_962d6d46-b85c-46de-a2a0-eed5831a1540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c7e0d73a-d047-4ace-94b4-d430976cfdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_962d6d46-b85c-46de-a2a0-eed5831a1540" xlink:to="loc_us-gaap_OperatingIncomeLoss_c7e0d73a-d047-4ace-94b4-d430976cfdf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_9cfa78eb-2c0d-4381-bc92-e6594737eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_962d6d46-b85c-46de-a2a0-eed5831a1540" xlink:to="loc_us-gaap_InterestAndDebtExpense_9cfa78eb-2c0d-4381-bc92-e6594737eb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_84257853-106d-49a2-94d9-1ca7f52f72a9" xlink:href="dva-20221231.xsd#dva_DebtPrepaymentRefinancingRedemptionCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_962d6d46-b85c-46de-a2a0-eed5831a1540" xlink:to="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_84257853-106d-49a2-94d9-1ca7f52f72a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6ffb6a26-f6e2-4bb1-a107-692b9857c545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_962d6d46-b85c-46de-a2a0-eed5831a1540" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6ffb6a26-f6e2-4bb1-a107-692b9857c545" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME_1"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3aa7f520-26b2-4d34-90af-b4a0188dec24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_50052ba5-c9ce-48b2-a1d7-0d03f8f5afac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3aa7f520-26b2-4d34-90af-b4a0188dec24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_50052ba5-c9ce-48b2-a1d7-0d03f8f5afac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eb3d9361-4567-4b9c-a877-843fe914cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3aa7f520-26b2-4d34-90af-b4a0188dec24" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eb3d9361-4567-4b9c-a877-843fe914cd72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70086262-c5b9-44bb-8ede-0d68592d4f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1443ff38-0901-4edd-9969-7d2aadd54f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70086262-c5b9-44bb-8ede-0d68592d4f8c" xlink:to="loc_us-gaap_ProfitLoss_1443ff38-0901-4edd-9969-7d2aadd54f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ad7cc16-6b4f-4663-96ad-8c411d5bcea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_70086262-c5b9-44bb-8ede-0d68592d4f8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ad7cc16-6b4f-4663-96ad-8c411d5bcea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_29af76c4-2bd3-46cd-9bd7-5e7520437cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1b2fd239-e7f0-4482-80e3-ee7fa62e9aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_29af76c4-2bd3-46cd-9bd7-5e7520437cf7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1b2fd239-e7f0-4482-80e3-ee7fa62e9aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_aa74b435-4f31-4093-9ebf-3be87b25976b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_29af76c4-2bd3-46cd-9bd7-5e7520437cf7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_aa74b435-4f31-4093-9ebf-3be87b25976b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a98c7fb-34b6-47d6-8948-3761e057ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3bc6087d-93e5-4024-9266-cacbd5558db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a98c7fb-34b6-47d6-8948-3761e057ba2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3bc6087d-93e5-4024-9266-cacbd5558db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_85b9282b-3d46-4727-8140-d9bbc6a89065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a98c7fb-34b6-47d6-8948-3761e057ba2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_85b9282b-3d46-4727-8140-d9bbc6a89065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_bcd615d4-1dbb-4e24-b118-82fab0b2f6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a98c7fb-34b6-47d6-8948-3761e057ba2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_bcd615d4-1dbb-4e24-b118-82fab0b2f6ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df9266cb-20e0-4a4d-8df9-52b90f27f406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20fe204e-4cac-4078-af92-ee817603fe78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df9266cb-20e0-4a4d-8df9-52b90f27f406" xlink:to="loc_us-gaap_StockholdersEquity_20fe204e-4cac-4078-af92-ee817603fe78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c2e91c73-1efd-439f-ba49-0fdbe060fecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df9266cb-20e0-4a4d-8df9-52b90f27f406" xlink:to="loc_us-gaap_MinorityInterest_c2e91c73-1efd-439f-ba49-0fdbe060fecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c16d6563-cffd-41e1-ac3e-2f43e5ff1d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c16d6563-cffd-41e1-ac3e-2f43e5ff1d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_698f6b96-3e10-40d8-8f78-668f62768dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:to="loc_us-gaap_CommonStockValue_698f6b96-3e10-40d8-8f78-668f62768dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_eabf4d70-cbec-4e78-8287-295d2e5493a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_eabf4d70-cbec-4e78-8287-295d2e5493a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f628f5a9-3df9-4a91-8adf-1603d56c8dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:to="loc_us-gaap_PreferredStockValue_f628f5a9-3df9-4a91-8adf-1603d56c8dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e4c33ccb-e888-4f8f-9682-43fd4596c449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3a3ead10-7248-4abf-8ed7-931545c3807d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e4c33ccb-e888-4f8f-9682-43fd4596c449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_731b0824-a1aa-46a4-a8e6-82df3eba0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_AssetsCurrent_731b0824-a1aa-46a4-a8e6-82df3eba0f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1744d90-896f-4b38-97c1-4f30a601e4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1744d90-896f-4b38-97c1-4f30a601e4d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_57023380-5847-42f5-a65b-dfc7bca33226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_57023380-5847-42f5-a65b-dfc7bca33226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b92c0ddf-0720-4930-a153-4773420cf637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b92c0ddf-0720-4930-a153-4773420cf637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d9485477-1287-4508-b746-a6f45fa3a89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d9485477-1287-4508-b746-a6f45fa3a89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_37ab85cc-aec0-48b6-bbdd-a205280e5a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_37ab85cc-aec0-48b6-bbdd-a205280e5a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_04929d5e-8bf3-49fe-8631-a5a466d65800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_04929d5e-8bf3-49fe-8631-a5a466d65800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b096e5ce-8013-4d9a-8d0b-787751e70e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_405fec21-5f84-4fe1-9c27-eb7c1903208c" xlink:to="loc_us-gaap_Goodwill_b096e5ce-8013-4d9a-8d0b-787751e70e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ee40c45b-7dc7-44da-a00f-ffec4b4dfaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:to="loc_us-gaap_LiabilitiesCurrent_ee40c45b-7dc7-44da-a00f-ffec4b4dfaf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87c6950b-d4d9-4649-9d1f-a2ea620317e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87c6950b-d4d9-4649-9d1f-a2ea620317e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f6e86251-24ac-4a21-a9b7-1a10bea8f7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f6e86251-24ac-4a21-a9b7-1a10bea8f7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_518cdb9c-09d4-4a9f-b892-414a91d013eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_518cdb9c-09d4-4a9f-b892-414a91d013eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8bcdb7da-a372-4c44-9c44-d321349ff2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4a07040a-7ec7-4ce8-998c-55d02b591f2a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8bcdb7da-a372-4c44-9c44-d321349ff2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfa819ca-b985-4c0c-a154-78094ccf17c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfa819ca-b985-4c0c-a154-78094ccf17c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d47c4056-45b0-41ee-8755-fb06a623ee8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d47c4056-45b0-41ee-8755-fb06a623ee8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3c164c16-e719-45bf-b400-d2d784ef4d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3c164c16-e719-45bf-b400-d2d784ef4d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a9ea8972-51cd-4756-a49d-abb2b95e629b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a9ea8972-51cd-4756-a49d-abb2b95e629b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a98ac430-a4cf-4d94-94d9-55c421f87b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_InventoryNet_a98ac430-a4cf-4d94-94d9-55c421f87b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_cb4a5569-9b7d-4067-871f-e0b454610705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_cb4a5569-9b7d-4067-871f-e0b454610705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdf80e1-5929-47a8-9a6b-26d891677180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdf80e1-5929-47a8-9a6b-26d891677180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_0920af4c-ec1b-4181-89c4-af5bba2208a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_653fad21-7575-4624-a7a2-352da93049b3" xlink:to="loc_us-gaap_IncomeTaxesReceivable_0920af4c-ec1b-4181-89c4-af5bba2208a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_05e7530e-641a-49cf-89aa-2e5001736b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_AccountsPayableCurrent_05e7530e-641a-49cf-89aa-2e5001736b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f198eabc-3646-439c-acd8-9871246f240b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f198eabc-3646-439c-acd8-9871246f240b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_33da0f2b-da15-46cd-9cf4-b7a6ad25de43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_33da0f2b-da15-46cd-9cf4-b7a6ad25de43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_826f0b5d-1fd0-4b5f-a0a0-28a827276ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_826f0b5d-1fd0-4b5f-a0a0-28a827276ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_32fcdfb3-d66c-4a53-8192-7f7e795a31ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_32fcdfb3-d66c-4a53-8192-7f7e795a31ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b9062bff-45cf-4ae4-960d-c3f9fe6cc038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23643e7e-1cf5-427a-9903-fd9ecedbca64" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b9062bff-45cf-4ae4-960d-c3f9fe6cc038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_14189b98-edf5-4d4b-9d48-59dbba7da0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_007cccba-715f-4ca5-8898-468045cb9e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14189b98-edf5-4d4b-9d48-59dbba7da0a2" xlink:to="loc_us-gaap_Liabilities_007cccba-715f-4ca5-8898-468045cb9e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_5e760402-c869-4e33-9e14-11c03e99b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14189b98-edf5-4d4b-9d48-59dbba7da0a2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_5e760402-c869-4e33-9e14-11c03e99b6d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012382bd-59ee-447d-aa07-8a89a0a7d483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14189b98-edf5-4d4b-9d48-59dbba7da0a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012382bd-59ee-447d-aa07-8a89a0a7d483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_2fee3ee0-ac39-454e-b146-2d6018f1d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_2fee3ee0-ac39-454e-b146-2d6018f1d4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_f7980e66-a19e-4f13-8997-8c5494f1f83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_f7980e66-a19e-4f13-8997-8c5494f1f83b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_a56c5ee4-c3bc-4781-a6f5-83e6c60d0687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_a56c5ee4-c3bc-4781-a6f5-83e6c60d0687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_d128c848-1618-43cd-b9ef-512cd7fecd77" xlink:href="dva-20221231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_d128c848-1618-43cd-b9ef-512cd7fecd77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_983a2047-3653-497a-817e-303b0e03e185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_983a2047-3653-497a-817e-303b0e03e185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_fb5e5bcf-de84-4294-9f40-d1aaf6d3908e" xlink:href="dva-20221231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_fb5e5bcf-de84-4294-9f40-d1aaf6d3908e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0fd320da-2632-4161-9ac2-2ecf91ea6ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0fd320da-2632-4161-9ac2-2ecf91ea6ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a033f76-1ef3-419a-aac7-6018210dfaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a033f76-1ef3-419a-aac7-6018210dfaf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_32bca82a-ca94-4e11-956e-58b5dc4d5658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_337609fb-ef1b-46c1-98ff-d7fe2ea4773d" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_32bca82a-ca94-4e11-956e-58b5dc4d5658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dae8302-b775-4404-9ed9-e618c8dcafc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_461632a3-7e00-4b69-ae40-c47e34ce8115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dae8302-b775-4404-9ed9-e618c8dcafc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_461632a3-7e00-4b69-ae40-c47e34ce8115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1724b3af-feb1-478c-ae65-477bfba530fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dae8302-b775-4404-9ed9-e618c8dcafc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1724b3af-feb1-478c-ae65-477bfba530fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43b35982-fc80-42ad-9e4b-a357d0d19b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dae8302-b775-4404-9ed9-e618c8dcafc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43b35982-fc80-42ad-9e4b-a357d0d19b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f6e0afd5-d4aa-4783-950f-0099c9f6c2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dae8302-b775-4404-9ed9-e618c8dcafc8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f6e0afd5-d4aa-4783-950f-0099c9f6c2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_099107ad-213f-45c8-b022-0842b5732121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_099107ad-213f-45c8-b022-0842b5732121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f2ad4654-a822-48ab-a0e1-b221b0a171e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f2ad4654-a822-48ab-a0e1-b221b0a171e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9ccb73c1-9479-4b97-8c01-4653acc71b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_ShareBasedCompensation_9ccb73c1-9479-4b97-8c01-4653acc71b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_848701c4-07be-4c70-870e-2df7b7a896ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_848701c4-07be-4c70-870e-2df7b7a896ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b2b84d02-e0a2-49b8-873b-e69546bd5732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b2b84d02-e0a2-49b8-873b-e69546bd5732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_f52528a2-e835-4845-b14e-6dc072db37b2" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_f52528a2-e835-4845-b14e-6dc072db37b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_749a2e96-5566-429f-a768-5ba0126c286d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_749a2e96-5566-429f-a768-5ba0126c286d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_19134c35-453e-4dc7-924f-00e174bf2cdb" xlink:href="dva-20221231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_19134c35-453e-4dc7-924f-00e174bf2cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_82557ac2-776e-4ef5-a31b-467c9b5b5f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_82557ac2-776e-4ef5-a31b-467c9b5b5f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_65ca59b7-f2df-4baa-b069-61b12d14ddaa" xlink:href="dva-20221231.xsd#dva_DebtRefinancingCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_dva_DebtRefinancingCharges_65ca59b7-f2df-4baa-b069-61b12d14ddaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_22a99228-f2d0-46c6-b68e-36b0ea779ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_22a99228-f2d0-46c6-b68e-36b0ea779ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_5a836c1d-e14e-4f98-a46b-0f2de4a803e3" xlink:href="dva-20221231.xsd#dva_LossGainOnDispositionOfBusinessInterestsBeforeTax"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_5a836c1d-e14e-4f98-a46b-0f2de4a803e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5dc8d306-60e6-4380-9069-86ec7d39bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_ProfitLoss_5dc8d306-60e6-4380-9069-86ec7d39bfa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_7648350e-cdea-4c7f-9c19-85486c40b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_7648350e-cdea-4c7f-9c19-85486c40b99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_95c814ca-1c08-47d6-8061-ba4ef7365859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_95c814ca-1c08-47d6-8061-ba4ef7365859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d9564f3-41fa-4739-a0c0-df9e4a7a8af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d9564f3-41fa-4739-a0c0-df9e4a7a8af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cec4f976-016b-4199-b38d-aca39afee2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_244182de-cfc8-4bd3-acb5-35ed2d6b3e29" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cec4f976-016b-4199-b38d-aca39afee2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_059d16ed-a07d-4454-8e3e-ea42460262a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_059d16ed-a07d-4454-8e3e-ea42460262a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e21a0064-d273-437a-acd0-a8e008c694e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e21a0064-d273-437a-acd0-a8e008c694e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_438e52f6-261a-45e7-a400-18679013ed2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_438e52f6-261a-45e7-a400-18679013ed2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_90e26e23-f612-4841-860d-8cc5682ccff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_90e26e23-f612-4841-860d-8cc5682ccff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_57719019-1392-4611-b891-23a6cb6fddc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_57719019-1392-4611-b891-23a6cb6fddc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4d8a8265-fe0f-4744-8439-829a495788f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4d8a8265-fe0f-4744-8439-829a495788f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_8ba44684-75c5-4c65-8eaf-27f0022e1704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_8ba44684-75c5-4c65-8eaf-27f0022e1704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_76e92d62-795e-4417-b99f-2940074334d1" xlink:href="dva-20221231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_76e92d62-795e-4417-b99f-2940074334d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_04241ce4-8d9e-452e-b470-04f30c699622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_04241ce4-8d9e-452e-b470-04f30c699622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_0056feed-4465-437e-8bff-194ecd57e5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72910bb-b463-49c0-8651-5951fb2abf1f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_0056feed-4465-437e-8bff-194ecd57e5c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8966bd5-662b-4ecb-859c-0658adf26556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d3a67186-edaf-4b77-90ce-99913a796507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8966bd5-662b-4ecb-859c-0658adf26556" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d3a67186-edaf-4b77-90ce-99913a796507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_20ba39e5-319a-47d4-8b4f-c8d574ded31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8966bd5-662b-4ecb-859c-0658adf26556" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_20ba39e5-319a-47d4-8b4f-c8d574ded31e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cda795a5-b015-42e2-b663-41b9fd1a7591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_09da6272-a041-4e00-a8db-403ba4b44925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_cda795a5-b015-42e2-b663-41b9fd1a7591" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_09da6272-a041-4e00-a8db-403ba4b44925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_f57903d4-3f48-44c7-9635-a8f7f9345a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_cda795a5-b015-42e2-b663-41b9fd1a7591" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_f57903d4-3f48-44c7-9635-a8f7f9345a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6978fe09-79b4-4298-90b2-58fe3eca5f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_68979954-7e87-43d0-b26a-8d1957b36221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_6978fe09-79b4-4298-90b2-58fe3eca5f30" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_68979954-7e87-43d0-b26a-8d1957b36221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b0c55b3a-d55e-483a-b96d-b61eeba1d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_6978fe09-79b4-4298-90b2-58fe3eca5f30" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b0c55b3a-d55e-483a-b96d-b61eeba1d95e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_3dbe267e-e58c-4786-8a01-21791d198906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_ffe62d64-ada1-4600-a9d5-eefcbda6d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_3dbe267e-e58c-4786-8a01-21791d198906" xlink:to="loc_us-gaap_HeldToMaturitySecurities_ffe62d64-ada1-4600-a9d5-eefcbda6d7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_efac3ba9-018c-454d-ac8b-44ae249d27cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_3dbe267e-e58c-4786-8a01-21791d198906" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_efac3ba9-018c-454d-ac8b-44ae249d27cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d599e248-df1a-4d01-b9f6-f1fdfab75951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9247ce92-7927-44d1-acea-4bb98e3c0b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d599e248-df1a-4d01-b9f6-f1fdfab75951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9247ce92-7927-44d1-acea-4bb98e3c0b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0820df20-486b-4af1-b33c-e500d77b243d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d599e248-df1a-4d01-b9f6-f1fdfab75951" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0820df20-486b-4af1-b33c-e500d77b243d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_0c788af3-b692-450d-bb8c-58e082ee2e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:to="loc_us-gaap_Land_0c788af3-b692-450d-bb8c-58e082ee2e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_0f496b35-0294-4020-a0e2-243101190958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_0f496b35-0294-4020-a0e2-243101190958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3027f7fe-d555-4fc8-a195-645a6c2e8b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_3027f7fe-d555-4fc8-a195-645a6c2e8b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4fda6ac0-e4ac-4840-8cd7-cd28deba297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4fda6ac0-e4ac-4840-8cd7-cd28deba297f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_262505ef-9bfa-45f0-929a-36f9e6bc2ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9826f02f-d925-420d-a62c-32196d9be551" xlink:to="loc_us-gaap_ConstructionInProgressGross_262505ef-9bfa-45f0-929a-36f9e6bc2ea2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45d9799a-526c-462a-8f3f-37d0e47a785d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4d0d2a39-df2d-413f-af62-a36c5483b9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45d9799a-526c-462a-8f3f-37d0e47a785d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4d0d2a39-df2d-413f-af62-a36c5483b9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3c226d2-aa11-48c7-8a72-269bdbcad20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45d9799a-526c-462a-8f3f-37d0e47a785d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3c226d2-aa11-48c7-8a72-269bdbcad20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dad2f08c-11c0-4f77-8b93-1b53f8dd627f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a7427f9a-8954-4561-a838-3014cdd1cb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dad2f08c-11c0-4f77-8b93-1b53f8dd627f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a7427f9a-8954-4561-a838-3014cdd1cb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_9096b355-0137-4ae9-a4e4-4e1c3b7cdb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dad2f08c-11c0-4f77-8b93-1b53f8dd627f" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_9096b355-0137-4ae9-a4e4-4e1c3b7cdb49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_a38e7f38-8144-4062-8275-02d0a898830a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dad2f08c-11c0-4f77-8b93-1b53f8dd627f" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_a38e7f38-8144-4062-8275-02d0a898830a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d2f9a94f-1b63-4ca8-9589-f7ecaf6d12fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d2f9a94f-1b63-4ca8-9589-f7ecaf6d12fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5c320e81-6d7e-4370-bae5-e18e6cd03534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5c320e81-6d7e-4370-bae5-e18e6cd03534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_92777009-9c93-4f1b-8858-5c92c5933bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_92777009-9c93-4f1b-8858-5c92c5933bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5ef7f418-5f45-482f-b31b-49e256129176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5ef7f418-5f45-482f-b31b-49e256129176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_611ae769-bc07-4566-836f-d5bebbffa324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_611ae769-bc07-4566-836f-d5bebbffa324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_248e5415-411a-4194-8ad0-dcf729a8afed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d236406a-5d7f-4b6a-a9ae-ae290568809b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_248e5415-411a-4194-8ad0-dcf729a8afed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_f9d08fcd-167a-4282-ba2a-357421002da3" xlink:href="dva-20221231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:to="loc_dva_PayorRefundsAndRetractions_f9d08fcd-167a-4282-ba2a-357421002da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_5d188fd8-7fc6-4af7-814a-bc214c9e4722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_5d188fd8-7fc6-4af7-814a-bc214c9e4722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_9fac2350-e438-4b52-8622-23ab311ad0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:to="loc_us-gaap_InterestPayableCurrent_9fac2350-e438-4b52-8622-23ab311ad0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_beedd54d-e729-4fc4-9cd3-c2f36b37e6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_beedd54d-e729-4fc4-9cd3-c2f36b37e6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_747b3747-bc58-4da4-8ca4-36111a83105f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_8371f284-cffc-41e1-a746-d66a75a12f1e" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_747b3747-bc58-4da4-8ca4-36111a83105f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e851aac7-25f3-49d4-bb16-c5182e73ada4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8e4b765c-5baf-4a3a-b866-2ae8c2aac547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e851aac7-25f3-49d4-bb16-c5182e73ada4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8e4b765c-5baf-4a3a-b866-2ae8c2aac547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9ced2e79-d7cd-4055-aa0d-784be4dc3178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e851aac7-25f3-49d4-bb16-c5182e73ada4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9ced2e79-d7cd-4055-aa0d-784be4dc3178" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b549bfbd-08d8-4673-86e9-8061bf0a5197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bbe02ef9-0599-4427-ac84-d39c7e45c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b549bfbd-08d8-4673-86e9-8061bf0a5197" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bbe02ef9-0599-4427-ac84-d39c7e45c45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b7e16ea1-6869-4bf0-9173-cda07a40b83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b549bfbd-08d8-4673-86e9-8061bf0a5197" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b7e16ea1-6869-4bf0-9173-cda07a40b83d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00b58c07-51eb-4438-89cc-dfd12fc32f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fe78526f-6153-410e-acf5-f727dabb68f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00b58c07-51eb-4438-89cc-dfd12fc32f86" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fe78526f-6153-410e-acf5-f727dabb68f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e14b1619-08c6-426d-b981-4d554a4a69a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00b58c07-51eb-4438-89cc-dfd12fc32f86" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e14b1619-08c6-426d-b981-4d554a4a69a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_304b919b-85ba-4411-a647-77f9883fc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00b58c07-51eb-4438-89cc-dfd12fc32f86" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_304b919b-85ba-4411-a647-77f9883fc9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c4e4b238-d066-4af7-9fcb-b2146ff846d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5d41275-ff3f-42e5-a560-3947e7ffedc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c4e4b238-d066-4af7-9fcb-b2146ff846d6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5d41275-ff3f-42e5-a560-3947e7ffedc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4d952a0d-dcbb-482d-b64d-9cfc3e6fa38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c4e4b238-d066-4af7-9fcb-b2146ff846d6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4d952a0d-dcbb-482d-b64d-9cfc3e6fa38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_68567bef-8399-43cb-9097-ca6a01897bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_c4e4b238-d066-4af7-9fcb-b2146ff846d6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_68567bef-8399-43cb-9097-ca6a01897bac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_b90df8e6-4680-4f68-8077-46582f884a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bbe022ee-6b6e-4e98-a7a5-c3ae04bccd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_b90df8e6-4680-4f68-8077-46582f884a06" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bbe022ee-6b6e-4e98-a7a5-c3ae04bccd8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_19473043-8127-40fb-96b3-3fb7ab24f621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_b90df8e6-4680-4f68-8077-46582f884a06" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_19473043-8127-40fb-96b3-3fb7ab24f621" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_f22be2b1-7d51-42df-b0f0-ff4168b9dad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_f22be2b1-7d51-42df-b0f0-ff4168b9dad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fdec4087-0c16-4130-ab04-4164ced6306a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fdec4087-0c16-4130-ab04-4164ced6306a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2de837e1-ac22-4b26-b787-a470b58377bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2de837e1-ac22-4b26-b787-a470b58377bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a1941c89-a642-4964-b9af-1cb46d8f31d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a1941c89-a642-4964-b9af-1cb46d8f31d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_f6bb9171-fed5-4146-aa2f-c592a03be096" xlink:href="dva-20221231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_f6bb9171-fed5-4146-aa2f-c592a03be096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_14ee9724-683e-4c8c-aae7-f2be796b8a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_14ee9724-683e-4c8c-aae7-f2be796b8a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f60479c0-fbea-40ec-924a-31464524b894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f60479c0-fbea-40ec-924a-31464524b894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b1ab31bf-9489-4013-a6c3-2fd9dd0949f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b1ab31bf-9489-4013-a6c3-2fd9dd0949f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_9906e7b6-8922-4eb7-b259-fa959bceb388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_9906e7b6-8922-4eb7-b259-fa959bceb388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e2b21169-232d-4f67-92ed-93c1a8f63433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e2b21169-232d-4f67-92ed-93c1a8f63433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_e83a8602-141f-48b5-9c5e-2f63ac69eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b7f69482-89a0-4460-8a8b-2e2ccbffd951" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_e83a8602-141f-48b5-9c5e-2f63ac69eb65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ca520f8f-7bf9-48c9-82e5-bde684a41ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_afcda867-f64e-4d84-b44f-cb9d3f8e32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ca520f8f-7bf9-48c9-82e5-bde684a41ebf" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_afcda867-f64e-4d84-b44f-cb9d3f8e32cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_201d6ae1-8efa-4426-ae5d-39d08384512f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ca520f8f-7bf9-48c9-82e5-bde684a41ebf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_201d6ae1-8efa-4426-ae5d-39d08384512f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a9b7aff9-56ee-4983-8537-89debd360d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a9b7aff9-56ee-4983-8537-89debd360d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e00305ae-d707-4df1-a406-97090284dc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e00305ae-d707-4df1-a406-97090284dc5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_28938dc3-5f93-4abb-a737-b75f0cb6a4ae" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_28938dc3-5f93-4abb-a737-b75f0cb6a4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_4c5e460d-b3ac-41ff-acea-03225454529d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_4c5e460d-b3ac-41ff-acea-03225454529d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_6b2a1718-a189-4699-a772-b2b2a9ff3f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_decfbe8e-c0fc-44c0-9e7d-855b101efb37" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_6b2a1718-a189-4699-a772-b2b2a9ff3f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_75a01de7-7299-4473-9bab-1b01753616bf" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:to="loc_dva_DeferredTaxAssetsReceivables_75a01de7-7299-4473-9bab-1b01753616bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4832b181-f25f-44d2-a92f-423e727357e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4832b181-f25f-44d2-a92f-423e727357e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_3bfb18ed-370c-4a93-940a-7bd626cb9455" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_3bfb18ed-370c-4a93-940a-7bd626cb9455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_89557555-81fd-436b-b71f-78f89cf33679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_89557555-81fd-436b-b71f-78f89cf33679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_50f241e5-ebe1-4838-bfe2-8e1648b18381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5f9b984c-4608-4cf0-b519-c5f0d3ce9ac1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_50f241e5-ebe1-4838-bfe2-8e1648b18381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_fc62a72e-08d0-4e6b-b0bd-d13aee964040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_493b50da-9919-423c-9275-9c8173e62b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_fc62a72e-08d0-4e6b-b0bd-d13aee964040" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_493b50da-9919-423c-9275-9c8173e62b9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_50877e52-ed0d-4af2-85fb-19c2f90baf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_fc62a72e-08d0-4e6b-b0bd-d13aee964040" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_50877e52-ed0d-4af2-85fb-19c2f90baf6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_090c601e-8f64-4501-9c44-5f7c565da6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_02a20031-89c4-4b0a-bd0d-998e6f593213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_090c601e-8f64-4501-9c44-5f7c565da6d5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_02a20031-89c4-4b0a-bd0d-998e6f593213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_f1d71c94-9f57-416d-97b4-fe1510620d0a" xlink:href="dva-20221231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_090c601e-8f64-4501-9c44-5f7c565da6d5" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_f1d71c94-9f57-416d-97b4-fe1510620d0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a7072164-4d5c-40d4-b750-6df47652c765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a7072164-4d5c-40d4-b750-6df47652c765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f029826e-6015-4744-bb96-534ceca68553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f029826e-6015-4744-bb96-534ceca68553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2936277d-6df6-4a65-a9cb-0cff22b7c95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2936277d-6df6-4a65-a9cb-0cff22b7c95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9cd50580-405d-4613-8b39-cf755c144373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9cd50580-405d-4613-8b39-cf755c144373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c17198c7-e40a-4c36-94b1-16528a04f4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c17198c7-e40a-4c36-94b1-16528a04f4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e9a74773-d60f-457e-a32e-3827928cea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c9fc325d-1a59-4a41-9a56-ade6bc8922cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e9a74773-d60f-457e-a32e-3827928cea1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2f12b28e-20eb-4882-8c8d-01daca8b01ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2f12b28e-20eb-4882-8c8d-01daca8b01ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b06384d5-3299-446c-86da-46a651687bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b06384d5-3299-446c-86da-46a651687bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9b7f9807-b56f-4206-b73d-4d75aeb8311e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9b7f9807-b56f-4206-b73d-4d75aeb8311e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_52aa56cb-9665-4055-876a-ab5b67475421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_52aa56cb-9665-4055-876a-ab5b67475421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_483728a0-fe90-4978-98c2-a101405c1882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_483728a0-fe90-4978-98c2-a101405c1882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_015e937e-dcde-494a-b816-89de06512b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7cfc62ca-a429-4a00-b4ac-3c8cbd53e697" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_015e937e-dcde-494a-b816-89de06512b7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f2715b85-4362-448c-b0b1-debf5918e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_88504bac-9970-4905-a5ed-60abb4ca9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f2715b85-4362-448c-b0b1-debf5918e35e" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_88504bac-9970-4905-a5ed-60abb4ca9b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_97367a2a-970b-4052-b567-d24dbdae6b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f2715b85-4362-448c-b0b1-debf5918e35e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_97367a2a-970b-4052-b567-d24dbdae6b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_5520f5cc-f61c-4a61-8651-cbf7546a32a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_ec721ad2-3eed-44dd-8256-17d4413455c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_5520f5cc-f61c-4a61-8651-cbf7546a32a2" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_ec721ad2-3eed-44dd-8256-17d4413455c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_b1377a21-85f5-4032-8259-76fd00548d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_5520f5cc-f61c-4a61-8651-cbf7546a32a2" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_b1377a21-85f5-4032-8259-76fd00548d56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1780cd34-1124-4b45-8309-80dcf7381626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1780cd34-1124-4b45-8309-80dcf7381626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e6c61409-04db-449e-9d02-73205ee07a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e6c61409-04db-449e-9d02-73205ee07a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9f85ad71-ceb5-4932-bc30-e74135d52d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9f85ad71-ceb5-4932-bc30-e74135d52d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0998bd1e-7984-4d74-8f6b-869c10139b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0998bd1e-7984-4d74-8f6b-869c10139b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0c9a47da-1cb0-4683-b1ea-dad6cd8f07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0c9a47da-1cb0-4683-b1ea-dad6cd8f07e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0387635f-3d4a-4422-9c64-c2375e01b7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_Goodwill_0387635f-3d4a-4422-9c64-c2375e01b7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b6e7158a-a807-4be0-b66e-c7e8ff1bdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b6e7158a-a807-4be0-b66e-c7e8ff1bdd49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9879ccce-d193-46ab-ae44-d2b603abf476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_9879ccce-d193-46ab-ae44-d2b603abf476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_0b116f4f-17b8-4feb-ac4c-721374226e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e941cda1-b9b1-4690-b6b4-d8e93614932e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_0b116f4f-17b8-4feb-ac4c-721374226e2f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>dva-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended" id="i012c3a29eef6447c8d612419ce5bff69_CONSOLIDATEDSTATEMENTSOFEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b68351ec-2824-4fd6-8292-698f9880535c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b68351ec-2824-4fd6-8292-698f9880535c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4a1d40e3-64ae-4e1e-9a1e-de42da2711b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4a1d40e3-64ae-4e1e-9a1e-de42da2711b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_42516eca-257a-4bb9-b9c3-911b9cc58925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_42516eca-257a-4bb9-b9c3-911b9cc58925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b4bd76d-554d-423a-88dc-a4c936d9f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b4bd76d-554d-423a-88dc-a4c936d9f39b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_9edf5264-8632-4322-bc1f-8ea64becbf07" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_9edf5264-8632-4322-bc1f-8ea64becbf07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_33c688d7-e1fa-45de-b277-7d01bd097023" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_33c688d7-e1fa-45de-b277-7d01bd097023" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_cbc1fbc1-4645-4660-98ad-4b18d24f84b9" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_cbc1fbc1-4645-4660-98ad-4b18d24f84b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_10410cf7-cc7c-450a-92b8-fe25bf5766f1" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_10410cf7-cc7c-450a-92b8-fe25bf5766f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_e4d52199-11f4-451b-b4e6-717cec1908fc" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_e4d52199-11f4-451b-b4e6-717cec1908fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_8ffa1277-5738-4769-b05c-849a1d8dfcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_8ffa1277-5738-4769-b05c-849a1d8dfcbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_9a63d5ae-c264-4d7e-95ac-05cbc09ba843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_9a63d5ae-c264-4d7e-95ac-05cbc09ba843" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d702c19b-c81f-4c8a-b8d3-c681651a9055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_197da20c-b3ba-41bf-a426-e3402daa4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_197da20c-b3ba-41bf-a426-e3402daa4fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c924e97-55b4-4e08-8878-61818413905e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c924e97-55b4-4e08-8878-61818413905e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_efc9d64f-ac4b-423a-ac23-84976729da21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_efc9d64f-ac4b-423a-ac23-84976729da21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_db652be3-97e7-46e1-8426-1a102efc2022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_db652be3-97e7-46e1-8426-1a102efc2022" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_534001d4-b49e-406e-91e8-fc55aba89443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_534001d4-b49e-406e-91e8-fc55aba89443" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f8430b45-c26c-4d73-98dd-c461f6b3bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f8430b45-c26c-4d73-98dd-c461f6b3bdb9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_349c6b2c-cfaf-4a91-94be-abd3607e0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_349c6b2c-cfaf-4a91-94be-abd3607e0efe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1ad931c1-ad2f-4317-a759-4b1f8b05ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1ad931c1-ad2f-4317-a759-4b1f8b05ef93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_4b03f71d-f4fd-4530-8888-228ed1bd13a4" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_4b03f71d-f4fd-4530-8888-228ed1bd13a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_4a70e8e8-10ff-4c72-8684-945678820478" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_4a70e8e8-10ff-4c72-8684-945678820478" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_69daa693-6fea-4021-acbe-148cf1effd6d" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_69daa693-6fea-4021-acbe-148cf1effd6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3c318eb7-465f-42a1-9d12-7059f9a55323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3c318eb7-465f-42a1-9d12-7059f9a55323" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_60498d61-baf6-405b-9f36-5472fffe004a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_60498d61-baf6-405b-9f36-5472fffe004a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_9f8f98f3-0801-48df-a968-2ecbc060c6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_9f8f98f3-0801-48df-a968-2ecbc060c6f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3052ca89-75a5-4b32-a1de-821db6eed965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3052ca89-75a5-4b32-a1de-821db6eed965" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f853474a-e5ea-41e3-8233-948a593eacbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f853474a-e5ea-41e3-8233-948a593eacbd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_a3f31d7d-dd71-4c4f-b964-9cf586b23b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_a3f31d7d-dd71-4c4f-b964-9cf586b23b25" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_a30e4c6a-47ea-42c2-9d38-598a934aa8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_a30e4c6a-47ea-42c2-9d38-598a934aa8df" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_bb7eef03-b36f-4570-a6e1-2eab99ddf4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_bb7eef03-b36f-4570-a6e1-2eab99ddf4cf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_ad4567e8-96ba-4015-83eb-3c35f93fcc9b" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_ad4567e8-96ba-4015-83eb-3c35f93fcc9b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_436b5f12-6b4c-4338-9cdd-e4640b41f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_465b2173-c08b-4f65-b30d-6d9ea0639919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:to="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f220694-bcc1-4075-b5b4-1aa7c343b30d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:to="loc_us-gaap_EquityComponentDomain_4f220694-bcc1-4075-b5b4-1aa7c343b30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:to="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:to="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_894f7d8e-9684-4291-a383-7cca9f23676a" xlink:href="dva-20221231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_894f7d8e-9684-4291-a383-7cca9f23676a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_771c9a13-d61d-4793-af8e-19aac186adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_CommonStockMember_771c9a13-d61d-4793-af8e-19aac186adbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef2fd65f-c356-40cc-a982-03c27c197add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef2fd65f-c356-40cc-a982-03c27c197add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_841ce041-261f-422a-ad62-be1a8573754d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_RetainedEarningsMember_841ce041-261f-422a-ad62-be1a8573754d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ecf7d635-9d80-4ef4-a5ed-9092bb12ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_TreasuryStockMember_ecf7d635-9d80-4ef4-a5ed-9092bb12ee6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a926320f-5cab-406b-99f8-a70b0537d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a926320f-5cab-406b-99f8-a70b0537d18f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1510bb6b-b94f-4572-aa41-ca0b8ae2fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1510bb6b-b94f-4572-aa41-ca0b8ae2fea9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i928bf7f380af4f328c22d01cb02805cb_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_29378733-3bcb-4590-9a02-abf59e4be006" xlink:href="dva-20221231.xsd#dva_NumberOfSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfSites_29378733-3bcb-4590-9a02-abf59e4be006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a7641050-6861-4a5c-8fe5-fb65f33431e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a7641050-6861-4a5c-8fe5-fb65f33431e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_07da574a-d720-482e-8db0-47750f1aaf5a" xlink:href="dva-20221231.xsd#dva_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfCustomers_07da574a-d720-482e-8db0-47750f1aaf5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2e85a420-24b9-4fc6-a0de-323eaf2e1bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2e85a420-24b9-4fc6-a0de-323eaf2e1bdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_7c2f716f-bfb7-4b81-a234-f8718602abc4" xlink:href="dva-20221231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_7c2f716f-bfb7-4b81-a234-f8718602abc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_ef7d904f-8405-4692-9d08-f0a0802bf754" xlink:href="dva-20221231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_ef7d904f-8405-4692-9d08-f0a0802bf754" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:to="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f7185e6-dcaa-4cf8-8255-f980a0e0c211_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:to="loc_srt_SegmentGeographicalDomain_7f7185e6-dcaa-4cf8-8255-f980a0e0c211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:to="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69515f42-14e0-46f7-80c7-d2b52e3061dc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:to="loc_country_US_69515f42-14e0-46f7-80c7-d2b52e3061dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_0081189e-1e6f-4ec0-a2c2-5bbe3b2a65e2" xlink:href="dva-20221231.xsd#dva_InternationalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:to="loc_dva_InternationalOperationsMember_0081189e-1e6f-4ec0-a2c2-5bbe3b2a65e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended" id="id61f44713bd2405e9571e9ac224f69c8_RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f2c1998-f707-49c1-914a-cebb2f35bc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f2c1998-f707-49c1-914a-cebb2f35bc5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_7a36cf68-68d6-4399-bbf0-5b591908cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_OtherIncome_7a36cf68-68d6-4399-bbf0-5b591908cda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a1a5884-dad4-4a2e-8809-b9cd8745d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_Revenues_7a1a5884-dad4-4a2e-8809-b9cd8745d2f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_76d431fb-7189-40eb-af6f-783467d93b87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:to="loc_us-gaap_SegmentDomain_76d431fb-7189-40eb-af6f-783467d93b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:to="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_515764c3-c43d-4d74-97b7-857faa2bca1d" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_515764c3-c43d-4d74-97b7-857faa2bca1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_ef827e64-1257-4800-9725-fb80a05843a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:to="loc_us-gaap_AllOtherSegmentsMember_ef827e64-1257-4800-9725-fb80a05843a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8042277c-4016-467a-bcfa-0bb089191752_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8042277c-4016-467a-bcfa-0bb089191752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_20670ee9-8007-466f-9166-0e30893f0d0a" xlink:href="dva-20221231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_20670ee9-8007-466f-9166-0e30893f0d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_967a8f47-f0d6-400f-ade3-bba90741cc2c" xlink:href="dva-20221231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_967a8f47-f0d6-400f-ade3-bba90741cc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_3081854a-b8b1-435c-9408-519a0773cccb" xlink:href="dva-20221231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_OtherGovernmentPayorsMember_3081854a-b8b1-435c-9408-519a0773cccb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_4b81e09f-f43b-4add-81d5-8cb8c61e3257" xlink:href="dva-20221231.xsd#dva_CommercialPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_CommercialPayorsMember_4b81e09f-f43b-4add-81d5-8cb8c61e3257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_e26cea0e-37b9-4fe2-b41b-c0ba93dea1fb" xlink:href="dva-20221231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_OtherSourcesofRevenueMember_e26cea0e-37b9-4fe2-b41b-c0ba93dea1fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9319a276-699e-4d49-95d0-effb2a49efec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:to="loc_srt_ConsolidationItemsDomain_9319a276-699e-4d49-95d0-effb2a49efec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:to="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4034ddd6-4cbc-4732-9a0e-f96230d53e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4034ddd6-4cbc-4732-9a0e-f96230d53e22" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended" id="iba047fbc45fb4a599b916247af3620f0_RevenueRecognitionandAccountsReceivableAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_4d67acea-48a0-476a-89da-d131754cf3b7" xlink:href="dva-20221231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_4d67acea-48a0-476a-89da-d131754cf3b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f93b5ac-bac5-48a9-a3d5-9df07e88ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f93b5ac-bac5-48a9-a3d5-9df07e88ec28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_245fe0c4-0dcb-434d-b6d2-6d88994f1124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_245fe0c4-0dcb-434d-b6d2-6d88994f1124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_884dbd2c-782f-4f51-9f37-55d04fb9f373" xlink:href="dva-20221231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_884dbd2c-782f-4f51-9f37-55d04fb9f373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_fb045ae4-573e-4261-923c-c0bd6d656487" xlink:href="dva-20221231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_fb045ae4-573e-4261-923c-c0bd6d656487" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_ead0998e-0f15-4ba9-a126-6e24ed68645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_ead0998e-0f15-4ba9-a126-6e24ed68645c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1d35611d-897b-41b8-9b2c-da7a1f774e09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1d35611d-897b-41b8-9b2c-da7a1f774e09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e88293a4-7708-472b-957e-470d9b78bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e88293a4-7708-472b-957e-470d9b78bfb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9332c6bb-6aa2-425c-818b-e58a0a69296f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9332c6bb-6aa2-425c-818b-e58a0a69296f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e1ef058f-9fcd-4b59-8982-9776bf1a7e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:to="loc_us-gaap_AccountsReceivableMember_e1ef058f-9fcd-4b59-8982-9776bf1a7e25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_9804dd0b-f874-4107-82bc-e4f4b15b5b9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_9804dd0b-f874-4107-82bc-e4f4b15b5b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_b7a72b8e-eeed-4c59-a646-c49998d3adf2" xlink:href="dva-20221231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:to="loc_dva_MedicareMember_b7a72b8e-eeed-4c59-a646-c49998d3adf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_f8973181-ca3e-4307-a104-d37a05916ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:to="loc_us-gaap_ThirdPartyPayorMember_f8973181-ca3e-4307-a104-d37a05916ce2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended" id="i2312f70c56ce47a2bbb1c80d4b219a20_ShorttermandlongterminvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9ddaee6a-6d82-4eb7-bce4-497e74251813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9ddaee6a-6d82-4eb7-bce4-497e74251813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1586aef5-4dd0-454c-b805-d4f5a7e095fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1586aef5-4dd0-454c-b805-d4f5a7e095fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ca70fb05-f7a7-4a85-a8f9-433ef8cdef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecurities_ca70fb05-f7a7-4a85-a8f9-433ef8cdef13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_f7c4376c-7d05-456d-ba2a-fc9d90c3f3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_f7c4376c-7d05-456d-ba2a-fc9d90c3f3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d37c5bda-df86-4644-a02a-d4dd1b06de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d37c5bda-df86-4644-a02a-d4dd1b06de7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_89d8110d-92fb-4248-b132-630d04b39480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_89d8110d-92fb-4248-b132-630d04b39480" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_17243936-d0e4-4c7e-b7b5-0777f9153a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_17243936-d0e4-4c7e-b7b5-0777f9153a0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:to="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c0605fe8-cab6-4e58-a455-11674982f298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c0605fe8-cab6-4e58-a455-11674982f298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d866e9bd-ff9c-48cc-84ce-1d08a326642a" xlink:href="dva-20221231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d866e9bd-ff9c-48cc-84ce-1d08a326642a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_b505c175-0c04-45e1-91ef-9bb5e79fd5b9" xlink:href="dva-20221231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_dva_MutualFundsAndCommonStockMember_b505c175-0c04-45e1-91ef-9bb5e79fd5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6d9ecf43-765f-46a5-b67f-5925e6ab8ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6d9ecf43-765f-46a5-b67f-5925e6ab8ded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_2ea7fcdb-f903-4ae9-9470-f8e7c6129dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_2ea7fcdb-f903-4ae9-9470-f8e7c6129dd3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended" id="i13a13e77ca5e4cef91d7bc7a95baa14e_OtherReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ee789d06-6058-45dc-a678-d88823e362a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ee789d06-6058-45dc-a678-d88823e362a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_943c1530-1068-4b4a-b872-33ba7d83526e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:to="loc_us-gaap_ReceivableTypeDomain_943c1530-1068-4b4a-b872-33ba7d83526e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:to="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_8ca60c16-ed5d-49df-bad5-2f29dddb7e5f" xlink:href="dva-20221231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_8ca60c16-ed5d-49df-bad5-2f29dddb7e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_ea88c40b-ecf1-4f58-92bd-d82244c9e96a" xlink:href="dva-20221231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:to="loc_dva_MedicareMember_ea88c40b-ecf1-4f58-92bd-d82244c9e96a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended" id="i3dca4895ddf249b9b1c609bed121ec4c_PropertyandEquipmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9eae2e2a-15dd-461b-989c-1c2c672846c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9eae2e2a-15dd-461b-989c-1c2c672846c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_472e4790-66e7-4599-ab4b-38a209d8449c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_472e4790-66e7-4599-ab4b-38a209d8449c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_e0b12521-2981-41bf-9be9-52706258cf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_InterestCostsCapitalized_e0b12521-2981-41bf-9be9-52706258cf4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2aa36fc4-bead-4c30-b48a-b51ac97cde43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2aa36fc4-bead-4c30-b48a-b51ac97cde43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ad09a30b-95d2-43b9-86bc-381b663abb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_BuildingMember_ad09a30b-95d2-43b9-86bc-381b663abb9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4fa22dc0-c5d6-4972-93e6-6fd5724e3556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4fa22dc0-c5d6-4972-93e6-6fd5724e3556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_fc896ec2-2333-4c41-9cac-20220ba04f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_fc896ec2-2333-4c41-9cac-20220ba04f39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:to="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e214ea9-4b3d-4bf9-b090-54c73a6251dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:to="loc_srt_RangeMember_4e214ea9-4b3d-4bf9-b090-54c73a6251dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:to="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e984f65-73b2-4cd2-9806-1bd08f93ddf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:to="loc_srt_MinimumMember_9e984f65-73b2-4cd2-9806-1bd08f93ddf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f353634b-3fd3-4741-a36e-82a36472d3d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:to="loc_srt_MaximumMember_f353634b-3fd3-4741-a36e-82a36472d3d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended" id="i305e5b6264ee4f648729ac1403e0a699_IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_344e2cc7-6335-432e-85f2-67a7605e5e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_344e2cc7-6335-432e-85f2-67a7605e5e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_39f249fa-4c10-44d2-bdeb-577b357a0f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_39f249fa-4c10-44d2-bdeb-577b357a0f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_3e4eb214-32af-4b4c-8ced-867ab0e69064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_3e4eb214-32af-4b4c-8ced-867ab0e69064" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7dfe7b12-47b6-492d-91de-16840d508c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7dfe7b12-47b6-492d-91de-16840d508c0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6b4bd0d-2357-4240-9407-51efad1041b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6b4bd0d-2357-4240-9407-51efad1041b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a9564a78-03b4-43dc-aba3-4a6369005d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a9564a78-03b4-43dc-aba3-4a6369005d25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef40042a-ee9f-4883-9370-1be4a5935fb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef40042a-ee9f-4883-9370-1be4a5935fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_488e9a6f-24c9-4336-bb4d-9d5467a32594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_488e9a6f-24c9-4336-bb4d-9d5467a32594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_dff9f339-ca97-49be-be4f-c47e11d85682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:to="loc_us-gaap_ServiceAgreementsMember_dff9f339-ca97-49be-be4f-c47e11d85682" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended" id="ibe6d7328b14f4647aaa9d62d0d126c51_IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b2d228bb-4d6a-4d9c-a781-f74668940e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b2d228bb-4d6a-4d9c-a781-f74668940e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51b61bb7-ebdf-4c52-8648-ffd77b9846a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51b61bb7-ebdf-4c52-8648-ffd77b9846a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2ef955a1-2ed3-4db1-8aec-82f35aae50c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2ef955a1-2ed3-4db1-8aec-82f35aae50c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00aac097-fd5f-414e-91a3-a59b0a21fe06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00aac097-fd5f-414e-91a3-a59b0a21fe06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1749aed8-7268-4d30-9e51-360c91535ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1749aed8-7268-4d30-9e51-360c91535ad3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2f809e8b-a453-4517-9005-3de73b349027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2f809e8b-a453-4517-9005-3de73b349027" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fa2cb52-cf11-4523-9453-4f599b72c9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fa2cb52-cf11-4523-9453-4f599b72c9de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5b08143e-cdc0-490b-bf4b-e078614ef704_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5b08143e-cdc0-490b-bf4b-e078614ef704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_420daae6-e667-4dea-86dd-ccc9dc70f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_420daae6-e667-4dea-86dd-ccc9dc70f1f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_6e322a62-58e5-40bf-b1d8-565edf4c64b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:to="loc_us-gaap_ServiceAgreementsMember_6e322a62-58e5-40bf-b1d8-565edf4c64b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended" id="i7728c701beae4586beb60350e710e2f8_IntangiblesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_fde975e5-5cf3-4609-8ff5-14ad2cf18125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_fde975e5-5cf3-4609-8ff5-14ad2cf18125" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_3f146be0-7456-42a0-b856-de23cdb0c051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_3f146be0-7456-42a0-b856-de23cdb0c051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_93e7bcf3-83a5-4d2d-8cc5-769acaef3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_93e7bcf3-83a5-4d2d-8cc5-769acaef3ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_34b67d5b-b9f3-49b5-8ba8-b580c879c716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_34b67d5b-b9f3-49b5-8ba8-b580c879c716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_972e71fa-c06b-4ec4-ac18-f996b29b0979_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_972e71fa-c06b-4ec4-ac18-f996b29b0979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_763d88f9-f96e-4d9e-94d3-4e51bf9eb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_763d88f9-f96e-4d9e-94d3-4e51bf9eb85f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_23cb69fe-ae2a-4d38-81af-0c0ac89b3f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:to="loc_us-gaap_CustomerRelationshipsMember_23cb69fe-ae2a-4d38-81af-0c0ac89b3f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:to="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:to="loc_srt_RangeMember_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:to="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_658c2d2e-80fe-4f62-b431-7f6c107e0778" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:to="loc_srt_MinimumMember_658c2d2e-80fe-4f62-b431-7f6c107e0778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c84d423e-49e6-41f3-b283-f50e6e68b566" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:to="loc_srt_MaximumMember_c84d423e-49e6-41f3-b283-f50e6e68b566" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended" id="iddb40767eb504972ba67aea7aa605093_EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f48a44de-1589-492f-83aa-bd1083322dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f48a44de-1589-492f-83aa-bd1083322dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_8049b884-8c5a-4866-a251-41b925e9935a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_8049b884-8c5a-4866-a251-41b925e9935a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_6cd5e7e2-181b-4f62-9684-ea42a2bf016e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_6cd5e7e2-181b-4f62-9684-ea42a2bf016e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ecf81007-5536-43b7-b7fe-0230b727dd70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ecf81007-5536-43b7-b7fe-0230b727dd70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_103e429f-e866-416f-8aab-7f7f70b67264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:to="loc_us-gaap_EquitySecuritiesMember_103e429f-e866-416f-8aab-7f7f70b67264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0da82c00-e234-484a-bbe7-10970deee614_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:to="loc_srt_OwnershipDomain_0da82c00-e234-484a-bbe7-10970deee614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:to="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_d82aebe2-6ee8-4723-88fe-648b9efd972e" xlink:href="dva-20221231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_d82aebe2-6ee8-4723-88fe-648b9efd972e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended" id="i22782b01118f4f798ff634c07e88a0ee_EquityMethodandOtherInvestmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6bf5809c-64f5-4984-8776-8e8e4258767d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6bf5809c-64f5-4984-8776-8e8e4258767d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_fedab28b-b203-426a-b90d-5149d8cd6d61" xlink:href="dva-20221231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_fedab28b-b203-426a-b90d-5149d8cd6d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ad3eb528-58ab-4e6b-a7c7-0d04cf2b410a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ad3eb528-58ab-4e6b-a7c7-0d04cf2b410a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8d06bf63-f806-48d0-b3cd-7e3811b5f51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8d06bf63-f806-48d0-b3cd-7e3811b5f51f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_7151b120-5268-411d-8325-fa35ba8240ef" xlink:href="dva-20221231.xsd#dva_NumberOfPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_dva_NumberOfPartnerships_7151b120-5268-411d-8325-fa35ba8240ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_18495c7a-5fbf-4a62-85fd-83ccb39e9952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_18495c7a-5fbf-4a62-85fd-83ccb39e9952" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_dd641443-249c-4c6a-80fa-d70039983660_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_dd641443-249c-4c6a-80fa-d70039983660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_26070ece-37e5-459f-9baf-2b78a3ad37b0" xlink:href="dva-20221231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_26070ece-37e5-459f-9baf-2b78a3ad37b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cacb80b0-56e9-4093-ad04-b63c96d5871a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:to="loc_srt_RangeMember_cacb80b0-56e9-4093-ad04-b63c96d5871a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:to="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6978b2e-1bef-4c8d-aba8-28460801ef42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:to="loc_srt_MinimumMember_e6978b2e-1bef-4c8d-aba8-28460801ef42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_780fbfc3-0a93-42b7-a138-3c0d11f31940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:to="loc_srt_MaximumMember_780fbfc3-0a93-42b7-a138-3c0d11f31940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e589cccb-47e3-4bdc-b565-a2455721dd71_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:to="loc_srt_OwnershipDomain_e589cccb-47e3-4bdc-b565-a2455721dd71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:to="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_b2b5bd25-eb4c-41ef-8280-ecb28a89f83f" xlink:href="dva-20221231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_b2b5bd25-eb4c-41ef-8280-ecb28a89f83f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_3e2c52df-a17d-4a4b-b99e-f4af78d4a384" xlink:href="dva-20221231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_3e2c52df-a17d-4a4b-b99e-f4af78d4a384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7a42f97-5c84-46f5-9e29-466191a141e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7a42f97-5c84-46f5-9e29-466191a141e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_2540d4db-5689-4f6d-a29f-ce169a51966c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_2540d4db-5689-4f6d-a29f-ce169a51966c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended" id="i376b45edd23345679685aa7a1daa7136_GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ab7b808-59b4-472a-9fe0-3b0973470bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_Goodwill_6ab7b808-59b4-472a-9fe0-3b0973470bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b1fbba37-620e-4fab-8d34-46e2b6179dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b1fbba37-620e-4fab-8d34-46e2b6179dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_536bb3ee-c2aa-49ad-b8eb-c29bd06dfb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_536bb3ee-c2aa-49ad-b8eb-c29bd06dfb70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1d668811-fa3f-4e35-8029-4b311b103d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1d668811-fa3f-4e35-8029-4b311b103d25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a7d4899d-ea12-4b5f-b99e-0132ccf62366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_007742e4-c8ec-4b6f-ae47-24f793e83c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillGross_007742e4-c8ec-4b6f-ae47-24f793e83c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_01274d4b-2a0f-40b8-a71d-0c42621e99b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_01274d4b-2a0f-40b8-a71d-0c42621e99b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_27b0194e-a26e-4d78-8dd2-1beba0413a80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:to="loc_us-gaap_SegmentDomain_27b0194e-a26e-4d78-8dd2-1beba0413a80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:to="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_b410226a-42c7-44fe-8f97-db49296f2ea0" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_b410226a-42c7-44fe-8f97-db49296f2ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3a889b35-49a6-4455-9c3d-ff2a407d1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3a889b35-49a6-4455-9c3d-ff2a407d1a1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended" id="i4aef15cb51f3498e899f5163ad552d27_GoodwillScheduleofReportingUnitsGoodwillBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e892037-01c5-4fa9-b041-8f67877f3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_us-gaap_Goodwill_6e892037-01c5-4fa9-b041-8f67877f3749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_220025aa-34d1-4893-925a-e2723a97ca6c" xlink:href="dva-20221231.xsd#dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_220025aa-34d1-4893-925a-e2723a97ca6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_4d282bc1-efbe-410f-9e70-484a801de06d" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForReductionInOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_4d282bc1-efbe-410f-9e70-484a801de06d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_837962aa-1545-450e-970f-74a8c15cc982" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_837962aa-1545-450e-970f-74a8c15cc982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_82f623e5-bb29-41e5-b40b-d1d17465103e" xlink:href="dva-20221231.xsd#dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_82f623e5-bb29-41e5-b40b-d1d17465103e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_603647de-3cc2-43f4-84e3-d5ca7d2c72c7" xlink:href="dva-20221231.xsd#dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_603647de-3cc2-43f4-84e3-d5ca7d2c72c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_23add1ca-aa26-493f-8120-ae671b1005dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:to="loc_us-gaap_SegmentDomain_23add1ca-aa26-493f-8120-ae671b1005dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:to="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_KidneyCareMember_389ac74e-3e7d-4dfc-998c-9ec1c617460b" xlink:href="dva-20221231.xsd#dva_KidneyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:to="loc_dva_KidneyCareMember_389ac74e-3e7d-4dfc-998c-9ec1c617460b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:to="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_205ec753-53f5-4ee0-8ec0-d5e477a0772c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:to="loc_srt_SegmentGeographicalDomain_205ec753-53f5-4ee0-8ec0-d5e477a0772c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:to="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_9e518b9b-1392-49a0-8b2a-ea169b0b541f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:to="loc_country_DE_9e518b9b-1392-49a0-8b2a-ea169b0b541f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended" id="ia2f290067d794c7da3cf53a5a47402df_GoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_00e1a4f1-9af5-418e-baf9-ce62f885d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:to="loc_us-gaap_NumberOfOperatingSegments_00e1a4f1-9af5-418e-baf9-ce62f885d5d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_58f546d5-6451-45a1-a9dd-afa35efc4cd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:to="loc_us-gaap_SegmentDomain_58f546d5-6451-45a1-a9dd-afa35efc4cd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:to="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_3a1d541e-93d1-4ad4-811c-de28ccd3bf21" xlink:href="dva-20221231.xsd#dva_OtherReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:to="loc_dva_OtherReportingUnitsMember_3a1d541e-93d1-4ad4-811c-de28ccd3bf21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended" id="iea0f5dedb7cd4525bc874032e3b47fab_IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:href="dva-20221231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_de61b730-6589-4537-9927-f0e85f871d4d" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxAssetsReceivables_de61b730-6589-4537-9927-f0e85f871d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_71f887fc-a16b-4a56-a2f4-8ba10287ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_71f887fc-a16b-4a56-a2f4-8ba10287ec4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_fef0f152-324a-4a11-bc20-b4406dd0215c" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_fef0f152-324a-4a11-bc20-b4406dd0215c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_774f9210-3179-4493-b6b7-0e9cd5697e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_774f9210-3179-4493-b6b7-0e9cd5697e29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0d6321c7-be21-4cc6-a50a-5e9baf948153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0d6321c7-be21-4cc6-a50a-5e9baf948153" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8cfd4027-7485-4eac-9a06-250667bcf279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8cfd4027-7485-4eac-9a06-250667bcf279" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d308d7c7-8d2e-4098-b159-f7f6ac71685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d308d7c7-8d2e-4098-b159-f7f6ac71685e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b2151729-1dc1-4c9b-988b-9e699220e290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b2151729-1dc1-4c9b-988b-9e699220e290" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1c54baa-cf4b-4ee0-90df-98212e51edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1c54baa-cf4b-4ee0-90df-98212e51edd2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71da9c1d-0ed2-419e-8217-6c4570223c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71da9c1d-0ed2-419e-8217-6c4570223c29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_bb4e1aad-1933-4cd1-af36-f2b502142456" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_bb4e1aad-1933-4cd1-af36-f2b502142456" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_259ef2c1-6c90-4900-8ee6-9e88c7e509a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_259ef2c1-6c90-4900-8ee6-9e88c7e509a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0e956acb-4a9d-4f39-9d2e-d1514d08d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0e956acb-4a9d-4f39-9d2e-d1514d08d4fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0875c67f-0450-4f5c-a4e8-48fc5cc17a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0875c67f-0450-4f5c-a4e8-48fc5cc17a68" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2a0a863c-005e-4765-814f-8eba2096f516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2a0a863c-005e-4765-814f-8eba2096f516" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:href="dva-20221231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a1db191b-4c56-43c9-9805-c90dbc2c3cd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a1db191b-4c56-43c9-9805-c90dbc2c3cd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_b31aa37f-f041-4826-aad0-f1fb2c2109a9" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_b31aa37f-f041-4826-aad0-f1fb2c2109a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a0270987-b468-442c-8f55-0c7f8e582b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a0270987-b468-442c-8f55-0c7f8e582b0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i47277dbc912840689e070a87bc882403_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:href="dva-20221231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_da3fdbcf-6ffd-456d-ac91-9fd06c11d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_da3fdbcf-6ffd-456d-ac91-9fd06c11d36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_4cd6ce0c-35b4-46a4-9982-a4355e124c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_4cd6ce0c-35b4-46a4-9982-a4355e124c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_26c12014-e4e6-490e-a784-28144cc925eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_26c12014-e4e6-490e-a784-28144cc925eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_922f68c2-268f-4c88-8766-613a34038d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_922f68c2-268f-4c88-8766-613a34038d9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_02b2c59a-8915-4b57-9b05-78ecae121662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_02b2c59a-8915-4b57-9b05-78ecae121662" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet_06c2ea72-0b3e-47da-90a1-f0f607c4176a" xlink:href="dva-20221231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_dva_IncreaseInDeferredTaxAssetsNet_06c2ea72-0b3e-47da-90a1-f0f607c4176a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dd628fbe-e6a7-4fd2-a271-05ec3ef442bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dd628fbe-e6a7-4fd2-a271-05ec3ef442bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_52bf0f8b-ca12-4603-b97e-881bd5eb0330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_52bf0f8b-ca12-4603-b97e-881bd5eb0330" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_43279a57-2160-4f37-9788-ac25222b378a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_43279a57-2160-4f37-9788-ac25222b378a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f4ab5a29-7759-4e3d-b2e3-c312d35cc72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f4ab5a29-7759-4e3d-b2e3-c312d35cc72c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_06651f56-7157-4c52-9257-cf4a20afa85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_06651f56-7157-4c52-9257-cf4a20afa85d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2ba3e911-098b-4dbe-9d0b-102f27afb5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2ba3e911-098b-4dbe-9d0b-102f27afb5c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:href="dva-20221231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d2e1f34d-2236-472c-8773-fa82d5f7354a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d2e1f34d-2236-472c-8773-fa82d5f7354a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ee4c0d03-b522-4b27-9ad4-fd1da6c0034a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_DomesticCountryMember_ee4c0d03-b522-4b27-9ad4-fd1da6c0034a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f092b175-6d83-46c7-9751-b9dc4fe8ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f092b175-6d83-46c7-9751-b9dc4fe8ce90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d4ae9565-500a-4650-8f50-28c1a6c170d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_ForeignCountryMember_d4ae9565-500a-4650-8f50-28c1a6c170d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:to="loc_us-gaap_TaxPeriodDomain_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:to="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_8735fbb0-00c0-4376-8037-05d15adb0162" xlink:href="dva-20221231.xsd#dva_TaxYear2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:to="loc_dva_TaxYear2029Member_8735fbb0-00c0-4376-8037-05d15adb0162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ed514ebe-e90b-41eb-9993-f1d3aab8edbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ed514ebe-e90b-41eb-9993-f1d3aab8edbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_564b1ba8-6624-4b4f-9f04-0a8dfa59ebad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_564b1ba8-6624-4b4f-9f04-0a8dfa59ebad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_db274822-5906-4dc8-867a-61db696a5a56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_db274822-5906-4dc8-867a-61db696a5a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_af1db2f5-70d4-48ab-97b5-c2308af1763b" xlink:href="dva-20221231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_af1db2f5-70d4-48ab-97b5-c2308af1763b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_af697df4-76a9-4e03-b36d-ee443ecc0eec" xlink:href="dva-20221231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:to="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_af697df4-76a9-4e03-b36d-ee443ecc0eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d67b98c9-2b0e-4872-bd6c-497c7700dbb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:to="loc_us-gaap_EquityComponentDomain_d67b98c9-2b0e-4872-bd6c-497c7700dbb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:to="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29abbc63-864b-4fbf-a706-cb40c5be5f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29abbc63-864b-4fbf-a706-cb40c5be5f3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended" id="ia1003c7711b54fbaad54ca29e379bf99_LongTermDebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_a612bc2c-213c-4bdc-a058-d6cedfc06f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:to="loc_us-gaap_SecuredDebt_a612bc2c-213c-4bdc-a058-d6cedfc06f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ba61a1a4-3528-406e-966a-2fa30f28b423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ba61a1a4-3528-406e-966a-2fa30f28b423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_89fc80ac-7e26-4f06-85c2-01046e182b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:to="loc_us-gaap_SeniorNotes_89fc80ac-7e26-4f06-85c2-01046e182b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_6aa42a5a-1d8b-426c-9141-646d630f7a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_6aa42a5a-1d8b-426c-9141-646d630f7a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c020900c-fcf0-4891-a6b7-cc9528938360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c020900c-fcf0-4891-a6b7-cc9528938360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_22685ed3-d86c-47e8-8647-934245de2507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentFairValue_22685ed3-d86c-47e8-8647-934245de2507" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_83b0b485-81ea-479c-8e12-896345716c62" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_83b0b485-81ea-479c-8e12-896345716c62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5f73d47c-77ad-451e-824d-0ee82b0062e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_FinanceLeaseLiability_5f73d47c-77ad-451e-824d-0ee82b0062e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_a56cb1d9-5097-4ae5-add0-22baf26bdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_a56cb1d9-5097-4ae5-add0-22baf26bdfa1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_4ce0cde5-ca45-4337-afe3-bb425e4cea90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_4ce0cde5-ca45-4337-afe3-bb425e4cea90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f129bbea-66cf-44a5-8d90-ab23d5c21a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f129bbea-66cf-44a5-8d90-ab23d5c21a14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_c643b22c-d8ea-4f45-b1a7-ee12ef5e2524" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_c643b22c-d8ea-4f45-b1a7-ee12ef5e2524" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a07e26f0-d6a1-45a5-85a9-2ac7ebbe0573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a07e26f0-d6a1-45a5-85a9-2ac7ebbe0573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_85dae419-22a1-4470-8038-6d05fdf516e9" xlink:href="dva-20221231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_85dae419-22a1-4470-8038-6d05fdf516e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_6f3881c0-305a-405a-b0cf-4e2b360f269e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_6f3881c0-305a-405a-b0cf-4e2b360f269e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de2e63c0-97fc-4380-9b90-71e3117d3755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de2e63c0-97fc-4380-9b90-71e3117d3755" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d54d368-d542-48da-a4a5-a6073a5f36cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d54d368-d542-48da-a4a5-a6073a5f36cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7439d594-1843-4df5-b1e0-527816901f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7439d594-1843-4df5-b1e0-527816901f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3fb6db04-318b-4bb2-8901-6e2122bfd962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DeferredOfferingCosts_3fb6db04-318b-4bb2-8901-6e2122bfd962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_060fcb4c-e491-4282-99c2-e614cd315582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_060fcb4c-e491-4282-99c2-e614cd315582" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4714d8e9-d57f-494a-9437-2644632951e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4714d8e9-d57f-494a-9437-2644632951e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAMember_07e71cee-1fa9-4f87-a769-bc4596e3e566" xlink:href="dva-20221231.xsd#dva_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_TermLoanAMember_07e71cee-1fa9-4f87-a769-bc4596e3e566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_78d92a80-5324-40df-9682-1116d02a0a19" xlink:href="dva-20221231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_TermLoanB1Member_78d92a80-5324-40df-9682-1116d02a0a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_f5d722cc-296c-421d-91fd-b2d4b218493a" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_f5d722cc-296c-421d-91fd-b2d4b218493a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7abfc93f-bdd1-4f5b-bf33-0afbd38cf9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_us-gaap_SeniorNotesMember_7abfc93f-bdd1-4f5b-bf33-0afbd38cf9a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f731e3d6-be09-4aa0-a309-f94ffc67caaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:to="loc_us-gaap_CreditFacilityDomain_f731e3d6-be09-4aa0-a309-f94ffc67caaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:to="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_79857e2b-8507-455d-b540-cb41ae055963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_79857e2b-8507-455d-b540-cb41ae055963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_875a624c-3187-4230-acf8-d2da3cf14eb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_875a624c-3187-4230-acf8-d2da3cf14eb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_bb088802-4f84-4fe3-bf20-3fcdf0003b59" xlink:href="dva-20221231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_bb088802-4f84-4fe3-bf20-3fcdf0003b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_a3ab959d-ebe1-4914-9398-b1ffad68b9c0" xlink:href="dva-20221231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_a3ab959d-ebe1-4914-9398-b1ffad68b9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_d72b40c7-770e-4d96-b639-b0b868fe1c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_d72b40c7-770e-4d96-b639-b0b868fe1c99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_fdb63ddc-b982-4a0d-b32b-e3f0769d1e1c" xlink:href="dva-20221231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_FinanceLeaseMember_fdb63ddc-b982-4a0d-b32b-e3f0769d1e1c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended" id="i08171bc0e59647eb84f8eebdba1d417f_LongTermDebtDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_739b4ee9-a2c9-4154-a950-e4c93939d399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_739b4ee9-a2c9-4154-a950-e4c93939d399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ff096185-1bb2-4ddc-8718-a96e27a505c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ff096185-1bb2-4ddc-8718-a96e27a505c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_07374466-696f-46f6-bc13-cb8814fc718c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInceptionDates_07374466-696f-46f6-bc13-cb8814fc718c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_21320674-4ed7-4d00-93c2-d9da32a975a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeMaturityDates_21320674-4ed7-4d00-93c2-d9da32a975a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b00ad873-0d0a-4edb-af36-a2c69194aca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b00ad873-0d0a-4edb-af36-a2c69194aca9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_be7cffe8-1272-402c-b20a-3bd75b168a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_be7cffe8-1272-402c-b20a-3bd75b168a08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8eaa037a-aaf1-499c-b07d-afb61a3385a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8eaa037a-aaf1-499c-b07d-afb61a3385a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70f12b07-bd28-4783-bb80-4649260566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70f12b07-bd28-4783-bb80-4649260566fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b7d6c0f1-38bb-4f25-9418-56673c3d9c17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b7d6c0f1-38bb-4f25-9418-56673c3d9c17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_a6a1dfa6-5976-40ee-bc7f-602c8c367a4f" xlink:href="dva-20221231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_a6a1dfa6-5976-40ee-bc7f-602c8c367a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_32fafba7-7f8a-4ede-9f97-daca999864b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_32fafba7-7f8a-4ede-9f97-daca999864b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_8113542f-164f-4329-8dfc-1876da95fcac" xlink:href="dva-20221231.xsd#dva_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:to="loc_dva_TermLoanFacilityMember_8113542f-164f-4329-8dfc-1876da95fcac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39aa6977-b069-4adb-b4d2-eba2caf1c16f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:to="loc_srt_RangeMember_39aa6977-b069-4adb-b4d2-eba2caf1c16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:to="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf204bc9-cd30-4d8a-9e05-500e5bde072b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:to="loc_srt_MaximumMember_bf204bc9-cd30-4d8a-9e05-500e5bde072b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ed25231d-a633-4517-8d3e-390cd5a9d7be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ed25231d-a633-4517-8d3e-390cd5a9d7be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:to="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_10272589-0536-4881-997c-f62a4f125feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:to="loc_us-gaap_CashFlowHedgingMember_10272589-0536-4881-997c-f62a4f125feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_80814649-cd3c-4a6f-944e-8d1c46e8e8e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_80814649-cd3c-4a6f-944e-8d1c46e8e8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0a28304b-fd0e-4325-a316-295f6cfd0751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0a28304b-fd0e-4325-a316-295f6cfd0751" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended" id="i1859169bdf6e42a6b3b4694c09350b53_LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c1b6549f-cef9-4d2a-a9cf-9962f470748a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c1b6549f-cef9-4d2a-a9cf-9962f470748a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_983ca304-7e37-456f-ba81-8badac5b3504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_983ca304-7e37-456f-ba81-8badac5b3504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_d066290c-262d-4c24-819c-37be6f82b850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_d066290c-262d-4c24-819c-37be6f82b850" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_daddf302-5342-4b84-ada4-8b3037598428_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:to="loc_us-gaap_HedgingRelationshipDomain_daddf302-5342-4b84-ada4-8b3037598428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fd5d3baa-12b3-4fc1-bd08-4afcd940b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:to="loc_us-gaap_CashFlowHedgingMember_fd5d3baa-12b3-4fc1-bd08-4afcd940b4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_76560f48-4c65-4ee0-8eaa-181167980cd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_76560f48-4c65-4ee0-8eaa-181167980cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_d4001d8c-b626-44eb-b58b-cb6d60594213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:to="loc_us-gaap_InterestRateCapMember_d4001d8c-b626-44eb-b58b-cb6d60594213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_97a3fcb2-aeaa-43a3-9106-11284ca49935" xlink:href="dva-20221231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_97a3fcb2-aeaa-43a3-9106-11284ca49935" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended" id="i14846f029ce2472b85f266824ac73a9f_LongTermDebtAdditionalinformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_08052b88-a67d-438d-9c7d-75dc9709a9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_08052b88-a67d-438d-9c7d-75dc9709a9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0a23cdb8-91f7-4425-95c3-ce9a89c5173c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_0a23cdb8-91f7-4425-95c3-ce9a89c5173c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_38e75370-cc20-4c33-ade5-555becfb0a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_SecuredDebt_38e75370-cc20-4c33-ade5-555becfb0a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e92f1688-e070-46ef-840b-2196f44d964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e92f1688-e070-46ef-840b-2196f44d964c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_30f8a02e-4b6a-4236-984a-266c98f80e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_30f8a02e-4b6a-4236-984a-266c98f80e27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_7bbf93e6-c60e-423f-8547-a815f2fe219a" xlink:href="dva-20221231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_7bbf93e6-c60e-423f-8547-a815f2fe219a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ff9fe63b-c012-4765-93d8-c0334d986127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ff9fe63b-c012-4765-93d8-c0334d986127" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_880fb21c-69ed-42e0-81cd-a6f962830be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_880fb21c-69ed-42e0-81cd-a6f962830be2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_57f648e0-2788-4dd7-bb01-b97232b3bb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_57f648e0-2788-4dd7-bb01-b97232b3bb6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f631e88d-3f27-4b30-81ec-d02c5424848a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_InterestExpenseDebt_f631e88d-3f27-4b30-81ec-d02c5424848a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32eb9631-6974-4dca-93c6-31574895708f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32eb9631-6974-4dca-93c6-31574895708f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAMember_aaeac07b-00cc-41a3-a9c3-cb110b6f9cce" xlink:href="dva-20221231.xsd#dva_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanAMember_aaeac07b-00cc-41a3-a9c3-cb110b6f9cce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_9fe0e234-392a-4e18-9578-e2628cb8cd9b" xlink:href="dva-20221231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanB1Member_9fe0e234-392a-4e18-9578-e2628cb8cd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAAndTermLoanB1Member_7f043aca-fcc1-4b14-af1c-fa14ad0bee70" xlink:href="dva-20221231.xsd#dva_TermLoanAAndTermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanAAndTermLoanB1Member_7f043aca-fcc1-4b14-af1c-fa14ad0bee70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_b73d0195-aa04-4fc0-8614-5c7694dc578e" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_b73d0195-aa04-4fc0-8614-5c7694dc578e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f23a9206-9a66-4f73-a76e-e85ca6702879_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:to="loc_us-gaap_CreditFacilityDomain_f23a9206-9a66-4f73-a76e-e85ca6702879_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:to="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_263b9913-79f4-4c26-8ff7-56513418696b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_263b9913-79f4-4c26-8ff7-56513418696b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_18daa9f9-b27e-42a2-bc64-a0f6cfd0e054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:to="loc_us-gaap_LetterOfCreditMember_18daa9f9-b27e-42a2-bc64-a0f6cfd0e054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d1d3311-458b-4d7d-b4f5-27684d775866_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:to="loc_srt_RangeMember_4d1d3311-458b-4d7d-b4f5-27684d775866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:to="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f81a12f4-e03f-439f-a52c-10523be06e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:to="loc_srt_MinimumMember_f81a12f4-e03f-439f-a52c-10523be06e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a03586be-f523-4912-b5de-9cddd365113c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:to="loc_srt_MaximumMember_a03586be-f523-4912-b5de-9cddd365113c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72e3b5a4-97a5-4533-ade5-46a5203e03e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72e3b5a4-97a5-4533-ade5-46a5203e03e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_3b66b977-03eb-4f09-a182-cdd81db0abaf" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_3b66b977-03eb-4f09-a182-cdd81db0abaf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended" id="i8f071ce017474b3e85ec8e17d6f6d95e_LeasesLeasesOtherInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:to="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717b19b1-861e-4575-940b-5bab7b78018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717b19b1-861e-4575-940b-5bab7b78018c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cf7d4011-5579-42c5-be11-af6ce29e225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cf7d4011-5579-42c5-be11-af6ce29e225e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d973337-e6d7-440c-8263-c06902a0eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d973337-e6d7-440c-8263-c06902a0eef8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bdc81eec-788e-44a5-b266-0a2156ee30e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bdc81eec-788e-44a5-b266-0a2156ee30e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:href="dva-20221231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:to="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9def94fa-c8ce-4a1a-93f4-a9848d7e83d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9def94fa-c8ce-4a1a-93f4-a9848d7e83d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_de986b46-1249-4e6f-945a-ca5b367e84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_OperatingLeasePayments_de986b46-1249-4e6f-945a-ca5b367e84dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b2bf9c67-0fb4-4445-a58b-390c2e36bacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b2bf9c67-0fb4-4445-a58b-390c2e36bacb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f6ccc31f-5899-428d-a366-9c6dd3bab841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f6ccc31f-5899-428d-a366-9c6dd3bab841" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_79ca38ac-8650-49da-a832-8628f5279a34" xlink:href="dva-20221231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_79ca38ac-8650-49da-a832-8628f5279a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:to="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b69b8a6a-59c3-4fad-bb43-59fce159d062_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b69b8a6a-59c3-4fad-bb43-59fce159d062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_06c1c2fe-f6f3-4e6a-b692-26d3a62f1d20" xlink:href="dva-20221231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:to="loc_dva_FinanceLeaseMember_06c1c2fe-f6f3-4e6a-b692-26d3a62f1d20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="ifcefef4000684236801adf7717966d90_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ea264122-2d4d-48fc-8ed7-ca04ff271246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ea264122-2d4d-48fc-8ed7-ca04ff271246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8cb28256-9909-4d09-aed2-17183756fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8cb28256-9909-4d09-aed2-17183756fe6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_af18f049-9c67-4692-9a1b-104ba0f17d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_af18f049-9c67-4692-9a1b-104ba0f17d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f8276110-dd4a-4a11-ba00-23c1bee10cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f8276110-dd4a-4a11-ba00-23c1bee10cc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_c44a6fee-6a9f-4076-ad09-0f851f96f7cb" xlink:href="dva-20221231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_c44a6fee-6a9f-4076-ad09-0f851f96f7cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fbd96ac6-d827-4f35-9939-85182d435e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LeaseCost_fbd96ac6-d827-4f35-9939-85182d435e86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:to="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a0398b2-c235-4b62-b36d-56a71d94d2d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:to="loc_srt_RangeMember_2a0398b2-c235-4b62-b36d-56a71d94d2d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:to="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8caa0be-acd8-4670-856b-f86f8e91360d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:to="loc_srt_MinimumMember_c8caa0be-acd8-4670-856b-f86f8e91360d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7d774ef-a280-4c40-ab22-5e80fc237785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:to="loc_srt_MaximumMember_c7d774ef-a280-4c40-ab22-5e80fc237785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:to="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_dd881768-7c03-4efb-a599-eec2f82678ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_dd881768-7c03-4efb-a599-eec2f82678ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_12b49353-1ac7-4ed7-b8ab-44c00778a3db" xlink:href="dva-20221231.xsd#dva_OperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:to="loc_dva_OperatingLeaseMember_12b49353-1ac7-4ed7-b8ab-44c00778a3db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended" id="ic77d2f378c6142879b23a6159eb5be92_EmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_86d9eb51-6daf-43f5-bf96-9a6462a2598f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_86d9eb51-6daf-43f5-bf96-9a6462a2598f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_d26c6a7a-dbb8-435c-8de0-534a58447995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_d26c6a7a-dbb8-435c-8de0-534a58447995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_413405db-bb89-49be-815d-f46c0f9d8849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_413405db-bb89-49be-815d-f46c0f9d8849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_50e62647-5565-43a6-bd14-9f05f16d6175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_50e62647-5565-43a6-bd14-9f05f16d6175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_9e24fa48-8548-4b3e-95cb-e03830780c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_9e24fa48-8548-4b3e-95cb-e03830780c55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_7977bf99-3cf4-475f-b4b9-2fe2d0e5e615" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_7977bf99-3cf4-475f-b4b9-2fe2d0e5e615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_a57bcf48-91dd-47fb-8836-34dfb8a16d2b" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_a57bcf48-91dd-47fb-8836-34dfb8a16d2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_a48d8bed-a218-4987-83d0-228edba193e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_a48d8bed-a218-4987-83d0-228edba193e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ca0f2d92-613d-4d12-8af4-6c693c4595c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ca0f2d92-613d-4d12-8af4-6c693c4595c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_776d16e2-25e8-4b58-8ff9-a5384917ca4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_776d16e2-25e8-4b58-8ff9-a5384917ca4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_8c1428b4-7b31-4499-a174-8cc818d4222d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_8c1428b4-7b31-4499-a174-8cc818d4222d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_139293a0-4e90-4887-8f6b-265757eded86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_139293a0-4e90-4887-8f6b-265757eded86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_3066467e-6752-4b83-8e56-7d4b2d058689" xlink:href="dva-20221231.xsd#dva_AllTrustsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:to="loc_dva_AllTrustsMember_3066467e-6752-4b83-8e56-7d4b2d058689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00d80395-4f18-4129-b2e2-2910f73320a3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:to="loc_srt_RangeMember_00d80395-4f18-4129-b2e2-2910f73320a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:to="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63b54b8d-2c0d-4023-82dc-74130bd2cf1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:to="loc_srt_MinimumMember_63b54b8d-2c0d-4023-82dc-74130bd2cf1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db9aee28-3f0e-4d0f-9c4a-408eb777a0cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:to="loc_srt_MaximumMember_db9aee28-3f0e-4d0f-9c4a-408eb777a0cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ContingenciesAdditionalInformationDetails" xlink:type="extended" id="i2df759c5ec5c4a3da4b1646ca3250f42_ContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a1c90520-7fc6-45ca-8e84-e849dcaa1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a1c90520-7fc6-45ca-8e84-e849dcaa1fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:to="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:to="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_c94b168a-9fb3-49fe-a822-db325d0d45c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:to="loc_us-gaap_TransactionDomain_c94b168a-9fb3-49fe-a822-db325d0d45c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:to="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncrementalCashPortionMember_59acf2cf-d1bf-4816-b364-e549aed45284" xlink:href="dva-20221231.xsd#dva_IncrementalCashPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:to="loc_dva_IncrementalCashPortionMember_59acf2cf-d1bf-4816-b364-e549aed45284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidForPortionPreviouslyRefundedMember_1a58a5c1-d405-4f6e-9827-8bd81c01770b" xlink:href="dva-20221231.xsd#dva_CashPaidForPortionPreviouslyRefundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:to="loc_dva_CashPaidForPortionPreviouslyRefundedMember_1a58a5c1-d405-4f6e-9827-8bd81c01770b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:to="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a4806ff3-2868-49ab-aebe-6a00fd913e3f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:to="loc_srt_LitigationCaseTypeDomain_a4806ff3-2868-49ab-aebe-6a00fd913e3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:to="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USAttorneyPrescriptionDrugInvestigationMember_a723fd1b-c785-4e98-af97-cd0f625ce9af" xlink:href="dva-20221231.xsd#dva_USAttorneyPrescriptionDrugInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:to="loc_dva_USAttorneyPrescriptionDrugInvestigationMember_a723fd1b-c785-4e98-af97-cd0f625ce9af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended" id="i7af2f9b6e1a542fbb452547973d4cd30_NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_75ce7e31-52b2-47b7-bcbb-14a9f6611f0c" xlink:href="dva-20221231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_dva_DissolutionTermOfJointVentures_75ce7e31-52b2-47b7-bcbb-14a9f6611f0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_e837577f-494b-4d0e-9f7c-a8c8ec200c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_e837577f-494b-4d0e-9f7c-a8c8ec200c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_0b11acdb-cbc7-452e-927b-4dbe207368fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_0b11acdb-cbc7-452e-927b-4dbe207368fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_dbacdadb-23f0-46d1-b9df-767b8b6bbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_dbacdadb-23f0-46d1-b9df-767b8b6bbb39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_c6f00b3e-7dc9-499f-ad04-f7e82494844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_c6f00b3e-7dc9-499f-ad04-f7e82494844e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_c4475931-74a8-41bf-b33a-30c1d9c0cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_OtherCommitment_c4475931-74a8-41bf-b33a-30c1d9c0cbbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_41556e47-d282-4187-9042-b8901e2e19d1" xlink:href="dva-20221231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_41556e47-d282-4187-9042-b8901e2e19d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6cd84b5e-0664-4bfb-b024-4509c5731c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6cd84b5e-0664-4bfb-b024-4509c5731c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:to="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_d1ee65f3-6dd8-4d88-a31e-96797977f8e4" xlink:href="dva-20221231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_d1ee65f3-6dd8-4d88-a31e-96797977f8e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:to="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_341de01e-47ba-4459-8a4b-29dac1e798e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:to="loc_srt_RangeMember_341de01e-47ba-4459-8a4b-29dac1e798e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:to="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96e0b649-dea1-464f-a237-d06c4ff3a483" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:to="loc_srt_MinimumMember_96e0b649-dea1-464f-a237-d06c4ff3a483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2833db55-18e7-4ad5-9530-706639dc52c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:to="loc_srt_MaximumMember_2833db55-18e7-4ad5-9530-706639dc52c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended" id="ia895ef0c6b294f57bbb22a1febcee723_LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e51060c-ac6b-40c6-9145-5ad9615a8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e51060c-ac6b-40c6-9145-5ad9615a8d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a360ab27-6d1c-403e-abc1-f6f14edd6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a360ab27-6d1c-403e-abc1-f6f14edd6664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6eb544bc-3b36-4bea-9425-671a9b7a28a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6eb544bc-3b36-4bea-9425-671a9b7a28a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c825af08-003a-40dd-a7f2-b1fa1c1188a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c825af08-003a-40dd-a7f2-b1fa1c1188a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc766316-ab11-4941-8698-557905d5cd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b3f0496-7cde-4398-a76d-2971a0a59699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b3f0496-7cde-4398-a76d-2971a0a59699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89a09e1c-7f2f-44b5-8a9c-5654435029ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89a09e1c-7f2f-44b5-8a9c-5654435029ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dc8a22f-9164-4b1b-83bf-7e8f69466bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dc8a22f-9164-4b1b-83bf-7e8f69466bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51ea2da6-ee40-4d67-9cb9-bd9417d1fd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51ea2da6-ee40-4d67-9cb9-bd9417d1fd5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b27bc1d1-3ff3-4fbf-98ff-7eb5f86c9767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b27bc1d1-3ff3-4fbf-98ff-7eb5f86c9767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9cc36780-16c4-4f42-bab0-81a0ee687421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9cc36780-16c4-4f42-bab0-81a0ee687421" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a1584b40-a163-4444-988e-df0fcacc159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62fb9f1a-e641-4835-989d-a9fab5344c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62fb9f1a-e641-4835-989d-a9fab5344c27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3d64e3c-8bf1-4f48-87cc-4788a3984bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3d64e3c-8bf1-4f48-87cc-4788a3984bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_66c8daf1-3a6e-41cd-b838-b2feb90cd788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_66c8daf1-3a6e-41cd-b838-b2feb90cd788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6c1cdbb-e54d-4d87-8454-0ea1e9e1502e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6c1cdbb-e54d-4d87-8454-0ea1e9e1502e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0e9cc7b-e407-49ba-a025-c0e6146fa6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0e9cc7b-e407-49ba-a025-c0e6146fa6ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_019fb4fd-75ab-42ef-8bf7-d9b00be971fc" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_019fb4fd-75ab-42ef-8bf7-d9b00be971fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ec49839f-0549-434a-a473-51486e1ab926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ec49839f-0549-434a-a473-51486e1ab926" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_03e2913d-cfdb-4c22-8f91-e8de275ed2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_03e2913d-cfdb-4c22-8f91-e8de275ed2c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62a43d28-2156-47de-aafc-fc1d86ce0eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_16be0f62-1253-40dc-a9cf-052814a5d0aa" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_16be0f62-1253-40dc-a9cf-052814a5d0aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4ca40a6-2baf-4ac7-8ad8-4483286bc293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4ca40a6-2baf-4ac7-8ad8-4483286bc293" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3660ef56-21e4-49f4-a47d-d1ca79f71266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3660ef56-21e4-49f4-a47d-d1ca79f71266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_88f41244-b384-4fc1-8c19-ce94d1923207" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_88f41244-b384-4fc1-8c19-ce94d1923207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:to="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f527800e-35f5-48a3-9704-120d0ac0bf3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f527800e-35f5-48a3-9704-120d0ac0bf3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_cf94e9f9-b663-4cad-b5ba-dab3ca1ad102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_cf94e9f9-b663-4cad-b5ba-dab3ca1ad102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_a14182cb-7fdd-4a3c-bd64-3e6a5c0b83a5" xlink:href="dva-20221231.xsd#dva_StockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:to="loc_dva_StockUnitMember_a14182cb-7fdd-4a3c-bd64-3e6a5c0b83a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended" id="if096b98431234936b8e9471b42d088e8_LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_aae49e2b-70ab-47d1-be7a-472a021d8752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_aae49e2b-70ab-47d1-be7a-472a021d8752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_28f4d83e-b761-47e9-8474-9ac3ebbdc07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_28f4d83e-b761-47e9-8474-9ac3ebbdc07f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6e0bafc2-58b4-4335-bdd1-5b0a6fa2fdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6e0bafc2-58b4-4335-bdd1-5b0a6fa2fdee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c68abda1-d2cd-4a66-9550-f914c82b4123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c68abda1-d2cd-4a66-9550-f914c82b4123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9cfeeee5-473f-4a66-a1a7-792301549f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9cfeeee5-473f-4a66-a1a7-792301549f59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f986b5d3-d419-41b6-8885-bf78ca17470d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f986b5d3-d419-41b6-8885-bf78ca17470d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0fe8b248-3053-4a8d-b2f9-68f58964c93f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0fe8b248-3053-4a8d-b2f9-68f58964c93f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_d3ad9e23-640a-45a4-99b8-41e809b03fae" xlink:href="dva-20221231.xsd#dva_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeOneMember_d3ad9e23-640a-45a4-99b8-41e809b03fae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_db7501a1-8727-42d4-b2c8-406efdd153dc" xlink:href="dva-20221231.xsd#dva_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeTwoMember_db7501a1-8727-42d4-b2c8-406efdd153dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_b836ba2b-908c-4558-acb0-6f10644cee94" xlink:href="dva-20221231.xsd#dva_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeThreeMember_b836ba2b-908c-4558-acb0-6f10644cee94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_662c4fdc-a410-4fa9-bc8e-ac4fee5dd554" xlink:href="dva-20221231.xsd#dva_RangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeFourMember_662c4fdc-a410-4fa9-bc8e-ac4fee5dd554" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_307b2b11-86b2-4ece-869e-7263194211c9" xlink:href="dva-20221231.xsd#dva_RangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeFiveMember_307b2b11-86b2-4ece-869e-7263194211c9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended" id="i5b43eb11faa94676bb9dd27f80358cbe_LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e9aa0911-e08d-48f7-96f3-caddc555ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e9aa0911-e08d-48f7-96f3-caddc555ac43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ff52f3d8-a5e2-4957-8e06-52841ff9a89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ff52f3d8-a5e2-4957-8e06-52841ff9a89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35252fdf-530a-442e-82f5-250a3ffe19a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35252fdf-530a-442e-82f5-250a3ffe19a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48054fa4-fabb-4568-a409-9ed7c332fc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48054fa4-fabb-4568-a409-9ed7c332fc35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:to="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80706680-770a-4efe-8192-0d7cf2ce5815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80706680-770a-4efe-8192-0d7cf2ce5815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_ef410341-bcd6-4e38-b059-ed992549c6b8" xlink:href="dva-20221231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_ef410341-bcd6-4e38-b059-ed992549c6b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i706b1ee89d32467b84335b923178cf96_LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fe11460d-0127-4fbf-a6bc-6aa9979224f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fe11460d-0127-4fbf-a6bc-6aa9979224f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_79b743d1-6b96-411e-a333-180926223b64" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_79b743d1-6b96-411e-a333-180926223b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_c63fa23d-f6df-4401-b104-1af9e67ea7c3" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_c63fa23d-f6df-4401-b104-1af9e67ea7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_110a7063-e30d-4299-85af-9974dba10caa" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_110a7063-e30d-4299-85af-9974dba10caa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_b6fe6b80-5adf-43e8-af1e-46d0b1b5e602" xlink:href="dva-20221231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_b6fe6b80-5adf-43e8-af1e-46d0b1b5e602" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb790161-d5cb-4d75-8fde-79799ea71609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb790161-d5cb-4d75-8fde-79799ea71609" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c351824c-541f-4678-bbde-907a8c234998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c351824c-541f-4678-bbde-907a8c234998" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_ba59ba04-40b5-4861-9cdb-cbe44364b462" xlink:href="dva-20221231.xsd#dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_ba59ba04-40b5-4861-9cdb-cbe44364b462" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d6c5bf7-e3c4-4086-8c4c-433fd879af31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d6c5bf7-e3c4-4086-8c4c-433fd879af31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fac8b4bf-192d-4894-b256-6d3607704689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fac8b4bf-192d-4894-b256-6d3607704689" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d7ccf898-3661-433c-8aaf-d44565fbaf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d7ccf898-3661-433c-8aaf-d44565fbaf54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_758e4159-8003-4015-b024-131870897fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_758e4159-8003-4015-b024-131870897fb7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_bcb173e9-7ee4-4dc2-9689-1d5a9029b2fc" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_bcb173e9-7ee4-4dc2-9689-1d5a9029b2fc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3bd3d25d-f6cc-4df5-82c7-46aac6e0a3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3bd3d25d-f6cc-4df5-82c7-46aac6e0a3f9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_521b53df-53d5-427c-89a0-f0710f4838f3" xlink:href="dva-20221231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_521b53df-53d5-427c-89a0-f0710f4838f3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_21ffae5d-c094-4671-a65a-88178683fcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_21ffae5d-c094-4671-a65a-88178683fcb2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aee8b973-f104-487c-bad5-91f60c30388e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aee8b973-f104-487c-bad5-91f60c30388e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23dfde39-79ee-480a-a1da-8ee7a72311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23dfde39-79ee-480a-a1da-8ee7a72311a7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_03663584-86c6-4fae-a8a3-2360643a27b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_03663584-86c6-4fae-a8a3-2360643a27b4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63565313-51bf-4533-8160-fba24b094cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63565313-51bf-4533-8160-fba24b094cdf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20ef6a7a-8449-481a-bb87-97f99873d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensation_20ef6a7a-8449-481a-bb87-97f99873d7c0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_80cf3ba2-291d-490b-bae7-9601033a45cd" xlink:href="dva-20221231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_80cf3ba2-291d-490b-bae7-9601033a45cd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed9287eb-106d-4bce-8af4-20ef8228547a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed9287eb-106d-4bce-8af4-20ef8228547a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_60757f08-170f-4023-a9f9-c107206322b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_60757f08-170f-4023-a9f9-c107206322b2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_587b1701-1164-4a6d-b776-d5ba74ca49d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_587b1701-1164-4a6d-b776-d5ba74ca49d7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec04674c-6088-4fb1-8a85-c4e10a98fff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec04674c-6088-4fb1-8a85-c4e10a98fff1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bf27ed40-a06b-494a-9bcf-6f119cf3648c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:to="loc_us-gaap_PlanNameDomain_bf27ed40-a06b-494a-9bcf-6f119cf3648c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:to="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_d3fe2638-e169-4c06-a845-74bb9acff186" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_d3fe2638-e169-4c06-a845-74bb9acff186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyElevenMember_d7b3b797-4c87-49a5-bb2c-4d6efbbbd357" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:to="loc_dva_StockIncentivePlanTwentyElevenMember_d7b3b797-4c87-49a5-bb2c-4d6efbbbd357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a32a7bab-c455-4cad-a5b4-a23eb04a2a89_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:to="loc_srt_RangeMember_a32a7bab-c455-4cad-a5b4-a23eb04a2a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:to="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06c5938a-de68-4e69-a0da-d03af2c5717e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:to="loc_srt_MinimumMember_06c5938a-de68-4e69-a0da-d03af2c5717e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4da308d2-f6b1-4cc6-a422-618a3091e867" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:to="loc_srt_MaximumMember_4da308d2-f6b1-4cc6-a422-618a3091e867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf7080e4-a037-45eb-b99e-2b6394226152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf7080e4-a037-45eb-b99e-2b6394226152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_e9b5f4fa-f376-4969-a1d0-75330e83631d" xlink:href="dva-20221231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_e9b5f4fa-f376-4969-a1d0-75330e83631d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended" id="ie0848cb339cf4299a6fd7a7884316dc4_StockRepurchasesTenderOfferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_90136533-8d39-4fe1-bd50-888fad02a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_90136533-8d39-4fe1-bd50-888fad02a86e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a7f8b537-3d0d-4ffc-b064-22e0a5d8ad17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a7f8b537-3d0d-4ffc-b064-22e0a5d8ad17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b0437538-b809-4405-99f9-faf577b95a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b0437538-b809-4405-99f9-faf577b95a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_8cf90e8c-d773-4e6e-9645-a8ceada81e2a" xlink:href="dva-20221231.xsd#dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:to="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_8cf90e8c-d773-4e6e-9645-a8ceada81e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareRepurchaseFeesAndExpenses_66661c9c-8dbd-4fbc-9993-f83906c94e31" xlink:href="dva-20221231.xsd#dva_ShareRepurchaseFeesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:to="loc_dva_ShareRepurchaseFeesAndExpenses_66661c9c-8dbd-4fbc-9993-f83906c94e31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_17d5784c-b75d-4e96-84e1-3334e7017509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_17d5784c-b75d-4e96-84e1-3334e7017509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_0d78485e-ba69-40c7-9c95-a037968b88e5" xlink:href="dva-20221231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:to="loc_dva_OpenMarketPurchasesMember_0d78485e-ba69-40c7-9c95-a037968b88e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember_7d2363dc-6cb7-42dc-865c-38fa2272e802" xlink:href="dva-20221231.xsd#dva_TenderOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:to="loc_dva_TenderOfferMember_7d2363dc-6cb7-42dc-865c-38fa2272e802" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended" id="i6d3f02b8b7f0491ea7401c10881fb499_ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afb02e88-23cd-4df6-9258-036ab7aaa251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:to="loc_us-gaap_NetIncomeLoss_afb02e88-23cd-4df6-9258-036ab7aaa251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_992f18dc-b07a-492c-a681-5183d7fb128a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_992f18dc-b07a-492c-a681-5183d7fb128a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_728187b4-113d-4f66-968a-b513a5ba3b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_728187b4-113d-4f66-968a-b513a5ba3b46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_5dfc84d7-5c7a-4bda-8c8c-7b0717914b7f" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_5dfc84d7-5c7a-4bda-8c8c-7b0717914b7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8c3d20b9-69ac-42e6-87d2-89257b350736" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8c3d20b9-69ac-42e6-87d2-89257b350736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_ff44ea0e-dc06-42be-9882-462bab020629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_ff44ea0e-dc06-42be-9882-462bab020629" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_d1407f14-30f2-49b9-a81f-08df6feb4d2b" xlink:href="dva-20221231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_d1407f14-30f2-49b9-a81f-08df6feb4d2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc375bf1-fdfd-45c1-8053-9db111d8cdb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:to="loc_us-gaap_EquityComponentDomain_fc375bf1-fdfd-45c1-8053-9db111d8cdb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:to="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c7052f66-68f6-4997-bd27-470e78af342b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c7052f66-68f6-4997-bd27-470e78af342b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShareholdersequityDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended" id="i96cf012de5754d458981b78b7210316a_ShareholdersequityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:to="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_caa8a160-f904-4086-bd69-d018eabe8547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_caa8a160-f904-4086-bd69-d018eabe8547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_6dede265-d78c-4222-a31c-188f8aadcd9e" xlink:href="dva-20221231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_6dede265-d78c-4222-a31c-188f8aadcd9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2c9a52ae-0394-4a70-8d21-1cf3d36d31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2c9a52ae-0394-4a70-8d21-1cf3d36d31ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_0daf0306-3433-4449-9d20-299a8138c981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_0daf0306-3433-4449-9d20-299a8138c981" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_773dd9f4-79b7-47ac-9d06-469dc4b923d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_773dd9f4-79b7-47ac-9d06-469dc4b923d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:href="dva-20221231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4825b5c7-e417-44d1-91f2-f051c0218063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4825b5c7-e417-44d1-91f2-f051c0218063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_e2605fd5-166d-45c2-95a3-6aa6c022fb2e" xlink:href="dva-20221231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_e2605fd5-166d-45c2-95a3-6aa6c022fb2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_21d454e3-b273-41a0-ac8f-6786cd8177ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_21d454e3-b273-41a0-ac8f-6786cd8177ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3827406c-225a-4696-adc4-408bb92ec82e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3827406c-225a-4696-adc4-408bb92ec82e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e382020a-8c82-4288-ba32-a39281f35056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:to="loc_us-gaap_SubsequentEventMember_e382020a-8c82-4288-ba32-a39281f35056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f405797b-ffc9-42d3-b937-20732d656ca3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:to="loc_us-gaap_EquityComponentDomain_f405797b-ffc9-42d3-b937-20732d656ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:to="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_44bf3b03-95f9-4cb0-8235-d6fb4defe247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:to="loc_us-gaap_TreasuryStockMember_44bf3b03-95f9-4cb0-8235-d6fb4defe247" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended" id="i9d1b7eb568fe4354ac1250eeeeda0154_AccumulatedOtherComprehensiveLossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9415e838-bd62-45fe-8e3e-f440aa368ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9415e838-bd62-45fe-8e3e-f440aa368ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e59e52ec-8971-4e96-a353-2755d2444589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e59e52ec-8971-4e96-a353-2755d2444589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_78f0a410-eafe-4314-8fda-fcc011bf90bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_78f0a410-eafe-4314-8fda-fcc011bf90bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1ae7547-6ac3-4a86-9def-a2debae90199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1ae7547-6ac3-4a86-9def-a2debae90199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0df44869-7271-45dd-81ff-3a3e7e30d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0df44869-7271-45dd-81ff-3a3e7e30d89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7baffda5-b2dc-4a51-a3fb-b9dda538a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7baffda5-b2dc-4a51-a3fb-b9dda538a47a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_43611eca-4fa7-405c-b1c4-5495477cdaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_43611eca-4fa7-405c-b1c4-5495477cdaf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46b37d88-1b91-4edd-b039-cbe58c017ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_185ae1d1-48f4-40e8-a679-979499e3b07a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:to="loc_us-gaap_EquityComponentDomain_185ae1d1-48f4-40e8-a679-979499e3b07a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:to="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ee232a1f-b387-482b-b347-8ad89604e0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ee232a1f-b387-482b-b347-8ad89604e0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5b8dba1a-0048-4b55-859e-43557ef5790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5b8dba1a-0048-4b55-859e-43557ef5790e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c9946766-a09c-4ac1-96bc-a9c2140ce5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c9946766-a09c-4ac1-96bc-a9c2140ce5f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended" id="i9dcc825678074efbbaab25ccb585cfe2_AcquisitionsComponentsofRoutineAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8560a371-e780-444a-9a67-8621aac2fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8560a371-e780-444a-9a67-8621aac2fb7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_39c4cf27-ac23-4e95-95ba-e1be7ef28776" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_39c4cf27-ac23-4e95-95ba-e1be7ef28776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_568fbac5-a2f1-467d-86ac-af14e9218369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_568fbac5-a2f1-467d-86ac-af14e9218369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_0a5d818f-6085-4145-90e6-e12987fd5dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_0a5d818f-6085-4145-90e6-e12987fd5dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_114a2f42-90fd-484d-ac0b-3d13aaee0af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_114a2f42-90fd-484d-ac0b-3d13aaee0af1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_fae44895-2d64-48e0-bcc3-a655348a2f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_fae44895-2d64-48e0-bcc3-a655348a2f57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4df1c3b-836e-42a3-a5bb-5b072a1dca72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4df1c3b-836e-42a3-a5bb-5b072a1dca72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_a21ed3b6-d37b-4673-b25d-032c4922d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_a21ed3b6-d37b-4673-b25d-032c4922d26d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_546fd214-90e2-4e3d-aa1a-48da66c7060c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:to="loc_us-gaap_SegmentDomain_546fd214-90e2-4e3d-aa1a-48da66c7060c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:to="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_d6642473-e082-4db8-90c3-6d5864418587" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_d6642473-e082-4db8-90c3-6d5864418587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_fd6f14b0-9f47-481a-bf10-32aa04fa2608" xlink:href="dva-20221231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:to="loc_dva_ForeignDialysisCentersMember_fd6f14b0-9f47-481a-bf10-32aa04fa2608" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended" id="i822764e3806346278f63637be5207b72_AcquisitionsAssetsacquiredandliabilitiesassumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_afa93597-6308-42b9-9da3-81356dc4593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_afa93597-6308-42b9-9da3-81356dc4593b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a4acf6ad-d79c-4f6b-b5d6-e76bfda8c6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a4acf6ad-d79c-4f6b-b5d6-e76bfda8c6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6434c07c-1cc8-4796-b6d4-f1ca4540783b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6434c07c-1cc8-4796-b6d4-f1ca4540783b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_471132c5-b5ce-47b4-adf7-953490892bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_471132c5-b5ce-47b4-adf7-953490892bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ad09865c-d859-40bc-b7b4-c9e59e096d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ad09865c-d859-40bc-b7b4-c9e59e096d9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_56689d81-1a7d-43bb-98ce-b7a76c2db7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_Goodwill_56689d81-1a7d-43bb-98ce-b7a76c2db7ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6b6f3ae5-1b51-461f-8052-174882b2d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6b6f3ae5-1b51-461f-8052-174882b2d73c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_52057523-435b-45c6-8583-b05c3e730191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_52057523-435b-45c6-8583-b05c3e730191" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_cfd13f3c-4031-4e79-bfa1-aa88db8ae987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_cfd13f3c-4031-4e79-bfa1-aa88db8ae987" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06120274-443f-429c-b960-575ca6f36f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06120274-443f-429c-b960-575ca6f36f45" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16022571-9339-4257-9c57-5a7a72bb0825_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16022571-9339-4257-9c57-5a7a72bb0825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_4ae61442-ddd2-4a2e-9f0b-b07be145ab19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_4ae61442-ddd2-4a2e-9f0b-b07be145ab19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended" id="iaa78c00d90ba4a82a21cf839756e39bc_ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5422e4f0-4b3b-4b40-82c4-e0525d15277f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5422e4f0-4b3b-4b40-82c4-e0525d15277f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_75ee3aff-df04-4a13-96c9-9d61bcd142d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_75ee3aff-df04-4a13-96c9-9d61bcd142d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23f183e4-c837-4f87-9fc3-504c52c03660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23f183e4-c837-4f87-9fc3-504c52c03660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8c3cb279-10ae-4214-8cf1-4ca8e8a10812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8c3cb279-10ae-4214-8cf1-4ca8e8a10812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2dec262e-61a6-4546-ac4a-39c97e50306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2dec262e-61a6-4546-ac4a-39c97e50306b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c59eebba-1dcd-4752-ad85-d571e6e83a42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c59eebba-1dcd-4752-ad85-d571e6e83a42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_13a9578f-3ccd-4c18-b149-8a43903405c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_13a9578f-3ccd-4c18-b149-8a43903405c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended" id="id73dbaab622549f39e2998f35195afba_AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3400f838-5ca8-4e32-bcf0-4c67102afdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3400f838-5ca8-4e32-bcf0-4c67102afdcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_25eaefdf-a3c4-4b89-9c4b-77a09f088cff" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_25eaefdf-a3c4-4b89-9c4b-77a09f088cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_8433f0cb-ec04-4ed8-8a03-ae74a2f4c07a" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_8433f0cb-ec04-4ed8-8a03-ae74a2f4c07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_80857316-0067-4297-a243-b4d4b2d55aa9" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_80857316-0067-4297-a243-b4d4b2d55aa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_485cf194-c7dc-4f8f-bcd4-ae8624e99e91" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_485cf194-c7dc-4f8f-bcd4-ae8624e99e91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_17adafc1-bb69-439d-87e7-5f7d525aec41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53b2803a-efb0-488e-8582-1a46f1f6331d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53b2803a-efb0-488e-8582-1a46f1f6331d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ac4d1cf6-64bc-408e-95d2-334361c674a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ac4d1cf6-64bc-408e-95d2-334361c674a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended" id="i444344ac810b48589ae3b8f4fad5acc7_AcquisitionsandDivestituresAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_dcee286b-f0c2-4355-9745-4b08fb62bc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_dcee286b-f0c2-4355-9745-4b08fb62bc9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6200ff90-cdac-4252-bb91-7c10e78c52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6200ff90-cdac-4252-bb91-7c10e78c52d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_465f325c-284c-4100-865f-d747ca0f13a9" xlink:href="dva-20221231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_465f325c-284c-4100-865f-d747ca0f13a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_aca40e09-0a0b-40d9-9604-6df753423e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_aca40e09-0a0b-40d9-9604-6df753423e4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:to="loc_srt_RangeMember_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:to="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c64260c3-0bb5-48a8-a373-7323b96a36ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:to="loc_srt_MinimumMember_c64260c3-0bb5-48a8-a373-7323b96a36ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05b16924-b0d0-456b-87ce-db9246ee192f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:to="loc_srt_MaximumMember_05b16924-b0d0-456b-87ce-db9246ee192f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_246b7972-a305-4789-87d2-c976b2ad31ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:to="loc_us-gaap_RelatedPartyDomain_246b7972-a305-4789-87d2-c976b2ad31ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:to="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_0c8a6041-4696-42e3-a6da-7958280fa34b" xlink:href="dva-20221231.xsd#dva_OtherCompaniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:to="loc_dva_OtherCompaniesMember_0c8a6041-4696-42e3-a6da-7958280fa34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_434cfb3f-fb88-474a-adbe-9a9618e809c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_434cfb3f-fb88-474a-adbe-9a9618e809c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_c8ddd8cd-1f06-4a8c-ad97-7beca937a0c5" xlink:href="dva-20221231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_c8ddd8cd-1f06-4a8c-ad97-7beca937a0c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8609bced-36ef-4965-a0c8-e716a7942797_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8609bced-36ef-4965-a0c8-e716a7942797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_551e1199-0661-4c4b-a8f4-f8435b6b19d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_551e1199-0661-4c4b-a8f4-f8435b6b19d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9ffaae0a-abe6-4a2f-af02-add61dc9575a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9ffaae0a-abe6-4a2f-af02-add61dc9575a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1ea8bcb-26d0-4180-98b4-b051716515d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1ea8bcb-26d0-4180-98b4-b051716515d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RMSLifelineMember_92232b96-36eb-4340-8d5f-1252d4dfd104" xlink:href="dva-20221231.xsd#dva_RMSLifelineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:to="loc_dva_RMSLifelineMember_92232b96-36eb-4340-8d5f-1252d4dfd104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e300f27-1d00-406c-bf51-6aa3f3111c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e300f27-1d00-406c-bf51-6aa3f3111c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_298c2bfb-96e4-47d9-8055-ee45cc1af227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_298c2bfb-96e4-47d9-8055-ee45cc1af227" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended" id="i803b1533213746bcb0520aae4e14bd35_HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_380a0e2b-44ea-48d5-be29-8da2b4615787" xlink:href="dva-20221231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_380a0e2b-44ea-48d5-be29-8da2b4615787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b0682237-4487-4fe3-9be5-c5e22a054282" xlink:href="dva-20221231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b0682237-4487-4fe3-9be5-c5e22a054282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_2772f29c-10ab-4ccd-830f-f732b9ae8d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_2772f29c-10ab-4ccd-830f-f732b9ae8d22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_a8d45f7b-5fe3-4b94-9f9f-204b95f95e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_a8d45f7b-5fe3-4b94-9f9f-204b95f95e96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60fbdb5b-07c4-4f56-951d-81fc5d0ea7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60fbdb5b-07c4-4f56-951d-81fc5d0ea7e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_1aba9023-696c-4149-8496-6392418ce6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_1aba9023-696c-4149-8496-6392418ce6f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_b96e2be3-1279-4ac7-bb54-8d97e10a44fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_b96e2be3-1279-4ac7-bb54-8d97e10a44fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_223e0470-6f14-4c1a-8415-9714d2fd5050_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_223e0470-6f14-4c1a-8415-9714d2fd5050_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4dad94ac-abee-4b46-8540-c459679b1b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4dad94ac-abee-4b46-8540-c459679b1b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_242bf02a-681c-45aa-862a-507d638cc267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_242bf02a-681c-45aa-862a-507d638cc267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_c7cbf091-6bda-4af2-93c3-193ab58bf93c" xlink:href="dva-20221231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:to="loc_dva_DaVitaMedicalGroupMember_c7cbf091-6bda-4af2-93c3-193ab58bf93c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_56e5c7f2-a5a0-4592-91bf-4a0237547785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_56e5c7f2-a5a0-4592-91bf-4a0237547785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_73c3bf6d-3746-4da9-be52-993ddab3a76e" xlink:href="dva-20221231.xsd#dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:to="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_73c3bf6d-3746-4da9-be52-993ddab3a76e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended" id="i4acc1c3f74e44fe1a2097464c63373b0_VariableInterestEntitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_b03a4cc6-f126-4a1f-8428-d15397efac5b" xlink:href="dva-20221231.xsd#dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_b03a4cc6-f126-4a1f-8428-d15397efac5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9d6d3bd3-ccd2-470a-8d8b-97c84f422dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_us-gaap_Assets_9d6d3bd3-ccd2-470a-8d8b-97c84f422dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_321dd4f9-d07b-4079-8e89-46af0937d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_us-gaap_Liabilities_321dd4f9-d07b-4079-8e89-46af0937d67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c27811b7-57b9-4d23-a9cd-201c7272dab9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c27811b7-57b9-4d23-a9cd-201c7272dab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_2a119f9a-c8c5-4587-bfa0-8d92daeb0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_2a119f9a-c8c5-4587-bfa0-8d92daeb0d9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i8f1c316c30374c2cb597eb86543f0a55_FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6751d098-339c-4b46-b438-a7562b8c8fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6751d098-339c-4b46-b438-a7562b8c8fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c1c914f7-ffe9-4b1a-b375-6ec3ce59c58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:to="loc_us-gaap_DerivativeAssets_c1c914f7-ffe9-4b1a-b375-6ec3ce59c58c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72bb5760-6278-4019-ac48-778e6f0b803c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72bb5760-6278-4019-ac48-778e6f0b803c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_80af693f-4d0c-4b22-872a-c450c1d82edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_80af693f-4d0c-4b22-872a-c450c1d82edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_80eb1df8-132d-49b9-93e4-d70356e9ef96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_80eb1df8-132d-49b9-93e4-d70356e9ef96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3234f1dc-8862-4496-b8cd-d464f0811ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3234f1dc-8862-4496-b8cd-d464f0811ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f50fd211-66f5-4957-a693-ad97f713694d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f50fd211-66f5-4957-a693-ad97f713694d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f8324fb-39b0-4e62-bb2c-26df5c25bf11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f8324fb-39b0-4e62-bb2c-26df5c25bf11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5b105ff-b877-4ae7-bedf-857173c4a299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5b105ff-b877-4ae7-bedf-857173c4a299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9688ad8b-9241-448a-9647-1c482bebf327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9688ad8b-9241-448a-9647-1c482bebf327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c96106d9-65d6-44fa-94f2-36ae0fbf3932_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c96106d9-65d6-44fa-94f2-36ae0fbf3932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2744ae84-2bdc-4263-aa60-33baa35408a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:to="loc_us-gaap_InterestRateCapMember_2744ae84-2bdc-4263-aa60-33baa35408a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended" id="i88153d52b2e640b0b9c938341b5ae216_SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e544154f-1e0f-4584-91bd-135050e42e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e544154f-1e0f-4584-91bd-135050e42e07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_88594a4a-446f-43e5-8bd9-dee506ae2c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OtherIncome_88594a4a-446f-43e5-8bd9-dee506ae2c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_15179d64-e9e5-4f1a-9dcb-fa3f80574c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_Revenues_15179d64-e9e5-4f1a-9dcb-fa3f80574c82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f681f98d-d2c8-4e10-afac-53755729094e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OperatingIncomeLoss_f681f98d-d2c8-4e10-afac-53755729094e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_55ee14ec-47c2-4a76-9c21-6aff6738a6c3" xlink:href="dva-20221231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_55ee14ec-47c2-4a76-9c21-6aff6738a6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_a5bde548-bae1-48da-9766-b2035b8908e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_InterestAndDebtExpense_a5bde548-bae1-48da-9766-b2035b8908e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_bdb55280-3a70-4a52-bea8-f6d7d6ac28fb" xlink:href="dva-20221231.xsd#dva_DebtPrepaymentRefinancingRedemptionCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_bdb55280-3a70-4a52-bea8-f6d7d6ac28fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67d7fe77-6285-41bb-b5b2-d2a0f0391b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67d7fe77-6285-41bb-b5b2-d2a0f0391b64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bf5eec3d-39c8-4e75-a6b7-5acc19732f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bf5eec3d-39c8-4e75-a6b7-5acc19732f60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4330d0c-98a1-4e44-ac80-00bd5d5cdb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4330d0c-98a1-4e44-ac80-00bd5d5cdb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2fc40d1a-d196-4d12-afae-3bf193945359_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:to="loc_srt_ConsolidationItemsDomain_2fc40d1a-d196-4d12-afae-3bf193945359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:to="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1a963f0c-c561-436d-9b87-c7f964d48d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:to="loc_us-gaap_OperatingSegmentsMember_1a963f0c-c561-436d-9b87-c7f964d48d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_e2b07fdf-e1d3-47c7-9bae-56b574dc25cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:to="loc_us-gaap_IntersegmentEliminationMember_e2b07fdf-e1d3-47c7-9bae-56b574dc25cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cfc1266f-16c8-4272-84a4-4dce42576e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:to="loc_us-gaap_SegmentDomain_cfc1266f-16c8-4272-84a4-4dce42576e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:to="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_a8615d76-c620-467a-8017-d1dde022ad78" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_a8615d76-c620-467a-8017-d1dde022ad78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f542a3c3-b0ea-45ab-8140-2e8fd5b4bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f542a3c3-b0ea-45ab-8140-2e8fd5b4bf43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7d5a7cbb-dc36-4734-9525-ff52e59d8484_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7d5a7cbb-dc36-4734-9525-ff52e59d8484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_953ca928-8146-4e04-b448-8b4ae5f3bf91" xlink:href="dva-20221231.xsd#dva_ExternalSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:to="loc_dva_ExternalSourcesMember_953ca928-8146-4e04-b448-8b4ae5f3bf91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_40e0f282-4608-4b42-8059-37a96ef3adb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_40e0f282-4608-4b42-8059-37a96ef3adb9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended" id="i99de919319414a3c948bc9a34454c2c7_SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d655b20-8090-414d-9ab8-7e8e86ba2f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d655b20-8090-414d-9ab8-7e8e86ba2f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ad452170-5dcd-4b18-b384-6a8f737367e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:to="loc_us-gaap_SegmentDomain_ad452170-5dcd-4b18-b384-6a8f737367e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:to="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_7c9b7541-89cd-4c2f-9818-8c60a110cf83" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_7c9b7541-89cd-4c2f-9818-8c60a110cf83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_9b8da94c-bd88-4a1a-99d4-ab5d18039a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:to="loc_us-gaap_AllOtherSegmentsMember_9b8da94c-bd88-4a1a-99d4-ab5d18039a9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended" id="i88870ec43bee4b7abf3853694aacce89_SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3681e82-4527-4460-b13d-751742cf6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3681e82-4527-4460-b13d-751742cf6cd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_95553737-e247-4b97-bfcd-f8d634179c27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:to="loc_us-gaap_SegmentDomain_95553737-e247-4b97-bfcd-f8d634179c27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:to="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_6b952ac5-8c79-4c75-8f6e-e9a42f83a396" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_6b952ac5-8c79-4c75-8f6e-e9a42f83a396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_9795a8bf-c04f-42df-b215-a473328ee876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:to="loc_us-gaap_AllOtherSegmentsMember_9795a8bf-c04f-42df-b215-a473328ee876" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended" id="i6b4a718bf5124dd4925bb8997fe6e415_SegmentReportingSummaryofAssetsbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:to="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7519540f-86af-498f-b983-3306e09664ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_Assets_7519540f-86af-498f-b983-3306e09664ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_38a22adf-1e7a-4ac9-9a67-1e48139d5b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_38a22adf-1e7a-4ac9-9a67-1e48139d5b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_03e57a01-a7af-4d8d-976e-a683d156d368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_03e57a01-a7af-4d8d-976e-a683d156d368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_585c33a1-4c7d-4506-93fa-1d0e71304142_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:to="loc_us-gaap_SegmentDomain_585c33a1-4c7d-4506-93fa-1d0e71304142_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:to="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_ac1620e1-49b6-4c64-b7db-691187d339cd" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_ac1620e1-49b6-4c64-b7db-691187d339cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_817e01dc-16e8-4e7e-87c7-644254c0c152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:to="loc_us-gaap_AllOtherSegmentsMember_817e01dc-16e8-4e7e-87c7-644254c0c152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:to="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_778561cd-906e-4b91-a9b8-e900e8f571b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:to="loc_srt_SegmentGeographicalDomain_778561cd-906e-4b91-a9b8-e900e8f571b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:to="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1212f353-2fdb-427b-a60a-daffbecff6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:to="loc_us-gaap_NonUsMember_1212f353-2fdb-427b-a60a-daffbecff6ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended" id="i18166a5d7eb34d61a40870990e94b935_SegmentReportingAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_89a773c5-86fe-4847-a28f-960421f4a2d0" xlink:href="dva-20221231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_89a773c5-86fe-4847-a28f-960421f4a2d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8ab31337-fb38-4a3f-9b1a-d4a99e751f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8ab31337-fb38-4a3f-9b1a-d4a99e751f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_9a7c37e7-aed0-42c8-87f9-3d58b580223d" xlink:href="dva-20221231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:to="loc_dva_DaVitaMedicalGroupMember_9a7c37e7-aed0-42c8-87f9-3d58b580223d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended" id="iaa98702f4b4449e3af1d2a02aa966818_SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_495af9eb-1bef-4b2f-970a-0544986cca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_495af9eb-1bef-4b2f-970a-0544986cca11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_23ce704c-2ec8-4835-a60a-a38812e1540a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_23ce704c-2ec8-4835-a60a-a38812e1540a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_75396cd7-56c6-424f-bc76-c85a164ba4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_75396cd7-56c6-424f-bc76-c85a164ba4f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_83ced488-e37d-499b-81d6-b7388e294223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_83ced488-e37d-499b-81d6-b7388e294223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_803862ca-62c0-4ecc-bc0f-80e753fa63d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_550c33eb-bda5-4359-a51d-6a4953019e76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_550c33eb-bda5-4359-a51d-6a4953019e76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_121cf4d0-a7ec-4b34-bf9a-4a7ba4f1d577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_121cf4d0-a7ec-4b34-bf9a-4a7ba4f1d577" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>dva-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_fd4a8850-3968-464d-819e-a6ebad7f0e4a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_5d53429b-fc18-485f-8f22-150048ed8c66_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c1893a4d-c1eb-4743-a577-de1e3b87f841_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c81c9f30-1c20-4d7a-a6ac-60b4a89456a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeThreeMember_9acf424f-a81f-46a6-ac84-a92bd239c960_terseLabel_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$70.01&#8211;$80.00</link:label>
    <link:label id="lab_dva_RangeThreeMember_label_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_dva_RangeThreeMember_documentation_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember" xlink:href="dva-20221231.xsd#dva_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeThreeMember" xlink:to="lab_dva_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_74cb440e-0621-4229-a46a-415f7c4ea562_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_fc44aa77-48cc-4784-9cb9-6e7cdc70ac78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e699c176-d2d4-4a17-81b6-1c6b339cdcc7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_425b5315-2ef3-4580-b9fa-d03c7cf037dd_terseLabel_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_label_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_documentation_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable months outstanding to be reserved per company policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding" xlink:href="dva-20221231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AccountsReceivablePeriodOutstanding" xlink:to="lab_dva_AccountsReceivablePeriodOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cd94f3e0-c068-431f-b960-88c871938d37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_e4c37e41-2709-4c14-aedb-79275cc11697_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of ordinary dividends, common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_0be7cdfa-57c7-4279-9657-10908590db1d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_bd00b7d0-dc0d-4569-b7e4-a3d748ebc00a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross, total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_98540d0a-e9fb-4b00-a7ec-92eacb4889d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtPrepaymentRefinancingRedemptionCharges_9dd023fa-6587-4058-8626-036e2041b656_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment, refinancing and redemption charges</link:label>
    <link:label id="lab_dva_DebtPrepaymentRefinancingRedemptionCharges_label_en-US" xlink:label="lab_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Prepayment Refinancing Redemption Charges</link:label>
    <link:label id="lab_dva_DebtPrepaymentRefinancingRedemptionCharges_documentation_en-US" xlink:label="lab_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment, refinancing and redemption charges related to long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:href="dva-20221231.xsd#dva_DebtPrepaymentRefinancingRedemptionCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:to="lab_dva_DebtPrepaymentRefinancingRedemptionCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_ffa4909f-0392-4652-804d-3ef336c70b1e_terseLabel_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service net revenues and accounts receivable</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_label_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition And Accounts Receivable Policy [Text Block]</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition and accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:href="dva-20221231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:to="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4f802dcf-b707-4ba3-9289-f303045b7830_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value estimates</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_4a3779ec-0dba-4496-9dd9-6192cfcfd60d_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c6d18e72-ee98-4830-b760-7dc322dbb4ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR plus interest margin</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_84c6e573-592f-49a1-abb5-5b09336ba030_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_KidneyCareMember_b20d0bdb-adf1-457e-ba9f-9f91048c2518_terseLabel_en-US" xlink:label="lab_dva_KidneyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kidney Care</link:label>
    <link:label id="lab_dva_KidneyCareMember_label_en-US" xlink:label="lab_dva_KidneyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kidney Care [Member]</link:label>
    <link:label id="lab_dva_KidneyCareMember_documentation_en-US" xlink:label="lab_dva_KidneyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kidney Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_KidneyCareMember" xlink:href="dva-20221231.xsd#dva_KidneyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_KidneyCareMember" xlink:to="lab_dva_KidneyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5665f521-0fca-46b1-b18e-acf93804d57a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_74dede0d-7584-4a0a-a9e5-40c19e56b2ee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_45d9191d-1a11-4c5d-ab5c-4bf712ba5f5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Interest Rate Swap and Cap Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0a37b246-febc-40a7-a657-3bc0372f1d9a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_0f93c62e-f6e3-45fa-891d-459e73840d10_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquired intangibles and goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquisitions [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareMember_b9a1d2e3-09f7-41d7-bf62-0bda5e9f74c7_terseLabel_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare bad debt claims</link:label>
    <link:label id="lab_dva_MedicareMember_label_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_dva_MedicareMember_documentation_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare governmental agency.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember" xlink:href="dva-20221231.xsd#dva_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareMember" xlink:to="lab_dva_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_de73974f-d67c-4070-92dc-524d87302e32_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash charges, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d4719198-8004-415b-a113-78da78d6ceb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7c0e4c2-c043-437a-a662-4f43b52599b4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_6b5d9f77-e113-45a9-884c-2d7c84d0f336_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3dee0e38-6627-4cbe-91d8-49d0c4ab0389_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f5a4fec7-fd19-4ce3-9199-d6d73483d792_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79ebeaeb-e4a9-44da-8e60-45a1bda97e64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock-settled awards excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_dd4d9b80-a17b-4cab-a993-b0a92dfc1e02_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued non-income tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_c06c612b-d4b9-4af8-9387-03ae5f9be64f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_ce0e1e80-b7ba-43e6-a54d-e5ff45df7c15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma basic net income per share from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_3aa7b5d4-ea9c-457d-afe4-5d12e662f95c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8522e78-57f0-4d8f-91ff-27af50da25e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b8f54fef-1030-434e-ae90-7ab7504d1653_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_edd37a66-1f59-4d89-92a0-8aeececfa561_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states where dialysis centers are located</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7f2d63dd-9810-4bb5-ac48-625d90cf7c3a_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_0b721882-eb93-4f0a-a74a-2395394113f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Range of Exercise Prices</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ebdcee5c-bae8-484f-9858-60bbad9f2295_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b38979bc-8a72-4f51-9cd6-f06391787b0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_2e0efe7c-c6d7-4b6f-afda-ded52f51cc77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_d188a194-7d7f-4266-afb1-bcd2132a08de_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_70ca735c-a0fd-4e12-ae74-b00536582004_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c74fc0ff-dd5d-4c49-b17a-4b56f0354eef_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_3e335f30-67d0-4fdc-b94f-504afdcf0b8c_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1b6e0e57-e531-4d99-9cfd-e57f746c3018_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_1c9f14ca-1bf3-4e5f-9f5d-66c099266477_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_eb7e1007-5090-4c1e-887c-93f6b5427357_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a976be0d-b344-44ba-be37-3803b560eaff_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_75d95d53-6b2d-4483-a645-5187956b6028_verboseLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination contingent consideration acquisitions, earn-outs</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_f9a217b7-7f0c-498e-8105-c78870c12e22_terseLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3565212d-7ead-4a3f-b840-fa17d5ab4873_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_824fc4b8-1899-4bad-94cd-7d65fb6e2589_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_af92e6d3-3f18-4131-b7d8-cdd0d380a05a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_21431978-c621-43e6-a924-25d730b52ca5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets held in trust</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fa0613fb-aed3-4fa4-98d4-16c163212697_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a9534e79-be28-42d7-945a-c863f47d1cd4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_5ce3ed8e-6255-4b0b-ac4c-a223a258a22f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_aae81d67-f2a3-4daf-80a2-ccee54c5a63e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0b0f2143-efb2-4c77-88b3-6c9a99d15d95_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_124331ea-df31-49be-9c05-bbb21e1f9129_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_0442e8b0-432a-4819-bd3b-5536955a7fb3_terseLabel_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_label_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage [Member]</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_documentation_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember" xlink:href="dva-20221231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareandMedicareAdvantageMember" xlink:to="lab_dva_MedicareandMedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_97392f22-565d-4daa-93c4-93dbae85882c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_6d6fb7b5-5e92-473b-beef-cc5ccfa40a76_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ec31df89-42b2-43b6-9e5b-83f0cc0bbfc6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ce2c4262-29d1-4cea-81ad-7a780aedd0cd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5b444a1d-a8ca-4ee0-b17f-fbde99777891_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_8c739b7f-298d-4ebc-868c-c241d0dd63b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_6246bd9c-6682-417e-a432-557da39da773_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to settlements with taxing authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_9b673252-cf62-4aa7-8604-5536e3f103e1_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Increase From Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest increase from contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d1019426-0a42-42c7-abdd-cb33d22ab102_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_24c4cdd8-ba4d-476d-9b42-cd75360d2e80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d574d7a3-5245-4ba7-9a90-48415e345098_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b785847b-defe-4fb9-a55b-414773f18f80_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_9b10f8d1-674f-4799-bef5-9b41299e6624_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3b9a6475-f75a-4d6c-acd0-693eead85197_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_6fea49d5-baf0-4a5e-a13d-f252d9a66e24_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_cb19cc41-82a7-4f88-96ca-bbccbb65364a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_dbaeb76a-5e45-47db-a349-5b266aff5c00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_ed3987a4-a85d-40ae-b947-5ce205c4f9a3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_58abbde2-6b18-4c21-9282-61cf645bdba1_terseLabel_en-US" xlink:label="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full share awards to shares available, conversion ratio</link:label>
    <link:label id="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_label_en-US" xlink:label="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Full Value Shares To Available Shares, Conversion Ratio</link:label>
    <link:label id="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_documentation_en-US" xlink:label="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Full Value Shares To Available Shares, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:href="dva-20221231.xsd#dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:to="lab_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e65a4a89-fb7f-471a-8e53-0e18545559c5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_ef3a73ca-cd1d-495f-a835-5f6eb25640b7_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3d50e212-1460-488a-8353-2a236bc5fbbc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f189774-123a-46ee-a92c-8698754247f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_03f9c1cd-34ca-47ea-8c8d-b7d67402fb0f_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_c67f0fc3-b18b-4f2f-8b75-5ec5ac2dfb20_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6d53e9db-2a72-4aa4-98ee-30d7a969e7e7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a91be487-452d-48c1-a4d3-cc641871967e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeOneMember_bef0c445-2695-40fe-bd44-75bdba06fe36_terseLabel_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$50.01&#8211;$60.00</link:label>
    <link:label id="lab_dva_RangeOneMember_label_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_dva_RangeOneMember_documentation_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember" xlink:href="dva-20221231.xsd#dva_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeOneMember" xlink:to="lab_dva_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3fff6aac-b616-4893-be23-e848dea5bc92_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherCompaniesMember_02335d44-6f69-46ce-afec-45f2058708ec_terseLabel_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other companies</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_label_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Companies [Member]</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_documentation_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember" xlink:href="dva-20221231.xsd#dva_OtherCompaniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherCompaniesMember" xlink:to="lab_dva_OtherCompaniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_136c8f8b-da15-4de4-be57-86895769bfc9_terseLabel_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_label_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_documentation_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:to="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e89b0a21-e9fa-4242-bc10-0801d303bf02_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_68d3259c-9b4e-4423-98d1-cffc74ced33c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ed6f8bc4-b26c-4725-9c26-8fb2974b03d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39289761-f2d5-4964-abe0-f5ab27db3d3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, and equipment useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_8670658f-ce4a-42d7-92dc-be8fe971a021_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_c6127a67-f045-4639-bf42-5f9dba6f5bda_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of other debt and equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b46ff1ee-cba3-4887-a8ba-4bf8d1d88ed7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a38609d4-9eb7-409b-8e4f-64ede3d23946_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_e635e675-6b36-4b1a-a14c-7312e233b273_terseLabel_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC joint venture</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_label_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_documentation_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:href="dva-20221231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:to="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d48ff1a4-4f0d-4118-90c7-d4dcd52f380c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock_37364aa5-4ee7-4443-954c-a2218f642d81_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reporting Units Goodwill Balances</link:label>
    <link:label id="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reporting Units Goodwill Balances [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reporting units goodwill balances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:to="lab_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_31e76804-6528-469b-b189-68d2301643c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_USAttorneyPrescriptionDrugInvestigationMember_61ac8e79-fc29-4b3d-9a7e-fc644191f85a_terseLabel_en-US" xlink:label="lab_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Attorney Prescription Drug Investigation</link:label>
    <link:label id="lab_dva_USAttorneyPrescriptionDrugInvestigationMember_label_en-US" xlink:label="lab_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Attorney Prescription Drug Investigation [Member]</link:label>
    <link:label id="lab_dva_USAttorneyPrescriptionDrugInvestigationMember_documentation_en-US" xlink:label="lab_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Attorney Prescription Drug Investigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:href="dva-20221231.xsd#dva_USAttorneyPrescriptionDrugInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:to="lab_dva_USAttorneyPrescriptionDrugInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_9af2bd16-79b6-4a5c-bda6-8b99402094eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_d237e3c9-28d8-4c30-8dd1-3f13f1f55111_terseLabel_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company and Restricted Subsidiaries(1)</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_label_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company And Restricted Subsidiaries [Member]</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_documentation_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent company and restricted subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:href="dva-20221231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:to="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InternationalOperationsMember_e0411c16-cf75-4616-ab17-a8c44a59888d_terseLabel_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Operations</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_label_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Operations [Member]</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_documentation_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember" xlink:href="dva-20221231.xsd#dva_InternationalOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InternationalOperationsMember" xlink:to="lab_dva_InternationalOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_88eaafdf-c02a-4a63-8b0f-4cde94191908_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase cost recognized</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d3dc83ea-d14b-4da7-a2bc-d64065e4ff03_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a57f883b-e39e-49ef-a483-8ccdc1e8a8d3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_5350affb-7e4c-4125-9dc3-2552465d5717_terseLabel_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_label_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_documentation_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:href="dva-20221231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:to="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_70f46252-8f29-47a9-840a-7d0c426e7d55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d75c999f-0cf8-45e0-bb36-b896b8774955_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_57eeda3b-9cc7-4547-839b-75838123f059_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma diluted net income per share from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_7354d673-7525-4a5f-a20e-380f1d171938_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d6e541fb-744c-4132-94f7-d73c7740b067_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0d4a38f7-0de5-4758-8066-9be08e444fa2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_ebae2531-833e-4685-92b8-d62917c10148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards, fair value assumptions, expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f099573c-e6bd-4f41-b471-c15ed34f4855_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_2e865eaf-20f5-4af7-bca4-a60d57ca0865_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_e749719f-a70a-46a4-b98b-fce4b9a19812_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_a9e5e98b-e933-428c-965c-24989e6a5fe2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on changes in ownership interest, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_112d136c-440f-42d3-a837-37a242b765f7_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on Disposition of Business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_586be126-2198-42a6-bdb4-e0ebc8f3a5da_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1aae3c0c-3ee7-448e-af92-4834d988ad2d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and international tax rate adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_65adfb33-39ac-49fc-9f27-b1f45921da74_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_46900abd-2946-4836-965d-801ac2ab29c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_ab0d53b7-cc28-4dcd-9538-e7246740af43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_279579e1-a8a6-452d-be35-44e4ba315206_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Valuation Inputs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_a207a705-1920-4e65-a76a-52eee37f63d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_2e9bf648-8b89-4c79-b5ed-8b1c983599de_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_33ab9195-3660-4079-acef-315aaaacca1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2149e683-9d95-4abf-a0c7-d325ee16eebf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ef896ce3-42e0-4d81-a545-a53784dfa1ca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in international valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_254818fd-a5f9-44d5-8cd7-cbe0199c0387_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4dfb52fd-a331-49dc-90d9-1bc5df40bff2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_38a4ea56-3e95-49a0-8e1f-c0f2339db3bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_052d8d68-0631-48b8-ad38-a05f6ecfc4e0_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Minimum Lease Payments</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Minimum Lease Payments [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:to="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_3150a8ca-e129-40a4-9ba3-f562e572570c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1942afd3-97c6-4e77-b34d-88caa0082f4d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3d86a95f-83d6-4e03-8508-15bb422bccd9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_23298a62-f8a9-4e43-96ba-74edf65b259b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_157b3eb7-4117-4f17-bd34-fbfa2e391857_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ForeignDialysisCentersMember_0d211ae2-a915-4e24-b94d-9526f4c32156_terseLabel_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Dialysis Centers</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_label_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Dialysis Centers [Member]</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_documentation_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign dialysis and other medical businesses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember" xlink:href="dva-20221231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ForeignDialysisCentersMember" xlink:to="lab_dva_ForeignDialysisCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_4116d79e-9a15-4a9d-aea9-e16a5ab7cc91_terseLabel_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_label_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_documentation_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:href="dva-20221231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:to="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d39af47a-f0a3-41f6-b874-ac780a6ebdb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ade4a24a-479d-46d7-b67d-542fb9104cd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, upper range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9354955d-c907-47b5-9b6b-e45d21d7c4ee_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of individually immaterial business acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_33a8542f-cbe1-403c-a7e1-eccd4f2f0e7f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_6bdc56f7-de62-4338-b73b-511d48cf9a7c_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_13dabd15-6e8e-4c75-813c-10ba83f0ee12_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_b426287a-f34f-45f3-8674-853c55c16b46_verboseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases term and discount rate</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc6dbfe5-1dde-450d-9c30-e72dd188d746_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13108798-2aac-4423-85fb-5f0e4e80177f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a836549e-2059-4f1b-80c3-44c7b715f79a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c77c66f4-a90d-4dc1-b3f9-30e4afa81666_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_4ff24902-a33e-4dba-b0d9-42ee89f6d1b0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholder's equity</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fb378f70-2d71-426b-ace4-186669255956_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cd213c7b-2428-412c-a4ff-2b519fa79d1d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8bc71582-3ddd-46d8-a931-5a9e64199647_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_8eee0a3f-b14d-43e5-a58c-291c08917df0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_80870334-da40-4efc-a000-7cd15db96313_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_ed05b1b0-98e3-465c-bd00-a99682e116b7_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_1502ca6a-4a99-414c-bb5a-77d9638ccfef_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d7239361-88ff-4453-bfad-7bd3e60e4646_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_dd1cc5a3-6b62-447f-bc11-a10daeb878be_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7fdc249a-9b61-45ba-819f-c97198a471a7_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_126338a4-cf86-4051-af79-108c8ca3fb5f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9aa8224c-c14d-4934-ac39-c6cb64f892fb_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ad3c6d8e-ac37-434b-ac9d-e8db2e754418_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_37c79951-4da2-4606-8dc1-018aac31387c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e67b49d8-278e-4747-84c9-cfd55e3f738e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_a8ad78a0-bd6c-4168-87a7-d5732b398627_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c5a58b69-7a81-4f9e-b4f1-63a9972418bf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock acquired, average cost per share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bed05dd5-c2bd-4b24-b45e-c3ae4179cd13_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_158fa0df-c8d9-4dd4-a8c0-40c47b542ffa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_f5ce37c5-1921-4273-8e9f-ca3bbf07e3d7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_270f047a-cf49-4e60-9b98-86e610f37491_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f40aa468-7d56-4933-be86-847920707af4_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_003b73b2-a889-4578-9b93-f7ef1fae80d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b6514d88-417b-4735-a8fe-6b996f8cbb2b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_71cff97b-115d-4aa4-8534-bdf6fc959b67_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap and cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ddc2beb4-d30c-438f-8111-7a74e0b84594_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8a989-839d-4fcd-8cda-f886d4337bb2_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_bcc1c160-3de6-401c-8075-6496e3a898b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareRepurchaseFeesAndExpenses_babe38ab-0fa0-49a7-a70b-286bbae91190_terseLabel_en-US" xlink:label="lab_dva_ShareRepurchaseFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Fees And Expenses</link:label>
    <link:label id="lab_dva_ShareRepurchaseFeesAndExpenses_label_en-US" xlink:label="lab_dva_ShareRepurchaseFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Fees And Expenses</link:label>
    <link:label id="lab_dva_ShareRepurchaseFeesAndExpenses_documentation_en-US" xlink:label="lab_dva_ShareRepurchaseFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Fees And Expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareRepurchaseFeesAndExpenses" xlink:href="dva-20221231.xsd#dva_ShareRepurchaseFeesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareRepurchaseFeesAndExpenses" xlink:to="lab_dva_ShareRepurchaseFeesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0c67f91d-b605-45a6-b514-7579c3a8e21e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_13fdcfcf-783c-4c81-a993-fbbfe53384b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1c0855fb-80ab-4c8b-9b39-6618687e6189_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_6ab450a4-ec9c-425a-a174-0c311fb46692_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3b3ac579-f251-4f30-bd9e-0e834c8407e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_dcd7bf46-0739-4888-ac01-0f3c4bf0c7f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Purchase price and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_ed617687-fa02-4caf-aea3-456754050d06_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Added by performance factor (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_d6460768-4073-445a-8812-25870273cf08_terseLabel_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expenditures for Property and Equipment by Segment</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_label_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_documentation_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of capital expenditures for property and equipment from segment to consolidated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:href="dva-20221231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:to="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2b1433e3-ba82-4d4d-b28f-7279bd31bb6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net income from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_597eedc0-5b2a-4fd7-bdbb-a13cc5d2dbdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_5d6518b9-e3a5-4a5f-a0c1-68aa9d4f04c7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e4344ab9-f9f7-443f-8500-6e3cf690d4c6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aa5e9182-e2c0-4da5-901c-5c18230ab4d4_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f489eecc-dc19-4051-8f12-c3293358d942_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_db421835-e4b0-46e6-9a12-5bf89937d51a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share attributable to DaVita Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6c504277-c156-46e8-afbf-0537c905b788_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New center and capital asset projects in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ee900cfd-f78b-4fb2-a518-2a2398c32035_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RMSLifelineMember_e5273cce-f62a-4e84-8b7f-5772f828b871_terseLabel_en-US" xlink:label="lab_dva_RMSLifelineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RMS Lifeline</link:label>
    <link:label id="lab_dva_RMSLifelineMember_label_en-US" xlink:label="lab_dva_RMSLifelineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RMS Lifeline [Member]</link:label>
    <link:label id="lab_dva_RMSLifelineMember_documentation_en-US" xlink:label="lab_dva_RMSLifelineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RMS Lifeline.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RMSLifelineMember" xlink:href="dva-20221231.xsd#dva_RMSLifelineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RMSLifelineMember" xlink:to="lab_dva_RMSLifelineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_840fa6c5-a295-4452-9ed3-2efa406485e5_terseLabel_en-US" xlink:label="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure</link:label>
    <link:label id="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_label_en-US" xlink:label="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Table Text Block]</link:label>
    <link:label id="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_documentation_en-US" xlink:label="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure Table Text Block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:href="dva-20221231.xsd#dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:to="lab_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_3df5067d-585a-47ef-aac0-94db7449c189_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_4a28f329-1b51-49c8-a11e-a88d9a303b62_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_28df7ea2-8708-4b88-8e2e-e3decb64456a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_fead4e6e-6948-4932-8127-630e118bbb75_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e992e65-a48b-437b-b0f1-d7d5bf8e6fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_222181b6-92aa-49c1-a11d-9ebd060c9270_terseLabel_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out consideration payment period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_label_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Revenue Earnout Period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_documentation_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition contingent consideration revenue earn-out period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:href="dva-20221231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:to="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_dcfc979c-67bd-4c4b-bf70-aac41cbcf530_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_a67a690b-4d54-4ae9-a89c-972cdaa972ae_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_79d0b998-4ecf-42d5-aea1-6bf6ba9c39c6_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_f4fa19e7-e4c0-4dc6-968c-41e53196e632_terseLabel_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_label_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sources of Revenue [Member]</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_documentation_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember" xlink:href="dva-20221231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherSourcesofRevenueMember" xlink:to="lab_dva_OtherSourcesofRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_83231156-a455-4857-ad3b-5cf7409129ef_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_943f634a-457e-4d50-8552-76362973790e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd01d73d-d4b6-4706-b6c3-00de7109c253_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59e4a538-8686-4525-981f-3d80aadc3d1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_ce31d7a3-f8f8-49b2-900d-400247103bed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock_31994b85-2cc0-4211-8d68-c0f17a8a9d01_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allocation of income tax expense (benefit) between continuing and discontinued operations.</link:label>
    <link:label id="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Allocation Of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Allocation Of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_ed678971-b9c3-486c-89ed-c1dc22927e18_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_c5e800ba-999c-45c7-8621-32679f6dc77a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cacaa91d-45b7-48e9-bd09-ba164fa8c2eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employees' base salary to be maintained into deferral account</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_2bcb4b38-aff9-46f6-be93-f050322ca195_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0b2422d5-d142-4d00-9f8e-93b514723d3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6e0181b3-5202-4f02-9d45-99781fe7fd9e_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains net</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_bf16db10-158a-4f40-8add-4956452d111e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_50cb7a36-5078-4d4a-ad21-4713f8c08b45_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6e579812-38ba-4ec1-bcb3-ca88bea23df6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_129d90ef-4d54-41d5-8330-bc389be768d9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_024b94d2-bf38-4816-ac3b-77a372be91a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_ee3a3c55-024d-476b-a68e-07cb0789bf1e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_eb7da17d-b629-40cf-bf58-d8b6bf05e74a_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a51b5058-9439-47a5-bd7e-c52c5d766f78_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_95c1a932-8df6-49f9-b907-56db66b55e06_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax expense (benefit), income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fa4bb4e6-27c7-498c-8ea2-2b6e941c6f8c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_406a3911-d572-4c9f-b19d-a07bf38088cc_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7961d9b7-6ab3-4988-92f5-594aa149dea4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_0953c88b-0f51-4356-8e0f-e25d84382166_negatedLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or other settlements</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Earnouts Payments</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Earnouts Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a3265db4-ef3c-49e4-b9a9-a8a60ae3bb4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_43b5fa04-c23c-4ff1-8c7d-69e160eca906_terseLabel_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-settled Stock Appreciation Rights</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_label_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Settled Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Settled Stock Appreciation Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember" xlink:href="dva-20221231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockSettledStockAppreciationRightsMember" xlink:to="lab_dva_StockSettledStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3f613896-d101-457a-8ee1-49cff21cf9c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_4cc34fd2-8847-4fb9-a59b-af462b39aa11_terseLabel_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_label_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_documentation_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:href="dva-20221231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:to="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e34affdf-63ea-4374-bda2-f8e2f3fa4983_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Summary of Results of Operations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b2221162-b946-4eb2-b68d-55e0556bc2a3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_34189033-d8af-434a-b849-1df4d90d08c4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Asset Categories</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_42933e0e-5fea-46be-8cfb-e465df9f9e00_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_482e96e2-8f06-4390-adef-1ab3e4a9fb7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_5b0bf5b4-8c90-41f9-bbd1-7fbea368488c_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt totals:</link:label>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_e4878e7c-7569-40c6-8b57-0b771656c7ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements</link:label>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Noncompete Agreements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:to="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_3c12b681-2189-4174-9559-8caed3a1cef4_terseLabel_en-US" xlink:label="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business units relying on operating activities of nominee-owned legal entities</link:label>
    <link:label id="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_label_en-US" xlink:label="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Units Relying On Operating Activities Of Nominee-Owned Legal Entities</link:label>
    <link:label id="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_documentation_en-US" xlink:label="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Units Relying On Operating Activities Of Nominee-Owned Legal Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:href="dva-20221231.xsd#dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:to="lab_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_32d56dc7-2ebe-4e0a-8960-a11fdc3cca72_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_ce31c32d-7afa-42d4-8cf9-c960cd313066_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive losses (income) into net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_37df6068-92c3-411c-a1a2-78e54d97bfae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_118937e2-785b-41fb-999e-5cc0fca0638b_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c79510ff-f210-4d72-811c-0b0aa641ed34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_62c7a0d8-f745-4a62-af1f-e728e110daf1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFiveMember_59f4310d-c9d2-4e0a-96e8-51978dc2d08c_terseLabel_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$110.01&#8211;$120.00</link:label>
    <link:label id="lab_dva_RangeFiveMember_label_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label id="lab_dva_RangeFiveMember_documentation_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember" xlink:href="dva-20221231.xsd#dva_RangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFiveMember" xlink:to="lab_dva_RangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d6e1912d-1617-456f-ae98-3827db18a252_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ba031847-fd84-4c7d-aed0-3aad83db7948_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e0806296-f7ae-474a-8368-9479baf0f1e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_a78dae1c-ab9c-41c0-ac8e-2ffe2d698ae0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method and other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_abb1bb0d-5ab2-4ea1-9c20-ad8ca4fad4b0_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3c563c5c-3db0-4caa-910e-dbc134886985_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_44b9882d-863d-4ca8-8631-032faa437e4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_95baafbe-7af4-4f3f-ab35-c38f4f94012c_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_9d017b6c-7b03-484c-a0b6-03ea52d0820e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c668350f-bc75-44e7-8bc6-69a2372e2efa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1457e0a6-65c8-482e-8c49-eff67e3f1a63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cde75b92-6427-45d7-83ad-dfe143efe4e8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3666266d-218c-4720-8a63-416751a2e59e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d605e138-79ca-477c-853e-e02e61444bef_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ff2f16e8-648b-4d61-a51a-6bd8f06464d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_14264b17-e0ea-4307-beab-87496f26fedb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ef946be9-64a3-4407-9a97-356ed62f352c_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesLineItems_b12cb27e-3f2b-42ab-9b48-3be2301021c8_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_label_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems" xlink:href="dva-20221231.xsd#dva_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesLineItems" xlink:to="lab_dva_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_335432d7-cb2f-415a-a1cb-b3f4ba34c075_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtRefinancingCharges_9bb483db-f18e-42bb-983d-39cef9017784_terseLabel_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment, refinancing and redemption charges</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_label_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Refinancing Charges</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_documentation_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges" xlink:href="dva-20221231.xsd#dva_DebtRefinancingCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtRefinancingCharges" xlink:to="lab_dva_DebtRefinancingCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_96bda2c2-fe4b-4200-9a6c-3283effbb1b8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_97b47347-7358-4408-911b-b691d1e98eee_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, expiration date</link:label>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_label_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMaturityDates" xlink:to="lab_us-gaap_DerivativeMaturityDates" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommercialPayorsMember_e8dd99b6-ae99-45c7-acd6-c633c2c4aba0_terseLabel_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_label_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors [Member]</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_documentation_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember" xlink:href="dva-20221231.xsd#dva_CommercialPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommercialPayorsMember" xlink:to="lab_dva_CommercialPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_3beb5f6b-2ea7-4c09-b03c-9be9e41b6281_terseLabel_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_label_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses [Member]</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_documentation_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:href="dva-20221231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:to="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8e04277f-0228-4168-a1fd-425b62a326f0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_03bd10b8-9864-4152-804b-573bdd9d8b1a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which dialysis centers located</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_a89cbc37-3577-4806-aa00-28202ae8a25a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:to="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a64f2db9-3f1d-47a0-95ef-01790ddd8388_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2ccaef2f-51e7-4482-b438-377de61bad42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfPartnerships_1dda3b87-4d95-4e10-aef5-9707a1f7bcbe_terseLabel_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity method investments</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_label_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnerships</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_documentation_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnerships that are included in the Equity Investments category.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships" xlink:href="dva-20221231.xsd#dva_NumberOfPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfPartnerships" xlink:to="lab_dva_NumberOfPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2472f76e-3b50-418b-a2af-e41198b93a28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_6285e96a-b525-427c-b88d-c13cf6537162_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_312cffb6-31de-43b3-81c3-6002f14c5297_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_a171d485-e9f0-4bef-b52b-3befb6ee6bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other potential commitments to provide operating capital to several dialysis centers</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_5fffb415-c50d-488b-a535-bfd81b3565b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c84e36bf-99e2-4143-8336-29ddf85cfea8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3d9970a-f3d7-4ef5-8852-4d0d522adaf9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d5a3ee1-1088-4d36-9619-906cd53d3fa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_811be878-8bc6-44a0-9482-43ae6570d44f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_e705823f-65b5-4270-8178-fb452f35099f_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_eb448e80-a4e9-4c7f-9465-d0f2dd75be0c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_9e91d4bc-22e7-4b5e-b357-ab82d81c3ae8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_62fe437a-ba3c-4a43-ba22-0990ca905578_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAbstract_ccc3df85-4141-4eb1-86b1-61fb5ae1defa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAbstract" xlink:to="lab_us-gaap_RestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2ce8e385-cd1d-4b93-94ce-2c338dd3e1f8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross wages</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_a828761c-b140-40aa-abe0-0669cd7af5d0_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_98ef301d-dacd-4fb1-940d-4f33039a6444_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_25f80588-edf9-4fbf-a079-65475e361ad2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_9cbea024-5547-40f7-91b3-da8284466440_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f0c6577f-f5d3-4933-9131-40d0a208c23c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9420f877-654e-4033-a4e1-00b5dcd0046d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_d7031c04-76e6-4d5c-8d39-2cb902650132_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsTable" xlink:to="lab_us-gaap_InvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_71c15d30-bdf2-45f6-891a-248990fb1eb0_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_41858078-7e2d-4298-b191-98f1f5151588_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c3d1b7fa-2a0f-4bb6-922a-8bc6e7685dd7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_e39bfd35-6b5f-43ec-8e8e-d71ef22056dd_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_381fb112-eeef-43c9-94ea-42a45b2f48f1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_06a767d1-d794-4956-9589-0d85392cd70a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_479beee5-bf1a-4a5c-8d1f-9c7cb8d3bdd3_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_label_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_documentation_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation, contra asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:href="dva-20221231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:to="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OperatingLeaseMember_fd1a6f6f-ad61-4a13-89ca-cfaa0b400867_terseLabel_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_label_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_documentation_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember" xlink:href="dva-20221231.xsd#dva_OperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OperatingLeaseMember" xlink:to="lab_dva_OperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_d1f800c3-52f6-4f2e-ae25-cd4660ba1f68_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_58b13ab2-22c3-4da5-b979-1bb72751ae06_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_244010e6-2f49-4fa8-a57f-7013f6fe7a7b_terseLabel_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. dialysis</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_label_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U S Dialysis And Related Lab Services [Member]</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_documentation_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US dialysis &#8203;and &#8203;related &#8203;lab&#8203; services&#8203;.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:to="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_e0ce9262-21a7-4f61-b2f9-45a8fb5b3e7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_acc8b9dc-3577-4686-afa5-7805dab1fdc4_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7de52def-5640-4947-a665-61478a84c7dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_f0cd33a5-c62a-4620-9dd8-fa58442aa57e_terseLabel_en-US" xlink:label="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount coverage</link:label>
    <link:label id="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_label_en-US" xlink:label="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit Percentage Of Fair Value In Excess Of Short Of Carrying Amount</link:label>
    <link:label id="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_documentation_en-US" xlink:label="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit percentage of fair value in excess of short of carrying amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:href="dva-20221231.xsd#dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:to="lab_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7ab1d572-4a27-4e02-a091-89fe731df7b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ac102d43-9a36-48be-8a69-eaae2ab7778b_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1a56a989-9972-4d04-9974-11524aa25d58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_a8efd7a7-b785-4369-9e9e-188e8abfd2c7_terseLabel_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis patient service revenues</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_label_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_documentation_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:href="dva-20221231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:to="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fd4bd458-f847-4be1-9e04-fa11c69462cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_79ebaa7e-cad4-40e0-a34e-03c3fb535e43_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense on property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_13d498bb-7561-4adc-82e0-d7450696b577_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase price as percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c85fb63d-a1e0-4fea-aaaf-3f11de1d635f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_e965392b-31d4-4e09-a80f-f8eaa2afbe25_negatedTerseLabel_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (payments) receipts related to stock purchases and awards</link:label>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_label_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to stock purchases and awards</link:label>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_documentation_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to stock purchases and awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:href="dva-20221231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:to="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_80e4f42b-3e9b-4a2d-bd66-c0721c23d628_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_7339fd95-7777-4831-94a5-c34a5684ec44_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7a39522c-9e79-4b07-873c-3b6092a30528_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1bf0c0cc-17fa-48c4-97ba-78555fdb6e13_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements and other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d66cb397-4c43-4653-8bf6-7572e185564b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0c97bfb1-f024-48dd-8c6f-6440c512ea5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_f073144f-6fa6-4881-886e-afd19fb03d4e_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_072681eb-17e7-43e9-a3dd-8f7818f94a2b_verboseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a083f40c-2389-454d-acf5-1bc24695d822_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_0a40d97c-87d9-4626-a214-e66f2ebede36_negatedTerseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_92a4e0d1-d4d7-47db-afed-d6516a5bb13b_negatedLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a66e5b58-62a8-4d7f-8b3a-bda090fb721c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e4c89f13-fd7e-4ae8-b46e-600efb1eae52_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_8bc65c56-47c2-4fa9-ba89-0eceebf4c418_negatedLabel_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivities, Discount rate</link:label>
    <link:label id="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_label_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Impact On Fair Value For Basis Point Increase In Discount Rate</link:label>
    <link:label id="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_documentation_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Impact On Fair Value For Basis Point Increase In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:to="lab_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_095d2adc-cfcd-4d54-862b-f92320532e95_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_c60e1be2-7b17-4898-98e2-433702b40b4e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_68e0f303-9ab3-47e5-b259-012d833079dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0358973b-70a5-4bf9-9eaf-05300fa492ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_66dc5f72-bbeb-47a6-9b6a-153b376bfb3b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_6e6237a7-621a-4d72-a587-bfae3423d02f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_2867e546-7233-40a8-b455-fe19509c1a81_terseLabel_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_label_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_documentation_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:href="dva-20221231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:to="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_029d7b68-d1d0-46a7-ba4a-690bf3b1fc13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_4e0da05d-44d2-4410-8dec-cf91f5c7a49c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41c8e378-0035-4001-a87d-02054672f01f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_01c5a79f-3f3d-46e6-93cf-fb14409188d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_4454bc67-51a8-4d49-9ca9-0bb9f03efce4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7b9596cf-68bc-429b-8d62-b064ee3aab83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ec56ab4e-99ad-4cbf-9610-7b298548d3ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Incentive Compensation and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_179d00fc-d816-44a6-9a67-bb1a63153001_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in noncontrolling interest from:</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_397e79df-3886-4ca5-9726-308863301786_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2e1639cd-2b13-482b-8a7f-0ecc40c2fb55_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_713d3a32-165d-4303-8587-aa08fcce84a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_b2558fa1-e5b0-4698-b7ea-62304e1700de_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable, fair value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_35fab70f-b0aa-4691-a82f-b912afbdd479_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_3f1ec624-1178-4983-a9af-a89ce5a9fdfa_negatedLabel_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and prepaid and other current assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_label_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Other Current Receivables And Other Current Assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in other current receivables and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:to="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f5247e3e-40dd-427f-bc6e-9b93ec25b20c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_901f94e8-6f37-4664-a84a-9946224afaf6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_425d784f-73da-4b91-b5fa-2e531672ffa1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_64e97644-1ced-4fe5-97f3-a854bca2e65d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_403923a6-62b6-4bab-9a6e-b4d193bbfbd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_faa6161d-44f0-4254-bb6a-f57d297f0853_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:to="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_75096e34-a88a-40bd-baef-1d67fd3acff7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_5bc503fe-341e-4f2f-ba6f-f09972ed1a46_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8cb687d9-81f3-436a-8fd1-95b0b8760fc9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0a8494ca-31c1-4caf-9b66-7892b9c8eb1e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from partnership buyouts</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7bc8decf-db7f-4247-ae8c-29ad21e09642_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fae787f-dd99-405a-9237-2289fa27fb81_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2d188e80-5392-4613-91f9-adea7a7fba7f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3001be59-3d5c-424e-8527-f9badd6a537a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares for earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_3ac54378-fd3e-4e27-84cb-b62307ccf075_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ea8fbf54-4e77-443c-a754-89417c50994c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_f2830c71-0ace-4423-ad9a-f950c7591fd7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of businesses acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9b55a1f2-6ddf-49ed-8d00-feed1ecfc417_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_01e0a31d-0365-40cd-92f6-8d9156c5b3cc_terseLabel_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions used to purchase shares, employee-related current liabilities</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_label_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_documentation_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:href="dva-20221231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:to="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_f86c3cd7-cc78-437a-9dd6-07883da02be3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_ea802d9e-7d96-44e8-909b-153e7dfab6f7_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests subject to put provisions</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests Temporary Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:href="dva-20221231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:to="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b64838b8-b674-41a9-806c-84a7797dbd56_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income from continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_7564d02f-940f-4f52-91c6-c0d0d5815ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from asset and business sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16ca1eda-1a72-4787-b460-e22d272835f3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dd762b6d-e249-49cb-9dce-5cb60431c9fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_737ed6e8-048c-492b-822e-6021f5cb9c67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan, distributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Distribution Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_8ec3f487-c9a4-4f82-8913-0cc246420f93_terseLabel_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information Table Text Block [Table Text Block]</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information in tabular disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:href="dva-20221231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:to="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a6018202-4cf5-4ef2-8a9e-5fc28a2c50fe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_14a53866-8f96-4013-8a67-5f7c0b02ad40_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AuditorAbstract_57a685c4-29fc-486e-9b63-f6b3fec0c99b_terseLabel_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_label_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_documentation_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract" xlink:href="dva-20221231.xsd#dva_AuditorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AuditorAbstract" xlink:to="lab_dva_AuditorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cdba7de4-ce8e-46cb-a3d8-168702302ccf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanFacilityMember_e4d4826c-8f1f-4c8e-9732-5168c9894a20_terseLabel_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_label_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember" xlink:href="dva-20221231.xsd#dva_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanFacilityMember" xlink:to="lab_dva_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_61268273-9b93-4b67-814a-ba355d72010d_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4560352f-6081-4f8a-8758-2e9509afb314_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_67f28456-86d4-4abd-b7fe-cde7a8501303_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_b7716022-07f8-4727-9a22-8c9bc010c4f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on interest rate cap agreements:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4cf64f07-5677-4b6d-aa43-a2905027e370_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_73e6ed0d-fcdf-4058-a9f0-62707cb7af5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7a711bd2-7e22-4b10-af8a-816dff6a4524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_634806e3-99c2-4779-b8a6-10566a7536df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6ec9ac72-49b3-4f18-a23e-419ac8d4ad77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_544b77fb-9291-4f9e-b89a-4d5dbb6ad61f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_bf2442bf-8505-4ab9-b863-7e801fbe7a6b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Political advocacy costs</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_c7eb14c4-ca6f-4b94-ab51-e7f4070a7654_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_b7a00898-9d40-4a44-9ee9-095120db2184_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6912beb6-6021-48ae-9fd8-442944e7f33a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_32e0657d-f94c-468b-af70-4e84d5a905dd_terseLabel_en-US" xlink:label="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment</link:label>
    <link:label id="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_label_en-US" xlink:label="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment</link:label>
    <link:label id="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_documentation_en-US" xlink:label="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:href="dva-20221231.xsd#dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:to="lab_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_54471fb2-4172-40f3-88d7-157a3d1df38a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of noncontrolling interests primarily attributable to non-tax paying entities</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_d7b6dd65-5f12-46b0-97b1-d19414267f3b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_48943149-abd6-45cd-9860-f88027293de9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dc6ba8c4-a392-4edb-9f99-632f9b6e8d8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities Arising from Temporary Differences</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3edcff86-bb47-4c0f-ab2b-681f4a5db2c9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_c3f46621-21e7-4af3-887f-422743930970_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_c96a90c6-1b4e-49dd-a432-4ec52e71f263_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e9aaf7e7-8af3-4fb2-9191-f4932ed64c1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed incremental shares from stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9731436b-111c-4285-a02f-93c7beea7d97_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves Type</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fcf49a11-0b14-4029-9182-22a20a0246f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b6cabf18-5682-4d91-bb2d-fd02c4839159_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ad0af7aa-d4d0-4e8b-904e-5a4fc438e236_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;other observable&#160;inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_59ddad16-7b9c-495a-8f57-da9d3827fcbb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for tax purposes associated with acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_de317cf3-edb8-4309-949a-1ff85d4ea8f8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_748667a4-f0f5-4745-9d21-1d502a794f0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9f9a7eb1-4c98-40a2-89ed-aac30c845517_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_e2ca61ec-1f2d-438b-821b-be90d95c5344_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4839f95c-1b5e-4fc4-bafb-69e3776feb78_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a73eab3f-05bf-4e57-a2a4-c5b0c8c810b3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8b41841b-55a3-4d53-90c3-b472267fc1e6_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f934d033-ae12-427f-8263-a3bc46057715_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-settled stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PatientCareCosts_78b28476-20b3-4aa5-91e0-ec71eb29e9e4_terseLabel_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient care costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_label_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Care Costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_documentation_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts" xlink:href="dva-20221231.xsd#dva_PatientCareCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PatientCareCosts" xlink:to="lab_dva_PatientCareCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4017fabf-5da9-43a6-850d-76fe8db44230_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f3b4ad4f-224b-4efe-9ffa-79800932c1c0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_3d02a6b2-a2c8-4f01-8a7e-c57cec70d50e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease cost:</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_fbc56834-9392-4ef7-bc54-04dcd062c1d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_19de053f-e3a3-45d2-a1f0-99a68dcb4101_negatedLabel_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate administrative support</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_label_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information Corporate Expenses</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_documentation_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:href="dva-20221231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:to="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_4eb8499e-f2f2-48ab-9477-f5859cce0a9b_terseLabel_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_label_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_documentation_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:href="dva-20221231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:to="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c8ad3b4c-9e86-4370-af9d-cc0daab0a172_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_c406187e-e074-491e-962c-de7f36c522c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_a59b2999-7c60-430d-8364-d6794c22a2c2_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesMember" xlink:to="lab_dva_DeferredTaxLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_ff35887f-4d18-49e3-a66f-85a030efccf3_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Receivables</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Receivables [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_90429608-463d-408b-8d67-73c49d0772bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, footnotes to the table</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:to="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1938408a-1045-4fc2-a259-27204ff291ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held for Sale and Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_772a676d-3f11-4bc7-b8be-ec7e14a1dc84_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3f2e9883-b1a1-487c-ad61-9cc81f8b4bf9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms of award (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_8090603a-b874-4e47-a7bc-7dc57664809c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_444576cf-9ebe-4b94-bfbb-37de8b31dd2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, lower range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1f20d721-3f97-4965-932b-33dc30663e85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_019b3aa6-ec4a-4dea-995b-ae97bc4fc7a3_negatedLabel_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income, net</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment Income Loss From Equity Method Investments</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:href="dva-20221231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:to="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_c6925710-3616-4ca1-a83c-1f5d392cbbfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_aaa22277-f644-449d-95ab-6d7c7c5389c3_verboseLabel_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG - discontinued operations</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_label_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Da Vita Medical Group [Member]</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_documentation_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DaVita medical group.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember" xlink:href="dva-20221231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DaVitaMedicalGroupMember" xlink:to="lab_dva_DaVitaMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_463f58b8-a741-4268-8f21-f09a246d2175_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d1d4d48c-d6fe-409b-b43a-947694a73198_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7ebc763a-4a8c-490f-980a-3b778c5ee418_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5f7e9308-c4f6-4bf5-bf28-07ce6cf192be_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_64de2106-f1b9-49c6-b049-41d0cbb285cf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of debt expense reclassified from accumulated OCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_dbcd5322-2032-4150-bb2d-93d3037f5d8f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive income into net income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d037e8c4-ee01-40dc-83dc-b9192dc7c33e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_1ea1f935-f823-4374-9e41-04d961a61cee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c8c5d794-02d5-4f5f-affb-2f3271ad1202_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_3820015e-5250-4a63-a2b0-c20b45b65ec1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_add5aad3-501f-48ee-9eba-12e9e9e5115b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1be5ef24-a2ab-418a-ad5f-1deea2c3d0db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f1ccdffd-23ad-4479-881d-7d57a1407e0f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_35816e33-0b0e-4459-a188-ca3f3634a8c9_terseLabel_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured credit facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_dd58f7e4-485c-4819-b7d6-3102dc293492_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_39d5bdc9-cc4b-494e-b35a-c93eb2ec24cf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_f4e95eda-f5fa-41af-8afd-6eb3dc2fb62f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_37d48835-5590-48a9-8fad-872b6894fdb8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b3496ce4-18a8-438e-965f-90631b6c5e68_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information footnote:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_d11b6379-1d36-4462-bad8-caff212c7642_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1e635416-095d-4823-815f-ff74dd5db3b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ef2340c-6597-4f8d-813f-104bb09f0372_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_4c0618e8-6c45-41e1-9ed4-59ce20315fba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_884c641a-8caa-4fbd-ad2b-13d4b8ae195c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseMember_80757eb0-4fbe-4f04-9e16-322dd43b1652_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Lease</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_3266daba-e72d-46e8-8510-106097061c25_verboseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_label_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_documentation_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember" xlink:href="dva-20221231.xsd#dva_FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseMember" xlink:to="lab_dva_FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4010366a-348c-44f1-9207-9b540c2f13ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ebf0b3c-4367-402b-9cf0-910d880727f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_d2e3f887-df14-4eb7-a401-4996cf1131c0_terseLabel_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_label_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense Policy [Text Block]</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income (expense), policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:href="dva-20221231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:to="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cee8933b-92e1-4144-bb66-bd0cd94ce219_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e83975b6-d0e0-4e48-b930-b1009fa431bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_ba262162-6a5b-4538-a4d6-82bce2a41604_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_64e9e106-e0d3-4575-aa68-534aee2c3812_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_1fb24a8e-54f5-44f0-9ac8-efab3af47c5c_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing and debt redemption costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_label_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_documentation_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:href="dva-20221231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:to="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_86f272ab-eda6-4540-b652-c81776891996_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, weighted average interest rate, at point in time</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f598393e-9d4e-4297-8976-f47f1166073d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ae5edd81-2b6b-48b3-8a74-7e1a1258d081_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0eb5cbbd-866c-42c7-8129-ccd86fc07176_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1e175f92-9a3b-4f81-9cf8-d8267c8cbe9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_45893fe1-f318-40bf-a1b1-1adf92e494f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity method partnerships</link:label>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_label_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Ownership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestMember" xlink:to="lab_us-gaap_OtherOwnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_67fe56a7-4cc9-4b77-8a71-08a210800b7b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_bc59292d-8c50-413e-b3ff-8d348bc8d364_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 4.625% due 2030</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_label_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:href="dva-20221231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:to="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c69bd5a-3c7f-45d3-8c3a-cf63008c992b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9683019c-aa08-438e-b4c7-132bc2c594d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1cc1eea1-6363-4a77-94f2-71e20954a763_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8fcc312a-fff4-476f-815e-cc6c3a714584_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income, net</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5d0bfab8-d85d-4217-84da-c791121a184d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_cb8b714a-1d6b-4995-8ce6-c226e173f4e0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAbstract" xlink:to="lab_us-gaap_TreasuryStockValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ea6dc8a-cc25-49cb-8a90-00dc721aaef3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47f25a6e-5c7a-40f5-9f60-15f01957b035_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenditures for property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_a3346532-dd10-41e3-8b99-d8cd8c80062b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and information systems, including internally developed software</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_bde1abdc-c99d-4e28-9fdc-56d75656b276_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt disclosure</link:label>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:to="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ddafd04c-eb47-43b0-8b33-da9d0245410a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_65d45e38-8101-41ca-845f-eb096fdcce40_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c06b0bbd-fb01-4eb1-a9fe-f5c3b8eef315_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableAbstract_1d20c595-c146-4b38-a0fc-78a62258ff3c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes:</link:label>
    <link:label id="lab_us-gaap_NotesPayableAbstract_label_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableAbstract" xlink:to="lab_us-gaap_NotesPayableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_885399cc-e92e-49a8-8d9e-db665a32e52e_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CashPaidForPortionPreviouslyRefundedMember_f4435763-3709-4704-aeb7-2d3a5daaab03_terseLabel_en-US" xlink:label="lab_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Portion Previously Refunded</link:label>
    <link:label id="lab_dva_CashPaidForPortionPreviouslyRefundedMember_label_en-US" xlink:label="lab_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Portion Previously Refunded [Member]</link:label>
    <link:label id="lab_dva_CashPaidForPortionPreviouslyRefundedMember_documentation_en-US" xlink:label="lab_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Previously Refunded [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:href="dva-20221231.xsd#dva_CashPaidForPortionPreviouslyRefundedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:to="lab_dva_CashPaidForPortionPreviouslyRefundedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_248390fd-6e81-41b9-a690-f1bba087372c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_918c6c0c-0709-4d88-92e1-a712e8304485_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments due under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_acfb0f71-a4d3-4cf6-822a-8e7eab1f928f_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_270c3ab0-1d26-4691-8837-817dede86271_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_57b7eaa0-738b-4cc5-aa91-29439ffd4dd6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_1349e6e9-81ba-4029-8f3c-ef28c6bc151c_terseLabel_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_label_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_documentation_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:href="dva-20221231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:to="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_6e080148-ec85-4bb5-889b-2001da4361d7_terseLabel_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_label_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c8979d9-5fec-491d-a5d6-6f44d481edf1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_5d462560-8be9-48e4-bbc4-fce097008d70_terseLabel_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier rebates and non-trade receivables</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_label_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_documentation_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:href="dva-20221231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:to="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_280537bb-39d1-4132-8015-0da53a308853_terseLabel_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_label_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_documentation_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:href="dva-20221231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:to="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5ae97807-f318-4151-a015-5ce179552c39_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7442839e-e4c2-4fd8-8713-b5e0b7d98048_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_946f509a-7675-4cd6-8c0b-6b6ffc0bce81_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_fcb720e6-8e7d-4970-92be-c64cbd06f9dd_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other - Ancillary services</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d6902d71-1cd5-45a6-8075-898140bba81d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity on revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_d8013452-dd9f-4ae0-b439-8afb63e1d094_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_69cb6da5-5b3f-4eaf-aa6f-b98520475db1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_612abc6a-d68a-4b8c-b091-83b947ad1588_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_362a5435-30c7-4db3-b3e6-b41bb1b43e89_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_f803784c-db1d-464a-a9f9-1fe3564af697_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_e8974d70-60a6-422f-8898-f65d02230875_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f0f69bb0-18c8-49be-b4cf-0a15cead7007_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_05cd3810-cf4c-4af3-b8c4-79dc6ae6c25f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts written off</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d9567f87-0966-419f-b8ac-cba991015552_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_785d88e2-806f-4f6a-a61e-84a467607507_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_43ea9650-75e6-4768-bf4b-1602c55690c8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_61dbdb9e-739b-415c-acc3-023aa2879cbe_terseLabel_en-US" xlink:label="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment</link:label>
    <link:label id="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_label_en-US" xlink:label="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment</link:label>
    <link:label id="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_documentation_en-US" xlink:label="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:href="dva-20221231.xsd#dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:to="lab_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_94bd10e5-fa56-408c-a8bb-5c6b578353bf_terseLabel_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in mutual funds and common stock</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_label_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_documentation_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember" xlink:href="dva-20221231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MutualFundsAndCommonStockMember" xlink:to="lab_dva_MutualFundsAndCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_34e1540a-3e8d-4da2-a55e-e59f137f9025_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Changes in Contingent Earn-Out Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f3980f39-c2f9-4c0b-9c4b-fa6f41cdbce3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3cc8993b-7c45-46cd-8862-eb94b31b529e_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to lapse of applicable statute</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OpenMarketPurchasesMember_a6f1ff68-0395-438c-b985-210863cc0bee_terseLabel_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_label_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_documentation_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember" xlink:href="dva-20221231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OpenMarketPurchasesMember" xlink:to="lab_dva_OpenMarketPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncrementalCashPortionMember_012881ca-51ba-4922-bec0-b4e48d56cd6a_terseLabel_en-US" xlink:label="lab_dva_IncrementalCashPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Cash Portion</link:label>
    <link:label id="lab_dva_IncrementalCashPortionMember_label_en-US" xlink:label="lab_dva_IncrementalCashPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Cash Portion [Member]</link:label>
    <link:label id="lab_dva_IncrementalCashPortionMember_documentation_en-US" xlink:label="lab_dva_IncrementalCashPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Cash Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncrementalCashPortionMember" xlink:href="dva-20221231.xsd#dva_IncrementalCashPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncrementalCashPortionMember" xlink:to="lab_dva_IncrementalCashPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5ef7e1bb-235b-49d2-8be0-a966433e8226_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9882b392-3c2f-407a-98c1-4f18eca99274_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99f92213-47fc-41aa-a818-c9a55b4c53fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2c053a88-648a-4a28-8e19-153400f6486d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_50ecda60-b999-4adc-bf0e-01de87fe2c79_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of treasury stock acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_090ae4e6-dd29-449e-a259-77cb38071473_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ba1a0697-b992-4a65-933f-e76109abfa1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_dbd009ba-f2d0-4a63-913c-e42a7084ca23_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_c6df10ba-6c10-4724-b4b9-9b8397f6bb75_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_17e2d147-95e8-4215-8905-13caf073fcca_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt, outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f9dc66de-b287-48eb-ae1b-0621acb19675_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_49edae57-bf66-4a96-8749-25e1d74dda7f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_a7e113e7-fa21-4384-9379-a08016dd0601_terseLabel_en-US" xlink:label="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sales of business interests, net</link:label>
    <link:label id="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_label_en-US" xlink:label="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (Gain) On Disposition Of Business Interests Before Tax</link:label>
    <link:label id="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_documentation_en-US" xlink:label="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (Gain) On Disposition Of Business Interests Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:href="dva-20221231.xsd#dva_LossGainOnDispositionOfBusinessInterestsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:to="lab_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_d2382f2b-bed4-4e87-ad6f-946e6aae0ae4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_157f9d4e-b76c-4815-bea3-d12302ce7c42_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_e1b5b7e7-2592-4ae9-87de-82985aa826e5_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_931110e1-2c99-47d6-a680-d86044efc7a2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_82da86f7-490f-4052-ae79-58e32bc5b8fd_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_label_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges [Member]</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_documentation_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:href="dva-20221231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:to="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_1a618499-4849-4f15-97b8-0ae254591f20_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems" xlink:to="lab_us-gaap_InvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_cf1ec5d6-8518-4e35-a97f-c105ba39be62_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_8e6164ff-9b01-4d82-a787-1041cf95f6bd_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of long-term debt, net of unamortized discounts</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_70745c75-4b02-4630-a37e-d40c2e6af34e_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_728b2bc2-3162-48fd-8d6d-83194b0b9e13_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income from continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_69c689c2-9c54-40b1-b00f-359cbaca0ccf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income from continuing operations per share attributable to DaVita Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5737b200-9be0-40ba-af2d-e4c5f1b0e92c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_84322008-ef1b-43a0-b62f-86dfb5e23575_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments that were considered at risk of significant goodwill impairment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_4e4caa68-fa4a-4820-9820-4c31b20a82ef_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_68bca249-2ed3-4bf0-a863-54cc4da51e3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_93b6181e-73c0-49b7-8078-16dfa64a6ffb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_7aa18477-2d8b-4475-863c-4a11b4f27d3b_terseLabel_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_label_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_documentation_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:href="dva-20221231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:to="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_dbfbbba8-5dde-4f0b-b487-03041b11c465_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_dad992cc-8915-4796-b221-976554485d6f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_203c804e-9b58-4935-ac41-888577e77377_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8bc9f68f-d941-4b86-96d5-246c0e59e4ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_1a3cc9a4-7057-49cd-951a-ff014c802c9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_361f03c8-6f52-4e3e-8840-975a9533a2a0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_96bdd4d5-1835-41f0-9b37-4efbce2810dd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_95438a7f-ff8a-4a44-a6f8-1546ae94ad69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7bd8d2c3-806f-4735-85fc-665508e52424_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment income from equity method investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_0b950033-f1ea-493e-94b6-35bc305b6f1f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b6f98e4d-401a-4fdd-a016-9837901adad3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_8dabcad8-7c97-4d46-95c5-bdc83f3b032c_terseLabel_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated tax benefits recorded for stock-based compensation</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_documentation_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation estimated tax benefit from compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:href="dva-20221231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:to="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_9ce6e7ad-f349-43fc-883e-553f7fca8524_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_08a94b42-896f-44aa-a0df-7b8ec7032401_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, effective date</link:label>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_label_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Inception Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInceptionDates" xlink:to="lab_us-gaap_DerivativeInceptionDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_f912baf7-a105-45a2-82bb-4b55e1c39c56_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_351e643b-dfbb-4095-a541-0022f4505dbb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_99503dda-b9c3-4681-b0ba-260dfc91a249_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanB1Member_5e70e3e2-89f3-4f89-8b87-0f5a042b3246_terseLabel_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1</link:label>
    <link:label id="lab_dva_TermLoanB1Member_label_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanB1Member_documentation_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1 member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member" xlink:href="dva-20221231.xsd#dva_TermLoanB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanB1Member" xlink:to="lab_dva_TermLoanB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_db92693e-81b5-44ab-89ca-48ca81bd4846_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities:</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bbb857cd-2f94-473d-b575-e26b818d877e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eea216f5-2994-4ff5-b88e-155a19faf5b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c799e3ab-d508-4bbe-ad06-0f2c941bec76_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8f15a197-c4c5-4f90-970d-418813d0284b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_995e2f9a-7d5c-444e-be88-590c7d96d7ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0110abd0-b76e-49db-b565-59865bc94636_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_95905afa-1921-47b9-85c4-6da18f4ac888_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee entitlement for purchase of the Company's common stock during each calendar year</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_46c98e22-aa87-40a0-9b8f-79e19932da93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_548a2f61-59ce-4e4d-b337-2b4cd86dca78_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_75f68cc8-8895-4ce7-9635-d2342fbece79_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_f39c897c-ebbf-43c0-bb02-12ff074012be_terseLabel_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b2e43b10-fffe-43b4-a53c-7661bfa2a2a6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_11942a5e-9d4a-4fc3-b8df-80c8bc86a76c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e249735b-e22f-4b15-8e01-c6ae0d94d55c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_059a4dcb-bcd2-47f8-a1d3-4b31212af98c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e843307d-5078-432a-ac65-d3fe0c923f48_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_61e3408a-0d9f-4173-98d8-4422b11b6c5f_terseLabel_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive 2020 Plan</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_label_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Twenty Twenty [Member]</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_documentation_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Twenty Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:to="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_56496bba-9f54-4d97-b2f5-3c11180b3d88_terseLabel_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_label_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_documentation_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements" xlink:href="dva-20221231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OffBalanceSheetFinancingArrangements" xlink:to="lab_dva_OffBalanceSheetFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_fb65c9db-024f-4ac3-9a32-df5efb4bd8c5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_408bbac3-a079-4d64-bbc8-721bfa5a1200_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AllTrustsMember_0dd8ecba-025a-47cb-9c10-8c33f52678d2_terseLabel_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rabbi trusts</link:label>
    <link:label id="lab_dva_AllTrustsMember_label_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trusts [Member]</link:label>
    <link:label id="lab_dva_AllTrustsMember_documentation_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All trusts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember" xlink:href="dva-20221231.xsd#dva_AllTrustsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AllTrustsMember" xlink:to="lab_dva_AllTrustsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_420a577b-94cd-4b52-8b50-14967710653a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b5e11087-cc2b-4246-b765-274e88421f9c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8a89b802-46e2-47a4-8bae-2bf164dfe157_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f8da6a97-d2b7-467d-bb6c-b7037d2242a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dc2ecf89-7ad7-467f-bc6b-1f1419a1bdc9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total</link:label>
    <link:label id="lab_us-gaap_Assets_fbdb71c9-1b2b-4840-98d5-7b78a20718e4_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_48fc9637-5985-46c0-84ba-c2f58bd8acd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_be784570-ff15-4136-843e-5c3bdc988ac0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_02b99574-0fd5-45cd-9cb4-57913bbaa157_terseLabel_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Noncontrolling Interests In Consolidated Partnerships</link:label>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_label_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Noncontrolling Interests In Consolidated Partnerships [Member]</link:label>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_documentation_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical purchases of Noncontrolling Interests in Consolidated Partnerships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:href="dva-20221231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:to="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0b0946ec-80c1-45e1-a30d-6b37a9619bf2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_9f550bd9-ce1d-4efc-8027-f3915ce0edb2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_500aec82-ec26-442a-88ae-41e931301f87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_346ab644-e62b-4c14-b90f-9ca1a22f4ddc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockUnitMember_092b3648-2079-4b25-8848-be29a91b4b8b_terseLabel_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_dva_StockUnitMember_label_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Unit [Member]</link:label>
    <link:label id="lab_dva_StockUnitMember_documentation_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Unit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember" xlink:href="dva-20221231.xsd#dva_StockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockUnitMember" xlink:to="lab_dva_StockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_07e46edc-a5bd-43e4-8c61-affd88d921cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6d3b5bba-bfe8-4ce9-8c8e-c87a7a0e9e1d_totalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_745d94f3-d68d-47c3-bdb5-8ae0571b3dfd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7379ab77-3a85-4c34-9b1a-2ebd3c4e18c7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_10ca17f8-0cb7-4b20-81f9-e9f04d813563_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_101ab717-ef37-4f6d-bc55-2126e51835b1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5c9cfbf6-f920-4da6-9226-6dd94af1903f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d56720e8-4951-4348-b09a-77eabfb83177_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_64229689-508c-42c8-a279-737be1fd2bf4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_b63df4f6-a229-489a-afcf-06e8817d7e0d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_a94cc3a1-03b6-4e42-aaaf-a6d6ebc5cfd3_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c93730fe-19ef-44c8-aac0-425c659a7431_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dbd3b71d-38b5-49de-9a86-ae8fb73e23c2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_6aad3b73-b35e-465a-9ac0-f6fa2162c328_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TenderOfferMember_bde8c00d-b9cc-427e-88ed-fd389f14cd60_terseLabel_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer</link:label>
    <link:label id="lab_dva_TenderOfferMember_label_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer [Member]</link:label>
    <link:label id="lab_dva_TenderOfferMember_documentation_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember" xlink:href="dva-20221231.xsd#dva_TenderOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TenderOfferMember" xlink:to="lab_dva_TenderOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed5d0a67-21ee-483a-8293-9799a385cb79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_637f4122-8e66-42d9-b6f5-cf565535c5f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_a6741b9d-6504-4a97-b4ff-eb9ee2adc7f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_ad75a264-f767-4297-9d7b-2ffd9d05a20d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_8be02d9b-a6e2-444a-a816-6e12acb60976_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:href="dva-20221231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4a57ec09-7c87-441b-b7d7-585c161111ee_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_20cafb3d-d54e-45c4-a556-1502d758e9aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis patient service revenues before provision</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cc6e0fb8-d2cc-4ec5-854a-650aaa79e094_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_e02dcc4d-efe2-4ec0-95bb-7b3ae9989bf1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_72505af0-9c98-48f6-b35e-55adf5ce4d31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_dd67afa9-8972-4b82-a079-3db709c5d16d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b4fa07f0-7bc7-4ac2-b586-f382dfe94fe3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_0a098c4d-d936-4930-bf99-2ed09abcdeec_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsReceivables" xlink:to="lab_dva_DeferredTaxAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0deeb631-0c82-42e4-8519-b327ce2d5c65_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f90e01aa-9666-47c5-a188-09a06d7a864a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExternalSourcesMember_95c4af9c-3218-4b6d-b414-53f4ce1b56b9_terseLabel_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Sources</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_label_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Sources [Member]</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_documentation_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External sources.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember" xlink:href="dva-20221231.xsd#dva_ExternalSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExternalSourcesMember" xlink:to="lab_dva_ExternalSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_76acdd41-5ba0-4c18-b519-934991100aee_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_d8e8b520-ff20-4db4-8005-a47e591ee789_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c70afb96-c4f0-4bb1-8622-23dffb99f6bd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_dcf201c9-a63b-4b5f-be03-822937378e5a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfCustomers_94ffd5af-acd9-4a0f-ad49-b08897a5df8d_verboseLabel_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients served</link:label>
    <link:label id="lab_dva_NumberOfCustomers_label_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_dva_NumberOfCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers" xlink:href="dva-20221231.xsd#dva_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfCustomers" xlink:to="lab_dva_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3550ba14-ee86-4532-9564-473978a3ac50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_489091ec-f1d8-40b2-9bc2-8dbb140c961d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_e557ec2e-91a7-4355-83d1-a2394d252b97_verboseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8f95602e-00f2-401f-ba90-e239e2568732_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_43de849e-82eb-4d2e-a3de-70dd314849e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_35735563-fc1a-49f3-8878-472604c68cf9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b5850e18-22a3-4093-b445-a5c7a48f7425_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_34b17231-b614-47a1-be1e-882f34c0f005_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_e05e24e3-baaf-48b4-b86d-a4b7b02ab5c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_c1b1c331-5ea1-43bf-b079-1fdee5791f33_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_1fbdb0b5-6a34-4127-a6d1-49ec74244a7a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_edca9699-0776-4efe-83f9-4fdc85357ba3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and self-insurance accruals</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9da902d5-e207-4091-97d7-61b04793617c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_258a1af4-3462-40f0-a2a2-974d3815e9b0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_809ee10b-0171-4911-a9a3-33c58daeebd2_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_537f6c9c-c35c-41bb-83a1-3539dfd35dbb_terseLabel_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled dissolution term of joint ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_label_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution Term Of Joint Ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_documentation_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution term of joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures" xlink:href="dva-20221231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DissolutionTermOfJointVentures" xlink:to="lab_dva_DissolutionTermOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bd35c952-9f96-403a-ab94-0b6261786d26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_406348e0-5496-457c-b367-6f396ec257d1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_2729a5b9-2cb0-4063-b76a-1898c24e7749_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b392d88b-2ba9-4b59-bb23-3a8ed77bb7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_46de3b28-7dfa-427b-9576-be9615de961c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense from amortizable intangible assets, other than lease agreements</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_81ffa865-9a33-4fda-a844-ea0080b4954a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest, net</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5e355f88-b03c-4eff-bf46-5dfe51e9dfe2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Carrying Value of Goodwill by Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd337cd6-4050-44d9-bd00-26fe53f2643c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_d6299d7f-0c26-4d8a-be99-3bf77da66e5c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_07c22d97-3462-4ce7-acf5-5f0627c8aec7_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_468d1a5e-93d5-4fff-8285-1f7b6bbe9b96_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5aaef505-7a41-4c6c-a50c-b0fa83db8416_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d4334f02-e9c5-427c-b08d-3655f6dbbc3a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f70f9035-2d5f-4940-994b-3fb2318bcb21_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total DaVita Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_66fc3b82-29e4-4fc5-88cf-4716fcde9373_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State capital loss carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_69611249-5cff-4f90-b19a-1d6507b7609e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6ddd4ce2-6bc4-4a14-b048-f87e58ae4426_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_d27d05f8-e36b-4f48-8a3b-dbd0ccf05be4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_a57661d3-18c5-4af6-b69f-42a0ce73e69c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f3759d3b-56ec-4092-b584-4b282cad6667_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_e522b479-98f4-4f6c-8dda-b3e3a47e716d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a4f54a22-3c46-4b0b-92c0-f043a4cb9b0b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d15320e2-6512-4b7e-a0fa-732ff669f3da_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_14602e03-8ca5-4eb4-9453-95d725deac1a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f4cbdb3d-7998-42f5-bc71-44fa8a87c0f2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_88044002-ef7a-466e-9b3c-ad0bd6bf8102_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense, Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_75b018c0-baa3-43d0-8c5c-b276222da463_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c5b949c5-a6ed-49e2-bc58-f1eba09c322f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_744af465-dc7b-4b50-9601-8ffd054fc6b4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense Components</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d9cc962f-3258-4c1e-b3e6-d6b221f6a8fe_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earn-out obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7b37127a-1b7f-431d-bb4f-1d1362492b04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af24186a-aebb-477c-8ea7-f03bd1ab30cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d78c67a1-2b05-48e2-83cd-1475bb91022e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_cf28ec8f-a176-4332-b845-787e82ce368b_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_3d28985d-d7f5-4f10-a1fc-74b93e7a5906_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d27099d7-c99f-4d73-9475-c35b095359f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_500837f1-55e7-4bbb-b88d-65c55e137f83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchases summary table</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_afc0a995-c800-4e1a-9023-6fd3dd8bee37_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_49264624-60fd-46f1-96bd-2a9e75d5f2b8_terseLabel_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_label_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_documentation_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:href="dva-20221231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:to="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_07852c1e-c914-4c66-a382-7173a757ec9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_01a932a7-906b-456e-8e89-8ed0c6266144_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_e77b2fec-864a-4649-8181-6b62b0fbdd60_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_63ffc855-65f1-4842-8bf3-7bad9ec20860_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_334eb85e-125b-41b6-bf54-b368b7bbfbce_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466f3044-a31b-4ba0-a135-5591e3b2a8f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_c0699c0a-8cf7-47cd-b5db-651d0ed7cbf2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9eaa52dd-1513-45c0-994e-f31a9d901854_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_14c00c41-167e-4ffb-b2ac-27a2104e0671_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_4aed09a9-ad89-41e4-803c-e67ccc0fc72f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of additional noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_b1a92017-d0b6-47d4-b51b-d15ed253e11f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_41168614-044c-415f-9989-d20b1e460208_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_6e9570dd-e00d-49fe-9cad-b64530433b3d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7b342e94-b00c-41c2-8d44-55bbbd47dea2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c07d2005-359c-4907-a352-43fd7fb4734d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4cd0a7ba-1b6f-4f96-bb23-6ede8eaec17b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_52d78c93-be39-460a-b11a-761727352a31_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8c93c82a-71da-4d5e-869e-44e57a40e941_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bcd43580-68bc-4997-8ee3-942a865b7a72_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_0501efbe-704a-45c4-b78e-6d7c96d028d6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_59f46b55-4670-40fa-ab90-a458a8224c96_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_1dfdd0c4-f239-4291-9703-f79e16325b38_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_5dfc3bd4-c50a-4e8a-91b1-ea48da0e5226_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense from continuing and discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a26e924c-79e1-4ec1-911a-17606fa698bd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_4437046f-fc36-4e8d-8ad2-3f1aa6fdcecc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5872aff2-200f-433b-9e61-be34a9c79187_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAbstract_4deeb533-1c23-485e-b045-5859ab18df39_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares Repurchases, Table Footnotes:</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAbstract_e0731d1a-a12b-49ef-b52d-a0a3eb94b6d1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAbstract_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract" xlink:to="lab_us-gaap_TreasuryStockSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_6cfef0ed-c1d1-43a0-85ad-f3422c4b8356_negatedLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_d6bf454b-4afc-43d6-9aa4-5253e6543edf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a57e76b0-764d-405e-9aa0-899ab8f4b8ca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_34919933-8262-42c7-9053-c42ca2fe0258_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_46f99b45-cc7b-446c-b25b-7b049d298119_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_0cc3563b-48d9-4ee8-acb7-3b4110228ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Routine Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:to="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_db54d10f-ecdc-44ce-9785-8552619d6464_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_99cc7a69-48cf-44e8-8b9d-1b5ac9355957_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_97fa24b9-af09-4822-adcd-fc4b3c4ba955_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_497b4ecc-17f7-49c8-aa7f-5f76261a228d_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dc1ec1d4-2b9e-4f97-943e-cc3f124503fe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d7fc5dfa-3e03-45b6-99af-2d69b866717b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_33638e7e-8fc0-4591-bcf3-7aa046d54764_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1ac5ac1d-e413-4cb2-9aa1-f27d3b17bf59_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_806313fb-fb9f-4b2b-912b-02063574f8c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ee9ba2ba-1f4b-4004-b40e-5a3ea293f29c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70204e9c-df02-4d90-969c-503092860c01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dee2cc80-8382-404e-b72f-fa5a2909a1fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0028df4a-7436-41bb-8dc9-f25fb85e76cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3c615a74-57d2-48c9-8d7e-a00bc30a01cb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_ae0a5d41-11da-4421-bcb8-4e3e9156a44d_terseLabel_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of concentration risk customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_label_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Concentration Risk Customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Concentration Risk Customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers" xlink:href="dva-20221231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfConcentrationRiskCustomers" xlink:to="lab_dva_NumberOfConcentrationRiskCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_40ab260a-3b32-4037-b26e-787e1c278ae3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_25eb021a-ed6a-4398-849f-ed23f86d0158_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_b90add12-18d6-483f-ac9f-ed3b5ff815de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01f20c11-824a-43dd-ba8f-ababd84642c6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c215034-2d24-48dc-8830-ab3c65742d0e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_764e3e4f-b83a-44d7-a39d-4623ee4d00ed_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_b9585a7e-8722-4d4a-8be6-5509d2c2c13c_negatedLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_label_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:to="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_5e6db601-a82e-4bb5-97a3-491a0ac911aa_negatedLabel_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivities, Operating Income</link:label>
    <link:label id="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_label_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Impact On Fair Value For Reduction In Operating Income</link:label>
    <link:label id="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_documentation_en-US" xlink:label="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Impact On Fair Value For Reduction In Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForReductionInOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:to="lab_dva_PotentialImpactOnFairValueForReductionInOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFourMember_4e4df16c-b600-4d34-9074-df4bcf65c5a1_terseLabel_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$100.01&#8211;$110.00</link:label>
    <link:label id="lab_dva_RangeFourMember_label_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label id="lab_dva_RangeFourMember_documentation_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember" xlink:href="dva-20221231.xsd#dva_RangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFourMember" xlink:to="lab_dva_RangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c9899fc2-40eb-4d99-9e52-46c4cd185d1c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a8e2d3cd-120e-40f2-aadf-00686f881bf2_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e447aed-3a20-4878-a717-c78064ff5fae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of grants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_2b73b5bd-dee4-449b-91ec-c76ebfb60fb0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified deferred compensation plan, contributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8c203415-11a0-4692-a8eb-b156ef9fa3c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_a488f860-2f2c-49ef-a61d-cabb7650c2c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9dc74b35-606d-412f-bdc2-7d9177cb3953_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_894f6f5e-b327-405b-9cb7-21c85f98d009_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash gain on acquiring additional ownership in business acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6174f585-a3f4-44e7-adf9-c9859580413c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_cbfca361-9085-4add-9625-99e0ef2d56b3_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:to="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_35c9ac45-1722-4177-bd40-e68d22819cbc_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_30d15b38-4079-4e82-b758-f986edc97c06_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_900cd89e-8139-4fe0-9302-a9491df5e980_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesTable_b0e8bc00-64cd-4914-9763-26b37eeaa89e_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_label_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_documentation_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable" xlink:href="dva-20221231.xsd#dva_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesTable" xlink:to="lab_dva_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_a53c0645-3d6a-4988-b725-f2a58e22d0e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_30ecbd3b-954f-424d-b672-f7f5ece55045_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_fc295a30-e536-422f-82ce-8b2517395baf_negatedTerseLabel_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of other debt and equity investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_label_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_documentation_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:href="dva-20221231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:to="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_c5659493-55ed-4cad-b22a-743a6f05bcd3_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_81492df3-b39d-42af-8a6c-aab8419f08d3_terseLabel_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_label_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_documentation_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Accounts Receivable , 6 months or More Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:href="dva-20221231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:to="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_6f923ff7-5e6a-44af-b93d-69b9171c8da2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_e2c371e3-5d7b-4ceb-98b3-90f27a2ba9d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maturity date, description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48534e8c-5d82-4934-9e0b-0f9b9a94d5c1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_85f7c5a3-f28d-43b0-81c9-826a81a84d14_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in debt and equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0fc3e5db-29a8-4790-8251-266e53e9c4ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6045c237-80c7-4ea9-85a1-93ffbdf53c8c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_d577be44-7a04-4ea4-96c7-5ec29cdccad5_verboseLabel_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_label_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</link:label>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_documentation_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:to="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ec89a64e-5b58-41ec-b2eb-8b3330d6c0e8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019a6c85-4639-4f45-b6d5-dc04997eed11_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3b735072-cdc9-409b-b8e9-1e8b9a08dccd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_623a4718-3580-46aa-8901-06e67195d5fa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8cc6eeda-2864-466f-8179-fda2b3a196fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3d3ba361-1cd9-46fd-b0a5-444f29d25447_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_86e0917f-ccac-457c-889a-57f700d9c7ec_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_022e5564-ad2a-49a4-8210-727932960bf7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_ced1ef0f-46a2-43ef-8eb5-4b7e19828565_terseLabel_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net</link:label>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_label_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net</link:label>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_documentation_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet" xlink:href="dva-20221231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseInDeferredTaxAssetsNet" xlink:to="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d1bfd5dc-b375-4b10-997c-80ba6ce271f4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_e64fa6c7-e1ce-4d5d-95db-2517740cae7e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts charged to income</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee7f7c0d-6750-481e-b028-f6795777ff6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2f1ba23f-b43a-4436-af14-a048d92c9da3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for employee stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e98cc9f5-0ede-45e6-9023-5f139195dae4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Purchase Cost Allocations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_e127a879-288f-4b41-8332-6aa35ad0ea5f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f331bf60-73e8-49af-9dc8-5061554529b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8097822-52ef-4711-ab02-87de25687cbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dae8bcc1-987c-46df-a988-db0c27cef790_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_a10d4fca-f1f2-4814-b79f-fcdb9dce8891_terseLabel_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_label_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid [Member]</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_documentation_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember" xlink:href="dva-20221231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicaidandManagedMedicaidMember" xlink:to="lab_dva_MedicaidandManagedMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_95a93d94-87f9-469e-ade0-f693094aa4c5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_550dff1e-186b-409e-8323-f61cd1640d94_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8a7cecc7-c6b3-412a-82b1-95a5b6d42886_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5403f265-5cbd-4f88-8c13-9ffd4d2a07a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_69f9a54a-740b-4b1c-856a-078841c9e865_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_d47b294e-ed35-4506-824a-eea60c4aeffe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_2b2471b1-3f76-405e-83c9-80e9df7ae3ee_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_9cadda6b-9ab4-4366-b82a-796b181e3fbc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fe29ad10-e17c-47d6-8e0f-d65b49b3cfcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled Amortization Charges from Intangible Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d6614738-39d1-4784-a8e2-804afe2e3614_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_2ac15d87-ea10-4bf9-b211-a3f455889a9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f4d884cb-3bb0-4f7d-93e4-b07100b667eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_f6283d91-a811-4d9f-b0cc-cce9928d2f7c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earn-out consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_49f25dbe-3722-4230-929c-d9c4066da7bc_terseLabel_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Government Payors</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_label_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Government Payors [Member]</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_documentation_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other government payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember" xlink:href="dva-20221231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherGovernmentPayorsMember" xlink:to="lab_dva_OtherGovernmentPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_a590b768-250d-499f-856c-58465d417c28_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_006204fb-ac14-4c42-b2a9-012647a4244d_terseLabel_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_label_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:href="dva-20221231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:to="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_fc1c85d9-b62f-46f8-9667-f16b123a8ab1_terseLabel_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self insurance</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_label_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Self Insurance Policy [Text Block]</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and self insurance policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:href="dva-20221231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:to="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f6dc40ec-e726-4559-8fd8-f8430b977191_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4464d8cc-a8f2-49c0-8c54-f0754b7194ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f12dbad7-37bf-44bd-8a43-cdc510a7dd87_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_33bf9a05-283e-4707-a95c-91e5444d618a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff2bcc6e-309b-49c1-b521-6504cc7e5ef9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c9b4894-2d6a-48bc-98c4-a20eb4843cf8_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1cefbbbb-6336-4554-b810-970f42114f19_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfSites_bb473434-e9c8-4eff-b0b9-b7ba9c3ba804_terseLabel_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of dialysis centers that the company operated or provided administrative services</link:label>
    <link:label id="lab_dva_NumberOfSites_label_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sites</link:label>
    <link:label id="lab_dva_NumberOfSites_documentation_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites" xlink:href="dva-20221231.xsd#dva_NumberOfSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfSites" xlink:to="lab_dva_NumberOfSites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f8e2dad9-c5e6-4ee9-9ef7-ca44de1cafc4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_002dcbd4-70c8-4ec3-8578-a463ddfbd878_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_39dc33bc-b9c1-429c-8d2b-ce7ac072ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_e2aa0e99-b926-4ec8-8f66-26cb96318b81_terseLabel_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersubsegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_label_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersubsegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:to="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_42698284-2931-4936-a923-3ba085d20185_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_b88a4072-b2f3-4c0c-9aa0-1b32dac51e33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c021c565-3cc6-4d22-b59c-08b1b1666b13_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_b17472ee-4845-4316-ba45-1a90d0b41730_terseLabel_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember" xlink:href="dva-20221231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeStockPurchasePlanMember" xlink:to="lab_dva_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_f2133b8a-52de-4cdb-9bee-a620053c8bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets by Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_fc6885c2-cf62-4815-94cf-3de3a9591cfb_terseLabel_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Targets or Quality Margins</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_label_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E B I T D A Operating Income Performance Targets Or Quality Margins [Member]</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_documentation_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA operating income performance targets or quality margins.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:href="dva-20221231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:to="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6c617bff-fd14-4932-aca0-345e38e42a0b_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_5c34a659-b3cf-4995-b612-ec45d12c90b3_negatedLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_644f980b-ef22-4504-9879-a62e3810f8ad_terseLabel_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit and other time deposits</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_label_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Deposit Commercial Paper And Money Market Funds [Member]</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_documentation_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit, commercial paper, and money market funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:href="dva-20221231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:to="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_650b7c83-5bae-4f91-8013-09ca0191b952_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_04383ac9-d1f2-4f59-811f-be4ab7ec6eae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amounts of interest rate agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6989d971-e883-47cd-bb0d-df8d7e0f96ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_48687d80-7868-4dd1-9552-6981ee0c1757_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89365e1e-4977-4fdb-bde5-70b1e989b6e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_744d4225-ab94-48ea-bcaa-a8b09664d7c6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_865ed012-31fb-469a-982c-5b185064de3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_b4912d7b-8599-40fb-8c08-c94b3e0e6692_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_8fa908b0-7d7e-4d07-a1f4-8278b251ebe5_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_eeb1fd92-fd73-48f8-b9d6-3871254aa638_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_a1d2842c-ff5f-4f58-afae-0380b2acc431_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_6a271abf-5cb9-418b-846c-ccb28e39dd77_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_75e4ab03-cfff-424c-801e-9fd6161528af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_465cc95c-3ec5-4777-bf25-4d197b01585a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award payment plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c3550cfd-9d55-4cbd-91ef-5f0c32cecea1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1369ec09-c7c6-4bde-b58c-d07eebf6399e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_57e292f7-c570-4b77-a72f-ee10631a214a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_0fc29dea-fc99-4c89-804d-9726259e08a5_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e9a737b1-a9eb-4a29-9505-bc1cdc74fba8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_61c08287-df93-406b-99e2-a98257d19fdc_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum payments due under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_88ab4f9f-dff7-4770-9a5e-7b038d332c2c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTable_f93eb1de-cb56-4a61-85f8-f3de47bca485_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_label_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTable" xlink:to="lab_dva_LeasesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad3e19c3-d187-43e5-bd94-2eb51f0fe0c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_43cc1af4-3b63-4277-87cc-e739c262a6d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_40c9e753-6c77-46cb-9785-84fd693badf3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_376dd7c8-1d04-4370-bc51-1f69df8860fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_642dfa14-4d12-4f14-af9b-060ea8ea6485_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_353e110e-f0fc-43f5-9b38-34d96c442355_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Depreciation and Amortization Expense by Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_b29372bd-32dd-4966-98da-09533f0ff933_terseLabel_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_label_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_documentation_en-US" xlink:label="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:to="lab_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_2f45a39b-6797-4369-b975-3187cffba135_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cf044519-645b-4d58-b116-1658da38e899_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a4944339-9cf1-4143-938a-5b8a085567e8_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_f92e3813-9d6a-46a0-a8e3-62a57feb7d9d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ac9cf123-403f-41b9-a45e-bd970adb7252_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9b283006-b318-4e0b-9850-56957a3629d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_cd29ddd9-3d29-4c6e-8e9b-a153af85b52c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e340465c-6707-4c5e-8d50-19608a177646_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_9beea219-bd2e-4e70-a8c2-e56d7fe0afc1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dc7b6bca-79ba-447d-9c5d-1914ba6f6042_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e0addf7-6a64-457e-94d0-2742e3173674_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d07eade2-44fb-466e-a1ef-794456535ffe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a3eb1b41-b55b-4e29-9000-f0aa6dfca350_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets acquired, weighted-average estimated useful lives</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_4b2f286b-974b-42d1-a8dd-ba32816774f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_496c0724-aef0-4df1-b283-3373675933b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of net realized (gains) losses into net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_1010b9d2-0e3f-471d-b34a-70bcbe332ad0_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_2880a047-5405-4e71-b4c5-f298eab5fc1b_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_c1982ccc-35c6-4ee8-a5cb-39da47b949a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_66968d31-c013-4d3f-9595-92583dec28aa_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_9d351e64-8ecb-414c-8083-048faea0af12_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_cbadc08b-063e-466b-b35f-bded2e8f4e02_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filer</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_bf836e21-c71a-42a3-8c54-a77708d65407_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_21e7bb85-134a-4ea1-bb46-c5d5d6c9c259_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_94d0ecd4-b79f-4936-a4fe-7ae5f34f0340_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f4340544-fc50-45cb-891e-f2080690a1ec_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_cdbd9ad4-f38b-496f-82f5-e13fc162dc21_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_25a1a2f6-eabc-4c4b-a3dc-857f240973b4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TaxYear2029Member_1d62aee4-f38c-46b9-90ad-7fa8d8c0d4e1_terseLabel_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029</link:label>
    <link:label id="lab_dva_TaxYear2029Member_label_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
    <link:label id="lab_dva_TaxYear2029Member_documentation_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member" xlink:href="dva-20221231.xsd#dva_TaxYear2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TaxYear2029Member" xlink:to="lab_dva_TaxYear2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_036dc8b0-1847-4142-948f-56eea39e8a65_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_f3c24e6b-2364-4bdc-913c-8c566e5d2efc_terseLabel_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_label_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_documentation_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:href="dva-20221231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:to="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_63790f07-fc3c-419b-bdfa-0d9b6935c414_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2bc73053-1c96-4a08-beca-3e852b55eca2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Asset Categories</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0c6f407f-5898-465f-b06b-fa844a974682_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_25198fb3-0c4d-459c-9605-615ba8dfe7d4_terseLabel_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_label_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_documentation_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:href="dva-20221231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:to="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_70558f2b-f365-41fd-b4d9-b5e014aa61f5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_72d28ffe-fd8e-49c1-842b-6e5bb04ef494_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d5610853-330b-4964-9c2c-417c6b261da1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_5516e38a-bc16-491d-b2f2-6f0fe7de5710_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, expiration date</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_90125469-e946-4776-8ce2-2a5a23c608a3_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_dfb3c42e-3061-4030-9045-76024a8fd05d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1768136d-a697-4f39-8508-de371f95a3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_fe281a37-61a4-4a7c-8133-8f74b0b27ec3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_3d971ec1-b953-40e9-9975-5f1ba3f09de6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_95d9f36a-babf-475f-9f58-a39f80e76358_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 3.75% due 2031</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_label_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:href="dva-20221231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:to="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_58417286-e0b4-4265-8823-98ee9ffddf14_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_d7b8bbed-93e6-4945-88be-a3dbcb112dee_negatedLabel_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount and deferred financing costs</link:label>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_label_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount And Deferred Finance Costs</link:label>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_documentation_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount and deferred finance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts" xlink:href="dva-20221231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DiscountAndDeferredFinanceCosts" xlink:to="lab_dva_DiscountAndDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7a539d9b-70e0-479e-bda4-f71527e5210d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_47b5126a-7345-4f22-ab2e-5c5299ac31bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less portion representing interest, operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4327288e-d656-44ad-83e2-25dd841783b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ff15c550-d189-4cb2-b199-2c3f58a2f8b6_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share attributable to DaVita Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bd195d3c-2973-47a8-b8b4-86ab0aaa5221_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_bdf0206f-2d4c-44df-b900-cb25e4153a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by the Company</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e2e516c9-2d1a-40cd-96c3-c933c870ec03_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0a8d2da8-5329-49e1-9db7-200a8d39a543_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ecdef3a3-c4d9-4f4d-a1a8-c44bb48a92bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_273824a2-0e75-4354-ab44-7c375d443ac8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0f72210d-1df0-454d-9a2f-4f1d13bd4c23_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_20b151bd-a2be-42bd-9316-022e11ee835b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_38ff21f1-52f6-467c-9c9c-724373c7a42c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6849784a-796f-44d1-91bf-f1fca6ff4a6b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanAMember_cd5a11a5-fde8-4381-81d5-60c6a1c7e0f7_terseLabel_en-US" xlink:label="lab_dva_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_dva_TermLoanAMember_label_en-US" xlink:label="lab_dva_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_dva_TermLoanAMember_documentation_en-US" xlink:label="lab_dva_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAMember" xlink:href="dva-20221231.xsd#dva_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanAMember" xlink:to="lab_dva_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_7af669ce-b0af-45f5-b052-99157a36d2a0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted cost method and other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherReportingUnitsMember_1cd80d9b-c0fd-4621-81c7-b824871a8fd7_terseLabel_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reporting units</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_label_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_documentation_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember" xlink:href="dva-20221231.xsd#dva_OtherReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherReportingUnitsMember" xlink:to="lab_dva_OtherReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_637bef98-e20d-48d2-b0b4-82c4c104cbb0_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:href="dva-20221231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:to="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_b9600ee5-bd5d-4157-b8ab-31177777acb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_cd584336-1756-40a9-8887-ed6cb63520f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_27f2bb4c-8456-4207-9a09-3163c0c13d21_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_46721769-29aa-4c39-b058-ae8bb662320e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_1acc06cc-3469-4d52-bcd5-90143d56b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanAAndTermLoanB1Member_c6d93934-2234-404e-a767-faa24d90ce44_terseLabel_en-US" xlink:label="lab_dva_TermLoanAAndTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A and Term Loan B-1</link:label>
    <link:label id="lab_dva_TermLoanAAndTermLoanB1Member_label_en-US" xlink:label="lab_dva_TermLoanAAndTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A and Term Loan B-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanAAndTermLoanB1Member_documentation_en-US" xlink:label="lab_dva_TermLoanAAndTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A and Term Loan B-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAAndTermLoanB1Member" xlink:href="dva-20221231.xsd#dva_TermLoanAAndTermLoanB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanAAndTermLoanB1Member" xlink:to="lab_dva_TermLoanAAndTermLoanB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_d06328ce-2796-4ee4-8db9-fbec75fe4a66_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value, gross asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_eedaddef-9eb4-4012-8fe6-c1b046abebdd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_b2ea465c-70c0-44d0-b8b6-c65d0a7e2840_terseLabel_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_label_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:href="dva-20221231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:to="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PayorRefundsAndRetractions_01221a73-fccb-4901-ac6e-bf396b833db3_terseLabel_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor refunds and retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_label_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_documentation_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions" xlink:href="dva-20221231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PayorRefundsAndRetractions" xlink:to="lab_dva_PayorRefundsAndRetractions" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_d670f764-3b3e-41fc-8f2b-2ab8e25919b7_terseLabel_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_label_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_documentation_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract" xlink:href="dva-20221231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesOtherInformationAbstract" xlink:to="lab_dva_LeasesOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_9a85b9ff-f07e-47eb-bc3f-d255edb54403_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State capital loss carryforward, expiration date</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_02c2be52-4575-4a93-8405-1cc355ac5b4c_terseLabel_en-US" xlink:label="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member [Member]</link:label>
    <link:label id="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_label_en-US" xlink:label="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member [Member]</link:label>
    <link:label id="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_documentation_en-US" xlink:label="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:href="dva-20221231.xsd#dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:to="lab_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_9736fa6a-2f5d-4d2e-aeb8-f8ac1f3833b0_terseLabel_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of legal entities that third parties held noncontrolling equity interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_label_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Entities That Third Parties Held Non Controlling Equity Interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_documentation_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities that third parties held non controlling equity interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:href="dva-20221231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:to="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureLineItems_681979a1-0cd4-4e0c-9532-f64dce013acb_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_label_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureLineItems" xlink:to="lab_dva_LeasesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0850b3b9-a3bd-435e-9bee-7e9f4ff8228a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments and other investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_fb1bed75-4f66-405b-a58a-4930954157fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_c51ae973-cf54-4bbc-a7f7-a28ae282b602_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_label_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceAgreementsMember" xlink:to="lab_us-gaap_ServiceAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d3453a8e-6924-4603-a113-b3519544b89b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c242723d-fd1d-431b-a166-6e3d11101afb_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Information Systems</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_61df8880-990b-4be6-bb3f-9fed2700acee_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_f7d8a9c3-1c88-465a-a077-21d397ec47aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term Investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_3075c164-8ad0-4247-8176-dbaf9a9387c9_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_20a28b48-b8ff-4d03-a06f-7805c2f27102_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_868f8312-800c-4b13-b5dd-da04bfb5be08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, significant impairments and other valuation adjustments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_335e848c-d871-4864-9bfd-56d74191b1f6_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseTable" xlink:to="lab_dva_ExpectedAmortizationExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3e542e2d-c69d-43a9-9414-99827bfea99c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e3709bc4-5213-4cce-9db9-c4718f100342_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_da6a79c8-957f-4600-b17d-9489dab1b01f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on foreign currency translation.</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_68a142ae-f991-43d8-b73d-9d42b666165d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_31bac266-3867-4a76-8cf9-48921afffc42_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest rate during period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_4ca51c1e-aa27-4be1-9ba7-8eb99bef31c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_42011757-fb29-48d8-8a31-e55374917d0b_terseLabel_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt outstanding principal balance subject to LIBOR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_label_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To LIBOR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_documentation_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To LIBOR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:href="dva-20221231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:to="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_c444db5d-44da-492c-9cf3-bdb050aebdbd_negatedTerseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_11bfedf4-66a1-4d27-b2b1-ac70c188e0a4_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_a671818f-dcc7-4c3e-ba5e-906b25695d84_terseLabel_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law:</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_label_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_documentation_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:href="dva-20221231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:to="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_f807a24f-e3b9-413a-b452-8462e481ca2f_terseLabel_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments to Provide Operating Capital</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_label_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments To Provide Operating Capital [Member]</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_documentation_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments to provide operating capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:href="dva-20221231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:to="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_cef90be7-cd85-4bf5-a9bf-d06d297aab5a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9edce7aa-92d1-4bb8-9c3b-324235f7b320_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_c96c4522-fe5f-4c6f-8070-7095794e7e74_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets under financing lease obligations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2c3e2af3-8f8f-4c71-a6cc-bf9692154dc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_9ebddd05-c447-4cd8-900a-ccf632a80650_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for uncollectible Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_6b0f8429-49cd-4746-9efa-09767b602e39_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_856b70b7-39df-4a70-806f-9126a7cd0666_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_8b469bb7-9753-4e26-9de8-2dc44ba6f148_terseLabel_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income (loss) from other equity method investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_label_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:href="dva-20221231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:to="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_44731542-c165-4575-856c-7d0e0b7d2786_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_5505a0a7-657f-41e3-af0e-0485bb3b9f58_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_16ecd878-6d6c-4dc4-ad73-93d62a7ac3ff_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_23c7ada6-b544-47a0-829e-9d3b157c45b0_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeTwoMember_4ce5ec5e-ae91-4abd-979b-458fd42fe4ea_terseLabel_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$60.01&#8211;$70.00</link:label>
    <link:label id="lab_dva_RangeTwoMember_label_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_dva_RangeTwoMember_documentation_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember" xlink:href="dva-20221231.xsd#dva_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeTwoMember" xlink:to="lab_dva_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_0cd5a46c-a2cc-413d-b34e-e83512ea6401_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_2b89a83d-7437-4753-9689-e616518198e6_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_label_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases complete footnote disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTextBlock" xlink:to="lab_dva_LeasesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_61d1f6e6-88b2-48aa-bab0-b78f4d45ceee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_9454c95b-41aa-4650-8712-22751fd4ea20_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4b7e63d2-34bb-4aa0-a5a5-3cc684a27484_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less portion representing interest, financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b8958cd4-01f8-4e79-a41b-88b2e789efc6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_ab1687e9-4ec7-474d-a0d2-a7551e60fff6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_e06500bc-1aad-4539-8e79-49f0b41435ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_49564841-f1be-4992-ae4d-d20f4d265121_terseLabel_en-US" xlink:label="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share, Clearing Price</link:label>
    <link:label id="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_label_en-US" xlink:label="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share, Clearing Price</link:label>
    <link:label id="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_documentation_en-US" xlink:label="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share, Clearing Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:href="dva-20221231.xsd#dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:to="lab_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_6ba81261-9524-4896-b09d-731eb4cf32f6_terseLabel_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_label_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="dva-20221231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a1a14ed6-ea40-492a-b843-3df6073dc9cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_73584b68-42bc-4b5a-a70e-b0aadfee7189_terseLabel_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid:</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_label_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Period For [Abstract]</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_documentation_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during period for.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract" xlink:href="dva-20221231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract" xlink:to="lab_dva_CashPaidDuringPeriodForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockIncentivePlanTwentyElevenMember_7426b176-3eb8-4d4c-8bd2-86d094f05223_terseLabel_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive 2011 Plan</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyElevenMember_label_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Twenty Eleven [Member]</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyElevenMember_documentation_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyElevenMember" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockIncentivePlanTwentyElevenMember" xlink:to="lab_dva_StockIncentivePlanTwentyElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_8bcc3aa0-d61d-4970-a8c7-156e9fb9ad0b_terseLabel_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_label_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:href="dva-20221231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:to="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>dva-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a258e43b-0014-4ff7-951c-bd296743129f,g:d7686aa8-e1fb-4adf-8ecf-125ac77280c0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dva-20221231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_322e80b7-f8e1-442c-a190-af88cba7004e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentType_322e80b7-f8e1-442c-a190-af88cba7004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0851d9f0-e563-4346-a3fd-ea446224014a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentAnnualReport_0851d9f0-e563-4346-a3fd-ea446224014a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_94a5a381-c06d-485b-8c03-e24ee282bf17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentPeriodEndDate_94a5a381-c06d-485b-8c03-e24ee282bf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_69241373-33c9-4bf5-aec4-1d927511b641" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_CurrentFiscalYearEndDate_69241373-33c9-4bf5-aec4-1d927511b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ca09ee1a-f721-47f1-93c5-8a09df7e9d56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentTransitionReport_ca09ee1a-f721-47f1-93c5-8a09df7e9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4f6f42d1-5ccc-4b17-b037-dcc416465e71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityFileNumber_4f6f42d1-5ccc-4b17-b037-dcc416465e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_483dfe61-f076-466b-93e0-fe930b0aea0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityRegistrantName_483dfe61-f076-466b-93e0-fe930b0aea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7e951de3-9faf-4494-972b-868768ba8e3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7e951de3-9faf-4494-972b-868768ba8e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_462c8f62-9c39-477b-8ddb-e62019a9c94a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityTaxIdentificationNumber_462c8f62-9c39-477b-8ddb-e62019a9c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_37ccb320-5300-4c82-a9dc-5d819b0ee90a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityAddressAddressLine1_37ccb320-5300-4c82-a9dc-5d819b0ee90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_751d1fa8-153a-4ce2-a361-926f50b369cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityAddressCityOrTown_751d1fa8-153a-4ce2-a361-926f50b369cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ad28bd46-5060-481c-9837-442e43c3666a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityAddressStateOrProvince_ad28bd46-5060-481c-9837-442e43c3666a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e26f0377-bad6-47f7-a5e3-f027783b3d3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityAddressPostalZipCode_e26f0377-bad6-47f7-a5e3-f027783b3d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6605b28e-4fac-4c80-85ef-59f270cb6b44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_CityAreaCode_6605b28e-4fac-4c80-85ef-59f270cb6b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0aafed22-f6d6-4825-9f24-7523508c71d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_LocalPhoneNumber_0aafed22-f6d6-4825-9f24-7523508c71d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5027f527-6f92-4798-98e1-ce2191872879" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_Security12bTitle_5027f527-6f92-4798-98e1-ce2191872879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_862bc0be-67e5-4fe0-adca-2c3d5985e014" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_TradingSymbol_862bc0be-67e5-4fe0-adca-2c3d5985e014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41e82c16-455c-4304-8c4b-ef1a5a44717d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_SecurityExchangeName_41e82c16-455c-4304-8c4b-ef1a5a44717d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e37a5f0c-7903-4ac5-a4df-9d6fd219dcc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e37a5f0c-7903-4ac5-a4df-9d6fd219dcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_79c4d05d-fde0-4e6c-958a-6ea102ebf7fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityVoluntaryFilers_79c4d05d-fde0-4e6c-958a-6ea102ebf7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_22f91ca1-80e5-4b56-bc3a-635e7a1e5901" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityCurrentReportingStatus_22f91ca1-80e5-4b56-bc3a-635e7a1e5901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_664ced88-0849-45f6-bc8c-b4c5337ce37e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityInteractiveDataCurrent_664ced88-0849-45f6-bc8c-b4c5337ce37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0c8a6b33-c8e2-4191-8ee1-bc35bb8c8cf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityFilerCategory_0c8a6b33-c8e2-4191-8ee1-bc35bb8c8cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8cb0b593-9262-43f2-adf7-cf415897891c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntitySmallBusiness_8cb0b593-9262-43f2-adf7-cf415897891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_600fe3fd-1253-4c0d-a465-540b6e1b8558" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityEmergingGrowthCompany_600fe3fd-1253-4c0d-a465-540b6e1b8558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a4e37c1a-fb87-48d3-afd1-4b5502d77dc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a4e37c1a-fb87-48d3-afd1-4b5502d77dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_772bff60-0ebf-4c07-a4da-b371d2306c22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityShellCompany_772bff60-0ebf-4c07-a4da-b371d2306c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_16d19521-521a-4a9b-979a-855d2b3c8c55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityPublicFloat_16d19521-521a-4a9b-979a-855d2b3c8c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3a57496c-891c-4f72-b891-ef7978aaed3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3a57496c-891c-4f72-b891-ef7978aaed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_07c0e24b-e334-4994-b8ca-06c65cf208ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_AmendmentFlag_07c0e24b-e334-4994-b8ca-06c65cf208ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_88e57a1a-7c4e-46f0-8092-5238390b1263" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentFiscalYearFocus_88e57a1a-7c4e-46f0-8092-5238390b1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6395a7f3-1756-45ac-8ab1-cea0acb1d978" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6395a7f3-1756-45ac-8ab1-cea0acb1d978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_43fa040c-f1f0-404d-9f89-ebb633ada91d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3e0457f1-03a5-4a81-a16c-12b2f9d9de16" xlink:to="loc_dei_EntityCentralIndexKey_43fa040c-f1f0-404d-9f89-ebb633ada91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AuditInformation" xlink:type="simple" xlink:href="dva-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract_a5d56506-4c51-4aef-9eb8-4e4b0e28afc5" xlink:href="dva-20221231.xsd#dva_AuditorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a1673a69-3ae9-481c-999a-635ce49d3e3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a5d56506-4c51-4aef-9eb8-4e4b0e28afc5" xlink:to="loc_dei_AuditorName_a1673a69-3ae9-481c-999a-635ce49d3e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_4c185508-bc3c-4462-a98b-dd63c6157f22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a5d56506-4c51-4aef-9eb8-4e4b0e28afc5" xlink:to="loc_dei_AuditorLocation_4c185508-bc3c-4462-a98b-dd63c6157f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_58ec3542-4f32-415b-bd0e-aec5f494d5a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a5d56506-4c51-4aef-9eb8-4e4b0e28afc5" xlink:to="loc_dei_AuditorFirmId_58ec3542-4f32-415b-bd0e-aec5f494d5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_3f9580f6-c958-4efe-bb26-7583ae93f4e9" xlink:href="dva-20221231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_3f9580f6-c958-4efe-bb26-7583ae93f4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_1a93ba69-3576-46e0-9e63-4107cca7a5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_OtherIncome_1a93ba69-3576-46e0-9e63-4107cca7a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f68c613a-8ec7-4517-8464-c68bf172eb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_Revenues_f68c613a-8ec7-4517-8464-c68bf172eb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_300db481-90ce-4cf8-8f3c-78a465fc1dd1" xlink:href="dva-20221231.xsd#dva_PatientCareCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_dva_PatientCareCosts_300db481-90ce-4cf8-8f3c-78a465fc1dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e6ecbf70-9edb-4a36-ae24-ab3dbf7d519c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e6ecbf70-9edb-4a36-ae24-ab3dbf7d519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_50929a6c-18ef-4b59-89d0-65110965c579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_us-gaap_DepreciationAndAmortization_50929a6c-18ef-4b59-89d0-65110965c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb7f6a72-54ab-4e39-aa7e-547480217017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb7f6a72-54ab-4e39-aa7e-547480217017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_163ffac1-6dc7-4432-ae5b-51886d1c619b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_163ffac1-6dc7-4432-ae5b-51886d1c619b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0928f829-5424-441a-a866-b1cd12b3dd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_868a21e8-bd0b-48be-8b40-e091111ca4f0" xlink:to="loc_us-gaap_CostsAndExpenses_0928f829-5424-441a-a866-b1cd12b3dd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1cf910f0-ceef-4387-9c69-879c6b06ef87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_OperatingIncomeLoss_1cf910f0-ceef-4387-9c69-879c6b06ef87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_a8db98ea-4971-4bf7-b349-42439aede79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_InterestAndDebtExpense_a8db98ea-4971-4bf7-b349-42439aede79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_35e2ea66-d68f-4ca7-9544-c70b750b033f" xlink:href="dva-20221231.xsd#dva_DebtPrepaymentRefinancingRedemptionCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_35e2ea66-d68f-4ca7-9544-c70b750b033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_71a73bcf-1a5a-484f-be98-0b542a493482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_71a73bcf-1a5a-484f-be98-0b542a493482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a8000c6-6cb6-4a60-a98a-11b510677dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a8000c6-6cb6-4a60-a98a-11b510677dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2eaa57b4-db03-45b0-91fa-43dee9e2dc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2eaa57b4-db03-45b0-91fa-43dee9e2dc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c31f1779-7243-454e-b6c3-8a2ee87139d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c31f1779-7243-454e-b6c3-8a2ee87139d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24bbc93b-b063-4972-a892-4e232ff1a9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24bbc93b-b063-4972-a892-4e232ff1a9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_921492ad-9f7e-4570-bba8-f420c96f8a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_ProfitLoss_921492ad-9f7e-4570-bba8-f420c96f8a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2535228b-3fb7-425b-b5b8-76f4c0ece478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2535228b-3fb7-425b-b5b8-76f4c0ece478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17bbcb5d-2c7d-47c2-bf7b-f45be01260a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_NetIncomeLoss_17bbcb5d-2c7d-47c2-bf7b-f45be01260a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e5c0c0bc-12bc-4a00-a3f5-fe5bbd6c66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e5c0c0bc-12bc-4a00-a3f5-fe5bbd6c66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4f3171b0-bf4a-4b8d-96c9-f7852ec31d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:to="loc_us-gaap_EarningsPerShareBasic_4f3171b0-bf4a-4b8d-96c9-f7852ec31d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1ba44d6c-0fa1-448e-b084-4345872730c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1ba44d6c-0fa1-448e-b084-4345872730c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dc5caba1-f650-4a7e-83fb-9507bda62c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22153d2e-d1b1-4811-996a-e1a35dc67bd2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dc5caba1-f650-4a7e-83fb-9507bda62c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_44918584-5d6e-4205-833a-81a80db76ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_44918584-5d6e-4205-833a-81a80db76ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f73f8652-07d7-475c-ab1a-544d21cd845f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_44918584-5d6e-4205-833a-81a80db76ab4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f73f8652-07d7-475c-ab1a-544d21cd845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6bcb04ed-c32a-487f-8b5f-68cca84a21d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_44918584-5d6e-4205-833a-81a80db76ab4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6bcb04ed-c32a-487f-8b5f-68cca84a21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0a45d811-ed77-409b-9b45-679c5d55098e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a21e97d-bf80-4739-b460-c9bcc31dddb3" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0a45d811-ed77-409b-9b45-679c5d55098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5cc20677-be78-4e66-8664-cfae4adeb88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0a45d811-ed77-409b-9b45-679c5d55098e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5cc20677-be78-4e66-8664-cfae4adeb88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_917918de-6160-44e3-ac39-d63ebab9dde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0a45d811-ed77-409b-9b45-679c5d55098e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_917918de-6160-44e3-ac39-d63ebab9dde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1351439-eeb8-4ff9-a58c-0067653c4794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0a45d811-ed77-409b-9b45-679c5d55098e" xlink:to="loc_us-gaap_NetIncomeLoss_f1351439-eeb8-4ff9-a58c-0067653c4794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME_1"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4a4de95f-89c7-4dc9-bc93-0f5c758bdb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_ProfitLoss_4a4de95f-89c7-4dc9-bc93-0f5c758bdb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9033c422-7d86-471c-b244-85812a27e03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9033c422-7d86-471c-b244-85812a27e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6b35d5ca-15de-4912-b5dc-73dbe9d4b6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9033c422-7d86-471c-b244-85812a27e03b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6b35d5ca-15de-4912-b5dc-73dbe9d4b6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_77c748d1-0668-4fab-bb25-81e97636bafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6b35d5ca-15de-4912-b5dc-73dbe9d4b6c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_77c748d1-0668-4fab-bb25-81e97636bafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d1d34a36-e6ba-411e-8ebf-2d79af30d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6b35d5ca-15de-4912-b5dc-73dbe9d4b6c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d1d34a36-e6ba-411e-8ebf-2d79af30d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_b37c4d7e-a2b9-4958-bbe8-b2399dd30ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9033c422-7d86-471c-b244-85812a27e03b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_b37c4d7e-a2b9-4958-bbe8-b2399dd30ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_76209cd7-0e48-4256-865a-91bc6107a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_b37c4d7e-a2b9-4958-bbe8-b2399dd30ef1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_76209cd7-0e48-4256-865a-91bc6107a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c38f51f2-9271-48cd-be40-45ea86834c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c38f51f2-9271-48cd-be40-45ea86834c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4897c432-55c8-4f4b-9b5b-de36f70df322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4897c432-55c8-4f4b-9b5b-de36f70df322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a68367de-c19a-4be0-93ab-5b1a62be512c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a68367de-c19a-4be0-93ab-5b1a62be512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73cacfcb-ba9c-40bb-b7eb-17b713335ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2591830b-9765-4f57-95e6-e660f302ba7a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_73cacfcb-ba9c-40bb-b7eb-17b713335ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e9b72e4-26a8-47da-92b9-c89a3b9cd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e9b72e4-26a8-47da-92b9-c89a3b9cd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1f109488-987b-483b-bea5-ac1151be3767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1f109488-987b-483b-bea5-ac1151be3767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_70bc5877-17a7-49ed-9f3e-0f776341a86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_70bc5877-17a7-49ed-9f3e-0f776341a86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_910a1275-a021-4dfa-870b-da60b5b3f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_910a1275-a021-4dfa-870b-da60b5b3f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ff58adee-f80b-40fd-938c-571da459fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_InventoryNet_ff58adee-f80b-40fd-938c-571da459fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4add0369-8d07-409a-85a0-e6f1e7c7f2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4add0369-8d07-409a-85a0-e6f1e7c7f2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf92d808-a536-48a8-a777-00009ae09d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf92d808-a536-48a8-a777-00009ae09d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_9db3ddac-2d0c-4291-9de7-84b45e38dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_IncomeTaxesReceivable_9db3ddac-2d0c-4291-9de7-84b45e38dc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5045be38-e72f-499c-bb40-12a093cd6bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_AssetsCurrent_5045be38-e72f-499c-bb40-12a093cd6bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0c97e80-5d1e-4722-9cbd-30785d7ebe25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0c97e80-5d1e-4722-9cbd-30785d7ebe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_27218c64-d0ff-4bea-97f7-4395224d8a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_27218c64-d0ff-4bea-97f7-4395224d8a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1f30eaba-7f3a-4ccb-bf13-f4d1724cef78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1f30eaba-7f3a-4ccb-bf13-f4d1724cef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_188abffd-0f08-4836-908f-4ed5c48f5d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_188abffd-0f08-4836-908f-4ed5c48f5d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8e385747-ebe4-441d-936d-b4c170498ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8e385747-ebe4-441d-936d-b4c170498ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_22ad4109-3c1a-4c9c-891b-f7f43b20b71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_22ad4109-3c1a-4c9c-891b-f7f43b20b71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e0ff388a-e8ac-4bab-8cfd-65fbd957ee62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_Goodwill_e0ff388a-e8ac-4bab-8cfd-65fbd957ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fe0dd3d8-2375-4ba1-b16b-9e23dbff5b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f4cfaca3-8eae-4e48-ac8d-3ccf54932e2c" xlink:to="loc_us-gaap_Assets_fe0dd3d8-2375-4ba1-b16b-9e23dbff5b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fd4eda31-df1f-469f-b3d0-75f45ba2a4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_AccountsPayableCurrent_fd4eda31-df1f-469f-b3d0-75f45ba2a4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_23415550-319c-49d2-8dc3-0612a33653d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_23415550-319c-49d2-8dc3-0612a33653d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1ed5cf8-9ca9-413d-801a-f6c676e47ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1ed5cf8-9ca9-413d-801a-f6c676e47ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac410e6d-219f-4d38-aac9-944db582e922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac410e6d-219f-4d38-aac9-944db582e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7f588539-094a-4d61-9e1c-188d930489fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7f588539-094a-4d61-9e1c-188d930489fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_6c4e3a7f-fe14-45b8-a372-aea3bb73d387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_6c4e3a7f-fe14-45b8-a372-aea3bb73d387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b44502a9-a59b-44cf-a85a-8f61d4c3b794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_LiabilitiesCurrent_b44502a9-a59b-44cf-a85a-8f61d4c3b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aadffc21-11ea-49d0-b99a-ce5e983d7e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aadffc21-11ea-49d0-b99a-ce5e983d7e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7b987ad0-fc4b-4a35-bc99-25c5086cfc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7b987ad0-fc4b-4a35-bc99-25c5086cfc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_946200fc-691d-4c0f-9676-2c1e1963f8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_946200fc-691d-4c0f-9676-2c1e1963f8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_33400928-0cb6-4dbd-ab67-9c540bad3b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_33400928-0cb6-4dbd-ab67-9c540bad3b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d80a95cb-f59c-4089-b611-80710b43c435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_Liabilities_d80a95cb-f59c-4089-b611-80710b43c435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c4dc8be-3053-494d-b16c-390fbf4344f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c4dc8be-3053-494d-b16c-390fbf4344f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3afae1d1-ff4d-4518-b481-8446a52bf4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c4dc8be-3053-494d-b16c-390fbf4344f1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3afae1d1-ff4d-4518-b481-8446a52bf4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_854592c6-e660-4539-8278-e8a10ff99679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_PreferredStockValue_854592c6-e660-4539-8278-e8a10ff99679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_225b2975-53ee-4fdc-b894-0c1d62860f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_CommonStockValue_225b2975-53ee-4fdc-b894-0c1d62860f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e8afaf5-53c2-4a71-bd6a-5fe5a895b175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e8afaf5-53c2-4a71-bd6a-5fe5a895b175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b1651db-048c-4a4c-8ebb-604501c9fab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b1651db-048c-4a4c-8ebb-604501c9fab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_645f866f-2f3c-4d15-b31e-937c77a8cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_645f866f-2f3c-4d15-b31e-937c77a8cb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd99bf3e-f3cb-4f4a-abfc-7d9d990a6323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_StockholdersEquity_dd99bf3e-f3cb-4f4a-abfc-7d9d990a6323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_14f836b3-fda5-4264-8c19-b1f75d6338ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_MinorityInterest_14f836b3-fda5-4264-8c19-b1f75d6338ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58dace45-5c5f-4de8-868e-58b8bfceaa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d48737f3-1289-44a0-925d-5c7b4302dccb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58dace45-5c5f-4de8-868e-58b8bfceaa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_48c2fbd6-6d56-4d20-a248-de2a9dc1ab66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_171e2a44-f824-4e17-abb0-6bc6ed9cd0b1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_48c2fbd6-6d56-4d20-a248-de2a9dc1ab66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8cbf7376-10c0-4937-8cdd-c9af627e9ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8cbf7376-10c0-4937-8cdd-c9af627e9ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bea3c729-42b0-4ee4-8481-32b16caa20f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bea3c729-42b0-4ee4-8481-32b16caa20f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0d06806a-2533-4240-b83a-29990c0eb2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0d06806a-2533-4240-b83a-29990c0eb2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c23a2b6-63af-42bb-a8df-a56628c44fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c23a2b6-63af-42bb-a8df-a56628c44fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0519f32f-80a3-4f26-85dd-9aa1a7ad47d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0519f32f-80a3-4f26-85dd-9aa1a7ad47d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_95be39e8-71f4-4ec2-b282-f2b2c2194027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_077086c5-95c7-40b3-8990-3a4ccf03a3f4" xlink:to="loc_us-gaap_CommonStockSharesIssued_95be39e8-71f4-4ec2-b282-f2b2c2194027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_efc8f36b-c6a4-4974-b8aa-63dfb9b91b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_efc8f36b-c6a4-4974-b8aa-63dfb9b91b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_37d36041-f66c-4827-ab8e-c903ccd1a779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_37d36041-f66c-4827-ab8e-c903ccd1a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_55365818-91e1-4964-909f-52d38fbac7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_55365818-91e1-4964-909f-52d38fbac7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4156bbb0-bab3-45ab-af51-6e4b652e8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4156bbb0-bab3-45ab-af51-6e4b652e8ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ef2e9bd9-db65-4f54-9a49-090a7e0e1eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ef2e9bd9-db65-4f54-9a49-090a7e0e1eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_da7adcb1-ebe5-452a-9d08-c892ef63352d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2017bde2-5476-4bd3-91a7-93250ff4243b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_da7adcb1-ebe5-452a-9d08-c892ef63352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a0f5903f-3d23-47c5-b258-21fd15a177d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a0f5903f-3d23-47c5-b258-21fd15a177d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2bc16a80-fc8e-41a9-bb9f-dbba0f6049a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a0f5903f-3d23-47c5-b258-21fd15a177d4" xlink:to="loc_us-gaap_ProfitLoss_2bc16a80-fc8e-41a9-bb9f-dbba0f6049a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a0f5903f-3d23-47c5-b258-21fd15a177d4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_2650867b-da72-417c-9142-45b711e9c79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_2650867b-da72-417c-9142-45b711e9c79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_748fc851-9a43-472a-a1e6-c440cd8e812a" xlink:href="dva-20221231.xsd#dva_DebtRefinancingCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_dva_DebtRefinancingCharges_748fc851-9a43-472a-a1e6-c440cd8e812a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b83ff32f-0b8f-49a0-9a04-7e3a4ea505c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_us-gaap_ShareBasedCompensation_b83ff32f-0b8f-49a0-9a04-7e3a4ea505c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_449574a3-f3f7-4aba-8b21-6fd474ea5dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_449574a3-f3f7-4aba-8b21-6fd474ea5dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_3593089c-b43e-4246-a842-bf332980f08e" xlink:href="dva-20221231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_3593089c-b43e-4246-a842-bf332980f08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_cc183794-6233-4a46-a88f-bcb438d1b41d" xlink:href="dva-20221231.xsd#dva_LossGainOnDispositionOfBusinessInterestsBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax_cc183794-6233-4a46-a88f-bcb438d1b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e4bccd96-16c1-4173-a3f0-6e0f7cbcdffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e4bccd96-16c1-4173-a3f0-6e0f7cbcdffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89834d04-e773-41f5-bcb6-73c6c1ac009c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f64e618-154a-4483-93a6-73f0bdaa738d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f64e618-154a-4483-93a6-73f0bdaa738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_28d18fb5-8aef-4115-9117-801133f54e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_28d18fb5-8aef-4115-9117-801133f54e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_10ee0da3-f592-468f-902c-f9c401701c6a" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_10ee0da3-f592-468f-902c-f9c401701c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_499c798c-4c9f-476f-ba61-6fe3a54451cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_499c798c-4c9f-476f-ba61-6fe3a54451cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_50839f8b-7748-4e1b-b553-316244f2d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_50839f8b-7748-4e1b-b553-316244f2d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5ee1ebb2-e1b4-446e-bec4-81603f4fe7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5ee1ebb2-e1b4-446e-bec4-81603f4fe7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_768e2ce9-6e3d-4d50-aa0a-8a6ea352f9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_768e2ce9-6e3d-4d50-aa0a-8a6ea352f9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8bd9638f-607b-418c-b406-421da8e9f9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8bd9638f-607b-418c-b406-421da8e9f9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f7dbbdac-06fa-4de8-a818-4b709084d563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f7dbbdac-06fa-4de8-a818-4b709084d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfcff049-83bf-4d2e-9b12-f1a599c7f7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26051663-afda-4201-a201-b8b312975953" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfcff049-83bf-4d2e-9b12-f1a599c7f7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b5b4cdf-4dbc-4102-ab60-c0939369cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b5b4cdf-4dbc-4102-ab60-c0939369cfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_87ad9938-0b5d-4c4c-a1df-b5ddea11ded0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_87ad9938-0b5d-4c4c-a1df-b5ddea11ded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_731a1f24-80af-4f51-b127-e03e2a48db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_731a1f24-80af-4f51-b127-e03e2a48db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_a804019e-a95c-4be5-acb9-affce356b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_a804019e-a95c-4be5-acb9-affce356b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_cd595d60-d734-423f-ab2b-70746f0a852d" xlink:href="dva-20221231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_cd595d60-d734-423f-ab2b-70746f0a852d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_5e4a311b-bb6f-4de3-be0e-e50301c780c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_5e4a311b-bb6f-4de3-be0e-e50301c780c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_67b7334d-637b-41c1-984d-e41effafd815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_67b7334d-637b-41c1-984d-e41effafd815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_dbf25af9-8af6-49b6-8cd1-1112a8f916a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_dbf25af9-8af6-49b6-8cd1-1112a8f916a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b5602802-f98a-498f-92b7-5c1f867d1db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b5602802-f98a-498f-92b7-5c1f867d1db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_4990a46d-7523-41cd-85d7-095e7da30cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_4990a46d-7523-41cd-85d7-095e7da30cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc7871dd-f7dd-4d8d-a2f5-c7524cec2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f41c7a51-c142-446e-9b06-6e9ffc5818ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc7871dd-f7dd-4d8d-a2f5-c7524cec2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9094ea47-8cd7-45a3-b12a-c731f0198ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9094ea47-8cd7-45a3-b12a-c731f0198ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_4f104a15-19f8-4161-9e72-e831a904e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_4f104a15-19f8-4161-9e72-e831a904e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_69fcf6c3-37bf-40b1-9f76-54df739f8b72" xlink:href="dva-20221231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_69fcf6c3-37bf-40b1-9f76-54df739f8b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_891df183-cf7c-4a9e-92cb-b02ce75f32ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_891df183-cf7c-4a9e-92cb-b02ce75f32ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57421887-f63c-4373-b094-9dcaf7a23329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57421887-f63c-4373-b094-9dcaf7a23329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_792b8b3f-be18-4f3a-96d8-9dc0831d4203" xlink:href="dva-20221231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_792b8b3f-be18-4f3a-96d8-9dc0831d4203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_65688292-0fa6-4286-acc1-5a42b7797408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_65688292-0fa6-4286-acc1-5a42b7797408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_ece88127-0cd0-4766-8408-38894cdf10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_ece88127-0cd0-4766-8408-38894cdf10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_7c93a1aa-f1f0-4f75-b307-4805525a3337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_7c93a1aa-f1f0-4f75-b307-4805525a3337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e01a4507-5a07-41ea-90d1-5a901676566c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6796355f-584e-40bc-b51a-6c49bc109441" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e01a4507-5a07-41ea-90d1-5a901676566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6f73b5be-8513-483e-ab2c-864268e23288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6f73b5be-8513-483e-ab2c-864268e23288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c222a50c-82af-444a-b0e0-ad84ccb30c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c222a50c-82af-444a-b0e0-ad84ccb30c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e240ed4-6f03-426b-b85c-fc4365280df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e240ed4-6f03-426b-b85c-fc4365280df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_585edca3-654d-4607-a9cc-067e182db57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d9adc74-48f3-4dc9-bd7a-4506bc39bb09" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_585edca3-654d-4607-a9cc-067e182db57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20221231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_57229049-c24b-455d-aa60-cdcb43466612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_57229049-c24b-455d-aa60-cdcb43466612" xlink:to="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f220694-bcc1-4075-b5b4-1aa7c343b30d" xlink:to="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_304f3ed8-3aa2-40d5-9d3b-702294e17751" xlink:to="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_894f7d8e-9684-4291-a383-7cca9f23676a" xlink:href="dva-20221231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_894f7d8e-9684-4291-a383-7cca9f23676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_771c9a13-d61d-4793-af8e-19aac186adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_CommonStockMember_771c9a13-d61d-4793-af8e-19aac186adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef2fd65f-c356-40cc-a982-03c27c197add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef2fd65f-c356-40cc-a982-03c27c197add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_841ce041-261f-422a-ad62-be1a8573754d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_RetainedEarningsMember_841ce041-261f-422a-ad62-be1a8573754d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ecf7d635-9d80-4ef4-a5ed-9092bb12ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_TreasuryStockMember_ecf7d635-9d80-4ef4-a5ed-9092bb12ee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a926320f-5cab-406b-99f8-a70b0537d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a926320f-5cab-406b-99f8-a70b0537d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1510bb6b-b94f-4572-aa41-ca0b8ae2fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_96b72acc-149c-4d0b-bc52-9281f2cae4a1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1510bb6b-b94f-4572-aa41-ca0b8ae2fea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0e0610a-8056-41c5-ad95-3a25361bbee5" xlink:to="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21affb40-01fd-47bf-bec9-333cd742086c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b68351ec-2824-4fd6-8292-698f9880535c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b68351ec-2824-4fd6-8292-698f9880535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4a1d40e3-64ae-4e1e-9a1e-de42da2711b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4a1d40e3-64ae-4e1e-9a1e-de42da2711b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_42516eca-257a-4bb9-b9c3-911b9cc58925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_42516eca-257a-4bb9-b9c3-911b9cc58925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b4bd76d-554d-423a-88dc-a4c936d9f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b4bd76d-554d-423a-88dc-a4c936d9f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_9edf5264-8632-4322-bc1f-8ea64becbf07" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_9edf5264-8632-4322-bc1f-8ea64becbf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_33c688d7-e1fa-45de-b277-7d01bd097023" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_33c688d7-e1fa-45de-b277-7d01bd097023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_cbc1fbc1-4645-4660-98ad-4b18d24f84b9" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_cbc1fbc1-4645-4660-98ad-4b18d24f84b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_10410cf7-cc7c-450a-92b8-fe25bf5766f1" xlink:href="dva-20221231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_10410cf7-cc7c-450a-92b8-fe25bf5766f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_e4d52199-11f4-451b-b4e6-717cec1908fc" xlink:href="dva-20221231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_e4d52199-11f4-451b-b4e6-717cec1908fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_8ffa1277-5738-4769-b05c-849a1d8dfcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_8ffa1277-5738-4769-b05c-849a1d8dfcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_9a63d5ae-c264-4d7e-95ac-05cbc09ba843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_9a63d5ae-c264-4d7e-95ac-05cbc09ba843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d702c19b-c81f-4c8a-b8d3-c681651a9055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_1c1b19f6-afbd-44e7-b027-7356c4b033b2" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d702c19b-c81f-4c8a-b8d3-c681651a9055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_197da20c-b3ba-41bf-a426-e3402daa4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_197da20c-b3ba-41bf-a426-e3402daa4fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c924e97-55b4-4e08-8878-61818413905e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_db3587c1-62a3-450b-8aae-c2eb622b2a9c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c924e97-55b4-4e08-8878-61818413905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_efc9d64f-ac4b-423a-ac23-84976729da21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_efc9d64f-ac4b-423a-ac23-84976729da21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_db652be3-97e7-46e1-8426-1a102efc2022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_db652be3-97e7-46e1-8426-1a102efc2022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_534001d4-b49e-406e-91e8-fc55aba89443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_534001d4-b49e-406e-91e8-fc55aba89443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f8430b45-c26c-4d73-98dd-c461f6b3bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f8430b45-c26c-4d73-98dd-c461f6b3bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_349c6b2c-cfaf-4a91-94be-abd3607e0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_349c6b2c-cfaf-4a91-94be-abd3607e0efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1ad931c1-ad2f-4317-a759-4b1f8b05ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1ad931c1-ad2f-4317-a759-4b1f8b05ef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_4b03f71d-f4fd-4530-8888-228ed1bd13a4" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_4b03f71d-f4fd-4530-8888-228ed1bd13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_4a70e8e8-10ff-4c72-8684-945678820478" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_4a70e8e8-10ff-4c72-8684-945678820478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_69daa693-6fea-4021-acbe-148cf1effd6d" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_69daa693-6fea-4021-acbe-148cf1effd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3c318eb7-465f-42a1-9d12-7059f9a55323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3c318eb7-465f-42a1-9d12-7059f9a55323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_60498d61-baf6-405b-9f36-5472fffe004a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_60498d61-baf6-405b-9f36-5472fffe004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_9f8f98f3-0801-48df-a968-2ecbc060c6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_38ac37d7-12b3-4510-ae52-aa2cd510590c" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_9f8f98f3-0801-48df-a968-2ecbc060c6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3052ca89-75a5-4b32-a1de-821db6eed965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3052ca89-75a5-4b32-a1de-821db6eed965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f853474a-e5ea-41e3-8233-948a593eacbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f853474a-e5ea-41e3-8233-948a593eacbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_a3f31d7d-dd71-4c4f-b964-9cf586b23b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_a3f31d7d-dd71-4c4f-b964-9cf586b23b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_a30e4c6a-47ea-42c2-9d38-598a934aa8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_a30e4c6a-47ea-42c2-9d38-598a934aa8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_bb7eef03-b36f-4570-a6e1-2eab99ddf4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_bb7eef03-b36f-4570-a6e1-2eab99ddf4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_ad4567e8-96ba-4015-83eb-3c35f93fcc9b" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_ad4567e8-96ba-4015-83eb-3c35f93fcc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_436b5f12-6b4c-4338-9cdd-e4640b41f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_436b5f12-6b4c-4338-9cdd-e4640b41f9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_465b2173-c08b-4f65-b30d-6d9ea0639919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ee02abc-3d17-438e-893d-8d916b8b26ef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_465b2173-c08b-4f65-b30d-6d9ea0639919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dva-20221231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04307b5c-fe35-43a6-a146-8808dcfa1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1bf28d2d-8307-469d-898c-f9c4aa8602fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04307b5c-fe35-43a6-a146-8808dcfa1bcb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1bf28d2d-8307-469d-898c-f9c4aa8602fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognition" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_6a9f96d0-93d5-4634-a375-6ae4ea647cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_91800858-a9f1-45e8-abc6-66ae53e4331a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_6a9f96d0-93d5-4634-a375-6ae4ea647cd5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_91800858-a9f1-45e8-abc6-66ae53e4331a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShare" xlink:type="simple" xlink:href="dva-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fdd8434b-b4dc-447f-a747-9329eebd85e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_31a01bb7-d119-4ab7-94dc-eccab0f66a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fdd8434b-b4dc-447f-a747-9329eebd85e6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_31a01bb7-d119-4ab7-94dc-eccab0f66a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RestrictedCashRestrictedCash" xlink:type="simple" xlink:href="dva-20221231.xsd#RestrictedCashRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RestrictedCashRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract_c5d581cf-a142-4bc6-8fa8-abbb7fa6fc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_f65282bf-52b6-4e65-a486-5fc2e191237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_c5d581cf-a142-4bc6-8fa8-abbb7fa6fc71" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_f65282bf-52b6-4e65-a486-5fc2e191237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="simple" xlink:href="dva-20221231.xsd#Shorttermandlongterminvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c17a36bb-16f5-494c-9cf2-6de25740573e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e58e281b-2c0e-4765-bbb6-7e76ceb71a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c17a36bb-16f5-494c-9cf2-6de25740573e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e58e281b-2c0e-4765-bbb6-7e76ceb71a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherReceivablesOtherReceivables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_c7f03845-3118-4a07-bdef-24124626687f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_3e91a00a-8453-4a2e-b6d5-8c57e1fbec52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_c7f03845-3118-4a07-bdef-24124626687f" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_3e91a00a-8453-4a2e-b6d5-8c57e1fbec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_68932d45-0a66-4f80-bb3d-b83b42a0df07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7ebdcbff-7708-4ddc-9792-59e7dd95d017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_68932d45-0a66-4f80-bb3d-b83b42a0df07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7ebdcbff-7708-4ddc-9792-59e7dd95d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Intangibles" xlink:type="simple" xlink:href="dva-20221231.xsd#Intangibles"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Intangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1a6d9f0-db50-40a2-92ab-e2f3f03cb106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4e2393db-bf8b-42f6-9a6e-d8f4a2d9d1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1a6d9f0-db50-40a2-92ab-e2f3f03cb106" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4e2393db-bf8b-42f6-9a6e-d8f4a2d9d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dc47e47f-d0aa-4581-8869-e95ffbc279dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_cc9a124f-7706-4cba-a0d7-7d4f47435585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dc47e47f-d0aa-4581-8869-e95ffbc279dc" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_cc9a124f-7706-4cba-a0d7-7d4f47435585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Goodwill" xlink:type="simple" xlink:href="dva-20221231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a072e2d-cadd-4fc7-ad7b-90244ba6c274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_4203e3b6-bd59-49c5-8e60-188a9dafef87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a072e2d-cadd-4fc7-ad7b-90244ba6c274" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_4203e3b6-bd59-49c5-8e60-188a9dafef87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilities" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_52c7f7b4-0b39-4bec-9b23-696555776a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_ee9c8f5a-0424-4ade-9c93-1809438ab181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_52c7f7b4-0b39-4bec-9b23-696555776a13" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_ee9c8f5a-0424-4ade-9c93-1809438ab181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49a7aeb8-f4f5-4b1c-a613-c09aafaf2ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_22b467e5-3b94-4d46-9348-2a3fc2c9d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49a7aeb8-f4f5-4b1c-a613-c09aafaf2ff8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_22b467e5-3b94-4d46-9348-2a3fc2c9d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebt" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2b082d2a-56cc-4b94-9690-e0b4474d10c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_adb34f04-ea15-4a4a-bdf3-156d87ec9a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2b082d2a-56cc-4b94-9690-e0b4474d10c8" xlink:to="loc_us-gaap_LongTermDebtTextBlock_adb34f04-ea15-4a4a-bdf3-156d87ec9a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Leases" xlink:type="simple" xlink:href="dva-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2bac2547-00a2-45bc-a43e-c769c5db4d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock_2199f8ad-90c8-46a2-9cf8-775e78dbcb95" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bac2547-00a2-45bc-a43e-c769c5db4d30" xlink:to="loc_dva_LeasesDisclosureTextBlock_2199f8ad-90c8-46a2-9cf8-775e78dbcb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="dva-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da2cdd42-70d1-4f43-bdf3-a1d6e3d434bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3c8659f3-ffad-42c3-95ec-96626fbf952f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da2cdd42-70d1-4f43-bdf3-a1d6e3d434bb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3c8659f3-ffad-42c3-95ec-96626fbf952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Contingencies" xlink:type="simple" xlink:href="dva-20221231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb4d8049-6296-44a5-8080-69ec1aa7a825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_15aa36d2-ceee-482e-9b43-08173aad57f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb4d8049-6296-44a5-8080-69ec1aa7a825" xlink:to="loc_us-gaap_LossContingencyDisclosures_15aa36d2-ceee-482e-9b43-08173aad57f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="simple" xlink:href="dva-20221231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f8e0cd2-8d58-4bf1-bd9e-a0e697290e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_50d7db6b-d87b-43cd-a3ce-429c11fcfee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f8e0cd2-8d58-4bf1-bd9e-a0e697290e31" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_50d7db6b-d87b-43cd-a3ce-429c11fcfee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="dva-20221231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be18fbdc-c730-4f45-b30a-235ed398883a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8eb2c3d2-ae56-4972-b7c7-440c3c664fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be18fbdc-c730-4f45-b30a-235ed398883a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8eb2c3d2-ae56-4972-b7c7-440c3c664fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockholdersequity" xlink:type="simple" xlink:href="dva-20221231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_614512dd-57f5-47ac-8f94-06ab8d6134c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_3fbca729-f715-4766-acf2-e09531c13b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_614512dd-57f5-47ac-8f94-06ab8d6134c6" xlink:to="loc_us-gaap_TreasuryStockTextBlock_3fbca729-f715-4766-acf2-e09531c13b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" xlink:href="dva-20221231.xsd#AccumulatedOtherComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bc42d9fb-45db-41b3-a9d2-18e3765db83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_10cfdb51-5dae-47ef-8989-a4564fa085b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bc42d9fb-45db-41b3-a9d2-18e3765db83a" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_10cfdb51-5dae-47ef-8989-a4564fa085b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fa2fdff7-3228-457a-b1c0-bb81e96c77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6126caa9-7d48-4adf-8b13-9f80dd7eca07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fa2fdff7-3228-457a-b1c0-bb81e96c77fc" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6126caa9-7d48-4adf-8b13-9f80dd7eca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="simple" xlink:href="dva-20221231.xsd#HeldforSaleandDiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2a0784fe-85c2-482f-b06d-9bad3a923eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b256b4b7-d9fe-429c-a117-65793355e715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2a0784fe-85c2-482f-b06d-9bad3a923eb3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b256b4b7-d9fe-429c-a117-65793355e715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="dva-20221231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0509ad17-54fe-4cd1-a632-f32e79324354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_f62d18a3-01fd-4a49-b16a-ac9b87f21f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0509ad17-54fe-4cd1-a632-f32e79324354" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_f62d18a3-01fd-4a49-b16a-ac9b87f21f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="simple" xlink:href="dva-20221231.xsd#FairValuesofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba5d9a67-35b8-474b-b4ce-4abbd1d8db8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6ed81889-c0fe-46c7-b178-4a09475ad3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba5d9a67-35b8-474b-b4ce-4abbd1d8db8f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6ed81889-c0fe-46c7-b178-4a09475ad3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReporting" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8cc7c922-bd8f-41eb-a807-db9f22328eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_47da7e6c-e2a9-46ba-90d4-2e8dfaeb0885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8cc7c922-bd8f-41eb-a807-db9f22328eff" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_47da7e6c-e2a9-46ba-90d4-2e8dfaeb0885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="dva-20221231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_161df68a-fdeb-4bcc-9665-35cf7f7c111f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_9fa5f9a3-bd48-4211-8a64-66d818c2f859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_161df68a-fdeb-4bcc-9665-35cf7f7c111f" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_9fa5f9a3-bd48-4211-8a64-66d818c2f859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="dva-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_fedd1371-adc8-40a2-8a6c-57e54b57b1a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_7e513f53-a7a2-4f0a-9dc2-6e1a148c8302" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_fedd1371-adc8-40a2-8a6c-57e54b57b1a8" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_7e513f53-a7a2-4f0a-9dc2-6e1a148c8302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dva-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7b61bb32-8ae7-49e1-9a9a-8be26ca48ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7b61bb32-8ae7-49e1-9a9a-8be26ca48ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_26219ab2-1073-4c73-a7e9-901e8df83dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_UseOfEstimates_26219ab2-1073-4c73-a7e9-901e8df83dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_1c854235-09bc-4c16-9676-b8e874ae10b6" xlink:href="dva-20221231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_1c854235-09bc-4c16-9676-b8e874ae10b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_1e6a5388-9344-4f8f-bdeb-4d86b9c8652b" xlink:href="dva-20221231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_1e6a5388-9344-4f8f-bdeb-4d86b9c8652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d713c00-9a27-429a-8d3a-78142e54b453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d713c00-9a27-429a-8d3a-78142e54b453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0ca07656-b082-4466-a025-8987e29683b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0ca07656-b082-4466-a025-8987e29683b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_56854caf-1a2f-473e-9848-176e490c7592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_56854caf-1a2f-473e-9848-176e490c7592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_4fbe67c1-d01a-405c-a92c-37e9edf6f133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_4fbe67c1-d01a-405c-a92c-37e9edf6f133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f5717171-84de-48bb-8467-8fa9a6c27d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f5717171-84de-48bb-8467-8fa9a6c27d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_67cb00cd-f878-4410-a5e5-bee7588651cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_67cb00cd-f878-4410-a5e5-bee7588651cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6df4dbe9-bd72-4c67-a810-d5108454c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6df4dbe9-bd72-4c67-a810-d5108454c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_93eaa62f-98eb-4adb-857b-cb3c2c9c6a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_93eaa62f-98eb-4adb-857b-cb3c2c9c6a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_441690a1-7521-45fe-860b-75f1274d0555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_441690a1-7521-45fe-860b-75f1274d0555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0a7c9eb5-d261-4c65-bf08-2f5268b9500a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0a7c9eb5-d261-4c65-bf08-2f5268b9500a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_05dcefde-57ec-4369-a018-030b987bb9fb" xlink:href="dva-20221231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_05dcefde-57ec-4369-a018-030b987bb9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4157160d-d58b-430e-b169-3a68c260ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4157160d-d58b-430e-b169-3a68c260ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_462b0fb1-e0fb-4e75-abf9-cfcea5e7532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_462b0fb1-e0fb-4e75-abf9-cfcea5e7532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1e39f3e6-dc96-4db2-bfe4-1e98ee44f9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1e39f3e6-dc96-4db2-bfe4-1e98ee44f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_207a7ae7-4e74-4502-9c54-d83707415393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_207a7ae7-4e74-4502-9c54-d83707415393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a676e230-4914-425a-a080-0204608f3ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a676e230-4914-425a-a080-0204608f3ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34ca0db0-5f54-427c-a233-50ea7e10a392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34ca0db0-5f54-427c-a233-50ea7e10a392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_54ea3858-5348-4eb9-b4c4-c2e6b699a7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_54ea3858-5348-4eb9-b4c4-c2e6b699a7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4c138a3b-05d9-47c6-9bf8-ecf476700424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4c138a3b-05d9-47c6-9bf8-ecf476700424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_543c09af-5a43-4fba-bf67-24bd5a0308c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_543c09af-5a43-4fba-bf67-24bd5a0308c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_a77f5cd5-a14f-4671-ba4f-6c134feeaa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286e9bf4-c02e-43e6-8fe8-2078cdf3d8ee" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_a77f5cd5-a14f-4671-ba4f-6c134feeaa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_134aff38-5c3d-4d68-b19a-3266c87983da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b7a38a5e-0f4c-41dd-8e74-a9c7e530b734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_134aff38-5c3d-4d68-b19a-3266c87983da" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b7a38a5e-0f4c-41dd-8e74-a9c7e530b734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="dva-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ad2698c6-3cfc-44c6-913f-02708c48e085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ccdec254-41f8-4201-a598-eac9779a3168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ad2698c6-3cfc-44c6-913f-02708c48e085" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ccdec254-41f8-4201-a598-eac9779a3168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="simple" xlink:href="dva-20221231.xsd#ShorttermandlongterminvesmtentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4045cfaa-ad57-438f-b51d-9c017878da8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_151d2ca9-f6ac-4127-b1ec-7b4f484a52e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4045cfaa-ad57-438f-b51d-9c017878da8b" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_151d2ca9-f6ac-4127-b1ec-7b4f484a52e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesTables" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherReceivablesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_02f090c2-1db4-4c1c-997a-9095ffea265d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_4747cb86-8c8e-4019-9abc-28e0fb173412" xlink:href="dva-20221231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_02f090c2-1db4-4c1c-997a-9095ffea265d" xlink:to="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_4747cb86-8c8e-4019-9abc-28e0fb173412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0ea0be27-7811-4185-93cc-ac71b424ef06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b83de46e-0f27-4cf7-ab8d-f04f8bd1f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0ea0be27-7811-4185-93cc-ac71b424ef06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b83de46e-0f27-4cf7-ab8d-f04f8bd1f4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesTables" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28d9315f-0c7e-48f2-8e6d-8f02d6913b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_f4c3aae9-e644-4089-8244-6031ee2edcbc" xlink:href="dva-20221231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28d9315f-0c7e-48f2-8e6d-8f02d6913b7d" xlink:to="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_f4c3aae9-e644-4089-8244-6031ee2edcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f98f0bba-5521-4d7b-9970-3fdb691f5bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28d9315f-0c7e-48f2-8e6d-8f02d6913b7d" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f98f0bba-5521-4d7b-9970-3fdb691f5bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12754efe-8666-4d90-bba2-48991f2f7408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_49c8518b-f48e-4349-abc6-48e89d4fcf60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12754efe-8666-4d90-bba2-48991f2f7408" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_49c8518b-f48e-4349-abc6-48e89d4fcf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillTables" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e726e1f1-54fb-471d-b664-5bf1d696cae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_8e672730-4c23-471a-974c-4e4695d83d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e726e1f1-54fb-471d-b664-5bf1d696cae9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_8e672730-4c23-471a-974c-4e4695d83d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock_79ec710a-9c80-4624-ace3-6118d739cee7" xlink:href="dva-20221231.xsd#dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e726e1f1-54fb-471d-b664-5bf1d696cae9" xlink:to="loc_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock_79ec710a-9c80-4624-ace3-6118d739cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_94bcae77-1310-4bf0-8c7f-6b7ce9cf2df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_58ead21c-9d7b-452f-90b0-547df662a0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_94bcae77-1310-4bf0-8c7f-6b7ce9cf2df9" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_58ead21c-9d7b-452f-90b0-547df662a0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a349a46b-435c-4ee8-9208-834a7fa82b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a349a46b-435c-4ee8-9208-834a7fa82b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_28d21ec5-d3ae-40ce-af68-f2422b1af42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_28d21ec5-d3ae-40ce-af68-f2422b1af42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock_31154144-34f0-479c-bbb3-07b3a65aab53" xlink:href="dva-20221231.xsd#dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock_31154144-34f0-479c-bbb3-07b3a65aab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_edaccefb-4b4d-4319-91ec-7732e9ce3c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_edaccefb-4b4d-4319-91ec-7732e9ce3c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b12c0c7-c1a7-4235-90d0-e688fa8b5654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b12c0c7-c1a7-4235-90d0-e688fa8b5654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_d22e7d56-bd77-4bcb-b451-7cefdbee7466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4c9c03e-ea79-4803-b943-cea7208983c1" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_d22e7d56-bd77-4bcb-b451-7cefdbee7466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e5991309-5d7f-4c36-8b39-20434af6123d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ef91b581-da6c-4abf-8d0a-cf7dcdfc10ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5991309-5d7f-4c36-8b39-20434af6123d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ef91b581-da6c-4abf-8d0a-cf7dcdfc10ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7225803d-f166-4a76-b7c6-37e28c3b39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5991309-5d7f-4c36-8b39-20434af6123d" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7225803d-f166-4a76-b7c6-37e28c3b39d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8bd8612e-38b6-46b9-af8f-b1f415d2de6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5991309-5d7f-4c36-8b39-20434af6123d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8bd8612e-38b6-46b9-af8f-b1f415d2de6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_716a860c-de1c-4f38-909e-f0a964723f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5991309-5d7f-4c36-8b39-20434af6123d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_716a860c-de1c-4f38-909e-f0a964723f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesTables" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_49426bd5-559f-4bbc-833f-77ef7d65cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_75348af6-62d1-4c0b-aa65-f12fad4387ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49426bd5-559f-4bbc-833f-77ef7d65cb68" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_75348af6-62d1-4c0b-aa65-f12fad4387ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_13a21f30-0ccb-488a-8165-094453c5b445" xlink:href="dva-20221231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49426bd5-559f-4bbc-833f-77ef7d65cb68" xlink:to="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_13a21f30-0ccb-488a-8165-094453c5b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_f18faab2-0b6f-4d5c-9298-2a6fb57c78eb" xlink:href="dva-20221231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49426bd5-559f-4bbc-833f-77ef7d65cb68" xlink:to="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_f18faab2-0b6f-4d5c-9298-2a6fb57c78eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="simple" xlink:href="dva-20221231.xsd#StockbasedcompensationandShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37131c15-eb0d-4152-b648-f2aecbd8d103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_3ec85c5f-1680-42a4-a359-6cf32d235591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37131c15-eb0d-4152-b648-f2aecbd8d103" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_3ec85c5f-1680-42a4-a359-6cf32d235591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_6240aa07-2ecb-427c-af7f-41b86c88b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37131c15-eb0d-4152-b648-f2aecbd8d103" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_6240aa07-2ecb-427c-af7f-41b86c88b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_85d1466a-23f8-4409-8f1e-e2e94523bcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37131c15-eb0d-4152-b648-f2aecbd8d103" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_85d1466a-23f8-4409-8f1e-e2e94523bcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="dva-20221231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6f54a40-cc6f-4312-90db-a387969b987f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_a4b69dd0-cfd3-41c1-93d3-0bddea24a987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6f54a40-cc6f-4312-90db-a387969b987f" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_a4b69dd0-cfd3-41c1-93d3-0bddea24a987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_61af7053-deed-4e74-b14d-3e16eed91743" xlink:href="dva-20221231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6f54a40-cc6f-4312-90db-a387969b987f" xlink:to="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_61af7053-deed-4e74-b14d-3e16eed91743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" xlink:href="dva-20221231.xsd#AccumulatedOtherComprehensiveLossIncomeTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9f8a0e2a-dd00-4156-9e1d-13a03d031a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_99e8387e-2583-415b-86c9-f56e095462b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9f8a0e2a-dd00-4156-9e1d-13a03d031a79" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_99e8387e-2583-415b-86c9-f56e095462b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_d71ee794-13d7-4a70-a62d-d755f8cd197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:to="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_d71ee794-13d7-4a70-a62d-d755f8cd197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_72167160-01fc-4651-aa73-40ea8b4fc493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_72167160-01fc-4651-aa73-40ea8b4fc493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_80f3756d-5cc6-4c4e-9dea-f89b09d1ccb7" xlink:href="dva-20221231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:to="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_80f3756d-5cc6-4c4e-9dea-f89b09d1ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6a1ca8de-7068-4efa-9cfc-0b5cfab4adda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6a1ca8de-7068-4efa-9cfc-0b5cfab4adda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_a65c8146-135a-4e50-9318-f1cf25d3e635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44c1061c-2040-4dfc-a954-4750f92d06e2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_a65c8146-135a-4e50-9318-f1cf25d3e635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="simple" xlink:href="dva-20221231.xsd#FairValuesofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b66ecf2a-9e87-4243-bf2e-f4b1f1a3e176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_be92c7dd-15c9-4db8-9f81-e86c4823620a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b66ecf2a-9e87-4243-bf2e-f4b1f1a3e176" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_be92c7dd-15c9-4db8-9f81-e86c4823620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b8c462a9-d4a7-4486-82cc-2a8b83f9459c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fbd5192a-4489-4d43-9500-128e78c8c641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b8c462a9-d4a7-4486-82cc-2a8b83f9459c" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fbd5192a-4489-4d43-9500-128e78c8c641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_b499209b-78e9-4ff4-a561-0c0a5b41d022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b8c462a9-d4a7-4486-82cc-2a8b83f9459c" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_b499209b-78e9-4ff4-a561-0c0a5b41d022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_1a29aa3b-fb80-41e1-9ae4-5e821debf850" xlink:href="dva-20221231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b8c462a9-d4a7-4486-82cc-2a8b83f9459c" xlink:to="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_1a29aa3b-fb80-41e1-9ae4-5e821debf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_37e70481-0fb4-4ce8-820d-50eb7184aaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b8c462a9-d4a7-4486-82cc-2a8b83f9459c" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_37e70481-0fb4-4ce8-820d-50eb7184aaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="dva-20221231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_52a7bf89-f5e6-42d9-8b45-fdbd4c8682c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_af8645e4-9a0a-488f-a007-2af67b34e14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_52a7bf89-f5e6-42d9-8b45-fdbd4c8682c7" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_af8645e4-9a0a-488f-a007-2af67b34e14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables" xlink:type="simple" xlink:href="dva-20221231.xsd#SECScheduleArticle1209ValuationandQualifyingAccountsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_4951fe47-bf0f-4ccc-b0ee-33d9298aab15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_4b3c84e0-a9e4-419e-a994-de6f5305fcfe" xlink:href="dva-20221231.xsd#dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_4951fe47-bf0f-4ccc-b0ee-33d9298aab15" xlink:to="loc_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_4b3c84e0-a9e4-419e-a994-de6f5305fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aca6afaf-a8f8-4274-8611-344bdacee1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aca6afaf-a8f8-4274-8611-344bdacee1b7" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:to="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7f7185e6-dcaa-4cf8-8255-f980a0e0c211" xlink:to="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69515f42-14e0-46f7-80c7-d2b52e3061dc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:to="loc_country_US_69515f42-14e0-46f7-80c7-d2b52e3061dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_0081189e-1e6f-4ec0-a2c2-5bbe3b2a65e2" xlink:href="dva-20221231.xsd#dva_InternationalOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_aaddb1c9-745f-4f4c-bb7c-2e636a53fbee" xlink:to="loc_dva_InternationalOperationsMember_0081189e-1e6f-4ec0-a2c2-5bbe3b2a65e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:href="dva-20221231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_85848d4a-fd8e-45b2-9d8f-b75f2744a6cf" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_29378733-3bcb-4590-9a02-abf59e4be006" xlink:href="dva-20221231.xsd#dva_NumberOfSites"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfSites_29378733-3bcb-4590-9a02-abf59e4be006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a7641050-6861-4a5c-8fe5-fb65f33431e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a7641050-6861-4a5c-8fe5-fb65f33431e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_07da574a-d720-482e-8db0-47750f1aaf5a" xlink:href="dva-20221231.xsd#dva_NumberOfCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfCustomers_07da574a-d720-482e-8db0-47750f1aaf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2e85a420-24b9-4fc6-a0de-323eaf2e1bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_2e85a420-24b9-4fc6-a0de-323eaf2e1bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_7c2f716f-bfb7-4b81-a234-f8718602abc4" xlink:href="dva-20221231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_7c2f716f-bfb7-4b81-a234-f8718602abc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_ef7d904f-8405-4692-9d08-f0a0802bf754" xlink:href="dva-20221231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_a93a1c01-f5a4-4f88-96db-655e05e843a4" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_ef7d904f-8405-4692-9d08-f0a0802bf754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract_2b52ec49-c491-4607-b5ba-e877ba43a1af" xlink:href="dva-20221231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract_2b52ec49-c491-4607-b5ba-e877ba43a1af" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_76d431fb-7189-40eb-af6f-783467d93b87" xlink:to="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_515764c3-c43d-4d74-97b7-857faa2bca1d" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_515764c3-c43d-4d74-97b7-857faa2bca1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_ef827e64-1257-4800-9725-fb80a05843a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3706900b-fe18-430e-a8fa-cba64545d1cd" xlink:to="loc_us-gaap_AllOtherSegmentsMember_ef827e64-1257-4800-9725-fb80a05843a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_8042277c-4016-467a-bcfa-0bb089191752" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_20670ee9-8007-466f-9166-0e30893f0d0a" xlink:href="dva-20221231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_20670ee9-8007-466f-9166-0e30893f0d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_967a8f47-f0d6-400f-ade3-bba90741cc2c" xlink:href="dva-20221231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_967a8f47-f0d6-400f-ade3-bba90741cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_3081854a-b8b1-435c-9408-519a0773cccb" xlink:href="dva-20221231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_OtherGovernmentPayorsMember_3081854a-b8b1-435c-9408-519a0773cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_4b81e09f-f43b-4add-81d5-8cb8c61e3257" xlink:href="dva-20221231.xsd#dva_CommercialPayorsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_CommercialPayorsMember_4b81e09f-f43b-4add-81d5-8cb8c61e3257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_e26cea0e-37b9-4fe2-b41b-c0ba93dea1fb" xlink:href="dva-20221231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_00904a16-9203-4de0-b858-30696f6e4bac" xlink:to="loc_dva_OtherSourcesofRevenueMember_e26cea0e-37b9-4fe2-b41b-c0ba93dea1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9319a276-699e-4d49-95d0-effb2a49efec" xlink:to="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4034ddd6-4cbc-4732-9a0e-f96230d53e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3b684257-ec81-466d-85fb-990f31d11637" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4034ddd6-4cbc-4732-9a0e-f96230d53e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75f4a391-da69-4d0e-98ee-fc056259a9c9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f2c1998-f707-49c1-914a-cebb2f35bc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f2c1998-f707-49c1-914a-cebb2f35bc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_7a36cf68-68d6-4399-bbf0-5b591908cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_OtherIncome_7a36cf68-68d6-4399-bbf0-5b591908cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7a1a5884-dad4-4a2e-8809-b9cd8745d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9c3c9cec-3767-4be1-9cc8-5260fc6656c8" xlink:to="loc_us-gaap_Revenues_7a1a5884-dad4-4a2e-8809-b9cd8745d2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_07d2e6b6-ca61-4670-be69-e4d4a47ebbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_07d2e6b6-ca61-4670-be69-e4d4a47ebbd9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d35611d-897b-41b8-9b2c-da7a1f774e09" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e88293a4-7708-472b-957e-470d9b78bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4f700104-9b22-4ff2-bbe1-c430642c777d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e88293a4-7708-472b-957e-470d9b78bfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9332c6bb-6aa2-425c-818b-e58a0a69296f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e1ef058f-9fcd-4b59-8982-9776bf1a7e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35f47fbf-7c91-4fe4-a071-e6966e8ecde7" xlink:to="loc_us-gaap_AccountsReceivableMember_e1ef058f-9fcd-4b59-8982-9776bf1a7e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_9804dd0b-f874-4107-82bc-e4f4b15b5b9e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_b7a72b8e-eeed-4c59-a646-c49998d3adf2" xlink:href="dva-20221231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:to="loc_dva_MedicareMember_b7a72b8e-eeed-4c59-a646-c49998d3adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_f8973181-ca3e-4307-a104-d37a05916ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_4ea5cbff-8c1d-4a94-9e93-11ae4ed9dc39" xlink:to="loc_us-gaap_ThirdPartyPayorMember_f8973181-ca3e-4307-a104-d37a05916ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_134812e1-7c3a-446a-9a5b-ed7fd67e228b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_4d67acea-48a0-476a-89da-d131754cf3b7" xlink:href="dva-20221231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_4d67acea-48a0-476a-89da-d131754cf3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f93b5ac-bac5-48a9-a3d5-9df07e88ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f93b5ac-bac5-48a9-a3d5-9df07e88ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_245fe0c4-0dcb-434d-b6d2-6d88994f1124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_245fe0c4-0dcb-434d-b6d2-6d88994f1124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_884dbd2c-782f-4f51-9f37-55d04fb9f373" xlink:href="dva-20221231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_884dbd2c-782f-4f51-9f37-55d04fb9f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_fb045ae4-573e-4261-923c-c0bd6d656487" xlink:href="dva-20221231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_fb045ae4-573e-4261-923c-c0bd6d656487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_ead0998e-0f15-4ba9-a126-6e24ed68645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da488c52-0671-40e4-80dc-7b040787f454" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_ead0998e-0f15-4ba9-a126-6e24ed68645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_fa05affd-dd5b-4ef2-b90e-3fdedd10e380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_fa05affd-dd5b-4ef2-b90e-3fdedd10e380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_00427c71-b969-4a47-9140-7fa128eb2d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_fa05affd-dd5b-4ef2-b90e-3fdedd10e380" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_00427c71-b969-4a47-9140-7fa128eb2d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d1057146-7097-4cfe-bb69-9748927fe534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_fa05affd-dd5b-4ef2-b90e-3fdedd10e380" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d1057146-7097-4cfe-bb69-9748927fe534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c04ca4a-f0d2-45da-805f-455ed54f4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_fa05affd-dd5b-4ef2-b90e-3fdedd10e380" xlink:to="loc_us-gaap_NetIncomeLoss_0c04ca4a-f0d2-45da-805f-455ed54f4a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_66ab8d0d-3b53-4a15-83cd-0e298f249796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_66ab8d0d-3b53-4a15-83cd-0e298f249796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_f0d32c9d-007f-4b25-87e8-24ede24d5ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_66ab8d0d-3b53-4a15-83cd-0e298f249796" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_f0d32c9d-007f-4b25-87e8-24ede24d5ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a88799b1-f3f1-4471-b3aa-c33c9a37ecf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_66ab8d0d-3b53-4a15-83cd-0e298f249796" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a88799b1-f3f1-4471-b3aa-c33c9a37ecf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fd2ab3ea-6348-4b64-ad48-baf726124c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_66ab8d0d-3b53-4a15-83cd-0e298f249796" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fd2ab3ea-6348-4b64-ad48-baf726124c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_02c450f8-91ed-455a-b667-db56cf40ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_02c450f8-91ed-455a-b667-db56cf40ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1615411d-618a-4287-9e47-117d2d92b247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_02c450f8-91ed-455a-b667-db56cf40ae76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1615411d-618a-4287-9e47-117d2d92b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_809d085b-e0d3-434d-90c9-146620689bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_02c450f8-91ed-455a-b667-db56cf40ae76" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_809d085b-e0d3-434d-90c9-146620689bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_701feb5a-b65b-4875-a98d-dd9f3696fae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_02c450f8-91ed-455a-b667-db56cf40ae76" xlink:to="loc_us-gaap_EarningsPerShareBasic_701feb5a-b65b-4875-a98d-dd9f3696fae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_8224b9cd-23ff-4d1a-ad13-bcfc867954ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_8224b9cd-23ff-4d1a-ad13-bcfc867954ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6601fab8-bd9a-4db5-996b-c29d350da45e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_8224b9cd-23ff-4d1a-ad13-bcfc867954ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6601fab8-bd9a-4db5-996b-c29d350da45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_5b191780-1588-49a8-aea1-13d8bfd210c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_8224b9cd-23ff-4d1a-ad13-bcfc867954ab" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_5b191780-1588-49a8-aea1-13d8bfd210c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c9605adf-253d-48b1-a86c-3f5827991b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_8224b9cd-23ff-4d1a-ad13-bcfc867954ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c9605adf-253d-48b1-a86c-3f5827991b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a12ca85-3539-477d-a604-e00e279163d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e1075e7-d657-4e2b-a76c-31ae5f7a69a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a12ca85-3539-477d-a604-e00e279163d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#RestrictedCashandEquivalentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract_a52cc05d-acf3-4a8d-a5fc-d89d9f088e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ed1e183e-66fc-4f89-beb7-ba90722e92e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_a52cc05d-acf3-4a8d-a5fc-d89d9f088e0f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ed1e183e-66fc-4f89-beb7-ba90722e92e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_960f5872-7aaf-4398-8bc0-7e69d19ae257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_960f5872-7aaf-4398-8bc0-7e69d19ae257" xlink:to="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:to="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c0605fe8-cab6-4e58-a455-11674982f298" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d866e9bd-ff9c-48cc-84ce-1d08a326642a" xlink:href="dva-20221231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d866e9bd-ff9c-48cc-84ce-1d08a326642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_b505c175-0c04-45e1-91ef-9bb5e79fd5b9" xlink:href="dva-20221231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_dva_MutualFundsAndCommonStockMember_b505c175-0c04-45e1-91ef-9bb5e79fd5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6d9ecf43-765f-46a5-b67f-5925e6ab8ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6d9ecf43-765f-46a5-b67f-5925e6ab8ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_2ea7fcdb-f903-4ae9-9470-f8e7c6129dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7d6353cd-f11f-420d-b1eb-f16ff5780cbf" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_2ea7fcdb-f903-4ae9-9470-f8e7c6129dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_df92fa90-bd62-4748-888c-5469cd00286d" xlink:to="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9ddaee6a-6d82-4eb7-bce4-497e74251813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9ddaee6a-6d82-4eb7-bce4-497e74251813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1586aef5-4dd0-454c-b805-d4f5a7e095fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1586aef5-4dd0-454c-b805-d4f5a7e095fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ca70fb05-f7a7-4a85-a8f9-433ef8cdef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecurities_ca70fb05-f7a7-4a85-a8f9-433ef8cdef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_f7c4376c-7d05-456d-ba2a-fc9d90c3f3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_f7c4376c-7d05-456d-ba2a-fc9d90c3f3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d37c5bda-df86-4644-a02a-d4dd1b06de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d37c5bda-df86-4644-a02a-d4dd1b06de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_89d8110d-92fb-4248-b132-630d04b39480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_89d8110d-92fb-4248-b132-630d04b39480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_17243936-d0e4-4c7e-b7b5-0777f9153a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_27fe873a-0ad4-45e2-96e4-eac351639204" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_17243936-d0e4-4c7e-b7b5-0777f9153a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_20d143f2-ec55-4ee3-88fd-465181fb3437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_20d143f2-ec55-4ee3-88fd-465181fb3437" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_943c1530-1068-4b4a-b872-33ba7d83526e" xlink:to="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_8ca60c16-ed5d-49df-bad5-2f29dddb7e5f" xlink:href="dva-20221231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_8ca60c16-ed5d-49df-bad5-2f29dddb7e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_ea88c40b-ecf1-4f58-92bd-d82244c9e96a" xlink:href="dva-20221231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_255ab225-962a-4644-b054-65274f7a52e6" xlink:to="loc_dva_MedicareMember_ea88c40b-ecf1-4f58-92bd-d82244c9e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d9c0dba4-3986-41b3-9f8f-24ea48023a5a" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ee789d06-6058-45dc-a678-d88823e362a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e3409236-e2d1-46b2-802a-08a13d5c03ce" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ee789d06-6058-45dc-a678-d88823e362a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_3a08c6ab-b5b3-4c0b-8f23-bad8cd748c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_Land_3a08c6ab-b5b3-4c0b-8f23-bad8cd748c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_f16368c9-1e2b-436b-bed5-790d45d3508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_f16368c9-1e2b-436b-bed5-790d45d3508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_93203641-5814-4555-a0b3-afba8d3b1dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_93203641-5814-4555-a0b3-afba8d3b1dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b5679f1e-b443-4d35-ba82-db7b689564c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b5679f1e-b443-4d35-ba82-db7b689564c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_06330ea7-b7a2-46b3-83cc-1f3410b35517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_ConstructionInProgressGross_06330ea7-b7a2-46b3-83cc-1f3410b35517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b112c84e-0f3f-427d-b396-a8024d53a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b112c84e-0f3f-427d-b396-a8024d53a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3399e56-684f-479b-9ac5-2d748cb27830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3399e56-684f-479b-9ac5-2d748cb27830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6b00fbf-c0cc-4c23-a557-834e1d72a354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_24e82cea-7c76-4b54-a1af-87cd7bae1a9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6b00fbf-c0cc-4c23-a557-834e1d72a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_96c2887b-d0bb-41a0-8660-5a86c7b941d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_96c2887b-d0bb-41a0-8660-5a86c7b941d2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2aa36fc4-bead-4c30-b48a-b51ac97cde43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ad09a30b-95d2-43b9-86bc-381b663abb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_BuildingMember_ad09a30b-95d2-43b9-86bc-381b663abb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4fa22dc0-c5d6-4972-93e6-6fd5724e3556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4fa22dc0-c5d6-4972-93e6-6fd5724e3556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_fc896ec2-2333-4c41-9cac-20220ba04f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c952c8df-66d7-465a-b9ca-cce176ef8ce5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_fc896ec2-2333-4c41-9cac-20220ba04f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:to="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4e214ea9-4b3d-4bf9-b090-54c73a6251dd" xlink:to="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e984f65-73b2-4cd2-9806-1bd08f93ddf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:to="loc_srt_MinimumMember_9e984f65-73b2-4cd2-9806-1bd08f93ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f353634b-3fd3-4741-a36e-82a36472d3d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ebcd9358-abe0-4ba0-85d4-113128c3f689" xlink:to="loc_srt_MaximumMember_f353634b-3fd3-4741-a36e-82a36472d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7757e549-f353-42f0-ae1b-e78f9486ea2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9eae2e2a-15dd-461b-989c-1c2c672846c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9eae2e2a-15dd-461b-989c-1c2c672846c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_472e4790-66e7-4599-ab4b-38a209d8449c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_472e4790-66e7-4599-ab4b-38a209d8449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_e0b12521-2981-41bf-9be9-52706258cf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3a5f2265-cad9-482b-bcdb-c59b4f6e693b" xlink:to="loc_us-gaap_InterestCostsCapitalized_e0b12521-2981-41bf-9be9-52706258cf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9256ce5f-1c29-4581-8221-3bde894a385c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9256ce5f-1c29-4581-8221-3bde894a385c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef40042a-ee9f-4883-9370-1be4a5935fb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_488e9a6f-24c9-4336-bb4d-9d5467a32594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_488e9a6f-24c9-4336-bb4d-9d5467a32594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_dff9f339-ca97-49be-be4f-c47e11d85682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d3305112-8526-4564-a3b4-d63ca2d5b47c" xlink:to="loc_us-gaap_ServiceAgreementsMember_dff9f339-ca97-49be-be4f-c47e11d85682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3aa7b5e9-578f-4ee6-a7bc-9344fb994901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_344e2cc7-6335-432e-85f2-67a7605e5e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_344e2cc7-6335-432e-85f2-67a7605e5e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_39f249fa-4c10-44d2-bdeb-577b357a0f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_39f249fa-4c10-44d2-bdeb-577b357a0f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_3e4eb214-32af-4b4c-8ced-867ab0e69064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_3e4eb214-32af-4b4c-8ced-867ab0e69064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7dfe7b12-47b6-492d-91de-16840d508c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7dfe7b12-47b6-492d-91de-16840d508c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6b4bd0d-2357-4240-9407-51efad1041b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6b4bd0d-2357-4240-9407-51efad1041b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a9564a78-03b4-43dc-aba3-4a6369005d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_916b6c17-3980-4651-932f-5eb275ce357a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a9564a78-03b4-43dc-aba3-4a6369005d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c89f77c4-b009-4659-8019-a717edcd1ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c89f77c4-b009-4659-8019-a717edcd1ab0" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b08143e-cdc0-490b-bf4b-e078614ef704" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_420daae6-e667-4dea-86dd-ccc9dc70f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_420daae6-e667-4dea-86dd-ccc9dc70f1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_6e322a62-58e5-40bf-b1d8-565edf4c64b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ecc18f9-cd7d-4f40-8b34-0579ff727cf7" xlink:to="loc_us-gaap_ServiceAgreementsMember_6e322a62-58e5-40bf-b1d8-565edf4c64b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:href="dva-20221231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4630f2f7-e372-4421-aabd-7d8d29e9a58c" xlink:to="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b2d228bb-4d6a-4d9c-a781-f74668940e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b2d228bb-4d6a-4d9c-a781-f74668940e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51b61bb7-ebdf-4c52-8648-ffd77b9846a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51b61bb7-ebdf-4c52-8648-ffd77b9846a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2ef955a1-2ed3-4db1-8aec-82f35aae50c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2ef955a1-2ed3-4db1-8aec-82f35aae50c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00aac097-fd5f-414e-91a3-a59b0a21fe06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00aac097-fd5f-414e-91a3-a59b0a21fe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1749aed8-7268-4d30-9e51-360c91535ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1749aed8-7268-4d30-9e51-360c91535ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2f809e8b-a453-4517-9005-3de73b349027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2f809e8b-a453-4517-9005-3de73b349027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fa2cb52-cf11-4523-9453-4f599b72c9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_2e1b0759-5dcb-47fe-a10c-4731168ca280" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7fa2cb52-cf11-4523-9453-4f599b72c9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9edec35-dea2-4b51-8d78-cb4aaa9f31ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9edec35-dea2-4b51-8d78-cb4aaa9f31ce" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_972e71fa-c06b-4ec4-ac18-f996b29b0979" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_763d88f9-f96e-4d9e-94d3-4e51bf9eb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_763d88f9-f96e-4d9e-94d3-4e51bf9eb85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_23cb69fe-ae2a-4d38-81af-0c0ac89b3f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59e2b5bb-d704-404e-a145-9e452d9d4121" xlink:to="loc_us-gaap_CustomerRelationshipsMember_23cb69fe-ae2a-4d38-81af-0c0ac89b3f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:to="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa6f1dbb-ba03-47d4-b94e-468b6bf9c3cf" xlink:to="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_658c2d2e-80fe-4f62-b431-7f6c107e0778" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:to="loc_srt_MinimumMember_658c2d2e-80fe-4f62-b431-7f6c107e0778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c84d423e-49e6-41f3-b283-f50e6e68b566" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f263e863-f11d-44da-b838-92737592523f" xlink:to="loc_srt_MaximumMember_c84d423e-49e6-41f3-b283-f50e6e68b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b263f6a8-a6ec-469c-b1c7-35d8fb5ad85a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_fde975e5-5cf3-4609-8ff5-14ad2cf18125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_fde975e5-5cf3-4609-8ff5-14ad2cf18125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_3f146be0-7456-42a0-b856-de23cdb0c051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_3f146be0-7456-42a0-b856-de23cdb0c051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_93e7bcf3-83a5-4d2d-8cc5-769acaef3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_93e7bcf3-83a5-4d2d-8cc5-769acaef3ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_34b67d5b-b9f3-49b5-8ba8-b580c879c716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4ebdb1cf-d57f-4096-8509-1a730708f9be" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_34b67d5b-b9f3-49b5-8ba8-b580c879c716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_984729f1-d6db-417f-9956-bd38ece846f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_984729f1-d6db-417f-9956-bd38ece846f7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_8049b884-8c5a-4866-a251-41b925e9935a" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_6cd5e7e2-181b-4f62-9684-ea42a2bf016e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2504b565-d252-4bed-a591-da63b8bde64f" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_6cd5e7e2-181b-4f62-9684-ea42a2bf016e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ecf81007-5536-43b7-b7fe-0230b727dd70" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_103e429f-e866-416f-8aab-7f7f70b67264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4f2431e-5e27-4249-821a-28850b183a73" xlink:to="loc_us-gaap_EquitySecuritiesMember_103e429f-e866-416f-8aab-7f7f70b67264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0da82c00-e234-484a-bbe7-10970deee614" xlink:to="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_d82aebe2-6ee8-4723-88fe-648b9efd972e" xlink:href="dva-20221231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_411050ad-3fae-4b57-9edf-fcde9e5302b3" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_d82aebe2-6ee8-4723-88fe-648b9efd972e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_317a2060-87d3-4331-ac44-ba8f671882a5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f48a44de-1589-492f-83aa-bd1083322dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_58963e09-f6da-4b31-a1d3-528e54789104" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f48a44de-1589-492f-83aa-bd1083322dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_da76d935-1908-49d3-93ae-4949d39d89d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_da76d935-1908-49d3-93ae-4949d39d89d3" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dd641443-249c-4c6a-80fa-d70039983660" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_26070ece-37e5-459f-9baf-2b78a3ad37b0" xlink:href="dva-20221231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9befcc76-e405-4cae-a962-d74c26c1e5de" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_26070ece-37e5-459f-9baf-2b78a3ad37b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cacb80b0-56e9-4093-ad04-b63c96d5871a" xlink:to="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6978b2e-1bef-4c8d-aba8-28460801ef42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:to="loc_srt_MinimumMember_e6978b2e-1bef-4c8d-aba8-28460801ef42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_780fbfc3-0a93-42b7-a138-3c0d11f31940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adaa82a9-067f-4062-a546-4f85979ba13c" xlink:to="loc_srt_MaximumMember_780fbfc3-0a93-42b7-a138-3c0d11f31940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_e589cccb-47e3-4bdc-b565-a2455721dd71" xlink:to="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_b2b5bd25-eb4c-41ef-8280-ecb28a89f83f" xlink:href="dva-20221231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_b2b5bd25-eb4c-41ef-8280-ecb28a89f83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_3e2c52df-a17d-4a4b-b99e-f4af78d4a384" xlink:href="dva-20221231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7faf0bd9-c5f0-4e01-a9e6-0724b3702977" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_3e2c52df-a17d-4a4b-b99e-f4af78d4a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7a42f97-5c84-46f5-9e29-466191a141e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_2540d4db-5689-4f6d-a29f-ce169a51966c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_40133946-d8e6-44d2-b079-f5ca141729ef" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_2540d4db-5689-4f6d-a29f-ce169a51966c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_6139ed1b-9347-4e8c-931f-53481b2276d8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6bf5809c-64f5-4984-8776-8e8e4258767d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6bf5809c-64f5-4984-8776-8e8e4258767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_fedab28b-b203-426a-b90d-5149d8cd6d61" xlink:href="dva-20221231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_fedab28b-b203-426a-b90d-5149d8cd6d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ad3eb528-58ab-4e6b-a7c7-0d04cf2b410a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ad3eb528-58ab-4e6b-a7c7-0d04cf2b410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8d06bf63-f806-48d0-b3cd-7e3811b5f51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8d06bf63-f806-48d0-b3cd-7e3811b5f51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_7151b120-5268-411d-8325-fa35ba8240ef" xlink:href="dva-20221231.xsd#dva_NumberOfPartnerships"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_dva_NumberOfPartnerships_7151b120-5268-411d-8325-fa35ba8240ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_18495c7a-5fbf-4a62-85fd-83ccb39e9952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a491f038-0565-42c3-8aec-2c22e786102d" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_18495c7a-5fbf-4a62-85fd-83ccb39e9952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82a43c06-6af2-490e-96bf-108757e86c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82a43c06-6af2-490e-96bf-108757e86c9f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_27b0194e-a26e-4d78-8dd2-1beba0413a80" xlink:to="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_b410226a-42c7-44fe-8f97-db49296f2ea0" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_b410226a-42c7-44fe-8f97-db49296f2ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3a889b35-49a6-4455-9c3d-ff2a407d1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8dd8e7fa-0e31-4b3f-99e1-a42a3b6afd11" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3a889b35-49a6-4455-9c3d-ff2a407d1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4dabccd4-d974-4e4b-bc5b-ab2daecca209" xlink:to="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ab7b808-59b4-472a-9fe0-3b0973470bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_Goodwill_6ab7b808-59b4-472a-9fe0-3b0973470bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b1fbba37-620e-4fab-8d34-46e2b6179dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b1fbba37-620e-4fab-8d34-46e2b6179dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_536bb3ee-c2aa-49ad-b8eb-c29bd06dfb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_536bb3ee-c2aa-49ad-b8eb-c29bd06dfb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1d668811-fa3f-4e35-8029-4b311b103d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1d668811-fa3f-4e35-8029-4b311b103d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a7d4899d-ea12-4b5f-b99e-0132ccf62366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_74927171-ad9b-4242-92c5-9cbfa532392f" xlink:to="loc_us-gaap_Goodwill_a7d4899d-ea12-4b5f-b99e-0132ccf62366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_007742e4-c8ec-4b6f-ae47-24f793e83c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillGross_007742e4-c8ec-4b6f-ae47-24f793e83c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_01274d4b-2a0f-40b8-a71d-0c42621e99b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c66558b2-0a1f-4df3-b4be-4b2e268ce5c1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_01274d4b-2a0f-40b8-a71d-0c42621e99b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f63777db-50c9-433f-9075-c89b6f27589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f63777db-50c9-433f-9075-c89b6f27589a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_23add1ca-aa26-493f-8120-ae671b1005dd" xlink:to="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_KidneyCareMember_389ac74e-3e7d-4dfc-998c-9ec1c617460b" xlink:href="dva-20221231.xsd#dva_KidneyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e019363-1779-4892-8dff-264ce28ce7a9" xlink:to="loc_dva_KidneyCareMember_389ac74e-3e7d-4dfc-998c-9ec1c617460b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:to="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_205ec753-53f5-4ee0-8ec0-d5e477a0772c" xlink:to="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_9e518b9b-1392-49a0-8b2a-ea169b0b541f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_200f98c6-eedd-4a1b-aa4d-a8543ad14c8c" xlink:to="loc_country_DE_9e518b9b-1392-49a0-8b2a-ea169b0b541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b7ec783d-34b2-4d0a-a62c-345124ced22f" xlink:to="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e892037-01c5-4fa9-b041-8f67877f3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_us-gaap_Goodwill_6e892037-01c5-4fa9-b041-8f67877f3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_220025aa-34d1-4893-925a-e2723a97ca6c" xlink:href="dva-20221231.xsd#dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount_220025aa-34d1-4893-925a-e2723a97ca6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_4d282bc1-efbe-410f-9e70-484a801de06d" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForReductionInOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PotentialImpactOnFairValueForReductionInOperatingIncome_4d282bc1-efbe-410f-9e70-484a801de06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_837962aa-1545-450e-970f-74a8c15cc982" xlink:href="dva-20221231.xsd#dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate_837962aa-1545-450e-970f-74a8c15cc982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_82f623e5-bb29-41e5-b40b-d1d17465103e" xlink:href="dva-20221231.xsd#dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_82f623e5-bb29-41e5-b40b-d1d17465103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_603647de-3cc2-43f4-84e3-d5ca7d2c72c7" xlink:href="dva-20221231.xsd#dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_20e2924c-b204-4c72-987a-af0ae868bfe6" xlink:to="loc_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment_603647de-3cc2-43f4-84e3-d5ca7d2c72c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ffc46b4-c46d-4e10-b1a3-e441b2d892ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ffc46b4-c46d-4e10-b1a3-e441b2d892ad" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_58f546d5-6451-45a1-a9dd-afa35efc4cd0" xlink:to="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_3a1d541e-93d1-4ad4-811c-de28ccd3bf21" xlink:href="dva-20221231.xsd#dva_OtherReportingUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_398a357b-f874-43f5-9d8e-54421d6071c7" xlink:to="loc_dva_OtherReportingUnitsMember_3a1d541e-93d1-4ad4-811c-de28ccd3bf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ef66df26-9f00-4df6-a157-4681ca772f3b" xlink:to="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_00e1a4f1-9af5-418e-baf9-ce62f885d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_e85bfba4-911a-4978-a21a-11667b69de03" xlink:to="loc_us-gaap_NumberOfOperatingSegments_00e1a4f1-9af5-418e-baf9-ce62f885d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#OtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_41acc32e-acf1-4def-9fd2-65739547ab33" xlink:href="dva-20221231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_dva_PayorRefundsAndRetractions_41acc32e-acf1-4def-9fd2-65739547ab33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_c634450f-6d0e-4ce8-a1fc-ebd28bb86d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_c634450f-6d0e-4ce8-a1fc-ebd28bb86d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_90cc5695-9e98-4e6a-9177-6c5dfc7f3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_us-gaap_InterestPayableCurrent_90cc5695-9e98-4e6a-9177-6c5dfc7f3c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_0ae08924-dd93-4168-9be3-6a850634cb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_0ae08924-dd93-4168-9be3-6a850634cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_af044785-7439-4781-9624-a3270e86f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_af044785-7439-4781-9624-a3270e86f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_367d708c-5206-483f-b300-895b1e978748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_04d41e38-7e74-419a-8a6c-5fb154835aa8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_367d708c-5206-483f-b300-895b1e978748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_51ea0f20-a02e-4587-981a-5fc8b09dfad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a32cb9fc-e43f-40d8-95e0-69e24b38fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51ea0f20-a02e-4587-981a-5fc8b09dfad6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a32cb9fc-e43f-40d8-95e0-69e24b38fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c0bb9387-e312-4c60-85a1-b0cdc46fc4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51ea0f20-a02e-4587-981a-5fc8b09dfad6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c0bb9387-e312-4c60-85a1-b0cdc46fc4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9703f359-7fa5-4e2e-9dc4-dbe844493417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51ea0f20-a02e-4587-981a-5fc8b09dfad6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9703f359-7fa5-4e2e-9dc4-dbe844493417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e63fff8d-410e-4b05-a3a2-fb7e035dc3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e63fff8d-410e-4b05-a3a2-fb7e035dc3b1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3bd9f4ed-9339-4859-97f2-5b5307261256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3bd9f4ed-9339-4859-97f2-5b5307261256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_999427c5-4c91-43c0-8844-cbeafd2da913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_999427c5-4c91-43c0-8844-cbeafd2da913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_83ca792b-ab47-4e0c-bf22-5bb9bdf66491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_83ca792b-ab47-4e0c-bf22-5bb9bdf66491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_53a37caa-233f-4245-bf79-80bf49f91a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac461a22-71fc-4ebe-9f0c-75a44169673f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_53a37caa-233f-4245-bf79-80bf49f91a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e63fff8d-410e-4b05-a3a2-fb7e035dc3b1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8be5ac16-1ec7-4375-ae32-14da4b069d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8be5ac16-1ec7-4375-ae32-14da4b069d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_23c238b7-91c9-40a9-ae80-a73736dd4150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_23c238b7-91c9-40a9-ae80-a73736dd4150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bccd0992-fed9-43c6-9cb5-bd17716fb1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bccd0992-fed9-43c6-9cb5-bd17716fb1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d68c91b8-c500-4415-9df8-ecd07b7de133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_251eab7b-afba-4e72-a5b3-1421ae3ad6a4" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d68c91b8-c500-4415-9df8-ecd07b7de133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f39c93d6-8ee5-47bf-b1f5-42ea2a4a9580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e63fff8d-410e-4b05-a3a2-fb7e035dc3b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f39c93d6-8ee5-47bf-b1f5-42ea2a4a9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_237db0df-9962-4078-be66-6cf41ea9cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80fb38e7-5dd6-4a17-b465-199b17a9ece7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_237db0df-9962-4078-be66-6cf41ea9cc44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_80fb38e7-5dd6-4a17-b465-199b17a9ece7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_b896b7c6-0d3c-4f3b-932f-09603c197414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_237db0df-9962-4078-be66-6cf41ea9cc44" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_b896b7c6-0d3c-4f3b-932f-09603c197414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_fb93f865-7c34-4f00-a36f-76e457c4107e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_237db0df-9962-4078-be66-6cf41ea9cc44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems_fb93f865-7c34-4f00-a36f-76e457c4107e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2eacffe-a6f3-4128-9842-c51b7de6ac92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2eacffe-a6f3-4128-9842-c51b7de6ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d46405dd-55ee-4ffa-8e01-6c1db28da1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d46405dd-55ee-4ffa-8e01-6c1db28da1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8b74915d-a702-4c16-8850-6d008802cb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8b74915d-a702-4c16-8850-6d008802cb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f949feba-8c85-43ae-b05b-8cda383f2124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f949feba-8c85-43ae-b05b-8cda383f2124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_96522bcb-6f6b-4697-b275-bcf28f9b3fd4" xlink:href="dva-20221231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_96522bcb-6f6b-4697-b275-bcf28f9b3fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_f15bdac3-b727-453a-aa1d-682679a34570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_f15bdac3-b727-453a-aa1d-682679a34570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_876a5830-69bc-4b0d-8619-5bdcf7d25929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_876a5830-69bc-4b0d-8619-5bdcf7d25929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fb800fb0-ddf2-49c0-843c-b823406addf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fb800fb0-ddf2-49c0-843c-b823406addf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4a04311d-c555-4748-8d4f-55941d163faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4a04311d-c555-4748-8d4f-55941d163faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0f45b5e0-6852-43cf-af94-fd7c6630eb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0f45b5e0-6852-43cf-af94-fd7c6630eb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_16d2ed8d-fa79-406c-9f00-10943760fefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_16d2ed8d-fa79-406c-9f00-10943760fefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7495dfb-168e-4ae5-afba-bcc726056e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626c6622-2ded-4877-83aa-9b3898a5a25d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7495dfb-168e-4ae5-afba-bcc726056e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d611c1cf-6e4c-4887-aadc-7465af72294d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:href="dva-20221231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d611c1cf-6e4c-4887-aadc-7465af72294d" xlink:to="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a1db191b-4c56-43c9-9805-c90dbc2c3cd1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_b31aa37f-f041-4826-aad0-f1fb2c2109a9" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_b31aa37f-f041-4826-aad0-f1fb2c2109a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_a0270987-b468-442c-8f55-0c7f8e582b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d9253156-e7e9-469e-96d3-39ea67b879e2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_a0270987-b468-442c-8f55-0c7f8e582b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:href="dva-20221231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_0c7d2183-d108-4d41-83a8-5f3a016b7638" xlink:to="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_de61b730-6589-4537-9927-f0e85f871d4d" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxAssetsReceivables_de61b730-6589-4537-9927-f0e85f871d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_71f887fc-a16b-4a56-a2f4-8ba10287ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_71f887fc-a16b-4a56-a2f4-8ba10287ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_fef0f152-324a-4a11-bc20-b4406dd0215c" xlink:href="dva-20221231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_fef0f152-324a-4a11-bc20-b4406dd0215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_774f9210-3179-4493-b6b7-0e9cd5697e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_774f9210-3179-4493-b6b7-0e9cd5697e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0d6321c7-be21-4cc6-a50a-5e9baf948153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0d6321c7-be21-4cc6-a50a-5e9baf948153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8cfd4027-7485-4eac-9a06-250667bcf279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8cfd4027-7485-4eac-9a06-250667bcf279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d308d7c7-8d2e-4098-b159-f7f6ac71685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d308d7c7-8d2e-4098-b159-f7f6ac71685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b2151729-1dc1-4c9b-988b-9e699220e290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b2151729-1dc1-4c9b-988b-9e699220e290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1c54baa-cf4b-4ee0-90df-98212e51edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d1c54baa-cf4b-4ee0-90df-98212e51edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71da9c1d-0ed2-419e-8217-6c4570223c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_71da9c1d-0ed2-419e-8217-6c4570223c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_bb4e1aad-1933-4cd1-af36-f2b502142456" xlink:href="dva-20221231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_bb4e1aad-1933-4cd1-af36-f2b502142456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_259ef2c1-6c90-4900-8ee6-9e88c7e509a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_259ef2c1-6c90-4900-8ee6-9e88c7e509a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0e956acb-4a9d-4f39-9d2e-d1514d08d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0e956acb-4a9d-4f39-9d2e-d1514d08d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0875c67f-0450-4f5c-a4e8-48fc5cc17a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0875c67f-0450-4f5c-a4e8-48fc5cc17a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2a0a863c-005e-4765-814f-8eba2096f516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_0a8476fd-95f4-4600-8fd9-c72013294fbf" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2a0a863c-005e-4765-814f-8eba2096f516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29462fca-8996-4cbe-a3b3-506b64016171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29462fca-8996-4cbe-a3b3-506b64016171" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ffc3a52f-65c5-4a3e-aced-c3f5d22dc1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ffc3a52f-65c5-4a3e-aced-c3f5d22dc1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_082ed43f-1b72-4a83-9f5e-d5ea176c0f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_082ed43f-1b72-4a83-9f5e-d5ea176c0f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2f6293a9-dc82-4801-bd90-ac3d8855d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2f6293a9-dc82-4801-bd90-ac3d8855d5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_723da0a4-238c-4b65-8ae0-439e904eeee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_723da0a4-238c-4b65-8ae0-439e904eeee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ffcf2acd-d267-494c-82f4-cd5d7b0b9099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ffcf2acd-d267-494c-82f4-cd5d7b0b9099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6b20d290-8c9c-4278-acf1-faa78caeea99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4acc5132-60e9-4f13-a9b7-9f97740220e8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6b20d290-8c9c-4278-acf1-faa78caeea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7610f99a-20a1-43c9-9b65-1f9b23e2f285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:href="dva-20221231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7610f99a-20a1-43c9-9b65-1f9b23e2f285" xlink:to="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d2e1f34d-2236-472c-8773-fa82d5f7354a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ee4c0d03-b522-4b27-9ad4-fd1da6c0034a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_DomesticCountryMember_ee4c0d03-b522-4b27-9ad4-fd1da6c0034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f092b175-6d83-46c7-9751-b9dc4fe8ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f092b175-6d83-46c7-9751-b9dc4fe8ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d4ae9565-500a-4650-8f50-28c1a6c170d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7926ea1b-5f20-46c7-8799-1863136f2e64" xlink:to="loc_us-gaap_ForeignCountryMember_d4ae9565-500a-4650-8f50-28c1a6c170d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_21daa4b0-77cd-46a3-bd8f-b20c07b4d4d9" xlink:to="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_8735fbb0-00c0-4376-8037-05d15adb0162" xlink:href="dva-20221231.xsd#dva_TaxYear2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_02eb97c6-86ad-48a8-b0c9-3521d8212b47" xlink:to="loc_dva_TaxYear2029Member_8735fbb0-00c0-4376-8037-05d15adb0162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ed514ebe-e90b-41eb-9993-f1d3aab8edbf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_564b1ba8-6624-4b4f-9f04-0a8dfa59ebad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_fd0c6906-cfc7-431e-bf98-8679f2bb7fa1" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_564b1ba8-6624-4b4f-9f04-0a8dfa59ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_db274822-5906-4dc8-867a-61db696a5a56" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_af1db2f5-70d4-48ab-97b5-c2308af1763b" xlink:href="dva-20221231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_af1db2f5-70d4-48ab-97b5-c2308af1763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_af697df4-76a9-4e03-b36d-ee443ecc0eec" xlink:href="dva-20221231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_5eee90a7-8571-45e1-9aa8-17d8d04dcd2a" xlink:to="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_af697df4-76a9-4e03-b36d-ee443ecc0eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d67b98c9-2b0e-4872-bd6c-497c7700dbb4" xlink:to="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29abbc63-864b-4fbf-a706-cb40c5be5f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91445221-1b45-45d3-bb06-4f7b709acd42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29abbc63-864b-4fbf-a706-cb40c5be5f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:href="dva-20221231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_889d6496-024e-4da6-b8a5-d18bf2e22d31" xlink:to="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_da3fdbcf-6ffd-456d-ac91-9fd06c11d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_da3fdbcf-6ffd-456d-ac91-9fd06c11d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_4cd6ce0c-35b4-46a4-9982-a4355e124c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_4cd6ce0c-35b4-46a4-9982-a4355e124c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_26c12014-e4e6-490e-a784-28144cc925eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_26c12014-e4e6-490e-a784-28144cc925eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_922f68c2-268f-4c88-8766-613a34038d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_922f68c2-268f-4c88-8766-613a34038d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_02b2c59a-8915-4b57-9b05-78ecae121662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_02b2c59a-8915-4b57-9b05-78ecae121662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet_06c2ea72-0b3e-47da-90a1-f0f607c4176a" xlink:href="dva-20221231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_dva_IncreaseInDeferredTaxAssetsNet_06c2ea72-0b3e-47da-90a1-f0f607c4176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dd628fbe-e6a7-4fd2-a271-05ec3ef442bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dd628fbe-e6a7-4fd2-a271-05ec3ef442bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_52bf0f8b-ca12-4603-b97e-881bd5eb0330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_52bf0f8b-ca12-4603-b97e-881bd5eb0330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_43279a57-2160-4f37-9788-ac25222b378a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_43279a57-2160-4f37-9788-ac25222b378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f4ab5a29-7759-4e3d-b2e3-c312d35cc72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f4ab5a29-7759-4e3d-b2e3-c312d35cc72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_06651f56-7157-4c52-9257-cf4a20afa85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_06651f56-7157-4c52-9257-cf4a20afa85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2ba3e911-098b-4dbe-9d0b-102f27afb5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_e2f96571-9613-4d0c-8e3d-b756bbbf661c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2ba3e911-098b-4dbe-9d0b-102f27afb5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f60fa7ed-8aae-4543-a31e-a8a2c78e9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f60fa7ed-8aae-4543-a31e-a8a2c78e9ba0" xlink:to="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4714d8e9-d57f-494a-9437-2644632951e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAMember_07e71cee-1fa9-4f87-a769-bc4596e3e566" xlink:href="dva-20221231.xsd#dva_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_TermLoanAMember_07e71cee-1fa9-4f87-a769-bc4596e3e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_78d92a80-5324-40df-9682-1116d02a0a19" xlink:href="dva-20221231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_TermLoanB1Member_78d92a80-5324-40df-9682-1116d02a0a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_f5d722cc-296c-421d-91fd-b2d4b218493a" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_f5d722cc-296c-421d-91fd-b2d4b218493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7abfc93f-bdd1-4f5b-bf33-0afbd38cf9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d013287c-44d6-4787-9980-90459afb0ffd" xlink:to="loc_us-gaap_SeniorNotesMember_7abfc93f-bdd1-4f5b-bf33-0afbd38cf9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f731e3d6-be09-4aa0-a309-f94ffc67caaa" xlink:to="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_79857e2b-8507-455d-b540-cb41ae055963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0a61523c-8ac4-46b5-9723-46518b2aaf89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_79857e2b-8507-455d-b540-cb41ae055963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_875a624c-3187-4230-acf8-d2da3cf14eb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_bb088802-4f84-4fe3-bf20-3fcdf0003b59" xlink:href="dva-20221231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_bb088802-4f84-4fe3-bf20-3fcdf0003b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_a3ab959d-ebe1-4914-9398-b1ffad68b9c0" xlink:href="dva-20221231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_a3ab959d-ebe1-4914-9398-b1ffad68b9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_d72b40c7-770e-4d96-b639-b0b868fe1c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_d72b40c7-770e-4d96-b639-b0b868fe1c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_fdb63ddc-b982-4a0d-b32b-e3f0769d1e1c" xlink:href="dva-20221231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d35dcd34-bca2-4d7e-8f7b-3645802e9ec3" xlink:to="loc_dva_FinanceLeaseMember_fdb63ddc-b982-4a0d-b32b-e3f0769d1e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_12f0015a-9736-4e95-b3ac-04813baa5184" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_a612bc2c-213c-4bdc-a058-d6cedfc06f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:to="loc_us-gaap_SecuredDebt_a612bc2c-213c-4bdc-a058-d6cedfc06f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ba61a1a4-3528-406e-966a-2fa30f28b423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_7803b53c-27c4-4b9c-9794-8fedcbc975cf" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ba61a1a4-3528-406e-966a-2fa30f28b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_89fc80ac-7e26-4f06-85c2-01046e182b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_c58c31f6-4aec-4a17-8fd9-1c850d7dd94c" xlink:to="loc_us-gaap_SeniorNotes_89fc80ac-7e26-4f06-85c2-01046e182b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_6aa42a5a-1d8b-426c-9141-646d630f7a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_6aa42a5a-1d8b-426c-9141-646d630f7a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c020900c-fcf0-4891-a6b7-cc9528938360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_c020900c-fcf0-4891-a6b7-cc9528938360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_22685ed3-d86c-47e8-8647-934245de2507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentFairValue_22685ed3-d86c-47e8-8647-934245de2507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_83b0b485-81ea-479c-8e12-896345716c62" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_83b0b485-81ea-479c-8e12-896345716c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5f73d47c-77ad-451e-824d-0ee82b0062e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_FinanceLeaseLiability_5f73d47c-77ad-451e-824d-0ee82b0062e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_a56cb1d9-5097-4ae5-add0-22baf26bdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_a56cb1d9-5097-4ae5-add0-22baf26bdfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_4ce0cde5-ca45-4337-afe3-bb425e4cea90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_4ce0cde5-ca45-4337-afe3-bb425e4cea90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f129bbea-66cf-44a5-8d90-ab23d5c21a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f129bbea-66cf-44a5-8d90-ab23d5c21a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_c643b22c-d8ea-4f45-b1a7-ee12ef5e2524" xlink:href="dva-20221231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_935e72c0-97c4-42e1-ae7d-d3f3034c1f10" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_c643b22c-d8ea-4f45-b1a7-ee12ef5e2524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a07e26f0-d6a1-45a5-85a9-2ac7ebbe0573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a07e26f0-d6a1-45a5-85a9-2ac7ebbe0573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_85dae419-22a1-4470-8038-6d05fdf516e9" xlink:href="dva-20221231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_85dae419-22a1-4470-8038-6d05fdf516e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_6f3881c0-305a-405a-b0cf-4e2b360f269e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_6f3881c0-305a-405a-b0cf-4e2b360f269e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de2e63c0-97fc-4380-9b90-71e3117d3755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_de2e63c0-97fc-4380-9b90-71e3117d3755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d54d368-d542-48da-a4a5-a6073a5f36cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_3644dded-d602-4b86-8393-11f379412d93" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d54d368-d542-48da-a4a5-a6073a5f36cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2b93bcc-ae69-4526-b18f-1ea0dd733a6a" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7439d594-1843-4df5-b1e0-527816901f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7439d594-1843-4df5-b1e0-527816901f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3fb6db04-318b-4bb2-8901-6e2122bfd962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DeferredOfferingCosts_3fb6db04-318b-4bb2-8901-6e2122bfd962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_060fcb4c-e491-4282-99c2-e614cd315582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7f7bf89f-3816-4748-ac0c-d9c9779ade87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_060fcb4c-e491-4282-99c2-e614cd315582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtScheduledMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_15d43cf4-0452-4b00-9dfb-cd17883ae672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_15d43cf4-0452-4b00-9dfb-cd17883ae672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fdf766-42d4-4186-91a4-1ffabfdbc8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f0fdf766-42d4-4186-91a4-1ffabfdbc8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_52912ff6-0e09-45be-9c3f-f216d971d588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_52912ff6-0e09-45be-9c3f-f216d971d588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a135b02a-2bb6-4182-91e1-90a1202cd680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a135b02a-2bb6-4182-91e1-90a1202cd680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2ce1e0ec-8e8d-43bb-acd9-96e5458d3903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2ce1e0ec-8e8d-43bb-acd9-96e5458d3903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a8940638-7124-4d20-bfa9-e807052a8580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7bfa42-5adf-4817-8a77-cd6bfc1c1256" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a8940638-7124-4d20-bfa9-e807052a8580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05ccc098-5af4-47d8-9f48-01f36a545f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_05ccc098-5af4-47d8-9f48-01f36a545f58" xlink:to="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b7d6c0f1-38bb-4f25-9418-56673c3d9c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_a6a1dfa6-5976-40ee-bc7f-602c8c367a4f" xlink:href="dva-20221231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94c45586-98e5-4c68-ab58-2409bcc0ca95" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_a6a1dfa6-5976-40ee-bc7f-602c8c367a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_32fafba7-7f8a-4ede-9f97-daca999864b6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_8113542f-164f-4329-8dfc-1876da95fcac" xlink:href="dva-20221231.xsd#dva_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a24cfced-d571-44b3-823c-733d758d1571" xlink:to="loc_dva_TermLoanFacilityMember_8113542f-164f-4329-8dfc-1876da95fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39aa6977-b069-4adb-b4d2-eba2caf1c16f" xlink:to="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf204bc9-cd30-4d8a-9e05-500e5bde072b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_464cfa01-1f8f-4a8f-acd3-6530df056524" xlink:to="loc_srt_MaximumMember_bf204bc9-cd30-4d8a-9e05-500e5bde072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ed25231d-a633-4517-8d3e-390cd5a9d7be" xlink:to="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_10272589-0536-4881-997c-f62a4f125feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_db49a5aa-d0b0-422a-89a8-0ca682622ee4" xlink:to="loc_us-gaap_CashFlowHedgingMember_10272589-0536-4881-997c-f62a4f125feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_80814649-cd3c-4a6f-944e-8d1c46e8e8e4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0a28304b-fd0e-4325-a316-295f6cfd0751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e145c5c-0306-4cf7-aed9-ea1ae219fb13" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0a28304b-fd0e-4325-a316-295f6cfd0751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4c0a6542-9808-4c9f-b128-dec41c259531" xlink:to="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_739b4ee9-a2c9-4154-a950-e4c93939d399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_739b4ee9-a2c9-4154-a950-e4c93939d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ff096185-1bb2-4ddc-8718-a96e27a505c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ff096185-1bb2-4ddc-8718-a96e27a505c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_07374466-696f-46f6-bc13-cb8814fc718c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInceptionDates_07374466-696f-46f6-bc13-cb8814fc718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_21320674-4ed7-4d00-93c2-d9da32a975a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeMaturityDates_21320674-4ed7-4d00-93c2-d9da32a975a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b00ad873-0d0a-4edb-af36-a2c69194aca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b00ad873-0d0a-4edb-af36-a2c69194aca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_be7cffe8-1272-402c-b20a-3bd75b168a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_be7cffe8-1272-402c-b20a-3bd75b168a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8eaa037a-aaf1-499c-b07d-afb61a3385a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8eaa037a-aaf1-499c-b07d-afb61a3385a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70f12b07-bd28-4783-bb80-4649260566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7a4a0a72-6c4b-4531-abe4-e7d129ffabe2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70f12b07-bd28-4783-bb80-4649260566fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77947e3e-6280-4d50-b147-b6bed71263e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77947e3e-6280-4d50-b147-b6bed71263e1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_daddf302-5342-4b84-ada4-8b3037598428" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_fd5d3baa-12b3-4fc1-bd08-4afcd940b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ae718115-708a-4693-a56d-de7b56c38776" xlink:to="loc_us-gaap_CashFlowHedgingMember_fd5d3baa-12b3-4fc1-bd08-4afcd940b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76560f48-4c65-4ee0-8eaa-181167980cd7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_d4001d8c-b626-44eb-b58b-cb6d60594213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:to="loc_us-gaap_InterestRateCapMember_d4001d8c-b626-44eb-b58b-cb6d60594213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_97a3fcb2-aeaa-43a3-9106-11284ca49935" xlink:href="dva-20221231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bfd6d94-725c-40a8-b1df-a12617ab72f4" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_97a3fcb2-aeaa-43a3-9106-11284ca49935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df013e55-fd93-4807-95b6-781154651150" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c1b6549f-cef9-4d2a-a9cf-9962f470748a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c1b6549f-cef9-4d2a-a9cf-9962f470748a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_983ca304-7e37-456f-ba81-8badac5b3504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_983ca304-7e37-456f-ba81-8badac5b3504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_d066290c-262d-4c24-819c-37be6f82b850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_cf3d1c13-40d3-400a-993b-2fced6e98e6d" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_d066290c-262d-4c24-819c-37be6f82b850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20221231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d405b16a-eb9e-4e8a-a2a9-78ff70508f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d405b16a-eb9e-4e8a-a2a9-78ff70508f81" xlink:to="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8f7943b4-c09a-40f3-bcb9-a89e6af7ce73" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAMember_aaeac07b-00cc-41a3-a9c3-cb110b6f9cce" xlink:href="dva-20221231.xsd#dva_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanAMember_aaeac07b-00cc-41a3-a9c3-cb110b6f9cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_9fe0e234-392a-4e18-9578-e2628cb8cd9b" xlink:href="dva-20221231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanB1Member_9fe0e234-392a-4e18-9578-e2628cb8cd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanAAndTermLoanB1Member_7f043aca-fcc1-4b14-af1c-fa14ad0bee70" xlink:href="dva-20221231.xsd#dva_TermLoanAAndTermLoanB1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_TermLoanAAndTermLoanB1Member_7f043aca-fcc1-4b14-af1c-fa14ad0bee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_b73d0195-aa04-4fc0-8614-5c7694dc578e" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69fa4342-a6fd-4f51-b791-896163347511" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_b73d0195-aa04-4fc0-8614-5c7694dc578e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f23a9206-9a66-4f73-a76e-e85ca6702879" xlink:to="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_263b9913-79f4-4c26-8ff7-56513418696b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_263b9913-79f4-4c26-8ff7-56513418696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_18daa9f9-b27e-42a2-bc64-a0f6cfd0e054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f0ac115e-be2d-4852-8fdd-9701f4d7bc26" xlink:to="loc_us-gaap_LetterOfCreditMember_18daa9f9-b27e-42a2-bc64-a0f6cfd0e054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4d1d3311-458b-4d7d-b4f5-27684d775866" xlink:to="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f81a12f4-e03f-439f-a52c-10523be06e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:to="loc_srt_MinimumMember_f81a12f4-e03f-439f-a52c-10523be06e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a03586be-f523-4912-b5de-9cddd365113c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f146688a-2a7b-41ff-9d10-77c7d3d690da" xlink:to="loc_srt_MaximumMember_a03586be-f523-4912-b5de-9cddd365113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_72e3b5a4-97a5-4533-ade5-46a5203e03e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_3b66b977-03eb-4f09-a182-cdd81db0abaf" xlink:href="dva-20221231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_78222323-0494-4c5f-9ace-1fe06d71401b" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_3b66b977-03eb-4f09-a182-cdd81db0abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03ceb856-0b4a-494c-80d3-348dca5bff5b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_08052b88-a67d-438d-9c7d-75dc9709a9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_08052b88-a67d-438d-9c7d-75dc9709a9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0a23cdb8-91f7-4425-95c3-ce9a89c5173c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_0a23cdb8-91f7-4425-95c3-ce9a89c5173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_38e75370-cc20-4c33-ade5-555becfb0a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_SecuredDebt_38e75370-cc20-4c33-ade5-555becfb0a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e92f1688-e070-46ef-840b-2196f44d964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e92f1688-e070-46ef-840b-2196f44d964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_30f8a02e-4b6a-4236-984a-266c98f80e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_30f8a02e-4b6a-4236-984a-266c98f80e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_7bbf93e6-c60e-423f-8547-a815f2fe219a" xlink:href="dva-20221231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR_7bbf93e6-c60e-423f-8547-a815f2fe219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ff9fe63b-c012-4765-93d8-c0334d986127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_ff9fe63b-c012-4765-93d8-c0334d986127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_880fb21c-69ed-42e0-81cd-a6f962830be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_880fb21c-69ed-42e0-81cd-a6f962830be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_57f648e0-2788-4dd7-bb01-b97232b3bb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_57f648e0-2788-4dd7-bb01-b97232b3bb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f631e88d-3f27-4b30-81ec-d02c5424848a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_InterestExpenseDebt_f631e88d-3f27-4b30-81ec-d02c5424848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32eb9631-6974-4dca-93c6-31574895708f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a0e27d9-46c6-4ef3-bb17-c9da34bd35f8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32eb9631-6974-4dca-93c6-31574895708f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesLeaseExpenseComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_81360852-7360-4422-bdb7-21b71e07f317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_7acd98a2-dbfe-4a47-adfa-403d714b6156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_81360852-7360-4422-bdb7-21b71e07f317" xlink:to="loc_us-gaap_LeaseCostAbstract_7acd98a2-dbfe-4a47-adfa-403d714b6156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_cb473ec1-0ea1-440c-8137-91783c9a73cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7acd98a2-dbfe-4a47-adfa-403d714b6156" xlink:to="loc_us-gaap_OperatingLeaseExpense_cb473ec1-0ea1-440c-8137-91783c9a73cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e937310c-dd5d-4b0e-b5f5-ab44202111ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7acd98a2-dbfe-4a47-adfa-403d714b6156" xlink:to="loc_us-gaap_VariableLeaseCost_e937310c-dd5d-4b0e-b5f5-ab44202111ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_9dc9fd52-4a7a-40b1-8149-773c9e295ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_81360852-7360-4422-bdb7-21b71e07f317" xlink:to="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_9dc9fd52-4a7a-40b1-8149-773c9e295ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3d8b2db8-c1c7-42f4-98c4-40fcede36e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_9dc9fd52-4a7a-40b1-8149-773c9e295ac7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3d8b2db8-c1c7-42f4-98c4-40fcede36e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_d3510343-927a-486c-aedc-9886ea040f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_9dc9fd52-4a7a-40b1-8149-773c9e295ac7" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_d3510343-927a-486c-aedc-9886ea040f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d725106c-71d9-4411-b6ff-8653910d2f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_81360852-7360-4422-bdb7-21b71e07f317" xlink:to="loc_us-gaap_LeaseCost_d725106c-71d9-4411-b6ff-8653910d2f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_84f9c607-ae72-4239-99bb-2e75fe10718d" xlink:href="dva-20221231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_84f9c607-ae72-4239-99bb-2e75fe10718d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:to="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b69b8a6a-59c3-4fad-bb43-59fce159d062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_06c1c2fe-f6f3-4e6a-b692-26d3a62f1d20" xlink:href="dva-20221231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b56e7764-8eaa-42f9-b7a7-f05f7650ae24" xlink:to="loc_dva_FinanceLeaseMember_06c1c2fe-f6f3-4e6a-b692-26d3a62f1d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9a532b8f-91d7-4bd9-a08c-fbe23110f76e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:to="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717b19b1-861e-4575-940b-5bab7b78018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717b19b1-861e-4575-940b-5bab7b78018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cf7d4011-5579-42c5-be11-af6ce29e225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cf7d4011-5579-42c5-be11-af6ce29e225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d973337-e6d7-440c-8263-c06902a0eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d973337-e6d7-440c-8263-c06902a0eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bdc81eec-788e-44a5-b266-0a2156ee30e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f87fcc2a-148d-47d1-9f73-089eb96b4f25" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bdc81eec-788e-44a5-b266-0a2156ee30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:href="dva-20221231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_16d95c8c-1c74-48cc-9822-ca01e914c929" xlink:to="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9def94fa-c8ce-4a1a-93f4-a9848d7e83d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9def94fa-c8ce-4a1a-93f4-a9848d7e83d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_de986b46-1249-4e6f-945a-ca5b367e84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_OperatingLeasePayments_de986b46-1249-4e6f-945a-ca5b367e84dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b2bf9c67-0fb4-4445-a58b-390c2e36bacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b2bf9c67-0fb4-4445-a58b-390c2e36bacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f6ccc31f-5899-428d-a366-9c6dd3bab841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2121c2b8-f50f-45da-9c59-7464844aeaab" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f6ccc31f-5899-428d-a366-9c6dd3bab841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_79ca38ac-8650-49da-a832-8628f5279a34" xlink:href="dva-20221231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_6e4037fe-c510-473c-b326-96c2c168fb83" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_79ca38ac-8650-49da-a832-8628f5279a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_68715d72-3d8c-40f7-bf87-5f50271c3866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68715d72-3d8c-40f7-bf87-5f50271c3866" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7544f2d0-34e5-4c69-900d-eb59d135a182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7544f2d0-34e5-4c69-900d-eb59d135a182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ccc966f3-b318-45ee-8b79-5c8ac1da674e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ccc966f3-b318-45ee-8b79-5c8ac1da674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ab6db674-0bf9-451e-b6dd-5d73beb0ab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ab6db674-0bf9-451e-b6dd-5d73beb0ab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c6cf6565-1881-4582-bcaf-e2c9887e57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c6cf6565-1881-4582-bcaf-e2c9887e57c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_47c29db5-9e48-441e-8436-36fbbb9054aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_47c29db5-9e48-441e-8436-36fbbb9054aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b2c00502-cab9-46ed-94da-4fef80aa505c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b2c00502-cab9-46ed-94da-4fef80aa505c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dde58010-2300-48bb-8cf8-7cdb93f9b987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dde58010-2300-48bb-8cf8-7cdb93f9b987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8155f1c2-3c8b-453e-bbab-621e3d053be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8155f1c2-3c8b-453e-bbab-621e3d053be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fbae493e-e320-4b3b-a07b-7870f4a1deaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_OperatingLeaseLiability_fbae493e-e320-4b3b-a07b-7870f4a1deaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_f61eb4c5-db5c-4e05-817e-e49131d0f82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_db65cd01-90f8-43f8-998a-b2285810521f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_f61eb4c5-db5c-4e05-817e-e49131d0f82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68715d72-3d8c-40f7-bf87-5f50271c3866" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38bf12b9-4ee7-4989-b651-804286babde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38bf12b9-4ee7-4989-b651-804286babde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b655a3f6-c7a0-4330-894f-4c54ce95b356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b655a3f6-c7a0-4330-894f-4c54ce95b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0acc76b8-9940-431a-8c99-f91afe398b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0acc76b8-9940-431a-8c99-f91afe398b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_45331995-c4be-409d-a296-179a40e55330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_45331995-c4be-409d-a296-179a40e55330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_315130c0-b0e8-4d24-ae28-7625a10122c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_315130c0-b0e8-4d24-ae28-7625a10122c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_464e2172-d3ef-4d85-854f-4a623f1fac14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_464e2172-d3ef-4d85-854f-4a623f1fac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_54d44afe-ecb7-4579-b329-52f9dd0b130e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_54d44afe-ecb7-4579-b329-52f9dd0b130e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_02d93bcd-35fe-4604-a4a1-0cfe24da1283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_02d93bcd-35fe-4604-a4a1-0cfe24da1283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_8d0e70ec-2373-4cc2-9f68-d0b45fb7fc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiability_8d0e70ec-2373-4cc2-9f68-d0b45fb7fc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1d6645b2-3fea-44d0-9488-fcde2a0dfe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_54c4c65b-066a-4b22-921e-7bfabf8a2146" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1d6645b2-3fea-44d0-9488-fcde2a0dfe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fd34bfc5-5dc2-4382-bcb3-48d96e2a21e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd34bfc5-5dc2-4382-bcb3-48d96e2a21e5" xlink:to="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:to="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a0398b2-c235-4b62-b36d-56a71d94d2d2" xlink:to="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8caa0be-acd8-4670-856b-f86f8e91360d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:to="loc_srt_MinimumMember_c8caa0be-acd8-4670-856b-f86f8e91360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7d774ef-a280-4c40-ab22-5e80fc237785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_73e8121d-f2d9-42c8-90fb-267369ff80cb" xlink:to="loc_srt_MaximumMember_c7d774ef-a280-4c40-ab22-5e80fc237785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:to="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_dd881768-7c03-4efb-a599-eec2f82678ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_12b49353-1ac7-4ed7-b8ab-44c00778a3db" xlink:href="dva-20221231.xsd#dva_OperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e4dfd64a-5ac0-4480-8fc0-3a2fed359a6a" xlink:to="loc_dva_OperatingLeaseMember_12b49353-1ac7-4ed7-b8ab-44c00778a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:href="dva-20221231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_0ef2e509-fd09-4ea0-8055-7be90dc6fb27" xlink:to="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ea264122-2d4d-48fc-8ed7-ca04ff271246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ea264122-2d4d-48fc-8ed7-ca04ff271246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8cb28256-9909-4d09-aed2-17183756fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8cb28256-9909-4d09-aed2-17183756fe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_af18f049-9c67-4692-9a1b-104ba0f17d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_af18f049-9c67-4692-9a1b-104ba0f17d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f8276110-dd4a-4a11-ba00-23c1bee10cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f8276110-dd4a-4a11-ba00-23c1bee10cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_c44a6fee-6a9f-4076-ad09-0f851f96f7cb" xlink:href="dva-20221231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_c44a6fee-6a9f-4076-ad09-0f851f96f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fbd96ac6-d827-4f35-9939-85182d435e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_12c419db-bedc-45e3-ad5f-1e793e543c38" xlink:to="loc_us-gaap_LeaseCost_fbd96ac6-d827-4f35-9939-85182d435e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_40d220e5-f418-4d17-b872-1e485f522124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_40d220e5-f418-4d17-b872-1e485f522124" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_776d16e2-25e8-4b58-8ff9-a5384917ca4a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_8c1428b4-7b31-4499-a174-8cc818d4222d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b7496034-7721-45a0-9a09-6d14e267c7e0" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_8c1428b4-7b31-4499-a174-8cc818d4222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_139293a0-4e90-4887-8f6b-265757eded86" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_3066467e-6752-4b83-8e56-7d4b2d058689" xlink:href="dva-20221231.xsd#dva_AllTrustsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_7bac085e-b691-4954-ba3b-ab881983d02b" xlink:to="loc_dva_AllTrustsMember_3066467e-6752-4b83-8e56-7d4b2d058689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00d80395-4f18-4129-b2e2-2910f73320a3" xlink:to="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63b54b8d-2c0d-4023-82dc-74130bd2cf1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:to="loc_srt_MinimumMember_63b54b8d-2c0d-4023-82dc-74130bd2cf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db9aee28-3f0e-4d0f-9c4a-408eb777a0cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0e8d89a-ca8c-4bb2-b278-f11adccaf9cb" xlink:to="loc_srt_MaximumMember_db9aee28-3f0e-4d0f-9c4a-408eb777a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_654cd049-ed68-43ac-9cd0-561d364ada6b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_86d9eb51-6daf-43f5-bf96-9a6462a2598f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_86d9eb51-6daf-43f5-bf96-9a6462a2598f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_d26c6a7a-dbb8-435c-8de0-534a58447995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_d26c6a7a-dbb8-435c-8de0-534a58447995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_413405db-bb89-49be-815d-f46c0f9d8849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_413405db-bb89-49be-815d-f46c0f9d8849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_50e62647-5565-43a6-bd14-9f05f16d6175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_50e62647-5565-43a6-bd14-9f05f16d6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_9e24fa48-8548-4b3e-95cb-e03830780c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_9e24fa48-8548-4b3e-95cb-e03830780c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_7977bf99-3cf4-475f-b4b9-2fe2d0e5e615" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_7977bf99-3cf4-475f-b4b9-2fe2d0e5e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_a57bcf48-91dd-47fb-8836-34dfb8a16d2b" xlink:href="dva-20221231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_a57bcf48-91dd-47fb-8836-34dfb8a16d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_a48d8bed-a218-4987-83d0-228edba193e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_a48d8bed-a218-4987-83d0-228edba193e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ca0f2d92-613d-4d12-8af4-6c693c4595c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f4e80f5c-3649-46f8-a9fa-89b220979c79" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ca0f2d92-613d-4d12-8af4-6c693c4595c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c64817d0-857c-4aec-b61d-21142e98fce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c64817d0-857c-4aec-b61d-21142e98fce6" xlink:to="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:to="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_c94b168a-9fb3-49fe-a822-db325d0d45c2" xlink:to="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncrementalCashPortionMember_59acf2cf-d1bf-4816-b364-e549aed45284" xlink:href="dva-20221231.xsd#dva_IncrementalCashPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:to="loc_dva_IncrementalCashPortionMember_59acf2cf-d1bf-4816-b364-e549aed45284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidForPortionPreviouslyRefundedMember_1a58a5c1-d405-4f6e-9827-8bd81c01770b" xlink:href="dva-20221231.xsd#dva_CashPaidForPortionPreviouslyRefundedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_6da5ce33-4b5a-47e3-bb41-afbb65fb8995" xlink:to="loc_dva_CashPaidForPortionPreviouslyRefundedMember_1a58a5c1-d405-4f6e-9827-8bd81c01770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:to="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a4806ff3-2868-49ab-aebe-6a00fd913e3f" xlink:to="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USAttorneyPrescriptionDrugInvestigationMember_a723fd1b-c785-4e98-af97-cd0f625ce9af" xlink:href="dva-20221231.xsd#dva_USAttorneyPrescriptionDrugInvestigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b4b428c7-510d-4dd2-8c34-67436674068d" xlink:to="loc_dva_USAttorneyPrescriptionDrugInvestigationMember_a723fd1b-c785-4e98-af97-cd0f625ce9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_f8d9fa53-7a23-457e-a1e1-9e4cdefa3592" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a1c90520-7fc6-45ca-8e84-e849dcaa1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_fd1bd430-7197-4e85-9acc-8cc12185fcf7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a1c90520-7fc6-45ca-8e84-e849dcaa1fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5db8ed54-ef51-4206-b2d0-06eb0a852fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5db8ed54-ef51-4206-b2d0-06eb0a852fd4" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6cd84b5e-0664-4bfb-b024-4509c5731c01" xlink:to="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_d1ee65f3-6dd8-4d88-a31e-96797977f8e4" xlink:href="dva-20221231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_52a81e28-cf30-40b4-847a-db4229ce2fb0" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_d1ee65f3-6dd8-4d88-a31e-96797977f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:to="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_341de01e-47ba-4459-8a4b-29dac1e798e8" xlink:to="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96e0b649-dea1-464f-a237-d06c4ff3a483" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:to="loc_srt_MinimumMember_96e0b649-dea1-464f-a237-d06c4ff3a483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2833db55-18e7-4ad5-9530-706639dc52c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41aa705a-c229-4c0a-b367-4f976f3b67c4" xlink:to="loc_srt_MaximumMember_2833db55-18e7-4ad5-9530-706639dc52c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:href="dva-20221231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_b59df0a3-bd0a-4cd6-ab24-17c92b5b6cb3" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_75ce7e31-52b2-47b7-bcbb-14a9f6611f0c" xlink:href="dva-20221231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_dva_DissolutionTermOfJointVentures_75ce7e31-52b2-47b7-bcbb-14a9f6611f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_e837577f-494b-4d0e-9f7c-a8c8ec200c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_e837577f-494b-4d0e-9f7c-a8c8ec200c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_0b11acdb-cbc7-452e-927b-4dbe207368fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_0b11acdb-cbc7-452e-927b-4dbe207368fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_dbacdadb-23f0-46d1-b9df-767b8b6bbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_dbacdadb-23f0-46d1-b9df-767b8b6bbb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_c6f00b3e-7dc9-499f-ad04-f7e82494844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_c6f00b3e-7dc9-499f-ad04-f7e82494844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_c4475931-74a8-41bf-b33a-30c1d9c0cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_us-gaap_OtherCommitment_c4475931-74a8-41bf-b33a-30c1d9c0cbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_41556e47-d282-4187-9042-b8901e2e19d1" xlink:href="dva-20221231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_16784d8c-4ae9-461c-8c20-b4c67a3f91a4" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_41556e47-d282-4187-9042-b8901e2e19d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56b036eb-4ca4-4c4a-a25c-0317f4736654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56b036eb-4ca4-4c4a-a25c-0317f4736654" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:to="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f527800e-35f5-48a3-9704-120d0ac0bf3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_cf94e9f9-b663-4cad-b5ba-dab3ca1ad102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_cf94e9f9-b663-4cad-b5ba-dab3ca1ad102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_a14182cb-7fdd-4a3c-bd64-3e6a5c0b83a5" xlink:href="dva-20221231.xsd#dva_StockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c650240-7bc4-4ba1-a2e6-9ca133b4b3bd" xlink:to="loc_dva_StockUnitMember_a14182cb-7fdd-4a3c-bd64-3e6a5c0b83a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24adb7c0-53c6-4bc0-9d35-702401e366be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e51060c-ac6b-40c6-9145-5ad9615a8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e51060c-ac6b-40c6-9145-5ad9615a8d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a360ab27-6d1c-403e-abc1-f6f14edd6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a360ab27-6d1c-403e-abc1-f6f14edd6664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6eb544bc-3b36-4bea-9425-671a9b7a28a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6eb544bc-3b36-4bea-9425-671a9b7a28a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c825af08-003a-40dd-a7f2-b1fa1c1188a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c825af08-003a-40dd-a7f2-b1fa1c1188a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc766316-ab11-4941-8698-557905d5cd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b537018-6f66-449f-8fcd-a048bbe802e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc766316-ab11-4941-8698-557905d5cd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b3f0496-7cde-4398-a76d-2971a0a59699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b3f0496-7cde-4398-a76d-2971a0a59699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89a09e1c-7f2f-44b5-8a9c-5654435029ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89a09e1c-7f2f-44b5-8a9c-5654435029ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dc8a22f-9164-4b1b-83bf-7e8f69466bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dc8a22f-9164-4b1b-83bf-7e8f69466bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51ea2da6-ee40-4d67-9cb9-bd9417d1fd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51ea2da6-ee40-4d67-9cb9-bd9417d1fd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b27bc1d1-3ff3-4fbf-98ff-7eb5f86c9767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b27bc1d1-3ff3-4fbf-98ff-7eb5f86c9767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9cc36780-16c4-4f42-bab0-81a0ee687421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9cc36780-16c4-4f42-bab0-81a0ee687421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a1584b40-a163-4444-988e-df0fcacc159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8d07cc2-eff2-4ca5-aa02-5ed5fe47f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a1584b40-a163-4444-988e-df0fcacc159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62fb9f1a-e641-4835-989d-a9fab5344c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62fb9f1a-e641-4835-989d-a9fab5344c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3d64e3c-8bf1-4f48-87cc-4788a3984bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3d64e3c-8bf1-4f48-87cc-4788a3984bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_66c8daf1-3a6e-41cd-b838-b2feb90cd788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_b2e6823d-2627-4cfc-9492-eb935076d8da" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_66c8daf1-3a6e-41cd-b838-b2feb90cd788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6c1cdbb-e54d-4d87-8454-0ea1e9e1502e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6c1cdbb-e54d-4d87-8454-0ea1e9e1502e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0e9cc7b-e407-49ba-a025-c0e6146fa6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0e9cc7b-e407-49ba-a025-c0e6146fa6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_019fb4fd-75ab-42ef-8bf7-d9b00be971fc" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_019fb4fd-75ab-42ef-8bf7-d9b00be971fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ec49839f-0549-434a-a473-51486e1ab926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ec49839f-0549-434a-a473-51486e1ab926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_03e2913d-cfdb-4c22-8f91-e8de275ed2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_03e2913d-cfdb-4c22-8f91-e8de275ed2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62a43d28-2156-47de-aafc-fc1d86ce0eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c7a7fead-ddec-4c67-8e7a-f6f895124cea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62a43d28-2156-47de-aafc-fc1d86ce0eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_16be0f62-1253-40dc-a9cf-052814a5d0aa" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_16be0f62-1253-40dc-a9cf-052814a5d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4ca40a6-2baf-4ac7-8ad8-4483286bc293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4ca40a6-2baf-4ac7-8ad8-4483286bc293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6ebdfcc-48cc-4a4e-8360-96fd6d40f572" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3660ef56-21e4-49f4-a47d-d1ca79f71266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3660ef56-21e4-49f4-a47d-d1ca79f71266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_88f41244-b384-4fc1-8c19-ce94d1923207" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_585ee670-2812-4cdd-a372-b8e788b778c0" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_88f41244-b384-4fc1-8c19-ce94d1923207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_801590e2-f6aa-4f1c-84f9-219c71834ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_801590e2-f6aa-4f1c-84f9-219c71834ecb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0fe8b248-3053-4a8d-b2f9-68f58964c93f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_d3ad9e23-640a-45a4-99b8-41e809b03fae" xlink:href="dva-20221231.xsd#dva_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeOneMember_d3ad9e23-640a-45a4-99b8-41e809b03fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_db7501a1-8727-42d4-b2c8-406efdd153dc" xlink:href="dva-20221231.xsd#dva_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeTwoMember_db7501a1-8727-42d4-b2c8-406efdd153dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_b836ba2b-908c-4558-acb0-6f10644cee94" xlink:href="dva-20221231.xsd#dva_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeThreeMember_b836ba2b-908c-4558-acb0-6f10644cee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_662c4fdc-a410-4fa9-bc8e-ac4fee5dd554" xlink:href="dva-20221231.xsd#dva_RangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeFourMember_662c4fdc-a410-4fa9-bc8e-ac4fee5dd554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_307b2b11-86b2-4ece-869e-7263194211c9" xlink:href="dva-20221231.xsd#dva_RangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e2b01f04-4cca-4d60-bd9d-094f96503081" xlink:to="loc_dva_RangeFiveMember_307b2b11-86b2-4ece-869e-7263194211c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bc159db4-efc2-4c94-8bcf-768012e69e75" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_aae49e2b-70ab-47d1-be7a-472a021d8752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_aae49e2b-70ab-47d1-be7a-472a021d8752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_28f4d83e-b761-47e9-8474-9ac3ebbdc07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_28f4d83e-b761-47e9-8474-9ac3ebbdc07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6e0bafc2-58b4-4335-bdd1-5b0a6fa2fdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_6e0bafc2-58b4-4335-bdd1-5b0a6fa2fdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c68abda1-d2cd-4a66-9550-f914c82b4123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c68abda1-d2cd-4a66-9550-f914c82b4123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9cfeeee5-473f-4a66-a1a7-792301549f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9cfeeee5-473f-4a66-a1a7-792301549f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f986b5d3-d419-41b6-8885-bf78ca17470d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1e20d155-a27e-443e-852f-f05157da6733" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f986b5d3-d419-41b6-8885-bf78ca17470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a25a7aa-fce0-413a-a52e-a8d6dde87b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a25a7aa-fce0-413a-a52e-a8d6dde87b5f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:to="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80706680-770a-4efe-8192-0d7cf2ce5815" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_ef410341-bcd6-4e38-b059-ed992549c6b8" xlink:href="dva-20221231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_853893dd-6dfc-4578-be77-5904850a0245" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_ef410341-bcd6-4e38-b059-ed992549c6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92280f2e-b2ea-4114-b967-e5a276a85013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e9aa0911-e08d-48f7-96f3-caddc555ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e9aa0911-e08d-48f7-96f3-caddc555ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ff52f3d8-a5e2-4957-8e06-52841ff9a89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ff52f3d8-a5e2-4957-8e06-52841ff9a89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35252fdf-530a-442e-82f5-250a3ffe19a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35252fdf-530a-442e-82f5-250a3ffe19a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48054fa4-fabb-4568-a409-9ed7c332fc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb6f816b-80a9-4594-a95c-43c729a78794" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_48054fa4-fabb-4568-a409-9ed7c332fc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_542df9bb-3a1e-4aed-bda2-a1a337913040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_542df9bb-3a1e-4aed-bda2-a1a337913040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bf27ed40-a06b-494a-9bcf-6f119cf3648c" xlink:to="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_d3fe2638-e169-4c06-a845-74bb9acff186" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_d3fe2638-e169-4c06-a845-74bb9acff186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyElevenMember_d7b3b797-4c87-49a5-bb2c-4d6efbbbd357" xlink:href="dva-20221231.xsd#dva_StockIncentivePlanTwentyElevenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b6315233-2e3d-42b5-860f-622ad8f6ba88" xlink:to="loc_dva_StockIncentivePlanTwentyElevenMember_d7b3b797-4c87-49a5-bb2c-4d6efbbbd357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a32a7bab-c455-4cad-a5b4-a23eb04a2a89" xlink:to="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06c5938a-de68-4e69-a0da-d03af2c5717e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:to="loc_srt_MinimumMember_06c5938a-de68-4e69-a0da-d03af2c5717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4da308d2-f6b1-4cc6-a422-618a3091e867" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6918edbb-332f-49dc-8a60-0b034fc784a8" xlink:to="loc_srt_MaximumMember_4da308d2-f6b1-4cc6-a422-618a3091e867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cf7080e4-a037-45eb-b99e-2b6394226152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_e9b5f4fa-f376-4969-a1d0-75330e83631d" xlink:href="dva-20221231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff1f53c-bb3f-4aad-8bb3-783b3333553a" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_e9b5f4fa-f376-4969-a1d0-75330e83631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70db644a-29e2-404b-922c-90c2eb992679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fe11460d-0127-4fbf-a6bc-6aa9979224f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fe11460d-0127-4fbf-a6bc-6aa9979224f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_79b743d1-6b96-411e-a333-180926223b64" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_79b743d1-6b96-411e-a333-180926223b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_c63fa23d-f6df-4401-b104-1af9e67ea7c3" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_c63fa23d-f6df-4401-b104-1af9e67ea7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_110a7063-e30d-4299-85af-9974dba10caa" xlink:href="dva-20221231.xsd#dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_110a7063-e30d-4299-85af-9974dba10caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_b6fe6b80-5adf-43e8-af1e-46d0b1b5e602" xlink:href="dva-20221231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_b6fe6b80-5adf-43e8-af1e-46d0b1b5e602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb790161-d5cb-4d75-8fde-79799ea71609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb790161-d5cb-4d75-8fde-79799ea71609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c351824c-541f-4678-bbde-907a8c234998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c351824c-541f-4678-bbde-907a8c234998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_ba59ba04-40b5-4861-9cdb-cbe44364b462" xlink:href="dva-20221231.xsd#dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio_ba59ba04-40b5-4861-9cdb-cbe44364b462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d6c5bf7-e3c4-4086-8c4c-433fd879af31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d6c5bf7-e3c4-4086-8c4c-433fd879af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fac8b4bf-192d-4894-b256-6d3607704689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fac8b4bf-192d-4894-b256-6d3607704689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d7ccf898-3661-433c-8aaf-d44565fbaf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d7ccf898-3661-433c-8aaf-d44565fbaf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_758e4159-8003-4015-b024-131870897fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_758e4159-8003-4015-b024-131870897fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_bcb173e9-7ee4-4dc2-9689-1d5a9029b2fc" xlink:href="dva-20221231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_bcb173e9-7ee4-4dc2-9689-1d5a9029b2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3bd3d25d-f6cc-4df5-82c7-46aac6e0a3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3bd3d25d-f6cc-4df5-82c7-46aac6e0a3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_521b53df-53d5-427c-89a0-f0710f4838f3" xlink:href="dva-20221231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_521b53df-53d5-427c-89a0-f0710f4838f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_21ffae5d-c094-4671-a65a-88178683fcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_21ffae5d-c094-4671-a65a-88178683fcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aee8b973-f104-487c-bad5-91f60c30388e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aee8b973-f104-487c-bad5-91f60c30388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23dfde39-79ee-480a-a1da-8ee7a72311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23dfde39-79ee-480a-a1da-8ee7a72311a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_03663584-86c6-4fae-a8a3-2360643a27b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_03663584-86c6-4fae-a8a3-2360643a27b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63565313-51bf-4533-8160-fba24b094cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_63565313-51bf-4533-8160-fba24b094cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20ef6a7a-8449-481a-bb87-97f99873d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ShareBasedCompensation_20ef6a7a-8449-481a-bb87-97f99873d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_80cf3ba2-291d-490b-bae7-9601033a45cd" xlink:href="dva-20221231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_80cf3ba2-291d-490b-bae7-9601033a45cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed9287eb-106d-4bce-8af4-20ef8228547a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed9287eb-106d-4bce-8af4-20ef8228547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_60757f08-170f-4023-a9f9-c107206322b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_60757f08-170f-4023-a9f9-c107206322b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_587b1701-1164-4a6d-b776-d5ba74ca49d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_587b1701-1164-4a6d-b776-d5ba74ca49d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec04674c-6088-4fb1-8a85-c4e10a98fff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bebb96be-3abc-4e1e-b10a-0d8dde5e739e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec04674c-6088-4fb1-8a85-c4e10a98fff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_12254682-1048-4aa2-ba13-1e7bde68fe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_12254682-1048-4aa2-ba13-1e7bde68fe5f" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d5784c-b75d-4e96-84e1-3334e7017509" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_0d78485e-ba69-40c7-9c95-a037968b88e5" xlink:href="dva-20221231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:to="loc_dva_OpenMarketPurchasesMember_0d78485e-ba69-40c7-9c95-a037968b88e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember_7d2363dc-6cb7-42dc-865c-38fa2272e802" xlink:href="dva-20221231.xsd#dva_TenderOfferMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_212fe3b9-34b7-4669-a1e8-709bcd213636" xlink:to="loc_dva_TenderOfferMember_7d2363dc-6cb7-42dc-865c-38fa2272e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_8d8f651c-3a79-4103-ada4-2def4dd8e1fc" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_90136533-8d39-4fe1-bd50-888fad02a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_90136533-8d39-4fe1-bd50-888fad02a86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a7f8b537-3d0d-4ffc-b064-22e0a5d8ad17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a7f8b537-3d0d-4ffc-b064-22e0a5d8ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b0437538-b809-4405-99f9-faf577b95a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b0437538-b809-4405-99f9-faf577b95a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5bd2ed4e-76a5-4003-87f5-7cdf82d224ff" xlink:to="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_8cf90e8c-d773-4e6e-9645-a8ceada81e2a" xlink:href="dva-20221231.xsd#dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:to="loc_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice_8cf90e8c-d773-4e6e-9645-a8ceada81e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareRepurchaseFeesAndExpenses_66661c9c-8dbd-4fbc-9993-f83906c94e31" xlink:href="dva-20221231.xsd#dva_ShareRepurchaseFeesAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_2ba5851b-d1c6-4241-bafb-0370e77ecb4a" xlink:to="loc_dva_ShareRepurchaseFeesAndExpenses_66661c9c-8dbd-4fbc-9993-f83906c94e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_e70b35af-2747-4d37-9a7c-1195355fe8f0" xlink:href="dva-20221231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_e70b35af-2747-4d37-9a7c-1195355fe8f0" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc375bf1-fdfd-45c1-8053-9db111d8cdb9" xlink:to="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c7052f66-68f6-4997-bd27-470e78af342b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_02d38f0c-43b6-419e-b782-22bc3d454f49" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c7052f66-68f6-4997-bd27-470e78af342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d6096412-0617-4d05-b83f-5f9cb76414e2" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afb02e88-23cd-4df6-9258-036ab7aaa251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:to="loc_us-gaap_NetIncomeLoss_afb02e88-23cd-4df6-9258-036ab7aaa251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_94caed14-286a-4aaf-be92-b1e41dfdd379" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_992f18dc-b07a-492c-a681-5183d7fb128a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_992f18dc-b07a-492c-a681-5183d7fb128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_728187b4-113d-4f66-968a-b513a5ba3b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_728187b4-113d-4f66-968a-b513a5ba3b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_5dfc84d7-5c7a-4bda-8c8c-7b0717914b7f" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_5dfc84d7-5c7a-4bda-8c8c-7b0717914b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8c3d20b9-69ac-42e6-87d2-89257b350736" xlink:href="dva-20221231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8c3d20b9-69ac-42e6-87d2-89257b350736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_ff44ea0e-dc06-42be-9882-462bab020629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_ff44ea0e-dc06-42be-9882-462bab020629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_d1407f14-30f2-49b9-a81f-08df6feb4d2b" xlink:href="dva-20221231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_c701c0aa-cb1d-4117-8323-744fbff7d812" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_d1407f14-30f2-49b9-a81f-08df6feb4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ShareholdersequityDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_569a24f3-acba-4603-8598-08e6bc9e1e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_569a24f3-acba-4603-8598-08e6bc9e1e0e" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3827406c-225a-4696-adc4-408bb92ec82e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e382020a-8c82-4288-ba32-a39281f35056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7f07a6f2-5f29-4f7a-8e90-78aa3d106b21" xlink:to="loc_us-gaap_SubsequentEventMember_e382020a-8c82-4288-ba32-a39281f35056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f405797b-ffc9-42d3-b937-20732d656ca3" xlink:to="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_44bf3b03-95f9-4cb0-8235-d6fb4defe247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1f7d4a10-7d7d-4e24-9ae0-a899a351f4d8" xlink:to="loc_us-gaap_TreasuryStockMember_44bf3b03-95f9-4cb0-8235-d6fb4defe247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_1f79f249-93a8-4901-9f5f-4ccaa73af4fb" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:to="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_caa8a160-f904-4086-bd69-d018eabe8547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_caa8a160-f904-4086-bd69-d018eabe8547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_6dede265-d78c-4222-a31c-188f8aadcd9e" xlink:href="dva-20221231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_6dede265-d78c-4222-a31c-188f8aadcd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2c9a52ae-0394-4a70-8d21-1cf3d36d31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2c9a52ae-0394-4a70-8d21-1cf3d36d31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_0daf0306-3433-4449-9d20-299a8138c981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_0daf0306-3433-4449-9d20-299a8138c981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_773dd9f4-79b7-47ac-9d06-469dc4b923d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockSharesAbstract_39e5e843-7efd-40d7-9a9b-b5409b65f32b" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_773dd9f4-79b7-47ac-9d06-469dc4b923d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:href="dva-20221231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_18892f0f-4570-449d-8968-af49b6bc70d2" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4825b5c7-e417-44d1-91f2-f051c0218063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4825b5c7-e417-44d1-91f2-f051c0218063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_e2605fd5-166d-45c2-95a3-6aa6c022fb2e" xlink:href="dva-20221231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_e2605fd5-166d-45c2-95a3-6aa6c022fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_21d454e3-b273-41a0-ac8f-6786cd8177ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_2054e500-644e-4c57-874c-324ea069d858" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_21d454e3-b273-41a0-ac8f-6786cd8177ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_26f39daf-1446-4ecb-9b5d-0574fe1b8dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_26f39daf-1446-4ecb-9b5d-0574fe1b8dfd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_185ae1d1-48f4-40e8-a679-979499e3b07a" xlink:to="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ee232a1f-b387-482b-b347-8ad89604e0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ee232a1f-b387-482b-b347-8ad89604e0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5b8dba1a-0048-4b55-859e-43557ef5790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5b8dba1a-0048-4b55-859e-43557ef5790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c9946766-a09c-4ac1-96bc-a9c2140ce5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b810d9c5-8ce0-4279-ae7e-af864e9d5f45" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c9946766-a09c-4ac1-96bc-a9c2140ce5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_53bf4c4b-ef9e-4545-82f6-0134a209d7bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9415e838-bd62-45fe-8e3e-f440aa368ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9415e838-bd62-45fe-8e3e-f440aa368ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e59e52ec-8971-4e96-a353-2755d2444589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_e59e52ec-8971-4e96-a353-2755d2444589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_78f0a410-eafe-4314-8fda-fcc011bf90bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_78f0a410-eafe-4314-8fda-fcc011bf90bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1ae7547-6ac3-4a86-9def-a2debae90199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1ae7547-6ac3-4a86-9def-a2debae90199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0df44869-7271-45dd-81ff-3a3e7e30d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_0df44869-7271-45dd-81ff-3a3e7e30d89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7baffda5-b2dc-4a51-a3fb-b9dda538a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_7baffda5-b2dc-4a51-a3fb-b9dda538a47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_43611eca-4fa7-405c-b1c4-5495477cdaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_43611eca-4fa7-405c-b1c4-5495477cdaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46b37d88-1b91-4edd-b039-cbe58c017ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_220b9ef3-b448-4e28-a7e3-1136bebe2d2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46b37d88-1b91-4edd-b039-cbe58c017ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_408606eb-c746-4a72-9526-46a5dc02e9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_408606eb-c746-4a72-9526-46a5dc02e9bf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4df1c3b-836e-42a3-a5bb-5b072a1dca72" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_a21ed3b6-d37b-4673-b25d-032c4922d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed4e28bf-46c4-4784-b9a9-e6860a47fd12" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_a21ed3b6-d37b-4673-b25d-032c4922d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_546fd214-90e2-4e3d-aa1a-48da66c7060c" xlink:to="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_d6642473-e082-4db8-90c3-6d5864418587" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_d6642473-e082-4db8-90c3-6d5864418587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_fd6f14b0-9f47-481a-bf10-32aa04fa2608" xlink:href="dva-20221231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f8a7ec42-f00a-4cd7-8269-3eb7ba0dc64e" xlink:to="loc_dva_ForeignDialysisCentersMember_fd6f14b0-9f47-481a-bf10-32aa04fa2608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cdb777e-47c4-415c-bf1f-3ac165368882" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8560a371-e780-444a-9a67-8621aac2fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8560a371-e780-444a-9a67-8621aac2fb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_39c4cf27-ac23-4e95-95ba-e1be7ef28776" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_39c4cf27-ac23-4e95-95ba-e1be7ef28776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_568fbac5-a2f1-467d-86ac-af14e9218369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_568fbac5-a2f1-467d-86ac-af14e9218369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_0a5d818f-6085-4145-90e6-e12987fd5dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_0a5d818f-6085-4145-90e6-e12987fd5dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_114a2f42-90fd-484d-ac0b-3d13aaee0af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_114a2f42-90fd-484d-ac0b-3d13aaee0af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_fae44895-2d64-48e0-bcc3-a655348a2f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9074e4d6-3968-4cd8-8435-509e7e2391da" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_fae44895-2d64-48e0-bcc3-a655348a2f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_dd897c49-fb11-42f6-9011-5d8d0708bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_dd897c49-fb11-42f6-9011-5d8d0708bb09" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16022571-9339-4257-9c57-5a7a72bb0825" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_4ae61442-ddd2-4a2e-9f0b-b07be145ab19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b7ff9e5-fa2c-4806-88f1-740474d4b817" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_4ae61442-ddd2-4a2e-9f0b-b07be145ab19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0c0d5d7-f3a5-4b62-a89b-6980037e1cda" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_afa93597-6308-42b9-9da3-81356dc4593b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_afa93597-6308-42b9-9da3-81356dc4593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a4acf6ad-d79c-4f6b-b5d6-e76bfda8c6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a4acf6ad-d79c-4f6b-b5d6-e76bfda8c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6434c07c-1cc8-4796-b6d4-f1ca4540783b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6434c07c-1cc8-4796-b6d4-f1ca4540783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_471132c5-b5ce-47b4-adf7-953490892bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_471132c5-b5ce-47b4-adf7-953490892bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ad09865c-d859-40bc-b7b4-c9e59e096d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ad09865c-d859-40bc-b7b4-c9e59e096d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_56689d81-1a7d-43bb-98ce-b7a76c2db7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_Goodwill_56689d81-1a7d-43bb-98ce-b7a76c2db7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6b6f3ae5-1b51-461f-8052-174882b2d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6b6f3ae5-1b51-461f-8052-174882b2d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_52057523-435b-45c6-8583-b05c3e730191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_52057523-435b-45c6-8583-b05c3e730191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_cfd13f3c-4031-4e79-bfa1-aa88db8ae987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_cfd13f3c-4031-4e79-bfa1-aa88db8ae987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06120274-443f-429c-b960-575ca6f36f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061a9e61-1b5a-44a0-9671-1e9bbadb96a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06120274-443f-429c-b960-575ca6f36f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6f208a20-d6cf-4494-8f6c-27d5dc7303c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6f208a20-d6cf-4494-8f6c-27d5dc7303c0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23f183e4-c837-4f87-9fc3-504c52c03660" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_8c3cb279-10ae-4214-8cf1-4ca8e8a10812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_8c3cb279-10ae-4214-8cf1-4ca8e8a10812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2dec262e-61a6-4546-ac4a-39c97e50306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_062734d4-0e18-494c-84d9-b7d5271b059d" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2dec262e-61a6-4546-ac4a-39c97e50306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c59eebba-1dcd-4752-ad85-d571e6e83a42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_13a9578f-3ccd-4c18-b149-8a43903405c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9032742d-7f23-4761-8115-ffe3cb5a995a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_13a9578f-3ccd-4c18-b149-8a43903405c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5f3de38-6037-4233-bf38-35b3c6734d0f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5422e4f0-4b3b-4b40-82c4-e0525d15277f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5422e4f0-4b3b-4b40-82c4-e0525d15277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_75ee3aff-df04-4a13-96c9-9d61bcd142d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a9c82a18-d7cb-4a91-bf41-9fd55271d486" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_75ee3aff-df04-4a13-96c9-9d61bcd142d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2bbb3e81-d4e9-44bf-ac0e-7a59b1eed19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_df6ff999-fe2a-44e2-add0-35be630a59b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2bbb3e81-d4e9-44bf-ac0e-7a59b1eed19b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_df6ff999-fe2a-44e2-add0-35be630a59b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5e06c7a0-0758-408f-bd9b-05708c10f808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2bbb3e81-d4e9-44bf-ac0e-7a59b1eed19b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5e06c7a0-0758-408f-bd9b-05708c10f808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_637ec36a-186c-40ce-ba85-177183517ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2bbb3e81-d4e9-44bf-ac0e-7a59b1eed19b" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_637ec36a-186c-40ce-ba85-177183517ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_c4ad3e62-a4fb-4fcb-b296-aa230826a721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2bbb3e81-d4e9-44bf-ac0e-7a59b1eed19b" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_c4ad3e62-a4fb-4fcb-b296-aa230826a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a0266a36-1ff4-4733-b256-cdb674694082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a0266a36-1ff4-4733-b256-cdb674694082" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53b2803a-efb0-488e-8582-1a46f1f6331d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ac4d1cf6-64bc-408e-95d2-334361c674a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_216d38de-f8a1-497e-8f13-52914e0861cd" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ac4d1cf6-64bc-408e-95d2-334361c674a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95a83558-3709-4db6-95f5-38cc38573433" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3400f838-5ca8-4e32-bcf0-4c67102afdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3400f838-5ca8-4e32-bcf0-4c67102afdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_25eaefdf-a3c4-4b89-9c4b-77a09f088cff" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_25eaefdf-a3c4-4b89-9c4b-77a09f088cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_8433f0cb-ec04-4ed8-8a03-ae74a2f4c07a" xlink:href="dva-20221231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_8433f0cb-ec04-4ed8-8a03-ae74a2f4c07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_80857316-0067-4297-a243-b4d4b2d55aa9" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_80857316-0067-4297-a243-b4d4b2d55aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_485cf194-c7dc-4f8f-bcd4-ae8624e99e91" xlink:href="dva-20221231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_485cf194-c7dc-4f8f-bcd4-ae8624e99e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_17adafc1-bb69-439d-87e7-5f7d525aec41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82dd125d-79e7-46be-af0a-ab2616b70a9c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_17adafc1-bb69-439d-87e7-5f7d525aec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2c5bed91-907d-4c0a-b577-a4d923e0fd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2c5bed91-907d-4c0a-b577-a4d923e0fd17" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a132ea52-4c64-4f7c-8b25-ce3d0cac9ef3" xlink:to="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c64260c3-0bb5-48a8-a373-7323b96a36ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:to="loc_srt_MinimumMember_c64260c3-0bb5-48a8-a373-7323b96a36ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05b16924-b0d0-456b-87ce-db9246ee192f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e3c9a82-f965-4d3b-8e92-07d5a81db967" xlink:to="loc_srt_MaximumMember_05b16924-b0d0-456b-87ce-db9246ee192f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_246b7972-a305-4789-87d2-c976b2ad31ab" xlink:to="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_0c8a6041-4696-42e3-a6da-7958280fa34b" xlink:href="dva-20221231.xsd#dva_OtherCompaniesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_82f52ed4-4eb0-4bfe-bc04-c299f5ff3f29" xlink:to="loc_dva_OtherCompaniesMember_0c8a6041-4696-42e3-a6da-7958280fa34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_434cfb3f-fb88-474a-adbe-9a9618e809c9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_c8ddd8cd-1f06-4a8c-ad97-7beca937a0c5" xlink:href="dva-20221231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d128ff26-92ea-44e5-a430-ec8addeafe51" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_c8ddd8cd-1f06-4a8c-ad97-7beca937a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8609bced-36ef-4965-a0c8-e716a7942797" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_551e1199-0661-4c4b-a8f4-f8435b6b19d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_551e1199-0661-4c4b-a8f4-f8435b6b19d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9ffaae0a-abe6-4a2f-af02-add61dc9575a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d062190c-0733-465b-a25e-556575bcf5d9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9ffaae0a-abe6-4a2f-af02-add61dc9575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ea8bcb-26d0-4180-98b4-b051716515d4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RMSLifelineMember_92232b96-36eb-4340-8d5f-1252d4dfd104" xlink:href="dva-20221231.xsd#dva_RMSLifelineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fdbc3fd0-68d0-4989-a0d7-325959dd56ea" xlink:to="loc_dva_RMSLifelineMember_92232b96-36eb-4340-8d5f-1252d4dfd104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e300f27-1d00-406c-bf51-6aa3f3111c47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_298c2bfb-96e4-47d9-8055-ee45cc1af227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3462bdc5-23bc-45e7-a81a-eab2cce1a052" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_298c2bfb-96e4-47d9-8055-ee45cc1af227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fc23804-e003-4c0b-ac50-c7aacaccc44f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_dcee286b-f0c2-4355-9745-4b08fb62bc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_dcee286b-f0c2-4355-9745-4b08fb62bc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6200ff90-cdac-4252-bb91-7c10e78c52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6200ff90-cdac-4252-bb91-7c10e78c52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_465f325c-284c-4100-865f-d747ca0f13a9" xlink:href="dva-20221231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_465f325c-284c-4100-865f-d747ca0f13a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_aca40e09-0a0b-40d9-9604-6df753423e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e9d77726-c7ef-4a76-809a-fef877874912" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_aca40e09-0a0b-40d9-9604-6df753423e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_93e6fa33-4c94-4b87-88c4-2a056e6550dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_93e6fa33-4c94-4b87-88c4-2a056e6550dd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_223e0470-6f14-4c1a-8415-9714d2fd5050" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4dad94ac-abee-4b46-8540-c459679b1b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a49cae15-913e-4fa9-bef2-02c82ad9b64a" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4dad94ac-abee-4b46-8540-c459679b1b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_242bf02a-681c-45aa-862a-507d638cc267" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_c7cbf091-6bda-4af2-93c3-193ab58bf93c" xlink:href="dva-20221231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4dbc0b9f-b679-4704-b6ae-9af72e76ec4b" xlink:to="loc_dva_DaVitaMedicalGroupMember_c7cbf091-6bda-4af2-93c3-193ab58bf93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_56e5c7f2-a5a0-4592-91bf-4a0237547785" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_73c3bf6d-3746-4da9-be52-993ddab3a76e" xlink:href="dva-20221231.xsd#dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_08914ee3-ca1d-4a7b-bb2f-0e9db6957c5e" xlink:to="loc_dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember_73c3bf6d-3746-4da9-be52-993ddab3a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_37ce3daa-fa31-4969-a2e2-1803bad9d426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_380a0e2b-44ea-48d5-be29-8da2b4615787" xlink:href="dva-20221231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_380a0e2b-44ea-48d5-be29-8da2b4615787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b0682237-4487-4fe3-9be5-c5e22a054282" xlink:href="dva-20221231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b0682237-4487-4fe3-9be5-c5e22a054282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_2772f29c-10ab-4ccd-830f-f732b9ae8d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_2772f29c-10ab-4ccd-830f-f732b9ae8d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_a8d45f7b-5fe3-4b94-9f9f-204b95f95e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_a8d45f7b-5fe3-4b94-9f9f-204b95f95e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60fbdb5b-07c4-4f56-951d-81fc5d0ea7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60fbdb5b-07c4-4f56-951d-81fc5d0ea7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_1aba9023-696c-4149-8496-6392418ce6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_1aba9023-696c-4149-8496-6392418ce6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_b96e2be3-1279-4ac7-bb54-8d97e10a44fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_42af0434-6745-4537-a633-cf9d1a434b74" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_b96e2be3-1279-4ac7-bb54-8d97e10a44fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b436fe99-0cd2-44c6-826e-bd5c46b02bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b436fe99-0cd2-44c6-826e-bd5c46b02bc0" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c27811b7-57b9-4d23-a9cd-201c7272dab9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_2a119f9a-c8c5-4587-bfa0-8d92daeb0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c306dff4-e605-4702-a564-cbb337cf3ba7" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_2a119f9a-c8c5-4587-bfa0-8d92daeb0d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4bfffe7f-19fe-4ce4-8272-3040e3d6e619" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_b03a4cc6-f126-4a1f-8428-d15397efac5b" xlink:href="dva-20221231.xsd#dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities_b03a4cc6-f126-4a1f-8428-d15397efac5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9d6d3bd3-ccd2-470a-8d8b-97c84f422dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_us-gaap_Assets_9d6d3bd3-ccd2-470a-8d8b-97c84f422dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_321dd4f9-d07b-4079-8e89-46af0937d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bcb80b05-5b20-4d17-b9ea-691fa368ef06" xlink:to="loc_us-gaap_Liabilities_321dd4f9-d07b-4079-8e89-46af0937d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33ac56c7-1855-44de-847e-e31740d802d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33ac56c7-1855-44de-847e-e31740d802d5" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80eb1df8-132d-49b9-93e4-d70356e9ef96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3234f1dc-8862-4496-b8cd-d464f0811ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b26445d-c4e7-4797-b197-5ab52ba19616" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3234f1dc-8862-4496-b8cd-d464f0811ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f50fd211-66f5-4957-a693-ad97f713694d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f8324fb-39b0-4e62-bb2c-26df5c25bf11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f8324fb-39b0-4e62-bb2c-26df5c25bf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5b105ff-b877-4ae7-bedf-857173c4a299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5b105ff-b877-4ae7-bedf-857173c4a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9688ad8b-9241-448a-9647-1c482bebf327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70055e1d-eed5-4c69-802e-5390dbb95cb8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9688ad8b-9241-448a-9647-1c482bebf327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c96106d9-65d6-44fa-94f2-36ae0fbf3932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2744ae84-2bdc-4263-aa60-33baa35408a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b9cfcec5-efe7-47b8-bfe8-b3df4c3ab0b5" xlink:to="loc_us-gaap_InterestRateCapMember_2744ae84-2bdc-4263-aa60-33baa35408a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e67615f3-0322-4162-ae79-17ac6f172bd9" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6751d098-339c-4b46-b438-a7562b8c8fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6751d098-339c-4b46-b438-a7562b8c8fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c1c914f7-ffe9-4b1a-b375-6ec3ce59c58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_151d44c4-1e3e-4bb7-a532-68b3a3c190f5" xlink:to="loc_us-gaap_DerivativeAssets_c1c914f7-ffe9-4b1a-b375-6ec3ce59c58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72bb5760-6278-4019-ac48-778e6f0b803c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_51bf385a-d0dc-4794-b314-1241fc36fb69" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72bb5760-6278-4019-ac48-778e6f0b803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8f4e5185-d6ba-476d-bc4b-1b9b5edd69f4" xlink:to="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_80af693f-4d0c-4b22-872a-c450c1d82edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_c175be01-c7f1-4e56-a089-b599cd2c7f57" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_80af693f-4d0c-4b22-872a-c450c1d82edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#FairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c7a4306b-a326-46a5-853a-ac29b35ed92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_072c1264-29f8-4835-8a60-795abceb3d21" xlink:href="dva-20221231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7a4306b-a326-46a5-853a-ac29b35ed92d" xlink:to="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_072c1264-29f8-4835-8a60-795abceb3d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_394590b6-9990-4c7b-a166-ea20a7d50e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_394590b6-9990-4c7b-a166-ea20a7d50e1f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2fc40d1a-d196-4d12-afae-3bf193945359" xlink:to="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1a963f0c-c561-436d-9b87-c7f964d48d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:to="loc_us-gaap_OperatingSegmentsMember_1a963f0c-c561-436d-9b87-c7f964d48d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_e2b07fdf-e1d3-47c7-9bae-56b574dc25cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2351d6d7-efbf-44ca-b486-8bf51e0b8dc8" xlink:to="loc_us-gaap_IntersegmentEliminationMember_e2b07fdf-e1d3-47c7-9bae-56b574dc25cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cfc1266f-16c8-4272-84a4-4dce42576e17" xlink:to="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_a8615d76-c620-467a-8017-d1dde022ad78" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_a8615d76-c620-467a-8017-d1dde022ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f542a3c3-b0ea-45ab-8140-2e8fd5b4bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7a42e347-a7a9-4fe1-b2ed-18c9afd1b6f5" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f542a3c3-b0ea-45ab-8140-2e8fd5b4bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_7d5a7cbb-dc36-4734-9525-ff52e59d8484" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_953ca928-8146-4e04-b448-8b4ae5f3bf91" xlink:href="dva-20221231.xsd#dva_ExternalSourcesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:to="loc_dva_ExternalSourcesMember_953ca928-8146-4e04-b448-8b4ae5f3bf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_40e0f282-4608-4b42-8059-37a96ef3adb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_acaecd57-49c2-43f8-b0d6-efeba5ab5688" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_40e0f282-4608-4b42-8059-37a96ef3adb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be867824-ba6d-4436-9cfd-1d18de028e3e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e544154f-1e0f-4584-91bd-135050e42e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e544154f-1e0f-4584-91bd-135050e42e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_88594a4a-446f-43e5-8bd9-dee506ae2c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OtherIncome_88594a4a-446f-43e5-8bd9-dee506ae2c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_15179d64-e9e5-4f1a-9dcb-fa3f80574c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_Revenues_15179d64-e9e5-4f1a-9dcb-fa3f80574c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f681f98d-d2c8-4e10-afac-53755729094e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OperatingIncomeLoss_f681f98d-d2c8-4e10-afac-53755729094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_55ee14ec-47c2-4a76-9c21-6aff6738a6c3" xlink:href="dva-20221231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_55ee14ec-47c2-4a76-9c21-6aff6738a6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_a5bde548-bae1-48da-9766-b2035b8908e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_InterestAndDebtExpense_a5bde548-bae1-48da-9766-b2035b8908e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_bdb55280-3a70-4a52-bea8-f6d7d6ac28fb" xlink:href="dva-20221231.xsd#dva_DebtPrepaymentRefinancingRedemptionCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_dva_DebtPrepaymentRefinancingRedemptionCharges_bdb55280-3a70-4a52-bea8-f6d7d6ac28fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67d7fe77-6285-41bb-b5b2-d2a0f0391b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67d7fe77-6285-41bb-b5b2-d2a0f0391b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bf5eec3d-39c8-4e75-a6b7-5acc19732f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bf5eec3d-39c8-4e75-a6b7-5acc19732f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01df59ca-f07e-42c5-9a8b-81688aee723d" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4330d0c-98a1-4e44-ac80-00bd5d5cdb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_aa46e841-935c-4466-83d6-192279f4a075" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4330d0c-98a1-4e44-ac80-00bd5d5cdb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ca31de11-aaf4-4888-8320-0e74dda13b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ca31de11-aaf4-4888-8320-0e74dda13b81" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ad452170-5dcd-4b18-b384-6a8f737367e5" xlink:to="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_7c9b7541-89cd-4c2f-9818-8c60a110cf83" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_7c9b7541-89cd-4c2f-9818-8c60a110cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_9b8da94c-bd88-4a1a-99d4-ab5d18039a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0274c4a5-a832-4d69-97d7-6daf6943db73" xlink:to="loc_us-gaap_AllOtherSegmentsMember_9b8da94c-bd88-4a1a-99d4-ab5d18039a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_65fe4791-4c39-44d2-9385-b5ad8303fc0a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d655b20-8090-414d-9ab8-7e8e86ba2f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b558a81-1f05-4557-9081-78e1e4bd1173" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d655b20-8090-414d-9ab8-7e8e86ba2f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d518ebe4-3d20-4b6a-9902-2dcede27c622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d518ebe4-3d20-4b6a-9902-2dcede27c622" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95553737-e247-4b97-bfcd-f8d634179c27" xlink:to="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_6b952ac5-8c79-4c75-8f6e-e9a42f83a396" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_6b952ac5-8c79-4c75-8f6e-e9a42f83a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_9795a8bf-c04f-42df-b215-a473328ee876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7635b124-3617-4b6c-bd5e-736fb0aa1b1f" xlink:to="loc_us-gaap_AllOtherSegmentsMember_9795a8bf-c04f-42df-b215-a473328ee876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_770bc424-8b94-4d67-ba5e-27db658a745a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3681e82-4527-4460-b13d-751742cf6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7bc30e42-dbd4-45ef-beb3-172ea1354006" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3681e82-4527-4460-b13d-751742cf6cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_83cdd0d3-5a1d-437b-9479-35bc0832d89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_83cdd0d3-5a1d-437b-9479-35bc0832d89a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_585c33a1-4c7d-4506-93fa-1d0e71304142" xlink:to="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_ac1620e1-49b6-4c64-b7db-691187d339cd" xlink:href="dva-20221231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_ac1620e1-49b6-4c64-b7db-691187d339cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_817e01dc-16e8-4e7e-87c7-644254c0c152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0bbfbc9c-9602-47e3-9014-b0ccdea79526" xlink:to="loc_us-gaap_AllOtherSegmentsMember_817e01dc-16e8-4e7e-87c7-644254c0c152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:to="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_778561cd-906e-4b91-a9b8-e900e8f571b5" xlink:to="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1212f353-2fdb-427b-a60a-daffbecff6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a984769a-2723-4b41-8354-a21d8346d48a" xlink:to="loc_us-gaap_NonUsMember_1212f353-2fdb-427b-a60a-daffbecff6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e974784d-1132-40c5-8abf-4fd8cf504c66" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_01aeb57e-06e1-47b5-9de0-814b661df647" xlink:to="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7519540f-86af-498f-b983-3306e09664ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_Assets_7519540f-86af-498f-b983-3306e09664ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_38a22adf-1e7a-4ac9-9a67-1e48139d5b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_38a22adf-1e7a-4ac9-9a67-1e48139d5b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_03e57a01-a7af-4d8d-976e-a683d156d368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_387d9352-d8dc-482f-a963-cd2e5702537d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_03e57a01-a7af-4d8d-976e-a683d156d368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_32847de3-15ee-415b-b762-bb6af665ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_32847de3-15ee-415b-b762-bb6af665ddd1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8ab31337-fb38-4a3f-9b1a-d4a99e751f94" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_9a7c37e7-aed0-42c8-87f9-3d58b580223d" xlink:href="dva-20221231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c80bcf29-98e1-4aa6-920a-1d8835882008" xlink:to="loc_dva_DaVitaMedicalGroupMember_9a7c37e7-aed0-42c8-87f9-3d58b580223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_361029b5-4e88-438a-8dad-3f32c9f7ee82" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_89a773c5-86fe-4847-a28f-960421f4a2d0" xlink:href="dva-20221231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_898ad8be-f5a3-4cb9-a3f4-56c8e5b7f35b" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_89a773c5-86fe-4847-a28f-960421f4a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a893fc45-3e15-4a5b-81c4-c2d56edda820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract_cd3ff026-a6f3-4af2-94d6-441c28fe6bfa" xlink:href="dva-20221231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a893fc45-3e15-4a5b-81c4-c2d56edda820" xlink:to="loc_dva_CashPaidDuringPeriodForAbstract_cd3ff026-a6f3-4af2-94d6-441c28fe6bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_bfdf7312-d841-4110-b798-4c0a63c5e92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_cd3ff026-a6f3-4af2-94d6-441c28fe6bfa" xlink:to="loc_us-gaap_IncomeTaxesPaid_bfdf7312-d841-4110-b798-4c0a63c5e92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d9c20a3a-e94f-40d3-8e84-8ac1a1d8a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_cd3ff026-a6f3-4af2-94d6-441c28fe6bfa" xlink:to="loc_us-gaap_InterestPaidNet_d9c20a3a-e94f-40d3-8e84-8ac1a1d8a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47928658-7a21-4fb3-a760-458266739abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a893fc45-3e15-4a5b-81c4-c2d56edda820" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47928658-7a21-4fb3-a760-458266739abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_617b9cb6-33c5-4fd4-a403-b8453ff084a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47928658-7a21-4fb3-a760-458266739abb" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_617b9cb6-33c5-4fd4-a403-b8453ff084a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="dva-20221231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_81b67561-377d-4277-a159-313b2ceb4739" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_81b67561-377d-4277-a159-313b2ceb4739" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_550c33eb-bda5-4359-a51d-6a4953019e76" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_121cf4d0-a7ec-4b34-bf9a-4a7ba4f1d577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1222a036-1741-47be-9f06-809115e344bf" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_121cf4d0-a7ec-4b34-bf9a-4a7ba4f1d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7e5da8d1-4819-4e01-9556-38a9c37cf9f7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_495af9eb-1bef-4b2f-970a-0544986cca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_495af9eb-1bef-4b2f-970a-0544986cca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_23ce704c-2ec8-4835-a60a-a38812e1540a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_23ce704c-2ec8-4835-a60a-a38812e1540a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_75396cd7-56c6-424f-bc76-c85a164ba4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_75396cd7-56c6-424f-bc76-c85a164ba4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_83ced488-e37d-499b-81d6-b7388e294223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_83ced488-e37d-499b-81d6-b7388e294223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_803862ca-62c0-4ecc-bc0f-80e753fa63d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_595bd7f5-d556-4c5d-aed1-3751271cf26c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_803862ca-62c0-4ecc-bc0f-80e753fa63d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dva-20221231_g1.gif
<TEXT>
begin 644 dva-20221231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MVCG$_QL"?PX6(?:)C28HJQRX@8\'AK]9=96'G Z; V^@"0O,9BF!>-'0;S\
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MD1Y'VIR95NU:MFW=OH4;5^Y<NG7MWL6;5V];L_MPDHRV# [&B1<A_"AH8:%
M@3C@A-K7%^W'O94MPYP\,EJT'Q,K2*08D: %AP]TC$Z<&O7J@:(=BK80NS7B
M-\M0]KV<6W=E:#E7ZILGKV?3IDJI+CV.U>A4K5>A*F?_'BQKU'7DMBJ5NBZ8
M,'TU3^K#O5O\>/+ES9]'GU[]>I+T*$?>%RK-1HP0"JL6C?%'FO#L_:?MCZ7
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MBM,I6!97G=3#5'$MY<9RTE$S(JG@;Z4[725Q)@>>44V!<# &4.POL;>A;EI
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MA'01GQ@&@OV/92"<#)J.[<@'M7S:K.7;OBW8$"R0L+68GBRJK@.LAW+4=TN
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M)G 1FLB&EH*6X_^6YG_V;-U9K9?$;)C>'L#I!BCBI(WI36EQR \<0 2:BC+
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M[,"$,%.KP?\VK_,R^L++1IW.*3TQ!5.\DT5T1,OT%4CD'<*6%61JV/=FU;@
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M:[--(]V3[+)9'1,2R(IRR"35P9*D<+:;HH'#("!Z*C'26V5UDTT"320//<>
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M8.F".!'63Z+2JHMPZ@%3C :-S(C!J[S,8$"B7<$BHQ[%^"0CF%J*1)@%2:4
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MTI"([C%2U$"%G[',=B8EQHE@P *'_CW%;U-SWJ6LR<7_$"D'IYTJ="?4))5
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M+@B%#G1<;(OD8@D+H[.V[]QJ1VLBI2!8%3S/)A163'M@;BX!DS6?4BZU%&3
M\O^B8=(: L#4(RM]9"4S+3]=\V"HT*+_0";U.%0CP^.W&I!%SW5VAJRTD(E
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M6PFIC\B$N6,QUK SI9LV?B$VH7&3_H*RZ+L4=+,(H&.,'X@LK$ T!CR>4%-
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M/YD<.-&L0..9)&0!"1E;SJV:.NYZ5.+<JI+$4]>#@RP\EE1+.J)CS+1*F)E
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M5%NO)8\+]K02WE0PJAWAX+2_^\"T'CUFO7FCT#%_[5QK."T$ 5O[;>@D#FJ
M\MB@9H*GMHTS$AV><%CW6JG47+=*H]>9<?E0#M6>U&%L/P0-D05 ;(QIU5_:
ME,/!H>-<*&DP.GXR5?42O9<R<IMWBELJXV1DW\&._S<VB^NAQ".O!:'>4U3-
M%<TU1<!!I":6%; EHHC\FL6B)@@-'_Y.%CV +&W&MYC40/?E/2'$-+X/ZT9;
M@8Z^\>WAN!NTX;N6544$"8IW+HI&&O:VH2Y!3'I=4^#?%(@E"VA)-T H" X$
MH[CCF<0]#%E4G_J6)/Q$Q =B$MN@8 (9S8E/?YM"DT-T(Z>3E(T],NG?7L(G
MHQ;J#73(:U&Z;/,]RS%0@;5C&*-TX  !5L<Q,B'6XV1&(?A)Y $CR:#]DLB>
MDH1L-HRA75VDMJ$.;JE$NA$-#K$G'1&]01.G(*&'S!(:+PW1=IFS%!*K6)R?
M-=$W:W/@'F=6 179$6LOTO\-!#?')14^D8E^(E]#*B"&:/2P*Z%B3Y"<=Y&/
M%*1&SGHB!_5TM-S * V-*<H.C4(KF*5PDYN"SUY>-[=/J6$SEMJDWTRV0)S8
MY <(2$J'3N*RR/PDD1ZI)2HS0Y.X21)K/[Q<'BT41-5%#I<5<$ OQ^0[:"9P
MCGJ$WTX*4BZZ!1)$7\D64_('00-&4YBJ[&35($80O\"A7U<LCMPV0:3]30N1
M4U,D^:X&SG":1WT%BR J,:,Y34HD.SD0"D#'M$/0O PBJI'F=KR#2LH,E&&L
M1*-+(@D[7CK@GG6)"*-,=YDF4DTB0,A-;O;UE3H&%"MZ6AWYX,4P)+'M@Z91
MS0__1H@ST+RI@\$Z59(:^"V<\@0K#]#A9V+9&I H"G)$I%1-A79)^?A49&3Q
MH5(SI1H;G92?8NU+-5ODLFQ^AY\-/&1IBFF1XC6T/',*F6V<*A<F":U;:5N=
M-,.:3]R$4H!+*64 J8B<T+"):Y@C*L#ZFCMG920'YHOKAV!D41(IUFO>X2:7
M^!.>"GR3LA@T26!4*E.PYE..[)R:6A R1=D8EEDW8\K%Z"69(JINFU+M(]?Z
M0A!<S7,E,+VB"8.;2>VX59-3S0OY7"DJ:RE,:'P\J%Z+REM%3<1S/SB.SG!$
M.X+.A9WKU*QN'#!9DA!'F52%+-B*!!S,Y>"U@RI33H5J_\-Q_0VNHO50Q9(2
MBO=L;311">)Z&^O,Y6CL)D$3B"O+:D67G V;<1QF:JGJX/T:)QHXZ!\0320^
M87X.PV,RRS(N=3TG9FYCIM%3P<BWW1[]"+:4W M>_7A+2Z68PC9J:6!">SXV
M@@@F2S2-L?B*XO#H(#P]15\LZ;,H0PX10VWI4%G.BK%G&E2\\P%)#I!9D@LK
MJW)=#=BS$E@?@PRW,RXKHT%5FV/52L5F(CX*PMI#N\T0"RB.LR4<K4J0>*)D
M*>E522D#;6BF!"E:RHT63GSDT3FS1$3@VF=*9Z:GB>H(TN>A*TG@ *-4M0]L
M5+/>;3N2U944NB21VHKJ*MUAF7;!2$0^/HD_6>0C$3'$LZY1KI8K#!3G*BLI
M)JS3+%.HTTTJLC4. +183/(]'0#!+6X^TH4B"LA#L^C10:+T=3G8:^0B%U)I
M-LHR %1L6L9LFU?AU+@AS6D@O>=0'HP>:B)H$,+(=D6I+DD<1 K$6C9S9KKV
M7* T_TU*ICA +C31Z;'#2N8GTL_@U4'>B_2*VAM3FH/?&ESV +GO'RNE-H6*
M47U9<TDG[W;,C#K(0.1)$DXG4Q^U&:R,/7.;#597FT3=:[#L19-3+RM;=[9I
MNM695'C-Z%03*0C0RZG4A.;XR!<!97Q_O%6M_A!@XW4XHS4N.99):HL7]W#1
M6=N1@LD7R!)?#R]Q9 &WP>?<-+7=T:=ND!_,NN8PU/O$9TQOAYDY*8^6.)5P
MC=DR%WV!XR-/NR6>E)"!(M0/U_J%<#R9*"J[W?KP4338 I^]"K%-TOS)I\\9
M[2[7+Y#NHF[H44Y2K'C6U(VW^3\];1&6OD_%>XQ+=J27%O_15)TD_;VSI0&^
M-N?-98P_4+O("C6:-J>2\J@)3ZW3-^8R"V_=)%KJ[,.)L',!U3(-UWZ.U430
MYBG_ <"VW_?R5GQ%1]7;. $SX7NTX0B.UU*LXMAF&%I_*SI5>+#2M/7&U[Q7
M@(!(G209GD#/J]24N(!)]6Q&#EP-_5U+UV"<3E7:)4E'TUT+*#P0]FR0M+!>
MD8 )!%+$F9"& Z0>26R;:0#/ERC:1EV;5JG+][P,_R4=1>T&?]Q+05A@0)6)
MZ#W,HJT&C+3@_^U=E9C0 !*3\^3?#K965&27;KB.\(T-YWF:5W$=U3AAMSS
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M] 23[%')M6PA!/'E\UUH('Y5"RU529BH*_I<]*D@5V@+^B2:9.Y9B119=N"
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M6*UZL$VYJ@*]!?5(Q@]@*E6^B(E6ZQGRW$0]0+L*)_CMPR;D(P._V10;,6H
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M.?GF&TSTC%5Z=Y*N2F7XH):<8[-]2,.BM"AK+"<M'66*5EC(4L0\"ZG-MF8
M[W-E+?+P2(FA*[<FLAQ2<I>']PI3.9>Q]O1JA[XN;F]5\.Q2D]\.8=NPF=G_
M#=.S# Y/SI-HBU-*F(JFZ^UI7Q:E^,FMASDJAM-LW$$"SPRJAS-:!@?^8JOZ
M#$YE]^NV*NV9-3"%L*WW.;=7-YO/G)@AL5/#@RA):T=NK'=Y%"1\SHC[=-M1
M+CB+SE9<192X;RI<T/=O "<':Y4WAV*4EO0R\O#Z9B+ F3C0O-40HT]_/VM8
M&E \IK9.W;*+E77" &ZN[\W2?N^_%?8(-3FC3WP;87IDWF*XAQ6%Q%KHLO=
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M5X>VJ60>  $HTMMG512/JC0MQ<3\#3G_)P3KF$>E]J%[6+L[F7;J,.KV'B"
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M&&!"N<[N>"%!ED7Q!QB P2Y8-BVHFLS]F%0(@5E4"DDAL<3#83O_L6:PD*5
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*!]G,9Q9R0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>dva-20221231_g2.jpg
<TEXT>
begin 644 dva-20221231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO)/VV/@)\4/VG_@5<_
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MO7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\,_XB5QM_P!!7_DE/_Y _5K_ (B<_P#JR/\ \R5_][:/^(G/_JR/_P R5_\
M>VOREHH_XAUP;_T"_P#D]3_Y,/\ B)7&W_05_P"24_\ Y _5K_B)S_ZLC_\
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ME+_Q$Y_]61_^9*_^]M'_ !$Y_P#5D?\ YDK_ .]M?1_\0ZXR_P"@7_R>G_\
M)GS/_$2N"?\ H*_\DJ?_ "!^K5%?E+_Q$Y_]61_^9*_^]M'_ !$Y_P#5D?\
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M$_$?C#3_  _<3Z=9:O=74TRQ*YC62:$913<+'Y8\P$D!7*^8>#M6_P""A_\
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M1_\ P3P^-_[(_P"VS^Q9\)-7^+^E?L^_#5?AO\1O!.A!%U?4]%:!XSJ-G"S
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MS^&M.U+X??$#1/ASJ&ISZ??SQR+>6J_V?$^H6%PNVW<2+&J_.Z2,NP*W3_\
M!$+]G']HG]E3]@S3?@S^T1K&N3-8>*-6?P-IOBF\2?5-)\,M<G^S;2\9&91,
ML(WF-6(B$JQ?+Y>U?KNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\)O\ @X$_Y2'7W_8HZ7_Z"]?NS7X3?\' G_*0Z^_[%'2__07K
M]*\*O^2G?_7N7YQ/S#Q;_P"257_7R/Y2/B2BBBOZ./YF"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OPF_X.!/\ E(=??]BCI?\ Z"]?NS7X
M3?\ !P)_RD.OO^Q1TO\ ]!>OTKPJ_P"2G?\ U[E^<3\P\6_^257_ %\C^4CX
MDHHHK^CC^9@HHHH **** "BBB@#^H;]G_P#Y(/X)_P"Q1TW_ -)8ZZZN1_9_
M_P"2#^"?^Q1TW_TECKKJ_B[%?[S/U?YG]P83_=*?^%?D%%%%8'0%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7X3?\' G_*0Z^_[%'2__07K]V:_";_@X$_Y2'7W_8HZ7_Z"]?I7A5_R4[_Z
M]R_.)^8>+?\ R2J_Z^1_*1\24445_1Q_,P4444 %%%% !1110!_4-^S_ /\
M)!_!/_8HZ;_Z2QUUU<C^S_\ \D'\$_\ 8HZ;_P"DL===7\78K_>9^K_,_N#"
M?[I3_P *_(****P.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&)KN&W_LRUAVS+<6R!MT,2L?ED<8)QSTX%?8-?G]_P $IO\ DX?6?^Q+N/\
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M5_F?W!A/]TI_X5^04445@= 4444 %%%% !1110 4444 %%%% !1110 4444
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MX,_9P\-ZK)IUQ8-:V$XCOKZRL]MWJ\\C!YKB:XWV4(B=C%%Y,DE>D?#K3/\
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M067[/?P#TS0+SPIIWP/\(6^EZA(DE_IL'AJU2WN73.QI(Q'M<KDX)!QDXZT
M?GE^PUX9_;3_ ."=?_!37PG_ ,$Z[[]JS4OC[\#_ !O\-M4\1>%]0\5[+GQ!
MX#M[1HEB%Q=IDRVDS-%!&S81V(\M(O*8/^GE<G\*_@)\"_@7;7MG\$?@OX3\
M'0ZC,)=0B\*^'+73UNI!G#R"W1 [#)Y;)Y-=90 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7X3?\ !P)_RD.OO^Q1TO\
M]!>OW9K\)O\ @X$_Y2'7W_8HZ7_Z"]?I7A5_R4[_ .O<OSB?F'BW_P DJO\
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M^,D'PIO_ !-:Z[Y-[;>7-!8/JEOIZ6WD_P!G0W4T4"IYXD:-7E51M6)_O>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_";_@X
M$_Y2'7W_ &*.E_\ H+U^[-?A-_P<"?\ *0Z^_P"Q1TO_ -!>OTKPJ_Y*=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0/ _Q+O] NK?2/$&GV[:OI^EZ@498+H17$<1F0-L<QNO'*Y<#+> >%/V6O\
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M ->Y?G$_,/%O_DE5_P!?(_E(^)****_HX_F8**** "BBB@ HHHH _J&_9_\
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M)77@Z4*M;EFKHY,;5G1H<T'9FC_PO_\ ZE+_ ,G_ /[71_PO_P#ZE+_R?_\
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M?+R;6M;T^XT'X3>(=:TVZT+Q!=Z=*EW:Z9<30EVM98S+'O4%HI-T;X&Y3@8
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M&?V/F_\ T#U/_ )?Y'C%%>S_ /#O?]K[_HD7_E?T_P#^2*/^'>_[7W_1(O\
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M %%%% !1110 5^$W_!P)_P I#K[_ +%'2_\ T%Z_=FOR<_X+!_\ !-#]MO\
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MH_X5+\0?^A?_ /)N+_XNCZI@?^?GXH/KF8?\^_P9Z-_PMKX??]#!_P"2DO\
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MLEC9_/1<,'<XPS ]"*[,#*,*]Y.VAQ9A"4\/:*N[GFM%='_PJ7X@_P#0O_\
MDW%_\71_PJ7X@_\ 0O\ _DW%_P#%U[?UBA_.OO1X7U?$?R/[F:7P*_Y&ZY_[
M!K_^C(Z]7KSWX3^!_%'AGQ%-?ZWI?D1/9-&K^>C98NAQA6)Z UZ%7B8Z49XA
MN+N>[E\)0P]I*SN%%%%<9VA7Y,?M>?"'PG\;_P#@ZM^%_@3QGJWBBRLG_9(E
MF:?PAXXU7P]>ADU?6" +S2KFWN O/*"3:W\0-?K/7R_XE_X)2?!/Q3^V?8_\
M% ]2^,GQ,7XKZ7HYTC2_$4'B"U6*UTX^;_H:VGV7[,T/[Z0[6C;+.6.6^:@#
MX>_X.<_V*O@Y\%?^"1'C3Q_X/\9?%N\O[;Q'H4<=OXM^/WB_7[)@^H1*VZSU
M35+BVD(!X9HR5."I! ->D_\ !:/XEZMX.^)_[ /A/Q<YC^&>M_M Z+)XREFX
MM7OH([<Z9'<$_*8_,DGFVM\N;<,1\@(^O?V]_P#@G;\$_P#@I#\,T^"G[27B
MOQ>_@T74%U<>&O#^KQV,%U<PLS1RRNL)F<@M]SS/+RJMLW#=5WXI_P#!/[]G
M_P#: _91D_8V_:1AU?XA^$/*@2UF\3WR'4;,P*HMY8KNWCBD6:+;E9LF0[F#
MLX8@@'R)_P '('A'7K+PU^RY\=?@Y"T'Q4\-_M3>'-+\#7]H,7$JWZ7 N+($
M<M%,;>$R)T98B""":@_:Q\%?\%*?V-OVS/B_^W]_P3>@\,?'#P9XJN-*3XU_
M ?5YFM]6L+_3M(M8UDTN< YD:Q-O(8CN8^< L,Q*;/K7X8_\$^/AQX,\;>$_
MB)\3OB]\0_BKJ_@".5? =U\3=>@O1H+R1>2\\26]O LUR8B8_M5P)KA59PL@
MWONCUG_@GWX87XT^/OCK\,_VD/BMX$U;XGW-K/XWLO"VOV;65_);V,%A&\<-
M[9W M)?L]M$IGMO*F.T'S/E7: ?F_P#\%!OBC^RW^V=_P3<_X)X?$SX$?#AM
M*^''B+]K+P/HVF^&M30"33K*$ZE8W.G,P/*1R6\D65.&$:L.U>L?\%]OV=?!
M7@_XI?L6?'G]G_P/IVB_$S1_VH_#/A;P]-H-A';2RZ1<+/+/;.(@-UNGV6/Y
M6^1$EE' D;/*?\%]_A)^R5^SG^S5^QG^QCX2O=*\&>#=$_:L\'QKH5IXB:SN
M;'1%2_2ZO?/\T3QX:8N]WO#"23>7WG-?H!\/?V*OAI+\4_#'[2'Q#^,/B[XL
M:_X5TZ>/X?:QXSU"QFM]"ANHPDTUI%86MM"\TL05#=RK+.8R5$NUV# 'RSXQ
ML[6#_@ZH\(W,%NB23?L57)E=5 +D>)+@ GU.*F_X)?\ _*;G_@HR._\ ;'PS
M_P#3'>U]):M_P3F^$.L_MQV7_!0V[^(WCD?$C3M!_L"SN(]8@%C'HIF>8Z;]
ME^S[# 7D<ECF7+;A(& 812_\$Q?V7#^VOJ_[>EE!XJL?&?B.+3?^$HTW3O%]
MW;Z-KEQIZJEC=7MC&XBN98 B>7YF45D5]F\;Z /SK^,&L>!?BY_P1#_:H\8?
ML >$-(\)? "]G\7ZH=8\4S76L:UXUU+[03>W=M&\R)I=J;B,+"\K7$KI'DPP
M$JYZ'_@KW/+<_P#!L9\)+F>4N\GAWX7,[L<EB1IY)-?4/AW_ ((#?\$^O#/@
M_P"(?PKL+/Q\_@/XBR7T]Y\-YOB#>GP]I%U=J5DN['3PPACN%^5HY)!*8F1"
MFW:N.B^(G_!&#]D3XG?L:^'/V#/$OB'XA'X=>'KBUN#9+XSEDO-2GMDCCM9+
MF\E5YV$*11I%$C)#&D<:+&%BB5 #ZUK\Y_VX+.TC_P"#B_\ 8>OH[=%FE\$_
M$-))0HW,JZ0Y4$]P"[$?[Q]:_0;PAH%WX6\-6?AZ^\4ZEK4MI"(VU35S$;FX
M /#2&&.-"V,#(49QDY.2?$/C'_P3E^$/QN_:[\&?MN^*?B-XYM?'?P[MKBW\
M$3:7K$$5II,%Q$T5S&MN;=DE$R.X<S>8QW8! 5 H!\L_ WP+X,U;_@Z ^.?B
M'5/"NGW-]IG[/GARZTZZN+1'>UN&EC@,T9(^20Q9CWC#;"RYP2#SG_!/G1=(
MLOVH?^"H'A"UTV!-+;QO'<MIXB'DF6YT6\>X?9TS(Q)8]^]?8_A'_@G%\)O!
M'[9?B3]O30?BAX]7XB>+='CTC7[R;5[:2SN=.C*&*T%JUMY4:1^7&59%63*D
MER7<MPM]^PS^SM^PIX<^/_[5FE_&7Q1:ZA\3= OM0^(]]XP\26S6.I7<=I<+
M#,RM"BV[)YKJJPF-<$+M(50 #Y@_X)$?LD_LR_&K_@V;T;PC\4/AIH$MCXQ^
M'OB.Y\2ZK=6$;3-<0WFH)#>-,P+"6W6&(QOG,?DKMP%KS7]@7Q_X"M?^"9W_
M  3L\(_'KX5ZCXY^/.I>)=;N?V?=#U#Q)/I=E;QV=Q>A=0U"=5?%E;:8]HZJ
M(I9'_<K&A!?'?_\ !O\ ?L@_"7]IC_@BO\._!%_^TQX[F\*:]I^J0?$;X7Z#
MXLM1I]R[ZI=K+;S-Y#7]C'/&@\R"WN;>.422,4/FN6^W/VOO^"6_[*7[9GAC
MX<^'_&>EZ]X2N_A%?I<_#/7_ (<:V^BZAX;"I%&8;26$8BB*00+M"\>2FTJ5
M!H ^5?V0-)^*.A?\')OQIM_B[XMT/5M<O?V9=$N;Z?PWH<FG68QJ4*1HL4MQ
M.[E$&WS&DRW)"H,(.C_X-]0IU']MA& /_&=GCW(/UM*]R^'G_!(+]C+X8?M7
MV'[9WA73/&'_  F]IX;ATC4+J^\=:A<QZYY4_GQWFI^;*SZE<K(L;![AY%#0
M0L%#0QLNI\)_^"77[,?P-_:-\=_M0?"B\\8Z-K_Q UNZUW5=,A\6W$FC6VMW
M,3Q3ZO!ITA:V^V.LDG[V5) /,8*%4E: /SJ_9?\ $OQ ^&7_  38_P""JWB3
MX*M/9:YI'[1_Q5;29M-RDMFJVT(>6+;RK1Q;W4CE2@(Z5[UX'_87_9D_X*:_
M\$=_ 7ASXA_MW_$:;X*WWP^T74);32U\(V-OH0TZ&)VB%PFAB2V-J\#Q29?<
MHCD5R<MGZG_9"_X)O_ G]BR]^($OPM\2^+-4L_BCK]YKOCG2O%FJQ:A;:GJM
MT1]HO65H0RR2 %656$;*W*'"E?#OAG_P;D?\$U_A%\8+CXD^!](\>6WAVZUI
M=6F^$Q\=7)\(RWBL'1Y-/_Y;JK*I$4KO%A0I0H-M 'E7Q_\ A_\ #CQ/_P %
M[_V)K&_M9/%&G0? GQ#-8ZAXJLA)=WGV>V\VUNKA9(T_?AR)OF12DI+!48<=
M?\$[&ST7_@Z"^-$>DVR6ZZO^RSHM]J:PKM%S<IJ<$*2OC[S")0@)YP,5]+_%
M#_@G-\(_BO\ MC>%_P!NO7OB1XZM?'_@G39].\)W&G:Q;QV>G6<ZNL\ MFMV
MCE602/N:4._S###8FU/#'_!.;X1^%/VVM4_X*!V'Q)\=2_$;6]"70M5N+G6+
M=K*XTE9$D2P^RBW$:1*T:$,@67(+;RS,6 /F[_@W<X\-?MAJ>H_;L\?Y'_ -
M.KZ-_P""N'_**O\ :4_[(+XN_P#3/=4? K_@F+^RY^SE^TKXS_:B^%D'BJSU
M?QSXDNO$6K^'I?%]W)H46LW2,EUJ4.GE_)6ZE5Y%,K!F59'5-BL17HW[4'[.
MGA']K/X&^(/V>/B'XCUW3_#?BO3Y=.\1)X>O$MY[ZQEC:.:U,K1NR1NK$,4V
ML0,;@"P(!^3/[>/P]\"^'_\ @S3\-7>@^$=.LI;?X4_#G689;6T2-EU&?4=&
M$UV"HSYSB:4,_P!XB1AGFO=OVEOBCK-__P %VOV??A1\0OV@/$'P_P!+\0_L
MUZK_ ,*^UK28-+<W/BBYU& W4"_VI9W4 DDLK1%!5%E)98U;$K(_T3\0?^"1
MW[.WQ1_8=TS_ ()S^./B-\0[WX3:5;VEK!H']O6Z2R6=H\$EG:27*VPF>&"2
MW1T!?.>&+JL:I=_:[_X),?LD?MU_L]>&/V?/VH+'7_$B^"F#^$O&AU5;;7]*
MD "[X[J&- 242-6#HRR>4CN&D4. #%^"O_!/;X"? #_@H_KW[6U_^TS\0_%7
MQ:^)OPZET[6=%\1OHZ6&HZ78S:?&;M[;3M,ME$L+?9(EE9N1,RX;)Q\<?\$1
M_AM\/YO^#;/XCP2^#-,8:WHGQ#AU@FR3-['&^H1QK*<9<(G"@_=[8K[P_9*_
MX)D_ ;]BSX>^(?"GP<\;^/;CQ#XIMHK?6_B3XJ\4'5_$4\,.X0PK<W4;I%'&
M'DV1I&J*9&8+O.ZLOX#?\$HO@'^S3^R9XA_8D^#GQ+^(>E_#WQ(EXEYICZ_!
M// EV'%XD-S+;--$)@YW8;*GYD*,6) /@_PQX!\$1_\ !G'?F+PEIRG4/@=-
MJ=^RV:!KF]CN<QW$AQEY%\F(*YR0(D ("@#3^)/Q8\0VO[8O_!)KP;\5KN0_
M#W5O L^HNUVQ-O?>*/\ A%X8-/>3/#3137$1B)Y#7+$9-?;5K_P2;_9]L_V%
MW_X)QV_Q'^(2_"=[1K$Z)_;UO]H%BTAE:S%U]F\_R3(2V-^['R;MGR5J_$+_
M ()<?LM_%W]DKPM^QM\5H?$6O^'/ C6+^ M;N]:,.M^&YK)%CLI[._MTCDCE
MA50JR'<S#(<N#B@#YB_X+3^$==T#_@H_^P/\;_@S"UOX]?XX-X:OKBR^6>\\
M,W"1R:G%+CEX8[9;AL'(3SG(QN.;'_!$#XIS_%_]M[]O'Q%\3;L2?$+3?V@Y
M-%FAN3^_M?#5BLUKI$2@\B$+%<$8^5F9FZMFOK?X4?L-?#WX?_%+2OCI\0/B
M3XT^)WC7P[I%QI?A;Q/\1=3M[F;0[2?:+A+2*UM[>WBDE"(LEQY1N)%0(TK+
MQ7 _&S_@D'^R_P#%S]J]OVV?"OC+XC?#+XCWU@ECXGU_X5>-)=&/B2U4*JQ7
MZ(K++A40;UV/^[3+$HA4 \*_X(2Z#H.D?M%?MX^']*TFV@LE_:PUC%G%$!&H
M= Q 7H 23QTKYG_X)Y>+_P!C[X??\&H-_<_MQ:!K&J_#.;7-;L]4T'PY=/!?
MZE.WB5_LEK;NCH4=K@0C)8(%#%SL#5^CO[,__!*+]F;]C[6?B3XJ_9[\4?$/
M0M:^*>K3:AXDU:3QW=W;I+(Y;=%#<F2W,BAF47,L4MSAB3,S'=7/^"_^"*'[
M$O@[]ACQ)_P3BFL_%6L_"3Q'<?:?^$>UO7_.ETRZ\\7)N+2Y6-9HW\]4EPSL
MFY?NX>0. ?+/[=&D_M$6?_!2/_@GCXA^.=AX1\.Y^(FN6NB>"?"R3W3Z!"=*
M@#V\^IS./M[E5C4F.W@0%"/WG#UZ7\;?^5GCX*?]FNZ[_P"G*6O1]4_X(4?L
M4^)M/^'+^._%GQ:\1:_\,-72^\.>-M;^*VIS:YY:QB,61O!()(;3:%_<VWDC
M(+##,Y;T7Q'_ ,$U/@GXB_;(\/?MUCQWXUL/'GA/P]_8'AO^S=5MXM/L-()<
MM8+:?9S$T3>8^2X:3D$."B%0#Y7_ &Z-4T;_ ()4_P#!6_X??\%*KB>'2?A-
M\?+.+X<?'>\8;+;3=6C4R:-K,QZ+\L9@DD;"I%$Y.2]>B^%OV<]!_:O_ .":
M/QC\:?'KQ?<>!K[]K".\U?4-<N(?WV@Z9?Q16'A^WD0E>(=/CT\2PDH#++<Y
M*;V:N6_:6_:\_8]_X+%:GKO_  2F^#6AZSXRU&P^)MG8_&3^U/!E];67A?2=
M)U%+F]N&NIXEB\R=[,V, 1C(7N?,V>6C&OMO]H3]GKX;?M,_ ?Q%^SA\2[.Z
M7POXGTHZ=J=OI-T;646Y*_+'(G,1^4 %<$=L4 ?G;\ OVLOVX_V6_P!L3X)?
ML1?\%D/@+X?\375[KMQ9? O]I#P%.WV74=2_LZ>U,%_;D!HIYK>XD1OEC4N4
M81.%,Z=E^R[9VEI_P<M?M/R6UND;3_ SPD\I10-[#RER?4[54?0"OI_PA_P3
M_P# &F_$#P7\1?BM\8_B!\3;KX;22S?#VV^(.JVEQ%H5Q) ;=KI3;6L$EY<^
M2SHL]X]Q(@=RK*S%JK_#S_@G+\(?AI^V?XE_;UT/XC>.9_B#XQTN+3/$T]]K
M$#V5]81!!#:FV%N(XTC\J/:T81_E)+DN^X _.+QSXL_;"_X) _ O5K/XH_#_
M $/]IK]@SQ3K,^KVOB709S!XG\&:=JNH&]62520+I$N+DR)(,DR;6,MME8U_
M9/P_KNE>*=!LO$V@W@N+'4;2.ZLKA5($L4BAT;! (RI!YYYKY?T;_@D5\!]*
M^$$G[,U]\9?BCJWPCN[\W>I_"K6?$EM<:5>L;D730O,UK]N2V:8;VMHKI(&R
MRF,JS*?JBWMX+2!+6U@2**) D<<:A510,  #@ #M0 ^BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110!'!9VEK)++;6L<;SOOF9$ ,C8 W,1U. !D]@*DHHH
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M.37I= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>+[I9=6T;P>TRC3+2\V$K'/L5YFB!_=>>(\*4*+]CT4 %%%% !1110 4444
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M?A8?&>I:I\%/'GPVN8&6WLKZX>X%E?\ G$1VH661V:25DV.\N/,C*,/UTHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>dva-20221231_g3.jpg
<TEXT>
begin 644 dva-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!# % W/$8\,E!&049:55!?>,B">&YN
M>/6ON9'(____________________________________________________
MVP!# 55:6GAI>.N"@NO_________________________________________
M________________________________P  1" PS$A8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"[1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !14,UPD.,\GT%"7$3]' /H>* )J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *CF?RXF8=0.*DIKJ'0J>A% %*WA$@\Q_FR>AJ1[6-NF
M5/M3+<F*5HF]>/\ /O5JF(J>5/#_ *M\CT_^M3ENW0XD3^E6:0@$8(!'O0,:
MEU$_\6T^]2@@C(((]JKO;1-VVGVJ(VSH<Q28_2D!?HJCYMS']Y=P^G^%/2]0
M_?4K].: +=%1I-&_W7!]JDH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_I2 OT51\RZC^\-P^F?Y4]+U>CH1].: +=%1)/&_W7&?0\5+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ2S4"'/<F@">BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH :R*_P!Y0?K43VD;=,K4]% %7R)H_P#5OQZ9Q_\ 6H%S*G^L3(]<8_\
MK5:HH B2\C;[V5J99$?[K@_C4301MU0?AQ436:_PL1]>:0R[15#R[F/[CY'U
M_P :474R?ZQ,_I0!>HJLMY&>H*U,LL;_ '7!_&@!]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 4KQ2K)(.<<5.C!T##H:DD02(5/0U3MV,<C0OZ\4 6J***8@HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J-U_Q]Q_A_.KU4?\ 67Q]%_I_]>@"U111
M3$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'-$)5 )Q@]:C%F@
MZLQJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JA:<
MRN3]ZK]4(_DO77US_C0!;HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ IKMM1F]!FG5!=-B$CU.* &V:XC9O4U9J.W7;"H]LU)0 4444
M %%%% !1110!5D^>\1?[O_ZZM56@^>XD?TX_S^56: "BBB@ HHHH **** "B
MBB@ IK(C?>4'\*=10!"UK$W0$?0TS[*RG]W*15FB@"MFZ3N''^?QI?M;K_K(
MR/I5BB@9&MW$W4E?J*E61&^ZRG\:C:*-NJ"HFM(STRM("Y15+R)D_P!7(?H:
M/,N4ZJ''^?2@"[1507F/OQL/I4BW4+?Q8^HH GHIBR(WW64_0T^@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHJ)YXT;:S &@"6BHUEC<X5P3]:DH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J-S\ERC] <9J]52_7,:MZ'% $]%
M-C;=&K>HIU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;
MP[F1!U-6JJGY[T>BT 6@,# HHHH **** "BBB@ IKMM1F]!FG5#=-MA/OQ0
MVR7$1/J:L5' NV%![9J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!" >HS3&AC;J@_#BI** *[6D9Z$BD^SRI]R4U9HH K;KI/1J7[5
M(O\ K(C^'%6**!D2WD1Z[E^HJ03Q,.)%_$XI&C1NJ@_A4;6L3=B/H:0%D'/2
MEJE]DV\I(P-&VY3[LF[Z_P#UZ +M%4_/G3[\61[4HO5Z.C T 6Z*@%U"W\>/
MJ*D61&^ZRGZ&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4)'>:<K&Q '
MO0!?HJAY-PH)$O\ X\:ELY'D5M[$XQB@"U1110 44A( R3@53EN6D.R$'GO0
M!)<W C&U.7_E44-MN!:7))[4Z&V"'<_+?RJQ3 K/9K_ Q!]Z;ON(?O?,/?FK
M=% B*.[C?AOD/OTJ<$$9!R/:H)((Y.JX/J*A\B6$YB?/M2&7Z*IQW>#ME4@^
MH_PJTK*XRI!'M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANAN@
M?V&:FHH J6C@Q!<\CM4]59X#$WF1\ =0.W_UJE@F$J^C#J*8B6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH "<#)J%+E'8* V3[5'=R_\LU_&H+;_7I0,T:***!#'E2,X=L'Z4W[3#_?
M_0U4DW3S,5!/I2_99?[H_.@9:^TP_P!_]#1]IA_O_H:J_99?[H_.FO!(BEF
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 07,GE1''4\"H[2/9'N/5OY5'*?/N=O\ "O\ DU;I
M@%5(6-O.4;[K=_Y5;J&YA\U 5^\*!%JFR.(T+'H*IB:XCX=,@>W^%))=&5-B
MI@MQZTAB$RW3?W4'Y?\ UZLQQ+$,*/J:2!#'$%;K4E,04444 %%%% !1110
MR2-9!AA^/I4-DQ5WC/UJS51_W5XK=F__ %4#+]%%%( HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&(523T'- %5/GO&/\
M=_\ U5;JM9C(=SU)JS0 4444 %%%% !1110!!=-B$CU.*DB7;$H]!4-U\TD<
M?J>:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX7J_Q(1^- %NBJPO(CUW#ZBGBXB/20?CQ0!-13!(C='4_0T^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "J!/G7WLO]/_ *]7)6\N)F]!56R7Y6<]2<4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HKEML#>_%2U6O3\J+ZG- #[9=L*^_-34BC:H'H,4M !1110 4444 %
M%%% %:7Y;M"WW<8%6:BN8_,B..HY%%O)YD0)ZC@T 2T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I"<#)I:BN>+=_I0 OGQ9QYBY^M.!!&00?I5&"W22+
M<V0<]J4VC+S')S^5 %^BJ(GFAXD7</7_ .O5N.02QAAD T /HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *E\V$5!U8YJ6)=D:KZ"JQ/G7O^
MRO\ 3_Z]6Z8!1110(**** "BBB@ HHHH **** "BBB@ HHHH **** (YUWPL
M.^,TEDVZ';W4U+56W_=W31]C_P#K% R]1112 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH *JK^YNBO\+U:J&YCWQ9'WEY% $U%1P2>9$&[]#4E !1110
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M+F$_QBG":(])%_.@"2BFA@>A!IU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5#<_\ 'N_TJ:H+O_CW?\/YT ,M/]0OXU-4-M_Q[K^/\ZFI
MB&3#,+CVIEB<Q$>AJ8\C%5K$X9U-#&7:***0!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !4<S^7$S#J!Q4E4[UBS)$.IY_P * "S3"%SU8U8IJ*$0*.PI
MU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52Z^29)!_G%6ZA
MNDW0GU7F@"R#D CH:6H+1]\"^J\5/2&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<Q>;
M'@?>'(J:B@"G:RY'EM]Y>E6*K7<>QA*AP<\T&[7:/E);TI@6:*J;[B7[HVC\
MO\_A1]GF'(DY^IH$6Z*I^;-"ZB0\&KE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -D;;&S>@J"S7$9;U-.NFQ"1ZG%/@7;"@]LT 24444 %%%% !1110
M4444 %%%% %:/]S<%/X7Y%6:KQ_O;IG[)P/\_G5B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\=?7/^-6JJ2?)>(WKC_"@"_1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %49_^/Y/PJ]5&Y_X_(_P_G0!:HHHIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0@$$'H:6B@"M9DI*\9_P XJ[5"7]U=*_8]?Y&K](84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !52[E965(S@GKBK=4(_WUVS]EZ?TH 5;7)S(Y)]
MJG2&-/NJ,^M/HIB"BBB@"O=KF+/]TT^*9&C7+#=CD$U(RAE*GH:@-I&>A84
M6**J_9".4DQ^%-+2P2+O8LI]\T 7** 01D=** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *MX=SQH.]6AP*JGY[T>B_Y_G5J@ HHHH **** "BBB@ HHHH *9*^R)F]!
MQ3ZK7A^5%Z GDT .M4VQ ]VYJ>D    Z"EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J5U_Q]Q'Z?SJ[5&^X=&[T 6J***8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"O>+F(-_=-3V[[X5;OC!I'7>C+ZBH;%N'
M0]0<TAERBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH AN'\N%CWZ"HK--L6[NQIMZQ>1(Q]:L
M* J@#H!B@!:***8@HHHH **** "F31B6,KW[4^B@"M:R'F)NJ]*LU5N5,;K*
MO!SS5E6W*&]1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.=ML+GVH AM?FDD?U_K5JH+
M1<0Y]3FIZ "BBB@ HHHH **** "BBB@ J*X3S(B!U'(J6B@"&UDWQ#/5>*FJ
MJG[FZ*_POT_S^E6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KS\S1#WS5BJ[_->
MH.P'^- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7:D;)!U!JPK!E##H
M1FH[G'D-FBV!$"YH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HZT44 5+5Q%*\;'&3@?6K]5+B 2#<O#_SJ)+MXQM=<D>O!I#-"BJ/V
MX_\ /,?G1]N/_/,?G0!>HJ"WG\X-\N"/>IZ "BBB@ HHHH **** "BBDSGI0
M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %49/WMZ!V7^E69YA$FX]>P]:KVB-EI6ZMTH LT444Q!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !50?NKWV;^O\ ]>K=5;Q>%<=C
MB@"]13(VWQJWJ*?2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%0W+[(6/<\"@"M#^]N7D[#I_2K=06
MJ;8<]VYJ>F(**** "BBB@ HHHH **** *][_ *H?[U31_P"K3Z"H+W_5K]:G
MC_U:_04 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "J]ZV(@/4U8JK<_//&G:@"Q$NV-5]!3J*
M* "BBB@ HHHH **** "BBB@ HHHH AN8C(H*?>6F+<,A"S(0?6K-(0&&" 1[
MT -21)/NL#3ZJW$*HN^,8P:L1OOC5O44 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KKS>
M-[+5BJ\'-Q*??% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWIQ$!ZFI
MD&U%7T&*@N>9HU[9JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!2_>PRL8T)!]LBI/M-P.L7_CIJS10,K?;)!UC
MH%__ -,__'O_ *U6:;)_JV^AH ()A,"0N,>]350M)4C1@[8R:L_:8O\ GH/R
MI 356N;CRSL3E_Y4Y[F,(=K@G'%06<8(,C<G/&: #R[B3[[[1Z9_PI"DEL=R
M'<O>K=%,17^W#_GF?SH^W#_GF?SJ? ]!2%%(P5!'THL,='(DBY0Y_I4E47@>
M)M\)/T_SUJ2&[5_ED^5O7M2 M4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 4[_P"ZGU-6!TJO?_=3ZFK%- %%%% @HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDR[XF7VI]% $-BV8BO]TU:K
M/C<6]PX;[I]/TJQ]LA]3^5(98HJO]LA]3^5'VR'U/Y4 6**9'(LB[E/'2GT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5*]8LZ1CKUJ[5"/][=L_8=/Y"@"TH"J%'0#%+113$%%%% !1110 4444 %
M%%% %6]^XOUJRHPH'M5:^^ZGU-65^Z/I0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54C^>\9
MO[O_ .JK3':I)Z 9JO9C(=SU)Q0!9HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 1@&4J>AXJO:L49HFZ@\59JK./*G24#Z_Y^E %JBD!! (Z&EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *KVG/F-ZMUJ=CA2?05#9C$.?4T 3T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %6?_CYB^H_G5JJL_P#Q\Q?4?SJU0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1D$'H:6
MB@"'[+%Z'\Z/LL7H?SJ:B@"'[+%Z'\ZD1 BA5Z"G44 %%%% !1110 5%- DO
M/1O45+10!4!GM_\ :0?B/_K5-'=QOPWR'WZ5+44EO')SC!]10,L=:6J.R> Y
MC.Y?3_ZW^%.2]'1T(/M2 N4TD 9)P/>JTMXNS]V3N/J.E0212F/S)&S[&@#1
M!R,CI2U#;'= A]L5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%1O*B?><#VS437D8^Z"U %FBFHZNH93
MD&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 4[_ .ZGU-6*@OU)12!P#S4D4@D0,/Q'I30#Z***!!11
M10 4444 %%%% !1110 4444 %-=UC7+' IU9]Q+YK\?='2@"\DBR#*'(IU5K
M+_5M]:LT %%%% !1110 4444 ,>)'.67)IOV>+^X*EHH B^SQ?W!1]GB_N"I
M:* *ML?*N&C/0]*O50F_X_(OP_G5^D,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (KA_+B9N^,"H+1-L6[NQHOF)*1CJ
M>:G5=JA1V&* %HHHIB"BBB@ HHHH **** "BBB@"E*_G2A =J@XR:NC@5#-
MLO/1O6HEDD@.V0$KV- %NBFHZNN5.13J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y;; WOQ26R[8
M5]^:CO#\J*.YS5E1M4#T&* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *CG3S(F'?J*DHH KVDFZ/:>J_RJQ5/_ %-U_LM_6KE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#)CB%S[4VV&(%HNCB!O?BG0C$*#V% #Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.* +5%5/](A_VU_/_P"O3TND/#@J: +%%("&&001[4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!5D^>\1?[O_ .NK55;?Y[B1_2K5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 5[M-T88=5_E3[=_,B!/4<&I"
M 00>0:JC-K+SS&U %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *:\BQCYCCVIU)@9SCF@"I+=L3A!M^O6ELR69R3D\=:+T#"-WZ4675_PH
M&6Z***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!7NSB''J:G PH'I4%UR8E]6JQ0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!6OON+]:;9=7_"G7WW%^M-LNK_A0,MT444""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)2U5O)=B;!]YOY4 19^TW&?X%_E_P#7JW45O'Y<
M8!ZGDU+3$%%%% !1110 4444 %%%% !1110!GO%(7)V-U]*;Y,G]QORK2HH&
M9ODR?W&_*FLC+]X$?6M2J=]]]?I0! L;ORJD_2K5HC(&W*1]:++_ %;?6K-
M!1110(**** "BBB@ HHHH **** "BBB@ HHHH *CGC$L9'<<BI** (+.7(,;
M=5Z9JW5"Y4QR+*G'/ZU<1MZ*WJ,TACZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJ&X?RXF;OT% %9?WUV6_A7^E6ZKV:;8RW=JL4Q!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5!?WMXS=0O]*N2OLB9O055LEPC-ZF
M@"S1113$%%%% !1110 4444 %%%% !1110 4444 %5+M&9EVJ3QV%6Z* *]H
MK*C!@1SW%6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWO
M^J'^]_C5B'_41_[H_E52;]]<K&.@Z_UJ\!@8'04ABT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5*]8LZ1CZU<JC#^^N6D/0=/Z4 6E4*H4= ,4M%%,0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 !&>M1-!$W50/IQ4M% %4VN#F-R#[TF;F+M
MO'Y__7JW10!66\'1T(/M4JS1OT<?0TYD5OO*#]:B:TC/3*T 3T54\B:/_5OD
M>E+]HFC_ -8F??I0!:JK:?-)(_K2O=(T3 9#$8IUHN(0?4YH GHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JO^MO/9/Z?_
M %ZGF?RXF;OVJ.U3;%N/5N: )Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***0L%^\0/J: *]]]Q?K3;+J_X4EW*K[54YQUQ3;214<AC@$=:!EZBD5E;[
MK _0TM @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI'.$8^U $%GRKMZM5BH+08@'N34] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<?
MZA_I5*V_UZ5=N/\ 4/\ 2J5M_KTH&:-%%% @HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"J_[F
MX5A]U^M6JK7G2/ZU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%-+*.K ?C0!7OGQ$%_O'^5/A79$J^@J'4/^6?X_P!*LTT 4444""BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "F2OY<9;TI'FCCX9N?2JTLIN&5$! SWH FLDX,C=6X%
M6Z:BA%"CH!BG4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 073[(&]3P*C
MM4VQ ]VYIET=\Z1CMU_'_P"M5H# P.U, HHHH$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!#- C(Q"@-CC%-M'W1E3U4U8JHO[F[Q_
M"W]: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M112$@ D]!0!6N3YDB1CZFK(   '056M07D>4_05:H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *1E5OO*#]12T4 ,\J/_GFOY4>5'_SS7\J?10 BHJ_=
M4#Z"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *CG.(7^E25#<G$+>] #K<8@3Z9J2FQC$:CT IU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M$@ D]!2U7O'V0X'5N* (+8&25Y35NHK9-D*^IY-2TQ!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5:[3*!QU6K-!&1@\B@"&"
M=90 >']/6IJJS6Q!W1?E_A1#<_PR]?7_ !H M4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5!=OMCVCJW%3U5'[Z[S_"G^?YT 3PIY<2KW
M[T^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH H6?WWJW52S^\]6Z8@JK=@JR2#M5JHYTWPL._44 /!#*".AYI
M:@M7W0X[KQ4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !102 ,G@"HC<Q#^/]#0!+138Y%D!*G(%.H *K7$Q'[N
M/[QZX[4ZYG\L;5^\?TI;:#;^\D^^>F>U QUM;B)<M]\_I5BBBD 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 50F/G700?=7@_UJU/)Y41;OV^M5[2
M/"F0]6H LT444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 55NT4*'QALXJU5:\_P!4H]Z )H>(4_W13Z:G"+]!3J "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9,_EQ,W?M4=JFV+)ZM
MS3;D^9*D8/N:LC@8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J\O-U$/;-6*K];WZ+0!8HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH BN1F!J6W.8$^E$XS _TIEJ<P@>A(H G
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "D) &2<"D=Q&I9N@JJJ/=.68[5% "W$X<>7'SGJ:M01"*(+WZGZT101Q_=
M7GU/6I:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDZ57ENX
MTX7YS[=* &WLAPL:_P 76B-!&@4?C4/[R:1788 JS30F%%%%4(*KS.9'$:<Y
MZT^:3RTXZGI4EK!Y:[F'S']*EL:)88A$@4=>Y]:>2!U-1S3+$N6//8>M4F,M
MP=_0#H*0S2HJI#=KMQ*<,.^.M2?:H?[_ .AH GHIBNC_ '6!^AI] !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!+<QQ\9W'T
M% $],\Q,XWKGZU2,LT_ ^5?:C[*-OWCFBP%^EJG8?=?ZBKE !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  2 ,G@53D8W$
MH1!\H[_UHFE,S>7'R/YU8AB$28'7N?6@"0<"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *0D $GH*6J]V^(PHZM0 VV!=WE8=>E6J9$GEQJOI3Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JO%S=2GT&*L5!;\R2MZM0!/1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR.19%W*<BGT %%%% !1110 4444 %%,:1%^\RCZFHVNHA_'GZ"@">J\]PL7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%0O<1)U<9]N:A:]7^
M!"?K0!<I"<=:H^=<R_<7 ]A_C2?9YI.9'_,YH M/<1)U<?AS4+7P_@0GZT+:
M1CJ2:E6-%^ZH'X4 5_-N9/NC ]AC^=(+:5^9'_/FKE% %=;2,=<M4RQHOW5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HW3&658E[=?K_]:K<CB-&<]JJ6JEF:5NI/
M% %E5"J%'04M%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5;F4LWE1\]CC^523S>4G'WCTIEK%M7S&^\>GTH D@A
M$2^K'J:EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JJ1OO
M,'HHJU5:,YO'^G^% %FBBB@ HHHH **@GF,954Y8]J1+E2=KJ5:@"Q1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$GXGDT 7&94&6( ]ZK27BCB,;CZFHA"\AW2L:E2-4^Z*=A7(EB>1M\Q/TJ<
M*, 8%+13$(2 ,GH*KHC74F3P@ITS%V$:<D]:MPQB*,*/Q/K28T.10BA5& *=
M112&%%%% !114$URD7'WF]!0 RZF96$:?>/>H/)E?[[G\\TJ^9-()6  %6*:
M0BN+9>[$_2GB",?PY^IJ6BG80T(J]% _"G444P"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBFNP1"QZ 4 5+QR[K$OXU.BA$"CH*KVREW:5NN>*M4
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4UV"(6;H*=5.XD,L@C3D _F: ")3<2EW^Z/\ .*N4R*,1H%'XGUI] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56X1HW\Z/\:M4=
M: &1R"1 RT^JC VTNX9,;5(]S&JY4[CZ"@"8D 9)P*KO<%FV0KN/K2".6<YD
M)5/2K"(L8PHP* (H8"K;Y#EZ;= >;%]?\*LU6N?]?"/?^M %FBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M43W42?Q;C[52DE::0;SM7/3TJ=8(U[9^M.P#7N9)/EC4CW[_ /UJ6.W"\O\
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M** "BBB@ HHHH ***:[!%+-T% #J:9$'5U_.J3O).V%!QZ"FFWE R4/X4#-
M$$9!S2UF*S(V5)!J[#,)5YX8=10(FHHH)P,F@ II=%ZNH^IJLTKSR;(SA?6I
M%M8@.02?7- $P8,,@@_2EJE-"8?GC)Q_*IK>?S!M;[P_6@">BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH BN'\N(D=3P*CM(L+YAZGI]*;<9EG6,=!UJT   !T%
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M,H=2K#(-,6&-#E4&:DHH **** "JTO\ Q]1CVJS5>X^2:-_P- %BBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWG**OJU6*KW',
ML*^^:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<XW0N
M/:I*0C((]: (K4YA'MQ4U5K0[6>,]C5F@ HHHH **** "BBB@ HHHH ****
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MW[BGTQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ,DC$BX/7L:BAF:!]DGW?Y58IKH'7!I-#+ (
M8 @Y!JM>RE0JJQ!/)P:B222V.TC<E2D17?(8AP*D9%]ED;EG'YYI19CN_P"E
M%H2LC1D_Y%6Z *4;&UF(894]ZO@A@"#D&HI8EE7!Z]CZ5%8N<,A[<B@"Y111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]R,3O0,OHP= P[BEJ"U.81['%3T""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.E !5>>Y"C;'RW
MKZ4QW>X<HG"#J?\ /\JFBMTCYZMZF@!MM"4R[_>-3T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%VN8
M<^AS4]-E7=&R^HH (VW1JWJ*=4%HV8<>AQ4] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!7DYNXQCH,_P ZL57'-Z?9:L4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %0W?\ J#]14U0W/_'NWX?SH ;#_JE^E25'#_JE^E24Q!1113 ****
M"BBB@ HHHH **** "BBB@ HHHH **** *S*T,FZ,$J>U NO5/UJS2$ ]:5AD
M0N4/7(_"G":,_P 0_&E,2'J@_*F&",] 1]#1J!*&!Z$'Z4M5S:CLQ'UI/)E3
M[CY_&@"S15;S9D^^N1ZXIRW*'[P(HN!/135=6^ZP-.IB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBH+B0_ZM>2>M( :Y4$@+G'?--^U?['ZU:MX1$G(!8]:EP!TI7*L4/M
M)/1/UH^TD=4X^M:-)UZT7 I+<H>N14BR(W1@?QJ1K>)NJ#\.*B:R0_=8C]:+
MBL/HJ$VTR?<?(],XH\N[]OTIW"Q*S!1EB!4#7&3B-<FGI:,QW2M^ JTD:1C"
M*!2N%BEYLXZQ'_ODT"29N$0@_2M"BE<91%O.W)?!],TGDW*]#G\?\:OT4 9[
M?:5!W)D?3/\ *H<DN#&I!]!6M28 Z"@#-#/%.'D!!/)J?[9'_=:K+1HYRRJ?
MJ*:;>+_GFOY4 5I+L%<1@Y/<U):0M'EVX+#I4JP1*P8( 14M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %4[J8Y\J/J>N/Y5-<S>4G'WCTJM;QX^=OO&@!\,0C7U)ZFI*
M**LD**** "BBB@ HHHH **** "BBB@ HHHH **** "FLNY2I[TZB@"&S;!:,
M]1S5JJ1^2[4CO_\ JJ[4%!1110 4444 %%%% !1110 445#<R-'&"O4G% $I
M8*,L0![U3FE,[B./I_.E2!YL/(W!_.K,<*1?='/K3 6.,1H%6G444""BBB@
MHHHH *J-^ZO >S?UJW5>\7*!A_": +%%-C;?&K>HIU !1110 4444 %%%% !
M1110 4444 %%(2 ,DX%5I+G)VQ#)]: "UYNI&^O\ZO56M(FC#,_!;'%6:0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MCED$498]OUJK;(9',S\DGBDE8W$P13\B_P"<U: "@ # % "T444Q!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444A( R> * (;I]L6.[<4RTCP#(>IZ4T W,V3]T5< P,"@ JI>K\RM[8JW
M39$$B%30!4LWVR%3_%5VLV2-XFY_ BITO.,.N3ZB@9;K.N3F=_K5GSI)1^[3
M:/[S53)))).2: +MG_J?QJ>HX%V0J/:I*!!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;B0R/Y4?/
MK3[F;8-B??/IVI;>'RER?O'K[4 /BC$2;1U[GUI]%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %:V^2:5/RJS59ODO%/9A5F@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH KQ<W,I].*L57M>6E;U:K% !1110 4444 %%%% !1110
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M:EHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *JR,;A_+C^Z/O&EED,S>5$>/XFJ:.-8UVK0 J($
M4*O04ZBD9@HRQP!0 M%,B?S$W8P#TI]  1G@TT1H#D(N?I3J1V"*68X H BN
MI-D6!U;BJMM'YD@S]T<FAB]Q+P/I["KL48B0*/Q- Q]%%% @HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9-
M)Y<9;OVI]5KT_NU'J<T );1%CYK\D],U:I%&U /08I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"M><;''8U9'(S45RNZ!O;FEMVS"A]L4 24444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5P0(C[U);@B%,U!<G)11UJVHVJ .PQ4L8M%%%(84444 %%%% !1110 4444
M5)#F]7VQ5NJ9_P"/[\?Z5<IB"BBB@ I"RK]X@?4U#/,4^1!ES^E0?9IG^9L9
M]S0!<#HW1E/T-.K,>-XS\PQ5BWG.X(YR#T- %NBBB@"K=J1L<=0<595MRAAW
M&:9.F^)A[5':/NBV]U- %BBBB@ HHHH *J7+-)*(EX_K5NJET"DB2#_.* +<
M,2Q)M7\3ZU)300P!'0\TZD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M4C*K?>4''J*!$3W4:]"6/M4)2:X;+?*M6PJK]U0/H*6@!D<:Q+A1^/K3Z**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *J7)W3(G^>:MU3SMO"9..>/Z4 7**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!&&Y2#T(Q5:WD\HF.0%3GC-6JCEB65<'@]CZ4 245521[=MD
MG*]C5D$$9!R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT 6Z*J_:)?\ GB?R-)]JD'_++^= %NBJGVMN\='VT_W/UH MT54^V?\ 3/\
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MH7D:1NW3ZU;EC61"K=*2%/+B5?3K4E245X[6)3G!;_>J>EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *]V,V[>V*BM\>2.*L7 S;O]*K6IS%]#30F
M344450@HHHH **** "BBB@".2)9.HP?45&KRVY_O)_G\JL4E*P[CH[F)_P"+
M:?0U-UJFUO&W;'TJ/RI(SF-_Z4K#N:-%41=2Q\2IGWZ4[[</^>9_.D!<HJM#
M<K*^S;M/;FK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ JM>_<4>IJS5:ZYEC7WH LT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8I-H]!2T4 -V)
M_=7\J3RXS_ OY4^B@!GE1_\ /-?RH\F/^XOY4^B@"/R(O[@I/L\7]P5+10!#
M]FA_N?J:/LL7]W]34U% $/V6+T/YTGV2+_:_.IZ* *_V2/U;\Z/L<?\ >:K%
M% %;[(G]YJ3[&O\ ?-6J* *OV(?WS^5)]C_Z:?I_]>K=% %3[%_TT_2FVR;;
MDC.=N:NU4M3NGD8=#_C0,MT444""BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]V^V/;W:K%4
MW/FW6.RT 2Q+LC []Z?115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** (+H?*I]#4RG<H/J*CG&8F]N:(#F)?;BEU&2T444Q!5<?/
M>*.R_P!.:G/ R:BLAND=S_G-)C1>HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 444UV"*68X H &7<I4]",53-I(AS$^?TI3?#M'^9I/M4S?=C
M_ F@!I:X0?.F1ZX_PJ6-Q(FX?E49CFE_UC8'I3XHA'G!)S5(1)1113$%%%%
M!1110 4444 %%%% "48'H*6B@""X!5ED7@BKD3B1 P[U"RAE(/0U!'(UL^UN
M4-2QHT**:K!E!4Y![TZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *BFF6)<GD]AZTD\ZPKZL>@JHB-*_F2<Y[4 "JT[[Y#Q
M5@# P**6J)"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 )4"'[/-@_<:K%17";XR>XYI,:+-%0VLF^( ]5XJ:I&%%%% !111
M0 4444 %%%% %)#F\S[FKM4K8;KDD]LFKM,04444 %0R7$<9(Y)'85-00#UH
M SI9FE(SP!T%6(+D-A' ![8Z4Z6V1QE1M;VZ5292K$'@BD,U**CMW\R$$]>A
MJ2F(*BN5W0-[<U+2$9!'K0!%:ONA'J.*FJK9'AQZ8JU0 4444 -D_P!6WT-1
M6'^K<^]23?ZE_P#=-1V/^I)_VO\ "AC+=%%%( HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J)YU ^W^%7JHQ?-
M>2'TS_.@"U1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'2D)P,U
M4+27+%5^5!UH 6:4RMY<73N?7_ZU3PQ")<#KW-+%$L0PHY[FGT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #9'V1LWH*K6J_*6/4U+<HSQX3L<D>M10S# 1A@CB@">B
MBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (PW*
M1ZBH;4_*P]#4]5HOEG=?6D,LT444Q$5P^V/'=N*FM8]D(SU;DU6 \^Y"_P *
M]:T*EE!11368*I). .M(!U%4S>9D4*/DSR35R@ HHHH **** "BBB@ HHHH
M**** "BHI)HX_O-SZ#K59KT[AM3Y>^: +U9\TC3R[%^X/\YJX)5:(N#P!FJ=
MH.&/K0@)E4(H [4ZBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK
MH'7#"E) !)Z"H/,FD8F)3M'M2&$+/!*(^JL>E:%9T8D>Y0R*0<^F*T:D8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-Q.(5]6/05-
M5+4.L9^O]* (XXS(WF2<Y[>M6:**HD****8!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%(QVJ2>PH @MCLN&0=#5RJED
MN6=SUJW4%!1110 4444 %%%% !112,<*3Z"@"I9?ZUC[5<JI9=7/TJW3$%%%
M% !1110 52O%PZMZBKM4[MMTBH.2/ZT 268_<G_>JQ3(D\N-5].M/H ****
M*:E[>1CL)4U*EU&W7*GWJ>F-#&_WD&?6@!RLK#*D'Z4M4IHQ!(C*3CK5V@"*
MY.V!ORI;,8@!]2345Z<1J/4U9B7;$@] *0R2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J%I\TLC5?JA9
M=9!]/ZT 6Z***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR'^56J* *OEW*]),_C_C1NNEZKG_ #[5:HH J_:95^]%^A%*+Q>Z&K-(0#U
M/UH A%U$>Y'X4\3Q'^,4&&,]47\J:;6(_P )'T-,1*&4]&!_&EJL;1.S,/K2
M?97'W9#_ "H M455\NY7HX/X_P"-&^Y7J@/^?:@"U157[3*OWHC^HI1>+W0B
M@"S14 NHCW(_"GB>(_QB@"2BD#*>C _C2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %58>;R0^F:M55M>99&H M4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "'H:JV1 9P>IQ5NJEPACE$B=S^
MO_UZ +=%,BD65<J?J/2GT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,T"R\CA_6IJ
M* *<3NC^5(/I5BH+OY94?_/%3TT#"BBBF(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JL_RW*GU_\ U59J*>+S "#R*3&2U',^R,GN>!4<
M<Y4[)/SH?]_.L8/ [_SHN!-91[8MYZM_*K5(   !T%+4C"J5W(7<1)^-3W,O
ME1Y'WCP*K6\>!O;J: (YT6-$ '/K6BGW!GTJA<_-(B#K_C6C38!1112 ****
M "BBB@ HHHH ***8[;$9O09H I$"6Z<GD#_]522;5B;@8QTJ.U'#-ZG%%RV=
MJ#J3FGT$2VJ9M6]7S_A45J?E8>AS5V)=D:KZ"J4/$\@^O\Z$-EBBBBJ)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!",@@]#45FQ25HSWZ5-4,L)9MZ'
M#4F-%ZBJEO<,7\N7[W8U;J1A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %5+Y28U8#A3S5NFD @@\@T 5HG$B C\:?43VKH=T3?A4?F
MS+PT?/TJKBL6:*ABE9W*L ,"IJ!!1113 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2J7C*C@FGT4 5HY'@^5D^4FK$<\<G0X/
MH:#SUJ&2W4@E>#4V'<MT57LW+(5)R0:L4AA1110 4444 %,F.(G/L:?4<_\
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MBBB@ HHHH **** "BBB@ JA:<2R"K]4+;_CYD_'^= %NBBBF(**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(2 "3T%+56]D*H$'\5 $,)WW#N!P<U8I
MD2;$ []Z?5(04444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %>']W=%>Q__ %U<JE<?)(CC_.*N Y&1WJ1BT444
MAA1110 5'< F!\>E24R8XA<^U $=I_J!]34]5[,?N3]:L4Q!1110 4444 %%
M%% !1110 4444 %%%% !39&V(S8S@4ZJ]U* OEKRQZXH +%!M9S@DG%7*AMX
M_+B"GKU-34AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5"#_ (^Y?Q_G5^J,7%Y)^/\ .@"U1113$%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 17"[HC[<U);-N@7U'%!&00>]0V9PSQGZU+&BW1112&%%%% !4=Q_J'^
ME24'D8- %>S(,1'<&K%4R#;W("G@]O:KE,04444 %%%% !1110 4444 %%%%
M !4,D\<>1G)]!1<R^6F!]X]*;;VX5=S@%CV/:@!N^>;[HVJ>_P#G^E,DMVB
MD5LD<GVJ[2$ C!Z&@ AE$L88=>XJ6L]2;:?!^XW^?TJ_UI#%HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJBG%\_XU>JB.+]O\]J +5%%%,04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"W1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2]/S(/8
MU8AXA3_=%5;P_O1_NU<484#T%,!:***!!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %2X_X^X_P_G5NJEQ_P ?<?X?SJW0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5!>?ZG\:GJ&Z_U#?A0 D?\ JE^@I]1PG,2_2I*8@HHH
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S!023@"H_
M/B_O?H:9<,6(C7DGFH_(D_N_J*5QD_GQ?WOT-.65'.%.3]*K>1)_=_45-;QE
M%)8<F@":BBDIB%J-YD3J<GT%-=9G4\A?853I-CL:-+2#H*6F(**** "BBB@
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MV\?E1!>_4TADM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 )68W[V5FS@9J]<OLA8]SP*I1#"_6FE<3 &9/
MNN?\_6GBZD7[Z _I2457**Y*MW&?O BI5EC;[KBJA4'J!33&O;BE9CN:%%9X
M$B?<<_G3Q<3#[P#?A_A2 NT566[7^)2/IS4JSQ-T<#Z\4 244 YY%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %6;]Y=HG8?_KJU56W^>=Y.W:K
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6OON
M+]:;9=7_  IU]]Q?K3;+J_X4#+=%%% BO>-B(#U-06@S./8&I+T\H/K3;(?O
M&/M0,NT444"*-X,39]14MFV8ROH:CO?OK]*6Q/S./:@9<HHHH$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53@^>Z=O3)J
MVQVJ6]!FJUD/OGZ"@"U1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %"Y^:X(^@J_5!^;O_@0J_3 ****!!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2 ,GH*
M6JEW-_RS7\: )TFCD;"MD_2I*HV?^N_"KU !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 5+C_CZC_#^=6ZJ7/\ Q\I]!_.K= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45S_Q
M[O\ Y[U+4<XS"_TH B@_U2U+4-O_ *H?6IJ8@HHHI@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4C$*I)Z"EJ"X+$!5!([X%(!(,,[.Q&3T%6*
MSB".M/25TZ'CT-*X[%ZBHHI5DXZ-Z5+5""BBB@ K/;[Q^M:%9[?>/UJ6-%\=
M!2T@Z"EJA!1110 4444 %%%% !1110 4444 %5[AB<1KU-6*KRD+<1D]!C/Y
MTF-%R)!#&%].IJ%[Q%X0;CZ]!3;J=3&%C8$MUQ1%$$4<#=W-*PQD2N\ID<8S
M4]%%,D*KOF>=4'0=?ZU8J"WXNW'KFAC1>    Z"EHHJ1A1110 4444 %%%%
M!5>\3= 3W4YJQ36 *D'ICF@"K VZ(>HXJ2JUKG#>E6:I$A1113 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)"@D]!0 M01G
M_3N/\\4ADDF.V,''K5B"V6+YB<MZ^E2V-%BBBBD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "J5U*7;RH^?7%3W,OE1$C[QX%5K:/:N\]6H
M >D**N" 3ZD4X(H.0H!^E.HJB0HHHI@%%%% !1110 56NS]T59JO=CY5/I28
MT-M>K5:JG;-MEY[\5<H0,*J7(Q+]15NJ=U_K?PH8(EM3\A'H:GJO:=&JQ0@"
MJ]W]U?K5BJ]W]U?K0P0VUZM5JJMKU:K5"!A1113$%%%% !1110 4444 %%%%
M !4%U_JQ]:GJM=_P?C28T6HAB)!["GT@& !Z4M2,**** "BFEU7[S ?4U&US
M$!PV3["@"('S+WV7^E6ZS8Y6CDW#GZ]ZG\RY?[J;1]/\:8%NHVGB7JX/TYJ'
M[-(YS))G]:>MM$.H+?4T"&/>#^!?Q--1[B4':>/7BF748CD&T8!%367^K;ZT
M# 6K-S(Y)J1;>)?X<_6I:*! !CI5>:Y"':@R?7M3YV;:$3[S<?2B*!(QTR?4
MT 53<RY^]C\*?'=G.) "/45:9$8890:H7$7E/@=#TH&: ((!!R#2U6LV)C93
MV-6:!!114-U)LBP.K<4 11#S[K<?NK_D5?J"UC\N$9ZMR:GI#"BBB@ HHHH
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M;9=7_"G7WW%^M-LNK_A0,MT444"*=]]Y/I26/^L;Z5)>KE%;T.*BLCB4CU%
MR]1110(I7O\ K%^E+8_>?Z4V\.9OH*ELEPC-ZG% RS1110(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y.V!_RIMF,0Y]
M327IQ$!ZFI(!M@0>V:!DE%%%( HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH HI\UW_P "-7JHVOS7 /U-7J8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD9@JDDX
M H CN)?*3C[QZ57:+9;%F^^Q%/B4SRF5A\HZ"GW?^H/U% R"S_UWX5>JC9_Z
M[\*O4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH J7/_'Q'^'\ZMU4N^)4/M_6K
M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !3)>8G_P!TT^B@"I:D;".X-3U!/"8SYD7'J!VI
M\,HD'HPZBF@)****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!" 1@@&H9+<'E.#Z5/12 S^5;T(J[$_F(#W[U%<IQO'4=:;:GEA2&6J
M***H05GM]X_6M"L]OO'ZU+&B^.@I:0=!2U0@HHHH **** "BBB@ HHHH ***
M* "F/&C_ 'AFGT4 0K BN&!)QV-3444@"BBBF 5 AQ?#W_PJ>J[<WB8Z@C-)
MC1H4445(PHHHH **** "BBB@ J*X;; Y]L5+5:^;$('J: (K88BSZFIJ9$,1
M*/:GU1(4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J&Y;$6/4U-5:<;IDC_ ,\TF-%NV39"HQR1DU-2=*6I&%%%% !1255G
MN\';%R?6@"W15:&Z5_E?Y6_0U9H **** "BBB@ HHHH **** "BBB@ HHHH
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M<=Z&8!UV@]\U;H 6BBB@ HHHH **3('4B@<]* %HHHH **** "BBB@ HHHH
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M'<OT53$\ZGD;OJ/\*<MX/XD(^E("U142W$3?Q8^O%2 @C(.: %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK+^\NT7LO_P"NK55;
M;YYI)/RH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%(6"_>('U- %>^^XOUIMEU?\*2[E5]JJ<XZXIMI(J.0QP".M R]12*R
MM]U@?H:6@0R5/,C9?7I5&%MDRD\<X-:-5;F D^8@^HH M457@N%9 '(##U[T
M37"JNV,[F/IVH KSMOG;'/.!5V)/+C5?3K4%M;D'>XY["K5 !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.\.61:M
M@8  [54E^>]4>A'^-7*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *1CA2?04M,F.(7^AH JV?^M/\ NU=JG9#YG/M5RF(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JK,QFD$2=!]XU)<R^6N%^\W2EMXO*3G[QZT 2*H10J]!4-W_J#]14]07?^
MH/U% $%G_KOPJ]5&S_UWX5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G>?Z
MU/I5RJEY_K$JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5)H&5O,A_(=JMT4 4_,
MG_YY'_ODT&6<#)CP/]TU<HZT 012>8F>_>GU7QY$V/X&_P _I5BF@"BBBF(*
M*** "BBB@ HHHH **** "BBB@ HHHH ***C,T8;:3S0!)12 Y&12T 1S?ZIO
MI45H/O-^%+._F$1IR>]3(@1 H[4ACJ***8@K/;[Q^M:%9[?>/UJ6-%\=!2T@
MZ"EJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0VP\RY9^PZ5
M-5=2;><$?<;_ #^E)C1H4445(PHHHH **** "BBB@ JE>G=(B#_.:NUGY\ZZ
M+?PKTH L44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%-9U3[Q H =4$ WWA/9<_X4-<9.(U)-2V<3(&9Q@GIFI8T6J***
M0Q"0!DG JO+=HO"?,?TJ&<F:X\L'Y5XIZ0HG09/J:=@(R9Y_O':OITJ2.)8Q
MQR?6I**=A7(I85DYZ-ZTD,S1.(Y.5]?3_P"M4U1S1B1,=QT-#0%NEJG:3?\
M+)^HZ?X5<J1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44UW5!E
MF ^M5WO8U^Z"WZ4 6J2J)FGE^Z-H]J;]G9N7DY_.BP%TS1KU=?SIGVJ'^_\
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M-,AX<G]?YTX7;K]] ?TI 7**KK=1GKE:E61&^ZP/XT /HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (YVVPL?:F6B[8<_P!XYIMXWR*OJ:G1=J*OH,4 .HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E5OO*#]12T4
M,\J/_GFOY4>5'_SS7\J?10 BHJ_=4#Z"EHHH **** (VAC<Y9!FE2*-/NJ :
M?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444C':I)[#- %2'Y[QF],G^E7*J60RS-^%6Z0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *BN3B!ZEJ"[.(#[D4 ,LA\KGZ5:JO
M9?ZH_P"]5BF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZ&J\#F&4Q/]TG@_Y]:0R]1110 444A.!D]* *,0V73QD<-V_6EA_<W13LW
M_I36;SKH-&.!C)IUV"K)(.H.* +U%-1MR!O49IU !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %074GEPG'5N!4]9UR_F7&T?=7C_&@!L:X7ZTZBBM" HHH
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 (44]0*:8AV)%/HI607&CS4^XY^F:<+F5?O*#^%
M%%+E'<D6[4_>4CZ<U*L\3=''X\56*@]13#&I]J5F.YH45GA'7[CD?I3EN)@=
MOWCZ8I 7J*JK=XX="/I4JW,3?Q8^M $M%("&&001[4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %63]Y>*O9?\
M]=6JJVOSS225:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN#M@<^V*DJO>G$0'J:
M"R&(B?4U8J*V&($_.I:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *K7I_=*/>K-5+T\(/K0!+:#$ ]R:FJ*V&($J6F(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *AN5+1$*"3GM4U% %.U1UERRL!CN*N444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !52]/S*OXU;JE/\ /=*OT% %Q1M0
M#T&*6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=\?G
M4>U7*HWIS,/84 6X>(4_W13Z11A0/04M,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 5+[^#\?Z5;JI??P?C_2K8Z4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55DMR&WPG!]*M4
M4 4TG(.V08/K4X((R#D4Z2-)!AAGWJNT,D)RAW+Z47 GHJ&.=7X/RFIJ8@HH
MHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %)2T4 16)VNZ&KM4(3MO2/[V?\:OU!04444 %
M%%% !1110 4444 13H7B91UQQ56V;*[>XJW*_EQ,WH.*J6JX4L>]-"9/1115
M""BBB@ HHHH **** "BBB@ J)IXU[Y^E1SR$MY:]._O4L42Q@<9;N:0QOVA.
MX8?A4BNKC*G-*0",$9JM,OE2!DX!H M44R-]Z!J?3$%%%1RRB,>I]* 'D@#)
M.!49GC'?/TJ%5>=LL>*L)&J#Y1^-(8)('/"L/<BGT44Q!44L"OR.&J6B@"NL
MTT/#C<OO_C2RW#S#9&I /6IJ H7H /I4V'<9#'Y:8[GK4E%%4(**** "BBB@
M HHHH *AN%S%GT.:FIK#<I'J*0$MNVZ!#[8J6J=@WRNGH<U<J2@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0C(P:SX?W<SQFM&J-VI299%'6@":BJWVGU3]:L Y&1T-
M42+1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !378(A8] ,TZJ=])\JQCJ>30
M! N7<NW4FG4BC:H%+6B1#"BBBF 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 1R9+*HZUH* JA1T Q5* ;[C/8<U>K,H**** "BBB@ HHHH ****
M"FM&C_>4'\*=10!7:UC/3*_C3?L\J?ZN7^E6J* *OF7*?>3=^'^%*MXO1T(^
ME6:1E5OO*#]10 Q9XFZ./QXJ0'/2H6M8F[$?0U&;5EYCD(_2@"U157_2H_\
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MHO\ $Q/TXJ58(EZ(/QYHMWWPJ>_2I*0"  # &*21Q&A8]J=4$R^;*D?8#<:
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MWIU4[YQL5 >2<F@"RLB/PK _0T^LQXF@V.#S_(UHHP= PZ&@!U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%07$XB&!RYZ"@!TTRQ+ENO8>M4<M+(9&I,-(V]SDFGU20
MFPHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1CA2:6F2'Y
M<>M)@B:S7Y6;U.*M5' NR%1[9J2H*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *0@$8(S2T4 1-!$W\ 'TXJ,V8SE'(^M6:* *NRYC^ZVX?7_&
MC[3(G^LC_I5JB@"!;J,]<K]14JR(WW6!_&D:&-NJ"HFLT/W25_6@"Q157R9T
M^Y)D?6CS9X_OQY'KC_"@":X;; Q]L4VU7;"#Z\U7GN/-0*%(YR:>ESY8"O&1
M@8H&6Z*A6YB;^+'U%2JRM]U@?H:!"T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<'; Y]
ML5%9#]VQ]32WAQ#CU-.MAB%??F@9-1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J,?S7?\ P(FKU4+7FX!^IH OT444Q!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5OONI]35E
M?NCZ57O?NI]:L)]P?2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"O=H"F_N/Y4L1S&I]J=<C,#U';G,(]J$!+1115
M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV@0^"3S%Y^\.M2U2MSB8>_%7:$#"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH 0C((/0U%9MLD:,]^E356GS'*L@I,:-&BFJ0R@CH>:=4C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBFNX12S' % $<\PA7)Y)Z"JJ*\KB1S]*0;KB4NWW1V_I5FFD)
MA1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?TJR  , 8% $%M"T0.YLY[#M4SN$4LQP!3J:RJXPPR* ,V2XDD)^8@>@J-"
MP+9-:HBC'\"_E1Y:?W%_*@"C+<><NQ4ZU9LU=8B'!'/&:F"@= !3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***9(P1&8]AF@!DLT<?WFY]!UJD6\Z<OCBFHN[+-SDU)5)"
M;"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9CS)E
M6GTMHNZ5G]/ZU,AHN4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &N<(Q] :J68_
M>G_=JS.<0O\ 2H+(?,Y]A0!;HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"M>_ZM?K4\?^K7Z"H+S_5+_O5/'_JU
M^@H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4449'K0 R49B?_ '35>U/[LCWJT2N#DC\ZIVI^\/I0!9HHHJA!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5[EL(%]35BH,>9=JO9?\ ]=)C1<B39$J^@I]%%2,**** "BBB@ HH
MHH **** "L^=3!-O4?*U:%131B6,J>O;ZT 1@Y&1TI:KV[D$QMP1TJQ5$A11
M13 **** "BBB@ HHHH HY\R49[FKU4&!CE^AJ\"" 1T-)#8M5;F+:=XZ'K5J
MH;DXBQZFA@AEH?O#\:FD&Z-A[5%:KA2Q[]*L4("@APZGT-7ZI3Q[']CTJS"^
M^,'N.#20,DJ*?_5-4M07+80+W--B(;<9E'M5VH+:/:I8]3TJ>A#84444Q!11
M10 4444 %%%% !1110 4444 %%%% !4<R;XR._45)10 EDVZ+:>JFK-4M/\
M^6GX?UJ[4%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5&[8O*L8/'>K$\ZPKSRQZ"JL2O(YE
M?O0!,JA5"CH*=115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%(2!U('UJ-IXQWS]*0$M%5S<9X1
M":3=._0;:+C+-,:6->K#\*@\EV^^_P#6G"!!UR?K0 K7*CH":=#,),@C!I0J
MKT %12QD'S$X(Y-&H%FBHXI Z^C#J*DIB"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>U %-1OO?^!']*NU2LQF1F/I5VD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"*Z.+=JBLA\KGWI]X<0_4TED/W1_WJ +%%%%,04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT.WW$_K1B=SRV/QQ_*IJ*+"N0"#^\Q-2"%!VS]:?13L%P  Z#%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0
M1GK110!&T$3=4'X<5$UHA^ZQ'UYJS10!5\JX3[DF?;/^-'FW"??3(]<?X5:H
MH K+=H?O*1].:E6>)NCC\>*<R*WWE!^HJ)K:(] 1]#0!.#GI154VK+S')C]*
M3_2D_P!H?G_]>@"W153[4Z\/'@_E4BW,1')*GW% $]%-5U;[K _0TZ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ.<[87/M4E079Q#CU.* &60^5S[XJU4%H,0#W.:GI#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH K7I_=J/>GV@Q /<FHKT_<'UJ:W&
M(4^E,"6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!4?F]7=T[?Y^M6ZJW'RW$;=O_ *]6J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUXIVJP[&K-%
M$$<JR#CKW%/J&6VQ\\7!':E@D,BG=U%.X$M%%%,04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5G_<W"N.A_
MR:LU6NQPII,:-&BFJ<J#ZBG5(PHHHH **** "BBB@ HHHH **** "J%PODW
MD'1O\FK]0W,?FQ$#J.10 P<C(I:AMGW)M/5:FJB0HHHI@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $-I_Q\R#V/\ZO51M?^/N3\?YU>J"@HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3)3A<>M/IC#?*J4GL-%RW7;"H]1FI***@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZTWS96^ZN/PJ8*!T 'TI:+"(-DS?>?'XTHMQW8GZ5-13L%R,0H.V?K3P .@
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M>=P^HJ=65QE2"/:@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*
M]3#+(/H:C!R,U=F3S(F7N1Q6?$>"/2JB)CZ***LD**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444R9ML+GVH AM/F9W/4FK-06BX@SZG-3T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'6BB@"-H8V
MZH/PXJ-K2,],C\:L44 5?LKK_JY,?I1BY3H=PJU10!5^T2I]^/\ I2B[3NK"
MK--:-&^\H/X4 127$;1-M;DC&*CL1]\_A1=0QI'N48.<=:?9C$.?4TAEBBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0\#- %*#YK
MK/N35ZJ5IS,3[5=IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D(!Z@4M% #=B_W5_*E"J.BC\J6B@ Q1110 4444 %13PB5?1AT
M-2T4 58)]O[N7@CH35JHI8$EZ\'U%0YEMC@_,G^?RH MT5'%,DH^4\^AJ2@
MHHHH **** "BBFF1!U=1^- #J*9YT>0-ZY/O3Z "BBB@ HHHH *J2_O+M5[+
M_P#KJR[!$+'L*@M%)+2MU)H LT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4'I110!1A)BE*-U-6JCN8MZ[U^\
MOZBDAD\Q.?O#K30,EHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH KS'RYUDK0K/N^BU>3E%/M4L
MH=1112 **** "BBB@ HHHH **** "BBB@"M?-B$#U--B&(E'M3;XY=$%24T)
MBT4450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9)((UR>O84^J\:B6Z(<Y SQ28T"133C<6VJ:N0Q^7&$
MSG'>GCCI2U(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *9*F^)E]13Z:_",?:@#-B/!'I3ZC
MAZ&I*T6Q+"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H)P,T4V0X3ZTF!
M)9+DLY^E6ZBMEVP+[\U+4%!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,L"2<X
MVMZBHLS6_7YD_P _E5NF2KOC9?44 07"B2)9%Z@9_#_ZU2P2^;'D_>'!IEF^
M8RAZJ:C/^CSY_@;_ #^E RY11UHH$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50E4K<$1\'M5
M^J=P0ER&]J #]^?XL4FR8_\ +3]:D61&Z,*=3L(A\J3O(?S-(82>KG\JGHIV
M"Y!]G'=C2_9U]34U%%@N1>0GO^=+Y,?I^M2446 9Y,?]VE\M/[H_*G44 -V+
M_='Y4[ ':BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN/]6/K5V'
M_4I_NC^54[G_ %8^M7+?_4)]*EC1)1112&%%%% !1110 4444 %%%% !36.U
M2?09IU5[R39$0.K<4 5[0??8]ZL5% FR,9ZGFI:I""BBBF(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F"J6/
M04 -=UC&6/X5';HTLWFXPHI((S<.7D/RCM5X  8 P!4ME#J***0!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %1S2K$FYOP'K2R2+&A9CP*H9:Y
MDW-PH[4  #3N7?I4R@*, 8%*!@8%%6D2%%%% !1110 CC*$>HJ*W/R$>]35!
M!P[+2Z@3T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:
MSJHY- #J*KO.W11CZTMN22Q)S2N%B>BBBF 4457DF).$X'K1<"Q15,J_4AOR
MI%=EZ$TKCL7:*CBE#CT-24Q!114,DI!VIR: )J*A$.X9=B337C:+YD8XHN!8
MHJ**7?P>&_G4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 02K
MY;"1#BK"G<H/J,U!<$; .^:G3A%'L*0QU%%%,04444 %%%% !1110 5#<C,7
MT-35',,Q-]*0! <PK4E16Y_=#VJ0D 9) ^M "T5$UQ&O?/TJ/SI)#B-/ZT7&
M6*C:>->^?I2+:ROS*^/;K4Z6L2=1N/O2N%BKYTDAQ&G]:>MI(YS(^/;K5T
M8 P*6D,BBA2(?*.?4]:EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+
MMPL# ]6X%35G3/Y\W'W5Z4 (@PHIU%%:$!1113 **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !56]/R*/>K55+X\H/K0!/ ,0I]*DIJ
M#"*/04ZF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU%"Y!\M^".E7:J70V3(] $E%%%4(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!LB[T([]J=92Y4QMU7I]**@DS'(LB^O^?S
MI,:-*BF1R+(@93P:?4C"BBB@ HHHH **** "BBB@ K/D/GW./X5JU<R>5$2.
MIX%5[9-J;CU:F@)J***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J\[&1Q$G7/-3.VU"WH*;9)G=*W)/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!6O3\J+ZG-6%&% ]!5:;Y[I%["K5 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=G$./4XJ>JEZ?N+^
M- $UL,0+[\U+34&U%'H,4ZD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JE><S*/:KM4YN;Q1[B@"Y1113$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5G^2YC?UJU5:
M\7Y%;T-3HVY P[B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ4F:@,"'U'XTR2/RP&4G@TAENBD4[E!'<4M,04444 %%%% !2')!P<'UI:*
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M 4444 %%%% !1110 4444 %%%% %62["CY$)]R,"H(II)+A-S'&>@Z5<N0#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 53^]?_C_2KE4XN;UCZ$T 7****8@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2IOB9?4<5%
M:/F,J>JFK%5!^ZO,=F_K_P#7H MT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5*8F>?:O0<5-<2[1L3[[?I2V\(B7G[QZT
M2HH10HZ"EHHH **** "J+?OKK';./P%6Y7V1,WH*KV:<L_IP* +=%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444R1MD;-Z"@"@[;[EF[ _P#UJ6F1#@GUI]6MB6%%%%4(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I+<;[C/8<T,<*34MFN$9O4U,AHLT445(P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *CG;;"Y]L5)5>\.(0/4T .M%Q /<YJ:
MFQ+MB4>@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 A. 3Z53LQF1C[59N#M@<^V*BLA\C'U- RS1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI:<S.?;^
MM6B< FJMB/OGZ4 6Z***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JUXGRJXZ@XJS39%WQLOJ* "-]\:MZBG
M55LWX9#U'-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HIIA$,#ECT%$\PB7U8]!4$3QAB\KY<^QXH E@A*G>_+G]*GJ+[3#_?_0TG
MVF'^_P#H: )J*JR7&\A(LY;C-60, "@!:*** *MZ_"IZ\FIK=-D*COU-5F_?
M76.V<?@*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !114=P^R%CW/ H JP_,[MZU/44"X3GOS4M4A,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDR[
MHR!UZT^B@ MKA/+".<$<#/>K(((R#D>U9R(KS.K>_2G^0Z',<A'Z5-BC0HJC
M'<O&VV8$CU_SUITMXNW$62Q[XI 23W"Q# Y;T]*K;)9SND) ]*=%"<[Y.6/.
M#4]-(5QB1J@^4?C3Z**H04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!6BXG<?7^=35 .+EAZU/0@84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!73Y)R/6K%5YOED5JL4D#"BBBF 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(2!U('UI:0J#U /UH @N'#8 .<4D+A6.3
MC-3[$_NK^5&Q/[J_E2L,4$'H0?I2T@4#H /I2TQ$4LNS@?>_E4"NRG(//K5L
MJI.2H)^E)L3^ZOY4K#*_G2?WOTH\Z3^]^E6-B?W5_*C8G]U?RHLPN5C([#!8
MU8B7;&!WI=B?W5_*G4)""FM(J]6%*RAQAAD4T1(/X13 B9VE^5 <5)'$$Y/+
M5)TZ446 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "D(!&",BEHH @,;1G=&?PJ2*</PW#4^J\Q4L HRW<BD]!ENBFJ"% /7%.IB
M"BDJ!IF=ML0_&D!8HJ 12'[TIS[4C>=$,[MR^] RQ5:ZZI^-2Q2B0<<'N*BN
M_P"#\:&!H#H*6D'04CL$0L>@%2,=16:;J;/W\?@*3[7-_?\ T'^% &G15"":
M>255W\=3P.E7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y_X]W^E
M9J??7ZBM*Y_X]W^E9J??7ZB@#7I#TXI:* ,JWD\J4,>G0UIJP=<J01ZBJ5S;
M,&+H,@\D>E5TD>,Y5B#0!J2*'1E/<4VW4I"JL,$5!%>@G$@Q[BK8.1D<B@!:
MS;W_ (^&^@K2K-O?^/AOH* +=I_Q[I^/\S4]06G_ ![I^/\ ,U/0!G)#*LZY
M4D!@<]JT::[JBEF. *K^?+*<0I@?WFH +X?N1_O5!8?ZX_[O]13KB%EBWO(7
M;/X4VQ_U[?[O]10!HU2OQPA^M7:IW_W4^IH CLHU=F+<XQQ6A5+3_P#EI^']
M:NT 5KU<PY[@U7LCB?ZBK-Y_Q[M^%5;+_CX'T- &E6=>2[Y-@^ZO\ZT#P*R&
M.YB3U/- &E;($A4=R,FIJ:OW1]*=0!6O5!ASW4U6LO\ CX'T-6KS_CW;\*JV
M7_'P/H: -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDJ^9&R'N
M*?10!EQY!*'J*?3KQ-D@<=&Z_6FCD9JXLEA1115""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 9*?EQZU=A79$J^@JF!OG5>U7ZA[E!1112 **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "JMU\TL:?YYJU58_/>^RB@"S1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[TXB ]3
M3K88A7WYHN(3-MPV,5"+>=?NO^1- RY15/%VOJ?R-+YUPO6//_ :0%NBJGVM
MA]Z/]<4X7B=U8?2@"S14 NHCU)'U%/$\1Z./QXH DHIH=3T8'Z&G4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 R4XB<^QJ&Q'[MC[U+<'$#_2F68Q!]30
M!/1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445#)<1IP#N/H* )J*BMY3*I) &#VJ6@ HHHH
M***JM=@,0$R!WS0!:HJK]M_Z9_\ CW_UJ47A) $?)_VO_K4 6:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"H1Y5Z/1OZ_\ UZMU5N_E>-_2K5 !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(<[3MQGMFEHH J-:RL26923[_ /UJ
M;]D?U7\__K5=HH I?9']5_/_ .M1]D?U7\__ *U7:* *T%LT<FYB#CIBK-%%
M !37SL.T9..*=10!6M861F9Q@]!S5FBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J3MYTP0?=7K5B5MD
M3-Z"JMNN%+'J: )J***H04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!#'Q<L/6K-5AQ=CW_P *LTD,:RAQAAD4BQHO
M113Z*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?FQ%>_;ZU0C.,H>"*TZI7D6UA(OXTT[ QE%"G<,BBM" HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***:YPII /LUW2,Y[5<J&T7;"#Z\U-4%!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5;7YII'JQ(VV-F]!4-DN(B?4T 6**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !10>.M5YKE5XCPS>O84 )>M\JH.I.:51M4#TJ%(V9M[GGK
M4]- PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ('XN4_"K559^)$-6J0PHHHIB"BBB@ HHHH **** "BBB@
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M=HH JQVSQ_<FP#VV_P#UZL#( R<GN:=10!3FL]S%HR!GL:2.RYS(PQZ"KM%
M$3PJ\1C'RCMCM59;)MWSN,>U7J* (]FV/9&=N.AQFH'LVD;<TN3_ +O_ ->K
M=% %1+-HVW++@_[O_P!>IU5PI!?+=CMZ5)10!5DMGDQOESCMM_\ KTT614@B
M7!'^S_\ 7JY10!'&KKG>^_TXQ3F4,"&&0>U.HH I267.8VQ[&FK9/_$R@>W-
M7Z* *SVX$!CCP"<<GO38[-1S(=Q]!TJW10 U55!A0 /:G444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !364.I5N0:=10!EE3%(4;\*?4]Y'NC
MW@<K_*JZ'<H-5%DL6BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1ODE5'4U)20#?<9[+
MS4R&BZHVJ .@&*6BBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4UY%C&6.*25Q&A8U76W>8[Y6QGM0 \W<>>C'\*DCGC
MD.%;GT-0M9C'RL<^]565HVP>"*!FI14-O*9(^?O#@U-0(*#QUHJE/*97V)]W
M./K0!.UU$IQDM]*5+B-S@'!]#2Q1+$N .>YIES"'0LH^8<_6@">BJMM.3^[<
M\]C5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"&Z;$!]^*=;C; @]LU%>'A%'<U8 P !VH 6BBB@ HHHH ****
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M"/H:!DHD0]'4_C3JK&S3LS#ZTW[&P^[)^F*0%NBJGD7"])/_ !XT?Z6OO^5
M%NBJGG7 ZQY_X":/M;#[T?ZXH MT56%XO=2/I3A=1'J2/J* )Z*B%Q$?XQ^-
M/$B'HZG\: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!6O3\J#WJP@PBCT%5;WET%6Z8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJG???7Z5<JG???7Z4 /LO]6WUJS5:R_U;?6K- !37#%"$P&/3-.HH H&UE'8
M'Z&HF1D.&4CZUJ4C*&&& (]Z!E"&X:/CJOI5Y'#J&4Y!JG<6_E_,GW?Y46LA
M23:>C4 7J***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5!=1;UW+]Y:GHH BMY?-C
MY^\.M2U50!+T@< _X9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !03@9-17$GEQ$CJ>!57RY)<,[]?6@"R]S&O?
M<?:H'NW/" +^M*L"#KDU(%"] !3L%ROLEE.6S^-21PA.3R:EHHL*X4444P"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@""Y_A-6:KW/W!]:G3E%^E+J,=1113$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!#<C,7T-+&<QK]*6<9B:FP\Q+
M2Z@/HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!"RF:
M?8#\HZU-/&!;D*.%Y%1Q'R[DJ>CU9D&Z-AZBI&01G,:GVIU16YS'CT-2U2$%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 45"\Q+;8QD^M*+:5_OMC]:5QV'&5!_$/PJ,R/*<1C ]:2:(1R!%.2:M*H4
M  8 HW CAB\L'/+&I:**8@HHHH **** (YI/+3(ZG@5#:KEBY[4MU_#Z<TZU
M_P!6?K2ZC)ZK3P]70?459HH$48GV.#V[U-<_,Z(.]02KME8#UJ>(>9=CN%_I
M_P#7I%%\#  I:**0!36 92#T/%.IK,$4L>@&: ,VW!%RH]#6I5&S0L[2'H.G
MUJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T@$$'H:SBIB
ME9#T[5IU4O8\J)!U'!H0$-%(IW*#2UJ0%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !. 33[-?
ME9_4XJ&4X7'K5R!=D*CVJ&4B2BBBD 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #60,5)_AY%.HHH *J7H&4/<YJW5.0&YF
M 3[J]Z 'V:D(Q[$U9I%4(H5>@I: (;I]D) ZMQ5:T7,V?09I]Z?G5?09I;(?
M,Y]A0,MT444",UQY<I XP>*T(VWHK>HJE=#$[?A5BS.8<>AH&3T444""BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JR_/=H
MOI_^NK558OGNW;T__55J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "JTWS72+Z<U9JJ/FO3_LC^E %JBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IC0]44_44TP1'J@_#
MBI** (#:Q'H"/H::;1.S,/K5FB@"I]D8?=?GZ8I?(N%Z29_X$:M44 5/]+7W
M_*CSKA>L>?\ @)JW10!4^UL/O1_KBG"\7NI_"K--,:'JBGZB@"(741[D?44X
M7$1_C'XTIMXCU0?AQ3#:Q'H"/H:!DHD0]'4_C3JK&S3LS#ZTW[&P^[)^F*0%
MNBJGDW"]),_\"-'^EK[_ )4 6Z*J>=<#K'G_ (":/MC#[T?ZT 6Z*K"\7NII
MPNXCW(_"@">BHQ/$?XQ^-.#H>C*?QH =1110 4444 %%%% %2XYNHQ]/YU;J
MJ_-ZH]*M4Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5.^^^OTJY5.^^^OTH ?9?ZMOK5FJU
ME_JV^M6: "BBB@ HHHH 0@,"#T-9V"DN.X-:54@-]V<= V3^% %VBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** *LORWD9]<5:JK=_+)&U6J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J71WS+&.
M@ZU)4$)WR.YZU/30,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZX5!]T=?ZUH#@8%2,IW<TB2!5.T8S]:(KSM*/^!"K4D:2+AQD5";*(]V'XT
M.-U$!G?G\*A)DNCA04C[D]ZF2UB0YVY/O4W2@!$0(H51@"G444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0M
M<1JX7.23CB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 55MOFGE;_/6K). 3Z57LQ\C-ZF@"S1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[5BK/&W4<T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3A:C^)B?H*L446"Y$+>,=L_4T\(J]% _"G44""BBBF 4444 %(PW*1ZBEHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M5)OW5RL@Z'K_ %JW56^^ZGU- %JB@=** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"P'4@4 +149F0=\_2F&?\
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M)-HV+]XU/;0^5'S]X]:AM8S(YE?\*NU#*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K
M_<;Z5E1?ZU/]X5JO]QOI65%_K4_WA0!KT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!GW+%[G:>BTE)-_Q]M]?Z4M7$EA1115""BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;
M(NX>XIU%(":UEWIM/WE_45/6><QN)%J\CAT##H:@H=1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 5KJ%I"&7G QBH%6:,Y57
M!]A6A10!562X;CRQ]2,4Y8"S;YFW'T[58HH **** "H9X!+R.&]?6IJ* *R2
M31#:T9;'0BD9)IS\PV)Z5:HH 9'&L2[5_.GT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 55^_?>R_X5:JK:_-+(_K_6
M@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %:]/RHOJ:L 8  [57N/FN(A^/ZU9H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *J#F_/\ GM5NJL?-ZQ]* +5%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 56O?]6OUJS5>\_U2_[U $Z?<'TI
M:;'_ *M?H*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444UVV(6/84 07%P5.Q/O=S3(HMIW-RU)""Q,C=34U-(&%%%%,04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -E.V-CZ"H;-<0D^II;IL0D>IQ3X!MA0>U $E%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5?O7W^Z/Z5:J
MM#\US(?3C]:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %5+?F[D/U_G5NJMKS/*?\ /6@"U1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *@?BY3\*GJ"?B1#0P1:HHHH **** "BBB@ HHHH ***C
MF?9&3WZ"@"2BJ'F/_?;\Z/,?^^WYTKCL7Z*K0;W?)9B![U9H$%%-9@JDGH*@
M#23,0IVK0!9HJ'[,G<L33'5X?F5B5]#0,LT5'%()%ST(ZBI*8@HHHH ****
M"HYQF%JDIKC*,/44@(;<_N_QJ6H+8\,*GIH&%%%% !1110 4444 %%%% !11
M10 53E_UC?6K+*YSB3 ^E1_9O]O]*3&B6+_5K]*=42Q,@P)./I4HSCDY-,05
M%++LX'WOY5*>0<'!J#[/G^/]*& V.1%Y;)8]ZD^T)Z-3?LW^W^E'V;_;_2EJ
M/07ST]&IK2F0A%& :7[-_M_I3HX=C9SG\*-0T)0,# HHIC>9GY2N/>F(>3@9
M-5Y9"YV)T_G3C$S???/L*D5%0?**0#(HMG)^]_*I:**8!1110 4444 %%%%
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M62-J )%4*H Z"H.);I O('?Z42R[L)%R3Z5:MX1$G^T>IIMB1-1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !60_WV^IK0>2?!"PX/J6%4_LDW]S]1_C0!HK]T?2
MG56C:=5"M#G'?<*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4K
MJ#!\Q/Q']:A1MP]ZTJH748B<,G ;M33L)H2B@=**T)"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* &$F.0.M7D<.@8=#50C(P:+>3RI-C?=-0U8I%VBBBD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %6[.=B#N:M 8&!563Y[Q!_=_\ UU:H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/ HIDQQ$Y]C0!#9#Y78]S5F
MH+08A!]3FIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "JEER7/TJT>AJO9?=?ZT 6:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH JW2E)%E7\:LJP90PZ&DD021E3WJE&)22BN5QVS0!?HJGY4W>4_
MF:3R)#U>@"[15+[,3U?]*/LO^W^E %S('<4F]/[R_G57[*/[Q_*E^RK_ 'C0
M!8\V/_GHOYT>='_?7\ZK_9D]6I?LT?O^= $WVB(?QBD^TP_W_P!#47V>/T/Y
MTOV>/^[^M%@'_:HO[WZ&D-U%ZG\J3R8_[M'DQ_W!3L ?:X_1ORH^V1_W6I?+
M3^XOY4NQ/[J_E18!GVQ.RM2?;1_</YU)M7^Z/RI<#THL%R'[9_TS_7_ZU'VM
MNT?ZU/118+D'VF4](_T-'VB?_GG_ ..FIZ*+!<@\^X_N#\J3S;D_PX_"K%%%
M@N5]UT?\BC-UZ_RJQ118+E?%R?XOUHV7!_Y:?^/58HHL%ROY4_>4_P#?1I/)
ME/63]35FBBP7*WV9CU>C[+_M_I5FBBP7*_V4?WS^5'V5?[QJQ118+D'V9/5J
M7[,GO^=3446 A^SQ^_YTOV>/^[^M2T46$1^1'_=_6CR8_P"Z*DHH B>%"I 4
M ]J+.3@QMU'2I:K3*T<@D2AC+M1SN8XV8=>U+%()$##\1Z5'>#]S]#2 @BBW
M?.YSFIZ;'_JU^E.JD(**** "BBB@ HHHH **** "BBB@ HHI&8*,DXH 6BH'
MG[(/Q-2H24!/4BBX#J*** "BBHWE5/<^@H DHJ".5GD Z#TJ>@ HHHH **:[
MA!D_E48:63E0%%%P)J*B(F'.X'VHCFW':PP:+@2T444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *H7K;I57T'\ZOUFNWF7#-V'
M2A +1116I 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4V1=PXZBG44@)K67S$VG[R_J*GK/),
M4@=:O(X= PZ&H*'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%(QVJ2>PS0!6A^>Z=O2K55K(?*S>IQ
M5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "H;LX@;WQ4U5KT_(H[DT 2P#$"#VS4E(HPH'H*6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LAQ$Y] :@L_\ 5-]:
MFF_U+_[IJ*S_ -3^- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJEP/*F60=#UJW5:]/RH/>@"0'(R.]+2 8 %+5""BBB@ HHHH **** "BBB@
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%+)M^5>6-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!',_EQ,W<#BL^(
M?+GUJS?L0BKV)J$#  JHB844459(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !&1@T6\
MGE2;&^Z:*;(NX>XJ6AHOT5!;2^8FTGYE_6IZD84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<-B%C[8J6JUX
MW[M1ZF@!]L,0K[\U-34&U%'H*=0 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** (ISB%_I26@_<#W)HN?\ CW;\/YTMKQ;K_GO0!+1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5>[C+(&'\-6** *\4GF)GOWJ2J[#R)
ML_P-_G]*GZTT M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6E&ZX
M4'I4U12\7"?2I:2!A1113 **** "BBB@ HHHH **** "BBB@ HHHH IR_P"M
M;ZU:C_U:_2JLO^M;ZU:C_P!6OTI+<;'4444Q!4<W^K:I*CF_U;4,""#_ %HJ
MW52#_6BK=)#84444Q$,\6[YEZ]Z@5BAR#5PD 9)P*@9?-8E%P!W]:3&A3,64
M! =QIT46T[FY:J_*GT(JQ%-NX;K_ #H0$M%%%,04444 %%%% !1110 4V3_5
MM]*=2,,J1ZB@!MK_ *K\:FJO:GY&'O5BDAA1113$%%%% !1110 4444 %-D&
M48>U.J.9MD9/<\"@"O;#][^%7*@MDVKN/4U/20V073X4*._6BU7"%NYJ.Z'[
MP'VJ:W.8A[4=0):K3P]77\15FB@12@?;(/0\&KM40O[W:/[U7J$-A1113$%%
M%% !1110!7NNJGZU*.1FH[H?(#[TZ/F-?I26X#J***8!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !11378(N30 ZBHHH#-EW)&>F*<;9^@E./>E<=AKR\[8QEJD@M]AWR<MZ>
ME210K$..3W)J2D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<
M<0C+$=6.:DHH **** "BBB@ HHHH **** "JDQ\Z<1C[J]:L3/Y<9;\J@MTP
MFX]6YH FHHHJA!1110 4444 %%%% !1110!'.<0M3K;_ (]U_'^=)*-T;#VH
MLVS#CT-)C)Z***0!1110 4R7_4O_ +II]1W#8A<^V* ((,M"1TZBG6+ %T/#
M=:+88B'OS3"?)N5?L>O]:&!H5GS$)>ECT_\ K5H53N8'EF!4#&.II#(#OE9I
M$!PM312!QZ,.HH:46JB-5W-C)/O45NF]RY.,'H*:$6J***H056N/DE1Q_G%6
M:AN5S%GT-)C+0Y&1145LVZ!?;BI:D8444=.M !14;31KU<?AS4;7<8Z F@".
M/]U>%>S<?G6A67-+YCA@NTCWK0A.8D/^R* )**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *=_
M]U/J:BJ:_P#N)]:A'0541,****LD**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!A
M)BD#K5Y&#H&'0U4(R,&BVD\J38WW3_.H:L4B[1112 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK<_-/&E6JJK\]Z
M3V6@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(0&!!Y!I:*
M(I(D,3 *!QQ@513_ %B_45I/]P_2LU/]8OU% S3HHHH$!X&351(3.YD?(4G@
M5:(# @]#2@8&!0!$+:(?P?K1]GB_N"I:* *\\44<3,$&>U,LT^\_X"B\?[J?
MB:GA39$J]\<T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5H?FNG/IQ5FJMIR78]S0!:HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH @O#B#ZFGVXQ GTJ.]_P!4/][_ !I(
M[F-8U4[L@8Z4 6:*@^UQ?[7Y4OVJ+U/Y4 345#]IA_O?H:7[3%_?_0T 2T5&
M)XC_ !BE\Z/^^OYT /HIGFQ_\]%_.E\Q/[Z_G0 ZBDW ]Q2T %%%% !1110
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M!1113 **** "BBB@"*X&8C[4V'_5K4DPS$WTJ*W/[O\ &EU&2T444Q!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !40'VB;'\"]:)F/"+]YJLPQB*,*.O<TF-#^G HHHI %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *E__ *M?
MK4*_='TJ>_\ ]4OUJNOW1]*J(F+1115DA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %-D7<,CJ*=12 FMI?,3:3\R_K4]9Y)BD#K5Y&#J&7H:@H=1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;3YI)']
M:GF.V)S[5'9C$.?4T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 C_</TK-3_ %B_45I/]P_2LU/]8OU% S3HHHH$%%%% !114<[[(6/?
MH* *H_?77MG]!5ZJEFGWG_ 5;H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &RG$3'T!J*S&(<^IIUT<0-2VXQ @]LT 24444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5KT_(H
M]Z?'#&8UR@)P*BOOX/Q_I5I1A0/04 1_9XO[@I/LT/\ <_4U-10!#]EB_N_K
M2?98O0_G4]% %?[+'_M?G1]DC_O-^?\ ]:K%% %;[(G]YJ3[&O\ ?/Y5:HH
MJ_8A_?/Y4GV/_II^G_UZMT4 5/L9'23]*/LL@Z25;HH J_9YO^>OZFD\B?\
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M*** "BBB@ HHHH 1AE2/456MCPPJU56#B1EI#)Z***8@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M8X4GT%+39/\ 5M]* "UCR3*W)/2K-16W^H2I:D84444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M>J6AR/X3DU60Y4>U:)&1@
M]*SI$\F4K_">E-,3%HHHK0D**** "BBB@ HHHH **** "BBB@ HHHH ****
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MN3WIH":BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *@N1C:XZ@U/39%WH5]:0#0<@$=Z6
MH87VG8_!'2IJ8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $+<7*GUJS5:
M3BX0_3^=6:0PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTMM)Y<FQNAZ5#5BD7****0!1110 4444 %%%% !1110 4444 %%%% !1110
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MI4@1>V3[TZ(YB7Z4^JL(AD@5^1\IJLC&.0,,94U8FEVC8OWCZ=JF@ME6(B0
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MDS?Z^3_>/\ZUJR9O]?)_O'^= &E%_JD_W14E1Q?ZI/\ =%24 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -8!
M@01D&J;63@G8X_'BKU% &:\,T:DGH.^:%.Y0:OLH92IZ$8K.3*NR'J#5)B:'
MT4459(4444 %%%% !1110 4444 (JX^II:**  C(Q4 Y(J9CM4FF1I_$?PJ7
MJQHDHHHJA"*N/J:6BB@ (R,5 .2*F8[5)ID:?Q'\*EZL:)****H04'H:*#T-
M("!?O#ZU/4"_>'UJ>E$;"BBBJ$%%%% !1110 4444 %%%% !39%W#(ZBG44F
M!/;2^8F#]X=?>IJS\F*0.M7T8.H9>AJ"A:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I&.U2WH,TM17)VP-[\4 1V0^1CZG%6:BMEVP+[\U
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1137.U&/H,T 06GS.[^IJS5>R&(B?4U8H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &NN]"N<9[TJ
MJ$4*HP!2T4 %072@Q$]QTJ>J]T_R",<LQZ4 0V@)F'L#5ZH8(?*3G[QZU-0
MC<*2*SH6"S*3ZUI5G3QF.0CL>E S1HJI;W P$D/T-67<(I9CP*!%2]_UB^N*
ML6V?(3-5E1KF4L>%[U=    Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J#F__ ,^E6ZIQ
M<WC'T)JY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5!>'$./4U/5:\!,:D= >: %A4+&O'49-24U&#(".E.JA!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $$T9SO3J.M$4@<<_>%3U6GB*GS$X]:0R:B
MF12!QZ-Z4^F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M JM>CY4/O5FJU[]Q?K0 VRZO^%6ZJ675_P *MT %,E?RXV;TI]5KQL(J^IH
MKPCS)E!YR<FM&J-H,S?05>H *SYUV3MCUR*T*I7@_>@^HH M0OYD2MW[T^JM
MDWRLOH<U:H **** "BBB@ HHHH ;(=L;'T!JO;C$0]S4UP<0/]*CA&(E^E-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% %2WYNY#]?YU;JG:<S,:N4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(RAE*GH:6B@"G$3%*8F
MZ$\?Y]ZL5'=1EU#J/F7^5)!+YBX/WA30$M%%%,04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!7DM^=T9P?2D68J=L@P?6K--=%<889I#$!!&1S14)C>(Y7
MYE]*?'*K^Q]*=Q#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH AM>&=:LU6AXN''KFK-)#"BBBF
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8X_NJ ?6I*** "F.&*X5MI]<9I]% %1[-I&W-+D_[O\ ]>A+-HVW++@_[O\
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MTK@/EE>=O1!VI0,#% &!Q15I6);"BBBF(**** "BBB@ HHHH **** "BBB@
MJ*4<@U+44AW, *E[#0Z/[GXT^A1@ 44T(****8!44HY!J6HI#N8 5+V&AT?W
M/QI]"C  HIH04'H:*#T-,"!?O#ZU/4"_>'UJ>IB-A1115""BBB@ HHHH ***
M* "BBB@ HHHH **** &9,4@=>E7U8.H9>AJF1D8-%M(8W\MNAZ?6H:L4B[11
M12 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JI\]ZQ_N_P#ZJM55M/F:
M1SWH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 56N_F9%]35FJTOS7:#T'_UZ +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%!.!DT 9]PNV=P/7-7HQB- >P%4U7[1<D_PYR?I5Z@!';:A;T&:SX?WDZ[N
M<G)J^Z[D9?48JA =DZYXP<4#-&D(!&",@TM% C/N(O+?C[IZ58LVS%@]C27V
M-B^N:=:*5BR?XCF@9/1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBD<X1CZ"@"K9=7_"K=5K+[K_6K
M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<# HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDO^J?_=-/J.<X@?Z4 16?^J8^]6:@L_\ 4_C4
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5KF%2A<###T[U9ILHS$X]C0!#"Q:-23DU)4%L?W1]C4],04444
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *K3?).K'H:LTR5/,0COVI %%0 S(
M -F0*7SF'WD(IW"Q-14(N%[J:7[0GO1<+$M%(KJWW3FEH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A'%W]?\*F
MJ!^+E3ZXI,$6J***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% $-RQ$?!QDTD=KN4,SGD9P*2[_@%7 ,#%2QD"VL0Z@GZFI@ !@  >U+1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S[H;;D'U _PI*FO(BRB1>J]:@1MP
M]ZJ)+%HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%%  1D8-+;2%'V-T/3ZTE,D7(R.HJ6AHT**AMI?,3!^\.M35(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *MW\SQIZU:JJWSWH']W_ /75J@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&.U"?
M09JO9C]TQ]34MP=L#GVQ3;88A7WH FHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *BNO^/=O\]ZEJ&[.(#[XH +0?N%_&
MIJBMN($J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"G:\;QZ&K%5XN+F0?7^=6*:!A1113$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "%5/4 _44TQ1G^ ?A3Z* ('@'5#
M@TV*1B^QASZU9JI!\TC-2&6****8@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "J\YQ*IJP3@9-0(#/+D_=%)@BU1113 **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&6<+\J_,U(!LOS7,
M8^E7*K00OO$LAY]*LTAA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %5HSB\?W'^%6:K7*$%94ZKUH L
MT5'%,LHX//<5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !114-Q)Y<9QU/ H B4^=.7_ (5Z5/4<*;(P.YY-24T(****
M8!1110 4444 %%%% !1110!3GBV-D?=/Z4D4QCX/*^E6W*A3NQCWJFR9RR*=
M@J6,GDFW#;%R32PP[/F;EOY57CD,;9'Y5;CD61<C\130#ZK70^Z?K5FHYTWQ
MD#J.10P(+4X<CU%6ZSU8HX(ZBKR.'7*FA QU5+K_ %@^E6B0HR3@52F</(2.
ME#!$UIT:K%06H^0GU-3T( HHHIB"BBB@ HHHH **** "BBB@ HHHH *2EHH
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M_P!0G^Z* ):*** "BBB@"M=0-(H*]5[>M-M8&C8N_!Q@"K=% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 E9]Q$89-RCY#^E:-,D02(5;H: *(.1D44W:T4A1OP
MIU:)W(:"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 P$PR!UZ5?5@RAAT-4V&X8-+:R;'\MNAZ?6H:L4BY1112 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***:[;49O09H KVWSSR/UJU5:S7$;-ZFK- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%V<0X]
M3BI(AB)!["H;SG8H[FK- !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 57O/]2/\ >JQ5:\_U2CWH E@&(4^E24V,8B0>
MPIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %([!%+,< 4M5W0SRD'(C3]30!$]VQ/R  >]-%U*#]
MX'\*NK&BC"J!4<L"2*< !NQ% Q(+@2':PPW\ZGK+Y5O0@UIJ=R@^HS0(6D=@
MBEF. *6J[H9Y2#D1I^IH B>[8GY  />FBZE!^\#^%75C11A5 J.6!)%.  W8
MB@8D%P)#M88;^=3UE\JWH0:TU.Y0?49H$+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4
M/%Z??_"IZAGXND/J*FIH&%%%%,04444 %%%% !1110 4444 %%%% !1110 4
M444 %%5+E]S[1T%04KCL:5%9U78$V1CU/)HN!)1113$%%%0SR;%P/O&D!)O4
MG 89],TZJ4'^M6KM"&%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M ,E;9&QJ&W'R$^IHNF^Z@^M2(NU OI2ZC'4444Q!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444A( )/04 13OT0=34T2>6@'?O
M4,"[W,C?A5FD,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1B%
M&2<"EJO@W$N <(O>D &1YCLB! [FIH8%BYZMZU(B*BX48%.I#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@""6W5CN0[&]J2&5_-\J4#/K5BJUR-CQRCL<'_/YT 6:*0$
M$9!R#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !523]]<X_A2K39*D*<''%5+<[69&&&S0!8HHHJA!1110 4444 %%%% !111
M0 4AX&32U'.<1-B@"!F,\@4<+VJT %  Z"JMK_K#]*MTD-E:>#^)!]14".48
M,*T*IW*!7R.AI,$6U(901T-+45O_ *H5+3$0RP*YR.#48MG!X8"K5%%AW(!
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MJ)/]T_RJ2HYO]1)_NG^5 &;!_KT_WA6K65!_KT_WA6M0!6DN)(QEH>/7=_\
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M*0AO+/0\BKCHKC##(H ADNXTX'SGVHMIVF9L@ #IBH+R)4VL@ SP<4MAU?\
M"@"]3))%C7<YP*?6=>L3-M/11Q0!,+F20GRH\@=R:1Y[B/F2-<>H_P#UU):#
M_1U]\_SJ9E#*5/0C% $4%RDIVXVMZ5/6.I*.#W!K8H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"I?)E%<=CBH0<@&KLR>9$RCN.*SXCE<>E5$3'T4459(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4QUR,CJ*?128$]M+YB<_>'6I
MJSP3#('7I5]6#*&'0U!0M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %0W)Q"WOQ4U5KT_*J^IS
M0!);+M@7WYJ6D4;5 ]!BEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH JS9:ZC7TP:M55'S7I/]T?TJU0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5
M;[HGXU:JK>\F,?7^E %E1A0/:EHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KW%P%!5
M#EO7TH KE3).P7NQJ^!@ #M4%H(PORG+=ZL4 %%%% !115>XN H*H<MZ^E %
M<J9)V"]V-7P,  =J@M!&%^4Y;O5B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JWG#Q
MM4U0WWW4^IJ6F@8M%%%,04444 %%%% !1110 4444 %%%% !1110 4R1]B%J
M?56Y?+;1T%)@/MDPI<]6J>J2RNO1N/>I4N0>'&/<4)C+%%("",CI2TQ!1110
M UV"*6/056VET>5_3BGL3/)M'W%ZFI)0!"P'3%(95@_UJU>JC!_K5J]0@844
M44Q!1110 4444 %%%% !1110 4444 %%%% !113)6V1L>_:@"N/WLY;L*L5%
M;KA,^M2T(&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5#<-P$'4U*2 "3T%10CS)3(>@Z4,$3HNQ OI3J** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHI&.%)]* (9Y/X%ZM4\$8BC []ZAM4W
MLTK<G/%6JD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3702*5;H:=10!4R]JV
M#\T9JRCJZ[E.12D C!&0:K/$\#%X^5[B@"U14<4RRC(X/<5)0 4444 %%%%
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M*+M1O-&GWG ]JID7$GWFP/3./Y4&V&T_,2W:G8"_UI:JV<NY?+;[R]/I5JD
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M0.116I 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ##<,&EM9-C^6W0]/K24R1<C(ZBI:&C0HJ&WE\U.?O#K4U2,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JK/\]RB]A5JJL?SWCGT_\ U4 6J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G )]* *UO\UQ*WO_
M %JU5:R'R,?4XJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5+KF>,?YZU;JI/S=Q_A_.@"W1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!%)")#R[#V!XJO):LHRAW#]:NT4 98)4Y!P16A#)YL8;OWJM>1A6#
MC^+K3[$\./I0,M4444"(I(1(>78>P/%5Y+5E&4.X?K5VB@#+!*G(."*T(9/-
MC#=^]5KR,*P<?Q=:?8GAQ]*!EJBBB@04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5O?NI]:E'
M2HKW[J?6I1T%- Q:***8@HHHH **** "BBB@ HHHH **** "BBB@ IAC0]5'
MY4^B@"%K=#TR*KR1-'UY'K5ZD(!&",BE8=RI#*4.#]T_I5RJ,L?EOCMVJU V
MZ)?;BA R2H9Y"!L7[S4^1PB%C4<"$DR/U/2@"2*,1ICOWI)O]4WTJ2HYO]4W
MTH$58/\ 6K5ZJ,'^M6KU"&PHHHIB"BBB@ HHHH **** "BBB@ HHHH ****
M"J]R<A5'<U8JL_S7(']VDQDH& !Z4M%%,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%13L57 [T ,D8RN$3I5E$"*%%,AC$:>
MYZU+2&%%%%,04444 %%%% !1110 4444 %%%% !12,P49)P*@:=F.V-<GUI
M3,ZH,L<4(ZN,K426K,=TK?A39(VMWWIRAHN.Q9HJ'[2GO^5(;E,'&<T7 6RX
M:1:M56M$PA<]6JS2 **** "BBB@ HHHH ***1V"*6;H* (KB7RDX^\>E0VKN
MTN&9B,=S4<@:16F;@9P!3K/_ %WX4#+U%%,F?RXF;OVH$13W.P[4Y;N?2JQG
MD8\N?P.*LPVX W2#+'G![5/@8QCB@906XE7^(GZ\U;@G$HQT;TIEQ;AE+(,,
M.P[U31BC!AU% &I12*=R@CH1FEH$%%%% !1110 4444 %%%% !1110 4444
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M08I!*GKS_GWJ[&XD0,O0U RAE*GH:CM9#'*8G/!/'U_^O4L:+U%%%(84444
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M@"D=MJDX)QV R: *]_\ ZM/K3+#[S_04ERTDI 6)PH]5IMOYD3DF)R",'Y:
M-&LF4DRL3UR:TT?>N=K+[,,52NK=E<N@RIY..U %V,AHU*]"*5F"@EC@#O6;
M#-*GRQY/MC-64@>4AIR2.RT 43R36P6 &2<"LJ6-HY"I'?BK<$4C[3,3M7HI
MH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4-TF^%AW'(J:DH S8CE/I3J9M\N9D]Z?6BV)84
M444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 T$PR!UZ>E7E8,H8<@U38;A@TMK)L?RVZ'I]:AJQ2+E%%%( HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH "<
M#-5K,9+N>I-2SG; Y]L4RU7$(/J<T 3T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5'.<0N?;%25!='$)'J0*
M%M!B >Y)J:F0C$*#VI] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 54?F]4>F*MU4ZWWT_PH MT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4455^V#=]SCZT 6J*9',D@^5N?0TK.J#+$"@""\_U2_[U+9KB,M_>-,(:
MZEXR(QWJT %  Z"@!:**J_;!N^YQ]: +5%,CF20?*W/H:5G5!EB!0!!>?ZI?
M]ZELUQ&6_O&F$-=2\9$8[U: "@ =!0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6]^
MXOUJ4=!4=]]Q?K4B_='TIH&+1113$%%%% !1110 4444 %%%% !1110 4444
M %%%)D>M "T444 5[L<*:?;C$0]ZCF/FRA%[=:L* H '04AE>[SE:BWR?WF_
M.KU%%@N4-\G]YOSH+.1RS8^M7ZCF_P!4WTI6"Y3!(.1G/M4D3,9%RS8SZTV#
M_6K5ZA PHHHJA!1110 4444 %%%% !1110 4444 %%%% !5><;)%<?C5BF2I
MOC*_E2  <C(HJ*!LKM/45+3 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "H+CED%3U!)S<H/I0P1:HHHH **** "BBB@ HHHH **
M*9)((UR: 'TUF5?O$"H \TW^K7 ]?_KT\6>02[G/M2N.Q-3)7*1EAU%0_O+<
MX892GR,)(&*]*+@-CA>?YW;"]JM)&L8PHQ3+7_CW7\?YU+2 *0@$8(R*6B@"
M/R8O[B_E1Y,?]Q?RJ2B@!  !@# I:** "BBB@ HHHH **** "JDI-Q*(U^ZO
M4U)<RE%V+]]J=!%Y28_B/6@!ER MO@< 8J&S_P!=^%3W?^H/U%06?^N_"@9>
MIKH' !['-.HH$%%%% !6;*,2N!V)K1)"@D]!5")#--STSDT#+T8Q$@/8"G44
M4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO+$
MZR&2$\]Q5BCI0!!%<JYVO\K5/5*9O/E C7IW]:=!*T;^5)T[4 6Z*** "BBB
M@ HHHH **** "BBB@ )P,FJ:F25V=7*C/%2W4FV/:.K<41KL0+0 S=<*/X6I
M$A+-OE.YO2IZ*=@N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !12$XZTPS1KU8?A0!)14!NE'12:;YLS_ '4Q^%*XRS32RKU('UJ#
MRYW^\^/QI1;+_$Q/TH >;B,=R?H*@ED\P@JI&.]6%AC7HH_'FGX&,8XH ?;2
M>;$&/4<&IJHVK>7,T9Z'I5ZI&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!2O4VLL@^AJ,'(S5V5/,B9?4<5GQG&5/4546)CZ***LD**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JD?-ZQ],U;JI!S=R'Z_SH MT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 57>U1B2"5S5BB@"I]C_Z:?I_]>I$M8UY.6^M3T4 (  ,
M 8%+110 57>U1B2"5S5BB@"I]C_Z:?I_]>I$M8UY.6^M3T4 (  , 8%+110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5K[[B_6I%^Z/I4=[_JU^M/7[H^E- QU%%%,
M04444 %%%% !1110 4444 %%%% !1110 UP2A ZXJC\R-W!%:%(5!Z@'ZTFA
ME=;D@?,N?I2^9++PB[0>]3!%'10/PIU $<40C'')[FI***8@HHHH *CF_P!4
MWTJ2B@"E!_K5J[1120PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"M(C1N9$Y'>GQR!QQU[BIJKR0$'?'P?2D,EHJ*.4-\K<-4M,04444 %%%%
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MVIU4[MSY@7L.<4 /MT+L9GZGI5FJ0NW P%3'T_\ KT?:Y/1?R_\ KT#)KO\
MU!^HJ"S_ -=^%-DN'D3:P7'M38I#$VY0,].:0&E15:&X>24*P7'M5FF(***C
MFE$29[GH* (KN3@1KU/6I+>+RDY^\>M,@A.?,?EC^E6* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J3S&5O+CZ=SZ_\
MUJ6XF+'RX^2>N/Y?XTZ&(1KZL>IH 6*,1K@=>YILL8=?]H=#4M%,0RVEWC8W
MWUJ>JLT9R)(^&'ZU)#<*Z_,0K>](9-1110 44R25(_O-^%5S+)/P@V+ZT 6@
MREBH(R.U+53[,,<,0WK2B>2+B5=P_O"@"U2$@#).!5<W$C_ZN/'N:;Y+.<RN
M3["@!-WG7&1]U>E6*:J*@PHQ3J8@HHHI@%%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 51O(MCB5>AZ_6KU-= Z%6Z&@"@#D9%%, ,<A1NU/K1.Y#"BBBF 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (PW#!IUK)
MM;RVZ'I]:2F2+D;AU%2T-&A145O+YJ<_>'6I:D84444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52UYGD/^>M6ZJ6?)<_
M2@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!6O?]6OUIZ?<7Z4R]_U:_6GI]Q?I30#J***8@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*6$2<CAO6HT
MD*-LE_.K-,>-9!AA^-(845 !)"<8++[4HN!W4BG<5B:BHQ,A_BQ]:>&!Z$'Z
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 5%;+YDS.1D#I3IFVQGWX
MJ2U39"/5N:3&B:BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4QXHW.67)I]% $7V>+^X*/L\7]P5+10!5N88T
MB)5<'-0VJ*\N&&1BK-W_ *@_45!9_P"N_"@9;6&-&RJX-/HIDLJQ+D]>P]:!
M!+((DW'\!ZU%#&SMYLO7L/2JQE9I-[ ,?0]*D^UR>B_E_P#7H&7:*I?:W]%_
M+_Z](;J4],#Z"@1=W L5SR!G%+4%HI$9<]6.:GH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *KW$Q7]VGWCUQVI;B?RQM7[Y_2F01;?G
M?[Q_2@!88O+&3]XU+115""BBB@ J-HD;DJ,U)10!!Y&W[CLM&VX^[YG'K4]%
M*P[D2P*.6^8^IJ2EHH$%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK.J]6 J-IXQTR
M?I2 FHJMY[-]R//ZTN)W[[11<9/TIAEC7JP_"HQ;$\NY-.$$8Z@GZF@!&NE'
M0$TWS9F^ZF/PJ<*J]% ^@IU %;RYV^\^/Q_PI1;#^)B:L446 C6"-?X<_6G@
M #  'TI:*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@F!CD65>N>:
MGIK*&4J>AI,"Q&XD0,.AIU4;1S'(8F[]/K5ZI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **@EN$3('SL.P[52EN9)>"<
M+Z"@#4HJ*#_4)_NBI: "BBHYI5B3<WX#UH DHK,:6:8G&['HM1LKH<D,I]QB
M@#7HK-BN9(R Q++Z&M!'#J&4Y!H =1110 4444 %%%% !1110 4444 %%%%
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M<ARZY/3K3Z* (OLT/]S]31]FA_N?J:EHH B^S0_W/U-'V:'^Y^IJ6B@!
M.@I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BGF$2^K'H
M*6:41)D]>PJ"*,R/YDG?H* "&,D^9)RQZ9J>BBF(****8!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !12=*:947JPH ?14#7*#H":;Y\C_<3^M*XRS2$@=2!]:@VSOU;'X_X4
M"VSRSDT 2-/&/XL_2HS<CHJDT]8(U_AS]:D"A>@ ^E&H%??._P!U<?A_C2^3
M(WWWJQ118"!;=!U)-2+$B]%%/HH$%%%%, HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #)N(7^AJ.S_ -3^-.N/]2_TI+3_ %"_C0!-1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O/
M]4O^]3T^XOTIEY_JE_WJ?'_JU^@IH!U%%%,04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!57]U,5['I4],N$W)
MN'5:(GWIGOWI(!]%%%, HHHH **** "BBB@ HHIKN$&2: '45"))9/\ 5IQZ
MTHMYG^^V!Z4KCL-#B*XW \'K5ZH$MHUY(W'WJ>D 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4C,$4LQP!2U6O3A%'J: &(#<2%W^Z.U6*:BA5 '04ZFA!1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D#J0*:98QU<?A0
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M<J:O@Y&15*X&8R?3FH1<2!54-@+4LHU**9&XD0..]/I %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44UY%C&6.*JO<NYVQ+C^=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<#)K-!W
MR,PZ$U;NWV0D#JW%5(QA1[TUN)CJ***T)"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHZ4 58?FNY&],U:
MJK9\[V/<U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M22ECLBY/J/\ /ZT^*$1C)Y;UI#'H-J >@IU%%,04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=U3[QQ4?V
MA/1ORI 344Q)$?[IY]*?3 **** "BF/(J?>./:F?:$]&_*D!-14:S(QP#@^]
M24P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *0G R:6HKA]L>.[<4@$M%\R5Y&&<=,U>J&VC\N$ ]3R:FJ2@HHHH IWXX0
M_6HD.+M#ZX_45/?#]R#Z-593F>'_ (#0!IT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4R1MD;-Z#-/JO>-MAQ_>.* *<0X)]:?2(,(*6M%L0PHHHI@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ",-PQ4EI+M;RV_"F4R1?XAU%2T-&A145O+YL>3]X=:EJ1A1110 444
M4 %%%(YPC'VH K671S]*M56LA^[8^]6: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JM>'Y%7U-6:JW'S3Q+_GK0!94;5 ]!BEHHH **** "BBB@ HHHH ****
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M.ER/6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ ICK_$.HI]%)JX%B"7S8\_Q#K4M4$8PR!AT/45>!! (Y!J"A:*
M** "H;G_ (]V_#^=35#=_P"H/X4 +;_ZA*EJ.W_U"?2I* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ )P,U6LQP[>IJ:8XA<^U1V@Q#GU.: )Z*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***3(SC(S0!6ZW_P!/\*M54C.;US]:MT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !3657&& (]Z=10!4DLP>8SM/H:K$O$=LBFM2FLJN,,
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M** (+HXA(]2!3X!B!![9J*]/RJOJ<U8484#TH 6BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9C<2B-.@[T@+:<(OTI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K<_-/$O^
M>M6JJ_>OO]T?TJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50@
M_B-79#B-CZ U2A^Z?K36X,EHHHJB0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F#FZ4>E/ID/-V#Z?
MX4F-%VBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 51E?;=%L=/\*O55G^2Y1^QH 9]J)Z)
M^M'VAST2KM% %+SI?^>?Z&E\V?\ YY_^.FKE% %+S+@_P'_OFC=<G^$_E5VB
M@"GBZ/;^5&VY_P XJY10!3\NY/J/Q%)Y-P?XC_WU5VB@"IY$_P#?_P#'C2?9
MICU8?F:N44 4_L<AZLM LV[N*N44 5/L1_O_ *4OV/\ Z:?I_P#7JU10!5^Q
M#^^?RI19+W<U9HH K?9$_O-2_9(_[S?G_P#6JQ10!7^RQ^K?G2_98O0_G4]%
M $/V6+^[^IH^S0_W/U-344 1?9XO[@I?(B_N"I** &>5'_SS7\J/*C_YYK^5
M/HH ;L3^XOY4NT>@I:* #%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!!=1;TW#[RTD$GF)SU'6IG;:C-Z#-5K4?*S>IH GHHHJA!50?/=?\"_E5
MNJMO\TS-28RU1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !52XD#2 =56K1Z'!P:K&U;LP/UI,:'K<(>
MN5J8$,,@@BJ;PNG)&1ZBF([(<J<4KA8T**CBD$B^A'45)5""BBH9Y"!L7[S4
M@&N3/)M'W%ZFBZ "*!T!J6*,1ICOWJ*Z^ZOUH&-M>K5:JK:]6JU0@84444Q!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1378(N6/%0?/<-QPHI />=%X'S'VIN)I>OR+4J1(G0<^II] R..%8^1R
M?6I***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *CE<1H3W/2GU JFXGQ_ O\ G]:3&B6SB(!D;JW2K=(!@8%+4C"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "DMN;AS['^=+260Y<_2DQHMT445(PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]ZN8PW
MH:L5'.NZ%Q[4 .1MR*WJ*=4%HV8<>AQ4] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<8]Z&P'6O5JM52BE\K/&<^]6(IO,8C;C ]:$#):***8@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8\J)U//I0 ^F22+&N3^
MJ+SW<XC3/N:586=]\I!]A2&-5&F;<W"]A5@  8 P!12T""BBBF 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114;RHG4\^@H DIK.J
M_>8"H \TQQ&I ]?_ *]2I9#K(Q)]J5QV&M/&.F3]!2I.C=3M/O4Z6\2]$!^O
M-(]M$_.W:?;BE<+%:>4, B')/I5JWB$48'\1Y-(EK'&X89)'J:GI#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *CG.(7/MBI*@NSB$CU.* "U&(0?4
MDU/3(!B%![4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O>']T/
M<TQ/N+]*=>GY4'O2#@ 4T)A1115""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1N%)]J=8CY&/O3)#B
M,U+9C$/U-2RD3T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JO+:I)R/E;U%6** ,UH9H^-NX>HYIA
M<CAEP:U*" >HS3NQ6,P2+[TX,&Z&KI@B8<QK^ Q56Y@$>)$'R]QZ4^8+#:*1
M3N&12U9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !30QBD
M#CH>M.I&&Y2*30T7000".AI:KVC[HRI_A-6*@84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 56O#\J+ZFK-5;CYKJ-?I_.@"R!@ >E+110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!4O.604M)<\W"#V'\Z6J0F%%%%,04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)
MC^[-6+88@6JT_P!P?6K<(Q"GT%2]RD/HHHI %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M58?^/R3\?YU:JK#_ ,?DGX_SJU0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4A4'J ?K2T4 1F&(]47\!33:Q?W2/QJ:B@"-8(EZ
M(/QYI)\+ ^ *EJO>-\BH.K&@!(!B$>_-2TU1M4#T&*=3$%%%%, HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M1E####(J VH[,1]15BBD!7%LO=B?I4R(J#Y1BG44 %%%%, HHHH *9)&)  V
M>/2GT4 1QQ+'G:3SZU)110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444C$*"2< 4 01_-<N?2K%5[8<,WJ:L4D,****8@HHHH ****
M "BBB@ HHHH **** "BF/*B=3SZ"HO,EF.(UP/7_ .O2N,E>5$ZGGT%1>9+,
M<1K@>O\ ]>I([51RYW'T[5.  , 8%("".U4<R'<?3M4PCC'1%_*G44 %%%%
M!1110 4444 %%%% !1110 4444 %'6BB@"G/#Y1$D?'/(]*F1@ZAAWJ5E#*5
M/0U4@)CD:)OPH0%BBD) ZD"F&6,?QC\*H1)14)N8QZG\*:;H=E/YTKC+%%5O
MM#M]V//ZTNZX;HF/P_QHN%BQ15?R[ENIQ^(_I2_9I3]Z3]2:+A8F) ZG%-\Q
M!_&OYTP60[O^E.%G'ZM1<+#P0>G-+4!M64YCD_/BFEYH?]8,K1<+%FBF1R+(
M/E//I3Z8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *@EFV_*G+?RI))6=MD0R?458M[98OF;EOY5+8[$<%L<^9-R?0_UJY112&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %-8!E((R#3J* ,P#9(R>AIU%PNVZSZ\T5<26%%%%4(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!;0[9F7U%7*HJ=EPI]3_]:KU9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !54?-?_ $_PJU56V^:>5O\ /6@"U1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!2FYNL>F/Y4^HVYNV/O4E4A
M,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV)'F1.IR?05'YDLQQ&N!Z_\ UZECMHUZ_,?>IP,# I 5X[51RYW'T[5.  ,
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZN45O0XJS4-S_P >[?A_.@1!9OB0KV:KM9T!Q,GUK1H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"J/EOC[C^E6JJS?+=1
MGUP*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9T]31J(D,T8_B%--Q&/4_A2>3'_=_6G>6@_A'Y4:@,-R.RDT>>Y^ZE2]**+
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M10 4444 %%%% !1110 4444 %%%% $%V<0X]3BI(1B%![5#>'(1?4U9 P,4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@".9S'&65<U61&G.^1LCTJZ0",'H:I\V\VT_<;I0!. %&
M,"EHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444E "T4TNHZL/SIIEC'\8H DHJ
M(W$8[D_A3?M*>C4K@3T56^U?['ZTGVAS]U!1<=BU154RS'HF/^ T?Z0WK^@H
MN%BU157RYSU8C_@5'V>0]6'YT7 LE@.I IID0?QC\ZA%L>[C\J46H[L?RHU
M>9X_[WZ4GVF/W_*F26ZI&6!.11%$C("1DFC4!3<KV4TANCV3\S4@C0?PC\J4
M #H,468$/GRGH@_*EWSGH,?A4U%%A7(-LYZMC\:/)D/WI/US4]%.P7(?LX[L
M32BW3W-2T46"XP11C^&E"(/X1^5.HH   .@HHHH **** "BBB@ HHHH ****
M "BBB@"&8EF5%ZFK:(J+A1BJJ_+=J3W_ ,*N5(PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH :\:R+AAFJK*]LV1\R&KE! (P
M>10! CK(,J?PI]0RP-$=\6<=Q2Q3"08Z-Z4[@2T444Q!1110 4444 %%%% !
M4%TV(POJ:GJ!AYMTJ=AU_G28T6X$V1*O?'-2445(PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+N\MM
MHR<=*H6R1N65QSVK2JE=0E&\U..>?:@",K+;-N4Y7_/6K<,Z3#CANXIL,@FC
MSWZ$56E4V\RN@XH T:*:K!U##H:=0 4444 %%%% !3'4.C*>XQ3Z* ,N/*L4
M;@@T^I;R+I*O4=:A5MRYJXLEBT4450@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@G R:  D 9-,
M+Y.%&32JK3/A>%'4^E7(XDC&%'X]ZAL=BLEL\G+G:/2K4<:QKM44ZBD,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>_<
M7ZU9JM>_<7ZT -LNK_A5NJEEU?\ "K= !5:\7**WH:LTC*&4J>AH H6K[)AG
MH>*T*SIH6B/3*]C4L5V57#C..XH&7*HWAS-]!4PN'DXBC_$U4D)+MN.3GK0!
M:LONO]:LU#:+MA'^US4U @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH JS_-=QKZ8JU55?FOB?3_"K5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44SS8_^>B_G
M1YL?_/1?SH ?131(A. ZD^QIU !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)CB%_H:?45R<
M6[4 5H/N'ZU)3(?]6*?5K83"BBB@04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "6/\ '^']:MU5L>C_
M %%6J@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2HX#F(>QI=0)****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!%-&20Z]14MO<"0;6X?^=%120A^1P:30RY1519WB.V0;AZ]ZLH
MZR#*G-(!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5>>W#?/'PW7ZU8HH J1S<[).&'>IZ2:%91SPW8U KO VR0<=C3N!8H
MI 01D<BEIB"BBB@ HII=1U8#\::9HQ_$*0$E0V0W2O(?\YI))T*$ DDC'2IK
M%<0D^II,:+-%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %-(!!!&0:=10!GR(UK+N7E#_G%)/<++
M$% (.>]:! (P1D5"UM$Q!VXP>U "VR%(5!Z]:FHHH **** "BBB@ HHHH :0
M&!!&0:SG0P2E3]T]#6G52_'[M6]#B@"&BA?NCZ45J0%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Q@
M7D6,=Z>3@9I]HFYF<_05,AHL1HL:A5'%.HHJ1A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:]^XOUJS5:]^XOUH
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MGTB?<7Z4M6B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "@]**#TH 6R^Z_UJS5:R^XWUJS4%!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C#<I&<9&*6B
M@#/:WE4_=)]Q4B/<+QM8_P"\*N44 5MMQ*,-A%]JFBB6(87KW-/HH **** (
M3.W\,,A^HQ4;)/-PV$7TJU10!'%"D709/J:DHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K67W7^M6:JV71_P
MH M4444 %%%% !1110 4444 %%%% !1110 4R601(6/X"GTQHPTBL>0O0>]
M%402S'>YQGUH>U=1E2&]JNT4 9B.T;94X(K1C<21AAWJG=J%FX[C-3V@(@Y[
MF@9/1110(*1F"J2> *6JL[&:00IT'4T 032&5RQZ=A5NT_U"_C56Y4))M7H
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M#"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!",C%5[?C<I[&K-5A\ERP]:0R:BBBF(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!" PP1D5$8F1MT;8J:BBP$.+@_
M\M/UH99P"?,)^C&IJ*5@N+;R^:G/WAUJ:J)S!('7[I[5=5@RA@<@TABT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !114,ERB' ^8^U $U%5?MHS
M_J_UJ:*9)?NGGT- $E%%% !1110 44=.M0O=1KP"6/M0!-14 FD;[L+8]SBI
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKHLB[6&13J1F"J68X H
M IL'MFX^9#2FZ7LI/UH^>ZDPO"#_ #^=6XX8X\!5&1W[T7&5 \\GW$P/7'^-
M.%M,_P!]P!Z9S5ZBD!4%DG=V/TIXM(1V)^IJQ10!"+>(?\LQ^-2*H484  =A
M3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHIKL$0LW04 .HJL+M78+&C,3^%6![T +1110 4444
M %%%% !1110 4444 %5[T9MS[$58J"[_ ./=_P /YT 5$.4%+34^X*=6B("B
MBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 -E.$JW H2%0/3-4Y>@'K5\#  ]*A[E(6BBBD 4444 %%%%
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M* "BBB@ HHHH **** "JUZ?D4>]6:J7W\'X_TH %X4?2EHHJR0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D;[I^E+2-]T_2@!UE_JV^M6:KV?^J/^]5BH*"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBK%(P#*0>AI ,1MR@CO2U# 2K-&>HJ:F@"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW3WJY5:1 ZX/7L:2VE*GRGZ]JD9:HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D?[C?2EI'^XWTH DL_]3^-3U!:?Z@?4U/4%!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ JCUN7/N:O517F=S[G^= $E%%%62%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C_<;Z
M4M(PRI ]* );3_4#ZFIJJ6LJJ-C<'/%6Z@H**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "JMEUD_#^M6JJV763\/ZT 6J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J.69(OO<GT%.D<1H6;H*KPH9G,L@R.PH 3=-<<*-J5-!"(
M@><D]:EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH J7'_'S'^'\ZGJ"X_X^(_P_G4]- PHHHIB"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYUW1-[<
MU)2'D8H A@.8A[<5)4,'#,A[&IJ$#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &/&KCG@^M-2
M5X#M;YDJ6D(!&",BAH+DR.KKE3D4ZJ7-O(&7[IZBKBL'4,IR#4C%HHHH ***
M* "BBB@ HHHH C:>-&VEN?I3U8,,J01[56FMF+ED(.3G!IB0W"'Y5(_$4 7:
MJW4F\B).3GG%*(YW&&D 'M4L4*1=.3ZF@ AC\J,+WZFI*** (+F+S$R/O+4-
MK)LD*GHW\ZNU7FM@YW(<-^E %BFNX1"Q[5 IN$&-H;W)H,,LQ!E8 >@H AMX
MS++N/0')J_2*H10JC %+0 4444 %%%% !1110 4444 %%%% !1137.$8^@H
M@L.2Y^E7:IV ^1S[U<I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3#
M&C=44_44^B@" VL1_@Q]#3#91'H6'XU:HH I&P])/TI/L<@Z2#]:O44 9_V:
M<="#^-(8K@=4S^5:-%.X&8?-'6,_D:0R$=5(K3HHNQ6,SS1Z&E$BUH&-#U53
M]152X:)?DC12_L.E',PL1>8OK2>:/0U+%:9&9"1["IU@B7H@_'FG=A9%++2D
M*J]:O11B- H_$^M/ QTHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5E^
M:\0>F/\ &K554^:]8^G_ .JK5 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 R7B)_P#=-5(/N'ZU:N#B!_I5:'_5TUN#'T4451(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (RAA@BHQYD!RAR*EHI-7'<B"O))O>@Q,&RC;?QQ4M%%@
MN0M'(WWFS]33VC5NV#[4^BBP7&6N1.5!.!FKM5+3F9S5NI&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;7_
M %DOU_QJU56U_P!9+]?\: +5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !520;+Q6/1O_ -56ZIW#B9U6,%B.XH N44BYVC/7O2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:Y
M_P!=']:EJ&Z_U\0_SUJ:F@84444Q!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!'.NZ)O;FFPG,0]N*E(R"#T
M-5X#C<I[&EU FHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4+QD'?'P1Z5-10 M
MO/YHP1AA^M352DS%(LB_C5P$, 1T-2,6BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BD)"C)( ]343742]RWTH ;>/
MB,*.K?RJ:"%8D!P-^.356/\ TBY#$?*O-:%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!5O)61553@M1!;B/YCR_\J9>@AT?&5'&*G1U=<J<B@!U%%%,0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1137.V-CZ F@"O:?-)(_K5JJUF,1
MD^IJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W/_ ![M
M^'\Z@B_U8J:\.(/J:BCXC7Z4UN#'44451(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 0PS&$M\N<U*+SUC_6EHJ;#N O%SRA ^M3I*DGW6!]J@(!
MZC-1M".JG!HL.Y>HJF'G3C.X>].%U(/O)GZ4@+5%51>#^)"/H:LJP90RG(-
M"T4=.M5S=H&(VDCU% %BBH5N8C_%CZBI%=&^ZP/T- #J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "JMK_K9?K_C5JJUK_KI?K_C0!9HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHIKMM1F]!F@"M([SR&./A1UJ>*%8EP.3W
M-16:_(S>IJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %2X_X^8_P_G4]07'_ !]1_0?SJ>F@8444
M4Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 56^Y<GT:K-5KCY71Z3&34444Q!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 -==Z$4RWF\L[).!V/I4M,DC#CGKV-)H"U152.9X/DD!*]C5A)4D'
MRL#[4ACZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBHYY/*C)[]!0!#<,991"GKS_GVJ=+6)/X=Q]34=G%A3(W5NE6Z0Q  !@#
MI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH KWG^K7_ 'J8GW!]*6]/"#ZT#I30F%%%%4(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $(##!IBL]NW'*'M4E!&1S2:'
M<9+,TQV(,+_GK2K&JC& ?K2JH4<4M"0-C3&A_AIC1;1N0G(YJ6BBP7)H)1*F
M>XZBI*H@F"0,/NGJ*NJP894@BI&+1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !56U_UTOU_K5JJMM_KY?K_6@"U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4%VV(<>IQ4]5;GYYHX_\\T 30+MA4>U2444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5G_X
M^E^G^-35#+_Q^+]/\:FIH&%%%%,04444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5;SYGC7UJU563YKQ!Z?_KH M4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2HY%6;5]T('=>*0$U%%% !1110 V1Q&A9N@J$7<?HP_"FWC9VQCJ>:8T8*8
M&>QH N]:*K6LN5V.<%>F:LT %%%% !1110 4444 %%0-=(K%=I.#CBF_:T_N
MM0!9HJM]K3^ZU2QS))]T\^AH DI"0!DD#ZU'-.L0YY;TJL0\QW.>.PH NAE/
M0@_0TM4,>3(KC)%7!+&1_K%_.@!]%,\V/_GHOYU!<S;OW<9SGJ10!(+F(G&[
M'X5*K*WW6!^E4Q$N,$9/K3<-"X=>E.S OT4V-Q(@9:=2 **** "JMM_KY?K_
M %JU56V_X^)?K_6@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52/]Y=
MLW9?_P!56FSM.WKCBJUD0-X_B]* +5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5)/^/T?3^E3
MU __ !_?Y]*GIH&%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %:<;)5<?C4U,N1F+/H:6,YC4^
MU) .HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %129CD61?QJ6FNN
M]"*&!84AE!'0\TM5[1\J8SU6K%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "JDI-Q*(T^Z.II\\X"E$.6/'':I+:'RDR?O-U]J!DR*$4*HP!3J**0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-
M=%=<, 13J* *4EJR'="Q^E$=U@[91M/K5VHI(4E&&'X]Z  $$9!R*6JC0S0'
M=&2R^G_UJDBND?AOE;]*8B>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK'\UXY]/_U5:JK:?,\C^M %
MJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IW'-ROL!3
MJ9+S>'_/:GU2$PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH " >HS1110 4444 %1*TD#$
MJ,@U+10U<=QR7B'[P*_K4RNKC*L#]*K,BMU%,,6#E&(-39CN7J.E4A--'U^8
M>]#SO*-JC:O>D @/FS,_;M4E-C38N.].JD)C&B5CGD4T1,OW7(_2I:*+(+C
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M!"Q\J=7['K5VJ<ZYCSZ<U8@??"I[]#4C)**** "BBB@ HHHH **** "BBB@
MHHI&8(I9C@"@ 9@JEF. *J%Y+E]B95>__P!>CY[J3"\(/\_G5V.-8DVJ.*0R
M.*VCCP3\S>IJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H);9).<;6]14]% &?F:V.#\R?I_]
M:K$<R2CY3SZ=ZG(!&",BJDUISNB.#Z?X4 6**JQW#(VR8$$=ZL@@C(.13$+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M -D.V-CZ U#9#$1/J:?='$#46PQ OYT 2T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %)N;ISZ4^HUYN)/J?YU)5(3"BBBF(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** *@_X^W^G^%3U73_C[D_&K%- PHHHIB"BBB@ HHHH **** "BBB@
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MWV>>0@2/\OUIUB_RNA['-7*0QJ(L:A5& *=110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $4L22C##\>XJJT4MN2R'<G^>HJ_10!5BN$DXZ-Z&IJBFM5DY3Y6
M_0U"LTD+;)E)'K_GK3 MT4U'5QE3D4Z@04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!7O3^Z ]34T8VQJ/0"J]W\TD:>M6J "BBB@
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MK%%%@N4B"IP1@U-#+D[6_ U*Z!Q@_G51E*,0>HJ=A[EVBFQMNC!IU4(****
M"BBB@ HHHH **** "BBB@ J&2/)W)P:FHH +>?S/E;[P_6IZI2'RYUD'3O5V
MI&%%%% !1110 4V1UC4LQXI68(I9C@"JBJUU+GH@_P _G0 ZT#-,TN,*<YJ]
M354*H51@"G4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UT5UV
ML 13J* *,EO)$=\))'IW_P#KTZ*Z4\2#:?7M5RH9K=)>2,-ZB@!W6BJ9$UL>
M/F3]/_K5/%<))QT;T-,1+1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 59/FO%'I_^NK558OFNW/I_P#JJU0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-D.(V/H#3JCG.('/MB@"K!]P_6I*9"/W8]Z?5K
M83"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH+D?=/X5/4%P<E5'6A@AUO\ ZK\:EI$7:@'I2T %%%% !1110 4444 %%%%
M!1110 4444 ,F7=&?;FI+5]\(]5XI*CM3LF>/UZ4F-%NBBBD 4A( ))P!2.Z
MH,L<"JK.]RX1 0O?_P"O0 9>ZDVCA!_G\ZO(BQJ%48 IL4:Q(%7\_6I*0PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2JTUH
MK\I\K>G:K5% &>)I8&VR@D59CD6094YJ5E5UPP!'O522U9#NA8_2@"S15:.Y
M*G;,"".^*L @C(.13$+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-E.(G/H#
M0!!:?,SOZFK-5[,8B)]35B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *ANSB ^Y%356O3^[4>] #$&$7Z4ZD PH%+5DA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 R+_C[_#^E7:I1?\ 'W^']*NU!044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 55FXO(_P *M57O$R@<=5H L44R%_,C#=^]/H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BB@]* *=I]UJL57M?N-]:L4T#"BBBF(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *US\LB-4BR*_0\^E2$ C!&15>>)53<HP:0R:BFQ\QK]*=3$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4V1]B$_E3JA8&:8(.@ZT,$364
M7!D;J>E6Z: %  Z"G5!04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2$ C!&12T4 5);09W1':?
M2F)</&=DRGZU>IDD:R+AQD4 -5@PRI!%+55X)(3NA)(]._\ ]>G172MP_P K
M?I3$6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JK=?-+&G^>:M55?YKU1Z?_KH M4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5)^;MCZ?X5=J@G,[GW- $M%
M%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 -B_X^Q_GM5RJ47%X/\]JNU!04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4A ((/0TM% %6V)CE:)OPJU56Z^65''6K5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI&^Z?I
M0!5M?]6?K4]06O\ JS]:GIH HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&X($
M9'K4U5Y?WDRIV'6DP'Q B-<^E.HHI@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 R5]B$]^U26<6U-YZM_*J]SU4]JT1C QTJ6-"T444AA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5#+;I+R1AO45-10!G_OK8\_,GZ?_ %JL
M13)*.#@^AJ<C(P:JRV@)W1':WIVH GHJJL[Q-LF4_7_/6K*LKKE3D4Q"T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH BFX=#5^L^?\ AJ^#D U+W*%HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %0W3A82,\GC%2MG:<=<<53MXEF+,Y)([4 6+9=L"
M^_-2T@   '04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !39/\ 5M]#3J;)Q$_T- %:U_U9^M3U!:_ZL_6IZ: *
M***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH @N>=B^IJ2H9N;A!]*FI( HHHI@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !113)CMB;\J $M5\R=I.RU?
MJO9IM@![L<U8J"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S_<'UJY&
M<QH?854E&4/M5BV.8%]N*E[E(EHHHI %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+;Y9Y%'
M3_Z]37$OEQ\?>/ IMM%Y<>3]YJ )Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "F2_P"I?_=-/IDW^I?_ '30
M!!:_ZK\:FJ&U_P!5^-34T(****8!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6E^6=6/
M0U-3+A=T>>ZTL;;D!I(!U%%%, HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *AN#\JCU-35"1OND7TQ_C28(O1KLC5?08I]%%24%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4PQH>J*?J*?10!";>(_\LQ^%--I">@(^AJQ10!4-E'V9A338D?=
MD_2KM% %'[-<#I+_ ./&C9=KT.?Q%7J* */F72]8\_A_A2?:I%^_'_2K]% %
M$7J]T(^AIXNXSUW#\*LE5/50?J*:8(CUC7\J *1E1[I6S\H[U;$B'HZG\:0V
MD1_A(^AJ,V49Z,PH GHJM]B8?=D_3%)Y-RO1\_C_ (T[@6J*JYNUZKG\!_2D
M^T3+]^+]"*!%NBJHO!_$A'T-/%U$>N1]10!/5:\/[I1[U*)XCT<?CQ4%T5=T
M"D'Z4 6XAMB0>@%24E+2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4;U=LBR#OQ0#D9JQ<IOA8=QR*J0ME,>E5$3'T4451(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=H-]PS]A3G.U&/M3
M[%<1LWJ:3&BU1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKL$4LQP!5!B]U+QPHZ>
MU &C16<8Y;<[U.1WQ5F"Y67@_*_IZT 6**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!I56^\H/U%,-O$W6-?P&*EHH KFTA/0$?0TU;-%=6#-P<X-6J*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*SWC>
M!R<90GK6C24 9ZR*W?!]Z?4LEI&_*_(?;I5=XY8>HROJ*I2%8?134<,,BG51
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !377<N/RIU% "
MVLF5,;=5Z59JA)F-Q(O7-7E;<H8=QFH*%HHHH **** "BBB@!"0!D]!522:2
M5BL0.WVJQ,C2 (.%)^8T]5"*%48 H SGBE7EE/UI8YWC/!)'H:T:HW481P5X
M#4#+D;B1 R]#3JK61.UQVS5F@04R25(^IY]!UI])@9SCF@"E+=.W"_*/UJ:R
M.8VSZU%>@"0'U%267^K;ZT#+-%%% @HHHH **** "BBB@ HHHH **** $9@J
MECT%5H%,DIE;H.G^?:BZ<NZPI^-6$0(@4=!0 ZBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *C?
M+>?[P_I4]0W0VS(U34T#"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\O%PGTJ
MQ5:;_7H?I_.DQDU%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 17!Q'CU-6[==L"#VS5*YZ+6@IRH(]*EC0ZBBBD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #K2,\RMU/2K-(   !T%+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O!\BMZ&I <@'UI+H
M9@/M@TV$YB7Z4T!)1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:4[YU4=JLU5A
M.96+<,>U(9/1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5R
M/W8^M7(#F%#_ +(JK,,Q-4UH<VZ^V14L:+%%%%(84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5YKE(N!\S>GI1=R;(L X+<5%;VZ[0[
MC)/(!H 8(Y;AMTAPO^>E2/:(5^0X(_6K%% %,03L-K-@#U:G+9K_ !,3]*M4
M4 -1%C&%&*=110 4444 %%%% !1110 4444 %4@P-V6EX /\NE7:KW%N9&5E
MX/0T 1M)+<2?NR54>^/SI=ET.CD_\"JS&BQKM44Z@"F7N8QEB<#Z&K5L[21!
MFY.:;.,PO]*;8G]TP]&H M4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M(!!!&0:H3Q&!]R\H?\XK1IK*'4JPR#0!25@PR*6HY(VMW]5/0U("",CI5IW)
M:"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBF2@F-@* (V=I'VH< =Z-LPZ-FG6^-AQUSS4M(9#NF'5<TGG
M2#[R?I4]%.PB'S_52/QI?M">AJ6D**>JC\J-0(VF1D(SR1Z5-8G,3#T:HS$A
M_A%%F=DS1GO_ $J6-%ZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)$61"K#@U
M096MY-K?=/0UI5'-$LJ;6_ ^E %7K140W0N8WZ5+6B=R6%%%% @HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#/")DP>&'0U21BA*/
MP16G5>YM_-&Y?OC]::=@(:*B+21'$BFGK(K=#^%5<FPZBBBF(**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 17$?FQ%>_455LV +(1AJOU1NHS%*)4[GGZ_
M_7H M44V-PZ!AWIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0S6ZR<CAO6I
MJ* *0@F8A&)"K[\?A4CV:X^1B#[]ZLT4 4UFG@.'&Y??_&K45S'+P#AO0TI
M(P1D57DM5;E#M/IVH NU%)-'']YAGT'6J@BN&&TL0H]6IZ6:C[[$^PH 1[TD
M_(O'O4D=Y&W#@J?TJ145!A5 IDEO&_;!]10!.K!AE2"/44ZL\V\L9S&V?IQ3
MDNW4[95_'H: +U%-1UD7<IR*=0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 T@,,$ CWJO)9HW*':?TJU10!G/'+#R1N7
MUZTY&#+D5=(#*0>0:SL&&5D;IZU28FB6BBBJ)"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!AB5B22>:3R%]34E%%AW(_(7U-'D+ZFI**5D%R,1*#GFI***8@HHHH
M *:\8<\YIU% #50*,"G444 %(R*W44M% $8B(^ZY%'E9^\Q-2446'<0  8 Q
M2T44""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 9 -MU@=*NU3MN;ESZ U<J"@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN\^0WX5-2.N]"I[B@!
MEOCR$QZ5)52WF6,%).,'BI?M47][]* )J*A^U1>I_*D^U1>I_*@">BH/M<7^
MU^5'VN/_ &ORH GHJO\ ;(_[K?E_]>C[9'_=;\O_ *] %BBJ_P!LC_NM2?:T
M_NM0!9HJM]K3^ZU'VQ?[AH LT55^VC^X?SH^VC^X?SH M455^VC^X?SI/M3G
M[L?]: +=%5/.N#TCQ^%'^EGV_*@"W153R9SUEQ^)I?LC'[TF?PH L%T7JRCZ
MFG54:U4(2&.0*?:.S)@_P\ T 6**** "BBB@ HHHH **** "BBB@ HHHH *@
MNQF GT(J>H[@9@<>V: &1',2_2GU% ?W2U+3$%%%%, HHHH *K7/WDS5FF2(
M)%P:0!UHJ!6:)MK=.QJ<'(R*8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1/"K$D$@U+10!7:*08S\P%6***+ %%%% !1110 4444 1SKNC/J.:L6LF^$
M9ZKP:CJ.U;RYVC/0TF-%^BBBI&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)$$B%3T-/HH S[=
MC'*8G[G]?_KU<J"\BW+Y@ZKU^E.MY?-CY^\.#0!+1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4UT61<,,TZB@"FT4MNV^,DK
M_GK5B"Y67AOE;T]:DJO-;*^63Y6_0T 7**J64C.&5CD+C%6Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI84F'S#GL
M14M% &:R-!*$+9!J2EOQ@HP^E(.:J)+"BBBJ$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 EIS([5;JK9#Y7/N*M5!04444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $/(Q5!@;:XR/NG^7_P!:M"H;F,20MZCD4 *"" 1T-+5>
MS<F,J?X35B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *0]#2TAZ&@"M8?>?Z"KU4;#[S_05>H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;F/S(B!U'(JG"V
MY<=Q6C6?.ODSY'W6YIIB8^BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'^XWTI
M:CE;"X'4T,":R'[HGU-6*CMT,<0!Z]34E04%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5PL3T5 99$^^A'X8IPN$/7(IW"Q+12!U;HP-+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!%&WE70/9OZ_\ UZT*SYTW)D=15FUE\R/G[R\&I8T3T444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4E+10!GVOR3NA]Q^57*J/\E]QW(_6K= !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI#T- %:P^\_P!!5ZJ6
MG_\ +3\/ZU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "H;F+S8CCJ.14U% &;"VY<=Q4E,G7R9\C[K<T^K3)8
M4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%  3@9--MT\R0N?NKTILI+$1KU-7(T$:!1VJ6
M4AU%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &?#\]VS-P>3BKE5KB%UE\V,>YQ1%=*W$GRGU
M[4 6:*!STHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *0]#2TAZ&@"OI_\ RT_#^M7:I:?_ ,M/P_K5V@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *=_]U/J
M::.E.O\ [J?4TT=*J(F%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1JWE3!FY![U>!R,
MCH:INH92#3[-F*$'H#Q4O0HLT444@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAB92[?*1_$*L4R5?,B9?44 9\#2!]L9R/0]*OU5LFX9>_6K5 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-]TTM-?[C?2@"#3_^
M6GX?UJ[5+3_^6GX?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %._\ NI]331TIU_\ =3ZFFCI51$PH
MHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!DIQ&??BK%LNV!??FJLWW!]:O(,(H]!4O<I"
MT444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JK>XPA_BJT2 ,GI52(?:+@N?NK_D4 +# \K!YB<>A[U>HHI#"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I(8Y/O*,^O>J[V;*
M<Q/^!J[10!G1.=Q1_O"IJ6[@W*9%X8=?>HXG+ID]>E4F)CZ***8@HHHH *0D
M*,G@4QYE7@<FD2*2<@O\J4FPL(JO<O@<*.]7HXUC7:HP*5$5%"J, 4ZI*"BB
MB@ HHHH **** "BBB@ HHHH 9(@D0JW0U1,,\70;E]N:T:* ,Y;@=&!%3 Y&
M1TJ2YC#Q,<#<!D&JUNV8\>E4F)HEHHHIB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *AF4@B1>"*FH(R,&A@30R"6,,.O?
MZU+6? _D3;&/RM6A4%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M4M% &:JFXF;>=I]*E%FG=FIMTACE$J]#_/\ ^O5E&#J&'0T 1"TB]S^-*+:(
M?P?J:FHH C$$0_@%!@C((V ?2I** *+6TH. -RCIS5U,[%SUQ2T4 %%%% $-
MQ+Y2<?>/2DLX=H\QNIZ5$!Y]W@\J/Y"K] "T444 9_\ J;PCL3_.KE07L6Y
MXZKU^E.MY/,C!/4<&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "FO\ <;Z4ZFO]QOI0!!I__+3\/ZU=JEI__+3\/ZU=H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"G?_ '4^IIHY JS/'YD17OU'UJE"W!4]151$R2BBBJ)"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (IN2H]:OU1;F>,>XJ]4O<H****0!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"6GX?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)(TIX&>/K0,O4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI@E4R&,'Y@,T^@ HHHH **** "BBB@ HHHH **** "BBD)P"
M?2@"@W[V]]E/\JN54LQEW8]:MT %%%% !1110 4444 %%%% !2$ C!&12T4
M0O:QMT&T^U/CB2,?*.?6GT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %-?[C?2G4U_N-]* (;#[K_45<JG8?=?ZBKE !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% %:YM_,&]/OC]:K1R9^5N&%:55;FWW_.GWAU'K33L!'14<<F[@_>J
M2K("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*N30 V239[FA8I
MI>HVCWXIUK&9'\Q^@/'N?_K5>J&RK%>.TC3EOG/OTJ<  8  'M3J*0PHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9*VU/<T^HVYG0'ID4F-%FVC\N(9ZGDU+114C"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HICRHGWF ]JB6
MZC+XP0/4T 6***:SHIPS 'W- #J* 01D'-% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444A( )/04 ,:>-&*LV"/:F_:8?[_Z
M&H+A4=BZ2*<]LTD'E.P5X^3P""?\:!CII//=8X^1ZU>C01H%'04R.".-MRK@
M_6I:0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4QHT?[R@_44^B@"LUG$W3*_0U$;21?]6^?TJ]10!FL9HOOCCU-3 Y
M (Z&IYT\R)E[GI]:IP-\I4]15)B9-1113$%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %131[OF7[PJ6B@!UM<>:NUOOC]:LUG2H5/F)P1
MR<5:MYQ*N#PXZBH*)Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "H;B81)G^(]!4U9Y!FNV#G@$\?2@")2\;)*<\G/UK3!# $
M=#4$\?F1%1U'2H[6?;^ZDXQT)_E0!=HHHH **** "BBB@ HHHH **** "HYS
MB%S_ +)J2H;K/V=\"@""R'[MC[U9JO9LOE[0>0<D58H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *:_W&^E.ILG^K;Z&@"&P^Z_U%7*IV'W7^HJY0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 5+FWW9>/[W<#O4$<F[@]?YUHU4N8.?,C'/<"FG80VBF))N'O3ZLD*
M*** "BBB@ HHHH **** "BBB@ HHHH *CVF:4(.@ZU(3@9I;%<L[GZ5,AHMJ
MH10JC %.HHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH CEC65=K#\?
M2J 4Q3,F<@5IU1NHF5_-7IW]J$ 44U&#+D4ZM" HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHI"ZKU(H 6F/Q(A]Z:9AV!-'E32X^0X_*I;&D76D1/O,!4#W:#[@
M+?I2I9#K(Q)]!5A(8X_NH![U)14\RY?E4('TI0UT/X,_A5ZB@"CYEU_SS_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S[E#%-Y@'RM6
MA3719%*L,@T 55(8 CH:6H2&MY-K<J>]3=:M,D**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H9(R#OCX(]*FHH =;7 E&UN'_G5F
MLZ6+)W)PU6+:X\SY'^^/UJ+%%FBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %-D_U;?0TZFR?ZMOH: (;#[K_ %%7*IV'
MW7^HJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %6:UW,7C.T^E5V\Z+[ZG'K_P#7
MK2I* ,]95;O@^]/J:2UC?D#:?:JTD,D W Y6J4A6'T4B,'7(I:HD**** "BB
MB@ HHHH ***"<#)H 9*<(??BK5HNV!??FJL49GER?NKUK0 P,"H;N4A:***0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$8/(I:* ,Z:(P/N7E#3
M@0PR*N.H=2K#(-498VMVR.4--.PFA]%(K!AD4M62%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%-
M$LJ;3U['TJG"65VC/\-:%9Z_\?,OU/\ .F@9-1115$A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5#,"CB1>H-34CXV'=TH8%F-Q
M(@<=Z?5&Q9LLN,IUSZ&KU04%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-(!!!&0:=10!G31_9Y 5.5/:
MGU8EA688;J.A%5'BD@Y^\OK33L)H?13$D5O8^E/JR0HHHH **** "HG)D<1I
MR2:=*^T<=34]K#Y:;V'S-^@J6RDB:*,1(%'XGUJ2BBI&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %-(# @C(-.HH SYX&A;>G*_RH1PX
MXZ^E7ZI7%N4.^/IW'I33L)H**8CAAZ&GU9(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444$X!)H :SJO4_A3 SR'$:FGVT0E
M=G<94=JO!0HPH 'H*ALJQ5CL^\K9/H*LHBH,(H I]%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4QE5AAE!'N*?10 4444 %%%% !4,Z(\9W\8&<^E2.ZHI9C@"J4LSW!\N
M-?EH 6S+$,"?E'3ZU:ID2>7&%].M/IB"BBB@ HHHH **** "BBF22+&N6/\
M]>@!]%5%NFWY<?(?3M5I6#J"IR#0 M5+OYY$1>6_QJW5*1)D<R\9ZY'_ ->@
M#0'3FHYU+PLHZXJK'=3N=JJ&/TJZN=HW8S[4AE&&X6- C \5.+B(_P ?YU*T
M,;')12?I4;6D)_A(^AH >K*WW6!^AI:KM8C^%R/J*CWSP<.-R^O_ ->F!<HJ
M*.=). <'T-2T""J\]L'^9.&_G5BB@"O#<E3Y<W!'<_UJP)(R<"1<_45'+"DO
MWASZBJSQB*Y10202#S]:0S1HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LY?^/F7ZG^=:-9R_\ 'S+]3_.F@)J*
M**HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H7
MS+((TZ=ZFJ.U/EW!0]^ :3&BY'&L:!5Z"GT45(PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH BGC\V(KWZC-51!<H,*W'H&J_
M10!FR1W# !U)Q5]%VHJ^@Q3Z* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "J5XQ:1(EJ[5 ?/?$^A_E0!8CC6-<+^)]:?110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V3_5M]#3J;)_JV
M^AH AL/N/]:N54L/N/\ 6K= !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 5IK1'Y3Y6_2J[1SQ=5W#U'-:-% &:DH;@\&I*GEMDEY^ZWJ*JM%-%
MVW+[<U2D*P^FNX49-,$XQR#FGP0-,V]_N_SIMBL+;1&63S''RCI[U?IH
MP!3J@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH S[E0ERN!@'!IU3W, E7(^\.E5(W(.Q^"..:I,3)****HD****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF/($XZF@!S,%&2:8H
M><[5&!W-/BMWE.Z3(7T]:N*H10JC %0V4D$48C0*.U/HHI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!I 8$$9!JE(CVTF].4-7Z:0&!!&0>U $
M,<R2#Y3SZ5)4,EFC<H2I_2HB;B#[PW+Z]:8%NBH([F-N#\I]ZGZ]*!!1110
M5'-,(0,C)/05)53'G78'\*_TH /M$TG^KC_3-.2VDD?=,>/2KM%(9&T2,FPJ
M,=O:JMF2"\9ZCFKC.J#+, />J =1>;E/RL?Y_P#UZ +M5)V,THB3UY_S[5)<
M3A$(5@6/IVIUI#Y:;V'S-^@I@2QQK&@51T_6I***0!1110 4AYZTM% %66T1
MN4^0_I4<,CQ2F*0_0U>J"XMQ, 0<,.] #Z*J_8G_ .>@IKV\L7SJVXCTIW M
M2.(T+-5>WC,TAF?H#Q_GVI@+W4BJ>%'7%7U4*H51@"D ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SE_X^9?J
M?YUHUG+_ ,?,OU/\Z: FHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *AF!5A(O4&IJ;(NY"*&!;1@Z!AT(S3JJ6,F4,9ZKR
M*MU!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%%% !1110 4444 %%%%
M "'@9JA:?-,[G_.:N7!VP.?:JUDN(V/J: +-%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !39/]6WT-.IDO$3_ .Z: ([#[C_6
MK=5+#[C_ %JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 1/#')]Y1GUIX    P!3J* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE?(!M<#!S@FKM07:[H&]
MN: ( <@'UHID9R@I]:$!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M03@9-!( R>E1*KSOM7A>])NPT@W/*VV('ZU:AM5C^9_F;]!4L42Q)M7\3ZU)
M47*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH @DMHY.<;3ZBH#!/#S&VX>@_P *O44 44NL';*N#[4Y[M!]T%C^567C
M208=0:;'!'']U1GU/- %7-Q/]T;5_*K%O!Y())RQJ>B@ IK#*D9(SW%.HH R
MYXI$DP^6ST/K3H[21^2-H]ZTJ* *T=I&O+98^]6:** "BBB@ HHHH **** "
MBBB@ HHHH 8J*I)4 9.33Z** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0G R>@K/B.Z5W]?ZU:NGVP-ZGBJ\
M"[8Q[\TT)DE%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@")6\FY#?PMUJ_5"=-R9'45/;3B10I^^!^=2RD6:***0!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%074GEQX'WFX% #);Q%X0;CZ]J@VSW'+'"_D*EM80$
M#L!N/(SVJQ0!3!GM_=?S'_UJL0W*RD*00U253.$OEQP"1^M &A12$@=2!]:J
M377.R'D^O^% $TUPD(QU;TJ..\1N'!4_I4<-MD[Y>3Z?XU+);QO_  X/J* )
MP0PR""/44M4!'<1$B,Y!]/\ Z]*RW,GRL3C\!_*@!UW.C(8T.3GDCI4ELNV!
M1^-)%;I'R?F;U-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)?\ 4O\ [II],E_U+_[IH CL/N/]:MU4L/N/]:MT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %,D7=&R^H(I]% &9 >"O>I:;.OE7&[^%N?\:=5HEA1113$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !02 ,GI2,P49-,CC>X;T4=Z3=AI B/<O@<*.]7XX
MUC0*HP*5$6-0JC %.J"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** *-ZVZ5(Q_G-/ P,"HY_EO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445')*D8RYQ[>M #ZH,?M
M-S_L#^7_ ->AII9SMC!"_P">IJ>"'RE/.6/4T 2T444 %5KB!Y) RX''>K-%
M %,6C'[SC\LU/% L7(Y;U-2T4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]2_\ NFGTR7_4O_NF
M@".P^X_UJW52P^X_UJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 07<>^$D=5Y%58FW)[CBM"L]E\J
M<K_">E-"8^BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***0D*,DXH 6F/($]SZ4F]Y&VQ
M@U8AM0AW2?,WIV%2V-(AAMWE.^3(7T]:O*H10JC %.HJ2@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JI>QY4..J]?I5NFLH92IZ$8H HHVY0:=44>8Y&1NU2U:)84444
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %4[N(@^:G4=<?SJY2$9&#T- &;(P8+*I ?N/?UJ[;R^;&&[C@U +(>8
M<GY.P[FK:J%4!1@#M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH IW[<(OXU+$@C0 #'K5>X^>\5?3 _K5N@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IDO\ J7_W33Z9-_J7_P!TT 1V'^J;_>JW52P_U3?[U6Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH I7J;760?0T@.0".]6I4\R)E]1Q5"$]5/4541,EHHH
MJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH)
M&3Q0 4A8*,DXJ,R%CMC!)J6.T9CNE./84FQV(M[2';&I)J9+-F.96_ 5:1%0
M810!3ZFY1''$D8^10/>I***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5NJ:_N+HK_"?Y&KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<
M_P#J7^E25'/_ *E_I0 RP_U3?[U6ZJ6'^J;_ 'JMT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-9U098@
M#WH =2$X'-59+U1Q&NX^IJ+9/.<N2%]_\* +P93T8'Z&G50-EZ/^E'V:5?NR
M#\R* +]%9ZO+%,BR.2"1G)S6A0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9J\SR'W/\ZTJHRVSQDM$21Z=_\ Z]" **C24'AN#4E:
M7("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"0!D\5$79
MSMC!)-#=AV'22!>!R:<EL\A#2':/3O4UO;"/YGY?^56:ANX[$<<21C"C'O4E
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M"UO&\F]AD^G:F74PC38GWB.W84^XG$*^K'H*J1(6/F/R3R,T .A38O/4U)11
M5DA1110 UE<GA\#Z5&8,G)?GZ5-118")863[LF/PJ100.3D^M+10 4UM^?DV
MX]Z=10!$8G;[[\>@IZ1JG0<^M.HHL 4444 %%%% #)(U?KU]:8(Y$X5QCWJ:
MBBP$7E,Q_>/GV%2* HP!@4M% !1110 4444 %%%% !1110!"^8I%D7UYJ^C!
MU##H:J.H=2IHLY"K&)OPJ6-%VBBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH J7T>4#CJO!^E0&:<INZ*.^.M:)&1S5&YS)<B//
M Q0!+;S&4'*XQW'2IJ:B!%"J, 4Z@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"&>!9E]&'0U31S&WER<8K2J&X@$R^C#H: (J*@C<QMLDXQZ]JG
MJT2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !4,P*L)%ZBIJ0@,"#T-# LQ.)$#CO3ZH6KF.4QMT/3Z__7J_
M4%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %1S.8XF8 $CUJ2HI_\ 4/\ [IH
M@6^'\2'\#4JW4+?Q8^HJ"T17B.Y0>>XI[6L1Z CZ&@"RK*PRI!^AIU4#:,IR
MC\^_%)ON8O5A^= &A15.*\RP5U"Y[BK3\HWTH BDNHT_BW'T%5HV,MWOP0/Y
M<4VT1'9MXR1T%70 !@  >U "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!2O(]K"5?H::IW*"*NNH="IZ&LY,QNT;4TQ,EHHHJR0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ ILC[%]STIQ( R>E1Q*)',DG$:]?\*38TA\,:)"99AG/0'_ #WJ
MN[;V)P!Z =J?-*TS%CPHZ"I;.'<WF,.!T]S4%$]K#Y2;F'SMU]JL444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $%Q )5R.&'0U6B<Y\M^"*T*JW4&\;T^\.OO0@$HJ.&3>,'[
MPJ2K)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"&=> XZBKD$GF1!N_0_6H&&5(]118-\CKZ'-2QHN4444AA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4QUWHR^HQ3Z* ,Z)S;2%)!P:N Y&123PK,N
M#P1T-5H96A?RY>!_+_ZU %NBBB@"K>[<+Q\W]*LVX*PJ&.3BJBCS[KU4?R%:
M% %"X0P3"5>A-648.H8=#3Y8Q(A4]ZIVK%)#"W^30!;HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J.?\ U+_2I*CG_P!2_P!* &V/^H;_ 'OZ"K55
M;'_4-_O?T%6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &2!C&P0X;'%9\1EB)*QDD^JFM.B@#.VRW$BAU*@>V*OJH50H& *=10
M4444 %%%% !1110!&\,;G+*"?6@0Q#HB_E4E% "4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1124 +15:6[C3A?G/MTIMM<&1RKXR>1B@"W1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 54O8L@2+U'6K=(1D8- %!'#KGOWIU,FC,$FY?N'_.*>"",CI5IW
M):"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***C<LSA$ZFANP$E%(+68]7 _$TOV-S]Z05/,.Q$<S2"-*=,
M0=L$?W5ZGU-2,HM(S@Y=N <=!54 GY5Y9JDHECC\Z0(O"+W_ ,^M:"@*H &
M*9!$(8PO<]34M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %"Y3RI1(H^5J>"" 1T
M-6)HQ+&5/X52@8@F-N"*:$R:BBBJ$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,M/EG=>V*?42';>*?6DQHT****
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4-Q )E]&'0U-10!GA+I   <#W!H
M)NL$%3S[5H44 5K2(QQDL,,U6:** "J$WRWH/KC_  J_5&_&'1AZ8H M44@.
M0#ZTM !1110 44UW6-<L<#I2@Y&10 M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'^H
M?Z5)4=Q_J'^E #;'_4-_O?T%6JJV/^H;_>_H*M4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %)2U1O&+2+$OX_4T 2RW<:<+
M\Y]NE0'S[CKPOY#_ .O4T=LB<GYCZFIJ (8[9$Y(W'U-172%'$J<>OUJW2,H
M=2IZ&@!89!)&&'?K4E4+=C#.8VZ'C_"K] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V1!(A5NA
MK.PT$A1^GK6G44\(F3!X(Z&@"M13&BFB[;E]N:19@?O<5=R;$E%%%,04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E,MG5
M)B9.">A]*?370./?UI-7&F7Z1F"J6)P!5.UE=9!$W([>U+?2=(Q]34%%:60R
MR%S^ JW9PX'F,.3TJM;0^;)S]T=:T^E "T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %4;R,HXE7OU^M7J;(@D0J>AH JJP901WI:@7,,A1^GK4]6F2%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0
M3?+*C^G]*GJ&Y'R ^]#!&A2U'$<Q(?514E04%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5#<1><F,X(Y%344 9\<S0GRY0<#]*D^UQ_P"U
M^567B23&]0<4S[-%_P \Q^= $/VN/_:_*C[7'_M?E4OV:'^X/SH^S0_W!^=
M%61C<RJJ=/>G6SNDIA;D#/X5;2&.,Y10#5-/^/YOJ: +E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44R25(Q\QY]!0 ^BJGVTY^YQ]:47H[H?SH M45 ETCL%P03ZU/0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'^H?Z5)4=Q_J
M'^E #;'_ %#?[W]!5JJMC_J&_P![^@JU0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5GR9CN]S\@G.?;_P"M6A4-Q#YL>/XA
MTH <.1D455M)?^63=1TJU0 4444 5KR/*AQU'7Z5/;2^;$"?O#@TI ((/0U4
MB;[/<%6^Z?\ (H T**0$$9!R*6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AF@253D -V-344
M 9D9*,8WX(J6B^ WKC[QH'3FKBR6%%%%,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%-D.(S0 6I&]Y6Z**@)::7/5F-2,VR
M(.KG<?IVJQ9P[5\QAR>GTK,LGAB$2!1^)]:DHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@""YA\U./O#I56&3/R-]X5HU2NXMI\U.#WIH!U%-1MZ
M!J=5$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %17/^K'UJ6HKC_5_C0P1<@_U"?[HJ2HK;_CW3Z5+4%!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9Z?\?S?4UH
M5GO^YO-QZ$Y_.@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4UW6,98XI)9!$A8_@*K00-.2\C'&?SH 5[A
MY#MB4_UI\=I_%*<GTS_6G/+%;C8B_-Z#^IJ$F>X]D_(?_7H FDN8HUVH V.P
MZ40/'."'1-P]J2*V1.3\Q]Z9+;N)=\/'X]* %NX JAXU QUQ4L,GF1AN_>JY
M2Z8$$Y!]Q3[:.2)B&'RGWH LT444 %%%% !1149FB'5Q0!)14)NHA_%G\*6.
M=)&VKG/O0!+1110 4444 %%%% !1110 4444 %%%% !4=Q_J'^E25'<?ZA_I
M0 VQ_P!2?][^@JU56Q_U'XU:H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** *5W$582IQZ_XU+#()8PW?N*F(# @C(-4"
MLEO,0@R#TXZT 7:0D#J<9JKONFZ*1_P''\Z0VLS LQ^;T)YH N5'+"LH^;KV
M(J"*YVC;+G([T_[7'Z-^5 $7[ZV.0<I^E6H;A)>.C>AJO)=*4(0')]:ELX=B
M^8P^9NGL* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !113)&V(S>@S0!1E/F71]%X_+_Z]/J*$
M9W,>IJ6K6Q+"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HISP!4M5YCF0^W%)[#01KYDBKZG'X5JU0L5S*6_NBM"H*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNH="IZ$8IU% &;%E':
M-NH-3TR[7RY5D'?K3P<C(JD)A13)7V+GOVJ-963&\'!Y!IW%8GHI%(89!R*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_5&I*CF
M_P!6U# LVO\ Q[I4U06G_'NGX_SJ>H*"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ II( )/ %.I",C!Z&@"E+=,YV0@\]^]-
M^S2OR[C\3FBW_=7+1GZ5<H 100H!.2!UI:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D 9/2EJK=2%B(DY)ZX_E0
MSYKJ? X0?RJ^JA5"@8 J."$0ICN>IJ0D*"3P!0!14![Q]PSR:N53M_GN7<#C
MD_G5R@ HHHH **** "BBB@!"0 2>@JL]X.D:Y/J:L.,HP]15:R*J'9@/E&<T
M ((IY_O':OOQ^E3+9(!\S,3[<5(EQ$_1L'T/%34 5Q9PC^$G\:KW$?D2J\8P
M*T*BGC\R(KWZCZT "L&4,.AI:JV<G!C/4<BK5 !1110 4444 %%%% !1110
M4444 %1W'^H?Z5)4=Q_J'^E #;'_ %'XU:JK8_ZC\:M4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1O#
M&[;F4$TT6T0_Y9BIJ* (_(B'_+-?RJ2BB@ HHHH *CFE$2%C^ ]:DK/O2?-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!%/'YD3+WZCZU2'GQK@QG ]JTJ* ,^&,SR[W'RCM_2KKQK(NU@"*?10
M!G$&"8J?NGH:FJ2YB\V/C[PY%5H'W+M/4528F2T444Q!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,F_U34^FR?ZMOI0!+9?\ 'N/J:L56LO\
M4?B:LU!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+<R1MB5?TP:LHZN,J<B@!U%%% !1110 4444 %%%% !45Q_J7^E2U%<_ZAZ
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M_P#6IUS*2?*CY)X./Y5-;0")<GECU]J $-MBW,:D;CR2:@CM'8_O#M45H44
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M+/BX<>Q_G0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5PDO .&]#4U4I;4'YHN#Z4D=T\9V3 GW[T 7J*:KJZ[E((IU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $%VFZ$X&2#FJD4@("G@BM*H)K9).1\K>HIIV @HJ-A+ <.,
MKZT]2& (JD[DM"T444Q!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %(YPA/M2TR4X0^]# 5%_T*0^I']*;9?\? ^AJP$Q88_P!G/]:K6AQ<+[\5
MF6:=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !44Z[X74<G%2T4 9UNV5V]Q4U,NHS'()4'!//L?_ *].1@Z@BJ3$
MQ:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8\JIU.3Z"@!+?
MYKPGTS_A5^J5D"9'<C (ZU=J"@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $K/_ ./:Y(_@/\JT:BF@2;&[/'I0!6>\'2-<^YIJQRS2*\@P!Z\<5<CB
MCC^XH'O4E !32 P((R#3J* ,XAK6?N4/ZC_ZU7 0P!!R#2S1"5"IZ]CZ53MY
M#$YBDXY[]J +E%%% !1110 5%<*K1,2,D#BB2=(^"<GT%0%YKC*HN%_SWH F
ML?\ 4-_O?T%6JAMXC%'M)R2<U-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17"
M[H''MFJ4)RGT-:)&1BLV(;7=#U%-;B9+1115DA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %17'0"I:9*,QGVYH>PT7& \@J.FW'Z5G1';*A]"*
MOVK^9  >HXK-Z5F4;-%-4[E!]1FG4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #64,I5AD&L\@V\I5ONGO6E4,\
M(F3'\0Z&@"FK2R,?+R0*7-P.L9/X5<AB$487OW-2T[@9IED7[\>!],5*DBN.
M#SZ5<(!&",BJDUISNB.#Z47%86BH5F*G;*""*FZCBJN(**** "BBB@ HHHH
M**** "BBB@".<D1Y!QS4EM;H461OF)['H*CG_P!4:GM,_9US[XJ6-$]+2$@=
M3BEI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :ZAU*GH1BJQL4[.P^M6Z* (X8_+C"9SCO4E%
M% !56ZN"A\N/[QZGTJP[!$+'H!5&V4R3-*W8_K0 ^WM]OSORW8>E6:** "BB
MB@ HHHH **** "CK110!7FMT*EE&&'I3K*3=&4/5?Y5([A%+-T%5K,,9F<#"
M<YH OT444 %131+*NULC!SQ4M% %3["G]]J3["O]\_E5RB@"G]A&>9#CZ59C
MC2,808I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9]RWFW(3/ X_QK0JM-:K)ED^5OT- $@&!@
M=!2U36:2!MDH)%6D=9%RIS0 ZJ<T+1-YL7 'IVJY10 R"=95]&'45/5">$QM
MYD7&.>.U6+><2K@\..HH GHHHH SW+7%P4S@*3^56U4(H51@"JEGS*[>U7*
M"BBB@"*Y7= WJ.:+)LPX_NG%2$94@]ZIV\WD.RN#@_I0!HT4U65URI!'M3J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6=*-EVWH:T:HWHVR(^/:@ HH'(R**
MT("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "R.V5T_P \
M56E4I(RGL:F4^7=(W8__ *J??1X8.._!K,LL6IW0)[#%351L'Y:,]^15Z@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBFNXC0L>@H J7LA)6->IY/]*FB01QA?SJM;*99FD;U_6KE !1110
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MK&N7( JI)=/(=L*GZXYI%@DE;?*Q'\__ *U64C6,848H AM8FC#%Q@FK%%%
M!1110 4R2))!AA^-/HH I#-M..25/\JT*K74>^+(ZKS3;>Y0($<X(XR>E %R
MBD!!&0<BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2$9&#TI:* ,]U-O-_L-T_S[5+3[M-T)/=>:@A.8A[
M<52$R2BBBF(**** "BBB@ HHHH CF&8S[<U$A\R1-W11^@J2>0*"HZG]*@!P
MI]^*EC18@!FNC)T YJ_4-O%Y40'<\FIJ0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFLRH,
ML0![T .JE>2%G$2_C]:>]Y&O" L?R%16J%W,K_A0!8B01QA1VI]%% !1110
M4444 %%%1RS)'U.3Z"@"3I5:6Z ^6+D^M1YFN6PHPGZ5;BMTAY'+>IH KQVK
M2'?,3SV[U<5510%  'I3JK3W2Q_*F&;]!0!+-,L2Y8\]AZU2/FW3\\(/R%)L
M_P"6EPQYZ#N:GBN(B H^3V- $D<2Q+A1^-,>VC?G&#ZBGO(B#+,!5=[IG.V)
M3G\S0!'*A@<!'.3Z<5H("$4,<G')JK#;R&022GH<X/)J[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 5[BW60$J '_G4%O+@B.3J.A/:K]5KJW\
MP;T'SC]: ):*K6]P"-DAPWJ>]6: "BBB@ HHHH **** "H9+>.3G&T^HJ:B@
M"GY<]N<H<CV_PJ:"Z#L$<88]QTJ:JMW'@B5>".M %ZBHH)1+$&[]#]:EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &LP526. .]4Y+QB_[L?*/4=:+[.]!D[<=*GCC6-<*/Q]:
M &Q7<;\-\A]^E6*K26R/R!M/J*AQ/;_=.5_,4 :%%58KQ&X<;3Z]JL @C(.1
M[4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!KHKJ589!JH]FRG,3?@:NT4 9A=XSMD4B
MI%=6Z&KK*K## $>]5I+-3S&=I]#TIIBL,HJ-O-B_UBY'K_\ 7I5D5N^/K57%
M8?1113$%%%% !1110 4444 %%%% !1110 4444 %%D=LKJ?3^5%-@.V[QZU,
MAHDODRBN.W!J.Q?$A0_Q"K-V,V[_ (?SJE:G%PGUJ2C4HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 5+Y28U8#[IYIT$@DC&.H&"*L$ C!Z5GS+]FF!0\'G% %
MVBD4Y4$C!]*6@"*2WCDYQ@^HJ#RIX#F,DCV_PJY10!!'> \2#:?4595E<94@
MCVJ&2%)/O#GU%5S!+$=T3$_3K0!H453BN^=LHP?6K8((R#D4 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "$9'-0/:1.<@%3[58HH I&R(Y23\Q3#%<)VW#VYK0HH S/,
M93B1"/PQ4@(89!R*N.BNNUAD52E@>$ED.5JDQ6'44U) _L?2G51(4444 %%%
M% !1110 4444 %1L=MPC>XJ2HIQPII/8:+T_^H?_ '36="<2H?\ :%:).^ D
M?Q+_ $K+!P0?2H*-FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SYL+>9/ /^%:%0SP
M+,O/#=C0!%14)6:#J,KZ]10OG3?<&%]:JXK#I9-@P/O&EBM"Z[I&()[5)#:!
M"&<[CZ=JM4FQE3["G]]J<+*('JQ]LU9HI -5%084 #VJK>2](UZGK_A5B:01
M1EC^ ]:HQD*3-)R3]T>IH )4V[(A][J?J:OHH1%4= ,54MHVDD\U^G;WJ]0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"9CD. .A-4ZFG R#WJU';)\KLO)'*GIFH99/&=T:GU I](  ,#@4M( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *9)(L:%F.!22R+$NYC^'K6=+*97W
M.>!T H 6:5ICN;A1T%/MX#,P9_N#]:((3,VYN$%7P   !@"@!0 !@<"EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO<W B&U>7/Z
M56$<\HRS$ ^IH O-+&GWG _&JTEYDXB7/N::MF/XG)^E3I$D8^5<>] $'VJ<
M=8Q_WR:%O6!&]!CVJU3719%PPS0!(CJZ[E.0:IW,QE?RH^1W]Z:;:56*HWRG
MOG%300"($DY8]Z '0Q"),#KW-2444 %%%% !3'E2/[S >U/J&:W63D<-Z^M
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MM5F\_P"/<^Q%-M?^/=?Q_G0 L,"Q<CDGN:EHHH **** "BBB@ HHHH ****
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MGYF]?2FY"L0V\+._F2# [ U>HHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[#M0!?HJM;7(E^5N'_G5F@ HHHH *HWW^L3Z5>JO=0&4!E/S#MZT .5%084
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M_,>U5I[IERBJ5;U-5V22$K(W4G- &I1348.@8=",TZ@ HHHH **** "BBB@
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M5=6@E'EL<FM(=.>M48(GFD$K_=!S]:OT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5KBX,3[0H)QG)
MJJ]S,W\6/IQ0!H2R".,L>U48<-(996 Y[^O_ -:HU228\ M[FIX[(_\ +1L>
MPH 5[M!]P%OTI@:XF^Z"%]N/UJTEO''T49]3S4U %-++O(V?859CC2,848%/
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH BFB65-K=>Q]*ABLU7F0[CZ#I5NB@!H  P  /04ZBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HI8$E^\,'U%2T4 4Q8C^)S^ J9+:)?X=Q_P!KFIJ* $Z4
MM%% !3656&& (]Q3J* (#:PM_!CZ&F&RCSPS8JU10! EM$G\&?KS4P  P!BE
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]:K!9KD^B?I_]>D :ZFYX0?H*O@!0 !@"@".*V2+D#+>IH>VB<Y*X/MQ4U%
M#$B2/[B@4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBF.VQ"QR<#/% %:]C3;OSAOYTMJ[NGS#@=#ZU"NZZF)8X4=O:K"R 3&(<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIR<#)Z53;==3A5X4?RH M6J;(%]3S4](!@8%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $4L"2CYA@]B*J_9)E^ZX_,BK]% %2"V
M97+RX)'3O5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,>-9!AU!%/HH 9'$L2
MX44^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  #6X   "=" (    1JY<<   'KTE$051X7NW:
M,0$   B ,/N7UM\*;"<9F 4           #"Y@<           "@Q$H(
M        :59"            2+,2 @          0)J5$            -*L
MA            )!F)00          ( T*R$           "D60D!
M   @S4H(            :59"            2+,2 @          0)J5$
M         -*LA            )!F)00          ( T*R$           "D
M60D!           @S4H(            :59"            2+,2 @
M    0)J5$            -*LA            )!F)00          ( T*R$
M          "D60D!           @S4H(            :59"
M2+,2 @          0)J5$            -*LA            )!F)00
M     ( T*R$           "D60D!           @S4H(            :59"
M            2+,2 @          0)J5$            -*LA
M )!F)00          ( T*R$           "D60D!           @S4H(
M        :59"            2+,2 @          0)J5$            -*L
MA            )!F)00          ( T*R$           "D60D!
M   @S4H(            :59"            2+,2 @          0)J5$
M         -*LA            )!F)00          ( T*R$           "D
M60D!           @S4H(            :59"            2+,2 @
M    0)J5$            -*LA            )!F)00          ( T*R$
M          "D60D!           @S4H(            :59"
M2+,2 @          0)J5$            -*LA            )!F)00
M     ( T*R$           "D60D!           @S4H(            :59"
M            2+,2 @          0)J5$            -*LA
M )!F)00          ( T*R$           "D60D!           @S4H(
M        :59"            2+,2 @          0)J5$            -*L
MA            )!F)00          ( T*R$           "D60D!
M   @S4H(            :59"            2+,2 @          0)J5$
M         -*LA            )!F)00          ( T*R$           "D
M60D!           @S4H(            :59"            2+,2 @
M    0)J5$            -*LA            )!F)00          ( T*R$
M          "D60D!           @S4H(            :59"
M2+,2 @          0)J5$            -*LA            )!F)00
M     ( T*R$           "D60D!           @S4H(            :59"
M            2+,2 @          0)J5$            -*LA
M )!F)00          ( T*R$           "D60D!           @S4H(
M        :59"            2+,2 @          0)J5$            -*L
MA            )!F)00          ( T*R$           "D60D!
M   @S4H(            :59"            2+,2 @          0)J5$
M         -*LA            )!F)00          ( T*R$           "D
M60D!           @S4H(            :59"            2+,2 @
M    0)J5$            -*LA            )!F)00          ( T*R$
M          "D60D!           @S4H(            :59"
M2+,2 @          0)J5$            -*LA            )!F)00
M     ( T*R$           "D60D!           @S4H(            :59"
L            2+,2 @          0-H!ZH,=X9"^1I0     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213639328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> shares in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-14106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAVITA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0354549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 16th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Denver,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000927066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213493056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AuditorAbstract', window );"><strong>Auditor [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, WA, USA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AuditorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AuditorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213012160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts', window );">Dialysis patient service revenues</a></td>
<td class="nump">$ 11,176,464<span></span>
</td>
<td class="nump">$ 11,213,515<span></span>
</td>
<td class="nump">$ 11,026,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">433,430<span></span>
</td>
<td class="nump">405,282<span></span>
</td>
<td class="nump">524,353<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
<td class="nump">11,550,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PatientCareCosts', window );">Patient care costs</a></td>
<td class="nump">8,209,553<span></span>
</td>
<td class="nump">7,972,414<span></span>
</td>
<td class="nump">7,988,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,355,197<span></span>
</td>
<td class="nump">1,195,335<span></span>
</td>
<td class="nump">1,247,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">732,602<span></span>
</td>
<td class="nump">680,615<span></span>
</td>
<td class="nump">630,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income, net</a></td>
<td class="num">(26,520)<span></span>
</td>
<td class="num">(26,937)<span></span>
</td>
<td class="num">(26,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on changes in ownership interest, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,270,832<span></span>
</td>
<td class="nump">9,821,427<span></span>
</td>
<td class="nump">9,855,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,339,062<span></span>
</td>
<td class="nump">1,797,370<span></span>
</td>
<td class="nump">1,694,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="num">(357,019)<span></span>
</td>
<td class="num">(285,254)<span></span>
</td>
<td class="num">(304,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtPrepaymentRefinancingRedemptionCharges', window );">Debt prepayment, refinancing and redemption charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(89,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income, net</a></td>
<td class="num">(15,765)<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
<td class="nump">16,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">966,278<span></span>
</td>
<td class="nump">1,518,494<span></span>
</td>
<td class="nump">1,318,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">198,087<span></span>
</td>
<td class="nump">306,732<span></span>
</td>
<td class="nump">313,932<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">768,191<span></span>
</td>
<td class="nump">1,211,762<span></span>
</td>
<td class="nump">1,004,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income (loss) from discontinued operations, net of tax</a></td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">781,643<span></span>
</td>
<td class="nump">1,211,762<span></span>
</td>
<td class="nump">994,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="num">(221,243)<span></span>
</td>
<td class="num">(233,312)<span></span>
</td>
<td class="num">(221,035)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 773,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations (in usd per share)</a></td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (in usd per share)</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="nump">9.30<span></span>
</td>
<td class="nump">6.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations (in usd per share)</a></td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
<td class="nump">6.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (in usd per share)</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares for earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">92,992,000<span></span>
</td>
<td class="nump">105,230,000<span></span>
</td>
<td class="nump">119,797,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">95,834,000<span></span>
</td>
<td class="nump">109,948,000<span></span>
</td>
<td class="nump">122,623,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 546,948<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 783,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income (loss) from discontinued operations</a></td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 773,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtPrepaymentRefinancingRedemptionCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment, refinancing and redemption charges related to long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtPrepaymentRefinancingRedemptionCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PatientCareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PatientCareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213588784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 781,643<span></span>
</td>
<td class="nump">$ 1,211,762<span></span>
</td>
<td class="nump">$ 994,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized gains (losses) on interest rate cap agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains (losses)</a></td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
<td class="num">(16,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification of net realized (gains) losses into net income</a></td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized losses on foreign currency translation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized losses on foreign currency translation</a></td>
<td class="num">(29,802)<span></span>
</td>
<td class="num">(84,381)<span></span>
</td>
<td class="num">(7,623)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">70,061<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
<td class="num">(18,656)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">851,704<span></span>
</td>
<td class="nump">1,138,669<span></span>
</td>
<td class="nump">976,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(221,243)<span></span>
</td>
<td class="num">(233,312)<span></span>
</td>
<td class="num">(221,035)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to DaVita Inc.</a></td>
<td class="nump">$ 630,461<span></span>
</td>
<td class="nump">$ 905,357<span></span>
</td>
<td class="nump">$ 754,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213096464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 244,086<span></span>
</td>
<td class="nump">$ 461,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and equivalents</a></td>
<td class="nump">94,903<span></span>
</td>
<td class="nump">93,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">77,693<span></span>
</td>
<td class="nump">22,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,132,070<span></span>
</td>
<td class="nump">1,957,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">109,122<span></span>
</td>
<td class="nump">107,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">413,976<span></span>
</td>
<td class="nump">427,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">78,839<span></span>
</td>
<td class="nump">72,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">25,604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,155,292<span></span>
</td>
<td class="nump">3,167,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">3,256,397<span></span>
</td>
<td class="nump">3,479,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,666,242<span></span>
</td>
<td class="nump">2,824,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">182,687<span></span>
</td>
<td class="nump">177,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">231,108<span></span>
</td>
<td class="nump">238,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">44,329<span></span>
</td>
<td class="nump">49,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">315,587<span></span>
</td>
<td class="nump">136,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,076,610<span></span>
</td>
<td class="nump">7,046,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td>
<td class="nump">16,928,252<span></span>
</td>
<td class="nump">17,121,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">479,780<span></span>
</td>
<td class="nump">402,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">802,469<span></span>
</td>
<td class="nump">709,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">692,654<span></span>
</td>
<td class="nump">659,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">395,401<span></span>
</td>
<td class="nump">394,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">231,404<span></span>
</td>
<td class="nump">179,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">18,039<span></span>
</td>
<td class="nump">53,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,619,747<span></span>
</td>
<td class="nump">2,398,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">2,503,068<span></span>
</td>
<td class="nump">2,672,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">8,692,617<span></span>
</td>
<td class="nump">8,729,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">105,233<span></span>
</td>
<td class="nump">119,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">782,787<span></span>
</td>
<td class="nump">830,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,703,452<span></span>
</td>
<td class="nump">14,750,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,348,908<span></span>
</td>
<td class="nump">1,434,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">606,935<span></span>
</td>
<td class="nump">540,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">174,487<span></span>
</td>
<td class="nump">354,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(69,186)<span></span>
</td>
<td class="num">(139,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total DaVita Inc. shareholders' equity</a></td>
<td class="nump">712,326<span></span>
</td>
<td class="nump">755,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests not subject to put provisions</a></td>
<td class="nump">163,566<span></span>
</td>
<td class="nump">180,640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">875,892<span></span>
</td>
<td class="nump">936,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 16,928,252<span></span>
</td>
<td class="nump">$ 17,121,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,411,000<span></span>
</td>
<td class="nump">97,289,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213034608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">90,411,000<span></span>
</td>
<td class="nump">97,289,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207396752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 781,643<span></span>
</td>
<td class="nump">$ 1,211,762<span></span>
</td>
<td class="nump">$ 994,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">732,602<span></span>
</td>
<td class="nump">680,615<span></span>
</td>
<td class="nump">630,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtRefinancingCharges', window );">Debt prepayment, refinancing and redemption charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">86,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">95,427<span></span>
</td>
<td class="nump">102,209<span></span>
</td>
<td class="nump">91,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(75,669)<span></span>
</td>
<td class="nump">60,483<span></span>
</td>
<td class="nump">240,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments', window );">Equity investment income, net</a></td>
<td class="nump">8,773<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">13,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax', window );">Loss on sales of business interests, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash charges, net</a></td>
<td class="nump">21,693<span></span>
</td>
<td class="nump">11,231<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(148,394)<span></span>
</td>
<td class="num">(138,140)<span></span>
</td>
<td class="num">(21,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(757)<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
<td class="num">(12,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets', window );">Other receivables and prepaid and other current assets</a></td>
<td class="nump">27,533<span></span>
</td>
<td class="nump">128,661<span></span>
</td>
<td class="num">(79,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(50,549)<span></span>
</td>
<td class="num">(26,387)<span></span>
</td>
<td class="num">(6,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">87,481<span></span>
</td>
<td class="num">(30,320)<span></span>
</td>
<td class="nump">37,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">34,536<span></span>
</td>
<td class="num">(16,717)<span></span>
</td>
<td class="num">(20,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">89,955<span></span>
</td>
<td class="num">(93,645)<span></span>
</td>
<td class="nump">105,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="num">(24,103)<span></span>
</td>
<td class="nump">36,921<span></span>
</td>
<td class="num">(87,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(15,601)<span></span>
</td>
<td class="num">(6,732)<span></span>
</td>
<td class="num">(19,851)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="nump">1,564,570<span></span>
</td>
<td class="nump">1,930,876<span></span>
</td>
<td class="nump">1,979,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions of property and equipment</a></td>
<td class="num">(603,429)<span></span>
</td>
<td class="num">(641,465)<span></span>
</td>
<td class="num">(674,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisitions</a></td>
<td class="num">(57,308)<span></span>
</td>
<td class="num">(187,050)<span></span>
</td>
<td class="num">(182,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from asset and business sales</a></td>
<td class="nump">117,582<span></span>
</td>
<td class="nump">61,464<span></span>
</td>
<td class="nump">50,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of debt investments held-to-maturity</a></td>
<td class="num">(129,803)<span></span>
</td>
<td class="num">(30,849)<span></span>
</td>
<td class="num">(150,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments', window );">Purchase of other debt and equity investments</a></td>
<td class="num">(3,590)<span></span>
</td>
<td class="num">(2,987)<span></span>
</td>
<td class="num">(3,757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from debt investments held-to-maturity</a></td>
<td class="nump">71,125<span></span>
</td>
<td class="nump">15,849<span></span>
</td>
<td class="nump">151,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale of other debt and equity investments</a></td>
<td class="nump">3,781<span></span>
</td>
<td class="nump">12,030<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity method investments</a></td>
<td class="num">(31,885)<span></span>
</td>
<td class="num">(13,924)<span></span>
</td>
<td class="num">(22,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investments</a></td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">3,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="num">(782)<span></span>
</td>
<td class="num">(745)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities, Total</a></td>
<td class="num">(630,347)<span></span>
</td>
<td class="num">(784,733)<span></span>
</td>
<td class="num">(825,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings</a></td>
<td class="nump">2,393,116<span></span>
</td>
<td class="nump">1,615,370<span></span>
</td>
<td class="nump">4,046,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on long-term debt</a></td>
<td class="num">(2,404,395)<span></span>
</td>
<td class="num">(861,115)<span></span>
</td>
<td class="num">(4,110,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtFinancingAndDebtRedemptionCosts', window );">Deferred financing and debt redemption costs</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9,091)<span></span>
</td>
<td class="num">(105,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(802,228)<span></span>
</td>
<td class="num">(1,538,626)<span></span>
</td>
<td class="num">(1,458,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(267,946)<span></span>
</td>
<td class="num">(244,033)<span></span>
</td>
<td class="num">(253,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsRelatedToStockPurchasesAndAwards', window );">Net (payments) receipts related to stock purchases and awards</a></td>
<td class="num">(37,367)<span></span>
</td>
<td class="num">(60,001)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from noncontrolling interests</a></td>
<td class="nump">14,797<span></span>
</td>
<td class="nump">31,754<span></span>
</td>
<td class="nump">42,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sales of additional noncontrolling interests</a></td>
<td class="nump">3,673<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchases of noncontrolling interests</a></td>
<td class="num">(20,775)<span></span>
</td>
<td class="num">(20,104)<span></span>
</td>
<td class="num">(7,831)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,121,128)<span></span>
</td>
<td class="num">(1,082,966)<span></span>
</td>
<td class="num">(1,846,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(29,066)<span></span>
</td>
<td class="num">(10,007)<span></span>
</td>
<td class="num">(13,808)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(215,971)<span></span>
</td>
<td class="nump">53,170<span></span>
</td>
<td class="num">(706,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</a></td>
<td class="nump">554,960<span></span>
</td>
<td class="nump">501,790<span></span>
</td>
<td class="nump">1,208,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at end of the year</a></td>
<td class="nump">$ 338,989<span></span>
</td>
<td class="nump">$ 554,960<span></span>
</td>
<td class="nump">$ 501,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AdjustmentIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtFinancingAndDebtRedemptionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Financing And Debt Redemption Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtFinancingAndDebtRedemptionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtRefinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtRefinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in other current receivables and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LossGainOnDispositionOfBusinessInterestsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss (Gain) On Disposition Of Business Interests Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LossGainOnDispositionOfBusinessInterestsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsRelatedToStockPurchasesAndAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to stock purchases and awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsRelatedToStockPurchasesAndAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Other Debt And Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsToAcquireOtherDebtAndEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201731152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests subject to put provisions</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non-controlling interests not subject to put provisions</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,133,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 749,043<span></span>
</td>
<td class="nump">$ 1,431,738<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (47,498)<span></span>
</td>
<td class="nump">$ 185,833<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,180,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">$ (18,656)<span></span>
</td>
<td class="num">(18,656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(17,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="num">(16,477,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,477,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">$ (1,446,767)<span></span>
</td>
<td class="num">(1,446,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,446,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,477,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
<td class="num">(93,908)<span></span>
</td>
<td class="num">(1,352,843)<span></span>
</td>
<td class="nump">$ 1,446,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">597,073<span></span>
</td>
<td class="nump">852,537<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(66,154)<span></span>
</td>
<td class="nump">183,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">$ (73,093)<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(80,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">$ (1,546,016)<span></span>
</td>
<td class="num">(1,546,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,546,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">(69,352)<span></span>
</td>
<td class="num">(1,476,650)<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deferred taxes from partnership buyouts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 936,148<span></span>
</td>
<td class="nump">755,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">540,321<span></span>
</td>
<td class="nump">354,337<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(139,247)<span></span>
</td>
<td class="nump">180,640<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">97,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(55,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">$ (787,854)<span></span>
</td>
<td class="num">(787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">(47,596)<span></span>
</td>
<td class="num">(740,250)<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 875,892<span></span>
</td>
<td class="nump">$ 712,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 606,935<span></span>
</td>
<td class="nump">$ 174,487<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (69,186)<span></span>
</td>
<td class="nump">$ 163,566<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">90,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest increase from contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasePurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Purchase Of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasePurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase Due To Acquisitions And Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208879472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and summary of significant accounting policies<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are comprised of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or end stage kidney disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ESRD or ESKD). As of December&#160;31, 2022, the Company operated or provided administrative services through a network of 2,724 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 199,400 patients. In addition, as of December&#160;31, 2022, the Company operated or provided administrative services to a total of 350 outpatient dialysis centers serving approximately 45,600 patients located in 11 countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, the Company completed the sale of its prior DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC (Optum), a subsidiary of UnitedHealth Group Inc. The effects of the DMG sale on the Company's consolidated financial statements have been reported in discontinued operations for all periods presented. For information on how the DMG sale has affected these results, see Note 22.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD). Prior year classifications have been conformed to the current year presentation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment frequency than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of our commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated in the period services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, for most of its VBC arrangements, the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, for most of its VBC arrangements the Company does not include third party medical costs in its reported revenues and expenses, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income includes interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow. See Note 4 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other income. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 5 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of the right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date.The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets, and interest accretion on operating lease liabilities, are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 9 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 10 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in LIBOR interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 13 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2022, third parties held noncontrolling equity interests in 689 consolidated legal entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement. See Note 24 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 24 for further details.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which extends the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors will cease or become non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The Company is currently assessing the other effects this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU creates an exception to the general recognition and measurement principle in ASC 805 and will result in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Early adoption is permitted for all entities. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944304988608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer</a></td>
<td class="text">Revenue recognition and accounts receivable<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,576,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,169,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,169,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,540,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,550,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December&#160;31, 2020 has also been recast to conform to this presentation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. integrated care and disease management business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1, there are significant risks associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues including determining applicable primary and secondary coverage, changes in patient coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $1,113,499 and $1,174,123 as of December&#160;31, 2022 and 2021, respectively. Approximately 18% and 16% of the Company&#8217;s patient services accounts receivable balances as of December&#160;31, 2022 and 2021, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2022. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209460352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings&#160;per share<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217442976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash and Cash Equivalents Disclosure [Text Block]</a></td>
<td class="text">Restricted cash and equivalentsThe Company had restricted cash and cash equivalents of $94,903 and $93,060 at December&#160;31, 2022 and 2021, respectively. Substantially all of the restricted cash and equivalents balance at December&#160;31, 2022 is held in trust to satisfy insurer and state regulatory requirements related to the wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company and the remaining restricted cash and cash equivalents held at December&#160;31, 2022 represents cash pledged to third parties in connection with the Company's ancillary operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944304988480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Equity Securities</a></td>
<td class="text">Short-term and long-term investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,693&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,083&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,310&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company holds certain equity investments that have readily determinable fair values from public</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets. The Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209460224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Receivables</a></td>
<td class="text">Other receivables<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables were comprised of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"/><td style="width:56.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944212992208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and equipment<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,243,107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,265,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,763,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $721,133, $667,755 and $616,626 for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $12,677, $15,275 and $17,944 for 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213393760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text">Intangible assets<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"/><td style="width:59.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over three years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was two years and three years as of December&#160;31, 2022 and 2021, respectively. Amortization expense from amortizable intangible assets was $11,469, $12,860, and $13,809 for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized no impairment charges on any intangible assets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2022 were as follows:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"/><td style="width:37.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207320640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments and Joint Ventures Disclosure</a></td>
<td class="text">Equity method and other investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses, comprised as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the Company recognized equity investment income of $26,520, $26,937 and $26,916, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $4,703 and $1,292 in other (loss) income during 2022 and 2021, respectively. There were no equity investment losses from other equity method investments in 2020.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's largest equity method investment is its ownership interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV). The Company holds a 75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in the APAC JV and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25% voting and economic interest in the joint venture, however the Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include 23 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other (loss) income, net. There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213623344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:40.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,309,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations continue to be impacted by the effects of the coronavirus (COVID-19) pandemic. While the Company does not currently expect a material adverse impact to its business as a result of the ongoing COVID-19 pandemic, there can be no assurance that the magnitude of the cumulative impacts of the COVID-19 pandemic, including certain conditions and developments in the U.S. and global economies, labor market conditions, inflation and monetary policies that may have been intensified by the pandemic, will not have a material adverse impact on one or more of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s operating segments described in Note 25 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the physician practices in its physician services reporting units, to the dialysis centers and other health operations within each international reporting unit, and to the vascular access service centers in its former vascular access services reporting unit. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its most recent assessments, the Company determined that changes in its forecast concerning expected patient census, the timing or amount of expected reimbursement rate increases, expected treatment growth rates, or other significant adverse changes in expected future cash flows or other valuation assumptions could result in goodwill impairment charges in the future for the following reporting unit, which remains at risk of goodwill impairment as of December&#160;31, 2022:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.660%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reporting unit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill<br/>balance</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Carrying amount<br/>coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sensitivities</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Operating<br/>income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Discount<br/>rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany kidney care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.</span></div>Except as described above, none of the Company&#8217;s other reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2022.&#160;Since the dates of the Company&#8217;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#8217;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#8217;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217378896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text">Other liabilities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"/><td style="width:51.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210766336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxes<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are allocated between continuing and discontinued operations as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"/><td style="width:49.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:60.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534,286)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580,472)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782,787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(830,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808,045)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $71,049 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $618,883, some of which have an indefinite life, although a substantial amount expire by 2042 and international net operating loss carryforwards of $357,266, some of which will begin to expire in 2023 though the majority have an indefinite life. The Company has a state capital loss carryover of $306,949, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $6,159 in the valuation allowance is primarily due to newly created net operating loss carryforwards in state and foreign jurisdictions that the Company does not anticipate being able to utilize.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $46,692 to net deferred tax assets, a charge of $16,044 to income tax expense, and an increase of $62,736 to additional paid-in capital. The Company&#8217;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $16,044 recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in a majority of the foreign jurisdictions in which it operates as of December&#160;31, 2022. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"/><td style="width:61.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $63,985, of which $45,825 would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company recognized an expense of $10,459 and a benefit of $2,589 related to interest and penalties net of federal tax benefit within tax expense in 2022 and 2021, respectively. At December&#160;31, 2022 and 2021, the Company had approximately $8,208 and $15,275, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. The Company's federal tax returns are under examination by the Internal Revenue Service (IRS) for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014 and 2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. The refund claim is currently subject to IRS review. The Company is also open to U.S. federal examination for 2019 onward, and is no longer subject to U.S. state examinations by tax authorities for years before 2014.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217375472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt was comprised of the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:34.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.586%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition obligations and other notes<br/> payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,964,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,908,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,692,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,729,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values using level 2 interest rate inputs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and LIBOR interest rate components in effect as of December&#160;31, 2022.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $3,497 and deferred financing costs of $18,816 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018. As of December&#160;31, 2021, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $4,473 and deferred financing costs of $27,207, and the carrying amount of the Company's senior notes was reduced by deferred financing costs of $40,914 and increased by a debt premium of $15,909.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2022 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company made regularly scheduled mandatory principal payments under its senior secured credit facilities totaling $98,437 on Term Loan A and $27,432 on Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company's domestic subsidiaries' assets and are senior to all unsecured indebtedness. Borrowings under this facility's Term Loan A, Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. Borrowings under this credit facility are based on the London Interbank Offered Rate (LIBOR), unless another base rate is elected. This facility also provides a mechanism for transition to an alternative variable base rate upon cessation of LIBOR.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings under Term Loan A and Term Loan B-1 consist of tranches that can range in maturity from one month to 12 months. As of December 31, 2022, all outstanding term loan tranches are one month in duration. For Term Loan A and Term Loan B-1, each tranche bears interest at a LIBOR rate determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as the tranche matures and a new tranche is established.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the overall weighted average interest rate for Term Loan A and Term Loan B-1 was determined based upon the LIBOR interest rates in effect for all of their individual tranches plus the respective interest rate margins presented in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $165,000 outstanding on the $1,000,000 revolving line of credit under its senior secured credit facilities. Each of these borrowings were priced on one-month LIBOR variable base rates as well. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2022. The Company also had letters of credit of approximately $108,826 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A. The remaining $659,269 outstanding principal balance of Term Loan A and the $165,000 balance outstanding on the revolving line of credit are subject to LIBOR-based interest rate volatility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. These cap agreements have variable legs priced at LIBOR to match the variable rates incurred on the senior secured credit facility borrowings that they hedge. Like the senior secured credit facilities, these interest rate cap agreements include a mechanism for transition to an alternative variable base rate upon cessation of LIBOR. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit-risk contingent features.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2022 and December&#160;31, 2021, which are classified in other long-term assets on its consolidated balance sheet:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">LIBOR maximum rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be">Debt expense</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Recorded OCI gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2022, 2021 and 2020:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.102%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location of losses </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,346)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of 2022 was 4.59%, based upon the current margins in effect for its senior secured credit facilities as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 3.96% for the year ended December&#160;31, 2022 and 4.52% as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s interest rates were fixed on approximately 51.3% of its total debt.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $339,247, $267,049 and $282,932 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs and the amortization of interest rate cap agreements of $17,772, $18,205 and $21,179 for 2022, 2021 and 2020, respectively. These interest expense amounts are net of capitalized interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209031024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureTextBlock', window );">Leases Disclosure</a></td>
<td class="text">Leases<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and December&#160;31, 2021, assets recorded under <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_155f47b5-2149-4835-8f82-29569b70bc53"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_6bdf6749-42f6-44d7-86f8-0f1107e1b206">finance leases</span></span> were $319,546 and $322,060, respectively, and accumulated amortization associated with finance leases was $101,361 and $75,252, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long term basis. Both the sale and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leaseback terms are generally market terms. The lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes short-term lease expense and sublease income, which are immaterial. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2022 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:52.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(456,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2022, 2021 and 2020 was $679,815, $673,904 and $663,819, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses </span></div>or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 13 for further details on long-term debt.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases complete footnote disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217270432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee benefit plans<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2022, 2021 and 2020, the Company accrued matching contributions totaling approximately $70,084, $68,658 and $70,180, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan, as well as other legacy deferral plans. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2022, 2021 and 2020 were $3,573, $2,962 and $3,637, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2022, 2021 and 2020 the Company distributed $3,731, $11,887 and $3,139, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2022 and 2021, the total fair value of assets held in these plans' trusts was $32,944 and $38,019, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other income. See Note 5 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210876816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#8217;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#8217;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 U.S. Attorney Texas Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney&#8217;s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company&#8217;s relationships with pharmaceutical manufacturers. The government's investigation covers the period from January&#160;1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government's investigation and that included total monetary consideration of $63,700, as previously disclosed, of which $41,500 was an incremental cash payment and $22,200 was for amounts previously refunded, and all of which was previously accrued. The government&#8217;s investigation is ongoing with respect to issues related to DaVita Rx's historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. On September 15, 2021, the U.S. Attorney&#8217;s Office notified the U.S. District Court, Northern District of Texas, of its decision and the decision of 31 states not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated September 17, 2021. The complaint was not served on the Company. In December 2021, the private party relator filed a notice of voluntary dismissal of all claims and the court entered an order dismissing the claims without prejudice. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. In January 2023, the private party relator served the Company with the amended complaint. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020, and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Department of Justice Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, the Company received a CID from the Department of Justice pursuant to an FCA investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. In February 2023, the Department of Justice notified the Company that it had closed its investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Company received a CID from the Office of the Attorney General for the District of Columbia in connection with an antitrust investigation concerning the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Kidney Fund (AKF). The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. No. 20-1641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On November 5, 2021, the United States Supreme Court granted certiorari of an appeal by an employer group health plan, the plan sponsor, and the plan&#8217;s advisor of the U.S. Court of Appeals for the Sixth Circuit (Sixth Circuit) decision in the Company's favor. The questions presented involved whether the health plan violates the Medicare Secondary Payor Act (MSPA) by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On December 23, 2021, the Solicitor General on behalf of the United States filed an amicus brief supporting the petitioners' request to overturn the Sixth Circuit decision. On January 19, 2022, the Company filed its brief in support of the Sixth Circuit decision. On June 21, 2022, the United States Supreme Court reversed the Sixth Circuit decision and held that the employee health plan for Marietta Memorial Hospital did not violate the MSPA. The case has been remanded back to the lower court for resolution of the outstanding claims. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 16, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact </span></div>the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127163<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209005088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Noncontrolling Interests Subject to Put Provisions and Other Commitments</a></td>
<td class="text">Noncontrolling interests subject to put provisions and other commitments<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2022, the remaining minimum purchase commitments under these arrangements were approximately $712,802, $469,760, $362,431 and $379,832 for the years 2023, 2024, 2025 and 2026, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $9,038.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 13 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209005088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Long-term Incentive Compensation and Shareholders&#8217; Equity</a></td>
<td class="text">Stock-based compensation<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are also stated on a full value share basis rather than on an option-equivalent basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2022, there were 6,815 shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Healthcare Partners Inc. 2011 Incentive Award Plan (the 2011 Plan) was the Company&#8217;s prior omnibus equity compensation plan and authorized the Company to award stock options, stock appreciation rights, restricted stock units, restricted stock, and other stock-based or performance-based awards. The 2011 Plan mandated a maximum award term of five years and stipulated that stock appreciation rights and stock options be granted with prices not less than fair market value on the date of grant. The 2011 Plan also required that full value share awards such as restricted stock units reduce shares available under the 2011 Plan at a ratio of 3.5:1. The Company&#8217;s stock appreciation rights and stock units awarded under the 2011 Plan generally vest over 36 months to 48 months from the date of grant. The 2011 Plan was terminated with respect to any new awards upon stockholder approval of the 2020 Plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combined summary of the status of the Company&#8217;s stock-settled awards under both the 2020 Plan and 2011 Plan, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.93&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.15&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.50&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:28.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.438%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the aggregate intrinsic value of stock-based awards exercised was $149,442, $208,585 and $49,258, respectively. At December&#160;31, 2022, the aggregate intrinsic value of stock-based awards outstanding was $289,942 and the aggregate intrinsic value of stock awards exercisable was $25,508.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:40.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2022, 2021 and 2020 purchase periods were $18,061, $19,626 and $17,148, respectively. Shares purchased pursuant to the plan&#8217;s 2022, 2021 and 2020 purchase periods were 285, 203 and 222, respectively. At December&#160;31, 2022, there were 5,702 shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2022, 2021 and 2020, respectively: expected volatility of 31.7%, 39.0% and 40.4%; risk-free interest rates of 1.3%, 0.1% and 1.0%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $26.50, $34.94 and $22.06 for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized $95,427, $102,209 and $91,458 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2022, 2021 and 2020 were $14,723, $13,853 and $11,775, respectively. As of December&#160;31, 2022, there was $149,081 of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation and employee stock purchase plans. The Company expects to recognize this expense over a weighted average remaining period of 1.3 years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company received $24,805, $46,990 and $8,957, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217423952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Stockholder's equity</a></td>
<td class="text">Shareholders&#8217; equity<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:38.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tender offer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The aggregate amounts paid for shares repurchased pursuant to the Company's 2020 tender offer for its shares during the year ended 2020, include the clearing price of $88.00 per share, plus related fees and expenses of $2,529.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2022 through February&#160;22, 2023, the Company did not repurchase any shares.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on December 10, 2020, the Board terminated all remaining prior share repurchase authorizations available to the Company and approved a new share repurchase authorization of $2,000,000. Effective on December 17, 2021, the Board increased the Company's existing authorization by $2,000,000. The Company is authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;22, 2023, the Company has a total of $1,596,085 available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company retired all shares held in its treasury effective as of December&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:52.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $20,775, $20,104 and $7,831 in 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209005088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated other comprehensive loss<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:48.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,065)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,498)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,781)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,861)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,346)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,466)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,688)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,154)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,843)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 13 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944299122896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Routine acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the Company acquired dialysis businesses and other businesses, including a transplant software company, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"/><td style="width:53.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2022 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:52.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2022, 2021 and 2020, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"/><td style="width:56.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2022 and 2021 had been consummated as of the beginning of 2021, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:62.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,624,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of RMS Lifeline</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company divested its prior vascular access business, RMS Lifeline, Inc., effective May 1, 2020 and recognized a loss on sale of approximately $16,252.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $58,947 if certain performance targets or quality margins are met over the next one year to five years. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 24 for further details. As of December&#160;31, 2022, the Company estimated the fair value of these contingent earn-out obligations to be $25,422, of which a total of $11,308 is included in other current liabilities, and the remaining $14,114 is included in other long-term liabilities in the Company&#8217;s consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2022 and 2021:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209207776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Held for Sale and Discontinued Operations</a></td>
<td class="text">Discontinued operations previously held for sale<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December&#160;31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. Upon resolution of certain prior post-closing adjustments with Optum in 2020, the Company recognized an additional loss on sale of $17,976, which was partially offset by $9,980 in additional tax benefits recognized under the Coronavirus Aid, Relief and Economic Security Act related to the Company's period of DMG ownership, and a related income tax benefit to the Company of $1,657.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944299122896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable interest entities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company wholly owns but does not wholly control these entities. However, the Company believes it has the most power over these entities' most significant activities, and the Company is fully exposed to their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, one of the Company's business units relies on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $316,639 and total liabilities and noncontrolling interests to third parties of $191,357 at December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 5 and 15 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217270432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Values of Financial Instruments</a></td>
<td class="text">Fair values of financial instrumentsThe Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For reconciliations of changes in contingent earn-out obligations and noncontrolling interests subject to put provisions during the year ended at December&#160;31, 2022 and 2021, see Note 21 and the consolidated statements of equity, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 5 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 13 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 21 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2022, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $168,000. See Note 17 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 13 for further discussion of the Company's debt. </span></div>Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2022 and 2021 at their approximate fair values due to the short-term nature of their settlements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944216270672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment reporting<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, the Company completed the sale of its prior DMG business to Optum. As a result of this transaction, DMG's results of operations have been reported as discontinued operations for all periods presented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, and its equity method investment in the APAC joint venture. The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial performance of the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to all of the Company&#8217;s various operating lines of business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,475,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,619,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,659,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,713,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,712,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,550,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694,636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, refinancing and redemption charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity investment income of $1,898, $3,177 and $5,866 in 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary of assets by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:58.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,084,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,375,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,928,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,121,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $113,781 and $112,500 in 2022 and 2021, respectively. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $117,327 and $126,381 in 2022 and 2021, respectively and includes approximately $207,162 and $190,029 in 2022 and 2021, respectively, of net property and equipment related to the Company&#8217;s international operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217270432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental cash flow information<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:49.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209031024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:45.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.772%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts<br/>charged to income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts written off</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end of year</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213593648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD). Prior year classifications have been conformed to the current year presentation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock', window );">Patient service net revenues and accounts receivable</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment frequency than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of our commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated in the period services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, for most of its VBC arrangements, the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, for most of its VBC arrangements the Company does not include third party medical costs in its reported revenues and expenses, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock', window );">Other income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income includes interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash and equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow. See Note 4 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in debt and equity securities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other income. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 5 for further details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of the right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date.The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets, and interest accretion on operating lease liabilities, are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Amortizable intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-lived intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity investments and other investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 9 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 10 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_InsuranceAndSelfInsurancePolicyTextBlock', window );">Self insurance</a></td>
<td class="text">Self-insuranceThe Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div>The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Interest rate swap and cap agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in LIBOR interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 13 for further details.</span></div>The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. These cap agreements have variable legs priced at LIBOR to match the variable rates incurred on the senior secured credit facility borrowings that they hedge. Like the senior secured credit facilities, these interest rate cap agreements include a mechanism for transition to an alternative variable base rate upon cessation of LIBOR. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling interests</a></td>
<td class="text">Noncontrolling interestsNoncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes.<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement. See Note 24 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 24 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which extends the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors will cease or become non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The Company is currently assessing the other effects this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU creates an exception to the general recognition and measurement principle in ASC 805 and will result in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Early adoption is permitted for all entities. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term and long-term investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time </span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company holds certain equity investments that have readily determinable fair values from public</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets. The Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company wholly owns but does not wholly control these entities. However, the Company believes it has the most power over these entities' most significant activities, and the Company is fully exposed to their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, one of the Company's business units relies on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_InsuranceAndSelfInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance and self insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_InsuranceAndSelfInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense), policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OtherNonoperatingIncomeExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition and accounts receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208894976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,576,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,169,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,169,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,540,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,550,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December&#160;31, 2020 has also been recast to conform to this presentation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208948016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income (loss) attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208906992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term invesmtents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,693&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,083&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,310&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208927408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherReceivablesTableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables were comprised of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"/><td style="width:56.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208894976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,828,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,243,107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,265,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,763,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944216619856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"/><td style="width:59.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Scheduled Amortization Charges from Intangible Assets and Liabilities</a></td>
<td class="text">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2022 were as follows:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"/><td style="width:37.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Finite And Indefinite Intangible Assets Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208989680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses, comprised as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201627936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Carrying Value of Goodwill by Reportable Segments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:40.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,309,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock', window );">Schedule of Reporting Units Goodwill Balances</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.660%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reporting unit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill<br/>balance</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Carrying amount<br/>coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sensitivities</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Operating<br/>income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Discount<br/>rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany kidney care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reporting units goodwill balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208927408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities were comprised of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"/><td style="width:51.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944216292992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text">Income tax expense for continuing operations consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of allocation of income tax expense (benefit) between continuing and discontinued operations.</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are allocated between continuing and discontinued operations as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"/><td style="width:49.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities Arising from Temporary Differences</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:60.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534,286)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580,472)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782,787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(830,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808,045)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"/><td style="width:61.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Allocation Of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210553600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt was comprised of the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:34.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.586%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,660,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition obligations and other notes<br/> payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,964,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,908,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,692,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,729,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values using level 2 interest rate inputs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and LIBOR interest rate components in effect as of December&#160;31, 2022.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $3,497 and deferred financing costs of $18,816 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018. As of December&#160;31, 2021, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $4,473 and deferred financing costs of $27,207, and the carrying amount of the Company's senior notes was reduced by deferred financing costs of $40,914 and increased by a debt premium of $15,909.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2022 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2022 and December&#160;31, 2021, which are classified in other long-term assets on its consolidated balance sheet:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">LIBOR maximum rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be">Debt expense</span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Recorded OCI gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Effects of Interest Rate Swap and Cap Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2022, 2021 and 2020:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.102%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location of losses </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,346)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208881440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Expense Components</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1) Includes short-term lease expense and sublease income, which are immaterial.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock', window );">Lease Other Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock', window );">Schedule Of Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2022 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:52.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(456,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Other Information in tabular disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeaseOtherInformationTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfMinimumLeasePaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213465200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combined summary of the status of the Company&#8217;s stock-settled awards under both the 2020 Plan and 2011 Plan, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.93&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.15&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.50&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Range of Exercise Prices</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:28.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.438%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Inputs</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:40.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.734%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210760768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Shares repurchases summary table</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:38.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tender offer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The aggregate amounts paid for shares repurchased pursuant to the Company's 2020 tender offer for its shares during the year ended 2020, include the clearing price of $88.00 per share, plus related fees and expenses of $2,529.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock', window );">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:52.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207456336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:48.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,065)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,498)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,781)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,080)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,861)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,346)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,466)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,688)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,154)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,843)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944216167632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock', window );">Schedule of Components of Routine Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the Company acquired dialysis businesses and other businesses, including a transplant software company, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"/><td style="width:53.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Aggregate Purchase Cost Allocations for Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:52.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock', window );">Schedule of other information related to acquired intangibles and goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2022, 2021 and 2020, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"/><td style="width:56.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Summary of Results of Operations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2022 and 2021 had been consummated as of the beginning of 2021, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:62.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,624,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Reconciliation of Changes in Contingent Earn-Out Obligations</a></td>
<td class="text">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2022 and 2021:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217251216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209078512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,475,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,619,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,659,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,713,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,712,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,550,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694,636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, refinancing and redemption charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity investment income of $1,898, $3,177 and $5,866 in 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Summary of Depreciation and Amortization Expense by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock', window );">Summary of Expenditures for Property and Equipment by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Summary of Assets by Segment</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary of assets by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:58.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,084,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,375,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,928,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,121,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $113,781 and $112,500 in 2022 and 2021, respectively. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes equity method and other investments of $117,327 and $126,381 in 2022 and 2021, respectively and includes approximately $207,162 and $190,029 in 2022 and 2021, respectively, of net property and equipment related to the Company&#8217;s international operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of capital expenditures for property and equipment from segment to consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944203044224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:49.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944208273600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:45.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.772%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts<br/>charged to income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts written off</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end of year</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure Table Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201551888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>clinic </div>
<div>entity </div>
<div>patient </div>
<div>state </div>
<div>country</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor', window );">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests', window );">Number of legal entities that third parties held noncontrolling equity interests | entity</a></td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">2,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states where dialysis centers are located | state</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">199,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember', window );">International Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">45,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which dialysis centers located | country</a></td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entities that third parties held non controlling equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dva_InternationalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201994128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 433,430<span></span>
</td>
<td class="nump">$ 405,282<span></span>
</td>
<td class="nump">$ 524,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
<td class="nump">11,550,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(91,241)<span></span>
</td>
<td class="num">(95,090)<span></span>
</td>
<td class="num">(162,029)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember', window );">Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,041,496<span></span>
</td>
<td class="nump">6,133,235<span></span>
</td>
<td class="nump">6,169,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">345,340<span></span>
</td>
<td class="nump">326,696<span></span>
</td>
<td class="nump">419,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember', window );">Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">759,579<span></span>
</td>
<td class="nump">782,430<span></span>
</td>
<td class="nump">744,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember', window );">Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">801,912<span></span>
</td>
<td class="nump">791,641<span></span>
</td>
<td class="nump">715,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember', window );">Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">3,660,522<span></span>
</td>
<td class="nump">3,596,721<span></span>
</td>
<td class="nump">3,540,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">22,211<span></span>
</td>
<td class="nump">15,553<span></span>
</td>
<td class="nump">33,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">68,529<span></span>
</td>
<td class="nump">66,290<span></span>
</td>
<td class="nump">88,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,512,774<span></span>
</td>
<td class="nump">10,576,167<span></span>
</td>
<td class="nump">10,514,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(87,035)<span></span>
</td>
<td class="num">(90,796)<span></span>
</td>
<td class="num">(145,286)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,041,496<span></span>
</td>
<td class="nump">6,133,235<span></span>
</td>
<td class="nump">6,169,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">759,579<span></span>
</td>
<td class="nump">782,430<span></span>
</td>
<td class="nump">744,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">336,991<span></span>
</td>
<td class="nump">328,256<span></span>
</td>
<td class="nump">334,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">3,437,306<span></span>
</td>
<td class="nump">3,397,697<span></span>
</td>
<td class="nump">3,370,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="nump">25,345<span></span>
</td>
<td class="nump">40,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,097,120<span></span>
</td>
<td class="nump">1,042,630<span></span>
</td>
<td class="nump">1,035,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(4,206)<span></span>
</td>
<td class="num">(4,294)<span></span>
</td>
<td class="num">(16,743)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">345,340<span></span>
</td>
<td class="nump">326,696<span></span>
</td>
<td class="nump">419,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">464,921<span></span>
</td>
<td class="nump">463,385<span></span>
</td>
<td class="nump">380,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">223,216<span></span>
</td>
<td class="nump">199,024<span></span>
</td>
<td class="nump">170,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">22,211<span></span>
</td>
<td class="nump">15,553<span></span>
</td>
<td class="nump">33,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 44,092<span></span>
</td>
<td class="nump">$ 40,945<span></span>
</td>
<td class="nump">$ 47,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202449888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,132,070<span></span>
</td>
<td class="nump">$ 1,957,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,113,499<span></span>
</td>
<td class="nump">$ 1,174,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue', window );">Percentage Of Accounts Receivable Six Months Or More Past Due</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AccountsReceivablePeriodOutstanding', window );">Accounts Receivable Period Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue', window );">Accounts Receivable, Noncurrent, Threshold Period Past Due</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfConcentrationRiskCustomers', window );">Number of concentration risk customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AccountsReceivablePeriodOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient accounts receivable months outstanding to be reserved per company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AccountsReceivablePeriodOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfConcentrationRiskCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Concentration Risk Customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfConcentrationRiskCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Accounts Receivable , 6 months or More Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202974624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income (loss) attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 546,948<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 783,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income (loss) from discontinued operations</a></td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 773,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average shares outstanding during the period (in shares)</a></td>
<td class="nump">92,992,000<span></span>
</td>
<td class="nump">105,230,000<span></span>
</td>
<td class="nump">119,797,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Assumed incremental shares from stock plans (in shares)</a></td>
<td class="nump">2,842,000<span></span>
</td>
<td class="nump">4,718,000<span></span>
</td>
<td class="nump">2,826,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">95,834,000<span></span>
</td>
<td class="nump">109,948,000<span></span>
</td>
<td class="nump">122,623,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net income (loss) attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations (in usd per share)</a></td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share attributable to DaVita Inc. (in usd per share)</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="nump">9.30<span></span>
</td>
<td class="nump">6.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net income (loss) attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations per share attributable to DaVita Inc. (in usd per share)</a></td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
<td class="nump">6.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share attributable to DaVita Inc. (in usd per share)</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock-settled awards excluded from calculation (in shares)</a></td>
<td class="nump">1,058,000<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="nump">2,301,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210553520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash and Equivalents - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and equivalents</a></td>
<td class="nump">$ 94,903<span></span>
</td>
<td class="nump">$ 93,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213105392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term and long-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">$ 82,879<span></span>
</td>
<td class="nump">$ 23,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">39,143<span></span>
</td>
<td class="nump">48,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">122,022<span></span>
</td>
<td class="nump">71,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Debt securities, short-term investments</a></td>
<td class="nump">67,872<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total Short-term investments</a></td>
<td class="nump">77,693<span></span>
</td>
<td class="nump">22,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Debt securities, long-term investments</a></td>
<td class="nump">15,007<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Total Long-term investments</a></td>
<td class="nump">44,329<span></span>
</td>
<td class="nump">49,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember', window );">Certificates of deposit and other time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">82,879<span></span>
</td>
<td class="nump">23,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">82,879<span></span>
</td>
<td class="nump">23,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember', window );">Investments in mutual funds and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">39,143<span></span>
</td>
<td class="nump">48,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">39,143<span></span>
</td>
<td class="nump">48,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">9,821<span></span>
</td>
<td class="nump">14,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">$ 29,322<span></span>
</td>
<td class="nump">$ 34,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207429424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 413,976<span></span>
</td>
<td class="nump">$ 427,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember', window );">Supplier rebates and non-trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">303,225<span></span>
</td>
<td class="nump">294,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 110,751<span></span>
</td>
<td class="nump">$ 132,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201569008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 32,656<span></span>
</td>
<td class="nump">$ 34,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">427,962<span></span>
</td>
<td class="nump">496,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">3,925,244<span></span>
</td>
<td class="nump">3,828,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment and information systems, including internally developed software</a></td>
<td class="nump">3,759,274<span></span>
</td>
<td class="nump">3,292,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">New center and capital asset projects in progress</a></td>
<td class="nump">376,633<span></span>
</td>
<td class="nump">592,063<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross, total</a></td>
<td class="nump">8,521,769<span></span>
</td>
<td class="nump">8,243,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(5,265,372)<span></span>
</td>
<td class="num">(4,763,135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 3,256,397<span></span>
</td>
<td class="nump">$ 3,479,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202987440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense on property and equipment</a></td>
<td class="nump">$ 721,133<span></span>
</td>
<td class="nump">$ 667,755<span></span>
</td>
<td class="nump">$ 616,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 12,677<span></span>
</td>
<td class="nump">$ 15,275<span></span>
</td>
<td class="nump">$ 17,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201556896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived licenses</a></td>
<td class="nump">$ 127,271<span></span>
</td>
<td class="nump">$ 104,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedNoncompeteAgreementsGross', window );">Noncompetition agreements</a></td>
<td class="nump">51,408<span></span>
</td>
<td class="nump">70,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Customer relationships and other</a></td>
<td class="nump">53,779<span></span>
</td>
<td class="nump">63,714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross (excluding goodwill)</a></td>
<td class="nump">232,458<span></span>
</td>
<td class="nump">238,423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">182,687<span></span>
</td>
<td class="nump">177,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(39,745)<span></span>
</td>
<td class="num">(52,813)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (10,027)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedNoncompeteAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedNoncompeteAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207400400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">2,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">11,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">3,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">25,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 43,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ExpectedAmortizationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Amortization Expense [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ExpectedAmortizationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202443008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense from amortizable intangible assets, other than lease agreements</a></td>
<td class="nump">$ 11,469<span></span>
</td>
<td class="nump">$ 12,860<span></span>
</td>
<td class="nump">$ 13,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension', window );">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201560144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">$ 231,108<span></span>
</td>
<td class="nump">$ 238,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember', window );">APAC joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">99,141<span></span>
</td>
<td class="nump">109,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Adjusted cost method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">15,564<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember', window );">Other equity method partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">$ 116,403<span></span>
</td>
<td class="nump">$ 115,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213765104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 26,520<span></span>
</td>
<td class="nump">$ 26,937<span></span>
</td>
<td class="nump">$ 26,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, significant impairments and other valuation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeLossFromOtherEquityMethodInvestments', window );">Equity investment income (loss) from other equity method investments</a></td>
<td class="num">(4,703)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, significant impairments and other valuation adjustments</a></td>
<td class="nump">$ 20,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember', window );">Company and Restricted Subsidiaries(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember', window );">APAC joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Company and Restricted Subsidiaries(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Company and Restricted Subsidiaries(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember', window );">Equity Method Investments In Nonconsolidated Dialysis Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 26,520<span></span>
</td>
<td class="nump">$ 26,937<span></span>
</td>
<td class="nump">$ 26,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfPartnerships', window );">Number of equity method investments</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeLossFromOtherEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss From Other Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeLossFromOtherEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Partnerships that are included in the Equity Investments category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201928736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 7,046,241<span></span>
</td>
<td class="nump">$ 6,919,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">49,047<span></span>
</td>
<td class="nump">173,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(3,350)<span></span>
</td>
<td class="num">(1,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="num">(15,328)<span></span>
</td>
<td class="num">(44,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,076,610<span></span>
</td>
<td class="nump">7,046,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">7,195,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">(118,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">6,400,162<span></span>
</td>
<td class="nump">6,309,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">16,750<span></span>
</td>
<td class="nump">91,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(1,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,400,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">646,079<span></span>
</td>
<td class="nump">609,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">32,297<span></span>
</td>
<td class="nump">81,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(3,263)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="num">(15,328)<span></span>
</td>
<td class="num">(44,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">659,785<span></span>
</td>
<td class="nump">$ 646,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">778,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">$ (118,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202986608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Reporting Units Goodwill Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="nump">$ 7,046,241<span></span>
</td>
<td class="nump">$ 6,919,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment', window );">Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment', window );">Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_KidneyCareMember', window );">Kidney Care | GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 281,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount', window );">Carrying amount coverage</a></td>
<td class="nump">18.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PotentialImpactOnFairValueForReductionInOperatingIncome', window );">Sensitivities, Operating Income</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate', window );">Sensitivities, Discount rate</a></td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Impact On Fair Value For Basis Point Increase In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PotentialImpactOnFairValueForReductionInOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Impact On Fair Value For Reduction In Operating Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PotentialImpactOnFairValueForReductionInOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting unit percentage of fair value in excess of short of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_KidneyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_KidneyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944217244352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember', window );">Other reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments that were considered at risk of significant goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202229776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PayorRefundsAndRetractions', window );">Payor refunds and retractions</a></td>
<td class="nump">$ 475,195<span></span>
</td>
<td class="nump">$ 410,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance and self-insurance accruals</a></td>
<td class="nump">68,440<span></span>
</td>
<td class="nump">55,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">34,162<span></span>
</td>
<td class="nump">32,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued non-income tax liabilities</a></td>
<td class="nump">42,806<span></span>
</td>
<td class="nump">41,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">181,866<span></span>
</td>
<td class="nump">169,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">$ 802,469<span></span>
</td>
<td class="nump">$ 709,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PayorRefundsAndRetractions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payor Refunds And Retractions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PayorRefundsAndRetractions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207097696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 926,604<span></span>
</td>
<td class="nump">$ 1,463,029<span></span>
</td>
<td class="nump">$ 1,287,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">39,674<span></span>
</td>
<td class="nump">55,465<span></span>
</td>
<td class="nump">30,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total</a></td>
<td class="nump">$ 966,278<span></span>
</td>
<td class="nump">$ 1,518,494<span></span>
</td>
<td class="nump">$ 1,318,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213151184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 201,932<span></span>
</td>
<td class="nump">$ 216,539<span></span>
</td>
<td class="nump">$ 47,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">55,593<span></span>
</td>
<td class="nump">15,601<span></span>
</td>
<td class="nump">21,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">14,247<span></span>
</td>
<td class="nump">17,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax</a></td>
<td class="nump">273,778<span></span>
</td>
<td class="nump">246,387<span></span>
</td>
<td class="nump">86,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(66,400)<span></span>
</td>
<td class="nump">59,528<span></span>
</td>
<td class="nump">198,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(12,289)<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">27,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="num">(4,525)<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Total deferred income tax</a></td>
<td class="num">(75,691)<span></span>
</td>
<td class="nump">60,345<span></span>
</td>
<td class="nump">227,838<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Continuing operations</a></td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">$ 306,732<span></span>
</td>
<td class="nump">$ 313,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213536976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income Taxes - Allocation of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Continuing operations</a></td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">$ 306,732<span></span>
</td>
<td class="nump">$ 313,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems', window );">Income tax (benefit) expense from continuing and discontinued operations</a></td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">$ 306,732<span></span>
</td>
<td class="nump">$ 315,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current tax expense (benefit) and deferred tax expense (benefit) pertaining to income (loss) from continuing operations and income (loss) from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=121829364&amp;loc=d3e40084-109325<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202522352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Federal and international tax rate adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment', window );">Nondeductible executive compensation</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Political advocacy costs</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Unrecognized tax benefits</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in international valuation allowance</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Impact of noncontrolling interests primarily attributable to non-tax paying entities</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">23.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Investment Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EffectiveIncomeTaxReconciliationInvestmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213707120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsReceivables', window );">Receivables</a></td>
<td class="nump">$ 18,304<span></span>
</td>
<td class="nump">$ 8,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">71,346<span></span>
</td>
<td class="nump">67,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">563,972<span></span>
</td>
<td class="nump">581,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">173,531<span></span>
</td>
<td class="nump">162,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">58,827<span></span>
</td>
<td class="nump">52,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">885,980<span></span>
</td>
<td class="nump">873,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(106,775)<span></span>
</td>
<td class="num">(100,616)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">779,205<span></span>
</td>
<td class="nump">772,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(690,914)<span></span>
</td>
<td class="num">(644,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(181,704)<span></span>
</td>
<td class="num">(283,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(515,026)<span></span>
</td>
<td class="num">(530,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments in partnerships</a></td>
<td class="num">(80,876)<span></span>
</td>
<td class="num">(84,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(65,766)<span></span>
</td>
<td class="num">(37,274)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,534,286)<span></span>
</td>
<td class="num">(1,580,472)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(755,081)<span></span>
</td>
<td class="num">(808,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(782,787)<span></span>
</td>
<td class="num">(830,954)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 27,706<span></span>
</td>
<td class="nump">$ 22,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207362304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 73,024<span></span>
</td>
<td class="nump">$ 70,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="nump">24,683<span></span>
</td>
<td class="nump">22,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions related to lapse of applicable statute</a></td>
<td class="num">(6,073)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reductions related to settlements with taxing authorities</a></td>
<td class="num">(31,507)<span></span>
</td>
<td class="num">(22,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 63,985<span></span>
</td>
<td class="nump">$ 73,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206329392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseInDeferredTaxAssetsNet', window );">Increase In Deferred Tax Assets Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">306,732<span></span>
</td>
<td class="nump">$ 313,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liability for unrecognized tax benefits</a></td>
<td class="nump">63,985<span></span>
</td>
<td class="nump">73,024<span></span>
</td>
<td class="nump">$ 70,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">45,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax expense (benefit), income tax penalties and interest expense</a></td>
<td class="nump">10,459<span></span>
</td>
<td class="num">(2,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</a></td>
<td class="nump">8,208<span></span>
</td>
<td class="nump">15,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deferred taxes from partnership buyouts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember', window );">Indefinite Life Net Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember', window );">Purchases Of Noncontrolling Interests In Consolidated Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">State capital loss carryforward, amount</a></td>
<td class="nump">$ 306,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">State capital loss carryforward, expiration date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 71,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Tax Year 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 618,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 357,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseInDeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Deferred Tax Assets Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseInDeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=dva_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=dva_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202008512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 273,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-term debt totals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt principal outstanding</a></td>
<td class="nump">$ 8,968,519<span></span>
</td>
<td class="nump">$ 8,964,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DiscountAndDeferredFinanceCosts', window );">Discount and deferred financing costs</a></td>
<td class="num">(44,498)<span></span>
</td>
<td class="num">(56,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Carrying amount of long-term debt, net of unamortized discounts</a></td>
<td class="nump">8,924,021<span></span>
</td>
<td class="nump">8,908,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
<td class="num">(231,404)<span></span>
</td>
<td class="num">(179,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">8,692,617<span></span>
</td>
<td class="nump">8,729,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember', window );">Senior Notes 4.625% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jun.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 2,224,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember', window );">Senior Notes 3.75% due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Feb. 15,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 1,115,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Acquisition obligations and other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayable', window );">Acquisition obligations and other notes payable</a></td>
<td class="nump">$ 120,562<span></span>
</td>
<td class="nump">130,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">2023-2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">6.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue', window );">Acquisition obligations and other notes payable, fair value</a></td>
<td class="nump">$ 120,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Financing Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 273,688<span></span>
</td>
<td class="nump">$ 299,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">2023-2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">4.51%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">LIBOR + 1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 1,498,438<span></span>
</td>
<td class="nump">1,596,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">LIBOR + 1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 1,468,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 2,660,831<span></span>
</td>
<td class="nump">2,688,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">LIBOR + 1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 2,587,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="nump">3,497<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">18,816<span></span>
</td>
<td class="nump">27,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">36,203<span></span>
</td>
<td class="nump">40,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt Instrument, Unamortized Premium</a></td>
<td class="nump">$ 14,018<span></span>
</td>
<td class="nump">$ 15,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Obligations And Other Notes Payable, Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DiscountAndDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount and deferred finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DiscountAndDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213468944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 231,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,587,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">67,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,627,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">35,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 4,419,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213174720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of debt expense reclassified from accumulated OCI into income</a></td>
<td class="num">$ (8,806)<span></span>
</td>
<td class="nump">$ 4,133<span></span>
</td>
<td class="nump">$ 5,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, expiration date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020 | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, gross asset</a></td>
<td class="nump">$ 139,755<span></span>
</td>
<td class="nump">$ 12,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020 | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of debt expense reclassified from accumulated OCI into income</a></td>
<td class="num">(11,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Recorded Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</a></td>
<td class="nump">$ 144,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest and Debt Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">LIBOR plus interest margin</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInceptionDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the entity entered into the derivative contract, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInceptionDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeMaturityDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the derivative contract matures, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeMaturityDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201859104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">$ 108,669<span></span>
</td>
<td class="nump">$ 7,155<span></span>
</td>
<td class="num">$ (16,346)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
<td class="num">(16,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">144,793<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
<td class="num">(21,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">$ (11,732)<span></span>
</td>
<td class="nump">5,509<span></span>
</td>
<td class="nump">7,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest and Debt Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Income Tax Related To Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="num">$ (36,124)<span></span>
</td>
<td class="num">(2,377)<span></span>
</td>
<td class="nump">5,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="nump">$ 2,926<span></span>
</td>
<td class="num">$ (1,376)<span></span>
</td>
<td class="num">$ (1,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Income tax expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201297584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="nump">51.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="nump">$ 339,247<span></span>
</td>
<td class="nump">$ 267,049<span></span>
</td>
<td class="nump">$ 282,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</a></td>
<td class="nump">$ 17,772<span></span>
</td>
<td class="nump">18,205<span></span>
</td>
<td class="nump">$ 21,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">4.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity on revolving credit facilities</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Secured Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="nump">108,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">98,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="nump">1,498,438<span></span>
</td>
<td class="nump">1,596,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR', window );">Secured debt outstanding principal balance subject to LIBOR</a></td>
<td class="nump">659,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">27,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="nump">$ 2,660,831<span></span>
</td>
<td class="nump">$ 2,688,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAAndTermLoanB1Member', window );">Term Loan A and Term Loan B-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAAndTermLoanB1Member', window );">Term Loan A and Term Loan B-1 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Debt Outstanding Principal Balance Subject To LIBOR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanAAndTermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanAAndTermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202452288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Lease Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Fixed lease expense</a></td>
<td class="nump">$ 552,194<span></span>
</td>
<td class="nump">$ 547,923<span></span>
</td>
<td class="nump">$ 541,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">127,621<span></span>
</td>
<td class="nump">125,981<span></span>
</td>
<td class="nump">122,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">27,079<span></span>
</td>
<td class="nump">26,846<span></span>
</td>
<td class="nump">24,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">12,776<span></span>
</td>
<td class="nump">13,988<span></span>
</td>
<td class="nump">14,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 719,670<span></span>
</td>
<td class="nump">$ 714,738<span></span>
</td>
<td class="nump">$ 702,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944203009408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesOtherInformationAbstract', window );"><strong>Leases Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Sale and Leaseback Transaction, Gain (Loss), Net</a></td>
<td class="nump">$ 28,005<span></span>
</td>
<td class="nump">$ 17,137<span></span>
</td>
<td class="nump">$ 34,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">696,291<span></span>
</td>
<td class="nump">684,186<span></span>
</td>
<td class="nump">661,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance Lease, Interest Payment on Liability</a></td>
<td class="nump">20,103<span></span>
</td>
<td class="nump">21,343<span></span>
</td>
<td class="nump">20,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease, Principal Payments</a></td>
<td class="nump">24,329<span></span>
</td>
<td class="nump">22,445<span></span>
</td>
<td class="nump">24,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities', window );">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</a></td>
<td class="nump">$ 278,108<span></span>
</td>
<td class="nump">$ 361,101<span></span>
</td>
<td class="nump">$ 401,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">4.51%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128295416&amp;loc=SL77919786-209982<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213121968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 492,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">500,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">452,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">400,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">333,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,175,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments due under operating leases</a></td>
<td class="nump">3,354,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, operating lease liabilities</a></td>
<td class="num">(456,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities, operating leases</a></td>
<td class="nump">$ 2,898,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current portion of operating lease liabilities, Long-term operating lease liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 37,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">37,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">38,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">36,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">35,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">145,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments due under finance leases</a></td>
<td class="nump">331,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, financing lease liabilities</a></td>
<td class="num">(58,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 273,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213174672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 319,546<span></span>
</td>
<td class="nump">$ 322,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_FinanceLeaseAccumulatedDepreciation', window );">Finance Lease Accumulated Depreciation</a></td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">$ 75,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="nump">719,670<span></span>
</td>
<td class="nump">714,738<span></span>
</td>
<td class="nump">$ 702,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember', window );">Operating Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="nump">$ 679,815<span></span>
</td>
<td class="nump">$ 673,904<span></span>
</td>
<td class="nump">$ 663,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_FinanceLeaseAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Accumulated Depreciation, contra asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_FinanceLeaseAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206398736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Defined Benefit Plan, Benefit Obligation, Benefits Paid</a></td>
<td class="nump">$ 70,084<span></span>
</td>
<td class="nump">$ 68,658<span></span>
</td>
<td class="nump">$ 70,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross wages</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employees' base salary to be maintained into deferral account</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Non-qualified deferred compensation plan, contributions</a></td>
<td class="nump">$ 3,573<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">3,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Deferred compensation plan, distributions</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">11,887<span></span>
</td>
<td class="nump">$ 3,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan | Rabbi trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total fair value of assets held in trust</a></td>
<td class="nump">$ 32,944<span></span>
</td>
<td class="nump">$ 38,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution made to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207406352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies - Additional Information (Details) - US Attorney Prescription Drug Investigation<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount awarded to other party</a></td>
<td class="nump">$ 63,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=dva_IncrementalCashPortionMember', window );">Incremental Cash Portion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount awarded to other party</a></td>
<td class="nump">41,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=dva_CashPaidForPortionPreviouslyRefundedMember', window );">Cash Paid For Portion Previously Refunded</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount awarded to other party</a></td>
<td class="nump">$ 22,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=dva_USAttorneyPrescriptionDrugInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=dva_USAttorneyPrescriptionDrugInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=dva_IncrementalCashPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=dva_IncrementalCashPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=dva_CashPaidForPortionPreviouslyRefundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=dva_CashPaidForPortionPreviouslyRefundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202979024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase Obligation, Due in Next Twelve Months</a></td>
<td class="nump">$ 712,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase Obligation, Due in Second Year</a></td>
<td class="nump">469,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase Obligation, Due in Third Year</a></td>
<td class="nump">362,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Purchase Obligation, to be Paid, Year Four</a></td>
<td class="nump">379,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OffBalanceSheetFinancingArrangements', window );">Off -Balance Sheet Financing Arrangements</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember', window );">Commitments to Provide Operating Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other potential commitments to provide operating capital to several dialysis centers</a></td>
<td class="nump">$ 9,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DissolutionTermOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution term of joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DissolutionTermOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OffBalanceSheetFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off -Balance Sheet Financing Arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OffBalanceSheetFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201504304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">5,943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(619,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(64,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">5,390,000<span></span>
</td>
<td class="nump">5,943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">2,618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants</a></td>
<td class="nump">$ 35.13<span></span>
</td>
<td class="nump">$ 32.15<span></span>
</td>
<td class="nump">$ 26.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (USD per share)</a></td>
<td class="nump">64.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">110.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">63.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (USD per share)</a></td>
<td class="nump">55.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (USD per share)</a></td>
<td class="nump">66.00<span></span>
</td>
<td class="nump">$ 64.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">$ 64.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">1 year 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_StockUnitMember', window );">Stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">3,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod', window );">Added by performance factor (in shares)</a></td>
<td class="nump">136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(1,269,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(332,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">3,072,000<span></span>
</td>
<td class="nump">3,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants (USD per share)</a></td>
<td class="nump">$ 107.60<span></span>
</td>
<td class="nump">$ 109.50<span></span>
</td>
<td class="nump">$ 77.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding at end of period</a></td>
<td class="text">1 year 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Exercisable at end of period</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206491392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">5,390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 66.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">2,618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 64.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember', window );">$50.01&#8211;$60.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">1,397,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 52.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 52.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">50.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember', window );">$60.01&#8211;$70.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">3,462,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 67.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">2,212,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 67.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">60.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember', window );">$70.01&#8211;$80.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">269,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 75.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 70.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">70.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember', window );">$100.01&#8211;$110.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 108.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">100.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 110.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember', window );">$110.01&#8211;$120.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 110.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">110.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944216176176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details) - Stock-settled Stock Appreciation Rights<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">34.30%<span></span>
</td>
<td class="nump">34.30%<span></span>
</td>
<td class="nump">28.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202920656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock awards exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,442,000<span></span>
</td>
<td class="nump">$ 208,585,000<span></span>
</td>
<td class="nump">$ 49,258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock awards outstanding</a></td>
<td class="nump">$ 289,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock awards exercisable</a></td>
<td class="nump">25,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,427,000<span></span>
</td>
<td class="nump">102,209,000<span></span>
</td>
<td class="nump">91,458,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense', window );">Estimated tax benefits recorded for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,723,000<span></span>
</td>
<td class="nump">13,853,000<span></span>
</td>
<td class="nump">11,775,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</a></td>
<td class="nump">$ 149,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based Payment Arrangement, Expense, Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,805,000<span></span>
</td>
<td class="nump">46,990,000<span></span>
</td>
<td class="nump">8,957,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants | shares</a></td>
<td class="nump">5,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase', window );">Employee entitlement for purchase of the Company's common stock during each calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Stock purchase price as percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares', window );">Contributions used to purchase shares, employee-related current liabilities</a></td>
<td class="nump">$ 18,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,061,000<span></span>
</td>
<td class="nump">$ 19,626,000<span></span>
</td>
<td class="nump">$ 17,148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued for employee stock purchase plans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">40.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Share-based awards, fair value assumptions, expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.50<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="nump">$ 22.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions', window );">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance', window );">Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward', window );">Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance', window );">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants | shares</a></td>
<td class="nump">6,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyElevenMember', window );">Stock Incentive 2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio', window );">Full share awards to shares available, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyElevenMember', window );">Stock Incentive 2011 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyElevenMember', window );">Stock Incentive 2011 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation estimated tax benefit from compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Full Value Shares To Available Shares, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213182048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Repurchases Tender Offer (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">8,095<span></span>
</td>
<td class="nump">13,877<span></span>
</td>
<td class="nump">16,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="nump">$ 1,446,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 97.33<span></span>
</td>
<td class="nump">$ 111.41<span></span>
</td>
<td class="nump">$ 87.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember', window );">Open Market Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">8,095<span></span>
</td>
<td class="nump">13,877<span></span>
</td>
<td class="nump">8,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="nump">$ 741,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 97.33<span></span>
</td>
<td class="nump">$ 111.41<span></span>
</td>
<td class="nump">$ 87.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dva_TenderOfferMember', window );">Tender Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 704,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 88.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>Treasury Stock, Shares Repurchases, Table Footnotes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice', window );">Treasury Stock Acquired, Average Cost Per Share, Clearing Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareRepurchaseFeesAndExpenses', window );">Share Repurchase Fees And Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareRepurchaseFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Fees And Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareRepurchaseFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired, Average Cost Per Share, Clearing Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dva_TenderOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dva_TenderOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209563008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
<td class="nump">$ 773,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interests</a></td>
<td class="num">(6,586)<span></span>
</td>
<td class="num">(13,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Purchases of noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling Interest, Period Increase (Decrease)</a></td>
<td class="num">(5,647)<span></span>
</td>
<td class="num">(14,117)<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests', window );">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</a></td>
<td class="nump">$ 554,753<span></span>
</td>
<td class="nump">$ 964,333<span></span>
</td>
<td class="nump">$ 778,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201965728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="nump">16,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount', window );">Terminated Remaining Prior Share Repurchases Authorized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation', window );">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,775<span></span>
</td>
<td class="nump">$ 20,104<span></span>
</td>
<td class="nump">$ 7,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="nump">16,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="num">(16,477,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock Repurchase Program, Remaining Authorized Repurchase Amount</a></td>
<td class="nump">$ 1,596,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CharterdocumentsandDelawarelawAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charter documents and Delaware law [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CharterdocumentsandDelawarelawAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminated Remaining Prior Share Repurchases Authorized, Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206336608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">$ (139,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(69,186)<span></span>
</td>
<td class="num">$ (139,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Interest rate cap agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(12,466)<span></span>
</td>
<td class="num">$ (1,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">144,793<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
<td class="num">(21,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(36,124)<span></span>
</td>
<td class="num">(2,377)<span></span>
</td>
<td class="nump">5,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
<td class="num">(16,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="num">(11,732)<span></span>
</td>
<td class="nump">5,509<span></span>
</td>
<td class="nump">7,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">2,926<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
<td class="num">(1,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="nump">98,685<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">(12,466)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(138,069)<span></span>
</td>
<td class="num">(53,688)<span></span>
</td>
<td class="num">(46,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="num">(30,554)<span></span>
</td>
<td class="num">(83,375)<span></span>
</td>
<td class="num">(7,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="nump">752<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="num">(29,802)<span></span>
</td>
<td class="num">(84,381)<span></span>
</td>
<td class="num">(7,623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(167,871)<span></span>
</td>
<td class="num">(138,069)<span></span>
</td>
<td class="num">(53,688)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(139,247)<span></span>
</td>
<td class="num">(66,154)<span></span>
</td>
<td class="num">(47,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">114,239<span></span>
</td>
<td class="num">(73,843)<span></span>
</td>
<td class="num">(28,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(35,372)<span></span>
</td>
<td class="num">(3,383)<span></span>
</td>
<td class="nump">4,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">78,867<span></span>
</td>
<td class="num">(77,226)<span></span>
</td>
<td class="num">(23,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="num">(11,732)<span></span>
</td>
<td class="nump">5,509<span></span>
</td>
<td class="nump">7,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">2,926<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
<td class="num">(1,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">$ (69,186)<span></span>
</td>
<td class="num">$ (139,247)<span></span>
</td>
<td class="num">$ (66,154)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207266080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Components of Routine Acquisitions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">$ 57,308<span></span>
</td>
<td class="nump">$ 187,050<span></span>
</td>
<td class="nump">$ 182,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">57,308<span></span>
</td>
<td class="nump">187,050<span></span>
</td>
<td class="nump">182,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitions', window );">Business combination contingent consideration acquisitions, earn-outs</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Deferred Purchase price and liabilities assumed</a></td>
<td class="nump">15,076<span></span>
</td>
<td class="nump">10,226<span></span>
</td>
<td class="nump">20,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Non-cash gain on acquiring additional ownership in business acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase cost recognized</a></td>
<td class="nump">$ 76,645<span></span>
</td>
<td class="nump">$ 212,130<span></span>
</td>
<td class="nump">$ 218,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | Foreign Dialysis Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944201413104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets acquired and liabilities assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="nump">$ 7,046,241<span></span>
</td>
<td class="nump">$ 6,919,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">6,389<span></span>
</td>
<td class="nump">9,134<span></span>
</td>
<td class="nump">23,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">7,481<span></span>
</td>
<td class="nump">9,277<span></span>
</td>
<td class="nump">37,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Customer relationships</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="nump">34,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Noncompetition agreements and other long-term assets</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">9,964<span></span>
</td>
<td class="nump">10,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived licenses</a></td>
<td class="nump">19,610<span></span>
</td>
<td class="nump">11,432<span></span>
</td>
<td class="nump">22,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">49,047<span></span>
</td>
<td class="nump">173,244<span></span>
</td>
<td class="nump">130,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities Assumed</a></td>
<td class="num">(6,081)<span></span>
</td>
<td class="num">(14,200)<span></span>
</td>
<td class="num">(34,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests assumed</a></td>
<td class="num">(867)<span></span>
</td>
<td class="num">(3,921)<span></span>
</td>
<td class="num">(1,729)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase price</a></td>
<td class="nump">$ 76,645<span></span>
</td>
<td class="nump">$ 212,130<span></span>
</td>
<td class="nump">$ 218,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213747552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details) - Series of individually immaterial business acquisitions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes associated with acquisitions</a></td>
<td class="nump">$ 49,047<span></span>
</td>
<td class="nump">$ 169,014<span></span>
</td>
<td class="nump">$ 94,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortizable intangible assets acquired, weighted-average estimated useful lives</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">18 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortizable intangible assets acquired, weighted-average estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213007104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma total revenues</a></td>
<td class="nump">$ 11,624,270<span></span>
</td>
<td class="nump">$ 11,706,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net income from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 545,859<span></span>
</td>
<td class="nump">$ 984,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Pro forma basic net income per share from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Pro forma diluted net income per share from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209718768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details) - Series of individually immaterial business acquisitions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Beginning balance</a></td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="nump">$ 30,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitions', window );">Acquisitions</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
<td class="nump">$ 14,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations', window );">Foreign currency translation</a></td>
<td class="nump">840<span></span>
</td>
<td class="num">(1,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss', window );">Fair value remeasurements</a></td>
<td class="num">(5,921)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments', window );">Payments or other settlements</a></td>
<td class="num">(7,358)<span></span>
</td>
<td class="num">(8,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Ending balance</a></td>
<td class="nump">$ 25,422<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="nump">$ 30,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions Earnouts Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206281536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,422<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="nump">$ 30,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_RMSLifelineMember', window );">RMS Lifeline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee', window );">Gain (Loss) on Divestiture</a></td>
<td class="num">$ (16,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Long-term Liabilities | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember', window );">Other companies | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other companies | Performance Targets or Quality Margins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other companies | Performance Targets or Quality Margins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration revenue earn-out period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_RMSLifelineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_RMSLifelineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206387664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 19, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">(Loss) gain on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (16,252)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember', window );">DMG - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessSaleEffectiveDateOfSale', window );">Business Sale, Effective Date Of Sale</a></td>
<td class="text">Jun. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Operating Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Financing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Investing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | DMG - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessSaleEffectiveDateOfSale', window );">Business Sale, Effective Date Of Sale</a></td>
<td class="text">Jun. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment', window );">Gain on disposition of business, additional purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">(Loss) gain on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal', window );">Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | DMG - discontinued operations | Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal', window );">Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessSaleEffectiveDateOfSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Sale, Effective Date Of Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessSaleEffectiveDateOfSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on disposition of business, additional purchase price payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit on (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944207359808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities', window );">Number of business units relying on operating activities of nominee-owned legal entities | Clinic</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 16,928,252<span></span>
</td>
<td class="nump">$ 17,121,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">14,703,452<span></span>
</td>
<td class="nump">$ 14,750,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">316,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 191,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Units Relying On Operating Activities Of Nominee-Owned Legal Entities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202793088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">$ 39,143<span></span>
</td>
<td class="nump">$ 48,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">39,143<span></span>
</td>
<td class="nump">48,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations</a></td>
<td class="nump">25,422<span></span>
</td>
<td class="nump">33,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,348,908<span></span>
</td>
<td class="nump">1,434,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">139,755<span></span>
</td>
<td class="nump">12,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">39,143<span></span>
</td>
<td class="nump">48,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">139,755<span></span>
</td>
<td class="nump">12,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations</a></td>
<td class="nump">25,422<span></span>
</td>
<td class="nump">33,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,348,908<span></span>
</td>
<td class="nump">1,434,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209083472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple', window );">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</a></td>
<td class="nump">$ 168,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944206969760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 433,430<span></span>
</td>
<td class="nump">$ 405,282<span></span>
</td>
<td class="nump">$ 524,353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
<td class="nump">11,550,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">1,339,062<span></span>
</td>
<td class="nump">1,797,370<span></span>
</td>
<td class="nump">1,694,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SegmentReportingInformationCorporateExpenses', window );">Corporate administrative support</a></td>
<td class="num">(129,669)<span></span>
</td>
<td class="num">(111,615)<span></span>
</td>
<td class="num">(146,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="num">(357,019)<span></span>
</td>
<td class="num">(285,254)<span></span>
</td>
<td class="num">(304,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtPrepaymentRefinancingRedemptionCharges', window );">Debt prepayment, refinancing and redemption charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(89,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income, net</a></td>
<td class="num">(15,765)<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
<td class="nump">16,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total</a></td>
<td class="nump">966,278<span></span>
</td>
<td class="nump">1,518,494<span></span>
</td>
<td class="nump">1,318,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">26,520<span></span>
</td>
<td class="nump">26,937<span></span>
</td>
<td class="nump">26,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,512,774<span></span>
</td>
<td class="nump">10,576,167<span></span>
</td>
<td class="nump">10,514,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,097,120<span></span>
</td>
<td class="nump">1,042,630<span></span>
</td>
<td class="nump">1,035,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11,701,135<span></span>
</td>
<td class="nump">11,713,887<span></span>
</td>
<td class="nump">11,712,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">1,468,731<span></span>
</td>
<td class="nump">1,908,985<span></span>
</td>
<td class="nump">1,841,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="nump">10,575,372<span></span>
</td>
<td class="nump">10,641,618<span></span>
</td>
<td class="nump">10,619,364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,599,809<span></span>
</td>
<td class="nump">10,666,963<span></span>
</td>
<td class="nump">10,659,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">1,565,310<span></span>
</td>
<td class="nump">1,974,988<span></span>
</td>
<td class="nump">1,917,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis | External Sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="nump">10,488,327<span></span>
</td>
<td class="nump">10,551,106<span></span>
</td>
<td class="nump">10,475,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">24,447<span></span>
</td>
<td class="nump">25,061<span></span>
</td>
<td class="nump">39,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="nump">87,045<span></span>
</td>
<td class="nump">90,512<span></span>
</td>
<td class="nump">144,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="nump">688,137<span></span>
</td>
<td class="nump">662,409<span></span>
</td>
<td class="nump">550,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">408,983<span></span>
</td>
<td class="nump">380,221<span></span>
</td>
<td class="nump">484,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,101,326<span></span>
</td>
<td class="nump">1,046,924<span></span>
</td>
<td class="nump">1,052,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(96,579)<span></span>
</td>
<td class="num">(66,003)<span></span>
</td>
<td class="num">(76,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other - Ancillary services | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">16,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(91,241)<span></span>
</td>
<td class="num">(95,090)<span></span>
</td>
<td class="num">(162,029)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(87,035)<span></span>
</td>
<td class="num">(90,796)<span></span>
</td>
<td class="num">(145,286)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">$ (4,206)<span></span>
</td>
<td class="num">$ (4,294)<span></span>
</td>
<td class="num">$ (16,743)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtPrepaymentRefinancingRedemptionCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment, refinancing and redemption charges related to long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtPrepaymentRefinancingRedemptionCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SegmentReportingInformationCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SegmentReportingInformationCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210428224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 732,602<span></span>
</td>
<td class="nump">$ 680,615<span></span>
</td>
<td class="nump">$ 630,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">690,949<span></span>
</td>
<td class="nump">642,711<span></span>
</td>
<td class="nump">594,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 41,653<span></span>
</td>
<td class="nump">$ 37,904<span></span>
</td>
<td class="nump">$ 35,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209705824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Expenditures for property and equipment</a></td>
<td class="nump">$ 603,429<span></span>
</td>
<td class="nump">$ 641,465<span></span>
</td>
<td class="nump">$ 674,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Expenditures for property and equipment</a></td>
<td class="nump">533,600<span></span>
</td>
<td class="nump">589,662<span></span>
</td>
<td class="nump">646,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Expenditures for property and equipment</a></td>
<td class="nump">$ 69,829<span></span>
</td>
<td class="nump">$ 51,803<span></span>
</td>
<td class="nump">$ 27,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944209501248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Summary of Assets by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 16,928,252<span></span>
</td>
<td class="nump">$ 17,121,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">231,108<span></span>
</td>
<td class="nump">238,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">3,256,397<span></span>
</td>
<td class="nump">3,479,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">15,084,454<span></span>
</td>
<td class="nump">15,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">113,781<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,843,798<span></span>
</td>
<td class="nump">1,746,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">117,327<span></span>
</td>
<td class="nump">126,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 207,162<span></span>
</td>
<td class="nump">$ 190,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944202550160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jun. 19, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember', window );">DMG - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessSaleEffectiveDateOfSale', window );">Business Sale, Effective Date Of Sale</a></td>
<td class="text">Jun. 19,  2019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessSaleEffectiveDateOfSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Sale, Effective Date Of Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessSaleEffectiveDateOfSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944213122928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes, net</a></td>
<td class="nump">$ 344,430<span></span>
</td>
<td class="nump">$ 209,754<span></span>
</td>
<td class="nump">$ 154,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net</a></td>
<td class="nump">350,999<span></span>
</td>
<td class="nump">279,002<span></span>
</td>
<td class="nump">326,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Fixed assets under financing lease obligations</a></td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 31,690<span></span>
</td>
<td class="nump">$ 22,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid during period for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139944210885392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for uncollectible Accounts - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Amounts charged to income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Amounts written off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>dva-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:dva="http://www.davita.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dva-20221231.xsd" xlink:type="simple"/>
    <context id="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic74d2bf2b4fe417491b67a410b426f67_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia364a716386a4cb1a9c39177212dcb31_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7cd26001e2547978cfb83fa3fade336_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fe6cb82c75840eabfae089d02e1e485_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7791c0dc3604a5096d82544cd2dc55d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc55a2cfbea54cdea8e6196c16ac8898_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if800aa66d9654ca986d7798400011ed4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4c968889cbc45d597559733ee1e7c06_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id50bdbd4176c403094afc0a6a0816442_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc1b76d4d30a4a71b13b8f4c91fb24db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a01430579214274b518179095689fae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie24f4ad97c874df3a74ffade9b367052_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2a7799ea30042b3b5483fabf59a20c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee5116d4e90c42a2a3c059b946951971_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43ebc619161a4e329c3ae8f647a68ea0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50da97fe1b274f648672b559db7812e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09cbd163c566489c8ab76a850aeba968_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2c4cc40ee544f8d8fc58a0361ea6027_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17d2f751df2e4644ba91a72008a0765e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i757a0e9ab6594add994f294dd3cdbf66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5427ec717e8648059aadaee70b6593f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72de044ff982442ba895166a41f82244_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if27174288e0445f8870a700e378d7299_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e4eaf9f852e421fbf29ec7d95adf14a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ab32047366140518741cdd1c29b2986_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i387afcd55d3346499dfe079c68d6aafd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d81a8050455482f899360e81a78be21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d6896e2941a48e2963273fd62c1f8a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99bfee231c604920b47c088b54ff3344_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if842ebd0fa3647a485eee028263590d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i50253e4de73648958a1dc9b043930734_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibba051f247e041dabcc31736129c1f12_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3dbaa5362c6b426aa3e151ee9c01964c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice9acef4149d442db28cf471388f4e4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52ec121281ae42de864df9afaf5bbce5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i356a876fece547c98e1997006099bed6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id55b58bdbade49e9b33062b2a125387c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf95daa74ecc406b87ec09f0ad0760f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i260caeb3a4e44b659a7def8d723d8f28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f29989a080c4de4b210d915a9c0f8ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ea9631c41ae445d9079a93421c94e37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf6d468c617d466c8c07ffbf3361572d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6392b172fe84693a759b4ef47376ca3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie34b55b3589b41aa8b4dc4e6ab94e9e7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id71233621bbd4804ad59b2cce80ee34a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d2c1e7f78214f40be85e6cb8292eb45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61831cf914934370a0e350538f48dd0e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63a634cd0d2347eeba744537d4975ff3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5e37ec44c0d4b32bdf6a4f6631a509d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71c1650937a14aa6b693db780617d335_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89a5fb336b324120926fdf3e7acd509f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbd379d095ba4b25a0520096ae331749_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if46a5e0f67ed4bad96cbd9179fa563a0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a7b6a5928a24b238a1f7131f1574774_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a984146d6674799aba080454fdc2cda_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia742be54e94c45f2b3dd8ff5d6c056e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b009a1142c248539196c3fba5d59fb2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice87a48ce280447786bdab788445cea5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7bd3f694f7e44856ae0923f71f737ae4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i482fd86c04c1456c8e86866bab4d7940_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63e08b129ee741c09e555e16d959b1c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1da226c056b94d07adbacb4d2befd882_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic954305add924c439027278f45b35571_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23acb46414744f3295a01b88b12f0852_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifed0d2be726f4c74911502d210cc0c64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iafefc99a68e9484292f1297292ffcc0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4439bdfa6abe4378a88454a4104bf810_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52c2f5e21bcf4d3c8ee4481538d06f47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1724a3d8642c4b77958c204145d9b59e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b6a7965dcd6428eb9c75d5330f6c0fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6712e682bfcc4d9f8819cac2f889a384_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8136708df2134930a9c053c1f17459e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie15e5f5845074315a06e0d1ae4277176_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47b6e5a2190441af8606765112836eee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaca689ecc20e4fe0876e7b122b0bc25a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94685d28e10e4104afa0fc7accb57c02_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic71b76b330e14df99ec3824e8fc1d7c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife78a29c23534d2a8188fe47f55108a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bfd61b594e04154b072d87e97ad8774_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45bb8de9b00141a78c540283fa20d761_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e3ef454cab24926be400fa579222ae9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77373f4271f44dbfa26dd7f49f949448_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55cc0568452c48b58599e76cbde4fd51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad1cf19f60904659aa80c183b19b6dfb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida4e3d014e894c2994a8742fc9556a3c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7ab9fa77fa447caa055395318311262_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i892eb918a47245d0a1e1b8efd2c4dc9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ddfba6879ce435ea2183e425ab9fb97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaedf8dbec52a412e999eb8b8b3560486_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88924eaa86cb4ed39e38a15a834b05ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7af410a4e989429d8103daa89df89d50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i472c110640b34063a31c98fa592e7be7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b372339e32a430185d84a645290c6a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61e6177dbf07446383109217efb2dbd7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0dedc540e3748a180d94fe4b0c46a64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07a7a6c01df54ffe95479935e6df2ee7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02a47a9e4ba544f1a9cd835d606410ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2adb818e8c884ebf9a40f34a6969b8d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96447c36e9e04484a7110d4eb4997b4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib33e8b9fed27435c92a9faac2bd00b84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie59ac085dc65418aa4e73ffc69429588_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40279a50dc004485905b9258f9cbe2dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i780f1053c3cd4049860e874c14a7dd7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3212e1642e634c7ead8a2a1478b91244_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea71308947784543a7b3e618b843de25_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9cb851214d4345d1be8b32b72599be61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i19d843ebfcaa422a8ad48b287a882104_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a085d17c9534f2296c3a6f7f9e97029_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23d812bfa6d44d2987c3fd8e4134ce1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i144a4dea34854fafa070bc26e0c1c022_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id42361f6c10f406ea541fb7608221768_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c06c7b0e13047ef8e5353fe708bc498_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd8a01cb9b6b4aa392aba562922d863e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i763a119f616d4f0a8615b9b7ca2e724e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4342659ff7e0470e9df98f9b56908101_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae02ab521c84469d86508390fd7a2b8e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i238f0b81bcfc460493a2272e9df9e660_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i328084074c6a4e6a80b7d005923141b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89ecc37a255b4ec79a6f4852457f2d7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5af4c78b3b84e59a62c25b4a0b8ba0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa2d73ec57c84c15a3ad9c06782360e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3aeafde1efc8421883fbe844a5ce2e26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i957d7a2748724eb48b7c1a29ca66b93f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6927c570b591490ab67989e54cd02d0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i868f0061ea624c47a87a5ed4482b8464_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if07190fe863941af86705544dac7d29b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd6a5d60792446838c6c118846730304_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id383f000ec994776adc163ceb21acbe7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4245725066c542b0a93347f794776227_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc19a6487a1842f39d795710dd4036dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e8f487f85e74665806c5ec5125515e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59795d3026d44baeac66a9a81a351db4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b96f4bb392e462a82c7894ad36ec7d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib92052f136ae48a8bd74fbaa0981d8de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc23e84f52624cb8b52bf0d015a4c3cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32f8d1d725f847c09697e3d7b2b29851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9910e7304043403ca7bd1e6601890eba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff8eba1380104ea6b216ee60a45a6e69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b6523b9338e417b9035c6d604cf594a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:KidneyCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf00b273a4bf4c79a1f721b650d77572_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:KidneyCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i911a2957827b44d79670188c18f6906f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0836866414f4437aac5b49b4350f9953_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54e50d4b1d0e45d6998ef4a07f8412ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5eace4b400364cb59a814210aca461e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7b49cc670fc4f9b8a4a550217fc1379_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic71d18b327ea4b429a6ba95d6c567050_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a1f2af5eec44aa990c6433dc345a841_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9728c466394b4bc781a51da4125c31a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d510a76f30a4b18aeb57c119e82770e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f0ee4ace34040a89985a562a8e65295_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bf82d2c8c7245f0a5bfe4df7220299e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8971b1ec05a244ceae22db238af44623_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31f2351c37ba47eda635e1d9ce143c6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34cd3fc8f85743c48fd5c0975951ea19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3287ae4a62414418844751404b975d19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i606724ebb1074323bb48035cf6c598e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffc4a5e5db954ccca57e0719d248d746_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ddb2df1c2114de4a00fc604f1818904_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01f13844d63440249e54982f46346b77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i280e7c36267346f08232e69492322e25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e791ab248d24b63ae1da6cdf0df3eac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c2ea2f7c8b2414aaeb0fb9101c24607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76e6ab0c8af4453689dd47207d80b526_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f6d0ad8a3f149508ef910626c9379bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice20b77c90c04919a53292886212c09a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e9c869de9534500954d1a4145291638_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29c1764e202c483caac7e78fb4caf1b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61d6664946ac4659978bc717989aed3f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d42086277b545f8973c9e4cd170ecc1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic69de63a548f40878bfa7836ee961e78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib94226c5496c4dc189b0f57a7e9d5b37_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i711f403972ec4e66b0f07af1bd51bd85_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id14241465c6d496e9fcbffe2bb81a4a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6332787d61e14213968fc6c3ed4533b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i509b9358d5b848688db2af3f7c28f677_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAAndTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0b283e992d44d15924be874a7cb3008_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanAAndTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53250a642d1d4d75b53407d691d20e86_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia154eee2b5544902b0df5b93083def6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a6df8d1ce4240b99834c54100161749_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f1024fd068b4449894448967a76d43e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bee71915f974aae9db45279fca80f9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4359a0f4c2824bf89e0c1d35492c622d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b4946c95eb8498498d19a6faf87f113_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26fc0451360e403f820f0bba263549a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0d695e6974549e6abbf008246487b2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5680e5007324449948b894d87e40d7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09a6f14a780d4294baf4b2885e32978d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81ab07f87a174fb2b7c3fee62cf056b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1eff9aaeed62457e946eb316f31451f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9860868c23e043df847009e53cc53fdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61afa366cd62422b84371143b00ef79c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86a6007fcdfb46cd8c45962e916984df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa80e3707e984cba98b264df4ba470fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib94215c12b694944b79ef5ea39279483_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">dva:IncrementalCashPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i569c0d52c6c6426faf8f5a35ede23d64_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">dva:USAttorneyPrescriptionDrugInvestigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">dva:CashPaidForPortionPreviouslyRefundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8274525480784946977c6314bbd7cc5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia707dbef043d49869bd8d75dec1d7c30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80d73225bc934812a0e7e7641b1ce671_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26a660eca1df4c6aac1cebc8b4113bc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7063491894094779acab6b28c5595e90_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75140de7fc2e44a4aae6591587030c31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f2232a592ba45f98e9d502b586f1a60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5730e25527b841269e9c3b2c7b43ecbe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9218664971064274b79221f47df0c986_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6bbcbd8a1eca4275a3ad805b14ce01b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d31f8da40914157a9a538177f086aea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b9b576fd9a14515a102d4388e16984e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8065cc2fe8ad46cbbb4359c02e4ac3e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife1e88888ab0427c992c8ee57d880fb7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i473afde79b764c408f9a11119b563a06_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i129545bae5ea4b86ba4108e9bde79749_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i654c073e58bd41ae9d35684155b57deb_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i965432f8e1b1446f8d9cafc77f04fd6c_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6f172bac13b435484bfaf9fd3326e51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47c9f860645046bd9f1febf1ee03749e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79f354c25ca54754ab7b68f40dbd8a25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i68b03430475b4c3fb8aa98e5d19c134d_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="iee7f88346f374e438ede97086d426ca0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i302d6e3229584f9787a6db6278186655_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:TenderOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdf6a41128b04e829699ee3d9fad57ea_D20230101-20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <context id="i308dd243211b43dd8fa4201f3e66d956_I20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="ia42ecc99f0d34577b08bc4c77cf7a127_I20211217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="ie70bc0dc3fda4a9fa940a388d85df82f_I20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="i99212cfd5b704e42ae8a23d830c5ab06_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc4fb47b5503432094dda9552d7403d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b572b098200416eae5a1f8ac48e51d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i023504d2da28478aa67984abd4233153_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a3e2cfd5fd0429fb8ec56a202d18e12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8db34850cf9c4bd1bf445296b1937a89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabc719a947474ef084095e5dfbf5b1c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30a8cf8431a94b6e8121190341001e59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43b284e90b0e45778d854e5fc253a04f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8d50e013b4f49c4ba46a1b25f6ce76f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id07c35a37fce4301b64251840f18ea70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81a9b7a989584fa9b3645a2917356a30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26689de70cd749e4bc3293f6430b6501_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41c27b8943f04af2b168da521c4dad46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26972a338b914625b313ef3169a93850_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d904111572c45258967451eb747b670_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49bba0c859f547afb380af3db15e5fbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i947410d04b404a509e32155ef061b479_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61bd7246d2204fc68658398f4ea88ed1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e816800cdb849e580bc97b00a96ade9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9679bed327fc47d683813151fab6f1c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82caecf20efa484fb484a9604065ba79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70356fef993349ccbcc20e9d53a0537d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80e5796ea824458fa6ca00e78cc84d11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e45f52112ed4e3c8f797f4c3e373333_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98c876b3393e45aaadb4d03fd8cb132a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic68ddedfe24d4a9f821e723337f057fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1d9e6f88ef54849931ad26b2c3ccf31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1896d04bb1d34718b1f5a2d8398d5ca2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabeffcbc0b614275bf1f744a78a560d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc0d0c8670b74d7aaae012b57540676b_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:RMSLifelineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="ia19082384d6a4829ab61b3ab014ad7e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4f53c09daa64d04b0b10d609326db79_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida34ede3bf60405f897e4559cf454b17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id450bd55eefa4117ababbc01a3cfbd33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f6457f2f67848de859ac828fdbb8f3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifcfafbc8e4034cf19ed10d81cff9dd22_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c251fa7a54142a9973f90b0af23a71a_D20190619-20190619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-19</startDate>
            <endDate>2019-06-19</endDate>
        </period>
    </context>
    <context id="ifc2f49e543f14e95b6a4a28258a7479f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5e67f2857a248e185adf3684768570e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55269373013d4ffc8c433eda840a84cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dva:CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc02c497e38f44dc90b9f84485fef045_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i733bd4e24d7945f59bb981466bfb570e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19e33e8346e24560ba9aa3c4a675008e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i415b7bb770484bd0a68b62ea80a8dd97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05471993207b46e89aa70bd43a844aa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i046167613ae64ec19f2ed82f74f07980_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f207592fe4649a4ad1c7bf0d4621f61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3f1beaedb6546c7b32d23163c1577ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8717705e768d484989644fafcac6b11f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6032b5bb440b4d2795466e62c1aa5b59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d883f152f344fb4961979059e6695af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i826c5858f92b46e7947460dfd1f33a3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0935c6e63e743ba9aba751b24c6f1de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b5df7fafeef499c84ae47517afbb88c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a2dfed1ea6e4e64a2d2a32df8448e91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibde9a8c8bca04d5b852b3c6a3f47238c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib664746092484ebf93084b60e56443b0_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d3ac6f3c4f74f8ea1b571333627e886_D20190619-20190619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-19</startDate>
            <endDate>2019-06-19</endDate>
        </period>
    </context>
    <context id="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7536f3521c54e9294023219e56f7c64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf9e8067c67e4837babe07d810db9729_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ac2a354bfd74090958bcef5319b2038_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8ea4a40bae848aca9676ecbe296c2bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i472575aaaeaa4644bf500b85f08f09c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i850cdf3eed294766a58ed299ab32d0dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13805c203e1b4b8b917db178e9c4d6dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d986fd59a394b0faac51a4aa5076ed3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11fb71602ed14a41843e5942b0069a19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="clinic">
        <measure>dva:clinic</measure>
    </unit>
    <unit id="state">
        <measure>dva:state</measure>
    </unit>
    <unit id="patient">
        <measure>dva:patient</measure>
    </unit>
    <unit id="country">
        <measure>dva:country</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>dva:entity</measure>
    </unit>
    <unit id="segment">
        <measure>dva:segment</measure>
    </unit>
    <unit id="clinic2">
        <measure>dva:Clinic</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN18yLTEtMS0xLTQzMjM2MQ_5871b288-8d76-42df-8f3b-8f6534b178ef">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN18zLTEtMS0xLTQzMjM2MQ_d59628a9-3f8d-41c9-9607-d5836597cc37">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN180LTEtMS0xLTQzMjM2MQ_d5a3724b-3c5d-443a-93c1-e4203e98bb4e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV80L2ZyYWc6MWE3ZTg2YjE1OWY5NDAxNTllMDA0MTU0NDc3N2YyYjYvdGFibGU6YjE5Yjg4MTNlNDVkNDYzNGFiY2RmNDAyNjkxZTNhYzcvdGFibGVyYW5nZTpiMTliODgxM2U0NWQ0NjM0YWJjZGY0MDI2OTFlM2FjN181LTEtMS0xLTQzMjM2MQ_e8b376c5-19f0-432a-a785-27a181c71564">0000927066</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzItMi0xLTEtNDMyMzYx_f799249e-a21f-4a81-a569-e7340ee836f3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzMtMi0xLTEtNDMyMzYx_046b9973-72f6-4bfa-9009-e0b02f727254"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzQtMi0xLTEtNDMyMzYx_fe719cb0-6457-411a-8aa2-bcd14ec67500"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzUtMi0xLTEtNDMyMzYx_3186ec71-fe63-42ba-8c7e-a21cb6efcdf6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzYtMi0xLTEtNDMyMzYx_5cb08682-4ae2-4c92-b707-25aa570c68f8"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzctMS0xLTEtNDMyMzYx_ff09a588-8ebb-4747-9470-337972f55a8d"
      unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjgvZnJhZzpjZWY3MGJkY2JjZTQ0YjZhYmJiNTRkNThlYjg2YzY2ZS90YWJsZTo1MWYyOWViYjU4ZWY0MmQ0YjlhZGY5MWI4ODgyNjQ0ZC90YWJsZXJhbmdlOjUxZjI5ZWJiNThlZjQyZDRiOWFkZjkxYjg4ODI2NDRkXzctMi0xLTEtNDMyMzYx_ed7ad72c-bcb4-40c8-8d7a-24b2823d7375"
      unitRef="shares">97289000</us-gaap:CommonStockSharesOutstanding>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="i7af410a4e989429d8103daa89df89d50_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzU_7c63ce61-685d-4d4e-9acc-71c3c700b705"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7af410a4e989429d8103daa89df89d50_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzYx_59c71f2d-14ce-4c4c-a7ff-264f5575f32e"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <dva:AccountsReceivablePeriodOutstanding
      contextRef="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODYvZnJhZzpjZmJjODJhOWQyMzI0OWNmOGVmN2I1MTZjYWVkOWVmNS90ZXh0cmVnaW9uOmNmYmM4MmE5ZDIzMjQ5Y2Y4ZWY3YjUxNmNhZWQ5ZWY1XzIzNjM5NDk5OTk3Mzk2_1a34c3fc-7ad6-46c4-86e3-9be7493fc7cc">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDcvZnJhZzoyMDI3Y2EzMTNlNzg0NmVlOWJhNDAwZjBiMjZlZTIyZC90ZXh0cmVnaW9uOjIwMjdjYTMxM2U3ODQ2ZWU5YmE0MDBmMGIyNmVlMjJkXzY2_a44d3eef-96b6-490e-8c11-267ce0e116a0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDcvZnJhZzoyMDI3Y2EzMTNlNzg0NmVlOWJhNDAwZjBiMjZlZTIyZC90ZXh0cmVnaW9uOjIwMjdjYTMxM2U3ODQ2ZWU5YmE0MDBmMGIyNmVlMjJkXzE5Ng_f060c318-be59-4eb6-9ed5-b1d33fab2f4f"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTMvZnJhZzoyZGMwMmVmNDY5MmU0YmE0ODI2MGZlOGJhYzVlNGU5OS90ZXh0cmVnaW9uOjJkYzAyZWY0NjkyZTRiYTQ4MjYwZmU4YmFjNWU0ZTk5XzE0Ng_c65b3fd6-8d44-427f-9761-97dbe3089d2b"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <dva:PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTkvZnJhZzphMWUyMDc3M2FmYjI0ODEwOTBjNTgwNzcwOTUwZGEyZC90ZXh0cmVnaW9uOmExZTIwNzczYWZiMjQ4MTA5MGM1ODA3NzA5NTBkYTJkXzgz_017e5bd4-65ba-49d3-8334-727b34548184"
      unitRef="number">0.0100</dva:PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i4bf82d2c8c7245f0a5bfe4df7220299e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzY1_9bd5be62-eaa6-445b-abc6-e1e708ba188d">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i8971b1ec05a244ceae22db238af44623_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzEwOQ_4972656b-fa8c-4927-8e9d-8971564a8f46">2029-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i31f2351c37ba47eda635e1d9ce143c6a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzE3OQ_ab3ae432-32fc-4aaa-aa77-808b356fa18e">2042-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="i34cd3fc8f85743c48fd5c0975951ea19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzI1MQ_5fb7cbc5-47a4-42bb-a3ec-727a0198de1a">2023-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="i3287ae4a62414418844751404b975d19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjgvZnJhZzowNmJhNWM5NWQ1ZmI0M2RmOGU5MGQzZTk0ZmZkNmFlZC90ZXh0cmVnaW9uOjA2YmE1Yzk1ZDVmYjQzZGY4ZTkwZDNlOTRmZmQ2YWVkXzM2Mg_8973a952-452c-4182-ba47-fba38e19f5be">2024-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be">http://fasb.org/us-gaap/2022#InterestAndDebtExpense</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf">http://fasb.org/us-gaap/2022#InterestAndDebtExpense</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7">http://fasb.org/us-gaap/2022#IncomeTaxExpenseBenefit</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_155f47b5-2149-4835-8f82-29569b70bc53">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_6bdf6749-42f6-44d7-86f8-0f1107e1b206">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate
      contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzky_e2879539-8c2e-4337-98c6-8334143f0e09">P1Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate
      contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzk4_088db54a-3f7b-462a-8088-20c441d5eff9">P2Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection
      contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzE2Mw_322d8253-1623-4a22-9c2c-2ca6557fe34c">P3Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection
      contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDAvZnJhZzpjMjM4YTIwZWQwMmE0MWZjOGY1YjRiNjFjNTQ1NDEzYi90ZXh0cmVnaW9uOmMyMzhhMjBlZDAyYTQxZmM4ZjViNGI2MWM1NDU0MTNiXzE2OQ_f50c8916-8bb4-4daf-980c-dd8178969ea6">P4Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzE3NA_68ec31fb-0f5b-4e00-b2cd-b215d57406d3">P0Y</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzMtMS0xLTEtNDMyMzYx_295638c8-5b01-4082-a642-756314a2ab0c"
      unitRef="usdPerShare">50.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i645e3e983d4e4bc097dfba6046d1aa0d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzMtMi0xLTEtNDMyMzYx_93c229e6-aa26-4f40-a809-64ea57ab9355"
      unitRef="usdPerShare">60.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzQtMS0xLTEtNDMyMzYx_df3cf2ea-38e2-42eb-b41f-b704540ba9e4"
      unitRef="usdPerShare">60.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iec54521d8c0f485882416c535f0b1e2f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzQtMi0xLTEtNDMyMzYx_5684dfb1-aa62-4699-a442-b2294b2c0dbd"
      unitRef="usdPerShare">70.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzUtMS0xLTEtNDMyMzYx_aa55d987-fc98-46c4-b1fd-50302c534f13"
      unitRef="usdPerShare">70.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i3609fd352a57416ba9fc3f1c58e6c625_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzUtMi0xLTEtNDMyMzYx_9c9701ec-5a17-4f56-bc73-9da824843a59"
      unitRef="usdPerShare">80.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzYtMS0xLTEtNDMyMzYx_49eb147f-0d57-407f-903a-aee0913cfc05"
      unitRef="usdPerShare">100.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i32d7e5bd8c2847aa9d256347f38ecf7e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzYtMi0xLTEtNDMyMzYx_425469b6-905b-4a01-97ef-10db06286d91"
      unitRef="usdPerShare">110.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzctMS0xLTEtNTM2NDYw_023d16ab-09b4-4ed8-a64c-9b16c8f6bbc4"
      unitRef="usdPerShare">110.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i81b5d2ab01ad4768aaa650665094b6e6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90YWJsZTplZWRmZjJlZTllMmQ0NTgzOWQ2Y2EyMmUxMjdhN2NkYy90YWJsZXJhbmdlOmVlZGZmMmVlOWUyZDQ1ODM5ZDZjYTIyZTEyN2E3Y2RjXzctMi0xLTEtNTM2NDYz_990c11ef-ac1a-40d9-8934-0c12cc6db8d2"
      unitRef="usdPerShare">120.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i68b03430475b4c3fb8aa98e5d19c134d_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzMxMA_9cd745d1-8849-4fe9-8ff7-d89e2938c0ab"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzQ5NQ_8688e474-1fdf-43bc-a94c-f64a5e165628"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzY1MA_4a6d92f5-147b-4228-bc3b-bcf75b7e0103"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzg2Ng_2c613cbd-4882-4b38-a1f1-9645ed28402f"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzkwMg_dd8c5970-080d-427b-b9d6-a57626480877"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzkzOA_a664d4df-bc87-4912-bdcc-d23f74253642"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzc2OTY1ODEzOTU4MzY_010b2c66-88d5-41d5-9c03-dc12e0cc6f88"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTIvZnJhZzoyNTA1MTI4OGZjZDc0N2NjYWY2ODY2NDA3MjhjOWM5Zi90ZXh0cmVnaW9uOjI1MDUxMjg4ZmNkNzQ3Y2NhZjY4NjY0MDcyOGM5YzlmXzc2OTY1ODEzOTU4Mzk_3b79439d-cf07-4254-bc80-3c56da347026"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount
      contextRef="i308dd243211b43dd8fa4201f3e66d956_I20201210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1XzYx_953e28ab-0899-4e1b-b6b1-424cf75e62a9"
      unitRef="usd">329302000</dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1XzIzNjM5NDk5OTk3ODY4_b1d75f13-b25f-41e5-82cb-9d150041aec6"
      unitRef="shares">-8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTgvZnJhZzo0NjRhMGRjZDdmMGU0MjYzYjVjZjExMTAxZDljMzUyNS90ZXh0cmVnaW9uOjQ2NGEwZGNkN2YwZTQyNjNiNWNmMTExMDFkOWMzNTI1Xzc2OTY1ODEzOTUxMTI_6b0980b2-57e8-4f8a-9be6-8e3cd294da63"
      unitRef="shares">-13877000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ifcfafbc8e4034cf19ed10d81cff9dd22_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzgxL2ZyYWc6YzJmNjgxNzQ0ZjczNDdmMjkwNjU4MmI4YWU5MjE4OWQvdGV4dHJlZ2lvbjpjMmY2ODE3NDRmNzM0N2YyOTA2NTgyYjhhZTkyMTg5ZF83Njk2NTgxMzk0NjUx_675d7e84-d0d8-46fc-9379-c45313900b20">P0Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0Nzcz_0a0a7dff-dd24-434a-bba5-f6dc68361432"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NTYz_02a86387-9ef1-4c88-b26e-88707311fe7b"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NTgz_1f2f1dc4-5649-4cee-a511-477651f7d513"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjA1_1fb62dcb-5b9d-4de3-95ca-5f6c63b26dbc"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjA4_4200a34e-2238-47a2-8961-d2f318339d4c"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk1NjEx_43b2fc60-30a2-45fe-88ab-19e351a81ba6"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzE1_9e56c00b-e5a6-46ae-af7c-e7b499f9e3eb"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i9fd7378a0b1a418b9d92ffcde170090e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzIy_5b916365-3cb6-4f80-accb-bcda90426e76"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i7d30dd64441049c8a20bbc1f0554695e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzcwL2ZyYWc6MDY0NjAyYTgwY2VkNGYzMDg2MzRkMTIzNDEyNmVhYzQvdGV4dHJlZ2lvbjowNjQ2MDJhODBjZWQ0ZjMwODYzNGQxMjM0MTI2ZWFjNF83Njk2NTgxMzk0NzI3_13f68a1f-e31e-4727-bd5e-00a262402f6a"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <dei:DocumentType
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI0_97db0f44-d022-481a-88ea-60bb8c8eba8d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NjJkZjJkY2ZkODU1NDllYTg2OGFkNTEyOTc0YzQyNzAvdGFibGVyYW5nZTo2MmRmMmRjZmQ4NTU0OWVhODY4YWQ1MTI5NzRjNDI3MF8wLTAtMS0xLTQzMjM2MQ_5cb0c0cd-13f0-49b0-96d7-c2dcc4154902">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8xMjQ_91b4b6f4-21c4-4267-9bc3-7e002be91acc">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8xMjQ_98181737-6595-4704-b731-6d86826f25c3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDczM2FmODkxZGY4NGM4NmE3YzZhY2JlMDhjMzU1ODAvdGFibGVyYW5nZTowNzMzYWY4OTFkZjg0Yzg2YTdjNmFjYmUwOGMzNTU4MF8wLTAtMS0xLTQzMjM2MQ_17a33611-7d7f-45b6-9933-c83293e38b66">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDM0_aaee72a3-5e1d-471b-828d-922a7a4d42ae">1-14106</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI5_63e62e4e-9b52-40b7-ab33-cf69d044c587">DAVITA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NTk0YWFiODI4MmY1NGQ0ZDhlM2UzNTg4MGIzOGNlOTkvdGFibGVyYW5nZTo1OTRhYWI4MjgyZjU0ZDRkOGUzZTM1ODgwYjM4Y2U5OV8wLTAtMS0xLTQzMjM2MQ_8bf5d98b-508f-4be9-974d-245d09515632">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NTk0YWFiODI4MmY1NGQ0ZDhlM2UzNTg4MGIzOGNlOTkvdGFibGVyYW5nZTo1OTRhYWI4MjgyZjU0ZDRkOGUzZTM1ODgwYjM4Y2U5OV8wLTItMS0xLTQzMjM2MQ_59daa0a4-fd57-4137-9411-b2f3094304d9">51-0354549</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8wLTAtMS0xLTQzMjM2MQ_9da88a2e-d3fb-4fe5-a911-752b8c67c0ae">2000 16th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTAtMS0xLTQzMjM2MQ_27e5eb06-fb85-46f0-b9fb-114e975325e5">Denver,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTEtMS0xLTQzMjM2MQ_6c6f2bdf-7a8b-4bb2-8fe1-8208a54f210f">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6MDMyZjVjNmE4NWRkNDIxM2FjOGU4NGU1ZWY3ZmIyODUvdGFibGVyYW5nZTowMzJmNWM2YTg1ZGQ0MjEzYWM4ZTg0ZTVlZjdmYjI4NV8xLTItMS0xLTQzMjM2MQ_a6388923-3302-443a-b528-554996ab48e2">80202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI1_8356f216-2ab3-486d-9625-75022663248a">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMw_5964701b-2e85-4289-993b-0086d5ace0ac">631-2100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTAtMS0xLTQzMjM2MQ_548434ac-0363-4f9a-a14e-0a917c17a3b2">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTItMS0xLTQzMjM2MQ_cde08074-6797-48f6-b562-9ec1d79f1328">DVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6Y2JmNzUyMGJmN2M0NDdiZmE1ZDUzMjk3ZDE0MGM3NzcvdGFibGVyYW5nZTpjYmY3NTIwYmY3YzQ0N2JmYTVkNTMyOTdkMTQwYzc3N18xLTQtMS0xLTQzMjM2MQ_15809f37-8092-4cf0-9931-b6e44ecacf13">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIy_2ceb4d22-51f7-4538-9cd4-2a699d8eeb42">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMx_75addd92-960a-4677-8743-2733f7d30c75">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDI2_5a414cb2-6cba-472f-be8b-babe6d3d4847">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDMy_a1275fd5-1797-4c1c-abec-dd951888296a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18wLTAtMS0xLTQzMjM2MQ_b331db37-3d79-472b-8049-896fa89dfae4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18xLTUtMS0xLTQzMjM2MQ_939f0df8-925c-4b57-8c54-8879886b3efb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGFibGU6NGU5M2YxYTVhNjVmNGNhYjk0YjQ1YmY4ZjNhZmE2NjcvdGFibGVyYW5nZTo0ZTkzZjFhNWE2NWY0Y2FiOTRiNDViZjhmM2FmYTY2N18yLTUtMS0xLTQzMjM2MQ_8ab2ded2-e3b6-470f-9315-f9d4631b0f16">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIx_a66b1fe6-9817-46f6-91cb-a8c5eae2f8fa">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8zMDIz_20a35594-91c3-4d13-b392-3c56a0be8357">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic74d2bf2b4fe417491b67a410b426f67_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8yNjk4_3da2dba6-a340-4cf4-a066-1236a34fa537"
      unitRef="usd">7400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia364a716386a4cb1a9c39177212dcb31_I20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8xL2ZyYWc6ODllNzNmZDhkMDBkNDcxNGE5NjhhM2U4ZDA1YzBmZjQvdGV4dHJlZ2lvbjo4OWU3M2ZkOGQwMGQ0NzE0YTk2OGEzZThkMDVjMGZmNF8yNzk2_9bf4fced-0062-40d6-bd5d-af41040aa9e4"
      unitRef="shares">90400000</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTE_a27fcee2-1d1f-4559-8c9a-78bb9ff1f723">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTI_0c69eeec-450f-40c1-ba4f-36fcf3263e02">Seattle, WA, USA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yMzgvZnJhZzowYjJlN2MwMTg5N2E0Yzk5YmY2OTMxYTAyNzVkNThiMS90ZXh0cmVnaW9uOjBiMmU3YzAxODk3YTRjOTliZjY5MzFhMDI3NWQ1OGIxXzc2OTY1ODEzOTQ4OTQ_d8da0b8e-afbb-4c58-95cc-e6c18583e884">185</dei:AuditorFirmId>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtMS0xLTEtNDMyMzYx_9cb0786b-994c-4d3c-9a0b-da13bed74efa"
      unitRef="usd">11176464000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtMy0xLTEtNDMyMzYx_b3d0d846-7748-41a5-8a7a-1dcb6b289efc"
      unitRef="usd">11213515000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQtNS0xLTEtNDMyMzYx_5082ff92-bd92-489b-b38d-13065cd7be06"
      unitRef="usd">11026251000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <us-gaap:OtherIncome
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtMS0xLTEtNDMyMzYx_02ddce57-6177-4ed3-861f-04ec2fc3802f"
      unitRef="usd">433430000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtMy0xLTEtNDMyMzYx_5e45395c-5ac5-4f60-b599-2ac78c9bdd23"
      unitRef="usd">405282000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzUtNS0xLTEtNDMyMzYx_a9e7fdba-e5ee-453a-9cf6-f15c51162caf"
      unitRef="usd">524353000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtMS0xLTEtNDMyMzYx_ff070a2d-74db-4dc4-93b8-e98280623d37"
      unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtMy0xLTEtNDMyMzYx_67756e4c-2f1c-4c16-b87c-6bf7010b0519"
      unitRef="usd">11618797000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzYtNS0xLTEtNDMyMzYx_baebbb6f-cfaf-439b-82a5-7fb23365c47b"
      unitRef="usd">11550604000</us-gaap:Revenues>
    <dva:PatientCareCosts
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtMS0xLTEtNDMyMzYx_d4e94472-0c64-4843-b7fc-506205a83fc0"
      unitRef="usd">8209553000</dva:PatientCareCosts>
    <dva:PatientCareCosts
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtMy0xLTEtNDMyMzYx_49ddb38f-56fb-4dd0-991d-1506e2a655b2"
      unitRef="usd">7972414000</dva:PatientCareCosts>
    <dva:PatientCareCosts
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzgtNS0xLTEtNDMyMzYx_f8f33a04-c840-4c62-b315-7e9596e2262a"
      unitRef="usd">7988613000</dva:PatientCareCosts>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktMS0xLTEtNDMyMzYx_b4aee041-6107-4886-bc8e-bb53f0f383c6"
      unitRef="usd">1355197000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktMy0xLTEtNDMyMzYx_81d97a63-6bd1-4968-a924-5a3ab828a49f"
      unitRef="usd">1195335000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzktNS0xLTEtNDMyMzYx_2f3e6a78-851a-4a83-9b12-a7836399383f"
      unitRef="usd">1247584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTEtMS0xLTQzMjM2MQ_93fa2232-3044-4eeb-b11e-dc219aa22611"
      unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTMtMS0xLTQzMjM2MQ_1cc29c7c-5296-4175-b4da-6098cae95b38"
      unitRef="usd">680615000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEwLTUtMS0xLTQzMjM2MQ_c95e7761-64c0-4d1e-ae17-155d415c3977"
      unitRef="usd">630435000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTEtMS0xLTQzMjM2MQ_74b4058b-bf46-46c9-9c2b-022216e73e06"
      unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTMtMS0xLTQzMjM2MQ_f277beab-949c-41cc-8b74-832de6656989"
      unitRef="usd">26937000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzEyLTUtMS0xLTQzMjM2MQ_199f9623-f042-47aa-bf1d-aad9f687b20a"
      unitRef="usd">26916000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTEtMS0xLTQzMjM2MQ_69fb6bc7-1c4e-43de-a917-f7dc2cbfd72a"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTMtMS0xLTQzMjM2MQ_7328150a-7859-40aa-a77d-e504cb650d1b"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE1LTUtMS0xLTQzMjM2MQ_ae080fc4-de73-454c-91df-9473f372c488"
      unitRef="usd">-16252000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:CostsAndExpenses
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTEtMS0xLTQzMjM2MQ_9ee93f44-9e70-4759-aba8-282066361fbe"
      unitRef="usd">10270832000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTMtMS0xLTQzMjM2MQ_76acd3b8-d510-4e32-97c8-37d7c1bce6e8"
      unitRef="usd">9821427000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE3LTUtMS0xLTQzMjM2MQ_b2508325-71b6-4902-b091-14d42b872945"
      unitRef="usd">9855968000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTEtMS0xLTQzMjM2MQ_17fc152e-5dd0-49cd-b83b-c3d3ec81fa4f"
      unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTMtMS0xLTQzMjM2MQ_e2a2423c-52f5-4ffa-9ee2-91fae0eb58ee"
      unitRef="usd">1797370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE4LTUtMS0xLTQzMjM2MQ_98fee497-f164-4aa5-93c6-377f8ee112b8"
      unitRef="usd">1694636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTEtMS0xLTQzMjM2MQ_174b2be3-c97d-4959-af15-d59ea5dbe31c"
      unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTMtMS0xLTQzMjM2MQ_3dac5cb4-056d-40ac-aed7-0ef2b971156c"
      unitRef="usd">285254000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzE5LTUtMS0xLTQzMjM2MQ_fe3a0805-825e-4f60-a022-d8e7a9f76937"
      unitRef="usd">304111000</us-gaap:InterestAndDebtExpense>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTEtMS0xLTQzMjM2MQ_d32061e7-8d2a-4a2c-be84-8cc4c2d48993"
      unitRef="usd">0</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTMtMS0xLTQzMjM2MQ_43e84d1b-92a8-483b-8fb9-5020fce55a85"
      unitRef="usd">0</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIwLTUtMS0xLTQzMjM2MQ_6d42a569-ae9f-4751-af0c-51414ed29561"
      unitRef="usd">89022000</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTEtMS0xLTQzMjM2MQ_a7fbaa39-18c8-4143-9606-4cebd59435c0"
      unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTMtMS0xLTQzMjM2MQ_c11ce9a5-2ec4-4534-9266-5f23065eb8e9"
      unitRef="usd">6378000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIxLTUtMS0xLTQzMjM2MQ_405739fb-903e-4059-97e2-65f676fdc113"
      unitRef="usd">16759000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTEtMS0xLTQzMjM2MQ_7ad1dc3e-0809-4e7b-92be-76f2631338c8"
      unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTMtMS0xLTQzMjM2MQ_c01c2b67-9375-4ed1-9328-cc89e1096815"
      unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIyLTUtMS0xLTQzMjM2MQ_4e9f0316-a1ed-42e6-a03f-32a44aef5fe7"
      unitRef="usd">1318262000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTEtMS0xLTQzMjM2MQ_44b5306c-e059-4b67-8bb8-f2d28cf9cad1"
      unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTMtMS0xLTQzMjM2MQ_fe890b45-9c22-4ee2-b28a-aeb21f2c3aa8"
      unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzIzLTUtMS0xLTQzMjM2MQ_a4094cc8-9735-48cf-ba4c-350699e80958"
      unitRef="usd">313932000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTEtMS0xLTQzMjM2MQ_add0940e-5599-4c54-94ef-8d303fee596d"
      unitRef="usd">768191000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTMtMS0xLTQzMjM2MQ_afa08052-c177-4590-8c32-10213d26f4b4"
      unitRef="usd">1211762000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI0LTUtMS0xLTQzMjM2MQ_07268fe5-afe1-4b5d-8a40-9ed0d6019476"
      unitRef="usd">1004330000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTEtMS0xLTQzMjM2MQ_35f6151a-73f2-4538-b9e9-2f3f06c1a510"
      unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTMtMS0xLTQzMjM2MQ_704a96f1-98bf-4c93-96ca-f5e7eb13d55b"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI1LTUtMS0xLTQzMjM2MQ_287a5881-4d21-4dcd-b475-8a1d02035873"
      unitRef="usd">-9653000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTEtMS0xLTQzMjM2MQ_c12f9ae3-d2bd-4642-99fc-4de0a048f665"
      unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTMtMS0xLTQzMjM2MQ_8c6df8b2-5ded-4b92-8024-3b5442bdef76"
      unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI2LTUtMS0xLTQzMjM2MQ_153aead1-fdb0-440f-bc6f-12aea58e5c7d"
      unitRef="usd">994677000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTEtMS0xLTQzMjM2MQ_24cc7370-9942-4c0e-ad45-2b957d6e1b13"
      unitRef="usd">221243000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTMtMS0xLTQzMjM2MQ_f44a2e4f-9bdd-4e29-8f69-80142a538b8b"
      unitRef="usd">233312000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI3LTUtMS0xLTQzMjM2MQ_1dd89227-b9a1-4b8b-bc12-ff2b761d2beb"
      unitRef="usd">221035000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTEtMS0xLTQzMjM2MQ_752b50c9-55f4-4b24-beec-049345043404"
      unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTMtMS0xLTQzMjM2MQ_bfbe13e8-3ff4-4db4-9eca-04af4d5b7d1d"
      unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzI4LTUtMS0xLTQzMjM2MQ_a553d71f-a8cb-496e-ac66-b116c509720d"
      unitRef="usd">773642000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTEtMS0xLTQzMjM2MQ_d1f13661-33c2-465a-8692-ca1019e2ef31"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTMtMS0xLTQzMjM2MQ_796b3127-146e-4b0e-bbf3-993fac549e6a"
      unitRef="usdPerShare">9.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMxLTUtMS0xLTQzMjM2MQ_62f80181-513f-4a37-97af-a3f0c6bb6daa"
      unitRef="usdPerShare">6.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTEtMS0xLTQzMjM2MQ_d2680893-b9f5-42ac-bbce-b60ec3597b91"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTMtMS0xLTQzMjM2MQ_16751f0b-a879-490e-a11f-4466aa259f9c"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMyLTUtMS0xLTQzMjM2MQ_fb867ab0-25c4-46a2-b964-9d437f30a03d"
      unitRef="usdPerShare">6.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTEtMS0xLTQzMjM2MQ_c7755c73-8307-40a7-a3ab-949604b916cb"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTMtMS0xLTQzMjM2MQ_4990c8de-403f-4f96-85fd-e31e72f1596c"
      unitRef="usdPerShare">8.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzMzLTUtMS0xLTQzMjM2MQ_dca85895-9057-4050-ac1c-510e6fdac2f4"
      unitRef="usdPerShare">6.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTEtMS0xLTQzMjM2MQ_ca706add-12da-44c1-932b-5ec20a946bb8"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTMtMS0xLTQzMjM2MQ_0e53b85b-e209-408c-a9ba-fb11522b309f"
      unitRef="usdPerShare">8.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM0LTUtMS0xLTQzMjM2MQ_fd63b458-df8e-4535-b982-b27139974939"
      unitRef="usdPerShare">6.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTEtMS0xLTQzMjM2MQ_ad91433d-d547-4686-a3fa-891b3cfb16cb"
      unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTMtMS0xLTQzMjM2MQ_b7b37094-f9a1-4594-9f73-84e83cc7fa73"
      unitRef="shares">105230000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM3LTUtMS0xLTQzMjM2MQ_adb0cb75-e2c7-4ae4-ac4c-9e797ecd630c"
      unitRef="shares">119797000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTEtMS0xLTQzMjM2MQ_5cc58850-53d2-435f-b523-4db4c8c8ea10"
      unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTMtMS0xLTQzMjM2MQ_bf00a8ab-8714-4deb-8b82-8509a26c367c"
      unitRef="shares">109948000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzM4LTUtMS0xLTQzMjM2MQ_09f98362-2f79-4480-8548-fcdd48c7c5a0"
      unitRef="shares">122623000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTEtMS0xLTQzMjM2MQ_9696f61d-9968-49ec-bc9e-9f71296429a7"
      unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTMtMS0xLTQzMjM2MQ_0456ca5a-e4e7-456e-ac29-134de1a41aaf"
      unitRef="usd">978450000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQxLTUtMS0xLTQzMjM2MQ_d7c7ab0d-e4d7-48ce-a525-ea1cd85e7fef"
      unitRef="usd">783295000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTEtMS0xLTQzMjM2MQ_a032ef1e-6788-4c7e-9fa9-f8cd41fcf3e1"
      unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTMtMS0xLTQzMjM2MQ_1b5c43e5-c443-4912-9f5d-ca7e41588117"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQyLTUtMS0xLTQzMjM2MQ_a85b1e69-0895-45a0-8bc7-876e84f9da3e"
      unitRef="usd">-9653000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTEtMS0xLTQzMjM2MQ_de2d7441-2220-4ce4-9804-c367a5a66a6d"
      unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTMtMS0xLTQzMjM2MQ_1e27cf07-11f1-42bd-878f-6f6798f2ef4e"
      unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNTkvZnJhZzowN2VmNzNjOWM4ZDI0MmFhODM3OGY3ZjdlYTM0MjVmNC90YWJsZTo2MTlmYzk1OWRmOWM0MTcyOWI5NmNiMTY1Y2E0ZTNlMC90YWJsZXJhbmdlOjYxOWZjOTU5ZGY5YzQxNzI5Yjk2Y2IxNjVjYTRlM2UwXzQzLTUtMS0xLTQzMjM2MQ_d0011813-0b73-44a0-a5ec-5998d5ec36b9"
      unitRef="usd">773642000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItMS0xLTEtNDMyMzYx_c12f9ae3-d2bd-4642-99fc-4de0a048f665"
      unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItMy0xLTEtNDMyMzYx_8c6df8b2-5ded-4b92-8024-3b5442bdef76"
      unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzItNS0xLTEtNDMyMzYx_153aead1-fdb0-440f-bc6f-12aea58e5c7d"
      unitRef="usd">994677000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtMS0xLTEtNDMyMzYx_5195d89c-bbb4-4bf5-a1e6-effb11595704"
      unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtMy0xLTEtNDMyMzYx_b467a3a1-d8ae-4f95-89a7-6a1611afd674"
      unitRef="usd">7155000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzUtNS0xLTEtNDMyMzYx_73647267-c426-4306-8caa-e1935e544695"
      unitRef="usd">-16346000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtMS0xLTEtNDMyMzYx_741042f7-6218-4559-8579-9e814e7eef07"
      unitRef="usd">8806000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtMy0xLTEtNDMyMzYx_ce9c69ec-e5b8-426d-9a84-432117fa07ad"
      unitRef="usd">-4133000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzYtNS0xLTEtNDMyMzYx_ca5bc5ac-252e-4abf-a53a-537785e7f24b"
      unitRef="usd">-5313000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctMS0xLTEtNDMyMzYx_83663247-4a80-451f-94e2-e50a73c7d557"
      unitRef="usd">-29802000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctMy0xLTEtNDMyMzYx_9bafc3c3-1d46-4d85-b978-a9886bd465f8"
      unitRef="usd">-84381000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzctNS0xLTEtNDMyMzYx_0de0903a-a00e-4b58-8fab-494a9ef1dada"
      unitRef="usd">-7623000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtMS0xLTEtNDMyMzYx_2595c2d4-6e6b-4063-a487-dd792b485665"
      unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtMy0xLTEtNDMyMzYx_e470bf58-7143-4f87-8588-58abe6a9750e"
      unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzgtNS0xLTEtNDMyMzYx_fb11f981-6457-469d-9966-047bb43ab1b9"
      unitRef="usd">-18656000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktMS0xLTEtNDMyMzYx_d117c68b-9cf4-453b-be9b-b929457eb89a"
      unitRef="usd">851704000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktMy0xLTEtNDMyMzYx_c4ca38ef-dd22-4625-ac5d-94b1208c6f5d"
      unitRef="usd">1138669000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzktNS0xLTEtNDMyMzYx_8cd1666f-affa-4ba4-857f-ae543ddffca1"
      unitRef="usd">976021000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTEtMS0xLTQzMjM2MQ_523d03f0-817c-49c2-880f-3e13bd563143"
      unitRef="usd">221243000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTMtMS0xLTQzMjM2MQ_2d290f99-0ad9-4ae8-ba2d-f0d40c0997e9"
      unitRef="usd">233312000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzEwLTUtMS0xLTQzMjM2MQ_f9424910-b575-4fb1-af53-565b91398152"
      unitRef="usd">221035000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTEtMS0xLTQzMjM2MQ_cd6a770c-10d7-4234-b9a0-d4a17acc6c94"
      unitRef="usd">630461000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTMtMS0xLTQzMjM2MQ_a52bc3a7-d056-41ab-820a-1c3adf6f64b5"
      unitRef="usd">905357000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjIvZnJhZzplY2RjYTgxN2U4N2Q0MzAwYTE2NWRjODUzNjNiM2I4Yy90YWJsZTo1ZTdkNGZiMzE2MjU0YmQ5ODQ4YTllODEyMmNkNWQ2ZC90YWJsZXJhbmdlOjVlN2Q0ZmIzMTYyNTRiZDk4NDhhOWU4MTIyY2Q1ZDZkXzExLTUtMS0xLTQzMjM2MQ_1d343ae3-6203-4c93-a96f-ff4942473215"
      unitRef="usd">754986000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzItMS0xLTEtNDMyMzYx_9c76a9cf-d750-4d8d-a042-ed7bf52e1a7f"
      unitRef="usd">244086000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzItMy0xLTEtNDMyMzYx_50f3bc6a-9871-4585-bdcb-915da85d3da9"
      unitRef="usd">461900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMtMS0xLTEtNDMyMzYx_b4389ba4-638d-4f54-b8df-139a3d65396a"
      unitRef="usd">94903000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMtMy0xLTEtNDMyMzYx_07059240-1b3f-43d2-b172-dfb65ad6cf95"
      unitRef="usd">93060000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQtMS0xLTEtNDMyMzYx_b1eaaf70-a509-420c-ba85-31fa5b3661dd"
      unitRef="usd">77693000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQtMy0xLTEtNDMyMzYx_096ccf26-e076-4c78-888f-daf161db0401"
      unitRef="usd">22310000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzUtMS0xLTEtNDMyMzYx_b222280e-3fb3-48b8-8db9-bf949e2f18cd"
      unitRef="usd">2132070000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzUtMy0xLTEtNDMyMzYx_25ba53f8-7186-45e3-913b-66f0670064ba"
      unitRef="usd">1957583000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzYtMS0xLTEtNDMyMzYx_85e25cbf-5e88-42d5-abc6-c6977583f74d"
      unitRef="usd">109122000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzYtMy0xLTEtNDMyMzYx_2fede081-7c4f-4429-a63c-6d625c95b4f2"
      unitRef="usd">107428000</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzctMS0xLTEtNDMyMzYx_7dfa6e77-bbec-4560-a709-6eeafb3f2674"
      unitRef="usd">413976000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzctMy0xLTEtNDMyMzYx_f06ffd1f-ea52-4d0f-980e-aef9b9150448"
      unitRef="usd">427321000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzgtMS0xLTEtNDMyMzYx_8dbd44c1-41c7-4d06-b070-9269d9b67c33"
      unitRef="usd">78839000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzgtMy0xLTEtNDMyMzYx_7b56dfd2-4176-49f5-a801-fb86ae57e1dc"
      unitRef="usd">72517000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzktMS0xLTEtNDMyMzYx_060fbf82-ab2b-4afa-8490-2ffd07fceee0"
      unitRef="usd">4603000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzktMy0xLTEtNDMyMzYx_cb8aec41-74ac-4624-95ba-39990e638ff3"
      unitRef="usd">25604000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEwLTEtMS0xLTQzMjM2MQ_14f8a0fc-5bb6-49d2-99e7-0c69250d9302"
      unitRef="usd">3155292000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEwLTMtMS0xLTQzMjM2MQ_d5ce1499-58db-4b07-9b88-d069a902982c"
      unitRef="usd">3167723000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzExLTEtMS0xLTQzMjM2MQ_ab526b2a-c3c8-4f13-a24f-f4465e04a74c"
      unitRef="usd">3256397000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzExLTMtMS0xLTQzMjM2MQ_ffe78f49-b393-4f3e-aa0d-93826f8aaf1c"
      unitRef="usd">3479972000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEyLTEtMS0xLTQzMjM2MQ_038f98bc-f057-41ab-9b8b-f61b25dd0b50"
      unitRef="usd">2666242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEyLTMtMS0xLTQzMjM2MQ_91a59374-edfa-4e57-b663-107eeb120ebf"
      unitRef="usd">2824787000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEzLTEtMS0xLTQzMjM2MQ_932da64e-b89c-4adf-a800-56a6d89ed1c6"
      unitRef="usd">182687000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzEzLTMtMS0xLTQzMjM2MQ_6d06bb14-afe5-41ca-8860-de46d4832bf3"
      unitRef="usd">177693000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE0LTEtMS0xLTQzMjM2MQ_9265bb60-2524-4264-9361-7a9a126b4b8b"
      unitRef="usd">231108000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE0LTMtMS0xLTQzMjM2MQ_4dcb61f4-ef83-4924-bac3-c315ca16cd91"
      unitRef="usd">238881000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE1LTEtMS0xLTQzMjM2MQ_0afb6658-e63c-4652-8454-8935b1b0d96a"
      unitRef="usd">44329000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE1LTMtMS0xLTQzMjM2MQ_4b490bfe-a946-4363-80f6-6a0fadecbd97"
      unitRef="usd">49514000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE2LTEtMS0xLTQzMjM2MQ_6d3e5259-0fa9-419d-a692-d92d7e0ad5db"
      unitRef="usd">315587000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE2LTMtMS0xLTQzMjM2MQ_ded38189-ca81-4d72-ba21-daec5b15c459"
      unitRef="usd">136677000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE3LTEtMS0xLTQzMjM2MQ_1b6b0e9f-0cca-4bfc-97a9-59718d6b7064"
      unitRef="usd">7076610000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE3LTMtMS0xLTQzMjM2MQ_3ed30060-06a3-49c3-8697-54f7fe8b9944"
      unitRef="usd">7046241000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE4LTEtMS0xLTQzMjM2MQ_3e900d76-bcfb-4632-b7cd-3f067e660033"
      unitRef="usd">16928252000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzE4LTMtMS0xLTQzMjM2MQ_d53a8fb8-2e9d-49e3-b077-349052c312fd"
      unitRef="usd">17121488000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIwLTEtMS0xLTQzMjM2MQ_b982bc38-0b82-4fc5-864d-5d27e8129331"
      unitRef="usd">479780000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIwLTMtMS0xLTQzMjM2MQ_341c7bd5-dfe7-460e-aa86-0a2cb825df86"
      unitRef="usd">402049000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIxLTEtMS0xLTQzMjM2MQ_78507d4a-fa44-420a-9385-6374841b1156"
      unitRef="usd">802469000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIxLTMtMS0xLTQzMjM2MQ_5281e3ae-99f6-4f95-a67c-0fa0664c4f4a"
      unitRef="usd">709345000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIyLTEtMS0xLTQzMjM2MQ_c12ad698-f497-4935-b96c-75e3f33242c1"
      unitRef="usd">692654000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIyLTMtMS0xLTQzMjM2MQ_0b949a6e-68de-4dc7-8348-c9c129f3d18f"
      unitRef="usd">659960000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIzLTEtMS0xLTQzMjM2MQ_507320cd-5118-4f5f-b776-3b5edb15df2a"
      unitRef="usd">395401000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzIzLTMtMS0xLTQzMjM2MQ_680ffc29-9186-4b0c-9299-1ef1264a3a8d"
      unitRef="usd">394357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI0LTEtMS0xLTQzMjM2MQ_dbd374f1-8616-4714-b126-f44d400dbc1d"
      unitRef="usd">231404000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI0LTMtMS0xLTQzMjM2MQ_8ede8d7a-94d2-4c56-b4da-0866192b0277"
      unitRef="usd">179030000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI1LTEtMS0xLTQzMjM2MQ_bbda84d8-7df4-4dc3-9496-58786fb5eed2"
      unitRef="usd">18039000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI1LTMtMS0xLTQzMjM2MQ_4502fdf2-8a79-44f1-b1b7-ea803741244b"
      unitRef="usd">53792000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI2LTEtMS0xLTQzMjM2MQ_8f7fe471-562c-4973-89a1-49e6e9085db2"
      unitRef="usd">2619747000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI2LTMtMS0xLTQzMjM2MQ_9e8f3e60-1187-409c-b844-596b2269e29e"
      unitRef="usd">2398533000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI3LTEtMS0xLTQzMjM2MQ_c3c087f5-e481-4b42-92e7-bdac05f92180"
      unitRef="usd">2503068000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI3LTMtMS0xLTQzMjM2MQ_2829a67e-57aa-45c9-b90c-39cee1260248"
      unitRef="usd">2672713000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI4LTEtMS0xLTQzMjM2MQ_cc5d5ac0-26a3-49f6-b16a-a1f8024fe1db"
      unitRef="usd">8692617000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI4LTMtMS0xLTQzMjM2MQ_c3950dd1-d4db-469a-b03b-82ed44cdca3f"
      unitRef="usd">8729150000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI5LTEtMS0xLTQzMjM2MQ_d0455619-571f-49b8-9bab-e6b36cedd20e"
      unitRef="usd">105233000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzI5LTMtMS0xLTQzMjM2MQ_047b04b3-c10c-42b0-962d-5e750b708353"
      unitRef="usd">119158000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMwLTEtMS0xLTQzMjM2MQ_c2e6af9c-5629-46d6-9520-d5d9bc08844f"
      unitRef="usd">782787000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMwLTMtMS0xLTQzMjM2MQ_4e5afe3b-97d5-4c04-9ef4-2666928538c5"
      unitRef="usd">830954000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMxLTEtMS0xLTQzMjM2MQ_d625b16b-5b2f-420d-8fad-cc542d4f4b26"
      unitRef="usd">14703452000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMxLTMtMS0xLTQzMjM2MQ_ebccba52-0dca-4b6e-9bcc-804db5be8046"
      unitRef="usd">14750508000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMzLTEtMS0xLTQzMjM2MQ_2bc64110-cd4b-43ec-a61b-e0254a196f6f"
      unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzMzLTMtMS0xLTQzMjM2MQ_6ada33c4-b1f0-4840-baa4-96e044479af1"
      unitRef="usd">1434832000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzIx_fd38237b-8d30-4476-865c-c3f36bcc8a46"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzM1_76c0ee90-16d5-4e30-880a-a7118cf33044"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmI2ZTZhMTUyNzliYjRiYTZiNGQ3NzU3ZDhmNWM5ZDU3XzU3_24c54c65-5397-4c8b-9e42-f2eeed881ca5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTEtMS0xLTQzMjM2MQ_19a50780-edce-40f7-a930-94afea5f6bc7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM1LTMtMS0xLTQzMjM2MQ_16b12f8f-4464-4728-b5ea-e606c8a443d3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzE4_80e139ed-80e6-48ed-9a9f-d7c21fa79e91"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzMy_1f08ab34-94af-46db-b41b-bb177fd60522"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzU0_71ad23c4-2509-45b6-b87e-ef09d7f44961"
      unitRef="shares">90411000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTAtMS0xLTQzMjM2MS90ZXh0cmVnaW9uOmYwMjY1NmMzOWVjYjQ3NGM5OWI3NTllOGQ5NmVlODg1XzYx_d8e788e2-9ad5-4a79-9ea4-1b4df749519d"
      unitRef="shares">97289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTEtMS0xLTQzMjM2MQ_8c7a40b1-db31-48bc-99f0-889dbbf41da7"
      unitRef="usd">90000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM2LTMtMS0xLTQzMjM2MQ_225fcb3c-ecf6-48ca-83d5-297805d03139"
      unitRef="usd">97000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM3LTEtMS0xLTQzMjM2MQ_9dbe0980-407a-4e57-b190-f3d9b9faaa7e"
      unitRef="usd">606935000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM3LTMtMS0xLTQzMjM2MQ_c3abca84-7066-4c2b-8bf9-8f89e81d1a01"
      unitRef="usd">540321000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM4LTEtMS0xLTQzMjM2MQ_4fd07d4f-a459-4dae-a568-f8862ba08a55"
      unitRef="usd">174487000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM4LTMtMS0xLTQzMjM2MQ_b610894a-fd98-4a8c-8b39-2cde29f15093"
      unitRef="usd">354337000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM5LTEtMS0xLTQzMjM2MQ_710a0e96-5f44-48b6-8907-a061d112b0ff"
      unitRef="usd">-69186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzM5LTMtMS0xLTQzMjM2MQ_288549ed-42e9-493b-a2e6-a43c0c22472c"
      unitRef="usd">-139247000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQwLTEtMS0xLTQzMjM2MQ_285f381e-b24c-41b5-a388-04ced18eb783"
      unitRef="usd">712326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQwLTMtMS0xLTQzMjM2MQ_bb6d708b-84bf-4559-894e-af7f6cd1b98d"
      unitRef="usd">755508000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQxLTEtMS0xLTQzMjM2MQ_4d1ee75c-613f-4b3a-aa10-5a63cf293ccb"
      unitRef="usd">163566000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQxLTMtMS0xLTQzMjM2MQ_349cc20c-aca5-4edb-8dc6-ed34fbc6acdc"
      unitRef="usd">180640000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQyLTEtMS0xLTQzMjM2MQ_816cccc3-5c41-482d-a60f-90fe8fe44020"
      unitRef="usd">875892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQyLTMtMS0xLTQzMjM2MQ_d5aceabc-b8b1-427e-8904-70fa867a38e9"
      unitRef="usd">936148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQzLTEtMS0xLTQzMjM2MQ_362c0206-fa23-4255-85f1-1972bf0fa531"
      unitRef="usd">16928252000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNjUvZnJhZzo4NDdjMGY4Y2ExYmY0ZTg1OWVlNGM2NjA1NDU3NDE1Yi90YWJsZTplYTJlYTRjYzI1MDk0MDk2OWI4OTc4ODUzODEwZTY4MS90YWJsZXJhbmdlOmVhMmVhNGNjMjUwOTQwOTY5Yjg5Nzg4NTM4MTBlNjgxXzQzLTMtMS0xLTQzMjM2MQ_879ee6cf-16ca-4d31-9812-0b7804573106"
      unitRef="usd">17121488000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtMS0xLTEtNDMyMzYx_2d385e3a-e2e3-44a0-b39d-7b669753f2d5"
      unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtMy0xLTEtNDMyMzYx_01555390-4d7f-4c4c-951f-a52df3fa8d36"
      unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMtNS0xLTEtNDMyMzYx_ee5489d2-b796-4089-b113-9a4fbe512a2d"
      unitRef="usd">994677000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtMS0xLTEtNDMyMzYx_500a7593-4ed4-490d-90a5-ee3cb380e61f"
      unitRef="usd">732602000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtMy0xLTEtNDMyMzYx_8b16fdcb-f28f-4e47-ab78-20ce5edccd1e"
      unitRef="usd">680615000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUtNS0xLTEtNDMyMzYx_86e02764-1097-46a7-9713-f018da173ab4"
      unitRef="usd">630435000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <dva:DebtRefinancingCharges
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctMS0xLTEtNDMyMzYx_f5606c5e-f236-4b0a-899f-057933c06494"
      unitRef="usd">0</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctMy0xLTEtNDMyMzYx_b46b1027-dcf1-445e-afc6-05e7b76dea61"
      unitRef="usd">0</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzctNS0xLTEtNDMyMzYx_995dd062-72aa-4f6a-9809-efe9d111dab9"
      unitRef="usd">86957000</dva:DebtRefinancingCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtMS0xLTEtNDMyMzYx_00783c63-0d04-4efe-bd5b-39b7d94239e1"
      unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtMy0xLTEtNDMyMzYx_578573c7-a7f8-4363-861d-e410a8642be6"
      unitRef="usd">102209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzgtNS0xLTEtNDMyMzYx_a044d800-5fc6-4c1d-a330-187567349288"
      unitRef="usd">91458000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktMS0xLTEtNDMyMzYx_681e6f7f-ffee-4036-9bd6-bdde9522def4"
      unitRef="usd">-75669000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktMy0xLTEtNDMyMzYx_83a21b69-ab01-42af-b1b7-b574b0363ed5"
      unitRef="usd">60483000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzktNS0xLTEtNDMyMzYx_4fca3f80-ba2e-488c-b05c-a72072660029"
      unitRef="usd">240848000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTEtMS0xLTQzMjM2MQ_23baacc7-c54f-4c61-b3ff-27a9186af5ba"
      unitRef="usd">-8773000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTMtMS0xLTQzMjM2MQ_9f18bcf7-86e0-4cf4-97b2-173dabce9786"
      unitRef="usd">-5215000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEwLTUtMS0xLTQzMjM2MQ_05da0e7b-f5d1-483f-a5f1-5a9f01e536ae"
      unitRef="usd">-13830000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:LossGainOnDispositionOfBusinessInterestsBeforeTax
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTEtMS0xLTQzMjM2MQ_cdf0ec5d-3607-484e-bb36-23621dade58e"
      unitRef="usd">0</dva:LossGainOnDispositionOfBusinessInterestsBeforeTax>
    <dva:LossGainOnDispositionOfBusinessInterestsBeforeTax
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTMtMS0xLTQzMjM2MQ_5fb6a06f-18bd-4db5-8fc6-d1b91b64b38f"
      unitRef="usd">0</dva:LossGainOnDispositionOfBusinessInterestsBeforeTax>
    <dva:LossGainOnDispositionOfBusinessInterestsBeforeTax
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzExLTUtMS0xLTQzMjM2MQ_4ec12103-74b8-4c4b-a4a0-e3397b38b992"
      unitRef="usd">24248000</dva:LossGainOnDispositionOfBusinessInterestsBeforeTax>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTEtMS0xLTQzMjM2MQ_a2594bc3-a98a-44bb-a72a-c35f04179f7c"
      unitRef="usd">-21693000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTMtMS0xLTQzMjM2MQ_0851b8ff-0d8f-4926-90d9-2d3b7bd1f886"
      unitRef="usd">-11231000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzEyLTUtMS0xLTQzMjM2MQ_53a60537-70bc-455d-ab8b-3aab4493942a"
      unitRef="usd">-747000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTEtMS0xLTQzMjM2MQ_4381b47f-5139-4707-b7b1-ac396590ec65"
      unitRef="usd">148394000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTMtMS0xLTQzMjM2MQ_f9439f0e-b68b-4ab6-aba6-a63bc5a0aed5"
      unitRef="usd">138140000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE0LTUtMS0xLTQzMjM2MQ_edb18e82-4748-469e-8b8f-621106357287"
      unitRef="usd">21087000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTEtMS0xLTQzMjM2MQ_c440dd36-5521-433b-b398-0e461d70bc67"
      unitRef="usd">757000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTMtMS0xLTQzMjM2MQ_ae29ed31-6e46-4266-b311-a3e8055992c7"
      unitRef="usd">-5720000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE1LTUtMS0xLTQzMjM2MQ_d30f1b3e-b9c2-41c1-bf03-dfdc756761a3"
      unitRef="usd">12349000</us-gaap:IncreaseDecreaseInInventories>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTEtMS0xLTQzMjM2MQ_85444a9d-3a87-4464-b0c9-12d6f0c6b87e"
      unitRef="usd">-27533000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTMtMS0xLTQzMjM2MQ_ad323b46-a9d2-4812-b32d-548e164aace6"
      unitRef="usd">-128661000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE2LTUtMS0xLTQzMjM2MQ_56ec39fc-9a4d-4768-b1fb-9d63b7cc901d"
      unitRef="usd">79277000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTEtMS0xLTQzMjM2MQ_23a2e56d-5000-45cd-a4eb-06de1ccf123f"
      unitRef="usd">50549000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTMtMS0xLTQzMjM2MQ_d9af165c-029e-4257-ac47-1cca0eaae483"
      unitRef="usd">26387000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE3LTUtMS0xLTQzMjM2MQ_b776f273-359e-40b3-b29f-10ed7a11bbe5"
      unitRef="usd">6123000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTEtMS0xLTQzMjM2MQ_2d5e3bce-eb92-448f-8b30-809cc091c873"
      unitRef="usd">87481000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTMtMS0xLTQzMjM2MQ_a6479853-cea1-4a24-9469-8954fafb0c99"
      unitRef="usd">-30320000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE4LTUtMS0xLTQzMjM2MQ_ff6cba83-03eb-43a6-aad8-eaf4d987655c"
      unitRef="usd">37200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTEtMS0xLTQzMjM2MQ_d25d0758-4ee9-44f1-bf44-63d91dc0b0c1"
      unitRef="usd">34536000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTMtMS0xLTQzMjM2MQ_ac2f0a47-e511-468e-8cc9-fa3958030667"
      unitRef="usd">-16717000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzE5LTUtMS0xLTQzMjM2MQ_21987118-33fa-4247-b299-5367ec508b2d"
      unitRef="usd">-20931000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTEtMS0xLTQzMjM2MQ_d4a3ce86-0245-4ff3-a72f-c38538b976cf"
      unitRef="usd">89955000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTMtMS0xLTQzMjM2MQ_d6750582-4e28-4043-b12b-7aee75009b4f"
      unitRef="usd">-93645000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIwLTUtMS0xLTQzMjM2MQ_0572fe0f-fbfd-4b67-89a5-6de8dbc3ff73"
      unitRef="usd">105637000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTEtMS0xLTQzMjM2MQ_4ceeffb9-8610-499a-a6fc-2ed8d8737952"
      unitRef="usd">-24103000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTMtMS0xLTQzMjM2MQ_dec448ae-032c-4e90-8083-e6b13f693683"
      unitRef="usd">36921000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIxLTUtMS0xLTQzMjM2MQ_60b1d25b-de8e-4663-b288-b78f5f0cbcbc"
      unitRef="usd">-87391000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTEtMS0xLTQzMjM2MQ_6d2d66b8-5816-4c40-ac09-aa7d8ca3595e"
      unitRef="usd">-15601000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTMtMS0xLTQzMjM2MQ_ee362926-e34e-4efb-a382-9bd0628816af"
      unitRef="usd">-6732000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIyLTUtMS0xLTQzMjM2MQ_528be780-0386-46f9-8b09-2490f76262b5"
      unitRef="usd">-19851000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTEtMS0xLTQzMjM2MQ_3b81e09a-a270-4fb2-b1a2-9db91dee7c86"
      unitRef="usd">1564570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTMtMS0xLTQzMjM2MQ_b201e98d-4e79-442d-8c8a-16614693519e"
      unitRef="usd">1930876000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzIzLTUtMS0xLTQzMjM2MQ_dba3e0b2-aae6-4acb-976d-85c9217ba078"
      unitRef="usd">1979028000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTEtMS0xLTQzMjM2MQ_5de7d78a-2dd3-42c5-b18a-6008abd4d68d"
      unitRef="usd">603429000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTMtMS0xLTQzMjM2MQ_b3827df7-609a-413d-80fa-2fc6580b68df"
      unitRef="usd">641465000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI1LTUtMS0xLTQzMjM2MQ_8d53a5e4-f171-4afd-bb29-308fbdbb95c6"
      unitRef="usd">674541000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTEtMS0xLTQzMjM2MQ_513fdfcf-9cb6-4ce5-ab33-cd1d919ce81e"
      unitRef="usd">57308000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTMtMS0xLTQzMjM2MQ_81c6ef0f-bd6e-48e3-9148-0d38139ed6c3"
      unitRef="usd">187050000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI2LTUtMS0xLTQzMjM2MQ_0f43f01d-640a-484c-9b17-81ebdf72a44a"
      unitRef="usd">182013000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTEtMS0xLTQzMjM2MQ_b27b09be-17b5-4c35-8940-f8ffc6f27b62"
      unitRef="usd">117582000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTMtMS0xLTQzMjM2MQ_6bdbc487-0c4d-459d-9aaf-ecc414573707"
      unitRef="usd">61464000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI3LTUtMS0xLTQzMjM2MQ_abc583fa-f971-4048-8de1-c4b0f000aa46"
      unitRef="usd">50139000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTEtMS0xLTQzMjM2MQ_7b440059-19bb-4e03-86d8-310ecf63a84f"
      unitRef="usd">129803000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTMtMS0xLTQzMjM2MQ_e5129126-0d7d-4457-be38-ce8dfddcfc79"
      unitRef="usd">30849000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI4LTUtMS0xLTQzMjM2MQ_260b2609-6650-4329-8810-e0b9baf41209"
      unitRef="usd">150701000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTEtMS0xLTQzMjM2MQ_e0f2588c-b2f0-4af8-9e1a-28b61d32c065"
      unitRef="usd">3590000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTMtMS0xLTQzMjM2MQ_24fd99d3-12e1-42c3-872d-63fcb6a6ee1b"
      unitRef="usd">2987000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzI5LTUtMS0xLTQzMjM2MQ_bf4ed3f9-8bcf-4903-9fa4-2a4229b57eb6"
      unitRef="usd">3757000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTEtMS0xLTQzMjM2MQ_88d91121-3936-410a-86af-278d729ead25"
      unitRef="usd">71125000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTMtMS0xLTQzMjM2MQ_df3b0938-1c53-478e-96f7-b23fe54a7e00"
      unitRef="usd">15849000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMwLTUtMS0xLTQzMjM2MQ_b99b0b3e-f897-4268-b149-4c16452952f4"
      unitRef="usd">151213000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTEtMS0xLTQzMjM2MQ_b6f301fa-1dea-44e6-baf2-d88936e8b5d3"
      unitRef="usd">3781000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTMtMS0xLTQzMjM2MQ_ee1ff909-58ae-43cd-91f9-2f0217e8bb95"
      unitRef="usd">12030000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMxLTUtMS0xLTQzMjM2MQ_8eeba1d4-c687-4670-81d9-d5611d5bf3ee"
      unitRef="usd">3491000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTEtMS0xLTQzMjM2MQ_c73beb6d-9c54-45e1-89e0-687b5ab7dac8"
      unitRef="usd">31885000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTMtMS0xLTQzMjM2MQ_bcb602aa-7165-4e52-a4ee-adfcced78d35"
      unitRef="usd">13924000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMyLTUtMS0xLTQzMjM2MQ_e2637053-cd16-41fb-9642-11ba3032a7a9"
      unitRef="usd">22341000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTEtMS0xLTQzMjM2MQ_f4adff87-7571-45e1-97bf-830310817db5"
      unitRef="usd">3962000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTMtMS0xLTQzMjM2MQ_ae0937d3-8fc1-4267-bf58-3118620cfad0"
      unitRef="usd">2944000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzMzLTUtMS0xLTQzMjM2MQ_91c781da-bb56-4300-9a04-92356e139de4"
      unitRef="usd">3139000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTEtMS0xLTQzMjM2MQ_79d4caac-e9b0-4554-8583-cba041890de9"
      unitRef="usd">782000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTMtMS0xLTQzMjM2MQ_c9a3657d-7940-444b-b381-62ad8b6c5070"
      unitRef="usd">745000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM0LTUtMS0xLTQzMjM2MQ_01f64c18-b8fd-402c-91eb-5239bdd9547a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTEtMS0xLTQzMjM2MQ_2134bc14-b63d-4bb3-b9ab-190b8be7ad8e"
      unitRef="usd">-630347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTMtMS0xLTQzMjM2MQ_c0a6abfe-4635-4302-bf5d-c4af6a087078"
      unitRef="usd">-784733000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM1LTUtMS0xLTQzMjM2MQ_4bae1451-8e32-43a8-a46b-298dbe276efb"
      unitRef="usd">-825371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTEtMS0xLTQzMjM2MQ_0b7f01f5-6a4a-4f81-a749-ccbbedb83396"
      unitRef="usd">2393116000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTMtMS0xLTQzMjM2MQ_640e41ca-fd41-43d4-b484-5927b551f378"
      unitRef="usd">1615370000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM3LTUtMS0xLTQzMjM2MQ_f465e912-d4a1-41d5-a519-95d208555e67"
      unitRef="usd">4046775000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTEtMS0xLTQzMjM2MQ_a744f377-7b6e-4496-b648-e767f259dd81"
      unitRef="usd">2404395000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTMtMS0xLTQzMjM2MQ_9eb2bb7a-d454-4928-bbe2-bd38f575e137"
      unitRef="usd">861115000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM4LTUtMS0xLTQzMjM2MQ_19c99c2d-8985-4c44-a7a1-e29297a08a2f"
      unitRef="usd">4110304000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <dva:DebtFinancingAndDebtRedemptionCosts
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTEtMS0xLTQzMjM2MQ_a4098aea-06ec-4fe7-bafc-5bb21b57859b"
      unitRef="usd">3000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTMtMS0xLTQzMjM2MQ_6b75734e-f263-43a2-8d4d-51b72fa5d9ac"
      unitRef="usd">9091000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzM5LTUtMS0xLTQzMjM2MQ_24561ad6-6a9c-4ff4-9724-319b8eee4440"
      unitRef="usd">105848000</dva:DebtFinancingAndDebtRedemptionCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTEtMS0xLTQzMjM2MQ_d4005b18-7866-48ee-bd30-7b6a1e6796cd"
      unitRef="usd">802228000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTMtMS0xLTQzMjM2MQ_e4474552-f139-42f6-a769-0f55573f702b"
      unitRef="usd">1538626000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQwLTUtMS0xLTQzMjM2MQ_09d94c01-65fe-4a3a-8662-902293f91a12"
      unitRef="usd">1458442000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTEtMS0xLTQzMjM2MQ_8d6387cc-cb9e-498d-b072-34c5bc2ad605"
      unitRef="usd">267946000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTMtMS0xLTQzMjM2MQ_6634536f-20a2-4aca-bf3d-0ab88fffa26f"
      unitRef="usd">244033000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQxLTUtMS0xLTQzMjM2MQ_dbf53f67-445f-4fc3-832a-25e72211e6b7"
      unitRef="usd">253118000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <dva:PaymentsRelatedToStockPurchasesAndAwards
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTEtMS0xLTQzMjM2MQ_bacac77e-3ac5-4395-95d6-aa08246c6bc7"
      unitRef="usd">37367000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <dva:PaymentsRelatedToStockPurchasesAndAwards
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTMtMS0xLTQzMjM2MQ_4a6f9f2f-7f32-48f1-aae3-5dc9b169e066"
      unitRef="usd">60001000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <dva:PaymentsRelatedToStockPurchasesAndAwards
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQyLTUtMS0xLTQzMjM2MQ_b223b624-1bc3-4b2d-88ac-7f44402f6ad1"
      unitRef="usd">975000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTEtMS0xLTQzMjM2MQ_4f8097e4-a5b1-4906-89a9-d8b6474ff335"
      unitRef="usd">14797000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTMtMS0xLTQzMjM2MQ_4cd40ac6-1a3e-4bdc-acec-721e370a7ecc"
      unitRef="usd">31754000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQzLTUtMS0xLTQzMjM2MQ_06274d2e-4978-45ae-9990-b06735f0d22b"
      unitRef="usd">42966000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTEtMS0xLTQzMjM2MQ_202472b2-c3f9-4138-9081-c4a41a90ca46"
      unitRef="usd">3673000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTMtMS0xLTQzMjM2MQ_53b3a4ca-9560-4a6f-88a3-04942cbb0db9"
      unitRef="usd">2880000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ0LTUtMS0xLTQzMjM2MQ_aee320e5-1259-4e80-8731-2d4c8360563e"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTEtMS0xLTQzMjM2MQ_ffa1c551-57c8-4c95-ac45-9d7b79b21bd8"
      unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTMtMS0xLTQzMjM2MQ_65cefd2e-db75-4453-8c17-7af00ba11629"
      unitRef="usd">20104000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ1LTUtMS0xLTQzMjM2MQ_048f5cef-3ea1-4e1e-90aa-638b4ccc88fa"
      unitRef="usd">7831000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTEtMS0xLTQzMjM2MQ_8ac7c084-8312-4f57-9fd4-2efd64eca74b"
      unitRef="usd">-1121128000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTMtMS0xLTQzMjM2MQ_8954dbde-6735-4ae3-a541-fdad003faa8e"
      unitRef="usd">-1082966000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ2LTUtMS0xLTQzMjM2MQ_41ad7a63-124c-4637-953a-cde3e6067db7"
      unitRef="usd">-1846777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTEtMS0xLTQzMjM2MQ_fcafc441-976f-4fc6-bf5b-cdb3df048440"
      unitRef="usd">-29066000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTMtMS0xLTQzMjM2MQ_2877af0f-8dfe-455a-90c4-0754ea79e03a"
      unitRef="usd">-10007000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzQ3LTUtMS0xLTQzMjM2MQ_260aede1-1955-4e21-8c00-07b066c3a5e7"
      unitRef="usd">-13808000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTEtMS0xLTQzMjM2MQ_9edd6eb5-257b-471a-a360-e519e464005e"
      unitRef="usd">-215971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTMtMS0xLTQzMjM2MQ_462325e6-7025-4b76-b566-2cf9c0c10e96"
      unitRef="usd">53170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUwLTUtMS0xLTQzMjM2MQ_24feb0c4-dbc8-4aaf-8de3-3a092f88d38f"
      unitRef="usd">-706928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTEtMS0xLTQzMjM2MQ_f1f47420-6bc1-4b37-b526-5f325be3ea1a"
      unitRef="usd">554960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTMtMS0xLTQzMjM2MQ_6dd51862-7d2c-48c7-8686-6f6385544d17"
      unitRef="usd">501790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icc55a2cfbea54cdea8e6196c16ac8898_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUxLTUtMS0xLTQzMjM2MQ_ea0e90d6-b3dd-49d7-8f4a-b6ebc086d0cd"
      unitRef="usd">1208718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTEtMS0xLTQzMjM2MQ_0fff2d2a-09da-4b1f-a45f-55a5a49a4cd6"
      unitRef="usd">338989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTMtMS0xLTQzMjM2MQ_21cd4b96-04eb-4abf-939f-d9b738beb6dc"
      unitRef="usd">554960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzEvZnJhZzplOWFiNTFhYjE0MzQ0MDJlODMxZmRjNTdhODMwNmFjZi90YWJsZTphYjRiNzVlNzNjMmU0ZGZhYmViNWVlNDRiNjVkMzI3MC90YWJsZXJhbmdlOmFiNGI3NWU3M2MyZTRkZmFiZWI1ZWU0NGI2NWQzMjcwXzUyLTUtMS0xLTQzMjM2MQ_86f0b661-b7dd-45db-bdae-e91c5ec49bc1"
      unitRef="usd">501790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="if800aa66d9654ca986d7798400011ed4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMS0xLTEtNDMyMzYx_d1683414-9253-485d-ac42-dfa958a1e8d0"
      unitRef="usd">1180376000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie4c968889cbc45d597559733ee1e7c06_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMy0xLTEtNDMyMzYx_9f727a5b-8c2c-4db5-9392-bb5d79b1a678"
      unitRef="shares">125843000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4c968889cbc45d597559733ee1e7c06_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtNS0xLTEtNDMyMzYx_8f048ba1-2e29-42e2-88cd-1c6664657a10"
      unitRef="usd">126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id50bdbd4176c403094afc0a6a0816442_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtNy0xLTEtNDMyMzYx_ea9c7a30-9f13-4f58-8bab-25b4781cac71"
      unitRef="usd">749043000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc1b76d4d30a4a71b13b8f4c91fb24db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtOS0xLTEtNDMyMzYx_9f3770e6-53c0-42bb-8dfb-9d63cd1dc091"
      unitRef="usd">1431738000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1a01430579214274b518179095689fae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTEtMS0xLTQzMjM2MQ_4c1fdd55-71ee-48f4-8ab5-b25961a43018"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a01430579214274b518179095689fae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTMtMS0xLTQzMjM2MQ_6ea3bc77-67e5-4bb0-b23b-f1d8c8b7d845"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie24f4ad97c874df3a74ffade9b367052_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTUtMS0xLTQzMjM2MQ_8d9ac5a1-630c-4e22-a31b-ab1e9adf65a8"
      unitRef="usd">-47498000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2a7799ea30042b3b5483fabf59a20c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTctMS0xLTQzMjM2MQ_d7fc9c69-adea-4fef-97a7-931fb24745d7"
      unitRef="usd">2133409000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee5116d4e90c42a2a3c059b946951971_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzQtMTktMS0xLTQzMjM2MQ_6cbf7696-685b-4b84-91d4-830302585360"
      unitRef="usd">185833000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMS0xLTEtNDMyMzYx_458207a9-06a1-4b20-a07a-399ede2f8e72"
      unitRef="usd">141879000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctOS0xLTEtNDMyMzYx_1119926a-0796-4395-afce-3972062248d2"
      unitRef="usd">773642000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMTctMS0xLTQzMjM2MQ_a8ee37c4-77e2-452a-9d34-eee1509f18c7"
      unitRef="usd">773642000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzctMTktMS0xLTQzMjM2MQ_4024315a-661d-45f9-87f2-bc1122f81be7"
      unitRef="usd">79156000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i43ebc619161a4e329c3ae8f647a68ea0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzgtMTUtMS0xLTQzMjM2MQ_b034bb03-c5d5-416d-af0b-c30aa0368894"
      unitRef="usd">-18656000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzgtMTctMS0xLTQzMjM2MQ_e36ffcec-83d8-470e-aa56-5a9aadf28e97"
      unitRef="usd">-18656000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktMy0xLTEtNDMyMzYx_d17eeb45-5d79-4a77-b564-f06cd69b80b0"
      unitRef="shares">222000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktNS0xLTEtNDMyMzYx_7bcbe91e-05fe-4f85-ae2d-69bb8e790a0f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktNy0xLTEtNDMyMzYx_6b7565f6-7906-41a1-a75c-5fcf435aee54"
      unitRef="usd">17148000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzktMTctMS0xLTQzMjM2MQ_865abc20-dc66-43c4-a8df-c97fdf08c637"
      unitRef="usd">17148000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTMtMS0xLTQzMjM2MQ_9306b077-9ada-4947-bf42-4fad4689d865"
      unitRef="shares">345000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTUtMS0xLTQzMjM2MQ_83a8eb99-8fc3-4799-a0ac-389fdc1ba15a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTctMS0xLTQzMjM2MQ_c9d29dbb-0dee-4021-afb3-1003698ba33b"
      unitRef="usd">-17801000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEwLTE3LTEtMS00MzIzNjE_27ddc493-e3ff-4f74-92b8-5defd3d3c87a"
      unitRef="usd">-17801000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzExLTctMS0xLTQzMjM2MQ_4ca1d972-f38d-4eeb-ae75-9364827f8915"
      unitRef="usd">90007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzExLTE3LTEtMS00MzIzNjE_b8d994a7-b0d5-41e7-8cdd-d78737e2e22c"
      unitRef="usd">90007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEzLTEtMS0xLTQzMjM2MQ_8e59b40d-2f2c-480d-baa3-358417d6d14f"
      unitRef="usd">163175000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzEzLTE5LTEtMS00MzIzNjE_821b0301-5137-4ad2-96a2-a9d713fa6ba7"
      unitRef="usd">89943000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE0LTEtMS0xLTQzMjM2MQ_34ba7a71-5a71-4cb9-b3fd-94020302a54b"
      unitRef="usd">30154000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions
      contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE0LTE5LTEtMS00MzIzNjE_d9d520e1-cf65-49b7-9b6a-86dce6ebb5b5"
      unitRef="usd">12812000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE1LTEtMS0xLTQzMjM2MQ_3d1f77ea-831b-42cd-9154-de59e151a548"
      unitRef="usd">3215000</dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures
      contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE1LTE5LTEtMS00MzIzNjE_c89bf644-f936-4e3d-9583-14840d9dc07f"
      unitRef="usd">248000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTEtMS0xLTQzMjM2MQ_1027bec9-67b6-4ed4-87f8-50cc3a9496dd"
      unitRef="usd">7771000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTctMS0xLTQzMjM2MQ_b89d76d5-430e-4f58-92ad-1356228d4407"
      unitRef="usd">4364000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTE3LTEtMS00MzIzNjE_7288c21d-ceb3-47f5-be69-83d172d017ea"
      unitRef="usd">4364000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i49b3e6c4f00d44f6a7743efbb29372e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE2LTE5LTEtMS00MzIzNjE_a3b7739e-f4a7-41f9-a3e6-591bb1d48b67"
      unitRef="usd">4424000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i46104711eb724866acbf5a1ca361a38e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTEtMS0xLTQzMjM2MQ_fd65ad26-5728-4803-a03f-0edcd48c19a6"
      unitRef="usd">151780000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTctMS0xLTQzMjM2MQ_cd7dc3b8-5711-45ca-ba81-6e03034c4b78"
      unitRef="usd">-151780000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE3LTE3LTEtMS00MzIzNjE_21ad0778-d81e-4c4a-a98a-0120d4857265"
      unitRef="usd">-151780000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTExLTEtMS00MzIzNjE_020b4261-5882-42b4-95ad-8b48d0a3e18c"
      unitRef="shares">16477000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTEzLTEtMS00MzIzNjE_9363757d-cd32-402b-9ed2-b80d78c85491"
      unitRef="usd">1446767000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE4LTE3LTEtMS00MzIzNjE_293e6f63-5acd-4ada-b829-92265af597af"
      unitRef="usd">1446767000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTMtMS0xLTQzMjM2MQ_d36662f9-a809-474d-a47e-9d63322e3ff1"
      unitRef="shares">16477000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic14fdac8e85d40699f273a014b4c25ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTUtMS0xLTQzMjM2MQ_5eabe2a0-d8ed-4bc8-9fc2-fa98bb4b0740"
      unitRef="usd">16000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTctMS0xLTQzMjM2MQ_0f648f7d-6fd6-4b8e-8cdc-99cd8fc1b915"
      unitRef="usd">93908000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i368fc702d8944be7b4aa430be1d5e734_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTktMS0xLTQzMjM2MQ_ffbdd447-4c22-4c86-9307-770276e8cd08"
      unitRef="usd">1352843000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTExLTEtMS00MzIzNjE_84a6e54b-0332-4f34-befb-f248933bbe75"
      unitRef="shares">-16477000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i50da97fe1b274f648672b559db7812e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTEzLTEtMS00MzIzNjE_3c952277-67b5-4834-9b53-23fdbdbed840"
      unitRef="usd">-1446767000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i337dd76d544f44b4a8fff19a7ef3ad42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzE5LTE3LTEtMS00MzIzNjE_89509270-bc9b-4b34-a563-7a23316b8ca9"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i09cbd163c566489c8ab76a850aeba968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTEtMS0xLTQzMjM2MQ_5f4b4f3d-b0d5-47a0-896c-da624aa732ae"
      unitRef="usd">1330028000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTMtMS0xLTQzMjM2MQ_43defead-cc5f-4dbe-9ba3-d6c9966c0820"
      unitRef="shares">109933000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e6c60da9a50491bbc678d9f0d6a59e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTUtMS0xLTQzMjM2MQ_b11778d9-8569-4793-8235-fe7a4aed94e0"
      unitRef="usd">110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2c4cc40ee544f8d8fc58a0361ea6027_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTctMS0xLTQzMjM2MQ_819d2112-76ab-4de0-b1b3-3a2af4f0278a"
      unitRef="usd">597073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17d2f751df2e4644ba91a72008a0765e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTktMS0xLTQzMjM2MQ_93644bcf-f98b-4b33-86af-8c78cf2352b4"
      unitRef="usd">852537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTExLTEtMS00MzIzNjE_03abb0e8-6fdb-4fca-87bd-13f06ca76944"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cfae378030d4db1937c4e1ebf0e54d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTEzLTEtMS00MzIzNjE_870edba5-5127-4129-9585-0f6681244405"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i757a0e9ab6594add994f294dd3cdbf66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE1LTEtMS00MzIzNjE_06e61641-a1c4-4cd0-9ea2-460f6c708185"
      unitRef="usd">-66154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5427ec717e8648059aadaee70b6593f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE3LTEtMS00MzIzNjE_ac449e3e-aa96-4279-8ed9-0fc00c71e096"
      unitRef="usd">1383566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72de044ff982442ba895166a41f82244_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIwLTE5LTEtMS00MzIzNjE_bab16fae-1544-415d-a787-e1726b4231d0"
      unitRef="usd">183186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTEtMS0xLTQzMjM2MQ_5bfc1c4e-dbf9-4f03-9ba5-a86c37bf2d3a"
      unitRef="usd">160359000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTktMS0xLTQzMjM2MQ_fa31cd19-82c7-42c6-a1c8-129073ce57d5"
      unitRef="usd">978450000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTE3LTEtMS00MzIzNjE_c55b29e4-5ec3-4f15-a163-f1eff5da206b"
      unitRef="usd">978450000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzIzLTE5LTEtMS00MzIzNjE_91652fbf-20b4-44cb-9c16-b04895305e5d"
      unitRef="usd">72953000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e4eaf9f852e421fbf29ec7d95adf14a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI0LTE1LTEtMS00MzIzNjE_eef6b3fa-d72b-4f2b-bf5d-28883215ec5d"
      unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI0LTE3LTEtMS00MzIzNjE_1f2a40eb-ed41-447f-88f6-cef4369c922d"
      unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTMtMS0xLTQzMjM2MQ_b8a61982-1813-4740-a31f-23f6fb8dc35c"
      unitRef="shares">203000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTUtMS0xLTQzMjM2MQ_3cdefe46-891f-4fff-85a1-215d8bc86dd3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTctMS0xLTQzMjM2MQ_22b0c37b-0968-42ca-b964-d5b291b72c39"
      unitRef="usd">19626000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI1LTE3LTEtMS00MzIzNjE_02b07713-3b3c-4cf5-b091-0585e23f5a9b"
      unitRef="usd">19626000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTMtMS0xLTQzMjM2MQ_0a44752a-b67e-447e-b289-20f100d3987f"
      unitRef="shares">1030000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTUtMS0xLTQzMjM2MQ_a303afb4-a638-4746-840e-3a411df8d965"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTctMS0xLTQzMjM2MQ_74e7c909-a0f7-4e64-b120-218eecce4491"
      unitRef="usd">-80642000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI2LTE3LTEtMS00MzIzNjE_58aa8186-d2f5-4200-a3f2-88896827abe1"
      unitRef="usd">-80641000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI3LTctMS0xLTQzMjM2MQ_62f6d6ab-f101-40bb-8b4a-2cbe2a5636c2"
      unitRef="usd">100714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI3LTE3LTEtMS00MzIzNjE_95c14375-ea06-49e8-a0d9-d4d048d0bf29"
      unitRef="usd">100714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI5LTEtMS0xLTQzMjM2MQ_1a971f76-2999-410c-8cfb-440f899e5c0b"
      unitRef="usd">159259000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzI5LTE5LTEtMS00MzIzNjE_d7be3235-d099-4a55-910a-c0352f00b4de"
      unitRef="usd">84774000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMwLTEtMS0xLTQzMjM2MQ_de24c25e-bb72-47aa-8244-80dfa318db2a"
      unitRef="usd">22672000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions
      contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMwLTE5LTEtMS00MzIzNjE_99810708-6b67-4bb2-a069-2c228ed9c4c8"
      unitRef="usd">9082000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTEtMS0xLTQzMjM2MQ_520dcd10-2b1f-41a6-bdb4-350d025c22da"
      unitRef="usd">5903000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTctMS0xLTQzMjM2MQ_8cf2d588-80da-4b3f-a84e-ffe1b458389e"
      unitRef="usd">264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTE3LTEtMS00MzIzNjE_1fd5d123-4b30-465e-a80e-23e4b4a996b6"
      unitRef="usd">264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures
      contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMxLTE5LTEtMS00MzIzNjE_b32e2345-548e-4690-b759-ac7d1020de24"
      unitRef="usd">1250000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTEtMS0xLTQzMjM2MQ_8501dd63-a764-4f27-87cf-e30ed838e812"
      unitRef="usd">588000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTctMS0xLTQzMjM2MQ_763470c2-9185-4727-a10c-cc55cdfd0480"
      unitRef="usd">13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTE3LTEtMS00MzIzNjE_cc64d57f-f725-43eb-9c24-1c1d0af4cc6a"
      unitRef="usd">-13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i9b9479cfe03244498b1ddb8792757c46_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMyLTE5LTEtMS00MzIzNjE_987378cf-18c7-4f92-b171-3a37e2e0bf65"
      unitRef="usd">1057000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="idaf2e0629d36497da38ae664ee7f8e69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTEtMS0xLTQzMjM2MQ_dc33e4c7-a327-4ea4-b390-35816db3de21"
      unitRef="usd">75717000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTctMS0xLTQzMjM2MQ_4c25c5a6-be86-467d-acb2-12bb0adc7953"
      unitRef="usd">-75717000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzMzLTE3LTEtMS00MzIzNjE_16708998-18cc-45b8-905b-cac001681311"
      unitRef="usd">-75717000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTExLTEtMS00MzIzNjE_c2382bde-6080-492c-85f2-758aa7e6e11d"
      unitRef="shares">13877000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTEzLTEtMS00MzIzNjE_e949ba43-59dd-4a38-bc16-acac82bae3b2"
      unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM0LTE3LTEtMS00MzIzNjE_a24e6c51-6d39-4986-a81b-88bf56d82b79"
      unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTMtMS0xLTQzMjM2MQ_d90a7a82-4b7d-4c30-8f98-ba440150cb77"
      unitRef="shares">13877000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i89fc8f160e0e4f529764ea23be02d9b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTUtMS0xLTQzMjM2MQ_3c1b264f-78db-42bc-85b9-225bd3aa14c6"
      unitRef="usd">14000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTctMS0xLTQzMjM2MQ_f3056b26-f893-4f04-b451-d4b9b156a0e6"
      unitRef="usd">69352000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id27ef1c8373d443180d1d4ec0da07e61_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTktMS0xLTQzMjM2MQ_420bc374-aa1e-44b0-a637-1934346eae36"
      unitRef="usd">1476650000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTExLTEtMS00MzIzNjE_663a240a-1faa-431e-86c1-116c4316b36c"
      unitRef="shares">-13877000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i4144c10c186349e8b0f75eb1a4781206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTEzLTEtMS00MzIzNjE_55d64478-102f-4d08-a23f-a0a2ecf2069b"
      unitRef="usd">-1546016000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM1LTE3LTEtMS00MzIzNjE_4fc7dd48-b06f-4e00-a9a6-192aa5fb4539"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTctMS0xLTQ5MDIxMQ_11cf0dd9-8fa1-4196-a457-e6991102cab4"
      unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="if27174288e0445f8870a700e378d7299_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE3LTEtMS00OTAyMTE_f7d7a6a7-ff6b-48b2-9f54-67cfc0d9c1b0"
      unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6ab32047366140518741cdd1c29b2986_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTEtMS0xLTQzMjM2MQ_5da68b8c-e42e-41fe-8c22-f932a0af6d20"
      unitRef="usd">1434832000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTMtMS0xLTQzMjM2MQ_135bf988-a728-4a72-8725-0c45d09bb6ee"
      unitRef="shares">97289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTUtMS0xLTQzMjM2MQ_eb7260ec-a575-4c67-b6d4-be5a280555a4"
      unitRef="usd">97000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTctMS0xLTQzMjM2MQ_849c48b2-1939-436d-b3fc-dc6c003ba354"
      unitRef="usd">540321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d81a8050455482f899360e81a78be21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTktMS0xLTQzMjM2MQ_40778cf5-8fe0-42ad-a399-32359509c964"
      unitRef="usd">354337000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTExLTEtMS00MzIzNjE_d6d5466a-d801-49d0-b0ee-34504c52dec1"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTEzLTEtMS00MzIzNjE_1713cfea-12c1-45f4-86b9-068cff5e68b7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d6896e2941a48e2963273fd62c1f8a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE1LTEtMS00MzIzNjE_f19551fc-aba2-4fbb-a58f-8528a343ea12"
      unitRef="usd">-139247000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99bfee231c604920b47c088b54ff3344_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE3LTEtMS00MzIzNjE_61fc4954-ead5-4a39-9732-4a15d657f4cd"
      unitRef="usd">755508000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if842ebd0fa3647a485eee028263590d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZTo5ZDY4YWY5ZjUwYmE0MzI1YTkyMDcyYWQwZWRmM2MxZS90YWJsZXJhbmdlOjlkNjhhZjlmNTBiYTQzMjVhOTIwNzJhZDBlZGYzYzFlXzM2LTE5LTEtMS00MzIzNjE_68e1d013-93a7-4db8-a9cc-c01b9ff1acb6"
      unitRef="usd">180640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6ab32047366140518741cdd1c29b2986_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMS0xLTEtNDMyMzYx_5da68b8c-e42e-41fe-8c22-f932a0af6d20"
      unitRef="usd">1434832000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMy0xLTEtNDMyMzYx_135bf988-a728-4a72-8725-0c45d09bb6ee"
      unitRef="shares">97289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i387afcd55d3346499dfe079c68d6aafd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtNS0xLTEtNDMyMzYx_eb7260ec-a575-4c67-b6d4-be5a280555a4"
      unitRef="usd">97000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbe5d0b2df8e4a5e9aeaf9c4bdc1201b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtNy0xLTEtNDMyMzYx_849c48b2-1939-436d-b3fc-dc6c003ba354"
      unitRef="usd">540321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d81a8050455482f899360e81a78be21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtOS0xLTEtNDMyMzYx_40778cf5-8fe0-42ad-a399-32359509c964"
      unitRef="usd">354337000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTEtMS0xLTQzMjM2MQ_d6d5466a-d801-49d0-b0ee-34504c52dec1"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5534c7a107a14c66a3dbd6d754cbed0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTMtMS0xLTQzMjM2MQ_1713cfea-12c1-45f4-86b9-068cff5e68b7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d6896e2941a48e2963273fd62c1f8a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTUtMS0xLTQzMjM2MQ_f19551fc-aba2-4fbb-a58f-8528a343ea12"
      unitRef="usd">-139247000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99bfee231c604920b47c088b54ff3344_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTctMS0xLTQzMjM2MQ_61fc4954-ead5-4a39-9732-4a15d657f4cd"
      unitRef="usd">755508000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if842ebd0fa3647a485eee028263590d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzQtMTktMS0xLTQzMjM2MQ_68e1d013-93a7-4db8-a9cc-c01b9ff1acb6"
      unitRef="usd">180640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMS0xLTEtNDMyMzYx_7a48cfe9-5749-4964-954c-1f96e6595d93"
      unitRef="usd">151379000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i50253e4de73648958a1dc9b043930734_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtOS0xLTEtNDMyMzYx_1106946d-038b-4e2c-ad21-5d7385bf86d1"
      unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMTctMS0xLTQzMjM2MQ_26390f88-eb9d-4a37-b96d-df5530a2b033"
      unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzYtMTktMS0xLTQzMjM2MQ_7397abc9-dd57-4a26-a68e-56d71db22dd5"
      unitRef="usd">69864000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3dbaa5362c6b426aa3e151ee9c01964c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzctMTUtMS0xLTQzMjM2MQ_01ab01cd-b318-4ea1-92c3-cefd151349f2"
      unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzctMTctMS0xLTQzMjM2MQ_63452859-2f03-497b-8c70-04b3f29c32aa"
      unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtMy0xLTEtNDMyMzYx_a711da4d-c644-4923-adc9-dbad222a9b12"
      unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtNS0xLTEtNDMyMzYx_5512098b-aa7f-4cd2-8afe-2667e8ef3a23"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtNy0xLTEtNDMyMzYx_ad2ce2f2-0cce-4cc5-bb25-6e6edd3200a3"
      unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzgtMTctMS0xLTQzMjM2MQ_a429813b-6485-42fd-9154-bb8a19f1a3af"
      unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktMy0xLTEtNDMyMzYx_4c89b458-55ae-4473-ab24-5117b1a2129f"
      unitRef="shares">932000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktNS0xLTEtNDMyMzYx_4225034a-7ff4-4c59-8897-6f9dc33f0b28"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktNy0xLTEtNDMyMzYx_91207093-02cf-44b9-81d8-e218a55ba97c"
      unitRef="usd">-55921000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzktMTctMS0xLTQzMjM2MQ_0e776824-5810-449b-b151-c757299f474f"
      unitRef="usd">-55920000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEwLTctMS0xLTQzMjM2MQ_17784afe-f779-41ea-b1ac-f0610b4d29e5"
      unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEwLTE3LTEtMS00MzIzNjE_4475cc64-c253-491a-a127-94de8f1d6ee8"
      unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEyLTEtMS0xLTQzMjM2MQ_fb360eb4-31fb-4d0e-8651-e12765c874e6"
      unitRef="usd">176957000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEyLTE5LTEtMS00MzIzNjE_76135a58-21f3-46d9-b59b-4512ade609fe"
      unitRef="usd">90989000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEzLTEtMS0xLTQzMjM2MQ_6095b9a2-d838-4936-b528-49a6b548cc54"
      unitRef="usd">10962000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzEzLTE5LTEtMS00MzIzNjE_8b7820d2-bbbb-461b-9bc1-a78fbda9e1bd"
      unitRef="usd">3835000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTEtMS0xLTQzMjM2MQ_458fa826-93a4-44b1-a19f-373251e7e786"
      unitRef="usd">2392000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTctMS0xLTQzMjM2MQ_db444fb0-10cb-4bf1-b82a-fe65359ae547"
      unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTE3LTEtMS00MzIzNjE_4912f70b-ef10-4a8d-8d9b-122ec6dd368a"
      unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE0LTE5LTEtMS00MzIzNjE_88a45c96-03cb-42c9-b783-74601f80c155"
      unitRef="usd">866000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTEtMS0xLTQzMjM2MQ_215f455f-a411-42b8-8dee-13a656d5a12e"
      unitRef="usd">11670000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTctMS0xLTQzMjM2MQ_10f63136-665b-44f8-be18-07bc68d3884d"
      unitRef="usd">6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTE3LTEtMS00MzIzNjE_96e148e0-e62b-47e1-85a2-21c8e1d5c4fd"
      unitRef="usd">6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE1LTE5LTEtMS00MzIzNjE_df87beba-2b6a-41be-8392-67e4aaaa5756"
      unitRef="usd">193000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTEtMS0xLTQzMjM2MQ_ffe8a130-3c37-4c82-875b-65a2f9880f30"
      unitRef="usd">-62487000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTctMS0xLTQzMjM2MQ_8770201e-58a7-4ef7-8c90-6b7972118dba"
      unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE2LTE3LTEtMS00MzIzNjE_b5323705-5996-408c-96d9-1c0fac707897"
      unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TemporaryEquityOtherChanges
      contextRef="i21270d38624c47798e98f2a9c7c100c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTEtMS0xLTU1MjM3Mg_665f503b-2d0d-4610-936c-2940ffe99716"
      unitRef="usd">457000</us-gaap:TemporaryEquityOtherChanges>
    <dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE3LTEtMS01NTIzNzI_9dcfb76a-bc45-4ff8-9bb0-51addca4de13"
      unitRef="usd">0</dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations>
    <dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations
      contextRef="i6ab81aecffd14af3a6d3820f3853ae91_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE5LTEtMS01NTIzNzI_03a21cf0-7b36-4cd8-835a-417ed97590e7"
      unitRef="usd">457000</dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTExLTEtMS00MzIzNjE_dd97214f-aad6-4f47-befb-97d429f6f5a8"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTEzLTEtMS00MzIzNjE_70b4ba11-b74b-45be-ae49-7e59b03983bb"
      unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE3LTE3LTEtMS00MzIzNjE_c87bfbdb-feb3-4139-92bd-57c9a126aa73"
      unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTMtMS0xLTQzMjM2MQ_1a9a157d-64b2-47bc-b365-f94935ab58c6"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i964f1cf020924d1aa111eeeb34a0fd62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTUtMS0xLTQzMjM2MQ_90565ab8-a15b-440d-9b01-a8d241400dd9"
      unitRef="usd">8000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTctMS0xLTQzMjM2MQ_b9500a25-a331-4be5-9b85-575a0d779258"
      unitRef="usd">47596000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i50253e4de73648958a1dc9b043930734_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTktMS0xLTQzMjM2MQ_538e4964-4edc-4e40-848f-1024896ec35c"
      unitRef="usd">740250000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTExLTEtMS00MzIzNjE_9f724765-7de4-45f3-b0c2-d07d9262cf69"
      unitRef="shares">-8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i67243aca27084ed2926bbc023f0b24fb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTEzLTEtMS00MzIzNjE_c543fd62-2699-4005-b1bb-37becd5258ae"
      unitRef="usd">-787854000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibba051f247e041dabcc31736129c1f12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzE4LTE3LTEtMS00MzIzNjE_e8eaa277-5cae-426c-8e1a-ff79a3a087eb"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ice9acef4149d442db28cf471388f4e4d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTEtMS0xLTQzMjM2MQ_40f3273b-8355-4477-b3d7-d3afdd8fc65c"
      unitRef="usd">1348908000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i52ec121281ae42de864df9afaf5bbce5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTMtMS0xLTQzMjM2MQ_3e424148-0796-4199-ba92-29ef6fc7e2a2"
      unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52ec121281ae42de864df9afaf5bbce5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTUtMS0xLTQzMjM2MQ_3cbf3df6-19b5-4032-bc45-0af42d62f263"
      unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i356a876fece547c98e1997006099bed6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTctMS0xLTQzMjM2MQ_f5f98eac-e2a7-486f-9354-ef9da568ce69"
      unitRef="usd">606935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id55b58bdbade49e9b33062b2a125387c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTktMS0xLTQzMjM2MQ_000af394-71f1-43a7-a5a8-dd97ffa90141"
      unitRef="usd">174487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icf95daa74ecc406b87ec09f0ad0760f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTExLTEtMS00MzIzNjE_29d20359-e093-4f63-9a75-0250b1700e83"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf95daa74ecc406b87ec09f0ad0760f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTEzLTEtMS00MzIzNjE_c052f2f9-1995-4b90-ae7a-4460b64c6d7d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i260caeb3a4e44b659a7def8d723d8f28_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE1LTEtMS00MzIzNjE_ca3af46f-9ade-41fc-a158-93ad5206066d"
      unitRef="usd">-69186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f29989a080c4de4b210d915a9c0f8ff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE3LTEtMS00MzIzNjE_247c41c9-9ba5-430d-8d95-8e470fd05836"
      unitRef="usd">712326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ea9631c41ae445d9079a93421c94e37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yNzQvZnJhZzphNmZiM2EzMTM4Njg0YmI4OTgxZWVkM2FiMGZkNDY2MS90YWJsZToyZjQyNzdiYTdkMzE0YzE5YmVlZjQxMDI2NzMxNTVmNi90YWJsZXJhbmdlOjJmNDI3N2JhN2QzMTRjMTliZWVmNDEwMjY3MzE1NWY2XzIwLTE5LTEtMS00MzIzNjE_aea1b8a6-9817-42d3-ad3d-56846c8d4ea1"
      unitRef="usd">163566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTAw_c3cf5cdd-2a99-40ea-81e8-9834488090b7">Organization and summary of significant accounting policies&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations are comprised of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or end stage kidney disease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ESRD or ESKD). As of December&#160;31, 2022, the Company operated or provided administrative services through a network of 2,724 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 199,400 patients. In addition, as of December&#160;31, 2022, the Company operated or provided administrative services to a total of 350 outpatient dialysis centers serving approximately 45,600 patients located in 11 countries outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, the Company completed the sale of its prior DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC (Optum), a subsidiary of UnitedHealth Group Inc. The effects of the DMG sale on the Company's consolidated financial statements have been reported in discontinued operations for all periods presented. For information on how the DMG sale has affected these results, see Note 22.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD). Prior year classifications have been conformed to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment frequency than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of our commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated in the period services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, for most of its VBC arrangements, the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, for most of its VBC arrangements the Company does not include third party medical costs in its reported revenues and expenses, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income includes interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other income. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 5 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of the right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date.The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets, and interest accretion on operating lease liabilities, are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 10 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in LIBOR interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 13 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2022, third parties held noncontrolling equity interests in 689 consolidated legal entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement. See Note 24 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 24 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which extends the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors will cease or become non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The Company is currently assessing the other effects this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2021-08 requires application of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU creates an exception to the general recognition and measurement principle in ASC 805 and will result in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Early adoption is permitted for all entities. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <dva:NumberOfSites
      contextRef="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzc2Ng_b8f22124-c6bb-4841-b4ed-511c531850dd"
      unitRef="clinic">2724</dva:NumberOfSites>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="id0e8fe1fe28d4c0f935c4349b97c8df2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzgwNQ_c6d07944-51b2-4c1d-b5d6-680e33f919bd"
      unitRef="state">46</us-gaap:NumberOfStatesInWhichEntityOperates>
    <dva:NumberOfCustomers
      contextRef="icf6d468c617d466c8c07ffbf3361572d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzg3OA_eb57689e-5afc-4911-998a-3e16544af64d"
      unitRef="patient">199400</dva:NumberOfCustomers>
    <dva:NumberOfSites
      contextRef="ib6392b172fe84693a759b4ef47376ca3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0Xzk4NQ_1af36fbc-790a-46db-b206-28dab7afd040"
      unitRef="clinic">350</dva:NumberOfSites>
    <dva:NumberOfCustomers
      contextRef="ie34b55b3589b41aa8b4dc4e6ab94e9e7_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzEwMzg_00e07b2d-7d68-46c0-9657-f4fd296fa85d"
      unitRef="patient">45600</dva:NumberOfCustomers>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="ib6392b172fe84693a759b4ef47376ca3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzEwNjE_5c363a93-3ce3-4ea5-afa3-84a6321425b4"
      unitRef="country">11</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDkz_f86aaeab-ecb0-4552-8ca9-e2200f350362">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD). Prior year classifications have been conformed to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTMw_11549ed8-e9e3-4dc9-91ab-8113cd56a866">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTM1_405fafb4-b576-42d0-9e03-d549bafecf6d">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment frequency than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of our commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated in the period services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, for most of its VBC arrangements, the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, for most of its VBC arrangements the Company does not include third party medical costs in its reported revenues and expenses, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;</dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock>
    <dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzUxNzU_6d006d81-3752-4035-bcd2-53758222fef7"
      unitRef="number">0.80</dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor>
    <dva:OtherNonoperatingIncomeExpensePolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTUz_e1a373e5-4c43-4d5e-8844-a4f25969bdb5">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income includes interest income on cash and cash equivalents and short- and long-term investments, realized and unrealized gains and losses recognized on investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;</dva:OtherNonoperatingIncomeExpensePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYy_d59cbcba-0f89-4158-a3e1-b3125923874d">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDk0_ff3fa891-2cda-41f9-a819-7b387644ece7">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYw_128d98a3-ce73-4234-bb59-53445bdc0b69">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other income. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 5 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTYz_960af1b8-1a8c-4edc-8a2c-e9a0fa9f846b">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTIz_74bb7e83-3305-4c45-81c2-c8df93feba47">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTMx_09cb1565-cc53-4ee3-8882-a4e5a4363319">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of the right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date.The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets, and interest accretion on operating lease liabilities, are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg2_579479b3-e7b5-45c7-a6e7-59452d497d48">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDk2_18437822-13c1-4498-954e-52f4a4d4116e">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg3_6abad38e-abb2-46e3-9012-131fc1fec302">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDgy_fe1396e2-f2b4-404b-9333-309c15c9ec1d">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 10 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <dva:InsuranceAndSelfInsurancePolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDgz_8c49dd01-bb39-4aea-83c9-60fed56b4c7f">Self-insuranceThe Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</dva:InsuranceAndSelfInsurancePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTQz_ea46e292-0f0f-4021-8883-201dafda6d5d">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDg0_4954e743-0c33-4cd0-a286-f11e794a7eed">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MDkw_da428e8b-3e26-454d-ab0d-673c2c6b7cb2">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in LIBOR interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 13 for further details.&lt;/span&gt;&lt;/div&gt;The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. These cap agreements have variable legs priced at LIBOR to match the variable rates incurred on the senior secured credit facility borrowings that they hedge. Like the senior secured credit facilities, these interest rate cap agreements include a mechanism for transition to an alternative variable base rate upon cessation of LIBOR. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTQ0_1af61039-cd90-4312-9491-dbe0c0e38fc1">Noncontrolling interestsNoncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes.&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzU0OTc1NTg0ODkxMw_ee739966-bc07-44fd-88d8-08551c6f4731"
      unitRef="entity">689</dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTI3_799aac4e-e260-4b90-9f7c-66c0d3500f80">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement. See Note 24 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 24 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODAvZnJhZzoyMzRmYTNmOWI1ZmQ0ZjM3YTU4MjQ2NDhkZmQyNjU5NC90ZXh0cmVnaW9uOjIzNGZhM2Y5YjVmZDRmMzdhNTgyNDY0OGRmZDI2NTk0XzI2MTA4_92a588ef-f7b3-4d22-afbd-9243ad0e2671">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which extends the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors will cease or become non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The Company is currently assessing the other effects this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2021-08 requires application of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU creates an exception to the general recognition and measurement principle in ASC 805 and will result in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Early adoption is permitted for all entities. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMyMzU_7377d7b1-4e48-4563-9d98-aec511944588">Revenue recognition and accounts receivable&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,596,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,576,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,169,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,169,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,370,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,540,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,550,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December&#160;31, 2020 has also been recast to conform to this presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. integrated care and disease management business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 1, there are significant risks associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues including determining applicable primary and secondary coverage, changes in patient coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $1,113,499 and $1,174,123 as of December&#160;31, 2022 and 2021, respectively. Approximately 18% and 16% of the Company&#x2019;s patient services accounts receivable balances as of December&#160;31, 2022 and 2021, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2022. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMyMzc_902f85b5-2c9e-4d3e-9fa8-b8d9fd0b76cc">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,596,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,576,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,169,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,169,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,370,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,540,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,550,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;During the first quarter of 2021, the Company realigned the classification of revenue previously disclosed in the "Other government" category to the "Medicare and Medicare Advantage" category for certain government-reimbursed plans which have structure and payment characteristics similar to traditional Medicare Advantage plans. The classification of revenue for these plans for the year ended December&#160;31, 2020 has also been recast to conform to this presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other consists primarily of management service fees earned in the respective Company line of business as well as other non-patient revenue from the Company's U.S. IKC and other ancillary services and international operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id71233621bbd4804ad59b2cce80ee34a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzMtMS0xLTEtNDMyMzYx_06f0456e-5958-4f06-aac8-937cf07a0094"
      unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzMtNS0xLTEtNDMyMzYx_af6da4a2-97bb-4864-aff1-ed0288b9c519"
      unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8d2c1e7f78214f40be85e6cb8292eb45_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzQtMS0xLTEtNDMyMzYx_424ab235-7547-417c-8876-861fbce0440b"
      unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzQtNS0xLTEtNDMyMzYx_a0ff548d-d2d7-4fcd-9055-a838e2c82682"
      unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i61831cf914934370a0e350538f48dd0e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtMS0xLTEtNDMyMzYx_6903711a-5c90-4cd6-a34b-5de9b6ed2e63"
      unitRef="usd">336991000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i63a634cd0d2347eeba744537d4975ff3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtMy0xLTEtNDMyMzYx_5ae7f623-840c-49ad-abef-39f3e817e646"
      unitRef="usd">464921000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia5e37ec44c0d4b32bdf6a4f6631a509d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzUtNS0xLTEtNDMyMzYx_72db835d-4ac9-4d7e-ae2c-f58135096ee4"
      unitRef="usd">801912000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i71c1650937a14aa6b693db780617d335_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtMS0xLTEtNDMyMzYx_58b0ea6d-852b-4268-9a8d-b2d871b5a760"
      unitRef="usd">3437306000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtMy0xLTEtNDMyMzYx_dc02079e-dee7-41fb-8009-11d009cbced2"
      unitRef="usd">223216000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzYtNS0xLTEtNDMyMzYx_723474b8-4076-499d-8fc9-9c5f9638e1b8"
      unitRef="usd">3660522000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="i89a5fb336b324120926fdf3e7acd509f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzgtMy0xLTEtNDMyMzYx_1116c05a-50e3-4738-aae4-5cb1524bf466"
      unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzgtNS0xLTEtNDMyMzYx_99bff99d-7be6-49e7-a259-1d9c2fc8ac35"
      unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="icbd379d095ba4b25a0520096ae331749_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzktMy0xLTEtNDMyMzYx_c61f9785-7869-4860-a08a-d489216752eb"
      unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i9d8fb9d3a6bd4abebec72c869c1d68de_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzktNS0xLTEtNDMyMzYx_b45508ba-8255-4c1a-ad1e-ac3ceca1b502"
      unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="if858c83dbb1b4a3fb3e7e43b5eb15135_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEwLTMtMS0xLTQzMjM2MQ_a878d0f4-6e42-454c-9d25-e68255d1e7a0"
      unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ia0933b6a7e064593981ce578ddfc7964_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEwLTUtMS0xLTQzMjM2MQ_5eda80d4-94b2-4748-b971-ad525542944c"
      unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="if46a5e0f67ed4bad96cbd9179fa563a0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTEtMS0xLTQzMjM2MQ_1c733099-6474-43fb-b59f-ea1b9c8d83f0"
      unitRef="usd">24437000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i3a7b6a5928a24b238a1f7131f1574774_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTMtMS0xLTQzMjM2MQ_4718df3b-fce7-4b58-8724-f8c1d20c1e4f"
      unitRef="usd">44092000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i4a984146d6674799aba080454fdc2cda_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzExLTUtMS0xLTQzMjM2MQ_0d0d779d-6f15-40e5-b4c3-53f66846f2aa"
      unitRef="usd">68529000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="ia742be54e94c45f2b3dd8ff5d6c056e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTEtMS0xLTQzMjM2MQ_27a4dbb6-b1c0-4265-b9c4-296fd9a21436"
      unitRef="usd">-87035000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b009a1142c248539196c3fba5d59fb2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTMtMS0xLTQzMjM2MQ_65fc31db-4af5-4376-be00-e017f2c4dac2"
      unitRef="usd">-4206000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEyLTUtMS0xLTQzMjM2MQ_74113f7f-562a-4fa5-b852-63b002a41809"
      unitRef="usd">-91241000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTEtMS0xLTQzMjM2MQ_91508860-76d6-43d3-9986-cc6417ec08e8"
      unitRef="usd">10512774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTMtMS0xLTQzMjM2MQ_23e637c9-cec3-4b68-8fb0-1ae1371c9ccb"
      unitRef="usd">1097120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZToyNTRiMjdlN2JiZDQ0YWJlYjZjODczOTJlMjVhYWNmOS90YWJsZXJhbmdlOjI1NGIyN2U3YmJkNDRhYmViNmM4NzM5MmUyNWFhY2Y5XzEzLTUtMS0xLTQzMjM2MQ_8cb9688c-7fd5-4c59-b186-2070dc8a80fb"
      unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7bd3f694f7e44856ae0923f71f737ae4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzMtMS0xLTEtNDMyMzYx_43076949-4c49-4b28-9e7f-9f2be9a055e2"
      unitRef="usd">6133235000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzMtNS0xLTEtNDMyMzYx_c6638507-6957-41ba-bb16-b538f5ad342f"
      unitRef="usd">6133235000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i482fd86c04c1456c8e86866bab4d7940_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzQtMS0xLTEtNDMyMzYx_8017a110-f359-4c98-bf8a-5b7ecc334f20"
      unitRef="usd">782430000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzQtNS0xLTEtNDMyMzYx_3a9fab04-4a65-4994-921c-7d743badfcf3"
      unitRef="usd">782430000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i63e08b129ee741c09e555e16d959b1c5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtMS0xLTEtNDMyMzYx_cf35888d-fc79-4bbd-b950-0a7ddc9cc35a"
      unitRef="usd">328256000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1da226c056b94d07adbacb4d2befd882_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtMy0xLTEtNDMyMzYx_441817ae-5a4f-45a7-92d7-47f5c8d9b89d"
      unitRef="usd">463385000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic954305add924c439027278f45b35571_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzUtNS0xLTEtNDMyMzYx_1f88cf72-fe87-47a9-8aa2-6ba194ab2497"
      unitRef="usd">791641000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i23acb46414744f3295a01b88b12f0852_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtMS0xLTEtNDMyMzYx_1128b82b-ad29-4ea2-84f1-76c099873b2a"
      unitRef="usd">3397697000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtMy0xLTEtNDMyMzYx_b2c1da61-43ec-4bca-b75c-34003d54bce0"
      unitRef="usd">199024000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzYtNS0xLTEtNDMyMzYx_e225b908-cd68-47dc-815c-14f0f6104453"
      unitRef="usd">3596721000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="ifed0d2be726f4c74911502d210cc0c64_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzgtMy0xLTEtNDMyMzYx_982a2d38-3d99-4077-9a83-363546fd43fc"
      unitRef="usd">326696000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i68017902fedc4e08a0297c03cc914ee1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzgtNS0xLTEtNDMyMzYx_3053781d-4494-45c5-b920-2ee923d8e391"
      unitRef="usd">326696000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="iafefc99a68e9484292f1297292ffcc0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzktMy0xLTEtNDMyMzYx_a190023b-67f6-4515-b762-e4d7fdc2b908"
      unitRef="usd">1321000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ieb9deead10ea4c73b63ddbee6d636abc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzktNS0xLTEtNDMyMzYx_be935c36-136a-4d04-b51c-86c1829916fe"
      unitRef="usd">1321000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i67eef4aaf49d49ccbe998507fe732c17_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEwLTMtMS0xLTQzMjM2MQ_b037eb88-537f-4d82-83cc-42393ca9dd68"
      unitRef="usd">15553000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ie9c0a4120a1845d5bc73fcfa1a59e906_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEwLTUtMS0xLTQzMjM2MQ_5cd1d045-e87d-402b-b682-bf86c18b658d"
      unitRef="usd">15553000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i4439bdfa6abe4378a88454a4104bf810_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTEtMS0xLTQzMjM2MQ_2734b2fe-be20-486f-9f3d-d006d352fa6e"
      unitRef="usd">25345000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i52c2f5e21bcf4d3c8ee4481538d06f47_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTMtMS0xLTQzMjM2MQ_586fe95c-64ea-49d0-820a-137847ce28c5"
      unitRef="usd">40945000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i1724a3d8642c4b77958c204145d9b59e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzExLTUtMS0xLTQzMjM2MQ_398e0071-44e0-4410-98aa-6627919e515f"
      unitRef="usd">66290000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="i0b6a7965dcd6428eb9c75d5330f6c0fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTEtMS0xLTQzMjM2MQ_b28844f5-f084-4489-9927-0f3ea7f7f33a"
      unitRef="usd">-90796000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6712e682bfcc4d9f8819cac2f889a384_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTMtMS0xLTQzMjM2MQ_3b763f6b-8090-45d7-8cf5-c134e8ab3a98"
      unitRef="usd">-4294000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEyLTUtMS0xLTQzMjM2MQ_c4701c72-ac2a-481a-8fa6-d12b91c03763"
      unitRef="usd">-95090000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTEtMS0xLTQzMjM2MQ_b7615f94-f702-4948-8289-a61050a3a61f"
      unitRef="usd">10576167000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTMtMS0xLTQzMjM2MQ_a95e9bd0-c43e-4b91-a52f-edc8ba6651f9"
      unitRef="usd">1042630000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTo4NTkwNmFhZjM5NmE0ZWI2OWEwM2M5YTg1ZDgyZWExZi90YWJsZXJhbmdlOjg1OTA2YWFmMzk2YTRlYjY5YTAzYzlhODVkODJlYTFmXzEzLTUtMS0xLTQzMjM2MQ_975b0fc3-e59e-431f-849a-5ae7ce3c8560"
      unitRef="usd">11618797000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie15e5f5845074315a06e0d1ae4277176_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzMtMS0xLTEtNDMyMzYx_36925de5-f910-4d0e-8b5a-b5fba4c7ad90"
      unitRef="usd">6169226000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i47b6e5a2190441af8606765112836eee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzMtNS0xLTEtNDMyMzYx_eb7f7b61-1e1e-41e0-bdbf-6df45afe7b9f"
      unitRef="usd">6169226000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaca689ecc20e4fe0876e7b122b0bc25a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzQtMS0xLTEtNDMyMzYx_b0cb7589-c7d9-4f93-b945-9a1085cbd47f"
      unitRef="usd">744862000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzQtNS0xLTEtNDMyMzYx_724450a7-78b7-4029-9e62-250a828828a4"
      unitRef="usd">744862000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i94685d28e10e4104afa0fc7accb57c02_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtMS0xLTEtNDMyMzYx_3660e877-d387-4944-98c4-d25d714db656"
      unitRef="usd">334714000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic71b76b330e14df99ec3824e8fc1d7c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtMy0xLTEtNDMyMzYx_cc2b4d2b-7efb-4d47-b8c4-104791d1b7da"
      unitRef="usd">380584000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ife78a29c23534d2a8188fe47f55108a0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzUtNS0xLTEtNDMyMzYx_33d11ee7-e158-40a6-bc6b-264e923b5d68"
      unitRef="usd">715298000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8bfd61b594e04154b072d87e97ad8774_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtMS0xLTEtNDMyMzYx_d5a3368d-212f-40c3-be84-2d99af322fde"
      unitRef="usd">3370562000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtMy0xLTEtNDMyMzYx_69c061db-4731-43f6-8164-6067c9bcb52b"
      unitRef="usd">170394000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzYtNS0xLTEtNDMyMzYx_69eb077a-378c-4a03-9606-d6d5a608b6dc"
      unitRef="usd">3540956000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="i45bb8de9b00141a78c540283fa20d761_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzgtMy0xLTEtNDMyMzYx_898c9f71-76c4-43a7-8627-d42ef399ee66"
      unitRef="usd">419662000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i47b6e5a2190441af8606765112836eee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzgtNS0xLTEtNDMyMzYx_0a99f5d9-da73-4b34-8b8e-7ff4e4a40127"
      unitRef="usd">419662000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i9e3ef454cab24926be400fa579222ae9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzktMy0xLTEtNDMyMzYx_338ec4b0-5839-442d-bc8d-dd8889310c7c"
      unitRef="usd">1227000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i48bab95f3ac24eda9d52592cefb49055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzktNS0xLTEtNDMyMzYx_ad7afc73-bafa-4f19-bf87-afeddeb986f8"
      unitRef="usd">1227000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i24c2b37db7694a169ba3332f7179d329_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEwLTMtMS0xLTQzMjM2MQ_eecf4740-7c29-4e17-bf72-c44f6c2e4824"
      unitRef="usd">33246000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="icff84a3ad73f4d5db5b094bef553e4dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEwLTUtMS0xLTQzMjM2MQ_56dec09c-acd9-4291-a1f0-147de4d31980"
      unitRef="usd">33246000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i77373f4271f44dbfa26dd7f49f949448_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTEtMS0xLTQzMjM2MQ_5a5656a0-0775-4c49-ac71-7ca900d76150"
      unitRef="usd">40571000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i55cc0568452c48b58599e76cbde4fd51_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTMtMS0xLTQzMjM2MQ_1ab148bf-08f9-4061-9552-0085cfcfdfec"
      unitRef="usd">47585000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="iad1cf19f60904659aa80c183b19b6dfb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzExLTUtMS0xLTQzMjM2MQ_9b0fb7cb-1beb-42de-828a-5cb1cf8fa1da"
      unitRef="usd">88156000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="ida4e3d014e894c2994a8742fc9556a3c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTEtMS0xLTQzMjM2MQ_e38861ca-2581-4838-821d-29dc6356a02c"
      unitRef="usd">-145286000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7ab9fa77fa447caa055395318311262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTMtMS0xLTQzMjM2MQ_f279847e-9ba8-4c1b-97d6-ba8413679e46"
      unitRef="usd">-16743000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEyLTUtMS0xLTQzMjM2MQ_e9cb307e-ecf1-4607-a6e1-f12f2c4a232e"
      unitRef="usd">-162029000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTEtMS0xLTQzMjM2MQ_8617215b-baef-443f-a24e-5cb6431dcaed"
      unitRef="usd">10514649000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTMtMS0xLTQzMjM2MQ_91154d5c-0573-4c04-a31f-00f598a50fda"
      unitRef="usd">1035955000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90YWJsZTpmOWQ4YTA1NTJjYjk0ZDVkOGJjNzM1NWMzMzcxNDdjZS90YWJsZXJhbmdlOmY5ZDhhMDU1MmNiOTRkNWQ4YmM3MzU1YzMzNzE0N2NlXzEzLTUtMS0xLTQzMjM2MQ_0b10f184-f56b-4a8b-b437-2ed5246a87a7"
      unitRef="usd">11550604000</us-gaap:Revenues>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI1NDM_750151c9-dd1a-4555-883e-a170d7397fb2"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i47bf51c50ea244faa3f0128c677d6f4a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI1OTQ_f325c691-2138-4358-8277-b652a6ee78c4"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i892eb918a47245d0a1e1b8efd2c4dc9a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI4Nzk_850a045f-17ef-413a-8120-9d2e86c92fdf"
      unitRef="usd">1113499000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5ddfba6879ce435ea2183e425ab9fb97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI4ODY_aeb3bfc5-ce1a-4520-a586-dac6d622b4db"
      unitRef="usd">1174123000</us-gaap:AccountsReceivableNetCurrent>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI5MzQ_23d05d0e-d088-49e5-878f-76df756066a9"
      unitRef="number">0.18</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="i88924eaa86cb4ed39e38a15a834b05ca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzI5NDE_35329a61-c045-4997-8964-7e7afb3feb6d"
      unitRef="number">0.16</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:AccountsReceivablePeriodOutstanding
      contextRef="i4eae893f308e45cc8671c45f27dd95c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMwNTM_1a34c3fc-7ad6-46c4-86e3-9be7493fc7cc">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMwNzI_4fc8682b-0114-462c-8ce5-51d70ccfebed"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue
      contextRef="iaedf8dbec52a412e999eb8b8b3560486_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODMvZnJhZzozNjJhYTE4M2I4ZGI0MzkwODc0MDIwMzA2NDM4ZTIyZC90ZXh0cmVnaW9uOjM2MmFhMTgzYjhkYjQzOTA4NzQwMjAzMDY0MzhlMjJkXzMxMDE_6e95d036-cee9-416c-b846-bc50690ed7c2">P1Y</us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg4Mg_f8b47af1-dd86-4584-b86d-394917dd1ede">Earnings&#160;per share&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg4MQ_8bfc35ba-70af-44f9-aaf4-930baee7e45a">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90ZXh0cmVnaW9uOjlhYzExZmU4NWU0ODRiYTA5ZjEwMWQxNmVkMmM3NTk3Xzg3OA_e7c10f37-5d8a-4d98-964b-9e826e959781">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income (loss) attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtMS0xLTEtNDMyMzYx_9696f61d-9968-49ec-bc9e-9f71296429a7"
      unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtMy0xLTEtNDMyMzYx_0456ca5a-e4e7-456e-ac29-134de1a41aaf"
      unitRef="usd">978450000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzMtNS0xLTEtNDMyMzYx_d7c7ab0d-e4d7-48ce-a525-ea1cd85e7fef"
      unitRef="usd">783295000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtMS0xLTEtNDMyMzYx_a032ef1e-6788-4c7e-9fa9-f8cd41fcf3e1"
      unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtMy0xLTEtNDMyMzYx_1b5c43e5-c443-4912-9f5d-ca7e41588117"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzQtNS0xLTEtNDMyMzYx_a85b1e69-0895-45a0-8bc7-876e84f9da3e"
      unitRef="usd">-9653000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtMS0xLTEtNDMyMzYx_de2d7441-2220-4ce4-9804-c367a5a66a6d"
      unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtMy0xLTEtNDMyMzYx_1e27cf07-11f1-42bd-878f-6f6798f2ef4e"
      unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzUtNS0xLTEtNDMyMzYx_d0011813-0b73-44a0-a5ec-5998d5ec36b9"
      unitRef="usd">773642000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtMS0xLTEtNDMyMzYx_e03724af-269f-4170-8b8a-fd269f642ba4"
      unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtMy0xLTEtNDMyMzYx_f4ecf64a-8d06-4ba0-933d-700ab0bd2148"
      unitRef="shares">105230000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzgtNS0xLTEtNDMyMzYx_b1e84782-44fb-4c4d-8d36-87ab049cb903"
      unitRef="shares">119797000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktMS0xLTEtNDMyMzYx_703430ad-af64-421f-b2a1-9842ce6805ea"
      unitRef="shares">2842000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktMy0xLTEtNDMyMzYx_3b6ddfff-c230-41ab-9dc2-de3ed1f5f7b2"
      unitRef="shares">4718000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzktNS0xLTEtNDMyMzYx_2d456b1f-4c7c-4529-a53e-7fa7eb4e728e"
      unitRef="shares">2826000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTEtMS0xLTQzMjM2MQ_ffa6a7fd-6ec0-4009-9a75-123c6d015393"
      unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTMtMS0xLTQzMjM2MQ_3670fb45-3ab2-4ce9-bb45-54b2ff0e077a"
      unitRef="shares">109948000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEwLTUtMS0xLTQzMjM2MQ_3c399e4f-931f-42bc-9e54-a04554d03c36"
      unitRef="shares">122623000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTEtMS0xLTQzMjM2MQ_d1f13661-33c2-465a-8692-ca1019e2ef31"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTMtMS0xLTQzMjM2MQ_796b3127-146e-4b0e-bbf3-993fac549e6a"
      unitRef="usdPerShare">9.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzEzLTUtMS0xLTQzMjM2MQ_62f80181-513f-4a37-97af-a3f0c6bb6daa"
      unitRef="usdPerShare">6.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTEtMS0xLTQzMjM2MQ_b2f7306d-4d26-4465-a639-85909743e64f"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTMtMS0xLTQzMjM2MQ_f09849bb-6650-4af8-b171-b85535f0ab1b"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE0LTUtMS0xLTQzMjM2MQ_6fa712e0-0f41-4291-bd9b-2c05bfff8db9"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTEtMS0xLTQzMjM2MQ_d2680893-b9f5-42ac-bbce-b60ec3597b91"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTMtMS0xLTQzMjM2MQ_16751f0b-a879-490e-a11f-4466aa259f9c"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE1LTUtMS0xLTQzMjM2MQ_fb867ab0-25c4-46a2-b964-9d437f30a03d"
      unitRef="usdPerShare">6.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTEtMS0xLTQzMjM2MQ_c7755c73-8307-40a7-a3ab-949604b916cb"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTMtMS0xLTQzMjM2MQ_4990c8de-403f-4f96-85fd-e31e72f1596c"
      unitRef="usdPerShare">8.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE4LTUtMS0xLTQzMjM2MQ_dca85895-9057-4050-ac1c-510e6fdac2f4"
      unitRef="usdPerShare">6.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTEtMS0xLTQzMjM2MQ_60fc1b76-ccb5-445b-977c-c167b02d167c"
      unitRef="usdPerShare">0.14</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTMtMS0xLTQzMjM2MQ_1afc3929-9e7e-4fd1-8ce2-6608d40176a7"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzE5LTUtMS0xLTQzMjM2MQ_e187cf62-c9a7-42e2-bb45-d3986badd4ec"
      unitRef="usdPerShare">-0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTEtMS0xLTQzMjM2MQ_ca706add-12da-44c1-932b-5ec20a946bb8"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTMtMS0xLTQzMjM2MQ_0e53b85b-e209-408c-a9ba-fb11522b309f"
      unitRef="usdPerShare">8.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIwLTUtMS0xLTQzMjM2MQ_fd63b458-df8e-4535-b982-b27139974939"
      unitRef="usdPerShare">6.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTEtMS0xLTQzMjM2MQ_07a8e764-9441-4bea-9d52-40490d763f1b"
      unitRef="shares">1058000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTMtMS0xLTQzMjM2MQ_da04e765-1ef0-4e84-82f4-6263b94f342c"
      unitRef="shares">116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yODkvZnJhZzo5YWMxMWZlODVlNDg0YmEwOWYxMDFkMTZlZDJjNzU5Ny90YWJsZToxMjVjMTdkNDNkMTY0N2Q3OGUzNDg0ZmZkYjAwOWEyNC90YWJsZXJhbmdlOjEyNWMxN2Q0M2QxNjQ3ZDc4ZTM0ODRmZmRiMDA5YTI0XzIyLTUtMS0xLTQzMjM2MQ_1f66e2a6-8801-464b-ad2b-d76c74694ecf"
      unitRef="shares">2301000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0Xzc5Ng_2d9693a3-e406-41cf-874c-cbd33f448f13">Restricted cash and equivalentsThe Company had restricted cash and cash equivalents of $94,903 and $93,060 at December&#160;31, 2022 and 2021, respectively. Substantially all of the restricted cash and equivalents balance at December&#160;31, 2022 is held in trust to satisfy insurer and state regulatory requirements related to the wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company and the remaining restricted cash and cash equivalents held at December&#160;31, 2022 represents cash pledged to third parties in connection with the Company's ancillary operations.</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0Xzk3_b4389ba4-638d-4f54-b8df-139a3d65396a"
      unitRef="usd">94903000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTIvZnJhZzo2Y2QyZTVlNmUyMzg0YTM3OGYwZDY0MDg5MzFkNzI4NC90ZXh0cmVnaW9uOjZjZDJlNWU2ZTIzODRhMzc4ZjBkNjQwODkzMWQ3Mjg0XzEwNA_07059240-1b3f-43d2-b172-dfb65ad6cf95"
      unitRef="usd">93060000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTk_462d78d7-282e-4cb6-817c-0fd3c3d54b31">Short-term and long-term investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company holds certain equity investments that have readily determinable fair values from public&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;markets. The Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTY_6547cbde-8cb7-4992-a430-f5d26e3338c9">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i472c110640b34063a31c98fa592e7be7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMS0xLTEtNDMyMzYx_12aa6e73-9035-45e1-aee5-691320189b2e"
      unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i472c110640b34063a31c98fa592e7be7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMy0xLTEtNDMyMzYx_4d0c62e8-0aec-441d-aff3-7a5e56caa065"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i472c110640b34063a31c98fa592e7be7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItNS0xLTEtNDMyMzYx_c049cff8-f614-4b7c-a36b-ba39596b096b"
      unitRef="usd">82879000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5b372339e32a430185d84a645290c6a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItNy0xLTEtNDMyMzYx_2a4b2d2e-2352-4ff9-b3bf-9867692105ea"
      unitRef="usd">23226000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5b372339e32a430185d84a645290c6a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItOS0xLTEtNDMyMzYx_734793a9-31db-4947-af73-c2c778e209db"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i5b372339e32a430185d84a645290c6a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzItMTEtMS0xLTQzMjM2MQ_6485241b-7480-49a9-8b1f-991313ff2443"
      unitRef="usd">23226000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMS0xLTEtNDMyMzYx_e36c4ada-5291-4292-a5ff-ee43db728383"
      unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMy0xLTEtNDMyMzYx_f5d2ac01-2922-426c-aa7a-0acb5665cfed"
      unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i61e6177dbf07446383109217efb2dbd7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtNS0xLTEtNDMyMzYx_b082d43c-fd10-45c2-be91-3f4eef1c8b3b"
      unitRef="usd">39143000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtNy0xLTEtNDMyMzYx_8b5491bd-0d4a-4fbc-a064-1a071eb00280"
      unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtOS0xLTEtNDMyMzYx_34b2a17e-8b90-477c-a820-06e27fa80be4"
      unitRef="usd">48598000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i9a9cdc79a81d405f862f8b518d12d4e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzMtMTEtMS0xLTQzMjM2MQ_e395d481-069b-48a8-9083-7ae375854d69"
      unitRef="usd">48598000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMS0xLTEtNDMyMzYx_4a68dc16-513b-4e02-890f-6d0a84e7ba4c"
      unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMy0xLTEtNDMyMzYx_41452aff-5ff3-4001-86db-7df8a6d0375c"
      unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtNS0xLTEtNDMyMzYx_65eeef6c-6665-4147-a4da-024159252f71"
      unitRef="usd">122022000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtNy0xLTEtNDMyMzYx_fbfbf3a3-0d38-4aff-89d4-dad4668dd892"
      unitRef="usd">23226000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtOS0xLTEtNDMyMzYx_dc812737-ba08-418f-93be-d452bfe04173"
      unitRef="usd">48598000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzQtMTEtMS0xLTQzMjM2MQ_47145979-d618-4f54-8584-790aa5c14271"
      unitRef="usd">71824000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMS0xLTEtNDMyMzYx_260ede19-2c9c-4f66-8ea2-2b66154daa8d"
      unitRef="usd">67872000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id0dedc540e3748a180d94fe4b0c46a64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMy0xLTEtNDMyMzYx_c27c534a-ac95-4db9-8c18-64c5152d0561"
      unitRef="usd">9821000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtNS0xLTEtNDMyMzYx_65106a0b-ee12-4b79-a78d-2d0c71f9eee7"
      unitRef="usd">77693000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtNy0xLTEtNDMyMzYx_e8d31f71-cfa3-4773-820e-ad505a7adcc8"
      unitRef="usd">8227000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i07a7a6c01df54ffe95479935e6df2ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtOS0xLTEtNDMyMzYx_328387ae-b6ea-43fd-9c0a-aa008d7f533e"
      unitRef="usd">14083000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzUtMTEtMS0xLTQzMjM2MQ_1af47e08-549b-4399-ad9e-e1b9baf8a2e4"
      unitRef="usd">22310000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMS0xLTEtNDMyMzYx_2e821977-7986-4b60-a457-c4e2dc1dc64c"
      unitRef="usd">15007000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i02a47a9e4ba544f1a9cd835d606410ff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMy0xLTEtNDMyMzYx_28d77d51-2b72-4fb0-b8d9-6a1aaa6c73b2"
      unitRef="usd">29322000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtNS0xLTEtNDMyMzYx_b8ac94ef-3f8c-4088-85c2-e285dbaf4bb3"
      unitRef="usd">44329000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtNy0xLTEtNDMyMzYx_ee4d7113-27c5-4cd5-99aa-3029dda22888"
      unitRef="usd">14999000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2adb818e8c884ebf9a40f34a6969b8d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtOS0xLTEtNDMyMzYx_06afb960-d8e2-42d6-a6b3-e4bbd187e118"
      unitRef="usd">34515000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzYtMTEtMS0xLTQzMjM2MQ_068f3130-89f3-4315-96de-7d5a2c13f0cc"
      unitRef="usd">49514000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMS0xLTEtNDMyMzYx_8d83822b-5342-4304-9cca-7d2aed48826a"
      unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMy0xLTEtNDMyMzYx_51914e7e-e80c-47cc-88fb-2465e5c7507f"
      unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctNS0xLTEtNDMyMzYx_5307e7d9-6393-48f0-8ee5-f737e08fb8fa"
      unitRef="usd">122022000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctNy0xLTEtNDMyMzYx_50980e67-a813-496c-9bcb-5584e4992f32"
      unitRef="usd">23226000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctOS0xLTEtNDMyMzYx_b55a4fc0-1630-4bc1-8dbf-23624536c0f0"
      unitRef="usd">48598000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90YWJsZTpmNDZiZWQ3MmUyNjU0NGYyOTAxZGQ3MjM2YjIyOWJkZi90YWJsZXJhbmdlOmY0NmJlZDcyZTI2NTQ0ZjI5MDFkZDcyMzZiMjI5YmRmXzctMTEtMS0xLTQzMjM2MQ_2acace04-2e58-4f87-9d99-c30f443c0b91"
      unitRef="usd">71824000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTUvZnJhZzowMThlOTQ5M2NmZmE0YTljYWY0ZjcwNjQzZDYzNzM1ZC90ZXh0cmVnaW9uOjAxOGU5NDkzY2ZmYTRhOWNhZjRmNzA2NDNkNjM3MzVkXzE2OTI_292d1024-91ee-4c6a-af53-4304348dbd49">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time &lt;/span&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company holds certain equity investments that have readily determinable fair values from public&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;markets. The Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90ZXh0cmVnaW9uOjY5M2JlNTUyMWZlNzRiYTdhMTRiZTI1MjU1MTJkYmEzXzgy_3506245b-2826-402a-9cfb-aa628a37227b">Other receivables&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables were comprised of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <dva:ScheduleOfOtherReceivablesTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90ZXh0cmVnaW9uOjY5M2JlNTUyMWZlNzRiYTdhMTRiZTI1MjU1MTJkYmEzXzg2_26114b62-e793-40cf-a704-a9fc38c1ecb7">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables were comprised of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfOtherReceivablesTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i96447c36e9e04484a7110d4eb4997b4c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzItMS0xLTEtNDMyMzYx_01cdb887-2c04-4769-ab49-121a85f04351"
      unitRef="usd">303225000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ib33e8b9fed27435c92a9faac2bd00b84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzItMy0xLTEtNDMyMzYx_93086feb-860c-4bce-a0c1-c93ba307dbf0"
      unitRef="usd">294574000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie59ac085dc65418aa4e73ffc69429588_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzMtMS0xLTEtNDMyMzYx_eb7c2a75-9d07-4c21-9497-449fbe1ff503"
      unitRef="usd">110751000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i40279a50dc004485905b9258f9cbe2dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzMtMy0xLTEtNDMyMzYx_6405eb02-54e1-452a-ad40-6646b5267342"
      unitRef="usd">132747000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzQtMS0xLTEtNDMyMzYx_502abcbc-db7f-4abf-b27c-e6a03781eca1"
      unitRef="usd">413976000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8yOTgvZnJhZzo2OTNiZTU1MjFmZTc0YmE3YTE0YmUyNTI1NTEyZGJhMy90YWJsZTo5ZGI2NzA5YjgzNzM0NzZlYmRhNWY1ZDcxNjkwZjdjNC90YWJsZXJhbmdlOjlkYjY3MDliODM3MzQ3NmViZGE1ZjVkNzE2OTBmN2M0XzQtMy0xLTEtNDMyMzYx_7c68943d-ba78-4b72-8a6f-555b649b8e45"
      unitRef="usd">427321000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzgwMQ_c81f6d45-d3e2-4612-900c-18ebf6cf8344">Property and equipment&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,292,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,243,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,265,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,763,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $721,133, $667,755 and $616,626 for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $12,677, $15,275 and $17,944 for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzgwNg_82352e9a-7260-4e94-ba26-5f273c38604f">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,828,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,292,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,243,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,265,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,763,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzItMS0xLTEtNDMyMzYx_59bd8397-d5e5-48ad-aa76-150672ff7f9e"
      unitRef="usd">32656000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzItMy0xLTEtNDMyMzYx_c0322f64-2569-4aef-b7cd-18c87063c605"
      unitRef="usd">34009000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzMtMS0xLTEtNDMyMzYx_b769ef75-e816-40f3-8105-c8cd3b8db57b"
      unitRef="usd">427962000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzMtMy0xLTEtNDMyMzYx_3045899f-7347-40d0-84b6-ac6974201e98"
      unitRef="usd">496455000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzQtMS0xLTEtNDMyMzYx_6e6d08d5-061a-4d15-81f3-5e278aa37825"
      unitRef="usd">3925244000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzQtMy0xLTEtNDMyMzYx_0ed07435-c9d6-4872-ae80-61233477b511"
      unitRef="usd">3828404000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzUtMS0xLTEtNDMyMzYx_31ae0eeb-2e9a-450c-a494-9bd2400b2127"
      unitRef="usd">3759274000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzUtMy0xLTEtNDMyMzYx_1b18580e-c73b-42ea-af1a-96fd02c67a1b"
      unitRef="usd">3292176000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzYtMS0xLTEtNDMyMzYx_5c8b7665-c6ad-4265-8ba4-8b54bacf6b86"
      unitRef="usd">376633000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzYtMy0xLTEtNDMyMzYx_44a9331a-8550-4307-ad3c-45beaddd0479"
      unitRef="usd">592063000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzctMS0xLTEtNDMyMzYx_f2cc344e-2d32-44d0-9efb-0dcc245ed161"
      unitRef="usd">8521769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzctMy0xLTEtNDMyMzYx_e6f0df83-a64b-49cc-a747-539256fff124"
      unitRef="usd">8243107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzgtMS0xLTEtNDMyMzYx_307e137f-fc08-4072-9f67-c0f2df8009a8"
      unitRef="usd">5265372000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzgtMy0xLTEtNDMyMzYx_78c473db-1fd4-4958-a923-ebebd7861c1f"
      unitRef="usd">4763135000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzktMS0xLTEtNDMyMzYx_691d2bf5-f691-4458-8411-7de12d6bbf0b"
      unitRef="usd">3256397000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90YWJsZTo5OGE3ODBlNmI5OTc0ZWQ5OTBiYTA4OWNhYTA5ZDdhZi90YWJsZXJhbmdlOjk4YTc4MGU2Yjk5NzRlZDk5MGJhMDg5Y2FhMDlkN2FmXzktMy0xLTEtNDMyMzYx_f4e1afc0-f66e-4314-971e-5beea0c69c6d"
      unitRef="usd">3479972000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i780f1053c3cd4049860e874c14a7dd7e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI0Mg_86758eea-fab2-42a7-bfad-dcb86a448e6f">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3212e1642e634c7ead8a2a1478b91244_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI0OA_be56d87e-1479-4d02-a642-cb0451a8302f">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iea71308947784543a7b3e618b843de25_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzI5MQ_cc028e94-cddc-43d1-9ab1-32cf2767ae10">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9cb851214d4345d1be8b32b72599be61_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQxNA_3f6d5642-2fb4-426e-ad5d-3f1ab60042d9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i19d843ebfcaa422a8ad48b287a882104_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQyMA_7a41f78f-d362-45bb-a702-a4041e3d5833">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ3NQ_2f1f858e-2532-433e-aa30-aca25d0252a0"
      unitRef="usd">721133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ3OQ_1f9abfd5-9436-4ccb-bdad-79160beb8822"
      unitRef="usd">667755000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzQ4Nw_650c80d2-8688-4ae6-b121-d229682c6080"
      unitRef="usd">616626000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestCostsCapitalized
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc1Mg_28ca746d-a7b7-4947-92ce-38ca901cd48e"
      unitRef="usd">12677000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc1Ng_1a7c64f9-04b2-4588-8ece-42685b8637e8"
      unitRef="usd">15275000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDEvZnJhZzowMDlkYjYwNzAzNmQ0NDAyOTBhMDY0Y2NmNDJlNjVlMi90ZXh0cmVnaW9uOjAwOWRiNjA3MDM2ZDQ0MDI5MGEwNjRjY2Y0MmU2NWUyXzc2Mw_1211a8a0-81ed-4a7f-a344-30d1635482e0"
      unitRef="usd">17944000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczMg_0b6398d6-25e6-420f-a651-cae08773f48a">Intangible assets&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncompetition agreements are generally amortized over three years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was two years and three years as of December&#160;31, 2022 and 2021, respectively. Amortization expense from amortizable intangible assets was $11,469, $12,860, and $13,809 for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized no impairment charges on any intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2022 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczNw_42b811d8-9fa3-4576-ab20-c2a6b086aa02">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzItMS0xLTEtNDMyMzYx_682045bd-7675-4c66-90df-634afe2a86ac"
      unitRef="usd">127271000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzItMy0xLTEtNDMyMzYx_56283df1-068d-4d3d-ab5c-f77a71ea75b9"
      unitRef="usd">104214000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzMtMS0xLTEtNDMyMzYx_a0fb5138-0c06-4840-8457-4ca412e98d27"
      unitRef="usd">51408000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzMtMy0xLTEtNDMyMzYx_e2a36594-5fa3-4d7e-9109-5927f1881110"
      unitRef="usd">70495000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzQtMS0xLTEtNDMyMzYx_74bd99ed-8221-4574-94fc-e0a73aece3bf"
      unitRef="usd">53779000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzQtMy0xLTEtNDMyMzYx_45e1ee0b-e9b7-4666-8ada-808acd5ac655"
      unitRef="usd">63714000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzUtMS0xLTEtNDMyMzYx_6befa8ab-8262-4470-a8da-9fa551e3b399"
      unitRef="usd">232458000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzUtMy0xLTEtNDMyMzYx_a0c17dd2-9757-443b-bbef-058cac73902e"
      unitRef="usd">238423000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMS0xLTEtNTU3NjMy_4422ab42-10d8-4d98-828f-db2b7bb38f4d"
      unitRef="usd">39745000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i23d812bfa6d44d2987c3fd8e4134ce1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMy0xLTEtNTU3NjMy_00bcaba6-99c3-428a-ad13-d1d221b38416"
      unitRef="usd">52813000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzgtMS0xLTEtNTU3NjQw_d5ad1feb-25c1-42a1-8f92-7a7a6dbe157d"
      unitRef="usd">10027000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id42361f6c10f406ea541fb7608221768_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzgtMy0xLTEtNTU3NjQw_9c836eb2-e7ba-49c0-97b0-f068cb80d58f"
      unitRef="usd">7917000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMS0xLTEtNDMyMzYx_932da64e-b89c-4adf-a800-56a6d89ed1c6"
      unitRef="usd">182687000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTo5NjE2YjU0NDk3OGU0N2QxYTQyMDgxNTY3Y2ZiYzdkNS90YWJsZXJhbmdlOjk2MTZiNTQ0OTc4ZTQ3ZDFhNDIwODE1NjdjZmJjN2Q1XzctMy0xLTEtNDMyMzYx_6d06bb14-afe5-41ca-8860-de46d4832bf3"
      unitRef="usd">177693000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3c06c7b0e13047ef8e5353fe708bc498_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzE1NQ_ae1cce33-16fb-41f3-a59b-e9e3a32f31e0">P3Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ibd8a01cb9b6b4aa392aba562922d863e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzE2MQ_e7dbed38-db78-457f-bb14-974002f77199">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i763a119f616d4f0a8615b9b7ca2e724e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzIyMg_df0239b0-0f97-4671-be32-278611586a8f">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i4342659ff7e0470e9df98f9b56908101_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzIyOA_dd47777a-7453-4834-a3ea-c32fb80dde83">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension
      contextRef="iae02ab521c84469d86508390fd7a2b8e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzMxMQ_b88da16e-c1c6-450e-ac54-0c6e250fa081">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension
      contextRef="i238f0b81bcfc460493a2272e9df9e660_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzMxOA_a642d6b3-8f2c-42d2-8d00-68f0a9294b1d">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzQxMg_29e52c6e-8293-4ef0-b0c0-83dd1868fece"
      unitRef="usd">11469000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzEwOTk1MTE2Mjg1MTk_52e458fa-80fb-45f4-a82e-8ab4a014d9ac"
      unitRef="usd">12860000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzQyNA_39556704-0e68-4709-b0af-ba558b2d9d4a"
      unitRef="usd">13809000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzUxOA_79ae94c7-fa25-43c4-b52f-1b498d6922ce"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90ZXh0cmVnaW9uOjYyNTNjYWIzMDJlYTQxNjc4MzM3NGYzMGNjNGZlZjA1XzczMA_e00340d3-41c2-440e-a666-07faf1a01242">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2022 were as follows:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzEtMS0xLTEtNDMyMzYx_c6be858a-a9da-4e74-ac6a-65f70f1f55d7"
      unitRef="usd">4742000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzEtMy0xLTEtNDMyMzYx_8a341e2f-68ec-451a-b0b6-6bbbea68b269"
      unitRef="usd">4084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzItMS0xLTEtNDMyMzYx_f74d6720-b151-4110-9c76-7b6bf71a7119"
      unitRef="usd">2849000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzItMy0xLTEtNDMyMzYx_e31f4b1f-a4f9-4cd7-8ff3-b34bbf2d74c6"
      unitRef="usd">3956000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzMtMS0xLTEtNDMyMzYx_37b9db4b-8c36-4de6-94d4-4199e5d0247c"
      unitRef="usd">1721000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzMtMy0xLTEtNDMyMzYx_c0e3a820-8f8d-41cc-8506-67471aa38946"
      unitRef="usd">3489000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzQtMS0xLTEtNDMyMzYx_64977303-d95b-4251-b047-1659a24c0d47"
      unitRef="usd">1092000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzQtMy0xLTEtNDMyMzYx_96d86d66-39b5-4c8d-8452-dcdf7b6733ac"
      unitRef="usd">3489000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzUtMS0xLTEtNDMyMzYx_d9f994de-e50f-4462-82a8-5e999cd169e2"
      unitRef="usd">730000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzUtMy0xLTEtNDMyMzYx_d3729a9c-5f94-4cc6-aaf7-70cca512fbe8"
      unitRef="usd">3382000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzYtMS0xLTEtNDMyMzYx_b85fe2ce-f905-4f37-8f32-41e9709ddd86"
      unitRef="usd">529000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzYtMy0xLTEtNDMyMzYx_fd330eb4-9743-4389-92c0-f13d731f9f4b"
      unitRef="usd">25352000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a085d17c9534f2296c3a6f7f9e97029_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzctMS0xLTEtNDMyMzYx_82bfa569-4e58-4525-8e56-0b72e54719d7"
      unitRef="usd">11663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i144a4dea34854fafa070bc26e0c1c022_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMDQvZnJhZzo2MjUzY2FiMzAyZWE0MTY3ODMzNzRmMzBjYzRmZWYwNS90YWJsZTpiZTVjNTQ3NmUyYzQ0ZjQ5YjhjOGQ0YTEzMmZkODM3Mi90YWJsZXJhbmdlOmJlNWM1NDc2ZTJjNDRmNDliOGM4ZDRhMTMyZmQ4MzcyXzctMy0xLTEtNDMyMzYx_983ef207-e004-48f5-94bd-dd2bc8bb1b7d"
      unitRef="usd">43752000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE2NTk_745b6cc2-de77-4382-a0ef-794c1307a58b">Equity method and other investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses, comprised as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, the Company recognized equity investment income of $26,520, $26,937 and $26,916, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $4,703 and $1,292 in other (loss) income during 2022 and 2021, respectively. There were no equity investment losses from other equity method investments in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's largest equity method investment is its ownership interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV). The Company holds a 75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;voting and economic interest in the APAC JV and an unrelated noncontrolling investor holds the other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25% voting and economic interest in the joint venture, however the Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other equity method investments include 23 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other (loss) income, net. There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE2NjA_39aca4b0-5027-4274-a0df-e44bfa3f758a">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses, comprised as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i328084074c6a4e6a80b7d005923141b5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzItMS0xLTEtNDMyMzYx_3fde99ef-2b4f-4ca7-bb1a-3c690c015143"
      unitRef="usd">99141000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i89ecc37a255b4ec79a6f4852457f2d7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzItMy0xLTEtNDMyMzYx_3fc68acf-5e50-40b1-bf6b-bb23b6812e7c"
      unitRef="usd">109153000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ie5af4c78b3b84e59a62c25b4a0b8ba0e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzMtMS0xLTEtNDMyMzYx_23e51f4c-82c0-4583-8621-b4aa0d95d12c"
      unitRef="usd">116403000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iaa2d73ec57c84c15a3ad9c06782360e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzMtMy0xLTEtNDMyMzYx_1202149a-db9b-4531-a299-41cf8af980dc"
      unitRef="usd">115185000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3aeafde1efc8421883fbe844a5ce2e26_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzQtMS0xLTEtNDMyMzYx_9b98c414-6b3c-4a2b-b471-4f9794e7e15f"
      unitRef="usd">15564000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i957d7a2748724eb48b7c1a29ca66b93f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzQtMy0xLTEtNDMyMzYx_9aba951e-863a-4eaf-b71b-f16188037dc1"
      unitRef="usd">14543000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzUtMS0xLTEtNDMyMzYx_adef49be-e2f2-4ca0-abcf-814c2ee70fce"
      unitRef="usd">231108000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90YWJsZTozYmZlMmFkNjFhNDk0MzdiYTIyYzhhZWIwYTdkZDIzOS90YWJsZXJhbmdlOjNiZmUyYWQ2MWE0OTQzN2JhMjJjOGFlYjBhN2RkMjM5XzUtMy0xLTEtNDMyMzYx_8b81d869-bb61-4c77-96f7-838402395e68"
      unitRef="usd">238881000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6927c570b591490ab67989e54cd02d0a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzI5MQ_a4e1e74a-9f73-4952-badf-229076b92a6f"
      unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i868f0061ea624c47a87a5ed4482b8464_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzI5NQ_f7ebe98a-7dfc-4736-bebf-a765b918ab98"
      unitRef="usd">26937000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if07190fe863941af86705544dac7d29b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzMwMg_17cd16ea-1d3a-4e5e-9df9-d2ab407a44bf"
      unitRef="usd">26916000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments
      contextRef="ibd6a5d60792446838c6c118846730304_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzgyNDYzMzcyMTE0MDQ_96149b4b-2c72-4190-869e-0d795c0f4a88"
      unitRef="usd">-4703000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments
      contextRef="id383f000ec994776adc163ceb21acbe7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzgyNDYzMzcyMTE0MTI_fcffe829-997d-48ae-ab2f-816b75b5a07c"
      unitRef="usd">-1292000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments
      contextRef="i4245725066c542b0a93347f794776227_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzc2OTY1ODEzOTc4NDg_26ff73ef-a6c7-4500-9b89-2e2ec9865318"
      unitRef="usd">0</dva:IncomeLossFromOtherEquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ibc19a6487a1842f39d795710dd4036dd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzU0Mw_8584828b-f082-44ce-af7e-92c1f58d16fc"
      unitRef="number">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i328084074c6a4e6a80b7d005923141b5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzY0Nw_4a0f1a93-04c2-42ee-99da-25a1d83df498"
      unitRef="number">0.25</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <dva:NumberOfPartnerships
      contextRef="i0e8f487f85e74665806c5ec5125515e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzk2Mg_58536e35-9bcd-435f-bedf-b3c7e7258445"
      unitRef="number">23</dva:NumberOfPartnerships>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i59795d3026d44baeac66a9a81a351db4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE0OTk_281d536c-2954-4303-b7c4-9a5bf7e7355c"
      unitRef="number">0.30</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i7b96f4bb392e462a82c7894ad36ec7d5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzE1MDU_15c3de5c-ed3f-4987-904c-ef79de11fc91"
      unitRef="number">0.65</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ibd6a5d60792446838c6c118846730304_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzcxNDY4MjU1ODI5ODA_1b5dba40-075f-40b5-b2e8-e7a36c71aada"
      unitRef="usd">20154000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTAvZnJhZzowMjcyZjAxMDg2YTI0NTAyYTdmZDBiZTY4MzIwM2JkMy90ZXh0cmVnaW9uOjAyNzJmMDEwODZhMjQ1MDJhN2ZkMGJlNjgzMjAzYmQzXzc2OTY1ODEzOTc4NTg_604902db-4675-4a21-bcbd-ad4266d6b53a"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:GoodwillDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MjI_3624fcb5-c3a4-4c40-aae4-ad85e9034580">Goodwill&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying value of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,309,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,919,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations continue to be impacted by the effects of the coronavirus (COVID-19) pandemic. While the Company does not currently expect a material adverse impact to its business as a result of the ongoing COVID-19 pandemic, there can be no assurance that the magnitude of the cumulative impacts of the COVID-19 pandemic, including certain conditions and developments in the U.S. and global economies, labor market conditions, inflation and monetary policies that may have been intensified by the pandemic, will not have a material adverse impact on one or more of the Company's businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company&#x2019;s operating segments described in Note 25 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has applied a similar aggregation to the physician practices in its physician services reporting units, to the dialysis centers and other health operations within each international reporting unit, and to the vascular access service centers in its former vascular access services reporting unit. For the Company&#x2019;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its most recent assessments, the Company determined that changes in its forecast concerning expected patient census, the timing or amount of expected reimbursement rate increases, expected treatment growth rates, or other significant adverse changes in expected future cash flows or other valuation assumptions could result in goodwill impairment charges in the future for the following reporting unit, which remains at risk of goodwill impairment as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reporting unit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Carrying amount&lt;br/&gt;coverage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Sensitivities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Discount&lt;br/&gt;rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany kidney care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;Except as described above, none of the Company&#x2019;s other reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2022.&#160;Since the dates of the Company&#x2019;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#x2019;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#x2019;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2022.</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MTc_aa6dfaae-1096-4fa0-9ded-900a92a4ea52">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying value of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,309,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,919,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ib92052f136ae48a8bd74fbaa0981d8de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtMS0xLTEtNDMyMzYx_4ff8f54e-5e73-4af5-b014-001e0a2c7c1f"
      unitRef="usd">6309928000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifc23e84f52624cb8b52bf0d015a4c3cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtMy0xLTEtNDMyMzYx_8c7f0376-fb52-4a8c-906d-25ff2f612d9a"
      unitRef="usd">609181000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEtNS0xLTEtNDMyMzYx_8cadd8a9-d277-4061-b811-b56ac7593172"
      unitRef="usd">6919109000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItMS0xLTEtNDMyMzYx_30b28e48-6a7e-49de-8580-6f9fad9efc25"
      unitRef="usd">91979000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItMy0xLTEtNDMyMzYx_4b887d77-db11-4d04-a72f-7fa61e45a0d6"
      unitRef="usd">81265000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzItNS0xLTEtNDMyMzYx_664aac41-e91c-4eb0-a6f3-c4798bc5f07d"
      unitRef="usd">173244000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtMS0xLTEtNDMyMzYx_023525f1-f1c8-43bc-b311-7ce992bc1c3e"
      unitRef="usd">1745000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtMy0xLTEtNDMyMzYx_1212029a-1733-4568-95ad-eefe7054246a"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzMtNS0xLTEtNDMyMzYx_62f4c01b-1e2f-43b0-971e-e304ddf8982a"
      unitRef="usd">1745000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtMS0xLTEtNDMyMzYx_60121e39-e791-4f12-93e6-af4c0fcc0f83"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtMy0xLTEtNDMyMzYx_670c79e5-ca70-41e6-9b10-b8e399f80b94"
      unitRef="usd">44367000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzUtNS0xLTEtNDMyMzYx_b59cb054-8fe7-47e3-a513-7366bf705fbe"
      unitRef="usd">44367000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtMS0xLTEtNDMyMzYx_2a2f649e-a434-49c6-824f-1c24bf096f54"
      unitRef="usd">6400162000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtMy0xLTEtNDMyMzYx_f8576f6c-dccf-4b0a-bc51-1b85e2c1d6bf"
      unitRef="usd">646079000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzYtNS0xLTEtNDMyMzYx_358355d2-a9cc-4ff5-a78a-22496530dca5"
      unitRef="usd">7046241000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctMS0xLTEtNDMyMzYx_af587c41-7ccd-473a-baa0-8e3bd082163e"
      unitRef="usd">16750000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctMy0xLTEtNDMyMzYx_0fbf8452-0a5c-4ea2-8fa6-4e1963b8dcaa"
      unitRef="usd">32297000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzctNS0xLTEtNDMyMzYx_552313d1-1ee4-440f-8c81-99c292290ddc"
      unitRef="usd">49047000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtMS0xLTEtNDMyMzYx_ca9681b7-cadd-46ec-804e-8caabd4b7bdc"
      unitRef="usd">87000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtMy0xLTEtNDMyMzYx_7ed599c3-a9bb-4c6a-90fb-d309da8d0884"
      unitRef="usd">3263000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzgtNS0xLTEtNDMyMzYx_ec81cdcd-1ea9-4424-9137-a773e6871b3d"
      unitRef="usd">3350000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktMS0xLTEtNDMyMzYx_37ee1d92-9cf5-417d-af08-bbdda7d38d0d"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktMy0xLTEtNDMyMzYx_520b829b-a266-40d1-9553-cc256999b36e"
      unitRef="usd">15328000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzktNS0xLTEtNDMyMzYx_c4a30b02-da16-4201-9798-584f8687c330"
      unitRef="usd">15328000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTEtMS0xLTQzMjM2MQ_66b83c75-8a16-432a-89e0-4af83b1edc70"
      unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTMtMS0xLTQzMjM2MQ_1bfa485e-c236-40a8-87ec-f9c7aadeb904"
      unitRef="usd">659785000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEwLTUtMS0xLTQzMjM2MQ_c8ac16b5-b27d-45db-93c2-a7285423478f"
      unitRef="usd">7076610000</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTEtMS0xLTQzMjM2MQ_d2cd22dd-1eab-4435-8829-5c13bc706faa"
      unitRef="usd">6416825000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTMtMS0xLTQzMjM2MQ_1d99609d-2b8b-46f6-a4ff-787e0fa79937"
      unitRef="usd">778774000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzEzLTUtMS0xLTQzMjM2MQ_bc86aac6-3ba8-4c17-a09e-3598948e5370"
      unitRef="usd">7195599000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTEtMS0xLTQzMjM2MQ_0ea064b4-15a7-4325-ae68-0d0691ac044c"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTMtMS0xLTQzMjM2MQ_390fc9c1-165a-471b-944b-a62c84ae3d11"
      unitRef="usd">118989000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE0LTUtMS0xLTQzMjM2MQ_adeeb60e-d8da-4ab7-9e8d-7b1061707404"
      unitRef="usd">118989000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTEtMS0xLTQzMjM2MQ_13d9acf9-a37a-4df0-996b-24ec39f0c6ab"
      unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTMtMS0xLTQzMjM2MQ_1b8d61b3-7746-4ac6-bfa6-f579026862f6"
      unitRef="usd">659785000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZToyNzMxMzIyZjljMzY0YTkwODFhODI3MzkwZGVlMDFjZC90YWJsZXJhbmdlOjI3MzEzMjJmOWMzNjRhOTA4MWE4MjczOTBkZWUwMWNkXzE1LTUtMS0xLTQzMjM2MQ_082c13da-a5d3-4e8d-8a53-53e538c1b963"
      unitRef="usd">7076610000</us-gaap:Goodwill>
    <dva:ScheduleOfReportingUnitsGoodwillBalancesTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzU5MTk_0e7490a0-1a74-491e-81e2-5e9b7a5c30f6">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reporting unit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Carrying amount&lt;br/&gt;coverage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Sensitivities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Discount&lt;br/&gt;rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany kidney care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.&lt;/span&gt;&lt;/div&gt;</dva:ScheduleOfReportingUnitsGoodwillBalancesTextBlock>
    <us-gaap:Goodwill
      contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItMi0xLTEtNDMyMzYx_e596057f-5a15-4aba-8ad4-ccdd61c84e4c"
      unitRef="usd">281781000</us-gaap:Goodwill>
    <dva:ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount
      contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItNC0xLTEtNDMyMzYx_08b5aad7-e97d-44f2-ae6b-bb48c5860283"
      unitRef="number">0.189</dva:ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount>
    <dva:PotentialImpactOnFairValueForReductionInOperatingIncome
      contextRef="id41dfb361f144a0bb39ec3e37b0d11c4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItNi0xLTEtNDMyMzYx_12b4cc6d-5915-4cf4-a5ce-a343b4d4cd98"
      unitRef="number">0.020</dva:PotentialImpactOnFairValueForReductionInOperatingIncome>
    <dva:PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate
      contextRef="idf00b273a4bf4c79a1f721b650d77572_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90YWJsZTo1OTllZGRjMTM4MDQ0NjQ2YjNjZDU5MDFiZTgwMjgwMS90YWJsZXJhbmdlOjU5OWVkZGMxMzgwNDQ2NDZiM2NkNTkwMWJlODAyODAxXzItOC0xLTEtNDMyMzYx_96e39deb-0c3d-4518-81ad-1fa23794eb0f"
      unitRef="number">0.092</dva:PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate>
    <dva:PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzUxNDQ_6612afbd-ac82-4127-bdc2-689e5b98219f"
      unitRef="number">0.03</dva:PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i911a2957827b44d79670188c18f6906f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMTYvZnJhZzo3N2M2MzdkOTFhNGI0NDJiODkwYWQ4ZWM4NjA3YWIzMi90ZXh0cmVnaW9uOjc3YzYzN2Q5MWE0YjQ0MmI4OTBhZDhlYzg2MDdhYjMyXzUzNTY_c12ff078-92b3-4011-9f5f-6490d2dbb3a2"
      unitRef="segment">0</us-gaap:NumberOfOperatingSegments>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90ZXh0cmVnaW9uOjRkZGFjOTU5NTdhMjRhMDI5MmU4MzU4OGMyYzJlNWRiXzc5_c8f7fc20-2d75-4f28-a17c-b35da96b69f5">Other liabilities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90ZXh0cmVnaW9uOjRkZGFjOTU5NTdhMjRhMDI5MmU4MzU4OGMyYzJlNWRiXzgz_ab13e75c-c19c-440d-b8e7-9c099372a840">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <dva:PayorRefundsAndRetractions
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzItMS0xLTEtNDMyMzYx_c4c7d574-3479-491a-b643-7e1aa03ab2d1"
      unitRef="usd">475195000</dva:PayorRefundsAndRetractions>
    <dva:PayorRefundsAndRetractions
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzItMy0xLTEtNDMyMzYx_489d7d52-73e8-40b4-8a4b-480cd8a42ee6"
      unitRef="usd">410038000</dva:PayorRefundsAndRetractions>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzMtMS0xLTEtNDMyMzYx_d9c9e177-5f76-47bc-9954-1a68d97ff612"
      unitRef="usd">68440000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzMtMy0xLTEtNDMyMzYx_3b5aba30-b320-48cc-9983-5f24c9936f08"
      unitRef="usd">55548000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzQtMS0xLTEtNDMyMzYx_bcc8d191-aaf8-44cc-897b-71c35096b097"
      unitRef="usd">34162000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzQtMy0xLTEtNDMyMzYx_8a60b603-9de2-4506-9f97-33220381386e"
      unitRef="usd">32926000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzUtMS0xLTEtNDMyMzYx_8f646334-c7be-4b8a-89b9-67ce3846f1fb"
      unitRef="usd">42806000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzUtMy0xLTEtNDMyMzYx_62888f7a-5af8-40b1-b53d-7fcf4fcb2af4"
      unitRef="usd">41784000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzYtMS0xLTEtNDMyMzYx_3745aa6f-a7c8-49a9-b5b3-dcce3ae0b40e"
      unitRef="usd">181866000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzYtMy0xLTEtNDMyMzYx_f6c6b4b6-6a01-4c87-952c-a51091cc43f9"
      unitRef="usd">169049000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzctMS0xLTEtNDMyMzYx_e22b64b0-024f-43f6-a2bc-e135cbbb05e4"
      unitRef="usd">802469000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjIvZnJhZzo0ZGRhYzk1OTU3YTI0YTAyOTJlODM1ODhjMmMyZTVkYi90YWJsZTozMzQwODZmMGQ5ODM0MjQ2OTBlYTI5ZjdiNTJkMDViNS90YWJsZXJhbmdlOjMzNDA4NmYwZDk4MzQyNDY5MGVhMjlmN2I1MmQwNWI1XzctMy0xLTEtNDMyMzYx_fa1dfad0-3791-47ae-8598-01ab761d3346"
      unitRef="usd">709345000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNTk_e63329f0-b362-479e-84c7-27054a81db88">Income taxes&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Income tax expense for continuing operations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are allocated between continuing and discontinued operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and international tax rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(830,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had federal net operating loss carryforwards of approximately $71,049 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $618,883, some of which have an indefinite life, although a substantial amount expire by 2042 and international net operating loss carryforwards of $357,266, some of which will begin to expire in 2023 though the majority have an indefinite life. The Company has a state capital loss carryover of $306,949, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $6,159 in the valuation allowance is primarily due to newly created net operating loss carryforwards in state and foreign jurisdictions that the Company does not anticipate being able to utilize.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $46,692 to net deferred tax assets, a charge of $16,044 to income tax expense, and an increase of $62,736 to additional paid-in capital. The Company&#x2019;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $16,044 recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains indefinitely reinvested in a majority of the foreign jurisdictions in which it operates as of December&#160;31, 2022. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company&#x2019;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $63,985, of which $45,825 would impact the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company recognized an expense of $10,459 and a benefit of $2,589 related to interest and penalties net of federal tax benefit within tax expense in 2022 and 2021, respectively. At December&#160;31, 2022 and 2021, the Company had approximately $8,208 and $15,275, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. The Company's federal tax returns are under examination by the Internal Revenue Service (IRS) for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014 and 2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. The refund claim is currently subject to IRS review. The Company is also open to U.S. federal examination for 2019 onward, and is no longer subject to U.S. state examinations by tax authorities for years before 2014.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNzU_93073eb5-69d3-4359-bd4d-a2135d2043a6">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItMS0xLTEtNDMyMzYx_155592b1-a639-4fcc-864d-48749011a902"
      unitRef="usd">926604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItMy0xLTEtNDMyMzYx_5b384fca-3e92-470b-9fcb-a6777690559a"
      unitRef="usd">1463029000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzItNS0xLTEtNDMyMzYx_1e8b86e1-e1ee-4b01-b13b-12ebfb1d37d3"
      unitRef="usd">1287976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtMS0xLTEtNDMyMzYx_251b5292-99d3-443f-8012-938bcb0c0f1f"
      unitRef="usd">39674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtMy0xLTEtNDMyMzYx_ebb49646-c47d-442b-b935-10c9e7b3e183"
      unitRef="usd">55465000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzMtNS0xLTEtNDMyMzYx_ac65273a-5c4e-4284-8de7-3fe43aea3dd0"
      unitRef="usd">30286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtMS0xLTEtNDMyMzYx_05ad6fb3-cd60-4c09-9e6a-63ec67063ad1"
      unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtMy0xLTEtNDMyMzYx_64aee403-c99a-4631-9e5d-0e4f4247f75b"
      unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphYTI5MTQ4MzhkNDA0YTMwOGVkNTkzOGI3M2MyYjRkZC90YWJsZXJhbmdlOmFhMjkxNDgzOGQ0MDRhMzA4ZWQ1OTM4YjczYzJiNGRkXzQtNS0xLTEtNDMyMzYx_947bb205-921e-4667-8742-ffb55677ed2c"
      unitRef="usd">1318262000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjc_774556a6-5b48-49ce-b6e6-ceacd818195e">Income tax expense for continuing operations consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtMS0xLTEtNDMyMzYx_b0160ae7-ea56-4f05-9c07-4443af6257f8"
      unitRef="usd">201932000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtMy0xLTEtNDMyMzYx_6b01744f-0029-4343-802e-2d97500832ad"
      unitRef="usd">216539000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzMtNS0xLTEtNDMyMzYx_1f555fe9-bda1-44d9-8ae6-55be50f4266d"
      unitRef="usd">47171000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtMS0xLTEtNDMyMzYx_3593e980-e667-44d1-a06b-31499b43d287"
      unitRef="usd">55593000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtMy0xLTEtNDMyMzYx_0b4c3bb1-f37b-445c-96c8-5dc6f063b14b"
      unitRef="usd">15601000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzQtNS0xLTEtNDMyMzYx_6cac47cf-fbc1-44d7-9149-1d08dbbfa6b3"
      unitRef="usd">21442000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtMS0xLTEtNDMyMzYx_44fb33c3-772c-4f69-97e6-344ac42335a0"
      unitRef="usd">16253000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtMy0xLTEtNDMyMzYx_fff777cb-ea06-45b1-8505-c725b5037284"
      unitRef="usd">14247000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzUtNS0xLTEtNDMyMzYx_bb1f22ee-7d5c-4dd0-a277-2c59562a0680"
      unitRef="usd">17481000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtMS0xLTEtNDMyMzYx_babb9137-ed57-4ba8-8ad0-9db8d9980fe3"
      unitRef="usd">273778000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtMy0xLTEtNDMyMzYx_bc4778f9-9853-45e4-8485-775e61e3204e"
      unitRef="usd">246387000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzYtNS0xLTEtNDMyMzYx_2199edc4-8adc-4c97-90bf-aacfe65c31eb"
      unitRef="usd">86094000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtMS0xLTEtNDMyMzYx_7739d6e0-b358-4986-bb5f-0eb9ff128470"
      unitRef="usd">-66400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtMy0xLTEtNDMyMzYx_33479d16-d478-4344-915c-e89ac6f2b6cb"
      unitRef="usd">59528000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzgtNS0xLTEtNDMyMzYx_43a4be48-bdd4-4bb8-ac3e-1dc448a80f58"
      unitRef="usd">198623000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktMS0xLTEtNDMyMzYx_f4ae91d7-98ef-4cba-87cc-136f2c68bd98"
      unitRef="usd">-12289000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktMy0xLTEtNDMyMzYx_746ff74f-fc53-4d13-a304-ff1a880408f7"
      unitRef="usd">5342000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzktNS0xLTEtNDMyMzYx_edc51601-df73-466a-978b-0ceba9ce2634"
      unitRef="usd">27206000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTEtMS0xLTQzMjM2MQ_d40fe9bc-e9ee-4fcb-8cb5-6e455892c5a0"
      unitRef="usd">2998000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTMtMS0xLTQzMjM2MQ_20a2dbee-9af6-4685-8825-5ecde2d6d641"
      unitRef="usd">-4525000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEwLTUtMS0xLTQzMjM2MQ_3a4fa9ca-f5ad-4d17-ac3e-bc00002d1971"
      unitRef="usd">2009000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTEtMS0xLTQzMjM2MQ_c45d66fc-4367-4a7f-8396-6f9aea4735f2"
      unitRef="usd">-75691000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTMtMS0xLTQzMjM2MQ_42cfcc6c-9b8c-47ea-a75a-9e92824a84d8"
      unitRef="usd">60345000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzExLTUtMS0xLTQzMjM2MQ_64c195cb-a929-42ce-8895-bffd4efd8eed"
      unitRef="usd">227838000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTEtMS0xLTQzMjM2MQ_084a6cb5-a59f-42d4-a21c-8ba345c95008"
      unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTMtMS0xLTQzMjM2MQ_ae83cd76-2954-4de3-9270-473cb92c28e2"
      unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTphNGEyZjlhMTA0MTk0NzRhOWU5Y2Y4YTIzMTNiZjdiNy90YWJsZXJhbmdlOmE0YTJmOWExMDQxOTQ3NGE5ZTljZjhhMjMxM2JmN2I3XzEyLTUtMS0xLTQzMjM2MQ_1de07f91-dd61-406b-8076-faf7148df52d"
      unitRef="usd">313932000</us-gaap:IncomeTaxExpenseBenefit>
    <dva:ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzODU_2d13296b-b6db-4625-b2cb-add271798df1">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are allocated between continuing and discontinued operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItMS0xLTEtNDMyMzYx_49fc3e25-efb7-4169-9292-fbc0949323a9"
      unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItMy0xLTEtNDMyMzYx_d2dea2f6-5f5f-4e9b-b56e-a5db9c30eb81"
      unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzItNS0xLTEtNDMyMzYx_dac3d8b4-4436-4515-b76b-a7120231b2e6"
      unitRef="usd">313932000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtMS0xLTEtNDMyMzYx_22879211-464e-4bc1-ab01-99ce79d3e6b0"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtMy0xLTEtNDMyMzYx_5abda9f2-f8cb-4ad4-976f-723b89486ecf"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzMtNS0xLTEtNDMyMzYx_6348bfa7-9ea1-486d-b30e-3b0006608272"
      unitRef="usd">1657000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtMS0xLTEtNDMyMzYx_22ac2b28-c431-41be-8bac-1024e53d3a3e"
      unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtMy0xLTEtNDMyMzYx_d2327c2f-8625-4813-928c-8b852afe40d6"
      unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4OTJkZWYxODdlNjM0NGNmOGEzZTU0Y2E1ODNjY2NlYS90YWJsZXJhbmdlOjg5MmRlZjE4N2U2MzQ0Y2Y4YTNlNTRjYTU4M2NjY2VhXzQtNS0xLTEtNDMyMzYx_ccc6ff11-e845-4155-a4ae-c7c3964c0750"
      unitRef="usd">315589000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjg_c560fc22-ead7-4cd1-be32-96a570576597">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and international tax rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItMS0xLTEtNDMyMzYx_d63aef5a-302b-4c5d-8876-1d4880725b8b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItMy0xLTEtNDMyMzYx_8887bb5a-1f34-4b20-a23e-f6c3dcaa447c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzItNS0xLTEtNDMyMzYx_0e21944d-afbf-4d32-b943-3d8b78ef96df"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtMS0xLTEtNDMyMzYx_6c393e57-c92d-4fe0-b026-400523dc6fb3"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtMy0xLTEtNDMyMzYx_c179d591-b4bd-4464-bee0-87c23bd69fe6"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzMtNS0xLTEtNDMyMzYx_80ecf323-306d-4f5f-879d-8666923e9aaa"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtMS0xLTEtNDMyMzYx_0ed387aa-1b91-4bd2-b556-3a425dd7a234"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtMy0xLTEtNDMyMzYx_ad8d9f1c-79a9-4356-a443-7f1ca36a54bd"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzQtNS0xLTEtNDMyMzYx_672e0305-f917-4dbb-a28b-f6202bca255b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtMS0xLTEtNDMyMzYx_90b9e65d-433a-4260-b6be-5b5f63268083"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtMy0xLTEtNDMyMzYx_a335007f-3353-4c43-b0c5-324ebf010697"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzUtNS0xLTEtNDMyMzYx_9adee00c-29a6-4bed-9a2c-1bdb6f7ebc7e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtMS0xLTEtNDMyMzYx_0845fb6e-6b65-4365-9bc5-0589a14a0dad"
      unitRef="number">0.011</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtMy0xLTEtNDMyMzYx_a2aa6d67-6ae9-4cc3-b62f-c006a9e96e36"
      unitRef="number">0.008</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzYtNS0xLTEtNDMyMzYx_6bcc4663-5f10-4b53-84ea-2d5e25b8ec48"
      unitRef="number">0.012</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctMS0xLTEtNDMyMzYx_54dc60eb-3e10-450d-9e5c-a390315d4aeb"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctMy0xLTEtNDMyMzYx_4e416886-6c00-4b05-8798-ca8729d4b073"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzctNS0xLTEtNDMyMzYx_6b4f8043-bbc6-4cf7-991b-9290ab5d8507"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtMS0xLTEtNDMyMzYx_853193b7-b80a-4590-972a-5ccee397b9f9"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtMy0xLTEtNDMyMzYx_2a12200f-edd1-4d72-aac5-0a54e493c2ab"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzgtNS0xLTEtNDMyMzYx_0a00a88d-339d-499e-923c-efbf06b09a3c"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktMS0xLTEtNDMyMzYx_df8528ab-4a91-441b-8242-3d1579d7c40a"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktMy0xLTEtNDMyMzYx_f5b7efea-774c-403b-bacb-8a64028964bb"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzktNS0xLTEtNDMyMzYx_2e8eadbe-a22f-4433-ae54-c35442671659"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTEtMS0xLTU0NTA4OQ_bd6bb00f-8504-4b18-8cc1-7186db840db0"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTMtMS0xLTU0NTA4OQ_a3b7337e-8005-4dd0-a0aa-635740b81952"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTUtMS0xLTU0NTA4OQ_4e4b5443-358d-4fc7-960b-876d45eccafe"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTEtMS0xLTQzMjM2MQ_8fc7c382-7347-440b-987e-c3b3435405b9"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTMtMS0xLTQzMjM2MQ_6bdb4e32-eca6-4257-aff1-0b4f19a346c3"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEwLTUtMS0xLTQzMjM2MQ_c10b0f06-d6ed-42a1-a331-b9ff8dbd4a7a"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTEtMS0xLTQzMjM2MQ_8d8d0885-4518-4a5c-b1c6-74703c7ce968"
      unitRef="number">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTMtMS0xLTQzMjM2MQ_b571f853-8472-4098-8c22-343d77211708"
      unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzExLTUtMS0xLTQzMjM2MQ_6ac67e21-cc12-4f09-b077-ef72ef963184"
      unitRef="number">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTEtMS0xLTQzMjM2MQ_e8ebc1af-e6cf-454f-9795-578f70e14d5c"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTMtMS0xLTQzMjM2MQ_fac2358e-8aa7-47ef-9093-d1ed4a592201"
      unitRef="number">0.202</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTo4M2QwNzM4YzY2Nzc0N2NkYTljZTNhYWJkMzAwYmRlOC90YWJsZXJhbmdlOjgzZDA3MzhjNjY3NzQ3Y2RhOWNlM2FhYmQzMDBiZGU4XzEyLTUtMS0xLTQzMjM2MQ_63ae6457-f43a-4c86-bc6b-360afe596674"
      unitRef="number">0.238</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNjI_f56b0d03-b234-407f-93de-c737a24a4f5d">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(283,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(530,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(830,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(808,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <dva:DeferredTaxAssetsReceivables
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzItMS0xLTEtNDMyMzYx_009b09e3-a855-4b8e-8a73-02569da276ca"
      unitRef="usd">18304000</dva:DeferredTaxAssetsReceivables>
    <dva:DeferredTaxAssetsReceivables
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzItMy0xLTEtNDMyMzYx_22a5420c-5760-4868-a283-69a312f13970"
      unitRef="usd">8430000</dva:DeferredTaxAssetsReceivables>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzMtMS0xLTEtNDMyMzYx_93a29f14-4391-4732-9f8b-5b032a52eb36"
      unitRef="usd">71346000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzMtMy0xLTEtNDMyMzYx_783c253a-587e-456d-863a-4b7c0af4ad14"
      unitRef="usd">67993000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzQtMS0xLTEtNDMyMzYx_a589d005-afba-41f3-9d5e-503fe26346e5"
      unitRef="usd">563972000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzQtMy0xLTEtNDMyMzYx_855d8721-3d66-4588-86f1-6fbb3719cacb"
      unitRef="usd">581199000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzUtMS0xLTEtNDMyMzYx_ed90f804-0b4c-404f-9226-d94bebe2cd3c"
      unitRef="usd">173531000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzUtMy0xLTEtNDMyMzYx_209ae013-7b21-4dd2-86de-ef6b1f8197ea"
      unitRef="usd">162987000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzYtMS0xLTEtNDMyMzYx_39f0ea62-7023-40db-9432-c366e4212235"
      unitRef="usd">58827000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzYtMy0xLTEtNDMyMzYx_056ccb77-a0c7-44ef-a4d3-a8ec49b4a99a"
      unitRef="usd">52434000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzctMS0xLTEtNDMyMzYx_f80e009f-514f-47f9-a411-a916feb38e77"
      unitRef="usd">885980000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzctMy0xLTEtNDMyMzYx_341242f6-20e8-4ec4-a7c0-96dfe811f6d1"
      unitRef="usd">873043000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzgtMS0xLTEtNDMyMzYx_4821b3cb-dc69-4b8a-9701-aadb181fe377"
      unitRef="usd">106775000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzgtMy0xLTEtNDMyMzYx_02ef4f7e-5923-4725-8572-c99891411ceb"
      unitRef="usd">100616000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzktMS0xLTEtNDMyMzYx_0c946340-9807-4ba0-a4ba-66241de016f8"
      unitRef="usd">779205000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzktMy0xLTEtNDMyMzYx_fae74ed6-2085-4edd-8509-29c870bf3d77"
      unitRef="usd">772427000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEwLTEtMS0xLTQzMjM2MQ_ffbbe5f9-9b97-4eb8-a82e-3efe0c5c21f4"
      unitRef="usd">690914000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEwLTMtMS0xLTQzMjM2MQ_dd3ac7aa-ccf6-41fc-9dbc-dd042fe865fa"
      unitRef="usd">644039000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzExLTEtMS0xLTQzMjM2MQ_70dbdb83-65fe-4730-97b9-4dc5a10cc6a2"
      unitRef="usd">181704000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzExLTMtMS0xLTQzMjM2MQ_e3abbb0c-a9b3-4756-94b6-587ddeabf3e7"
      unitRef="usd">283913000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEyLTEtMS0xLTQzMjM2MQ_7283bd8a-8968-46f6-97b1-3b64f181a743"
      unitRef="usd">515026000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEyLTMtMS0xLTQzMjM2MQ_f703f1c1-dddb-4cfc-979a-5fde790fd8a5"
      unitRef="usd">530839000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEzLTEtMS0xLTQzMjM2MQ_8c096c15-97af-4cbf-9741-2f464680a442"
      unitRef="usd">80876000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzEzLTMtMS0xLTQzMjM2MQ_7b3bf97c-41ac-481a-9cce-bad85efd7ead"
      unitRef="usd">84407000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE0LTEtMS0xLTQzMjM2MQ_84dbb073-b3d5-4379-ba4e-6343b7072d88"
      unitRef="usd">65766000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE0LTMtMS0xLTQzMjM2MQ_23b3d6ed-57d9-4636-a195-598ca5d14de1"
      unitRef="usd">37274000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE1LTEtMS0xLTQzMjM2MQ_1db3abe5-f4e2-4af4-9877-dda53e8113ba"
      unitRef="usd">1534286000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE1LTMtMS0xLTQzMjM2MQ_cebc95d3-e144-496d-8f39-57ec4c1b2219"
      unitRef="usd">1580472000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE2LTEtMS0xLTQzMjM2MQ_d9253c03-29e0-40eb-8009-fabceb975723"
      unitRef="usd">755081000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE2LTMtMS0xLTQzMjM2MQ_2182020d-9261-4cfa-8948-2f964b4fec0c"
      unitRef="usd">808045000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0836866414f4437aac5b49b4350f9953_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE4LTEtMS0xLTQzMjM2MQ_8d7a9ba5-a83b-4fc4-a776-4f9d0514906e"
      unitRef="usd">782787000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i54e50d4b1d0e45d6998ef4a07f8412ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE4LTMtMS0xLTQzMjM2MQ_b40df824-d8ad-4138-b639-a1b376e00282"
      unitRef="usd">830954000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5eace4b400364cb59a814210aca461e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE5LTEtMS0xLTQzMjM2MQ_e7369d01-705b-433d-ac2a-b5391237200e"
      unitRef="usd">27706000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if7b49cc670fc4f9b8a4a550217fc1379_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzE5LTMtMS0xLTQzMjM2MQ_9e447236-606c-490c-92f2-7b1f9aba6c88"
      unitRef="usd">22909000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzIwLTEtMS0xLTQzMjM2MQ_8b804482-6746-48b3-ac55-441c2b2b6fab"
      unitRef="usd">755081000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTowOTExMWZmYTIzMTA0NTZlYjIwODkwZjg1MDdkZDg2NS90YWJsZXJhbmdlOjA5MTExZmZhMjMxMDQ1NmViMjA4OTBmODUwN2RkODY1XzIwLTMtMS0xLTQzMjM2MQ_ef327f40-240f-4ff3-afc2-2f1103144be8"
      unitRef="usd">808045000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic71d18b327ea4b429a6ba95d6c567050_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzExNDQ_c44bdf2e-fd89-4921-bcde-cf4b37f2f7cc"
      unitRef="usd">71049000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7a1f2af5eec44aa990c6433dc345a841_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEyNzg_13672519-f23b-456b-9839-62b0563bfa98"
      unitRef="usd">618883000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9728c466394b4bc781a51da4125c31a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE0MTg_b96f7c2c-b6e4-4e24-b480-bd1e22253864"
      unitRef="usd">357266000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5d510a76f30a4b18aeb57c119e82770e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE1NTg_bb014181-6474-4a25-9be2-0fee32537576"
      unitRef="usd">306949000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i6f0ee4ace34040a89985a562a8e65295_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzE4MzI_630d6940-9d73-43a5-9e93-e98b88802c95"
      unitRef="usd">6159000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <dva:IncreaseInDeferredTaxAssetsNet
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNDk_09826bcb-19ae-49f4-9542-2d6d348039a6"
      unitRef="usd">46692000</dva:IncreaseInDeferredTaxAssetsNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNTM_e5f5436f-616d-48a4-a252-7bb99b39d099"
      unitRef="usd">16044000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNjE_d379d3ca-dd0b-4738-959e-4208fca1a59e"
      unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib07e0ca479aa4f65a17cb083396efff0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzQzNTc_e5f5436f-616d-48a4-a252-7bb99b39d099"
      unitRef="usd">16044000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzQzNzM_706c45b0-93f3-480d-bdd2-45ad19a9b2d8">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzItMS0xLTEtNDMyMzYx_bdb16a80-1664-45dd-bc3a-cc3cf644e676"
      unitRef="usd">73024000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzItMy0xLTEtNDMyMzYx_7ac08252-1e77-4b6c-8582-48ca577dee99"
      unitRef="usd">70202000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzMtMS0xLTEtNDMyMzYx_ff5e6ec2-5b13-46f2-903c-49166682efa5"
      unitRef="usd">3858000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzMtMy0xLTEtNDMyMzYx_0501b436-6837-436e-ac5c-9ae18a2e0dd5"
      unitRef="usd">3335000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzQtMS0xLTEtNDMyMzYx_5d58a30b-d001-4167-8419-950d25103f04"
      unitRef="usd">24683000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzQtMy0xLTEtNDMyMzYx_a674b2c7-bba5-4a32-9a0b-b5a99b46e59a"
      unitRef="usd">22616000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzUtMS0xLTEtNDMyMzYx_33ee2051-9822-4f95-8dca-0afbb17c4db0"
      unitRef="usd">6073000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzUtMy0xLTEtNDMyMzYx_95648ecc-df51-48a9-b2a0-d30a1ee637ce"
      unitRef="usd">751000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzYtMS0xLTEtNDMyMzYx_5c01e33a-aff7-4182-85b6-9e1a5619586a"
      unitRef="usd">31507000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzYtMy0xLTEtNDMyMzYx_0bf1c63f-89c7-4372-a325-83631004c9e5"
      unitRef="usd">22378000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzctMS0xLTEtNDMyMzYx_3820bed4-f1bf-4d2d-880f-b2d17ff89f84"
      unitRef="usd">63985000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90YWJsZTplMTNhM2U2ZDVkYjY0N2ZhOGM0YjY5YmZiZTc1ZDU0Zi90YWJsZXJhbmdlOmUxM2EzZTZkNWRiNjQ3ZmE4YzRiNjliZmJlNzVkNTRmXzctMy0xLTEtNDMyMzYx_bdb16a80-1664-45dd-bc3a-cc3cf644e676"
      unitRef="usd">73024000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzMzOTY_729043d3-6b3c-44b3-9222-6ccf79974708"
      unitRef="usd">63985000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM0MDk_be403102-5ec2-4261-ad34-75ea7055ba34"
      unitRef="usd">45825000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzU2NTg_97fd5e64-4d36-429e-bc59-d3817efbb22b"
      unitRef="usd">10459000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzEwOTk1MTE2MzU2OTI_f8f42b83-92ce-41dc-aed9-a158419e2f18"
      unitRef="usd">-2589000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM3OTE_6ccf75f9-4da8-4174-af4f-acc4ff442570"
      unitRef="usd">8208000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMjUvZnJhZzpkYzkwNmM3MWQxMzM0OTVkODVlMzc0MmJkMmRlOWIwZi90ZXh0cmVnaW9uOmRjOTA2YzcxZDEzMzQ5NWQ4NWUzNzQyYmQyZGU5YjBmXzM3OTg_b919245f-fbc8-4993-aed8-01e8be57cd3d"
      unitRef="usd">15275000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0Njc_ef60d279-9a29-49e5-bee3-475687852147">Long-term debt&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt was comprised of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes&lt;br/&gt; payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,964,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,924,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,908,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,692,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,729,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values using level 2 interest rate inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and LIBOR interest rate components in effect as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $3,497 and deferred financing costs of $18,816 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018. As of December&#160;31, 2021, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $4,473 and deferred financing costs of $27,207, and the carrying amount of the Company's senior notes was reduced by deferred financing costs of $40,914 and increased by a debt premium of $15,909.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2022 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company made regularly scheduled mandatory principal payments under its senior secured credit facilities totaling $98,437 on Term Loan A and $27,432 on Term Loan B-1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company's domestic subsidiaries' assets and are senior to all unsecured indebtedness. Borrowings under this facility's Term Loan A, Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. Borrowings under this credit facility are based on the London Interbank Offered Rate (LIBOR), unless another base rate is elected. This facility also provides a mechanism for transition to an alternative variable base rate upon cessation of LIBOR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding borrowings under Term Loan A and Term Loan B-1 consist of tranches that can range in maturity from one month to 12 months. As of December 31, 2022, all outstanding term loan tranches are one month in duration. For Term Loan A and Term Loan B-1, each tranche bears interest at a LIBOR rate determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as the tranche matures and a new tranche is established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the overall weighted average interest rate for Term Loan A and Term Loan B-1 was determined based upon the LIBOR interest rates in effect for all of their individual tranches plus the respective interest rate margins presented in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $165,000 outstanding on the $1,000,000 revolving line of credit under its senior secured credit facilities. Each of these borrowings were priced on one-month LIBOR variable base rates as well. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2022. The Company also had letters of credit of approximately $108,826 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A. The remaining $659,269 outstanding principal balance of Term Loan A and the $165,000 balance outstanding on the revolving line of credit are subject to LIBOR-based interest rate volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#x2019;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. These cap agreements have variable legs priced at LIBOR to match the variable rates incurred on the senior secured credit facility borrowings that they hedge. Like the senior secured credit facilities, these interest rate cap agreements include a mechanism for transition to an alternative variable base rate upon cessation of LIBOR. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit-risk contingent features.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2022 and December&#160;31, 2021, which are classified in other long-term assets on its consolidated balance sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;LIBOR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Recorded OCI gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2022, 2021 and 2020:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location of losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 20 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s weighted average effective interest rate on its senior secured credit facilities at the end of 2022 was 4.59%, based upon the current margins in effect for its senior secured credit facilities as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 3.96% for the year ended December&#160;31, 2022 and 4.52% as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company&#x2019;s interest rates were fixed on approximately 51.3% of its total debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt expense consisted of interest expense of $339,247, $267,049 and $282,932 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs and the amortization of interest rate cap agreements of $17,772, $18,205 and $21,179 for 2022, 2021 and 2020, respectively. These interest expense amounts are net of capitalized interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0NzE_7ab4b7dc-81c0-43a0-9293-68a048ee895d">Long-term debt&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt was comprised of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,660,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,224,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes&lt;br/&gt; payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,964,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,924,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,908,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,692,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,729,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values using level 2 interest rate inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and LIBOR interest rate components in effect as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $3,497 and deferred financing costs of $18,816 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018. As of December&#160;31, 2021, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $4,473 and deferred financing costs of $27,207, and the carrying amount of the Company's senior notes was reduced by deferred financing costs of $40,914 and increased by a debt premium of $15,909.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:SecuredDebt
      contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtMS0xLTEtNDMyMzYx_087042b7-13e8-400d-93c8-6525ac7914b1"
      unitRef="usd">1498438000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="iffc4a5e5db954ccca57e0719d248d746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtMy0xLTEtNDMyMzYx_9c342ddc-0a09-47a5-9174-cb94a3a95f4f"
      unitRef="usd">1596875000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtNS0xLTEtNDMyMzYx_61bc3b68-d539-4526-8d3a-272eb509168f">2024-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtNy0xLTEtNDMyMzYx_dba44cf8-bcb2-4041-a633-ccfc0f4934ef">LIBOR + 1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzMtOS0xLTEtNDMyMzYx_08a32bad-d2f7-4edd-bc33-5194a31d80e9"
      unitRef="usd">1468469000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt
      contextRef="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtMS0xLTEtNDMyMzYx_6b77f9e0-321f-4250-966b-b3f6b1d2de01"
      unitRef="usd">2660831000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="i6ddb2df1c2114de4a00fc604f1818904_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtMy0xLTEtNDMyMzYx_dfb37313-ffd0-4d28-83fd-e9b17ccf502a"
      unitRef="usd">2688263000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtNS0xLTEtNDMyMzYx_c0911c4c-4a5d-4894-9ad0-00b6928eb2c2">2026-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtNy0xLTEtNDMyMzYx_03d5c125-c2a3-4c08-8548-02f97b602aca">LIBOR + 1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ifa340e8b1fe34672a60d14f4239a9aa3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzQtOS0xLTEtNDMyMzYx_22f34dcd-1f23-41d5-8180-c5bfa87de76d"
      unitRef="usd">2587658000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt
      contextRef="i280e7c36267346f08232e69492322e25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtMS0xLTEtNDMyMzYx_e08007f3-71c1-4e47-92c4-d68196a92848"
      unitRef="usd">165000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="i0e791ab248d24b63ae1da6cdf0df3eac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtMy0xLTEtNDMyMzYx_aa910120-50c2-4602-9664-930d575f4c2d"
      unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtNS0xLTEtNDMyMzYx_e6c8696d-a85c-4f0d-a372-aaba1032b9d1">2024-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i3703680d944e4b12832c5aa556b2499b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtNy0xLTEtNDMyMzYx_3fd7e68c-1df6-41cb-99fe-aff0418a2cef">LIBOR + 1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i280e7c36267346f08232e69492322e25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzUtOS0xLTEtNDMyMzYx_cc79f7fc-ac4c-4146-9223-ae263d4b6c8a"
      unitRef="usd">165000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SeniorNotes
      contextRef="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctMS0xLTEtNDMyMzYx_6ce0044b-5c38-4d37-87af-7b52572df3ae"
      unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="i8c2ea2f7c8b2414aaeb0fb9101c24607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctMy0xLTEtNDMyMzYx_8e221df5-c2f8-4939-923f-ee001788ee8d"
      unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctNS0xLTEtNDMyMzYx_fb796baa-ec43-414b-b0a2-1bb921b57800">2030-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="if334b3b21bd9456e968fadf9551f3286_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctNy0xLTEtNDMyMzYx_12e91537-1d85-491e-b199-a44921c5eb89"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9b8b6f5c971943e8a89fc94eb8b323a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzctOS0xLTEtNDMyMzYx_56af03c6-6d84-41f2-bac4-dac03fa1db2e"
      unitRef="usd">2224063000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SeniorNotes
      contextRef="i76e6ab0c8af4453689dd47207d80b526_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtMS0xLTEtNDMyMzYx_17f3c612-7ca1-402a-8277-8f7fa095602c"
      unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="i4f6d0ad8a3f149508ef910626c9379bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtMy0xLTEtNDMyMzYx_fdcd9f33-c9f2-47ea-ae3d-f727bccee171"
      unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ice20b77c90c04919a53292886212c09a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtNS0xLTEtNDMyMzYx_97ccf89d-b67b-4a13-9572-bd8ff6c18e68">2031-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ice20b77c90c04919a53292886212c09a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtNy0xLTEtNDMyMzYx_ca26660f-3c90-4743-b45e-372abe8fbd81"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i76e6ab0c8af4453689dd47207d80b526_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzgtOS0xLTEtNDMyMzYx_782ad7e3-2a27-43a7-90dc-fa200bca8af8"
      unitRef="usd">1115625000</us-gaap:DebtInstrumentFairValue>
    <dva:AcquisitionObligationsAndOtherNotesPayable
      contextRef="i0e9c869de9534500954d1a4145291638_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktMS0xLTEtNDMyMzYx_d95083c0-ced6-4ceb-a1af-c33d0500112d"
      unitRef="usd">120562000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <dva:AcquisitionObligationsAndOtherNotesPayable
      contextRef="i29c1764e202c483caac7e78fb4caf1b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktMy0xLTEtNDMyMzYx_2a86fcf9-b8d1-401c-9293-3f4820d578fe"
      unitRef="usd">130599000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="i61d6664946ac4659978bc717989aed3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktNS0xLTEtNDMyMzYx_637d66bd-b992-4da6-b79c-5561293b880e">2023-2036</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i0e9c869de9534500954d1a4145291638_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktNy0xLTEtNDMyMzYx_3c4300ae-e591-4f70-b754-585d21358851"
      unitRef="number">0.0656</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <dva:AcquisitionObligationsAndOtherNotesPayableFairValue
      contextRef="i0e9c869de9534500954d1a4145291638_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzktOS0xLTEtNDMyMzYx_4e4267a4-b10e-48a5-9972-383aecc86dd9"
      unitRef="usd">120562000</dva:AcquisitionObligationsAndOtherNotesPayableFairValue>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTEtMS0xLTQzMjM2MQ_f26f119a-5858-4d1c-8fae-c1554572ecd1"
      unitRef="usd">273688000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ic69de63a548f40878bfa7836ee961e78_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTMtMS0xLTQzMjM2MQ_09b18b24-c914-4a3c-be84-ddaf9d482a14"
      unitRef="usd">299128000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="ib94226c5496c4dc189b0f57a7e9d5b37_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTUtMS0xLTQzMjM2MQ_82557a96-cce6-4d30-bfb8-0014b9cb76ce">2023-2038</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEwLTctMS0xLTQzMjM2MQ_5e5217b2-04c7-479a-95d9-3219ae83fee5"
      unitRef="number">0.0451</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzExLTEtMS0xLTQzMjM2MQ_59c43f43-f286-49dd-84d4-0ba820254183"
      unitRef="usd">8968519000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzExLTMtMS0xLTQzMjM2MQ_f57d2c29-b1d9-4513-9e0c-963df867df4c"
      unitRef="usd">8964865000</us-gaap:DebtInstrumentCarryingAmount>
    <dva:DiscountAndDeferredFinanceCosts
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEyLTEtMS0xLTQzMjM2MQ_0c47b1a6-b341-4588-a768-37cef5310f35"
      unitRef="usd">44498000</dva:DiscountAndDeferredFinanceCosts>
    <dva:DiscountAndDeferredFinanceCosts
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEyLTMtMS0xLTQzMjM2MQ_158edb25-74cd-4f8e-ac5e-9573600e44d5"
      unitRef="usd">56685000</dva:DiscountAndDeferredFinanceCosts>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEzLTEtMS0xLTQzMjM2MQ_3ccaa37c-a8d1-45d1-97db-842bf4f3b1c1"
      unitRef="usd">8924021000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzEzLTMtMS0xLTQzMjM2MQ_bee78896-7766-4a1f-b9d4-ac4992c3f536"
      unitRef="usd">8908180000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE0LTEtMS0xLTQzMjM2MQ_35fd7958-1e9d-4fee-97c4-e4c9021943c8"
      unitRef="usd">231404000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE0LTMtMS0xLTQzMjM2MQ_e2b38100-f454-4432-9588-eba7228ba3ca"
      unitRef="usd">179030000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE1LTEtMS0xLTQzMjM2MQ_ea2716b7-bb9b-44b7-98b7-6fd2d6e3504b"
      unitRef="usd">8692617000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTplNzBkYzRkNzk0YTI0YWFhYjY2NzNhMWI3Y2U3MTlmMS90YWJsZXJhbmdlOmU3MGRjNGQ3OTRhMjRhYWFiNjY3M2ExYjdjZTcxOWYxXzE1LTMtMS0xLTQzMjM2MQ_53f35147-6925-4300-bcdd-899b56388a9f"
      unitRef="usd">8729150000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i711f403972ec4e66b0f07af1bd51bd85_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwNzE_2b4baeb0-074a-4a57-a914-a3ebabf58dd5"
      unitRef="usd">3497000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i711f403972ec4e66b0f07af1bd51bd85_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzExMDY_35021ae7-41b8-46ea-b49c-1cb280c40796"
      unitRef="usd">18816000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="id14241465c6d496e9fcbffe2bb81a4a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEyMTI_4cc26cf6-e088-490d-bb4f-beb6bdbf8a7b"
      unitRef="usd">36203000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="id14241465c6d496e9fcbffe2bb81a4a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEyNTA_ec286937-3746-4519-9603-04f313efce3c"
      unitRef="usd">14018000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6332787d61e14213968fc6c3ed4533b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEzNjQ_f81baead-c1de-4af1-a52a-09a086f23b72"
      unitRef="usd">4473000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i6332787d61e14213968fc6c3ed4533b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEzOTk_58665adf-2887-4922-952b-7808890b1ee9"
      unitRef="usd">27207000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE1MDE_a2817060-af6d-4d2d-8042-0a7c5b245fd0"
      unitRef="usd">40914000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i9f4bfc276c044d4fb2de0c2e6e0db8f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2MzQ1Njk_69088458-ac0a-4506-a691-5dd7b667ee90"
      unitRef="usd">15909000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0Nzk_fa95549e-59e9-4567-a227-083d4fb1dd66">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2022 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzAtMS0xLTEtNDMyMzYx_cf274d69-324d-4d0e-9094-3bd7b53fb770"
      unitRef="usd">231404000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzEtMS0xLTEtNDMyMzYx_4fe94a8a-cf8b-44b4-9a8f-4fdfa243a7dc"
      unitRef="usd">1587867000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzItMS0xLTEtNDMyMzYx_131829bb-b5c0-4e84-b140-992e4152547d"
      unitRef="usd">67112000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzMtMS0xLTEtNDMyMzYx_a004d617-1a4a-416b-bb01-d6cbf8f42b7d"
      unitRef="usd">2627310000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzQtMS0xLTEtNDMyMzYx_0cf797ad-cac8-47b0-ac00-0c61e026e489"
      unitRef="usd">35176000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTo2NjIxMmFjNTk3NWM0MDFiOTEzYmIzYWFkZTVhOGFkMS90YWJsZXJhbmdlOjY2MjEyYWM1OTc1YzQwMWI5MTNiYjNhYWRlNWE4YWQxXzUtMS0xLTEtNDMyMzYx_dca6177c-87fe-4480-95a7-976b1f39ff41"
      unitRef="usd">4419650000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ie4500016ea7f411bb43d67d4fa2d01e5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE3MTQ_e76d588a-4542-4421-9518-2bc9ac58ce1c"
      unitRef="usd">98437000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i01f13844d63440249e54982f46346b77_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzE3MzY_12fcbb03-c85b-46cf-9c46-4482a8a70bc6"
      unitRef="usd">27432000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentTerm
      contextRef="i509b9358d5b848688db2af3f7c28f677_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDMzMTg_3121706c-c0bf-4389-9212-1d4278ee8522">P1M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="if0b283e992d44d15924be874a7cb3008_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDMzMzU_f3536611-0ad2-4cbc-8e74-a507f30eb907">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:SecuredDebt
      contextRef="i280e7c36267346f08232e69492322e25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ0MDQ_e08007f3-71c1-4e47-92c4-d68196a92848"
      unitRef="usd">165000000</us-gaap:SecuredDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i280e7c36267346f08232e69492322e25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ0Mjc_ceffc8aa-a453-4e43-82d8-573593906b2a"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ2NDc_bca2f8a3-478b-4271-9ffc-56f99eeed5f2"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i53250a642d1d4d75b53407d691d20e86_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDQ2OTc_71904e0a-bd4f-4c09-991c-620f837271df"
      unitRef="usd">108826000</us-gaap:LettersOfCreditOutstandingAmount>
    <dva:SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR
      contextRef="i606724ebb1074323bb48035cf6c598e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDEzNzI_c5034f0b-991b-4196-a782-f006471f2ed4"
      unitRef="usd">659269000</dva:SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR>
    <us-gaap:SecuredDebt
      contextRef="i280e7c36267346f08232e69492322e25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzEwOTk1MTE2NDM4ODg_e08007f3-71c1-4e47-92c4-d68196a92848"
      unitRef="usd">165000000</us-gaap:SecuredDebt>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0ODE_641cd5bc-8fd1-4c69-816c-ae76197adb88">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2022 and December&#160;31, 2021, which are classified in other long-term assets on its consolidated balance sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;LIBOR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzItOS0xLTEtNDMyMzYx_cedbc85d-60ec-4e9b-8a61-26c4269111be"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Recorded OCI gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia154eee2b5544902b0df5b93083def6f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMS0xLTEtNDMyMzYx_560ada60-cae3-4f8f-a781-62e22afc4c4c"
      unitRef="usd">3500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3a6df8d1ce4240b99834c54100161749_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMy0xLTEtNDMyMzYx_922c8301-623d-4452-8614-2fdd8b18c289"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInceptionDates
      contextRef="i3f1024fd068b4449894448967a76d43e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtNS0xLTEtNDMyMzYx_e1726c6f-43e4-40e9-b58d-78ee8de2334c">2020-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates
      contextRef="i3f1024fd068b4449894448967a76d43e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtNy0xLTEtNDMyMzYx_833b9c0f-7b3d-459f-9256-5b0264d1be32">2024-06-30</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtOS0xLTEtNDMyMzYx_216ba01c-2cba-4845-87d7-bcdc06f5156d"
      unitRef="usd">-11732000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0d840b26f5ca44299c9df5e44f90fc95_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTEtMS0xLTQzMjM2MQ_2f42a3e3-a556-47c4-b12d-7ac81773c99f"
      unitRef="usd">144793000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1bee71915f974aae9db45279fca80f9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTMtMS0xLTQzMjM2MQ_f707b9d5-f690-4acc-aedc-a0aa4265bba9"
      unitRef="usd">139755000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4359a0f4c2824bf89e0c1d35492c622d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTphMGUyYjY3NDNlZmU0OGU0ODM4NDJkY2VhZTg5ODE3Mi90YWJsZXJhbmdlOmEwZTJiNjc0M2VmZTQ4ZTQ4Mzg0MmRjZWFlODk4MTcyXzMtMTUtMS0xLTQzMjM2MQ_cd407a6e-d05b-4481-a718-d5f951cab127"
      unitRef="usd">12203000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzU0ODI_bb495593-2f6a-4fb3-aa88-56c7870e6060">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2022, 2021 and 2020:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location of losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtOC0xLTEtNDMyMzYx_0a09470f-a940-4b87-b894-83d6a7900eaf"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtOC0xLTEtNDMyMzYx_f81a1b0e-11ec-406a-abc1-bcb197e86aa7"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMi0xLTEtNDMyMzYx_7e5aaa8c-3b51-497a-a6db-a5bd6135efa5"
      unitRef="usd">144793000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtNC0xLTEtNDMyMzYx_3779a0a6-f371-49aa-81fd-90501615aa9f"
      unitRef="usd">9532000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtNi0xLTEtNDMyMzYx_9633976f-29f4-481b-a6cb-0609319956a2"
      unitRef="usd">-21781000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i9a077f9cf6aa4b54953d1c9f69a4b68f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTAtMS0xLTQzMjM2MQ_4b5ae866-e589-4fb3-aae5-2baedbb4b749"
      unitRef="usd">-11732000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="iae78a02aa9e5419ea04e75f6a91b7549_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTItMS0xLTQzMjM2MQ_4b721913-6792-4dad-82bd-998c535226df"
      unitRef="usd">5509000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i2250811a97b8497b821ff145a717a8fc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzMtMTQtMS0xLTQzMjM2MQ_033e91cd-a124-4a74-9084-792990105caa"
      unitRef="usd">7081000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMi0xLTEtNDMyMzYx_f10a30b5-3342-45a5-86f2-1b865a0aff66"
      unitRef="usd">-36124000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtNC0xLTEtNDMyMzYx_da828a60-85e5-447d-864e-db9b7b2efc81"
      unitRef="usd">-2377000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtNi0xLTEtNDMyMzYx_6520726d-112d-4eae-976b-7558aacfed92"
      unitRef="usd">5435000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ib01c6e613af04d908d20a505b715f20e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTAtMS0xLTQzMjM2MQ_338e0c7e-0407-4e7e-ab2e-84761f149f71"
      unitRef="usd">2926000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="if6146c91ebdc4900a11cb8112ee55294_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTItMS0xLTQzMjM2MQ_93633496-cc84-4b82-b85a-ee2fee8089c3"
      unitRef="usd">-1376000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ib4bad21dc69244c7a2637812f6de30a9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzQtMTQtMS0xLTQzMjM2MQ_0d69f2fd-9967-4a0f-9b29-d0fe0b0702cc"
      unitRef="usd">-1768000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMi0xLTEtNDMyMzYx_2d2aaf33-b99d-4ca5-b00f-625434d13f41"
      unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtNC0xLTEtNDMyMzYx_e2bfef1a-ca05-4039-82fa-ffb445621544"
      unitRef="usd">7155000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtNi0xLTEtNDMyMzYx_ff72ce53-2337-40f7-aab4-25ca7d0faa0e"
      unitRef="usd">-16346000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTAtMS0xLTQzMjM2MQ_5f7ad3f0-d906-4de5-b6c5-4a84c858040d"
      unitRef="usd">-8806000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ied1852acd1a940848a9e6f6259c6c8f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTItMS0xLTQzMjM2MQ_37f14e62-890f-4ff5-ad53-e5f4450ecf89"
      unitRef="usd">4133000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ida1cfb1c6eff48a29352f2970a5eeb65_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90YWJsZTpkYzZhMjFiM2VhYTM0NzZkOTI5MTdmYTYxNTgxMWM1Yy90YWJsZXJhbmdlOmRjNmEyMWIzZWFhMzQ3NmQ5MjkxN2ZhNjE1ODExYzVjXzUtMTQtMS0xLTQzMjM2MQ_0da88264-3e7f-4b2e-871b-cc8c69e4bed8"
      unitRef="usd">5313000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i0b4946c95eb8498498d19a6faf87f113_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQzMzE_de9632c6-547b-44a6-beda-345f5243fd7f"
      unitRef="number">0.0459</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ1Nzc_f3ef8767-a07c-4f0f-8b24-969761238e98"
      unitRef="number">0.0396</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ2MDY_4b982d23-4eb6-4ace-91cc-f1130afe632c"
      unitRef="number">0.0452</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzQ2ODY_d184bdcc-2c37-4b9e-a2ca-c4ca71580d4d"
      unitRef="number">0.513</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InterestExpenseDebt
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxNzg_66cc3ef9-d22f-4665-b49c-fe4c6de51e45"
      unitRef="usd">339247000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxODI_d8487b32-9007-46d5-a072-7c43cac6b6c4"
      unitRef="usd">267049000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUxODk_011176e8-17e9-4577-9eb0-5fca64d95b7b"
      unitRef="usd">282932000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNTY_61916064-653a-4511-a097-8e094b353962"
      unitRef="usd">17772000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNjA_303e4d43-8316-4078-9622-bd85564a6245"
      unitRef="usd">18205000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzEvZnJhZzphMGQ1ZDdlMWFjZjI0OTFlYTdmYzY0ZmE4OWRmYzI5YS90ZXh0cmVnaW9uOmEwZDVkN2UxYWNmMjQ5MWVhN2ZjNjRmYTg5ZGZjMjlhXzUzNjc_a709af1f-bab9-4130-88ab-626885eb143e"
      unitRef="usd">21179000</us-gaap:AmortizationOfFinancingCosts>
    <dva:LeasesDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjE_2e3aefa7-e241-43bc-9307-42dba88fc989">Leases&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and December&#160;31, 2021, assets recorded under &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_155f47b5-2149-4835-8f82-29569b70bc53"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5Xzc2OTY1ODEzOTc2MjQ_6bdf6749-42f6-44d7-86f8-0f1107e1b206"&gt;finance leases&lt;/span&gt;&lt;/span&gt; were $319,546 and $322,060, respectively, and accumulated amortization associated with finance leases was $101,361 and $75,252, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long term basis. Both the sale and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;leaseback terms are generally market terms. The lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes short-term lease expense and sublease income, which are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2022 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(456,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense under all operating leases for 2022, 2021 and 2020 was $679,815, $673,904 and $663,819, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses &lt;/span&gt;&lt;/div&gt;or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 13 for further details on long-term debt.</dva:LeasesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i26fc0451360e403f820f0bba263549a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwMw_41707540-d62f-4595-b1fe-c84db16e1cb5">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwOQ_24a54570-7550-4045-8045-9b8564cdfbe1">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i26fc0451360e403f820f0bba263549a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzI0OQ_e83715ea-0eb7-4183-a8c5-080dc3f61169">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzI1NQ_bb268b4f-f111-4473-92d0-828f4b962f5c">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzU1OQ_b03f717e-a2b7-4c6c-b5d4-a9760177f05e"
      unitRef="usd">319546000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzU2Ng_fa2216ec-a80f-4c6e-934e-7045daa239a4"
      unitRef="usd">322060000</us-gaap:FinanceLeaseRightOfUseAsset>
    <dva:FinanceLeaseAccumulatedDepreciation
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzY0OA_1928aba3-8336-468f-acd7-a6d6fd320462"
      unitRef="usd">101361000</dva:FinanceLeaseAccumulatedDepreciation>
    <dva:FinanceLeaseAccumulatedDepreciation
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzY1NQ_5d9d4033-585b-4f35-a43f-e5fba9149fd5"
      unitRef="usd">75252000</dva:FinanceLeaseAccumulatedDepreciation>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i26fc0451360e403f820f0bba263549a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyMTE_41707540-d62f-4595-b1fe-c84db16e1cb5">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyMTc_24a54570-7550-4045-8045-9b8564cdfbe1">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i26fc0451360e403f820f0bba263549a0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyNTc_e83715ea-0eb7-4183-a8c5-080dc3f61169">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie0d695e6974549e6abbf008246487b2a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzEyNjM_bb268b4f-f111-4473-92d0-828f4b962f5c">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjg_8415bb60-37e2-46b1-9629-a4a2d400f177">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;(1) Includes short-term lease expense and sublease income, which are immaterial.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtMi0xLTEtNDMyMzYx_79f0053b-cedd-4a4d-8d5a-e06f2f4e9d83"
      unitRef="usd">552194000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtNC0xLTEtNDMyMzYx_cfe0d300-4841-458b-8a9e-da3636b01dc0"
      unitRef="usd">547923000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzMtNi0xLTEtNDMyMzYx_ca10351c-a954-4769-9b6e-bbf29edff9c3"
      unitRef="usd">541090000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtMi0xLTEtNDMyMzYx_74072d4a-7b33-44ec-b351-da33018c805e"
      unitRef="usd">127621000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtNC0xLTEtNDMyMzYx_15f6e419-366e-4709-a97f-f43ad0eabb55"
      unitRef="usd">125981000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzQtNi0xLTEtNDMyMzYx_1c72abb1-3036-4ba9-b815-40f77274bf18"
      unitRef="usd">122729000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtMi0xLTEtNDMyMzYx_f9563b3e-3aac-4e94-a3e3-7b3c41158ee2"
      unitRef="usd">27079000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtNC0xLTEtNDMyMzYx_e07d8284-0011-4039-8552-6156ffca401c"
      unitRef="usd">26846000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzYtNi0xLTEtNDMyMzYx_4212a2df-2743-42bb-8e5d-f8e2ba794e83"
      unitRef="usd">24720000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctMi0xLTEtNDMyMzYx_4d0c4cea-d53c-4fb4-81a0-3d20a4c8706e"
      unitRef="usd">12776000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctNC0xLTEtNDMyMzYx_32acfabc-4b89-473d-80e7-8eba577b913b"
      unitRef="usd">13988000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzctNi0xLTEtNDMyMzYx_f64eb740-4267-4e32-a46d-3bd833b527f4"
      unitRef="usd">14421000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtMi0xLTEtNDMyMzYx_87c73007-c2d9-49c6-be97-3ecf20f61a1c"
      unitRef="usd">719670000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtNC0xLTEtNDMyMzYx_09a7e0f1-c7b9-4fb7-9875-51ff18e0bd4a"
      unitRef="usd">714738000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTo5OTFkYWUyZWQ2MGU0YmU2YjBlYWI1YzJhYmFiMDc1NC90YWJsZXJhbmdlOjk5MWRhZTJlZDYwZTRiZTZiMGVhYjVjMmFiYWIwNzU0XzgtNi0xLTEtNDMyMzYx_6c7de1f0-7fe0-4d93-8ca6-3ba414009d7d"
      unitRef="usd">702960000</us-gaap:LeaseCost>
    <dva:LeaseOtherInformationTableTextBlockTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNjk_995cfd0e-7c24-4e68-a43a-afa3e92aee70">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:LeaseOtherInformationTableTextBlockTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtMi0xLTEtNDMyMzYx_65151ab6-b3c9-4385-a090-371e36b48660">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtNC0xLTEtNDMyMzYx_e8bcb424-25fe-44f7-b825-bf2c9070995b">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzMtNi0xLTEtNDMyMzYx_9ce13d8c-0dff-4bd7-9e55-9e3ec80a73ea">P8Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtMi0xLTEtNDMyMzYx_a0c3fbc1-1f4f-4a07-9bba-6ded1e78d10c">P9Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtNC0xLTEtNDMyMzYx_9724dc06-987a-48b3-bd3c-babfe759e465">P10Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzQtNi0xLTEtNDMyMzYx_7dc5897f-c2a6-46c1-83db-e4b361b1e5ee">P10Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtMi0xLTEtNDMyMzYx_c9007351-6703-44af-8dde-53fc1d45a970"
      unitRef="number">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtNC0xLTEtNDMyMzYx_a2e7d9aa-d13f-4b90-b3ec-5ac23edd9ecb"
      unitRef="number">0.035</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie7791c0dc3604a5096d82544cd2dc55d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzYtNi0xLTEtNDMyMzYx_90853a61-318f-4de2-bbd1-fae57a4d10ab"
      unitRef="number">0.038</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2d42086277b545f8973c9e4cd170ecc1_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctMi0xLTEtNDMyMzYx_28c0134e-7754-4adc-a98d-f1e84ff37cb4"
      unitRef="number">0.045</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ic69de63a548f40878bfa7836ee961e78_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctNC0xLTEtNDMyMzYx_95af0cc9-e41b-4a66-bb22-d37fb73b6e79"
      unitRef="number">0.045</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ib5680e5007324449948b894d87e40d7b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiYTZhNmYyMWNkMjM0NzFjODJiYzE2ZDI4OTEwYWFhNS90YWJsZXJhbmdlOmJhNmE2ZjIxY2QyMzQ3MWM4MmJjMTZkMjg5MTBhYWE1XzctNi0xLTEtNDMyMzYx_b590f873-aa40-47e8-a2c4-dcd1b6c88bb4"
      unitRef="number">0.051</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItMi0xLTEtNDMyMzYx_f304a952-7ccb-41f7-8197-87aa2236d8d5"
      unitRef="usd">28005000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItNC0xLTEtNDMyMzYx_b73cec6d-7fa6-43dc-9c17-b289f429e341"
      unitRef="usd">17137000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzItNi0xLTEtNDMyMzYx_7ac2dc4b-7896-497c-b914-ac6d187b44d1"
      unitRef="usd">34301000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:OperatingLeasePayments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtMi0xLTEtNDMyMzYx_5f17f884-6592-4f51-b972-91d20adfa0e5"
      unitRef="usd">696291000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtNC0xLTEtNDMyMzYx_af590bed-68e5-4d34-ac7d-fe157cf90e81"
      unitRef="usd">684186000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzQtNi0xLTEtNDMyMzYx_0b96fd94-b12e-4da5-bda3-dd27c0612ffe"
      unitRef="usd">661318000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtMi0xLTEtNDMyMzYx_da87101c-ba51-44e4-8599-fcf577ed9ea4"
      unitRef="usd">20103000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtNC0xLTEtNDMyMzYx_c18f1779-f2d3-4f5b-90a0-28da0030f0f2"
      unitRef="usd">21343000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzUtNi0xLTEtNDMyMzYx_6a950e68-a7e4-46cb-b1ea-387f59881ff1"
      unitRef="usd">20981000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtMi0xLTEtNDMyMzYx_100e885e-7843-455d-8444-26d90bc816b8"
      unitRef="usd">24329000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtNC0xLTEtNDMyMzYx_5ddd640a-d6ea-441f-addc-2b095124ba3a"
      unitRef="usd">22445000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzYtNi0xLTEtNDMyMzYx_2e1413fd-6ee1-498c-9b10-27e05e071d4b"
      unitRef="usd">24780000</us-gaap:FinanceLeasePrincipalPayments>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctMi0xLTEtNDMyMzYx_549baf9d-538b-4598-8d57-8bf92ef262b4"
      unitRef="usd">278108000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctNC0xLTEtNDMyMzYx_31b9d627-05b6-4dc3-b427-4b77542aec80"
      unitRef="usd">361101000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTowMDI5YmNiZjQ1YTY0MjFkYWJlZTE4YWUwZmI1MTI5ZS90YWJsZXJhbmdlOjAwMjliY2JmNDVhNjQyMWRhYmVlMThhZTBmYjUxMjllXzctNi0xLTEtNDMyMzYx_98f24d66-c54a-4c0e-90c3-31b7688dd82a"
      unitRef="usd">401559000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:ScheduleOfMinimumLeasePaymentsTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzIwNTk_240abcae-9b86-4aba-b17b-6b7112349572">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2022 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(456,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_d67d3c73-6919-4dda-bdf1-d30137c634fd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMC0xLTEtNDMyMzYx_ffe627ff-f565-4f18-98c1-126b4ab143fa"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfMinimumLeasePaymentsTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzEtMi0xLTEtNDMyMzYx_68aaf226-760d-493b-95e5-3e2f9b7fd026"
      unitRef="usd">492566000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzEtNC0xLTEtNDMyMzYx_1bb1dbab-5d8c-4abc-8e6a-3c8aa7adaf0f"
      unitRef="usd">37442000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzItMi0xLTEtNDMyMzYx_4f69a345-669a-4872-8e44-ef2993a3a524"
      unitRef="usd">500422000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzItNC0xLTEtNDMyMzYx_c7ab1d8a-fa7a-44f3-97f9-892540f9d332"
      unitRef="usd">37951000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzMtMi0xLTEtNDMyMzYx_d0ae8f29-6730-4d0c-b47b-eb83abd64421"
      unitRef="usd">452080000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzMtNC0xLTEtNDMyMzYx_9cb814d4-8b7e-4154-82a8-4cd9cecf740b"
      unitRef="usd">38125000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzQtMi0xLTEtNDMyMzYx_0617fd7d-2916-4835-8432-ee765f27f495"
      unitRef="usd">400879000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzQtNC0xLTEtNDMyMzYx_72d9c47a-117f-46df-92f0-2e2627c67261"
      unitRef="usd">36908000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzUtMi0xLTEtNDMyMzYx_db559aac-672c-4e1f-8d16-f9ccfaf0a42a"
      unitRef="usd">333580000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzUtNC0xLTEtNDMyMzYx_61cb453e-5697-46e8-a0d1-256ee5ae7cba"
      unitRef="usd">35569000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzYtMi0xLTEtNDMyMzYx_7f99c8c2-4830-4ef7-891a-82dae78c482e"
      unitRef="usd">1175340000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzYtNC0xLTEtNDMyMzYx_bb0442f4-852d-4570-ad5e-1d042e5c296b"
      unitRef="usd">145987000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzctMi0xLTEtNDMyMzYx_9849bcf1-b7d1-45a7-b632-e722a27e6017"
      unitRef="usd">3354867000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzctNC0xLTEtNDMyMzYx_ae9f6d25-67ca-41ac-a63b-65c9ce222cc4"
      unitRef="usd">331982000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzgtMi0xLTEtNDMyMzYx_dfa769d2-9d46-4284-8d37-64d22e83814c"
      unitRef="usd">456398000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzgtNC0xLTEtNDMyMzYx_8e1f1ba1-9921-4c42-b06e-515eb4a2dd04"
      unitRef="usd">58294000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktMi0xLTEtNDMyMzYx_562b7567-953a-42ba-9962-3becef20068d"
      unitRef="usd">2898469000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90YWJsZTpiODc5Y2VhOGM1YWI0YTcwYWUwNDQ3OWM2MDBjYmRiZC90YWJsZXJhbmdlOmI4NzljZWE4YzVhYjRhNzBhZTA0NDc5YzYwMGNiZGJkXzktNC0xLTEtNDMyMzYx_3c233235-5445-402a-9348-3fb4b4eb7fed"
      unitRef="usd">273688000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCost
      contextRef="i09a6f14a780d4294baf4b2885e32978d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NTM_6c6eca8f-e701-4550-abe9-35ea0dbbf44b"
      unitRef="usd">679815000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i81ab07f87a174fb2b7c3fee62cf056b7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NTc_9dd4e985-d800-487f-835a-50c1e993a2d5"
      unitRef="usd">673904000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1eff9aaeed62457e946eb316f31451f1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzQvZnJhZzpkODg5NWJhZmZjYmY0YTMyOTIzNmFlNDM4MTAxYzE0OS90ZXh0cmVnaW9uOmQ4ODk1YmFmZmNiZjRhMzI5MjM2YWU0MzgxMDFjMTQ5XzE2NjQ_3bb3fefe-7a11-4222-adf0-2cb50cc2cfe8"
      unitRef="usd">663819000</us-gaap:LeaseCost>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzIyNTg_9ae9c813-f3ef-4728-8e61-81794f6a3e47">Employee benefit plans&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2022, 2021 and 2020, the Company accrued matching contributions totaling approximately $70,084, $68,658 and $70,180, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan, as well as other legacy deferral plans. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2022, 2021 and 2020 were $3,573, $2,962 and $3,637, respectively. Deferred amounts are generally paid out in cash at the participant&#x2019;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2022, 2021 and 2020 the Company distributed $3,731, $11,887 and $3,139, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#x2019;s general creditors in the event of its bankruptcy. As of December&#160;31, 2022 and 2021, the total fair value of assets held in these plans' trusts was $32,944 and $38,019, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other income. See Note 5 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzQ0NA_0909f6ed-f66b-4e68-8177-542b1bb8668a"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzQ4NA_4fae016f-d737-49f7-80f4-4c131f590251"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzczMg_23a7e76f-6fec-4fd7-8b8f-7a898c29ca38"
      unitRef="usd">70084000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzczNg_4a647436-5113-4a05-ba8f-e49eed760ef3"
      unitRef="usd">68658000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2Xzc0Mw_d7b8b9cf-2fd3-4898-8a45-cbc2cde23796"
      unitRef="usd">70180000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i9860868c23e043df847009e53cc53fdc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzExNTY_ac76dfe5-7663-4ceb-a8ca-e2c36b0c7f29"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyODY_0591438f-2b45-4069-9264-12fdedd656e6"
      unitRef="usd">3573000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i61afa366cd62422b84371143b00ef79c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyOTA_1f24aec3-32f7-4138-b2fb-4d75d970081d"
      unitRef="usd">2962000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzEyOTc_d39b6588-0d6e-4765-a00a-80386b3e1f90"
      unitRef="usd">3637000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid
      contextRef="if65a60ee425a4744b36f8394d902fb12_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE1OTg_e83dd24a-2ccf-4009-af4e-47c28f679503"
      unitRef="usd">3731000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid
      contextRef="i61afa366cd62422b84371143b00ef79c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE2MDI_936bec5b-fb2b-4f1b-8a7d-f81f31c70c4e"
      unitRef="usd">11887000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid
      contextRef="i3a5e9ffd926a4e6b8b8c322f8e879da3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE2MDk_e44413b0-ce65-42e3-ad6d-63d7ef2613c8"
      unitRef="usd">3139000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86a6007fcdfb46cd8c45962e916984df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzE5OTM_fc4a6e16-866a-4d0b-af82-810e047d92ca"
      unitRef="usd">32944000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa80e3707e984cba98b264df4ba470fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zMzcvZnJhZzpiYzMxMTk4NzQwMGY0NTMzOWRhYTBiODM4MGE1NDY0Ni90ZXh0cmVnaW9uOmJjMzExOTg3NDAwZjQ1MzM5ZGFhMGI4MzgwYTU0NjQ2XzIwMDA_a1fd6343-2dd5-461f-b5a5-2d0bed847c16"
      unitRef="usd">38019000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:LossContingencyDisclosures
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzE4MTk1_b108fa69-c736-4f65-ac39-5dfb529d5cc5">Contingencies&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#x2019;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#x2019;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; suits, governmental investigations (which frequently arise from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#x2019;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Certain Governmental Inquiries and Related Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2016 U.S. Attorney Texas Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney&#x2019;s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company&#x2019;s relationships with pharmaceutical manufacturers. The government's investigation covers the period from January&#160;1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government's investigation and that included total monetary consideration of $63,700, as previously disclosed, of which $41,500 was an incremental cash payment and $22,200 was for amounts previously refunded, and all of which was previously accrued. The government&#x2019;s investigation is ongoing with respect to issues related to DaVita Rx's historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. On September 15, 2021, the U.S. Attorney&#x2019;s Office notified the U.S. District Court, Northern District of Texas, of its decision and the decision of 31 states not to elect to intervene at this time in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Doe v. DaVita Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The court then unsealed the complaint, which alleges violations of the FCA, by order dated September 17, 2021. The complaint was not served on the Company. In December 2021, the private party relator filed a notice of voluntary dismissal of all claims and the court entered an order dismissing the claims without prejudice. The Company is continuing to cooperate with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2017 U.S. Attorney Colorado Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In November 2017, the U.S. Attorney&#x2019;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#x2019;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 U.S. Attorney New Jersey Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In March 2020, the U.S. Attorney&#x2019;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#x2019;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#x2019;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#x2019;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Doe v. DaVita, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#x2019;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Bayne v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. In January 2023, the private party relator served the Company with the amended complaint. The Company is continuing to cooperate with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 California Department of Insurance Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020, and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#x2019;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#x2019; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 Department of Justice Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In October 2020, the Company received a CID from the Department of Justice pursuant to an FCA investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. In February 2023, the Department of Justice notified the Company that it had closed its investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 District of Columbia Office of Attorney General Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In January 2023, the Company received a CID from the Office of the Attorney General for the District of Columbia in connection with an antitrust investigation concerning the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;American Kidney Fund (AKF). The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#x2019;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#x2019;s reputation, required changes to the Company&#x2019;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Antitrust Indictment and Putative Class Action Suit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#x2019;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Outpatient Medical Center Employee Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. No. 20-1641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On November 5, 2021, the United States Supreme Court granted certiorari of an appeal by an employer group health plan, the plan sponsor, and the plan&#x2019;s advisor of the U.S. Court of Appeals for the Sixth Circuit (Sixth Circuit) decision in the Company's favor. The questions presented involved whether the health plan violates the Medicare Secondary Payor Act (MSPA) by "taking into account" that plan beneficiaries are eligible for Medicare and/or by "differentiating" between the benefits that the plan offers to patients with dialysis versus others. On December 23, 2021, the Solicitor General on behalf of the United States filed an amicus brief supporting the petitioners' request to overturn the Sixth Circuit decision. On January 19, 2022, the Company filed its brief in support of the Sixth Circuit decision. On June 21, 2022, the United States Supreme Court reversed the Sixth Circuit decision and held that the employee health plan for Marietta Memorial Hospital did not violate the MSPA. The case has been remanded back to the lower court for resolution of the outstanding claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 16, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#x2019;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#x2019;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact &lt;/span&gt;&lt;/div&gt;the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#x2019;s business, results of operations, financial condition, cash flows or reputation.</us-gaap:LossContingencyDisclosures>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM3NzQ_61d9d12c-c890-4cfe-a148-398c79c0282f"
      unitRef="usd">63700000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ib94215c12b694944b79ef5ea39279483_D20171201-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM4MTI_9c0c08da-1ab8-4a68-a018-8834bae25fd1"
      unitRef="usd">41500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i569c0d52c6c6426faf8f5a35ede23d64_D20171201-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDMvZnJhZzpmOTY3ZTlkYjliOGM0MTE4YWQzZGY4NTZiZWY1MDU0OS90ZXh0cmVnaW9uOmY5NjdlOWRiOWI4YzQxMThhZDNkZjg1NmJlZjUwNTQ5XzM4NTE_abeef089-0c0d-487e-9fa2-88f5d4118460"
      unitRef="usd">22200000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQ1ODA_5fd05404-3d7e-4f55-aa88-983c9d4354f0">Noncontrolling interests subject to put provisions and other commitments&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2022, the remaining minimum purchase commitments under these arrangements were approximately $712,802, $469,760, $362,431 and $379,832 for the years 2023, 2024, 2025 and 2026, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $9,038.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the letters of credit disclosed in Note 13 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <dva:DissolutionTermOfJointVentures
      contextRef="i33514b55ca394cd7a575fa78ed291e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzI1OTI_bb4fad8c-3eb2-4524-b923-c198ecfd72b4">P10Y</dva:DissolutionTermOfJointVentures>
    <dva:DissolutionTermOfJointVentures
      contextRef="i4a1982f37d8f4445bdd38a9db3d2ff05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzI1OTg_865a570a-8288-4f7f-a85a-75845398a67c">P50Y</dva:DissolutionTermOfJointVentures>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTA_0b052b54-358e-444c-9f0d-4fa4631073e6"
      unitRef="usd">712802000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTQ_88075b70-30f9-4236-8adc-b55aca46dfc1"
      unitRef="usd">469760000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NTg_b30a9a7f-8d5e-4186-8e00-7ed773fb0e38"
      unitRef="usd">362431000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzM4NjY_34bd58fd-e214-4c5f-ab9c-2a0f6278118e"
      unitRef="usd">379832000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:OtherCommitment
      contextRef="i8274525480784946977c6314bbd7cc5b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQzNjg_e6572ae3-681b-4793-a144-84bd0566d458"
      unitRef="usd">9038000</us-gaap:OtherCommitment>
    <dva:OffBalanceSheetFinancingArrangements
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDYvZnJhZzpmYjgwY2M1NzgzN2M0MTA5OTAzNWJmNWM0ZTE0OGU2Ny90ZXh0cmVnaW9uOmZiODBjYzU3ODM3YzQxMDk5MDM1YmY1YzRlMTQ4ZTY3XzQ1Mjc_4c9d0a3e-4cfe-4b85-b867-53a2ffec7c6a"
      unitRef="usd">0</dva:OffBalanceSheetFinancingArrangements>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5Nzg_1b84a222-d8a8-4046-a606-38919071183d">Stock-based compensation&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#x2019;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization and summary of significant accounting policies" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information on how the Company measures and recognizes stock-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term incentive compensation plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#x2019;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are also stated on a full value share basis rather than on an option-equivalent basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2022, there were 6,815 shares available for future grants under the 2020 Plan. The Company&#x2019;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The DaVita Healthcare Partners Inc. 2011 Incentive Award Plan (the 2011 Plan) was the Company&#x2019;s prior omnibus equity compensation plan and authorized the Company to award stock options, stock appreciation rights, restricted stock units, restricted stock, and other stock-based or performance-based awards. The 2011 Plan mandated a maximum award term of five years and stipulated that stock appreciation rights and stock options be granted with prices not less than fair market value on the date of grant. The 2011 Plan also required that full value share awards such as restricted stock units reduce shares available under the 2011 Plan at a ratio of 3.5:1. The Company&#x2019;s stock appreciation rights and stock units awarded under the 2011 Plan generally vest over 36 months to 48 months from the date of grant. The 2011 Plan was terminated with respect to any new awards upon stockholder approval of the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A combined summary of the status of the Company&#x2019;s stock-settled awards under both the 2020 Plan and 2011 Plan, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.01&#x2013;$60.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.01&#x2013;$70.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the aggregate intrinsic value of stock-based awards exercised was $149,442, $208,585 and $49,258, respectively. At December&#160;31, 2022, the aggregate intrinsic value of stock-based awards outstanding was $289,942 and the aggregate intrinsic value of stock awards exercisable was $25,508.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated fair value of stock-based compensation awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#x2019;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term of the awards:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#x2019;s historical exercise and post-vesting termination patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#x2019;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#x2019;s common stock under this plan for the 2022, 2021 and 2020 purchase periods were $18,061, $19,626 and $17,148, respectively. Shares purchased pursuant to the plan&#x2019;s 2022, 2021 and 2020 purchase periods were 285, 203 and 222, respectively. At December&#160;31, 2022, there were 5,702 shares remaining available for future grants under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of participants&#x2019; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2022, 2021 and 2020, respectively: expected volatility of 31.7%, 39.0% and 40.4%; risk-free interest rates of 1.3%, 0.1% and 1.0%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $26.50, $34.94 and $22.06 for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized $95,427, $102,209 and $91,458 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2022, 2021 and 2020 were $14,723, $13,853 and $11,775, respectively. As of December&#160;31, 2022, there was $149,081 of total estimated but unrecognized stock-based compensation expense under the Company&#x2019;s equity compensation and employee stock purchase plans. The Company expects to recognize this expense over a weighted average remaining period of 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the Company received $24,805, $46,990 and $8,957, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzE5NjA_e0a866de-d1d5-4c1c-85cd-dd8ed6f0d841">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions
      contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI0MTc_461a362a-baaf-4d94-972e-22192eaca955"
      unitRef="shares">1</dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions>
    <dva:StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance
      contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI0NDY_5dc47461-0422-4cf2-a0aa-d737c515e742"
      unitRef="shares">4</dva:StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance>
    <dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward
      contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI1MzE_e80a27b3-411f-472a-9578-a12590e7f336"
      unitRef="shares">1</dva:StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward>
    <dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance
      contextRef="i0c7b0e47886c485ab3eea202de3f181f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI1NjA_527fcb7e-4645-4506-858a-3cf341b6c4af"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia707dbef043d49869bd8d75dec1d7c30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI2NzM_91add530-bb04-4eba-96d9-28e4eed1d674"
      unitRef="shares">6815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i80d73225bc934812a0e7e7641b1ce671_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI4MDc_cd06a372-1001-4a79-a9f4-f12986f8d074">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i70676e0b814f41d19fa3a297db951b3b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzI4MTM_f5c0bd67-233b-4823-bb15-8a36a71435ae">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzMxMjk_10a77849-7ab2-46ba-91e2-87bdfe085124">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dva:SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio
      contextRef="ia534b2a58f814eef8d69b47f530568c8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM0MTk_ce9e09a6-c7ab-4357-bde6-87e2efc41ebd"
      unitRef="number">3.5</dva:SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i26a660eca1df4c6aac1cebc8b4113bc0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM1Mjk_e1342705-9f0f-414f-a5d9-cf0739075389">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7063491894094779acab6b28c5595e90_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM1MzU_02971008-0ffc-4a0c-be07-8ab9e70b154d">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NzI_1529f44b-d67f-4823-972a-4004f716497f">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A combined summary of the status of the Company&#x2019;s stock-settled awards under both the 2020 Plan and 2011 Plan, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i75140de7fc2e44a4aae6591587030c31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtMS0xLTEtNDMyMzYx_b85f3c02-6907-434b-a68f-935f86a6fa58"
      unitRef="shares">5943000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i75140de7fc2e44a4aae6591587030c31_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtMy0xLTEtNDMyMzYx_e4f76ea1-bd20-4055-b038-431dafd9f17b"
      unitRef="usdPerShare">64.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5f2232a592ba45f98e9d502b586f1a60_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzMtNy0xLTEtNDMyMzYx_82ecdaaa-8be4-40e1-8ac4-2207a51cddf7"
      unitRef="shares">3385000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtMS0xLTEtNDMyMzYx_7bb8ad50-8eca-460c-9b31-03fb6bc023fd"
      unitRef="shares">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtMy0xLTEtNDMyMzYx_32574841-b1d8-4672-9cad-7767fdac57bf"
      unitRef="usdPerShare">110.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzQtNy0xLTEtNDMyMzYx_ad26ba32-f461-41d4-9eb9-ccce01f1e8cc"
      unitRef="shares">1152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzUtNy0xLTEtNDMyMzYx_4daaf5f3-a497-4008-9efe-ed601cc200d4"
      unitRef="shares">136000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtMS0xLTEtNDMyMzYx_ace988a9-ad71-4064-8956-e54244c9568a"
      unitRef="shares">619000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtMy0xLTEtNDMyMzYx_9241b15f-eaa9-4dc9-b6ce-e54de4365a2f"
      unitRef="usdPerShare">63.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzYtNy0xLTEtNDMyMzYx_ab962d21-2d46-4a37-8c04-2e496e48c938"
      unitRef="shares">1269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctMS0xLTEtNDMyMzYx_de09ef91-a1b1-4522-8be7-264ed625f6c8"
      unitRef="shares">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctMy0xLTEtNDMyMzYx_d650a853-0b2d-49e4-9930-7a118dea7cd5"
      unitRef="usdPerShare">55.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzctNy0xLTEtNDMyMzYx_18c642e1-4ee1-455c-969b-55af3e64f18e"
      unitRef="shares">332000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtMS0xLTEtNDMyMzYx_9454e602-bdb6-4a8a-ab52-f5b13966dd2c"
      unitRef="shares">5390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtMy0xLTEtNDMyMzYx_bf94e425-b0d5-4830-89ce-270ca0ac7ec4"
      unitRef="usdPerShare">66.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtNS0xLTEtNDMyMzYx_8a193ad2-cf75-4236-83d0-079a589a2805">P1Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9218664971064274b79221f47df0c986_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtNy0xLTEtNDMyMzYx_7f78ff96-7401-4673-9407-c58390e732a0"
      unitRef="shares">3072000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzgtOS0xLTEtNDMyMzYx_96ea0d73-7c92-46d8-972b-ba94e26e8556">P1Y11M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktMS0xLTEtNDMyMzYx_2877c3be-657d-496e-aafa-8b489abe66a2"
      unitRef="shares">2618000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5730e25527b841269e9c3b2c7b43ecbe_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktMy0xLTEtNDMyMzYx_a1030c44-6e9a-480c-8c69-8035a5d6216b"
      unitRef="usdPerShare">64.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktNS0xLTEtNDMyMzYx_543a0bad-3f51-427d-9fb0-7f70ff61f3c1">P1Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="i9218664971064274b79221f47df0c986_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzktNy0xLTEtNDMyMzYx_a2c13371-dfa5-44f0-950f-5a48eb020598"
      unitRef="shares">0</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzExLTEtMS0xLTQzMjM2MQ_bb1d8998-96db-4397-9327-9ad9f571947e"
      unitRef="usdPerShare">35.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iffc34995567241ad817bb54bfb7d870d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzExLTctMS0xLTQzMjM2MQ_f994e8f7-b05e-4eb2-a272-559a0bd89b4d"
      unitRef="usdPerShare">107.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bbcbd8a1eca4275a3ad805b14ce01b3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEyLTEtMS0xLTQzMjM2MQ_1b6828c4-80bb-4788-b90b-0ec661011266"
      unitRef="usdPerShare">32.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d31f8da40914157a9a538177f086aea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEyLTctMS0xLTQzMjM2MQ_69474836-d156-441a-a85d-815976d96862"
      unitRef="usdPerShare">109.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2b9b576fd9a14515a102d4388e16984e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEzLTEtMS0xLTQzMjM2MQ_94aeeb5b-95cb-4cdc-a2e4-0f6bfefe3c1d"
      unitRef="usdPerShare">26.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8065cc2fe8ad46cbbb4359c02e4ac3e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZToyZDRiMmJkZmZlNmE0NjkwOTI4MTRhOGQ2YTA4ODYzMS90YWJsZXJhbmdlOjJkNGIyYmRmZmU2YTQ2OTA5MjgxNGE4ZDZhMDg4NjMxXzEzLTctMS0xLTQzMjM2MQ_732fef8a-3976-4d94-be16-3070cfad312e"
      unitRef="usdPerShare">77.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NjA_711bb92d-105c-4ef2-a71a-545ce92bd254">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.01&#x2013;$60.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.01&#x2013;$70.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItMi0xLTEtNDMyMzYx_5304b77d-dd7a-4e69-80ea-35061a3ba5e4"
      unitRef="shares">1397000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItNC0xLTEtNDMyMzYx_776f3c79-ca01-4cb9-b32f-6369f1533a81"
      unitRef="usdPerShare">52.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItNi0xLTEtNDMyMzYx_3de68470-9090-416c-9d21-793f44763fe6"
      unitRef="shares">401000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ife1e88888ab0427c992c8ee57d880fb7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzItOC0xLTEtNDMyMzYx_89218c42-1c4d-4927-a545-ed7082a62ec6"
      unitRef="usdPerShare">52.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i473afde79b764c408f9a11119b563a06_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtMi0xLTEtNDMyMzYx_d404c18e-3d7e-40fb-a7c6-48b04ba5de44"
      unitRef="shares">3462000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i473afde79b764c408f9a11119b563a06_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtNC0xLTEtNDMyMzYx_2b3a51a8-b484-49ae-9ff4-acbc57241e51"
      unitRef="usdPerShare">67.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i473afde79b764c408f9a11119b563a06_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtNi0xLTEtNDMyMzYx_973f8ce1-ef34-4500-80ec-173fba04a46b"
      unitRef="shares">2212000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i473afde79b764c408f9a11119b563a06_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzMtOC0xLTEtNDMyMzYx_bcf07528-5a04-46c0-93d1-800c038e6895"
      unitRef="usdPerShare">67.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtMi0xLTEtNDMyMzYx_819b40a3-c0aa-4731-876f-f782eda9a293"
      unitRef="shares">269000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtNC0xLTEtNDMyMzYx_549756b9-a48a-434f-9582-558cce9c4f45"
      unitRef="usdPerShare">75.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtNi0xLTEtNDMyMzYx_80e47618-fde3-4412-9f0e-00acdcd7c45f"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic49615a7c9ba40cda423f5c1fdcc9d3f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzQtOC0xLTEtNDMyMzYx_4e2b7e9a-5acf-494c-b07f-839910882c2e"
      unitRef="usdPerShare">70.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtMi0xLTEtNDMyMzYx_06e75e4c-791a-41d9-b82f-907219dee410"
      unitRef="shares">132000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtNC0xLTEtNDMyMzYx_701662d0-4247-4bf0-9de0-51d5e1ab954a"
      unitRef="usdPerShare">108.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtNi0xLTEtNDMyMzYx_0736e403-6df0-43f0-9080-083578d2cb20"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i9188f4fd1e3c4de9b56bd241605dea3c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzUtOC0xLTEtNDMyMzYx_ef8ef19f-107d-47aa-81d6-ddd979fd3493"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtMi0xLTEtNDk4NTQ4_dc515b43-b3c3-475c-8941-afa6914cc87e"
      unitRef="shares">130000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNC0xLTEtNDk4NTQ4_884a22d5-ebe7-46a7-80a4-d4d1b1d77aff"
      unitRef="usdPerShare">110.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNi0xLTEtNDk4NTQ4_a2f08882-d07f-46fd-a6a2-e082645e8191"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i129545bae5ea4b86ba4108e9bde79749_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtOC0xLTEtNDk4NTU4_1c70de3c-503d-45e8-916f-0405585c496a"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtMi0xLTEtNDMyMzYx_f66901e1-bc94-421b-91d7-07960d58fd03"
      unitRef="shares">5390000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNC0xLTEtNDMyMzYx_fed62002-256e-4472-908d-5c53b4cbe794"
      unitRef="usdPerShare">66.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtNi0xLTEtNDMyMzYx_f80b9b17-ba76-406a-be53-8494a7542f89"
      unitRef="shares">2618000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo1OGY5NGU5YWE1MTQ0NTBlOGE1MjliODE3OWY5YWZiNi90YWJsZXJhbmdlOjU4Zjk0ZTlhYTUxNDQ1MGU4YTUyOWI4MTc5ZjlhZmI2XzYtOC0xLTEtNDMyMzYx_d1aa2a1b-6944-4d40-8d71-0363fbc7e9c3"
      unitRef="usdPerShare">64.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MDQ_4373086e-23b5-431c-9764-7bb18ae804f6"
      unitRef="usd">149442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MDg_b0cdb14b-1e54-4b8f-ba4a-021ccbfb5e84"
      unitRef="usd">208585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzM5MTU_4bcf07bb-7139-4d05-9ec6-670700c647fd"
      unitRef="usd">49258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzQwMDg_91daaae9-9d7d-4cfa-9b60-ad0ae3d11e11"
      unitRef="usd">289942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzQwNzc_1e28f7cc-fa79-4c29-9a62-bc27d070e84e"
      unitRef="usd">25508000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5NjI_0397c07e-bcbb-4eaf-bc69-f256225b9fed">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItMS0xLTEtNDMyMzYx_6d1dd51e-a8b3-4524-90e6-3a8b76288b3d">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItMy0xLTEtNDMyMzYx_cfa36180-f588-4c7e-b314-471ec1db051a">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzItNS0xLTEtNDMyMzYx_b6781c8d-ab8c-4d39-a17b-93c384813d66">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtMS0xLTEtNDMyMzYx_cd9c9706-4eb8-4641-90f9-6d9f42631ff9"
      unitRef="number">0.343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtMy0xLTEtNDMyMzYx_9d180dc0-f3c5-4e63-8157-70e626c6b5b7"
      unitRef="number">0.343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzMtNS0xLTEtNDMyMzYx_4ff6526e-9149-4454-bd23-7b38464c5fe6"
      unitRef="number">0.282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtMS0xLTEtNDMyMzYx_88063a08-fadf-4aa9-a9c3-932ca78aef4c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtMy0xLTEtNDMyMzYx_42905482-61ef-4ed5-8ce4-ea1e6462c3a5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzQtNS0xLTEtNDMyMzYx_c1e04357-cbc8-49e1-800a-f40fecb758d1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtMS0xLTEtNDMyMzYx_6c2322ae-bad9-41f5-8a4d-3ed3a4a42513"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic3d84754766341c79ebed44c8c49b5f9_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtMy0xLTEtNDMyMzYx_6b3f7abd-8f86-4ee5-a808-23ea0988645e"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2aa67a8e011340a78d0127ddb3969f88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90YWJsZTo3MTYxOTY4ZDVlZDg0MjhmYWZlNTljZDFlMDdmNTNhMC90YWJsZXJhbmdlOjcxNjE5NjhkNWVkODQyOGZhZmU1OWNkMWUwN2Y1M2EwXzUtNS0xLTEtNDMyMzYx_8243aaff-a5a4-404e-97b7-2bf4ba4d2356"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc1NTY_6ee9707b-909c-4ff9-b705-9b8d588d36dc"
      unitRef="usd">25000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i654c073e58bd41ae9d35684155b57deb_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc4NzM_7e95c406-053c-4dd9-b99f-b4a13c9b76fd"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i965432f8e1b1446f8d9cafc77f04fd6c_D20221231-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzc5NTA_fd96a496-021f-4d11-a325-70aace75647b"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares
      contextRef="ie6f172bac13b435484bfaf9fd3326e51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMjA_b78b3ae9-9af1-4f55-9bf5-c3e4623903df"
      unitRef="usd">18061000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares
      contextRef="i47c9f860645046bd9f1febf1ee03749e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMjQ_f5fc5b6b-f8c7-44f8-a363-afd1ef163e0b"
      unitRef="usd">19626000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares
      contextRef="i79f354c25ca54754ab7b68f40dbd8a25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgyMzE_9f71f338-50e5-4a1d-8593-eef7a4c675cb"
      unitRef="usd">17148000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMjU_ab678efd-5fde-41cc-bfe0-b305039de7ab"
      unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMjk_956f555c-e396-42cf-9317-95a80c6888f9"
      unitRef="shares">203000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzMzY_e035adeb-39c9-4d42-a664-f268f1160e1a"
      unitRef="shares">222000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie6f172bac13b435484bfaf9fd3326e51_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzgzNzI_34fd58ad-74a8-47a6-92cf-f93a7a7916b4"
      unitRef="shares">5702000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3MzI_bfd26127-1125-46db-a9a0-0525c9ff3052"
      unitRef="number">0.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3MzY_7b98648a-ef4b-46d0-a551-4b1e2a1fa0e1"
      unitRef="number">0.390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3NDM_22e628f8-cdd2-40c1-93e4-9bd0011fb070"
      unitRef="number">0.404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3NzU_0884daa0-6e03-44ad-81c8-c15a8893da08"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3Nzk_9880203f-b9f3-4763-921d-567a94e90388"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3ODY_7dc17683-d644-46cd-9f4c-782390e2a3ca"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg3OTQ_ac7d2bb6-f46c-4f84-810f-cd1d4b64aab1"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i13585ad1e13d40269fe218e3db22047e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MTI_755c82dd-20f6-43ba-b924-46b448be301f"
      unitRef="usdPerShare">26.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iacc0fabdd6e344538ef36adfb86c9811_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MTY_9686ea45-a16c-4a82-8934-ae10684af0a7"
      unitRef="usdPerShare">34.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f21b2a3cfbb49e584575be6f90308ae_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzg5MjM_be1516d9-40d1-4232-aff0-1957abea6871"
      unitRef="usdPerShare">22.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNjM_09f81b71-3733-40ad-afe7-80a565f72b8b"
      unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNjc_55ab2b7e-cdae-49c8-843c-b986adb7af2d"
      unitRef="usd">102209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkwNzQ_61fddbe9-e241-4a70-9090-2f1f9bff8796"
      unitRef="usd">91458000</us-gaap:ShareBasedCompensation>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNjc_935c958b-ee29-43ac-96bd-38c7ea53fa4f"
      unitRef="usd">14723000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNzE_7fb54eb7-5af5-4d83-af24-08caa2ead0cf"
      unitRef="usd">13853000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3XzkzNzg_14308b2a-ff64-48f9-87dc-0f1c70895fcc"
      unitRef="usd">11775000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk0MTY_b849c9b1-25a5-4f01-a150-1423164b1500"
      unitRef="usd">149081000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk2NTM_b0831b01-fd6f-4f00-b089-819fadf8a11f">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MTM_86e66e39-7657-4466-b876-f47f86ddf6be"
      unitRef="usd">24805000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MTc_1b497923-5625-456a-8c34-ca53fd5ed321"
      unitRef="usd">46990000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk3MjQ_3faa4ae8-120c-477c-8d36-5c9013629a00"
      unitRef="usd">8957000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNDkvZnJhZzpkN2U1NzZhYTY1YTA0NzdlYmQ3M2NiMDFkYzQwNDQ2Ny90ZXh0cmVnaW9uOmQ3ZTU3NmFhNjVhMDQ3N2ViZDczY2IwMWRjNDA0NDY3Xzk5MTQ_4b08d433-7ea7-434c-8404-f80e9da17685"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:TreasuryStockTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxNzk_eca59d31-593a-429e-9f7c-3982e2c6330c">Shareholders&#x2019; equity&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tender offer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The aggregate amounts paid for shares repurchased pursuant to the Company's 2020 tender offer for its shares during the year ended 2020, include the clearing price of $88.00 per share, plus related fees and expenses of $2,529.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December&#160;31, 2022 through February&#160;22, 2023, the Company did not repurchase any shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective on December 10, 2020, the Board terminated all remaining prior share repurchase authorizations available to the Company and approved a new share repurchase authorization of $2,000,000. Effective on December 17, 2021, the Board increased the Company's existing authorization by $2,000,000. The Company is authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February&#160;22, 2023, the Company has a total of $1,596,085 available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company retired all shares held in its treasury effective as of December&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Charter documents&#160;&amp;amp; Delaware law&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired additional ownership interests in several existing majority-owned partnerships for $20,775, $20,104 and $7,831 in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxODE_c8a9a760-0da0-47e0-b33a-baa280c7713c">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tender offer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average paid per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The aggregate amounts paid for shares repurchased pursuant to the Company's 2020 tender offer for its shares during the year ended 2020, include the clearing price of $88.00 per share, plus related fees and expenses of $2,529.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItMS0xLTEtNDMyMzYx_f900b864-8f17-4f6f-9cd7-1d1849e66349"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItMy0xLTEtNDMyMzYx_730daf29-5d43-4c81-8ad6-dd5a5b69f459"
      unitRef="shares">13877000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzItNS0xLTEtNDMyMzYx_5cc67655-3f34-4784-a0b1-16c4c7d92830"
      unitRef="shares">8495000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtMS0xLTEtNDMyMzYx_260a4fc3-de42-4dff-a584-b9e1ada8448c"
      unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtMy0xLTEtNDMyMzYx_13d6c710-fe75-40cb-ba16-06fcc728fafa"
      unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzMtNS0xLTEtNDMyMzYx_78c35132-6ab5-4dda-9030-13da3efb38f9"
      unitRef="usd">741850000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iee7f88346f374e438ede97086d426ca0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtMS0xLTEtNDMyMzYx_f8581737-610e-43c2-8198-356ab6f59594"
      unitRef="usdPerShare">97.33</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if8406d9c0cd74a3fafaf2763d483cdc5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtMy0xLTEtNDMyMzYx_d0867c44-c94c-479c-89ba-e77b3d436128"
      unitRef="usdPerShare">111.41</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i302d6e3229584f9787a6db6278186655_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzQtNS0xLTEtNDMyMzYx_f8e693d1-9533-4e81-8325-29ef7fe8b81b"
      unitRef="usdPerShare">87.32</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctMS0xLTEtNDMyMzYx_72580129-a2dc-431e-bbf9-e016c6deddb0"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctMy0xLTEtNDMyMzYx_17667432-a647-431d-9304-0ccd0c26ee41"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzctNS0xLTEtNDMyMzYx_094bc759-a9f0-487e-96fd-253b939d1efb"
      unitRef="shares">7982000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtMS0xLTEtNDMyMzYx_49bfca22-f47e-4869-913a-a25c94a02798"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtMy0xLTEtNDMyMzYx_7ca2f130-49d5-47e3-b1a7-47b20de1605c"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzgtNS0xLTEtNDMyMzYx_22090614-3596-410b-be97-4c69b7716e85"
      unitRef="usd">704917000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i79796daeb663494bae2f4ba44b76bfce_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktMS0xLTEtNDMyMzYx_3bbd36fb-98be-44e2-b85f-1c983af482d1"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i47b773f6d89d40b2a446c297885ecea5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktMy0xLTEtNDMyMzYx_8594d02a-a67d-48bf-a44d-88cdf4e5393f"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzktNS0xLTEtNDMyMzYx_d37c6dd3-59bf-4af6-bdf6-723ddff50991"
      unitRef="usdPerShare">88.32</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTEtMS0xLTQzMjM2MQ_95dda5ae-6864-4468-b227-7d04e6fadb8c"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTMtMS0xLTQzMjM2MQ_dbbbe27f-7e23-453e-9ce6-bf8c184a9ed4"
      unitRef="shares">13877000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEyLTUtMS0xLTQzMjM2MQ_af2be58b-0bb4-47f2-8f44-e0df4b968b85"
      unitRef="shares">16477000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTEtMS0xLTQzMjM2MQ_bb101ee5-4d37-4ee8-a117-3f9eb774a9bf"
      unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTMtMS0xLTQzMjM2MQ_a1789482-3bd4-4ed5-a641-7c2e35403b7d"
      unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzEzLTUtMS0xLTQzMjM2MQ_feff5357-ac7c-4d89-9b54-12604fac4b8d"
      unitRef="usd">1446767000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTEtMS0xLTQzMjM2MQ_22b1e361-b992-47f5-919d-5ca99de1ee5d"
      unitRef="usdPerShare">97.33</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTMtMS0xLTQzMjM2MQ_a0eb0f61-e95d-44a0-a9a6-d8e0b2aac9dd"
      unitRef="usdPerShare">111.41</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTphMmM1YmJlZDc5YWI0YzBmYWM0N2UxNWQ5MGFhNmYwMS90YWJsZXJhbmdlOmEyYzViYmVkNzlhYjRjMGZhYzQ3ZTE1ZDkwYWE2ZjAxXzE0LTUtMS0xLTQzMjM2MQ_d8e9876c-0c65-4488-9169-666d5d13e605"
      unitRef="usdPerShare">87.80</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <dva:TreasuryStockAcquiredAverageCostPerShareClearingPrice
      contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzM2Mw_55a35c14-f48a-4c9f-ace5-ced0aa01645b"
      unitRef="usdPerShare">88.00</dva:TreasuryStockAcquiredAverageCostPerShareClearingPrice>
    <dva:ShareRepurchaseFeesAndExpenses
      contextRef="i0db2e8688a4e40259f2909d0efbb1bd9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzQzMw_30ca4536-968b-445f-a352-bf94e65b6f66"
      unitRef="usd">2529000</dva:ShareRepurchaseFeesAndExpenses>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifdf6a41128b04e829699ee3d9fad57ea_D20230101-20230221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzc2OTY1ODEzOTc4NTc_ac6ed0fd-baef-46c4-aedd-234e2c7609ec"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i308dd243211b43dd8fa4201f3e66d956_I20201210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzc2NA_765f6451-24b4-4c21-bfab-087e30b9c5cc"
      unitRef="usd">2000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ia42ecc99f0d34577b08bc4c77cf7a127_I20211217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzg2MA_df317954-76fb-4ae1-acaa-225044b617cb"
      unitRef="usd">2000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie70bc0dc3fda4a9fa940a388d85df82f_I20230221"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzEyNTg_c45dfe83-bcff-415e-8899-370a89696389"
      unitRef="usd">1596085000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzIxODE_623ee99c-e1be-4c28-86a9-f79934dab34a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzI1ODM_b47ca5aa-6fa4-4626-bfbd-67edf569f074">P3Y</dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation>
    <dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxODI_e5a3e4b9-cc5d-4cb6-90ee-32df4bbc584b">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItMS0xLTEtNDMyMzYx_de2d7441-2220-4ce4-9804-c367a5a66a6d"
      unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItMy0xLTEtNDMyMzYx_1e27cf07-11f1-42bd-878f-6f6798f2ef4e"
      unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzItNS0xLTEtNDMyMzYx_d0011813-0b73-44a0-a5ec-5998d5ec36b9"
      unitRef="usd">773642000</us-gaap:NetIncomeLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtMS0xLTEtNDMyMzYx_b165d718-ae7a-4724-91ef-ddcb41f3ae8b"
      unitRef="usd">6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtMy0xLTEtNDMyMzYx_44406b95-8b5f-45f4-860e-b75f2dea4b99"
      unitRef="usd">13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzQtNS0xLTEtNDMyMzYx_fed7b504-52f1-4893-9b1f-4ea7e794785b"
      unitRef="usd">4364000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtMS0xLTEtNDMyMzYx_3d673bed-f156-469b-9d80-82198b074e2c"
      unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtMy0xLTEtNDMyMzYx_a9cb9a6f-0cdb-40ba-a830-47d1288c75a1"
      unitRef="usd">264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzUtNS0xLTEtNDMyMzYx_5968c276-1a1a-49f2-98b4-e45c1dc314b8"
      unitRef="usd">0</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtMS0xLTEtNDMyMzYx_4b17e67c-29db-4363-900d-c771fdd15a3b"
      unitRef="usd">-5647000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtMy0xLTEtNDMyMzYx_c15cf372-217a-45e0-abe2-f7deb6f87e40"
      unitRef="usd">-14117000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzYtNS0xLTEtNDMyMzYx_82ac4089-499b-4c3f-8d74-75894a3020b3"
      unitRef="usd">4364000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
      contextRef="ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctMS0xLTEtNDMyMzYx_18e3a188-0324-4b87-91a0-3d08a270b3af"
      unitRef="usd">554753000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
      contextRef="if9e6a0b6976843a8ab514c1897521a9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctMy0xLTEtNDMyMzYx_758402f7-f918-43f7-8bc3-c9c0641b5bae"
      unitRef="usd">964333000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests
      contextRef="ib3d6e2c5a6eb44db9b065d99fadef021_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90YWJsZTo2NTFmOWEyYWI5ZDc0YWIxOGJiZTQxZWJhNGQ1MTFmYy90YWJsZXJhbmdlOjY1MWY5YTJhYjlkNzRhYjE4YmJlNDFlYmE0ZDUxMWZjXzctNS0xLTEtNDMyMzYx_b9afc14f-342b-49b3-aa73-1a55ceaea42a"
      unitRef="usd">778006000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxMzM_c6ee5cd0-4fdf-4c0e-9cce-0ba279342434"
      unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxMzc_aa456ffa-3cd5-49e7-bbcc-7eb69c09d2ff"
      unitRef="usd">20104000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNTUvZnJhZzpmNmFmYzY3NjA0Njk0MTUwODg0ZTc3NmNkZGNkOTQyZC90ZXh0cmVnaW9uOmY2YWZjNjc2MDQ2OTQxNTA4ODRlNzc2Y2RkY2Q5NDJkXzMxNDU_eddd8eb1-a763-4bf2-8274-8184b9797d08"
      unitRef="usd">7831000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI4OQ_09ea3546-d738-469a-a863-844ae1844193">Accumulated other comprehensive loss&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;br/&gt;cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 13 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI5MQ_2af86319-7f0f-472e-a6c1-98c54cf3f632">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;br/&gt;cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i99212cfd5b704e42ae8a23d830c5ab06_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtMS0xLTEtNDMyMzYx_7f54fd7a-ef13-4b1c-85a7-414a8042f1eb"
      unitRef="usd">-1433000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icc4fb47b5503432094dda9552d7403d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtMy0xLTEtNDMyMzYx_175edc17-4230-4db7-ab2c-892ab27fe5d2"
      unitRef="usd">-46065000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b572b098200416eae5a1f8ac48e51d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEtNS0xLTEtNDMyMzYx_02cfe3e6-d3ba-41f9-9f87-b6cc15988f56"
      unitRef="usd">-47498000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItMS0xLTEtNDMyMzYx_36c843bc-aca6-4de6-b188-98fa9604c066"
      unitRef="usd">-21781000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItMy0xLTEtNDMyMzYx_75abfaf2-e7ed-4310-b3a1-fb7d737af2d4"
      unitRef="usd">-7080000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzItNS0xLTEtNDMyMzYx_93b3e5c9-154a-4360-a4ab-ee5bf6064398"
      unitRef="usd">-28861000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtMS0xLTEtNDMyMzYx_cf03eabb-d8c5-4984-ac5e-86605769f314"
      unitRef="usd">-5435000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtMy0xLTEtNDMyMzYx_0a23e1c1-89fa-47c0-b63f-5bc72f2a8a52"
      unitRef="usd">543000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzMtNS0xLTEtNDMyMzYx_04cb4db2-81f6-493e-9828-082061947eaa"
      unitRef="usd">-4892000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtMS0xLTEtNDMyMzYx_5685a8f3-8b96-4ace-b0ce-18172671c774"
      unitRef="usd">-16346000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtMy0xLTEtNDMyMzYx_f4d5a327-92d6-4b51-96fe-76f2b8dcdbb0"
      unitRef="usd">-7623000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzQtNS0xLTEtNDMyMzYx_cda5c507-cd0c-427f-bee7-1c6833437654"
      unitRef="usd">-23969000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtMS0xLTEtNDMyMzYx_0e666e5c-a3b7-4234-8c1b-ffd8ac03b97d"
      unitRef="usd">7081000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtMy0xLTEtNDMyMzYx_ec73e8ef-0879-43ff-9955-706222d7e561"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzUtNS0xLTEtNDMyMzYx_70435649-4fbe-4ca1-a503-3be8c4e1333e"
      unitRef="usd">7081000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtMS0xLTEtNDMyMzYx_e1c87bb1-2535-48e9-9eec-8650fb576af0"
      unitRef="usd">1768000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtMy0xLTEtNDMyMzYx_77d058e7-aa31-4b94-ab06-7cb5f43aaa9f"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzYtNS0xLTEtNDMyMzYx_1ed8388e-ffd3-4c7f-8cf4-17c699c9ac07"
      unitRef="usd">1768000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id09c8012ff39464da59fa5e6ca0d53dd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctMS0xLTEtNDMyMzYx_066ae9a7-b8ed-405b-b513-dcd99ec42a20"
      unitRef="usd">5313000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i023504d2da28478aa67984abd4233153_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctMy0xLTEtNDMyMzYx_27b0c8d6-c814-42cf-b6b4-6e4e88eb57c0"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia1b3ae7788df4d7095b10d8a7944153c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzctNS0xLTEtNDMyMzYx_32109c6b-1bf2-4cb9-a045-1353b2b9922f"
      unitRef="usd">5313000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a3e2cfd5fd0429fb8ec56a202d18e12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtMS0xLTEtNDMyMzYx_64f22739-1b05-4334-8f7e-736a6995d69a"
      unitRef="usd">-12466000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8db34850cf9c4bd1bf445296b1937a89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtMy0xLTEtNDMyMzYx_31d9021f-12e2-41b8-9e81-edf92b9c506f"
      unitRef="usd">-53688000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iabc719a947474ef084095e5dfbf5b1c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzgtNS0xLTEtNDMyMzYx_ba4c2c41-6820-41d6-9cbd-ede53e57c48d"
      unitRef="usd">-66154000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktMS0xLTEtNDMyMzYx_3ab15561-215b-4ce7-b01d-c31b46c5a708"
      unitRef="usd">9532000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktMy0xLTEtNDMyMzYx_d0155f5b-ddcd-40b7-a95a-a83acc66f1e9"
      unitRef="usd">-83375000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzktNS0xLTEtNDMyMzYx_897cf786-0d1d-4d61-a516-309f984fbcdc"
      unitRef="usd">-73843000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTEtMS0xLTQzMjM2MQ_6f2fc800-89b1-489a-b94d-80f52c279a84"
      unitRef="usd">2377000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTMtMS0xLTQzMjM2MQ_9873ffe1-0bff-412f-a77f-3ec6406596b9"
      unitRef="usd">1006000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEwLTUtMS0xLTQzMjM2MQ_b5076430-5d74-4936-b71a-7fe6b5eb57c5"
      unitRef="usd">3383000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTEtMS0xLTQzMjM2MQ_c208a887-208a-4e39-8414-80e4c1eee74a"
      unitRef="usd">7155000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTMtMS0xLTQzMjM2MQ_01163ba9-bf22-4dab-991c-f177a0ff5b3e"
      unitRef="usd">-84381000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzExLTUtMS0xLTQzMjM2MQ_06f10b46-6090-415e-977e-f9a6752a039b"
      unitRef="usd">-77226000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTEtMS0xLTQzMjM2MQ_580af43c-5ac1-445d-ab0b-f2c4084f01a7"
      unitRef="usd">5509000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTMtMS0xLTQzMjM2MQ_0ecc7d83-830b-4642-ae41-9f231b08c267"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEyLTUtMS0xLTQzMjM2MQ_e74a3192-eab8-4553-84ef-c6d9a65bfc71"
      unitRef="usd">5509000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTEtMS0xLTQzMjM2MQ_23b397a1-911e-4269-b4a6-258773d9d827"
      unitRef="usd">1376000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTMtMS0xLTQzMjM2MQ_be57997c-ac90-49c2-ae00-886b9d5db3fb"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzEzLTUtMS0xLTQzMjM2MQ_dc33c44b-0ee0-4e3a-87fd-9bccaca76864"
      unitRef="usd">1376000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i8a7a0c600c9e4715a7a0ee30465f998e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTEtMS0xLTQzMjM2MQ_84718422-1c22-4043-a581-2f70da7eee76"
      unitRef="usd">4133000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="iee90c5d9d3a3427ea15898dac180fb23_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTMtMS0xLTQzMjM2MQ_d0fe3d70-3eb9-456a-86a5-f624ae7633b2"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i5f88a23e3ce648f2a557c57e2ebad2fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE0LTUtMS0xLTQzMjM2MQ_a1682b16-2ae7-4243-a537-363004eeed9e"
      unitRef="usd">4133000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i30a8cf8431a94b6e8121190341001e59_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTEtMS0xLTQzMjM2MQ_efe4b43f-fd01-49da-95fe-88e807723db6"
      unitRef="usd">-1178000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i43b284e90b0e45778d854e5fc253a04f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTMtMS0xLTQzMjM2MQ_22521b74-940d-48c1-bfb2-a357af78c498"
      unitRef="usd">-138069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8d50e013b4f49c4ba46a1b25f6ce76f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE1LTUtMS0xLTQzMjM2MQ_043a7844-d43d-4e81-bcb6-4edcd8fd6e3e"
      unitRef="usd">-139247000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTEtMS0xLTQzMjM2MQ_1f823ff5-6504-4d8f-ae61-836649aba8fe"
      unitRef="usd">144793000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTMtMS0xLTQzMjM2MQ_4b5888c3-da96-433d-8e81-210b50d36534"
      unitRef="usd">-30554000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE2LTUtMS0xLTQzMjM2MQ_e56ac574-f2b7-489c-9c77-6908187dbd45"
      unitRef="usd">114239000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTEtMS0xLTQzMjM2MQ_7e76166d-c242-4710-9561-aa2a3339bc5d"
      unitRef="usd">36124000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTMtMS0xLTQzMjM2MQ_acce7ac1-e7df-4894-bbd9-99effaed5947"
      unitRef="usd">-752000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE3LTUtMS0xLTQzMjM2MQ_0ddd7dcf-d891-4aaf-a32c-821c073e441f"
      unitRef="usd">35372000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTEtMS0xLTQzMjM2MQ_21d489dc-af23-4167-af03-fc36322307c4"
      unitRef="usd">108669000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTMtMS0xLTQzMjM2MQ_222a2042-0123-447c-8139-c79d7605ee40"
      unitRef="usd">-29802000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE4LTUtMS0xLTQzMjM2MQ_a11a1895-5eb3-4c43-ab2a-e69f9684abc6"
      unitRef="usd">78867000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTEtMS0xLTQzMjM2MQ_c94bbdf3-d93e-42ec-961f-0c488e854cc5"
      unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTMtMS0xLTQzMjM2MQ_6dbdcf81-fd90-4503-abd4-bf99b9ee0533"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzE5LTUtMS0xLTQzMjM2MQ_f0a7cddf-1ff9-4b44-b53c-db33cda16d1f"
      unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTEtMS0xLTQzMjM2MQ_dc63e0b0-6e0d-4d84-9248-360b978433d6"
      unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTMtMS0xLTQzMjM2MQ_0fe00f57-25b2-4196-9636-d556c030e855"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIwLTUtMS0xLTQzMjM2MQ_437d6229-f37b-4964-b059-f4cd406afa59"
      unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id07c35a37fce4301b64251840f18ea70_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTEtMS0xLTQzMjM2MQ_2225ee1a-bd27-412a-b9b1-6b3ea78b7cda"
      unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i3283c42262ce43d4b9e6e52caead9e8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTMtMS0xLTQzMjM2MQ_980ac5fa-3929-42a9-a2e0-42eb9aaa2ceb"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ic5e0561264cb4177a9e0962d2154d9f1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIxLTUtMS0xLTQzMjM2MQ_948a38d2-e78f-44c0-97b2-e4f6c06990c9"
      unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i81a9b7a989584fa9b3645a2917356a30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTEtMS0xLTQzMjM2MQ_1f99c7ba-843a-443b-b8e7-3faa59b8104a"
      unitRef="usd">98685000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i26689de70cd749e4bc3293f6430b6501_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTMtMS0xLTQzMjM2MQ_ac78fee3-08f7-4c70-8d25-8babdf912373"
      unitRef="usd">-167871000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i41c27b8943f04af2b168da521c4dad46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90YWJsZTpiNTRhYWJiYjQ4MDU0M2JmODcyMzRiNmUxZDU1OGZjMS90YWJsZXJhbmdlOmI1NGFhYmJiNDgwNTQzYmY4NzIzNGI2ZTFkNTU4ZmMxXzIyLTUtMS0xLTQzMjM2MQ_62158d4c-4be6-4168-a180-481b7dc3698b"
      unitRef="usd">-69186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjEvZnJhZzo1ODgzYzVkZjU1YzY0MGEzODJkYmI5M2YxZDE2MGVmZC90ZXh0cmVnaW9uOjU4ODNjNWRmNTVjNjQwYTM4MmRiYjkzZjFkMTYwZWZkXzI5NA_3e7596bb-2f18-4091-8731-e75726d57a1f">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzA_b7f8baa5-8458-4a64-b324-e13094f21b4c">Acquisitions and divestitures&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Routine acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, the Company acquired dialysis businesses and other businesses, including a transplant software company, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#x2019;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2022 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2022, 2021 and 2020, as well as goodwill deductible for tax purposes associated with these acquisitions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average estimated useful lives (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill deductible for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro forma financial information (unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2022 and 2021 had been consummated as of the beginning of 2021, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,624,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income from continuing operations attributable to&lt;br/&gt;&#160;DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of RMS Lifeline&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company divested its prior vascular access business, RMS Lifeline, Inc., effective May 1, 2020 and recognized a loss on sale of approximately $16,252.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $58,947 if certain performance targets or quality margins are met over the next one year to five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 24 for further details. As of December&#160;31, 2022, the Company estimated the fair value of these contingent earn-out obligations to be $25,422, of which a total of $11,308 is included in other current liabilities, and the remaining $14,114 is included in other long-term liabilities in the Company&#x2019;s consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2022 and 2021:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments or other settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzg_fccf831f-8f46-4558-a159-326431a04343">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, the Company acquired dialysis businesses and other businesses, including a transplant software company, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItMS0xLTEtNDMyMzYx_ce3b0247-733a-4433-b123-250f1188ce66"
      unitRef="usd">57308000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItMy0xLTEtNDMyMzYx_cb15a8ab-327a-4504-994a-1f656b36c654"
      unitRef="usd">187050000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzItNS0xLTEtNDMyMzYx_d5bce40b-4563-482f-992e-f4978bd11537"
      unitRef="usd">182013000</us-gaap:PaymentsToAcquireBusinessesGross>
    <dva:BusinessCombinationContingentConsiderationAcquisitions
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtMS0xLTEtNDMyMzYx_3c7b70f2-c1ae-4e99-96f5-b952d761d943"
      unitRef="usd">4261000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtMy0xLTEtNDMyMzYx_5b96e5d1-1449-4d64-8d9c-e0a10472ef17"
      unitRef="usd">14854000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions
      contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzMtNS0xLTEtNDMyMzYx_e739cd7d-bf12-46d9-8079-dc5a7158dd98"
      unitRef="usd">14042000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtMS0xLTEtNDMyMzYx_3d16ccb2-ef32-4d53-95fd-3d4aba7ccb92"
      unitRef="usd">15076000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtMy0xLTEtNDMyMzYx_47f025a0-461f-4c23-99ca-7a045e1b56f6"
      unitRef="usd">10226000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzQtNS0xLTEtNDMyMzYx_7d187fa9-d34e-4b67-b216-dc0e5876d0da"
      unitRef="usd">20415000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtMS0xLTEtNDMyMzYx_2f801f58-76cb-46e0-b1dc-fc2503e81761"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtMy0xLTEtNDMyMzYx_31287fc3-caa6-4875-b4b6-1cde82b91ad1"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i5d904111572c45258967451eb747b670_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzUtNS0xLTEtNDMyMzYx_9a3fa27d-9a4b-480d-98bd-bc3a7772bb78"
      unitRef="usd">1821000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtMS0xLTEtNDMyMzYx_b6905540-a8fc-4e9d-8c9d-af8428accbd3"
      unitRef="usd">76645000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtMy0xLTEtNDMyMzYx_fce342b4-fb81-4cd9-bd45-063f5c510674"
      unitRef="usd">212130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzYtNS0xLTEtNDMyMzYx_b607d6d5-658e-4819-9761-3efdfa7373aa"
      unitRef="usd">218291000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i0e816800cdb849e580bc97b00a96ade9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctMS0xLTEtNDMyMzYx_716097c8-5b9e-4b3d-a70d-867877c5a079"
      unitRef="clinic2">5</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i9679bed327fc47d683813151fab6f1c7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctMy0xLTEtNDMyMzYx_c8686ce1-6e16-42cd-bf8d-dd0ad9906aa1"
      unitRef="clinic2">19</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i82caecf20efa484fb484a9604065ba79_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzctNS0xLTEtNDMyMzYx_ade365a4-a51f-41e7-b7a6-3074f27aa978"
      unitRef="clinic2">8</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i70356fef993349ccbcc20e9d53a0537d_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtMS0xLTEtNDMyMzYx_0a251739-96e7-4521-af76-8b0da757d22c"
      unitRef="clinic2">11</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i80e5796ea824458fa6ca00e78cc84d11_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtMy0xLTEtNDMyMzYx_0680966a-e67e-488b-b524-6ed6a4ad2788"
      unitRef="clinic2">17</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i1e45f52112ed4e3c8f797f4c3e373333_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo0MzBlNDE1MTcxOGY0YmQ4YTQ0NGIwMGQ1M2M1Yzg1Ni90YWJsZXJhbmdlOjQzMGU0MTUxNzE4ZjRiZDhhNDQ0YjAwZDUzYzVjODU2XzgtNS0xLTEtNDMyMzYx_7624d9fc-6a95-40c6-b43c-95aefaabfd82"
      unitRef="clinic2">66</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMzI_7bb02827-17c0-4647-932c-eec874b15165">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItMS0xLTEtNDMyMzYx_5af167b7-7fe0-4f6e-b07f-5d4200915ead"
      unitRef="usd">6389000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItMy0xLTEtNDMyMzYx_82a698a5-a975-485f-b849-ac90a77f439a"
      unitRef="usd">9134000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzItNS0xLTEtNDMyMzYx_2df9d7a2-5aa0-44ca-a40c-0246c587b100"
      unitRef="usd">23607000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtMS0xLTEtNDMyMzYx_4e18610d-d651-4761-9731-86283d51f7f7"
      unitRef="usd">7481000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtMy0xLTEtNDMyMzYx_a5bedcb8-2b01-4f41-9af3-4df1d25aa84c"
      unitRef="usd">9277000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzMtNS0xLTEtNDMyMzYx_98fa0512-14cb-4f4d-aa95-10af54e4d9d3"
      unitRef="usd">37457000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtMS0xLTEtNDMyMzYx_b4c59ac0-707a-44e0-a400-4d2824d04e36"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtMy0xLTEtNDMyMzYx_390dc4aa-7346-46ad-a80b-672848937ecc"
      unitRef="usd">17200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzQtNS0xLTEtNDMyMzYx_1f8cf6ed-1c40-4d32-86e9-b644d4a862c3"
      unitRef="usd">34625000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtMS0xLTEtNDMyMzYx_77e2134f-e333-4f05-afb6-c2b90690e6ef"
      unitRef="usd">1066000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtMy0xLTEtNDMyMzYx_a3a1e96b-6eb0-4e94-bf4d-2b932c53e966"
      unitRef="usd">9964000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzUtNS0xLTEtNDMyMzYx_41bce88a-5710-47a7-b787-298f01a6ea2e"
      unitRef="usd">10168000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtMS0xLTEtNDMyMzYx_8244ba19-fee3-4314-b549-339ab7ce8a02"
      unitRef="usd">19610000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtMy0xLTEtNDMyMzYx_6ec31968-b93f-401c-9f27-6600cd920974"
      unitRef="usd">11432000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzYtNS0xLTEtNDMyMzYx_1a0321e7-20e5-402f-b85e-95cc596470bb"
      unitRef="usd">22136000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctMS0xLTEtNDMyMzYx_90a2916b-20e0-4b81-b6bb-c14976a11e8b"
      unitRef="usd">49047000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctMy0xLTEtNDMyMzYx_cf50a936-866e-4735-a3fa-0b0488d95c70"
      unitRef="usd">173244000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzctNS0xLTEtNDMyMzYx_e5067bc0-ea9e-44a6-9d02-9796d3484c03"
      unitRef="usd">130057000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtMS0xLTEtNDMyMzYx_afe31183-f73f-4f69-bf41-adf807a9c088"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtMy0xLTEtNDMyMzYx_8e9dceae-e830-46c7-8f7d-97004d960e09"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzgtNS0xLTEtNDMyMzYx_62612a31-8b63-4cf7-8d96-e6b8bf4cf451"
      unitRef="usd">3962000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktMS0xLTEtNDMyMzYx_6a784050-9cdb-43a0-ab4c-be9cb82fbafd"
      unitRef="usd">6081000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktMy0xLTEtNDMyMzYx_24195b94-418c-45cc-b1c5-a05544796649"
      unitRef="usd">14200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzktNS0xLTEtNDMyMzYx_f4c4c8f1-2f1c-4f7a-987a-6731bc8e03c8"
      unitRef="usd">34068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTEtMS0xLTQzMjM2MQ_221938e4-14c0-45b3-8b5f-28c12c9e0e32"
      unitRef="usd">867000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTMtMS0xLTQzMjM2MQ_c658f53f-237e-4587-8870-47a5ccd3482c"
      unitRef="usd">3921000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzEwLTUtMS0xLTQzMjM2MQ_22a21901-761d-445b-a6e4-a48272ee867a"
      unitRef="usd">1729000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTEtMS0xLTQzMjM2MQ_71c81e20-1ec1-4daf-976b-6da1973e4390"
      unitRef="usd">76645000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTMtMS0xLTQzMjM2MQ_15a4048d-0f10-4e2d-b57b-8e64977fd8e1"
      unitRef="usd">212130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTozM2Q2MmE3ZTQxMDg0NTUxOTRhYWRhMjgzODNjZDAyOS90YWJsZXJhbmdlOjMzZDYyYTdlNDEwODQ1NTE5NGFhZGEyODM4M2NkMDI5XzExLTUtMS0xLTQzMjM2MQ_3d13f4d1-5b50-41f4-945d-0ee75c67c72b"
      unitRef="usd">218291000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwNDE_2e647c44-8dcb-48a6-801c-e01dad504e29">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2022, 2021 and 2020, as well as goodwill deductible for tax purposes associated with these acquisitions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average estimated useful lives (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill deductible for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i98c876b3393e45aaadb4d03fd8cb132a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzMtMy0xLTEtNDMyMzYx_12c17565-c5b6-44da-91ea-5ee1fc93a125">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic68ddedfe24d4a9f821e723337f057fa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzMtNS0xLTEtNDMyMzYx_d2456973-5a1d-4ffa-827e-dd773b919680">P18Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if1d9e6f88ef54849931ad26b2c3ccf31_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtMS0xLTEtNDMyMzYx_36e7e85f-b554-4eb2-a87f-bd346233068e">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1896d04bb1d34718b1f5a2d8398d5ca2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtMy0xLTEtNDMyMzYx_7c1e4a06-3f51-40fd-b3ad-95266801a9cc">P6Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iabeffcbc0b614275bf1f744a78a560d6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzQtNS0xLTEtNDMyMzYx_df2d0b98-c4d1-4aa3-89a9-3dfcfddd7857">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtMS0xLTEtNDMyMzYx_20936701-7ffc-4c2a-9f25-a95dd1f6b190"
      unitRef="usd">49047000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtMy0xLTEtNDMyMzYx_ab6ba0b8-b1a8-4606-aa8c-f16e0d587f26"
      unitRef="usd">169014000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTpkMzI0MTkzNGY0ZDI0OGZlOGZiZGJjYjcxODYwZDQ4Ni90YWJsZXJhbmdlOmQzMjQxOTM0ZjRkMjQ4ZmU4ZmJkYmNiNzE4NjBkNDg2XzYtNS0xLTEtNDMyMzYx_420f24d6-1271-49a6-ba83-401245fae8af"
      unitRef="usd">94318000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwMjg_4153a927-95e2-41e5-8005-c4319e910839">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2022 and 2021 had been consummated as of the beginning of 2021, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,624,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income from continuing operations attributable to&lt;br/&gt;&#160;DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzMtMS0xLTEtNDMyMzYx_173ff227-3d31-41e9-a327-70ac3a451193"
      unitRef="usd">11624270000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzMtMy0xLTEtNDMyMzYx_dde19100-6286-4b73-bc5b-0cc512355af7"
      unitRef="usd">11706823000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzQtMS0xLTEtNDMyMzYx_8108fb26-dc5b-416d-853f-3b536149dfda"
      unitRef="usd">545859000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzQtMy0xLTEtNDMyMzYx_ed9b9181-acce-4ae8-b0b3-95c2078e9d81"
      unitRef="usd">984227000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzUtMS0xLTEtNDMyMzYx_c1b551bb-bdd2-4cea-b37d-84d1e8a6b49f"
      unitRef="usdPerShare">5.87</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzUtMy0xLTEtNDMyMzYx_caf9c2e9-13ff-41b9-9713-1dc901c8c3bc"
      unitRef="usdPerShare">9.35</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzYtMS0xLTEtNDMyMzYx_d9dd8a4c-bbd2-453e-ba8d-a01631de3796"
      unitRef="usdPerShare">5.70</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo5YTM5NGVhNjFhMTc0NTZhODViZjY4ZWQ5MjAzZTBjMS90YWJsZXJhbmdlOjlhMzk0ZWE2MWExNzQ1NmE4NWJmNjhlZDkyMDNlMGMxXzYtMy0xLTEtNDMyMzYx_13798c3b-47f9-4f72-80f2-8966d884b241"
      unitRef="usdPerShare">8.95</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
      contextRef="idc0d0c8670b74d7aaae012b57540676b_D20200501-20200501"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzIwOTc_63dbef9a-17a6-4f9d-8e6d-c5b3bda20847"
      unitRef="usd">16252000</us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3Mzk_0698cfe7-81f2-44ec-9c59-d7ec7aec1978"
      unitRef="usd">58947000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod
      contextRef="ia19082384d6a4829ab61b3ab014ad7e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzIzOTc_88db0e4e-b3d3-4e63-b463-d33c0b5b430b">P1Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod
      contextRef="if4f53c09daa64d04b0b10d609326db79_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzI0MDM_972d62e0-a245-416c-857a-9a9bce414c71">P5Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ida34ede3bf60405f897e4559cf454b17_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3NDQ_5c74c606-52d9-45c2-9582-c5a57b61e800"
      unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="id450bd55eefa4117ababbc01a3cfbd33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3MzM_87e70ddc-76da-4b6f-96c3-3a9a8a2b5404"
      unitRef="usd">11308000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i5f6457f2f67848de859ac828fdbb8f3e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzY1OTcwNjk3Njk3Mjg_63b10018-580f-4bc1-ac2f-71c9309dd6c8"
      unitRef="usd">14114000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90ZXh0cmVnaW9uOmM2NmE3MDQxZDVhODRlZTM5NGI1ZjE3NWE4Yjc4NDc2XzMwNDU_10845a42-0d71-4bcb-a4df-499a610523e0">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2022 and 2021:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments or other settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzItMS0xLTEtNDMyMzYx_e69b0b74-9d8c-41e6-93c7-c2531a8bab35"
      unitRef="usd">33600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i61bd7246d2204fc68658398f4ea88ed1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzItMy0xLTEtNDMyMzYx_b27fb64e-8066-4e94-809d-76ab0bdb69f2"
      unitRef="usd">30248000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <dva:BusinessCombinationContingentConsiderationAcquisitions
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzMtMS0xLTEtNDMyMzYx_69538b15-b763-4681-9dac-1684d8b820f8"
      unitRef="usd">4261000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzMtMy0xLTEtNDMyMzYx_c1b54980-a22b-46bb-859a-44cbfda921a1"
      unitRef="usd">14854000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzQtMS0xLTEtNDMyMzYx_2b23dfa7-c9c4-4de8-a301-1e02ad08e690"
      unitRef="usd">840000</dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations>
    <dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzQtMy0xLTEtNDMyMzYx_5652d48f-f853-44bd-b8f6-fa3350350cbf"
      unitRef="usd">-1674000</dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzUtMS0xLTEtNDMyMzYx_5a561bb0-ef27-4e8e-9f16-bc1ffae598f1"
      unitRef="usd">5921000</dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzUtMy0xLTEtNDMyMzYx_21a847eb-dd2e-410a-898e-d89b91a9bb60"
      unitRef="usd">1292000</dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments
      contextRef="i26972a338b914625b313ef3169a93850_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzYtMS0xLTEtNDMyMzYx_ae9c09a9-180b-48d4-8116-52985caf24e5"
      unitRef="usd">7358000</dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments
      contextRef="ie7273e4ee6194dd6a6f0d63596b6851d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzYtMy0xLTEtNDMyMzYx_47bde8ba-6c5f-40d9-b3d6-4b1388eef9b8"
      unitRef="usd">8536000</dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i49bba0c859f547afb380af3db15e5fbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzctMS0xLTEtNDMyMzYx_d7a1fedf-98b4-4450-ac06-6a8f0f1216f3"
      unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i947410d04b404a509e32155ef061b479_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjQvZnJhZzpjNjZhNzA0MWQ1YTg0ZWUzOTRiNWYxNzVhOGI3ODQ3Ni90YWJsZTo2OGEzMDY5ZWEyZGI0YmFhYTMyYTZiMzFhODE0NzMwZS90YWJsZXJhbmdlOjY4YTMwNjllYTJkYjRiYWFhMzJhNmIzMWE4MTQ3MzBlXzctMy0xLTEtNDMyMzYx_1067a283-3124-45e4-8523-ea5221a6c161"
      unitRef="usd">33600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzI0NDQ_69e65536-a782-4df1-973c-ade09ea71094">Discontinued operations previously held for sale&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DaVita Medical Group (DMG)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shortly after December&#160;31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. Upon resolution of certain prior post-closing adjustments with Optum in 2020, the Company recognized an additional loss on sale of $17,976, which was partially offset by $9,980 in additional tax benefits recognized under the Coronavirus Aid, Relief and Economic Security Act related to the Company's period of DMG ownership, and a related income tax benefit to the Company of $1,657.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <dva:BusinessSaleEffectiveDateOfSale
      contextRef="i1c251fa7a54142a9973f90b0af23a71a_D20190619-20190619"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzg4_1aa71c19-b712-4f87-9f20-902607cd97ac">2019-06-19</dva:BusinessSaleEffectiveDateOfSale>
    <dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment
      contextRef="ifc2f49e543f14e95b6a4a28258a7479f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzQzOTgwNDY1MTQxODM_bb994b96-386f-49f2-9155-67a4af5457a3"
      unitRef="usd">13452000</dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ib5e67f2857a248e185adf3684768570e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzQzOTgwNDY1MTU2Mzg_ae96d771-950f-401e-bc46-ef2432fe95b1"
      unitRef="usd">-17976000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal
      contextRef="i55269373013d4ffc8c433eda840a84cd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzE0MjY_ba1d9aa1-889a-4f34-92e8-fcf3ca83051a"
      unitRef="usd">9980000</us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal>
    <us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal
      contextRef="ib5e67f2857a248e185adf3684768570e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzIzNjM5NTAwMDAyNjE3_e93d21e6-ee5e-41f3-b5f4-3e95e9ff15db"
      unitRef="usd">1657000</us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="ib0f6ba9ac72d4d8b82649810f4dde956_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNjcvZnJhZzpjYTU1OTA0OTc5Zjk0ZThkYjI2ZjNlMjg3MjBjMzNkMi90ZXh0cmVnaW9uOmNhNTU5MDQ5NzlmOTRlOGRiMjZmM2UyODcyMGMzM2QyXzcxNDY4MjU1ODU3MDI_0a0a7dff-dd24-434a-bba5-f6dc68361432"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzMyNDU_b31d128e-4d88-43f6-b037-c303aa5cfc55">Variable interest entities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated care subsidiaries, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company wholly owns but does not wholly control these entities. However, the Company believes it has the most power over these entities' most significant activities, and the Company is fully exposed to their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, one of the Company's business units relies on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the VIEs described above, these consolidated financial statements include total assets of $316,639 and total liabilities and noncontrolling interests to third parties of $191,357 at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 5 and 15 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzMyNDc_98cd08fb-e49b-4624-b83b-fca80f2d2601">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated care subsidiaries, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company wholly owns but does not wholly control these entities. However, the Company believes it has the most power over these entities' most significant activities, and the Company is fully exposed to their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, one of the Company's business units relies on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <dva:NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzc2OTY1ODE0MDM5MTA_1ed2033c-9de3-402a-8c69-376b1309d4b6"
      unitRef="clinic2">1</dva:NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities>
    <us-gaap:Assets
      contextRef="ibc02c497e38f44dc90b9f84485fef045_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzI1NzU_84859472-f3df-4b02-bc63-252fe80be297"
      unitRef="usd">316639000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="ibc02c497e38f44dc90b9f84485fef045_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzAvZnJhZzpiYmYyMjlmMWY3MDk0OGVlYWZlYTRiMzNlNTk5Y2ZkYy90ZXh0cmVnaW9uOmJiZjIyOWYxZjcwOTQ4ZWVhZmVhNGIzM2U1OTljZmRjXzI2NDk_3023105a-97eb-4a98-86e5-2cc58f04b1b4"
      unitRef="usd">191357000</us-gaap:Liabilities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzQyNDg_d69aadb2-37b6-439f-ada9-664635569a6b">Fair values of financial instrumentsThe Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For reconciliations of changes in contingent earn-out obligations and noncontrolling interests subject to put provisions during the year ended at December&#160;31, 2022 and 2021, see Note 21 and the consolidated statements of equity, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 5 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 13 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 21 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2022, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $168,000. See Note 17 for a discussion of the Company&#x2019;s methodology for estimating the fair values of noncontrolling interests subject to put obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 13 for further discussion of the Company's debt. &lt;/span&gt;&lt;/div&gt;Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2022 and 2021 at their approximate fair values due to the short-term nature of their settlements.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzQyNTQ_3a20a377-58ef-47f6-b2c5-e3e98cab7017">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItMS0xLTEtNDMyMzYx_83d3f416-8caf-4aea-8dc4-293a93ca4bfd"
      unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItMy0xLTEtNDMyMzYx_e7fc20f0-4aeb-4424-a356-c07e4c60e897"
      unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItNS0xLTEtNDMyMzYx_8506e270-79a9-483b-b6bb-32261429bab4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzItNy0xLTEtNDMyMzYx_f53d5e21-f691-4e9d-b29e-9788ba9f9854"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i046167613ae64ec19f2ed82f74f07980_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtMS0xLTEtNDMyMzYx_a47e65f1-25cc-499c-8b94-d6f74528615a"
      unitRef="usd">139755000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4f207592fe4649a4ad1c7bf0d4621f61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtMy0xLTEtNDMyMzYx_e5e9e161-6fbe-488e-9cd3-9d34cb189600"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id3f1beaedb6546c7b32d23163c1577ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtNS0xLTEtNDMyMzYx_fef8ab4f-6b71-460e-b742-410e8657c14e"
      unitRef="usd">139755000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8717705e768d484989644fafcac6b11f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzMtNy0xLTEtNDMyMzYx_619256eb-d25b-4351-b8e2-9521cc0c4770"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtMS0xLTEtNDMyMzYx_d8747771-ed2c-4416-8e9c-b035d14df9e8"
      unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtMy0xLTEtNDMyMzYx_bd4c60d7-1056-4764-a7fd-9f530e9e1859"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtNS0xLTEtNDMyMzYx_d5c3e534-9487-4d65-b90d-8930f295ae38"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzUtNy0xLTEtNDMyMzYx_239a214c-4f69-442f-ad8e-acb37c28d20d"
      unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i733bd4e24d7945f59bb981466bfb570e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctMS0xLTEtNDMyMzYx_083a38e8-c293-45ca-9fc4-23b8c00ba278"
      unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i19e33e8346e24560ba9aa3c4a675008e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctMy0xLTEtNDMyMzYx_7c2275a9-f72b-41b5-8947-ca4a1c08fad0"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i415b7bb770484bd0a68b62ea80a8dd97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctNS0xLTEtNDMyMzYx_3b63b841-748b-40d1-8a25-c3d3c3efb1d1"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i05471993207b46e89aa70bd43a844aa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzctNy0xLTEtNDMyMzYx_ac5e4d86-f045-43cd-8366-5a45c4de367e"
      unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTEtMS0xLTQzMjM2MQ_17ff0d63-3eaa-44e1-9741-e458c1686374"
      unitRef="usd">48598000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2d883f152f344fb4961979059e6695af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTMtMS0xLTQzMjM2MQ_97bbb32e-43f1-4def-951d-4e444b9dcab5"
      unitRef="usd">48598000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTUtMS0xLTQzMjM2MQ_aab11dae-c873-4468-ac44-7b6b1210be97"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEwLTctMS0xLTQzMjM2MQ_d9c55095-1988-4557-9b7d-dc5638a9c09a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="ic0935c6e63e743ba9aba751b24c6f1de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTEtMS0xLTQzMjM2MQ_66f7e702-7e20-49c8-a22a-7d0d439219ef"
      unitRef="usd">12203000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3b5df7fafeef499c84ae47517afbb88c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTMtMS0xLTQzMjM2MQ_948c6fb8-2f90-4c55-b6b2-3363fd878663"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5a2dfed1ea6e4e64a2d2a32df8448e91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTUtMS0xLTQzMjM2MQ_5db12087-2b3f-47b4-aee3-6329fa575764"
      unitRef="usd">12203000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibde9a8c8bca04d5b852b3c6a3f47238c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzExLTctMS0xLTQzMjM2MQ_562f86fb-9a96-4699-a393-6194bc57a8a8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTEtMS0xLTQzMjM2MQ_3eb084b3-4d71-4f9a-9c66-b4123a03f1cd"
      unitRef="usd">33600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2d883f152f344fb4961979059e6695af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTMtMS0xLTQzMjM2MQ_b899eabe-1922-41d5-9436-cfc6ec26e847"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTUtMS0xLTQzMjM2MQ_a166d2ba-c97b-4383-aefb-d32d16269258"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzEzLTctMS0xLTQzMjM2MQ_2a427f56-0c7a-4d63-9f0d-655f1fe8ac39"
      unitRef="usd">33600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i6032b5bb440b4d2795466e62c1aa5b59_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTEtMS0xLTQzMjM2MQ_b8c16009-64c9-49d2-9c1d-f4bb67f505a5"
      unitRef="usd">1434832000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i2d883f152f344fb4961979059e6695af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTMtMS0xLTQzMjM2MQ_ba275f75-eca0-4d65-83a6-a12b964fe5e1"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i58ddb8ea0c9e4f0d987bf7fa40c27bfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTUtMS0xLTQzMjM2MQ_aebe1fbe-4e83-4852-b41d-6e29ae7a03c0"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i826c5858f92b46e7947460dfd1f33a3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90YWJsZTpiNzdlNWZlNTA2ZTA0OGQwYmRlZDExMjRkNmY2MjUzOC90YWJsZXJhbmdlOmI3N2U1ZmU1MDZlMDQ4ZDBiZGVkMTEyNGQ2ZjYyNTM4XzE1LTctMS0xLTQzMjM2MQ_401123c4-3f05-44f5-9596-7dd76452bf46"
      unitRef="usd">1434832000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple
      contextRef="ib664746092484ebf93084b60e56443b0_D20221231-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzMvZnJhZzo2ZWFmN2IzMmM0ZmU0NmQxOTg5YjdhNjc3MTBkZDkzNy90ZXh0cmVnaW9uOjZlYWY3YjMyYzRmZTQ2ZDE5ODliN2E2NzcxMGRkOTM3XzM0MjE_cfedd12e-a0a9-4171-a54a-a1fd2f3801be"
      unitRef="usd">168000000</dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTU_4fd8cc54-ba5c-48d4-acee-5bc6a0807893">Segment reporting&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a summary description of the Company's businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, the Company completed the sale of its prior DMG business to Optum. As a result of this transaction, DMG's results of operations have been reported as discontinued operations for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#x2019;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#x2019;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, and its equity method investment in the APAC joint venture. The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial performance of the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to all of the Company&#x2019;s various operating lines of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,475,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,619,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,659,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,713,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,712,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,550,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from&lt;br/&gt;&#160;continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt prepayment, refinancing and redemption charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity investment income of $1,898, $3,177 and $5,866 in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summary of assets by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,084,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,928,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,121,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity method and other investments of $113,781 and $112,500 in 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity method and other investments of $117,327 and $126,381 in 2022 and 2021, respectively and includes approximately $207,162 and $190,029 in 2022 and 2021, respectively, of net property and equipment related to the Company&#x2019;s international operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <dva:BusinessSaleEffectiveDateOfSale
      contextRef="i9d3ac6f3c4f74f8ea1b571333627e886_D20190619-20190619"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzQ0OA_8281586d-855c-496f-99b3-b6eb01f9abf2">2019-06-19</dva:BusinessSaleEffectiveDateOfSale>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTE_2f531efb-e044-4486-8827-6caa42588366">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,475,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,619,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,659,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,713,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,712,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,550,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from&lt;br/&gt;&#160;continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt prepayment, refinancing and redemption charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity investment income of $1,898, $3,177 and $5,866 in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtMS0xLTEtNDMyMzYx_5c493ddc-3588-41ec-8201-dd709c61540e"
      unitRef="usd">10488327000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtMy0xLTEtNDMyMzYx_e9b25565-564f-4ee1-a7bf-ffde300be5f3"
      unitRef="usd">10551106000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id7536f3521c54e9294023219e56f7c64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzUtNS0xLTEtNDMyMzYx_88ad61a0-1e19-4883-9fda-eb6406e1a152"
      unitRef="usd">10475273000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtMS0xLTEtNDMyMzYx_1a31a45a-e74b-4fba-9262-3c4094ed596f"
      unitRef="usd">87045000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtMy0xLTEtNDMyMzYx_d0447951-b0d0-474c-a74d-e10fec6d83a6"
      unitRef="usd">90512000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzYtNS0xLTEtNDMyMzYx_ca462fad-c73d-4a84-b67a-49245077ac8d"
      unitRef="usd">144091000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctMS0xLTEtNDMyMzYx_c35a0471-da8f-46e5-bda9-5c5e9394741b"
      unitRef="usd">10575372000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctMy0xLTEtNDMyMzYx_7bff6fe7-2936-4a91-91b9-1ca45d762513"
      unitRef="usd">10641618000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzctNS0xLTEtNDMyMzYx_e1c4143c-9348-465e-937d-e31c2bb6ffa3"
      unitRef="usd">10619364000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="i40b2dbc1ce114797939f5aad6f3904d7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktMS0xLTEtNDMyMzYx_39036bd8-c8e9-48c8-8db2-fa032d641f09"
      unitRef="usd">24447000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i2b5db159a16c47ec9a56d056d1856bbd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktMy0xLTEtNDMyMzYx_cfd9e2ac-81fd-4398-bb3a-de39ae449cad"
      unitRef="usd">25061000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="id7536f3521c54e9294023219e56f7c64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzktNS0xLTEtNDMyMzYx_f60fae0b-a172-40ae-8aaa-736b137ff435"
      unitRef="usd">39376000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ic6ee7874a4ec476baffd44f0de7b4385_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTEtMS0xLTQzMjM2MQ_ef188418-3fe8-4834-9427-b19b2bad5d57"
      unitRef="usd">-10000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i37741ed06c4149b48abc2c9d89b203a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTMtMS0xLTQzMjM2MQ_da02ccde-1b4d-4cd8-b831-729cf63c60ca"
      unitRef="usd">284000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i0079c6231c9f4050a1090ac8f16320ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEwLTUtMS0xLTQzMjM2MQ_b5b7e02a-73ee-4fc2-b0ce-24c9a8d11788"
      unitRef="usd">1195000</us-gaap:OtherIncome>
    <us-gaap:Revenues
      contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTEtMS0xLTQzMjM2MQ_854ad6bf-b895-4dea-be49-a4379e09a9c9"
      unitRef="usd">10599809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTMtMS0xLTQzMjM2MQ_f4b2c4d9-5295-430a-a126-8324be082c64"
      unitRef="usd">10666963000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzExLTUtMS0xLTQzMjM2MQ_92d4ccdf-09fc-4983-b222-85147b39d539"
      unitRef="usd">10659935000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTEtMS0xLTQzMjM2MQ_f7851abb-cf02-46d0-b78e-cbd3bdcd939f"
      unitRef="usd">688137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTMtMS0xLTQzMjM2MQ_f72000f6-0803-4f5c-b07e-07be06292b0b"
      unitRef="usd">662409000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzEzLTUtMS0xLTQzMjM2MQ_a68e13de-ccc9-4b45-a755-f8bc93a9a29f"
      unitRef="usd">550978000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTEtMS0xLTQzMjM2MQ_a74b0c49-022e-4d89-9923-434f6d2982ed"
      unitRef="usd">408983000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTMtMS0xLTQzMjM2MQ_b25c5c60-1dbd-442b-b53d-de4359deee96"
      unitRef="usd">380221000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE0LTUtMS0xLTQzMjM2MQ_04344502-cb89-4056-8368-90be88659dbe"
      unitRef="usd">484977000</us-gaap:OtherIncome>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idf9e8067c67e4837babe07d810db9729_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTEtMS0xLTQzMjM2MQ_30d45efb-f5e0-4284-852f-ba8d89306af0"
      unitRef="usd">4206000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9ac2a354bfd74090958bcef5319b2038_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTMtMS0xLTQzMjM2MQ_d912baea-b873-4346-94f8-eb5d7f7f4392"
      unitRef="usd">4294000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic8ea4a40bae848aca9676ecbe296c2bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE1LTUtMS0xLTQzMjM2MQ_af432ced-91f6-402a-ad46-8cbe73085019"
      unitRef="usd">16743000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTEtMS0xLTQzMjM2MQ_625b498e-a77d-4284-93f8-7bfe9d5b03d0"
      unitRef="usd">1101326000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTMtMS0xLTQzMjM2MQ_5e549e21-dd0d-4fab-bcda-5b63a90eea83"
      unitRef="usd">1046924000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE2LTUtMS0xLTQzMjM2MQ_acea0e9a-a2d1-4741-8097-dfcae8f71922"
      unitRef="usd">1052698000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTEtMS0xLTQzMjM2MQ_0664af98-ad9e-4726-839b-1ddffb3685b3"
      unitRef="usd">11701135000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTMtMS0xLTQzMjM2MQ_6b288d0b-7c7f-40e4-948f-b8007ba5665e"
      unitRef="usd">11713887000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE3LTUtMS0xLTQzMjM2MQ_f0500c55-bd43-4a3a-bb8e-ad2b5ec8cd09"
      unitRef="usd">11712633000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a954a883b794886b687507ce63ab2ad_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTEtMS0xLTQzMjM2MQ_dbfc0df7-e2e8-49ab-8a94-3710926431ad"
      unitRef="usd">-91241000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20b6b2a3747d49bd9cb5c6f6638dfea4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTMtMS0xLTQzMjM2MQ_415869a3-11e6-4ad2-be52-0966e072ed94"
      unitRef="usd">-95090000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if54211ce80ea4b1eb202fd9374566977_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE4LTUtMS0xLTQzMjM2MQ_a8c7fd70-3112-44bd-9152-ae702bd8d597"
      unitRef="usd">-162029000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTEtMS0xLTQzMjM2MQ_add396db-c08e-4059-9168-17630fabc03b"
      unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTMtMS0xLTQzMjM2MQ_b5efb199-bcd6-476f-9d4a-ae1cfcbaff3e"
      unitRef="usd">11618797000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzE5LTUtMS0xLTQzMjM2MQ_a67e81a5-49b5-4915-ba15-3167a2ca5ca1"
      unitRef="usd">11550604000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52bd588526ec41f682a3607d1df3369c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTEtMS0xLTQzMjM2MQ_34b3e0f1-a79e-4c0c-b3b0-5041c79de087"
      unitRef="usd">1565310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie63e5294e3dc4a2a9537688d891bd742_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTMtMS0xLTQzMjM2MQ_aedea622-2896-49eb-a119-c4c552c9e869"
      unitRef="usd">1974988000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73479615c7d64bb091b14c5ecb87f31e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIxLTUtMS0xLTQzMjM2MQ_1731c4ec-0d30-4d6b-ad38-5f80325298f9"
      unitRef="usd">1917604000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTEtMS0xLTQzMjM2MQ_e155f6ea-80ca-45ae-ada6-3a00c60f18ea"
      unitRef="usd">-96579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTMtMS0xLTQzMjM2MQ_3701bc95-3e03-42a0-9dbd-e7d674415b59"
      unitRef="usd">-66003000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIyLTUtMS0xLTQzMjM2MQ_aa7e5771-b916-4678-8f12-d9c6e2c403d0"
      unitRef="usd">-76261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie3f06865e2ff45649b4248f4c3b2618b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTEtMS0xLTQzMjM2MQ_b19eb193-6817-48e9-bddf-e66c98b8a2f9"
      unitRef="usd">1468731000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f90b9a4c2374d0080561a3dc159689a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTMtMS0xLTQzMjM2MQ_ecbf1503-b8d5-4879-9dca-e5fa0d55daf7"
      unitRef="usd">1908985000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i48fbb8f679ee410bb4d57041d9ec424a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzIzLTUtMS0xLTQzMjM2MQ_4537563e-a543-4cc8-8c9f-f8ee006d82f9"
      unitRef="usd">1841343000</us-gaap:OperatingIncomeLoss>
    <dva:SegmentReportingInformationCorporateExpenses
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTEtMS0xLTQzMjM2MQ_6ed37481-5265-4b1e-9a3c-fff2eb8c1758"
      unitRef="usd">129669000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTMtMS0xLTQzMjM2MQ_10227f03-fa30-4bda-8cc9-c7c7900b7742"
      unitRef="usd">111615000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI1LTUtMS0xLTQzMjM2MQ_0b31253c-c2e3-42fa-a5dd-b85fe578507f"
      unitRef="usd">146707000</dva:SegmentReportingInformationCorporateExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTEtMS0xLTQzMjM2MQ_b92b4f98-1a05-4b48-acbd-c08e105e8745"
      unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTMtMS0xLTQzMjM2MQ_59538317-96b7-487d-8103-ebfbbdb9e664"
      unitRef="usd">1797370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI2LTUtMS0xLTQzMjM2MQ_864d2b80-d8b2-437d-8c6b-9544cb05986f"
      unitRef="usd">1694636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTEtMS0xLTQzMjM2MQ_174b2be3-c97d-4959-af15-d59ea5dbe31c"
      unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTMtMS0xLTQzMjM2MQ_3dac5cb4-056d-40ac-aed7-0ef2b971156c"
      unitRef="usd">285254000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI3LTUtMS0xLTQzMjM2MQ_fe3a0805-825e-4f60-a022-d8e7a9f76937"
      unitRef="usd">304111000</us-gaap:InterestAndDebtExpense>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTEtMS0xLTQzMjM2MQ_d32061e7-8d2a-4a2c-be84-8cc4c2d48993"
      unitRef="usd">0</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTMtMS0xLTQzMjM2MQ_43e84d1b-92a8-483b-8fb9-5020fce55a85"
      unitRef="usd">0</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <dva:DebtPrepaymentRefinancingRedemptionCharges
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI4LTUtMS0xLTQzMjM2MQ_6d42a569-ae9f-4751-af0c-51414ed29561"
      unitRef="usd">89022000</dva:DebtPrepaymentRefinancingRedemptionCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTEtMS0xLTQzMjM2MQ_a7fbaa39-18c8-4143-9606-4cebd59435c0"
      unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTMtMS0xLTQzMjM2MQ_c11ce9a5-2ec4-4534-9266-5f23065eb8e9"
      unitRef="usd">6378000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzI5LTUtMS0xLTQzMjM2MQ_405739fb-903e-4059-97e2-65f676fdc113"
      unitRef="usd">16759000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTEtMS0xLTQzMjM2MQ_29d801c7-876c-4759-acec-b6dabe8a2660"
      unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTMtMS0xLTQzMjM2MQ_f1c8450c-4399-448e-a8c8-0c2232bc9e3d"
      unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZToxNjE3YjBkYzllMDM0ODBjYmJhN2EzMDA4ZTgyYjE2MS90YWJsZXJhbmdlOjE2MTdiMGRjOWUwMzQ4MGNiYmE3YTMwMDhlODJiMTYxXzMwLTUtMS0xLTQzMjM2MQ_773dd8a4-2945-4f56-9930-05fc28e62c75"
      unitRef="usd">1318262000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4c1ec430648f4bc1b56ece5709e7ceba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MjE_6d029ae2-e3b0-4fbb-ac27-7ed854318e5a"
      unitRef="usd">1898000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i77751cf20e0e48f6a53bff39c9bb2340_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MjU_529d0e11-fe75-48e8-a2bb-372dacef0575"
      unitRef="usd">3177000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i14934bf9ceb64aa4816849e74753a63d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI1MzM_32f2bf39-28da-4737-a24f-39f623da745d"
      unitRef="usd">5866000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMDg_ffeedbe6-aeda-42c6-9cd0-0fe16b44e88f">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:DepreciationAndAmortization
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItMS0xLTEtNDMyMzYx_2919b2fd-ed0b-4faf-9e14-0b0090a50694"
      unitRef="usd">690949000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItMy0xLTEtNDMyMzYx_cf44e902-7abc-495f-8a06-dc6eed065baa"
      unitRef="usd">642711000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzItNS0xLTEtNDMyMzYx_f7383b32-cbd0-4a31-81eb-9e1cc4a15490"
      unitRef="usd">594552000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtMS0xLTEtNDMyMzYx_a59d38fd-0f99-4d9e-9e97-8c61d78e94c5"
      unitRef="usd">41653000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtMy0xLTEtNDMyMzYx_74906ac3-b6cd-49c0-8fdc-23fdd92c8f92"
      unitRef="usd">37904000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzMtNS0xLTEtNDMyMzYx_660d61ff-f485-4179-ae2c-edeb5a5c457b"
      unitRef="usd">35883000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtMS0xLTEtNDMyMzYx_389fc2bf-cc75-412d-9130-f7cf9858be8d"
      unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtMy0xLTEtNDMyMzYx_4a9b388a-9719-4b6c-b610-054fa044f805"
      unitRef="usd">680615000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo0YTM1Y2JkZTJkMGY0YzIzYTcxZTgzZjYyZDY5NGY1NS90YWJsZXJhbmdlOjRhMzVjYmRlMmQwZjRjMjNhNzFlODNmNjJkNjk0ZjU1XzQtNS0xLTEtNDMyMzYx_3457e8e0-0eb0-412c-a467-1f3246cd6bf3"
      unitRef="usd">630435000</us-gaap:DepreciationAndAmortization>
    <dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTI_ac66d93c-8552-4dbd-8695-fa3388a6c3e4">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItMS0xLTEtNDMyMzYx_7e0c4148-d0c5-44ad-9dc3-9c399c06f247"
      unitRef="usd">533600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8136708df2134930a9c053c1f17459e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItMy0xLTEtNDMyMzYx_027e243a-d275-4842-a5cb-2780954d0284"
      unitRef="usd">589662000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie17cb95539b04046a906e4ba917b3681_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzItNS0xLTEtNDMyMzYx_203873cd-3546-444c-bc09-80622943ed39"
      unitRef="usd">646870000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ice87a48ce280447786bdab788445cea5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtMS0xLTEtNDMyMzYx_1a7c93d2-70a8-4e32-a753-22b8a1c10106"
      unitRef="usd">69829000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie1d5b34189e440598421ee1070cf12f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtMy0xLTEtNDMyMzYx_ed71baae-d449-4213-8eeb-d7908ef4a47e"
      unitRef="usd">51803000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i180712eb78424b97a1ec1af506fd3ff0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzMtNS0xLTEtNDMyMzYx_8268ae98-16a1-4e7b-9190-b3a4bd0b2f05"
      unitRef="usd">27671000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtMS0xLTEtNDMyMzYx_3b653394-ff17-4360-b739-a77ff0ccab81"
      unitRef="usd">603429000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtMy0xLTEtNDMyMzYx_ed4dbf21-ec15-4d11-aa64-0d2181001ea1"
      unitRef="usd">641465000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTplZWQ3YzAzZWE5ZjE0NDY4YjkxZjAyN2M5YThhMTY2My90YWJsZXJhbmdlOmVlZDdjMDNlYTlmMTQ0NjhiOTFmMDI3YzlhOGExNjYzXzUtNS0xLTEtNDMyMzYx_fd3013a6-1ab5-400b-b616-7815635f8eaa"
      unitRef="usd">674541000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzMxMTM_b9c191b3-50c4-4989-b5b6-e088592afc6f">&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summary of assets by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,084,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,928,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,121,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity method and other investments of $113,781 and $112,500 in 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes equity method and other investments of $117,327 and $126,381 in 2022 and 2021, respectively and includes approximately $207,162 and $190,029 in 2022 and 2021, respectively, of net property and equipment related to the Company&#x2019;s international operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzMtMS0xLTEtNDMyMzYx_5f3a0c28-41f2-4bbd-94b4-179e619fb17e"
      unitRef="usd">15084454000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzMtMy0xLTEtNDMyMzYx_0e47c6b4-0e56-44c4-a36a-f0c23f6c44bc"
      unitRef="usd">15375000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzQtMS0xLTEtNDMyMzYx_7d34f0b4-e955-4b0a-9912-21978e2ce7e8"
      unitRef="usd">1843798000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzQtMy0xLTEtNDMyMzYx_cbf10b25-3fb0-4c9c-9b46-666a0e7023ac"
      unitRef="usd">1746488000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic7cd26001e2547978cfb83fa3fade336_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzUtMS0xLTEtNDMyMzYx_601c7587-3e3f-44c2-b7b5-0013419c991b"
      unitRef="usd">16928252000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1fe6cb82c75840eabfae089d02e1e485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90YWJsZTo4MzM2ZDgzMjcyZGU0ZTFjOWM0ZDZjNjRmZmJkNWRlZC90YWJsZXJhbmdlOjgzMzZkODMyNzJkZTRlMWM5YzRkNmM2NGZmYmQ1ZGVkXzUtMy0xLTEtNDMyMzYx_9523dc4c-66b9-407a-974e-10a640bae9ac"
      unitRef="usd">17121488000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iff8eba1380104ea6b216ee60a45a6e69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI4Mzg_3ab320ac-e699-4180-a90e-0ec338410488"
      unitRef="usd">113781000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i32f8d1d725f847c09697e3d7b2b29851_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI4NDU_0d145c08-212f-4fea-9f20-d2d295fcfabe"
      unitRef="usd">112500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6b6523b9338e417b9035c6d604cf594a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5MjU_12d39cfb-8b92-40af-a757-04ddb770cb12"
      unitRef="usd">117327000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i9910e7304043403ca7bd1e6601890eba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5MzI_18e34de2-3f78-452f-8fdd-06de2d448e9f"
      unitRef="usd">126381000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i472575aaaeaa4644bf500b85f08f09c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5ODk_77b2df1e-e6d7-4498-a989-e2a8d7831810"
      unitRef="usd">207162000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i850cdf3eed294766a58ed299ab32d0dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzYvZnJhZzo2ZDcyNzcwN2EyMDU0MDU0Yjg0Mzk5MzEzMTVkYTJhMi90ZXh0cmVnaW9uOjZkNzI3NzA3YTIwNTQwNTRiODQzOTkzMTMxNWRhMmEyXzI5OTY_cbec6d74-b6c1-4adc-8b75-93fa76aed667"
      unitRef="usd">190029000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90ZXh0cmVnaW9uOjdmOTNjMmUxYjUzMzRjNDY4MmFkYjA4Yjg4NzNhOTk1XzEwNg_2417337a-5e4a-4590-9b28-ed3292e9315b">Supplemental cash flow information&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90ZXh0cmVnaW9uOjdmOTNjMmUxYjUzMzRjNDY4MmFkYjA4Yjg4NzNhOTk1XzExMQ_1a3b9419-c45d-4f55-89cf-dbf4219df541">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtMS0xLTEtNDMyMzYx_b38e93fb-3fc7-42de-9ce0-ce3f3031abd7"
      unitRef="usd">344430000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtMy0xLTEtNDMyMzYx_f8cc3f23-a013-46e5-a294-b01a00063a99"
      unitRef="usd">209754000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzMtNS0xLTEtNDMyMzYx_b98de2b8-4060-49f5-a88e-3eff1a73b1c4"
      unitRef="usd">154850000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtMS0xLTEtNDMyMzYx_1e90923a-f898-49ee-bd14-19273e0d4f0f"
      unitRef="usd">350999000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtMy0xLTEtNDMyMzYx_07d3b211-e5b3-4a8e-9379-1adb3ab415dd"
      unitRef="usd">279002000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzQtNS0xLTEtNDMyMzYx_c7536df6-aee9-445e-9a00-eae266f0c08a"
      unitRef="usd">326165000</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtMS0xLTEtNDMyMzYx_49bf87fd-fa71-48c9-9f71-1bcd57874323"
      unitRef="usd">1928000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i2f27fb012fe04ec989530042e787ddde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtMy0xLTEtNDMyMzYx_5ce7537c-0359-4665-b2b3-1bdf91044b05"
      unitRef="usd">31690000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="ie5c61880c0ee440fb7b331fdd2107c2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zNzkvZnJhZzo3ZjkzYzJlMWI1MzM0YzQ2ODJhZGIwOGI4ODczYTk5NS90YWJsZToyYzM1NzFlZWZiZjA0MzFlODRhZjJkNTk0NzA3NTg0Mi90YWJsZXJhbmdlOjJjMzU3MWVlZmJmMDQzMWU4NGFmMmQ1OTQ3MDc1ODQyXzYtNS0xLTEtNDMyMzYx_763b7658-4f4a-42f7-8eeb-11cedc689082"
      unitRef="usd">22042000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90ZXh0cmVnaW9uOjc2YWU0ZmFlMzYzYTQwNzJhYzc4NGFlZGZmMmZiN2NiXzY2_026229fe-d1bf-4cd0-8ba3-adea41770fb8">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&#x2014;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;br/&gt;charged to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at end of year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock
      contextRef="ice569de73c8c4774b5d001cb033779fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90ZXh0cmVnaW9uOjc2YWU0ZmFlMzYzYTQwNzJhYzc4NGFlZGZmMmZiN2NiXzY2_67c70093-0407-471e-92cf-974aa5cd5bd7">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&#x2014;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;br/&gt;charged to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at end of year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i13805c203e1b4b8b917db178e9c4d6dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtMi0xLTEtNDMyMzYx_def0fd78-18bc-4ce8-bfb4-87ec37550239"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtNC0xLTEtNDMyMzYx_5d849147-8516-440d-b428-3cbef6eee6f5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtNi0xLTEtNDMyMzYx_02705f77-c85d-4e31-b09b-99f621702a8e"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1df2dd00e26145bfae6b99c3db568f60_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtOC0xLTEtNDMyMzYx_829be3fe-7a90-42de-9c14-efc16cf96b20"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0d986fd59a394b0faac51a4aa5076ed3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzQtMTAtMS0xLTQzMjM2MQ_4cbea93d-662e-4350-af33-25983e7d8330"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtMi0xLTEtNDMyMzYx_54a16155-ee12-4a4d-81e8-0a6c187a9a3c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtNC0xLTEtNDMyMzYx_67057a60-5cd6-429e-b71b-37a75bdc28cb"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtNi0xLTEtNDMyMzYx_7d72f238-fc73-4793-a0c7-d00ec6ccb7f0"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2df4cc4b590f44fba91eb4fe183c47f2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtOC0xLTEtNDMyMzYx_c545885f-eb24-47eb-b71c-067dda10d928"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i13805c203e1b4b8b917db178e9c4d6dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzUtMTAtMS0xLTQzMjM2MQ_bfe94e4f-61cf-48e8-8166-564177c150a5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i11fb71602ed14a41843e5942b0069a19_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtMi0xLTEtNDMyMzYx_d237cd83-31c7-4097-8634-63f0aebb71e9"
      unitRef="usd">8328000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtNC0xLTEtNDMyMzYx_f4f22095-9fac-4c5b-bf31-96d55f944f80"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtNi0xLTEtNDMyMzYx_6a03042b-59de-483d-9e5a-9a43282b5927"
      unitRef="usd">13458000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6b53dbb1cf71415daa37bfa469137483_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtOC0xLTEtNDMyMzYx_1ae99666-2e51-442b-8367-0aa85a5101ca"
      unitRef="usd">21786000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie45bdc3e42f04f4f91fb18c0ba7f4d04_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMjgyMjZlYzUxMTQ5MWI4N2IxODNjNmQyMTdhMjFhL3NlYzpiMjI4MjI2ZWM1MTE0OTFiODdiMTgzYzZkMjE3YTIxYV8zODgvZnJhZzo3NmFlNGZhZTM2M2E0MDcyYWM3ODRhZWRmZjJmYjdjYi90YWJsZToxNTlkYTlhMjg4Yjg0MmZlOWNmMDkzMmI2M2ZmNDJiMC90YWJsZXJhbmdlOjE1OWRhOWEyODhiODQyZmU5Y2YwOTMyYjYzZmY0MmIwXzYtMTAtMS0xLTQzMjM2MQ_5489e9fe-df7c-46ad-b84a-57dfeb8d7c17"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>138
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTSI$#H!E#H!Z"Y_3NHXP6\L)[7>AP#<B.45;1-3=[G\^)]#7=<9VB$  RT
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M$9S-GOIN@H"4,$[X(3"!@)@*RLD>>$"/[^EQ+[U;LY:EETLS/NK=.6 L8'C
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M]F:U^;X6D %B,Q V)8:I\T:Q">#"B-%X1$^S3FPR_V]E[VL 0:KN;U]0TP?
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MKH^ *K5A94HYP69> '3,CZB9%J#JPH!%KLX9X(>^!'Z&M'"L>VQ<F1+/Q^:
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MR42M!>KS957)YQ?Z"W8_QKC\'U!+ P04    " !HBE96]HN$ 1$4  !A"@$
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M_7WLAZ'?'+^]Z]IEMSL4&'__J>^';S]<COPO_>[W8XRK_P=02P,$%     @
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M+@58T3J,A6]]V3H##8(06MZ;\F_-6!;?NYJ0J2W^2)MX*)Z^^?Z/49VQ0MH
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MO#U0.UTJEEKMRZ AU9"Z=YY%(LE)G*PVQ_5'1.17LXZ+MW]Y'4<S!9IS2FP
M=/U23$>ND?(:X(!3./J,]$O\[=7KB^QQ"TK@!M*/LZ%2!G"N"VR>4.8CH=UQ
M+2UF9=BE,(,EA>F]EG?9.X<3SBY2VHG K@.&*]<]^UEK@LP="=1[84WX2'S;
M(BDP+I@Y6C'YAF#JAG27!N,\54ASY)@1!3_+^R0).W(-]LVTUX!84U&,F_B5
M:W%:JT@KQ1/T$_6[(QDHML>I >-(+*D2K:RH!$.H"=907,K8-@+"L5'P@<R!
MS"<_(PK%4TYH:X<*0T.)DH-#Y1ENP\5LAYE%B(FTPEFVLA RCP>+6MJXJXLY
MG<1;@4JG\01YE%:<] =HT6"9:_"4P]E O%:4D]Q9R,'$^(A3KE)H"*7U!XFS
M&#HFGOYDF2!&#Q73#RN##NK-=]KW9*9E/8R*4KWK$8T)!B]V1"'<2'$%U8^"
MLV:#55E.EL/ %$:0G*\+>:BAYA)R('"81[D?6N8RYAD2I3.D0BJUW+3T$"$Q
M[I$&6 3& IHG^\F>@B%(Q%$Q69P\%<SQ)7I9?()"4'CG)>$E";] 0 @)A:LT
M@\*HI+]1(9P;'Q&^).ED0(!4Q.Q) 6-.5D4VFF'0]'KV07GI8Q%>?T  4/J=
M"A#] S:=(#SD,LFW&,9+3<1WVTOX(FEU>Z4%$*O7=.'C5M*I76!4DM#LNWR,
MK'0P^XUS&CT%X]LN5FW3C/A\(G)KSR[I]<D:X<#P&GEE"-R)]VU#C]19%1\=
MS@WG NG+833O3#O58CF2IQ1+'D!_+U6@4'.@J C:B\97& YTOM#SM6;\#]-0
MD6_,&5UI"W-UW*64^*7?3Y9L>B0AS\ZUXB0,DV=PU=J ^>BRZ0AXT]A!73WC
MA$@[O7R_(Y?P>$DL8!(.[/'P2.S[2EVI,8582T6\W]""I6:/R33K$6JUDL5"
M5QTAR>]Y#%)D032I\9BV1B\A.F79(I%(0)+@UOJ47O"[5@TBS[IL6G;+LVX-
M3K<9K_.&C;1F8#T!<#'5J><WT_X.H>5R["]9!FQUTO/!P+=G7WB/O/4_K<?C
MP>(05+B+Y3]V--VV$4>7".G$P"&3DLAO:(9)J.--X523";?%&IHHLXJ<@ESM
MI.YH7\Z[5R)Z)L4\R4G$<FWR4UY(LKX)("4CK:I+GP#9E?9>S7<H550V@[8U
M;,X3_4X?9)]M =(^T)*G/4<%]]@GLO7Q>=GJ8*9I^>F_&7A&L35B=B79QVEC
M=$EMFL&/EPW"-?X7!0\7H+ESHQ6=L4O"2BU[6A5-'"FMHY&UVI>5FT:@D35Z
M2/1Q:;J,CN&VD:+<FK.:B98W2O8Q0--L[SGCIA:.72C.6UN"*8V/K8,F1Y28
MFI0T,<0 Z0=.VCHIEENZ,$8:FXE1%051?&S1-:%9 R6SN$,OK;.?0FA)$=N$
M\0+@V6)IASEIL&\8H= "A+9"U5J0?. X[\S72#&&+>5=%&RO*-*?= 9'GG[5
MQ*YY5?WX!>IZ*D2D<E,EG@*''-%*7A7?EPP$DF/@)>!'%?\=_'?>.W-5I0F(
M'8^SJY*N&=U:;<+@P,FR$9$ WG(XL7E6Z,X4*U'X+-'!.<Y*VIF >UTZ)I(*
M#$=]]0%*DY= M/=)PZ7D7JQJRMW%G)! H$XV911IF#70K7+,#2D-MJ8;TDS&
MZJ-UUFNS]$B^'6EX%AIQ JD9M5>:\YM(XC04?4BW4RFHTY*IK(7E9!CAX&A4
M$DXZ(%O<]).']QB0=?(.6772)+>*U)TTP=SQD0EI."7E:(\A:1;H-!N$1#A3
M$9DJJ:4\;D13:JN]_YD0<Q.E-&?)K(O$4LR/RH^T/$.R1]5^K';.$ U\6(-2
M]3RK2* OTR-FPK['B$'K,^ 6W6,V($@!@,"/#(%\DS3-)<8I-AE;?'%5?.<8
M$5/7H)6OD'XDN1\;R7FUK6UMWA=-4*1-:MKR8XVU9_*6\7E>*$]F&1K.X&&9
MK72&18*5IIA$Q')I4>Z>#Z-H"\A/VN&=?<W3I.S(S6/P&BSSQ]* XV^7_>9R
M8O019$F;(_BL1M*@)U;$9FY\VHE*]L[W\$J.P9RHT>1T+2V718GS8WER2U>=
ME^>2[.VF^95%EDRCD$^NPZ1AG3$)A) 9&;3WAB#,_0IV##QVWDBBO>,<8AK'
MI2HS+[- Z*U&.)+_>A=B E2:FUE/.UR+1M"^U6F_S3[/EB@.H/XD6-NVVMMO
MM([]3$+)14#L5DA1(4;%FBEAE&!UAPQ'-1?]?ADZ\1."(CO8$YM+XT)+;!M.
M&A"[$>%5VI17<WJ':$9RP$X&J!@A2.B[V&< +3C]1=MV-'NH:9-3DCCG%5W&
M=!=+WCN&+#XL@KU[?J/[EF=K0AXC>+F+*M$/"YK ;D#G1_+*TY3%G"A-@Y1P
MUF!]U=2'G$-F\[]]:-7Y[ -20"7"P>";PNG47F;K3]_HJZ%I(A@"^9[I+$-;
MS:FB%K<-%Z,T,S0NZ6TMVZV9)?47<(A0B_V<TR<_KLN9SQHL1^XJ,3,D1.M^
MH&B02U9X-?8S++;4GL,7L5[*G_@M!W\"@Y9@_ "_D"035*S8%38$WYRJ]?S(
M06[)-$XZ++I**]XZ3HXD6[R9PTG:!SCS[67T&"DA]IJ!3^HYQE"6:U>)D3;Y
M9,\>82NK Q]#7,LY&Q,@%G2)A:3-?\&EN!.,9GSB!LA@4T#E%<ZXPLFPRKJF
MO=!WD%&><F5F\SG(5*(I+@*U[-4EVBL[=F)C/[QGIUAXUF#.]VW^WMF=6Y@C
M&>NJ>-4#T5*W"270#U.U4GQ2EI:1T=U#$ZYRZHB1&6HMH >"T?C$J1<2VL(D
M\^T%3BV?M%"+TY$>]OW#8;2ID\)./&9KITUX'V))B ]T0WK$$R/94Z9RS$38
MTVT1/ODSW]MF6Z*.3R7L#V[4(GS21$%&_=",,34?RTRKI#+J-",-D9!#74/C
MP\%;.^QV,H K<;[7&H4X$"-=:4:7*5U<7:;4[*_M#Y/HJ$%@KN72)!-W.M=E
M[;X47B2)>$@]7!?_^7G.R$$78TY9H1'U9(5QXM# !2E[D',/<2R-?- _S,>*
MTI$I^IM\1"=S;?5LR#DQ^?\8AC]$Z>."<09]"\97%HJCMI&I&QN"?V=L3@ M
M0JSQ9:J.#_PXU\G\-!H1IH@D9R%PLF,LTR-+2[[V.FLIW(3SUI";TY[UI&9W
MJIH<M3>!_#S0?G#-V!5X5,%,2WVL5/_>&VGIIHX,;!"3;I)(MJO_KR3O-<.Z
M& MWGZSY[)9Q/X2@4IV[P-^D)S63YN$T][MP9)0)54?T<=ERB7R&H7'+IT21
M7DF%(YX^6#YV&H#&CJZ2LF@ XK(SHX?0MBMAU.(16'AT_31^>!FYE3L);(SJ
M1Q.=LL4"W/-'7#FILUQ48( (?5$"+FG5\#)@!..)1)F+<PQ.O70_BS_X(:[O
MIP.+-]UOYNE802R;0%X[IJ?&^C44FSDL2035#TNX/*J.X1XAO[^M=O'9<NTB
M5Y@Y<1E>,"67"(@I2MC#7QJ.<T/UOX:*#TVR9+D^_)9DRZ$U>4%CKER;7!:D
MT97PT'7:4<1WLI!\<T./-A!8UI5#&CS-VFDN@5B%"&JMM0_N2^0LD)+I0!2:
M)/F8]ULIVV=-*)KPR#:ZCB>YTL/]<A#/1'0N4?,-GL> )T*J53G6"LF;H!+,
MDR6':?^%646>.:VRN(*5]2VD#,C" I+_Z2"Y]YY<SE^FDB/)MMS&<_A/D>&]
MR(G_HYY6C/^808-UJ%;H#QOOW:* ),U\(:HW"<B?9&!$H8OT08[P!C/695:-
MP_<\49!0V_@E:][XJ)SK8]I7'@_ L[LUM_1^IH'WW%^BR?*Y&\#*=5:/M+#+
MFL0LZ#56'WFF&26_/]6<)H-X+F55SLD%%I&7>08QW$ZT1T[_T+K9-#[!O.?7
MRZ!WZ]K-9>QA2(?'$=X>EI)5TX<'-=GTX=:&U9F^!N;O1 %(O\;M$=SFH-UH
MZ=$Y3KON#VTO;;6Q8T(SI>%-NSR@X>+JXWHTM($07/9:\$^?TA9]5F%M)$8L
M(X[VR>T&D$#T29_E6'W2Y2<+<[']+!HX;7A;$SLWS?SHIM6Q(K'SC(DDXQZ]
M-UIGR79HE6S/*I*:$R:UY[A=C]@J,6W(9KHQM#'%8A[V+[XJ:^F]O6MQ=NR/
MXP+#@(Y+8F"EAS"3=K3DW'MZ=$(.'B0GWPU>*XMJ1%.XWBY/!U/$Q[B+;UT-
M;JZT=2CMV4J/>X<KW28KDDM=#27.3GK.Z3D]5R4>+GV4^,HG>04)/-/LF)F3
MJ^*-(YP>9"2=,7AF:Z2\I [@]KEG'REA#X+GI97+B2L-]4R8M K)*26YG$)=
MPL25B>O0 B3V+2GI3MY2I-;>7R>$I^6!-&?W$_T4;Z,(X:GUGX6-CJLYE$<)
MHA/:EF::IQIUJ,;#WE6E7M41':AH#WUF$$=<O[.58!4',IC1G()=--R)J8A)
MZ2:S5&(038C0W(%2NL]6)%F8>'(%I.+9WC>Q56J^0SOIGE$(1L@N6%=.:CA+
M?1Q/AQ./Y1K!DTPH73C9A0ZAE>24QV0P%R=L\I.E^5T7$ONB#V1QV^#IZ.;/
MO$IKQ,S1DBLC9<8K]".2>]IRXP$Y$@BMWY,K*BXSNQ=LB-*:1SF.0[/F\]Z\
MDAFWQ_*]XUKZC";Y'M5;T0\NW;!C-G!'JQ(^OU]@^1:&'SJ]"&%Y,<15@@2I
M"Z74X8<1+ XUKDP+&5ZD3AM[@ W@>2^LG/<@<;=C7UE_?&;JD\T(!7U_[N&T
MT5P>DNM':#O(-:N]+#(OU2UVX0&?Y T-$*W9=!O\N[P]MTQ![L%B#;QWQF6N
M:EL:ER=;I7D*IM^HR#K$4*V5A*#R(#T_17M(5HH]?^M=0'T@R3MG<3?GE;6)
MNN@FOOC0FKA/ R^])2F0K=TWG&Z+ "0)VP?V--TF9"47=BE-868%K2QO]$A"
M?MJYDS,(J0S%:9--U<Q%8 &]N''-*)<]G5V:,,K6@V2/<#*-EL]<ML5/0A4S
MGZI3X&!?%.EZNS+MK!*<D,")WY0 /K(1/ %:C='(V\ONCOL5A_KXYE ](9PF
MF$V&(2F)F$K)2H=A,TY>X$[;&1!H44PA/PI7X!1I58SK1;3"M$B112I\7%&R
M8:!>+B@,9;C0;S1@GT!,++C9T*S+ZFYZ"P_",7=^2OIDO8"W/$069FO']4D6
M^+8O/J82#>-W;U_]\"Z?CV43/J;-P_% V\ZHXN-8R7DX;4X^6IIK80V6D.:>
M;=;@H:S#B1U7&0:9V0\-IK5#.LEJ1-)=RO%C[(K#6ET6\WVT'//]]=Q%8&=_
M"-D!\;\OQ?_6S,92%@3Y$[M1,?:[YMFY[)C'S!\*QB7% ^7)@W?<6G30.&V,
MG]UZ%K(Z":6??/I93EKKMFC#T05<%=\NW=:4?,G!^T9NW/0:@,F]162E[NVX
MJIXD8@3QW,%OO8C<@:0'X7#4 X?J$Q5G%T*]AC8_#6*^J%:8>.7HADZN/)LW
M;V3+27ZTV]A"$B*K0\7S:G:\J;1[$<C#M_G-)L$/)MK <#/8*SW>J(<CIB/N
MS.66?F*%&ZS>'5JB5WR;G'G$=N^;K5W2!3B.TD+J!=>D::FJ]&9;4=C8[6('
M:5$%B)TO?)-=Q<U.D:^KT\;NDXOZEE@N>SVQ[H=6;6/(2I)7R3@A<:\V)<JZ
M'($4VU?A $-5FMM=ZI2X0&[I'K&9@7K4';O9?27< 15O<O/<([<YOZ])HHL>
MFSKM6=3;5/DX?<P+)@/O2[BQ?'X=Y5X^YP&UBS'F[.ZW>)N?]M.C8O;0A6J5
MI+#Y<K<T&Y_3*.Z@GNY.G@HQ$)\!&1J1\U'.B.?WC%2FXTFO9>CB1#;5!\.8
MX//-F0,Z>;ZGY>NALQ7F6IOE4+C0:L:#Y=269K$#MTCS0;90OI:6YW"6-C2Q
MY3E*.?!E#:E+=T[^MELF<?5$3<QA5IW@<UX4BA&Y/'AAMC:L6?;<#E.Z^75\
MH0"?NB#I3;M?G*OPX^UXRY_5HF;UV%6\%_BDS?L+L%\]G<'%T)C3!8\\DI7<
MZREGAW!0)FV*6IUZ'5E/S6_;HB^"_L[8^9@BG9S;6G9W3V[VG7?()MO/]RB=
MBIV0-I.+(ER*FZC-KB$O;JAV1SLB8T9;79%O S0F?S+BEG:XY@#C50_'].FW
M+V]?711Z\Z;B>S-HAHB[&QSX[7,P/#Y"[__J[E/^^C S?HB?8$6.2 C6/=^;
M_;8KOL>RX -="QR#1O/D%]?R,]\T6CQ]>?OS!1%UQ>]>7K]8%>^<%7[>X8EW
M.*RQ+Y[^U!_(3GWZXM.+S\E_X([\K '^FWCA^_((]&CD[[M@Z$"!37Y1D&L7
M/\8CX%+I3SNC[=0SK@Z/][Z3'#%>Q0MX^42Z-BGM^SJYTYA[J#0ZR+J@5OG5
M3DXN4+9[3$@-:9?+E6&K+56B""Z%BP8,H91[6@)-+Z_7<CVI2AWTGZ\[!"?X
M=N-PP)]>)7([O7!5]OSYS4KW?7[B16P2MT:P-P3FB K'N8C#7)&0VP.LCG+B
M6/.%*N';^%<5,C$C<E60;BZO/WF4($GR6OZ\ L:[G3JXPV\T6Q,>M6O5V,N0
M@Z1%^,M&M?H\<ZI?7*E0@G-_+KL)Z* +"OLIVT:CXK!=FB!/KF$.!]'C83Q\
MW7?NDGSO]\+X^_Z2^^+3R[5U=$@";GX53W+@!/.>&Q\O0US%49^(0FRO.QU*
M">5B:&5_&H3&ZQ?'2R3GSU-KB_\(TZ"!49*]/!87 ;J>35\UGK95)-?725_Y
M2?TKIN#%9@8NL3+8GX-@P=Y.3:T7,UD#0Z=_X>6#=]&2'/Y0C;V*X?,'Q?#Y
MY35)SBLS^*^CP?=!#*\_)C%\F=NTEU;+?FW(\3(6#<)WWR46R$ ,,R8@AH]%
MN )<K9R!YLO;U\4GHB=R-0-G7%Z'=DL.9EYKGZ8O5GDV5FYA8R_P;/<T_]V9
M?+PJC!<*]IR>7O**5$RP%IS]D0N*(^1:F&&5Q?FER6G8&?Z< V;#PHGOTE8G
MK0=V-=BLIA&0.UEA^"Y=JIX%YLX;N0.3RX:6,%/SKDM&1RF*KG+O1'(8D7_7
MK+D$RND^ L6#.DFR L>H^.)[GR!SN4$'1@"CYQ];;B*B!SM<S3ZY-EUO2@#5
MZ;"$8'Q).%MZ3>:C7:890W])F^8I4IT,C6MB>[3Q3,=AO)7SN^P08#/U%D:$
M$5Q3C5CP.-U<^HM>SY(_S49BM^4_0*=7^<A?:0O?%O8W[E[*GW:+C\L?R"-S
MMT7)N'4;>O7ZZ@\?/Y%V??LP]@?^0V_K?B09YW_N7%F[ 0_0[YN>?"_]@ G"
M7_[[^G\ 4$L#!!0    ( &B*5E:"B.8(!P@  .46   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;.U86X_;N!G]*X0WV28 Q]9=5G9F@$FR11=%VB#)
MMBB*/M 2;3.112])SZ6_ON<C)=F>>&:2AUX>^F!3%,GO>LY'D><WVGRQ:RD=
MN]VTG;V8K)W;OIK-;+V6&V&G>BL[C"RUV0B'KEG-[-9(T?A%FW:61%$QVPC5
M32[/_;OWYO)<[URK.OG>,+O;;(2Y>RU;?7,QB2?#BP]JM7;T8G9YOA4K^5&Z
M7[?O#7JS44JC-K*S2G?,R.7%Y"I^]3JC^7["7Y2\L0?/C#Q9:/V%.K\T%Y.(
M#)*MK!U)$&BNY1O9MB0(9OS6RYR,*FGAX?,@_??>=_BR$%:^T>U?5>/6%Y/Y
MA#5R*7:M^Z!O_B![?W*25^O6^G]V$^:FQ835.^OTIE\,"S:J"ZVX[>-PL& >
M/; @Z1<DWNZ@R%OY5CAQ>6[T#3,T&]+HP;OJ5\,XU5%2/CJ#485U[O*#O);=
M3K(/LM:K3E&DSF<.@FEX5O="7@<AR0-"XH2]TYU;6_9SU\CF6, ,%HUF)8-9
MKY-');Z5]92E,6=)E"2/R$M'-U,O+WU WB=YZ]CK5M=?V-^O%M89H.$?IQP-
M8K+38H@AK^Q6U/)B @I8::[EY/+''^(B^ND1([/1R.PQZ6,NED9OV!L$E*P$
M'MR:O?%(D.:4R=\FU.P3S$37@ ZUWG7.TH!4UV+12O9I+:%WLQ7=W>]HP*^T
M;'''K%R!B<ZOW!I%_&5;<:=!;[TSM60WTD@F+%OJ%CRWK]C?I#!,$AP8DBDW
M"VG&A+)?IQ^GK%&BO;/*LC^[-0;/V%57J[8ET11954,UHF!UJQKA(.>]<(J,
MZ$=' U^Q=[)1M2 +8-_8N6JN1>=06M@S5O HBWE6%4?/8:IJPCK186ZS?UGF
M%<_+:FR#G2M]+4WGHY&F!:^JF&5%QJLD9O,HYA7(@!@B5S7\8RG/TI*G4<&2
M).5)7.!-440\1Q2"O&_W(LURGF;1V#YN?<SSK.C_#PQ*$E@1#TTPX47\DB49
M6<JRC$=5PHHY+*S8SZU"S1$$&LOTDJG.23-@8<3'BWG)HS1_R5YD/(D*M%7,
MDPQ"/VD'E<]8#(?CA)=E1AUH*'F<1/0<\R*J^+S*O!'!G!K:E 4T ])4>T>Z
M-][!S2$ EA+:@;,.?JN.83&,LEOI*_V 9$:,( &+G<63M033&VP#U&JOL-/=
MV?8TN (9W1$Q/'I_^>,;'_<@07P-71KT\0KQ0QRPDYH0R^EC](C_*_2(4\ S
MS?%\V'N"(/,$H(G&]FN")'.>Y 4(DO)TGK,2P"BR^)@@*=!05"6+JXI'288W
M>57P,HF_GR!) 4G%V#Y%D!0ZPO^!07'.\SP=F@."$.ERED6\0E,4/*FB;R5(
M%?&R*@)!JHP(DH,$T3%!2H2]* -!LH07Z4"0>([5Y?\),A D^H\3A$+O:5%4
M/$F*@21][PF2H*3.BV1LOR()"4_3C)<QL#\'$.89*P&_I)K?(TJ)04B(T::5
M)PJA$?SZ7J)D<85=*!G;IXB2)&7_?V@02@3VEK[IB9*\)(;D)3;%$I[D;#[G
M,2S\1J+$V-J2.3$E1@G(4O^0H"Q4]S:3#'6D"EQ)<\0@#US)\P@;2MA,WNZ,
MZE8>FDMEK&._[82!5E)/998?HA8VB%:MB"CTMFZ%M6H)__T'$U8,<,=WW[72
M.PO.-<K6K;9[;DWNYQ:?\$#>2@.23H<I3Z3F8 5.7*R6QN%D=2#RS$BU6>P,
MJ=VV M&\6:MZS=8"C,:'[:YVNUXZ/M!\>.NUH"]):5 S5&V912I $V^2$8WJ
MV7<")U[!U'\7/AP1LA.NV7[ZT&=WCS%XC=HB6JO90DHZW=4""8)!*&UTT@SA
M4E3A(!C&D-*IA]?_0 G\-Y<^"O=&?-9&.>_5L89':K$-%CT!,?XXW;E_6^]Y
M'K[PZ3S0)X,!2%_.Z"S<[#7W(<99X41 R->5\45X- SLD1!QF+,A^E-V97&T
MMK51BY"V/VDG66 L+<?/@JP>CKT]E#*K83 I\6<F";3CV$XUH+>2DS(?TL 9
M)[Y $,8,W"2X6L(=G-3MM?1Y@'V]&,H:J=TM/@,[-$]W*TW"56=W!DD&1XBE
MQ!LPKEM)R]E*:OB]A;;]8*.62WB!!9@0.D$,\( (NWV1K(<SX+AVCZIP^E+6
M[DC, 5P';(0AB*W;74,*&@D%*,+T++;;%K&C0]]PG"/1%H?$KJ'>H)$/OE 6
M!M%'YM1:FZ8O[9Y"LI-+Y4(2W8D0&@P35$@(PP!T+. 3VVJK/"E):B=7(G2:
MSSC[$CSZY 3J!4'^2/O//;/KG3%D(,BD=#,%;("3;M7*0SR'R/7G7ZRE>K71
MD.?@*7:7YWWH]Q\.(\BU.1XX=8@>RE^P8:Q@HY%6'LM ,*A"$-&0>AD\)0,=
MS5:F%W2&2HI$[VM7>S=E;X=/H'UE.6'1'C3[E_=*!3_ R4/[ #^H)U0F]BLV
M][\8^OGA4F"[-?K6YQ]%^EG,XQB'XJKRTJA;9C@,IK[2+D_<%="TL%T?^WYU
M)#>>/_<SX^+YO9+YXP_S)"Y_VA/CT5@M1$M4MM]I3N_K'D96W:+G[\1TV_A:
M8OI;DDX?%:]1H^>#[OJ-$ZL( E\9,+UW2W,RX<;3&JC:BI8^5(:]ZL3.0-DR
M5*0V]G[AWQ>V\!UPZHIK=G#UB'4K?\%JF;<IW$*.;\<[W*MP=;F?'BZ WPFS
M@DK6RB661M,RGZ"R^TO5T'%ZZR\R42V<WOC'M12--#0!XTN-7:+OD(+Q9OOR
M7U!+ P04    " !HBE96P)<<O+,$  #$"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RU5FUOVS80_BL'=2@20)7UYK?4,9 T'=8/'8)F:S$,^T!+
M9YL+1:HD%<?_?D=*ENW&R?)A^R)1Y-USS]V1CSC;*'UOUH@6'BLAS66PMK:^
M& Q,L<:*F4C5*&EEJ73%+'WJU<#4&EGIG2HQ2.-X-*@8E\%\YN=N]7RF&BNX
MQ%L-IJDJIK?7*-3F,DB"W<07OEI;-S&8SVJVPCNTO]>WFKX&/4K)*Y2&*PD:
MEY?!57)QG3M[;_"5X\8<C,%ELE#JWGU\*B^#V!%"@85U"(Q>#_@!A7! 1.-[
MAQGT(9WCX7B'_K//G7)9,(,?E/C&2[N^#"8!E+ADC;!?U.87[/(9.KQ"">.?
ML&EMLSB HC%659TS,:BX;-_LL:O#@</D.8>T<T@][S:09WG#+)O/M-J =M:$
MY@8^5>]-Y+AT3;FSFE8Y^=GY1Z8EERL#MZCA;LTTS@:6<-WJH.@PKEN,]!F,
M)(7/2MJU@8^RQ/(88$"$>E;ICM5U^B+B#1819$D(:9RF+^!E?9:9Q\M>G27\
M>;4P5M.F^.M4PBU<?AK.'90+4[,"+P,Z"0;U P;SMV^24?S^!;)Y3S9_"?V5
M+7DE1DT8QB=\S0PO )\N< ,%$T4CF,42%ELH^0,OR0@DB0*7A:H0F+6:+QK+
M%@+!*K!KA ^JJIG<.A?WN?$G@"#8 VHZT"";:D%1U!((HJ(CZ.,9(&TPEDD7
M(H)O/WH]:^NHB*9$T@+J'"^<$YV/XAX:R2VP#=.E(2:,QI265""47+DTF\7?
M) *.-JG8$KEM:'V!!6L,>NH:"UYSE-; FGB 89:;):< 9+PF"'IP#?A8"UY0
MK =BX!A9U!5QU 1@N482*PLH^(HON.!V2]/?FV[>1'##1>-(G^I!FYKQ;$IG
M1UH%N%PZWE3 PS+XG-\9M%;T%6!U[7)@7NFTJZ@!,J?*.*I'A:(%XXI<>RX-
MG5B?'EC2=-/H;6=:H5VK,H+?VO(H65!*'M\X0LZ#^DLMLTJWL4J4BA2JG:#*
MEJ[@_<YRVDG[SQL^7X<-TH/X+96@WX6Y@#_("-#)"I HH-]0.V%PC\0]8OAU
MOU//A#+F_,F&O6%?N67P21;1!>U<2?UK7#7I]Z:[M'Z"83X*I_F$1M/Q),R'
M,8W&DRQ,IT/JGBE:-^)RX)5D9)C"VS>3-$G?P]DT' VS\T-&+U!Q,4=QF,?Q
M<<QQ%H[R].GA>'HJ+KJ#W:U,TW Z32&)AV&:Q9 DTW \'<.5H;\NX1"C=CLR
M 4NMJJ[9M6"421I.*&8>CI.)&Z>C?L?NP(?A),L)?.JKE*1I.$JSCH#\+UJP
MWPE4F&CB.Q%EKB2C:)@_VX.]6QPEPWTOXBB>G#_EMS=_N36C*,X.&>3[BOP/
MV8X3>DVB:1LKF[XNV_S';$\P?&V^5/'A$8<$KBC^NUZ0CJ6G4UQ\]-I5MAMJ
M=^"=$)TEYY"$\9"V2C*B+97%B9^[:[<3,T8YS2+7#<GL3LI.H?:RB$<Z<Q3M
M0-"WG9 <D?\WJ3OUZQX<W*Q([%;^_NCDLY&VO63UL_T5]:J]F>W-V_OM9Z97
MG+HG<$FN<30>!JU2[SZLJOT];:$LW?K\<$W7;-3.@-:72MG=APO07]SG_P!0
M2P,$%     @ :(I65@[RX2@D P  3 <  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&ULC551;]LX#/XKA&_87GJQXV2]M4L"-.T.V\. HMW=/0SWH-B,
M+526/(JNFW\_2DZR;$N#OMBD3'[?1\JB9KVC!U\C,CPUQOIY4C.WEVGJBQH;
MY4>N12M?UHX:Q>)2E?J64)4QJ3%IGF7G::.T31:SN'9+BYGKV&B+MP2^:QI%
MFR4:U\^3<;);N--5S6$A7<Q:5>$]\C_M+8F7[E%*W:#UVED@7,^3J_'E<AKB
M8\"_&GM_8$.H9.7<0W ^E?,D"X+08,$!0<GK$:_1F  D,KYM,9,]94@\M'?H
M?\?:I9:5\GCMS'^ZY'J>O$N@Q+7J#-^Y_B-NZWD;\ IG?'Q"/\2>"V/1>7;-
M-EG\1MOAK9ZV?3A(>)<]DY!O$_*H>R"**F\4J\6,7 \4H@4M&+'4F"WBM V;
M<L\D7[7D\>(./9,N&$NX5KZ&7_Q9RD(20M-B"[@< /-G ,<Y?':6:P\?;(GE
MSP"IJ-M+S'<2E_E)Q!LL1C 9GT&>Y?D)O,F^Y$G$F[RPY*]7*UF0W^/_8]4.
M6-/C6.'(7/I6%3A/Y$QXI$=,%J__&)]G[T\HG>Z53D^A_Z94V:WQX5NG'Y5!
MRQYNM"^,\QTA?/V"3PQ+XXJ'H[6\F*W8L>$/HB\UPK5K6F4W4*M23N3OX=$X
MR &WAE<7T[.+;!*_O[J8G&7G&2@&V55L5DA#LW;;&Z/$$%?P6XQGUFQ&<-_)
M)BG+6AFS 7D$:!9)QV0<*E@IHVR!)RBUAQI-"=H"DYPX8 =>L?;KC:R%QE)$
M%7X.?%5G%#O:B"D\A$WD(915$2')059?.Q'ZI^MM%-:&.@:TJ*:(C=3H)5B4
MK5 1M.36Z,.T4R825FB1Q#9:K;31O(FK8<HA^3<10Z:CBM.-M'_P($,ZLN_V
M*<0/30KS6=OJ9;L6V_%\PPCCOQXB8VIKL*QVI6LJH57$H3;I:.&LW0[@7G-]
MJ.Z-%_9"&R.7 <@M0[$2/SIV<-*#"=<@57&."[WK+ _#;K^ZORJNA@GY(WRX
M9SXKJF0CP.!:4K/17V\3Z5Z<W8/#KHWS<N58IF\T:[GND$* ?%\[QSLG$.PO
MT,5W4$L#!!0    ( &B*5E;=7OLG9@0  .(*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;)U6W6_;-A#_5PYJT+THEB7+L9W8!O+1H056(&BZ[6'8
M RV=+"(4J9)4'.^OWY&R%26UO6 OIGB\^]WW^>8;I1]-B6CAN1+2+(+2VOHR
MBDQ68L7,0-4HZ:50NF*6KGH=F5HCR[U0):)D.+R(*L9EL)Q[VKU>SE5C!9=X
MK\$T5<7T]@:%VBR".-@3OO%U:1TA6LYKML8'M+_7]YIN48>2\PJEX4J"QF(1
M7,>7-ZGC]PQ_<-R8WC<X3U9*/;K+EWP1#)U!*#"S#H'1\82W*(0#(C-^[#"#
M3J43['_OT7_UOI,O*V;P5HD_>6[+13 -(,>"-<)^4YO/N/-G[/ R)8S_A4W+
M.R:-66.LJG;"=*^X;$_VO(M#3V Z/"*0[ 02;W>KR%MYQRQ;SK7:@';<A.8^
MO*M>FHSCTB7EP6IZY21GEP^ETO;<HJZ R1R$DNOVQN43&DOAMV8>6=+D^*-L
MAWK3HB9'4.,$OBII2P.?9([Y:X"(3.SL3/9VWB0G$>\P&\ H#B$9)LD)O%'G
M]\CCC8[@?7EQ+X0[7%GO_J<?#;=;>,"LT=QR-/#7]<I83;7S]Z$HM#K2PSI<
M/UV:FF6X"*AA#.HG#)8?/\07PZL3'J2=!^DI]+X'E*P3/APR_#3T>XH"OI<(
MMZJJF=Q^_#!-XLF5 ?,.P1 R13UM+)=K4 6U$!G.)46Y:8$SP8SA!<<<F($2
M17YNU3DUH/-GZX&Q];%OSH;;$MQ8XF)+F$XKEVPE$ K&-3PQT5 ZE2:>'*O:
MCX26&,(&-3I=A1(TI,PE!3/#:H6ZJ[B?*'$;\%VPORO+Q '*+6I+GF3,.MW.
MUUH9WN9)V9+@+$VX/=G &4R3<#J9T8>/:7+5)R6C,$DN7KWM2&]JH6IL0]J+
M1N;&Z\I459&_-$VRQTYZ- OC=+0_]M1T&HYGT_W1T[[C.X,X24(7DIY!'?<D
M#J=)"KT"ZN?H#"XFA.9$9\07.X%)>#%SJ%."FCCT-!Q.'8&TC.(A_':P^.)Q
M.!Q.()F%([(D3>F8.='9; :C-!S'8TAG=*3_UP.?2]/UT&6_W']Y5>B[^GVQ
MC5$QU9K+C-=,4#&NF'R$[$@E^+*EAO SQB5M5^=N]KCV<252,DD_&A&J=JBN
M&MM:L']5$F&+3 _>F/G2@ >M]):]KL#WVO-*H\$6_R5>'IYEF6JDI3ZFY>%H
M+VO,E,Y=LU-?5.04_P==Q1I+C5GRK 16UUH]<Y*B!^H::N=^3Y/<S_WJD%V;
M#O8->2274"I!3>+20QO,H<%"[EHHV1/^]W0IM*J@;E:"9Q0W_8BT+[W)B$:W
M*;G1=W16'K#!1=,%SZ>'S&1 T])8L,HW.>#S?IZ2[C5SPXV$C%$9]T'S6;4'
M!K94\OP'I;D=M[3-H-8^^A5M?<8#02V8-(-#_UA1;^^H4*_]=D7!=%EO5Y".
MVBUPU^W>\L+>;G]?F5[3GP (+$AT.)B, ]#M1M5>K*K]%K-2EG8B_UE2/E [
M!GHOE++[BU/0K;7+?P%02P,$%     @ :(I65E,W^$MS @  A@4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL?911;YLP$,>_BL6F/;$"AH0V2Y":
M=M/Z4*UJM>UAVH.!(U@U-K.=TGW[G4W"4C7-"YR/N]_]S^:\')1^-"V )<^=
MD&85M-;VBR@R50L=,V>J!XE?&J4[9G&I-Y'I-;#:)W4BHG$\CSK&95 LO>].
M%TNUM8)+N-/$;+N.Z;]K$&I8!4FP=]SS36N=(RJ6/=O  ]CO_9W&5311:MZ!
M-%Q)HJ%9!9?)8IVY>!_P@\-@#FSB.BF5>G2+FWH5Q$X0"*BL(S!\/<$5".%
M*.//CAE,)5WBH;VG?_&]8R\E,W"EQ$]>VW85G >DAH9MA;U7PU?8]3-SO$H)
MXY]D&&/3>4"JK;&JVR6C@H[+\<V>=_MPD' >OY% =PG4ZQX+>977S+)BJ=5
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*56;6_;-A#^*X06#"W
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M(>?,F1O)::_-%[L!<.2YE<K.HHUSW<UX;.L-M-R.= <*5U;:M-SAU*S'MC/
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MUQ;I:RWE&4<26C255A.MMIKRM56BTR&B;4,9K<@@I4&-<N9CY')$B:A+OE4
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M#(A.L$WJR@R>8Z+Q L&VHTY!0)LPCTY2&8.]IVIW&">%][D$FPPMV B<[!T
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M?CO\!EZ:9"=IP2ORPN1O2K)()<@0)L^.LXQ+[89B]JURZ0$MSI UG@MHDX]
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MK=\J69>\0E-T"NB",DRE!?C&Y)"EP.#6%%ILX%5GC^C22M4QT@K;OPGUO4&
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M'J/9[=6"'\MEU+M%]?_@_YU7A!\7PS80I$6,B4U/H"'%322>7@)XZK>15C1
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M<4X?>,PMV/,?I HBV-2&55I"W,O\@:DM,[3<B+K.80/]8KP"U:72;M,83B:
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MG$U&3/O[8S^PS=K=V<X:"P[F'I=2E%+3!'R?-ZBY;D ;["[Q;_X'4$L#!!0
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M?_)\AL<4H.I8S]&BS  +JF3G8XAV48YKXK#VN>!+ BA\'@A9!I&8H_G$E(V
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MV'B04%\<DLFIM^9I\3FD(;>*'WT80&="^C(RK [?E6[3YY2]>/HH]9MT*^8
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M/] &O,\,W(H_2$'[=?OR7U!+ P04    " !HBE96S=&N\2D)  ")&   &0
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MR)2E/N/-DAH[:A= ZPNE['[B"G2_BMD?4$L#!!0    ( &B*5E:CU%$\Q0(
M *$&   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;*U5:V_:,!3]*U?I
M5&T2;1Y0RB@@A4=7I)8^*)VJ:1],<@&KCDUMI[3_?K8#&94HF[1]B5_WG/NR
M3UHK(9_4 E'#:\:X:GL+K9=-WU?) C.BCL42N3F9"9D1;99R[JNE1)(Z4,;\
M* CJ?D8H]SHMMW<C.RV1:T8YWDA0>981^=9%)E9M+_0V&W=TOM!VP^^TEF2.
M8]23Y8TT*[]D26F&7%'!0>*L[<5ALUNS]L[@@>)*;<W!9C(5XLDNAFG;"VQ
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MC:2YZ<+\0U!: W,^$T)O%M9!^5?J_ )02P,$%     @ :(I65A&X-T;9*0
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M_I\E@ZBMBUM&3]%MBEN_;?W&5V4[%*^JJAO;P;?;XI>N\95WH7BJ?UU\]VR
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M":D[%X@DC._D9+<Y7W^$19[I?[#G=__U)HVF!V@**98!>-8O673D)Y)?0W9
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M*45-$3RUX4^(5"+<="K8[X59'S29:<#P$;,R/9-;;'8'*\WAL@#(S#J@__'
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M9!G&:FH%R(K#XF:<J.T)&TJV!^GD;&9&X2:GO90I\3:%N:;Z$XUGFNTS>TM
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M<SC0AL"4X(3/Y0FC%@QY-I4D?1Q,,XJ>VSEP_U^J;[. HIR#5$$>6R?CI6W
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MRR4%X5M\&4 B,+GKY!HO4J(PK99O;$!.W_4ILQ)[DG&6*+8][$3H3=+JSN]
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M77O3/D:JQ*TO=&MUK2KAT,XE>NA!]*,CP"-X*RM5"H\ \8V-L^I6M YS#KR
ME$2<$EZD#^K=5%5UZT2+<ZO[SBPI2)(58]GA7.I;:=H0C3A.25%0X"DG!:.0
M1Y04R'*,82--B?Y!3'B<D3A*@;&8,)IB3YI&),$H=/:>[T7,$Q+S:"SWHZ<D
MX6G_NP.(,41!AZ*#<$ /@7&/%#@G4<$@S1%A :]KA<DH$,MZ9JG626,?Y@<+
M!WE&HC@YA -.6)1B65#".!J]T0ZW? $4'::,9!GW#=PA(Y1%ODY)&A4D+W@
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MT/@$6M]K[9X'OL'\CUG_!U!+ P04    " !HBE961;;<X8<#  !,"   &0
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M3-D-^'TN,3Z[A3V@&SPG_P%02P,$%     @ :(I65JY'YPZ\ @  [ 4  !D
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MU[<*=[->2EY4LM9%4S,E%^>C2^_T*J7Y=L+OA=SJ@S$C2^9-\XUN/N?G(Y<
MR5)FAB0(7![EM2Q+$@08?W0R1[U*6G@XWDG_9&V'+7.AY753_KW(S>I\E(Q8
M+A=B4YJ[9OLWV=D3DKRL*;7]9]MNKCMBV4:;INH6 T%5U.U5?._\\)8%O%O
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MI7;"6O<9SDVL;NC3UT);JRL:KJ4H9(L"\'ZI@5?T$S0P? L]_Q]02P,$%
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M/<'P%/KJKJ  "H*O&Y45(#B]KQAB,"W'^)Y&O"\8V<@2ZH^+;0O20?+_ -W
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M[1"?\GG4X21!9*\DT#&!!MZQ4&#Y7CJYF!F]1\9' YI?A%9#-I!K![\IC\[
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MT<<4W7YN:6^LVKE/'$ME,;_<<B,X7I-( /^OE+*'&SJ@_^9U^P]02P,$%
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MO>1$0.""7..S\WX NIU%K6!5X_L_5Y:FB=]6-+Y1.P,Z7RAE]X(+T/T09G\
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MVHBAF\[-WP>E=3#[4R'T>F$3E/^S]E]02P,$%     @ :(I65K8*7J@(!
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M^PR42[#G>RG-*7 CT]V0R1]02P,$%     @ :8I65AG*(PM6!   +A8  !D
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M+Y-,9/)-M<EDAUE4?$231/;^LBN.'I7TM?"#=_I(:-UD--(-)^.7NK8=&)R
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M@#*'AC2-HCT)AV8H-$@CMX+)J&!R5,%+Y6G'R@//1W9&EDIJ/"$C49:+^^2
MU"2Q8<WWR#OL:!R%0>9FGX_L\Q_< JVQ^Y9=W0EF,%<JP,)4\C[!7'SS QX?
M$RPF4;9_:QV&<99&8?3&O0V#ER87O"OB^Z%NP#C[6. H?TD:Y=D>8Y=AG.7Y
MCK2!L;_3H>WSZ#-32]YH(F"!R.#<OB?4\.(8)D:V?=.^EP:? /UPA:\T4-8
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MY]H!,5ZA(A%?Z.YW7 <T4KPE37CY"W:UK>> 9<$%36MGV8*49-4_>JZ%.'"
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M<R'*KJ/O)EHT;5/\(+1)X'98FJ\@D-; K*^$T,\3VV</WU6+_P!02P,$%
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M ';DSNO4:4'EBM:6LRFI\,5>,X#3XLHI+7)%:_]3W917H;7(<)\!7NDOM&0
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M>C_4(>K2+.K(K()O4.(;-+F7^.J(%<JA59JU<CL;>L,P]/5CVQ[#J(L;A,'
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M?GO306\Z,'KAT:8G1!24B88#^GTY$Y*KS^N/S6<K'-F%=<E=B!4N8.2HFA+
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MJ6Y\X#I O5\P)I\Z^E+I_T/D_P!02P,$%     @ :8I65F1^#<4: P  F0@
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M!H9&M]%UZ%X-G>%@9*_;@7EMYCO!P/?VS:(.,]>_:IGMB>DW8OI'Q>A:J/1
M\HZ<BFC8<L Y4/*N1?3:P@WZ@VX)02,A."JAKFRI*OM\ 112(B\0U*TFY:Q
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MV",)+&F>ZF>Q^PRE(.M@+%)E_Y)=:>M[),Z5%ED)1@\RQHO_]*T,Q!$@&#8
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MOS*Z1B/S0O <D0>AT&TKV+^06R3T$;!A1A-34$.6DOPA#;FQ9_)&*AA\98_
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MPP(;-U#6 /<W4IK7B?U UPK._P-02P,$%     @ :8I65AEW]Q/W!@  R"\
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M_#U)OI6D]W$:I<N2E(3+;A1ECTG\')5=L[%1UV"S%CUDYM(@Z-!CO>=8>H#
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MTJ.*[XA)/V$DTP[XVRZ]0LC!%^A0'[BP(XPF\!S*&"MIC.W:^!23WT!BK^/
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M+Y[DI21B2\'V]BC8I8+=4,#N'@6G5'#>JN"6"JYFIC!%\Q 2228CSM:(*VE
M4R^:3*T-YB>Y6O<'R>%K GIR<LOR^=DCY1D*Z9-$9^AZ-H,E$8C-T$TN*:="
MHGLB*7I8DR4B>8RF\+R<<TIA^4'P)*22)*GX",K?'D)T\N$C^H"2'#TNV$J
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M4ZX$X/N,,?G:4 -4_U!,_@502P,$%     @ :8I65J46E'V4!@  ;"L  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#8N>&ULO9K1;MLV%(9?A?"*H0/26*)L
MR<X2 ['58@$2-$C:[6+8!2W1ME9)]$@Z28<]_$A)MDR9X>+V9+UH;(G\17XB
M#\]/\_R1\2]B1:E$3T5>BHO>2LKU6;\ODA4MB#AE:UJJ.PO&"R+55[[LBS6G
M)*TJ%7D?>U[8+TA6]B;GU;5;/CEG&YEG);WE2&R*@O"O4YJSQXN>W]M>N,N6
M*ZDO]"?G:[*D]U1^7M]R]:V_4TFS@I8B8R7B=''1N_3/XF"@*U0E?LWHH]C[
MC'17YHQ]T5^NTHN>IUM$<YI(+4'4GP<ZHWFNE50[_FI$>[MGZHK[G[?J'ZK.
MJ\[,B: SEO^6I7)UT1OU4$H79)/+._;X"VTZ--1Z"<M%]3]ZK,M&@QY*-D*R
MHJFL6E!D9?V7/#4@]BKXX3,5<%,!=RL\]X2@J1"\M,*@J5"A[M==J3C$1)+)
M.6>/B.O22DU_J&!6M57WLU*_]WO)U=U,U9.3:U8NWWVBO$ QG4OT#EVF::;?
M",E15M;C2K^?MS&5),M_4B4^W\?H[9N?T!M5 'U:L8T@92K.^U(U1XOVD^;1
MT_K1^)E'^QC=L%*N!'I?IC0U!?JJ'[O.X&UGIMBI&-/D% 7^"<(>QI8&S5Y>
MW;=4CU]>W7/T)MB]FJ#2"Y[54R_DJA22;]1$D^CW:U4 74E:B#]LM&NU@5U-
MQX\SL28)O>BI "$H?Z"]R8\_^*'WLXT4I%@,)&90'.PH#ESJDVLJ)>4"L06:
M<:K&-OJXD4*J(9N5RQ-T6;!-*6TX:]FHDM71\V&B7NK#/B/G@X]E!"1F,!KN
M& W=C'00D#H(I&K,G:#'*EK2%)$'RE7T5Q-=W:5"(DXD/4%$HC53UW0 D&H5
ML.&KG^@'^_Q.O<$0=R Z6W8L1" Q V*X@Q@Z(5;3U0"%T@U7@PRM*<]8:H,4
M6B$%X[ #R?GD8R$!B1F0HAVDZ(4C+:Y&VBWEB8IM>HQ-*:EH?<B>U,B[:D :
M1>X45!O&R(9QZ <=BLZF'4L12,R@.-I1'#DI;N&@]T\J_Q-J1FJ:-C*C@R 6
M!&,\B#ID#HOA,/(&8[-8;"DVPN.@G=)&;\:[WHR=O5$AF,OL[SK/4&&ZFDAQ
M)A(=F84: )P6V:802,5L=7-!N8KC:IB4I$ST@)DQ(:WIQ_B@N7X41=T 5)<:
M[9<:86_8Z?JA%O;]:&SON>^UV9?G[/L]+3/&T3U--KI3S0KU@219KK(P:L^J
MG)+'+O2@:C&4FHES+YGU05.F1@X*):1:#*5FHL0M2OR_YP3-(P^3@DZ@F;G;
M=C1)(#639)O&^\[\=G)''UC^H".5OJ,C7%)-<RLAT"0>5"V&4C,QMGF\/X"=
MVY#I^0Q4+892,U&VZ;[OSO>WRTT]LUGKA]!:I6!)ME;F?TYRM;[:I_'P<&$-
MAY[7]4=-N?VEM5,D=C?T6T&T*;OOSMEOR%-6; HT9US5U0 2HAZ7R:^HVM;:
M3MQZPJ*%>UT.#S,)K_K7Y0*:SD.IF0C;A-YW9_3;L53[[-9F6PE!9N S4+48
M2LW$V&;T_@@VNCD=PM$H(=5B*#4396LG?+>?^.8=']]B!;S1"'?=N/OY1],"
M4C-W3%L'@MT.I-K[O6:D1)<V)N[:QXXS4+482LTDUYH-#&LV,*C9 %6+H=1,
ME*W9P&ZST4%9;?ID+,T2=$N^-E>VF8D5+3Z8N>/1(.AN<[A;<32SU[ 5N+45
MV&TKOC.):]2-8#?0T$9=:):"PW$XBKI;).[V?BN/UA]@]T;_/@\W#B0V\S]I
M(I%DZ/IJ^O'.RF=PT.UP.,9AUZJZ6W7TF'H-8X!;8X#=QJ!=#*;O;+^ 3=WU
MCXYAH)O_4&HFN]9+X!!V.8!T 3-0M1A*S439>@KL]A3?O1Q$!W,71X.@N_/K
M;L71S%[#0.#60&#W;P+?NQS8?@((O5'@=Z'9"NHD.>@N!Z_A G#K K#;!>SE
MM=4/!T9H0_^@FZS4UM_* C*_GX&JQ5!JYHF$UBT$'NR9!%#[ *H60ZF9*%O[
M$#ASZL,@IT>HE:%;QT>%/D5CY07J$:#43%ZM1PC<'N$_)W2]EV<E")GWST#5
M8B@UD^K>&2/@0T:PIXQ@CQF]A@$)6@,2N W(RR>T6\?']8RV;3+/W'6/)@9J
M-_I[QQ +RI?5<4Z!JM_QZT-\NZN[(Z.7U4')SO6I?Q;7!S];F?H<Z@WARZP4
M**<+)>F=1BKGY_71SOJ+9.OJL..<2<F*ZN.*DI1R74#=7S FMU_T W8';"?_
M E!+ P04    " !IBE960FM%FD,#   %"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6RM5MMNVS@4_!5"6RQ:H(TD2M8E:PM(K 9;H)>@Z>69D8YM
MHA*I)>DXNU^_)*6HMDJ[>?!+)%(S0\[PA#[S'1<_Y 9 H<>V87+A;93J+GU?
M5AMHB;S@'3#]9<5%2Y0>BK4O.P&DMJ2V\7$0)'Y+*/.*N9V[%<6<;U5#&=P*
M)+=M2\2_U]#PW<(+O:>)SW2]46;"+^8=6<,=J*_=K= C?U2I:0M,4LZ0@-7"
MNPHOR]S@+> ;A9W<>T?&R3WG/\S@7;WP K,A:*!21H'HQP,LH6F,D-[&/X.F
M-RYIB/OO3^HWUKOV<D\D+'GSG=9JL_ R#]6P(MM&?>:[OV'P,S-Z%6^D_8MV
M/39)/51MI>+M0-8[:"GKG^1QR&&/$"9'"'@@X"DA/D*(!D+T7$(\$&*;3&_%
MYE 218JYX#LD#%JKF1<;IF5K^Y298[]30G^EFJ>*]Z!#D\@^T-M'74WZN>1M
MQQDP)='+$A2AC7R%WJ"O=R5Z^>(5>H$H0U\V?"L)J^7<5WH?1LVOAC6O^S7Q
MD35#C#YPIC82O64UU(<"OC8PNL!/+J[Q2<42J@L4A:\1#C!V;&CY?'KHH)?/
MIP<GW$3CF416+SJB]ZD#011E:]388ZFX5)>NF'N9V"UC+HQ+V9$*%IZ^$22(
M!_"*/_\(D^ O5T3G%"O/)'807SS&%Y]2+V[H(]1#=-!7M"N\7B2U(N9R?"AF
M,QSF\=Q_V(_% 8O3'$>'L-(%"X,\&&$'5F:CE=E)*]^(H.2^@=^[Z76RO?5#
MG":FF@_<N&"S/)O 2A<,ISAWNTE&-\G)NKZAC+#J&76=G+.NSRE6GDGL(+YT
MC"\]60Q7+1>*_D?L[R5?]2'6B$@)RGD+I[^<(DZ#-)^4A .59'$RJ0@'*D[Q
MD?+.1D?924?OF *=DT+:4%\2C2YWVE!%P>DH<U5Y.MGKTH&*\BR;.'*@XGCO
M'^; 43XZRD\Z^J@;M9_%[;*0_W)1I&&>I,'$@PL6I]'4A ,6X#R9GHN_UR"T
M(-:VT9)ZCUNF^E_9<7;LY:YL"S.9O]8]7M^2_93I&\0/1*PID]K]2DL&%ZF^
M0T3?=/4#Q3O;AMQSI9L:^[K1?2H( ]#?5YRKIX%98.Q\B_\!4$L#!!0    (
M &F*5E8GHPQ1N 0  !(4   9    >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM
M;*U876^K.!#]*R/V:M5*V8*!)*2;1&K#O;N5>K=1V[OW8;4/#C@)*IBL[33M
MOU\;" G$H%3E)>%CYMCG>#P>9KQ+V0M?$R+@+8DIGQAK(3;7ILF#-4DPOTHW
MA,HWRY0E6,A;MC+YAA$<9DY);-J6-3 3'%%C.LZ>S=ETG&Y%'%$R9\"W28+9
M^RV)T]W$0,;^P6.T6@OUP)R.-WA%GHCXL9DS>6>6*&&4$,JCE (CRXEQ@ZY]
M-% .F<7?$=GQHVM05!9I^J)N[L*)8:D9D9@$0D%@^?=*9B2.%9*<QW\%J%&.
MJ1R/K_?HWS+RDLP"<S)+XY]1*-83PS,@)$N\C<5CNON3%(3Z"B](8Y[]PBZW
M'=H&!%LNTJ1PEC-((IK_X[="B",'N]_@8!<.]KD.3N'@G.O@%@YNIDQ.)=/!
MQP)/QRS= 5/6$DU=9&)FWI)^1-6Z/PDFWT;23TSOB12-0_'W(-:$P1W-XTFM
MRX5/!(YB?@F_P8\G'RZ^7,(7B"@\K],MQS3D8U/(>2@T,RC&O,W'M!O&1#9\
M3ZE8<_A*0Q)6 4Q)H&1A[UG<VJV(/@FNP$$]L"W;UDQH=KX[TKC[Y[M;+6R<
M<DV<#,]I7Q-!6 )280@C'J1;*H!A071RYW"N'DYECFN^P0&9&#(U<,)>B3']
M]1<TL'[72=4EF-\16$5&MY31;4.?/FR(%"RBJSRZ>_ S2P(DA)M7^69%X)&H
MS%A:P+-47*=O^S@>O!/,.-B0Y%$MXSO$[[J-,3L/R2F1O"8D_SPDKW5.%5G[
MI:S]5NAO$<4T()\6M7V444' W1.PW491VY&054 -"BB=FI^"J,@X*&4<?#(Z
M_?VV?Y3;O@=SP@)"A4[*?"24YQ-UTK].K2O+&8S-UV.=&LSZ53._P<PKS2I\
MAR7?X3E)[?2$^>=FP063Y_^_.FK#+E-;EV!^1V 5,;U23*\U>)YP3+*C(5-U
M@8,7>&:8<IP54SWX0^Y N+A/.;_LP5]$&S3Y",.C5;8]RZH%P^S4"@V1,ZR%
MS*F5XSH6TD?,J"0Y:HV8&>9KV. H!!DL@!.U%[@L/8)X*ZL&58/(6()$*K!E
M1):B M(EQ%G.B2.\B.)(1(1?Z[B/NHRJ+L'\CL J@B/K4 Q:'TM*<_RNE-47
M>3F6=[3J@]' 'J%:".GL/!=YM?3DZ^P&R$$-B0<=E;CH(R?6'965%>%B3PYD
M$KHO N9=2Q2=3,RVD.74>6K,D-P'=9HZM)'7L%F0?6!I?X3EG,F=$FUPW+Z&
M]NED7,<>U:EIS&S7K9\<6K2A9S50.]3#J+5.G,H,!K70A!O.B4P'#POY>4)E
M.KBC\/4M6&,J3T[Y15A8W1\2@9:^<YH$AQZRO#K_4SMG@)"%Z@*<VKD6ZO='
M#0H<2EG47L]5%E?+I-7_HRFM4S2_*[2J=H=Z%?6[_9Q"K=7@A[7L$LWO"JVJ
MY:%H1>U5ZSX.XSS)[/8U*RYJUHJV/=@TUZQ(7V:Z_9/CH\FPOO?T=OUZ8C6/
MFB4)8:NLZ<0AFW;><2B?EHVMFZR=4WM^JQI>61/F )-WR[YCMHHHERHM):1U
M-92+QO(&5'XCTDW6DEFD0J1)=KDF."1,&<CWRS05^QLU0-D&G/X/4$L#!!0
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M''J]@S6.W;6S03I2:X*L"Q5H7;'_V.GJ%5_0Z5QJMSR;^26J&%B7,=!>Q_R
M2>L5#SH6TDZ+'U=J3=)U^0-?K7\4*Y6")RQ=D4P4.R(:MA&:5>SL?.M2+72E
MU@19UU:P=]FIS&D)YE0M=*761%M78=!:CNS65KLI2TU.![.6WB0% B<Z84@&
M9@3HW6&)\PY1%TSOFA8I 4<14ZG%V /]M^Q\V'T]F^PE"C%85V+07O_\R;*/
MW]7<1.=4D8IWN2#:SP6K?$=D?_%@7AH$1UL6?K?O'](K6@5[K="@APYV/PRM
M_)[?-^]^P+H2@O9*)+3$%U/Q2GR#8Y_Z/CR,[[@5A$'0/PQP< P+^@-S@*@N
M0I"]"#F=S,%_X G/9A1(OA;2&*!=^]P$Y%0M=*76Y%J7*>BR90IR6J8X50M=
MJ371UF4*LI<IGYE467F.*0<;G*SSS(Z%(%* )4ET]BZ&K!$K.OZ*T*!SN.-J
M:A9X<'#P3=H=/1=$>^_X*B5\D1\#"I!//L693_6T.FJ\S0_8#I[?P9NP.#"L
M98KSRT?,%S03("%S)>E=]]4"B!='@L6-9*O\D&S&I&1I?KDD."9<-U"_SQF3
MNQO]@NI@=OP_4$L#!!0    ( &F*5E9@M/?3Y@(   $)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#DR+GAM;+U6R6[;,!#]%4(-B@1HH\5K4EN EQ8UD*!&
MTK2'H@=&&DM$N*@D9<=_7Y*2%1>Q=0B27B22FO?FS0S)T6@CY(/* 31Z9)2K
ML9=K75SZODIR8%B=BP*X^;(2DF%MIC+S52$!IP[$J!\%0=]GF' O'KFUI8Q'
MHM24<%A*I$K&L-Q.@8K-V N]W<(-R7)M%_QX5. ,;D'?%4MI9G[#DA(&7!'!
MD835V)N$E],PL !G\8/ 1NV-D0WE7H@'.UFD8R^PBH!"HBT%-J\US(!2RV1T
M_*E)O<:G!>Z/=^Q?7/ FF'NL8";H3Y+J?.P-/93""I=4WXC-5Z@#ZEF^1%#E
MGFA3VP8>2DJE!:O!1@$CO'KCQSH1>X H.@*(:D#D=%>.G,HYUC@>2;%!TEH;
M-CMPH3JT$4>XK<JMEN8K,3@=SP37A&? $P(*?423-"4V79BB!:^*;I-W.@>-
M"55GQN3N%DVT%I+#%BTEJ$22PAG-99D9U!J4)EF%.T&$H^^Y*!7FJ1KYVDBV
MCOVDEC>MY$5'Y(7HV@C,%?K,4TC_Q?LFU";>:!?O-&HEG$-RCCKA!Q0%X<"$
M,D>G)V<MO)TFCQW'VSG"^TWG(-%,,$:TV;1:H5]7Q@0M-##U^U#@%5_W,)\]
MC)>JP F,/7/:%,@U>/'[=V$_^-2BMMNH[;:QQU>DJ9 "K2E8R0@S4=K7!DN3
M;*0%$BZJ DN]/11"Y63@G-CCOX[[G4$0C/SU 6V]1ENO5=N")]+I,5MPAE6.
MED):I8<$M#*],(?]1F?_E2O>?P.U@T;MX']4O'(RW*MX-^P=J_BPT39LU595
M&9,4F8MV5VY[M:R)N3CH%MW JGQ^_BM%K=0O3.I%(_SBE;? Q1NH#8.GNS[X
M'YN@]K)_[J,H>K8+_+VNQ$!FKO<JE%AO58-J5IO^/JFZVI-Y]7-PC65&N$(4
M5@8:G _,P9=5OZTF6A2NQ]T+TYF8&^;F'P6D-3#?5T+HW<0Z:/YZXK]02P,$
M%     @ :8I65L7&-K+F P  R T  !D   !X;"]W;W)K<VAE971S+W-H965T
M.3,N>&ULO5=K;]LV%/TK%UHQM$ :/>SXD=D&_%BP $MCU.F&8=@'6KJVV%*B
M2E)V\N]W*2FRN\C"YFWY8HL2[^&Y#_)<CO92?=$QHH''1*1Z[,3&9->NJ\,8
M$Z8O988I?=E(E3!#0[5U=::01851(MS \WINPGCJ3$;%NZ6:C&1N!$]QJ4#G
M2<+4TPR%W(\=WWE^\9%O8V-?N)-1QK:X0O,I6RH:N35*Q!-,-9<I*-R,G:E_
M/?/[UJ"8\0O'O3YZ!NO*6LHO=G ;C1W/,D*!H;$0C/YV.$<A+!+Q^%J!.O6:
MUO#X^1G]IG">G%DSC7,I?N61B<?.P($(-RP7YJ/<_X250U<6+Y1"%[^PK^9Z
M#H2Y-C*IC(E!PM/RGSU6@3@R"((3!D%E$!2\RX4*E@MFV&2DY!Z4G4UH]J%P
MM; F<CRU65D915\YV9G)!YF&,C5*"OJRA=O4H$)M-*SR]6>*'!@)R]S 4LD=
MMZG0P-(([DV,"N8R2;BA'-'\]S"-(FXCS03!E/5BX_YV@89QH=_!&^ I/,0R
MUP2A1ZXA_I:%&U9<9R77X 17/X [XAIK^#&-,/H6P"7':^^#9^]G02OB L-+
MZ/@7$'A! )]6"WC[YET+;J>.:J? [9S /0[,E,(U)]H47DQ#CAH67(="ZEPA
M_/XS6<*MP43_T120<IEN\S)VQU[KC(4X=FA+:E0[=";??^?WO!]:G.C63G3;
MT"?+7(4Q%3S<KP7?%LF\@$6.-HL?\-' PQ[%#JN<-+$O\?L%OCT>=I.^'PR\
M8.3N&GA=U;RNSN:U0JKF"'Y#IIH(E<"#(T+=WK#?\YH)]6I"O;,)/<1<G>;3
M>\&GTPNZ';^93[_FT__G?&@?KQ&6C$<7!1VXD7DCI_Y+3OWAH',B:8.:TZ"5
MT_UF ^]G3+ T1%@5>G/#4QK94V>J%*/=4>R7)DJ#%W5T(F/#FLVPE<T=3WF2
M)TUKM1J>N>-\[W :>Z]S<%3K_,=^'*F*WQK@%74/42XP@HAK+45>2 %I2P)R
M Y\E3PWLR$MRI5D(VN%]#YZHAG4;U^# -6@O!O9XJAC:+<^-XD%%_%>2$?__
MT!'_("1^NY+\ZVIHA[_Z&]5P$!>_75V.8VY[']OW1'249JB8#3[,6<8-$XT\
M6Z'/#?-!AOS>*Y5+J]Z=Z\=!OOQV_2J;RTP:\H13-QE^FY*L2HFL4Q*6*;$?
M->[HK:!"8^))<PTAVI:VN:SZ+W1EZ'4&?Y$6]ZBY3E!MBRL$X<H\-66?7;^M
MKRG3LCD_3"_O.'=,;3EUT (W9.I=]JE>5'EM* =&9D6KOI:&&O_B,::K%BH[
M@;YO) 6E&M@%ZLO;Y$]02P,$%     @ :8I65J5+Q#-1!@  7BH  !D   !X
M;"]W;W)K<VAE971S+W-H965T.30N>&ULM9I_;]HX',;?BL5.TR9=26R3 %V+
M1)OM;M)-5PUM^]M-#$3+#V:;LK[[LY.0$&(,Z;G]HTV"_=C^Q#;/]UO?['+V
MDZ\I%>!WFF3\=K 68G/M.#Q<TY3P8;ZAF?QDF;.4"'G+5@[?,$JBHE*:.,AU
M?2<E<3:8W13/'MCL)M^*),[H P-\FZ:$/=_1)-_=#N!@_^!KO%H+]<"9W6S(
MBBZH^+9Y8/+.J56B.*49C_,,,+J\'<SA=8!'JD)1XGM,=_S@&JBA/.;Y3W7S
M.;H=N*I'-*&A4!)$_GFB]S1)E)+LQZ]*=%"WJ2H>7N_5/Q6#EX-Y))S>Y\F/
M.!+KV\%D "*Z)-M$?,UW?]-J0)[2"_.$%[_!KBKK#D"XY2)/J\JR!VF<E7_)
M[PK$004T.E$!5170405XJ@*N*N!+*XRJ"@5JIQQ*P2$@@LQN6+X#3)66:NJB
M@%G4EL./,_7>%X+)3V-93\S^R;/5E: L!9^SD&;J)8#[/)73BI/RQ6016*P)
MH^L\B2CC;]],$!Q_ !]_;6/Q#*[ HIPQ(%^"A2!BR]75?$=8Q,&W3%:1C_/P
MY]6=?#M16_LA(1DO6IBO&*5R.@D.W@54D#CA[Z7V'\ !7#7.;QPA1ZOZ[(35
MR.[*D:$3(X,(?,DSL>;@H^Q%U!9P)*::%=JSND-&Q8"&0X#AGP"Y"&DZ=']Y
M=:BI'EQ>W36,!M=O'A=ZHQ-ZQ5L!\XW<+L*X?!_%JI=O8#'_RM_KB!L5U19U
MS3<DI+<#*<HI>Z*#V=LWT'<_Z&C9% LLB;5(CFJ2HT(=GR!93G8=KY%-7C;%
M DMB+5Y>S<LSSKQ_MX(+N>KC; 6( (]T%6>9NI$;QS,E#+R+LVK9:V=AJ3XI
MU-7WVM/,FXZPZ\I5\70(S-B+OL LB;6 ^34PWPCL+T8R(3?/,US\#A>HJ!QC
M,;;5%XLEL1:6<8UE;,3R\3=E82R_51SPG?(+ (T[@*Y\..T2,C;;EY EL1:A
M24UH8B1T3^27>G(>S$0#9M3E8FRL+Q=+8BTNTYK+M,\.1*4#D7O/AK(X/\MJ
MVMU]\%2SS#3E=+M48.SI"SE M[%_[B5KB#PFM#>)2OIPB,B'DRX*<Q_Z3AQ;
M:FUB!X89&HG]*$()&EV1)\ID: 26)&;@B21;JM"MU%ZMMZNE[O0 %_:&$!_#
MTA1#0^@=31M-,>0/QW6I]NA0,SID]#+[T8']Z&BUR8(-BT.J'1>RZ7*LJ@6V
MU-HT&XL-S1[[O-/YM@C4:BN7F7Z5E4VH65^_:7\T]/WC>6/53]M2:X-K'#4T
M&M#&\5S 9]3E Z$[]#L+RZJ!MJ76!M18:&CVT+7WN0B1IYE">.A-CPE9=<RV
MU-J$&L\,S::Y\3X7 /*[@#QOZ'6FD%7O;$NM#:AQS]!LG\TFZ )H73O=W93&
MG6\IS=X5F'OZ4A*-2X9FFVPV01>0F.A&.2V"K^H''H.QZJ5MJ;7Y-6X:3ON9
M!D95REE-K##/!".AV)*D;#")EWH78<D'5WAMJ@6VU-I9Q\:C([-'-RU4'<HS
M<K"T'F.0ENE1B$%$GG66]=ZLU!>C+;4VQL:X([-Q-ZUR+4:S7(41[S$B[S1&
MHU)OC);4VAB;" $9/7.5-]YFL3[*,=?NNXZMJ@6VU-KDFF@ X1?FB9'5Q+I5
MM<"66AM:$PD@<R3P?Y/%E?RA2\%XXG63%.9^]*;V&N$!:L(#9 X/+LP8HVXJ
M'4(/:>!8C0QLJ;7A-)$!,D<&\RB2:!Z?U=Y?_.=<!@I@*4U*?GXVZ7+LOH:7
MU4#!EEJ;5Q,H(,MY=J1)M$/D:S+MYI9[<WJ-, (U802RDVU'FG0[QKI59S5(
ML*76IM,$">CU<NZHFTS'[EA'3%-0M]L'YLZ^$ 9N+#U^O;0[[J;=CS&86^_]
MO_77\.VX\>W80L+]DC ==U/FT!T/CW,6VF+3X7$"7E-L/!Y.L#X#CQM_C7MF
MX%\03&.K)MRJ6F!+K8WWX-1+KY3\V2CPC%P5!4*X#P-')Z- LU)OC*]ARW%C
MR['9EO<-IL_(N05&/3:KOMR66HG-.3AXEU*V*@XP<KE.MYDHSY753^M#DO/B
M:.#1\SMX'91''1N9\N3E%\)DQ,-!0I=2TAV.I7=FY6'&\D;DF^)XWV,N1)X6
MEVM*(LI4 ?GY,L_%_D8U4!\IG?T'4$L#!!0    ( &F*5E;LT,U>=P4  ,L@
M   9    >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;,6::T_C.!2&_XJ502-&
M@B:^M&F@5.(V6J09+0+-SH?5?@B-VT:32\=V*4C[X]=.0APFM>ED&]$/-&GC
M<UZ?V.^3VDPV.?O!EY0*\)0F&3]SED*L3ER7SY8T#?D@7]%,?C//61H*><H6
M+E\Q&D9%HS1QD>>-W#2,,V<Z*3Z[9=-)OA9)G-%;!O@Z34/V?$&3?'/F0.?E
M@[MXL13J W<Z684+>D_%M]4MDV=N'26*4YKQ.,\ H_,SYQR>7!!?-2BN^"NF
M&]XX!JHK#WG^0YW<1&>.IQ31A,Z$"A'*MT=Z29-$19(Z?E9!G3JG:M@\?HG^
MN>B\[,Q#R.EEGGR/([$\<\8.B.@\7"?B+M_\0:L.#56\69[PXB_85-=Z#IBM
MN<C3JK%4D,99^1X^585H-,#(T !5#5"ANTQ4J+P*13B=L'P#F+I:1E,'15>+
MUE)<G*F[<B^8_#:6[<3T2YXMC@5E*;C)9C13)0*7>2IO.@_+LF41N%^&C"[S
M)**,?_PP1M _!=<_U[%X!L?@OKR?()^#NS!;4'5P_439+.84W+)X1CDXO*(B
MC!/^:>(**5JE=F>5P(M2(#((A A\S3.QY. ZBVCT.H K>UMW&;UT^0)9(U[1
MV0!@> 20AQ X "[@JG^\>K-DP'51<9$!&S(4]3I6@R4"M^&S',0"G#.FJJ..
MC\"?*U7;HU_J5-7O[R\R'+@1-.7_;*M7F9MLSZUF\0E?A3-ZYLAIRBE[I,[T
MXP<X\DXM/2-USX@M^O1\$[*( SF]N9 C(\X6X##.JLI] O]NK6$INPP\+@(K
MKWB<#G'@R=?$?=RB:%@K&EH5?2_FG2QT^$B9]!% 7VJZ*FIZ^.W^"JPH*Y5M
M'8!E K^A;#3:+FI4BQKM4J9*2OB0T)W+-&J5"8W@V%@FOU;D]UVF,D'0+!,9
M!-C3+[A=X[C6.+9J/!AZ P\6!@-/#T;RQ-NFPQJDX_@/:HG!.\[LH(>>04^3
MP.MK;E>1FZ,6XL WCEK8P!/L>]Q6&9H#=X@&Q#!8(=+24%^3O(K<K!?QH+E<
M&CS0ZOY[*1?^K7)I<D [.NJ'@]>2^!&03X9243&)=A)8YE%C3BM4SF%0J$D"
M[2@Q*URO5K^E< M13+=6(P7:F5(88NV.OLD=[5&ZFHC&#/3?T2"A%7)=.Z?Y
M!.V ^C\..6[->$Q&R#SE-9&@%0M[F?)!&^V^<<HC312T$U&Z."1J$P4A:*X7
MTD1!O1,%M8DBZU4\I;WQ*(0T79"=+GNSRRK/*[L<F>T2:=8@.VOV9I=5GJ9=
M^J;;K'&#[+@I'+*VR[')+NU1.CH*TLA!PW>T2V3E7=?.:6*AG7X%=;%+M.UG
M4&">_9I/J/??0:C]0\@?#L8D:+P,,C5IT$ZDZ>2<;=(,S873F$&]8P:U,2,G
M*89O%PYKY& [<O9FFU6>5[996,K;)H\UB["=17NST"I/TT+'AEN.-8*P'4$'
MLJ\-#X709*+V.!U]!C=6V]YUN:V/]3:L.89[6W'#[24WB,V/4%A3"_>^YE9E
M:'H!],:# !NT:>C@WI;><!LZIE)IWN#>>5-E\'>0I?F"[7S9GTV.VS99VH9!
MH@8.M@-G?]X8M.HGK6R[/*)!0^R@*>U0FR,RF:,]3M?U>HT8 M_1'(F5;UT[
MIPE%=EJ"Z[0=T5Z"@]B\'4$TC4CO2W"DO02G1MO(8(ZDL7NS$TRZF"-IP\14
M*LT1TCM'2'NIS21+(X38$;(W<ZSRO#9':#9'HK%"[%C9FSF2-ERDE?TBSVWL
M+Z>4+8I== YF^3H3Y59S_6F]4W]>[D_KR\MM_J\A6\09!PF=RZ;>P)?WCY4[
MY^6)R%?%;O5#+D2>%H=+&D:4J0OD]_,\%R\G*D']_PO3_P!02P,$%     @
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M=@'T?:F4?>FX";HB+OT?4$L#!!0    ( &F*5E9MM07!D L  *]H   9
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ME&9#:;2DZ69C1C'U23M\NFSF,6?MZ$EQEF8=B%[EXQEJ'^_>3[^_7R8LWT_
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M-]_:73>A[CJ49D-I%$ISH#0716O*K'+73;6[_I4E8?Z(?GY/_LB3=&I6;\5
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M5)CBIWP^>\G*CU(2L"5':N<3/O$FQ:_C%&^R>)/_.,MCG&5QF+]<,V_!$E&
M_WT9Q]GK&]' _C>*KOX+4$L#!!0    ( &F*5E8 [P9!C00  -L6   9
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M7&,D+)8,$->7HC'L3^0-\OWLR?]02P,$%     @ :8I65CN+GG,K!   /A
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M)*#?$-!_%0'R5 8Z84\]3^<$B_L'K =0^LR5;]#0-.BD:8[SKC-B(FAP8,;
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M)T(+P/<EY^IYHC=H_F4P_A=02P,$%     @ :8I65NOE,SR3!0   "<  !H
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M"I"?+R@5+P=J@&[3V^Q_4$L#!!0    ( &F*5E;^;1&6-@8  /HD   :
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M-E,L-$&:!3B_%4*?.F:#NG2=_P=02P,$%     @ :8I65H)R!A$< P  MP@
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M+$ : WR_$$+O.F:"ZELE^@M02P,$%     @ :8I65GHA-LN0 P  F@L  !H
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MR;W+)5OLBJWO.ZWN$#NC\$=6[7BR8UVRQ:[8^H[54A/9M>9AW8P 3>@SA(/
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M?=1BE_CG7']T*H*=LL6NV/J.U2*8V"O9;C(K 6K&/@U#@@V5-@>1C"&98XR
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M97NLO/U2%YOFH/5#4=?%NOFX$LE2E H@?U=UC[<OZ@:[P_VS_P)02P,$%
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M-AM>W1VJCF2E.4W?,*G.YJ:9J?L6<&V@OB\8DYN._D%S@XO^ U!+ P04
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MBDU?-&/3H)4;6NMI3"57;ZG"R20E&S4I$MR3+>.2UAOP :3ME *V!M="$"G
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M"K0+P/-"*;LWW+49'[WT#U!+ P04    " !IBE96T'JM& H#  "!"0  &@
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M2EM6CXRJH\6VO':70IM+O&QNS+L,I068[RLA]%/'3M"\]*+_ 5!+ P04
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M,&_ P.) I.?E&E]MO$(.UP&VIH<J!)LI7HG83/%< ^+.&S"2Q+W:6!Q@8*N
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M!T.8'7-41J@E1'KIL)>L7NL)M7!(*AUFJ;B%A5H\)),.LTQV%89:+"20#K=
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M,&C' <4/#N">K' TOZMI3_EQ0*&9V)\=@$#=FPD_/(#[Z0$8U+U&H9FXGQ^
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M4+T#0.^@>@> WD'U#@"]@^H= 'H'U3L ] ZJ=P#H'57O"- [JMX1H'=4O2-
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M2P$"% ,4    " !HBE96T!N$=^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !HBE96F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( &B*5E8V3E0F P<  "\M   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !HBE96ICC 5S$"  "B!0
M&               @(%&#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ :(I65E5?YPF[!P  /B0  !@              ("!K1$  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &B*5E9(GJOE5 0
M +(/   8              " @9X9  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !HBE96HAJA[V,(  !D)@  &               @($H
M'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :(I65J0I
M[7C4 @  TP@  !@              ("!P28  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( &B*5E8K :W3H0H  )@Q   8
M  " @<LI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !H
MBE96]HN$ 1$4  !A"@$ &               @(&B-   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ :(I65MJ!0\$"(P  !7   !@
M         ("!Z4@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( &B*5E:"B.8(!P@  .46   9              " @2%L  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :(I65L"7'+RS!   Q L
M !D              ("!7W0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !HBE96#O+A*"0#  !,!P  &0              @(%)>0
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &B*5E;=7OLG
M9@0  .(*   9              " @:1\  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ :(I65E,W^$MS @  A@4  !D
M ("!08$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !H
MBE96F<=OKC0$  !Z"0  &0              @('K@P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &B*5E8_+P<[%P0  )8)   9
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M970R,"YX;6Q02P$"% ,4    " !HBE96,YM\:70-  #E)@  &0
M    @('RJ0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M &B*5E8JP51CX@8  *D0   9              " @9VW  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ :(I65K+$/>/E!0  SPT  !D
M             ("!MKX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !HBE96C\4XA 45  #Z/@  &0              @('2Q   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &B*5E8;?.)"^0<
M # 5   9              " @0[:  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ :(I65FE&FZ4@#@  'RL  !D              ("!
M/N(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !HBE96
M1VWW RX(  !<%   &0              @(&5\   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( &B*5E: A?<A.P0  /0)   9
M      " @?KX  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ :(I65KNQ5 Y/"0  T!<  !D              ("!;/T  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !HBE96VA1MR:,$  "7"@
M&0              @('R!@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( &B*5E8_WQA8;0<  'D3   9              " @<P+ 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :(I65DRBOZ],
M"   Z18  !D              ("!<!,! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !HBE96S=&N\2D)  ")&   &0
M@('S&P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &B*
M5E8SB(K6OP(  #8&   9              " @5,E 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ :(I65J/443S% @  H08  !D
M         ("!22@! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " !HBE96$;@W1MDI   \D0  &0              @(%%*P$ >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &B*5E;D%01#N04  &40
M   9              " @555 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ :(I65KQA^2T&!   V D  !D              ("!15L!
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !HBE962'2T
MY&@#  "X!P  &0              @(&"7P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( &B*5E;YCNOK? (  '<%   9
M  " @2%C 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M:(I65LK/E0P3 P  ;P8  !D              ("!U&4! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !HBE961;;<X8<#  !,"   &0
M            @($>:0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( &B*5E;K"F@1V@(  &X&   9              " @=QL 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ :(I65E:RRGAH!
MA H  !D              ("![6\! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !HBE96KD?G#KP"  #L!0  &0              @(&,
M= $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &B*5E:A
MI(@)]P<  .<4   9              " @7]W 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ :(I65BLU&@#F!P  %Q4  !D
M     ("!K7\! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B*5E9\@HV!3@<  /\2   9              "
M@2J; 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ :(I6
M5N8.JVYO P  L0@  !D              ("!KZ(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !HBE96Y*'.<N0&  ".$@  &0
M        @(%5I@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( &B*5E8> IQ+Q0(  !P&   9              " @7"M 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :(I65BY;+U;= @  VP8
M !D              ("!;+ ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !HBE96M@I>J @$  !X#0  &0              @(& LP$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &F*5E;/'%UE
M_0@  &M.   9              " @;^W 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ :8I65@%>HUKQ P  31$  !D
M ("!\\ ! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !I
MBE96:%M=G#\%  !5%P  &0              @($;Q0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( &F*5E;RHD^:+P(  "T%   9
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M970V-2YX;6Q02P$"% ,4    " !IBE964N^^*'\#  !C#0  &0
M    @(&LW $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M &F*5E9@I-LA5P,  !0,   9              " @6+@ 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ :8I65A;PR^"+!   OQL  !D
M             ("!\.,! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !IBE96X4$Q'1T#  "@#0  &0              @(&RZ $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &F*5E8P\Q!//@4
M $,B   9              " @0;L 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ :8I65M)QL[[O!   A!<  !D              ("!
M>_$! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !IBE96
MZLTDW,D#  !]$   &0              @(&A]@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( &F*5E:8,_WQ8@(  (@%   9
M      " @:'Z 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ :8I65DQ%]MO= @  3P@  !D              ("!.OT! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !IBE969'X-Q1H#  "9"
M&0              @(%.  ( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( &F*5E8X&]#5PP,  .P-   9              " @9\# @!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ :8I65GPAN7C;
M @  >P@  !D              ("!F0<" 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !IBE96^V0K,WP$  #W$   &0
M@(&K"@( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( &F*
M5E9?-*((H00  *@3   9              " @5X/ @!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ :8I65OD4[<.< P  %@H  !D
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M=#@T+GAM;%!+ 0(4 Q0    ( &F*5E9H-:^.W@0  *T8   9
M  " @;0Q @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @
M:8I65J46E'V4!@  ;"L  !D              ("!R38" 'AL+W=O<FMS:&5E
M=',O<VAE970X-BYX;6Q02P$"% ,4    " !IBE960FM%FD,#   %"P  &0
M            @(&4/0( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4
M Q0    ( &F*5E8GHPQ1N 0  !(4   9              " @0Y! @!X;"]W
M;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ :8I65A9Z*5 P!
M@@\  !D              ("!_44" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX
M;6Q02P$"% ,4    " !IBE96TW&16&P$  #.%P  &0              @(%D
M2@( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( &F*5E8O
M[9I<. 4  *0=   9              " @0=/ @!X;"]W;W)K<VAE971S+W-H
M965T.3$N>&UL4$L! A0#%     @ :8I65F"T]]/F @   0D  !D
M     ("!=E0" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F*5E9MM07!D L  *]H   9              "
M@59K @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ :8I6
M5@#O!D&-!   VQ8  !D              ("!'7<" 'AL+W=O<FMS:&5E=',O
M<VAE970Y."YX;6Q02P$"% ,4    " !IBE96.XN><RL$   ^$   &0
M        @('A>P( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0
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M965T,3 S+GAM;%!+ 0(4 Q0    ( &F*5E9MD4-\KP,  ,8.   :
M      " @=R5 @!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4 Q0
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M965T,3 X+GAM;%!+ 0(4 Q0    ( &F*5E8"&+.L+0,  .,*   :
M      " @>FK @!X;"]W;W)K<VAE971S+W-H965T,3 Y+GAM;%!+ 0(4 Q0
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M965T,3$S+GAM;%!+ 0(4 Q0    ( &F*5E8H=K6@3P,  ,T-   :
M      " @>+$ @!X;"]W;W)K<VAE971S+W-H965T,3$T+GAM;%!+ 0(4 Q0
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M965T,3$X+GAM;%!+ 0(4 Q0    ( &F*5E:S5YC<4 ,  *X5   -
M      "  6O5 @!X;"]S='EL97,N>&UL4$L! A0#%     @ :8I65I>*NQS
M    $P(   L              ( !YM@" %]R96QS+RYR96QS4$L! A0#%
M  @ :8I65G3[=\2M"   8$T   \              ( !S]D" 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( &F*5E9)1 W'0 ,  $%%   :
M  "  :GB @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M &F*5E9FO511D@(  '="   3              "  2'F @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !^ 'X O"(  .3H @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>412</ContextCount>
  <ElementCount>609</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>115</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restricted Cash Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RestrictedCashRestrictedCash</Role>
      <ShortName>Restricted Cash Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Short-term and long-term investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Shorttermandlongterminvestments</Role>
      <ShortName>Short-term and long-term investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Other Receivables Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesOtherReceivables</Role>
      <ShortName>Other Receivables Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Equity Method and Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestments</Role>
      <ShortName>Equity Method and Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Stockholder's equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockholdersequity</Role>
      <ShortName>Stockholder's equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Held for Sale and Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperations</Role>
      <ShortName>Held for Sale and Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Values of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstruments</Role>
      <ShortName>Fair Values of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/EarningsPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Short-term and long-term invesmtents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</Role>
      <ShortName>Short-term and long-term invesmtents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Shorttermandlongterminvestments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesOtherReceivables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipment</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Intangibles</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Goodwill</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilities</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/LongTermDebt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Leases</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-based compensation and Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables</Role>
      <ShortName>Stock-based compensation and Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholder's equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholder's equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Stockholdersequity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresTables</Role>
      <ShortName>Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AcquisitionsandDivestitures</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Fair Values of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</Role>
      <ShortName>Fair Values of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstruments</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SegmentReporting</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables</Role>
      <ShortName>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Restricted Cash and Equivalents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails</Role>
      <ShortName>Restricted Cash and Equivalents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Short-term and long-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvestmentsDetails</Role>
      <ShortName>Short-term and long-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesDetails</Role>
      <ShortName>Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails</Role>
      <ShortName>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails</Role>
      <ShortName>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Intangibles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAdditionalInformationDetails</Role>
      <ShortName>Intangibles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Equity Method and Other Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails</Role>
      <ShortName>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails</Role>
      <ShortName>Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillAdditionalInformationDetails</Role>
      <ShortName>Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilitiesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Income Taxes Income Taxes - Allocation of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes Income Taxes - Allocation of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails</Role>
      <ShortName>Long-Term Debt - Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails</Role>
      <ShortName>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Long-Term Debt - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtAdditionalinformationDetail</Role>
      <ShortName>Long-Term Debt - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Leases Lease Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails</Role>
      <ShortName>Leases Lease Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Leases Leases Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeasesOtherInformationDetails</Role>
      <ShortName>Leases Leases Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ContingenciesAdditionalInformationDetails</Role>
      <ShortName>Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Stock Repurchases Tender Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockRepurchasesTenderOfferDetails</Role>
      <ShortName>Stock Repurchases Tender Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails</Role>
      <ShortName>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Shareholder's equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityDetails</Role>
      <ShortName>Shareholder's equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails</Role>
      <ShortName>Acquisitions - Components of Routine Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails</Role>
      <ShortName>Acquisitions - Assets acquired and liabilities assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails</Role>
      <ShortName>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails</Role>
      <ShortName>Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Held for Sale and Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Variable Interest Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails</Role>
      <ShortName>Variable Interest Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails</Role>
      <ShortName>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Assets by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="dva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 55 fact(s) appearing in ix:hidden were eligible for transformation: dva:AccountsReceivablePeriodOutstanding, dva:NumberOfConcentrationRiskCustomers, dva:PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment, dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms, dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount, dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection, dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate, us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife, us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations, us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations, us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:ConcentrationRiskPercentage1, us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment, us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill, us-gaap:OperatingLossCarryforwardsExpirationDate, us-gaap:PaymentsOfDividendsCommonStock, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:ProceedsFromStockOptionsExercised, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend, us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit, us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent, us-gaap:TaxCreditCarryforwardExpirationDate, us-gaap:TreasuryStockSharesRetired -  dva-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="dva-20221231.htm">dva-20221231.htm</File>
    <File>dva-123122ex211.htm</File>
    <File>dva-123122ex231.htm</File>
    <File>dva-123122ex31110xk.htm</File>
    <File>dva-123122ex31210xk.htm</File>
    <File>dva-123122ex32110xk.htm</File>
    <File>dva-123122ex32210xk.htm</File>
    <File>dva-20221231.xsd</File>
    <File>dva-20221231_cal.xml</File>
    <File>dva-20221231_def.xml</File>
    <File>dva-20221231_lab.xml</File>
    <File>dva-20221231_pre.xml</File>
    <File>ex1014-nonxemployeedirecto.htm</File>
    <File>ex1031-formperformancecash.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dva-20221231_g1.gif</File>
    <File>dva-20221231_g2.jpg</File>
    <File>dva-20221231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1635">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>144
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dva-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 47,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 1635,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 412,
   "dts": {
    "calculationLink": {
     "local": [
      "dva-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dva-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dva-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dva-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dva-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dva-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 967,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 53,
    "http://www.davita.com/20221231": 9,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 66
   },
   "keyCustom": 89,
   "keyStandard": 520,
   "memberCustom": 56,
   "memberStandard": 57,
   "nsprefix": "dva",
   "nsuri": "http://www.davita.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.davita.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.davita.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Shareholder's equity (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.davita.com/role/ShareholdersequityDetails",
     "shortName": "Shareholder's equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ia42ecc99f0d34577b08bc4c77cf7a127_I20211217",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i1fe6cb82c75840eabfae089d02e1e485_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i99212cfd5b704e42ae8a23d830c5ab06_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
     "shortName": "Acquisitions - Components of Routine Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i26972a338b914625b313ef3169a93850_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
     "shortName": "Acquisitions - Assets acquired and liabilities assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i49bba0c859f547afb380af3db15e5fbb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i49bba0c859f547afb380af3db15e5fbb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
     "shortName": "Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i49bba0c859f547afb380af3db15e5fbb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails",
     "shortName": "Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i947410d04b404a509e32155ef061b479_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
     "shortName": "Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i26972a338b914625b313ef3169a93850_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i49bba0c859f547afb380af3db15e5fbb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
     "shortName": "Acquisitions and Divestitures - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i49bba0c859f547afb380af3db15e5fbb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
     "shortName": "Held for Sale and Discontinued Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i1c251fa7a54142a9973f90b0af23a71a_D20190619-20190619",
      "decimals": null,
      "lang": "en-US",
      "name": "dva:BusinessSaleEffectiveDateOfSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dva:NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "clinic2",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Variable Interest Entities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails",
     "shortName": "Variable Interest Entities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dva:NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "clinic2",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.davita.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i733bd4e24d7945f59bb981466bfb570e_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ib664746092484ebf93084b60e56443b0_D20221231-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Fair Values of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails",
     "shortName": "Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ib664746092484ebf93084b60e56443b0_D20221231-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncome",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails",
     "shortName": "Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "dva:SegmentReportingInformationCorporateExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
     "shortName": "Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
     "shortName": "Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i19278411b5e94b34bf5804b68ceec8db_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
     "shortName": "Segment Reporting - Summary of Assets by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "iff8eba1380104ea6b216ee60a45a6e69_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i9d3ac6f3c4f74f8ea1b571333627e886_D20190619-20190619",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:BusinessSaleEffectiveDateOfSale",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Segment Reporting - Additional Information (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i13805c203e1b4b8b917db178e9c4d6dd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i11fb71602ed14a41843e5942b0069a19_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restricted Cash Restricted Cash",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.davita.com/role/RestrictedCashRestrictedCash",
     "shortName": "Restricted Cash Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Short-term and long-term investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.davita.com/role/Shorttermandlongterminvestments",
     "shortName": "Short-term and long-term investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Other Receivables Other Receivables",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.davita.com/role/OtherReceivablesOtherReceivables",
     "shortName": "Other Receivables Other Receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.davita.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Intangibles",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.davita.com/role/Intangibles",
     "shortName": "Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Equity Method and Other Investments",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestments",
     "shortName": "Equity Method and Other Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.davita.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Other Liabilities",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.davita.com/role/OtherLiabilities",
     "shortName": "Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.davita.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.davita.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.davita.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:LeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.davita.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:LeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.davita.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.davita.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-based compensation",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.davita.com/role/Stockbasedcompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Stockholder's equity",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.davita.com/role/Stockholdersequity",
     "shortName": "Stockholder's equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accumulated Other Comprehensive (Loss) Income",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome",
     "shortName": "Accumulated Other Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Acquisitions and Divestitures",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.davita.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Held for Sale and Discontinued Operations",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations",
     "shortName": "Held for Sale and Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Variable Interest Entities",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://www.davita.com/role/VariableInterestEntities",
     "shortName": "Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Values of Financial Instruments",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://www.davita.com/role/FairValuesofFinancialInstruments",
     "shortName": "Fair Values of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://www.davita.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Supplemental Cash Flow Information",
     "menuCat": "Notes",
     "order": "34",
     "role": "http://www.davita.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS",
     "menuCat": "Notes",
     "order": "35",
     "role": "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "shortName": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "36",
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables",
     "shortName": "Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.davita.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Short-term and long-term invesmtents (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables",
     "shortName": "Short-term and long-term invesmtents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Other Receivables (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.davita.com/role/OtherReceivablesTables",
     "shortName": "Other Receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.davita.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Intangibles (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.davita.com/role/IntangiblesTables",
     "shortName": "Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.davita.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Other Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.davita.com/role/OtherLiabilitiesTables",
     "shortName": "Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.davita.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.davita.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.davita.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables",
     "shortName": "Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholder's equity (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://www.davita.com/role/StockholdersequityTables",
     "shortName": "Stockholder's equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Acquisitions and Divestitures (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresTables",
     "shortName": "Acquisitions and Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Fair Values of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables",
     "shortName": "Fair Values of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "54",
     "role": "http://www.davita.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "menuCat": "Tables",
     "order": "55",
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)",
     "menuCat": "Tables",
     "order": "56",
     "role": "http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables",
     "shortName": "SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dva:SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncome",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
     "shortName": "Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i1774863faf1d4bffb2fdedbfefa619d5_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
     "shortName": "Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i892eb918a47245d0a1e1b8efd2c4dc9a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Restricted Cash and Equivalents - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails",
     "shortName": "Restricted Cash and Equivalents - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Short-term and long-term investments (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails",
     "shortName": "Short-term and long-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Other Receivables (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.davita.com/role/OtherReceivablesDetails",
     "shortName": "Other Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i96447c36e9e04484a7110d4eb4997b4c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.davita.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Property and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
     "shortName": "Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i0a085d17c9534f2296c3a6f7f9e97029_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
     "shortName": "Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i0a085d17c9534f2296c3a6f7f9e97029_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Intangibles - Additional Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
     "shortName": "Intangibles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i328084074c6a4e6a80b7d005923141b5_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Equity Method and Other Investments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
     "shortName": "Equity Method and Other Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i2f27fb012fe04ec989530042e787ddde_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i1fe6cb82c75840eabfae089d02e1e485_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
     "shortName": "Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
     "shortName": "Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "dva:ScheduleOfReportingUnitsGoodwillBalancesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "dva:PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i911a2957827b44d79670188c18f6906f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Goodwill - Additional Information (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
     "shortName": "Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i911a2957827b44d79670188c18f6906f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:PayorRefundsAndRetractions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.davita.com/role/OtherLiabilitiesDetails",
     "shortName": "Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:PayorRefundsAndRetractions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Income Taxes Income Taxes - Allocation of Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes Income Taxes - Allocation of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails",
     "shortName": "Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:DeferredTaxAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
     "shortName": "Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:DeferredTaxAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ie4c968889cbc45d597559733ee1e7c06_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ie4c968889cbc45d597559733ee1e7c06_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i1fe6cb82c75840eabfae089d02e1e485_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i2f27fb012fe04ec989530042e787ddde_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:IncreaseInDeferredTaxAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i2f27fb012fe04ec989530042e787ddde_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dva:IncreaseInDeferredTaxAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails",
     "shortName": "Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Long-Term Debt - Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
     "shortName": "Long-Term Debt - Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i3f1024fd068b4449894448967a76d43e_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInceptionDates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails",
     "shortName": "Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "iadf9a7efc7ba405ba5b1cb720aa3f8f8_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Long-Term Debt - Additional information (Detail)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
     "shortName": "Long-Term Debt - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Leases Lease Expense Components (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails",
     "shortName": "Leases Lease Expense Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Leases Leases Other Information (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
     "shortName": "Leases Leases Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
     "shortName": "Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.davita.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.davita.com/role/ContingenciesAdditionalInformationDetails",
     "shortName": "Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "if1c4d6e69abc4ed094ed34712b7a27fe_D20171201-20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i75140de7fc2e44a4aae6591587030c31_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ia0f13ef082744f8cbd9d595a2ac158cc_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7cd26001e2547978cfb83fa3fade336_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
     "shortName": "Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "i58d918dcf77445d9902141fae4d11d7e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Stock Repurchases Tender Offer (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.davita.com/role/StockRepurchasesTenderOfferDetails",
     "shortName": "Stock Repurchases Tender Offer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ice569de73c8c4774b5d001cb033779fa_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails",
     "shortName": "Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dva-20221231.htm",
      "contextRef": "ic7ee36d3237d487889a18c9b08d9365d_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 115,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "GERMANY"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r948",
      "r949",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r948",
      "r949",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r948",
      "r949",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r948",
      "r949",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r953"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r948",
      "r949",
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dva_A2019InterestRateCapAgreementsEffectiveJune302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Interest Rate Cap Agreements Effective June 30, 2020.",
        "label": "2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]",
        "terseLabel": "2019 Interest Rate Cap Agreements Effective June 30, 2020"
       }
      }
     },
     "localname": "A2019InterestRateCapAgreementsEffectiveJune302020Member",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_AccountsReceivablePeriodOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient accounts receivable months outstanding to be reserved per company policy.",
        "label": "Accounts Receivable Period Outstanding",
        "terseLabel": "Accounts Receivable Period Outstanding"
       }
      }
     },
     "localname": "AccountsReceivablePeriodOutstanding",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_AcquisitionObligationsAndOtherNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.",
        "label": "Acquisition Obligations And Other Notes Payable",
        "terseLabel": "Acquisition obligations and other notes payable"
       }
      }
     },
     "localname": "AcquisitionObligationsAndOtherNotesPayable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_AcquisitionObligationsAndOtherNotesPayableFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Obligations And Other Notes Payable, Fair Value.",
        "label": "Acquisition Obligations And Other Notes Payable, Fair Value",
        "terseLabel": "Acquisition obligations and other notes payable, fair value"
       }
      }
     },
     "localname": "AcquisitionObligationsAndOtherNotesPayableFairValue",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_AdjustmentIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.",
        "label": "Adjustment Income Loss From Equity Method Investments",
        "negatedLabel": "Equity investment income, net"
       }
      }
     },
     "localname": "AdjustmentIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_AllTrustsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All trusts.",
        "label": "All Trusts [Member]",
        "terseLabel": "Rabbi trusts"
       }
      }
     },
     "localname": "AllTrustsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_AuditorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor information.",
        "label": "Auditor [Abstract]",
        "terseLabel": "Auditor [Abstract]"
       }
      }
     },
     "localname": "AuditorAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "xbrltype": "stringItemType"
    },
    "dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration revenue earn-out period.",
        "label": "Business Acquisition Contingent Consideration Revenue Earnout Period",
        "terseLabel": "Earn-out consideration payment period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.",
        "label": "Business Combination Contingent Consideration Acquisitions",
        "terseLabel": "Acquisitions",
        "verboseLabel": "Business combination contingent consideration acquisitions, earn-outs"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationAcquisitions",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Contingent Consideration Acquisitions Earnouts Payments",
        "label": "Business Combination Contingent Consideration Acquisitions Earnouts Payments",
        "negatedLabel": "Payments or other settlements"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss",
        "label": "Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss",
        "negatedLabel": "Fair value remeasurements"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_BusinessSaleEffectiveDateOfSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Sale, Effective Date Of Sale",
        "label": "Business Sale, Effective Date Of Sale",
        "terseLabel": "Business Sale, Effective Date Of Sale"
       }
      }
     },
     "localname": "BusinessSaleEffectiveDateOfSale",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dva_CashPaidDuringPeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid during period for.",
        "label": "Cash Paid During Period For [Abstract]",
        "terseLabel": "Cash paid:"
       }
      }
     },
     "localname": "CashPaidDuringPeriodForAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_CashPaidForPortionPreviouslyRefundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Previously Refunded [Member]",
        "label": "Cash Paid For Portion Previously Refunded [Member]",
        "terseLabel": "Cash Paid For Portion Previously Refunded"
       }
      }
     },
     "localname": "CashPaidForPortionPreviouslyRefundedMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit, commercial paper, and money market funds.",
        "label": "Certificates Of Deposit Commercial Paper And Money Market Funds [Member]",
        "terseLabel": "Certificates of deposit and other time deposits"
       }
      }
     },
     "localname": "CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_CharterdocumentsandDelawarelawAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charter documents and Delaware law [Abstract]",
        "label": "Charter documents and Delaware law [Abstract]",
        "terseLabel": "Charter documents and Delaware law:"
       }
      }
     },
     "localname": "CharterdocumentsandDelawarelawAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_CommercialPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Payors in healthcare industry.",
        "label": "Commercial Payors [Member]",
        "terseLabel": "Commercial Payors"
       }
      }
     },
     "localname": "CommercialPayorsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_CommitmentsToProvideOperatingCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments to provide operating capital.",
        "label": "Commitments To Provide Operating Capital [Member]",
        "terseLabel": "Commitments to Provide Operating Capital"
       }
      }
     },
     "localname": "CommitmentsToProvideOperatingCapitalMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]"
       }
      }
     },
     "localname": "ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "xbrltype": "stringItemType"
    },
    "dva_CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member.",
        "label": "Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member [Member]",
        "terseLabel": "Coronavirus Aid Relief And Economic Security Act Additional Tax Benefit Member [Member]"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMemberMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_DaVitaMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DaVita medical group.",
        "label": "Da Vita Medical Group [Member]",
        "verboseLabel": "DMG - discontinued operations"
       }
      }
     },
     "localname": "DaVitaMedicalGroupMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_DebtFinancingAndDebtRedemptionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Financing And Debt Redemption Costs",
        "label": "Debt Financing And Debt Redemption Costs",
        "negatedTerseLabel": "Deferred financing and debt redemption costs"
       }
      }
     },
     "localname": "DebtFinancingAndDebtRedemptionCosts",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DebtPrepaymentRefinancingRedemptionCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt prepayment, refinancing and redemption charges related to long-term debt.",
        "label": "Debt Prepayment Refinancing Redemption Charges",
        "negatedTerseLabel": "Debt prepayment, refinancing and redemption charges"
       }
      }
     },
     "localname": "DebtPrepaymentRefinancingRedemptionCharges",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DebtRefinancingCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt prepayment refinancing redemption charges related to debt modification of long-term debt.",
        "label": "Debt Refinancing Charges",
        "terseLabel": "Debt prepayment, refinancing and redemption charges"
       }
      }
     },
     "localname": "DebtRefinancingCharges",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DeconsolidatedNoncontrollingEntityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidated Noncontrolling Entity [Member]",
        "label": "Deconsolidated Noncontrolling Entity [Member]",
        "terseLabel": "APAC joint venture"
       }
      }
     },
     "localname": "DeconsolidatedNoncontrollingEntityMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DeferredTaxAssetsReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, receivables.",
        "label": "Deferred Tax Assets Receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "DeferredTaxAssetsReceivables",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DeferredTaxLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities [Member]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_DeferredTaxLiabilitiesOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.",
        "label": "Deferred Tax Liabilities Operating Lease Assets",
        "negatedTerseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseAssets",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DiscountAndDeferredFinanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount and deferred finance costs.",
        "label": "Discount And Deferred Finance Costs",
        "negatedLabel": "Discount and deferred financing costs"
       }
      }
     },
     "localname": "DiscountAndDeferredFinanceCosts",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_DissolutionTermOfJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution term of joint ventures.",
        "label": "Dissolution Term Of Joint Ventures",
        "terseLabel": "Scheduled dissolution term of joint ventures"
       }
      }
     },
     "localname": "DissolutionTermOfJointVentures",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBITDA operating income performance targets or quality margins.",
        "label": "E B I T D A Operating Income Performance Targets Or Quality Margins [Member]",
        "terseLabel": "Performance Targets or Quality Margins"
       }
      }
     },
     "localname": "EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_EffectiveIncomeTaxReconciliationInvestmentImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Investment Impairment",
        "label": "Effective Income Tax Reconciliation, Investment Impairment",
        "terseLabel": "Nondeductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationInvestmentImpairment",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share-based compensation estimated tax benefit from compensation expense.",
        "label": "Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense",
        "terseLabel": "Estimated tax benefits recorded for stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.",
        "label": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares",
        "terseLabel": "Contributions used to purchase shares, employee-related current liabilities"
       }
      }
     },
     "localname": "EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments In Nonconsolidated Dialysis Partnerships.",
        "label": "Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]",
        "terseLabel": "Equity Method Investments In Nonconsolidated Dialysis Partnerships"
       }
      }
     },
     "localname": "EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ExpectedAmortizationExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Amortization Expense [Line Items]",
        "label": "Expected Amortization Expense [Line Items]",
        "terseLabel": "Expected Amortization Expense [Line Items]"
       }
      }
     },
     "localname": "ExpectedAmortizationExpenseLineItems",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_ExpectedAmortizationExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Amortization Expense [Table]",
        "label": "Expected Amortization Expense [Table]",
        "terseLabel": "Expected Amortization Expense [Table]"
       }
      }
     },
     "localname": "ExpectedAmortizationExpenseTable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_ExternalSourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "External sources.",
        "label": "External Sources [Member]",
        "terseLabel": "External Sources"
       }
      }
     },
     "localname": "ExternalSourcesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_FinanceLeaseAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Accumulated Depreciation, contra asset.",
        "label": "Finance Lease Accumulated Depreciation",
        "terseLabel": "Finance Lease Accumulated Depreciation"
       }
      }
     },
     "localname": "FinanceLeaseAccumulatedDepreciation",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_FinanceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease [Member]",
        "label": "Finance Lease [Member]",
        "terseLabel": "Financing Lease",
        "verboseLabel": "Finance Lease"
       }
      }
     },
     "localname": "FinanceLeaseMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ForeignDialysisCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign dialysis and other medical businesses.",
        "label": "Foreign Dialysis Centers [Member]",
        "terseLabel": "Foreign Dialysis Centers"
       }
      }
     },
     "localname": "ForeignDialysisCentersMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on disposition of business, additional purchase price payment.",
        "label": "Gain on disposition of business, additional purchase price payment",
        "terseLabel": "Gain on disposition of business, additional purchase price payment"
       }
      }
     },
     "localname": "GainOnDispositionOfBusinessAdditionalPurchasePricePayment",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_IncomeLossFromOtherEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Loss From Other Equity Method Investments",
        "label": "Income Loss From Other Equity Method Investments",
        "terseLabel": "Equity investment income (loss) from other equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromOtherEquityMethodInvestments",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_IncomeTaxRelatedToCashFlowHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Related To Cash Flow Hedges",
        "label": "Income Tax Related To Cash Flow Hedges [Member]",
        "terseLabel": "Income Tax Related To Cash Flow Hedges"
       }
      }
     },
     "localname": "IncomeTaxRelatedToCashFlowHedgesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations",
        "label": "Increase (Decrease) Foreign Currency Translation Adjustment For Contingent Earn Out Obligations",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in other current receivables and other current assets.",
        "label": "Increase Decrease In Other Current Receivables And Other Current Assets",
        "negatedLabel": "Other receivables and prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_IncreaseInDeferredTaxAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Deferred Tax Assets Net.",
        "label": "Increase In Deferred Tax Assets Net",
        "terseLabel": "Increase In Deferred Tax Assets Net"
       }
      }
     },
     "localname": "IncreaseInDeferredTaxAssetsNet",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_IncrementalCashPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Cash Portion [Member]",
        "label": "Incremental Cash Portion [Member]",
        "terseLabel": "Incremental Cash Portion"
       }
      }
     },
     "localname": "IncrementalCashPortionMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_IndefiniteLifeNetOperatingLossesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite Life Net Operating Losses",
        "label": "Indefinite Life Net Operating Losses [Member]",
        "terseLabel": "Indefinite Life Net Operating Losses"
       }
      }
     },
     "localname": "IndefiniteLifeNetOperatingLossesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_InsuranceAndSelfInsurancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance and self insurance policy.",
        "label": "Insurance And Self Insurance Policy [Text Block]",
        "terseLabel": "Self insurance"
       }
      }
     },
     "localname": "InsuranceAndSelfInsurancePolicyTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_InternationalOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International operations.",
        "label": "International Operations [Member]",
        "terseLabel": "International Operations"
       }
      }
     },
     "localname": "InternationalOperationsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_KidneyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kidney Care [Member]",
        "label": "Kidney Care [Member]",
        "terseLabel": "Kidney Care"
       }
      }
     },
     "localname": "KidneyCareMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_LeaseOtherInformationTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Other Information in tabular disclosure.",
        "label": "Lease Other Information Table Text Block [Table Text Block]",
        "terseLabel": "Lease Other Information"
       }
      }
     },
     "localname": "LeaseOtherInformationTableTextBlockTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_LeasesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases Disclosure [Line Items]",
        "label": "Leases Disclosure [Line Items]",
        "terseLabel": "Leases Disclosure [Line Items]"
       }
      }
     },
     "localname": "LeasesDisclosureLineItems",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_LeasesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases Disclosure [Table]",
        "label": "Leases Disclosure [Table]",
        "terseLabel": "Leases Disclosure [Table]"
       }
      }
     },
     "localname": "LeasesDisclosureTable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_LeasesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases complete footnote disclosure.",
        "label": "Leases Disclosure [Text Block]",
        "terseLabel": "Leases Disclosure"
       }
      }
     },
     "localname": "LeasesDisclosureTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_LeasesOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases Other Information [Abstract]",
        "label": "Leases Other Information [Abstract]",
        "terseLabel": "Leases Other Information [Abstract]"
       }
      }
     },
     "localname": "LeasesOtherInformationAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_LesseeLeaseDescriptionLineItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Description [Line Items] [Abstract]",
        "label": "Lessee, Lease, Description [Line Items] [Abstract]",
        "terseLabel": "Lessee, Lease, Description [Line Items] [Abstract]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItemsAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "xbrltype": "stringItemType"
    },
    "dva_LossGainOnDispositionOfBusinessInterestsBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss (Gain) On Disposition Of Business Interests Before Tax",
        "label": "Loss (Gain) On Disposition Of Business Interests Before Tax",
        "terseLabel": "Loss on sales of business interests, net"
       }
      }
     },
     "localname": "LossGainOnDispositionOfBusinessInterestsBeforeTax",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_MedicaidandManagedMedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid and Managed Medicaid Member.",
        "label": "Medicaid and Managed Medicaid [Member]",
        "terseLabel": "Medicaid and Managed Medicaid"
       }
      }
     },
     "localname": "MedicaidandManagedMedicaidMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare governmental agency.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare bad debt claims"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "label": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "terseLabel": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor"
       }
      }
     },
     "localname": "MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_MedicareandMedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare and Medicare Advantage",
        "label": "Medicare and Medicare Advantage [Member]",
        "terseLabel": "Medicare and Medicare Advantage"
       }
      }
     },
     "localname": "MedicareandMedicareAdvantageMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_MutualFundsAndCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual Funds And Common Stock [Member]",
        "label": "Mutual Funds And Common Stock [Member]",
        "terseLabel": "Investments in mutual funds and common stock"
       }
      }
     },
     "localname": "MutualFundsAndCommonStockMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure",
        "label": "Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]",
        "terseLabel": "Net effect of transfers from to noncontrolling interests on stock holders equity disclosure"
       }
      }
     },
     "localname": "NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "label": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "terseLabel": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests."
       }
      }
     },
     "localname": "NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.",
        "label": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities",
        "terseLabel": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities"
       }
      }
     },
     "localname": "NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures",
        "label": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures",
        "negatedLabel": "Sale of noncontrolling interest",
        "negatedTerseLabel": "Acquisitions and divestitures"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.",
        "label": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures",
        "terseLabel": "Acquisitions and divestitures",
        "verboseLabel": "Sale of noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NoncontrollingInterestIncreaseFromContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest increase from contributions.",
        "label": "Noncontrolling Interest Increase From Contributions",
        "terseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.",
        "label": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Units Relying On Operating Activities Of Nominee-Owned Legal Entities",
        "label": "Number Of Business Units Relying On Operating Activities Of Nominee-Owned Legal Entities",
        "terseLabel": "Number of business units relying on operating activities of nominee-owned legal entities"
       }
      }
     },
     "localname": "NumberOfBusinessUnitsRelyingOnOperatingActivitiesOfNomineeOwnedLegalEntities",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dva_NumberOfConcentrationRiskCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Concentration Risk Customers.",
        "label": "Number Of Concentration Risk Customers",
        "terseLabel": "Number of concentration risk customers"
       }
      }
     },
     "localname": "NumberOfConcentrationRiskCustomers",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dva_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number Of Customers",
        "verboseLabel": "Number of patients served"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entities that third parties held non controlling equity interests.",
        "label": "Number Of Entities That Third Parties Held Non Controlling Equity Interests",
        "terseLabel": "Number of legal entities that third parties held noncontrolling equity interests"
       }
      }
     },
     "localname": "NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dva_NumberOfPartnerships": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Partnerships that are included in the Equity Investments category.",
        "label": "Number Of Partnerships",
        "terseLabel": "Number of equity method investments"
       }
      }
     },
     "localname": "NumberOfPartnerships",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dva_NumberOfSites": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of sites.",
        "label": "Number Of Sites",
        "terseLabel": "Number of dialysis centers that the company operated or provided administrative services"
       }
      }
     },
     "localname": "NumberOfSites",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dva_OffBalanceSheetFinancingArrangements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Off -Balance Sheet Financing Arrangements.",
        "label": "Off -Balance Sheet Financing Arrangements",
        "terseLabel": "Off -Balance Sheet Financing Arrangements"
       }
      }
     },
     "localname": "OffBalanceSheetFinancingArrangements",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_OpenMarketPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Purchases Member.",
        "label": "Open Market Purchases [Member]",
        "terseLabel": "Open Market Purchases"
       }
      }
     },
     "localname": "OpenMarketPurchasesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_OperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease",
        "label": "Operating Lease [Member]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_OtherCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other companies.",
        "label": "Other Companies [Member]",
        "terseLabel": "Other companies"
       }
      }
     },
     "localname": "OtherCompaniesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_OtherGovernmentPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other government payors in healthcare industry.",
        "label": "Other Government Payors [Member]",
        "terseLabel": "Other Government Payors"
       }
      }
     },
     "localname": "OtherGovernmentPayorsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_OtherNonoperatingIncomeExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income (expense), policy.",
        "label": "Other Nonoperating Income Expense Policy [Text Block]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpensePolicyTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_OtherReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Reporting Units [Member]",
        "label": "Other Reporting Units [Member]",
        "terseLabel": "Other reporting units"
       }
      }
     },
     "localname": "OtherReportingUnitsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_OtherSourcesofRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives).",
        "label": "Other Sources of Revenue [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSourcesofRevenueMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ParentCompanyAndRestrictedSubsidiariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parent company and restricted subsidiaries.",
        "label": "Parent Company And Restricted Subsidiaries [Member]",
        "terseLabel": "Company and Restricted Subsidiaries(1)"
       }
      }
     },
     "localname": "ParentCompanyAndRestrictedSubsidiariesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_PatientCareCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.",
        "label": "Patient Care Costs",
        "terseLabel": "Patient care costs"
       }
      }
     },
     "localname": "PatientCareCosts",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_PaymentsRelatedToStockPurchasesAndAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to stock purchases and awards",
        "label": "Payments related to stock purchases and awards",
        "negatedTerseLabel": "Net (payments) receipts related to stock purchases and awards"
       }
      }
     },
     "localname": "PaymentsRelatedToStockPurchasesAndAwards",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_PaymentsToAcquireOtherDebtAndEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Other Debt And Equity Investments",
        "label": "Payments To Acquire Other Debt And Equity Investments",
        "negatedTerseLabel": "Purchase of other debt and equity investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherDebtAndEquityInvestments",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_PayorRefundsAndRetractions": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Refunds And Retractions",
        "label": "Payor Refunds And Retractions",
        "terseLabel": "Payor refunds and retractions"
       }
      }
     },
     "localname": "PayorRefundsAndRetractions",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment.",
        "label": "Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment",
        "terseLabel": "Percentage change in discount rate used to evaluate fair value of reporting unit for goodwill assessment"
       }
      }
     },
     "localname": "PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment.",
        "label": "Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment",
        "terseLabel": "Percentage change in operating income used to evaluate fair value of reporting unit for goodwill assessment"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Accounts Receivable , 6 months or More Past Due",
        "label": "Percentage Of Accounts Receivable Six Months Or More Past Due",
        "terseLabel": "Percentage Of Accounts Receivable Six Months Or More Past Due"
       }
      }
     },
     "localname": "PercentageOfAccountsReceivableSixMonthsOrMorePastDue",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section\u00a0203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.",
        "label": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation",
        "terseLabel": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation"
       }
      }
     },
     "localname": "PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Impact On Fair Value For Basis Point Increase In Discount Rate",
        "label": "Potential Impact On Fair Value For Basis Point Increase In Discount Rate",
        "negatedLabel": "Sensitivities, Discount rate"
       }
      }
     },
     "localname": "PotentialImpactOnFairValueForBasisPointIncreaseInDiscountRate",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_PotentialImpactOnFairValueForReductionInOperatingIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Impact On Fair Value For Reduction In Operating Income",
        "label": "Potential Impact On Fair Value For Reduction In Operating Income",
        "negatedLabel": "Sensitivities, Operating Income"
       }
      }
     },
     "localname": "PotentialImpactOnFairValueForReductionInOperatingIncome",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "label": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "terseLabel": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple"
       }
      }
     },
     "localname": "PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical purchases of Noncontrolling Interests in Consolidated Partnerships.",
        "label": "Purchases Of Noncontrolling Interests In Consolidated Partnerships [Member]",
        "terseLabel": "Purchases Of Noncontrolling Interests In Consolidated Partnerships"
       }
      }
     },
     "localname": "PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RMSLifelineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RMS Lifeline.",
        "label": "RMS Lifeline [Member]",
        "terseLabel": "RMS Lifeline"
       }
      }
     },
     "localname": "RMSLifelineMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Five",
        "label": "Range Five [Member]",
        "terseLabel": "$110.01\u2013$120.00"
       }
      }
     },
     "localname": "RangeFiveMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Four.",
        "label": "Range Four [Member]",
        "terseLabel": "$100.01\u2013$110.00"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]",
        "terseLabel": "$50.01\u2013$60.00"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three [Member]",
        "label": "Range Three [Member]",
        "terseLabel": "$70.01\u2013$80.00"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]",
        "terseLabel": "$60.01\u2013$70.00"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of capital expenditures for property and equipment from segment to consolidated.",
        "label": "Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]",
        "terseLabel": "Summary of Expenditures for Property and Equipment by Segment"
       }
      }
     },
     "localname": "ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting unit percentage of fair value in excess of short of carrying amount.",
        "label": "Reporting Unit Percentage Of Fair Value In Excess Of Short Of Carrying Amount",
        "terseLabel": "Carrying amount coverage"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfShortOfCarryingAmount",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts",
        "label": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts",
        "terseLabel": "Dialysis patient service revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition and accounts receivable",
        "label": "Revenue Recognition And Accounts Receivable Policy [Text Block]",
        "terseLabel": "Patient service net revenues and accounts receivable"
       }
      }
     },
     "localname": "RevenueRecognitionAndAccountsReceivablePolicyTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure Table Text Block.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Table Text Block]",
        "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure"
       }
      }
     },
     "localname": "SECSchedule1209ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Allocation Of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule Of Allocation Of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of allocation of income tax expense (benefit) between continuing and discontinued operations."
       }
      }
     },
     "localname": "ScheduleOfAllocationOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Finite And Indefinite Intangible Assets Table",
        "label": "Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfMinimumLeasePaymentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of minimum lease payments under non-cancelable operating leases and capital leases.",
        "label": "Schedule Of Minimum Lease Payments [Text Block]",
        "terseLabel": "Schedule Of Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfMinimumLeasePaymentsTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.",
        "label": "Schedule of other information related to acquisitions [Table Text Block]",
        "terseLabel": "Schedule of other information related to acquired intangibles and goodwill"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfOtherReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.",
        "label": "Schedule Of Other Receivables [Table Text Block]",
        "terseLabel": "Schedule of Other Receivables"
       }
      }
     },
     "localname": "ScheduleOfOtherReceivablesTableTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_ScheduleOfReportingUnitsGoodwillBalancesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reporting units goodwill balances.",
        "label": "Schedule Of Reporting Units Goodwill Balances [Text Block]",
        "terseLabel": "Schedule of Reporting Units Goodwill Balances"
       }
      }
     },
     "localname": "ScheduleOfReportingUnitsGoodwillBalancesTextBlock",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dva_SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Debt Outstanding Principal Balance Subject To LIBOR.",
        "label": "Secured Debt Outstanding Principal Balance Subject To LIBOR",
        "terseLabel": "Secured debt outstanding principal balance subject to LIBOR"
       }
      }
     },
     "localname": "SecuredDebtOutstandingPrincipalBalanceSubjectToLIBOR",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_SegmentReportingInformationCorporateExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.",
        "label": "Segment Reporting Information Corporate Expenses",
        "negatedLabel": "Corporate administrative support"
       }
      }
     },
     "localname": "SegmentReportingInformationCorporateExpenses",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_SegmentRevenuebyMajorPayorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue by Major Payor [Abstract]",
        "label": "Segment Revenue by Major Payor [Abstract]",
        "terseLabel": "Segment Revenue by Major Payor [Abstract]"
       }
      }
     },
     "localname": "SegmentRevenuebyMajorPayorAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "xbrltype": "stringItemType"
    },
    "dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty.",
        "label": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]",
        "terseLabel": "Senior Notes 4.625% due 2030"
       }
      }
     },
     "localname": "SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One",
        "label": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]",
        "terseLabel": "Senior Notes 3.75% due 2031"
       }
      }
     },
     "localname": "SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured credit facilities.",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum share value authorized for purchase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase",
        "terseLabel": "Employee entitlement for purchase of the Company's common stock during each calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted average remaining contractual\u00a0life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted average remaining contractual\u00a0life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period",
        "terseLabel": "Added by performance factor (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_ShareRepurchaseFeesAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Fees And Expenses.",
        "label": "Share Repurchase Fees And Expenses",
        "terseLabel": "Share Repurchase Fees And Expenses"
       }
      }
     },
     "localname": "ShareRepurchaseFeesAndExpenses",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Full Value Shares To Available Shares, Conversion Ratio",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Full Value Shares To Available Shares, Conversion Ratio",
        "terseLabel": "Full share awards to shares available, conversion ratio"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFullValueSharesToAvailableSharesConversionRatio",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "label": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "terseLabel": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance"
       }
      }
     },
     "localname": "StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_StockIncentivePlanTwentyElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2011 [Member]",
        "label": "Stock Incentive Plan Twenty Eleven [Member]",
        "terseLabel": "Stock Incentive 2011 Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwentyElevenMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_StockIncentivePlanTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Twenty Twenty",
        "label": "Stock Incentive Plan Twenty Twenty [Member]",
        "terseLabel": "Stock Incentive 2020 Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwentyTwentyMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_StockSettledStockAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-Settled Stock Appreciation Rights.",
        "label": "Stock-Settled Stock Appreciation Rights [Member]",
        "terseLabel": "Stock-settled Stock Appreciation Rights"
       }
      }
     },
     "localname": "StockSettledStockAppreciationRightsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_StockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Unit.",
        "label": "Stock Unit [Member]",
        "terseLabel": "Stock units"
       }
      }
     },
     "localname": "StockUnitMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "label": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "terseLabel": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options"
       }
      }
     },
     "localname": "StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "label": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "terseLabel": "Stockbased Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award"
       }
      }
     },
     "localname": "StockbasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "label": "Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "terseLabel": "Stockbased Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance"
       }
      }
     },
     "localname": "StockbasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dva_SupplierRebatesAndOtherNonTradeReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Rebates And Other Non Trade Receivables [Member]",
        "label": "Supplier Rebates And Other Non Trade Receivables [Member]",
        "terseLabel": "Supplier rebates and non-trade receivables"
       }
      }
     },
     "localname": "SupplierRebatesAndOtherNonTradeReceivablesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TaxYear2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2029",
        "label": "Tax Year 2029 [Member]",
        "terseLabel": "Tax Year 2029"
       }
      }
     },
     "localname": "TaxYear2029Member",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Due To Acquisitions and Divestitures.",
        "label": "Temporary Equity, Decrease Due To Acquisitions and Divestitures",
        "negatedTerseLabel": "Acquisitions and divestitures"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TemporaryEquityDecreasePurchaseOfInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Purchase Of Interests",
        "label": "Temporary Equity, Decrease Purchase Of Interests",
        "negatedTerseLabel": "Partial purchases"
       }
      }
     },
     "localname": "TemporaryEquityDecreasePurchaseOfInterests",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders",
        "label": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions"
       }
      }
     },
     "localname": "TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase Due To Acquisitions And Divestitures",
        "label": "Temporary Equity, Increase Due To Acquisitions And Divestitures",
        "terseLabel": "Acquisitions and divestitures"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders",
        "label": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TemporaryEquityRedeemableNoncontrollingInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interests Temporary Equity [Member]",
        "label": "Temporary Equity Redeemable Noncontrolling Interests [Member]",
        "terseLabel": "Non-controlling interests subject to put provisions"
       }
      }
     },
     "localname": "TemporaryEquityRedeemableNoncontrollingInterestsMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TenderOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tender Offer Member.",
        "label": "Tender Offer [Member]",
        "terseLabel": "Tender Offer"
       }
      }
     },
     "localname": "TenderOfferMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TermLoanAAndTermLoanB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A and Term Loan B-1.",
        "label": "Term Loan A and Term Loan B-1 [Member]",
        "terseLabel": "Term Loan A and Term Loan B-1"
       }
      }
     },
     "localname": "TermLoanAAndTermLoanB1Member",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A.",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TermLoanB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B-1 member",
        "label": "Term Loan B-1 [Member]",
        "terseLabel": "Term Loan B-1"
       }
      }
     },
     "localname": "TermLoanB1Member",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility [Member]",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated Remaining Prior Share Repurchases Authorized, Amount.",
        "label": "Terminated Remaining Prior Share Repurchases Authorized, Amount",
        "terseLabel": "Terminated Remaining Prior Share Repurchases Authorized, Amount"
       }
      }
     },
     "localname": "TerminatedRemainingPriorShareRepurchasesAuthorizedAmount",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dva_TreasuryStockAcquiredAverageCostPerShareClearingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Acquired, Average Cost Per Share, Clearing Price",
        "label": "Treasury Stock Acquired, Average Cost Per Share, Clearing Price",
        "terseLabel": "Treasury Stock Acquired, Average Cost Per Share, Clearing Price"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShareClearingPrice",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dva_USAttorneyPrescriptionDrugInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Attorney Prescription Drug Investigation [Member]",
        "label": "US Attorney Prescription Drug Investigation [Member]",
        "terseLabel": "US Attorney Prescription Drug Investigation"
       }
      }
     },
     "localname": "USAttorneyPrescriptionDrugInvestigationMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_USDialysisAndRelatedLabServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US dialysis \u200band \u200brelated \u200blab\u200b services\u200b.",
        "label": "U S Dialysis And Related Lab Services [Member]",
        "terseLabel": "U.S. dialysis"
       }
      }
     },
     "localname": "USDialysisAndRelatedLabServicesMember",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election",
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election"
       }
      }
     },
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date",
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date"
       }
      }
     },
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate",
     "nsuri": "http://www.davita.com/20221231",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r388",
      "r730",
      "r731",
      "r736",
      "r737",
      "r788",
      "r871",
      "r876",
      "r999",
      "r1002",
      "r1003",
      "r1074",
      "r1077",
      "r1078"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r388",
      "r730",
      "r731",
      "r736",
      "r737",
      "r788",
      "r871",
      "r876",
      "r999",
      "r1002",
      "r1003",
      "r1074",
      "r1077",
      "r1078"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r388",
      "r435",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r457",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r517",
      "r519",
      "r521",
      "r522",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r1000",
      "r1001",
      "r1075",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r388",
      "r435",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r457",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r517",
      "r519",
      "r521",
      "r522",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r1000",
      "r1001",
      "r1075",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r640",
      "r797",
      "r833",
      "r872",
      "r873",
      "r912",
      "r930",
      "r940",
      "r1004",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r640",
      "r797",
      "r833",
      "r872",
      "r873",
      "r912",
      "r930",
      "r940",
      "r1004",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r591",
      "r640",
      "r672",
      "r673",
      "r674",
      "r793",
      "r797",
      "r833",
      "r872",
      "r873",
      "r912",
      "r930",
      "r940",
      "r998",
      "r1004",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r591",
      "r640",
      "r672",
      "r673",
      "r674",
      "r793",
      "r797",
      "r833",
      "r872",
      "r873",
      "r912",
      "r930",
      "r940",
      "r998",
      "r1004",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r395",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r460",
      "r461",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r914",
      "r939",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r460",
      "r461",
      "r857",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r877",
      "r914",
      "r939",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible.",
        "label": "Accounts Receivable, Noncurrent, Threshold Period Past Due",
        "terseLabel": "Accounts Receivable, Noncurrent, Threshold Period Past Due"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentThresholdPeriodPastDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r38",
      "r195",
      "r899"
     ],
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Accrued non-income tax liabilities"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r24",
      "r293",
      "r313"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Insurance and self-insurance accruals"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r142",
      "r343"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r51",
      "r58",
      "r238",
      "r367",
      "r959",
      "r960"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r53",
      "r58",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Interest rate cap agreements"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r349",
      "r826",
      "r838",
      "r839"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending Balance of AOCI",
        "periodStartLabel": "Beginning Balance of AOCI",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r367",
      "r368",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r238",
      "r785",
      "r834",
      "r835",
      "r958",
      "r959",
      "r960",
      "r977",
      "r978",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension",
        "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Amortizable intangible assets acquired, weighted-average estimated useful lives"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r678",
      "r679",
      "r680",
      "r977",
      "r978",
      "r979",
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Deferred taxes from partnership buyouts"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r193",
      "r194",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-settled stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r431",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other - Ancillary services"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r975",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for uncollectible Accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r539",
      "r765",
      "r966"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of Debt Discounts, Premiums and Deferred Financing Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r130",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense from amortizable intangible assets, other than lease agreements"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock-settled awards excluded from calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r238",
      "r958",
      "r959",
      "r960"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r291",
      "r312",
      "r347",
      "r383",
      "r443",
      "r449",
      "r455",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r730",
      "r736",
      "r753",
      "r938",
      "r1000",
      "r1001",
      "r1058"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Assets, Total"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r338",
      "r352",
      "r383",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r730",
      "r736",
      "r753",
      "r938",
      "r1000",
      "r1001",
      "r1058"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r259",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r725",
      "r924",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r725",
      "r924",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r1042",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Pro forma basic net income per share from continuing operations attributable to DaVita Inc."
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r1042",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Pro forma diluted net income per share from continuing operations attributable to DaVita Inc."
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r1042",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro Forma Summary of Results of Operations"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for tax purposes associated with acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Pro forma net income from continuing operations attributable to DaVita Inc."
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Pro forma total revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Noncontrolling interests assumed"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r219",
      "r221",
      "r222",
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Deferred Purchase price and liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Fair value of contingent earn-out consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r220",
      "r223",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent earn-out obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Indefinite-lived licenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Noncompetition agreements and other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Liabilities Assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Aggregate purchase price",
        "verboseLabel": "Aggregate purchase cost recognized"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Non-cash gain on acquiring additional ownership in business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r91",
      "r341",
      "r896"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Restricted Cash and Cash Equivalents Disclosure [Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RestrictedCashRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r92",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash of continuing operations at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash of continuing operations at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r281"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Less: Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Cash Provided by (Used in) Financing Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash Provided by (Used in) Investing Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Noncontrolling Interests Subject to Put Provisions and Other Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r977",
      "r978",
      "r1047"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r363",
      "r365",
      "r374",
      "r822",
      "r830"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to DaVita Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r231",
      "r232",
      "r250",
      "r363",
      "r365",
      "r373",
      "r821",
      "r829"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r230",
      "r250",
      "r363",
      "r365",
      "r372",
      "r820",
      "r828"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive income:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r72",
      "r371",
      "r819",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r278",
      "r279",
      "r463",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r278",
      "r279",
      "r463",
      "r840",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r278",
      "r279",
      "r463",
      "r858",
      "r1072"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r105",
      "r106",
      "r278",
      "r279",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r278",
      "r279",
      "r463",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r240",
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "New center and capital asset projects in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r969",
      "r1037",
      "r1039"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r969",
      "r1037"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "International"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r208",
      "r706",
      "r714",
      "r969"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r969",
      "r1037",
      "r1039"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r104",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r292",
      "r295",
      "r310",
      "r388",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r766",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "LIBOR plus interest margin"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r25",
      "r295",
      "r310",
      "r541"
     ],
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt principal outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r532",
      "r752",
      "r908",
      "r909"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure [Abstract]",
        "terseLabel": "Debt Instrument, footnotes to the table"
       }
      }
     },
     "localname": "DebtInstrumentFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r285",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "verboseLabel": "Debt interest rate during period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r353",
      "r907",
      "r1048"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description",
        "terseLabel": "Debt instrument, maturity date, description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r388",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r766",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Debt Instrument, Periodic Payment, Principal"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r159",
      "r160",
      "r161",
      "r162",
      "r284",
      "r285",
      "r286",
      "r308",
      "r388",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r766",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt Instrument, Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r284",
      "r286",
      "r1005"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r284",
      "r286",
      "r1005"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt Instrument, Unamortized Premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Senior Secured Credit Facilities:"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "terseLabel": "Non-qualified deferred compensation plan, contributions"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution made to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Distribution Paid",
        "terseLabel": "Deferred compensation plan, distributions"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualDistributionPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r969",
      "r1038",
      "r1039"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r208",
      "r969",
      "r1038"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "International"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r208",
      "r707",
      "r713",
      "r714",
      "r969"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r294",
      "r309",
      "r700"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r686",
      "r687"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "totalLabel": "Total deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r986"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r969",
      "r1038",
      "r1039"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1035"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r702"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r196",
      "r1035"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Investments in partnerships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r206",
      "r1036"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r577",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r617",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Asset Categories"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r581",
      "r592",
      "r594",
      "r595",
      "r920",
      "r921",
      "r922"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "terseLabel": "Total fair value of assets held in trust"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' gross wages"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r89",
      "r140"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation expense on property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Notional amounts of interest rate agreements"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r355",
      "r356",
      "r752",
      "r900"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Interest rate cap agreements"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r50",
      "r261",
      "r287",
      "r354",
      "r900"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "verboseLabel": "Derivative asset, fair value, gross asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInceptionDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the entity entered into the derivative contract, in YYYY-MM-DD format.",
        "label": "Derivative, Inception Date",
        "terseLabel": "Derivative, effective date"
       }
      }
     },
     "localname": "DerivativeInceptionDates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.",
        "label": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r260",
      "r262",
      "r266",
      "r268",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r257",
      "r260",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r257",
      "r260",
      "r266",
      "r268",
      "r272",
      "r273",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r265",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Reclassification from accumulated other comprehensive income into net income",
        "verboseLabel": "Amount of debt expense reclassified from accumulated OCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeMaturityDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the derivative contract matures, in YYYY-MM-DD format.",
        "label": "Derivative, Maturity Date",
        "verboseLabel": "Derivative, expiration date"
       }
      }
     },
     "localname": "DerivativeMaturityDates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r264",
      "r266",
      "r269",
      "r271",
      "r273",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r257",
      "r258",
      "r270",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Interest rate swap and cap agreements"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r566",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "terseLabel": "Diluted net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": {
     "auth_ref": [
      "r4",
      "r17",
      "r1041"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal": {
     "auth_ref": [
      "r5",
      "r7",
      "r17",
      "r1041"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit on (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal",
        "terseLabel": "Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r1",
      "r2",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Held for Sale and Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r924",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share attributable to DaVita Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r375",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r409",
      "r411",
      "r417",
      "r418",
      "r419",
      "r423",
      "r743",
      "r744",
      "r823",
      "r831",
      "r903"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income (in usd per share)",
        "totalLabel": "Basic net income per share attributable to DaVita Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic net income (loss) attributable to DaVita Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r375",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r411",
      "r417",
      "r418",
      "r419",
      "r423",
      "r743",
      "r744",
      "r823",
      "r831",
      "r903"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income (in usd per share)",
        "totalLabel": "Diluted net income per share attributable to DaVita Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted net income (loss) attributable to DaVita Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net income (loss) attributable to DaVita Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r1050"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r689"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r385",
      "r689",
      "r716"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in international valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Federal and international tax rate adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "terseLabel": "Impact of noncontrolling interests primarily attributable to non-tax paying entities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Political advocacy costs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedTerseLabel": "Equity compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r1034",
      "r1040"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Share-based Payment Arrangement, Expense, Tax Benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r158",
      "r333",
      "r367",
      "r368",
      "r369",
      "r396",
      "r397",
      "r398",
      "r400",
      "r406",
      "r408",
      "r426",
      "r472",
      "r556",
      "r678",
      "r679",
      "r680",
      "r709",
      "r710",
      "r742",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r785",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Equity method investment, significant impairments and other valuation adjustments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investments and Joint Ventures Disclosure"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r84",
      "r125",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity investments and other investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r348",
      "r751",
      "r898"
     ],
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities, FV-NI",
        "verboseLabel": "Investments in equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r122",
      "r311",
      "r942",
      "r943",
      "r944"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Adjusted cost method and other investments"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r532",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r746",
      "r790",
      "r791",
      "r792",
      "r908",
      "r909",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r745",
      "r746",
      "r747",
      "r748",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r532",
      "r594",
      "r599",
      "r746",
      "r790",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0prices\u00a0in active\u00a0markets\u00a0for identical assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r532",
      "r594",
      "r599",
      "r746",
      "r791",
      "r908",
      "r909",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0other observable\u00a0inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r532",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r746",
      "r792",
      "r908",
      "r909",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r532",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r790",
      "r791",
      "r792",
      "r908",
      "r909",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value estimates"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r770",
      "r776",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r772",
      "r779"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Finance Lease, Interest Payment on Liability"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r768",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum payments due under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less portion representing interest, financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r771",
      "r779"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Finance Lease, Principal Payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r767"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r770",
      "r776",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r781",
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r780",
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r345",
      "r493"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r135",
      "r803"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedNoncompeteAgreementsGross": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time.",
        "label": "Finite-Lived Noncompete Agreements, Gross",
        "terseLabel": "Noncompetition agreements"
       }
      }
     },
     "localname": "FiniteLivedNoncompeteAgreementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r735",
      "r966"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Loss on changes in ownership interest, net",
        "verboseLabel": "(Loss) gain on Disposition of Business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee": {
     "auth_ref": [
      "r818",
      "r961",
      "r962",
      "r966",
      "r1068"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee",
        "negatedTerseLabel": "Gain (Loss) on Divestiture"
       }
      }
     },
     "localname": "GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r344",
      "r477",
      "r817",
      "r906",
      "r938",
      "r987",
      "r994"
     ],
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r479",
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r489",
      "r490",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-lived intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r486",
      "r488",
      "r490",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency and other adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r478",
      "r485",
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r478",
      "r485",
      "r906"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "negatedLabel": "Accumulated impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r481",
      "r906"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r121",
      "r467",
      "r473",
      "r985"
     ],
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r120",
      "r983",
      "r985"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Debt securities, short-term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r120",
      "r983",
      "r985"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Debt securities, long-term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r89",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r68",
      "r90",
      "r229",
      "r401",
      "r402",
      "r403",
      "r404",
      "r416",
      "r419"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r384",
      "r715"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r288",
      "r303",
      "r327",
      "r443",
      "r448",
      "r454",
      "r457",
      "r824",
      "r905"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r384",
      "r715"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r443",
      "r448",
      "r454",
      "r457",
      "r905"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r230",
      "r383",
      "r399",
      "r443",
      "r448",
      "r454",
      "r457",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r744",
      "r753",
      "r905",
      "r1000"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r61",
      "r301",
      "r304",
      "r323",
      "r375",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r411",
      "r417",
      "r418",
      "r744",
      "r823"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "verboseLabel": "Basic net income from continuing operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r61",
      "r323",
      "r326",
      "r375",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r411",
      "r417",
      "r418",
      "r419",
      "r744",
      "r823",
      "r831"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted net income from continuing operations per share attributable to DaVita Inc. (in usd per share)",
        "verboseLabel": "Diluted net income from continuing operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r17",
      "r324",
      "r337",
      "r719"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r17",
      "r230"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net income (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r64",
      "r324",
      "r326",
      "r375",
      "r415",
      "r417",
      "r418",
      "r1066",
      "r1067"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Basic net loss from discontinued operations per share attributable to DaVita Inc. (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r63",
      "r89",
      "r124",
      "r302",
      "r322",
      "r440"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity investment income, net",
        "terseLabel": "Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships."
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r924",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r18",
      "r19",
      "r20",
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r496",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r385",
      "r690",
      "r698",
      "r705",
      "r711",
      "r717",
      "r720",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r386",
      "r407",
      "r408",
      "r441",
      "r688",
      "r712",
      "r718",
      "r832"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails",
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current tax expense (benefit) and deferred tax expense (benefit) pertaining to income (loss) from continuing operations and income (loss) from discontinued operations.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations",
        "totalLabel": "Income tax (benefit) expense from continuing and discontinued operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesIncomeTaxesAllocationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r366",
      "r684",
      "r685",
      "r698",
      "r699",
      "r704",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r86",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r298",
      "r321",
      "r956"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r965"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r965"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r419",
      "r646"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Assumed incremental shares from stock plans (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived licenses"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Intangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r134",
      "r799",
      "r800",
      "r801",
      "r803",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Amortizable intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross (excluding goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r129",
      "r133"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization",
        "totalLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Debt expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Capitalized interest"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r70",
      "r537",
      "r542",
      "r910",
      "r911"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r376",
      "r380",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest, net"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCapMember": {
     "auth_ref": [
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.",
        "label": "Interest Rate Cap [Member]",
        "terseLabel": "Interest Rate Cap"
       }
      }
     },
     "localname": "InterestRateCapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r435",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Elimination"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntersubsegmentEliminationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in subsegment consolidation.",
        "label": "Intersubsegment Eliminations [Member]",
        "terseLabel": "Intersubsegment Eliminations"
       }
      }
     },
     "localname": "IntersubsegmentEliminationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r351",
      "r897",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r340",
      "r350",
      "r425",
      "r474",
      "r475",
      "r476",
      "r798",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investment Holdings [Line Items]",
        "terseLabel": "Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "InvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentHoldingsTable": {
     "auth_ref": [
      "r330",
      "r331",
      "r850",
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.",
        "label": "Investment Holdings [Table]",
        "terseLabel": "Investment Holdings [Table]"
       }
      }
     },
     "localname": "InvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r469",
      "r1069"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments in debt and equity securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r955"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method and other investments"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r289",
      "r307",
      "r332",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Shorttermandlongterminvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r954"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r1055"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r1055"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r782",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Net lease cost",
        "verboseLabel": "Rent Expense, Operating Leases"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Expense Components"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]",
        "verboseLabel": "Leases term and discount rate"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]",
        "terseLabel": "Financing lease cost:"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments due under operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r783"
     ],
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less portion representing interest, operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Secured Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit Outstanding, Amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r383",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r731",
      "r736",
      "r737",
      "r753",
      "r904",
      "r1000",
      "r1058",
      "r1059"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r297",
      "r318",
      "r938",
      "r968",
      "r984",
      "r1049"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r339",
      "r383",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r731",
      "r736",
      "r737",
      "r753",
      "r938",
      "r1000",
      "r1058",
      "r1059"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity on revolving credit facilities"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Other Receivables"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Carrying amount of long-term debt, net of unamortized discounts"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r149",
      "r388",
      "r1006"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r149",
      "r388",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r149",
      "r388",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r149",
      "r388",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r149",
      "r388",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r149",
      "r388",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Other Disclosure [Abstract]",
        "terseLabel": "Long-term debt disclosure"
       }
      }
     },
     "localname": "LongTermDebtOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Long-term debt, weighted average interest rate, at point in time"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r501",
      "r502",
      "r504",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Equipment and information systems, including internally developed software"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Equipment and Information Systems"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Total Short-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Total Long-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Short-term and long-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r21",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r49",
      "r296",
      "r317",
      "r383",
      "r470",
      "r511",
      "r514",
      "r515",
      "r516",
      "r522",
      "r523",
      "r753"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests not subject to put provisions"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Fair value remeasurements"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r163",
      "r233",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Purchase of noncontrolling interests",
        "negatedTerseLabel": "Partial purchases"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "verboseLabel": "Ownership percentage by the Company"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r65",
      "r90",
      "r305",
      "r325",
      "r337",
      "r361",
      "r364",
      "r369",
      "r383",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r416",
      "r443",
      "r448",
      "r454",
      "r457",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r744",
      "r753",
      "r905",
      "r1000"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income attributable to DaVita Inc.",
        "totalLabel": "Net income attributable to DaVita Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Amounts attributable to DaVita Inc.:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r235",
      "r249",
      "r361",
      "r364",
      "r407",
      "r408",
      "r960"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r154",
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Fixed assets under financing lease obligations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompetition agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r164",
      "r233",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Partial purchases",
        "verboseLabel": "Purchases of noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest Items [Abstract]",
        "terseLabel": "Changes in noncontrolling interest from:"
       }
      }
     },
     "localname": "NoncontrollingInterestItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r227",
      "r556",
      "r977",
      "r978",
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling interests not subject to put provisions"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]",
        "terseLabel": "Senior Notes:"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Acquisition obligations and other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of businesses acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which dialysis centers located"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r981"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments that were considered at risk of significant goodwill impairment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "verboseLabel": "Number of states where dialysis centers are located"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Unrealized gains (losses)"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "totalLabel": "Unrealized (losses) gains net"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r443",
      "r448",
      "r454",
      "r457",
      "r905"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r1053"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Fixed lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r768"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r768"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r768"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r773",
      "r779"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r767"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r781",
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r780",
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Operating loss carryforwards, expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r22",
      "r99",
      "r110",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other potential commitments to provide operating capital to several dialysis centers"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Unrealized gains (losses) on interest rate cap agreements:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]",
        "terseLabel": "Unrealized losses on foreign currency translation."
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r55",
      "r754",
      "r755",
      "r756"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized losses on foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r56",
      "r367"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedLabel": "Related income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Recorded Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gains (losses)",
        "verboseLabel": "Amount of unrealized gains (losses) in OCI on interest rate cap agreements"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassification of net realized (gains) losses into net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r158",
      "r362",
      "r365",
      "r371",
      "r757",
      "r762",
      "r763",
      "r819",
      "r827",
      "r958",
      "r959"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.",
        "label": "Other Indefinite-Lived Intangible Assets",
        "terseLabel": "Customer relationships and other"
       }
      }
     },
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "auth_ref": [
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term investments classified as other.",
        "label": "Other Long-Term Investments [Member]",
        "terseLabel": "Other long-term Investments"
       }
      }
     },
     "localname": "OtherLongTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash charges, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (loss) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (loss) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOwnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holder of an ownership interest in a partnership who is not classified as a general partner, preferred partner, or limited partner.",
        "label": "Other Ownership Interest [Member]",
        "terseLabel": "Other equity method partnerships"
       }
      }
     },
     "localname": "OtherOwnershipInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPensionPlansDefinedBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide retirement benefits, classified as other. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Other Pension Plan [Member]",
        "terseLabel": "Deferred Compensation Plan"
       }
      }
     },
     "localname": "OtherPensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r148"
     ],
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type [Axis]",
        "terseLabel": "Partner Type [Axis]"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "auth_ref": [
      "r166",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type of Partners' Capital Account, Name [Domain]",
        "terseLabel": "Partner Type of Partners' Capital Account, Name [Domain]"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Payments of Distributions to Affiliates",
        "negatedLabel": "Distributions to noncontrolling interests"
       }
      }
     },
     "localname": "PaymentsOfDistributionsToAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "terseLabel": "Payments of ordinary dividends, common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r76",
      "r726"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Acquisitions",
        "terseLabel": "Cash paid to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Purchase of equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r75",
      "r119"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "negatedLabel": "Purchase of debt investments held-to-maturity"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Payments to Acquire Other Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions of property and equipment",
        "terseLabel": "Expenditures for property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Purchases of noncontrolling interests",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r591",
      "r593",
      "r599",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r634",
      "r635",
      "r637",
      "r642",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r617",
      "r920",
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Plan Asset Categories"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value, Issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r957"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Contributions from noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r378",
      "r963"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distributions from equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Proceeds from sales of additional noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r73",
      "r119"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities",
        "terseLabel": "Proceeds from debt investments held-to-maturity"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sale of other debt and equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r964"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from asset and business sales"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r79",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r337",
      "r361",
      "r364",
      "r377",
      "r383",
      "r399",
      "r407",
      "r408",
      "r443",
      "r448",
      "r454",
      "r457",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r729",
      "r733",
      "r734",
      "r744",
      "r753",
      "r824",
      "r905",
      "r934",
      "r935",
      "r960",
      "r1000"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r141",
      "r342"
     ],
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross, total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r143",
      "r319",
      "r825",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/PropertyandEquipmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r143",
      "r859",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, and equipment useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "Purchase Obligation, to be Paid, Year Four"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase Obligation, Due in Next Twelve Months"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase Obligation, Due in Second Year"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "Purchase Obligation, Due in Third Year"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "terseLabel": "Reclassification from accumulated other comprehensive losses (income) into net income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "totalLabel": "Reclassification from accumulated other comprehensive income (loss) into net income net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r56",
      "r360",
      "r367"
     ],
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "negatedTerseLabel": "Related income tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Assets by Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r113",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Depreciation and Amortization Expense by Segment"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Noncontrolling interests subject to put provisions"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Noncontrolling interests subject to put provisions"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r617",
      "r786",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r617",
      "r786",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Lease Obligation",
        "negatedLabel": "Payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Abstract]",
        "terseLabel": "Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r91",
      "r97",
      "r290",
      "r315",
      "r341"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash and equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/RestrictedCashandEquivalentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r163",
      "r316",
      "r837",
      "r839",
      "r938"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r333",
      "r396",
      "r397",
      "r398",
      "r400",
      "r406",
      "r408",
      "r472",
      "r678",
      "r679",
      "r680",
      "r709",
      "r710",
      "r742",
      "r834",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r620",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r638",
      "r639",
      "r641",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r620",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r637",
      "r638",
      "r639",
      "r641",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r434",
      "r435",
      "r447",
      "r452",
      "r453",
      "r459",
      "r460",
      "r463",
      "r565",
      "r566",
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Dialysis patient service revenues before provision",
        "verboseLabel": "Patient service revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r370",
      "r383",
      "r434",
      "r435",
      "r447",
      "r452",
      "r453",
      "r459",
      "r460",
      "r463",
      "r470",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r518",
      "r520",
      "r522",
      "r523",
      "r753",
      "r824",
      "r1000"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "auth_ref": [
      "r778",
      "r784",
      "r937"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "terseLabel": "Sale and Leaseback Transaction, Gain (Loss), Net"
       }
      }
     },
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r58",
      "r1051",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Reconciliation of Changes in Contingent Earn-Out Obligations"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r210",
      "r211",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r159",
      "r160",
      "r161",
      "r162",
      "r284",
      "r285",
      "r286",
      "r308",
      "r908",
      "r910",
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities Arising from Temporary Differences"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r260",
      "r266",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Effects of Interest Rate Swap and Cap Agreements"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "verboseLabel": "Equity Method Investment income from equity method investments"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r126",
      "r337",
      "r383",
      "r470",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r131",
      "r134",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r906",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Changes in Carrying Value of Goodwill by Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Scheduled Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.",
        "label": "Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]",
        "terseLabel": "Schedule of Components of Routine Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Aggregate Purchase Cost Allocations for Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r116",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r182",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r643",
      "r645",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Range of Exercise Prices"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Valuation Inputs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Shares repurchases summary table"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r241",
      "r243",
      "r245",
      "r246",
      "r247",
      "r730",
      "r731",
      "r736",
      "r737",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Scheduled Amortization Charges from Intangible Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r25",
      "r295",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "Secured Debt",
        "verboseLabel": "Secured debt, outstanding principal balance"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Abstract]",
        "terseLabel": "Long-term debt totals:"
       }
      }
     },
     "localname": "SecuredLongtermDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r463",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r499",
      "r500",
      "r906",
      "r1070"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r443",
      "r446",
      "r451",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]",
        "terseLabel": "Segment Reporting Information footnote:"
       }
      }
     },
     "localname": "SegmentReportingInformationOperatingIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r299",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of individually immaterial business acquisitions"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceAgreementsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.",
        "label": "Service Agreements [Member]",
        "terseLabel": "Customer relationships and other"
       }
      }
     },
     "localname": "ServiceAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average fair value of grants (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Exercised/ Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "auth_ref": [
      "r673"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "terseLabel": "Share-based awards, fair value assumptions, expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of employees' base salary to be maintained into deferral account"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock awards exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value",
        "verboseLabel": "Weighted-average fair value of grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock awards outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "periodStartLabel": "Outstanding at beginning of year (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r650",
      "r669",
      "r670",
      "r671",
      "r672",
      "r675",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of exercise prices, lower range (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Awards exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of exercise prices, upper range (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Terms of award (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock awards exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Stock purchase price as percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r335",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r463",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r497",
      "r499",
      "r500",
      "r906",
      "r1070"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r158",
      "r333",
      "r367",
      "r368",
      "r369",
      "r396",
      "r397",
      "r398",
      "r400",
      "r406",
      "r408",
      "r426",
      "r472",
      "r556",
      "r678",
      "r679",
      "r680",
      "r709",
      "r710",
      "r742",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r785",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r426",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r28",
      "r29",
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock purchase shares issued (in shares)",
        "verboseLabel": "Stock issued for employee stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock award payment plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r158",
      "r163",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised/ Vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r28",
      "r29",
      "r158",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r163",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r118",
      "r938",
      "r968",
      "r984",
      "r1049"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total DaVita Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r227",
      "r228",
      "r248",
      "r333",
      "r334",
      "r368",
      "r396",
      "r397",
      "r398",
      "r400",
      "r406",
      "r472",
      "r556",
      "r678",
      "r679",
      "r680",
      "r709",
      "r710",
      "r742",
      "r757",
      "r758",
      "r763",
      "r785",
      "r835",
      "r836",
      "r968",
      "r984",
      "r1049"
     ],
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r382",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Long-term Incentive Compensation and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Stockbasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r764",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r764",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r764",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r198",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "State capital loss carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "State capital loss carryforward, expiration date"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Fair value remeasurements"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r45",
      "r383",
      "r470",
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.",
        "label": "Temporary Equity, Other Changes",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "TemporaryEquityOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]",
        "terseLabel": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Third-Party Payor"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury stock acquired, average cost per share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r29",
      "r158",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares [Abstract]",
        "terseLabel": "Stock repurchases",
        "verboseLabel": "Treasury Stock, Shares Repurchases, Table Footnotes:"
       }
      }
     },
     "localname": "TreasuryStockSharesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchase of treasury stock (in shares)",
        "terseLabel": "Repurchase of common stock (in shares)",
        "verboseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r29",
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury stock (in shares)",
        "terseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "Stockholder's equity"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Value [Abstract]",
        "terseLabel": "Treasury Stock, Value [Abstract]"
       }
      }
     },
     "localname": "TreasuryStockValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r158",
      "r163",
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchase of treasury stock",
        "terseLabel": "Value of treasury stock acquired"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r683",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Liability for unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r695"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Reductions related to settlements with taxing authorities"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax expense (benefit), income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r694"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r693"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Reductions related to lapse of applicable statute"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r703"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance related to changes in the estimated tax benefit"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r389",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Amounts charged to income"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Amounts written off"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": {
     "auth_ref": [
      "r974"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r241",
      "r730",
      "r731",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r777",
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r410",
      "r419"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted average shares outstanding during the period (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares for earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r409",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1074": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1075": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1076": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1077": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1078": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/subtopic&trid=2208821",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127163",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127197",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919786-209982",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121829364&loc=d3e40084-109325",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r945": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r946": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r947": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r948": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r949": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r951": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r952": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r953": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>145
<FILENAME>0000927066-23-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000927066-23-000011-xbrl.zip
M4$L#!!0    ( &F*5E8,KX296Q\  /^0!0 3    9'9A+3$R,S$R,F5X,C$Q
M+FAT;>V=?6\;N9KE_]]/P4EC>V: EAT[+]TWZ1M EAW''=L1+,=!SS^+1U64
MBA"+U"594BN??DC)CIU.TA-@=^_.UCG=@&-;<A55O_/P]>'AK_]R_&YT_?OX
M1#6IM6K\_NC\;*0>#?;W/SP9[>\?7Q^K-]<7Y^KIWN,#=1W$19.,=V+W]T\N
M'ZE'34K+%_O[Z_5Z;_UDSX?Y_O75?KG4TWWK?=1[=:H?O?JU_"9_U5*_^A^_
M_LM@H(Y]U;7:)54%+4G7JHO&S=6'6L>%&@QNWS7RRTTP\R:IP\>'3]0''Q9F
M);O7DTE6O[J[SJ_[NY]_W=_>Y->IKS>O?JW-2IGZ[X_,\X/9L^=_>_S\X-FS
MPZ>_S)[(T\/I\P.II)H='A[\_//_.LB%W,]OW_U-3!NK__ZH-6[0Z'+_%\]^
MV7NV3"_7ID[-BX/'C__GH^T[7_TZ\R[EVX7\Y[MO=U?YXEI)_Y$&8LW<O=A^
MHD>[/[U[N?+6AQ<_/-[^][*\,IA):^SFQ;]>FU9'=:G7ZLJWXO[UIY@I#*(.
M9K9[8S0?=2Y3+M[VQ_6NQ#_GZUCC]-TG.'CR2R[TR1^-F9K\/ _V#M3G17[X
MP27,\V=/?KF[[H/"5_EAZ_#_J/23]T>3L^.SX=79R42]>ZVNWYRHT;N+\?#R
M]V]_F']^X9]^M? 2E9^I8UWI=JK#CS\</'_\\LG!3T7:A[N?OH?'+]_ D61J
M]=W[IS[4.@SR)[.RC/K%W3<O:Q.75C8OC-N6;_M'+V^O/O4I^?9%D?E*AV0J
ML;<WV=YO]_)M!/SM<"^'4PF"E)6?ZKL;W\;'WO:E_51_^=KS9WM/'C_YYLN/
M]PZ^^=I?7?;IWL]/GOT?O^KA\[WGSP^_Z[+[VP>Q>QCY<<>EN+\_>O+H[@^6
M4M>Y@GMQN/Q#'7R.T.K9%T]\][#_^5&VK=@NI=6?I'C[N?_B(STN'^C1=[WU
M*Y]^)^#_5I__MRZ86)NJ-'0E9-^%N3CS4<K/GSV7_R^9?U$Y;3_S,%=)M=9.
M'1NQFVCB3^K\?(2A@J\_D6-M92U!]Y9X5?G.[9J-MZ9V>J-&^>.2>]^YUV("
MPQP&]RQYUNHXN!L=B!L'M]4N7XV\87C[UFCRQN&=GW@0 H<!WN:_J\2IUSXL
MB!T.^X6N2YG4F8M=$%?E\?B9J_:0V0^#^>B=]!>]21M&.DRD.],*>^PXO$,E
MM1%U*J'6CN"!P >_+LD(1(Z#/.EH.%K# 1Z;VJ_)&X9WJAH3N9Z"1#QI:\D;
MAG<7D[F/;S7:(BC<]\;0LS!]!W\DQDV#J>=<70%B[AP;<R3>P;$UQP+.["<H
MWM$0-Q+N%/R2P&& :ZE8GR/QKI@$ T2[9N\<BK>U>M5QP@6(>"Z-9;83'/ W
MQMK[W!<USN-RIT-LS!*9_BB78>:#,[U-;CPRH6H8[G>/XUUC?&]16ZDY-@.J
MVJVXRI,W#F\3F;X*A+O3\R!$#H3<-](R>Q6(=VK6G''#(IXLY]N >*^%0[+O
MP+V_]<%Z]:7SXNW?/RVNB$N_,S]]$?)UDEGI+^Q [_[JUDKQ\?V?R#1ZVZ5O
M_\E_ Y?*PU*F@Z_YF.Z^-N$>^UP/ID'+8B"S7-878M>RB8_^K[FGT@"3!IC_
M7 -,5=R'73*NTS5&G4DSS$_-9I"J83<)IYL4<F$]4TVPB-/L%HJWFW:T/04"
MKA-3_Z& E[U[7*U  M[.C+;T5P%"[CT[Z5BXXS+D\K)>1Z*^=G%E[(-S*;84
M,OE40WLP7.L_)/::^]I[MN= H=XY9A#BX.ZJ1>-Y/ 42\9D/K-"!>%LKH69O
M'8HX5\Z@@(>6.650O(-ACC 2\"0<E>'P'LG<<MT,B;>5_- )' =X:UBA0_%>
M,O4%"KC;D#<<[PE7QM&X+SDRP^+-@1D4;I/D?J:-+FDH+FF9?& '#BG2@^4(
M[<$#>;\WV5,WINS"5F?1BJM[F^:6V0=OK1KYSCTX]UF]ELK8<A+TN6E-TC5K
M_]WSNI"P*8) U0//?^^_ F(E-7OZ2.U_+@W/ @<"KFOAYF,@W/F1NSQ@M>K\
MAK0!:(>,.O?D?'[UWD#SP>&Q5 "" DZUST-8.JC"@3_S:_ERWI;X0?"_S?]V
MU6+#FA]. 8W,9IK)=$C G=-,AX<"G@*/+ ,"KH.LR9NFV=]OFGU(T^PE3;-I
MFDW3;%S3[%%CECIQ\@NHH^1SVRP=B>,0[T+5<#<X$G)3#OF\,I[9"CC,K00Z
MNB#AWK0E^Y#(D9 S 1T*N'&Y+.INQ;+VZLB[F6G59&\(G5T\]B%U<[%])E]"
M_;JX*N<A.F,>)^9]+@YYX_#>,!4!B;>?3NG<!07<6L,:'0IXUTZ[.+BZ' Z.
MY<8D(?/>,V];'2K]98?]_A@4*J#?"G"5=YVU3#I#8JZKKB%P(. I_])]9OCS
M:=< ^I;_G15(CPU_?! NH@,%>\=A&Q3NP,54(-QKS90H+-Y1)T8X#O$@N_-H
M21R&N(_1T%T;"ODFYM$XB>,0[\PJL%('XFVGFB,S).!!5^*2(7(@Y%9S]SX,
M[V/AL R*MI4X>.US*_XA?VGRA9=-R'>?;S+\O3'TJEG_Z;?<LX*$._@Y_02
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M.S,6V56"09ZKM.-\V0N?W\)(1\)^Z4,Y2\ZI,YO?Z%G/X]"?+'65OS<Q[2H
MR:,#5OJOKO4?TM]C%8T.B\A.'4ZPY^\Y]0D$_'*L+L3)7)=LASQZ;_.'V1![
MW[&7^VA6[$# 6\[- -%>,;B!<(\G:O3VF)S[SCDWV8T.#&P8X)UC/0Z%>V$<
M@0,!#^+FG@<GHW&_V9V:=*G+8DK94A?5T=X-]#SZ@V>!A'U$[/W'/GR87SI0
M$]^E9JUC4N\:X^%K^VOM<C<WZAY7]Y\)P,^*.>&F:!Z>_=V#0$(?R[;R+NJ4
MN'S^ZK/'@:."<N%S[VKOX*L P.K_TH>UJ1JBQT,_SA\Y;NQ*G!%X_@\?!HX$
MKKN8R^9]I #0*H"=F4B9!&#/[U*OI.YWV-_NC%#CI/>*4P0T[TDNJBQ]GV=U
MA^I\>R1)\F&S<PVI-,=XKU[GVYA^A_KMD*X<^4[>=T^BS\!W+?E]TT[J_>_+
MK7U@_@W2.NV)Q*1.7/WE CUZL-^8XO[0WU'[EOSKE'OMTM4Z%*MG1GOOHSV7
MAME7.+R+&0]QP^"N34R>O&%XVSIDX@2. WRA3H-?:>;3HI%OER9H-4F2,OP1
MAV=]GX$[27XM#:MVF !/R6H:4R 1[V;260[/<("_OWIW?#8\+QZB^>D'_Z>#
M%G:].A-U^?VY-J$<W;HWA&[FQSZD;BZ]/7SAM9@P,]K6K 9HQ_W]=MS/:,>]
MI!TW[;AIQXUKQ_U:;,7-);WO-;\6EQH?ENP@P1 O!].*51]DHX8Q%@>)BMEG
MKT;E/E+[_F(/C@Y^.%%>1KW,10'BO=JN7S&Y% >YS5<M[D]C"0OUUM1.;YA?
MBK%EY'5Q7TY,)0>*]J!UXVVMAKE,,U-.TOASS)_OG>^-H*.^7.8W':+>]%D&
M2Q_2-(_>&/LXL=^6VQ(X#'"32\-T%23B^2V&'3H@XIVUGP<YLXTQR)^*JQK#
MR3DDX)Z\H7@7.TH"QP$>'/MN4+P# QP*>.+B.1#ME?&)>T=P@!^/U%EYZFZ;
MTRF6Q/M.7$\;"=P7 @3<Z3+']G:DCO5*6[\L!U83>^^Q;R)'9D"\C<T?CYF/
M2,17^MS,.#S#(6XEQG+H$Y'C(/>1[3@2<&]KS?P7,-[%)I?,@9@;82,.Q+N3
MJF& XP /TEK-;AL4\3PL>^-;1CD0<RU,A<#"G>OT<XGJ1L^%4ZUXZ'U40S?7
M5L<_)Z]3!  BT$Z-?.=2X!Y$,.S'.O\Y&WLDZAOKJP6)XQ WLYGAS#L0<)^X
MT@+$N[,53[[X#MSTP[[SPWY./^PE_;#IATT_;%P_[#<26N\XX0'33\K .=$!
M1#LNM+4$C@-\S4$O$.V/VM)0#8FXSGU2XL;!;5LFFB'Q7M. !8KW9MH%5N@X
MP,OW?LTZ'0FYG7/O-A1Q;[GV#,7;Z4W+<1D2\2Z6>9?/CBKY\8>G/[^\]DFL
MNM(N?QWE)[ UX)H'2;I6$QU6IBK'MZ>U#PMU;EI3?C^6D)P.L3%+BJ;'HNG:
MJ;<UAW=(Q#E] \7;\?0R,-ZYK*4G\!?GEZ4:_O2RWW-W!T $VR,K&?THT;^1
ME.+*6+J[($&O21N&]MGQ2 T^L]#^VL[@/QW("Z:!L0^IFXOMLP8N9!9$#=1_
M*87C(:708RG<S^7==?++%-^[6?ZWK;5C>]#W]N#; L@PPG;.UYJ9#\X(Q0 O
MAFO]A["32!W<2!XC;B@$7"&4$DCM*0%8";S.!3 U>P6X"CC5/LS9+T16P-93
M<FS%.'8+<65PYK;'?)RT2Y-_P1$CNB1\EH1?$S\H_EPCO,TPNFJQ4<-<+YRY
MVHBC''#E<"X+K4Z"T=0 L 9NC:BI 5P->#=79]M#X:@"6!5<2-A0 M@2,%5C
MYL(%9F0)U(-ARO5 +BME "P#YW3TB<-#9 W$Z+M@* %8"5SJE7 Q$5H :_6;
M#E'OY@S'VKFXL2OA,@+-S[_'_/QGFI\O:7Y.\W.:G^.:G_]%Z^I#:G1P7)QG
M7RO'0F.8N8F+_V'?>MO9IAZ@]3#Q76J8STL=;'7 /3Y4 ;N*5,-.#=O:8-=)
M6%AI\JTH!EPQ-+HLVZYU3%0!M IV\PE"'8#K8"Q5<8G;Z8'U KP>MIU':@!:
M Q]8#2!+X,:414D.&OLO@>#_T7G#<T!PB$^.U<B'91?5J DF)F;L(2 _4V^\
M+27.\-O\638_J3-707M 0V G=TCN;[6KQ=JM#S3K=P#@W)D+15OGZTVZMC4<
MI2/PWA[=Q98; ?6D:J1KIUV8,[(1<"]#Z9S3C!6'^+;9?G :(SSUDKK:5^*_
M265<\IQ?10GQWW39"\\)=2#@P50-(QP&^-M<5IZDCL2[-=*0-P[OE4X\$!N'
MMY; ZAP(MQ-#W#BX0VQD3> PP'>IC&_>79S<'W=.Y/U&WD[%6L8X#G WC^5P
M>Q+'(>Y,M2!P(.#YD9,W#N^4'_F&P&& E_I<AZDO7Q]@1T]R*I?YW8=%?[GG
MNW-]%";.R[E1L?%!$SD.<K?=<D+@0, ].^O?P9MFWW=FW[_0['M)LV^:?=/L
M&]?L^UQB9"H94#])2RQ;>T@<B/C:^YK <8!K3FX!T9X7RZQCO=+6+]L,@,1[
M3MQ,<VDVZFK$I8J^+U6<E^\;WT7.70/%=\N\(B3<+M_*J;&$^^0B-=%A92K-
MU>A79S;_SIO8<_[,)82*^92LSE=ZD$]XFRI.^+V';\5QLS8.[ASDC01NYP0B
M/C/:<L85"/C<6\W,82#@;JZ.M%3-G[MO1-][]*%61V*3:9E1BL6=%3P0[6Y)
MVD"T0\U%<R#@FW(X 5MO&. 74INY<(8="GCDD@H2\+GC% P6;V^-D#@.\85W
MFITV(.!MZQ-];X& +_.@[#3X%:,<"'J(NIP22.1 R)/AV R)]R:N/HMQ+I>B
MH(^-#DQW0P+NW>#8_/%@\DV]ELI8DPSSV7>5H157]U< J=&<>H4*^2YWYUC'
M P'_Z!VG7H& ZWIB=9<:-M^C7(:9#UG^_87=^I C^RMCM;TQ-/O^A[FK?<6F
M' IY,+5A9@P4\59S-QH.;V-M\FM&.!!Q)RUQ ^%VVB\Y'/\.XC2_OC.__AO-
MKY<TOZ;Y-<VO<<VO+[P3VC3@=)2\TXDC7R#>0?(O"1P(.%.-D'!W+N4(5Q]T
MO*_6'UAGDG^_^7=VSOU 0+QO_D,=RXU)HH;VH]ZHTW;Z!AGXJ0[Y&AL$WGET
M6C4$#@/\* _,AV::WS,G=2CJQS_^</CL\.54.X*' 7]<-@>Y[<%DA(X#W2VT
MC=-=P#>6Z''0^_Q)YZSBD9!W)K*"AT)^8F-^^&6S&Z'C0&]KUNM O$^UR5WW
MA0E50^Y0W(,0-PSNLWP)ZQM&. [RBSPP?_K\I2L5^]Q*/15.P0/AO]1=C.2-
MP]OHH-W'C"!TK1K*MC\WM+'V8489@,K@*+?ZQ@V.@DD?*0)0$;R1MAT,&\OQ
M'9 $QD4 5KK!6*)>BUV0/0S[J_R"RQ$?R!R,^55'Z$#0)U63J_9V<%)K8N\[
M]DU(=-G&29>^S'^K:?L!Q#O?6WB*(1#P;M6Q0@?BO1)N<,0"SF,R@'"/AFJ@
M+DP]&"8K+I>+R/N/?'"Y]5@12]@ L"=^1-+])ZW]TH?$OCD0\643\KWF&S7*
M'U,-K37B*DWP.. O=%U*I88Q^LI(RC?Q,W6J?9@;@1?"[7, T,$X2)7+I=6D
M6('FOAVK__[7 FMU)#Q^'@>XJ?*8C;QA>/LPS<4A<'IL?[_']L%CFFPO:;)-
MDVV:;..:;%]R(@RLHY0:+3&I=XWQZHUO"1\(?C'\(&\4WN]JXP,=UH& Y_X*
M$Y!P<)<F_"J/SEFGXS!?Y!"?\T18(.(V1SAQP^ .XN;D_>EYC'(99KD;V]^U
MZ7>A[B+7+H BO,PO$C<*[BBLSX%PK[7C+C\@W)N&IUSA\!Z+;76^/XD#$2=M
M*-JM<$(5"+A+#6?0D8"'130U^VQ Q)/)3UWE?YN2NTG@_0?>+1C?,+BU+#CE
M@H0[6.+&P>UJYBUB$0]5P]U[2+QCDPM+XC#$9]K,9JS3@8@WQDJM[;(Q,AC)
M]A3*LTQA'B3I6KTUM=,[<Q9*H?=2R!%?F7P%-6I\<>*XJP74NYD:6IE*2T,6
M7!40/0[Z3Y$_K/[1F9V#0!; F:OVJ  L!?B9.A=721GKPU<!8^U<W-B5]#CO
M^6LBN,DHNJ#9!@#5 !?B9*[;S(#4^T[=3'G&#1)NI]?>UUR< T*>4IQV8=[<
M-^IC"<GI0/B]AV^E,C6#'8BWH;\(%.^4Y".!0P%G@ /Q[H*9=KO^NHG%&?)(
MNUDNWD]JLC>$GI,=^Y"ZN5@@]B.)E92P)WLX]A.I9*5;LO\V>UII?[+2/J"5
M]I)6VK32II4VKI7VGQM1-IV][S;YJ;9T!P :'WOCHDXT:P,BOI Y[=J0@+N*
M>X^ <(?D+8'C  _Y5RMCF8>$Q+QS6CH"AP&^"?FRS$2! 7XE;=0\X!>(MZL:
M3KP@\:Z]738DCD-\,^T")UYP@.M:?<CC,K\F<R#FE36S&8GC$)]U/ X#B;<3
MJT;;!U\2 5[G^CU_=^$[5Q,^&GP?DCKV]9PF/W#H@XF5)W8P[&_*39)W! \&
M_ERO3=PNLQ$]&/H+'W)EG_R:48^&/E^6E3T@]MRO;]1Q_GD+?Z_\/X;.?$93
M0$FC4L.L@H[>;6CL)WJMK25V-.S)AU:=RX(]?#3TJ='J31[;<?H>C?QUOGMI
MX7/WCMT\//P?=$SJ2$O7>KIU0M(O=HX$CP$^OV"J[2R^[R+G=5"XGYN9SE_<
M@C[\&,"O@Y94_+=OZ_JXM7ZR9N:#,T(5X*K@S.9W>\,3.8 U<&'JP3!9<;FL
MU &N#K:+/%IBH@AP13#QW9T(SL>4 *($RBP JP!0_@2/ ?[N'"X>S@1&?J+#
MBJ![#YK6&$"T5\;1*N$[>-//^Y.?]R']O)?T\Z:?-_V\<?V\KQI?:QY=B=-1
M,M6BI+>0. [QNJ8/*!)O-V>$8Q'GR!<(=BZ-NA%K:04*1/URF$=IQW)C$FW<
M<:C[:K'9VD@E,?<ND:JL7YA*4P#]%T#)3>3P' BX$]K! N'VD4-S(-S+1B=6
MYT# N]@PP)%X\]Q$)-P;X=0Z$.\N+D@;B';4UA(X#O"R Y +9SC ;]2PDEJW
M&Z+N.>J)E"R(J51LP(&8-Q*X7(;#>_CV>#3XTR*I&DM(;KNKCT9N/><O3EU(
MJ#QG6)&8U\2-A#O7[:^UFBQ#+C/)0Y$WTA(X#O"EMDQL!>+=N;JXKY X"G$M
M4V$2,Q#ORG>!O'%XNVBFG(## =Y(S9/MH7BOA;8K4, W! X%7-LIN^A0O/-O
MYR0.1#RTW',$!3QI9L$ \3:NU.B3) _G7M MCLME?M,AZDU_P7NQG$['"72C
MW8.\IYV9.:GWGGJK/;MO0+R=7G-.'8>W]9&-^'?@IK'U)V/K)S2V7M+8FL;6
M-+;&-;:>>*MKJ3D>0NLO^;:XX]D'O@Q$CX*^2\T6=A"K7N>;FOKK&\&H@_[K
MX([_67[^\R!)U^JMJ9W>J%'^[!0!A@A\X%(7%O,JZ$@/+BSF.CCU)O?Y(OM\
MB/BM+.C"AH5\72KY8?%K2E^L>5(".!+XAD4^%=!W!2PE++@N!L0[R+QC*X\$
M/!=UZ>G'",3\\Q15TNXY;4T_%RC<*^TB<Q6AD.>/Q\E8(.#Y5QR5 ?'V(1B.
MRG" =W,)ULN,R'&0.S4R:?.5I;6]\[T1]"9"&/8?'JZI<VT5AKXL-5MW).!1
M<[@&P_LZEZ%]N&F8Q'M//,P;5NE0P*VF@1<0[TV^$7G#\,[--\\T0^(=IM[J
M[68F4YFE_/C#X9.#E_GKTV<O\VTFOC(ZY1\/G[T,1J(Z3[5 S]$<!?EH;(_U
M$-B=PPG_1JL/WM?VLV.O[B?DQH3?8_C% (/Y<$C 0^KFP@5U(.))K+K*G7J[
MW::LWLW4959!4W[R^?U"":!)X%K_4?KQIC5E#_N=BT%CEE0!C@IHV#O*99CY
MX(P@,#^7J0^2?#":9LVO;KT\$,!?Z:@E5 VA][^*[ZSO(F=O@(BO7=0<P0,1
M#_F/VZ_L3M\;LV[O,_>KD1KD%KPVPB'[J]OGT&_88UVL1Z9=F,/SIDGW7SZC
MG4GW4YIT+VG239-NFG3CFG27EO/D7(TE>DYPX_60L\K+U7[W8<'IKKLGT6?@
M91L920.$]N!4^S#7R:^=NM+SW(2)Y:S7)P&8F$)NZ<OJ_B@/5]IICQ>U L^O
M0HK];L[3I*%XMV(]>>/P=DZS*0?B'=.#E2M:/X!@7]--&PEWOALWC<+@?C_U
M+M*V#0CXPDA#W#"XG:F\(6\@WKDX\>LF?43?:_3+9>ZYW8C]D\L+\PO[C7TR
M&AS+C?GR\"OXB.__/J';:-^=D,*U%9B@S]P[/3B2J&MU4IY^%D#4)8OBTX*B
MOU]0I!Q@Y;!=?*<"4!7P+BL@:$EJ;,4XM@N@,L@5P9G-[_;L&@!+X-QW)JY,
M[C%2!+ BN##.Z>@3NP2X&KC4*ZDI &0!K-5O.D2]4<5%;JR=BQN[$L>1 JHJ
M[MS%='#J76,\=0"K@XGO=CJXGS^E&F#5L/.<&^9FXMW"2I-O13'@BJ'1N^J!
M&H#5P(TI._?9)J!*((\?RN;-TD'@P %*#JZRFLG!4,2UY0X?'-XZU$P%Q\%M
MJN0#3X0# EX.#6$+#D7<RER_T6)3HXXO"!P!N.OTBB?Y C%?:;M1NR G[;[3
M]G.Z+N#@_I#+RD$X%/"F\HY[=)&(+[RKV6'[#N T#?]D&OZ,IN%+FH;3-)RF
MX;BFX1_$+CB=B=13LM8L'YQV3MY]YYT?N6'7&(AX;*9=<%R&!D*>%L;1O ((
M>!>UIZ<H$/",F9E%0,"UK1G@]\^C_T94)2-<G=B%.@U^Q4@'BO3,?2)5D#8_
M?)[^  7>\S0 ..R-24XS9Q@'N+',&,;B;?UZ&KQ??*5RIY=PS^&[LK&3T0X#
MW/NZ"J4/3^1 R&<^U"0.0WPCKLX%T-MV//#X71STOTNHN;*&A'ON&=XXO+M*
MS)+I,3# _T,":>/0UM8:#L>1@"^;36B,M9$K*VCL,_56&.S_.[O OK4YZRL[
MEZ#WCCW_]MZQ_:FO-_F?)K7VU7\"4$L#!!0    ( &F*5E9!!#C[.P,  !4)
M   3    9'9A+3$R,S$R,F5X,C,Q+FAT;<56;6_;-A#^OE]Q=;"V R)+HN0W
MQ36PV4D7+,W<Q*NQ3P,E4191B11(*J[WZW>4Y-:MZ[;YT%4?B*/NA<]SNCMJ
M^F3QYWSU]_(2<E,6L/SKMYOK.?0<UUT'<]==K!;P^^K5#81]SX>5HD)SPZ6@
MA>M>WO:@EQM31:Z[W6[[VZ OU<9=W;DV5.@64FK63TW:FTWM&UP936<_39\X
M#BQD4I=,&$@4HX:E4&LN-K!.F7X+CM-9S66U4WR3&R >"6 MU5O^0%N]X:9@
MLWV<J=ONIVYSR#26Z6XV3?D#\/1%CU/BA>-PXC'")F%"1G'LD1$;#(:CC 2$
MQ/_X"-)%\]9'FUW!7O1*+IR<V?.C<%"9BRU/31[YGO=S[V,[JC9H:F05#8/*
MH#*3PB (A4%;L8U]=()A[XQ#"[X14<.S<]VK$UE(%9UYS7-A-4Y&2U[LHF<K
M7C(-MVP+=[*DXMFYQF_C:*9XUAIJ_B]#K B[V6Y;'B.,4W#!]KQ\8LE<OLMY
MS#'+0=__&/$QRU@:(\N(V,@'\!/\"$R=IGXRD/^E0/]W(N92:%N5,H-KD;**
MX8+;.[;A&E%AG2[KN. )_)HDLA;&UNP55^41U^\-/_P4OD\0_II!TC$P$DS.
M@(M$JDHJ:KL6XATHEB$/D5A58Z$:;IV!-MB,MI\T/+^5N@]!$#@$#R/DO)6#
MB3_Q.]D/?'_2RO[$"X.PDX>3<#CJY,&8$*^3P]";=._'P\$ 7U.1-MO &P7#
M7P 17$E5PKTS;E2G\5EX+3I_3 8C<N@;VL\G:X6NR!RII,V$N6*QJJG:@>5B
MY\DY;+G)T4I7+'F?,9M 6?#6)^."BH33XC S%MEG%'"?Y"RM"P;7U^# &UK4
M+6AK_[K&ZLYVMEZZTM$6Y8*^X89BK27]]X19EB$<_L $TXT1MPV!(]=",TH6
M(!^8.D#0TL30_:^UG)U0MI2^>W<=E6?374_/PM&%;E;X8_GJ)=S<+$]TSN<G
MR(^!?8\W%-XMY["F.L<T&RD>,=M^4*[WU?[TS!]Z%_N2?V2!/&:.#Q'6-U^$
M!U$.+]A*MK\7D6(%M2UP\LKM#O4^N- 8V[8VQRY?N8V[M?UA:'Y=9O\!4$L#
M!!0    ( &F*5E:S[AP*\P<  ($D   7    9'9A+3$R,S$R,F5X,S$Q,3!X
M:RYH=&WM6EMSVS86?M]?@<JSJ3.C&R6Y2F3',XZMM,IVDXZK-NV^[(#DH80Q
M2+  *%GY]7L.0.IB2:G<;6*[TSPX(G$[EP_?.0?@V5=7[R_'O_XP9%.;2O;#
M3Z^_'UVR6J/5^M"];+6NQE?LN_&_OV>]9CM@8\TS(ZQ0&9>MUO!=C=6FUN:#
M5FL^GS?GW:;2D];XND53]5I2*0/-V,:U\S-Z@W^!Q^?_./NJT6!7*BI2R"R+
M-' +,2N,R";L0PSFAC4:9:]+E2^TF$PMZ[0[7?9!Z1LQX[[="BOAO)KGK.6?
MSUIND;-0Q8OSLUC,F(A?U40'7H0 81*\#,)>A_=YI]\Y"=J]7ANZ<702_#=
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M6+CW<YCRK_\XQWTF=/X_4$L#!!0    ( &F*5E;]-QVJT0<  .4B   7
M9'9A+3$R,S$R,F5X,S$R,3!X:RYH=&WM6EUSVS86?=]?@<JSJ3.C;\F6(SN>
M26QGJFZ;=%)UL_NT Y&7$L8@P0*@%/77[P% 6I(EI?)ND]C=S8,C$A? _3@X
M]P+@Q3?7[Z[&__SIALUL*ME/O[S^873%:HU6ZT/OJM6Z'E^S[\8__L#ZS7:'
MC37/C+!"95RV6C=O:ZPVLS8?MEJ+Q:*YZ#65GK;&[UMNJ'Y+*F6H&=NX=GGA
MWN O\?CR+Q??-!KL6D5%2IEED29N*6:%$=F4?8C)W+)&HY2Z4OE2B^G,LFZ[
MVV,?E+X5<Q[:K;"2+JMQ+EKA^:+E)[F8J'AY>1&+.1/QRYH8G)V>]@;=R6DR
MZ/3II,W;IV>3;H\&_:AWFO0[_^I R1;$0Q]CEY)>UE*1-6;DYA_VN\W!26[/
M%R*VLV&GW?YKS8M>7B0JLYA/HW_X&8;9&LS21]O@4DRSH3>I%KI6S9&22@^/
MVO[?N6MI)#P5<CG\=BQ2,NPM+=A[E?+LV[I!&!J&M$B"H!&_$72">OYQ$50>
M8!PI,JI,Z'2=TC?_^&[T>C1FO4ZSNZGQNN%<3V&[57D8=DWW",XF_964__GF
M:CQZ]Y;UVEUV=?-^/'HSNGKEWAQJR6?7N[]3[U&=?:](LE?1+6F,5F<1:2N2
M);,S;I\=G9R=;UFP%UEW;5_:BD[SV5'GM'V^_7?$9GQ.3--<T *+V<Z$83S+
M"B[Q,E?:,I6Q-TJGK--N_(VIA%WSOPO+V2B+,.K)BZ=@?W>O_:^Y@=4P,5VR
MVTPM),53J@<WE/;'"HID"H2'>;C(X)XE*S*K"X(=H$#/AG ,9RF>M(#K$A[A
ME68J%999%>2V!#**R!BNETXDY;>$>=?&-'@70QE,*3V58@XG$ D-ZH18AN[0
M)";-%C,1S9@IW)]5_P5I*@=Q!J3"2'"LH^N%L#,8:'**O()NW!RJJ1AFSM$M
M9I/ENAN>2JA[#P\UL41D<*:+R\IY=<09XFC6:^TB2[ 6N,ND^!W)(L:8"-":
MI^H(KM!RR7+XUT'#04;*5>Q+MYM[4P->L4_1=2=12 @@X I1\=,9KT_$S8PE
M4BU,A09-4V$L\KMEW+T,>D/+^EI03:7,EK9/):[]O7$=;SCAV=%9MS,X-V7D
M2K9VD%=)(O!X;)Y[#XT8U^1C =^*B23G,T8 P$0*,W,]G%B*%>]6O7N.A8FD
M,@7Z.2[02H:@Y%I%%..U8<>(04P(:G#TS<=HQK,I(7]8]KZ0D.CT>*-S<DQ!
MB\Y)')["HW I.@M@<.,SMQ;7,!)BYG0Y>*)D8Z($$SD[[R,'$BX1/#RA53C(
M>>R(I2$IL</>Z5=+V,?\>:7CEY_^?,,+W7[S1<<YXIH,"C $RO/S[Z.H[E)'
MQ MS>!?'X1,"(LJ90E90A<8 H("Y,)Y8($69'\>5+RM*6J<U39)[B)5I8063
M>DEYKE& GJ"+45+$?AM@BHD1L>!:. -$2%Z>:#,W4F%<0O&+TOCLXVD(^PPH
MA V [Y1S8#LJ)'?L";.\$JO$A!XAS:UG9_R:D!,$P:$_Q;L);3=,>WYK4'M2
M^)X\)GSW^MOX/IC#MF!^./L=C':LD+F('8BYP>;7T3PW6 "N=G+(YCJN4 ;<
M"SX14MBERZV[IG5KS@/28RTLEPW1M=K+9Y./I4%YH7-@W?A:((J4CKT"O@J;
M4H84+P%YM%#NUI(308498(TU)W(0^I\=V-%C G8@[ILYEX5G-Q=U2A*4;6*.
M>)D=Y===Y7$ 6X?'W169QS$Z@FE-J/LFJK#[-3@DG_ [:7)%;?+[]3Z;5.6R
M7YH4/ %]/ S=!']B*,:/"8HEQX8H;Z/%[4;+VL^W[(3D YC5U04JB@KM,+&6
MA'>,FBIC\=X=+&$L$V&@7POD< Q]O*=+ G"#\^Y)EXIC<T-^(YUM'D$\#UK-
MN+FK6!Q;^L5 L4\CWA\EQ2^Q7;XE6>ZJ[\G7_VL7[5\ CV_7=/+'[YK\>5%<
MH;&^X@E'6^N(6%&&B^D#JH*MNO-..X[:TRIM[A*Q?X$ATU182_0)4IXHI'K7
M'@OHYP<Y!F[ @<9Q+/YW%7 %=OJU$%#? [O((K__?O[_S='GR+&O),HFE'$"
M.'-;4;>IC00!%66>O-ND+(C?NL07RBB?^GP!Z _:JF.2!V&MW$^$@X =[,%C
M=#1T1QY[<5F6C>@"<*&ZJX?L:Y!Z39&FV!3]1MZ8DK1W'BC]+V361[A[>84$
MFF@P21UP(,]_ )0_+RV15P_Y1V1S)>?DDE#&I^6QKRXID])<JB6A=3%3@23Y
M!JZ!PS\D0S</NC$9;-[]5/=6UN^ 2OD)@$JZ >=+GAL:5C_.P>ZYY,NAR+P+
M?:?S<O2)LE:E0W>C-G=9 FF\G,-/%YK+R[;NX$4%40MPVKB:N;R+:X9[G9:-
MMQN[@T'5=V?[1N>6'UY7$E7,RZE=B2M-SK.7M5[MWHH8=O./K+/I+ >/^\8%
MNVK[[@6_T-W:%JK];>:SH_[@_+,LJ[.#YO_Y*RWIE?&;=W3WKG,_ 9#^)P!2
MK@Z_FG*8Y0ZZ6&7/)] 3H+ 7/Y_71UN7K]Y'N[WS'_KE:9E^-1.4L#=W-/HN
ME+,^%X]=SL?^6&^[I.4Y[]'>2E\C,?EJE+VAB<8F:AF*^FZW[K^WV)LB[GT3
MD:OP4<@PG/G.:>LKB=5J\+3?7G7A$RR)PN[OLH\>]WYR4?X-'X#X3U$N_PU0
M2P,$%     @ :8I65I8IARE5!0  3!8  !<   !D=F$M,3(S,3(R97@S,C$Q
M,'AK+FAT;>58ZV_;-A#_OK_BZF!] -;;B>-' [BVLKCKXL!6TG9?!EJB8J*2
MJ%%T'/>OWY&2XCSJ(AO0.L&"P)!TQWO?\4?V7XPFP^#SF0\+F29P=O[NPW@(
M#<.R/GI#RQH%(S@)_O@ +=-V(! D*YAD/".)9?FG#6@LI,R[EK5:K<R59W)Q
M:0532XEJ60GG!34C&36.^NH+_E(2'?W2?V$8,.+A,J69A%!0(FD$RX)EE_ Q
MHL47,(R*:\CSM6"7"PFN[7KPD8LO[(J4=,ED0H]J.7VK?.];6DE_SJ/U43]B
M5\"BMPTVIR$*Z'BAW:&M@W:'M#T2>M0[L-L=.PK;?SEHI(7LY9I"KA/ZMI&R
MS%A0I;_;<LWV?BY[*Q;)1=>Q[5\;FO6H'_-,HCZ!Z\O'4LP#89)>2X,D[#+K
M:I<:Y=*:'/*$B^Z>K?]ZBF+$)&7)NOLJ8"DMX)2N8,I3DKUJ%I@&HZ""Q25C
MP;Y2M G-TZ^KTN0VRDE81FL7'%<9[7\Z&;\;!^"YIG/7XMN.$W&)ODN>EV)O
MV1YBL*G8D?%#?QJ,C\?#03">G,+D&(8G8_\8_$_^\#P87_CX":G^=*MC3\61
ML_/I['QP&D P>?*V.H=P;L[,H0DS?Z@#[WC[=O/)VSV8P6 T.0O\$3RG<-=!
M[M@'JL*#$Q]F@^F[P:D_,R:?/OB?83 ,%,6U;???=3#+(O2LZ[;S'S]]6M]T
M;IQ!R+.,AFH3@163"Y +"H,L6Y($IC3G0@*/840NF"0PSD(37BN.EWN'KFOW
MACS-2;;6;T[O#:"08RY2<&SC=XBYT-+6E B@Z&L$(QK2=$[%RSWGP.YY3E-M
M)"Z0 F*6(/W&@AD-EP*W-G259!'XU^&"9)<4=Z T946AK,5_Q1GA=@4+*BB:
M>=NTTOC:LB:,F_">7#$JX+V)H8MPZ"_IUR8,%XS&J  52G9%81+'+$0N%*>D
M51XV ;])%N-#OA3%DF"N)(=-+RJ/VKVR%94_).*YVD=O<U<\JI(JZ3,BYB2C
MA3&Y3N@:!J&.MJJD)M()FK]_V'M05%LWN5L%EY,HPAW<2&@LN][!O9(SG,.=
MU9QCUD;_?.V].V%Q;'-?A2' 3%2U'B^39(T]D>:)JKV;>A3T[R435$&;0J5H
M5K6,X[TF6/8"G/W7T9N;M&ZJ]Z9RJ]PZ':^%6>WT5%T_/GN-YYUS]TGFG&4X
MHE*B$XEC4!)<&>%7G<.Z( @36!&YH(7*?5.129( +D-C<$@B(<=B*)IZ5<PR
MDH7J.PJ,-#;7 PRYEDE9.CRG0NLL[LT8\U&[1_LN_JNQJR3SA-;\<RXB*@R,
M;T+R@G;KAU[$BCPAZR[+=)3THEXE?<ZEY&E7H>HK->M"DE0ZM+J27 %NM]W1
M^%LIQH*44:VYPN.FK6F6C!X2W7:[7OM-^IW%EA8O:HXZK97J"*.<%!B[MPVO
M<:\+NFY^#<[=8*D*N.]<Z5=CQ]CC0>'J$\W+O5:[]T,ZY_!1^F<[ZMJ-\_!^
MA^X/+L:;L\LN0J"AR@X#,!E-Q[^=^W_>.TI_IS%;WVG,:BKI*9:C*SQA$=0^
M?*=KRQ;<VK<_^5"@ _,-)'D3H_\8G><5@"VH^3%!^)_,[F,Z%TLBUN51QW7U
M4<?;UDF6WHJ?S\%Q  5&&-$2Q^I'S).46(8A9$;@*VF&!B%"TE>*%7:.8+Z^
MP<WJ#+3 8]*<(FLN^!53QT,\(]W"0QHXK1B"K;D"X!4\0R'W>>*ER%BQV AX
MS.E1 $,\AE;&,2QS_*+,I(7<CL+N73WFO+Q[[0J:$-4$#RXC-X-/(RM[LX3,
M<?HMY?8EVZIXZ\UF]5O>L^H;WZ-_ %!+ P04    " !IBE96\</$.SP%  #E
M%   %P   &1V82TQ,C,Q,C)E>#,R,C$P>&LN:'1MY5CK;]LV$/^^O^+J8'T
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M83:&P>ED-(;Q9-J?#B;],_R$TM%\;V#/)9#SB_GBHC\-()@]>U^]([BP%_;
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MZX+\_TQ:VQE=U(_09>=D6H?F<F]XL.;+_/B2KI*>3V-/$0%-'9NB&!MPX)H
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M%XL)J$0**P/9<ZS;P+0$%2(C)4<A"B*!PKI,29@00YUID<')E4'E9KG=$I3
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M41;2P$X.K<AU)EWI@ ';,!+[U\ ]DBUQ;39S&IB+3.R_(+.0$*(D*Z!(7XN
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M1-GJU\U25A%.9=%:00EE+I L8F)[C\E'D%+')%H Y]VW+UT39:;8-03I X@
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MKGF<39@D-?A5$[269"*6#3Z*B[)4JRBDB%N6&,96(/N_3HM)E4TU]U\T*T@
MJT"#-E,818XA;K4 %4%>3'M?&K(Z$"#$MB9."276N!"16""89M,JK52]9G0Z
M7O-!1%%K0-;$\TI*LA@K!5^)T,UF]BY,_<]_!;;E_PI*S&< <1':520)T/FR
MZ@9=E:#C7",(-DM0FDP7_%4,%S'W+/-P8 $.;*'I1Y:]+^[W7Y.<JQ:UIFQ)
MNRNNA Z'<(T(; ACO)8I\O,W#+I+++/J*Y'+6$QJH4/BU0(C%J A@GL2)"<P
M7F5(0)J,"TEFXJRH\.DQL!E19P(_O"5#4H36T3'HII]38.L<J,U_*X'BE8AJ
M@]<G>2K%B4G%=F;D"Y\P.TKLB"2<6#X)K<CS*;',B-@@BOI_'POYPG/,'9"[
M8I@BJ_YO9Q#,"QEOA";T*BMHO\/HBWPR&K"B'JC7=PQLJ<Q%R>2G)'%,3S]^
M(G\[C-HLHMZ .L3$;%@RH*;G#4!P\^"CA+H.2!S^'M'2AK[$ET:49AG\L+>F
M6$7S"2VGNO>S0"Q'(I8JS0</55= DA<PXH9HWHI8\UAP*Q+(26;P@#H>H;[E
M.8%'21Q9-(R=T/)]D*A9'#F6P /'M%"\[N"!NR!B7"Q1(.FYF.FL7>;]$,-[
M:HCQY9/]=Q@E)(E!&3%-#SMX,6\0,9<!E01B1$Q*0PP^"<U%F#&2F*' Y]L0
MI%?TX+%1YGZ-L73CYJK3&D)*%"!X@@P,\L>ZT8 W:(-3X::WH#;B[K05C(7)
M%LUEB'<@2@'UR(P1Y\+&AJ0"$>RJR!@*3BC(W7I6*+R_H65M'!\?-X'NKP /
M#<L<_/MV:-$)QA[L<%Q(>_(+D,LH"FVZ^:#TTG3>4B&D9OL*C:HBF]3SK\B[
M>/G/J/QEQI#3_1O'%N0@LNW MCT>NY:%?#KP(RMP8H_!^5';HG_[._J=J\9)
M.:9#D%-+3C\!)@&(OZ#9#9U6V"^Q"S4 ,DT;1A&-^<V+_:E]%[]:EECB4;?=
MW[(**=QSK<>GAT?_;VZ5MQ_ZMW7H_,G=1,*]P'7^<7M@]#]NC8O>\\WPUF]!
MS?FN[^P]-_B^-^]:J^_O@4#PX(LU]US'?OC%[MDDN->H*LAAM:,$?EKOH>V>
M5G!/CU'?:IGMI-X C];6V[U%$4>K7,7KZV[&]6M.^"3V= LL[K^],([W'A8;
M[U5G9J4.Y]X7_K#L<GE;.P:M2]48^);+7ZWN)$OBF8V@OF!G2?)H.Y/K8SQ6
MK2-?B  7? K61%=F+<95B1:V__JZ_HIU '4H]#]_H;-JYE*C7!>KC"([8;E@
MO>BB'W'>N8O.BV^^8_N6R]U 6KJ_):9;8KH48NH&.R_?IM4GXQ6-ZZ+<$M2O
MQ]JO&2G%&[:])T!+#>NW!U9(ML1IV9*>M_/R75YR4 4Q6.:\IDEBH.<4W5Y;
M4K5II$K<M^L\ 5HEY2-[*_9M*>N2*&NX\_)-68SQG/F6E&X@*0V?%"EUMJ1T
M2TJ70TJQ-/@??$@S PAJS$4-S"U%W3R*BO?LDB=#4<F6HFXIZI(HJKOS\@3>
M,<YIPNNI<9A6F.LP*;>2ZB;25?>GT=51REC&-XS^;#>U]$T]/(%9M?UO0\RV
M>UI&B-E#QYBMY $\R3 RP]TJ&-]R3UOMXH&T"]<"[4*F9NM.0F^[6=FJU_G1
M?R9I/=V%[S*1*W;>9I(9)UB5"A/*<F;(KGG&FTD97]%*IJ7*=SM-E[9JR\:I
M+0A&KOL$S$&&MR746T*]#$)-=EZ^Y;" :\ZV!'3S""AY*@34WQ+0+0%=!@'U
M4=+M%$M%0_JDJE)56W6_4Z[J55-T[*#(F:R*B\\  9YDLNK9V9C+U6S%V0VD
MQ@ K[I,($_:WV19;<KP$<FR;[L[+/[$H7UJ+XC""OL('F?Z]X^<T:%1,:D/9
M*3!#8TMS-XWF"H#PGP3-#;8D=TMRET%R@YV7K61[WI9P1=)[/AF/,_$[+:>B
M<_:6QFX>C04(\/VG0&/#Y6:_;2G7@U(NR]IY>2!*]V)]1T&O0#RDPY(K"B:Z
MT^S+AB)4U"7/]:]8^Q!?:"E?*UEN2=S&D3@$E2="XKY)==_2N%6G<01H7"'Z
M,4F)3"10L&V<[V:2*?)DR-22"Q%LR=3#DBE_Y^69:!1RG,O"[##4ED!M'H'R
MGPR!.M@2J TB4+:Y\[+5\#":D9:BW<6KHH2Y<N-?DS*M6*KZ&8GV16]*?HWU
M\X_S:JP:'6U)VL:1-(0,/[B;I.DMZ7G)AG4J[SUZ3S+^TWJFKVC6Q6.E77S/
M7:P'2[7,+4O=));J(4O%%H!%6>T:1TT7OC/=A0_M%0>ZE8SQ&KOOH;5U:V#=
M0"X*P."'3T$QL+ZIK/>6BJTZ%0MW7K:DZZ#3@71+I3:/2H5/ADI]4^'$+95:
M<2KEV#LO5:KDU#B[R4&ZNDK'&'%^ .=.T]SXC><<Q"[T9,OOA?35AK:K2/5;
M$S6WU&[CJ!T"S1.A=M]4VW!+[5:=VKD[+S5=$R0+3:] [ZH>$;LH89FR<2VH
MGS+Z1VJCQC',"G(<XUME<R,)&\!'8#X)PO9-)0:WA&W5"5N ):73/$['(*=U
M0A%?<:X"KGEYG<;;X)Y-I%K!UZG6UM&T=33-.)K>;_U,W\HTOZELUI9IKCC3
M) 0MM%=IE-8@YR](53+.XRO.)MF6:VX@U\3;#ZPG(>M_4Q&I+=E:=;+E[[Q\
M5908]C#XMW$^&8UH.=T2J,TC4/[7"=16K%^B6+^E=8]-ZYS ;D0T87O]O*5S
MFT;GQ!U;Z''\P3X$6[S?(+QW=UZ>P[G2>IN0N)E(CQ<\N%.Z^:6F4<;UYPUJ
MO?QG5/XR\]+VRQ_]<D:0)/:>[P(<C(M*E"-\40IOZ37_]29E]96&NLZ+$CE>
MF.TK-*J*;%+/OW+[0KI_X]@I^[^=>]3/,W?T2U=EB]M#/HA*3C\-:%+S\@7-
M;NBTVOFEM^I1F@]FMORMJUU,#*3)]^?;=^W6OCM_Q_<\3F=GP=Y R1S"80&?
M>Q&.'Y_,+=Y8VR'-VI/_WO_OWR85C%=5MX)^?X>2PJ7HZJ]?V/YC;EF,^"*M
M 7+BNRFO.(1W>0;;, K,BKU)*V[ (H%+8>1"FAOU55H9)1\796WL'-+W,.S.
MKK&#E?8Q!I7FTQUCYX;C9Y,*_RXFY8[P$(H!C2J%3=#2 .@=X4 )?%87AAP)
M9/!X3SR<UA5PU!PP/&5BZFH252E+:9GR:L\XFY3P6#ZAF5Y+D1N-T6+7^,^$
MEC!#-E5?5]WO_]PUXDE9H@%V]MM@\&\Q/1WQG,E:++"X^JJ 8]#/)FD&ZRE*
M(YF4>5I=P2_C25EA\3]\N)(9=X;E/*//\3'+?<:>H_R)9]2V#3"./L>B!HRQ
M']?XM14Z9->@E9R<,_BYY,:(,F[0:PJ'!MS*2$K.\6%XM817ZZNRF RO##AD
MXX;#"=5\U\@*>5NT-C0PK@)DW25%7M7U^,4OO]S<W.PQ>@T#[L7%:)46O_-2
M7$U58.E<A%M:%3G<R-08EQC*$XO;$9Q W+,&%KQ""3"BID\/:@1D]4 "0:\!
M"^Q5D<J"OL_.CPZ>[QD7^/31@4&SJ@# 2',,-(*W]-6OZ8T#QNP-B^M56OG.
M2^,&J!4B&.^@?DO&TK9:@"KG.0&"!0N/ #TCO!?.Y(4!%:L%(0&L[:"I@(R\
MJ&&D6&<:,2.:2I*(\5_PC8"0AM[N?3?']5:6XYY=8]P(C 6GT^$!#\M$;<MV
M[?!QE!6Q"[7R%'$QXU3D9U]QFM57,5[SN"RN4PQ93HIX4B'S #Z*08 (0_BL
M>(KQ# 3@<HIT(1WA.QSY6(:1TW Z69IPT=1F#% G &J8%1'-LNF>\9<$)]"1
M-)_)D#U4=3.U +]/*<OY5,Y6J7@=R=.Y\6[O7'+>*PKS1ISG:B\"V(T8-HVJ
M:K,BP:3SO+B6.( +&Q4"8>#X;=.8<EI68F5B.OP>H;]9/) J+G9;U2!)B^$J
M7LOR9ED!?\.BTE(O61ZF\1&&@%\?F5+<>=7_\U^!;5F_WK&$1X<VH!C91, 8
MG'&6P@6!7#3,"ZSVCN<XENG_<"V[(#:-D72D\D EU(TS%%7&6(^IJG;A;+,Q
M?B\8%$<*IX -Q^)Y!<Q)OCT50*9&E/+%53$"@0/@ ^\65B%+SDOEI%(P(B8&
M"6J,M!<_^P5@H?J49L@5<Y"<</B$QFDFF& #S3'RO[J6C#(J,A"(%/0,<((R
MC25HC0K '-@'X(RL^*DWB]&V@ (UCZ]RN)JAYK"47:,G'IX""LN'DO**H8H$
M:"]\(1<A, %& -8N&38UKFDV ;6/(A+'DPRM1_+<J#&^2K.B*L97 EMA.+D,
M."0XD0[B@R)[-8,*L*::T]$(UXM, X]0#2[NLQTYF?!,O(Q<)<TG!7 =5F("
M6%W<T!*6&%^E_!JGQJ>T_+"#)RB864,0\##+.N>EO&8XNV(*OPC1L@#"L+>S
M>HK,G5AQ(?BUE+?@/ 19J>1^R@)HER8E#%0:N#_CV<&_#Z5,535/X]M##H>"
M9-60UPS'=U7< -O.,G& <IC*N"G*3PB9(-VAT'=#JUJAS&? ,B/))BF\/*DU
M18ZRHF"*>@B0N8+%HT+4+!06!/<*BDDUQC8-"#X%WM<0/A%(D@%>9UU*KO:R
MAR$E0$0M,41:B?FP8H@ _T)1SZE^*YGD0D71K[GP+(49$M3R$%RTPJ?*B5 -
MJH 1( (CV>;-"N@(AGA@?OWHL++?[$A13BV?ZP/!<\3-ZLL6YR#H 9QJ;>1(
M>($< DCHPU1\NI1/)11E_CWC6-Z]FNU_VP'Q@=V6J,(/^>Q:D!1+Y@CB(%#.
M!G"/SM\>/M^56L"GO+@1&DG[]"R<'YT+0/^-QQ1H$&Z@"T)Z_0@V.8JT"/EI
MB2P$*#,H-;L&#M!2JY+_9Y*67%,@6&U#]VM0BVJI-<-!4#U%A^F@?CRI1'X$
MLI@]XU"_JZ"VY",0*3*!-,7G%!,D!"9)*ED!'(,*7(Q:C,(GF[5%>)IUJM+)
M1ASFW3/>Z&^KB2+O<@BQK1;;];Y*/IR@@0+7-U"+Q7?:70+6TO&T:3!8(I9)
M)$_QM6LNMH\!TIF\X9+'7/0$F#^1/6/-4.="2!'JGHUA >>,!W'0!9%QF1;"
MJJ/1*15FE)'(Z9,7F0%)5>Q(DC> 0$4H-> *XB=;A,T"JT"V%J3UMX!3R#-Q
MMND8I=4,A5W!> $R+J9C;AR+Z>6/QWBG$0<Z!T(0? )"35X)J6E<9--X6M5S
M7 .-*_EP@,8K@T[J(AV-)CGJW36-/PFQOL,AI"Q6X!NP A2CL!9YC?8"T!&K
MNIS$2DB#T]!"2_= 6N!,\^LB0\!"KM,(:SD?7Y5"LJDDRK&4UPC[>27)?C86
M: K/*&3! \4Z4KL@->4I9AS)SX?9)$8;%RY9&Q8:MH&C*L[&RQ@M@B7P-31V
M A$:H:PN=6)055%T6CV _D;5'XV+D;+F\@>VYSZZ<C"O"M8W1:,.-D2LU0NU
M_@?@(!)LI1"*9R!4PN8-!(!29;!E-&H5R&>]YYXW1R?)1-62!0&S,]*8PEG)
M9'87+D:FR&$G*UB3W@AN'#>H)Y,K+@OX'50;6"6JUH@$2JM>K/L*%BK5*?BM
M*^HWJ"4UW3&= JZ4W92^AZ;<CPX9QR G,-G]2]@RT>("C&D4\5)Z,!QK%S1W
MV]X5)XVZ49E326Z-HND/ID&']4&#LA'P26RT*^I1-$<,5T#AKUKR=,<U42;N
M2%]]C5&;K@$.+,L0649H\,=W*IA3@S1"W*Z< ^T%8UC2YQ35)R"5Q-WU3+.!
MNG4S)6&8.%!\>0<"LSI*:A>(GQW_^Z"#;,VMS.JT>#F:I8[:K/KN!1%[U^P<
M&9Y^F5:?E)X[-V!9HGVZ[;6!5]S"%ERTY<Z-IZVF=PT5ERB:SN'_G;"Z9^S#
MKCX6I;*2=:3MRI#M19'W:X#N3MX<G5@)4H*>$6-= >@OWO</ /HE:%\5%X!V
MCRQ#,:2E@<)( [*%EMQ;5"MFF<"N_!4@;Q?%C=M(Q*YQ<Y7&5Z SMPX^6K7#
MW;:6-3SJ9G]?0U<-;;MW'X&ZCEM(+X7787,9NABON:82.PM.<L?0<"#T40K?
MC*FH9M9X&^9(MC3LM1JA4'K5I]4\,'00"(F L*/,KV29MMH]XX@"&"I(;D4Z
M0YK;J[A,(\ELABBJH"&5 \ID6@Q1KERE_B=P\,7-[3#Z,T);EA<)LOB$[=OC
M:Y8;*K-.ND9KQ5XS^G?66K$7F.2%N;*4QDU\4 OEMSFBA(4 Q#A80&.>D[9H
MQ$=A-I>F?JFE%HQ*AX$RMW-ALX] W.?77&(LXG"2\<]IE KKW(VR\*-@.6Y\
M\E1:YU%[CXL1:,A7: 9HC0YQQ^M1*>,[>B::\!"A9VN/'5J11&!AZS(#C@IO
M*-J^R*/7]0;LB>SZ4IM_<0LC-#FB#2FO,=Y@HG441FNZ*P80ER+B970]..%^
MV\4="_K?&NLPOD18>$%1 C+=>OA$!(\2PW',$XY&8-CZ_]#1^%?U:]HF^@M3
MMO^K\>S@Y/RY:G4Y1><M>F!@RC=HR* CX]F?QV^>:XD SFA4H$R'QN_F++J^
MR$7:0>L<DCHEGDU?JT3M$>22GH;S[<>(INW\KF,4#/5K9RF"' PX%7U"KV"D
M <BR97-*;^4>JFE5\Y$^FU((NP"_0S2[SNM&C3L"-],!HP:\-"CJH]E5)DF!
M^ZE6I/%.AZ@25X!NG[CTVLIP!CP,'J>5E#5$5(.,@N@8?Z4EL\&W1G:6AB!<
MFK2-R\-HS MHLS8N&KOA@<#KRGAV= %*S FB=2,TPJEF%&20*RFZ"[@\.5>P
MV0=-42E, ^9QZXT&F#PY?HYS_XOF$Q1'0%>P)*@(QEXK+1,C,_#<=G@.- &)
M52,*H&$13A<]G'U-=\Z&.X,OD2YH)C37!CS%_C*4&-E$.!^;%_AG+/F3UK(W
MK'3@:MT6D3N_4N[*F8N7CO5N.-$M4S^T+^_1&<O[CINUKR/*: JDG*7$H;1K
M<]5Q K#FF&O?WMP -%/VUD1X*483@#IA5T+Y;Z@"[)8IMZ*(#^A7JFJ>RXLT
M ("J;S 4I&=IWFVMAY*D]*,*D.K#%Z5H+J^NB$HR@_PUXZ!Z"!H)6"C=G'#<
M' 5U1684W:Q:#IISSKI:I>;R2&0J"?A8"U!B1%P(ND^;-O<Z2D*H52HR0MH+
M09%MM1B!W@85JI5PCJ=8[2;'""T#Z4FSK(.>E/!O"7D'.+5H>(4CP*:>'?S[
M &B;%(6D*L7YIZXC1'AI9=B!B%50_CMTI8A P)[;39HRZ721UV361Z&X;)]V
M*3.JXL\H9'4HV-JYH?#V-"E<(&BA?H=A$;DV_B"-!:((NV>2B.?%#4B 0RY%
MM88G"J8FHR'0$PC@#OQ/AJD@ P6A'JX=(WY5U&>&%/JZB+6RKA]L!%CAW<4(
M%.F7V36J0C@GT9$C$*@SBW#?U/*Q*(6=,#%#Y_5.!.*,]BZ\:DJ#;X)) &,*
MN!D5(**"0X0PRX6+;L')U7TK6#<NIR->:8M'.]/M+]['V,QP<G2W'< *$\4:
M,UV07>$Y%=/A4+8SX_M2$4CC*Y@;#TJ+'UAK5+Q$*X'2VA;0S"=GT);#Q;,_
M.SLX.7LN*4;?-'._U>;HJ_BQ]?:GQ?5\Q2J*:Q6/M3=4<B%78$55XQHE!"E%
MT!AF'J7Q;@L-"KBY$ACUQ_@V+8$"1S3^-"P+(.(J6JMC9WK3;.D 'HC3AO:5
MU]*4*TS%UVE5@%06%6PJ8^9S!,?6/-T5!I%IB*@(C)$WVS-3 @[0(T6)6QSO
M12SJW8C-B-B@U[#V<7-M32N NX]TS42H,^P,!'!GA;A^_/NFY;],2L$T:\R\
MTF6OXECUR<AS>G9X\OIYQW[9A@/)X#1U'0,=X]8Q@'9B8)OH5NEB;OP0L4P:
MV44P.&CE'BQICJ_]7F0H(L"T?_QQ@',W>2 ">*6CX'<I]<GEBA22?<0_*8$(
M+<B /;2<'B-[1(2KCGN2NASPSU:WZUI=53Z*'$\&<G>^+75\^-VC"&$S W!$
MTLLJ0R$C;T(D>^DN25,MJ&H;FRM/Y6P>SM>9M[(P(GBN)K2^PL2(9LOSP?5P
M?>COX\N4RHU3E*EL6]L3OO^^OCN./_QZ''_O1BUGSUU::/_!V?OCPX$5-OB3
M J;'(E.K:XY?ZI6NF=0KR)H25J5U8$CS] N5%J\;:8Z1QRR-)QU;%7)RY*03
MJ7/Q) &N5VG))RY*$"VNTW)2@>:B;NXY4/I<" <RD%\-A@@@HDNS:1-&A&,L
MOM_6*RN'TMZBCH+(8>1"?S4N4&Q$]L-S6$^12WF@#7K'=U%^P=AG.66EY^Q8
MOK38L]L1LE3$<R7#XE$GA!]!26"%"E9OO>GJR;74BV!)DI]+DVGWVE00N.3+
M< PTX2J7 ^.;!Q%7ZO@MA]GG^,TIR;P1E48 LXBD 66#[T6Z"QD1%T"51;[N
M^*G5.KO&+97>B!R@"T(H'7(54-#++MCMFH\Q%A<58)56LF=<%'))<.&M29=Q
MG=PJ,:0]*_V-$#EJT))3*0/#CI2M6D9JRU!%C3.SD-ID)4AVA@)W&R@!BGI=
MQ+I#-LBK,$<M DBU+1=O"-'LCD.:3ZU1MR&&Y[&\@X[95\4EH@4'K>0B5*L
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M>G'7#0#T.#5>L:9S7=K6$>BV$1&=RW?6(R)B2:<#T#;IAQ(+#)?D2P.QI%)
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MN-_%)FR1,)"C6P9-+,DD$P8Y3.!"-[U*AQ22A^"(LM.2LN1)!8=/,%NX6T%
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MNYC+@Q8H>E]5^UZH?"^;A;<8Z-1&M'4,#:P#T05K7/$7^H=? <KA&*8OTER
MD'CI>S1IU]]SS!!-3'4)?YB>6%F?]H3UZ9>:S7_GNWN@O]_ZM;EGW?K=7<,"
M'03M_E[#_B*6+)>-E9GAQ/]OQVF,#&UKEH%"WCCF/$ET M,+>_S9L/0ER /"
MG*;90Y/G]?/)@;#\W0M5&VA3)]8<AOUMAV$:"XZDQ-6LU)FXOL2VV6U_X[V+
MS9JKO=5_]/;XS0"?B/_6$.#O9#K?!>X+CF)-P/U;H7WQI3\!:%]#\GYVM_3T
MQ B[LZ7K/T+7Q<;]%8?X"Q%F^; 0KXY#"<LH6^-I"%W<T#M:0W3POI/RW_L<
MG@:RK"%;.&C5WF>M MU$_<V9=)X_-4:QY10_SBDL9\6Q0+**.PTSC5WF ?B&
M,IO J1BLF* 11F]QTQ@+_/U#G.4!3FI]L>\786O;AL ):[6W#8'[8>>V-NHI
M4K;^WOHF2Y%+T[JBU6OFB#G'#'+#"GU;.KX2SD3%F59U$:F%32)6I\&SZ)6'
MUEG<_7\F<&ZBK_+1^=M.F$R; MX<F'R@R:#&V(Y,^?.$"[O;&%A4UQS)\'#,
M>,174^F>2-*R4AE[6/9<%>F6P=98EVJ8ZG( S<S-BD56VEQDD?YEH-V&,Q'K
MLIUSQ'.>8/YC6W-@P2;5_M:NBM+K]MX['B5Y'#K]7U8/[P9/S#KI&'J[@-3)
M. ,-4STKO[RGUN2)E2"FLDA!O_#EW.V)PJ<:S*8RYJ-WEYU04WQO1)F^(FI@
MV#W6?(7?LYDM]>.9,%$Y$:5>>\^H*@NC,<5ZM!DB2J&KW#;A*TV7CC93[[;B
MJI(DJOJQQ2V/=KV:3=6(OC]ZMRE!S\LIQJ:-BY0C+%=U.A(E0#"C<"@.Y=G1
M^7[U7)3QC=,10 \,@7UQ@?;!G1E8%)1FQ5"5<"L+F<@BFWJBA[7$]H 847+-
M=5A7A@4]%KK)F[2L=H.=?JV=_H3M\>FHN3WC!!,# ,?Z55+[^16Z^E;_1M?-
M(=[4L^DPRG0481*, !91K442/E'V5]"=& Y[*,(,>[!2MS ,&YM4M:@H@N(F
MH&=;4+;)/)%-([!II!A5!DY@')=L/R'X-9P'S##J(]H\Q'>S#7$6#(]<Y-V6
MB'XO+_/N;"B*V82BR&3F!0E57),+3%@6F"^JXN@*/[?9Y7;5R?3F\]U_S&7[
M-S/U)[F7&W/=(/.=8FYI)6GNF[)HL/^-(HVZJ\R;-ZJGS"PZ5JJ;2E.\4)<G
MQVH(D6B;.XE5 G=EC!0IL__1AKD)EJ_>ZA;R$D&G*,-@OITL6 LO"'$$AP>9
M8 +D"GM"JZPBC)V;8J6?7J&?/X_?[(D/NV%Y\&&OCEASI<<CA'C>\IZFOBW>
M_!O5#:HR]F6G%-LT Y7;.RIJV<2U66(WM7U1U(_:M.BNK%/#^QP2KV5/++:I
M;8'<"].F5/#2+41%AMAF4TT0[CQ?&$DO63>BUJ>+B7MP?S(JKEO!HS^=K%$M
M*W,MF$R7!*A$F%<A<I5!*%"%WM4]-O4X1QQNM'M9HJ0^R)*JTA&.(GA>WG)P
M63Q)_#B>E%ATJ1%CNCL5)$GDH0F AX/=%:#1D6ID)YBN<"KK(0@(;FH"B.QN
M+)4EJBB+H%@JBH.I>E#7<)Q,9\$ -4YUEW3%59M=R^]UA>_N6L5AJ3"AIIH6
MRL\RU#Y5K7G*"1)V4?NIEL1VIFM[K=M_RW@F5HA#'G,Y4!<(&XS\ZO:;[D?-
M/@1AQH&;&M-(%F)1_14#"D7Y%+%@L06Q[*8R5W=;(D@?RV9A'0]1Q4146.L6
M,VL#T-7DW=(->HU[AB9OHF].,X$^REU8;4NL1*-FG85)6\%0 [\@!3^:=+0<
M&J\[\4XQGA"8MFI"W1?Y2SX214>Q6B.@ G)TT5$6;@#9HX[,[&4>".0J,+)2
M" "Z.7P35UF(+@GY4*)BHZ%I7-,5:)JZ\U@'6U8V'S:5[10][ZIZ^_T0RP,5
M78WI! (L.YVH>D1*5+N#+[ .2%YW2@\I.M'78E&)P;+\J2R^([-66RJSBTL:
MB7ZIB#;XSV0LJZHH45ARU#?G JO$*<,"(AF *T$*]U;DPU*<Z^)7Q/0R6T<%
MA\M96(_C42'^P)F)LH:):C7672R6VNR6/)8&+'DG4O*,ZXF0XM3;6*I.5T]9
M.TWW+#?.^;B67=&L0'=%Z^8>W%XLL%<H$.O^X8N:$TGK!-(O<5=M0Z:#JT)P
M^A%R*IE^U*VH!XK9Q<%S2<OA)U!\)CF6?D=B^R\*-PDO2*$8_NXK5IV5S%?Y
ML,UY"5;F=#6=541YIV("2')'<=^5O<<S0.Q.;SM;LNNTJD0#NPXO$?T(!&[T
M4:FGX@N)0=%_P,9;JE&*X>18U0R9;,U!S02)H%CY(J\FD-HR5X!3*.L2R'"E
MJ&V0"R59U(+N0X"SVW"KJEF& ME]T2I$53(\SC].X*UG^_\^?MY58#H;7JS3
MM<L"XB$VTA$"1/U*FG&4N!IYR9%=W=5B5 ^15D9N#N1/)48>Z^*5*#%+:YF2
MP 7D5AU$$J<MV*\4H&87]+]-E[R^R"GHWEB4!(>)8-*!)'B<S=#EI@B4;ALI
MZPLXZX8-HL">$K25%/G;A UAAP<RB:G522S+>/;;P?YS5=1#%RT5C.=:%85O
M60\U_MO:LT$%@4L028"R)@\ YC-)0P8PUR J0 )'/4QVMP) K)[C.)BN4'+-
M,QHQLRZ*3ZI>KCQPRY'25"]^O]$AX3;M?^B:7%AAJU=J5>1OL XU3&!2@!T-
MGCXH!LH2V8BH*'3SQ,BP[HCBB-5$+%_1<5!!FW6H+:N<$)&(<$(U0IK&;:TV
M5<4S@/$:U>;9S(3]$=PT: ?&*UJ.4&D4 Y\WQWL 9XB7MML6W<5.H/0&J4,S
MEV5JQM Y!JXVHVLGWF-#<XMOMG5"2SCU3O4JU!FM6T>+X$AST<!T?PPPHT[)
M;H;[UR3GAF/N=HK#W6,L46W8ZKR$=)D+ JG;>6&G(P%1NPM.H#]N7S73)( )
M3JE=[NM& /KN%ZFL+$Z0BKA(H>VY2F32U72!RP1D9DQ?QA8:HA? KB$[2XB<
M%UUM2/EO -NU)BLDY+Y& /J_XJ; GFC'4B>(]:VY,'O&:UV[>E?E4VM;"0JK
M]QMDM[,SFNLCD$5&Y<YERHQ,'+_O26[KQ70 T%\/9_F23D>E%J<C3'.7XGDC
MX5'9-68 $F>-_"W5UIX4^R.^ZH'\-X-[6_A= GVU .KE,AS'$"MHJE\V!=/P
MC=N7*+1=;#*'C;_27EV!QL9WZTI;0J/U?JGF]\<QXJM"6.V:;36Z:6=D22U$
M$<'FN5LWK;NJ= 7X&]Y8>:3@2NLV).LJ33K5J&[?4*E%\EDYIE]:E"I;I]I]
MGR5EQ8WN KUP(C'2NG&H[GE41B"54V%>&*$&:JA*J3UKBRPY(6Y#EAA6X+^H
M?]M%OXL'.BNQJ%W3'$#47!O)RG6H&PNCXP@+_,545K2%)6")C Z,:.=JNZ#&
M(]J]D%U=[6V^5+S WLXERD *A:5B.]*?+/S?I1;>02&):*:B'\X[G1UDU4!E
MII7!%]-.L .V!T5SCM!;;])*L#MATTG@(=;98 M,RL*EG62TW>QYLUGCC5PO
MS7LUK/DHG8Q:,WM3T4_B";HI5:.,HAS27'63%,A11+)28K,>30?@5I(.O6N,
M4M*FOF#Y;7C C31UMQ1ODK>-0'3C0(X'(?U2JD#"7(?:>5#I^E0:=1:C 9!+
M*V.<H!;-T37KAL/!,HPWV-&I6:(N\XBU'JZUE[(W!S9DRL<"D-2B%#PH_4//
MTS2LRGM.D5A6UA-#(J%6;74!O; M9 U HP(4J@ZR110;A46UL#]T*GHW5+PC
M'3;#;T#]E7F'[0\$JZT"@6TW\NQD?W<FS[#D/8/Y&R0Z!\^ECUIR):QE*D4,
M+$Z/L*V(ED Z42O\JI@IO2_\JFT58ZD6Z!I _7@>,2,L2_S[&VISOPA/*OQV
MV$19Z:)*)_MJ94H8T4M!Y 1]5WHHN\1E5Y54+:5[7SADYY^0VTI H@%J,-#A
MUL]>O3I_/ONPJF E2OY6:C'/SD_?5,][YZC+%U44E85*>+>0JW72^6T+L 8[
MRZ!A[D#XIM H(_KG-+\^[U80;=T02%UVE8*+\LF<75@T L (D<Y%#QH=KV]>
M;+S'@@H*T:J5PU3$5*Z/?L]X U)>J8V,S4)WV[L1[CT1C=?&QL'C?45J1J)#
M,TY+8T7;.CU@XT"<PJZ8ZA(AG9ICO92(*Y5LF(L>.LV6=E5!YZ:@AI"[==,C
M(-<3Q80T:Z<&7*;H%Z0-:+N2_K:'WQIVVUO#\X[*@@+2XU7%LJ5W%R+ZV^_4
M^.#Y%<(M:T,*.RBG#W6O/=ZF0;9"KKZI4[3:E3WC.^6U6Y;4ZRV)$0A:LFP6
M"E"O)$J4B%[QJ!2@):W-B-B]9D8'E_@-P>4).@-X<UJ(5A8"D.7/S_L&=.7I
MDS*W>AKI!Y5M%-L"8M()V?H-E3L2YI(.+V6JJ7H6YR8TKNDJ-=,Q2S@K6X]7
M)<J;=YJ*ZLZ>5:5]R<I%J-B]6G&WL@RNJ..)+/*>)W13F&+*UIH5IIU*+4)X
M1Q%]T/.@-=^W31N2B3"C*E5D/C!:LZ;>T-WXBJ:4OV15O7CIKA@O6D\(0Y0H
M#@30AQX3&6N,;;3D<AF0""0Q(M12 K[N^MI*^9-<\F8VOS@,FD0&QPU:W:*^
MM$\+_TXQZ'RC;?#8-Z,C>J:L92[]J"2M9<\PE,51TD*U67!9N&B86MK[YF-%
MNX&QE6QY+AJLBJ* 4L700;8S-D*]A(8$=+E+N\:T5^-'&I1K'?[<U(M#9602
MUQN&^IWTS/5$_OVY,EF[*'VT2B7R[D5V%<&?E/AQNX&GQU!GK0Q:%U[4L4H\
M,!EK24HF,C16-T#ZI-!A68W2I\Q7#:Z)WMNHM&);:%2)6Y]2I:3N>8OVW$J
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MVB0XC$!MG$^% Q$8HP0U(\$4X=;[%<?:N105)C%9;X-(O,A0$K9Y(8RB=44
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M/3:"1DS3,.L=!T. #>HK35K6*!$=Q:&23G'A=_DR91?ID7+\\!I7\68[6F;
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M[5BTQ3$#/TLF,VL<BQ=G02U];G9$4%JG;M?X^ETF$USMWVW6Y'MFC";5#+3
MJMS%FW&1K1GH?9;5ZP ?7]9NI6I&O[:S8WYHPZEVW/I]Y0T":+5(^P><BNTJ
M)[D+-B\TOA-HC"A5$3>X>H/"O)=$P@":8^:$I/[61OF&6+\(H/,H5K/I_8<V
M=:J;-FDA/T-&@F1,_.-G=>9?5 5=G%\UW@1-@FS@O"W4C+#H$>O2S%@N,1BL
MOD:;'Y#A3I[2ZKZNKK=:(#P'V4>_M)FR3 5$&B8XV#;%I;>)W(K?W0TU>!;C
M**'*W%)CHRFP)E]D!L6VNHO^]_/ACKE)@5=S7@GY'T8Z:-+VA[RJ.VOEG-8O
M*;N8/E!J^J#6[1$UI2EQNW_4=A5Y@9I5-3UEJ6[N3<M7<B'5N^D)9HI<;J0#
M-)2%]&G#BXZ65WX'4GXZ)M;/WWD,YQ05TJUE\'[+V#4MV2S;U=:X,R<M+J1;
M7@:&$?Z"R.J&@<YFL(:T^QQK!:4#4L>FL/@:EL)IFO20@0]D3L!ZE7XSCR&S
MQ.Y#,M97UHSXR[?R7KMQ]\>*U0Z"F)P(5TYU*INV(;\,QI,4F?SLX <PQ1!O
M;ZJ)Q4SF'0Y).>6AG8MS?HCJ.(H7L 1VY0\+J)P)'Y>2<>J_<CZN03,X<WZQ
M\*'#BF&XY(,KB[WNELTUE\U/;MZ6K.;H]RE([VHW=?D9^_ULNF1)>(,%[<_H
M0"A1:$?E5<3N.-B@#)E28)BOTOII5V@-C(M#5?5V\WW39L)/ T=Z5GQ2PP)#
M[#+/IB* @:D/3+#=?O(@$TUF(55XEZONYO3F]C!Q#<"#R,NP)VM,!-PA8BH]
M9JJ#T#H''W] 50)"N\G4[B;NIB;NL,X7D(2D62(E>+\M1=,=KA?$3K*%G[N&
MU9I+Q_S,1()/>W(W-3<U-6\76K-EH19- #+K(EASC/2E_WNMS%53/L@*4=*&
M9TR,5^'CNTF[J4E[0[2^4]'?4YY&YE+)C]4/IF/,>Z?>09FLT^R4WV?>(+H0
M1[*+2UZ/:&',[2;4C3E9&_Z8DXKR";D[4[)&[QFM_,IPRI:64 _?/_K^[0-P
M[4(&M@6++B4Y"NB!^+N11"Q)S+JZ\$8ZFSO*M,P&?+.>9ZZ]TCZ /LNF:XDV
MC6MNPS+NMQ91E;>D-D#)J!&A-\4>,;L(\R+KKUY-D?H[>/'BV>C^]V^/7KUZ
M@(_1M8[DMN$SSY^\W/$%)'P!C[:$+V!GAGY_,[3)"O5LD/#"<TG1>^JC%<(L
M)&J3_!;RS'"US8;5OUL!-_;\D)7MY-#QA9"-NF"[[A;(;UL@[_Q0,Y_8"9&+
M-YJ?C%S K/,^]8Y]K7D](M%$/J=<^;,@, 7'JEXHWIDT8--.?J5\7\OWD%*!
MK#R><*H9TB_3M1!5D_1._F+3VH<$,45JJ9$#R75XA[%$@/P@A<N8V#JHEHM_
MV\_$[ORCFUIW'],4G](#?6X2G>I4M$)28(-ES!_WM.03MUGU&M/PLSEEEG&2
M>Z3E=5(M7/(UHJ %KRMY9[0TFS$+:@CU:_H$@2PV%MRC)!&D@LR[BF0HY<+!
MKY3D0/TOE+;W B'[U+-Z.;*$#KL%_?LNZ.^'RT?6\)3N&"XDV<Q8-PKFJK?V
MT[H3F*_D0*4RY8H9?-ERHOJHOG^/%94(41?,H=JY"LO::6U%2>/I,WPJ@Q#_
MW&@86PK(P=K5EE4K?W$BS<-'%0MVS-IFY<,J%(ZM6@^*R'R*^9]2%$('NH#R
M K*04W\L,DY!ZEU:GP>_94[L^L2M!F9<B"#NCWYQS!G7UH0-H' KWE4M9>$7
M4\$GLYNQ=)D:08JOVGPU$'":TS8O0>3&4:->U'I_T05#'5Z<05!5]\6V_!IB
ME:!GAF+Z8@F<*/ELBY5P"$$&G(?RW83J\*1]RX&H]U2\42X%VV:?L5V=5#5_
MDP!QWCU8^;6B^>!Y2X<"22J&XF6$3- 'KEJTM_)Q'4P%0Q&J^9B7$X]GNLT)
MEF$7%3M>HG?G'W>L@6N -&2-1L%=2 /*%V0,IGZM,'NA+"*\D#]?6T@<4V[O
MF&MM*^"OYKQ8U.FK6")-K5+WKSQ^*L%A$^I4BFVG1EB$2LK\<5'&L1K1O,4B
MX,=/5^,B$6"7+)6L6D&7(TF_Y/"WL^8#' =?DHE30?,>P1G^+F!0/7BU/_K)
M7V;T;39%O-(3AFON',?J>[ML"! 2K4"$2@GHZ?.P3?O[+^_=*K&R\4CNQIB/
M[K'Q'8O8R3JU'G[3C4DR 7@+:XV#R9TY_U0S.'N4J!N'2%G^GDQ4)Q*']8LF
M6K 9,/3^^ ;!Y_[^O<\Y8>\80>V/*/FUHIE[:.$!6^8_O&_K/@<D#F]^*96I
M_("#,U0XYV)Q4>!>8@<'85"IFC4]Y?5>A"""HP*&T6J;_V>X5H*\P-'74 C#
MI5'V!B\BL\0=6%8BEF8;-\7,&0 0QS]:QT7ACN([>H?ODK1V/*''!J#,W[=P
MXB K/98ZO(@"Y25T.!@$K.CW*FIGC/(Y'4L$8&[F:UODUZRT"$VM, CE+*MG
MFGT8/N#%EQ&N==8TT2JFF(8PVF\^_/1:([HM=(0!U(K0N!FOE9DC8JU4 WMX
M?8F(,!8[86V.HPO!>T ';$GZV7Y _P.O9![77=31,UF?  TEP!<QJ'+TFY_1
M)%(8#8>/_&>6[)5$I6$^%N0 ^='UF5O++-I'1^6#Y")XB<^<IK1JAH0$A">/
MQK9-;N+R^K?XX)8K<-V.'CT\>#'&W)"/7D XIEU"<$,]^2---+PIB8@:-N:G
MUF\I&B/.392NIE-0ZD5D':I)$8XU" \4A9E=5T9*ZTT@+*A@GN3%S,= @6.^
M7Q<BR=/[A]^_/7K \#^\QJBFYPNJ<_1Z2(WXL,X'K"P;6LG,JTU:CT-^D05+
M)EF-1Z_=G@MO/K;6#1>FA#=5: GC&/:%OPR;'MR"KG0.AS[K2 GQ@'S1Q&_&
M6XWL)7(2""IQG+AIUC9.-I),C7<-1;'/OP.+&9'JI;??#F7&A=]!HG]LJW[S
MRFI74LF0]5,X-V>TV\SI).8-[T[^D8AVEFO[Z%'G1:[+(% ?[!:YK I,2%<^
M$Q$"7?DD543"^'J7W8=,% R@S%A[5VD\.L^:%?9IYEUE!^CL.6&%2*ZZ8B]Y
M+?(T+,D7'"MS."0)9P&D%HF/DEH+F[6C^,;[V35.)_\MO^OH\6*N.D D1/)#
MQ/ZRT<'#O;7S2X.6AW]6LWB2!<>1BAJ@:5Y/VP6=75 .O QDJR'=YX-LQP9A
MJWEZR6YMG1R'L8-8'<FDJI]6;7+IV-^R?AWB4/8F@NV2M3'&5\0GFL5H5U!I
M6 JR[.13M#D37!2GBR51TO7")'.G3M<XV*1TM;K$F:'+<Y:(UB8=KI.\TKPX
M=I*/POW6:;D50N[!+A!@)3TH[Z:[V@,\PW:4:\9&"_9_S<9#S@.K?0S+(JH#
ME-G4+12P2'I"% (BQ,6P]R)X<*P@>IN$_4,V2G>?_ E"MF_%?W[E':Z]'_+I
M*<"T'Q@ZNV5F '["1>]#F_@DGR!@[^>XQZ/3$EZH*&50-HY4$->L-HM4E _&
M."55^>'-M8+#>&8N<2[:4I;36$I2= &DG^4GN&I84Y G*_UIA^KZK)TZOMJY
M#U]&+I=GH^WD[P_LS5RD?_W=9BV5.*D+2X+.'?;%8E\>;P?VY9:&9]G6/H83
M+Q(T!+*.JX4WVC,MX+*I/:XJ9.BEACK&>2.=P9*<(+L^H9SOS(ECTP_,#>8[
M=')H;2,X2?1Q/7.W+1Q36SI5T&UT$34QE"#J5I?:*W4J24\N;[A=5LY*$?/1
M'ANY7(@<X.%+<K/79&-O/# KUK48GIC1S_H>S=5>!)=OR[PY@6,^62>OA.%I
ME_ >7#DB[[D)"Z=%$6BN#>7\L?_V6V_L9Y.6I;=2)_NC'_V2(']:QYZ_,/6K
M8.(DDIN9Z@ &JK$O .FH#V2SN&3Z79O/7!&&FC[RJF"Y&$?*9_[W\G:4@%.+
M+/.BZ0OO1?@M ^J&N4Z^9)\N'S!3&%@ SX/&Z;2MJC>W&\)N/N@NF'0.YT?4
M?;%@P=\YQ;*8"Q\5 CN>KN?.6LZ1+@]+-DZ==OWT)^]^-ONU;5:2./41+%_O
M ;U''XH.8=UP4VT^#HE%63\G-56+L*UIE%<5)2@U]^K7PNJ<@+!8 C1T,1]B
M,!TF&] T3#AP\:!?LJ%@/&-SW(5[<\.&(]_FU>$K/YC>/'.7["4KB (A'[_F
M\S5')2R4/"?K+@:;H+^D[1YZ<+VG3$X%N4&%FQV[J^UM_W+X-LKBI#)-5"14
M0.6$@?:FYEQ\-E*QS&]2KBWX.5\Y&2\%[+"GCC"'QBV[K@U5F38RB[32*'E"
M-T"BH2W4_/@3D6Q$, ??XG.'_&2$,;[_[:&@C\FHQ"!F53LR:0K6CILM+MQH
M=OPU.I7J[[__\,7H/<$%,-QO.1/N'^@[X;^X__[M=P^D?Q&IUD</'SVDJBFG
M(3*;&LLI140KF(9K4<U,#E=6^87^/M\%6_V=;K^C\!;Q4%K)&L14+@@@ '"4
M*(TS; +*U Q!S#J8+1M$UH[=7BEB1NZ#UCLE)(+ZKFI6(=\<WH_C]%6:&#RG
MN?1/5YD>Y']D94NO0>E0/W 'V^937![3!'76:'&]N7++6'LTPTH ?VJ)GU2:
ME9/V@9"(LA.U/_I&Z]1031:HL20NS(0&IJ)F5;=3,FRS$8=.E*++P2)A.S/C
M4XQF%>R0Z6"_^'WW1[^<.+Y@? )&5*PVW][><MPU]Z.%/X3(37"TC)EH";0E
M?CGO3=9[]%\AO["I0'.&2");K9[Z"^8>(=5MX*F:W8Q%Z12)I%+: 15+J2F+
M_!;PSK:MZ;>")(&%J DVTU*J1C&_$906\S*BU,PD#8UI*S3*RW 8VXDW]'D&
M!!3B3S8(9;O@6D:R;#NX2FN[PRR%V%LX400"%#[ J#\D]'GU;EBU;SYE9+R:
M ,-)GF2(RB"D)2Y$N";06/\SPU5U,.0GO&AP2@/2QT)*%2G+?8!R1^(=7#;^
M;\6,I$M923KHE:(M+2!9+X'=FK]2/>F$W'7TL)7,\3/PN6Q*]BWD30<_8P^>
MWD$S'CD_YM4Z(-]"B3>Y#6!S ;G+U494H5);F!S;J*'RVD#=,BXBVL<D\RI+
M]FTYW:=ZA9]7!G[NC[YEG-VBJMVFM'1W*=/MV*DUBUI-MG= D!8E1"FR4X$
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M]5,P^J@ZOZAQ;]N@T1\,0T&,HCNR4E)8[&N$70)7MZ(YE$0>D]2]XV9SX>;
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MA[IP?B)HPNV6'Q*7AF11P&T @1W[I/9X5,#J@N %9%R629Z&4QF]S"H &G6
MF?+W&%X5Q#PX+<U<>HOLU!)2L@2G]8J$8D3=3[O^@AAPH"K8'[TO1_]HBU"8
M'V]Z?'XF>5CR%?")5'2D]W+G"<4>N)R.<WF.Y@0L4]GTA(:?H#O(ZLSS0E.1
M04_:'5<K=N-JI,W!%P</EBF@!M04&+M:%&8OP7UI5WO5?*]T*]21,@*G49@%
M1F]Q)5'L9S(;/ 8_,_>&X\SM-S#>X)0#6*SM(^R>.WT_>9NE]XW=*L):+.!9
M]0$Z8]AKDPA5DKUY[9<1:=WS!X+.%%)]A#IF&!21@G$9!Q<- W^?K97HQNL4
M*H#E 77J8( A0T7CP+0 )U75"'"#OV%)V,EKI_M%-6YZS?EGS-636YLK\)]T
M:8HN7L3=MEL"%9&.HNWO8\>\$^?<\T^_1$/>A&@-RN-[*O3M4(.A'&.:&;8.
M_9B'TI#>)@*]77I5^TZQ]UJM4:^AR]()!SJ%L'I .GO&Y3@!8C%SF"J9[8]^
M :\ 349;K "="U4>3>4GF=&!=#1%QIJ&]>'\T&+X;0O!M&?3TA9Q6"H^!XS^
MP)->S,(]7,K:R,*-'3+$Q,T#3W?26Q1K9@E/*<*WKD@VT%29$2$]6#,JI'OD
MN$R/<'(V.&UAY=XS*4]9CA/=$@8)-7S)7F8^,!F'ED&5+39$S+$"^CK[.:=&
M\4@*\\]J]$$VM60JU"L$H#9V$G> =N/^/N[?:,P)H4EZ5DO)Q)*ST<*$S,K#
ME]]16=$[Q7Z3O&EX'^(O!R]'][_[]LT#K0!S6D9*^(PJ]ENO/I9C7%2/V(GI
MBQD2 -7O7&Q#UBYL7#&GTII:&*YF^3NR]=7C0]^:@%/4!IOZX5S2'"XV3JN]
M<&KJ<^!H=?*:ROV4Y%*"/#=N,DYJVSJ"RY:9V2@?P=;2MAA^D(K2YRW=Q 1B
M.%)2K%*FNF\.N1!%G+Q^,X(^$EA(88GPXU,I6EB4'[*:^8P'5J6MD-GRG'S%
MMC'1W0#HH6);*([%WM;4I0WZW /5S+MGIJ[;&/#^Y[>O]PY>$,0&[("WC[P*
MCP3@$A5ER2">9#/V%"EOK'$'Y1"UYIJ>4929\7M7-D *P/@HN'/DP^4>8XIQ
ME5Q"ZK;TK7DU;4-FEP_F,3H!Y<JTXO;83>CDT_W><-EB$512@IH\UG@)2?MW
MM+>)2Z1>@7]DZ"D@;2(/H2AS9,M!]@E+EZ3Q\77L8N66K2*KOHZ? 9L+"I^(
M5K$5S8@(VZJX'2=5LZ1U-2;?7[<'J7P0E*%Q4.+V@UOQ,SGB^]6WF:%^0/:7
M9RTF__4OF]'2EK92ET87L=/O#4B.R6I53;4CT\ && M7+#&?)I\R-$K:O)0T
M;.#+JCF 59<1;=L9YO87AQ\98>M-1[X23+LC51IAS&2W1UXP?5"N>Z2KNM,(
M*TA=OT.\&53>-8'6A\T3$(EWL!Q_,>Z[URX??219YL)T3.,WB^IEX=6UP<3P
MPHUQFHB0T'@4--<)<W+<YK. .%M4LT!A@94B+"W]-MX957#&":XPQ&'4P8:O
M!8")#Z)R-P](#6V<2\H?NB*:BZ%)MY5<OG#6;&R(8./]A^]?:7_0+1=BLY6E
MJ+.<8W=R*-7:[0V@A'C]H\UR)H9)%KTN'DDJT,<B2A<GHY*QV0'HM>W$LC%_
M@9_!+^[AM1@X,)1^Q]^6G$!&/=T_.GKS@!A65GLK<F5IZRT)F K$<#6?\\/>
MYO+PN_',^4@$!D >4BUT/,CI&(B'T)U<-<8-YBGBOP)S8"G,#'>E/Z8-]^W^
MK>[2PPX'0&\3B//%+81=AM@\4-]).LH_RS0<F 1R ROG()EGH$-;]>A6%?$N
M66SA_(_Y"JK_88\%MA8\'9]1LYE+2"HX31H#% VZI(54Z^+8O0RN5CFF68*Y
M9<BL"\6?7!(L*(57!.(KLY40PM,J#GYUM!#!BQK>U-T&H/,,OHWE7S+XVTX>
M3U#J:VDEE8,\H5E5-&*GVX$]N/"X9]ETRI/6"&B65RV8#AB_:<L* HR(1R^H
M%YD#\3\A0V4V"4%6YWZ6M9$OX7]N#./PX)(;I]AG < R$S^!* ?['\*0"#]&
M4O%)1!1$*H^MT)5'=(/;3,28-(3$)YF5RO5D4W_E)2F_ '7^!&)\)#/TII$1
MKGMV*!+UG-+"O>Z1[F&\96[J*S88_:B5NW]((JKGR-KE8"B3DR92ROG:,"9X
MI]U=&<\C;"2341'Z7"8!HT!K-9B[7G4\T* L0"L;Z^(WR"_R>@\*C(B+>A P
MUL'M)),:5MD=8GAIEY0<:VC\PK"D4/'^?/18:&Q6+H%N=04TNR6.<&DPVH*E
MG;/O\:V;WP'-==<:2=\1%T"(8^*K8AB$LAI&:R/RY8_:DO?P2'=L^+I@.%XX
M4!B)M"9LZ?E/;#OM-J%<IQ_;6QW:'6[.]@<\W [<W%VF=WJ_,L)2MO=W2\[_
M]\IAGA!EZ&GDM[)AK3?INY0]-66D.\G^D]4S^OD\:T2@A8*5^/L%TJ:%_)WJ
M.U4CN%D-0< &)E"(:4']J,0_VIB+ XT@51N^D _>B:ED)E1N^D(1%(!DSA#P
M2$1AZH2ZE7 NVOM*+UQ-I^TR\-/;]Y\4Z!3L=2RA90N(-SRP%(TE>"6A-NE5
M,.JX'876;F02RZ$$@# M5/Z(%D8[FUV.A#BP,Q(Y#KXUT%$9E1V-PG;6L&X9
M!2PJG!.$-! H"#CIF@. 0$]Z3ZEE@ NP61!/#3&(T!$"6] )-.+3=]FJ=0(K
MU=?Q T43M_(#\8T$9*%;[<+,3\1M2]P^<P*CT=<JPR/ZX ^27%24:U9[X16$
MW$F=2:;UVFN7X^[R9S;&?[>]["R7:@AUI<R'@:9Q?_0F&08KGC?K!H2Z36M'
MS*Y[I\XMNW3)VQ:^)"LB\['*N3:(6Q$.;T>"[\+U*6HVFW/IQIL0L 6%OD4U
M$-H_KT*("ZD8Q89Z,"==<PO^&43;/ZPX8Q-J45NV:CY"]@$K 301RK. I2,<
M,*B40)8,N[-A'6!BP1=**/PFS&[$>K'&(3#**Z-J@^2/27:D^28L530",PW^
M>/3[09JN%MA^"W>>A8K'PJK_:#PZJU:"W3)Z!-I,3!51'C1((9&@%9"+NBYD
M]*+2Q =!A;P)9\G;1+(*LE2C/97<,:PKO\AA_ MQ4]W_\.;MOP0GTS"1-W/T
MTJA?DMNS)'?*$V?W:P<!%Z+R6 #W+SR?TT>91V)L\F%*06]^MPHD=]4R!IP=
M28Q>P?L4C1C::^4/&=%W1-[6.SE6%BCE.9-74K2?S%_M?F4$$;(K<)T$FMV?
MM##WYZBC4(XRY1'CT([R#$N,>+Y"7J0K8C8G1IG>Y1OC)NCJL"Y9E0IAI0LO
M?#4:^7F++#&0K KMHB=)%63Q'H$7L_\R.&%O< ]>,;NT97;TC>:6PTPJ-GD6
MFN"LE8LIZ)#WZI8UXS#&+:E*NG'3D&,J7FB/"D\)5TC:'O6#4BJ,-;?NS?PC
M,6MD-ON5ZD: RJDD""/K(R-20IIQ\7J(,CV_VWKHDL=%2K?+NC5CWE\9#$WF
M/^$;L82>9&JOQ2#7(Y^)7^GE!/^2#9X#&:=\]K_W\LFC1U\]>O3,39\>'#QY
M<3#YZOGDX*O'TV>S1P?/LT<'V?]]\NS>[7/G/]_ G:]JJZ;^*.[SEEFP=UF9
M';N 6PXH&.$X#?CES$C,]E_:TF J?"_G0S^&8 REZC+#JT[T6&61^]QIPV*B
M'$$'T!?VF7^QR!_//#@E$8S12<X88DZ-4.Z@"PY@R%?5I^%G6)V^J$:B1DHN
M!W@5A+S+FJP0 XO]OQ=4[ENV-6N&2JY&+R7@H+]?=<4LR1"6QWN%F_O9?-I9
M0WL'7]W:(@)Z^]DMU@S2L3EXPL'B*Y2E%&PJ.O7K2/,[ZE)0\6'":A@Y0TB8
M,._<Z%R]W,W7#<W7Q]IHNI.3SSF(%,(#^^##CX*/>[^9Y@[GK82HI%174=+U
MG)#N(E_'JA<=!R!US;R!\TZ*X"VBA3.8#&F 6H</K-4W@STQ-FWX>+3WVRVB
MFUI$K]E?#;O>BM_:@VL8!\H.J++.!RT8,.XN*;:]2.3D\FD/:/8-M]\MBQL[
M"TBR41>%P+G59Z>4\AE#.,0IB(R9U(3 LQ0<95T)\U:Q:11?R^G"UU<I'HE.
MREE"?,<Y)MRLK,I$O=";(=%Y\Z-0NOKER/ 9[!;%[[PHWE 3!J\"QN+1X;$D
M.-J*$E#-RBTQN6B\.F-EI0NFCUW760W0"2&H '9SV2D?0Y;)+_GBMM4<?G&:
M IA6,V?=;&X=$8W'Y-P>CQ80B0A;[)N*I+C\#Z^A&()0>N.Y#JNL[8_$>L&T
MD$[$L[BD)"*A+F+A_"BO%U3P,9-T4JWHC9B;*NWPT=X0S#BV^)5V+6=P*!]#
MH92(1\:G7#,A[^$)]0T8>.Q[ZB,A;4@)=E"&/!F*KD1/>M,%^%D;D5[AXF@5
M[F@$6N3S]P_?O'\0W)K#DRROK7R!6<S_OPA;0"MNM7)N\^2-[N-W#S:OY;\D
MP.1@"P$FMPG&I+0EY[.-*'H$@4>B7<+&$D7Y-+#M3H3X ;4LG*5!9#:OI^U"
M]V_.2_W]V^_ ]!#H6 = G>N !@@4QVYT6D*4JE ,.:D/@?,BRXM^R?E"][#J
MLB?$7*+-T*>=K>Z3_PP2C$AE,#]NO@S5 H6KIE(V7-EE=H8_-HD[-D![P=!6
MTU-FQ!FP%E=,#KZXP\E!DH# 2&S9N4ZG3 J%\L_DSU?$RMSZ+1T-4WU'JC=@
MG8,RDA(ECD27$.H<'Y,GQ%!Q&&'UMR77;A9H]*U)'!,XEZJ'RXIK\=SUZVR,
MQ'3QT72#%,08P&ZYF^7M D,RLYP&IG<B5-!4R",<JGC+EK-#J,- D\%OWD9H
M(^@VM(?G*;%19#PYJ3I\-7BS_[AP:4EINO*8F ]#O;5A@:EYGH)[ LA%P60S
M.8L-WJO/:P%D63H@(QZ0@4H^M^ 82Q1W>^SQC9G_ !1QLVB6RE7400V -)9
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MGVZ>NV+VY=#B2$EAPP+- 8_BN</:03.7;I6PB7_U]R2:A$R;O_9'WSAORLK
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M[U*+-[9 O@ULS90+9I'',*]/'A[</WU K3"D^1J@@$+.KAR.V.7WWWPX.GI
M$EDS\*.Z64J\1!^R3/#:>!*6H]*U<M0Y]T[T:)*5IU;#=V<F;FP5X$9A+F+H
M574CZE(YL?%L@1Y CF'^K;A"X2KDE$VRZ>E>NQSYT+60OD]J?1 Q5?E:;U&
M<XG"86Z1R68L#RU=3+6_039=@S6%VVOL]W G__O0+16R/-J'(ZV2Z&V7K(-<
MIW V$Q#!/<BH);R2S=0[.IGDW!/TZQ?A"<1;\O^KO]G1D"1 E"?; 439V97K
MVI6 EG_5-#F+JV@4+? XVE"@3BL;5["Q;QK1Q2/P->>"$CBF,4(G5=N@B4J5
MH\;"Q,HM%3Y,_)+ M1U.5$EI6KNU\J[(\J2BE!4S^T?1"-:%) 1]6QB%$F#R
M5P,GVI?VHR\Y3]1]3L83QQRK*_G$"R_OKPU8\ @>U.[@N[&#CT8]3L3WU _/
M/+9$A\*%KI424LWR8VY+=;/<K 1O<F;SMF#9D82N/UD*2-&C,6E&5+SL\PI)
MCK!(:\9[#(Y*JOYG.9&".4F$(X2J%DX(L=@WWJV-&UH;/R--N%J/CJI<Y%_/
M_('J'81ZG7C+2!"YM  TF,B*AJM9DD5HOISYV426)&#(H[B+JM1S80X$<4(0
MCUX")GL$[%[5*[J-/2MF]&ELOVA2S&0WZ*)'H7ZD:4T+GGY&GH_O'"D?W8($
M8FB#'+N5(.PG><6=@]Y!\ELLUD*R('F=B(#L5O%-K>(/)^00<]/HCY62V<_R
M1O&KS&M*!RSQBJ1KXT=_!'WYBCLY7D<NT(S@ [PXB4V5DGS*S.\6ZD$3TFPW
MK3<&"<K\?8Z@/Q$4:6P%O>F6C*.C,B_<)VUNF*S91 @&8 %GBX]#VOK4C=RN
M1FWI#Z+9Z!SF;.+F%8OD^'-L-\$WQCQ%Y39N5M3NFW^ZE248"#,=I]; (KPW
M?9RS\$TH[FD;*=MHQ+]SOWE7M*F!!O)^:3T+Y 94 5;&7D-R3YHFXCYS*6C>
MEC,23M"B=*0XGE70\0';.U_HSU 5]-MN] :T)EM6R.GSTR8 5,;T+;.UTJ\*
MM\Q+?]AG)=KE$O00F?\F6[C0AC36@IK05X</X#08R^((:IK'3EIV0#\"F^*M
M#"%,BW4J=82^ -1V(([I%VD!N60EASXFYYG^1@$;/?L*@!%I[TW(M0QN%6XX
M=:B2]A*C& PZ/RC5\6X!\!6U^TNZ!?$F9T3(RWDNM"4#^8$N9>T1_):N)X]
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MJ @N G@FCW0I)?-(8RR\ARC$)]"$;)7=@WVS755V$4A$<"7482@ZD50QG+X
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M&[X&,<4M[%L(S@NC7J\K"H]!)R<JCO/SYA4$DST'VP+S@(^%>='1]^G8K2A
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MHT)^PG <^5/40YFFWK7_3A-LE#DC,DT3-/2.IR?>-*KSM+@F7\UN7>^\27V
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M6F/)=EQ\-LZI")J0F1%-IYF7D*WSO-JU["BGY]D7_-EJ&-<S"%@Q]TQ'Z1%
M$4.!/%RL1C5N:PW;W5::C%.T'S4",RX&16?CQ5%=,A0&2M5K7 CL1 =<(+W5
M??-FSORVX,I^F#'=_4"_W$=T]04">>RPAZ,ZAGW>8= "$[(F]J56ZXS>^]]3
M-DPO-G34+7]#;HBBG1$383Y_]$@=EX\RZ/LB @)H14(,D/N -\-.J ]N$CN<
MP(O(+SN(+P*'3V5BIXA(U[F=S45 2T"[K%<[*9L/K#LM[F=AV0R@N:SXLMF$
M$ C^2SPG\<4,*<PD6U1XQXZ&=VZ(P",D/1'2B+&@N@"QKY89;.8!VF[#&N-A
M%5RYD,!1,"_[<M'*!U RGO9.6"O#+Z&M21P([V*:JT$IN@-0#!"]ORU\6G$<
MH,8M%_7Y>4*GNW U.L;UD1<-*WW.FR_7$B!!!;HX&/9R ASR),%\-O5B+U)+
MT!SS4IQCC%5+X;;;ES365L_8!YR\3Y%[>P7K7M1;O@SC.-X'[Q)A^U)L&LY?
MR1!AOJ%+1>*CCP$YU/=WZ\HN1]3]4BU/9S]D=1=^7]3WR%P[YUWVCUTX2 ?^
M>F ;5G:,6/<WPH0/G$[P&>3'9V0[_8>5"3 A4V]0919<5]NVL<Y:*W</]1KP
M589*M0M!:M!@I$//]2]\(BQIUL"?]3XVQ/BKE ;HJ@^'*]4MU;]29V XV^A/
M]M ) +227H2&WALI2BVV(8";J'KOR<O0%[FXV\2*=*NV'<*I)D:ZE'F9CAOW
MK?E,%-MB/2WL'4RC=O<>;@L6GFD58\-P\*47W(BVY%?@)>LF?H"RM7-R2GQ'
M:TGP>6:'0"@RE3ZS$ H@32ONT77!1/,8=&B?#46-&A^BE'K5:#-8C3Q0OV 5
M[XKHL*/N0=HN9A114)44*X?#7K&$H=R%LQK!SLPK;21LY]R>B/Z@?!4AVMU&
MVM>TE5DS?ZORLM5$"SM9 ]R1#](5<87^R4.%_MH-V4CLMV^GHW<,+; 4B(W,
M,QFV]K#;4DV%&P_8 !N&"+Z5"?+H]AR-4 *]Q4T[$NT"/)J>^,&].-\^N;.]
M.,'CDYM!@G!H2Z_!+B_;F1+GD5U%I<5Z)6F$SKP6I!SV_>C8NX9/ZCW?%3&'
MJJ0/]K6I)^/^@$1S*)$-=C $-Q<(9NVRU%E>_8DZ".+RWXZZ4I#AMI-^+8\,
MGNJ:I3WB[A<$E$'Y2@9F0+,#=KV8W_'IVE;L-Z\172HBS#?[20HHA<6W$0$*
MYF3E7K!(>GJEW[>LB)#"^/A:ST'!";6H'Q%[(:Q(.+1 *D?!!(DGPFK!E=/9
M9):4&81P60ENHFF47Q1D>/:/[!E6^7RC?0S8<V /!!]MQ((B^=;:M,^G8*8R
M\_-*D#!(MD\I!7R,?%1+D[QE_.[GM9=H(6[_A'IZ/<";>WD-R2+(\>X+1Q%;
M#H[YBJP+=\.K'S85<%="<,ZE&\G&!7HWPJHUZ95(;& L5VMR:6K0I,!,0T!.
M9'KCFGS5U7JLH?H?G!/8)2,C&2XJR,[PJ(%(K5Y#]6AH?ZM%L!*_J-)+\W7;
M+I6234O$#)[BV;T@Q1N<2[^#(Q%I(["0+MW3V1L5>RJ.T:>!P0#F-3)2]#9,
M9A--L?$?X:#A*\XF"=%#]JNNXH.^O\1MRQ 5=?6<?O,H'5!QUS!5#WQ 'ZAU
M<L_ND)>:Y+R&%Z7" <X,5VSD=]?0[::6GTMF!M/S*C7<PR>SF)7RNU F#/]<
M2+5%>1A1(WFK<H7.>Q.G*_@E2W7>@H'@\!EN44Y&EX-/X;,-?S;EGMGK0XH9
M["M_KW5.<S*CMHF>VT)O& 8RP:P38[2[]2:.Y(9RH14.$G&JG%LA5U2^I/XH
M#C!>[KR3BQ.7=73GJ#ZUJ3IT\=HN8FDN=U)#S[F]_&K.G]6<47KS)TM!?#94
M!<>T";YCU5.Y =HS5UVY@6GX^!YR\>G@OL5[>,812\: >@T:/23T=>_C#R7*
M6!"61*A3*_(Z?MXT4O&)>7\$.=:9?!ZFL,2FBA-=%A"0K<.,5#5=JH1Y\)O"
M74V\([QRF3]V0FDPW?5J',;U"M)--,LN;XL$X Q@XUVK10!,)PI#.C 1V9H*
M#)T)[:%;&>3=D='CKE""W^G;26BD$&T8*3D<B^4(Q8]2P^J KL9&2CC[\:<X
MAQ5C7A>03A$XQ1X*"'TJQ#^HW\/A)A^@GNL)E'\NP__!SB7QE:D<N)*J/N'%
M^?90=GKG!XM(D@9 CF9LPI#+J!0I3*''S%HK' 8ZL4\M=)JZJA9D'5?=H7RM
M8MWV+@NF<WW4Y;%,^N\X,4CB9*GWGK2<\502:XX(;_,PC^X'7WWBK3&@@JL/
M[S[@XB#!S\JZ716;:BQ$NDLXP+CK&@#?_O'.)O^<F*#+"S!5;I%HE+9Q2PPM
M9M;7(*0-0P=O!V5Q=-<A=>3*Q&'NG4%74E"2W.F-WB-9#E0/&T3&&=7AO-0<
M(J:68S] 49U%-I:ME.LE[_(/8_TF?5*J+R??F_)XL*[B+%9D\L*',* 0WX ;
MD7P*X6:[3Q02WT&6VN<FYI+.M-$?TOV!K3#4MIA#T_A+3[ /2&<+>16BQ-%#
M;S%$0NC&B (F.[,F&PR-'"\:X?^BSAOW^W-LHR(+01I@$9,HCR.]IQ&NTB8*
ME[*-P0L'HS(S?>##)JE@!/?D=<IEN-!K9)J$?XG:.(]:%*V@:G4IWLY$]*J!
M/YY=GS>]'3=V]MIM"%;;VP(DN(N<.[[>P>Q!<IMD%)P#1$UL[<R0@U5N$<"R
MD*L8Z]*+#K5S)E>>HS51'G6;8UW.*R%.S*2[]VW:Y*/!"XHJD"XBIQA<.>/-
M;X;!H4893<V^O8-WS'0F)IVP^ .(W:,N&@"VR$,P_J.H"6TBFV9>+D00.*B>
M$X%2!C=(-1X\.Y@\#M$^]<:*@ >C8,$')+0OW84]>'UVXETA[1-N7.9G+EQ]
MBCIEU"/?=R->X>0RYP )VT%!94G0()&PFXH(%A,QG/@SN:5^0$%X%,33!Q3$
M@>E)]R4D5*Z_-YDTFPHUO_\4_BLF07Y.R6JT[<ZBF>-'.HEO,+_1[,SL0F"/
MJ35$0E+7T_IP=B'</SFI*X(QO*N73;4CA^&HLR7]F'CC0>X9DR!"M.<;D^!J
ME!YH@.T)F%QE!U'A4M&682,:$;!52RG/<2T_$.NEK.O)9(K/7[V1*TW#%-GC
M&N @P<)W%+[(X) 2J**ZYVH-(IL&]G88!O:Y;%^C6XN-L-+&:I.1==>$9/GX
MVPG"R.5&"*)$73+]X)Q$*2FX%BH;-!J T]F+<'=S'7]P/'%:_<\Y^G$K#\RN
MC$K2T5JP 9U[]O('KS&1FVT5<N^'DWBOH&;T3'*ZM<JF*D"+U]I_"6B 6DV_
M%49ZLF#B\$XCR36DMQ?A_""(N9DND^:S%9+OA3<\I%KAU,Y[OQ$Q :O,$4IR
M=K';MK_5)=B_<5%#@IQKUX]^?/G#8ZW$ ?4$>,^7=CQ^>'&6GMKP%4OS.PE9
M\:3+V=L79Z_/9&5(41H9MF7O\R%>VHF39::3IR AKE.@<^V0!!$BPBQHTH>L
M]1_<YJ4V?VG'B!7N'05FRB9FWY-HE2;'$/ST,;CT,)YJNW<,18X%T</5,<*L
MCQT?*1C6H_XQ)B#[(?QXW5\XK"M75N*"3X1(IKB 0A-] 0I;8D,BP6X<'[BZ
MH@!^L>A42R>M$=2LH%RK'1&T1P"B' 5G^+Z.OL?/*FPCC)-@GP.6V+3G$)H7
M[2F$A_$^=+49KW7E(":I[<68^-KV-]?[H4Z+GKTBW7Y(G*0\80FX<#^<<& N
M/C_W>2E.Z^BW\AGN"A?=^C%9;S]V)0QAGXY#-?D185^RQ_L'"FD#-:B"M:J)
MEY=:%+4&S'+&?).D!7;A<H/?#NM*5T)Y?@ZYD<%*K/&=\O%BM^N9S'OF-K[A
MSG7;PY$-[.IS9H*(LA]J&<5*,P3!E"?L4%_/?U+4O=X3=(@ IB"V7&7;S%(I
ME/;XP[EK!.TF]G"CF!25V" I4"'/G\,IOA3QG#A=@R^T09>"BGPX\K['?F,T
MR.&X !QJVT&SQ(BVP^!\G)*?78%QE;YP2B=+#Q>#4N9A6].^-!=#> -A#-^_
M.=,WPM$BL;3AY_B.JV+&"5L[P99#:3K9ZB&>_J<8WZBWD'J5_!40OH;=238C
MC&0,$46]16M"17E$F;"%F]>X- MA'-+:7F[!"38PIZ(X4R7%I3W B_C>CT/W
M(REN3PQ+<<V'P;!B)0'>[Y1*PSEU)R5QZ%#&1'\FW/O;D@@3<*42QA5;*=QB
MXGBD/S%9GY&P0^B:XSFF(EC,#SC5E?!7;B+?R(9Z7:EN"=6;/S7!W3VSK=SN
MC!Y<[ CXUJPIZSN:I(@\)<IOSMNE-!.26"AZU%+5AC^YI4L"?$G%7['J$7$U
MA#<MJ57N\QXY,QJ;_D0>R3M(Y*>PI#6=2$6Q ((.XK;T ?G8SJ//;2-$C9-P
M5LB5=W5X)C[;2+K09T9]N5Y>QK+'A%C@RI 9QB6Z.DES'L[($EU"'1NQ:LX0
M_YQCG8P&B?='.%WH]>#JLFP[H<#!3#)36!2NPJCH/VHEVXMP7[<C#3:12"5G
M_KJ2IG<+B?M9*C,=Q9NLT8-"$.DQS'-$"[^FP<).3XUD\KWQ%5_?67Q%KIU>
M5"[]_7D<\.O)M&&_LI0BB^+MQ&<P!4#UH2B4U$C>-XE3 G+2+)\$URJ_F5=2
MN#&5QOMWD8G:#:;J04X3/2-SH[B)ELD4H80HO"N1!/*B R ;XDDA[].-&Y@]
MEP5F @(74<]8<Q9=064_(JL;.6H"L(+N/!54##MAJ/%*8C!E_@*:C_5Z.=-=
MYDD50BBS%?IX 7>4BS ,N7(ZEK3!;23\0-ZETQ9G0HQ>>U/.O#J11A!T5U4G
M^@\]J.G>.^?HN9/[I,329%ZLK9^F=Z8R>>:K-M4VK D$$T(FZL]T0SQ08AQ(
M#1=5+RJX3;<7XGB!-P;6GQKJK3' QR8(X>4/V-Z7&WT-FH*TW.'*'C<X&4N#
M%J804H%$D,5<ADV]&,2!&*6TKOO"A$H1&P\E:\@?HG.PYF^WS(RJG7A^EY+D
M(?=AM8AV8+U30XEYG#BG!_MJWXO)!+0=KU;>AS/Z'KL=-2E9+<T#4IIBM]5Q
M9Y.N(ZD/T63AS[D7B/? U047"8,1,0@#R$?I<\>FIBR!,3,2F2F^:S^XERMF
M/P!&H*G#FKSBZ?Y+, +;PL>5 .$ (S2#?8XI6'T%;JM[*)9'Q?(O'XKE!Z8'
M;96V:=;QJ0P[6>R979.ZWVA9U;Z$^#-_X9TCV=A 26.D *3F42$><!34J +K
MY;YUV^.?X&19,\<]NX5^J6*OQ>NT>U>2:N+B:!Z^PXD?$-YEKYT6/5]>+8=4
MBRZWC'U?7+20G+G"2B+VU>'MR%8NSB$V5C_$'V,I$[![;;<!'M?)N"BB],$S
MY4JG/R%!M+["<T4DZ4QL^8MLD-,'0,(6J2,GV]>_GZ;8-A5R6W."O[;XG9J$
M+FNF2X(M#'E-C*'Y_EWFED&*)?2CR%XD2+QBXG3PEK N2!DJ%ZUGQB$&@$-_
M?4-$,VZ==,5D(-J\P(E/&=&KMJM(B5W.HR8'?."I>9S)>F+J&M*S/&C].OA6
MY%!,34<*_F37W[\T026-L9Y3#>Y;W, W>=7RO*NX7TJI!Q15:MP!T9U.E_/D
M49*9I<(>O.JJ_@U\"JP/@Y$C02@D<FXH<<PD4@/"6I@4'.66V<_Q[ 75QJIX
M8?W(2VVJ*\BT,*5ON<&Z9G"_7^7/4M,F9PFU[!18F4S&R/A)RIIH2[P7>69*
MZ7T'&,4=R$:X8O7^#>?2X8B55MZJSM>.IRZ4[?[(%98NU3[/MQ?GTF._[3K#
MQ7Q?XV0U7<-HF.%^%>N8NL/BVO12'I",=2;6JLS&)_K'\IQ1N?!C_BU\K$@7
M-/3X@+L)+B"B39N!ROS"+RL^=!Z'74Y&]SD<O@4V8^%V@F$1W('YH2$$JHDA
MJ'([3#98T@U*A#>,#F N2XN9],MTP$::%^'-G900]O)T60GNRLKB$KHS&'_H
MH-S>2=G)W[%QUEJP40A&0?A9TJU&96$>>GXC<H79PJKI)G#[4>X7]_Q$QBVY
M:^AVGUI633)Q/@F+W<UZM\_DVEV@@1N7FYR[$2+3JEH;,^U,0^8H6<;W=3HH
MG)\RRNN;#70_<U51T6J!RIO7?[Y1U7);;M@JX78=UU7<=55@3=/9$NSDKSJL
MTBX5FBPQ(JX<DYUR%Q\#,F+7RMP'^#IU=0Y'I)G^[1MJ(PN1$"X28:_P'F+7
M.]9Y7&K/@SKY>^-FXE8XRQ4ER8C9$\VS?U#.YV:84I(_4\ID)YP@?JT5)=.*
M/&3^7-U+8$?PSDM+\.&AD!V/>9^)GRCT.9;&(U\\\F>P!]AG1L-_[LFJ LT,
M\CE*1C6!Y0T)[6/ISB_ :0 /Q8SA/AE*.Q1'..O*NJ=&WJ9M  5IM9TI#9%.
ML0:95&[D->T<W/5(SK)@:@:E#,!H,PSYDFJ(<:.5HIPVFXI?23I>3(/&](><
M!@.0/P&"@ANS+UW+%[6>G<[>&!\&0WZ1W@I6F4F>&J#Q)#K(3'8K! ]K*&U0
MXU^D+V=(F/2ZQX2BQUJU7GO:<YH0[M)$+I&3?'5DCAW# ;^%.2#$_Q%Y)Y:$
M!9JIDF)_6E &71U_K22&8C\MRMMQ\_@&7JXC^I!XRT4^*&TT3($ ^'D7UG[H
M\*+VAR=EO%)J5D>J'#/LLC>"*P! G(9 P6E#.)^N><8UDVK5GFYO?F=A.[-Y
MH[JH;2NV,##J#ND?2/PZ387N.T$(&<GQI_C*2+DLM\*%%P:SW#7AUECTU^AM
MN@$0QQE.MYJOZ*QAU1L ?7W/;"LAE!@)I>OWJG3?,L*()PL>]?S5JY>&I&^7
MU3IAU;&HYK)<C]7)'&$8XK^Y$KN34W,2&S4+G26$ZX(X9QH4?:&CR^AI2!0#
M!VYAPF"(D6:TG0&**60!=.]"227X[]HNDX.%YR_@Z,YQQ,GW+I_W/><Z, 0
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M$<LQ;I&0T8O)]E&6DTUPM.F)VR#DZYAPK=[I*?*WI3%ZHG"=E,#;"/@$MP
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MX'N/@9"\ K4X;6OZCY1Q<I*&>%BNFUHN;,92$=>'>;ZI>0:78;VN@-(40=8
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MU(G&LA<F>X+8EN(9WO- #M9E[\);;#3(6"%CZ*.SUR]!1)R:'-"_<IS887N
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M%>@AP)^!_\M*%1$A%F0B<0)7?E5.Y/:!'K7PD2++1&7*+S1N\NLI"^PTI)V
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MKRH(OVEKI*5"8HZ>!+P?11LPX5).;NUK:<\D.;,EM#NL+?7E:%KO8TP:@6U
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MDPH-Q[VSVM08AW8;&,+$*9TE M'BU S4F>G\E%8#-,2C&5KX;3.0;"+[VIA
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MN<;2)U+PO 'VX+)JF_I(?A$S&,+ X+81>CE]%E(8PH!+3L7JK3*G0'O]<\+
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M)UM7;O*B=6?XEA.ODYB0%653AR\0]FDG6/VZQ\3!UJ;U/K:[WXO+*!-B#TP
M"$-::05:9:5IG1?J+D27S3%I(K%IG=SQ>,^YAN -F!4W&"^%?Z0T$*M0=#N'
MY@',4U,YM:2M6%=KD@SJ)GS<C5Q?P4Z(1P*,W_XYCPI,,P1O3&**@NGX#)V5
MUF3$AF1+XZ)ZCV)H0UO3IP.[2ABN6.(2V#6(-:-!9W:ROF:93)C6)*=3A_&X
MS;J":U<EU)'U1>'^Q,HS70NJ.[D[UCXOFD!*5E.')J;K =C) C?%@;8Y]L*
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MH;!\J5 N\$_.U]@J>S3\F\]A(6#X##S/>!X[)US/ISLA%/_+BW1RDTS4"E*
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MY'0M=$,?RCV)F!O;80>!UQ3:FAMJT-;^A0');6HCOPZ\4-<)S EQE5E'@;%
M#">'A^G%8"/)G)\B;_T>.RE0U;[]_.F-SJ.%@LMIVE00J1;M?LJ8EAK&@A/<
M$>78R)2K%&?8&5B2QQVD<!13B[FCZW1@7>>N[,KA3"HLUT!T4&:!,3/GSM+=
MG?W#T0XX^P<;._O_0*<Q )<?>Q:70 MOM5W A1QN)[GN&%KP7OJ( #COPL"9
M)?Z'NC1,N #.7MB6"3$+6\)>P;UQ'U J"E'"AK$]Y:"?Z+,MZRE_374=V/$"
M*O>^Q[9R)*@W_IG#1A\>ZSE%JSM/DPG-O2UZ(%WA)6<=@BXJB/B&/7RT WOX
M<.,]_![SF9\9>^=-4L8IH4+LW$X&^7!ZF_IZ3\_X//PN]9Z'IUM9[WG^\-.\
MI)KHXM-OP;MW=U8P1]N+KF\5S-'F"H:[TC0L[R=U29'-K")8WI/SDA) </Z]
M)3K6$+[!O1&?G6SK^Z@RL;5W6*-1!!\UW2W:?WQM\-FRR^Z8_OK0R ^BY0VS
M-.$P)TX</NA_\^(+SPM8]U*\8 V)<C$;YVGPYE\73%6)NERJ^&+5E83$6_\M
MRFJP>\6X&8;!:']T$-R 6_*GT]'@X SC=YS'' 07,5@\$S'M7S.$?T&?A=)+
MS&O+!!Q4<X0P Z BJ+Z'5JKS>4(O TX5_.<X/#L]<8EE$$6+*W=:652F'I\F
MEU@9.<D5TX_K4A*VOFS/L=O%,P;S?\IXR*:FC3IQ)&>+_LF52B?. ,9(B9E_
MD6;HI)#:OQ@\/T+6B<18VD798[KG5(,Z&;2@&P9W&YZ='7*"1H>Y<)ZQ\Y08
MP@BC+Y&.3T*)5$)Q["QC2_I .$$N+W.247HN!9'D]@8('-WC4F?5&T\0*(""
M2U9TX:5M\"X[ZH$)T<+<P6X?H6V>KD5%,P!=H[;-9/^'X8KF]EMF_S:%WX]K
MQ/-$XTD2G RV;>;>FT2I.97>6$@PG,V+3$(C(""_&(?CM=?P_,GV1W\P_=&/
M.^L:*P.V*W/8K.4]W4F##0^X@6M+EI2/R4]JKNV$'=/*O[G=[P'WM97U# 8+
M-RD-=H=C!+44[(0YS>"$':W5/G],+RN/TFY/ =MV3_>'_Z1_.$=LG#1:_)1D
M-'2ZZ%SN);X2FOG7&*>+HU0,=)I;_E@\@+.3P='P$)V JH#_3?2#Q3\8D'_P
MYVK2_NQ@?W!T<+CTX_W!<.EGJVX[' V.#@_N=-O5GQT=GCWSP9X,S@Z7?[QE
M@ST=')^M-[-_)LEEZ87]@?OL?UX<O+ N,J7,?AK-OP9#WU_%QM?F%N'=\;V5
MSLEM?AXYXA\I5V]4A;QXQSN-H_C+99'#F;XG0YO2_YVO>%EVSK?I=7_+T3YB
MGX "#]BR3^8__::5ZW>9D'V<CA=WNX<H85&K<)^ CN] 3]!.3?J%E"J05\KS
MC*Z#<3/[R;XG"0^,= =&LM$I)Y!_K($B%XR >9BB9R*N%U5Y<[-;OSC?<R?8
M(IU@@G95P45+OBJR/64+Q4AT9O&L[[IZH6XYH&12T0)</J-+5VTTW.Q&.[$T
M+WD]I+^,UX$227E=1D2QS9TL5FT10<"KC::])>1QK-3J,_3A#(;;O12:* GG
M!<-@#_''XJM 8GJCI:IBM-D,[ <=\T#-=ULU$:-PN'_(4<WFFV^XWO2^^^N_
M[49ZM/'(YJ[^YH79.@']T[>LQ@:K\!CO-ASN#\[V=U[H>LVP XO4:X9=T@P@
M<T?[X?%H^'ARM['U<WL$8>M$Z *<V)1LG[_5F0H.]K_!].EX_1U1< ?AZ?'9
MAH+6O=CWJN#6=4.?YB*='0V.COM%VNY%>AH[Z9L79NOT_/JF0M<K;K?,#<.3
MT_WP]'134^$[RMVS")34*4=)/JMYI2@>^TWFPD[[0Z/1SOM#3WR13D\&PSZR
ML.6+]#1V4A]9V"USX>CL.-P_/>HC"_<YS1_B*D<; 2V&-RH6@^%;4BN[ZQ51
M2>;H?.?]HGZ9^F7JEZF/,CS/*,/=S(;MBS*P*)UMN2Q1X=>W!!;\2JL#>.])
M7F-AN![[VL4^.Z(73\/]LSL:M=]OKK;<%;MGH=BZ7;2Q(_<=)VB[=\O9R>#@
MX)GOEEZ=]NIT/0&YZSW(9/DS]5;M3-_:6T/FDV<V=#'D7,<^L^PP%8-IRT9(
M;^Q3G0E#W[Q(-'BVT^.FF1K^HZD?#&:=M#4:L'&$$6?B"_B!8+Q6WPNKW_\T
M&NPSC3C"[2YYB1-ZB:'[$A9^SQG"CZ4%W/*?-%XTGJ31]N5;S!-$X.:VMX\)
MUQ'"$M\4_Q4D+4)!8SQ?H?F!J;MFT,=,7>95PBR3#ON'BV?:18BM804-]8*:
MM&?/OR'L17QH<MW\H%)4H$[-Y/#KIQK6:K@_/MH;VH)U7# 'WM_R_A:*.L/Q
M]O"6--YZGIO7=0#'+%(QH?I.=.?MKO7A7W!SL1H7%B%A--(("09?$H0 FSI0
M9H<#\*JT+#D;P@&7DB;ZI:)/A @.(F1CJ<M!<&&QYQ .;O5.,A@,/%9$D9PG
MP@B!_<;T'KS3762YUEV=%GY78N_:K7]W4);#'0!E.=X8E.630G!JI[.MQTEZ
M\9>CH^^"DW1TLI4X28\NI2=W@ ZZ-U2&NVN$X_W;-<(VXR+\DA?(FK27YOD7
M5*D6]6'[CLL-7XW @"ZRK 89^"14CUD +SP#LV/O[^Y!0F?9/<I7J '"2V>"
MN96/V1V6+8(&8"8R2A5E#MO55$V(9:DT*%=((RATHYJRNF 2S6S"EB1QP8*O
MHS$M55!&4[0DBC$2D,'_7BP?RPOFWIG8BS^R>>D ;07_@'\N^8#_I!#I,KB(
MJ9]T>'9VI#E\5KPOD^P(9%,7"FP8O(G^!3+P8TG8O4@71RC9@FQBN$BG=84H
M4 E8X'%EB-CBO ##YCHIZC)X^?K#O]Z]V1N>O7)%P1E+-":J!B3[C%("MRVO
ME&)VU%2#ZX2"X(T,9L+X*+^@I5LJ9(LD4J0:H>+'S JD"8725&GK6,PUX>\K
M+&E\C3B&>&T%YT4ULYC?\*=9\E7>6.QU351.7:#(60I2=TE4V;;K5Y##-=@1
M8H3 -U&2#8$VNS3ND$)-J$V?\JR&'C6%R+]">HHH)G( /<'!-5R,+ #.2UBT
MIFC.K\=0-,@>2Z1?] @-=V98+B[3'!9#XRGC=<3'T?8#&)\*A1V]27LW7"TS
M S0$395"F&0W"KZ-V&1"Q6>$@7&4-7N@2%?N['"+G!-["@$V#4%,4Y<H2XFA
M6DEB@=I"(PK^?(GCS0P%K[,T\VA!?RYXI,ZB"\0R;W#J&-:T>H3$IIF)X0]?
MDDFF%O1WNKU!7KY KD42E)?O+UZ1-Q:HK #QM&S B)6?,3H7P\DXYKFT&:-S
MT$!==<%60[./H\S]%@@*?*D"KR&&%YVR8*W4BHS=;7Q5S='F>(DMZ%?]G9L<
M*0)?\/R%+X(7K![Q)V3LPG])!>$/. _X+[)&$FJUPM\$]QM^I&Y@& "V:L,-
M01TQ+UE3ZR*V6)5,%RO?Z%;-B'?EA<4@A-:!VJ/S!(*. /-UL+<Q D"(VQ9[
MV+J'D=&.$\'/=A%RY5&L+) C#1VZ(!^G6LTCAIK&"JCG?(N"P,&)8''56R,9
MN6*.&QBT,!\3_R*!&8(()T5<STK2.O!MC-TX[Q#J;4B<<PP$K^E+34MVQ&QR
M+O4RG%YP4B* 886V@7\3(<>F,YP/(Z234X6AF(;79%Z.E:\63)@#.T,VD!PI
M#2--,LI\<<AYACXOOAQA[7W)F)D&&_GYYR(IOY3R%P&S8[ YEI4E'Z\Z/-?"
M?4*C3N*/>YB#^>GPJ&'F[0U/M\C.0VMM=&SBRMLP*'_^AH=L\B\YX7COF;,2
MAC]1LR0.S=Z>17&1:P8!H8+&TP[T$Y&I^T>>/B&O>8?-B-]T*L256C45^LP@
M$$?ZB/\",MMM=1%ZYNH1-X_7T#U;YU=@.<-1EA'"2$8A0+%M\$=-$Q1Z9RJ>
M,=JT67:^%M;@MI>>TPCM<=JP%BE:*J>9'CU?HG]#U?H]C1%-"ZH/<%!CJ6,T
MH3K !\'$JPH1%#2%^/E:EMBW6%[GEG@8CK!HPMH;#,%+@JV7Q2:3V;63&QJ;
M;&]0=>8BBK.#E9-DI7>/\V6&WM2;?RU+VG2F,6=YMB=\N\CFG-]45UK/IOD-
M"FO31#XW,P$+ZJ]B? 6N #Q(K*()'!IHR[Q\_?<WKUP^,&W]:,(=YR.'"TQ<
M-#@Q(\W S:0=>C.<TX$QSRM%ZKY+6[6S09,Q_K_SQ].MP39IU1=_R=0E9Q9\
M>]ZQD]$C$FQIZ_%X-K_C '>Y/IR+.-<2JMR<CI:E/:T]T4F#[S8@9<$)0_Z0
M:8VV HPT)9. /;HRNB;_SS'[SUD/+M#J00JQ*[ Q%-&]H^B!7!;U7)0:;?-4
M7;.Y+\HU /,E(W(UP5GFM!F-C?YT!3.HB&X.-0MI?+3UQ1MQ-G6WYK?O3[38
M..]X/:9ZP/]71.1"J%$PHZ" -?7E$E7(QBF-*8"=CK]IXK@8%IQ\ +Q+GF4J
M#0/O]"(.;J1'I'0"J1QFY$87@N1$T:OK,X_4/+W+,EMIP@$>% <%*H1/4*;*
M)'1AU7GR&26EHPX1NAZXR/"&JGDNQ.[;B\0:5CQ\)9DT.K(#B@?[3T$K$7P(
M6/_>?'MD\PUF$;<R;')-!&X-";/33>KR2B%34\S)+'1;F"N0G!ORCHE0[@;I
M5I,R%3N'F2I%6HK@LDXF?-0K]'QBUB6$<HV:K3#>?VHC;W(L(W$;_#RI8\VW
M1+I/ D*%2F;CNBB5C2M8OFSA*@V;-_#UJM&I'"Q@>A72OD2R3B3;K'SVYM&"
ME9*-:*">=2T*YEJ*<!:#]Q<V)\P[6+M?)J(':^#M)*8!,_:?O,DL(L>,V'F0
M[9LHLF9"(<D!OJO\QC\A,! @YN*$8XL+#JPY1*#E>;\7'W$OBCZ'?TART!\W
MII6[P3 BWMI2$@@06]C0Q.!2UZ6-H=H;:@[7' \*'7<79D5R^9?MX! CQVE>
M831"Q369+EP/807;"P"NJL9 O#ET^VVTS]$O,AI]Z!(_1B^BCWU<P,&/(?C"
M91:>)I7F5:W8#%VN(J,%@CB2(D3M:,Z<@F@ZK8DZR6\R#$0%%(2DR+1E@07C
M+:52(B^&?+Y*M1=>\J!A0'/:@'9)4X>'G45$#5<1W> BB<UVA#FY2L;6/L*!
MU*41:3\Q0K'!(F%4<N)[KF>HTY-2'&)K*=I3$.^8YJ70AXA#F;N!BL80O^?)
M(<0L, P;P; #9MWEO%->7$:9KFJC8ZPQ-A**4E*4UNC L9J9O68W!@XL)+E>
M8X5D-3"^2\+0#)90R.-SC1..96UU87.D$Q4GI<C0>W@-5551\%Z!*XQO^M>\
M9-Z)MS#0?*%4\%=26L'/Q+A2!1\QR!Y@5BT=!-<FW/PNBP?ZKR]?Z/N^>'5.
MD\Y1*PX=B[;-!9Y3:V+\G9:C+VIQBUJ.=X-YMGTD;<T!Y&QOHB_5(N_L@Y5[
M3<LM_&?!$IH@A965XX6Q^6GW3_)YU?02>!?$N ]%RBF^"-NS$JL"DPI[Z-T6
M"575XFTI?<\I*H,B'%'D@=A<NW7'N3M@9-6AG,A8.];62&K$9DS4KS5!Y\9M
MKG!L5-#@$]TFE9KUULNC6B^-D!88E 4E9D'"HH2#HK.\XO(/$^4WL5+GRAE5
MU3@\ZA0&TS$E;0"0'7*-EX"4R"=:[B3"6V=L-M/Q2!%HOH3C[GIO7"MK68L?
M$+IQ)C*00PP/PY=338YD@T(+8R\XX:O0*Y[5 3H:@X374@HFSE65T!"6I@',
MV)@#N@_I/*Z4+\GDK$ZR+4WEA"!'BLR<&5'<K:Q,69[R";NVD7_J(!FX(X7^
MZ$R&IA7+71VHUE4*7IPZGV,50)UQ=5?$([@]IFV<:!,<<SZ3%#CO<QI37>JZ
M@V*RA['DA0Y!Z9HS)G\')4(U99K:S54!K2>8A*8$EN%=\,#YCTWK:"[XH$9=
M(!_ RV&O""^A>/Y82$[OZTU'5[B\W]#;=&PMR<10B%,JL!376-(&D_:#%253
MS?HJ3^KH,,AGNNYFDDBUJ)PH:%!AXHE:=J9%-%,ZVQ#1X9&JKW!4+;)(*R Y
M6,0PA"M5=IT4><:B>4O6!GLJ*DD%<86BY&5TP/0\F"E%?Y%,JEM"=$XLE]?,
M^I@3(R2\(:>/SP/R8'A7HVUP62BG6E4<U)!W<\"[&7SNB?;0:)SLZ5/7ABF#
M=4]0^")[Y=BY-2\2:A:AC8F;OHZD$J?$;.DY+B88$,QOYM8/.$/CFJ@"+0*I
MOLUYUA<\:J./BSI5N@S(A W/T7GGR38)-OZ*GF-GH!@3G$[9S-6Y=0D=V^DT
M(F9D2XP6T$EC:50AE<?ZSYL<3>L18)@]CE+5:YU'U3J-2)I3Q>F%W)Q^)5-Z
M^39#:F.TD#\I[+AZ(V4(LL12R2C?3R;6@+0/$75DA4*\*S]GV5'L.599?(7F
MB=D_JG>Z'E..LCPCE920\S\&NZ34>2R3YHK*,H\3$B?26U15@G7X,96-2S?
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MNQ()0?2-/-5GNPR17T(A'@+-G4'&8H,H,+ZI?%+R7N.9I\1#'M=4\;:LWVD
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M9VL5#JPN^9"G&1W=46&BP5E409;,+/FJC2_;*NR$5$!B=*64N0;D0,QT3([
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M.L"I:@HR?W9V.CC;7_XQ; 3S67=U^L&JXG1/X2U7:>WZ12V&W[?0=BV1:MA
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M H1WG?YOC0>&VQ80?&WCO[JTQE;4P*#3ZHI,2F>*6'K-)/71N\TTDE-JN,J
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MG6!%AS_8NY3JW[4R7-5C!2M((/P7\,9I, RY=*^Z BFXO K^5F<J.-@/'=:
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MQ<,#;K9RI+NVCWY7P0U,ID'>1864SZMD!O?HH+D729KF>34'?5\9I%SY8*9
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M)51W8"8P1=I80?=O1G61[HU^(LH<H!LONKK$WQR'$W(.T,&_OB -] [)@P_
M> Q9S_<LQW52+O/C0!L5W,V&%L*/R)&OOA0>#_'Y3[YW^<OU]6=MPED8 \L"
MP7&+5AMR>'L]F\HMMDUQ@[/L64J&$1R1>U&2<#-[A0V!EN-H_2LY06]Q[.ER
M>)E.=- =+/C!N?^.4VZ>LGM^.0PX^W[)1K#9*^;.V#Q\]5.1]H'P%V"X>'QQ
MR+__;1C JRL^O)J3!@M\8Y!W_W(0HQ6OG CP8VVC58#R4'*!NK S*@VWD1&+
M)S-[QPCI;#J%Z$+D3WD /% 8Q:*-@&/-IFE2^P+XAZ'->,"U'XQ&I]O18(LN
M,AW^$7XU:!G)KQK Y>$4>?*!NW-=^PJ<;',+R"OD./<E_;CX-K8_<KP8/RZW
M@9P^8R$H9 =@":#0[ #6 @:?IPO9&F>!!R\53X"OXHX<3SP6X@<C]BA_*9HK
M:<D8C@;\"Y0K<^$3_F@4\@@_$3D3VLQ(F_G!=_RGQ:9(+9H3\<EV=D"5$)_A
MFB;O(%H=[P'@L(!O@!2A.P/Q#T8G0[3E3P!:\%LPEX@:<N@11E3R(BW%K#]C
M1XA+C3].N6<[$8IK7&<(F[2UF1.- 2\IKO"M:>"#_6Q+I*(."!F84GB)S=W1
MI<V!I #5-CXX1<,(!ZC,QHXU3B@&U,64$)K13'X9W^.)UEF[8MTQO&:V4@IH
M0&RKG^(U0?LB?G7M#M27,P+;TT/;+0XL3AJ8^->. UR=WH1UW1@M98:S; #P
M;(;/_6#DQ 3^_QA-[P???< W\1BT&GS2B8H?B\,U7P)9$3IA1-A*B \M=7X/
MUGP /X36F-NQ"P\ 5$'6^<$\(XJ4[S4T[ -)!)[CX_]8,9Y=[$8;,30Z"&@1
M)E,0(*= (8_PU0BDFO;#H)\_VU<>3+1??<#]M9"(9F_UGW^^-.@!-)&0-V!7
M 0=."<29UFR4>L=0JW<6!,R[Y_177;OQTH4:":"0VN<@'#5.WLL[;G'T7X1A
MVS(: I(S+FB%0 P8SY)#M#1;(DD<D?P"!#+QD;A]ZWO=6.3GN:1O)T10D?Q*
MR18AEK3D$83;@-WD&83=WP.-H;^8X8A-P#^,A&@B&@(/$WO]H )"K%R2?3OB
M BD^@;"M=\W.C\474'B:S58S$6-<-@A"?HIPK701^+;8($Y\Z'6:/^*_A>>Z
ML"G8\@<^#&(&Y+_,RVO8RUC'7O@)H ]!DR1=8M<E0/5R##[2P.,#=YMT<L9@
MZSB>YEYEA%Z"B\49!>#VP,C]RC'R#%4A' .7&OIHN"3$2=,=$%:+PBC9HZZ]
MVUX*&)ND0):*LV\Q4#'S_AW8?W,@>TTX:FCL =%$<\+N/1!T-*Z9L/N=:]B?
M))I/,6X$]$'A*$!O:FD1'I-S@H4$^T8##>AF#'\*4?#@(_S1$5:B7801V%Q@
MTC'QQA,/@G?M6\*WP">7'Y 6&#[@P?D7'R TP!;)G@Q6?2/Q,&@9$E'((,GQ
M:5$_CJ:P!_S;PMO:/?? <T H2?8-%YG+U#-=@,:SBR <^R[PY00>?! \G&OR
MEK@+>;-7UWXFRTO:0?BG /9C\09931NWF"$2+%3TC<!P1J4D&)P\=JD&R(*=
MBQV"U-!"D/K<!E'K!Q-!"=;8 4"%.8\/WAK!=H<H)^?D+J&YC($7._^!CR!/
M+20K"XUDU"1"6.&QT^6!ND!T8\ 5#HW+R:U&8XSP  6.P":G50$@URE&F9=1
MT 8X9 C2PG@81J#+A.\&RIGA X[GX&^D>X-H:6C#.%HX(NXXYP#CF3(B8);%
M700-JE]X<.('%!F&PU-4$HC-A^^[X"/B(\0X$8ELL4?P,>'OL"%)%? 3THAC
M<]1E3 A\J3C S<1._Q1\ H@'#XY%>FH##,BU2@P%S9\A%:QI(8R1;O$DGG &
M!.O.+^$-;@N?R ELX?X*?RW@@#)!X+F-CGC]W"&4!B("3P%!4%^(9J1J(<WQ
MM 51E(L= &2RO.DEV OH 83$&]R^JNR= $X+$6&YLI<"[8'>:O6WNA0HLZS1
MU'MM<Z=E-_^MT]KN!D-MMC*;[9:Y<EIWO_3D=?1@Z=$5]\V"M0]S#]M;$%^K
MYV3_2[_3U]9GG/[Q;W!#'A,N59F>!KLF8+[H&=?UIEB58+3^#G6K8LYJHQ6#
M3OLZ\#8YOZ<$.&,?XN!$8:.(:B]$=>BL]V/D-WU*#?O4GI\FGEX$O@+8V)Z\
M^$,/]3DUDL]KP%"]U#"ST=]U0LLI]B,X1?1V%7I/%;VMUHZM3!5R:X!<<\>J
M]A='[E[[R%;<MA"Q;+Q)$Z;%F?63+6L;J&Z8AZYK*JL!%(8.C:&R8EQAZ- 8
M*EN,ND<,[;6#4<5UZ;LT)?,YRK2^!6>[6NLU-<AKB*&VFH5:<0SM&,U0"#H4
M@H[8V&%/?NFS.[QTC];>Y1./-&N,Z:>8"^/YGLP+$HD_E.&29"?Q%4[M7K=\
MG#XP)VZJ7I1HX:[\B$/;=\K1JS:"5#2KX@@Z^@B>JC2).YX)<8?Y[Y1)[?IA
MK4T$\SDF0GT-\ M3=6ZM,':,\D-X%'8.AATU7+?"R#GXW T552# OZV[)= Z
MUV"!4<(44,[.P>596V&GNMA1K%-AY!PG#*J2Z3G6PN\MC5X6OBY,G5J?P%A'
M4C4;/;/]K$3.9T&I1B[)61'%<\LN%%&<'%&T.DU%$HHD]EG@<122*+1Z5AVS
MLW,_HV.VZE>]MW[57[CL!Q\N]X%)&_"(A!G,ETF:_&SHZH.=B)[LWH,MCJ@-
M4^DF/@W9T##IM'4=.DS[S"SLU:1]\V%%[0'V'U,+)]$XJ_YMSLTZD4TT!M>(
M^CN&\O;T)T"OO$ =I9C&3D43]LVG!EK@1<E64*%X%><8!!S'''#[!!#8JB<"
M2R(M01C=F(-L\,(1#V2OW5Q'8M$^;HM6:!M8]QR[W/>:JLO]<]M@WF$_SUP#
MT+KUM\>N;R-0C]2 5O9_"^,)=K']"_L=+G0NS9]TL7-RN+EU<M(.?ZOF;]W5
M$#JLO=L=Z$;'W*D97%,?]';K'[9I6;,'!OBN;<DV_:W;[KS,9ENJ9=G]VG8R
M?RPW&M: 77;IWO6<-CRUZ\'SK.9%.W0N6NE9;N_F5QZ>I7H:E6#&$X'0A8V*
M1?20E0V-1=MBV>";&O7Z,7S!I@[/%H?#3H&7Z>^:S2+VN@R$$_4%+B[?3)^'
M>E)M6&U8;5AM6&U8;?BL-WQ2#2/NR'PYLRX1.*5IQ]R FE[HUA!)8HA.[4O=
M:R$%KN58J"ES[.=D_:TDK<J=]H=G';':7-/K]VM?@:LHKDX49S0Z[;(M8ZJ7
M,%P/,0V;P9P)%--9<.DYRO'4V&?5$:O-/H.>WBK;U:)ZMJBBN3K1G&$8>GO'
MUL=[3U^LR1WY73P,^9\Q)I1$_IKK;9IE9SNV3#1*YX$R;Y[<$T1C .K].!TQ
M*Q; 5V&!EJ[]3@DOU Z9N6YN?&CA G[,71I5'>%(RCB8:X 9,33^J8OWN@VD
MN^-<&\6!F/WJA%8<AG)B+@VNI<N5/*3%Q&XQJ)#%T=@/G+_D?#J UR<_XIHQ
M0 QBP@+.[,7[*"J]D6._&0 ]@E^(X;(G,*/U^H$Y+J5,N,Z?L6,#=&I& ]?$
M .M83LQC#<?:D+DTZ!>'V?]@MMOIX%&D!6!,8IJ%^:2]PBSW$,@ENHQP3G$V
M!A.G;48B?2V"4^%*S U];<SLA3'M<81S-2F)E,8?]UO9'UF*!3G%] =#;VI#
M^==U@YY+S&C6M;?B5]F7Q,O1V G7?X#^9L=6DA3+<[.Y46RY/!(5:ND;^6,B
M6W+Z3 .?2-/Y,-]6)%S"Q]@&] %L-_P581WR*0L$MA#B"_@SFH,\ C?O5L"#
MI4LB^''V*;*\!*M8(/>^!/"\CG)32+O6UM*.4C)QU#M@3<X51\IS?>]>,(48
MONW1U'<GR!*M$9BU''7Z]O:WFW>7H!#@^S:?.)9HRP2V"P-JPCF^?O)+.,1W
M'DU=1J/$/3%OO) X[G@C5\S>"X3^ 2ZD['8>ACC&N $$# K:#D!->^D\:3M]
M()$,V7S=A#L0>X@V\6]BV2E(*C(W:$VT-[*QR, E.$48?@+TVAS_X8LAK<GX
MUE03:$G"*G(I@W7#V"7>3R'CHP3Q0;7>N_X0!S,O R4'#S%/&M8@#L4ASZ"1
MDR,4@"P6W;R:-@/6AA-,J2;6 T. 4O!SXZIE7C%: 6/ +8B$V$O0ATO:SFCD
M6'@F&B9,HXCK1JB_TS!>'#TM#EN@$6T4^)/\%-YLE'8(#UK">$SQG:=7>I/)
MR.^BUMA&Y8AOP8,X^#D,4SDC1W@+= +9$Q:'F%**R'"D"3V*Y=NA-08-Y,(7
M2+[(LH]4>\&I0?:DTDC(H&Q(='9>?PBNAH3"R!>OPO_RD',ZF*">/ 3P"0^0
MK!FF!L9U- ;ZO8V198%\ QS)#2</<+^K8$E4)Q"Q @?9'T (!)19BZ!(ZU'"
M>/@-3':$A)R@W4BYH9&)YP8)9/ (T+C'B?#W,0@97TH8<7# "/PFQPI#/O<E
M<&5]3 /YV^:A%3A#3J[##0A]S;C6M2].^%W[()?(@#[FC&#TZD5J#':V9E&\
MN,C_"3TD&$)PI/)A&.FZ_L(;W[C-5\LRQK'_YY4S-,V^:7:YU3&,]L 8]GM#
MH]^RNK9I])AIL/\8@^:K)R73BPNBI1PX.M07I$]D?DGF@ 'L?_S+]?5G;4*.
MZ"EDOH=I/5JP?%YF?XM#M)\DMY/:!P[EVH7KA^%K*DI9\R<6:K(\AI,V8QJ.
M*TZX'U07BM$I=8&P+)3*N 2((MC"%+=U@8!^#6X.UK*@@$/RIR72"A=A%XC\
M>'Y/4^@9EM& _&4+[]S\XZTVC$. 2!@VLE\+B8*R!],=YVD1GGC$R0\8SKU.
MS"=7CWP4_LLK2-D'$!GB6RAD)O2B$Y)G+ZJ"6)BKYI%G"$&81OP>A!X*;PT#
M4&2R(*Q)Q 53G^SYQ0+">(K@()LDY!FMPD9?)8A\E5(N2<X,04-NL3A,RA0)
ME%(+T];Q+_D7X=%1[!)]>!::)7Z#BA;1,F.NA!J^"V 2L*2M"(.K=K;SW913
M;222;2,/HAA+0K9A$M1J"#<D /[ W)C,6]2]/  03<B31X/6AV4>>)#\&Y]/
MRK&2=5 [@O)JX,^P%7?^%R<51LK,G1-G@XZPP\3\S0@7W@ '!AC& 6V=:G"B
M;?N>2_,"C0A0Y]E/>!PX+6Z!ON^%PKJ>QD")(?KB!9L-"'Q13B+14Q1!T@WL
M0T0<4 E3[ K/@9]$/T3 )RE.S4.(0$-AB8V R0D!,HP11HD!]"24Z#2TV<*1
M)*N(DW-OC/M!'P).%/RWM"12UULJ:P_W[2[3Q7".*=/2*DOL=P<LE%R]L.T3
M,R5[0.(!1@ :I!,G58 !+"%,-V(L^GUJF-6-S6XR82=D1A;FE8"+V"-YWQKY
M=O0KLCG1['.\F$"?LTNC".R_6"@(C&*SW\#PTFX\2Y?PY^%B43463 ?A?\O5
M$PM66,AP8D%SHD@;B1PW-&5$3<@A(C*UR VI@%A_'G@J8XU,P#1V8Q.2,@F?
MT][ 6;:BG+.0?9^2^<FJM!./?(FJ-@!2%9?FBTN-(CAJ45QZ1(;_ &1&*A6I
M;@0^[J*COYJO@ZSNVL, "KXCC5@*ZV;R5MZ/H/.^83T7O7D;#2DD<OJ58.^\
M8$BB?Y(10;LDCC\R%X9PR#BZR-SM7-QFY;/@WOKP.0^-+ES=2WG7\8B5A=7'
MK;$'^+B?OVYH4S<.A8^;[I3.M7&O !J+<UL^BCHP9"ZID)"[HTL[G:$&#TYY
M(&38QP4CAP19HLW1\ A#A!J%0X84,DZ#' P'G(9.%AN8<!YEP8PDX)&/7\@K
MBX+4S)D._,^8/(8GK0>,ZGF)54IF01I<+$0MMB:-+.J0FK\B9H#63>WT*]U_
M.!-RFD14:HCEF%3C13%*O/0I.@_K/ >T3=)? "EE ?:\(LI@)8O'_-BUI5U#
M 7I@V4 $:!R0\8+B$1T-M)T0G6$\#$&OQE'B2XA8_,0/(VE4DU(J..5;X:5[
MA.)J$-UZ4XCOLM75YD#O-O=?7=W1>SO6;&_^6Z>U7>>C,GOMZ_T7*01O]=MJ
MKS6A 6R]LEO9_NG0ZPOMM;/=?IY=G']:C0NTI=K\U<W<#&-#-[=MRO,#L&$6
MRU_6U9HWZU9N3K%8\F.2V.YSVAWDC[^^BL@X03A>+X6A7QR.&TES;7_"TP'Y
MVS0<3_2;C\G[WB&@O_,Z+R2HRC]Z/L227$5M01<*?NO@=XO^^.$YZPS >Y._
M[U00?@$(?\7;XOUR_Q[A7"M0OLWE=^ZW?=@6W9QJ!ZU5#9U*=6@ZB5$DMZMO
MZ%5)8:W+NQJ=;OW;6RB:JQ/-71CF<69'*FH[1VJK]1!916MUHK76$7L0*8([
M0X*[&/24=*L20DZ:V(Q64U%;E3!RRM1F-'8>MW: 7E'5ZT2JGJS^D^?4)_(M
MA7%I@A/-0ANSX'['[K'UG8S=/V*WNSUU6%1K[-!*M[X46[:_7(4)5B&HX@BJ
MRAJG22C]LM:SZK2Z6UM\CJU6D_(C4?!B^6%T;IWRC?H'/T\<0__GO_JF8;XY
M'31598W3))?ZYP4H!"D$'54E*@15&T'F$=NIJPBS>K*J$>9*.US73_2,*NOP
M%C.[6\#.MA]C:7N)L;VG=E^X3]!46P48C6YWQSE(^X!.Q><G*=XX9]ZX,,SV
M4<2IXHJ*4(#BBN=E%"N>4#QQ#CS1;BL32C&&8HQE9=%7VD(QA6**1;]"<87B
M"L45"Y&H=J=9/S-JZPF=76QE+3YXB01YU3/WW\YUL%4WU[>R;SQ\+I[@N(Z
M&G%I$S:G#JMA/*'?<3BTA5-TN&;'/)E:5&AG[X\TP@BW-2_&SG9;MXZ'H]>G
MA6I7;P[,%VA)V3?Z]6GSJ-J2U@BN:J^UVJMJH;IK"U6C8"VH%JJJA:IJH7HV
M3?%4"]5G/WH^Q%*BA:IJ3[D3<%5_U9<"K^JO^M(05OU557]5U5]5]5>M[EU
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MFVMSSH)&PG$![@F1C/MG<UK>=D8CD(:8P24E;7),7?L +(O<C2P&).)XP,-
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MB=TGR^.)>)8!^T._-2@^5X#_M78A #N=TH298?2:.OH"MN]%2W7D2+-I#!8
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M[CQT0D'*\ U<3Q1S34'F>A'*#]</Z7[+XQ$BS9]P6>R0D:TVGD\1^Z3&\:$
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M_)=^IX-(Y() ;3!I7'^*0CVG0^%1PY":W4+C)""+ ROG7%?7T-/)W)" 3_V
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M37B(+")[J  :O%2QK'@2"W]>.$"32>R!G14)B*&!DS/BLFLO_,/;L<-'  0
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M9_)R()XF>3J:QS'.AU?O<C2'0!9&:A.XZ-KU,A)SWQ%9N/B_ B%/$$3 5_.
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M"/@]"VAP.>HW$%(.&SHN!F3A>ZM63CK#@5Z<LB!MR90]&F;173KFH]SS- Y
MLF%[7X]:#P4V;8 Z!?]+O].U>^[Q@+GN'/_,I]0+-\N]GXHN7ZYLZS4;.]8X
M::"$RAF6UJ8^&#B.? *.#8H[#NBOH,@O'&G53&4?/@"-:$.,8*7.<7B0 &U#
M6[S3P+WFP&9S>-%MX+9B[*V%6X4OC9@3N/-D>CDM&N4Z^=$SZ.%*N1XF+:P
M"SQ*?\)\->;-W\!&TYUNPAP=JOB=@,OMBQX"'E@N80@:EJB !Q,GV@IMST50
M0Q()PZY3%G>FLB<Q?\0J"R>* [YX:MK[D.,Z$R!\,*'@*ROVP6+ =.#\Q5)
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MPX-IHP1W#6W&A=@"LI>-#862>@Z+$$>D'+DQH[%N(/ZZ$BXE6C8VM*1#8 ,
M'R:$B\8C$"QJ!A'^2*(2ST)$0]I<<CG1931M7[D<!E$N<A[7'R[WY".WJN4C
M2Y28S0HYFSM7]FXE/8XE+(2W<I?U>A5&]<\^6*HD$Q/+=^D<1S+OV&]@(6#A
MC;YMY[+*1,!OI^"&H^9+9.:3]_=5)IW?I5IFV!N4"_<=-0DI J1^*W^^H2PA
M"$4) 5)6ADDBN3 >AH[ML !=[8N<4GF]H)ZU1#.GB?F-),Q GRI\-RQDA3E4
MK]4@6SBKXDI^RREG3/B9%N;-CEQ_)N,-#'24M,9$+IDTD:-QP/G_9^];F]HX
MTK;_BHK:JB>IFG;Z?'#VI8H8DH>M (F-[<5?4GT$V4+BD80-_O5O]XS$:80-
MUDB,1&]M;(RD49^NJ^_S#=*ODB[<';@[06:=Z_BRJ8UC.LY^&<A1JOIUO:MS
MPP78 9WONO\Z/R6W=R7.]"ZK!;FU$+-TNY]?Q.4O!;%!=30?^+FDOX[2("L;
M16G0B!K\M5J9K%)Q+*/BCEIYC\+Z@ V^7KS1>6^RF>FOJ=)4+63ZU0)VKNI"
ME5P_R83U>--%:XI%WHMDW1L-;L&YF&4G*9U5X[C09;^HR:).KKWI5MZX_@ZN
MU.?J.OGI;;][%:DY^KGS4UF[^.=B3E'^GL-37.NY]^FX[59H.^5:H%\[WU!I
MUTBCK3">R&BB"TPN1F^&Y\G:. G1)<G@%UE@5*DDY_W_*\FPFW;Z]OTZT^#R
MXT:5)\?P(X]35+6[%05.Y(XGG\#WU-;10ZZ>9-*=7 25X^/*KS!K>Z_MN%7O
M@CN?ZI:!E),#E8[3[2/TH %=L4PZNB5[CEYT$J4.DZ7UGJX(-Y3P*V:M*KDG
M$%0F]UL=Z6YJ\.4G)E?LU-\PI=][6+N\KH)WZ;I*/3I2H[<D9_7TE]'5W:K/
MSN)82Z/U\'SJ$HDC/>_=!N^;Z\^G=^Q<V!/=/_8WK5/31Y9S>GKH?._ZN[8%
M7V_BPR_ <HZ=P])9=/WJ9 ,K8]47WSGKZ?[-)HK5DJ>O*KMOF-)[---OH,W@
M/#[BQ)=M"Q\FH:4C%(85&5^)96EWIF\IKA[HSGV)@N$P<D7\?QC&455PN5J)
MB4EF,O1*NKEVA U*3\.HBF89=D>?1O=^[731OCN#[XRON+F4=\=3^8@2TEV%
MC[0SY;A>=-ZD+I<WWGPU-W\1#U>_-$FE ]Q)IJX$[FX<BD].G;IC4Y]6LO?$
M%9=:1DZ>^; YWEKD4@2['LW$,CK]IIDNR_/J$G1E!%'9RR8N<!QV-RW]J/)Y
MQ=OYF@2+)"Q]\:F[S^CN5Z2++PGQ$]G^EBOB 3-YGSQMO:[_/#GQ-X T=8KI
MF\?;7%U/-_2/IV>*1UZRKQ(/)O]2V2&CLY<LI#-L):WBN\.)UZ<<=T5 I]6X
MRXZ\Y_W4$RG)=3ZEC28BF;X<=?-1>84-!Q5]Q7M@F$ ]4:"JASWTS$R9<>AO
M?^]@>/?RN_7RY,*KOLM>"9U3Y_#+SD_HYXF.73+35$&N7*97&"V_?#*YBJ8F
M#WX MR:?+_XY@O7SH/=Y<FF4UW&W5 ;C=1A5\?YQR26C<_.Q$D-+KVWEA;OH
M?#QWQQ/DE/MQ-<,)ZN[9(#>(0^\/XLA[X[*%;2==^DF0OH&B*]?>]SEVK#_Y
M?B(#'>EVD/K,E&$0E?02OZ=(_'%C<!.NN&=TY8DI)GA/[QU580%^.K+13:_C
MC <D-NC?)+SZM@TF#H/XILO)-C_80U-KX]P:'BGE,Q=WYS*QXEE<Z02K4=5E
MKE-&"YQ781C'_=*"TL(I?W."6Z-R&\]+O2T>VRJ+"546G@=#[[8'?[(<*4+B
M7P@63+ H:O1Z"0'Q&QZVI#<31.\S )40'5:8.(]20!GH4XF_H]$@#G$\%>,G
M=V\Z^@_Z^JGWZ]J0E  9WU7>Q1-[55R<>/(3T[SH;(TF>LGU+5\I"W&U$A$E
MY36%DT3<#E*O]-+>]KEBQWZ47:I_N(_GH_&UG'AC':>2RRU>;R.^OB?1)WEM
M7)D%*FWQ"CG3^^E&D%.2J:R_=;925)$=EXL_,:Q6+%G9'\NV\G$Q1Y41MA1R
M;K1&'T2=[WBB,TVMO?%!#SN1Y=?,Y,?(KU9'F2]^W_3N&5T=N9(W2[FWO#I'
M5S>-KGIW7=TXU87SR5^6&L;IV0WK:?_L?#R1*I/ /3EB]ZS6]14[Z!\/RF7H
M3S46.YBTFZ\TPXA;UPW!#ZMWQ:E$(7-\K526MI?X\*O/%64P5!+LKR[$&\II
M_/X4X5U)OC[I;NE?UY^U@T&2T:\^:LK6Y>-)!-GG^.92CIZL?QQB^NXXN#A?
M&X7W> !L">$][^(WE@#IGIKSX6@JZ[ZJ9C6EK>^MY014DQG</(.G4<,9N(B*
MXR2E7T[#LVZ)\[<BM.[:-VK+5!J^)AN7?>6W?>7X?E]Y*[S>;:/1Q!,ADM_@
M2VEFGQC>INB[H4,GZT9%?Q5SQ/$/*W- Y+F95%;JBQ,%=$+1-T+ADNH]^>W$
MP1._OV;.G5S$-1/N:'(-SH#+H\6L:I:C43'1S"=^S>IK;E#[ _#],%J]]G3=
MSRHS%N_N1+]!2=]G]@7<@Q,U(FH#Z7UW1Q<?'D]*O*3*<S)U9*8NPA=) DF6
MERCY18FD,KI%:><\_5A:@/1EO-OBGU6L[K5DDZZ07@3NE'WOKI!)DN(D\OS&
M-T[V^Z;I<S"LQM[KEI.:Z"I1%HLH39])<EL9I59-,.[(0X_9K>-3WX=K&>^V
MA!9?'4R=EI7US8Y3A%3I^;R>RZT#>I]X4NU>][X'Q\E=?O4S%W :T?\DYZG"
M@(LKV8L,487P3@<1G_%PG)=1[=<>K'*,#]()6B@3/U+GW+D.OHQ+UHO:0:\Z
M_CX-N :!TT?9MEISB<U2/#N(_Z#*65U'DW232%K')V6*1KE(Y?-=Y)^):-I-
MYSIU7"PQ$L7.[N"\\KB<=RM^BI-S\0?;T]W3^'<4W*/^=]J9O'Z<KK%^&D0<
M4)3WTP&?PK;T$E76U9^N;J:B5$*3KZ#7/>V.)^'L=SZ93"RE65U?D41"WI59
MKXRJN.;M./*1[P4P\<F.SDNO4YSJY^Z@=WUX])>?*_=M^>C:6:ITCIMZ>_*0
M:&N'D;<J*_#T-G_H.9QN8,H$*K,THFH>].?!L%01XB*4E9F[I?79I-]=WZR5
MV7YZ1_<&HQ0TTD^&QBO[].45G:R#]NM_".G?T$1?=+8KITQZ^B1W>;J<#WQZ
M,<%/A,'QQ$]U92HMHVSTE0NMQ.T=;\4TF^%;OOVSP=EY[]'3OGNQWZ='?V^$
MM=&4Y_#*6ST]H97G;.*<*0=44<D-H^?*G<#U4QP>C)F)_#A)P;G*)/S^-\S4
MY&>=\A\[U;<\?]\?S1R'-6W09!_\1;*IQ"UX\/*9=#OH2LV:[-*787+PI B\
MX<2G._'$6M]-SI?RUHH#'"478[IN*\/LU63O>]XD%,1?^2?+$WCG0>5LTA/B
M%*H17GUOE1,8;XHK;]C=1;Q*4JVTK\D_JK5(WHUXL58VNWA"XF$W*7;UD;=@
M.;XK/U0$4@IIM>F#P9>1&.EZ+4W3$_=4J4.,/D7EIWKDI_[@2\^[8Y_\/\F"
M-[G>9\WGAA(458UT<Q[/T(*J,S)Y1','^+[SEHX,2KZX1,1IGV\ /.F9?IJL
M-W733S,Y2\_#SS=9^W9UC\DVCT^&@_/C6R$#U]NES>#SU/4X>5L9[Y,B0C_K
M;J^416X^M@KEN+&X116S&O_AQ^EZ&5V+*5-A\G[ZO\7WA%_Q_2RC4]N\T+^,
M?KG*,_K>2"=6Q_+)K1C\-/8]:9155O1,#7DB,8RZ"3(X#NE%IR5I%&]\1%62
MB=_KLE3 ^&$>1?)D*SX- ZUR\Z:QH-G ?<O ?;=XU \F@_&<#):3P6XD@Z5?
MYH2PQ2:$/:+->YN/T-VDL&\E>?W/G2ROG/'QS#(^9F>?3:V$T\)%TURDV?EE
MUSG\2S@^[3H]=<YX9L>G]53X]%EUW\G!?5P.YLWDU9QD^^ DVX83VP8/R4IZ
M>FRL?;;:-W+-9A7FNUF'[X<NK7YIWRO-1==FV'N+2SVB ,OM@BMWDOBOJPW^
MS^A&)=H'BZL_DG8W1RYP/1DOY^*M?BY>6U/Q?@3'R6MX+=K>*]G>2 U[7(W.
M*S17TYB4_2RK:Y4+,C&1/X(?*K:Y*N;9'7V:),]<C_J+UY]*YBD]/E,;MA]=
M,=<=WVB][-TL/UUMC+<*UUWY&=*(;B[7[42Z&RF"HY3Z5T4HW+#FEZZB\D;M
MNI($K@M<3J/ANT-[?II6S_IO9;I-'4FC=<QTVTXI!MTKZ>C/JPB3464%6POS
MQ5;'_O#54X7[3,('5ZQ2[H,+F73F6J''U-5%/W=:6E+77I74Q3]_>W.76DQW
M$75T[:+KZ%ZM99E32;ZSG@LOH'OW;"^S@.[R*0_AI'A-<HHF!96Z_93JUK\9
M0E@&OS\4XRF+)>6G3C:H7.=R6VY5 4A$$F_I,E7TXS1:.27YI CA6\%JMX6"
M"))P7G7*F 0IIY,YB1N;\L2UA'(5YY)&97P5$=B_*H%NKJ<^R5.:5'JJ(AI&
MY2FYJC5Z':=V(P[B2A2](K/!+>$B?7$9V=--K6%F9.2LI\,^C30]]HF&FKW;
MZ^C=ILUXMU5+O-MM<64_I/]'6\;ZZF#_S<&?N]M;ASO;G3>'\:_4_.--Y^#W
M-/Z#O9W6S^ GE[H33ASKHQ-]52YF<#ZJL@'\19+>T@57O9[,Q?KGEGC;[S2<
M_0:9LI),E]ZH43+R(XT:F7J!,6Z^42-ZP8GXH<=^^S5&\F YO?_E9EI@5DQQ
M;S?$1@$HFFCXC%C;IU5CQ7):1[,S[6[-<S6W<?9\']RW>T*9I3P=+X72Z=>9
M#F^EIIS<LTU-^%87\V>P<"@OW(\M''P,@TRED+)YZS?7:)7?F1?A^XM@M/UT
M/!R<]QV8G%5KO0_A6^?_FWV3ERRJE\=_^SOI[Z.[I/*]R3^8&6!G%=;G7XN;
M_Z]WFV.W:N+_[EXD,/P^G!1I..]WQZ]3I^KSD=LH;:9Q].4OXFEA7#DOB)66
M"D$-<Q B:R A0JB@_]E.USI$$('T \($;72<M]U3W1O]OPT0(=77IPF$G_7+
MU]6Y^WTX."V]A/'KWW?')Z_.1W$M_'!WFL:^-7'L'NJ+?3\^"'\EET"*9/A]
M,'S;GT9@115Q&I:UT:D2K.* +\8O^^>GP W*=MQI&!'4<=U]">_21.3(NTNS
M/?C\)W[]^8CLG;N/.Y\__*$^'ISN7NY]/([_?>@=?7U[L7?X-]M[OTOW\>[%
MP?;^Q_W3OR_W#MW)WL??3_XD^_$]9]V]C[LT_H<_O-]#>X<[\.#P]^[!MNON
M'1Y_/?KZX=/>QQUR=+A[<?1.7NX??OK\H?^?DP]?!U_V\;O3_:_['P_>[]$/
MV[MP[_3WDX/M/7+PQQ'Y\-'UC@[WX-['^)Y7"AZ]_\_HP^$ [QWV3H^^?D('
M[U^?QL_!O4-[>?!^E^V?[L?O.T)'> =^.-SO[4T_\]__G)A3USOX>'1Q\/[#
MQX/#M^S#'T?LZ.O?%_M?=]G1QT_X*,YM_^.[CT>'KWM[^.V7_W[]>[SW!E[\
M>;@SWM_>N]S[>G3QCXK[+20W0"EJ 77$ J6A 4XC8KP3U >]L8E0@00O**?_
M_N7V ;M'VFT,;NG51\+N6_+/][C_K@R5:3/3YAW:Q &+8"#"P4/JK9**$0@I
M]D(*YYPO:1--:1-EVEP'VKR\0YN&..@DY2#>FQ)0I!F06FB G#7<8*E\L"5M
M8D0*AEBFS4R;SYLV/;,<20DM])Y2&(PPA*#@7.1*8;$K:1-.:1-FVEP#VMR_
M*VTR*'$("@/CXA]4*@,,D0X@ CFS3A@/>4F;$/,",[0JM/EHDT,H_[=2)H>#
M,K;V/OO"U:SQXV8]D^!7FN@:4ZO/1^!8Z[.7Y<+OEAE6F9Z:HZ>W=6488N?B
M]@G D1" >D> Y"B ).?C8(F$.&QL4D(*2N"\W#2; A8JM=WYRGL=!L\>PXWI
M>!G#B\;P7<V,><J(8A8P;1F@@4-@F%( :RND528*G"1B&+("2YPQO+X8;DSA
MR!A>,(9K:H)67@1G-/#,>Q#QK(&R@8. 6(K]Y-CJ> \S3 O"2(LPW)#GL?QN
MS*H@U#:K!(>#<9D?,(=*T(A!:*5YJG%]86(<R;:,!DGJJ*XLA  %U-@!09T!
MU%D*%#$2>"6QA!P31T1IR^!0%5(]-\]91O_3:!H9_0M!_UTU@PO!N*<6X( L
MH!9Q8*2P@)L@XFX9R)"JT(]D(93(Z,_H7X*.DM&_"/37%!2CO3&&!V"##H 2
M98#$FH%(Y9@0SJ(@9TKT,P;C_;\R=_^S\&-<UR1)2?$C/WKYD CL^Z;^HR'5
M[>.MA^<M_+!1*J]G.]?SUA<T:<5 ^ 5NNQ7CKVFO4%TV*Q^-Y[)DK+? TFC,
M\&3A7\5U?Y66/0LMS0DMQW6#A:->42HP@)930"4EP(A@ 8,<0Z8E"19N;,H"
M0Q7EEKGMJM]@A1502M8;QHW&L&88+Q3&=RT/5#EGB R \9#LC@X"I9 #*.+8
M8\T9,WAC4Q1*X(*BIE2/#.,6PKC1F,H,XT7"N&9""#(0HB$%5E((J.48&((8
M$%XQ%8&,.=8EC*4L.&K3;=R0D6!E](,_JMI[5<%@=]KM=T?C85F**0=!+LVI
M.=F$K;[;NK4%.Y4-)Y-5<V3UJ:XZ&*I]E!01X/%BB:J#Y,!8Z8$QC 082*K"
MM;&)"L)8@>9W=N2PJO8BNW&'94;V,I%]5YN0R"FA.0'<. 2HXA)HA2E@FF@C
ML=14A81LI%A!R-QY;!G9[45VX\[(C.PE(KNF8.! /-=" LF0!E1+ I1!&,1?
M$4Z4BI=VB6Q,1<'DW':"EH91KH*"L>W/AJE_\U7]?7V:"BY7E;:S+V)I.L;-
M?4BD=6,7,E<UQU4[7Q)/53K&WU_W/N[AO;__421HC D&!%(*J/<&&(0\<!8C
MI>-+'*&-34%PP>'<:1O9IME>5#>N7V14+PW5>W=1C:S%R@H+&%8<4"08,-1I
MP*&25GO%#)$;FUS"@C=6(R.CNH6H;ERWR*A>&JK?WD6U5<P+P1'@U$) 7;RF
MM4<"(,8<1<P2)41$-8$%G=]BL#S'1?LJ6;:B.N:*>V]VRI:TG6[_LQ^-J_Z=
MDV:U?3]^9@Z<GYY2NZHR9_\<C$:I;$^U+7M^?#)PNU=[DYW.37+WY0P]*VXD
MA4Q&[2K0*)%QJX"RV("XA1CQN-UE!1[,"X;K%2Y^SG;>=8!VXRI6AO830+NF
M;,5=%<9K Q15-BI;U@)I! 628.<YCW0N50EM1>H>V@SMM8!VXWI6AO830+NF
M<2&E@N*8@!!I&E"A=;R_D0-:.Q6X% 9#74$;\79 .^M:>1&>IS<O<65J&7NC
MZ^C@2]\/1R?=LZK7:J3-']<^GX6YL/GP0=WMIXTYZ+^)=]%!^.U\U$U-9V_?
M7*%[X1WXZH>#?&D][M)",U1-KH+AQ@J +/6 $N>!5DB ()S%U@0G4H1SV8X9
M_]HB,V$V_K?=I9?1O' TU[1+0;!$#&H@)%. PBB":B$<\ Q2:SB##IF,YF>
MY@94S%&<;_SIQV"=U<MYL5U3+[6'$@9+01*Y &74 H5< (H*$HC EDJYL8E2
M2?8VQ=YD]:IA?][JU)P<U(JXS./*N[=&QII3>>-J5IDXNM5WDPCOS-Q-,C>9
M%3;IO2*!4J"\@("**)IIHR7 $D/."4?!1*9 L, "%I(T5?#Z88!9(;? <V6
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M4<GQ6 $9>/P#HE1?ED@C3<0Y(05!\]21S3AO,<X;5U(RSI\8YW5=QCFI,!;
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MWYZ;LWB[VSL?>[<8=_'S9?''+\#:L?B3N)HGQSD;2W^ X6=U,K5",&8% 9)
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M)RB-FQ,W*:I]G@(E(04I]%0SS;GF;F.3<5C$D])LC=4&8-1R6WXFU$RH3Z^
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M\/4_1A9OMXK;CA9H:[V>S\*CK$<GI2QETP_^_\Z[GW4OZ5KS5-594_/9>AK
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MJB-SA8F.'HU\#I]8O( QV8&=BS/?'_FMOBMY:JM<_<Q/C?/3C.[*TAE'J46
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M +1<80:=(A!O;)(",59@U52\Q<,PLD+&C><*^L:B/#/H%P?Z6ME_QZQ'5"G
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M-ZO(JL6>ZZ!L"OY04>EQ'"B&(7#,*6.AE)1&I4=(7(C<B'2= =V4>)$!O51
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MD!+8A,CXC*3Z_+Q06!:XZ5YR#6#JB6U?F5TSN[96X,[LNEQVK8G24B@?MS*
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MF0*JH ,*:@:\)]:0U(T6A8U-07#!X1JJ(QG>BS(I9'@_!;SOVAND03PX:T#
MJ96\IP)H(V3<P\CGWEGK4.I=D^H/H+E[UV1XMQ;>C>OG&=Y/ .^:\BZYAUAP
M"A!4 E"N!5 B*N\!(NDT$D0;&N%-8$'G;TVU/.5]&L<:!^N_S0BK_,XF+1@K
MH7:95*[-G^G+9,9(+88GZ0_),!'5L*%W_O2L9#)[HH?'?FU*NK57&7.?]<NT
M,:^O]^)5M?:WF3MT+[P#7_UPD$G[4:1MZRI78!QRRWR4R0@'U$ -I%(!0"84
M(19RJFBRT\BX;[^VJ";4,Z_JUEZ5*X-X\2"^JU@9R@V*LA=P-B! *4LU9BV/
M(/;"".Z\YBB#>/U!W)AB]5 09QUJ/B37="BEF'.08R"PUH &KH&24 $?O'((
M(:>-VMB4O%!L;O]G2RLTKH#V4!89 $:/O"L;<OG^J'+@^(OT<RT2-UM^%N6W
M>9/:C/R6-N+5C7W()-4<21W7=08(14II)P Z2 &-W 2,8P809813%!/EH[BA
M6$%QFX(TLAFWI2I#!O,2P7Q7=V!"LLC' F@1)* DPEIRY("G"&K)*38^!8%"
M7&"H,IK7%LV-.V4RFA>/YIK^H"&E3D((6-+_J8U UH1 @*1@7!"JL)3Q:D8%
M94U5-6U;_.0*Z _;460:#J/R,(V5U!?/S;_PJ#:^\VL-][3ZG&Y$U=7S4%_L
M5 K<;[[OP\KT(5\)LOI4UR.X1)X'$4 (W@,*"0?*.!Z5"><5P]CY0%-_K(+S
MNN21N_>V%=I/&^B5 ;T\0-<"O(C&R' %=-Q30+$.P" C@&&1M".\B4\)KAP6
M5,Z=WYI1W5I4+R"^*Z-Z::BNZ10T6$V"A,!H'*]I*2TPD%F@!88"<PXA5AN;
MF,)"SM\J(3LE?A2@5;7CJ%)\]E5NUD2[*%(>5O9(+$VW2+[3ZP2YBK)2ZNCO
MP\%IM4=[?GPRB&0VW:CL5&V0P'9F]N$F1FMK!;",IDQWCH A(0 LM$*2Z\",
MWMB4A1!K6'<C8[TY;2-CO6U8KY6C5P%)8X, *1X]8CU0H(3!  GBM+%>"<DW
M-EF!<X[)&F.] 1TD8[UM6'][%^N0.0V]," PE_H^DE2\)B# M H0>4:X]AN;
MB!22S-W0-KL[?A2V"26="-=1/.[QA] QYZ/XIE$J0%^U.QS]N)+R' PJC698
MI-WX0W?[!_WM[FC:AN,@_#;9DVD'RM%O/I)7,K;DN.UF".QBAF)B78#>,@<(
MAR(2&/7 &,(!)APCIYUGTN?([?5'>*/I%QGA3X?PFCK"@N$:\@"B5N( =88!
MF6(S'#(*&4X-D2$C?/T1WFANQIP(SYK(O#"O:2*1M%'<20*B="93+4T#="KP
MZPE1<:>E40HG)TF!LX_DZ?!Z,#[QPTY<>E#6I9MD=F</R=-$7Y6[L3_HI[VH
M["D3OVYFJP;9ZG*&VJ$Q4]18 K22&E!J3/+F:F )"Y"BN*W"1K9"!5?9(;*^
MT&[>(9*AO61HU_0-*!DR,@0 72JRI3 '"CH%L"-1Y'0HR.3^0*B(FYFAO;;0
M;M[_\0!H9_0^$KTU-8(1S2$C @AH+*",.:"--(!H;2A51%&L-S8%;5->Y3,K
M?OWJ1/>CTI":Y]ZH93T:^?&HK!S5N^Y'7RH6R>$1I^MM^9.V_W?>K?3UZNVN
MF]R%W?'Y,-?!7OPSGIF^NV5MG$P\F$-O??=S:L'\O/3<):<9W;XIX^TX]'KD
MMWWU]VY_NA^OK[8CR\,-WJAPAJI+B42&B@ 8(@I0 06(LA "VA+%F8+><A;E
M82J+>+G.D6649>'V(KOQ-*.,[.4CNZ;I!D6)"M #PZ.$3+7A45;6\0].C&4:
MZC+;"!%9(%J/_LG(7@=D-YYJE)&]?&37M&#O#))>XGA=4PDH5QY((P/@D9LA
M)TQ@*4KS-)1U1?A)@/W,(OI2C&M_/!AV<]F")]4G;NQ#YIW'\0Z:%8T7KQ#G
M" >,800H(28UZ)4 >LJ12R8Y+E)!@GE()X?HM-9FOCAWV'>0F\6))F%=4Q2T
MQ\H[@@"/. 84<QYAC1#0Q$O(F%+8BI01)/#<20(9W>V]CY>@*V14+PS5-27!
M$1B0(5']5S9J"L@B8 (DP 5G4[$SCC2)ZC\N"&U)]:!GYGRH@NVN/0^5OZML
MNM)UY<^#\AWV?#A,Y0HJ']KS\D\\>:6".H>5V_:JVI-KF\=HJ^]NOK)5;E8F
MN09)#L_02"2CE&KE -%2 $HY!09:!1!V/$#+C11^8Q.+@I$<J+>^V%],Y8*,
M_39AOZZV.(*)B1I+Q'\4<"3"46W!#C J/>)4:UM69L:RX#R'\JT8^)]$<<F@
M;QOHZP& W%NB@@5*4P>HX!(8% Q0CA,CK%40N8U-H0HLLNOCZ;2:WJ!_#,9^
M>#J/UO(LK"Y+\()<121GIEH04Y&9-=4TCGL;Y9%XU@!EU@%-O0&0.X^L#7$G
MP\8F@P5KB_TE6U17+ZXJ8WL)V*ZI'D[I@#BS &+E <5, !W9&T1<:^BU]E22
MC4W,"S)7 $;&=GNQO01O2<;V$K!=TS",$#SR-@&$)6Q#0X#!*@ $O1,:(6-\
M*M)>Q!UM![2?F=OD*F?C3%\^OX2-=FD6T[WX_^Q]:7-;1Y+M7T$P)N+-1"#5
MM61M[@Y&R)(\PQ?6TC*[Y[F_.+(V"S8)L %0EO3K7Q5(:N$%95*\ +%4SY@B
M ;!X;]4])_?,5Q='T;BI1V["939%5$GZD"!Y)P#19K!>,K#,A< <#]84O<.:
M(=KF\=PR9*_9L+AU)E;#^$HQW@UK:#3.*@DA$0<D@>!0.RAGC)ER#6^Z@T/)
MAG)).E:KVMA4>&^6:=% O5)0=XR*G'7P9"4PF3R@K&58%"TDRAB=-5JI4$!M
MAN5<-TAP[UGLHJ!B>GY]9GU-Q/(7@Y3V+(RQ6;;&L].SD\G[E%ZG$YJG^..G
M-A*-O7ID+[7$[(BB'*=1%C E5\R.7%-)$4'+Z'@,K.@DO+ 7#I74+4-\NT"^
MJ69'@_NZX-ZU0(+(C-! 4KQ8(-HFL"&X\OA)IRR33-<R+ZZ'AK?HQFXB?77M
MT1K2'P[I';-$\&)[<&Y!RDR HF#>"^>@R'&3@F+6BWAP*-C0+6F&V((=Z\JF
MNJH ^:QU6HMZ/' ^U67:9V.KE;#5T;(IE1%)AF0U,($*,&=9NS)G"-*JVD'>
MZ) /#JT;.M5&UVT9PC?5#&E87PO6NQE6VBBF:HN;)"P@0PF>"P^&4BKO,.>Q
M8-W)H<8NUEL49%-AOEE1D ;NM8![R5A*4[D[0_8Y GIMP#I2H&.RT0>9<TUC
MX$P-M=S53LY;8'Q<="\?S.E=:V/U$/-?EH9M:X#JXF".Z[FT &[_E+5L$"4N
M'F7OP&K. )TC()T#B!1MM$8:IR[F5W&V(6FAS2>Z<37F#=X; N^NN9$"HJ4$
M3(I0; Y7<RJMA*0]EUD[J6M!A]1#)^Z=6-DPOKG"?)UQCX;V-:&]8W]HYGD4
MRI<]M0E0ZUKB82UX8[/*+/CR?XLT:NE:V&,3BLCW-O"QJ8;(M=*TYCQ9#7DM
MFTVIHXA:>PO*<ETGZ3*@P!P0F6@#2>54.CCD:JC9?<BK>48W%^EK#X TI*\!
MZ1VC)"6I11U0F206-25E#R2M .<CTT5?X9IRK40U4C2@[R30UVF.-*"O"^C=
MIE;"^L+=#)BT1:3K[,#Z(M(%.I:-%EKX.JG'#:W:$)'>9R1$FLTV1EZD^: .
M<QV<32=O1S'%@7__^6C+<@QOO]TTN=P8/YG&-(7YY.R[NB^SR<DH#JYN;?M(
M[B$3MLIY/2G']>KRM+Y__X]9];*\O#JQQQ\/K!%;C\3V88FM(KWEB=58B3 ,
M,'L!GE/18*)W/*9DPF+8]E!I'"K3UW2!6V-IB]RN^\L/O<==&C\\%#]T+!Q?
M>#TY&XMQ8VIAF8A@@R7@6G/43BKNJB]CZ"0;6M-7;5GCAUWBA][SQ!H_/!0_
M=&>8>)*)%:V!*!7#B(('9W0A"16<X,83,W;!#\8-F;#;P@\]17,VPV@R2P%<
M$33()Y,_9H,\G9P.1N.W:7;-7OKN1H/I%GMQJT.ZD5'[\$[U=9';P,?+@=2V
ML[_M[-.CPL4CL>$1WL?EJBM%SP:37!TK1;C.WR]Z;:1_GX_.3M-XWE).U^8R
M>47OZX[/CB>/0]G^:7IU>2*O3F@\?SR.SZX.I:D\/:H\RV:LJG*NT10;2,0H
M 450X'GY43-FR4>,VL:#0\WD$$7K&[Z;^.[=Y='P_5#X[KH\I!4F9E, [0B0
MRV+-L%S@GH-6EOD"[QK413Y$?9_*MH;OS<5W[RZ+AN^'PG?'96&CDJ020N:F
MMN_,$;P7#B2SV4?O73G[@F^#0X4[F%RZ#:9'A<CLPOIHV:0/9V-\?SXK5SB;
MI=E_3R>SYDSMDYF6S4I57.:80P87?$T<30JHR!T(D4?'74B6IX-#98:%JC8C
MRZ3EDVV=8=% O5)0=\P)RX-.F67P42= FR0XCA98E)9+EZ(.M93>FB%3K5WX
M;J)Z]>9$0_5*4=UMD)%19L8C:&144(T!G.<&BH3V,1M!B%11+8:,WZ?<?$,S
M0K? B"@&=KG^>!G=7 PYO>@4?HF4P:Q@8,^Z9CRH=7%Y'C^4X_BI;OW+?$5:
MCW,>G8QHGAZ/8_E8/*\!Z-2FJ?7.9,NFH'IA/',^ 3=>%:-#*K .&62;<ZAS
MUKP6A<FX&2K;K6)IE?6[ OC^+8\&^$T ?,<@T3[Z@-8 "W5 NW(1'%&&% )R
M5$8:9@X.=0UO8,/[SN*]?YNDX7T3\-XQ5<@'96OW\.QJO(.A!1L3AX">Y?(T
M$J%>C#GGLINN\'!XW[.8QZOS:7A#LU2SK6+R\\M\S(65/WB33B+,)U!@<CX=
MS=^WH,C#!47^IYS%\>3YY4G\E$+]MZ6:]\MCRT:K&E_$%%,.N/,>,#$)5D<+
MDK,4LI9D:\-A+MS0WJO#7W.D;BZ\5Q\>:?!>#[R[O314@2X7&E@TQ2PIA@CX
M)"V$9&/12D,.YF*JJL7[9%4V=&\NNE<?)FGH7@^ZNW.,-//E/P=:*P8HA0-K
M.8/$O/.4D0OF:D\L-C2;TA1KW^(EGQD@DT5WOX49<E7P,7__N46R7V&3!S%
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MRA=B]3)FAG;1\%RX(;N7ZM5\RIO+'ZNSLAI_[!I_=*PW84T-/V6PL38U58K
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MMOFLR\%FKEEB";,2SFA,)*1/3$3G91\VW\5CTOBZ3[[F/QX_[V0PN")UR0I
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MQ\?/G@Y^.B[_/'_VXOBGP<L?!L_^_H^CXY\'L!!FH_%YBAM_-_\9BZRCZ6Q
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M<GUY6Z.MT43'6K,2FNC8+M'Q3/YX,<Z//?]P].'%;\]^030J!(T0A*JU1)R
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MLHN2'^V_]D:4A52>"!TL 36;$J6D)KFGA>!<AX+#1:%*#8'Y;-Z6ALGO#5X
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M/24FIP ;+)<E=_<CE^/)941UQU#DR08FH/DY8D)$ G3 @[XQ'L$C;J6F ^"
M&\5XJ4EL,U/;UNM"R<NLUKA!R3+8FF7.4C)AFPPV\YAP-YF?1HUIC(6"X'E7
MYU*<+V;V5%?K49N[0/>_^U2%U+N/X<)#A(.G;[/7 61!+15LJG4:^X4JHB55
MI#2 ! 7GWOKR?L#!\AXLV>W=!85MJ]D0'AH33/)2G_IQLMW/%E6TR]7)2XVC
M,LD:&%'1=??6_JX&4)*A!+[\_A04G0L"2!*G<!X=$7&DZ !,>;.CQI9B4IF1
M:0#<2(50\&5U$%";.9]"T+ \N)]5_XAC@,"?M)B4P]H8>I;F\*6O9&61&%<S
M?;\W>-G4<N/QNTVVJ_-S/1I_6S'E18O4O6@"HLG[UY1)IZ3."6 .:#0LY\08
MH8C(.1?&V<P4&VU.[B86O5@MO!0C-!L\6JF]=,=0J9N"TA0C0N]H[?V/Z^P6
MEDKT"JL@4=QH$" 5FXIVY;/H-#_#,/(/37&ICV9XHG8U698 B#Y2?S)*/EJ8
MR"3Y#S#XKB,JM56X.K.+P!6C$QLYJ@E*J"-!FZS\VH;L?*H]T/QRO6S6TCC=
M2>A/H5;+ A.=CU:S09N"36B(CH;L6C*;=G3,Z*R+486K]ZDK$T8O0W,TT5O2
M$26[#T8'WA9M\XK2GG6Q,QC5^WD'?\5.XN\$>5P/OP"_'UZK(M.!&DFHEI9P
M[RR1FEGBE<Z"5D'RPMP?^,63OWL VYEY4@/GR=N5''\IA#JF#F %PS":53AI
MC&3"?TT7\^^1K"=^WE2202!+:%-7!VGR%I,KM\Y</-6S,VW](C8J;<J:I=@2
MTHB$V.QH/$IID";&BG>$Q5%#:JVBN :/,3*X]K%%)V[,76A"2[NQ9DUUNU7!
M=!GPG5(%$"DQE"\&[OM4 :<)PEY&9H1%U'$Q\1]_'&,II#H"KY[FX!WVK?#-
M1VV8%ASD L=KY>9FL6C,QSBYLU$4=+\IP/TZ0P/Z_.+7,;;AFSAD<>>]O)D
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M:3*O"T>D8(9P5DBBM'3$,"=+:H0NBPRTD"$HH<,\^VR'TP[;:Q\\M0<II)5
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MS>%?L=$_KL384MGPL]'$^<G\!X*_N6V$5M>Z09W8U:_^]M5=*?<$PUU(59&
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MQZ='3__]]NCIS^-7Q\_/L ?Z9@/A/"OAA!7A%O\P3!+ERT!48,8KG0GA&?9
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M*<@HBG_2L!__3,A/&_5^3?9Z!W:%F^Y*[SH5&\]N4?<3<7X=M;:\EL?N%<A
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M$+D2.4@;E++B.@5L>CK^JG2\H34$5BK)2T^4T1)4?VJ(*EU!X"=.\Z)4GA=
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M)L!JW@;?S'R[.Z3D7<K(*Z'LX5 F9IB#$B=/G)+(>R<0YP(L0:4\\D0JAVF
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M19R)P8GL4;8,*X[/78E/);H78GHAH.];_K9W)9!>,&0BTMXIQ(VAR'*&41+
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MP(>11-D"^RXCQ&B:N(!Y+)X)/O"A%UOPR9_Q]Y-F&.R/M]5+WQH!(+[XBG6
M=<>#Z[]R">8\/$+L/3\[*$3A$R+F?+Z&\W/IYWYO/)XCNQ>1ZT5["!H*P_U@
M6R?VM+_T[ZL "^@ZNKS0RWD2%^?YU6RU7/U[H[%:V:A_7+XZ#0LXUOIF8_U;
MI;%9^;A9_[;YY\;::F-]K?)IH[Y:_[BQ^F?E6P->J*W7&]\JJ/+;.6K^Z]H'
M&^V'%_OW[XORJ+^%;JME>Z#9': A^Z#??5!XP(?N,5PV]*N5^,M'( U'@!K%
M^Y5@!_;Z1[WNP5;^XWH@PS,T8 (F1AMT]$%&[0(V)A^D<"8&)TA,V#*L.%ZZ
MYGNW;EHW\)070H81J/?OC.I7<+L?ARA]L>,5(&V]!QXYB"%; Q7;K^S'5H '
M1:-KGA8+WHL^$\=0L8.*;</6 ,/.9G-_4*V<[#?]?L4>'?6ZO\!TR)<:P+A[
ME63AQT_;.LZW&E36HH]M%WM#9LM(M9)967'Y;,1<K^VWD\3%(!1#A]4B4HK*
M?K<5^@5+L*"T<3C0R_LUR,N@LF]_1EAJ&V T("QY9V]V,CF^LI2IUVU7CL"J
M:/JI)7N91VT7++X_24]ZL0U/"P;-93Z5Q>V"M\R8B:P460<*+8/)LA5@K?U!
M9="M)#"X .::_4&^:!=F8*] %/A2O]_US4+V"^4<7 SD__T?38GZO5\!XH/^
M"]H*/ T^%F**O5ZA1.VCV.D/H>FH!=,PH0G3]&@V82I@S5&J*971"T*X(4XK
M1S3S,L 8+"46"+Y>NE7'7FB/D<M#;)C^^<1FX)]=&'6]"^2YT;,AKG;")JQ@
M[RL@5O-G5H#^6K/O6]W^<2\VX,9_M+K^\,4MQ+VQA0B66[VYT_A.X%KMG8;'
MV^W\.; 4L].CL4'JC?73G<]?]FNGDQ;B-EB57UKUQO?3VH^=5OWL:W,[CZGQ
M%:ZW =>#:S:^',+USOXYVSO=90)G3[!#(&42<4PM,CXY9*VD&C942I6;- \3
MX8$FEISPDC,3G65<!1Z]DTQPK"?-PV+J\XXSGOMIL^&R>LS<W6^]YU,Y%L)/
M^^&;WX_AN!4WTZ04-?+/=RQ =)=*P"4G*8HJI[\  4-688ZL29YI3V"%U)2_
M8!&XP(T;T)3(5DXB;",9VGO-/H \F.1Y2TC H;LGV<4VX=Z[ 8YE-GR'CCF4
MG?SCYRR\5A?V;N'6\YFC'_7CA_$OOX=F'_:4TP_-3C'JXDN_7[4RLE$XX=(K
MIG7X]LA>E&+9,)%-QM$)H]&-1];D<F%-3G@IA^\)N2RXN?9MO$RN?>^FRQ*S
M+.CU;]]TV9O?,U@_S6#9G2Y[RRFN&PYK#:VHYXETJ$><UCI_*K/H3S7%4O#0
M;SBT8RI@PEQYMG>T=)?BI/<(*"S*(\]>5UHD7,[G@:\](_U&)X[<1Q'>1#W(
M;\='1ZUFL>N[PNN>#<MLX@VR!7&5OM[O+/"[S0-XOPUDC>1<>2:CB9ASS:TB
M!(.YXK@QRG%_UWS^27NC'@>OK+#OPTR28;"_*W8^;]#ZV:K8/MC+$5%</X-Q
MMK_NUW]LDYTU_ZM^<'BR<Q .ZA\G@OT'K</M WC2M1:,+4=$MUB]_7=SY_,Z
MV3GX^[!>1$?_:-=I#?]SMC%]VA2LP^"T5HAZ,&:XD@996#Q$*+%:),R9($LK
M#.<LU'F5 %F8Q*BR87:)=_?#.\=8U,ZD&*@"U?"&@OUOK:<N8.PTOVM:4XEW
MSX1WDTGWAF$M4W1(RWPBU/F(+/8$><-<CKL%EQ-%J>%5H<JNV0NDI+488"A%
M<D88Q@-]RS;;#ZMD/N/YWUY1IRB,]5B+X*7@1%O+HV(I>6DX-4+KDILM$E;5
MIKE9=,I3JP0R 2O$/27(< ._<9-<)"D)S)96@'!7E9A7]]0%RDLO-7FLR1Q3
M9:S P>-L90F#A3-4Z&2\R\7L2]:Q8)H\R3HDQR(Z3)'@D2 NJ$4V<(RDY-()
M*A7C%#29T:KB\VJ/5_9'>9+*;%<Y77DHYADFZ,W@^+RJ7Y0X_APXOC7-R 2F
MUGGG47 J(6Y=0HXJCZ*TF"E-HK=D:8435C7JT6>VYZY(K\.=5D)J":G/?\ZP
MA-1G@M1):JR\U(:S@)Q5&O'<Z$=;F9 0PDENG(Y< *12567TT4;NPD#J'0X;
M/B97EF&RL+FRZJ5R9?_J=8]@34[_:MG.8+43<M;[44Z=7K@4V;/:VOK%(<JU
M0L-.0#O/X+JXOK8*VO['?FUM&V_3>KN^]J55/_B[56M.':(\V?SQM5D_6 7M
MK-&=M2U<6]L0M<_K)_6#KP?;=!O7VM]I_<?WTW_.]DYJ6[M>DR0#%RBPW Y
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MCLPSU'JX%[:A3)X.MM/C\;X_>VNCDS?;B\ON2II]>MQY #LZ=#B/?N[$_XZ
M"]K#L9SR\_UB<!G%N1)"WNUA)N%:F,<.B'QYH/<;L3W.9WH$"[4] "5K*K[
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M1E-B0!1D<X+@_V2OWO/@I_'I^TM .GO22.^>N9'G^9O&0HW=QO,%(.0V7%;
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MC$I)$KJR)G63\V55A*A189R"XF6)'@7%#XGB6=F#.6&=91@Y1C%('#ZC6#,
M->7>&"83UBMK0C0%O[/HL404OP3[UP00XXSN<7!UPK/G60/Z$02)S<E(@R:4
M3_ * RV=@=[-RQ'.>QV((<C:!-H/!P;21CFDB&<"&^FP42MKC#>)G(^2NIWR
M4R-;3@'QLN6( N(' /&L&*&MQ$YBADR(%'&!)3+)*,08I9AIPK2, &+:-%36
M",0OP4@Q%2-@Q-$D>&!H?USV]BH6B@>P4-C.VUY_Q_Z(@\J%:>? =L=A-=5G
MA:>6SE,?YX4-G227C''DE8N(.VU!V' &2>4CTUPFDMS*&J=-C>_,4\5H45]@
M+]5H48#]\,">%4 DU5HG99&HM CL"'*"!:223SQY1VWB^0REJ32O$;!?@AVC
M D4Q7MRWC%$-\P<8O?[)!2_XPCY+9Y_=>;&"*2ZLE0E9Y8%]C#7 /HZA "N8
MP<[B8(_)N>Y(4\LZZ3_%B%%3N:* ^>' /"M*).FEXTXB:3%!W&N%C* >64&P
M(=YSE@R 69HFYLO*75F,&=>#XNTDM<LY=QB,;^B-<ES/M,$OUF-N^0/T;*A\
MJ7)9(?'[)'$_+Y%%2IWD#B-,>4) V1)9ZCR*A GOG,,B@CZH,6UR>6<27SJ*
M'ME.5/BT\&F]1>/"I_?,IW-"L24!-CZ,F#(@%"L;D19&(TRL4Y($QKA<65/8
M-!F_<SQ&;?AT0<K+Z^5=NFXB$%'?1"#TL1*!G-G.ZY@!Y.,$OD?? +K'K<,M
MMO7YW8^MTRVX[].W[8U/G:U3C[<. 8:'[SO;GS>/]V;3.!R^_[J]LTYW3_V/
MO8TW&=*B]?D=;WW^>-H"6.Y"&_?^_"AVO_YQ^,_IN]/6SK<O43)&3<I>>I("
M^@R@CWN%J,*"6TV"TWHV"4A4F4V5,"* ("2LQEJ[ *N1A. M-[.9'S;/SH9O
ME?_CUZ^[W+QDM<A)D94EF',CM0;)VA,6$@Y$\B>1BN**D?!"" GSPD/BW%EG
MI< 1@.\T(<;CE;6="\7.K??C[$.Y6G?[PAS 7@KD5J6RR&FAAE6,P?34_J1Q
M&(<'O7!>POM_1^U^E;XI9POUO?UN>YI0,L04^SGE53[VKQXUN/2LG$)C6BI\
MMDQYOB4GS8+'QRH]5$Y46F6<NI HJLI.!4WOC$+EKE@]*=^5^7B<&Z_=M5V?
M,^<-AO!!E;IJM?%QTL&<!VK2F^NTU4*[+I2([XW?-\ZE-\G]$=H)GC-NL8O#
MX]S *B?(?#NJQ^>WG3W@BM?FA%?[C=BUXYQ8<,<XEU\N[EYERCH;Q)-H\U1.
MIF:V/;GYYV7E>S!;5;'X!0FF'J*F^I1TS^NJCWG@CPB]B>=4#/\,8)]<[X:W
M\#GLE#5+K_,(O'SZ\8MA6+'H!(+A9Z!E"H-<X %435 S \6<V>M66:\1K4UV
M E<M@<N<E/J]PRF19SA,4LT!UL>Y]0;#10EXKI\]NAYI>!19!2GVEK7F*;E>
M"IH;E0/7JTK=1^UR36]7:_YY-;;D#+K4)R*>9M*@W;SOQFX60DK^H&>:!J?D
M#UI*_J R<-<>./SB$B]-A?V28ZGD'?G5(>G=RD\LBM[)VL9?O<'@+:@:K\\T
MC>TS16-&,XV#Z7)]*B< MU-5QR< 1P?9T@]MXENG!]]:&^MX=V?K>/O/3[D<
MV>GVGYMLBVZ=[.9,L:]G3@ .WT*;O_UH;>S#=>_PUL;[@ZW3=;[W^1W9WMGB
MNU\]M/6_[=:?[[\MS,A$A!"&.H*L9 ;QE./T).BZ7"MN,"'68+JR9JAL2GQG
M%]N2D:DPX]-F1IJH2@X3FB+FT1MM!,.8TZBT"B'$BAG)E!FO%==8F+$>S#A[
M-BH<T\"'%K%H\ND,=L@D[X HE5+28.!-N[)&FERR)J9/H=QUX<;"C??(C5%X
M2;3&'L?(.4Y..<9("@$(47D:*F[$4V[$A1N?##>VYJ3&J)V6D:!(8@ZXA"EU
MA#E$:'3)D<!48)D;J59-HY85&U&RVRTEN]TP]KL5?&RGQ(C7606>G,D6+EL>
MERW(>$<%<8*"B&>JTU[.$M*P.2'#M(/Y]CB17,'1-*6J4XQI"1Y_AJI=0?Q]
M('Y6LXO.<2.Y1,#L 1!/'7*&"42P-Q&$UD@TJ[+C<;DLI]>"^!HBO@X*2T'\
M/2!^3E^Q7@JJF$7"<]!7J.9(@W"'6(J<V6A9"!CV> P*2YT2Q"SI6'(,7+I*
M1<UUDSNIA25NZ0$&Z-EP?QWTNZUVM]=O#T^FN0W7N^'R4][\[PB^WJJ\J#>[
MW^&2!66GRV9QE\UB0>I2+&R0R3'D@\2(>VR0B=(BR:*7"DMF<Y$:(V63JB47
M;G@"0:;+.1<H9%W(^FFIYH6L:T'6<QGBN 7E#0-9&V,1EXP 68N <.2)4ZZ2
M$BZ?1 BBF]PLV8.ET'6AZT+7M;2K%+JN UW/&6(,5\Y1+)"A) )=2X6TXA2E
MY(202L5 ?:9K!G1-EU89X/'I^M8I!R9=FT"19PO.46]010&_ZL<.7/D]3N+;
M)CB]<->DP_C\%NN@;Z/AU;?,^>T_4K3B6T39Y=#"BS\/^N>A/?L1N7ZTWY!-
MT-Q7MG-L3P8K_[X<B]CN3A\O]&H>Q/KT?W&BAHWU3YL[ZXW-UNO5*R,LZ]+6
MUO;.FP^-G>W&Z^W6A^V_-C?6=]YL--YNMM9;KS?7_VI\V($/MMZT=CXT4..W
MLX0!__I5Z.@Y7N?#21ZIJ[^%')7:'\>1#PYL?QPJ#IO("!X;!LU&_.$CD 3L
M3./O&\$.[=5=O:IC:_]Q_7^O+4+ PNP$O\R[,).G03G##&A.DH7(24S&VT@9
MPXDKXRR63R&@^4'2EIQ'T.?4#KUNEA&FT?0@:+SY<12[@_A'[,;4'I;H^:_^
M"XPS;.56(N%XSIKK@9]EE,A'ZX,FFA@QMQPEBPE3+TT2@7O!0,.W)L!R=J#>
M:Z>OSFI2)5V &:C2--PXA/WG&5%N%LR^$)>_[%@)@G]R<>5/JK$E"+X$P3^W
M27RF(<DE"+X$P9<@^/NU8D[2BKZZSHI91AA"O6VZU^?96]>.*.-9QG.9X[FD
M$)TGXQ+W-L)<S@?JW-EQMW8=O7$V[N=Y=K9TO[3)CC=91W,FJY=QWM7Z\\W)
MWM?.P=;..M[:^89;I^\/MC]_%+MTE\,[3K=V6NTJT?;)['G7&[R[\]_#[<]O
M?FQMO/NQO?..P;/$WD[GZ][7 ^C/UH\M^M^<:)LM#"YR&!C,1H6B%1+QE$^^
M/%:(<\YLDE2HI+,H1IJ&W?FTJWZQ!H6FGBE-+=TCJ]#40]+4G!<53*7B/"&,
MJ4&<<88TIA'18)3 6#-J ] 4D4W!EE57I=!4H:DGYXE4:.H!:6H^[4020J28
MTW%; C)4,$C;*)$0+@J<.)42:(JK)E&D1BSUTL*X/N0L_*4T\$.K>-6PKW?#
M7SU?J.E>J6E!T! 3AD6C,8K9IQ&HB2"+I4.,<&,<9X%J5<64PW4UJBY:2@4_
M$<6H@/L!P3VK'F''/7..H,24 W +CXST&HG@9<*2.<)SD(EH2GQGN:. N[[@
MOB]UHH#[X< ]IU1(;T$,\PDEYRNE0B$#FS8B >O@7++2L6S[:'*^K'B$&N6J
M>S)*1<E;][CG1]/Z8(6<[HV</LZK%9PGV&(\0TI1CWB2!AD5)6*< VM1QH3%
M('G()A5W5BOJ9Y<ML+[W\Y8"ZX> ]5S=Y9244MZA:+%$7(!JH046R"LJG,!,
M4<T!UKQ)N2JP?KZPOK?SB0+K!X#UG"KA'$F4QHA4$+!;AX"1I4HAZH41D@+6
M==ZM59/KYWH^0<6JJKLJL=,;VD[#CZ%RH1+J78XL[I8'XTF3V'VI'%<$618.
M6QZ'[2[P6+/.&<(4BD$HQ)W52%L@,A.<#L9HG&(VARC65,O.?E;[;#F%$!Y5
M62F$\!"$,*NKN$SJ.AEDM&"@JT2.--<"*26B))%1F&,@!"Z;3-]962F$\!P)
MX;[4G$((#T (<UH.)<;$X'F6"T#+\48A@UU"UOH4I?",1+>RIF43+SO?7JG\
M<Z<"P#%%@$VX7?#CKSM</XJZ0SS>=4U89<C*D"TA2O&)>WQ>$:7XS#U'?GM8
M(\D .@R_S<I"4UJ?S$&1B>Y=)MJ?MYHHQ4R0$2/'1$YZI25R3B2$HS,I$:JY
MPBMK4C9A)<W)1/\JSF%UA?AC6CT*L!\!V+/6#\:X,H%(%+C2.3*.(T.$1U$;
MZV6B3GI0=H1I"KHL:VA!=PW1O7031D'WPZ-[SI3!F>4N<HU<"!QQYS2RGD5$
M@N=<6XV3T"MKQ.BFI'4*VWAISI^WCRA[NFXD]=(N+KFH%[*Z=[+Z-J]C)&ZC
M(=D]7<>$N'<6:>4](@SD$"^U"R:3%6U2/1^C?WT=H_B+U5<*N3<=H\#[P>$]
MJVDH+E-2/*'D\SEK( Q9ACE*B5@0/#G6*4>0-MG=PU *Q.L+\7M3- K$'QKB
M<^I&#%X 4 D*2;%<_<8BH[1#V$=GC8]4,IY]JYH4ES+$3SG4[$681);N]WEF
M$AE[KQ>.NG>.>G.<^6FL:;R#-F_1K7=? NPZT3B/HHD1\>0=TMX))",70AOJ
MJY@SVC2F6#R?&KQO8E18@K+QJR/+ O0'!/K6+- IMC0XP+BQ28(XH@72F@HD
MH@^1!ADD)RMKO"FH*&>63P?C=5 V"K(?$MD?9Y'-+$^@4%B4A W9EJ#&YQK.
MY[5' S&*Y"T<XSMG\ZSIJ<;3B4,+$\C<-1!M,AC/S<V\7L<@%RH,KW<#_/L:
M/FR_E++!#\1H/Q8H)9Z+(&7RB+.<7\^JA#0S$LED;+1<,9'HRIH236GF0VMO
M?/A1F_B3)9I-GQLQU.'8I-#!P]#!G.K"J4_>2X^,T\ )*EIDE;#(1$,UY5;S
MH%?6)&XR/J^[W,Z26CCA67'"O:D^A1,>AA/FE![)/3'".V1-+F) ?40:F!ZY
ME */*>@8<Q$#JIJ:W=ER^5"D\!**\MTI)O"\2'PC]$:YE/*TP7<CM]J-TO5+
M.BQ_@)X-ZR_]S*I8N.Z?[$\6Z(-8<ROSJ905)@'9!XXL)1YI9T'D\R97K1E[
M[N)E9R58 J >V0!>J+50:_V5[$*M#T*M<[JUC9KYH"2B1G#$0V3(4(5!RV;>
M&>JICG1EC6'95'>O65BHM5!KH=:'ME44:GT0:ITS49 0L4J&H! D03P7"-(8
MF#;9I C7(0D:@%H)6T8YV-I0:V7#^/?0PDO7JD[EQ=WNCBH/2_@DM+]/T= :
M'0*:_!*4MO&"#]_MJP_^((91)VZG]4ZGYZNW;J<K(+"36[D#K_X#+OWV1%?Z
MWC\'V!]^ZMK/9K1]^/[K]LXZW3WU/_8VWIQNG;X3K<_O>.OSQ]/6Z;N376CC
MWI^P^K_^<?C/Z;O3[8V/7V@@C!I8G$X&A[BD CF:#6O .(HH PL51C@"'QS!
M& _[HPA3#;,X78N'MK_?[E8KRDSWIW8WQ.[P%575=OG A$O';KW3\W5XINW'
MAATOAQ@:+@Z/8^PV)@L3%GS#=D,CM >33^":WE'L5VL';AX 4<+-QX/S7$K5
M(EX\!A*:-\$1RAOT=! J1)SA=XQ"&(R./1K$5]-??H=&''7LR:MVM^I2==/O
MDZ=/0)T='6806(WY^.O?C]MA>/!*D570C//&,S$G3EX\_I:L5GO2#*F,OV-J
ME1)SY==XE5SYW<\>2_2J4NI6C_WY=YKRTEAUO0G[A7WYEX=,1,Q=NT L]3&[
MU#^,^*5FR$ ME+YVH^TW(G!2:&Q$'P]=[#<8:=XDB]--$EW=8(NM][CE#?8Z
MV<&NT^&7-G"D#-SM!@[?1W*U6JO-K\\%D7.YX]ZR9CYO4\)+LA24\ZWE60IZ
M?'OGO]_V/N]"6T*G]74+M_YL'6[_^>9T;^<CWJ5O2&[C+H5V?9BQ%'S=%_EY
M>U_?0%\^4M"Y\-BZT.JT=MY_W=WYR+=HOO?3P3^GFPO*?IGD602U*R:G$">Y
M[!<U-)<HQ(8;1IDU]W2Z]5PLK(7U7@[KE:.G)\EZLQDP @W1TB212"(A'HU#
M3LB(K C.>(:CT^2>#IX*Z]4+_(7URJG0\V2]N:0@P7H6M..(<Y9K01*!G)(.
M645@VAAQ-,I[.A.JD=OJ4ZRGL/ATX(6E*7S4A"$79F![.@&9OU**?C@]X_NK
M-QB\[?<.%UZ],>K#@/]]8 =Q>S3\&\:@%RX37FK_B &=QGZO<-V-N&YK7J^E
M5"L# CCBDD?$G2?(@MR.C/%1F<"B=#C[@VN8_-]KE &I9#FKN\96J*#F5#"K
M[ GK@C6)HJ2]0]P&CHR2"2G*G#9<R^A3H8(70 7+#\1[""HH:M#=^&!.#9*,
M:Y>L0B9:D ^T#,@Q'!%SL%*EQ)HJNK)&FE+<V>!=H]2(Q7VXN \_/;WK"D/1
M^:'U&9$.%M+KX,V/8=_"1+2[MG^R.8R'+R(Z^J'8]=TBQ<MZZJA&GC-@5^)B
MCI3SB&#*HV"!619+N%PAY4+*3U8#+J1<=U*>/^]D%#2<A'3VL.>:Y$ [G6.8
MM: V18Z#+(%VA90+*3]96T0AY9J3\IP=PGLO4R($1<V!E(D0R'(;D5>>&<D]
M5@+GXUC1% O*+#U54KX<HE?%,OW[4D3>?07H38%R'J0W-M.UO\<S[+RWP_@^
MPAM]N].>6/->>)1>Z^O^%R\D3IY2%&U0B/M D(N,(B.M4%@H*8QZ>E%Z.P>Q
MT;\TV6?1>4/XZG7O$!IU4IT+J-\'C3A=+3FNKP&D&1NIWSN\&,EW,7"O&ZJG
M?%S]L-I(X\J;%_+NCN]O/]4 /[,J&+U-@!\WJUBSY8>A\55MZ#W$S*G[B$9\
M<HT5RPSP>U01=S80Z"9IXDHDXG.:Q&<:P%9")DO(9 F9O%\U_^UB<>XN]=M>
M3'KD[BAO.\L]-MQLO9U5\JZCVJT/)Q.9ZU6.AKW^R:6+SPP<B#Y1M6]JX=BB
M[XY;IUM\]W27MN"Z%FU]V\VIA'9:!W#-MZW3]>/=?-_K.0O'Z=[&.MLZ/?C:
M^KK+0#UDNS2G,&IUMNC; U 53[<V_FB#NL@7!A<&R6Q,PB*&J0.]402DM9*(
M!*XU5E0X[8!#0/Y\ M[FCP&C_[G.IG2?1:E>-B_=\>2L\%)->&GV.$P#"SD'
MO$02XX@[BI&E+*(D/0O>6LZ5+[Q4>*FNO'3'PZ/"2_7@I;D3(1PI,9P'9)-+
MB =&D3.<H1RUIW1,1H94>.G:O+3,*G^J_D7^,BSC!:4T#IJ-;APV>NGL ,*-
M#X5+X.#]*:-S!_/7H=9JZM:[X:\>#-F%LCZ%4V_&J0L" 4&D,RP*A;RA 7&0
MY)'#5")8*H*"M">38RMK;'59=7I*Y$\]87U'7:[ ^G%A/:O">:),$(8@QQW
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M^&#K36OG0P,U?INL\1C^]2N".S_N_KTN7?TM@-*=+869. :@ DTM=[T1/#:
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M9A%5-#J!#9$:9%7_0>@?=*PL>"HUI9*>)9.>K=CWO=9Q!M3=]-GV6CEE)!=
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M1X4$-R$!25%ZIZE70G,<K4LV8FT"II%$KL6\X8H*"1X/"::B%N"M!NJI08Z
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M5'5"[MW*O#)E;PNRLC)E*U/V84'V;?>D5V'LXC!V9QIC+<8\2*)0SM5!G$A
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MQ#AX-2<AZ>,W[<5X'9?V^6WY1ZE<9UHLG']4KW-,[_34FU\3;+X.P[<9*ZR
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M.0YK&[JN<:72*GBNX'F5PCX5**\&*$^E>C"5"(^2(FUP0CPE@6P OR.*Q+G
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MC&X<#[<<D#3$7@V.&_(YQMAN%WS79?9 S?8S=<*(^K:4&4;JM7RT:K:7PRT
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MK$).YJLD1:FE*DI,%+AQ=29X7<M[0^&*U695F+!4%E*%!8O$@NFFT=$D&:A
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M)5=[/,<>^WT3 H]&"Q0TQIF)+"'-A$4">Q(S%QD-(N\QJQL\'>LK9/HVVTP
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M1\.=<FBZ_>%XX-:G79NIP5?YX?L>//^SV/_^]NO>ZP\4])WO!]C6[_!WN!_
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MP9*;0-[ "580Y3_EZ&075(,OI84S-:WW#7\_K]7"5NBM(,_S@YT/1S3-F>"
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MI.TGP%C1U89N/C@"XR[BO&>=7\I?XV%TWV!FO;@1Q?GTPW6UF6@7"EX48-Z
M&3<#XYP$5,)#,0FI\O95H94C!^!RH,NAB^,:Z<^ ,K^-8N!2M"=%7@_K&2Q)
M, ;T5?X&(ZN'9DL/0+PICGDV<%60%=XX-="!.QYWJV\*M!OA;?C%'L!<$S#Z
M9/@XF^J&_N"\H\>C$UQ_F&=X]>*[^V=E+SP:[M*#P/@U* YPQY3M[32\J0OO
MUL>]?L@PB\:P^HN>PVIQU3X#N7P!3C>,D;BP(K^%#?RE_%*]'68ZZ.L@'NO
MW6KB@XO7 MXT</\95Q8]D&>[O0YFB>.EFQ?35Z M$%AP8DV)GFE]CLMU#:KJ
MG(%@#0'+M1[BPV+[<<BEF;MXFM),,[NYBZ+PKIY6G"^.[R''',0$]0A>=.<$
MKNJ>U[09L(N%=1[$F,!R&*AN, IN]R\:#M!XV.GJK\,QZ&R; &!.8\927*O-
M)AWQ!TTR//%9B>&"Y@K3!I($'G#Z@P=UX1 ZU4K-'):R%X(MZ]2?7R);\WB&
MX *,NQ\ #XMGHUW1I2OZ:TS$&ENT'?S2),]N!GR.KHM)=.SF_'K#@8\GO.8
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M<?:P'ZO,H%;],&($?K[C<8_O?W][E#&;6Y888E1.B3#>$<VPI&ZNC,P-34"
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M+#?$B];ZSB*:PU27<:_)_(D(+J8= 7XK8E&@>J6K9-D@$;&O"89!:M#<L8.
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M>MFY*5:<&U10_\9%BMC_L-^@__C!BWZOJMS\%S[R":NE&'?]^<BXW-%<9\3
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M,NWT3Q/0K2)[[Z)[09'-<B&%XAFQ+,V($$P3K5)+%$MSF=D\4UF"BFR^E?Z
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MDV=2;"59CI*QLB15+X[?LJT@-.=X4_PN45LJ82N_IELW_4XJ<:,[+QHL2[=
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M@3&DE*+WTQ &GQ>:"BVP%U.R"13Q^!A#BX5:+-0:RAX9BULPE!7&4YDFBJ3
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ML-PZ)QC=>,YNS_]:=^4Z0;PGX:Z\&3=KK5F/B>$M9E52EF6)I40D0A)1>$J
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MG,Z49.BEVJ)+XF+0 GVIG7G.8X /00HJ>]'X/>-#J$SW IM<GO6')5[P+$3
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M!O-3X7'N@MSPYB]XQ->3TIR$O-6S 6SJ (0AC,QTQRBS8(C'K@=Z9#<\7EM
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MW^GO2V3G7[2:4"1ZK<V54XHE&;0)'#L*LBP]!7ZD1?31/F!D>9'HNTMT+<Y
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MJ<;3C]E>FJ\:#*)X"I(;OMNNCUE]RIZPK)D%./#]$%YT>T<3<C21\(NORH\
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MC7?2Y2.O^LN58^_%M7KXPW:JOKMV>*5?3@,43/-P%7&?F<OYF54$ODT*CS'
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M:P=VM:O.3!CIDP[UMY#; ?7'^#(X!%P8C)&E-X+;!D"#^,/'XV$#8&)\/0.
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M<K"C@*6SIL3UB,4E1<N7D&G[=S^'4PU/*[=4!&$ZSA[T4DQXE1CT= W_[EA
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M[XDMQP5_"_X^\]#"@K\+Q]\:G27"PH+K@'#*E:$B#<@)Y9".DANE4M"1K&W
MP=LD[-ZE4PH %P N +PZ[L\"P L'X)I)@07"$@\$"2< @$GBR' !>!RC$EXJ
MKV@N0T%TDYI%M7%\8@"NC!+_'N9-"/^&]O>-Z;A:L.OZ;3^5F\FO5P7%1R%-
MB(IY[;E2W(F ,?$.,Z:42?;S5F:*F&""+BCC6$;"=_OJ@S^,8=2)NZFJNK_=
M'>_O2DPZ=AC#7N^2$6ZPEY]R#[[\CT[/?UO1;7[PWT/LC_[IVD]FM'L$&Q*V
M^L[6NQ\'6_"^K?>=@[T=V++;Y "^J_7I-=__ZGEKR]/_GNV<P+;^3$$94)YS
MI$-N(::M1#I74HJ8!!L$!K7!K#4B@,$QS/*P/XJPU+"NTXUX9/M?VMUJ.YGI
M0=;N9BQZ155UJ#XR.-,,SGN'$<"MT^F=9-\V !X\)GQ\T!A_*@9D81O;+Q%&
M-@2X@[\T1H.81IU&KM0X:/12PQ[U8*.?Y4V2O>.3^CV3NO0-.P'71ACU\W?D
M_=C,/TE5S3X#>A/>"U_8Z>1_OTS2@P'@PP@$/-\*MF?.D6P<C_K'O<$XF+CG
MV]73G+2'APW8Q8,X_JK)GGUUC@>5;,U?"#E_(2JI/ >0,0S @G3L\2"^FK[X
M/;0'QQU[^JK=K::U^M#ODYM/4$4<UU"@^KKQY=]/VF%X^$K)=3,^*"<VRLD7
MCZ^2]>K2#*J-KPFY#OONVLMXG5Q[[6>W)70=#MT[W?;GUY2X_DM?RL-R?+/;
M_L)H_4L/%1&U]\[1H;,_)?8?1UU4,X"DYFJ+^]'V&Q'$,32VHH]'+O8;C#2O
MG.[WG9M+A.>F9_QR3UK&U&O#D&XPVLL#OL^LK>+$D3)Q=YLX?!N9?!:1@)]N
MJ!/]UNXV3@''!O]Z=9/-==W4+&S7W3G,X>4^Y(*R\RIJJ)9\6R^P ^_J1NE/
MDL6?3[VJ^Z62+M\"_<P<8K372CK&#(M<6&N#XP&S%+1WA-&Q.81,S2'DLCED
M:C*<V@#?7%^+=@K_FV/T_UA!_E_M=#7D",;G7P'7S0? BII*QA;!XV\[9]MX
M9^_;6>OM/C[8VL:[;P\Z\%_[X.U_ONY_]?",^R<'6^_X^6>F%L&C;-E[]V-W
M;P<??'T/S_2.'QQ]A/_^\VW_J-5NG;WFK:]_?&MM?<GFE7HJ%*&>*"$%\L))
MQ'FPR)!HD8B1)&^8)53D5ATUD]E=3MLB4'/LBU('H& ITMP+TB2=BP13QIA*
M6*B)?1%/!0H7@5HN@:IE%@7*A32*(6%SS%Y*%FFJ(@I!*>9,+@Z?BSCJGPK4
M@E3\E=")KFW!>1^%_MG 0R+!1)FTCDEPS8UAQ 8J'?7,^\3(3]P/!1Z>&A[>
MU6L/,!E5U"(A)P1'/#J*K%;P:V!< NQCJ>/:!E_(<;M 6O=LY(EH(W/8D2,P
MX8IH1Y*P-&3?=Q#>TJ*_+K<\S>JORI/(+9:()4$0QRD@QVQ 1E ))RVQQONU
M#5GDZ8'DR3H8CG<>.TDX5<(EDA3G5FDK) ZRJ*]++4]U]371@)W1R.<@$6XM
M0]I8@UA(/@508K50:QOB)MKK=)M.]Q(?>WR?CBN6>_SD'B_!J_#V!@$/]TF;
M>F[!D_.&N!)'U5.D %T*X_I[U/>'=A#_!FB,FYU.SU?&_NGV>_WC./IA5;5R
MZWPC;A[!S+^(^,?'.MWF-.ZDV#"I<D(E*"V(>VIS>SZ!K!$AD"0=R>D_BVF,
MLWPYU07*GBF4+3J;ID#9\D'9+/&U3L+QY31RQ&K$)5!@:[5'B<B(@] J4;FV
M021@&;EWLZ""907+5C0QI6#9TF%9S>C *4Z4!XD(501Q8R5R5K/</YERD6S4
M-JUM&-YDI%Z-[XE[H_X\L>1F60F$K8N'S$NH[OBJ/81!^!MD*OS=[XWW>R.U
MN[;KV[;3:%\DKC1^&W7M*+1!5/YU-?3_8=)H?B;1_=Z;_%B7TFI><O(,C.<S
M)X)90Q4R(E+$211(8RR0YXR8: @&-'T>R3.GS<9Q/Q[;G/&2'<?PVW3?.CMH
M#YJP W-2(CS%$#[>CX-19UBET?2.8W\<?I?38-JI87-"S*64EBK5I=VMMG"[
M.\K?>>DS<"'OT6E2#6D<VM!P,5;OKYXMQZG:ZJOR-[L(,]JM;I*J#S1S-[+.
M* -0]8;VT3& 6;[J 6\LW-^&KZ/!L'*#PVC]8;[;-/FGDD%X[T4"T*!Y7BNS
M$>$4ZPYB-2,7(YI*,GQA?NJ+9F@- $,X]0;K-TWBF0 GROK3TV3Q:+/.J+I+
M%H_,22%T\;DF<ETQ\P"),9+<+=WF5P_+;_9 -TS^>%+E>C:&_KJ0TWDZPOF8
MS(M/X%G]-7RFJ1]/D&PTP>+ZK9[5Q)(%B<E3#NZ>8/=\UG,>(WDI3LT+MC;L
M <,#/?=[[(Z*(_/%6,SN1*UO:3H;3)GV^_'N>@D&L9[8K[CV/X<M^/Z=/8];
M>P? P?]I'WS=YP>?X%F_;IX=[/WQ=:=6IZ5SN'/V#;[C-=WY]!KN_XX C^>M
M3_\Y:GT][!QL?3O=V6IU=M[N_*BR,F8-8D2QE"B0>!88R23>( N<!REL/;-<
M$&)R1W'2E)0WJ;IWI:QBWR]H]4AH11-5R6%"4\0\>J.-8!AS&I56(80X-P"W
MH-4RH=6L*Q)6C1C8"$A2+1%WBB'GA4/8>P'K)X1-JD(KA6534[9$:/426H->
M*(C=.)R:_E*_=W2->=,.A_VV&XV->L/>_[C^OR<KM&7_:0]M8[OKU^^3M_O<
M\'K>$)\-7C^J=MF*P^UJ?_[5&[R,%FB/A-IS,I$TP3HY*E'(6,V)#$CG1B/,
M"28)-R$%N[8AN&AJ46\OL/+9^P6PGBE@/:J"60#KX0!K5LV,P3A#-$$6%$#$
M;=3(8<>0$9YBI:,)FJQM& V,F-X[>G>!@/6RC)#9]>XO:YJ@6#8&A[;_,YWS
MDHXYHWTV[J)S%AO!BD'XW['_(6^1Q>J>]!811*]M/T=H#*9/\D?>QN>8C0MF
MWP"S/]:53$^<$,0YY$*@B/MHD6,*-$T>2-16.FX2*)GKNJ1;%'A:-7BZIZ99
MX.G1X6E6I?0V&4^C082E!!S8&60488@$;^"@T9XY#RKE.KMW,ZABL[RC/AG:
MG5$.IWQ:C;(8!9X'9#^A1KDUWL@%M&\%VG.2>(,)05OND7-9IQ0LYFR1@"PF
MDI$0F3(RZY3W=XL7JV4!J)>C4Q: NB- U6JJ @)EU1%QE0SB25&D<8(?1LJ@
M-7>4D[4-O6X6U6*T)+-=GSGT ?9RSI9YO_.AD2M&Y7?<)-=ER9*?_NP=P3>?
M@CK\/0ZR/MP>#AK'_7:OW_AN!W[4L?U&MHL/!@TW$?GFE3$W*X6W.<GW@;LT
M=NQI@U3]@7"5%-0_[]O6L(U.#^X$D#683)\]/N[W?E0E^#NGC?]S"W],\#A@
MKZ7"3O&@K+41X,T))3B62KI)A3 QJ1"67_S<'_/6MKO9W;+;S6N[FSX,>_[;
M=O?#R W:H6W[I[O]UP!VP].=.#SLA>UN-6/// CH[FF#VR>[>_ZS9,'%9"PB
MRDK +!-R3\Z0RT(S%RS%FN<8'MFD@M90:R9Y+%^>D+**C%T1L<G.YCG5Z[@W
M/I%>C<OA?X^3#*_)Z7GI4Y.<!'SQ$>L&O7Q>7?N16L#Z$TGO&\3,S/Q<^GEX
M7B;MV'X!1;8?[3=D$SSN*]LYL:>#M7]?12B I\GMA<Y NT3CK\7F5^/?VOQG
M>V^SL=WZ\_H<PV5YUM;NWNL/C;W=QI^[K0^[?VUO;>Z]WFJ\V6YMMO[<WORK
M\6$/_K#SNK7WH8$:OTWV>"T-NGZ@7+0^K.=1/-%0?PLY+[,_J*"_LJ94B:V
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M:P#6)!$LKT*>86:M\,D+,7M(04"CT!9+I5G,AI'U.L'2"P8V4K#)SQY23/8
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M +HYUU^*25O'$Y).@;$M<41.<8HXP5%+H3SAL5;F:J"K@6X"=%H1I;"(2NK
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M3*)!:Y:(H(EQGAPWDAAEL#!12B-LJC%I=3"I-8M)1CGG&(V(PQ8B'F)"1I"
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M,:Q@%R:6G_5+=SP:VTXC 5L-?RV6&'[L]O.L^_ZTW'$[B 7=#*I=2P"H\#)
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MH'TI89LE@G9A6]H7)??]\NKWW8.=[5^SF/H<>S"#?,EI/&^<Q4&AH?9\?FH
M5!SU!\.2-!=._9*VOC?G=A8;U4*%@B=!6&:H*"DF3S 4I%T@1R;%U!E[$ WP
M7;E"!5EGWAB"<M1.,+8L2*Y4ASQ^ (=Q"?"P"I><>W7-:(K%*EX<M(>G#1M.
MQL,\M8(S"KZ" 8_S:T&9R"1;,-STA+*244G!8BFF*!Y4A2=.\;!Y/Z"%P9*6
M6PG$#RK@68$Q_7)7CN&UL%:9*MK%JEV]MP."(BM;F72O7@^H78D"6&K;Z&9P
M/.O$DJXJ_LB[4!#99$P!<.U\".,XLX-1+PZ&Q^VSYA4''H.JTA]D%?SR&5<\
MTFU_+7FIE":+6:7"9-@J"] );TR@WA12=@@#K#AI,M:*PO(H2R:Z%) E1H1<
M_F(B@4MLR./\4@V\,1K WI:62SG7R^FY*E(S9HP8?8DQHPO(OV(]\]S;5_SP
M8?/]9OX,B)&).>O'P^:EKIO5V,QLTQK 9*D+Q:EDD6*5%ZUNWO3I[0X1Z*0+
M@P-9<]YHCX:3]^87QJ]G)<)-K7F%"$!I;3<NWU_PRF9CNP"1Q1I\GD#&3A"*
ML*YY:6+UN9IU2?<9BL#JLI^N-J7<D_*JZUL"+^OW !T*#BLAM)*:)<(4S_TV
M2M[(-+ 6A?+TM;@9UNE_[E)N1<K"?V$HUSRZ9%C.$90X"LDY<_CCSJ05,?IV
M3^+PV;[X$Q ,H-QV=JO5VZE6;K=WZ<?83XO='<.=<3SHORQ68[?W=[7$V^4*
MERO6JI;Y:;M"COYSC'WWKY[]VXSW\]C^/F2')ZWSPXMWW:.#M_1HYY78W^FT
M]^@KNG?AO[;>O#O=/VBQ_URT,+S_HT\Q!$(CLM@:Q(DBR IND24IT,0T)BZW
M(9:ZB1>$]4XK7ZH !CLEA"IJG,C!PC^L?AN"%C,Z[@>0+)_.2^ L*7FBXE^1
M\_ N\#\E,M=1^E6+](_A8L4WKU/&,% #VME&R39RO%3SD_43\R2#6'41:/6Q
MQ/<IO:8R.UP[E.H:Z"13ML]$?1^.!N-"RP1-[_PLRZEL7C7 K(F=!BUUQMMH
MWC,D +,+T<&=US<HDU6IUI4(>&W+JI7B.>[N#(RU?,&+0L* R/KM2SN,CB=N
MV:F[*A<9OKK%NF&_,Q[=?,N4ERS+B3AX+-\5XG1F?:;^/AY,QG,&4(<<(.8I
ML@F&^\)VOMCSX<8_KU,\D'OU>*$W\R*NSOSGFF\7\]_9_FOW8+NQN_?R9CY>
ME;'N[1^\>M\XV&^\W-][O__OW9WM@U<[C=>[>]M[+W>W_]UX?P!?M%[M';QO
MH,8O%8W'\.OW .K*P_O;JDSU%T#L#FAL)<(< ZQ4BEU_#(\-@!3Q:W:_9'VU
M_#W;6?;FJ=XTL:U_N0'0\ (.6'D@_]<,D)4Z!<:**L]"$ 3S(+6-5LCHHO#$
M,*/]QM9^ 9NIW0,E'Q2B:0 N?,!@+4S9\=GPM\/*]Y4_9,<I"(P2K[-P!$#/
M(/^-JZPO#,U2*6X7GH"I+\_L>?E-:8' ]X-QO.8&:X(LR$KNM&<LOZF$]RS0
MG.UDDZ60X8MG5CX<[)A><5OI:9M_:N'#*.S?2W7YNF/\ZNE3+O+ON]SS)? L
M$+93"O$U[2. " ;MHK!.CON#$<H6!6BPA:%52K;V8,H!EA6/.5$V1_X%33A*
M-:4R>D$(-\1IY8AF7@90D2PE]B-3<N.[=/](4$#%9KFF\W__Z]I)T4R; 3 3
M3(B*>>VY4MR)@#'Q#C.FE$FVM!XPP=/6P_5CT/?Q4U[H=Q-7S@YH&IU^=O4<
MP&M^[_3]Z:,K\H=7BOR./P>E^PLHW^>MG0\X_SD\^81;%Z>B=?'JHG7PU^GA
MP1_'K?:<(G^Z=['+]BZV\W._[!V\A3_OX)UO+_8/3N&^UM>]O]\=M[JOSD&1
MASE\^,A3T-X+CIP5'G$=.+(^1B2<EQ9KK+1A&XU+";2=[:$8#78:C#K!$_>*
M:X(MI3X&ZIR)&F^  NKM6<9JX/^-K6KUKSQI<P>#UXA](1A^_YW7QQB\9T(!
M4E*FN=#21>:Y$-0FY6WD;F,-Q,)U_;Y_5N2N9C]D>^*PRB"7CZH&[<)!E I=
MO_"77+HZ,FQ-'"L=ZQK925/H[1,73..7^9LFO_W:O'IBMJ ^#8KGG+9#+YZ#
M>,@V0G7IU)45^N=#U$[.+KQ\91Y+NSB) T0L\W,!?:N)Y?F JM/I3(XERR?.
M/^;7YO312;N0=8.<R)B]LP$45Q![@T+-!UOO+)/<M,EQ:4/<TXX63WS1'H&&
MXF^QQQO[@T^V5SF^-^Y[<-\<2FF'#\?=;E[M #P\:)=GD7/6V)7[;MULYOU>
MXUNRQ@1FO4R %4GQI*,E3BC"&)-41:UEEC7$8$D,FGR8]DU-$M#?@[[TJO"O
M A7N &'NI_S5=9]2UD)0%]Y^G!^ @CU'V;>)8N_9R:*W>'_[HZ:: %('I$46
M148F9(QCR('2BTDRUB6ZL?7'N =<;+)21LRL(&E>/T"!_W9B!JQ"%;.E\ST#
M!@ F$/M.Z\T5"H+"MG\V&G<+MZVM_.$EY0,@3GFRF_F^?PPG'O/"ZWJ%8,<6
M8,=E?_;E*3^ 5'% 4XFGZ:L+E@,<@V_:_3"\4EC7C:T.%OCKK@36L%0 IE<G
MQ%3ZV"='&\46Q3-;P/BTXE^R3'$H7QU[#>*G,4@$,&E _PYC'T,EY3ZWXY?2
M;[_(?^B/VS%-B]'H"S':Z-I3D%?MXL/T#T '+A\3P@[U?7D/[$]_/,BR#.BE
M=(0!" XO?9"7XYX^?;G!GSD5C%*-**]K05 3JBQ-HN\,O'+ 79)]NQ2*+XN[
M7GV-?ES(POV40'H.G@)E7=+) A(KSZ/CCVA"2U5VRDNF;Y[B^QRUE ^D\NEX
M^Q.L:?]S+#^=C$&7"VU_=3*>'U.%.)4>\.DXI<JNW?YS^V7CI-_.9[WP-=@U
M)>7<517\[QC4EE28SQD$)^M\&3=1G/Q72UV=VP-ZE4OP37;W1466BE%#:7U=
MF>7E RYO UZ+G_J#M8M+NQ4(WH!M%=E62U* 7%[P\G0R;\,52E;:<P?8OV<_
MQ>NF50;4=G7*._H^=HR'%925$!>G .X*W6X-;?]8!/J;C1Q5^<U!-R\7YQJ/
ME(P<VH-\7#-S!;P@'\;VBA-DP.A/L0??Y^.&^+6\[WM& 5PPS"ZM+\=MX,2%
M[K)\;%Z\'+BE/V@"*?= ;$V"N_J]3Z5G!T::3R0_E[88C*G<TLOQ9<=;!.9I
M9[&7CYZK@*;BQ47X0;@:5;D9/R,SZD.2;QZ2L/J0I#XDJ0])9CE@H=?MNUZT
M&:^;]%81[;2!/]P(IA.V)#*K--$P<W^9 W-?CMYWUX+W]]/^!"?_'/0!N?_=
M'PY?#_K=RB,Y/.B_G#H1>-Z^X%<?:1*,Y'J2$7...-<2:4T5@EVUG JMF92S
MOMWUT,H2L%?_2Q$',ISR<8'4'%[ZIHN KN&<*@+WE/-J_ (Z:^%\S(K13)K(
M]*/F;@21?NW@J0I&+P/)2_[)5T_I/I=QL\6%1=#LB]LHPZQ8Y4I-GPCK(O<G
M.U;MV3"^F'SX#;3PLXX]?]'N%6M6W/3;=8C,$FTFYZ?8U/+G*V&WB4N!5Y5+
MJMY<_;Q9_#23JE3^)NFFTOK&G_$FN?&W;SV6X$W.S0\]]MN_"7;S2Y_-8 6_
MU6._4S]K)>HDJF546R/B-I,JI?#C3&M.YRBF=7B59S8Y\6XPTKQ+$;2GLXE3
M6=Q75>UR)F2!VK<I:K=Z&YQUI&5-^#9U I_2PI%ZX7YLX?!]%%%<D9(&BR?]
M?D:#?'$;TKE%P\D[T<+J%3OXB1JEWRF;4:]GO9ZK4?)U<<WO%2SYNABYKIT.
M+:.:\+IN_",43ZZ7[-DMV3(K2E.QJ58'7A8OP9]VU,Z*477,O!P%:=V)X!%D
M=KUDSV[)EJG),+7B.//J:Q5:4$4NW+HZUH))/[4J>HNFN-K4?(>T<HX=#<X3
M'PGARBC#3!+6!IF8P3RHA>>%WZZ65TBH?$*8^T;E(?S='AV_' ]A/>)@=U+J
M9+L(BXGAP'Y=ES3Q'SM1+"OF];_NY6>=_'YZ>-'IM'9:>'_G]Y/#[A_'\(R+
MULXV/SKX='YX\HJVWL]4S,O?'<"8WKP[V?_[PY?6Q5O>>K/7/NSFL;6^M':.
M._L[?\"8#[_^YV)20/35:&^G==ZZ./SZ47AN6 @>,:$UXB1ZI&%'40@*&R^)
MX#CGF>,FU[K)J/K9@GG?P,'[*A+Z'0VY1J\GBE[4B>"(,)9(SU7TQ@H9,/PA
M6DCG0H%>9()>MZKU6:/7XZ+7^0QZ1>.H$%(@(7E"/$:"K'()I10BP]A%D5B!
M7D*0)L&R1J\:O=8$O8(2#/0L08D7/!IJ.*:,$A.%3,I+7J 7GJ 7KM%KY=%K
M;U;WTAI4:6(Q(I$8! I6[MP9+(I.<BPCL4304O=2HDD56R'T6J:K;>7MWZ*X
MU6P<VXT>%'JW55@(RFN-7%[&J+3BED?0NZ2S((UY[C@1E>-,B]IJ7"_D.IRW
M&HEEQ'(!4*6X0SPYBPR5%#'/L>$Q""/3QI963<S%"O4<7K:C\]FS.E.*DQ@P
M&%B$&\>U=9YZ$S3HY9A94IM8:\?JLR96P)PK(PAR.&#$%?=@8O& (L$I>AER
M^ZV-+0,F%EE6-X6:U5>0U3%6QDM@8&\2QP);@@VV7B<B&<4^UO;(NK'ZG#WB
M+9<T6:!KQ0+B5G/DI+*(&\H%5@IV.X ]PGD3&[)"O+[,PSBQZH?^US/.SVX(
M ?@AZV2^[?BW0]">'L@)ZH+06N0"<)PDJ:EE$JM 0F),&E^;+NL%<G[>=/%,
M6,P50<'JA+B, KE@#1)>1,-R&S#B2I>Q$DVF?EJGN2M3/;(_N0:*6P%%E"P*
M"J8N"YY;:HU@2FH-A@]Q07%:&SYK!Q2SAH]R*<D4%:*&2="&#$&PN0814)-$
M4)(*4IXM24Z:DN@:*&J@F <*Q<!ZED1X%21W#A1G1SB(&N^T2HS49M/: <6<
MV11)]GXQCPSC&C0*$>&3"BB"K4R=DRG9"BB(:3+)UP4H[BNW;+IL@>#S&?"/
MRMK[5:.X[YA1#QPF^V2?L4S379+5#]G_7BCM7:3JTQ:<2X\]+3A[MRCX40O$
MY0G$TWD3&S:(21<T\CKFN :OD0Z. DEA1D$-(@F;C2W*FYP_P7C2FH7O+0"S
M9N'[8N%9X]>G8"*U'FF2 N+,:.0<L[# S-C(N?$VY'X332Q_^B2@9N'59>&E
M1R'6+'Q/+#QGEB:)DXW8(4L411S;B+2U%BF0S82IE#@3&UL,3%*U2G'1RXPL
M7 >+H XNW-CZY6&C"W/[:/CT36BJT><.Z//J2T:>T@YX>]$Z:='6VX\Q$:TY
MT8BEJ,$*8!P93A5RQ#CJ;!!!J.P6F\.>7^MXH55EU,<,#:S9\V?8LS7+GL%B
MZGV(B#@.&KX'<]UI1I"BQB?)O,3>@H:O?]I=73/IZC+ITH/Z:O7^WCCXPRP'
M.^%4Q#1K]#$BGCQ%#O8,4>Z-U8$0I34(V"8QJQ2#_ZR"]0[Z(]N9:1)SDXY_
MOX?H*[<T=T[SO/W\GPP\WU<XXK#&YB5B\]<%QH\6W ;I$NA41B >HD4N<H,L
M9\I$;*SQIHPR-*:IL5F7F( 'REJOL>[98=U]15366+=DK)NS)!-WU/-@$&P?
M8!W#%EE")=*,<A>QIE[R,OY)RJ:1RTICK[&NQKI5FO@*!(766+=DK)NSN0T-
MW/N0$#8IMU#6##E**=*"<.68"8*5>IT4IFG83QO>:Q;KN3:5N<LP3]38GFLK
M>^_-!1X[#O.)#O)9563=BZ-[2?U\VMYN[DGTH)]*KD%G]<0)&7T4"INH?'2+
MVQ_6N1BK*Z$O%GA>D@)9;)U#/F&*N P8.:4C\BXP%WS(<<0;6V!9-@FKHT^?
M,+<KI03QB>*((S"\M(*YE)CQQCG*.*Y3-->/V^=]#PKL))PDPAHSQ)/PR&$5
M$58N8DD-==@!MTO:Y$MSLM;<OH+<3KAAW"7C<_%$:[DF4G.0ZUP)9B4+=9[E
M^G'[G/5MI8Z$!1#FWAO$'1?(*B%0TLX;9HVE6;8+@9M&+2L?>]6LZY6W34K3
M.BXCT>U9Q. LW2JI8W#N!Y'P FO#*NZPYP;!SD3$@S;(& J:".-)!FHTC6%C
MBV/=-/JG#S[J2+K5Y>*E6QLU%]\;%\]9$8X*+[S$B 07$.?4(2=8@"7F3)@0
M8S1R8XMIW*1TE0K?U5R\ZE9$S<7WQL5SU@$&H<L%IL@[$,,<BQR"(#4RV$6M
M)3"RBR"+-0?KX*<]?RL:$;ORUL'RTMV>A5LC)!,UELI+!6H%4\ZZB%70! =G
M%#7UD<6: 1=98$0P'+B(R:$D(D:<:HZTH DYF\/?P#*T"0-P->E3;&!4\_J$
MUXWUU#(!^D=0'!MLA'8^)L%(D3*GZP.+]>/U^;0[0ZBS.1Q<J\)-()'A2:/H
M1%!))<X,+7C=+*M.7,WK*\CK7D?++<= "IIKZZV12D;O(C4R%PVLCRO6C]?G
MCRN FZF/ 1F2)!@DU"(;@.$U[+-B6 M,<K"@;"K^5'M[K4F&GKU]&. M?"3/
MN-SM?858U9'-RP0KNL (D50X;G1$5JE0&B&&@6*B7(HF"(=9P$4V,29-1G_:
M$+DKJZR1B_09L_]]Q5S5[+]D]I^S2T04W$2:&[]C8/]D'7(^6"2<9-;@&*W.
M1:R;F,NFH<LJ"E*S_Y-B__L*PJK9?\GL/V^J^&AQ-&"@T$!RES^"-#8*A>3!
M0DV*&$H+]A>T*<U/QU8]%/L_PV(CO9A30I9WOO*,X2RRA*66(M*4N)"YBAG-
M=HUGCDJB76W,K *<L07&#)8@?Y+1R 83 <Z*;'3C$ DA)<>D%BYK,Z2IP)HA
MZY.F6??N>=#J:,E@9RSWE"D>,-982&)9\$08J8VMK9D5X?\Y:T8ZJG7 #BFO
M$N)@C"(#R(V<QE@Y*R2 >LG_A#6U7E8>6,W_3XK_@6*<TTDJ$R,GV#D>A,*<
M@$SQH G8VIQ9$?Z?,V<2%AA[D5M[<H:X91;!3D90!Z@3T6L?<@>2@O_!GF%K
M4Y+F61W-O.JTN^V>+;BTGQKMNE#ZG0JE$VL$MUHSIT#V:>FD5@(K'R6SCMKP
MXX72:QB[!QCC"\R8X)+'(2D4:2ZA;JQ#VAJ.F"+84,D9R5U8#&E2/A^67I=1
M?Q)L3+$#;=:"!:("-RX8[X2724JF0XJ6W\((J=GX0=EXSAKA1&AI+$.$Q-Q)
M.%#DHJ (&RDC5C0&PX&-11.;NAO"$V7C)#@PIX\: \\Z$ATP:PH&V!J,4:/4
M+6R)FHT?E(WGSTBT5RDHC!B@+.+<Y< N8&,;%:8NZ"!,;F@B:1/3^5H3C\+'
MS^K\XV6_5UA<=A1#766]KL9YZUC<**0)43&O/5>*.Q$ B+W#C"EE4AVSMA*(
M+!9EWX? C P.>:QCSO@S@,A2(Z(DP\DZCYDKW#P2FZ9>6D3]NKAY:ZRKL6[6
MFDQ4)0?J98J81V^T$0QC3G-+O1!"K(^T5@3KYFL4Y Q!8DP.RP,C4LF$3. 6
MM$_BD\]M$%EYI"6);BKSW(ZT:JRKL6XV?$=XX 6-/8Z1<YR<<HR1% ( G/*T
MCD9<%:Q;4.=-14VL0-RX_!<1R%GXBQ&I+/56>$L*K,NEWB1>&[UN2<=W*X),
MBRNKOZ].Z/IG<6!',.I&UPX^M7N-7SK]X?#7%TNJK\Y@"T)_[#IQE6N7/ZU1
M+M.;1,S*T/%B07.M:=_/I&$^487B:>H,2^^XMS^!P;((U+\! VOU87GJP^ZB
MYGN,.Q9Q(LBJ'/WKL4>..8P$YL0K$R+6V5'?%%(TV8(&Y&M?9Z&&IR<*3TMO
MDE?#T[W#TYPGQ\80K:0446TD6#?1(4N(09Y[(:@W4<L<G-@TBC>-7J4ZUC4\
MU?#TH'WM:GBZ=WB:<[X0Q8CGT2,<&$8\2("GP#0226-&0?KH5,(344OTO:RC
M>R6T/T^>73T"Y>M?$%W W>,5W_]67[NECDINBEL,Z[>S_K"=:>/%(': G3_'
MW[+; ;'B[MG5M<.8'["Q]0NYBIF!I:[#RNZGWLX-864U]-XO])XO,%PC$2+)
M:)'&WB(N;,Y8L1(QB[&78-'J:#>VC&P*M2(!9G6@Z+(Y>@DE=&J.?BR.GK/U
MF,+$>2,0B[D_&;48F=QC((*&K#@GP@F3^Y,U,9Y/0JLY^DEP]!*JXM0<_5@<
M/7\V;17H5XH@9XA$7"J-="(4!>-EI)Z7=?*4;%*Y(CE9SRH(O"R",TD3+8^>
MZ_(WJU'^IH:K^X6K1>V0'3$1_C D-5&(ZVB0"R&A**4WVFE+2V\.E[JIV$\W
M-UJSJ,$:"1ZG$$Z-!/>.!'.F2/0N$0%6B--! !(H Z:(MRB*9'$0(MA4G(J;
MHEEA71*K1H*'*(E3(\&](\&<"<,%4T*RB*S(U7&\!Q/&FX22CA%C&72E$VA.
MFFQIK0GJZ-HE1->^B\".OMUI7Y;%&=X4;SOJ9]:]RHAM%PS62(-^]U]N\,]J
M%S-WMWOC?%_U!+BGX2*P8)S<,K)?X_"G G=7)>AUI9_QK,)K7_8'9WT@M]BP
MH=ONM8>C07$RV!B.S^"'T3-K"7@7?^+2\I7#9_NB"M=_%_.B%V*X%+XPALLM
M>O7U+/:&==[+4@7SHD: ,@8PL#1!@DI0T1V)R%CF$1 UC4Y[HH0&P4Q-4\J?
M.0!<O9"PFKV7GZ);L_?CLO><!4X C54""SS9'%GE@@6]VQODE5<&8P=8GHOL
M%SF\\_9WS=Y/@KV7EI5:L_?CLO=\_W''"!4@KCV-^:P_63"P0T!.BQ2%T@*K
M!.S-95/A^?3\1V'O9=:370.38\H:OC*72R.W[O>W&K63:G_@_0+7HM9_SE#'
M<[<,8G$V.[A&UKM05%4B6$2MN,C^0,9,$TNZ+LU_ZMY?:UU9J$:">T>"^2Z
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M1=)<>6RD49$%Y:BC1@M2X- MSDQK'+H'')I+:XVP11* !T>1L[D\1Y9)BQ*
M$TO2<^Y\@4-, 1;]?(K_&K=B>31-]/N)6VNDEM(;U-*[5%IYVO'JTDE!F3.,
MZ<B)<@8SX660F/LD#+>U'O=8^+F@ZXD*C"<,^!F-$*#'88N,(1118I2.U$<5
M->!G4W/65$8OZ=QSA2)#:KZ=\"WL.XZ*Y71WQC'S5KE HI28:(/!,JOUGD?D
MVUF]Q[M$L*,"L91KOGOCD7%<(BFEA5W$E-FL]S05ETVN5XEOE^2 *]ZM5MRB
MFHY?N,'1_;UI_WBA_>=@@2YK=9X,B'OE Y4Y#I0*KD"&^^0T2Q;^'R)CLE:^
M'@O$%Z1)@&CU2FB%6&0I&Z\4.>4$@NUCG!@/$MD!B,NFH;I)Q4^795HNTZRX
M_ZT&SAHX[Y)EG:+T3M/,D!Q'ZY*-6)N :221:U%KOX\(G+/:KQ&4!<\]J+O.
M((Y5;BS'(R+82HZ=C:;0?E634+(,]7<U@'-!Q.[BP$>V$H&/Q&QR_D.!CT9O
M&GSSSPN"_B875-S/RNE^*VRHFLDM(Y!^?.F+_E+3?4(0T<L/MC6WBK6=.E-_
M\+=?7Q6U*6A>A=V>[XP#O"(W*1F=-[IQ=-P/1=N2?N$U;O<^Q^&HR)#((<+_
M\PCGR;M70]CM;:=41*S'X?NQ&[9#VP[:<0B@W_?%M]N]\$>_W1O]!9?G=BQ/
M6Q#\>$P[C.WBTT=F':/8>@3; 3A.-$;6X(AP](QI#ONFL_>1L*;2\SD7!9G<
MA2*6=;)74\2]4,3>SH>/.! N/-8(&!-,HA1!LB>*4:"!&I%\LB['%1#:% L.
M\W+CL,S4!67DO6PV8,7/HL_G.YWSS<9MT@96&\+I<X+P91TEU0Q['PPK6B<?
M/A(:F/')(>T,!57<IER'4"',0W!*8>\(S0RKFHRJGX?P91U2U!1Q/Q1QL?N1
MZ,AXB!2QI#3B G!<IQ 0EO!EX%Q'DX BJ&RR14+]VQ!>?-V>0(X].QOTO\*J
MC_)/=Z$C#DJ $M;::"V7/'?\P-AID;!.V'AZ6V2Y,5MW+S[QA-V?(9/]G=./
M"M2ND$@$W2\HQ+G1H/MI@R*U.BC-<CF#G!H!1OR"@O1W!@XML ^)Q0AZ!%=2
M6J'S1Y,UT("#ORUPU!O^0QM^</C1NPBR6W'DI">(V^!!9BB!#$M621N#E IP
MP> F7E 4Z#NXT,RJ12^.;FI]603YQ- 8]1N@E#1>]KN@/9W_O_^C*5&_Y8:S
MHSCH%8G(MM/(3R@^#V<Z!=^NP72QNXY23:F,7A#"#7%:.:(9+ "\T%)B/S)E
M-KZMB)H'2,I=W).7RLW20S;_]STGA;^TP^/7G?Z7]^.SLT[,6V<[.^VA[_2'
M6?*N3A+XZ82'V-')*?S^1P>>3UH7+7QX\9;N[\!O;W:_[+_9Y?L[_N+PX%3D
MON_7>2AT]P_V3EK=#U\/3SY<M"[>G>1J!ZWNZ]/#DVT.?,CW+O:.@9_(?RY>
M?=G[])&"$@QK:9&(W()H-1@91S6*@5%#HV%$N!+WBG;0VQF)3.*8B.@T]YJ+
MW.:#D>@#C[!%GFDZFS,^O?(-#]O12+ ?P"$EM@&5S[/!-(\L;*;\W4'<=[&!
M]_XXAG$GYE;*WZ:PU6J3_.!D]K7U]B.Q8'-Q8I#G(H 1+@32H..CX!*GQ(0D
M.%F_+LD'@/NE!]S%3-$@*3ZWLQ8Y_"[%KU&Y 8TWA1 _U W9;"KR8W4!OIG!
MSS>E_K%6P-]I,(Q5/5A3=T.NNR$_M4U\HCG^=7&$NAORPR[<\^N&G+7[QIEM
MAQ=U18FZHD2]GFNXGLM,$"!TDXH5AZS=GN]WLVGZ-?[_]LZ^J6U=:>!?Q=/[
M//>A=^)@R>\]]YZ9E(06#@D4:#GP3T>V9>+6L7-M!PB?_I%D)X20M $28B=[
M9DZ!Q"^25OII=[5:I37NPWS5-NS-#%?=S)C3I1^ D'>E<]Z33M@<6)7UB)<Y
MN8HHU.'E?1MU[O?#JXNKX.I'0VFSWX^;I]VK'X<_.^<_%;Y&T3F_5L:1J^,H
MU,,?[?NO:OOB6WC5.^RUFU_NVQ=?M<ZG_5Z[]P4=GW]1VTT7'3>_#&?FP'!4
MB]JJ[\BJ[YJRACTJVRY59)>JOJJHB#B>^>Y/5=-JFEJFC>>0  .P]*:G!P"6
M5HFEZ>!XWW)=U<>J3!2DRII!=9E@6Y.91 GK8X9*;)M;AW;-A+P\@*7*8&GI
MJ?<!2RO$TI/\^HYM>10[EJPIAB)KML^P9%E45IE!BXBI.LC5>*8>K6;I9=*6
MEN0UJY YFM&$IMGS3-%%,V24KKK//@]E,^&Z E,T[T:<K!4*C:L"7&>D\4'4
M5FRL$MFW;$98FU+9\9 F(QN;*E4\S5=\9HKJ2LVVEW7@7HF2^ "6-A1+*S!%
M 4NKP]*3[(RFISI,+#+5'6:*$J;NV:IIRXAXCDH<#>F>QP^XMFN*\NKL%H E
MP%)U35' TLJP],04=4U=-3S?D FEMJQI.L,24129$HH-PV=BM0C3EK!10TL[
M1+-$J=-*39A.',DB!C??-LJ*+79R^$%$(E?\Q7=\!%E TY>%>/R^3<J'IE=$
M'?S&6PI-!DVVS%B,BCN_]H.[<:9&I@!X-)D@3TA)2J788<7,=X>!=VQ+]+VE
M>\?8+,<GN>/DA"19\8<X_S?/22ZZ89Y)K#@5V$.@$RY/)[Q\ZD'3;,>W3-]C
M?<U$LF:YMFS[[#?DN)YN6J:F8I4GU+5QF9+I@J$*X'I3_QF :]W@FO:QZ2YE
MYJSIRHJJ,V/6,'39P8[*P.7Y-E(TS5%T9LRBFF&_>ED5R 7DJJJ+#<BU9G(]
M<<.9ANJ8AF[)FL^S&6#?E"U*'1DAEWJN8=D*3PR <8U-6"4BUXQ<H(OE!7F\
M3_/1'O&\%DZR.Y5,8>*V8B")9'1/SRXJ=@3GHVSBKF+KN/)P"W'2.!QD\V]Y
MLJEM3?OU]V5-GTJ_,O'O,Q*MB/02^5W=Y$$*UU1V$DI^RL1GE?Q PELR3-_M
M/M[>'T3R9,-/M]E\R3V1'VL&5V9-RSOPAW30ZY%D^'0#X9H2OK3^_GSP\>!<
M.N@T6W__+MG!1#J"B?0':.HPCG%]WC;_@6W7D6J^)/^!53?SQ E+W:2OUFUS
ML3WZSRHK?ZRZAJW_3-+OYM-,XX>GS>_"OK\RW2(O-YN:XSQSTP?AO,O/;/LW
MF3D&Z5TW<(+LC[474.HF7.7I9EG_P^[N[>UMG16S?AW?[#82M\OHGNY2[YHD
MNQ[)R*Z-3<4P=EEI$;)5A'5DJ@9&JK'K:3:;-%6/WC&MJ-[-V(R%Z^C?NV0:
M3?/U[V?XO%_4<=:A=+;RO*0G ]:8W(';N$ZHR/92DT8'\_#D8>.T"WI-8OJD
M69.</(D8Z<71M=0DWX*,2 >16Z])>YQ:CI#D#97V2$*ESW'(FR.M24='>S5Q
M(YMG>5K"VR#KCG*5\?QC9S17?NVZ*BY[^!M9/#E90K.X)GUEJC'U/E,2LKL_
M,5VFS]\=)WW^5NK5)P\BG)\('>%?9$)_@;!?>BE :-,A9&%+T71[UQ,L,AY#
M"&\]A!H,.)[(1-B)ZQ)Z1)XSVL]R]&!%L,>JY7D*22:YK (DB*050(RPJT-R
MR^$UX@KK$@O![>'.,.AQ3K&?Q E"7D0W3ZV8OU6Z[;*G#:7X-F(7I:/LND->
MUN-^-NC51H59,2_G5;>^@S0 *8"T1"!5=44U- 92W;+QE#:G;CU(V>B/&00>
M>,H(,1>.(_HY-+NE-%J,?_R&Y3!P#IL1&E&>\%KPT()5LWXAA;7V&P+G+K=7
M85C:867O)_0FB <IS^;=$SG/WM=W;* P4+@$%-8-GE:7=73VD<;4V1O"*J>B
M[PB92DYA]84V]5H7GZSE!LU59KHXI6DFP+/'2^2S,F64P_,!2IQAG*:/IH94
M\H.0W25(R!.&,]HQP!6:ZUE6/&4\!;!G=.*; N\"QT9]XK0M0!H@;6U(4_)?
M,>9X,Y1=CC.YF'C91)X4(\09AB.^O<Q<![ZMRZ] \^.6QJS[.&182OGB]236
M).+%??XU@]6QF\6"55I-G*I0W\$JT IH51Y:\5^9.;Q;5$A#10;Y04(-&^>D
MTD 3JPZI#D;B$USB.I56-[#^OTRUB@+V22?.V,N\ 65 4I7'IN[A(**2+5"E
M_,K,Y4^=<#)>#TA"HBQ.F,U)^)DPA9DJ;N?' 7PDT4_^?%[%RSCY*;5I&#(\
MGB>#-!L=$E.3.O5&KA2*SREEJAW0$FA9.5J"7E<96N['28^3Z5>,%!@;'6SU
M*6<=I=).<3P>/R=/:N4=@CT'O0=L ;9*B"W39-B:)!897+-I%BLC;+ULT0.P
M50HE3ZV;NC(;8&BDY#6$P(MUD;)H>+.]=PM*2 06Z_4%MKNN0%;&6CO?:@;4
M>NM4)B'!K BS(I\5-9@5USZ(GZG,_VHN?)XRK[Z?.T.!,@_86ANV%*2))7.^
M'0_9#&#Z"%?ZUD<N-6GJ)D%_M.!\1MU!(O(8U7>P D,9AG)IAC*R^4A6N0:"
M%(059+L)]9@1-@I$RP<U4F!WR9][HF6>QNB-;%HLHD'L7]FTH[B_!>S:W  .
M^9KOTZ\>BA*PVO-#[HNP._'B Y%/341%<J.X)AV>M./DFK78GH@RS#_DAK"X
MO/UU_U-N/1]E7FX;N[&<#B./Q]!PAI%K]JRT-C:Q&V+S*QD9TQ])XH9DF.;?
MG_ 8PZ* 9X,@92\\BMF[]P=Y *2(0?P4AQX3B'1&W&YQW]>S1DTJRGF6D2BD
MPY'^5-Q:*Q:W>4CB(,J$79_7)2^R%[L#<;;SHT+SRR]H&*;2/DFNXU'MQ44D
ME!II&KO!*" TE8C7"Z(@S8H 2O&4FB0V+V8T83>(3_(H]EM6*-Y/"C$Q1<T
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M1CJ,]#6.=%U,XX;*^NC=X[A*!(&5HXBL!397RQ]C/JOWQ*[J5-I92+E_SQ2
M"FZ$ BQL(!9&SC]5L71-5W8]S= U4Q%AFL8$%2!.\SE4:-U1=\!'_3.0@# @
M 9!0=B0\V 7X95&5FXB$HYCUU'/*_G@8VR=)?)V07C'&'XY"WV$W2<C .[WW
MDD=35@'A%<PHZ?78;^E[( 808Y.(,9'0$J(97T0,X 'PH)(\L)%M:9HM4CY:
MMLEX8-L>GE A(-AQ! 2^/)@$+E<%<@/C:Q2\WJ2 . , 0OF!,*$AE"N8<IU
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M22"9>\ZC[8&>OH]M:TOJ2LZ13'W%9)3<-XBU=MR?M'PBJ=-&(XPU:2D1E0R
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M=^.%-[Z"5GJ%J)8.YW202RF3#^"NN?+?DIZA5NVM^>'6?H9G/\B/Q":9.3G
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MQGF.[R3,M#;P!:_&"OV7[#K<0[)@HNQ?#B97W=O$B]UUS<W6-VO?U/WO<.$
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M;K2$C$APBY_$:!B.T"*AQPQ>^),E8JX=\(IV6A/+^2ZN@W\M1$I6SO.W:MZ
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M_CK'<<;5Y&S>.YJD:U\:5=%,IIM_.0H11\M/!XL9? SA\^#M=%*&\S>3V6Q
M3"P<D8'1FHAI(B=B!@\VH3="LI*YO3Y#=2@S&LM2E"7,XE*>ZT?_6.?N1QS-
M9YM/EK.YG,G;;U_-WO[C>$TK_0+KDU[1TGT^&<^'XP6M_///.%W*84;?&"VJ
M,G@[F=8/SN;SZ3 NYB&.\,/DEPD]8#PG,= ;/KX>SW&*L_E >^Z-80$B6@;*
M%0<Q.@.8/7(;N>':-YZ3;D9R?7ZO\/-LFIY-IAFGI#)_>/85JX);:\_5L,(T
MW2+N];6[_L:/L\7%Q?*9,)SCQ>;?5U7:A'/S2>]$OF(GC;\M?5\,9VDU',S?
M1_,+SL_+A_#K0+HB+-D4,%YXFC2-9&A,!&YL8B6A3$YU2LJ'\6U#-?&4J=90
M/,T(M,91>;R!.K FA4(O!>82.22>10B&QIY%2@%]ULG%QCRY \:A(WN'7Y!F
M>C:0VDH1R3FRQA90UDGP(@C(@653<O22MQ[.YMU]TIZ'2OHFM_>:WV:\?3Z9
MS6=GX_SRU\\XGE44B4?IH@)RHC4HTL7@+7F#12A#Z+P+MK7%O8EA1P4&3TK<
M!TUX,[&3LKPRGBRT3UH*B#)+4+(P<!8C"*F"%H8QYTICF5\#<.AHKE@9U"SQ
M;"WDR,G**.[ \2#!YB021JLHG#B2$WU:-;6_A&\R=L_9[8:K6[F07A0>ZOK4
M3&?R (R'P 7])) &G(-6NK6#MC/(7BFY=F3I5EC=F3VC&"_):7 Y$K,]4M0A
M4@9+;JF63$@=Y5'-WO9CRE_"X"U)&<?SYV&*R\<.;&#2,<:J'T'.!$TF>&,%
MJ(39B<1H5#=4^JWMEKN>VR<-=Y ,-[P]>/*:4?*O."9/8T0#.LL7P_%P-J]^
MQQ=<#V]@=9*1.T=X(JU*1DZ'BX*!#SP&G:P0JK7[_0BD/@6:3<C0A2B:\>,%
M?IYB&JXFF)!=U#V5_UG^.L@I1Y&5A*"+ 46&&'PQ$@S3127+96F^3?8 G&UX
M(9\B+UJ)H*-MJY?_O1C.O_V,\T^3_'K\A8QK/5XAK\TH*2.Y:4E1F*%0./ I
MD<'U!3VSS-KF[M!6P+;AB3J6"]24*.WETL[,A.&X CL?OP\C/"\_+6;#,9+7
MQQ,Y?2)P<"X'BD,5&;U(.LZ5Y)$S3HY!Z\CI/BS;$$,_26(TF?UF7+C<>F*&
MG&RG-03%ZH:&I[=+4<__D.!H%K-K??1T]];>;E[O^AF;XX=I2/-_#N>?GB]F
M<UI^T\OCA[,9R6V&^4/X=;E+3!'MEV$]IGXUF?Z=ENIHA&D^I"#E+*7)HBY-
M9F@V:&T"0U+DBL);\*SN\'CMC"W,1*.W<)\[ ]@G/WPO%EWUO_LAQG9' ?-/
M2]"$?<"SE5+2.HY.6U!.>M(57(+FVNH@K-.QM6-VY?5]<M /8LFA4]N1P]7L
MS#.Q&!3W'JR3B:+.K"&RB&!,U,$GJ:TP3_"8NXOY_0G+9(JK[Y$BP-G+7TEC
M$)F'XS#]]IHX.+MGDDTJB9M0YS=1U)9<(@N.-;YG.1G+-;>MMW@Z'$Z?+$ /
M5L7NR0G'(5)CS4- UW[H3SC&,IP/D+Q182TY'Y:3&C39@T?TRR0XS;GPRK8^
MN[D'2J]VM'M+R<,D>$1#MO_Z\$9DDY6IECG5 2$$$1@@9NTD#UPK]E05;9O,
MD&21D?L2(#-%(@^)?*"Z!Y"59-Z2?LFE]0P]FAG2=Q-R'#[>\C@/E%[#!;L:
MS=DXO\ XWVQ%^U2"=?5P+K$,2CH.,7D!:#3I#6DQBO9K[2XD3TS[GX9-#81X
M,*%JQ%U?_G:*G\.WNA/YCLS0.(P3C?(=9KSX7&?H^:<P_4CAFE-"4RPE@3-#
MV'R@$%J1B>(IV*)%L2+<B&#OW G9_HT[GA[\OHC4H?#:[G_0F"?75>>&[*:4
M:((P4 P*4#%R")S9FJT9/87R22O=VO8]B&C'8XC?%=\ZD.D-GOW;CS>G_0W]
MWL6-DP&_#J'!G1-Z9->W3FZB;G3OY'K&CPQ+?<! F$CRRU*!9Z% 5(%Q1\%M
M$ITF3'4?S0PT8UK$H"%Y\M>4HW$&GBVPS&1Q18<2TM&#DCYYX/LS8O>]EYVD
M<9)+'M=W ][AY[I),/[XDO[!_-L H\Q>&@Y*&XH HD\0G+7@E"SHN4K9MCXK
M;0:^3X<"77'N6+(]@2TCF_#VW<N_O?SE_>M_O&Q^E?*NIW=GX1X=2R-C]WQR
M\7F*G\A5&7Y9NTX;+NRU"V@9<T88 4E'7Y/ (CCRO4E[&:>]R*JXUK:D\1 :
M9MQS10NC2 ?,,UHTF#-X;SS8+$+(62OZN]]%QOTI6?9 SOXN\FD; ]XQ(171
MY44]';)-B1LP496:^2W!FY#!)<5YUC%AX(V9LPVN/AG(/G&JN4P;9O/?.TL#
MX4.Q)BD0L5YF,(GH'\G3U&C)U5#2IM(ZM>D!.!V.="\^\"A*%M(#VL*(#TZ
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M-X8^%]:XG#LX@KF&H=\J]2!.'#3=S81^EO.PCCV,WH9A?CU^'CZ3$SVZ FZ
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M)[!.!XNIB3[9*+GUD>.'R3)B?+N8ID]AMHQ(S[Z&:2:#&37JF&B<6"L,B)K
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M[5VLA(& .H.LA4&E4YJ+SEFQWU;+T1IE=L^1 ^72W;6R*\IZD#&5B XAL5H
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MSE^/9_/IHNX"+UU%>LW9Q60QG@^8"'45\UK@EN8C4L 1ZSKQWJ$IVDO!V^_
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M-M@]*:GV%UN'R05G*2TNZE,P+_.<:V'W*7["\8Q UH3X52;@_HD#.[[@\*2
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MGAO&@JN^Y]9 ?M[,.X%V[W.4US\+/\/5E]'8C[_=%Q>++#"7-?$YX XOP9!
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M9?C!!]]/;X<O_9?^U ]FR,,Z\H\PST7!)QA_[4>8+_4CQ-'%7*7SF+&0+NK
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M=/S>5B!->B(*9B&4N)]"RG./?D-BG!B42W9>*;%>$=_49EJ!=CYL:JF3!AF
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M-'^PE)LT$=N\%RUKL+.)4A@=B4EE0*+2B03//<G1)4>CR *.=0"<K +^V.?
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MHB%")9N#\LDVG/#\K*[!'L*>1@IYCCD>9S@Z9MF32'4@$J(D'CUUDIW3@;M
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M W'HAKC\P(_H#+P9C7_WX]0STG'##/H6R872V8$3AVX!<3%DKP07CM<^'C?
M./YV=YB&U[>X0R7;H'/6S6!.[8,)EEJB7)#ESJ\G+@,EHDR;0H^!AE"["O9T
M0U$/5L06Q>XDQ0:VS!+'<DCTJ^LQ[H?S"="]P'((7ABB.2WC"'P@-I7. !IX
MT,RXU&U"SAX:WH3G?+1^L+0;W-5:8OO[N#_%8_5]SK/)39 ^CS[Y$BOX^1I/
M3)A,?D.I]Y30(0@ $KGW1#J?2+ 0\%L7$M4IA^K-\G8">#Y<J:^/BDFP=;"X
M<.A?#%]>C\<PC-\^C_UP,A__]5>48;D VV-):VL9*]>&\#@$H8BEQ2T,@K'
MJ$B\=G?S[NC.AS:5-=$@#G=S!'J3I'4N$?"L]!A5>1XO1M>0QY@U%]V&S1QL
M2.R_AK^.BT I-49RD"3:,CXMZ$P\2$-XZ9\AP(JH6E%[!N!<K-W=I=G0,IK?
M3H/T(L;KJ^O9#GQ[86WV'E'&C4PR$.YI*50)EJ"_F0B-DFO.P+G0*3F\A]H?
M!7<NE*BKA0;FTVU.90EYGD21R8<8DR3)&;3EH"3#H@K$!YX\Q.@YK9UQV@+E
M6)<#ZQ*@AEQ/?>GO9BW+(.C2=%L&EV;Q<FX"967<G^>SN;G&HOV?>*DZ#)Y*
M)KRM;5(_".CTV<D#-+[.HFJ2;W#2++ L.ZYW -,H 7D'R&D2CA45M4Z!@Z7<
M7/6(P(+)GE 0K)CAF: =C&Z Y%X$[7-BM6/!1U#Y(RG$8VE\%^%6KD+[[=/R
MQM6L6&IFO;SSX1.,O_;C;:&49*@=[<LE>4.DS$!L29^F@.Z@TYF#[W(7KM/#
M3M!S8G]EC%I*LD&$_,5@,$M-+HF\+(ORMHPV+[W>?$EUJN+0BT1RYEY2DYAG
MM?OP;4;R')5?4;9;7^X&6=ZE+3/*\XQB?WA1PG63Y=__[ =^B,0]/+.[ZY.J
M97,/6N):!E=ZR$S%H%@6TEFPSF7%M/!)*9ZXZ>W[T-I96TZ!.RYCZ=*'MF@T
MG#AK//&9>K#:A@RM0E;O:F=M>QKES*DPA+*H2N+!D8!'*RD]V:TQ61A9VT4]
M?2)O/UUN3^/M(,/*5<YWWH#;SFSO\QO?'\\J&]X.7_^!+\/D??YTB;_Z/B_K
M'EY<E7%//<XIY<I[(F3"#=DZ01Q^3X ;+KPST:_7*FVT/ X&\ES9<'PMU+XF
M,<)M>(J658FIQ>G[X0WH-Z/Q1]QI8U'#V^'[NY56Z))SRT-D!'()YS"*)SD8
M.FL=;RE+0'7J0)P]'_^<Z7(,B5>,<CX*^6=?^DF48<L(= Q^@G1_U9_,QLE]
M1"N]9X5QNN0FF9*EL00%X@RB-X@[XID?G>6'4N4Q$&=+F*K2K]R/\W8OG)?=
MW>/T;Y.2TW[]%=>"4&^6]?ZN:8>KO*F>F$QP&YWU"[2\I =!D1!*XI*5KR0-
M)+'$C-2J# /JPJJ&&)\UZ9Z*[BJFGS>O:_5M.611F@HM30(B8N1$BBR)E2!(
M4M&;Q%'RT>Q%R$H SXN-I]!:T[:C=S,>P4 T5B2T" /"2A1EI'G$;Q5#^4'B
MU6MHGUSN\!#OK(9<GTGN4/B46,1U>*Z)="(36SHU>]"FE/)0E:J/.7E.N<.=
M-+Y;[G 'R;?/'78 \]WF#G=1U,.YPSVDW%SU%"AS0@O"C'$E>L")33D3KI'>
MW$8POGJ=R5//'5;3^"["K1R:^;_]-(1O+_UX>:%-6.>CD6BK0+E=GW(DSI6K
MV1!9U,5RIJ&#A;G^N:=."NTDXE$E^53NUG5#Q[_"Z&+LOUSVHQ_,J4@5'D!*
M$"7*L"< 2BQ$B@8F2&,\-6AA=GD['^O:O0W .9S']21<N<7E@LBKD)8G10=0
M%?M!;05R@K;:=10U:B7EROVB'@)',VX_F@"DT@R%!3R.9"+>*HGG$Y/15GGS
MCZOZAYID'U7SW85;4>.SF,/X6^_5ZYX#Q6QP@3"!)Y9T'M<4N"]7&;0+-"CY
MX)RJ"<0_78R^_K3XQ+F&%]_<*OCV><?M'%1)\*.#I';,2_F5Y\)V^MAJA1A[
M3WKU/'-'J3;).!E-\B)F);SRTDC*4^YU>D+M$@NP*N3@)7&,E1MMQA+/\2O&
MM#9!NP2TTP3N4Y98+,=HW43-E_Y)CU)@7F9&G"][(;- @L^.1- \6ZN22K4G
M4VT%\Q1BPKMH>]U7JR/E!H6 VZQ?R%JGC#ZIRY06%T43SY0A4EMT5_$8S")4
M5OZ3B^L>HO :<GT><5UELY(Z*:+1,2)2^=*K#T]<7V;N08XRIN_Z3LA.&M\I
MKKN+Y)L'][J ^5[CNCLIZL$HWSY2;JYZX2P^W022;;GU5#PGE_ <4U)REC0U
M;#VA_!Q4?E!<MY[&=Q%NY;CNK(K];O'R32T[2^@  7&BU 'Z)(EE+.)[PFV,
M283,NXQ<W_J 4T=Z=Q+ZJ+;$CN%.SFMC/OL_2@%ZAO$8$G[CA^E=WX?^ #\=
M)B_&?:3V11'6S2#45_V,OPV'70BH^/"#7=-6@EAS8,'3K/#;8&*2BJL0D5E4
M<!!!FNQ#KR*._=_X%1"W9C#U5AJ=$W$JEU8_:,787'HS&U[:7SB90Y>>XYL^
M^[#.V3=2*F4RT\E'B-#_6FRN"1Z!F@4C*-&JM%14PA#GN"&9HE&/+S5+LDO5
M[T//.-X>544S=]MD5Q)= X?T'C;\8OFS1=O,CS"!\5<H]^M>Q#B^]H/)[+^P
M^J[T#$/WV>2(UK8.N.,JM+MYJ9H*GE%N#439:?[C#E9)+>S/E%HG56%EV^?>
M&FXB-^]*[?(JR@R99J8X$5SZ$FAF)$1.29"2ZI0H9ZK+U93N3WRF]&@HU@;-
M4AY .II,9O=B\KP7%O+4R.PXHT2P4A@@G2!!!T,HN)B4=@9X[<*6'> ]4[JT
M5D2#%G/WH19_H$>3%AP]!A* H^T?(VYCBGJBH,PM==(R53M-L!G)V3%A9_$V
MZ!%W#]6\-9B-.4F*=I.1MF22?23.4TVXHB5Z'#,WS?>$(W=<.X[2=Q=O@W+X
M>ZC^?5;37\0Z&(Q^+Q>[>TE0FPSRTB8.92BG)8$I1[+)VD?#M%7-#=#[L,Z-
M#@<*_CXW='5N_ K37D!SI8P*("S%LDFY0)RU^ =H]*YF-PAJ9TDVX3@W[>\J
MVOOJ-A75O6*^WM0C#-/;X=0/+_KH7,\QKW_?2RPJ&;PG,<LP+SIR-&5<!7H(
MH%@9%]".&_N!/A\B'4%I]UEGV[#NP[@,&IE^^S#PPRFNHLS.^C*[/F98\BZ6
M7I.0.)', 4&@AN@HE4%VB-C21>D"\2P954<A]_GC*L4V5J#>]<07+ ]! O,^
M$>:$P+TU,>*ST"3SH- #EURJM28RC\4V'GGB,V5!0[%N"&S5#+*N0%V9KM?C
MRD'F>)[JZ"B1K@@!0..A:FTTH*BK?E?G45#/E!MMA+Z!%@>G];<P>.YE@U-H
M/9<PK$M$9N&(*^9U0N-+)C2X<>E'(<2913(.$O0&$E0+?-XL>C4H2ZU1L<RZ
MIU(A0[.*Q$NP1-H<58S,>%U[H,Y#>,Z$!@>+>@,/:@8S5V%QCRO6(A)*%3K7
M1BMBF<RX4872W5B79GA'V0?.1/<'B'>#U@]J.;*RQGGI(HTF<68%[CT4B9=*
MLSCA+5%9>,IT,%K8#M;?^N>VKNBM;MD=))BG4L6[Z#?YZ1+@[A!4SU)@CN&!
M$Y4F4D0\<"Q5!&V0%"*/ LW3RF_T-BS'KMT]7+FC!D)N4+"Y"=>BUJT+LD:%
MN]M1G::*MX[V.E#B -$?EQS)<248@@,#92RR ^)T$D0X\-H$:QS4#DT>FQ2/
MU/D>FQ.[2+Q=S<N*2;)L6"Z8]P+-T5QZQDK+-?$^49)9#CQR=C\@L$,DZ%15
MO[7T\&@4: \A-JBM6TZCCK.):]-Y,&H!S5-NJ+.&!*GQU),\HFVD%,'3,%M0
ME@?J*[_I#\!Y]E2H+?)C=(1?L80JWS+N^LDUJ[GWOFLL#3<&MW#'N)546P?4
MH.=@0K262RIZ71]2N0X;>'9:&8;D8Z(T)$&Z@$@D&*5#"%EKUJ7.L&8=]@W+
MMY=D)2\R"C,3G='QDJH,MT?1$I<3U9&Q)'3MN.&3+H7;18OW-I,Z8FYQLFQ%
M]OJ/+_WQ_+4H77YE3#H"+EJH,DM:E]NUSG+BI5 *2F,=5_NN6%=L9TN. U30
MP-O );]$^Z@_7<6X["^/5.6420(22CLT"L0;*PFW3,H8\1R&VIO% W">.2%J
M";I!<?5&:&LT=9QG;2,G7-N,3I:UQ!JM"0K""SR&;7*U^X5V@'6.G#A \ V*
MJ.\7]*U7?2U;*R^X3#GZ3LIY8AU393:S(2Z@(VXL1(_[&=.Z=HQB5XS/G#5-
M55*Y;_K*=(%-Q8)H#''PAA,:1,FO)$\<]0P=\JRIB9(9[;L9T0\\Y9FJN[+X
M&I1=WRQU<8WL9QBB<*>]E#2W9=H(:&^(S FM&8Z++]W<!&1TK4.G#G8[; %;
MH#Q3U=<4<(.2ZA?I/Z\713*?1[<^]P??3V^'+_V7_M3/9^[U% _(11M(](R7
M%)\@P1D@UK*0T*BA0M2NL^X,[IESHXT2&E1D_S8<0QQ=#/O_/=N]%AR>]*3@
MQGD\B_#\*145Y6:S0>O&1ZXXYT$86SO$N07*,V="#0$WJ(G> NOSI9_^?70]
M2/.Q1*]SACCM?RT"F0T>RM('Y;DCQBA'Y$P(' 2)@O$D5(P=&Q\?3HM'D)XG
M:VJJIV*A]".H;Z3S 7 /G#7GF%T:@#%,IHO#$ZTEK5A6FIA9PZ^H>!F79\J5
M <^IS]ZJVB[L 7#/DU[5%=6B'GL?[(M^"3T>O #'T!9S>.+*A$::2S001GGF
MQN>@8NV2S /@?H<DVT=1-:N[-Q8Y6>N2EDX3RF496N\U"=8KDI@-F0/'K;5+
M!Z\G4]IW@+^[OV">2FG?S2)>7$\O1^/^]-NL0B5Q*$.J$^%<:'362W[9&$%P
M.^-)92.4K&WO;D;R),KZ=E+L-K=X?P$WR*3<1[4L6.B JU%)WS9,IRGHJZ&W
M1ZEP@-"/20KCN(;2!5]ECLZ9+O?CC7.$62V8T/@*:/FLR?!((=\QN;"+K!MP
M %&@W=&/+^?C#!;E1@ RTE1B,>B,$QDX>N>E#V5.##?#2*FH?AQL!'+\VJXZ
M>EJ_P'&PD%NT<R]=:='V+!5L@_]S/>Y/4G\VIGL!+U/' S.*Z&3%?,'.*$:"
M2U%FL!&JMZ%X!-*9L*&FX!OL"&]&8^A?#.]R-4E?[AHJHBCUB$F5ZS#X![>1
M(5>9H:EV+<XF'&?"@(-%W*;.X@.,^Z,T'VZ$6Y"7@1)C8BJ%/[A+)9O+V-I(
M39!)IMIWNN\ >/9NP/[B;*G;Y;RC#G :&?UK4$YCZQ^@G&UJ/D"R;0KG[L"B
M'((S41.K/<*RWI) HR-"(>#2A2;(VMOW413]B!W?3L^["+3RU1N$\A_@QRAP
MMS@Y+'H>.>#"*"Z$2&$0%A6&4)68\BE0ME[5M#% =^^#CW_:'B3F42T9-3"V
M-Q=8%E9"4DQ"*9=P-!#)(!#G'#J5+ GO@X6TWC*]41WKF9RZ%<3<H%)Q([!?
M_14LB-X%7KL3^2%H)SNA:RBR"ST.U,*QRMY78.9$HW94DYC1ZY"" 0G96=PD
MC<L\!)-][5OX)R')XZ?["3BRB_ ;<&-1/+5^<6-QRBDM PMX2FK-)9%!YC)*
M3!+J;<I>.0B^=A7!@X!.8D'44]^HE>P;6!CW"Z]__K9>ESN/8@=NI.6<J"(&
MF>)L\9YHEH)VVBN_WJ>O00W\9FS/WOYHHH0C-")?YJ4ZH&IDA6Q&=!KCHXT6
M'^E/?( *6J2%-J-3 'BD>D-LJ9^0"LHL6MSRF$DV442;>/6\T!&)\8C!<4I>
M["+YR@&'M\.%?.%=/\.O,+US??2F885'ZRKPK(BA219?'8TN$Q2)7%"+?VGT
M^AC@+65"79YV?,.BAEY&385:T:@H"#]<C^.E1RCO<VE*,1I.45SXBQ?+8K7)
MV^'+T7 R&O23GT+ZX,?3(8PGE_TOM^BU,RE+8K0O];@EURET(@!2"HB1 G1I
M0W XDF=/ER,KH\4<V.40U-+7>OKMY>CJRVAX,P0U:1.<C8[P0-'HLH:3D'0L
MD[2C,92F$&I7G#P(Z-E;HO7$W>!NWAJFI>G3 50CZW,CH!./ASY<<:-64F^P
M/6P&YYB4"D\#PH)4N%TFW+-",:FR"88Z'Y.L?5_[B%3H.C;Z2$S81=@-&+#E
MFN#B].+.AQ"U0$.ZS-#((1-O2A@G2!I5@-)QLS(3'@1T?(NB@M+NW=*L)?%C
MC*%^-QI>?(;QU2L(TT_Q$M+U $9Y]:?[-QWK_MD'MQW;<QEKC<<\HU3@>\Y8
M4*@:[Y.2T7,'PKB0G>MU?\RA@8(P?3N<3,?79:=Z=W/)(O#@1(B1>-!E-#!'
MVX793!AXFI(1PJ\W3Z@0*=@(Y?!0R.K'3EX$_-+':<]8*H(2D7 32[S7173-
MG"0V0XHA.J-B[<3M%BBG\&X.U_K]P,?A<FY1)@OQ&OVX@J[G->.E7ROA#/'(
MD'"A5%E2FF2E'*G.HG;H?.7QIU;SGBI9=TSVE&>3(.?J\E[!)([[7XI$W^=_
M]^-^\<'*M>*?_03MK8!@/?.RU)Y8(JDNG3TUGB/9"YJY#9+7G\S:'=]YD*.9
M1AH45?XZFL+D@_]60-TL/BH;!<MH?WF(91*UF8\-8-$JFDQ*3M9N$+ )QZG9
M4.=$.%C"+<)8,.R/QC-D/>MRM-1'8H 7BQN-8ZLB)Y11J8%9'G3MJ:TKCS^^
MC@_7Q[VS8#]A-M#KJF4\ZTSSJC\I]W+QK+K=VIQ08'BDN*&5K8T#0UJ;1)+(
M@@H966:UK\1TP74>;WMU#338\^^N^Q<_O9[=""F]1[3WDGOE"4OERC[7>.PQ
MR8B6.FD\CXROWA1].YKC,Z*^]AXT#?86?7,S<IF0*7;**\0XO)A7-/<BY=11
M&DF.F1)I'2Y>!T-B=&B_.&&%KC_6N0NRLR=+%94TWTW>^/ZX5!A C_,R=CP)
MDFP)Z!HHY0/2$"?*M,\$7-':MS6V0#E[:NPG](H%XB7Q]R+^UW5_,A/L^S#H
M7\QJ3$I;F,5$B%NKJV=%H$':,ND-/*)TI7<)X\0Z+:0R3,=.5SVZ/_&,&-!0
MU U*]-[TAZ7":#8*>#D=YENO=!E(TJ"5;,J%&,7**&A9)D-#F0%"-8?:$:B-
M0,Z(%O4$WB!3OMWJ60F.]+S2,3!TNA1UICABBOB4*.$\^,QU2/4O!'0"=H8L
MJ:^0!CUPBQ2F"RG\'?H7EU-(+[["V)>^V[>V4$^6V0X)P45?DH="&.(SE RB
MY KP;WWU%@\=H9TA<UHHI4%'W-5M< UFD4AI65!@H@4=\07H9<9="'A :ATS
MD=+C>9D<)3YPD53DS+/:A5N[(3Q#)C544<56N[N96[>&>-12!,XC&N+%[LKX
M$@3F#0$TOB K-,2YK&KBGJ.W<PSA-^B@NT@.KFZ5+Q?3\(9I933>4C1"2YD2
MH"PT+2V4K"96.$$8R\(XR7ARM9-R.T(\C]AL2[TTN&U]5P2SNWK]X<5BX(BG
M)<.0*6+SI02[;(?*.\)]-(#[)%6F;2+W+I[C$Z2I,A\TEP_01.WYM8MS$E>\
MK-1?G*HO1Y/II&=5\B 98N$%FC2TM(NP1">J<LJ*:>@TPO;AQYRG[FO+MT'D
M=?7<18C+B[W%H%HY*M\.X^ Z(5\7(EIX>WV8]'06UC(\DP55>$Z6/P(MUA7P
M(#1%'\_53OT>BOD\R782C38XLKKA7\#N)>"@Q<PDS!%]1(M?!33I#0/!F$G"
M*'42^BT _I-K^^FJ01RY&]B>3$HFH2W!_Z(\;/+$%T_1:VJ$5UGHZM6LW9#]
MDTH[:J=Y%/K&6[QU5F^+_[()V;I,A&6E1;(L$WTHNI,N.F.<3V"/E+J\#^X\
M7+$VNFC28V(5Z&]#?S4:3\LPC*5MV#-2N*2<),S*,H@AEV #4**X0<2.LBQK
M)[,>!75JDE13Z(.T.50;#3M.O,_XWV*AS?P$D8-.@4HB6"GM":'D7RDC&M#1
MXB$G5WU@ZT8@YTN+0Z7>O"YFA:L?QG#5O[[J4;3'8Y"1@'3H/7++B7.1$]!,
MQB284K8^*Q[&=+X$J:B+YJ&^^;UYQC.E#!TX9\J<!G"XDPD?"966B>"]PAVN
M*3V.,M_H>$;&[E)]*M..5FWXS_AO9C>GI6$R67!H3!OT[YW$)4EA"$<[7@ON
M%(/:]-B$X]@M)JKI]H&\]EXR;E3-OXII<5FZ"ZI&'28V(SI-BXG#-?8(!0X0
M]_'(D"@3W)I(T'LOIZ(U>'"5X R5ROD<:,ZU>V4>DP2/-)<X%@=VD7+M1NF(
MYMW(#U\L&AI0 X9% ,)R:8"4$8HW>#2&B% T"%!ZS=W<W";][L>>IFC@4$F/
MZHBI<LNQ)92?V0*+L<EQCXM0HO14I2D3I]'"9(SI1+FGGG5)PZU_[MGH;"]!
M57[-YI?X%D'3>>_=-SZ6ZMG^31N[K)+A'&U1[DIQ/6>).);+=.8D T?CPJUW
M;]FHQPZ/>O:JK2W.!O[YRK7-)?U\R-&)3$)*Z 1F%4C(0A"*"TW"QNQ\_<8(
M:R">M>;KB+:!?WV'@?,QB-D(!@*7%H#B >$])5[@5]G)G*,VT?O:-QWOHS@7
M[^E ^39XN^\B6K9-[X"ID>>T"<]I_*9#=?6@Z@\0=(LQ YNP4:^9XB(2ZTLA
MJ@X*&<_+B$)D>.#>9UM[*-SQE/^(OW0,W>\BWP8Z_PA?1X.O)0EP!]SR'')6
M&>"!6$4-D4JAN:$D+>W@F >JT#>H73;Y(*#C'_>'ZVS42N -^E[=/>AFA+=&
M><UE+&DA1,0%$CYF2Q)/7L1<1JZTK9P]IX/_0/DV3Z6LS$SI@JO96(C-F$YC
M !RJLP<I<*# FS>V6,&7A$HQ"4E"])S(9(#8; (16BI+.3B(;3>"$T^>.A8/
M=I%SDZC.S!%],[H>?QBAM#[U__C\^^A-_^OR:MFK:_C\._[WV^?+_OCFX J!
M6FM+*5RV>"3.[BZ6&<DBQX3[9>D.UR5HMS^"4^?B]]7@O2A0<_%7CM^NH/Z,
MFH4Y;/@*P^VHWP]A.:! ^."42P0","(=D\0)9TE@.?ND;7"1[L:;W4&<%W4:
M*Z'!D;-Z*W%V37'Q]3(:E@PO[:<-,:9T/4\.O2\M' DT6&TSL.AJNZ"/0'KF
MC&DA^(I!J4+HU>O.RP!XPH>G%$EP%E?J*?I& ETE$)D:[1)#/!VVBON?_,RU
M64%<6QV+1JW<7\&X_]5/<6M::29;IY/[@Q]=M9%[]T6L]7&GEAD6(@7TYJ6!
M8/'0!@@I>)8D,[G7^2F'FOK+CWYW4T!F/#+%&TYT+ , E& $_Z$D8!+C#H^#
M /6K+._!.-R)67[D; X3[G.SB0>+*ZA&N" !'/$\.B*9DL0[10G(B,>><$E4
M/T\>!'2*_><PS=]W9FK)NWE0:]9&^M.7,?CT?KC:7YKU<J9.,ZL(*\7/LNR=
MUC"+8#5PXQ55L3XONF$[!XHTT$*3^,?M?AMAUMFI-'J:]*@11DJMB78Z$ZDS
M&D.1"1*#M4SFB!AK=_G>AN4<V%!!RDUN(2QQK7;YFO0X$YQJ@ZXU)(.DI!0]
MI,A)<LD+[IU1OGYU^48HYZ3[_67<)!*^P=#Z*PJHS.;\"''@)Y-^[D-Z@Q)Z
M$>/UU?6@3%U\__+MV^%T-!_D]SIGB.4S/I0;$Z/AKS#M!4I]LD80FJ@OBPO$
M9Z'+::@=<])'W\[<J+N6<R+?";7<X.+ES'TO<\+&<%D"VK.-%:'.Y]9/+M\,
M1K__#=(%+-?Z(D]A?+O@.)]Q/"RS2WL!3,0E6L(X2EE2CDXDQU6)D(P*3%M/
M;67&UL3__%EZ,FTVN4=^_XW;^L*-8G_[:W8S&_%]GO_"^TTR>EV<[4D?[<G7
M0WS8>":*G@7OJ3">>)]+B-.A$*A)^(X&S;P05C7HEOH$%O[\WX4G(<:=^-.@
MN>NM$&[N?+[/:UYWS]#,.*(B(9792,:6_J&6HA4M'==4:9UK]R?J@NN<*%A)
M^@U:N-["F9>IR$B]+HU#G*4()[I, D-@":)DD2NG1+L-[\AW85MI>W=)/I4[
ML)LVS8_]R3]F90O!)!V1K4384(:\<D6<9)8@18V((KG(ZO=KV8[G=,5=!^BY
MPR&UE[R;1K1>(ME*<X"5>PM=L#4K\_K_V7O3IK:2Y%_X$V5$[<M+NY>YOM$]
M]F-[9N*^4F1MMN:/D:\DW.W[Z9\L"0$& 4=2U9' >&)H@_ YOURJ*K-RNQ_7
ML5*]6DGQ7O5H)(*QU<2KJ+1VAM9&UK0VC*/]5#L0BOD0(R/GMG7ON?'5X]$$
ML&-HQRZ<;YP.]DHP[F^VJ?\%O[[Z-,^KHVIQ95W_[XOS+!G)CVW220SR5-"
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MC5",0%6XT"4/LD!V4)&M0,9WUAL)ZG8?GX.YW,%F>8UGM0+PP^><EW_,+A,
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M([[5XV]Y'C9M8V[V:!:&9_G5>5J!#!C_Y^,<SQ>$BR!N6HFOYK21!+PJ",0
MTD;DM;JS*$#O:"78[&1J[<0-0S:>GK26Y>TN8^T%T7$DP]5)^*I.+%M=#JW7
MSQ4O:+'S*(*#HEDALSL1T*@]6&64H^TL([:^?!T,[MDH31]Q=#=E+SMD+B8I
M>T>GI@$N%!G8>37=7)-RHP[2D#:KU+H]X78D1\@MZR.Z!RW6O?C>V2?>=):X
MQ/:63EP,JWR[21"A^&@LL!+HQ%5* ]84$>E9%%D:VB9;;R'#D#U7;>D@EPY[
MR4V45TW3KE2;7/,8)2^@G:\^.]GI*,EN)L"I3K0)3K6NYGT0T,^@*X=)H:'C
M6X];LI)^W/5>$<W+Q=NP).;5KD6__1T_US28WV?SU><;Q2;^3*R/*!V2FVXT
M'<:>.()."OI6N**%]2C5 -_F$ Q/WC@950A=VJ1N<P37J30>M:0%0\<EKQ<Z
M(7E 1CYA"9GDSUFQIO7U[ -PQNHLTS?<TX;;I])I9DO213 ^.#0(NI;/D_.6
M( 0EZ=L2,]<^,=.WR^$Q$]*:R??QQ+1=^#QF'M(07#]K8MI.,AN:D+0/PT=5
M"&VRM4:MYV I46M_+%HH3)/*:X99M!\9=MJ):7WT8 <^-TY,NVD>7Z9-,1/)
MVB9;JI@BJ].-0%0+$"9)-*+P)(:TP+C[Y!-*.]N)X[-F[!HOR^QZ:%'#)+,'
M']HHQVPX\%LI9K3^2BZ*,69<;4SO&,=4K.76&[+[V&3 \P^-1=4 &=EP%_-\
MP^@447&? H2<(CFON::RZ@(\6R^S5C)*-V YW?N"-F[$CUY032MX6S;CTB89
MA5&<#&615"TE+>3R9+*$R&Y6I0C+A6I=J? XJF/XGX?*=[M3T8SW70JM[R)\
MG\_S7WBVFB'D8A!.:/*T/?.@4LVQS4D M]Q)JTW)G1S->R$]5[W8E^N=[\7?
MUPR!M^5?EU<G$RS<%:8\K&Y>53T)/?( G*F K'";7.N]X@$XST$96G&[\Q7W
M+6A7L[NO.C#CV;O98L7]W^K)O9B2:_W'=%&S580UY$9#2K7N"SD' L] R,A#
MSIS%V/K>H0GP9ZY<G238^!K])@&O8KSX<K&:Q_IK_CK/A+B"G42ED/;$# 9]
M <6L(0;1GLF*T[QX4^SM -VC'LT]KWK**M&#FQWJ*E?8:B_W20G)&XP&DJN-
M_8O4=!Y*#P3#D;4D=6Y^U%R]_"D+^C!.-AS:M(VTRU+@7$36I%2E:I;*R, Q
MK<&&[%F*IH3;XYD&.4VC1"/ZK,S#^73LR,./W30$,NE=$! %:9L*1D"0)H$V
M:'GR*HDTZ- _U48^C62VM8W/+KSKV/UE"(SGU\9G)^;?TP9F'\YU%*25V7'!
M$Q215O4C#CPK 82QTOA2'!N6P'1L 0YJX]-"?KLPK&L;G^@B(J.="&-RY/]9
MVDNT"5"<*2Y[+@T;E)CX--KX[,3V>]OX[,*SKFU\HDW6JEP A:M#FA4##$(
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M%ZN5PJ477A(+5/;TQ57GK9B:TZRMMCGE]L7N.\![_D9(+UEU"!EN@76YHH8
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MR1#7ZDAQICWDY+W0RD<3;LVRO[_%TI 7GJ!KTUVVMYLO-1?,O=>Y1PT^;L9
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MK#.ZYF]+R?/]QYH->.C!H\IV!7YK_%AF3KE(HO2QU";X:$JR:)U3DIL4U63
M\P_,X5K-+/OE#!>+M^7C/./B8OY]]=8_KJ+F.B21D\I@#9)/7EL;.5LTV)B*
M$ZE./VI=DC, UJ%GZ@]/71>ROXKTVGE.$\^X-*NZD20]J)(YA*09..<*)B;0
MF=8EW0_ &7\S:ZT5MP^]5KQO> &P%=JZ6.\264W,_#,O/\_2!&UQ0=-9+U,=
M7U$*[=#,*! B,]3)8>*M4Q:'X'KFBM)"&AV,\Q\P;N!=5J=5E._R>E[6)# E
MZ81U$!SS=6B0!E_S=0L6;6WP&J7IJ34/8'OFFM-**@W#-0]MA6&QG&-<3D1
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MM&\XB;>B>4HIJ11&QUD@O]-YS#*XH@HFC3':AZ)Y#[ZT8[0N^V2M%8;\XUQ
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M&W)$+RVRJ >8(0>!&-]>:2S0V3&DT2-G!\\JQ@^?<U[^<=F&?+5XG&$^Q)Q
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M2E(+M0>;K 5R@(::U7CUH-'UOH0>HBSM\SPZ_RG]&$]*DM_GJ^^EGFZ<%S_
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MM7.4M@)Z[JIA?:ZT&&0VQ[(L'.@ IE'MQAT@ARG6J,BH]>ZQ/:C<XK:X \J
MY$E(0\" (V4$+?$\H83;X"!'YG7UUOX#L/R1 HRA.-Z'N)7G@'_]_'H$Y]?3
MT?2DI!V?EY3B=^ _I\G/44A+-0:L9BH:38(N4_BT 6(I,Z@BQW*]<8CFGFFP
M-@K=:;&#^2UW8<:X)25;S),]/Y\%.>^IJ5E)#B((XFD"(A44KYFDA">;H_+2
M9RDJG^[U2)XB\RO2ML4U?N47^NAT@\%KH@(3O"<QH-XBC9#$*:Y(SHHGY:*5
MMG9FP:.@?AGEKRIW&M3R;@6X/#0=(+92"Q^'=R!EL2YC^XC-'EP9^OY90(4
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M3RS/I)1ODQ!Y4H9R?(RK.Z;O(#A2/TH?[C^XLW8G<8O7:8;FS"CFT&#/Q&K
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MQF"H,11J#(<:(Z$0 !0"@D+ 4 @4"H%#(4@H# "%@: P,!0&A<+@4!@2B@!
M$2 H @Q%0*$(.!2!A"(!4"0(B@1#D5 H$@Y%_L?^?V*#X  P' "% ^#_B0'G
M!<!Y07!>,)P7"N>%PWF1<&, W!@$-P;#C:%P8SC<& F' . 0$!P"AD.@< @<
M#D'"80 X# 2'@>$P*!P&A\.0< 0 C@#!$6 X @I'P.$()!P)@"-!<"08CH3"
MD7 X$OF_0?A/C?\H^:^N_X+_C0(O ,D+0O*"D;Q0)"\<R8M$&@.0QB"D,1AI
M#$4:PY'&2"0$@(2 D! P$@)%0N!("!() R!A("0,C(1!D3 X$H9$(@!(! B)
M ",14"0"CD3\#^R_0?M/[?\H_Z_O_PO^_XWY#SH* / "X/N?\[\W <#Z#'C
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M+Q^\28P:YN&]F@/EBX7UK6'1-FA*/)*<F')+D">Z!:(0A4'ISN\#.)T_SD>
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MG.H*S^P'/,T(#.<#7*&-E&-2+3&60$Q@#VU*_TZH])\BZ>%!H%8V<4%HW4-
M82%F\T*?]]/1BHO6&]5EN^,E) 7!9I(43UQ-'KF?Q!V;PX@C^\[5T;]1V[;\
MN3^2@0V<8_;3!96<\556<SX6I)[T)!5R7X+2 M@UPCI; ]Z*ISMKSQM=Y!#8
M]BP%CN6%T4\\<KX/-]U%7>@'+C\9[<RG"XOE&99L4@%WSDO^T8AQ9"ZAJ"Q7
MX'7AHG^Z@(V)^684)'>GK6'\HUQ>VK?M3?-,C1KDG^IZV;79+CZ'>9S($3%J
M,BC/4/UT9,VL72+V1'RA']9(:_D,OYQ]<W;6P4DBMHI(_TJ4/_=SID)!>HJ(
MZ;L"@8_"7THAY9/!H)("VI$W1=F\,]T<A'4OLF$ TQA.+T9".@8I]!;/"_F[
MH]))C"P*$9J=U8AQ@IIE]1"UZPZ"7Q7-<FJ=A,ARNBL5O[-63+2R3P/44Z54
ML)EBM'\SN>^BYFR&W*V3LXFD,EPE(YKF*O(NLE&V^]_H91IQ7!HHR7A6P0U:
MAW=1Q8X:E^<OS>+"CY9+ATM<;0]0\]0^_$Q3M :U1IP_)=N:_:K:\D"OSVW1
MH53)_J%S6=!)?8'"^_OA:ZN]1R#%4]O0V$-"TAT:<54)!=X T8Z""$BC2E:J
M>7JA-7%!O4^BH.,].=USU/?WWG0RHL<$>_'O&M=OL>+GWWU/,UQR6W:KJUQ(
MHCR_.>VVR_C%^3,>L]BG:-!G\?AZ;;3*AX<%[F!.[/I ++ ?N3+^QJ9:DTH_
MF24DXV6F]Q6#A/\GW9_Q <B0T&_#*:F,]*M>%#WCO,4C'@/GGP&5AU%Q481,
M1,T YGW%.'QJN=AKP Q:/!JVW$CBL@*!SO+OLZ9Z[UWU;':=,F6HX9%F/K_U
M<"RUT;%V%HO:&B^W,..@[>A:(UI/:XE^X.LT3'Z8P)E4W>L("M$YLO,WC4?Y
MJL;.]YS&31HQ8OC)'@RR60QJ6R50DRN+'L^=X3A:TQ]6 X%7WR:+3;TM.Y]]
MLE-[\ BFDBB97[A<["KEHR3V8K?6*:^F/^;QCY?("%MT,9+RJM=0955@)! &
MI.J6T-R?1U71)_<0#8H>B,_K__Y88AGLY")I>E[,^<'Y2YUFHX!L.N+T38MI
M)8\SDH'/?37P>P]/WH! H6"$J-[Y^$?+EY!?1POE:N4V?\.R[[C4OE'R+*BF
M$N$T4:3=J!5=7_ZMO\JH'=F;B1),PI*:J8@ET^13B*5RQ!]-9K'@JH[E&L,"
MIL,-C_E*A)]?31!5MVN4AV\M>]';MLT+2 >6S;5*5CN&I\/*B[YH]A\U?"&0
MK(M6B&_^)(>CK\R:H2RLP5[@:/CJ6O,7%L&$8V>%(+U U\].H-\C"H'.8K1A
M)P<"Q#L"X+SE*M+?\X%4H<,FU'N6+(QT1E_,WK4HKC2(S*!.,&QX=Q:/T'7J
M]X:QNLX\C+$U2MNMV24T?@AH7%0[3?XBQ$UC>2<DJ5UNN8BL#SS6 .LKZ:F(
M&AN;.MVW$NYO<^+SG@UQB:WV-+<8LVN]>"Z[B&DX:*%KH(T-1_E!&A8MKII/
M.QFY4CLKY$!/=J2/\JNBEMT^%^GT=F5C MR,XMV+JB<2.^TJ!RNRN@,MX23@
MLA^V]UJ6[WY.BK^-F"2=[=''R3UE<B!&1U68\ M!(U-]X"?<SI_;.B%#Y>TS
MM!A7;.(:B^:HZ:N(_PT'5?'30]!,'F0,<^U,C'ZWB#\LNIULZZ4Y%*CIR/(7
M]!4'\^%P!_<>0!LKUY*"OX49JTJYUA;H#C!D*([N)WR.9\=#;5+PWP/J>$AS
MZ^Q2@&E&;"AK*2WU5P%O'%?$*-3SQM8-<4/=P+2_J+2B<5Y&>Z[I")Y?Y^N-
MG7G/#12K4949*B=/5OEUW4UIIW7H3E=&4:PWSJTC=*DZGHZ'_#^_9O1EU*'C
MHA*1P*=IB+;WWVNH*<@0.WLUK%#/70<7^X*^]UQ6>COZ^2"=]D<JJ0.6$)U4
MU5^;+A]_O?(@G)\&*E5+<3PG_A\^K4I>%K!,\[2$\4B%WDQS(C^]>#Y0>["X
M(GHA:*N]+PK[(!WK1O5;##)2RU8]BTZYQ'^$T X+M!%<<R8@3K]AM& VFB@6
M#N?OP5TG< +)*!1=XE:";B#:I/I2V<O7M!$ZZ-$EH)]T(3FF'A_,TJ=(T:-O
MRB6-VSM!EB:T-*T >*8GXAF1BJM%5^;FS<'%QFAB>B(2Y PU+SJ %$HCL!67
M+70 ._E%DNQ3$.D)E(\C=0T?HW0205G6VJ@/]'O*<U95R58+JWTEE>S3DDJ;
M#'5[D^GP#4=UHA=[AON^Z2'M*;&E1RW;2$@S9QV!"/4<.L.?Q#(G,F;@>+)Z
M.T] I;.LL"@Z.@- *#[K5>A$NAH;LKCPM%>]0%N?WX68W%\LI/%2P=F()I45
MJ[N:\ &=Q+*.S4D@L%^K4'G<E:K(:#1_LE8D0#UW2/LS>'6)@Q5^QHQA81G)
MDTFTZKA2-*Y4J/;[9)XY72=K)C;%_,YNJFKDU)=!ICY%)*3:OW$Y39L:TT+1
M,%L^^DO9 ]PI:PD5YTM%NHB9E D&W;A,^/F4]ORC0K&JDOBJS,5[U)*J[?CU
M)?ZCBH2IW'J-87/]@5QUJBNX>1V5N*R_;&N-F"5G0U\UH;+O:NVKHUI/$>*6
M!%3FRA>#V0O;+34N?C3/UX)XRM\HEEUDB?4PFFG/Y<:E9H9.TE6_-MH<WS1F
MZ3K'*O@;&",W-ZM*S+WSWA ;"P<\E3;D(YJUT(@M,-%6UZQJ N0WL'XM\HR^
MT&?)^VIFQGR/?Y/FJJU'._]%F2L732*D@UWX#E?@9"L[=&3&Z.W?"BE)%X1>
MHU -1YJFX'>AM52!M<[RA0*U:*?,#$]MUCAR3I?[CM?DJFAD\MV.98)32YL$
M&3T1[#8C#'M4K5'*W7F5T]7)7[C-*$Q+5\??^/(?3?FM&(!8&O>\:Z6MV7TY
M@&4&.E$^@ICZEZ_:>RN]+.2%H::NF)49J2T=S74:J[;"YO'+=DI8V^,J.OKM
M^[*X>HF#5MFPSJ:6[]],<U*,]8D]:],4!2/)A_9N<F=<GV<44-=54Q;XL47P
M=722A*BMI'.ZWH"6]TA4?\.*WHL1]R*4>930WS4!:^RH(Y)^Q)O;JT4D:O)(
M-Q%$,5+F90KHU@#J=*6C4!O)YC9FU'I2@Q6TFY08P+UQ[+S9MRSL=N28BI,P
M3U==O&6^#YZ]?CL)\>-X@VD"5!)5;@2^_G#CHU^/?8IBK3SSYG0+4SFFAE-(
M_S(];"HB:;+Y6,G"M;MPZ@P/5* %C?KV09>3:E,!<[5!^=J3/;P@]+%0314J
MQV!</?71/Z^E&9JV!&7]@"-!=2N<$@S\Z&92SX:/,>;G0?,KIN&^I[AE:K?%
MF 1G JNSQ3S(.[+K<@)#UC$*[8BHU6"%GK8I]--Y+*O14M)7:NS"3](6!BD]
M($*G8,O-+;P;Y7]X16O+1M7?3)(<1\ Y"WB_@KN-,TO/.70PE\4:$>C-!+WH
MQ[]#B&=%*Z<Q/UP=!LM)=YA'@<"5XRS5$ZQ4-U^GY^U3O9*;3+QC<DU<I-"X
M_KBV'_B8,VPQ+&GWXK29KZ-_:Y'SKQ3[*Z_/\%J\#!G52:"ID2_QA2'$S[?L
M:].ES,S9ED%_-$EJT->'0[5RWL0C,%_S/MF0X(>^ 25S$B&UP]:G8:RW&(F_
M'HK 0NC<] 5#\5X='D5^^:37104LU?H.%-.2A.L^\]SY6JP[/\J/X)UT;%FU
MD8ULL.'G/[H=)G'-9B$<9<$'24\5.AT(%(FVM)8\:X<*2:]IUAVW;?J'11<C
M2R/YG\D9/?0W(P4,4/)8,T>SX$R<$==&^;:8,RUH_GI_C\Y!F6?IUWFG6$%H
MQ/268=$_S(D/B-*"(Q4/W<SERR,W\M/F\"QISV_<5$E$1IY6!&^BF5_A\LRM
M=  __8E^U%CV"K=X'Z9D-$^'_/=4JTP:8^5BWW9)C47O\\!EXUT&<XU-6PJ&
M(RE!(]"F^CGLOP<5*,6@F2R<X&6,JTZ"FHITO\VXJI"1R^V*-WX%Y-"2FDR"
M(N:B('5LKV3Z:H=/),I%P.14%_48QB44( 1 (-\5)3PZU":[I%^^>RC<2BOV
MXBX;4R$*7.D.!,FE#W1V5@ OW)./Y15+F2OK9J@-;K#].X0X+JEK'Y,;KW-)
MQGBJMNFHBOJHT<<_MR>-FG5):'!QX2H-/1:@W3!.SC3A9M'N$HNU2,-Z#<J!
M\H!(W-'.CMI\]?@ZEY%3U[%_!R,S)#1<VL177 G<J8K5/LV!*)A^@@1%H^GD
MW&T^?;<4/]0%WVN-ZZY2JI@SB,X6N4*Q!$8%2:!2>KG8#F%%1*Q8WS3P%:/'
MMUEZ).E@JTO,P)&VZF7.)<V/14NO9ON388IC51L85[8)CKG (*QT<,!4*!9!
MD-F4DR/./DY\I3J[V#DUO5&!9TSK@=&D#]*1YN,HBB_:(' CL:"Z_B?I]"8K
MBQEI.PH/?]S2@/E0#2<L4S$L7W86!7@]^*F0L\&?A^2%95@H90K&QX'>?=XX
M99=9\.,Z/;$9VR9*W4(S/I0*TRZ3>A^GHY*JB."%.I"YJ)UD)$A$XQTT%0HC
MZJ.I^2,Y"UWB5I"J>6;"BDI4$G!XM3>:R,J%Q303=:C1TFH@J"94C1'>7'M-
M3;N9?NR:0G*6'LY5XHT=;XVEH=$N?S68?'6+'QT^V^I!LA[-(8^2*R(HOG$S
M5]"6E$.-K=_7:N_Z*HZKW;:8:X2DXJT1XR=:LN?H1CW4V@AUXI/QGA-<<O!=
MWO $GB"*1%@FL!'9G#R7-(A*.WLD.3\+I\B@HA\*%8ZR>JVWJI4M@8'> &$J
M[.U?5>B_$X;MD^AO:+-TE6?:]C0U2+H^]WLJ*X8HX":,LAK!DO:H""A=AVN7
M-,WZZ>?8=)7:!\H=F9 I_0=DFCZQA+%2^>C0(J=&I?Y<%B4W+*R]U^_Q,C.9
MY#LU/V9@38G-:<9*)U-4YIY)M'U,5,?+IH:%C*"5:%HDE^HX+CXK9SL!XGZ<
M$V9/Z$'U24.:23"R:U9$]!,!TGUA[5FVFH>6"]%\\QD^N7I-0P$HE&IXC!L&
M9)!PJ2AM[/6:A*GD7-M"L?FL=-MKBH:GS^0JA%3O]#&=E@M"/JD-D%X@Z70L
MV19V9PLCK?2I:>MMY7%^E2S4$566*Q@D%@L--239%2KN\J6'+-&UIBYSUZ9X
M\Y"8U*P4"-:)RU.,SJF]>VEZ15X6\D[K?D  >&I =331P(*KD]-L+R-_MJE:
MM5\L99@D;<0,]RG[UISNP6IX)6^H3S?&Q[[:]ZBXSKW:O<>I9<^85MFR-\J_
M@UO8K=& X=1"T,WY+)3E$<Z'H:U.AD]"\,Z@4YM:S75"/ 6N;&Q\,Y(F"!MD
M*3'$.L=OVD[$%:+_)BWS>VO@2U0.G?YT!\Y,875MXQ8U%M]$;$GG/?J0SSG[
MQ*I(PJVZI$Y6B"8+K@7"W3K#X'X.$(HVG$-!+]A=9S$Q^Y)(X:L$H+Q=*J7)
M+L#NPY,9G%7DOH*H2B^(/FN+Y\OGSD+4RQZ3 Y(,/9 8&^D\6L@N$XHKPMWD
MCIP0-'0(:9);%=K'NI713%,/H5F)-P4KP-!"^;/Y+.@?8CLNJ7<8M0)NG_(>
MB[78L5U2<SV^# =R"?OGK$#R-J$1N%^OL02<\I/^,CZ/+UN&K]J_H\7<)YP5
MK .DPF@N<LVDIN:V"693S7_#@=!VY2O:IHJ:S:;)K7DS3(%1DF_F#61:3!=L
M3$[]B0+4V-7\39S8R_:I6;$!Q.54F-%_,YR82O"*TJ]F@-WA6\U'V\/\&T1\
MF6W=A65\L%:TY@2_U6 M"*-+Q2<MLDY#[>!VAH !!N*MN/=IJ1_S*E+)TR_,
M@&RBO2GWV\OLUM<X>([]:K[(4I5M5-/)8MH)053TM@;F%1/*%=/8%TD&8@T"
M-NTLV0RI'2-/W,\K[-\./$V$4#!6[+!6:VFK!Z:?!Y?CF&JB1U#<%5:CHYG7
MB0D:L))=<-L.N>KQ^#7N&RK&&H<S%ZPZ1;[=.^WZ#S:1'FZF*@RI.J0]"TYV
MAF5G%<(B([Z\5IDCV^\)X_Y L3 _3%:_-]-3Y[F+ 7XK@DTJNE%Y/J0B269Y
M\A&1TM?VDV9518JT,X?]'PEE.1%O K&U23?3K2=.XKL\$O >A0G"-D+(L3];
M5L/ZJ_V.CTH:K391O<.^;$?2U%AZ[22/XHM9S,O.KBT4)*V*L69%&73P/%'-
MC@8=M8TSFS#^\ T%OX,-NU62NO]OU>5?K$[<;G?'&3D5U6KN68Z@%)-ND^07
M _7]X<2F'<ZZPYP[O810?E[-XE5?FT^_-FU9V5[EB*0N8.,94NZMCC7*&XCH
MJA#_J50=K2A+/)1"UGUWCV/J"OED=66^OM.Q3I5F>6:,"."FFMLHOQ&)O9"1
MNO_,(+;_Z6]BHZ'M2?-W\W2#!&Y<40FUD"_?'?_P)M3:RX0"1#<FWV67LCIN
MQEV:D95^G[XG) C$]ET1\8XJ?*D]<DM?/MU*M6UGZ[5+^T1BBBWY%5-(#.\/
MBI-@CO5YFF%=>AI&I:O2<H%*F[]-]MM4BYONXW<"B\+/*4XC*+;CQ@D(1&]X
M8@\4BTX_)O?Z@%P3RAI.V<PC6I12$$M '%3-E,=5PN+@%+YV*L*7G7]0SWWS
MG?;O2<O%4:H6EX;#='C8T9M?7;P32^& VGU<Q1UY,ITXJ?P5NHFOIY5#V+/(
M\$)F;/7-?1;MOU@5'*^&4=SF'A=%G8ZKO*:?>5*@-&(U XNJO&G9^3FHOH#[
M[K54KSS3J/9=VU,)>DH"J^_O2AW8K5/VHN,+\=>R9DP;WV%/5+F\\MLK_4>H
M,O AS5#\F=KXJYF)$0]))]'JCVKX/[-X+]',#Q%L_#>\Z_C4D*!OJ-32HFN4
ME@(C:@%PO]-U4N&BM Z/6PBFO<1V]X:S:%SV)T!-QAY-ZE/K#>WYT9W;T!J^
MS'_G9^90?\7ZKOJ%>S?^KF$.8V&V%0$LXX]Y>.RJ12YM>TK[TAI%,08VGGU?
M][NLQD0ZLIV2MDI@ERS?R1W;6\TSV2$;0H5Y_+JK\Q_"/YUX:?/4SZM]CPM"
MH#(?C7YQS+"<7U%;C>^WTFY7O0V]^$DOY:)G<?Y90>6C5P(NNX!#7(%3OHNG
MN4E! U"K<\NH:IN0/&E+^B='ULIC//9B$>[;CB^?_GAAZN:0:T/ T;2VU>+K
M5P.'K;0*I"7/:^2FI7BGE<.2Q@DB'2<!"Q2B#(/M,1DB-T4LT82$3>[!\&M6
M.X=6U0-H9"%7O+N!XF3VO35)P _=KJTATIYE(EA_U_[WW[PI.(3]=?0>?XC,
M%ML)TY,K,H%+]SN_;MI&S$@E(&C%4H6I(_X!L8Q,U]DZU^Q4,:WFY$D_E9I[
M=9&_[B7>_"ES!SJ1L;S^)J3FQUATU9H[\+Y_MCM+*>?YD#ZV8?!/U'9Z!?=K
MW-/1Y-/#RW(SB\"^KTY!?K?+L4*G:O 2LV0SR7Z4M%H+R;70F)9EEE"Y@'AH
MZ6O@_66<WW^G1FS>KW;7:_=2;MX4+8L7/^V5@)HYE'I+W<\:<K-8JK@!EN]:
MZU]98#*.T&[^<G#89I:WHY<_2WPK"W^KET&E%\125,E$^4O0$M,)"\-I*38B
M(4;[.CORYP,C58R(.AJ=F8)(0Q!CB&@T(UK4JT<1E\>H]S'O/Z/KS#R,8/U*
MU?M9?Z%R7'.,N7"L--8"8W"=-6D?')V7Q3$(DCB6IYM8KD:6XNPF #^4.U5D
M:)G>^ ]5<=IGHNYC?8PJY0U^Z+D65!8*>&RP$#*/U\>*D]Y EP*BBI[BI<[[
MR[R%88P]\8_ZE[^M\,]06YTD@A"_R]KT%ZWPK_MID'M&2!8[<%WQA]Q880PP
MF.B3V(:8S2KX[869BQ$!)8#>A1N0$4[AV$*J+\ )E]]JV8MM..Q?;#M(7]R)
M-B&\E"#<ZD])B&^/E>LIP)Q@YK>8D9R/"BM$3S/^D%_E,1LY),\645FBO8Y_
M7RP;N*H$>2KM,*EKS)Q+1:Y)_'5'O^TFY'Y;LA@6G8=C8>X#9G[^_#Y-5!,&
M$6=*NC8IZE),(HJPC'].*MK&"((@G?,(,("G"I R"G4<I$,4&TU/XZ$&F=G'
MH(5=W(K=5*<-=)V*6Z(+-6*T0DOG3*RZPMX )6],+%PB'KS8ZY&Q42 VL; V
M5B7S1#01J8F^F<%^3 KE>]OP:U;\$J?GJBM>\^QOZCGS=XB8'KWRV0(AYY5F
MUUN.Q1*IX%^79[><2Q6*_MDBU/SX!.E ?#F H0_S:I(>,06;2^!># PS\ U1
MPU(41_9]?#:_>\_)1K;KQ=F7=8&-@<#S UB,],,/J:#1K=&2S=[3S9%HX'8J
M!7_">"LA)>L+"DI['!TZO5+<7I_]>/-KNAIF; G^_:4JM1P!SR>1\XX(K;K9
M?:E#M(DV)*\)'=>U6&8S=J<)G#_3UBD:*TH\=V:;"=&4E'4KI[O\6P'7Q'EW
M;4$T 8V.">2J:6[X?0'1.)WSRGOXV.S&+>W?4M;RPW5C4H;#8J+H\-^C$5=6
MM5,+J 872A!#E"PY8DTF:)*=,@:_E315\+89LRCX6=^,*5XQKFK)&^X45.Y%
MNE] JX(5>@<@B,\+L-5& S^RI K-2;!:\![L$8,)Z7-C,*1"XK(,,R792M-O
MN O,_2R(*4NR?VF(EF;1J=8[>)*OKI.I)OZMP.;B;GS<B15)EN2 \D:>C!!F
M$M^]\7IVK7V;HZ\:AU! 1S%8)GR;[\J@*;%<31GCGQ>S;C6"CAQ/CWT/K?E6
M]BY^+"N1?<O9N ;/CH,ZGT'E-P1M'B^DTB M68JGL78-?2/-/!3![*ECOD=;
M9T:P7J+ (!S*%J$[%HK(UI,3YT[$W(3N*@2O)%G3V*6),%7723WSZ;-QPW*;
M%XUI\KHW6+"+ YKD?LO3"(GBMM@>M-=FR."LD)M*CDQ@P 42T[4$TI;Y6&O?
MXUL;TWU TWFPBL"DMELB+#OXSO(1FW?(IU_L6+X*XW$SV6""A6;]JM5W[@&<
MO3G7V&X\S/UFJ?3#5O!FJ6&/1A6:9$U[DO,S9%IP 7M\XD".CIO\IKCO]_:K
MD@U[T;MTPH $GP5PDGB&H!]*M:YU3&N#-*7T+-?60:-&?0\>F(.C\=5,IYUQ
M>6V?+P>)[:W;1[%MSUVNDCFM(P[BI$=%C)*V4+TMJUQZ-56$D]711[9$^5=G
MVWF&YQ]+O')"5W_EE]5ZUD$/H_._57FZ+Y*ZE$^Q9:M7RI1P;SCNXG2T$%%O
M+A%B_$1C6A.>M=D_9D^JU_OBMW#$).F+09H:*[I\&'I5H]*Y;US O\;;8^([
MZ9EE\Y."EFZ%XKWL;R0VX]3ACO'1P*O#?#<^D5L6\<V71U4WNJR2/-W<+(_7
M$W8_%RA__WG24O]2\_[WWY,[S(0&=+X*6>S U]M42A (Q,=I41&*ACBV[RE#
M'YVTUNO4D@RG9.Y.FG\?*ZD=$3)):S7I*G>9@Z5&1Y3\,Q$WFB&<&<] B03X
MO4&S\4M&SW#" )U-4\+( 3,18OK#K0J.NJL^IBUX*F=[LBU)M!_J.'7,$._S
M&6+B:*/P0XF%Z7N%]$7ESJ557\]P:AS#+Y>E'Q0B!2$+K$&Z= LW9/^!6&N9
MDO[93/HE,BC^JSVCRA??S\]'Y;#FE0-P D'D7SBIM)6<N,%2GEV7D)G+S09$
M(D#8$(&3:9T?CJ0_EYE9":FZ-'T_*_?OJR<W4_(0M/+3G"\#OZ3O,S6TQ-#Y
M$,<CS&9G*_EB6$->\+F &GTI9A!6[PUVX9RS'.ID_0B)&@=!*/KLQRM!C2]G
MYJQY_@MV?GBVX=6%319Y9*\6T5T'WAS?JZ,"";I_FJYLZ^S6="U8+-3SDL\J
M& 9M4D8L*5$%AVY)?<V;PJ\"B<R\2Q8;E!0A\3,JQD%!)7 )7HPV7(W9-D*(
MTTM.Q,;[^%Q_M:QI[2,2_^L'$>>K.'L,S&0L5#>1.4@DA%&FA9%AL+N?V6I/
MF!FT9+'I(&2LE08U)N-H8I5=#=>J .-\"[5.HFUXR*D?UX;SP'8E*L_*K\K!
M4CEJLZ!L.3ZZ1 A-L2[W\BL+65X\5R[MRB*1W NE<OQ;)46FUNZ:=3_UR/R$
M+)SO>T!OHGF=W.2U?_1=;^5D/(CZU<1D_@*""&I*D+9C%&%<6&[GISLQ>R1#
M?_'7Y!^*\ RVSTPF[..4I[N2=*6;+.+^'HDVT3"-K-%,[%$9:C3#<#1%<<B#
M%;.S#(L,)Z56J&5;*.(%S3F_$C59T1]T1U :H(5,Y2%B18T9_I6<#QP8=H-U
M@MOJ$P^8G=]-DXBA^[9K:)PD-]GT9*$#-7AJ0[:?OAQ]$ZT)2GL5T8T@YPEK
MX<D>761?WW[-KHH&#)OWCD0>K>:=RN1^J <<:AM:=O;<@08+(_1C69HI_F&'
M,%;ZC'#5NN[F\)!(%[=I!$LWV]-,QAN_[@(S.Z78OJR$3+W]>YS>D$T7M\?$
M9HNN8VZJW?HIG I+:M$XDD3#HIR>"A5ME#-D W5SJY9]8*SA,OH@VX[Y63F@
MSKV.9<?-E%YVK\M*#M0/III,6^M>\&H1*O&\7+@1OA.Z@D<1FO3A3?_(&G=A
M(-4R\<]-T/6;"LI]]3Y[FT[B,JO38Q!Z!:A5M7[4M:E\ZM3!T;(7;-++30B$
ME@OQGU,S8U8NO3FKS*/3]M+MA/@OYC<VH5^$QDMZ= [P.IN<RN=O>*U^'F T
M98WG6E=/HBBR)S!1:G,0M'G^H/<TXE<;EY5!UK0A6'A^UWA()W?RG6EU^!_R
M=RA8G9JJONN=%@NWV6NW'Z:':F&!_X0MU5[:LZ<&)<F)2FIY7#4H-:B^.B9C
MTCF.TQ&?\TQ-'G_.3,80\.X47]&O9:_M_JK:J;BU3BO,'-&ST\Y^\SL6_:SG
MDY( ZV9J@6]BN*^WT]"YPMKOKV<]QVJL),? Q]/B#T=XAM9^)%DILW$QK1 C
M,0[->,T<R+8)EB%CL6S$]W$!UY<=F5-BCK+YU _K?I(#[O2"*J]5XS@JB<8;
M!7Z[D(?H<-B752[;7&Q-4:2X.7<NY\VK,T[EC_8K&*F/R?U&35(C3;Q)F],H
MION"[27<BNV'9OF'Y"O&W=FE_-1?,^4K!,-/56F.WA;D_@L_,M.((VQ7^C3T
MH.B[N<'$C4YWB$'YVY@$?H1*QQ7@U:T^1C0O7SGAWY :F6QQ^?@)F'C-7A M
M=8OV"@I*4/7Q:5:%_)_T5VEEPG?]=/A>W7FMONN/N1*_J%0/AY^/BIC], 48
M/4]^;RC0#CR\]+@QE7VU9XOM'\X77G%@CS @6Y&-_>A-\7<S94G(^]V9>>HU
M\V82$=J8MDU4GV$#9(I7-.W0T^1?1-;D)O#8DSZ)G]*?;8+0I_Q?(),Y'68-
MH,)[UK('KJ-H5W[WIH+<>J<RE.9IB>HK7VP.^03AM3%E+7IY/U9GJ*W+98Z&
M2[3*TI[256*[$/#BX^;,1+Q9,Q*S')K,TZ)N09<H=QG]0Y\</6@WV*!<DQ_:
M.(HHIM(YN*F@.D=//%,']!2QC.Y,CNR1GP%"$=@$DSDT-HR4/Q+4NG3_,N]1
M_8C]?)^-AD4+EIALKBG'6ES[0V4^8:5\XKDHQ__V5J?DW_UN&QTM^_F:EP\Q
M\'B5P<L^Y2[O(79M(L!B1R$6G[KT;'3#L(]):8A9J,5R4.6+:=X!Q@],^ST(
M#9'>G:^];2*0:R)^;!23+TB/X&,I'HG:? #VD4CE0OB.W!LSZ^:8KOWR!U_R
M*;OMP1TBH47-OV<LXCVFB6^T<.J^8@F;RK18YZ[2BDS2E/992BW26D:QW)KM
MJ9=B.3?_P](^918_1@\)4:6!&!TRT?%4V2N5$@S[*!.4F'S*PF[X7G$U@T9N
MB/C+1?_#=4M>X,WV#06SE[;'AH+D4;5 6*PO$XWD(LV@*.%]]^RM3,9A;+[,
ME2K6Z+Z6H@;9Z%1E! M]V#X2FJU"9Z,3RJ##5J-FDFA$/7F75DP\E/!H7FZZ
MG'\'7T@/7/Z>.1^GGG^E3R32,6Z\\ZTW@G)()X$'K!5M;JA_7%U$;O6<9-N3
M1\#\S6**+];>=>K-2$$>&;,R5E(SNQDS<7%[]VK3FY'\U"-7KF0:6VQH7C%.
MND-$%M;;T E286V#/O37UE";+B6Y@)I_UE_M%NWY.)S\$MEMD7ZL]LT::L8'
MQ:4._>:SMR]IEA;?:?S(F".=TBO9[8NJQ?'QE0H3";JTN>BP&ER<].OP-^[S
MN+LSF(Q9_AAD+6<J*V<G"U2F!*E8-^P=?-O1POI'Y#JPF<-^XNQ55=3R+0*Q
MKGV\?2])TK&CZ8&3SD1^0KM&BYO_/7$#/RL %_]@9-GE(.A'[-:+BH@+:J*Q
M&D\Z?M#36MNJ9@2DQ-L>:_'-UP.A!?ZLK!"1XPUZPA#RI/YNIG?"M6!'>ZIO
M]1LMF+.-AX'?:@:7*5!@X S CKQ$G$,#QQZ*=>(;E07V6",^Y4"^VB$,KM I
M1C.L6CT_EQ SL.2]L9</H2?Q >!X_06)G>)N:ZC-Y0"5U[?$&L]38- Y'8^R
MW[I+XTCGV2"X(0<>5&?@0.WZUGVY,NSB"P5'<[)N9MZ7)CH"4+KUM=0NV5X<
M9W<!:@"GV-G8:J]^[#^ENF2CZSQ%ZA<^3)I,-H5;SGD]6._K&F#Z2?9_OQU%
MU2;B:SDHS/=!$E:M-V6ZEO59=K\9EYFS%"W-KAF%@*O"*MP#$BE6YNPQJFV*
M=-EKDUZQQ+>$3;C7)+7^1KC?G;=.Q2_N);T5GHS423*;W:1CV"*C!RI!J.!<
M)QI6W D4DP82@ FVK]!LVC3^:25ES**-E*[\!'2#KX)$JU6+L8M1-ODF+AIQ
M!8JS!P$>3)G(.MC&@CZ@U&FZF5U]=MD=C$TW,LH!4>3B&^>FBD^FN^Q@\X#S
M-7\L&?LT'-5:AB48F4WQI,G6#K;"KB$VB=^1F=3D5KZ@PON(.BG;,V-KLMSC
MR.H_.^OWE;QA<\)/3/,M5XR@NK5R]%F#'5B7 SK]G5V?&AV6SO?#\W/ZQXLW
MJ^;SLM/<HZE1@,84/*SN>$6N%_>B:_)N*FJ)*'R<:)+!:#P_@@/U*"J"Q.:E
MJHW:J\]V71LU--:J _1B!!,=+$ B"0 JGL>:1(H<7HQPH185*GN?P<F?2@?]
MN(*DU 4Q3<?-IV(+NYVP>)<G>MP'V:O-_#A;^@P.'^*BF?C\Z/Q#9/[Q^]\>
M.^8M!1,>A=\81LXPN0YJTLYT7'UG".GDT8N2A4<6A^Z.E\*@PQ;5*,SF7LQ3
M+!Q>'U%7%&K ZS8G.PW.=1",V.0+X9$HA0-UU9U:YHXM.]W8BL6IU %,C1K>
M:[EEO?18Q[;%_$53)VU#CSZXUB-_:O.47S1]+'G<T[_- 8OJM=JCX7Q]##JO
MAR?+=\NTPW/'TF/X:DRLKKF7NE3QMU/__?2^[CE^*2>A/9O91:,[2C\^N(QU
MMV72"?OK\B'P>@?'R2BN[2HUSA::=]66R&%M@0TT 29LG1GN@H@/][XM=4Q-
M-P>H7IY;O9#$Z^K4:@80)3"G_N#/0_=JJYC5\2*3R^?=V5V71!!,)\;&;X![
M2EC[IW_F3V'J"9 QXI%(%Z%JVH98$5"G7>OL[5*](F8TR47=KOF<[T87J:=X
M5PB<5K_EB'N5#-?$QEW[9M)3QI)3L<IV!$ 5M'@SEXKMX(-9?+VINTHY[=V
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M%T'9=:M,P2H]BF%+I\28RXURJT*;394OXR9,K%X-*N^)&W/=NY4*W7&&D:J
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MVL7"$A3/X#(R?V13/D9@-J4@HL4!] FNL@)"]T%C_]I#]KRG1-5#@$IF(=)
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MIE&JOVU=FQT;:CW:2]O$LF$AIZV&.)F5!CW*X#-L#]',A&T<N)B8EUG&"@/
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MH9A8-/'/-V"GAD)#TU+05(%I\11-E>D11=GEJF8A#I*#>Z$UD::?%((L(Z'
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M2/=Y* 5LOI<"R$NA"6"DA_'9A$YT+ZMPBJ;0&8Y)KW)2IX.D-$[)R"6!NY5
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MT5J6'#@%[4DYD6/+I+E%UM$]ML-,@(PF^M)13S/(0S&1;YR4!MT_F1PXT:Q
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M+MU7+UK8I-'>Y(#P$ C6@U3?\GQH4VK'AQNMWJSXH*U!@P0'_OCQ!HXF3:%
MA4JL.%JH:,L8%[2KUF+6K'3G7J7[(/#1SBBCP=EKH8)DK&\KGP9YN2/#B6H%
M+B,9MF2]DM$>L,4=-R=JU#I_YB1X$IIGHU^9[H/3^BISG@V;-]_\(';QH8QQ
M1*0\M6?JY3ES-KR8 T[U\N97UDXYFV2T: [84NRX&SKXWI-W3@W94$?'@P81
M(I2##P2E801A<""FS"F/-=;8,HWE5A=OJC7'T6X,U8331#E0=YZ'']J6@UO9
MV5=B=Z=M1AZ(*[+_J%(T.>AVXDWUG;@:! 4]\,9)Z:5T7$O1:"*=10696*2,
MX7W$DT9L 5@003_  4=BGR'G(G)[66A!:J9IA)&,KE641HLNA0(C$#=&E.&1
M5<W'DUND[?6&CRII\H,#][6IY49Y:D910S".-.>8*VD"'&M;,N===AA)&!Y&
M#B@SJ&U<JI;E1!)6:.2>'6DBJ*2?OD326/O@ *-$%>@@5TU\[GG5FA%MEQL$
M,/HUF":@M%<E44G!H68%E>WD'7UR>0=<1:'H"JJRMI'JI:;;#2L5L7]JLJRU
M*J4W)V,.=/2JL$HNFI9]!G7*%#U%\7B28[?11:N?%;EJ6;1V:><:94/N_R53
M8%+FJFYQIK6)Z*4RZC!D&IY^&DUD&6GF;7<3.B315DE%NE)H$\GZ+:,",\>1
M0,B=>ZU)RHD&%W[R&NFKQ-.!&LI>;,;K<&6:Z0"E>B*?ER["),7VHG] +20:
MGY(]:V)% ,*X%92=YKKSKIM@=:B\0W.7<L4X6_L?!(Y2JC'5\\:9+-8XPU1;
MKR6/"_:T$MY4,*H=X>"TO_O M!X]9KUYH] Q?^U<:S@M! %;^VWH) YJ@/+8
MH&:"I[:-,Q(=GG!8]UJIU%RW2J/7F7'Y4 [5GM1A;#\$#9$%0&R,:=5?VI3#
MP:'C7"AI,#I^,E7U$KV7,G*;=XI;*N-D9-_!CO\W-HOKH<0CKP6AWE-4S17-
M-47 0:0FEA6P):*(_)K%HB8(#1_^3A8]@"QMQK>8U$#WY3TAQ#2^#^M&6X&.
MOO'MX;@;M.&[EE5%! F*=RZ*1AKVMJ$N04QZ75/@WQ2()0MH23= * @.!*.X
MXYG$/0Q95)_ZEB3\1,0'8A+;H& "&<V)3W^;0I-#=".GDY2-/3+IWU[")Z,6
MZ@UTR&M1NFSS/<LQ4(&U8QBC=.   5;',3(AUN-D1B'X2>0!(\F@_9+(GI*$
M;#:,H5U=I+:A#FZI1+H1#0ZQ)QT1O4$3IR"AA\P2&B\-T7:9LQ02JUB<GS71
M-VMSX!YG5@$5V1%K+]+_#00WQR45/I&)?B)?0RH@AFCTL"NA8D^0G'>1CQ2D
M1LYZ(@?U=+3<P"@-C2G*#HU"*YBE<).;@L]>7C>W3ZEA,Y;:I-],MD"<V.0'
M"$A*AT[BLLC\))$>J24J,T.3N$D2:S^\7!XM%$3510Z7%7! +\?D.V@F<(YZ
MA-]."E(NN@421%_)%E/R!T$#1E.8JNQDU2!&$+_ H5]7+([<-D&D_4T+D5-3
M)/FN!LYPFD=]!8L@*C&C.4U*)#LY$ I Q[1#T+P,(JJ1YG:\@TK*#)1AK$2C
M2R().UXZX)YUB0BC3'>9)E)-(D#(36[V]94Z!A0K>EH=^>#%,"2Q[8.F4<T/
M_T:(,]"\J8/!.E62&O@MG/($*P_0X6=BV1J0* IR1*14385V2?GX5&1D\:%2
M,Z4:&YV4GV+M2S5;Y+)L?H>?#3QD:8IID>(UM#QS"IEMG"H7)@FM6VE;G33#
MFD_<A%* 2REE *F(G-"PB6N8(RK ^IH[9V4D!^:+ZX=@9%$2*=9KWN$FE_@3
MG@I\D[(8-$E@5"I3L.93CNR<FEH0,D79&)99-V/*Q>@EF2*J;IM2[2/7^D(0
M7,US)3"]H@F#FTGMN%634\T+^5PI*FLI3&A\/*A>B\I;14W$<S\XCLYP1#N"
MSH6=Z]2L;APP69(01YE4A2S8B@0<S.7@M8,J4TZ%:O_#<?T-KJ+U4,62$HKW
M;&TT40GB>AOKS.5H["9!$X@KRVI%EYP-FW$<9FJIZN#]&B<:..@?$$TD/F%^
M#L-C,LLR+G4])V9N8Z;14\'(M]T>_0BVE-P+7OUX2TNEF,(V:FE@0GL^-H((
M)DLTC;'XBN+PZ" \/45?+.FS*$,.$4-MZ5!9SHJQ9QI4O/,!20Z069(+*ZMR
M70W8LQ)8'X,,MS,N*Z-!59MCU4K%9B(^"L+:0[O-$ LHCK,E'*U*D'BB9"GI
M54DI VUHI@0I6LJ-%DY\Y-$YLT1$X-IG2F>FIXGJ"-+GH2M)X "C5+4/;%2S
MWFT[DM65%+HDD=J*ZBK=89EVP4A$/CZ)/UGD(Q$QQ+.N4:Z6*PP4YRHK*2:L
MTRQ3J---*K(U#@"T6$SR/1T P2UN/M*%(@K(0[/HT4&B]'4YV&OD(A=2:3;*
M,@!4;%K&;)M7X=2X(<UI(+WG4!Z,'FHB:!#"R'9%J2Y)'$0*Q%HV<V:Z]ER@
M-/]-2J8X0"XTT>FQPTKF)]+/X-5!WHOTBMH;4YJ#WQI<]@"Y[Q\KI3:%BE%]
M67-))^]VS(PZR$#D21).)U,?M1FLC#USFPU65YM$W6NP[$634R\K6W>V:;K5
MF51XS>A4$RD(T,NIU(3F^,@7 65\?[Q5K?X08.-U.*,U+CF626J+%_=PT5G;
MD8+)%\@27P\O<60!M\'GW#2UW=&G;I ?S+KF,-3[Q&=,;X>9.2F/ECB5<(W9
M,A=]@>,C3[LEGI20@2+4#]?ZA7 \F2@JN]WZ\%$TV *?O0JQ3=+\R:?/&>TN
MUR^0[J)NZ%%.4JQXUM2-M_D_/6T1EKY/Q7N,2W:DEQ;_T52=)/V]LZ4!OC;G
MS66,/U"[R HUFC:GDO*H"4^MTS?F,@MOW21:ZNS#B;!S =4R#==^CM5$T.8I
M_P' MM_W\E9\14?5VS@!,^%[M.$(CM=2K.+89AA:?RLZ57BPTK3UQM>\5X"
M2)TD&9Y SZO4E+B 2?5L1@Y<#?U=2]=@G$Y5VB5)1]-="R@\$/9LD+2P7I&
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MF;&7 >'.XY@&1$I**/C;1V*F8597-IW*>)RD:%7<7.;3.U85I='A1= $$#B
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MP17_-3WD-4XPG-3&902C7I:/1VT1PN2U07HC8GNU$=-.I[!"[<8 #M3@9]5
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MGZ5<0"=%PL&@F 1</0$$\G$I,=6D'U*L_8H9]*I5^U.=#@"5A=&%P#BTD%I
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MCZ_=9O+I_;(;+]P0/;Y-NA'8O[%+<H&(I/P\CR%'WNGL6+G%D$DW7-E0,)%
MIGT5=AWIPET]#T?/P@&"+%R/+.HW>._QVZ87H-.%IT5@#U=@5O).JV?"-4GX
MR3_RPB'M+IHT<O3R),%?!,;(E[')IT=X\E'W8;^Q#YBK]PT2JY]WIS>R(E<L
MV#ST'A]:U+)+*)C\=#R_Z8N2M3]*\#]: *%O7[1]_P5#&<GQ PB0!P\@6-#1
M$ +#!Q8J.JQ0,8=%CA<A5/@8,J-(" ] GH1@I.2/A@\H/L !AV!!FC5MWL29
M4^=.G ('[CNEB65#D!9%6BAYT>+(C!8O7CQ9L6A#"T L.*VP]&-5"SE@I@GU
M4VQ-GSSI%11*E>-2I28K=@Q)M2+)K'.=/H"#8!)-93UIEBTX,UI:( [2@)JY
M#W!-@M'@Y*C $LXFGCAS7';;]&E'E)LQEC0*LFU<T4X[:NT<NB1*UJMSQ#7M
MV2)#EK5__$@(!TZH98ES0JO,LUYPXL6-'T>^T[$#KSD89JS $(AFHQZG(FW=
MVN%5J \@)P0/!W'@Y,-QAO_*P9PAZ-,/(?R@"]ONU8<L*^C(>#N'LF4U^R8'
M$*?A? L,#I<D.K"CMD[#Z+,%'52MM,R\NRL'@LP+,$, SS*NGL0T>0R'!X;Z
MJ*62XF-*/@M.TL&!WC2$\28"&S/H,>8L8.DA[$J4Z(<=L]/1KNT63.JNR!H"
M[P&P:"0PQN#J64S&@J*,9C#<<&N*N[64PNXS[> :Z2Z7C.C1HO1R.*Q)\G+R
M*4J:'*L-MJ-.)$HDI;8*DCN3O,+A!QS2^._-Y$(9JB$U-J&Q)@\'>LPK[WYX
MD2"!W"RHOVA$9,FKH3*MH+E.O?N44TU!'=734D/UCE15OQM155%3S3$C5O/K
M5%;L/V'"[0WQ0D$L,5\%-:Y-FC!TLEACC_N5QE#2^$&]EKQ[KZ7V.'KH09&L
M,BFNAH!H[H?=U,2)0$J!'>P!!X#P<:ZHLA5-176Q2M4KYF0ZMKR=B!VH572A
M@LPMHARME2B!^P6UH5</AE53'#2IMV$-B?4UE$8_A6[/5IL[$$FG.$4R4(=A
M7*PQB1W-U"3NK K-RVJYR_/.V?R-SJENTQQ+T8+P_1A&@DYY+%6J=.#JM**
M))JC^T:J#<G)JEP3V#4)Q!G891G:Z,>(FH*O*PGO[&RC30]#3K"_:"*TU1'3
MV&V?92S=!Q0U,L8M#:C_B7LCC32 J-O;N]\ (@TCU"A"#6]_ %P-O/LV8F_$
M%>?;;\4+'QP.P@-/_'#'+?];;[PAA\/NS?56 PX0-=$$E&5"8;+FXL#-R;QQ
M<X8=]BHW>6/$44L[6K7XK'M*HDYOPRV'-S1A&D!*<4Z,4!&) @(T+Q=D2"N-
M'NV3^*9CSY!8->R&0_ TWA"\\>X[[YO\--0 '^WS T>;</ 'A[SPP]6H_+&Z
M7\0^_]49BR:434#LW/8JUS[)H:UP?A.<X<#WAO[H;R=NB@:&RM*8_CT&-UT1
MF.^LQ1H(M00^&<D8>/H$!V4DRB91&QOL4,@_IY''2E?R5WLT,QJBE>@CS7%
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M'A)6\^BZ&O9V_B7YEP"+Y?:I;E+<HV'0\HHAO7*1_DD\,,(WRDG5\*B3QE4
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M,RZ<D9U4CQ#$(J@-N23L(804=&)15_*2<;BUM$G7LFYZY6#>\^J&CQV6!A$
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M!-T^,#%-Q2P^GD:G:8I^Q@M$:8J_0DLXQ6 N/(ZR"&[]*GFY\%,[T\_/-7U
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M2+_ ^,45,0$+F>? @45?AA@R]6)*>T[O5%UU.FWEVX1KU@C=U]I$KDZQN<1
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MI LA@--*H+ZW%4I$?32UMXHVR:_TO/GHK&68Y>%K.3!FN(K<6D<1(K0?8(>
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M*?(\X 1J=*%#TP#*CBS;,FAO4)ZQ6YP5LL98SZG_Z"2FN'M%,"0EXLMY\4T
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MHTV]?FAX?N]?]M<G-]M)E 0:W#H6^K\[-87*N>*EK O<$22(PHQM0H_+,</
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M.P<>XR&R8?FU#]9;C+F6W,C\B[L&7J>E_>W++HTNM"I0]ZG3Y"$&3%_%L'"
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M<_O:%.YTW,,]TC7^Y.XRV&ALFO.M^&D1TF3@9,WY$\F2)]S?H:?C$&>VW%/
MCX [W2&[)18-^C 2@_D[>.<H"H-W@(3#\O!D]K$*;A/L(P_QA+L8@<7*WX&R
M!.SE)KGW(2[;\O#?&U,[13U*AF6H!IJM>^UVU,F?])WE(<:ZV'& #L<9%&<N
M+4ART !CO)VX@V632*WT=QYR.A$CF]2?U.P]8^$0/WU95D'V%+\8-HZ'*+<
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MJZ5^W8-V$!#"WOZ<Q[G1T-#1KWS3CQ^/ #X.KIW\0LP@&8")#\3,!Z)6 V
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M[X)(LIY#?@+)JXJ@8&S&0&?-_/532^C+6LKPU=FM,P,8I2;SS*;*KE-!)&-
M 8]EP( !@_\:B/@5$W-OD5>G=EHBMGZT:V*W!X26EX<7Q0H%AE7VHJ*?19&+
M%(&04<1Q/>8KLL.=*#CK$D0STPZN2I%MSL0Q815^A&M^W_%9D=R%E6$C1%SI
MK*N.F'_[<><'CX),X3;G Q^>=HAQ*H)HO;CN%T*A'6M"%3I1,'B(A2_V-.3*
MG=[PP>%#=Q)8JKM@9J,ZZU&7!!-1T97-V5'5<6$2(S#XD-6,#+$C02!O8[
M"(E5R):BB^;L?>Y4(% WITE',+6)IVLSVMX,\A%:NBAY@PJ(%>L#B.4#SRF%
MJEJ^9@ZMT$##523*U2!J/A9<%1+M$)&6$5.#3<A#G+1M,"EH;$4?C^,9[Z-<
MPU3JFT]OSUA^<FKIQ*)E\RQJ#]_W0EANLK++-TWOZ4$=5@%S!@P8,/AVS*$/
M'FI?784NS?I&M\G-,*L?>NE]PJ^UD96T'T03AA[NV3)I]2>WPQ30#8,V<>WZ
M7#E2+:)Z1&M1-I+$7/SQ0#U#M\N"FTYO(Y:940'['\EA FS*275.+F;49B2K
M;[>DRZR$.U!ZQ3;<%5.!-.S>!<CR9"'BC\R]/S$@SW9##AF7WGE6Y94"4^LT
MQW7F)"U6U79^LYM;_%K147K;]&5LW/;&N-J\=SN'N$D4 &VV>+ _]TZ!4UA^
MV\F:]=S=6>5PYJ:+N*.=EJ2MQQ0Y-K1.QQ@G)8?^1"O02&G*6.UGNZT/V)P_
M /5/7/5(M9K\8B&;4 $]ZR$<)W[$=B$).FRIU&G:FJC],9.0VKUEI%2[$ZYZ
M_/C1Q".PPIPVH2*I 0VIY6;O\JL%KZ!02H64<I-5^\P)?FFP\8WM,L'1.X?.
MX=81_@9ZE0$#!O\;A([=>]2]8JEDX\G<D^(U?<*%>Z5U9!?!_(U+\GI] ;A4
MII3*8U'V8B4!D#DN7JAG(SAG<=3BZ9F\J>=3)07(%'P2RW7"$Q26S3:+!#@Z
MK/;<"-K3VG3XV0JT+FC)@JE> --WS*+Q2V#3J#T)"Q"4!(^YN4YQZQ $VP94
M#4^QZZZ0#7"[XC;>SAE. <A;5[./(6HE=N?Q @!W*+X:SO7!"C5/:CF\-U26
MU2I BPHLM8*""1OG;MZB DQ40)E287Q,Z9BMI._%%>*V5@Z_SA0@]9^V\6\
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M=%DTT'LSD-<LLI9ACJ_)KPDVK)RO;$Z_2P4L%]JNPX<0Y6*$]OQP_T/!MS<
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MS_<_-LT1T)5+8D J]B*]_N)"L%6EQU4*BJ<.LP6?OFSB/-T8;!64K;PX!(4
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M) L>+JMP/D[^O<$9Z2,<+)&IH?18P^\6/)SS'N5:3T@I25N^Y$M5N++,]N]
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M_?6.WLFB.G8)Z]Q& P,>&8QT:, UX!S:S#Z%5.^IVR7<3Q'0\UM1G:7YX6+
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MWSB==HLA=RG0LC*Y+3,,'GUT,*PV [N@;O"X?LTM90?(D"]"LXS3"^7]RQR
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M:3A5YP>538_T'!!-W[T!_HMFN-'\&<Q]-X<J[3A[HP,O?:@Z,;4<]@SAKXN
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M! HAS?/DY=7W<<<4F*2/N<%Z-7NFE!@%&+5J9#W)#3:WT[/ET>&QM*OK$YN
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MMOC$MBN>]^#EF"LWCYT([B56;7@")6H2PGO@#<GHQ>RO;F-0Z#=1OJQ_MX%
M"%'>TQTGP@(FC, [JN)@R(4:/1TJ>J$O7;;[G'H5\M(YNVL3Z#!"" \M #SS
MPN)1[2Z*]2]FKK'N=XD]+K ^CAQX51#P9'9]O'2WB4:QZ!@."2[2)#/U0]M#
MP+&]-WI/)(?JN8C%<FGTR]/G.G)M6YJTHSS6:GT"<)DR%5[>Y@V^T=S$QS-%
ME$[7(==&OK]T&G>F"]@KMME11E*:91^,@&S !1*,! >M.<''#9[+8FKVBB:B
MY:+CO:E/(NX6.1HWK\",LD?.C;L86YV)Q!+H,YEVURM6O?I!AI0Y@X/_S'4P
MA_@SJ1J8%&B92@YDZNB_W&[;'[A3*W0O&ANWS&#Y\O;L56F'[Q]UX6(Q=SI\
MW^E).\0K\0342U&8'MS%PS^7W:Z'&'<_,7!#8[3QL=3U#7">",EU6<4F-MRG
MHLPB8^C_E+;DEX 8[<QA\%'!9)++"-,(&+%9U<*Q-.]/9&1*35GH3(WJTSQP
M35J&\Z4KW$OVT VM%]MR_M>8-10\&MQ<D-WNL@F@D9F VGEB;GB%"7;)FCG9
MQ4@X2'C?<=W^TJ$X%/!JX;SZ6B-3Q:G;]ZY/-:-Q:O#*^0 \R%^*DP4)!GQ[
M'\[MVN6MAW ]<NEX[TCSA.'BK]R\!4,M4RIFZ'(K!@^2HX7FMG2X4!?LKW[+
M%0/<MI2?(_G/_$[7 YGET.>1&R+J_Z[V[*<X[73(/[]CA^/*:O0<T97"X0LV
MU?]QR]+NL;)=!!'RK[TA579*-/%#APCQ!3JA5]5QX\+MW\QCOF6Q@>8<Q:9M
MW[%Z2??I*\0("$#]M *U]8*GH+/O^<8F?F)W!POSA.GB B;!ID*4)=$23OL#
M'"NX3N0N9ZYCFT 4(&:/XY67QKHSR:_,.,P;V[I"_1'1I^;$\?A$B;[$3D#U
MDGOO\26<FU']]3QO77 '[Z_[)U]EO/J>OCZ%A?K4MFS-,,LGACHY&BG\XV1/
M7?!0M_'YE-:2R=Z?!=[6A4^1\3:6:@5Y@_S@1I;:6BM2V^!:10OJH29,5I^I
MTY=WKP'7>V\U>3T6HOA*R[D@O/**TRF95B[?\-0LOK,-I I5]20\-'[)2K$P
M^7RDS_ODK='EU3-B&LW#1"G'<@M,\O-U(5+<A?765WE*0$COGMB!IFQBI2L/
M6N;_F+W])Y@5&;5C;T<^^13;GT5/P',"&7UBY>LNZ7IC1<3P&AN30,'W=GR:
M2N?\)7:*@BAT-2UV5_(YK6.O'3312/>$%9E>='"O>>ZI3TK,=MBO#\16?N3T
M1GA^=:J:ZQ$NZNU2(R=_ITO!R>!"<S+D2=48'@=J.?)/)=4H-T/V0W*N4L7B
M@U*!591IB>NU+-D'I3VEZ5#I]S'6JA,Y*AB!07HWZ*.81T'&7?&J_"]*[SST
M;NW.V>T7W0)5]V,60L]87O+R*C)ZM@.^(&C/I-R6#Y-I7;V"GO&0EM;\I1<$
M5S0.'7@R$JZ' &+?:]:>\<5&]P:#ZCBBDQ;;?:N:>(\I8,^K*=\ #._G2?".
M5,LZA>D<P+(?D"A1?DW6W,K6(V9B3T)6EBTQJ?Z'C*Y?/_,"#WE5"/8;P@?F
M"DAX"J7E1/R%HZ'</MPKF]_/:M7M*'W$Y^.4EO[;N>/ACE/0VEOM!FK?]O[\
M6_<T#Z6>\DFXHPW8CW9.G_I(XC+CX!52'(L4K*:J\O3^/ SSK\TX<-E=S8M[
M$SACCC7F%@@:7A_*HXJ,[,_X+TZ*E?.)(&U=IM:I.T-[%=LI.+,)?GAI!>.'
MW&40TX(_E@?4B2SFEY'TT\4N0WTK3>?K\H2  N6B>X-13L;@?=?62_V3*G1T
M-+][ O-K@_%L N%E2.XQX\D0<PLMDEN4(^N!_(NH#TTV 0_GX#=N.+@I4[^Y
M?*+2Q#]!H_?'!A:)#MHWCT$4O:L^ZQD/N*&K>0CWVA?KU=_H>_U$9OM_,F%Z
MG!NPH4;RPNS^_!VT[VJ.=%=[4BK>S":W=*7)6Y&*33QK#Y+;X5@A2LS)S/%!
M4GVI<=>Y0I_[^3JX@^2\S8+I66UZDDWC6ZPH9G0T/'U@7'C1^]7;3VVW^Q$K
M^[T-&OC^D<BD)JY(USQW4#$#WO!U)V]'L0@3=_45A&>^%Q&-K"!* 2I^_&2Y
M;4-#LH2*W)=MPGQVF3!R56Q$H[V]\2FL8/K4 Y7&MI(6J/6)XJ4AWNB77,18
M*]3%(VJ'Z@!82-BHH_#1M;I,(W_YG=/+H=(N+L)7U]*+3+)^>(9#+^15O;6<
M@)Y:XS]8-FCX8;AG#WD*P<!BBQ+ZQ=B-(N<J1C% .IG^KGG]V$'I%*6SRN^Y
MP#]8ORRS,8Q-)=,#X 3"D'A1*.E>JBLG2KV %5ZB%6BG?QC!/P*#%:0U=MG=
M.]@XD*G,43^_FE^C>-1(T3/9$-H284XZAJE_Z:A5+VX"W!+>3 L8+"FC7D/6
MK;99JQ&$TOX%Y5J^H:MRX,?XAYKJZDRJ2JR\5^;"#9YBP(\PQ0D;-S<!2.9I
MK,JYO^'N*%B?S02MN4#-9,;WMCLILU-SX7?>?2Y_@1P\77\*GAI.Q%1B[ ':
MR  EU@_UXBR]' 6P>IEE'N'!I25<S.^&+E:&Z#HN=6=OFKT2J_9^R^':ERM*
MX;V#>Q3"$8##ZNA:.B)I$Q@C& J4V/E&F@DX>V.G>8$0KIN^=.=WU;*YS8!-
MFZ&7LY^NA1*1VE6=$37?NY;YM6&%:Q:(TI[H,+&>]:5_U^B/(;;X1-,X6$2M
MVH0XES97P&QI:*C^B!^^" (F/Z?]>;&^(/S.<'>BEM^]X7@ (]JS^X=]/A7V
MEU[8.NOJ<=I54-'U$0S.=VP"]-O,2(>"&29YBI]M?\$XV.@L]O0B:Y*DU'-(
MM1WEM2'[VM7]@XN4D8-VQM=UKTV"W["Q@4CIC^X!-ODC&-RQ!="8XSX]5F\V
MN6V<XQ3M7^A>6:&SHY',;IL 1PF<>[2"JB5\+F6'ZW=.]UC%]!H#WG0$7;L!
MZ6,U^DA<1#XR!IU36@0],17Z2CVY;_4-#T.&9R#/5SO*,61&,B<B]ZO<EJ]R
M3?H62,PZPO/FU(:J#PB(W 2PEBG9[5?N55=I?_YZ)J4D#76T+QBB*#;K<_/N
ME9J@4(^#\>'UT6M5Z$RGZ-4YI->BU$CL_G>Z>FTXCUU(=SRK]./SH+C]\4 \
M2E@XR#1T],0DR=E(=UXPK+<\!YN0.<XA51B0DOE'S1 5\FS,EZ?,2KNV0N=,
M,+43EO$9UA039QL31JM=H:_?M;4MAI707!8KNF:@]_CR_"'KN>PT:G.AH7@E
MNE20T+APN^$![\CH@2(#@4/R4[X!,V%5G84 <-:5U;1! 6V.=TC6+M+7_Z6W
MA5=:H4L%;):D*([+'>P_JYB%,5M_U>@9O^<-2YSU"JP>%;!#AY?Q2T>9K#15
MZSXEPX;M+,BZV=7%C-I;BP9JORK2_M\FS,1I1V&'S5HZHOF<^PJ$L-A587X=
MI;6<0ETUQ3V\ 3;-XX^ZL)-W'5P#W?V_?C/X6+*-35BVGQ)#G-4^F^O)IC1E
MY^[NCS;HSK,16&)UB&C(W_=,EG\_+*)I]$JO[ )&L_XI]A2#,[-<0,T^"D_4
MI<L55)ZO,4$7RU-60XVCWCV\0?);B%?;7/IQ?8R@-NL=5B>/'13,Z3"SR#5"
M*SW[O589=G5^YNF'@<X<N%?J/,YS/]1:K4&XH'C1" ^:_"]0AO7PL7(]\BV4
M+;ON(];^T]()V<A[,!&T%>I=XF)S-FOZU(5P:]=&)X[=.C6-B;I/MW#EKR7R
M^WF\=52Z#/)/E;3%%_O>>Q3EC87=E!H/F/1(H>,QE,HRWL\8Z_!C;2L25!W)
M;5 O%0?=&X(A<MU,<!<DRQ<:]M2-G-A;9:AI4_@OR'5_;@=L96?/V[[:AL"_
M_' CW.4)UH!!K#/>>#=@JU<^MKYA/S2IMC;.-*&E9BR4IUWBE/R8#F-TNF>F
M%'M#>9)&JK:B--/V>#S(Z-JN@[TNJZ]KJI_/ @.!*U#*:583AZZ5F/!L:7#S
M;M<KBH_UJ6/T&3V^7U)&8U+E<37X#9(PV0$O61WS.'X5!_OLM,MT;4:L,V$K
MBKK]5S*>@:QHS%<Q;,6CH*-L)WET:5M&A7P*X?6EP%FV-7V):=*UAY(-V'VA
M'48FG21PA"W/YK?%5:^_4D"SD]=9E+^H8!Y<G4FLD$#T<&+-6FQQ)DR5/OY;
MXZ\OFQ-^8],O6\VC(]!7P;@3JE:8<8M/A+ZFG-MB=#?%N,NN/[2L]3VHE1YY
M/S=Z$0,.32;,/LO_-E?!R? 50OA'HIL#UIQ4E#1XTR[@7+^J40 SALS-D)+C
MBI,&KR1W; A1"D$Z1$_J]Y B*[=I_.>%U)_6% 8+*&"[C@]"*7B>'S_.$MT"
M1[WB"2M<C'V=.MS25OK!(BT-!8\."YV =FRM&H@H5,X1.F]<*.F'F,9)67+2
MB/*,"R-^-QJQ6KP+KK[8WH'*%][AQ*ZP39)<*]5'J+)9ZF:E>E5;,#LH5M#(
M3+J)WPCU$^T"J3&K[=_9UR3"8*,]*QQ9*VG8JB:A@JN\D*CORHG,/8T677GD
M-!7/UGKM1PG,7Z(2C1_KM.SNTT742/N"E2?"["AS=I;S3A[%@(ORKO3'VF)V
M@?Z"H^F7]M.J"?6%C>/A"S6\45IA;Y[6Y9[V?VNU&OS2DP KECJ=AA+^KMPT
MX-CVS)Z&\&1SV++$JL$NQ;E!^$6[I;R%#C3%!#UXT%</ QI$,:KX^L1,;LTC
M_[<-8_0(X@J/S[^J"%>,N=/20PIVV,2'EV\GK<,;F(]@;_/OVE SP[I;3B'I
MV?C,#.=9QA&>^?:MV!HZ2ES?1@>!=$;=EXVG5*EENG!P+.YB![:#CNWW.I2L
M-&1^>LQDT<!''ZD[K0C>H @O>F\>-L 3^I,TP6WX6B-M>_ME%^;],GKW4^C\
M%L2\;Q/@Y4UA1F$ZSY/S/9,;RY#E"1JOU^W]'-+MARSRF%['!WYH.]88=0&?
MG5NHBA;%2]%9]S,-6E:_-I@Y0&L_W(4ZWVYU;%NKKYK.>6)N92$##4Y6XIA@
MAMFUVRLN>(Q=BM(V.;A'G@HG6L+;RW#,MIM%<<%I,4UHE_CK@^TM-(8NAWV6
M(/37W2\<C:!44#.U46<[OPUMKC:B2*O:YA</^%/0\K1U7)01E#%\TQ%/\CSZ
M?5H/#C'FU@!JS LS)=SE5>_A!/].R&&6I-P7F/]OU^QS+//Z6QME//K)DQK1
MKG5OII0,7/"AG_<^*  \Z#5',L(-E$-%*;%1Q[^8O3U;=RVP2JH0.L)9)SIP
M0:\ATRPH8:4 CQ9/*FQ#>4'OFS]FD^WCV1"^"'E9QUN@RR2!W./SN-56 L]Z
MZLS1M8D-,+P\!-^PH<9S,"W^ ?]&)^W<'_%!?6,[=9=4Z4[K8;M"@SJ\=0"Y
M5J<]R,<NAJ\-KO+EIWS^=Z"Y.%M:97KYMO&Z<-> DT]AS^'\%?TMB#[*?<!#
M,28.,K5O FJ19V#6,I3VX&A,N('22U*Y2BELL0GD6&:*AO<C,V4^CCJF8"[=
MIFN:=%)Z*45Z]DO@1GQEQ\\B&Q)LQ1F]=0Y,5"MYQD=1%%-SO4VQB?G.L&>A
M[";W38!2VA/=O=X%;.A8?,UX6?TL5NLHI2]_Z>T&7<6Y"7BW:%Q-PFP!:"6F
M63@VL$&.WGN $( ',?@W;[B_,\;^&*6_Q3R;,K-Y_;K&"E*N!'YX)9:I!/^5
M,=KPP.C!3<#U]7@*?5S&)?Y2:05E>4')4;4Z-"?F8X, 5X@<RFZ[T*<]Q;\\
MQLR^ZG3;4J-ZN0P#)@Q;-1F(\ HZ7 'DCN_RK(%Y]KXZ@\X$A,<YS?-8\@J]
MR?1R>&?A5J!N+TA;&1>VIU4^"?O=8Y0E;[<)7+--5@-4[O.5GM6JLS;\=#7=
MH5$*W/M\8!WLF=?;+RCG+ZD5R@'Z=<V85GKY_K&EFI/P_ 1FOTD[2I%S00\G
M$0@;51:AI>R.+XNX-T<*]BCHZ,"S]V5I;@+-I&CA\%9&)7U_9+0AU#43\PGW
MH06_\.AIS]Z#6SNOJ>7&JY8CCBT=_V]VL/@S&D94<RFT4%=TXQS3JEV5'S;J
MU$)Q?>W>U0T[X.K:B15N)V3SE.%KZQ#U4DZO^-\;WW7I3\*6LPV40&<X9)ZN
M[]3A?%++'3!E&,%&UC:1K ^'N.,SSX7* O?XXJ1-51K?EYB6UEB%1 !8S<Q>
MBO:VL[>,IDC'VL40"@" *ZBPFM5B=B:?7)-6E5>9LGT*Z;GY1C@8S^^V?.%F
MZ6LUM%G@#B/7A</^T36"4MI=3F%WI9Y?T^O3]6XZ53PG]O'"%)0LM$#5'='P
M:,9R)@_"@)23#^Z9U0JOS6U50J4U7AAU]O'/V%/ ].X@Z:P+46!156Y*!'JW
M'UWF\=G**FUO,DGL:[%*PH;PDN5DS]3/'!_&TT,9C]NE'1E2L [.<8AJ*C<,
M5^[V%2P.R3!1,(M/(M?:MY'>DLN(/HG3U4$P(FV;[P$HO;\<5\QD.G7_2;;,
M<3EN;1=+AG5,Y*0.[VTAK%/_S;.<5P,&I!U\_\>#<<JO'46K(/07LA7_O#67
M;@+A#Q>),3%ZFP#W9:*7@?&NTP9_1JJB0HJLK9K;V *M4?KG297Q0K:!=KT[
MZ(QVE8<R"/](=3DFO#,] \RD+S2R(Z[3KB<=Y7WA3OOB4 RM7FDU]"'GRT6X
MN/RDQ[[*]'7AE]<@P70$*&4'ZZ[>$P,UX?FL/#PA ?'_#.$ 3FSV<*N7V":0
MEPLW<TRR%UA'4W9\=@<2NF?'<A"WH1+K;.70AGWQ&<N/&8]B+1&85W)#"?9\
MZ1%U0%@A0X4:WX.2OK,^-^/\&&+EZ]]Z>\+9S&P:]/8/=H;"RWRC1WD(**!(
MS=C_G0G@3,5DL:AS!?O(^O@=PM44^H7BU9[]"W[&5GJ'I2UUBVB*RFB]PKSH
MB[ZX4PJ:9339D^OG"TS##ZS.PCQ9B-+.WQ< %AD&2E8^21[G$S@ W 5BX2;P
MR!B1&+%Z;^WG/:@O/J&2[!DL!Y670[5<Q.)*+1_W"5\>FH].?NS90DW&42VR
M[B1'958%97=BRH8:H'R!^.@CKD-]*T:CO\4PA3)QC-!.@#=@/(@%X+ZO;B&P
M0NW8S1H#YSFQ?2 *O<9DH@>9=?;\/88['R%]TLYAA1344(_@I(T)O"77B3?$
M;5O3LRS?/X_6Z,;6F]UZY(T>W_<VT!9J%R36,5/-3G'!!_2PZLX)^Q>SAGS4
M2NE%O&%D5,\7U-&_^.8[[R\<-EECC)4VAEX>H_:N)7\U02D[DB/A_\77R?1T
MUPR"O$),7QA[52ZZ+M+F>XCT&IO/'WT8FG0HSE'Z<NHKR?;O?NM"!$G7ZO)#
M=4Y>V,UCZ^3O:9L92I;E5&7>4GF:[TO[F"R^ 69_$3_\DG;$0GB"_J!R]*3]
M&[H72<C'5_.SM:..QHG7'>S,2$N\X2Q\SN38>']A1&/KT3!=XZ[7FT"N(<Q%
M7>"4.^?.G10.<9ANG4W@4#)Z@LCJ_(T'J])]^N?O,.4:>[WIFO$?R 1,,[""
M]B-KZ79+61N)";>CDU_=HG!MXL"[K4\D(P+7-H%4[-#;XU'V Q?"UZIRC]._
MK_KT:$K?\XWA59C%"<N^#1VQ2.YEN_OFT=,1A)(1J 984R);L0- B:]3IMF9
M[+M^PO_X%E&3P=ZP=,:[D%CIS+C!=SZP# F/P\.Z>\<4^\!4 @NNJ\8]J.M7
MTKR2#:&O[^<9K4ER/UY,:W>W\HFU0EW=$7'+!G]P#L,*WP8Z:XC^$Y3MG38^
M_#G]Q^%B#;[3&52VT8V7<2T^18=8/"Y&+X=/G 3Q*>J)0C\!R\ 5 WV6N;J:
MG)K<IKDN?,64]X:B.79L-0,>_6!=.LA1S":KPM3V X/I[\&]4\.)D'VD,R2M
M3"OKN$C.UWZ^CZ?V&4G Q3Q\K>8R:%*($O=V+-8E>0F+2U=_<R[ -):UVDHS
M'/U>7V*?EI:B&7>F6<Z;,$$]="YXJ\^G=FB',/5[EE[#5M:]]$?(DA,N)PZ<
M0NZU-C [9? 8<_2#9'=.N^R1U5NE3/=<E\E4*!=-'E=WUXU:ML/C5>E3O?A7
M_9Q5AODY)S?4I%1@W9Y+4A3) N?43_D%?Q"VLM>WE="<H3F-JF>T.;8$>I%R
MC70&(TD1K.;QT#G_(\^+]$R4$]SO!%"[U=BI"L7*,E;490(GOU.#F6S;7 ?F
M5@;&BD"=EY<9AK/L.YS>Q)$.T^=O>?M33$J2<L+7'$EOLE;/Z\(+H.0\@_FD
MG'NOPFIV[MO]<CZP;KFVD1W1N>TZ[;$$5*R)V<Q]B"I,6WA:1YRP2]@D;#24
M]814_35GI.68[EZ'*F^*#6$*9U1>B4%2F6FLC?I:#M.P$M.WB /'>BX=\L;$
MW2K>3ZI;1A.N#?#E8S"M5]/R4VH N<^.DK%FLT(0@Y-J@&1#.-$C?T0CEGM]
M88NDB(^LM*CH'_?CQ\G<E#UFPYZIF:Y7GL+A_7<*07Y.K-8'2256WM59]@H)
M9*8Y-D[U4-,*O/S[$H#]E\.)J0P$O.2=+R/ L?GGB>A-H,+H[T-.L]WV%;Z%
M"UC?1U^_"RD=B+4W4&+_Q/0;F>[&?I['"_4:?7@3:.=&IYP_8&1]@SH9D=0M
M:^)'?N8D!#]PPV+K!'W1D.)W&^X#E;$.6 N\7NU73JY_9M2&-:-U?LN!?"G<
M=LJA=ZGFB'!GTB]>"K2LXH)HQPE3WXJL/0[#ZZK)S,]8EB)?"97N$<J@9J8;
MM_^#[KC1:3,GL,1.T[0(4/0KO7(V'U8AD_?O$NRVE-1MG'*LPRH+"9\&D)2"
M]D[S=2OO85PGDOLVU,S38F^JA KI<\@/5ZKI? 8RE-5T^*X^'.7G(MT0N__P
ML:6,VE#Z7V&6J&4E/*X4S%QCM7@K4Y<TK38A>,+P67O*V;.NH)8[A5_@3K:5
M/1-?W)9:['>>YEX2HSBTT6FWMW"GZC(W%'&Z54(],H3/3X\L@V:3^T &J:R'
M=<]/+&#,CE9B*+9@;S8D=^:$#+H389JDV^<)^9K*OY(\WWJ-/]?,7T_B@'57
MQ8EA9Y9)X>*=\^6>^]L+TD9 !E^/--74I!(8A!F:"YB[.2K#F1*<G>L0Q!@*
M^=M!CWD.(7D-V!T.D%.$H0S-2#E&;QU%4@Y#X1A]=W\T])!=(LAP//L<*6<Z
M]<79>OQXWI'G?(EJ@#IO")(NVR\LIO"_WXF2=6<[%1XT( HIK8I51 $7XI)[
M+1MBP/E]@#>-W!\,!'8X)00S.2 3]0Q,-B:8*@2E3$AQ_C>#1=VUV?RV9')K
MO(AS@LLJ7%GO 82?<36%W#WRHV&E7E@](60>W<32Q_]Q0'@Y9?NXPK&,^EJ7
M&N/2>T?FA]\G9>A3[WE9[K8T6@C.T0-M?[G-NFM_QP]ND>["]2FT/_\@([<C
M#8*Z/RP0O2>'CD92B:D:E >J9*=B/QZ[:;A[H^T:9*PS@MPF)5VCFKK;]+2!
M=.:WKG.1SZ]NV)_;:&K5;7I"C.ETE!N7LO8+B7=[ W[!,\DH1(D'M5^NW]=N
MF_A]$#+*;@=O;Z\S&H3A$YV)YVM;EXW#YU*VU99:YLJA1%0HOQ)B20DR;*>W
M#[HJ8#B>:;.70[Y]+<SG;O:.N\:D@'4#!!WA?+%G6J\?JGBO'2>OTUHW7&,$
M9C(X)8Y9^G$DKF%9^MXG9J3T#F?5-8)5Q%XT%N<>QDE'@.%<=B/W*!92B()\
M;[)3LTQ_YNKCSW%!-ALC0_GG-P%\!Q9W<:%)X!LNTWZ6A0U.^S47@[7S/9V8
MN;)\=_ &!>.EK=**V?P@<M^9%PMGD=PGM(R3ABY^#)A2VM7-H*3P H,5.1>T
MZP_Q19]G: =8X0DA@;$B'37 L$C#Q+GAB74I+N9;8=$\LX>-)C.7/_I VKY=
MI-RR+96*38" :=>G.7JZ=E1V'5RCX;('WU_E@3308DBR<ED.-+4C0[&_4KKF
M)\N84&+6_=#(IYM-"A4L]&?=%'2,'NX;]6!:;;) "_TF4_$YJDY 73L&$%H]
M)1F]=\KLOG-[0F=[^)<@J]0@A"Q,KKIH9VKBCCJ_=A>]HD3M0Y?G[P]ZD>)2
M!P@*97N[7_U&0@I6?";.D-\U,T[5Z8C:6L#Z:#:</H71/U[%JO7G[3__W0\^
MY-N2;J]VO"DR"A:!O >U5@\%!<2;_H&HVA<TJAR-+V;<F7J*4:ZG=I6:RAB@
M\@Q#[+O:QXS?;ZAB\R71_:LLK6 M%(]AT@Y[N6'F3:88(OG]7[S@SMPLQ+MK
MXS7*FU\BGXQ^\^61*8B.:EXE'16,&E:X_@+MF[:BQI,#$.V0OEU.'+N5]K!<
M97 @';1KK[%94[?''VF,K$_X-(MLK!Y='Z=8H#.__H&"\^DH]FB(=YWH"CSS
MH7)[09896NLMW2NYW4KU4';N&0PA/O92S\H=IDSS-#_FW!PEY^V$^!L=N1F]
M=\'(5^ 1?J'SX.<\+93J0R<8CK_&WA'LO+0_1OH*L[J&]O\";T6O5WH_K<@Z
MF?/+8E\-'?7=^EGH+;39RAP>E"5%WF,/Z3F!#.16U;1.FCDP?I(;<2/^8A+P
M)OE5YLEKK]/>KRWH78"QVU+>V;[_(L>TY29P1N.:4F#2:/SRK590]*R.L/Q*
M+V5^%8@",;"A<J$M$SVD=U@:ZN('_2[\_I3" PW!"56.N?HA5T[CI:6'9R.M
M.<LW['W/6F&%3I$.R .5;WC94*5D%IYIDTP:Z+S+^XS;LP#QR(IVK4Z:P>X.
MVO$Q!:%=Y_)NY!;73T1#5A>M,"]M?VB)^.+QP+%-H&N+WJ=(;D[@VH;PE O+
MI"8!E91NQT>6J1*B:)@<<-OB\;DH3=S#C\^8S]L]HY5<MVY'I@]HO@OIU(B<
MTC4K;>ZGL:.L =7$R:[E[53\BQ#UKOA970_K :/'CK'Z[E+ %+R'3C%;6H'O
M</N.<?$OC[E?9; *B$0^R;_'; (*;?DM^C0U^_29E%&F0M^7QPSK7C=F,&T,
M#IUH?/Y&GZ:4C(0&$=38]!5H1/\U"'E6L:J .2*IB+1$T@YO@-],?/M/@4?U
MWAS8_G21?(U*W0LH5@Z8,O2GJS\&FN#7VL9VH1]7**'B'.A,,+AR,"TUS,V'
MJ>$3!??7D=H>$ 51L 9WS]S,ZZ#3[6F#5"3/X? TOWX9B^Z-H?.<3C7PXDMY
M_4.Y#43S4_T!* RB%%I7(26H]VO>V2T?*)@D/9N<J2'_0TE<Q?&U]H(3!7ZU
M9F49XE5VNN\"WT%%<"&8)F$@A"4^5V(5NDV7(F4'S)#?>YPC^92R&NO^!T%U
MF,44VBC@Q5%6]B1QDH>_ 1^[5#"4(X (&.$.Y?77W/\Q1Z$^NU5-G$;M$/UZ
M&$=FFJ](SFO5YZ$O9XE2#WKEG]L@E!00",H;XP !]L:=G<''U+IL"OKKX)9:
M:EZ3K!H?'__<.7)2F$+TD8,?4S'8-/OL@$AV:I,YYC>IPI>:BL21BXK<?8US
M\:U8603T?*2&*1"/REU*AFT@GAQCY]QIP-?Z8VW[3QIXGVJP@'9\RJWM5Y]G
M:6P"%M$<HJTZ%S[!K71<F,>U"/1*>FJP-4/Q9QK)G3'[;I-N0PI$NGVZ11Z$
M$;&GQ$KR4%4BC]GYR9$JR(02T\5J;M<]&\))UU_Y:'Y4C)52V4W,=WS7F9E"
MGP1_N3'6L[()W#AJDF_D[!-KBP*"SP8C?;GSI7D !@J412*"WXE9OG3]6,IV
MNRP!]";@YI?=0@$_L-'774+.>.#E.*]UVJDFP#0MPI5SPH[L)RBB:@^H9),^
MB>;1G3<U![EB$;B^NC)9OP8\09\&!1;QD*^_J7OZ"L(4$&;W#RD 8"XO1P0]
MH]O23UZXS222Y*5/9?-XFFU=QR2TI#9W4OCAB6"'=S#7+%,D>O]8](J^A*=U
M?63(0ZOT>*O<D5J)L<54T6WNFC7A3DI!C?.-5ZLSO%ZW-4.D<K066>UA0L]\
M:8OD(FH%M+A[]847OY-;DG[#MT<!:)+##&C-YUACWK=0[[CM/-T>[\87BJ41
MM8LD(\W.?DNDK8;@27!844H*^ 8G4 /U=2QM/M=DD=/PFZAW43U\.8;[6:(:
M8'SQ=/.I_&&=-7D,,<]RP@B=0E]YOL'[?=\*\@:X7TQ#13'6]L?NJQ*#R9!#
M&(0+K.32EGKQ=$(!MZI!@I&%=<0G5G1D6_HF<,D'N>%IX H;.K%%X9/;J+-^
MFM".;7@.5B;H_T)#%&Y,*D[#7FX"4SBX4==8G :>6$B!^'^7@9BZA?[=XSIF
M!X%D;8R-)+]L$6#^W5&B-YJ;KFBTP EI ](#ZPSZ-)/_!'G/WS3ZVP-/R5S:
MQ7)PL_[@E8[8M?2)+]*P_Z(.KL23*)=ELW88>U2?KP\T[[5-B.8-LTV@0XF!
MFB6RI:WCVIWJK3J5G(5\>3?OYS]K/O$V2Y6#B KZ#%.D7BHN4F:\HT+MI)#W
MKPH>>O?F9[5R2?;UC_2%I@WT%BS0BW4K[8LM=WX/%R(DSJ?B%6#LQT#!N1->
M%G[1@7,G<Z/UX'Q50_:YN,FBUG=JIVST$Q[6*+'F"?1>,[VT7?0F'R$^/F(+
M+IVB>B!"_>YL-Y;OKLU[_*3]!>]Y;N4GF-SV0U[A[)FE+V)H  I?882DE/4*
MIF&2[*"S>-O_2M46,Y_WE+B'3#[5@MTK$M/7A^AXG&2CW4?@B#,0_75M]S>,
MSL%Z@?=<F 8?KD=Q?&G9M,+D@SSN :TZL;"%++:2IO)/7Z'8,X<%=K[I*+_Y
MSH5=\5Z;M4INVB:P>_?B4.9I/HL@")==B?='S&Q;1@8E #QARXBLMCN]E W;
M+98 UGBSL]979#KN78EU> LTP00@[EZ4=@6V 4] A11QJOSNU/ >^_6G194?
M-^P>A4B=?[(:AWVB>9<.7\,;+Q6BXJ_U!%1D-/<QE=9'1WQG[S+T,BT]^-E3
MCI!+M).2!B9,L>&5X"8 5EI")UM7*X=R*QPA:L@O*1:=]56F3<WIW':,;B;+
M+]YM9_>,+RG7B9+I1_6GQ=YVCL6SI:B*]KB"O0N@\(N"JR9,UO$/_]<E6"U.
M_K0I;(X>"V\*"1O.5'4\0@]5]:\L!&ZSK9WR6'N,E*LR*9$(OJM"Z330F7^;
MWN_>]/"]-K:H0975B0"3.=W6=#!>@2E3R\EEE#+H2&5E$?,^T+&UNA22-W;N
M'GBY;V VN2VG@V;-4(@WC"E73N1VZ)).<GXF<"8M@EE=N3XSA3*>K!!,U9\(
MF[UW"48;Y6Q'V5 ?_NP^1%4OIRXXY<W@PGJH'5E>//47O>;_@RD['0TZZSR6
MDD*K(U%=YE 1F&OP\B1O).9(F\SR,<%D6$0"_6<PD7R195C?$(R[R[OJ-*7E
M+_C0,C:A?2@7=N5P/<S+-N.W/:U?FS =]=F0ME8E%BD6V8\4BT/I,M;'-/BG
MR+(HCPY;K^66>B-KPPOKDZ?XB;$(%.#GD*[@7&4 S0DBE<7K]AQL/5CZX)R6
MC39C/%G]Q%+0=2W*QMMNX4+X;%WD5/C'E.UY^RXQ>!?H%)VY'S#59)PTW*24
MJCDFF'1;\33]7*0?:IM96JK9'3).G!7\":SE]T^Y]M]U]^ZTEQB]"TAW2U\!
M7JHDD'FX_77N35Y+'SMVZ6_@G+[*T'4+9S:!)\&X#I6N!%^?+%^QUG^1; *\
M<@V#ES[O,TZ >PV4)YO>3[[B_<\"*/.O^F81AU>AU2[DQ8/Z1B:#GGO/%-!*
M)W^OTOQ\2^"_I-(?0T']_@5?=661!XB/AA/ =AI\M''()OFXW]Q S=$C%0=*
MF_4:<@S<]]Y)".PW1?7K3 2T_T&/E)J'Q5\"G-$:- "\]_2$O6YZ.&)9L8[V
MES\\.A*>RQL+&PP)"==^M ^7_W+5$R:IW!'AK:829O! ^!(-X6(BNJY%/XR3
MBO[2)C!I>@<%MS\KP"3^,,P7[CK2[H6JTMH94<@2^82GPW;GON%4SLD-XW++
M&-EL4#>UXG;YFK%9QB)1:,G1.UYSQG:_OZ?ZHU'0U?,L2K,F7(I,5R# .DRO
MUX'KA<73U5&(B :Z<8]L6,C7G;OX&9:3XD] %/L7Z(P/1GG28U'SI9'-;1$.
MI3&/O%O).JSVVV^ #'X??OY-?>6Y,DT\J%"?6N9"H*5J?!'LW>KAM]XN1.G_
M0<BH!#<!Z"8P$Y_N\"C;DA3ZKJY9]_2A"V]9.2J8K>I+U$ ?;P*FD#Y<$71.
M<8JXS8_Q 82?R?,A[++-6T$F]:%\?0J39?[=%79&;D\;9TE>T>C"$>^=>OHF
MX;W>.GI*K+O?/S[_88!87@(?73ULA;2 -(\9?3H)VP&;>_2.=[DD*YSPZ,/F
MCX*BHSQ?$ZOO71_K]POQNK=^'R.P7,-G>CRQ34;R!>=DKY. -5WI,D:8 G0E
M0W7$LJX"6B[0>^3]XI-U$>T[?,J\UZ_750#Z\]?1ZR]H%6ZOVW?.L9LU1D?V
M].>]9(NEC\]<\G@JE#V";P91R$?7<5._)]#G3!]XN1/S9!-00%0;V3VN:D1J
M/P"H@+/ZU'M:"I5F+HW=GS8\_@-9S5 NOH$\EO:5M"F-4O&QHDU!M_@^*=9!
M!*5S/ZF*Y3)%.B'!0+IHW;U'K'(="=)N08'4+K6(LRFN@"'Z_]A(M EA80\_
M%P_8/-3@[G?PIC7-,'MUK_)H5MK,2]ECT@>@*I>$OG$C>LONADN<-_4639N)
M37Y-:*^W*U,#_;U;Z")? 35:P%4J@_((F;F>+IXN 4L.TA?5B'OYIYI,R.Q]
MQL++EN[#1"F/A>R!</XN5E*4SBL)\OG(C\?LL>M)#Z]#N:B'DDOOM(NGPT_E
MM[10+\(M'Y0C<='<F>SEX>A>"(18 9BFX7:D9>_B!>'+@Q]%XD$4TB#4I]:W
MZ3_FT#'7/93QTK;BQ=)<OO"3R4GOQ5K@W=]=\Y!CC*ZNA0-C"_%$]N$D[ZF0
M*D__^NNOO&_\N^BK<[V(N3Y%\LC)KG'PCF;\22)>CYM01* 'W/ZY]E+DE!)#
MC"UY8ZG#RW#M@<)DJTA %$0N&^'SD;"EW?99TIR_:_ 9,[J][1VH *[SW5OX
M ?(:<+2-=J5_\J]1RV1K3CRUV]%@OL@.9JA^( 0SU3.EQ!(0&=D6A^LIHZ[M
M96G+@?]FM4AHK#'F0AFN0]DOS#(5]\2?5"(+R(C"RV[9]\MQ%2%2RX[>XLJZ
M27<^=>WY'"9C7_JY:0/3/%#!;%N.OF]*(&-V2P<A4]Z+^\TB[DCERM.9HU(1
M$MHH)%X'VKY7](<=O:^M>$O88[S@W?[="MC3> 6P)_.;W]MW_2_>:O^+2HGC
M>-8#("!.IUPT&QO_$%:X":S:KR!-'_V:\N,+.>+V%8N!:YDX)ZL7<D2:#WG2
MXW8]#COOLT@A\4GN' 2/^MNI'W07+92V,]U^F'-A,8.Z$.[BE,2R/:/O^.(^
MN]*74K5QTI///Z+E;SM6;@*=]WB4NPY.*=%W@>4H[5L:!>KYM\6 \Y5HU [9
M<(L?Y8]63S%)2T<I38T_1V/^_,[*%7OA'#J%>@3?4A#JB+E<GSLI"17?P@6%
M/(4]W$^AK;M-!R[0I^57?;&=T$)EK>HD'%G7<!S>H$8! X[0B&ZM4\'+.=Q
M%"IF[B$?MUL:Z(:-*LG$]JU/3H,HS%SG*?5FNLIF89/3O0G6W7(E\^C+5OUK
MX7VFV\R"KY[ C9-;ND&';YYK7M:4!LN\WTFJL7MCY^_L 9+\4\)&XHZ@[IYK
M\SW<89*W@_OPH:AK]<28A,.":W6(M3FCLW[G]COW-5&Q.SJ.K,^^)%6WK?\2
M%1K,]940'B*_T93<U87#>FES1"0'H,:F+VR75L3S3WBM2X%TB)KX(3(PM\/D
M&*^:'=^T4F4 *Y-S1.$WW%"EI&#CE]ZGO-M-2?$>+$:?QK;0\IV5XN/7UW$_
MK#W8$G8I(14P"V-Z55P:;;$.+1LC_'B<5.<)Q\?DS13I"\'E1]>O8<#;BH,6
MJ;UW2G[(JYI\ST]62H&;]VD06]8W <)BVL3M8.8 ,B._T21_>R2>E:]\JWSU
MY?PVI>D/@[N\]&FD]\TB!S46<47:C;;JUA/&]M]]4QPU/M2'%>&=+UO.[M^O
MBI>*4UW^D9#WW\&1V74%95).'SYMX)G<D/[8@946Z@(5+516$HF>4F+N/17%
M0Z]UK%G;^0R/&K6,$L:'K-DF%DGZ V@LU6\"Y>W)%_5FBG3>UVW4K*/GTS>!
MI(NK^M00\H/<6\_\I/WV"12NQ.Q=B+Q"=-WZZW96/2!-;$1C"X7I*^+]D'B7
M6+6!L"S>!%Y#UKTV@5PC&;%EC9&31=ZT(TJL/O_58^4FU7=9R'Q279%[UI/>
M7)]&KSAYQJ?0^_XF<,7'S8&,(*Y58#98*H.4@D= %(;3$IM L_@JA^)KV?4%
M[DB<*^E_%.J1OE?=QKS=P@QD+)DHAR +QY'W"9,L5R8R%AP@8W<W@4H=<U+*
MZ%$"66C>!#@S),R3!_F)5,9"*?1>,U7E2/"9+HOD%/+;G>KS(JJ$+U8MH$AW
M"FP3.+D)'$W?^ ]S7QX(Y=Z^_]@BR5*C4':%:4-(MAED7\8P8X]"8BI9HI M
M61H[42F,=18D(4M)*4N6[)0U6[90V8<QOQF]Y[SG_9[E;3OG_?UQ6V9XGF>>
MY7-OUWU=1]:'\UJAG++]WAOID276E3CJGZKQMFX<Z8H&CZ^1@95%2^KVCXEN
M6/B/='CMYI]O)P-\5$5G_*B5?[/-^I76?WWO+!>CS7\[3CF\2GS&AWG*:QU4
M\3OLV[%_O11-(E)W3172U5&N@9E#=#9_Y2=)DR#$A4I;RAE+79DC ]9Y<,JI
M? EYZ@]6WOQ:3'FTU]@W5M?Q,?FW% 07JD\2W*_>0@U03@4S]3;]_EJ!A@(B
MOB>CP*JPC&@\>G+"M.LNY2@.:%P13DJ4_M,63L:5NR+FNRMM\G0RI:[)\R0B
MYH7.+$XB9MZ\2YL23Y.J_C]I+^UQVQUL:M-P[%VV/9>/%)NEQ["OYGJ?>+N<
MO0H3=K[YSINY0!T0X.("%<'UMI0S6LE A>/VUU^MRFW58KKZEFE8.-4;5=78
M.P8)-DL/#*:JZOVW"IBLHD)TEC5!]JJ^ #7Q6U3Y_AC.X?&VS[7SQ_)1EF6>
M^ZLA1_VN95P30&_EER2)T>!W*LS=BI\T;E6'"WX]_;^3AW4NXPB4-3W]7%BM
M&V5[QXX/&274F*?G7$PN9_'C']$>TQKTHCPXP(,VH<538-DRE?;]MP]U>(AT
M7).V1HMU,&VTS"SO)+;>Z/O\9MUUG8 2>W ?*K QO].(R="SN2M578'A&2#/
M\EM$\K;GB?5[C;RVD^8I!WMMS$E8<JCD;-(C5JAPA9I$HV9ODL=CYS ?UTW*
MK#_$HG 8'-WIXPY[=#S8:1\90 SJ'()TL.$S:V J<MS22-V0A%?J&CU*Y6TT
MYDEC2_M/V.$7<\0VF>;-!Q#4.8AH,&SVV!BT"6Q7%R;5J)R@5A^_%KEJE"NU
MB\Z.95DHX,B)L9:C+&<Q2]BVS<GNM_NT/CT941)C)]K''3Q75DGRV-;/<A4-
M*YLTC.,MT15]=YP,3!O2,OC<T%YOSK(^P8%!3H!+>I"[SXNOM@BE7'SJF5^Y
M8BAE?MC.X&@ID3F\*<5/V(H-OB&CZ!F+%7%67I3CFM1BCJ4L5Z#(4B+;)[SM
M=4UASK5<>6_$PC]6J?T:HS._AK=K8>DZ[[7O]J*,][BRVCND6,'#I#X]2E)D
ML>/GET%5Y.A;:%6/];&I-(^9$K+B2./KX'Z''XK=_YL9:GBWJ@,:+2?Z#?WV
M(O0=0V<+^*VI2NBF]:6PLOT4IR/M5;)UN5VXFW^(VEIO\ R=$^<W0"%3]D^,
M?!J^5Y>W?),?ATOJ$6[A6)"FD3L^J8Z4S7U2NQ^B UO() ..U'8Z4$+%?.2S
M\;&-&1UJ/.&FD^H*W=FJ;VJRELO6TO[M%1S<N,)I]QDCQ.ZS[",=PP'<]LJF
MRBLY2 ;,2[J^]]C_N60F;?$DJ2?:VY=Z.$GH!=+S17Q>C2 L2V(?Y<W_'Z(:
M&OAJQ<E^!?_4/$M""?^AEQ=ZR4#^5V@#_Z@1NM&>.:PUN:U0=DUPG=QTG_$4
M]X6"^>KGO/A3,778RW"#=[K?&_@ASY*:JDHG_%_ER%A\<,F.YY%VS,;7!TV)
M=_X^W:=:FLM3_6<QERY^1I'4W/GO<M#A1@WI&(6%$M,>^;XJ6K1(^C8UTS\[
MT]NQZU?KE*+G<SHUNC>41]?]D_\ &?XU!BZNKJ]ASN:N3-#T<.\4AACK/8KT
MG%-,'8-N ZG?O9H9W[T%^]?"=,$)WC'*14 10N-*[562>,BH/W/\8I;+03CR
MR:O>])&/E#P&=MAAK3FZ)CSB@;EI#LVB] M7KKE4#*ZZ=/8E27P8Q/]BM16W
M_9A-/^QU?..=\L,0RN(-I</0)H8S!34D/)W?*$KO]RF0D0%]V,TEI+(N_ D;
MP*CR%15.("*")Z1CZ,YV?<.S#:6OWO'H<:#^Y'/0;;I -?548FK-#4@GI*7-
MG S@(19Z9]!BZ3&;+E-COYH@U MW?__QSQECT8P@W_!EN_<OEA<P=F.E6BO\
M1[V9PPZ][ LJ\/'$#S^*4H8U#F3G&M'&O;4?&VUN0>0X[2 #6R_B<RC[VB4-
M*\?X,BA3;]\,[0SW8!=8EO9O?+,Q[[$(YS-DX-)P +\ZO#1*ZY;;*T'KT$.&
MPO4?0%JKHOQ76K;D<>I9]ODWNT%VZETJBSCK=4J)U9&6Q)G*.X)?K1DB=HYZ
MQ*J)UTD#4V*XK!VR].=W=XQ( TL>*HFG&"N8IH5FC6/-XW,.!I\LX;=X3-D5
MW\@4%1G\9W"M.PAJ(_NN0$R$QG-?;<Y4E_MQIWM=I[8#CK5"=5*A GN-I_*B
MB2%DP(?X'>03_\VV=A5F1SP_PG]I(0^,=KQ>D*#DPP-@U26WFHCU<<#R=I;]
M=+@8Z)7!;KXBHMWVSP0CG^V[#W6?!RMIH'3$<%P_^.!^\X/.^>KE]E6$R_,]
MJEFWX@>EK?EC3<MD3FMTTK78!APH3O??QK'X/O[#O&C?K>@\JB+.Q7*#G,<?
MFS]GK<&M^:2HZ@&T?2^]XY33,\WAY7*02&&U/1XJ*Z[PXLRSV52I=#%"I4.L
M?^<KDEAUO;<$M7A@4U17Z7=DD@H7-U0'S-(SOH#;Q-\%M;S_#1G-'V%,!E)+
ME;/SD'ORDUPR'M &'*J2K0KJ286^^PESC3]H# ?:UZKY.E&"8?&D5L3L:P<B
M\TT+B;U:FD/073A"Y=F[1;7STEZFPAL6;*]OAR.05B>CWFT@G,MY ]<W)?B:
MRO@_-_HA?--/=QUIH4K?YO?43>^F2KI@K*,F_*GJ&R9K%OX>^*I9R%+H$"4,
M,201CLSYW4P?%EZW^TP%BWJUD@%??WFX$%]493(@CX:J3'Q1#_I'8H?C:>:F
MC)3,+E#$Q_.M0/V2C'/2U/W2T[%0YEQ>-ZQ0(L$\.KE.U/$'F<*^QJ*>@PHO
M<1IT\-]>DIZ^):4E9-V/0AH20)=  KS?F_>"M^4OVDT;=QB3 0)*;YO$WJI0
M4JP1TL?X[J5U5+7VG^6*#"Q>E\]7)&%Q^;=8HN07\#1]F*A%+;T_)(GX6DLK
M\\47>:"2<JJ>^M:,+)O$\_#DBQS,$7A'[,B7/^);VY.KRZP?^78D#50W(ZP6
MGTAL*ZV[0"?]7C]3O%G&.RXQYMM61Z-+& ;"L=T,S;=V#VMZB]ZK'[#RW10E
MYJ@1YL-V)4%E;+?NN6PKW]:3VA\[9X20K:P1#RO\=S0D*. AX.M(XXAK_!0]
MW-QVN_O .AC6E? L!9TWKC?HX3J'UB\L,:D=V0!9G8E[3O'TQ=PIDNOF1(1J
MG_]._JH4095>B(4,S?:Z#4[1:?WY,Q?+2]?!U ZJK[CC@S!9O4&O3RMMX:[]
M-XB(#N,'5A&J08_\BCX"$T#6=Q9.[6-#]RY^<%HPI-\JK.I9><!X]09I<7V2
M6XU%HDESZ=)RII3+LP6!MDY1PS@:;A%THD+,%3^VO-W;J"/L'#%NXD[_4<&W
M3YT:G' Z6-F1NEQ9E0A;O+@@G6@S=9<T]2_';Y+D!KNU^^"5NNR& SH#5N;C
M>%XR0.QT8-K%,56+Q]A=R'NIYNXVOI#S6Q@.WNJUV:JK>THF7.FY^UCMZRLB
M<!95R:F!HC::U#-[-)OF_6YN*0U/ZZM,)0/6N<8B,1IED #L:2NS?(Y2UR+B
M4H[ J/TE@NPG[LSYO=LK7^=W_-J5S?>AN.J914X-ML7)C8\YW:F?9@>#X4$D
M;_\G8G06E'VS]):^=%M_LH4;:ZYEHI]\=[5M,,8>WL<<U:I=:N/L2&= _9NU
MN44R$&SVD Q$NR[*6*^17(C(\",KR_S&%'^ LR^+.GJ-2B]_>-@](H'8PH#>
M//4XZ_<B<OWQ,TV OKK)[MB==:<7.:6TXE@RZ'ZAPPB>M56[]E:YKX6^4Y4,
MD%!DX+'QMKH;XRY$]+7%('E.@6L5ZH"^W49:Y<#&M3RD)?_B]HWE!4Y4 +,X
MF+'\!JN4Y235'U5]%O+J4T['FIAR&S$M_51H'(W.HD2# )$G8F]$Y]OXQANW
MRO::7-6\I@1.WZ],55OYJ57HXI/SNQ8RW:_+R*0/"PT.R$CQ'/P=M=$_8."^
MJ]T<V-,F!,+5Y5S_QV1@Z@^(NXTMI"\^P6Q0"6QV%6^V$S0NN+C%<6RBWD_6
M7_(=C%YI';<2'8B&J&RFZU<J7U[W!:N7A9&!7938 KP'QS@-+_H"S@L0,=G,
MP-LZ[1Q3JQK%%6_$S^K&+E)CBY/+VIV7_?B'-'O0]Q3M#2E^E*$\;+&.B(X]
M$UE.G7-<^*7MJ#LWX/^L,N&D(DOG'ILDM]J6)*!"'63T3\=?O[N#5/V31J-=
MP"3#M>[4C_*5F]CJ7]V+%E1)_1 (: OS3M] I.CY]VT2L6@N7:DL%:]T"%VK
MQ.-Q&*;MF=9D(%GTS<C&/)+BF?&%UJ_]P<HUFMH0V$;%IJIA"KS->#5)\6Y@
MVY=Z\Z.&V-;GF61 EX\,4,40#UPLXS7D@<F_\V\XTD+]@_R>_;RVD-B,F0L#
MPM0)4P(E[C.="7IR=CYKMU._1>YP$AR&Y$\ U)9*27L^9^V&>\>N($+$FC\>
M&=,Z1;F& &8+*9M_;B/DWF$A2(VX<A/;,L187[; FV.EA3[EDO^@S>N;6J$9
M^>.&I"B(2:;LN;>1@!D]WW6C3IN"J#:_FZEVPIFI68!E.L$W"=X&Z_BE?M["
M4 [&)KC)*_OS2'HJ4#6.2]0136]F4NNC94?]M_@S4W^?GV4TJ_S4KMECSVN[
MJ>J)7ZJ2KR5N#LI.S(;.4V^<BX^.+&\7[=5<AEA00BW$VEG249(_L<.W(/H$
MR9&VG]-XQH@OE@S(*ZXV:U&V!=TU04BY1 ;F&Q:D\2Y5^@\CRTAB_YVX3U/A
M0G!TL38R?P]3SI0C3=>Y,/<IE/?Y<P]E;%0,_EX8Y5W! WLX.FB=.KJY(T,+
M,,R/ZIG.*L:YFH K\*M</IUH1]KO%3O-KCNF\:(G61V0K2[<<R0M!ZGZYD.9
M_0=O?_G*/^W?TVQONQ@8ZMID6G*^-MH W/2\ER[U//(<E135*4T*]0,0"CH1
M,K53HZ9K"[E4VXDOW'MB4">N(=QU5E^7NCY^(Q^_L39@?X\&N;_\K,+IYJZ
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M.#ZOY@V[CT..];VZC)[[-,%T;?][==GL.M<]_'8&N'&YP(V;--;4J07"&+*
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M$PY1[F+D1</3-I4ZQ<A\MMD.[R0@JH%DY__8%)47=^IHRCKE G-D^IQ,+G.
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M)%"HOPZK732Z>55RT,]O2DRH(U-)</P[,F"4JJ-WYLI3TTL+,H<TR,"AMV3
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MP35F@_@WY]H_!/FYYL7<F95:@=0]XBK9G>*?8/;FI]<Z_$(0Z:1+Y1,>#FL
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M;:_L _=G\'5R>%<$JNU,4;:,XDR;JEZ"[0[&M<WN)[N_BTDI8%Z2HG=*Q37
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MVUGPJX+3&5+7Y0:G(78">SHM#AN/B'<%N:ZBT']MVOM;#'KF67C<38@=Z=S
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M5%+SVMV<D!514%4K>;"F;6G)@B6<.[D"9#5K;4J(Y)^ [K[V9#@EZ@1'*"K
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MA.&3"0RL98OC9L9(Y_3#[WD<N2S/Y#/$<]T#+E\;CD-_@8Z'06IP:ZD^A[I
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M"<=AWFN0:A95^M1$MH*6Y#<*\I6L60IB96?M/I^\B7X/-I'/=#23-R+%^_W
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M8YCL\J\(I\*:9U4C\-4&0)0;)WKWXUOL4FITY\,)HR9![L*COBY-\BRI(W.
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M*\EY&?#![XTK'4K =DOAY'TIV$G&E5BQYE>/JX[NWIW5]?/IC7)3/"C$16[
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MD6]X= E_:7>-@LK.D) &3M>"9<#L8Q;&8N?M=M@_)N__+\"Z:+J-[SK+_&7
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M[&[ZI;2.1K6[VA8GKM=Y+S+-[O\KA1K_$* W6N2Y7XGK[]..T5*Q*HMD6@R
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M!XH11KF3U7/9UQQ$ZZ08#,'B]$$0@R;+AK[*NRZJ\UE_JF5(=?)<@,'=GY=
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M55I(^XA&,;MGJ4JA/IKPF#;V$J;M$O,.I#9%38!?F%F6%_8[HTRZ^Y&I6LE
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MQ;R^VF)78:*W/^NZ(R)L9M?!0"TF1\%+5MK<VOY7TEBMC4;KN#]P<9H8ZW=
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MT5LY%X>[#JT"';MU>&8+E-/_2CS\8#!;-Q[F0YFNAS.7X48/5,UFVP8)BPK
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MMX9O:]$MAQ0S_,8&<9L%=6:+2.,BCX#L. <1IK@4T\W9^G!,F"2I\Q&[/ N
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M+4"M;8]QQQ"[9W*E"8H]'7F4W?NO,6__C5!N/W+VSJ<PH*)U(\_ .@G?<ZO
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MP@M1^TU+".)F%N<@KN!\#A[E>!L!(<*$Q40:,\ 5=//W#XKX"_\=,-_ ]EB
MMQC&;'"&Y=S!LZF&]C8'3CHV!93X7I,XM7VP#@HH'Y)OBH;*HLY+7)JY%*N^
M?Q68GV@_LLMM%=@5$%]SZ&OM:&*IG5)ASM)H/LIRJ0#Y'U$XS6P>X/*<@@DY
M0ESW=,:_A5[$@/JO-^KWRBTNKQGU-D2X^WE(*_K^MVWAM>4B1E9:6R[6]@X)
M&:Y/\E'6!8E(]^ZOG#&G[RMH11?$U^0[@^E*S3>#6:T">1"KE&3@>QR@8*$@
M)D=?4I>MW2MCPG/OK$<7-"_W:,1/?H>N\'\!XP[_RV8!73MN6"-\)@>:\OKF
M$;W%NO(*'?C(]7_-O_K?!5+Q9=:#F-!Y/F5>4.KRE$/KT]2<5<#J%E314%55
M(S1'7)R%V.RTKI^G]]7-7 9?,/'9A[V-\51,JU71K=OEB*\(E* ./3S5*-0)
M&;0@EJ3N>+Z@!#KQI1;BM='Z&Z[PQ<[)B%R-CB;?3<E F81.>\\<OD&=TWQV
M"ZG#1W0Z(/[MDQ'*+DBC>*;YVW@OSZ5DJXL!V/3E#RLFJX"_^5(I8_E*+L,\
MG]'T'BXBA,=P]\L*1G+:^G@4W'=_SI3I%O<%3LW-4KE0DM[BY17I)^=Q>J(X
M7M .WO;M(E$YXU\Q0?+2ZTW(HS1QRT_#(XE:"Q#!4VZ.\7 H?-M_0)[[FXZ.
M+>%XC9*SN:5;>%+=5R;GORWFL@;F4[4[4(%K+DZ[8=%M)%4/?V#N,3&VIJWT
MVA;3H<Y5(%]S\WCN8+3A]<!ZA]\<T_"9(WL5<'\87_P"TE7:UL9\RF[^Y!2"
MM+EJLK4[Y]-@BR\:_/0Y;+C!8*:%>BUT[<9"3M]6Z+PJ_O*92+T2,>%?GC7Y
M]846NRXN5]7EO[SQ**R7T'PU!G8N;S(=*37. C[4-BF5\9< Z_\X6-1DPL,
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MZ=5)XU^S*6)7 0)FP43CF@IEC8N]VIC6O)8JP>3TDE4 M4@BM05]![E 9N>
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MT#-A5D3/LEJQ',[X]\YR$%]-"M(Q*N>B23'NM%^K!0TEA%.;<E[.LQC_5O,
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MRD!3./UO%2 %LYF.]8MKIL!N)C)2P^;F,-5$,KH^K]U-,DN&U1PL=W<5**'
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M]!62R^<.=X@.T&J&>/ANI9-T_I"-KU*/#[XXN@'HW6F,TS+F5N<5\ZC/^NE
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M.,^P\&2CQ4IZ,81VNSM._]2XD.,.\6)">X!!M_<8]1PC,1B<>&AU&!%]>=R
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M$2;[E!<D +KZJ(60+EA-\X'%NH$3QZ:YWZV=S^[@6WN_V$;I?_!<!F[U_)/
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M;T>A&:;O]B2J]F!H%&'Q$IT%.'>-Y_7DK?H'F$ZHE>J5M@MR7 X& .KAA3_
MN/H7D%,+6(HB+107Z%9NV9F#'1(L<T+)32II<$YXM0W]I/GTYIN7(2Y?OSF?
M@YK)#E-32T474*)6-Z'Q(3F9PSCN(+CBV+LD?1*7_2=QI\+1+PT+R->68?J0
MSX-$S8LW\F[06LTHE8=?C(T_0B]KO%SF:-R$Q2+@?Q72(C*5Q^%M:RN'=7M=
M.;Y N K8_WLH2]Q^VK8>!KSR^74#P7L':\WBN83I$2" 7OM.:!@Y"T$!'J)
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MZF^+307O"'E<O-I4Q4I4U2W[STU1%9J\;W\4U4)R1/(\"6",TQRB%'&8AUA
MD@I*>"8#@<BBWK[:"[&"OWWII#!#68WS!P<]ZQ/?:RFJ]:9DNY7N87EL^5(K
MEU[K\I]7Y$%4CZ2]00FKC8)&_G_MQ 0].?_YYYU2PP%=3@73<GJ$P.]:R/_W
M)%!K]DR<I;82UN4^#&MF"\/NXZN4!@8#22IJE&@?H0")HI_%LJZZWT#]&_,%
M7AKEYX-9OBT[#4C)+DQ">\7/;*V,H\<:/IL/;4PZJ5JOG5Z0!F EPA_ NN2B
M5,;O$74.7MK7F[)4YN^[=2F*N]57\N/MCT>QJL0KL1*RJ!<)3V(480HE"Q4;
MY(DR5&6D*"T) I0+GK,T=6&#"^/-C17>K]0H*V/9DJ4;'5Q"UHX6/.(U,CVT
MDH)65*!D!:VPX*=6W#_Z(PI+8#P1QJ71)B4.2]7W"<3VMF%$\G[%U ZZ$F]$
M\^?[U<?Z7I2_*I6:<3\4A!9+Q5NB6B@NP3%1E@4+A=K^JGTQ)$F602Y"$=,\
MDSD*75C%9?"Y48R1%"S7JSNHAGL RYVH;H3C- -V[#,6KB-342<V^*D3_(^@
M6($&Z9WPX(,%U,[$- 0S3RSE-/2DE#4$E'W^&O2,863V1M#Z_:JJ2^,;?$W*
M\JE8W=T^K#>K>L'RD&$9!S!D40 1SXC:&Q$&TX"JG1-&24H2%_(Z-]C<R,KL
M70%7$H/'LEBQXE']N-[4VB&H?:QNC'469CN&\@7>R(ST0=/[5TWO6N ;\)=R
M77GD'!L4/'',V:$FY10;I?<YQ.H>-\[@W\CBLYIK\54A+'X1#U24"TR81!&2
MD.2AA"@E*20L1Y#@B/(HQ@RG@0U'''OXW#CA'[/@3T'X7_\AC\+PG_XQ5S\$
M=C1P%+GSG_VU>(S\F1O1@)$-_-Y(=]HW<AD+WAY.F?WG:)@\&V4FV%@SX#GE
M&\935Q@6"Z/F(.D?CMXR"7.=$[9CJK/7#+-FWA4K?5SW01M-G_79Y4?Y6R5N
MJTK4BPPQBE @8)!&(411A"%1= 51F,B,(4&2-'(Q9LZ,-3?>:D4%1M8;8*2%
M:PF5O, ([&;,G$/9SI;QA-W(''<1MAM I)H_<,L4KVR6YE1=K;!E7?R=G/6J
M.YL]%H!YLGK.C32IT6.A\K[-8W/+,&+Y5*X?15D_?5(O2'V[XF__<U,\ZJ7D
MEBH3B[!Z(1E"A&091#EC$&7*!,*,8IB*C'&6!81EN0N]7!QQ;B33"7P#C,A
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M^;%\^Z-6(NG=;4H3CF660:'M#)00#/,<,1@I[LH1#W0=,J>#3K_RS8W,.O5
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M@=2>&"%.8"[20&^10\H)SD3JY+OS(M7<Z$@K!3NMFO:54-FP]5+MG8A.9:V
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M@D)]0(K, 6D<08QD!GD6LRQ# 0W2S"6>TW[HN85J*LD!4Z+K+G.Z%"20G<R
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MQ$K(HMYW+H4(BS2/(>989U]2"4G ,LCC*!$B3(6@<ACY.\LR-Z+?*= 87MM
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M=5/=):FJ0A:LR="4BA&^DA^+7 @1D%A"&B+%6['0;<QS!B,<LB#'8<:ED_?
MLWQSXSC=-I(L3=/(.Z5 !7[2CE'AVI[1^RP&>1;$,8*<H  B(94Y&@0!S!@/
M$TYQ&H>Q6YS."\[C-($^MP\FK&<MP>;4G.K^YA]?OP?KMG.]KI:BPX!T@PM
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MU'A;FP>4L0^41^I@79GIN$ZU =LN@O0,X< TWE@+6N;.@,&T-+BIJ_ 7-3K
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M[E3+_]WFST^7-E>Z3X(=6?N&=F#^?2T^MC.X!+-MLC\B=0'($S=:#3DJW;F
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M?[PI&BGL-Q),2[D!O$Q- J(2?C(*1/JY,=OX^K=:K"A?'CQ AX_:J<?+T]K
M#^X7E@D]!QAMQ> 'B/;BP=,=NZTC/CX]+U8O4GZ5ZV\YEZ<[D-[3'^_D4JI\
M4YT\[?^E$7E0280R&4N( B$@BC*]HN"IA(216/(H85'@U&'<CUF36V64+8?9
MZY;#^^ZNLT928F:.DD'MF]O"P]-\VJU#QI^EH9<EIWI"=YX@YY6(7SP]+4P\
M&37J.L4OD(?+%L]W]Z#!_E>Z+D]!FD/]4BOXI9;M)D&H")(8IBK.($I3I-<K
MB$)"4!I%B"JJG!(QK4>>&OTVMNXSE1M-Y1YJZA>AMZ/100 =F"D/5-'/0/OR
M!JKG-@ .H6Q^<=RW4R^W@>.B0KG5#3KGIQY$OC>\;.Q;[*/>.8H2D6&D8!8+
M"A$C(62)TBL(F<2AT6!2-'258KL^[/1V5QH;6ZL^YVS1ZVC;,98W!$?>#MEK
M#IC%] [1WZ\CVB4)TQHB?RF5UX<<.T'2&H03Z8[VUSKN!,M\_E7RK=$X""-V
MGV_T-S]%DF0I0C#D4B]AE33U*BK6L9)13:&13!.K>M]3-Y]:)%0:9<Y>PN@G
M]C-HS+7<[SN%WI7-U9Z8#,P/KG#8[YQ=\/O$0U](_I>'U;=_UY=5S[O^8?^8
MG[S9./M>%]S8[61=^DS?,^X/E9A[O:"ZTY-7')X.S5$0DRBF*4PCENHX@3)3
MWBHA0R(D,6.*B8XGVQ:C3^T!;Y^OUN8WVQ6@=.#$Z6IGB6J;V7$]V/:,^8C'
MV?WA[G&"[0";]W-KF['?Z+3: 9;S9]0N-W$_F;Z73T;P?_U2R00T4<^=_HH^
MZO^:;IIUZ[>YHC0-T]"(4ZL ZO41@LRTNE1))B(=LP0XB9L5T;U=!JG]Z!T6
M1O<C$-X=76]RN@#/M<4.9Y<.R%\_0O8,Y$CQ3V-T+38RVY\;-X:;]C([TP?!
MUOX,>!B,QSKO]86UT_&M.V07CFH=;C;:L:R[@^TCV Y7^U'JO/V^U.3XF#_?
MR;715J(/\MW+ZT*]ZB/S+ E(*F.S=X\I1 $3D%&I8"C23(F8<J6R/N*=UI9,
M+=1M4E:DMG3UE/.]E$O9^DF"F[N;]^#__74&C/W"= EITJD/ZG!-V\75VO$P
MH/N,VH7$H\S3P.^7LYJ@.V? WALS00<75!\;3B;4&=.!E$/M[7A3,5%GN*[I
MB[K?L..9Z8(6Q:VZ7Y?J@B^E.%>U/$T83X)821BC4$*D3$8\3154 2%9)$5(
MD=L9Z;F1)L>>QM!2O* V%92V=ML2.(^OY4&H#]2&/OCL")C[H>8U,'P=8IX=
M9]Q#RVON'AU27KV@JX;5PU.9=U=G7Y[2GL2<I3@3!.)0Q1#%>O&-E0@A25C
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MC=%@9W67Z/V7-AP8RQUG<U8]8+GM[QG7L??_/4#J?@S@@)&O\P";)J<]&'
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M<CKK/]W>W :YSESP\A#;\;#_#,Z6!_[^T!O[T/\X<",HS%GBXNOX_TQKTX8
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M0X;(&8)"!"%$ 6<PC]5_*%8K/<XR%L=.R[V73<QM'&@L!)V):@V@C'1<F!T
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MD RU(>CYRU5S:GWJK+4AT!S(7QOTF($1?Z*NA?CRH+?^B]7=T;.<!0YSEK*
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M0/:0QGN=76^6Z.L$SKY48#<-#&/V=YNR6(BR5*,.+1;U.E>PY>-"#R!W7*^
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MSG/!U,(YB!("4<8HQ"P,8,[B6"91FN4\,ETX'SQ[:M_V-T)I =:5A>:KMT/
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MYEWK>V_E5!4:M[WJJ,:,*]"]UI*YVL@)U(QQ!;19;1AGK0T<8IJ@S'MYR]0
MMIFK48M7M6>TD2OQI/>Z?XB[!5L^B\_+LJQ*<^]JD\N<DY3@#/*(9FI R3BD
M-&5J>AG$&8\B%!$KG>,K[9G:H/'^27=6"8I%4\%JSPOPB_;@5U![8SDL7-EQ
MAOP_7G?X)OK&$WWTU_'E9+?4[K2]X[,:O2-\77'ZE=:,2]YNH#MB:4>/'4;'
MC0 M9Y%@,L<P([QB50DI2RD,98A"3$+*&9ZMEVLR-V-5>UW9W<,];OU65MV
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MTN4ZT1M;54(G0/G>RCXA>^-%0O B&)Z4;]Y(]N^BNY>T;UQ)];6K!+4NZ&R
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M=6F0&<IQ@$/!H QY#E% %0E2%L&<4QJB@.$T--IX.GCNU(BM,0UHV\RC3[I
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MJ<O Y4.R,;G%A7S\-ZUW="__*.L$YYDF!Y9'BA%"3B#BB8!YB@5$2"0908'
MR(H@>EN;&D7<'XC%K[2Y<"GA1OV#5 G@UXC&'V)MQA_.$/3,($=B\=]:])2Q
MM4*"+Z7X,Z!X48D_;.L-%>+/N-VO#G_NIL%Q\IOGS5RK@U63FA-G04W*/64<
MQ4D>P#2G>EL%9S 70A>FB$B>)C0CF=5&K''+4R.9CN%@6:UHV-XY:%'9#GZ9
MZY-EZ]AZP]XPHQXO&'NFH=O[]W?@=KU>%713J>V#];+-;W*OB6"-D+M(>\-V
MQPZ[MX/C1 R^Y0,&ZJZHC^M]E2+[*!;LM9-4.PN2(!22"I@%6J(N80C2+!<P
MY1G#*0^BG*=6LBMGFYH:,^VLM*Z.TX.G&=6X0<DSM^P!Y'^E=!D35WHKYQL:
M5V[EHL-':BN7[W 6'?=EN>[NI&")4IHD$*59 %$@"204!Y"@)"=Y%"%%%E=&
MQ>TU.#6R\!\-MX^W&8VX1-$[F1Q'O[4(:IL]D8HI0OY"WO:;>^M0MY/.&X2X
MG;[/LH:&*&:W&UZH'OM4K)[O^"SDDO- 33EDI/=G(QQ"G 4QE!D681I'"8W-
M*ET</GEJ]-$8![1UX.Z#82F ([SZ6>$J%'RO4PP!,)>W/^?LB2^Y%.QOC\L?
M_UO=4W_$ZB^[;_?X2>.(R)]S8"OU?O:":P35'LC/CS_U<8YX)Q9"%NMZ/K%1
M4XJ==LYI19V//]<KHEHL%F3U6H=))5RRF'($61*HU8/("<0A#:$@*.<D$$D4
MJ6G!<DWF9M,"#S9:4<'64G]?0C/TK<E/\ NMW?L5B-K=.OV,;;T%9,$![SC:
M%OA4G@X15G/;^69SE#?N4L^\UO2F#K5M_ ._-![^>@-V3H*=/S>@ZV?G%ZY%
MUKQ@[E11S:V%;R"?Y@7BTUII?IJRG\%]:.KN/*R(FA_JYW\3+\O5>D:B5&"U
M$(1Z\J;& J8F<_JP/<S2()4DQ3DURDOH:V1J\[K63K S%-26FD_QS@)Z>;;G
M B;/!#D (:LYX"4(!DT'SSYTM)GA);>ZD\2+UPZ;+WY:KD3QN'BO56)6K\U)
M"D)Q%J!40C7O2_6$C\.<\ C&,B0DE9P)QFSV@4XU,K6/O+&Q&N1O-^NG*O'<
M;OIU$DNS^=.U"'G^OD^"X^'HJ0\&1W.2DTV,.JGH<_)P5M![K?VP_EGUP/SK
MTW(AFG#?),\B(F6D< HDU&F%$(LTU*%TB&"6X3 W*B]\ZN%3^\(K^T!EX*6X
MVLO 71ZVKX'#\^=L@835,'W.Y4'#\]'#1AN6S[G1'8[/7N.NCAXMU82>K6>(
M"T&3.(8ABV*(=/4,&J $)GF""0US+F-\?3FWIC6;MW2<<FZGZV2!7>DQM=9^
MJ((B/BV7Z\5R+<I_O;[B6 N^"+(XY&J!0\*(0H2%A#2)."0!B07%B*;<*G;0
M$?3C)%WJ.FZK'<[N4#6;%#G"RC.9GGD__VQ-=9F#?1D0CX7<VI;>O)#;@<LF
MA=P.;[&O"_\@GM5RBZQ>Z\R'MAJKMOA#4=:A67H;9KT\79/UWQI5M91)(0/!
M(5.THF9<)(!Y0CB4,8HBAF@>)VE;%?7"G,N=54:?TW[A5-][+EWKS8MJN^JE
M"].[D9$?B<A:CYH\M9M=#>SJQ&+/+1V!>$9!#S2NC=]KYJ7.WZ#W1BIE/EHO
M6M4H=XQW3PUR5RV-5F/<,33=&N*N'SUL;?-!2+%:"7XOU9_JZ>^7Y5I]JRF5
M*$%J3DTD4^,@3R$F!,%$ZRVF"8H%MY)Y/=G*U*;4K9&@M1)49MI-K$_C:3:E
MOAHEWP<)E@!93Z%[ 7 T>3[=QJC3YEXW#R?,_1=?F9%7GVOJ$, 923*1I32
M68HX1$$B]">OYK\8$YI+-?=EQ":.Y$0;4XL#V260%0,"2$^!&".L6HUCF$=I
M!%'$,HB#)(9,_95$4@118J5<>2V(HZ8P[D647H^E&6=>B9!GQK0%9WA:XK'[
MKI,1.RV\30KBL8MG$P]/7#J,*;^(OYHJ'>JI7U?+A?HKJTNLGM&N327&%"60
ML4Q-GU#*(-75E#,:(,PCG(>A53%36P.F1@_*?D"V#H!*?H>LN.6LRKH;S,C#
M)[B>F47CNK,=[!L_CJ;M4/0<$9-U\Z.RUE!P#BEM\',&JMZQ)\$W<W$O]:*3
ME$_WJZ]DM6[^<<O44K6.;REWWUK 6)RDL6*[G&.(A,@A832#,45AJ'HM)\RN
MFI"]#5-CO=:%JHCAKFR.^M>WI5K5+P3HNF$I-S:@B\SHT#/PGAFQBWECLGKU
M=2;V>OOOK@_@S_I@T@LW7@&E*U&N 1:,*Z\U'*(CH:PK'G6%\._M@E>1!O]W
MLRI*7C#=0A-8QFF">!A(*!AG:AK(U&HZRQ.8)TF4AIBG*+6JV'BAO<GQGS9W
M@ )P#Z*&%.8.)]]TI2VMLDOJ@)^NL1Z"]PR!<:D;W-/:^"+"EUT_J2AL<-MU
M^^X/Y&<EBU.JO[0_:Y(,OHE2K'Z(4E=C9VRU(?.R^E/PSP6AQ5PQFBAG&*N5
M)DG5Q"MG4JMFY3"GF,.0)H3A.$EP8A0DZ-JPJ5%28R&8[TP<MK-_=8_9'0:,
MV0]CG1]4D<J54S?5W[>_:!R[ :UK%4&VSMV MA,_&W3BX-,'5X@[/K"XVJPW
M.>-P!>:Y8Q%GSQ]&X_\06MU,\-L?8D4>FW#3>UD'-G7DIC\4\XVZ;"<74N6
M;4/N<"9)A"B&1 ::R:,($LXXE S16/T_P4EB0^)NS)H:A;=> 5*[U<AU@^7.
M(<O@4D?=9\;HXW>*9S[?]D?C41.NKA?@39QE5W#]F]#4H3Z[6IC;1PBF6X0=
M\;<CHT9E;[= 'G*WXZ?;AXN^7SX_%^MJ$U4-#GLB6QWY6[T[-$,XHT@P!L-,
M9A!AED-",@D3F:5J)4^B*#=+J;5J=FK,V[$<*--!CRZ9-M^P^(]E5_2SK#^
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MK=41! A2% B8D%B0",<RPE92P&?:F1I3-0<'NSV?H0<_YW UXRD':'FFHR%
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M:Z'=#+BK9LG.FAL+^X&I]+;!NORA)>D,M&:DXZHQNKSXP-J3)7B5**.:A3Y
M.[81O3RSYPY263'GMBJ?,P^"2' F$,R"TFCD,<1)AB%%:2R$8@)GV*5AR<'3
MG:AQA XE]V8,T%1]ZE-1ZQ \2W>U+R1#.Z-U8<%:,H\NYBF%?3F0!\\>UST\
MI=8KY^_D17T+Y[/-/G"EZ;GP7KLS\Y@('L>,0V9V=)$I>8!%Q""7&>5!%DDN
MG$Z SP\U-?/&2-H*4)OM>U$8:5WKXY\%V.[3]@/;P-]Y3\1ZE+V_!(:W2O=G
M!QJYN/TEA5_7L[]X1]\"F^;;V[)"/I@G?UCD3W7-EB;E7$:4!I(0S1@F;%KJ
MU1ZK-(51RAE)XQ S;)4N8SWBU(CC2&#0EMBUK.8EL.W8PRN$ Y-(%WH#)/A;
M0^.M=N:E\4:NFFFI_NMZF;8W.NXVRWS^8;G19/7]B2X636VH.8I2@B.,8$1B
M;8>0.(641#&,&0UP(J(@Q(G5GO/IYT^-0RH102GCKI."Y:[I&00O;!Y?C\O
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M$K #W9)@?$$Y-+WLY*Q"/(U)4>/JVV*P@L1;V9"NL4:N'&*A]NOB(38WC=S
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M[-)HHQ*4I>K'C&-[FQN%<--11?LDOW^?RQ@%ID,E3+,@TRRA?3HLM)D7DC3
M-,RR%%F5XMD_<FI$\+LIH&1"5K29;1DKU<*G^XOOI_7 '_7O7S[=?W@/OM_?
MW'_X?OW'^UK'#J>LOKCZ/.M_[+_,UJ-&^?A>B]Y\7R?^TO/H=M_(;U?09%^6
ML.5-24FCD$ F(JF]J<QLI_((RB05F9(!5=RI^Z'=L%/[%%M2.Y[1VJ%L>2CK
M';NA3V';S2+WA9X.BH<.X*RXX>3K -9NT'%/7)V >'7$ZG:W^WYM7;[CY<-/
M7N[]?M&OTESPC*6,4Y@11B%"F8"$)T*OZR%B-%5I@*PW;$\-,#5J:60$C9#
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M8AZ%,F,,)S TI\%(TA RAE+($Y&(E!,>)7W"?]RDF&B,3RV=&]$XXF_'/0/
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M5>$%$VDU3Y(PE3&FD/$PU>1J^FU%*H*I"LP6J$RRT*ERD.W 4Z/2G=QE(T3
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MI:1@78E:;DFN]\+:KP@=N%Y>Y/V@-?#*7 %52UE&I7WS#)3]>N<'L)$6J7[
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MHFPSL,O7,%8?9;;9%40#:U,<790"@^=28E?OW0I^6S_>-Z2#>_0'"8.S775
M8(0&E=3@:S>N/=Q[%YB\.?I6@X[L\KL \=KY=[J['SU]S)=4ZU)69&J&^$I?
MRJ/K9;/;\#)'G"8A#R6D-,I,IE (":,9Q)(1PJ2*0VYUG.PV[-2,FUIJ4(K=
M^IAJR8T#OI/=C:8LI\&.IOR#.S!-><'5F:;<8/)$4Y:#CDI3;D <TY3CW>ZQ
M+F4):BD,'=YM-\6&+DV:U5=-@3Q_IHMW=&'&_[YE_RWYYG[U^=.[NV]S% 5A
MF"495"PR5I3VP#"-0RB3),X0"3,16-?!["/ U*BKU@$(8Q&L]EJ YT8-P"H]
M0%$I8B+W2U7L@SUZS50WIXV!_\#LUD!?&F,M!<!. U"K &H=P/TXT-O'W@P]
M!2/%XUPQ%9XJ,U\#9$?H3J_'CA;.<XW2[1"?JY[COO TIV^'YVYWV@W5K^GR
MH5SQJD#X.4<("68Z#R!ABO]%'!*N8L@$"Y* 2OU?L3MTMUMU[$?O<_P^1KI+
M(RI8&%F=TET<X;^\AGA&\VT/Y,$>VE+P.CEF$&CMUXAA(!YI9;AY6FV7Y1&8
M.!4U\@+H9K/.V7931E]ITTC_M?IQ%[\O<J7OE)J!"F#X#ZQ.?@">%A)WM#N6
M#X>'C;9HN"O87BIZW.VV0!3K3:O.TS^;')J;I?C/+5WDZD6/<L.Y>:M:E:[W
M<8MAR)04"L$TI:%I6)-!%C'3>3T+>(BQ#"BR<5"NE&-R?LKM/SZ\__WS!_#I
M$_SGS>??;^X_W7T!-U_>@__\_>;SIX__^O3E[^#F]O;N]R_WW^T([]J9ZEY<
M1L1_:#_EPRUH-)F!,((!F8%V(;I_[A/%E@+LU0.-?@<5\KU&J'I"N6L31P_1
MVL#1_]IOWEP[^BB<Z0FBAD1]/:Y'L\Y'NM94TRS\A7[9WLL%_9.:*K-_[L*%
M:)J%.,0*"LXSB'@L(:.FIG^0LBA)22*P%8':#SDUKJRE!CNQR^^R$1SH__QO
MAVZ+=JA?MK3]8SDP[UV&L5?G=DM '5I3>@=VK+:37@!V:RKIA%57PTB[!XW7
M#-))L8-&CVYW]FFR_/245]GC]ZNOZ]6/7,B=P7U;]3=OZI?A(*,14E":?BPH
MC"ED*(D@1FDD$0XYC:QB@=V&G1Q_[R4W'F4M>\NYKZ5W:9EK/0461#X(L$.3
M>0O3^PY,>_4CM@;7I=_P$""/UD_XX 5^KL'>[WOP2@%OG8)=L>KL!&S]L!$[
M_;HJ>-C)U_GNGC7OMZR0#^5 MZMEL5KDHGS1RA9>9?\6+A4)F,P@%SB!B*D$
M4L*TJ1ZD(B(9I2QQJD]Y<<2I47M+8' @<=4SSK$$_D6\[>)"O*(X]&9$-X#>
MN^A88^.KV/W%\<:M=6^K_JM2]]8W]HY/RS?R<_[#),%M]!N2LT6]<7LBT=_4
MKONHKYT3*;C4/ -))$+3D =#PF,&XPA%<:(R%D=6[<"O$V-JK*3?PLPY+JT/
M_'9\-#RH Y-4I0 L-0![%:KCN!DX6?VCKH)I-/$:RG8%DOY"V_H(,7:HVQ5
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MT.1*%2:L=3+*+',[@-QY]W[P&'#BLY%8^\Y^5A[F&%9T&\-T% Y!E9#J7LC
M:2R@?1&6I6BB4D?!8?-M^P%@R&G.0T77L\KK*?ODP^?9]#H%PT(HF(6 8BI<
MG= 42PD%5@NIF4N69W>4VK??N)_J!YS+/$J$/:O_#-/EG*!+/'X:+R<XTF25
MBA863/&"K)5WM)4A!W)[N.?."F?]4>K??N-^ZA]P$O,H$?:L_D_S4.N8SKY=
MQ-EDY(R(B44$8Y$D4)!!R"F 2#)K3Q:,\>,L_IW7[:?X ><M#Q?>0!;]FS_2
MYS ]QW7"E:,3B9.]TIKV+,D4N*0B8.%!!Z4LM\=Y?[O>NA\&!IR3/%J4@P@'
M_HZ3R?^:4K![AF%!^UA^MUA<TD:&T@9=6 +KF22I) U!Y0(^FY+)F.64]%&8
M>/3U^X%C\%G(%L(=!$K^-IM<D@+FJP.[^6)D?5*9Z0PED[%32!+QV@4P&#@3
M&(LM+3)-6Z_=KUQJ\-G'8X0Y"#1<U76LC^WK-DA*N%R,!/'.4^#@6-T&HS80
MDR0^I$8;.&K/6IR![W[[?M@8? ZR@6@' 9%W4WH:B6/\%5^'9;ABBZ)CE3 [
M!\PI3WMDJ7RX!%$E+:5-9!B/JZ]][.W[063PB<@&HAT$1%;6[U58XOEL_FW$
MD@LF2@G)(45.%"V!0XJ<".8Z1D><E./*J7:\=#] ##[U>+@@!X&#LXLPF?Q\
MN1A/<;$8N119U%[6,Q8B7Q9!L52QD(KBVGGKR XVP,&=E^Z'@P%G((\5Y"!P
M\.8"Y^>TY?UE/OM]^?G5[.)+F'X;&<8*UO)Q+C2YRHEE<I6-!JU8-,BCT_JX
MG.0C+]\/%P-.3[82;,_X>)?*_.0RC^DW3I9+7*QU\'82SD=!T;Z6:LUH=!:4
MRQ)"R;RZ2)J);&U.["AX//SN_= QX.QE([$.PGB<?:90^QK:UHI8BF' *'BJ
MT+8UO X0I>592&;2K9=WS!ZR\<[]P##@C.:18AP$"#Y<QLDXO9W,PG+$3>9>
M"P[TOT!R\!&\]0'(K&41);E!ND7^:N.5^T%@P G-XX0X" 00="]J:>@L_>/L
M,XEM<7JYK->+:[)^1-*PRI,@JNL#JE@!D3X%+);<H1 PRQ85VH_1L!]&!I_7
M;";FGD%S<H'37.^BK#8]9A-#49/U4BI0WBLB/ 4@0V=T*H(Y+$?AX\[K]KOO
M-^!DYN'"&\B5KMM[:6_I.Q0Q.=0VD*&S22$H4Q@XY@49/^FD9Y$+(X_2_P,O
MW@\) TY=MA#HH#"QOL.Z9L)(KX,M$KC5]5@OD&$+L1[I!Q92Y)F,6D-4;+QZ
M/UP,.%_91JC#<"R(C7F8O)MF_.-_X;>1DB4PQ1(43JA63&7PQ7G &(V4(0?/
M6Q1,;KUV/T0,/F%YC#";H>%??[HGQ/?TC<,:PZS"Z..:P=Q[1(,&,(^3=6S3
MEZ]A=)T^N,9%T%D;S6A))\T)%UC 8W2@4$5R#UPHVU4#]^2PX[%'N7CK1ZV*
M,PBB5@;C00;T5[7:WJ].T1(JGR4>6>6\\;*>FKL<J9,[_MV!DNO;IU^3_?ZJ
MA=1()4[A*G/U (3"$67JO1X7(6<CD^%DQ8Y,!FV]L*>>+NT5?Y $AZ'\M^/Y
MQ;L\T@Z3U$I0$"KK49B.$#/#VFM"%^55UN&X,\4[K^NI@4M[Q1\@O6'NRJ].
M?ST[??_N]<FG-Z_//M&_O[SY]=/9Z=MWO[XZ_>7- 7OT$P]LL&,_A^0C]^_+
M!9R'\&54;U5?X.I>TZJ7TS6*7! <O<T0BR.OS$H/41D&R<>4),\YQ\?"X1(6
M<:7LJ_>LEQ!.EHOK[]RNI2=(.=@BT-KXB%]Q>HEO:<&\FDU7C_O[>/GYU>5B
M2:^:TQLGES5M=;)8(/U__A3^^!67IV5UP:OV?7P[F_]&9$TFF);C.,&3E.JE
M\\5(%J\=*X8$HNO:*@@Q"@-6N[I+RJ+0[^'K=$9@/QY(2U3=V*;!Z+''[>U:
ML*?+SRMVB>L1#U[&E5NF5YTRD)&AKTW7.+,I!1MT?"RC?<@2W7A]/YY.%P [
M5K8#@,75^EB,BG'DE,E06\!:4)I;<,HH2,;59FN"'(''LMB'8.+ZW?UX0%T"
MXB"I'HZ&V3),FJ#AU6RQ7)Q,\YL_ON"4#.*M,,Q*'*ZZ<I$"N8C@HF* S'/Z
M+P55'JN7. 0=#]'23W>[+M'21.I]1E"TSWX@#9 \7I$05^R,)&,Y4L0/GB6D
MB*(X<(7B0.MJN5!))!*^AYNS_=Q^O9,VFIHU$ML MH^_X!3G84(B.<D7X^FJ
M'5>M,+X2T @-IEALW0-S;3$N#<6!0D&(,M/WL^;^L;+,0^S&$R3UZWTT!5 7
M2A@ IEXCO3F-USHAGB[JE8;_7N>4-//"AWIBX+#4LC(/SF<&1G/.O-%)/WK7
M^! \/4).OXY+)UAJ)?P!X&B]5;^?+18U^GOS?R['RV^_X/+S++^;?L7%LN[?
MBU&*MIA@!6@52%A(&W<(%NE+JQP3W+)'NS8?GJYX@K!^W9Q.L-5>(<]'F5^C
M;(KG==!&FSTPC*>5J=/I69C@:;DII>=&EA(2!Y.K\Z^D(+NK(VCNG,F< @/?
M.LQ^B)9^FO]VN^NU$/NQ /K4S%IMRVA$QM85)SP!G_9JI7B X(R!R%/F@K;N
M+%L;IFT:^FD6W"EJCA+S "+TTR]8G;OI^:TQ'?%4/&>%@DVL^[)T%GPRM#E;
M^A"9P>):(V4'&?V:F$[2>D?*>@!P65WZI*V5$/\:X_(Z(@@N1^\P@/*VWLXH
M%J*LUS^%DCY@1MM\9]I-2;\6I@O0-)!XKUY-S4I4PC_,\4OX=K&Z5%[&TS!-
MM! ^$J$77ZIZ7GT.\W,RGU*CP$#V,AM7+WN$.FI,*4B61:M99%)NI8UWIGGV
M?V,_K<N[.I[J2-+#<6M61R._SJ:SN[;T>EE8'JR,=>9<T+0VG"H0T3M@D;;C
MH+Q4[K$JFX-/HAZDJ)^.YYT?3K71P.""^GJD.YY>$E-7>_5LNO@9RVR.Z]_[
M%/[ Q9L_2(BD.5I:\V_O2+(+DD:JA\&SR60EC[7%'HG@&&/)@$G1@ HDX.!=
M ,ZCYLQ8FV/K9&6'[/33D+W;K748NA^$7W?%XM4R_AFGM'<0&QB"ME%!CK5#
ME(X,/"^TKF5&]"ARTJWMZ0.D]-3RO7O\'2?T[\*$WE3%?*C97]+8<CD?Q\ME
MB!/\-'M@!9'T"K?6@R67EJ2@$*))$DCBB,YRZ;</_%[ >A["24]MZ?NUG)VK
M?#!&\UH*K\>+M!8$YELYK(J_:(F/A(HQ>1F!@GI9HS8!P=7FK"BD*(4''QZ[
M"'X\G!^GKZ?N^"\'TH;J&8#-_3"?T4ZQRB!YP947H=Y5LDB+QC*(,3@H2K#D
M37'!/'8Q\!!@W;Z]IZ[Y7<+F0-$.P!X1F&\QOY?!%5IJ(5P$6:(%)6IMO8X.
MK"DJ,4RH'KU4>@AVGDUD3WWYNX18MXH:Q"'F'19'W))UC3J#2"0Q99,@L=E(
M"TE'9%P8%EJ76=PAH*<&_R^&H6<)> "6ZDV83PG>BP\X7S7NN)&($%S++! R
MC[Q>\./@O0F /$B=D[$QMXXW'Z*EIZD 76*FB=@'X/T\'7X0AS^'Q3BMV!RA
M3BRQN+H7GD %QNHH> T%=8S9)&.:WT]X)HG]EJ&VP<6S8\3#E70P!K_B/,X:
MH7!;:BM>1JI(;GDD3[&H "HZ\AY-\E"LTP+K"FU>9K&3D'[K4CM!U/$"_UYL
MU^OQY)(\L?7"X#$H10L 6 DD,N60@E2G0$FEG156LO38]>'.K-<FD?U6KO9G
MOPY6U" MV!4WHYQT"I%X*$:3CU&K)1T%'N U(XD%(QYO6MC"AEV1TF_5ZHM8
ML4.$/@ []G<<GW\FND\(D.'\:N[8:;G7A^]&9DIY[C0M!YT-4@C+-/%7;[+Q
MX%B.UH3XV&BG0T#U7!I[F@?5I<O?J9J^(QBN?85B97%&"V V6Y*D3A B#Z#)
M;@N>LE.Z]:749Q'8;QC0+58.!.;S%3=<5&YZ"W=ZE9J8(E.8(4E1BV9L 1=U
M >-2"D[1^F^>]G@FB?V&$T- 9A/E#0";=Y//UP)C0=4)\QPP6UI@K+98CDJ#
ML3[IK#7S[K&).,>?!#QK"_ZN"N:.%_@ 4/-T-#32*8E:V001;6U@8@PX4WL3
ME( J9(S.O7R6K=\=M8'JGQV5/DL/@T/6X\?T=\_*;J:3K=MYCCRW9/4S@N&T
M-)5""2'12LU&8@S1YXS=%*LU(+[?_;5KG+Z45@< Y[OG<H5+S151BZO&=Z5X
M"-HE8+1 C99)6=\ZZ'W^P6=G>;GVL#I<NLU./5^P->!HJ]JM07- >F3G[0&W
MR;YI$/A36R'1NSY\?//7-[^>O?O;F^;-%'<]O4/1/<E,HS:+-[[M:5FOI)-I
MKI-VYO@9IXOQUZMJ]]M4IR;K*UF=N&+J4'%=KPFA 7(K6)%,Q&!#8POV3!(;
MUM*IH#)ZBMV<KU>]<R(W/WD)K.ADM8L4.;9F]KFU=%W9ZBYQ\4B)W7,D/H#=
M?77Y:8=8*B_7[LQZP !]?XYA@:]Q_?%&<)Y)VIF$ )N=H5"2)XA"*7#:<1&$
M1?;H^)^#KZ@=176_[NE+8O.%-3Q@3+\F+K^N&C\M_N,R3,;EVZJOZ5\QG^.^
MHC!1DDN7 G!-'KSR7$#4.8&5.:+/JI;WOQ#8&[#3KX5^:63NN3!>&B8#7C%5
M$Z_"XO/;R>SW%?_7/676]P@_8IJ$Q6)<QNN.]B>%2*J7#ZQ-5KG,@1E3XY@0
M:^M?#:[F'(TT,936%T4;LS#,E?'BT'S&7M(U3K['9?(@XYEGN>HSB,0C*,X1
M7!T&*K+U@7;T+'/K>PK-B._7=?JG61I-L#&P/A8[^']+ZW]\/GUU2:1-T[=/
M\S!=D*S7W1-77TW6[.?_NEQWN-M365':I+)%"")Z4I9V9#MJSRLAO<]9,BRM
MK].^-(_#7&D]NV># -2 -Z-]Y7-MAT[FXP69RM>7\WJY>26BFTNDU@CF4[;
M4+EZ2ZN>O.D GL=D.+/!8.NZR1=@:YB^W3!PW7@1M@;9@-?=IED<)>F*YD6
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MQR\D$)DE4,)S\!DM.!651NER$MV,)M@BI-_A0DWWK&/%/ "LW 6Z9K7UKG2
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M;K3^0+'&$2H8 )!6[MB&O*[9$%)QK36M,EX+_7T6X'*2P P704JC96Y=:?@
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MG'2MLD8'SC@$[:*CI84AJ-RYS>ML>E5GQ5D# G(/0!B ;7TJB3LB]UD4BN;
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MU@C5$;_TS _SV=<Q2>[G;[\M:E^+F[Y0)VDY_KIN/;:Z!7Q)W[OZX6QZ*Y7
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MN]XQ5V^[S8,Z+T4F=+%@R-4OCM&N)#-$)Z,2@>5[0QR/7I=/$G6LA7KP!;O
M;C'F%$L!:QDMKYS)5[!>@/9H<_8Z,_YB AB</6J+GVWKU)F>AFF4WM$3IN?C
M SVES;]N8((>)*:1Y?G+;)9_'T\FI-;;5VT[QS<H"CS4&;D,<M0,% L"O @1
M4!1)NU^*G+7.J#^+P..CRX?>< MPA4)ZF2/$4DN&1#'@@T'(KM 6G'WFN74E
MUQYD]6M_ND/1_;"OK8:&:8+6X>OZQD2X<@;?'946>^J)+0[[GD/TRZ?%<E(6
MZ]E/9J%.IG4<G#,>T.M28A+6Y]8]_5XN+;8I^\VW[E@=*?E $<EJ@R9/(,4
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M=BC3NC9U7]KZ'4[7&0"[T,PP<S+O9]/S3SB_J!=U#D[*['A(@ZS,4Z2UZA=
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M"AET:V-S)*E#9U2>AIP'+R07T%<'1]V^S+W^>8?131J&5S*1H67 F:D=6E2
M6+/!I(S!9B>U,*TK%D^A=UB 7@10.WKMGUV['2#Y/@?K:8="ZQ"%T.1U4$"S
M#&TBTPJ,%E85&[3 UFUW'J-C6.1=#@4/4M)/5,G B2V?KK]_OQI7YR?6)!Z2
MVM(7(B?T\RQDO'/DK!\X70J&)6X LZ9CQN<",60--2$MYQPMZO*,(W?,NKV<
MO,=J>7HAD0^=)W5__BX&YY)BD;R3VI&O:$?A<<R0:_FE2AZ]V2?Y[H@AQF=[
MCFD*A1/$U<%Q=,_H$HR7=O=6/K<A,DK%O* X%D4FODP4X.KM&W.!RZP3D^FL
M3M03M T+IL$=IE9:ZP"-VS'\G6&$B-;YS P81EM*Z9P@&.MH7SDG)$K:M*UO
M2G=3TY&CU$S[C^5(G:Z*/BOT/LRFWW&V^+DNN/U>;P6/O]1ZZM,:7&SM36RC
MRZW->A^NPF135K5<]/;"0J$3=7RQ399,5Z13,O!0P-F4;0S(@V^= /LL4:>:
MGG<DWI$,S"43(D1-YE@E.L9=$;*Z:HY84RZQUG%877=8<])6W]MVY&"Y=G ,
MO;X>KUX(2!J_??L^F_Y8=:?^QZS.O"C<2.-JA\':V4%)0VR15P_6LTS&4&KF
M6GM"3Q(TK/MS7O2TTT0'L'J'88YU;.1#3KP43!K%03M>'Z"TAL!HJX02@\LR
M\IQY:\.SDYIALY[.;([:Z* #-/T>2) 3G/V\*Z,5)U$;ZPM'B$J1N:6-0);6
M"<C11N.\-BJUKNS=3<VP>4_G15,C'72 IC?3"<GC.JTZL)'4OI"BUAN#&2D9
M!@O1!E'#"%F[Z2?@12I..T1KWOIE\PERADU\.B^>6FFA T#M%-1Z>W NDE-U
M5K*LY3LV0Y3>0*  564M@Y>M"\B?IFC8I*?SPJJA+CI(_7V5TO6WY3CD_ L2
M$6F\[HQ%D?I27Y/\ZEN=:+BJ%]O)_*A(Z3UJ \8IXMOZ"#XD#6(9D41AG6Q]
MI=2*]F%3J<Z+UD'T>SBN_0K7DSI^?OV[9[.9?^!B%$UDK,0"B9'55XG"YZ"U
MI4- (<]6!*E;E_(]1<]>"'0O$X'-]-#,6I[]]K-Q3\6#ESC3/>G%>R@^#TQO
MDG#.1L@L1E \,'#&,-"USZR-7O$L+K6/VV<-[EQJ]>AEK;:HE8<BZV N41C0
M5HR UA6OG,$@6M^=[4M;[Y>PA^!F=Y9@0_UT46.QDY_7/V]R@T0(TI2D(&+(
M9+$EHZ#<!8B:A^3I/$#5NA9L#[)Z2?-KB8A]S]$CE=-S6'LGDR1Y3?%4+F!,
MMC6+E[CQ*4!*R*VIU92H+X6W7I+[FD-A7Z@=J9<.H+9Y^U@G%H7,?)",8AA=
M1ZW+Z,G^QP32\6B,##'ZUC<F]RGH%$#'*GC'2],1TNX *X\^:ZQ9424(D1.#
MI+.IO2,$>(D4%9>L+85)4NOFC]J[R>GTM;(1BEKIH0-(/?JVL6:E).<-)@%"
MROJ>KSB0A-(2""P&IHKTC2'U!#F=OE<V@E0K/0P(J?EL,?I89WPOCWF%@BL,
M'E2L(U9B\1"9IT!&)2N#$9KGO;*'Z%/O (>^NP7-O05[20\]@Z-]O&![0,,F
M8SJF[&7MC1N1$=DUL-59 >>2"Y=D,6XO8[(/'H;T9$Y0UK:ZCY#<P K_?3P9
M?[O^MB;<HW>J& U61O*N$KE8WC$#/&9&:)<YE[TB\F=4?F_1@95^C,JF+>0W
MM.+#7W<(K[;-2!5!ECJLU]*!13$?@A/T+V5%EGFOS)3G%']WT6'L?S/%'RV_
M#GS(G4?>NYL<=1ET$8*@G$(F8^A$A%A[;R;M(T$<C9>MA]8^3]6P'N6P=W/'
MJ:9GL/USCN7ZZMVX(!G.@ )% *YS+; G87GG$_ DDK'"*=,\,VX/LCJ]63D2
M"?L"[4BU=("T?=(21F2-45GRZ(Q!BOFT]V3ZJ^5V03"?G5*^=;NP?>CJ]/ZE
M#=::*Z8#L/TVH<_"^>+-=+Z8OPG?QXMP-?XOS"-DD0LM. CO>"T@K+WTT8,6
MEE'\X%)1[0=Q/TY+IS<P;4#51 %]UL$1:^2BCI?=:-9;A+Z^_>FK^1P7\V4I
MX.>O8?*/Z33_.;ZZ.CXOY,0%&V2)M&2Y4<[(9HU:X[)%1QU_?36=7]^9+NN%
M-@EUJ8<C05D3]!Q)&&3,Z+P*TNG6Y\I!!+;+)?F58MX%OAO_P ?+KOQ?&8*-
MNNXX<GAKXR0#](,$7BI5HO?*L]95,_M3-ZQ3=SY,[<XM::JO#D[>)_AY_?/W
M\!_3V9NK,)\OK_.P*,84>;"(GEAS3A)7E@&/J(*FP+_$UMF9!Y#72ZY)6X1,
M+Z.NOI%XR]@?X=OFO2E+R33G IP6IG9=5A!D5)"-3$%D'57S5L4'DC@L(L\&
ME?TA>;+>.H!E;7,Z_?8=%_CJRPSO/W8[ASZ8VLXD+9O(&XA19?!9*V.#%-JW
MMH>[J>D6;*>#8'H6C72 K4\X^S%.#]G(I?A:V$&1G*?HG0(NH(U8("F+G&>G
MC6N=/KV#E&%O4BZ)JA:ZZ !23XCL]J; <Q--XK:V96++%JQD[D4!C5%8G5!J
MV[J1[3YT]9+$,)0'=YR".@#=;Y.,93=?;_]*5]<U[W 3L(U(3BA2LF"DU&2G
M!=*6+0+(1EO#-&KDK:L2#Z6QV_/T2)0\N/ [H\HZ@.0= 3[F+ZR*@J4O0OD2
M0"5. E190,P8:5O;6(7'2O-WV7WHZO;0;0.]YJKI &[+N]1G]M1(HB+Q< 52
MA%+[]R9P"3,XVD.1H?',M(X7]J%KV(>-L\.MN6HZ@-LV_<L]\]!FVUS01EX'
M?L::C2TH$N(9@1NG6-;,)7:&U[,]*!NV7\X%#M?FZNF@)\438KO3SN#>,S2:
MJ&)F&02)JPX;8N 5LZ YEI Y4SRV?KPXG,IAF^U<\K@]A]JZ:"JQS=@?N'BX
MW4)M2!6L U;O!)2L+5UCJ,.OC20#SW06K4L6]Z%KV*8\%[>%)ZNFSWX3=Y[<
M-Q<)]_;4FZ]A]@7G50';$@F3_&X<XOAJ.5:K2=Y!&Q+:9B*<02R#Y"8DYXNU
MM8*73%G=#!X<XQZ"Y19SRIP<QI>8FU#[_+_]ZSNFK=.@_FPR7S=T5T:R(HH%
ME);\%B4XA! SV.RR\.B#=ND9F.ZSSDO**S@$#W=G*C25=0<QR2'OC3HRQY5$
M2+565'D6(185 9EUABLLEOVWRR1HCXD3<@<.45#?V'OTH4AC2KQ._D[99E"%
M'%P7I0*FK2_%"IM*ZVZ??]O<@8.@<F+NP"%ZZP"63[U4"Y9#0 -H#(58&0,X
MDS.DE'Q.EA7>'(%_E]R!@T!P0.[  1KI %N[WJL-2B&"$: =:E L%H@\.]!&
M8RXJ&15; ^MOD3MP"JI:Z&+@@6A/>!ZW]P ">626'%R=4P1E"T+@+-%7DG/C
M4A#;D]P/]?[?#9L+<#8?["PB[L */76Y^)#-/RA@__PG7OW WZ>3Q=?Y*(HL
MA*NM_K()] ^?*&QR'(I5QCBO&)K65W*G4=QE:' D>@ZX)VZLRA<'W/^+8?;Y
MS^E(\VAXC+3U8RZ@DA;D(R@'I61KHW?*-!_0=A2A75K/(6!ZC.)>)CH);DB"
M+5[KP$%@;9V0(P<7,($316IR;C5+K7M6'4GJ,$D'O2+T8.6]2(S^.KV>C1@+
M(3%OH61-.Y$K!,]#[2_N(PN"%VP^?NXX2H?)4>@4H0>K[F4"E'YWQ*WR 2E*
MLZ).6<^2@4?-01K:?US35LRM.RD?1^DP>0N] O10U;TX@+XJM/(-JZ(XYM%%
M"*JVQ='<0GTG!YG1RBB59^*"-]C/D3M,CD.'4#U>B7WCM0X-L26(%,FS3H5S
MXD9(\$N^BO8^6I%\;IUM^#1%PPP0&AIUAZJB^WR:QF-;]OWDQGTX+CVDY; D
MANPQ8Y(:,M;!>Y$.39>M@Q15",$7R5/KO=MKPXTHC"PF. B&@B]E?(+(DP6I
MLRN17 BG6Q?'_3T;;AR"J1,:;ARBK[X/T0=/Z]X*M+P$2,S0"8%)04C<0?'>
M1$%!E[<7O,[I(TWFW @Y(6GF$'7UC<3'7T@]BJACA&R9 L54]5>4IA"+'(SL
ML^+B@LG\+SMIYB"HG)HT<X#>.H#E$RD:ULCLZAM]\0;K&Q.26UOO2BG(C\5C
M=+KU>)B_3=+,(2#8/VGF$(UT@*TWU_/%]!O./N+54E/SK^/O&U:$3-'X&H35
M)JW$A -7AVFRQ$)R/LIB6X/K"7)>6/+,">AJI9,>ICTL;7L(IO!,PHB!U?[E
M64'T)!%E7#2T*9),>P'II<W^.(L?=KQH>\##IJ,],8[.2"B<YUK,'B ZPK(7
M5EKMA1;[#8)_6=,_#E+6CND?ATANZ"$0]Z97&.V2R+5)!B/SI8H1$)7D8(M)
MG%EDUC89 M'?](^#5+9S^L<A\AM:\?>F5R2GLA*2:/9H0/$B(0I'TM ,#1+T
MM=GK??OE3?\X6O%'RZ\#CW*O^EF%,=-)5R!K6\@]\@:<9AYXL)+9.LTF7O!E
MY%UO$T"&NL Y3D%]@^XC5H=\//ER]^GI \[&T\Q'):.W&C7H1-M*&>+0E:*!
MJY!%*MSQYA7P1Y+:;7!])&;V!V4S!7: TU?I_UV/:=G=[/X+QU^^UH?2'S@+
M7W#%YVLLTQE^Q G^&:[>S][6![%Y[4LA"U>FCI:R2M/9( *C$X:^RDB!8HX4
M%>K6-Y"-6>@VK&^#ZR$5W@/>[VS9]^5!DRDOT<:Z<9T,&E06&5Q*&JSQ(04L
M,L36J8]/4_0".G^=A,9VZN@ 7+]]^Q[&LWKY^I"7Q]HU1F.SIN#;UY/"1PTN
MD@<5M6/)69\L;XVU@PA\ 1W 3H'>^935YY"=.HYH\?-W7'R=YC#)ZYY[/W"^
M^(:+R?RI/YXL3NAYTV;=!JD^9Q! HT2@NTO?6?+5)/^OZ7BR^'?ZYIJ8OIV3
MXI05OG#()D<*P G[WM.9&[-TF- IT[PR_4 2VR4#[5AXW>69VR"88>!L?=&2
MDD-(2@'MS&(L=TZ$UM'2?I0-&QR=$T^[TX":::J#D_Q#F"TF./M,O_Z^K+_9
M#%U[E=+T>K)87J [1D>!<XK<$AU .6,@"+V<PN:%1N]E\TRT/4GK)?6G'2JV
M!WJ>044O WEW7G6%9BIJHR$+71/X,-=2']K(P<CH8D:C6K^('T3@P"-ESP&1
MPV%XI+XZ ./2"7K_9V7IZ_C[;^L)E)OWGY0U6A3 '8^K]Q]O2(@8E @B%L9-
MZROSI^CI'FK'PN"Q9MDM=-(!OFX/A"JXU9RK5!QGM9.MEH:.A&@AUKH+)B2+
M5MB<;?NY$]M4])*O<;;#\T3!=P>=-V&!7Z:S]4W2>C-$5822'$&C6/9(]N $
MI_#4.<TB=S+8UF6BSU,UK)DZ5>]/PNAD)70 J]6.^X3I>K9L:KOF@C.)BD(D
MP.H<*&X*N! BV$+_9=%8T7PNQ..4] 2?T_4];2[\@1--;L[EY=9B.3B1& ,4
M4I%?J0+$B!8X\Y9E1#1\+]0\DVAR;]%>,@::'UVGB;<77*P=0,4YTRQDD"5@
M+;RRX#$7*"FC1RV9B'L=3?LB8\AH[$3%/:;^(Z0X</.^7S!-)_/IU3C7B0K+
M=/W)@CZ??O?+V\EBN556PPP)^QC)@S>(#I05$IRCX]@H%SV67,M2GKEQ/V2]
M#B!QC#*G9Y9L!Y[(LZ;T]AE,.V\D,@_%Y$"BJ^:4DV'5PJ%6UGG>O%?W_M0-
M^XQX@5CJ3(KJ ()W>/AM\JJ4\=68]MC\TW6<C_,XS,A%>S6?3]/RI]NO"Z.B
M7%"J#DLBMNOLI%*?\<G49\Z<E$+DE!NC\B2".[\Q/Q)%.R.V<ZOTY;V"UR>R
MMHTL3EGMS"_>!S$[T#MW#M9D+S5PS^C$]KG.O*_.@:]?^^Q\\SY??;YS&R[)
M%^*QCB^FH!I='63,"VBI'(]"D)CV*E7Y;_[.?0B>CGSG/D13 \>DSW'T\*>(
M]0UC&<+E;!172H)0/H%*)M0RH%"K2YGTWDEC]KJF?R: /87&SL_S(_ R'4!Y
M X-T%Q_KH-%'+"E9 ZB8)DYH,P=O!'&BDC")H]ZOH=DS,'R:BN%BZ,NA8'H6
ME0P]4>'QG?G;9'6+<'.I\,LX7/V<C^>;=]V[Y>^&688)0=HZ/T+[ CZ& B):
M%V3(TFZ/FGM\WL+)E P'PI9XF ZFG!YJT9?;,H44'8L,M$%?<YHEA,P41".3
M-UD[R_=**7MIO0G.<DP>)]8>L+"&<,@A.!$\,+/,<*>-$[0RH(K3WA*:N4RM
MT#"T(3E263OZ$APBN:'+T^_5U:/QUD6!P,ERDL%TN4[:=2"<,LPQCD6)!BKO
ML"_!02K;V9?@$/D-K?A[=?66W*]8D@06"/"*3BD@CAW(Q#+G17*O6L14'?8E
M.%KQ1\NOE_?@50J.=CZE98=A),)C3K#,#@Q":6T%S]GN533[M\L3./;8/UZ\
MO>!B[3S;$@J+V4/2A9$ &"?G&0TP*U24E@EO]ZKT>9EY @<I[HD\@4.D.'!(
M^F$IHC?3;]_#Y.>K2?Y(&V(VKHW*[S[1;'*M:D>W+#1@5!3!T\D&3C@&F*)P
MP?GBMIM6/1I\'K)F!] X1JG3"TCXI6282!1)BUSH<*QC-(.J1:T>H:A0K,LJ
M2*?V0$W3#).S>!BM$',6R7;QO)^FW_ 3*6/9,/1=_0M5+4O3:X,2Q5O0R2E0
MIM1.D8)B,6.XYX'35FC=U_H)<EY$#LDQSDIK5?2+JDV6%^-2>G+MLZN]PU06
M$)GU4'2JG%CAL77!VI,$#9U/W4CM^\'I"!UT *AEV@)9W>EWG!$;DR\K[M;#
M6C97O5JQK'($;6IF2C$4]->4\83<^*"Y-V:O>[)#B]&>H:M+>!T#@\>*T%KJ
MI .<'9"!%93GA4D'K(8C2B2YF@,IDA!HG>%,M$YM:YQPV7SHW 4/RS,IZF@(
M_L!9G#8]/=]-Y_-?2;0[^!N96+1C/H%1="PH7TN7K37@T*$2VEECVZ=6[D%8
MYRD71^+BT<.UI8H&CASO,[0T[;NX*I@#1;X4UXC:,%J80!$.RZ"Y\MFE;++9
MNJE\-';<?\7.7R=/0]09A=_!>?K[>#*=$2.;$O6;</P#SE+5XA=\_7-U&S,*
M66+4PH%VH0Y;,1&"31989BH5$15GK?NH'$!>YW?E;<S:N=35Q;&Z%W/W;W96
MOS)RF9$IKRVS'2,OF;Z%*%,&B])Q'G71O'7 >C2QG5^37!"G)ZMRX"/YC^L:
M0=UV$JE)32/+-8]<,-#+V<FUA;N30D,)4L?@A&+;=R>/'KZ/?7;G,</IQ^S)
M NW@0'U<.$N7X?/7,/F,W[Y/9V'V\[:SY8@[Y76R 72)!50P IPNE<V4(D5@
MWNN]<DE.KJ!XBLIA1D]?V&R=67E]5EMMVJ>^^5J3/>;CR9LPF_TDB_SOX>H:
MIV7SY_'G1R3V%_5JX!-^.;'C:(M5&U1?-6=^D+'#3@0E$YV7)A1!<2Q#\'2*
M F?.:HO.)-_:_QEH[/!FV=4%E:)8*Z6L('NKR,6M;WE)DY\;1:8]GX)@K1_
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M'ED<VY_;4\+&0>J9-I+5T%W8-]#_!TZ_S,+WK^,4KE:P9YI,I9:@9:T@161
M<2>#K"GHM(&"4=&B]>=. OI\;3_F_&@GYZ'!LMHN=UG83!1FK!#"#2#FVGJ(
M1[*6*D-P6I'YY"JY)F#91<" /=#;*';:6LH#0F4Y;GKV<_3+VY%'S5WT$;CT
M-2$[D RB"/5VT_C(HE9/EB_.,?V/+],?_W/]B2MHK+^Y1<;M>@/"H(W2IB=)
ML .W\N%]E6 H/)G&6C:N0"4KP#M+9K.P@,ZX6/!<;P3O#LK<ND %=;M8Y#0Y
M=P24D4%RM)BTP'C2]<G?0V2*0YU\YZPMTJK6H4=?"3E'JG!G.LX!\APXR+AW
M4WE;/_V^_!K&LV69VF^3MW\E"LC>ET]?Z5??ETT1VZMOU42.!)$D= BT9S*O
M+KL$3]\#"DMAF[<I;/?=>C0J.9F0WEZ=CD'2Y34R=+/;Z8+8&X?E<TA:O)_<
M,/GK=/:13':J"OQM\OY^E[&1RL*)F#A@J>\NG!6*["Q;3A)VC&=D)N\!NB.7
M[^T]ZEBH74+Z#5^FS@"QUZ'.C:FCXHBU&88Y;:YZ\UWWT4=:?N2D]:;F(W&M
MZ@"96LYHB5]+G":N4_).G JTYXCH(S7GS'!KJHGA07=CMU>UWP_VT#_G-0ON
M[0_BGA:\$<3[^T^'))>;)YKYG$S^LBN $S4)!37$6/.4>/U*L0B9YWJQI3F3
M^PP(/R>-?:0&-8!L+WH<^IQ^((>[>_,4(1@FC;(90:9$$9@L"IQ""5FG8+,@
M325[%)@;$3AL:Y)S(GD(#?;=I*3Q[.>]/K9A_LG%ISD?EC[ 2TG*1 7TSPP*
M.8/(@P14BD>1*60.K5_'NT@VP6),+L* +XS5IR@#@6L+RCA..\2*(F-COO\&
MR2:'H&7?9)-#--'!_=S3;^+:%4VBT6"4IBA?ASK+(F<Z"(+42,)+^?_O(W*8
MR@]*-CE$_CV Z=X[N_2.J+01BJL5R_5US&>'H)42/!MF^;;7]=\GV>0@Q3Z9
M;'*(E =V\)<="^ZGK=[T+>!94W "7M;;Q)#)O>,\0:[Y&"G+6,0^#9]W+M!3
M^LE!"INVEEX'5N)AO(%.QQ*# L]YK<JS#H*@KS@WQD;C,S)Y)J_ML+?#B^>A
MG'*TG";G#H"RZ:9Z<QVR,:$CQI '53CX4',N.&V?&(J'A$84YW36N77#T9W$
M].'P'JGDZ3DDWF< OK2?[\8ACJ\H@CVE#&37)S4(L_<BLE%D_6"MAP$24YG.
M%>G 8CVKN _@@DFU52S7RDD=0NLN&L]3==K@RY_UU:E<3_*J[=;R$TE)\Y'B
M(24I$$(BF*N,A8QN%F"TE5XK&Z*4>_@@NU<8UE TUO;]69=-A-K!B?,JI=DU
MYM\F))=:1K6JZ5Z,DI%*:5; Y-JO(B'95%X28,S"Q>A,5JVO5W:0,JR;<B80
MM11_!RC:S R@?5&=N T7GJ6DC:\#]KRKXRP"'='6@DDZEV2+3++]L,O'*!DV
MM>#,&&H@_ X@M-P)H?8<^!S^POE- _?5@^#R9QO.6$#FO%"0<YU'SXT#'U&"
M"4XSVC@IJN:]%?>F;MBT@DN8J_9*Z@!^J]Z2=)[/?MX1WX:94)A2UFFP2GJ@
MKR@J,,1;D,(R=*;8YB6(3Q(T;"+ F4'63A6]X.H1-J2QV3)'$A'+F3FR0)2,
M@?,Z<J00UJISQQF'8.EL3_&7P-*)XC\>1=-%N#I7<'_'Y-YV2%C]\#66Z0SO
M_,+Q@?\QJS2X%#B9N487!C?+/ )+S3&P4LME&45[2CL+WO$Z5":YR'PN(;<N
M_WB"G+;S4=],)XOQY+J.^%K=BU%D^U#P],5\,4XC,KTI^AJ=J-KKBV4ZZC4R
M,!Z%BM*56,X[-?4@<GL8'7TZHIX>GGH^_75PI![!ZKIAW2BQ&+TDN:*L3<B2
M(8M?7R(C2SDI4Y)JGBQS/+7#7GQT!-1CM/<R<;H]@W&9U+//5&1OF2Q2>[ E
MU))<4HLGF4".Z)127BK>.O/@@NP->WW3T4ZX"#ZZ]W??3+]]GTXJ7QNGD'[\
M]J_O.)EC$U=WGP7:>KD'LW0!!Q>-+*6X7$N1:A<^IBG(#@)*M,BDSDG&UI,I
MSNC@KB._;>&^Q@F6\>*QW7<CB$"'"P]"@*U7\ HCUN2$!%8'I;CQQLK6?<V.
MI[9?]_80/&W;R@MIKP.O8<WIKTB*"E</6!W)F'U1F,'+>O_ER*9[6P3HJ"6S
MPG"A6X>=SY T+.(NA8S' =E$3?V@;IG"24[%._H+CS#EO5?"UN+[Y#G4@93@
MR'V %#&4+'+PO'76VEZ$#1LI#8O ABKK!X?KB.\A.TZF8+VH0Z"4)8&1K&(1
M=5M%'W,Q1OG6/LDS) T;FPQL_5JHJ1_4[9#B2,L@;0H4+]3FK$HH3=Q8#X[%
MHGSQ/,@S@6X'1<.^,0^+N19*:A;A'@^Y7];+'B-%46\=HJ7=56(@*5H!04<)
M7 D>4(9L@FJ,QQ/([?<:\Y2 Y%+ZZ\ Z;EA=^[J[-J"+J$/B!CC6N:W2DC11
M"N(J!Y*M\=FVCI+WHVS8^.1B0-D!T(9:ZPB+][S>7;P)F81TT8+GM;,Z"YYX
M<PR"E5::G!77K6LY#Z%O6,,X-"Z;:[ C=*[]XEU<U:FVS'LZ:##7CO_)U%%*
MY*]D;BTW)9)S="Y+^21EP\8R0R.RH=8ZPN*=1P;:;?3O-_3#\6(^RL8ESZ.#
MI&NA'6TE\+DX0&+31IN1;U=_M/<BMV@:-JX9&G]---5!:+-K Q7IDY?9@$/4
MH&PL0'N&OA(81%#!:]?Z..[2SITK)&DA]^[??N]NDJLE%NF3S_0,?.!:;5^$
M3V'T H_#0MH<62[@O1'DF5D'$8T!DXHB4^A34JWO(,Z>_?A(=,1*E XMZ$S[
M1P5N(2JC@7L?N0T>$YXGK::S(+85$O8U68?(O8,3;]GS;>D=8+YQ#BI7I6!:
MO"_W<W0>_>WUL/"O88[OKQ>;H>'.FVC)T619)E!%1O!2%&#>,)FXMXHWO^@[
M#RO]7@*> M\>]-Y!J'& P_RH#.9O_R)=$ C&DS#[N>KI4**7Q=&6MTDJ$@$Y
MOD&: M:@TC:1>V3Q,I;W%#;Z=33/8+4OIN_NG=2/2$RG\=5X^9&O<?$GXN2?
MG[:O8FN+T##)[Z]G*X,Q_K'YZ:Z$T"9N[=FI:^L(7U:8%W"=C3#)&"% T#J@
MG+7@9 C@R>7Q+N@@]'F*$,[B.M](^YXF[BOMU29/JE[Z7M/G_;SWRZ-"D6BB
MSX%@2JT5%@Z\4P*2YO5ZPX3D6S<W:D!VOR[Y(0C;-NZ7UF<'_LL^+#_^7('S
M459&U4&9H#4B'5PE@$/&Z2#E.0J7 V]>4G0*O?TZXN<&;1,-OA"T_C&M9U@=
M-!*O<.VE??I**GI-<4:NQ0;TD^5OOIG.ZR.P59[K#,&R6EC%#3BG66T^PYQC
M(D7=.L&I/1?]^MKG1O89M7WJR(_/%X7]]@M>_8U?QO07JP;'X6I4O/(%(VWP
MY#0H&1 BTY&^S4$Z6<A?;GVATH+N8=_%AH1V4XT.W SX$7[O\7I;KU<G^8QG
MRS$0WF@A8HI@BHF@C+<0A=404Q&ND)A+5L^$?L>N/6R3F=:HNX@&7K![L.R4
M,BI<QQR2A&B%!:5E'0[/,Q@GC/5!*FU;O]&>1/"PS6MZ._0/U^$+ 6Q-AEC>
MX'Q!^B'Y[,Z:H)VL/2IBJN_D&9SA'HCS5&P6VHO6G06/H7,O>-J_(SQ/TM@+
M0>7-R*<UB?1+J\$K_[X<^%2U?'4U_;/V]1R5Z!@KD4'.I4Z[KG582B:(3DC%
M3* ?M\ZV:LS"7EAV?T<LGTO/+P3F=S+15&!*<CI+DM8UE4@Y<%D5T-HKGKF1
M)82!S.X!&83^[PC2([7TL@+\I8/S*O_']::O"2M*QV6O*J?KE+Q4(%!(""5;
MDK9D&*T> )#;=.[W5,#^CK@\264OQ$)NM^59_>K:*1]QDP5FEZ$$6XL83%K-
M-N',*VD-*UA:MU(_F>C] /NW?-QJI\QNT?O8:_@(K?(ZEPC<. 054*^2V6-*
M5ABF#;++G.V/4;<?'O\F[U8GJZ?[!)D[GG28Y#O]>5_-QG/BNVK@,W[[/IV%
MV<_-?6]JU,CVU,7;IK<T%<4%LE>RX3QQ.K0-*HKCG;,00DY01VN'8H7PS9OO
MGR%[I=X&WU'":O082S8+[B1DSAS4KM-U)SO010;&3;1&NF=@]MCG]ILG<H@N
M[]ZCGR2Y#D[%U^&J!NN?OB(NWJU+*Y9#*@//D7L>025MJF_JP3NF(7F68Q))
MIMSZ(7P7+<.@YG3M3L\@ZDXALQYOF;W0DA,3:-'7!R($;[($Z3$8&YWUV#I[
M;3<UPQJ;-MK> T)'B'[@U]\[Y_R=0WX]SS1*'H*T!0JCS:6<,-40,RB\1)$$
M!1?![W'R/+5&?\ X1H?3,PBT ^NRO"3Y@X+058^CU>WRFI7 A&7>+2N@R/HJ
MD< 5K8&L<G&HG8C-X[(GR!DV?[ QC%J+?V 3<^?@?G<S')4%IZPI&;PNBN12
MAYR4[(&B1L8E>7@EEL.<VG?##A!NYJ(T$5D_I\H*M1\QX?A'E<E\E-'P:.N3
MJW:^)@)8\%Y8LHGH='&6Y^U0[;E3Y<$:77BI1VKN\;/D-#%V<)8\X*7&?NN?
MK6\Q/Y*:9C^6;2;6$]WFZT&4=T[2D>6%(L*2(/":^!3(M@9!8G4Q<":<Q:1:
ME^"UHKT+RW0:+ =59V]6[68Z]SL,]/EWN"I86.%:@!0JU$IQ#A1/,#JM%3,Y
M,\%U.L;&[5QQF#3S\UN\-B+NT?[=<C:=S]^$V>QGF<[^#+-,>\*JXBD: ,GK
M:X[R$B(Y"\#0IZR-M]@\C>P \H9)^[Z,%6NDE"[QMLS"9-E(P1/%#2@H DV)
MS*UF 33Z6-^['=?G:J]UGY)ATK@OA**#1=TC8/XQHSTP<JED1<$F6%4K&3 D
M\($9$)H9"F!3$?;LMFA)R3 YU9<!S.&B[J&]S!YYAUDRERWM 9?K("KF'42N
M/11;3$B6&Z?/[JP?F3/://_Y,E Z40FG)MZ=!UE_X&(4R:'C5GC@.55SZB-X
MY^@?:"CN%8R.WW.US;U+QS#YQI?!SJ%B[LL(W0D._C&=YC_'5U?+072+,/E2
MJU%6/&Y_/\H\:15#@%04!:"(#/RR XVC6 PUQYQ;OY.=3/0P^<3G!N$%%-B;
M>;O#\H?9E(*/Q<\/5V%2)RC6F8G?EZ5^EN?@$\\4:F11)XTC$&L63*HU4Z)V
MHSZC"[8/B0,E$E\0D&VT,RC\=K].WK]D66^K&!7R$#)P+R4=!)E#*-) $5$S
MP>LHDZV);@<\_CZVXD#)O>>\PVHIXWY*(AYG\.Y<5Z$]%I%JLQ+/0/DJ.D1#
M3H1SR:)^F#AP)HMUZ+3>]KFZ%[11QVJ@XT-Q?9."7E.D4I\'?*Z-)SWX&LID
M<E559K6*J'6IPA/D[ >DON_:6TN]*PC=2.GN<P%S5B=C"S"E:4,4G2 H=*!<
M23HE;H-Q9\+08_3L!Z*7=8M^LMQ//N+.'%:.1" Y&9F ,8U  M/@N"ID6F,0
MS)NB>>LIMX]3LA]\7MSU^;&R;@V<RW1@G9;7^&4\F9!3&"BBF.3J':XE4-^=
M_CF9T>]_F8S_:RF<=3_;^>)K6/PR_6.Z^!UQ\?MTAN_&_XE7/S]_#1/ZX6?"
MW?SK]"J?H2GK90@^9Y_6 41^B:D'7AE14@#GO:$P(B($&25H9J)1C!MN6]<'
MG+%UZU:A;MFAD[=_I:OKJK]7WZ;7Y/)^H/ \C*MF/T_?_A6^D6VJO_X1%]>S
MR?SC].KJU]53[DB%E#19)3"LYF06+B'X.LVK>&L5JY><K5V!<_/4;S'/(=C<
M/AFZ0D('3[0[^!^5DF30HH#1=:1VD"3CA!F2+#H+D1./K>.C':0,B\.^\#)M
MK[RC,?A].<'ATR+,%N=$(AF"6;W>HE-W?GU5;[N67<Y7^>NK*1+TVQ^F\_&J
M>I@Y@5G) CQ:0;P[2:(D;R]K#-R:Q(IJ/<BF#>7#UAN\1)R?$QK]FN;'N?Y
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MOICFY<HJN?3"RSK9(_LZD]-9LDI3NW&TU3938-P\6]R#O'%GLYSN:!Q*8QV
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M8,=>F+&=#6)>])FX?X_=<B*-8;E0H"UX5J!\4?4>BE($'M'Z8KDPYW/I>8
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MVD*>R+_D;-%2!,2Q]770X$SM9D@OK7K=)V9Z"*U:"N2GE??W)[Q/F#1&:J?
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M"W"3L'A>C./%NP1)U*N S%G-CXB@I=7:"L^\:IW@=@\9(YM-@Q\G1S)^Y##
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MV?RF"VR2I3!A $VA_89%@%?)@%*\SF7))A3<X>#YQ6/&'NK=6/:W#YZ6#.[
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MQ>ZA^BJGR[C*3ZW-+7-2SD&6-=CE?;V+2@:"I3V8A5="M)XPMRMM.P%2/7=
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M@IO!QDR%2,?JL:4']I[2 W>0'M +MT1D2<\<Y"TBL2\E$:[Q=CJ^+Y,""[F
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MG4?-.;&G88RP>K/;6.!DN*D*K>G?>2[BTOC!?"2@J$!8V3X-ZAY]1+#%D*E
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M  !D=F$M,3(S,3(R97@R,S$N:'1M4$L! A0#%     @ :8I65K/N' KS!P
M@20  !<              ( !^"(  &1V82TQ,C,Q,C)E>#,Q,3$P>&LN:'1M
M4$L! A0#%     @ :8I65OTW':K1!P  Y2(  !<              ( !("L
M &1V82TQ,C,Q,C)E>#,Q,C$P>&LN:'1M4$L! A0#%     @ :8I65I8IARE5
M!0  3!8  !<              ( !)C,  &1V82TQ,C,Q,C)E>#,R,3$P>&LN
M:'1M4$L! A0#%     @ :8I65O'#Q#L\!0  Y10  !<              ( !
ML#@  &1V82TQ,C,Q,C)E>#,R,C$P>&LN:'1M4$L! A0#%     @ :8I65D>.
M*2JE> 4 '@TZ !               ( !(3X  &1V82TR,#(R,3(S,2YH=&U0
M2P$"% ,4    " !IBE96)NXC \LC  !GC0$ $               @ 'TM@4
M9'9A+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( &F*5E:6F1J#PC0   TB @ 4
M              "  >W:!0!D=F$M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( &F*5E8>Z,RS\+H  -4_"  4              "  >$/!@!D=F$M,C R
M,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( &F*5E8AI_&9\L@  /7(   3
M          "  0/+!@!D=F$M,C R,C$R,S%?9S$N9VEF4$L! A0#%     @
M:8I65KX/-*01@   2*$  !,              ( !)I0' &1V82TR,#(R,3(S
M,5]G,BYJ<&=02P$"% ,4    " !IBE96E0M4KI;Z 0!J  4 $P
M    @ %H% @ 9'9A+3(P,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( &F*5E9V
MCU-:[MX!  J)$P 4              "  2\/"@!D=F$M,C R,C$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( &F*5E:)<B>I=QX!  /I#  4              "
M 4_N"P!D=F$M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &F*5E8)8J93
MH0X  .EN   >              "  ?@,#0!E>#$P,30M;F]N>&5M<&QO>65E
M9&ER96-T;RYH=&U02P$"% ,4    " !IBE96G;-)>5$E  ![V0  '@
M        @ '5&PT 97@Q,#,Q+69O<FUP97)F;W)M86YC96-A<V@N:'1M4$L%
3!@     1 !$ =00  &)!#0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
